<SEC-DOCUMENT>0001410578-22-003483.txt : 20221117
<SEC-HEADER>0001410578-22-003483.hdr.sgml : 20221117
<ACCEPTANCE-DATETIME>20221117173009
ACCESSION NUMBER:		0001410578-22-003483
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		76
CONFORMED PERIOD OF REPORT:	20220930
FILED AS OF DATE:		20221117
DATE AS OF CHANGE:		20221117

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CureVac N.V.
		CENTRAL INDEX KEY:			0001809122
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			P7
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39446
		FILM NUMBER:		221399728

	BUSINESS ADDRESS:	
		STREET 1:		PAUL-EHRLICH-STRABE 15 TUBINGEN
		CITY:			BADEN-WURTTEMBERG
		STATE:			2M
		ZIP:			72076
		BUSINESS PHONE:		49 7071 9883 0

	MAIL ADDRESS:	
		STREET 1:		PAUL-EHRLICH-STRABE 15 TUBINGEN
		CITY:			BADEN-WURTTEMBERG
		STATE:			2M
		ZIP:			72076

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CureVac B.V.
		DATE OF NAME CHANGE:	20200410
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>cvac-20220930x6k.htm
<DESCRIPTION>6-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='UTF-8'?>

      <!-- iXBRL document created with: Toppan Merrill Bridge iXBRL 10.1.0.3 -->
      <!-- Based on: iXBRL 1.1 -->
      <!-- Created on: 11/17/2022 10:27:54 PM -->
      <!-- iXBRL Library version: 1.0.8263.24741 -->
      <!-- iXBRL Service Job ID: 751cbc79-9c20-4614-afd6-fc8f8849f06f -->

  <html xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns="http://www.w3.org/1999/xhtml" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:cvac="http://www.curevac.com/20220930" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:country="http://xbrl.sec.gov/country/2021" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2021" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ifrs-full="http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full" xmlns:xbrldi="http://xbrl.org/2006/xbrldi"><head><meta http-equiv="content-type" content="text/html" /><title></title></head><body><div style="margin-top:30pt;"></div><div style="display:none;"><ix:header><ix:references><link:schemaRef xlink:href="cvac-20220930.xsd" xlink:type="simple"></link:schemaRef></ix:references><ix:resources><xbrli:context id="Duration_1_1_2022_To_9_30_2022_GrYkE3mhHEiRA4fxgfABRg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2021_To_9_30_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_VirtualSharesProgramIiMember_H9asqvfrLUqv97coIp3GBQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:VirtualSharesProgramIiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2022_ifrs-full_ClassesOfFinancialInstrumentsAxis_cvac_IfrsCashAndCashEquivalentsMember_ifrs-full_TypesOfRisksAxis_ifrs-full_CurrencyRiskMember_srt_CurrencyAxis_currency_USD_GbIyOSI9fU6k0lhzbRaN6Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">cvac:IfrsCashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CurrencyRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2022_ifrs-full_ClassesOfFinancialInstrumentsAxis_cvac_IfrsCashAndCashEquivalentsMember_ifrs-full_TypesOfRisksAxis_ifrs-full_CurrencyRiskMember_srt_CurrencyAxis_currency_CHF_GzG5BBakVUCREUh5rLOPgw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">cvac:IfrsCashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CurrencyRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CHF</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_9_30_2022_ifrs-full_MajorCustomersAxis_cvac_GlaxosmithklineMember_ifrs-full_ProductsAndServicesAxis_cvac_ResearchServicesCombinedWithIpLicenseMember_CAXgAqyHKkO0WaEKjGrFrA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">cvac:GlaxosmithklineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">cvac:ResearchServicesCombinedWithIpLicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_9_30_2022_ifrs-full_MajorCustomersAxis_cvac_GenmabMember_ifrs-full_ProductsAndServicesAxis_cvac_ResearchServicesCombinedWithIpLicenseMember_72wIU7VnlkKKba3jsZpOBg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">cvac:GenmabMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">cvac:ResearchServicesCombinedWithIpLicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_9_30_2022_ifrs-full_MajorCustomersAxis_cvac_CrisprMember_ifrs-full_ProductsAndServicesAxis_cvac_ResearchServicesCombinedWithIpLicenseMember_khvMaOJtOkK4x-wZSKmcOQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">cvac:CrisprMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">cvac:ResearchServicesCombinedWithIpLicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_9_30_2021_ifrs-full_MajorCustomersAxis_cvac_GlaxosmithklineMember_ifrs-full_ProductsAndServicesAxis_cvac_ResearchServicesCombinedWithIpLicenseMember_xJi4YZnmz0Wq6SdDwRVxBA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">cvac:GlaxosmithklineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">cvac:ResearchServicesCombinedWithIpLicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_9_30_2021_ifrs-full_MajorCustomersAxis_cvac_GenmabMember_ifrs-full_ProductsAndServicesAxis_cvac_ResearchServicesCombinedWithIpLicenseMember_awc6N7gG0USv7ZRK4TKDjw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">cvac:GenmabMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">cvac:ResearchServicesCombinedWithIpLicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_9_30_2021_ifrs-full_MajorCustomersAxis_cvac_CrisprMember_ifrs-full_ProductsAndServicesAxis_cvac_ResearchServicesCombinedWithIpLicenseMember_PH-MVv0gkEKmWXldRQgZBA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">cvac:CrisprMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">cvac:ResearchServicesCombinedWithIpLicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_9_30_2021_ifrs-full_MajorCustomersAxis_cvac_BoehringerIngelheimMember_ifrs-full_ProductsAndServicesAxis_cvac_ResearchServicesCombinedWithIpLicenseMember_2uKPlzeQMkesCPFChkjwGg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">cvac:BoehringerIngelheimMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">cvac:ResearchServicesCombinedWithIpLicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_9_30_2022_cvac_GovernmentGrantsAxis_cvac_CoalitionForEpidemicPreparednessInnovationsMember_QaC72j_xJU248NAuCm-NTA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cvac:GovernmentGrantsAxis">cvac:CoalitionForEpidemicPreparednessInnovationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_9_30_2022_cvac_GovernmentGrantsAxis_cvac_BillAndMelindaGatesFoundationBmgfMember_fYCkAgnPgkW1HP0kse2SZQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cvac:GovernmentGrantsAxis">cvac:BillAndMelindaGatesFoundationBmgfMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_9_30_2021_cvac_GovernmentGrantsAxis_cvac_CoalitionForEpidemicPreparednessInnovationsMember_-JHShxg3uU65FRp662VaIA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cvac:GovernmentGrantsAxis">cvac:CoalitionForEpidemicPreparednessInnovationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_9_30_2021_cvac_GovernmentGrantsAxis_cvac_BillAndMelindaGatesFoundationBmgfMember_Mbzwa-uYGkGbrTexrLia1w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cvac:GovernmentGrantsAxis">cvac:BillAndMelindaGatesFoundationBmgfMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_9_30_2022_ifrs-full_GeographicalAreasAxis_country_NL_ifrs-full_MajorCustomersAxis_cvac_GenmabMember_7itxWD0v3UC7-_TEXbaZxQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:NL</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">cvac:GenmabMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_9_30_2022_ifrs-full_GeographicalAreasAxis_country_CH_ifrs-full_MajorCustomersAxis_cvac_CrisprMember_HR3g4DsNXU-KQMdhdtvSTQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:CH</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">cvac:CrisprMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_9_30_2022_ifrs-full_GeographicalAreasAxis_country_BE_ifrs-full_MajorCustomersAxis_cvac_GlaxosmithklineMember_shjcQ9gwY0mzJMJm_89JCQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:BE</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">cvac:GlaxosmithklineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_9_30_2022_ifrs-full_ProductsAndServicesAxis_cvac_ResearchServicesCombinedWithIpLicenseMember_JmxbMa7EOkGM2UmzZvcaYA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">cvac:ResearchServicesCombinedWithIpLicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_9_30_2022_ifrs-full_ProductsAndServicesAxis_cvac_ResearchAndDevelopmentServicesMember_xgWEhIWVP0aG8Oi39YdQdg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">cvac:ResearchAndDevelopmentServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_9_30_2022_ifrs-full_ProductsAndServicesAxis_cvac_IfrsProductMember_ykNdeTyQ_U6ifIHGuP-a8Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">cvac:IfrsProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_9_30_2021_ifrs-full_GeographicalAreasAxis_country_NL_ifrs-full_MajorCustomersAxis_cvac_GenmabMember_SSbVK8fnGE6ChnWCps9ySQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:NL</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">cvac:GenmabMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_9_30_2021_ifrs-full_GeographicalAreasAxis_country_DE_ifrs-full_MajorCustomersAxis_cvac_BoehringerIngelheimMember_GLkAvVsjY0iIfdOVguCCiQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:DE</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">cvac:BoehringerIngelheimMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_9_30_2021_ifrs-full_GeographicalAreasAxis_country_CH_ifrs-full_MajorCustomersAxis_cvac_CrisprMember_H5jO5eGbWE6vAapf30CSfw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:CH</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">cvac:CrisprMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_9_30_2021_ifrs-full_GeographicalAreasAxis_country_BE_ifrs-full_MajorCustomersAxis_cvac_GlaxosmithklineMember_eVwoaEVfAUKlb5HYdjxaQw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:BE</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">cvac:GlaxosmithklineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_9_30_2021_ifrs-full_ProductsAndServicesAxis_cvac_ResearchServicesCombinedWithIpLicenseMember_w9Lhj-1fbUylhw2h1TnuCA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">cvac:ResearchServicesCombinedWithIpLicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_9_30_2021_ifrs-full_ProductsAndServicesAxis_cvac_ResearchAndDevelopmentServicesMember_FqOeAMlR502ph1Wxt4STrA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">cvac:ResearchAndDevelopmentServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_9_30_2021_ifrs-full_ProductsAndServicesAxis_cvac_IfrsProductMember_WafA2PzZ0kOs4a0LCkTNpg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">cvac:IfrsProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_9_30_2022_srt_TitleOfIndividualAxis_cvac_VincentStphenneMember_PA_nLHYdokKpQK-0_a7lSg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cvac:VincentStphenneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_9_30_2022_srt_TitleOfIndividualAxis_cvac_BaronJeanStephenneMember_xZT627rXM0CHsP6C5sklyg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cvac:BaronJeanStephenneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_9_30_2022_ifrs-full_BusinessCombinationsAxis_cvac_FramePharmaceuticalsB.v.AmsterdamNetherlandsMember_APxhOynMm0ePvj-djFEXLQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">cvac:FramePharmaceuticalsB.v.AmsterdamNetherlandsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_9_1_2022_To_9_30_2022_UpNYd37lHEq8lbtMmcgfVg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-09-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_9_30_2021_ifrs-full_BorrowingsByNameAxis_cvac_IfrsLineOfCreditMember_w0otbseHCk-9ZLH1m6FDbA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">cvac:IfrsLineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2022_ifrs-full_ClassesOfShareCapitalAxis_ifrs-full_PreferenceSharesMember_hPye6EgKFUuclVhFCyaxog"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:PreferenceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2022_ifrs-full_ClassesOfShareCapitalAxis_ifrs-full_OrdinarySharesMember_QerVWaOy8UeUozR8lPK5KA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_6_22_2022_To_6_22_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ExecutiveBoardMembersMember_HGJGQ29fb0mCC_uf2baYzw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:LongTermIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cvac:ExecutiveBoardMembersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-22</xbrli:startDate><xbrli:endDate>2022-06-22</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_8_1_2021_To_8_1_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ChiefDevelopmentOfficerMember_Sovw0LhIOky6A14jJLrI2g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:LongTermIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cvac:ChiefDevelopmentOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-08-01</xbrli:startDate><xbrli:endDate>2021-08-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2021_To_7_1_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_srt_ChiefOperatingOfficerMember_lTsgjULrh0unxpPIyz1Ojw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:LongTermIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefOperatingOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-07-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_12_1_2020_To_12_1_2020_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ChiefBusinessOfficerAndChiefCommercialOfficerMember_T3JjiYhNB0mcje4uQOSblw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:LongTermIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cvac:ChiefBusinessOfficerAndChiefCommercialOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-01</xbrli:startDate><xbrli:endDate>2020-12-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_11_16_2020_To_11_16_2020_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ChiefScientificOfficerMember_YqQecowO2kuyd-MSikFagg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:LongTermIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cvac:ChiefScientificOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-11-16</xbrli:startDate><xbrli:endDate>2020-11-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_5_1_2022_To_5_31_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ChiefScientificOfficerMember_v1kWVxI7sE-mtWe59zilhg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:LongTermIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cvac:ChiefScientificOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-01</xbrli:startDate><xbrli:endDate>2022-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_VirtualSharesProgramIiMember_-aEvT6TgvU2aaNALbBrVfw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:VirtualSharesProgramIiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_9_22_2022_To_9_22_2022_srt_TitleOfIndividualAxis_cvac_ChiefBusinessOfficerMember_GRzsO5WyQEanIaFIpuw0tg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cvac:ChiefBusinessOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-09-22</xbrli:startDate><xbrli:endDate>2022-09-22</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2022_To_7_1_2022_srt_TitleOfIndividualAxis_cvac_FormerFrameEmployeesMember_sBysEqLlSUqSMftPMXcxQQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cvac:FormerFrameEmployeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-07-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_6_22_2022_To_6_22_2022_srt_TitleOfIndividualAxis_cvac_ThenChiefExecutiveOfficerMember_MEmTtrB-PEWG-6nmSb4NZw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cvac:ThenChiefExecutiveOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-22</xbrli:startDate><xbrli:endDate>2022-06-22</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_6_22_2022_To_6_22_2022_srt_TitleOfIndividualAxis_cvac_SupervisoryBoardMembersMember_8ClvViKS_0mYv0ZZa7FsSA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cvac:SupervisoryBoardMembersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-22</xbrli:startDate><xbrli:endDate>2022-06-22</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_6_22_2022_To_6_22_2022_srt_TitleOfIndividualAxis_cvac_ExecutiveBoardMembersMember_hf65wxXOEECOwq5tEDpNWQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cvac:ExecutiveBoardMembersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-22</xbrli:startDate><xbrli:endDate>2022-06-22</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_2_10_2022_To_2_10_2022_srt_TitleOfIndividualAxis_srt_ChiefOperatingOfficerMember_iNHQybO4Pk2sc9tkHPztxA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefOperatingOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-02-10</xbrli:startDate><xbrli:endDate>2022-02-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_12_23_2021_To_12_23_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_MembersOfExecutiveBoardAndVariousKeyEmployeesMember_sPT0TmgA5UyfJUOLzYAeKg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:LongTermIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cvac:MembersOfExecutiveBoardAndVariousKeyEmployeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-12-23</xbrli:startDate><xbrli:endDate>2021-12-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_6_24_2021_To_6_24_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_SupervisoryBoardMembersMember_WzScVvwhuUOXBAORYNGw1A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:LongTermIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cvac:SupervisoryBoardMembersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-24</xbrli:startDate><xbrli:endDate>2021-06-24</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_9_30_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_TreasurySharesMember_kiA0yBP5YEWvkTpVKfGscg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_9_30_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_jUcA_4Uo70GmthvPRsVfbA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_9_30_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_H-Nfcg0EfkKBQso-1E13qw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2022_cvac_GovernmentGrantsAxis_cvac_GermanFederalMinistryOfEducationAndResearchMember_fN4famsHHEKl4JoAfEVlag"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cvac:GovernmentGrantsAxis">cvac:GermanFederalMinistryOfEducationAndResearchMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2022_cvac_GovernmentGrantsAxis_cvac_CoalitionForEpidemicPreparednessInnovationsMember_62kXYP2DG0q3hObonbIX3w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cvac:GovernmentGrantsAxis">cvac:CoalitionForEpidemicPreparednessInnovationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2022_cvac_GovernmentGrantsAxis_cvac_BillAndMelindaGatesFoundationBmgfMember_Ws8aHSUk1UC3pLQKXdVR0g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cvac:GovernmentGrantsAxis">cvac:BillAndMelindaGatesFoundationBmgfMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_cvac_GovernmentGrantsAxis_cvac_CoalitionForEpidemicPreparednessInnovationsMember_Vs0aCSCnvE2bQnX-4agCZg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cvac:GovernmentGrantsAxis">cvac:CoalitionForEpidemicPreparednessInnovationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_cvac_GovernmentGrantsAxis_cvac_BillAndMelindaGatesFoundationBmgfMember_nd5DnUyNxE69QH5CpJLGZw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cvac:GovernmentGrantsAxis">cvac:BillAndMelindaGatesFoundationBmgfMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2021_cvac_GovernmentGrantsAxis_cvac_GermanFederalMinistryOfEducationAndResearchMember_f9iNDb6krUGTFEUGF-sh0Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cvac:GovernmentGrantsAxis">cvac:GermanFederalMinistryOfEducationAndResearchMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_TreasurySharesMember_QUC-XwhKoEK4nQE0wgA-OA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember_hG_33slvv0iz_A0sabMEBA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_pOxIHb_0lkKnDUS8JXZwmg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_6KA0EJhWSE603b7Uov1rMg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_CapitalReserveMember_DnDn5AHz-0-rleJrp9WdNg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:CapitalReserveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_TreasurySharesMember_LnSXiw4SC0GJbguDola8gw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember_obI4hBRbIk6bCNEX25ONyQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_0fN-yvhfRke2bER127GqTw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_spYNfmXLlkKn0qRrA7DHrQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_CapitalReserveMember_hKeYNzP2pkyRPXTqS3GOeg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:CapitalReserveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_TreasurySharesMember_1xV3xniJzEa6h2UaD4ZV8A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember_S8HeFlbOnEmNPym3RRCQYQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_A7iYghLG40G30BtbFyy3Fw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_25XvQwjzSUOoEVBaH6bxAA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_CapitalReserveMember_uETolOLN8EO7z8AXUFUrdg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:CapitalReserveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember_ZhVYR0CYCU-n8fXSTddhVA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_ifrs-full_ComponentsOfEquityAxis_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_4SMzjwIAMEaHB7TnvYKL-g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_ZWlHBf5sd0u18E_i-Im1zQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_ifrs-full_ComponentsOfEquityAxis_ifrs-full_CapitalReserveMember_VibTw9zPlkmYxEg1Vcd6Nw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:CapitalReserveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_9_30_2022_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_cvac_CurevacSwissAgMember_uQhhLoLXmEqQ0Uh4SUqsVA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">cvac:CurevacSwissAgMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_9_30_2022_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_cvac_CurevacCorporateServiceGmbhMember_w8u7qadVykiL43suHZX4cQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">cvac:CurevacCorporateServiceGmbhMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_9_30_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember_LBd2SxQlf0unc-mzWThKow"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_9_30_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_pqJl73EEck6icL9CscAZ9w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_9_30_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember_dCKGn2XnRk6SRLx6s50FAw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_9_30_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_N1rU63L0z0CKfWKFMPE8ug"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_5_1_2022_To_5_31_2022_ifrs-full_CategoriesOfRelatedPartiesAxis_cvac_BepharbelManufacturingS.aMember_OIxhC3wEcEmjhA5CfZ3lqQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">cvac:BepharbelManufacturingS.aMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-01</xbrli:startDate><xbrli:endDate>2022-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2021_wVcf5oroJEG4KeEdh1LnEw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_gDhEGYRPKEaVXa-xMDWqsw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_9_30_2022_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_ifrs-full_GrossCarryingAmountMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_cvac_TechnicalEquipmentAndMachinesAndOtherEquipmentMember_fDP_vLfur0CDvezFllAP3w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cvac:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">cvac:TechnicalEquipmentAndMachinesAndOtherEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_9_30_2022_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_ConstructionInProgressMember_BqU3Y93BzU-k13235fXn4g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_9_30_2022_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_cvac_EquipmentPhysicallyLocatedAtCmoFacilitiesMember_7vsnG93SaE-EN8D8ClkcNA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">cvac:EquipmentPhysicallyLocatedAtCmoFacilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_9_30_2022_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_cvac_CompanyOwnedGmpIvFacilityMember_ZPOcXZnMYk-Um0cwVb1ZHw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">cvac:CompanyOwnedGmpIvFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_9_30_2021_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_ifrs-full_GrossCarryingAmountMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_cvac_TechnicalEquipmentAndMachinesAndOtherEquipmentMember_4EQ5xotfIUujKtdlrzbPVQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cvac:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">cvac:TechnicalEquipmentAndMachinesAndOtherEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_9_30_2022_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_ifrs-full_GrossCarryingAmountMember_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_cvac_LicensesSoftwareAndPrepaymentsMember_zeXSak6OQ0iEmjYXe9qo9w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cvac:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">cvac:LicensesSoftwareAndPrepaymentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_9_30_2021_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_ifrs-full_GrossCarryingAmountMember_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_cvac_LicensesSoftwareAndPrepaymentsMember_CzUp1LGslUSZTIy-JKWdLw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cvac:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">cvac:LicensesSoftwareAndPrepaymentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_8_2022_ifrs-full_BusinessCombinationsAxis_cvac_FramePharmaceuticalsB.v.AmsterdamNetherlandsMember_VaKO9irU5EuHdCnXXdyNiw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">cvac:FramePharmaceuticalsB.v.AmsterdamNetherlandsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-08</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2022_ifrs-full_MajorCustomersAxis_cvac_GlaxosmithklineMember_ifrs-full_ProductsAndServicesAxis_cvac_ResearchServicesCombinedWithIpLicenseMember_ifrs-full_RangeAxis_ifrs-full_BottomOfRangeMember_7jTi8_0PcEeLFJbzx_wjrQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">cvac:GlaxosmithklineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">cvac:ResearchServicesCombinedWithIpLicenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2022_ifrs-full_MajorCustomersAxis_cvac_BoehringerIngelheimMember_ifrs-full_ProductsAndServicesAxis_cvac_ResearchServicesCombinedWithIpLicenseMember_k3sZmRwsjkSNWebj2XPVlg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">cvac:BoehringerIngelheimMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">cvac:ResearchServicesCombinedWithIpLicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2022_ifrs-full_MajorCustomersAxis_cvac_GlaxosmithklineMember_ifrs-full_ProductsAndServicesAxis_cvac_ResearchServicesCombinedWithIpLicenseMember_0AbiwODFUEmyJLdIgNcTfg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">cvac:GlaxosmithklineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">cvac:ResearchServicesCombinedWithIpLicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2022_ifrs-full_MajorCustomersAxis_cvac_GenmabMember_ifrs-full_ProductsAndServicesAxis_cvac_ResearchServicesCombinedWithIpLicenseMember_yfdi7QFOIken6nwnl1VeyA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">cvac:GenmabMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">cvac:ResearchServicesCombinedWithIpLicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2022_ifrs-full_MajorCustomersAxis_cvac_CrisprMember_ifrs-full_ProductsAndServicesAxis_cvac_ResearchServicesCombinedWithIpLicenseMember_N0CWO_7EbUeynG_1C6XLwA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">cvac:CrisprMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">cvac:ResearchServicesCombinedWithIpLicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2022_ifrs-full_ProductsAndServicesAxis_cvac_ResearchServicesCombinedWithIpLicenseMember_LDTxHzpQykydqGAuWhIjZQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">cvac:ResearchServicesCombinedWithIpLicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_ifrs-full_MajorCustomersAxis_cvac_GlaxosmithklineMember_ifrs-full_ProductsAndServicesAxis_cvac_ResearchServicesCombinedWithIpLicenseMember_PJOVtNdDh0SBq-RS-4qaSw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">cvac:GlaxosmithklineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">cvac:ResearchServicesCombinedWithIpLicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_ifrs-full_MajorCustomersAxis_cvac_GenmabMember_ifrs-full_ProductsAndServicesAxis_cvac_ResearchServicesCombinedWithIpLicenseMember_g3gSYGvJiUWtJe5m702osQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">cvac:GenmabMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">cvac:ResearchServicesCombinedWithIpLicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_ifrs-full_MajorCustomersAxis_cvac_CrisprMember_ifrs-full_ProductsAndServicesAxis_cvac_ResearchServicesCombinedWithIpLicenseMember_lhcV_FVDUEqAgO5rXoI-qw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">cvac:CrisprMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">cvac:ResearchServicesCombinedWithIpLicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_ifrs-full_ProductsAndServicesAxis_cvac_ResearchServicesCombinedWithIpLicenseMember_SuxVutvjF02TZJEYT5xAUg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">cvac:ResearchServicesCombinedWithIpLicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_9_30_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_CapitalReserveMember_cVl-lTMdZ0SyIz4MzbLhUA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:CapitalReserveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_9_30_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_TreasurySharesMember_hUbz0huuf0-lvXUrSj2p7w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_9_30_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_CapitalReserveMember_g_0bQScme0WTxJwAia-iSA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:CapitalReserveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_jm3ww8f3H0egT8wSnNVZZw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsResearchAndDevelopmentExpenseMember_GiIhuFW_ukOtSf0Bvkce7w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cvac:IfrsIncomeStatementLocationAxis">cvac:IfrsResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_12_31_2019_ifrs-full_CategoriesOfRelatedPartiesAxis_cvac_DietmarHoppMember_vhtIRbibYkK_L7RHLy0f_A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">cvac:DietmarHoppMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_9_30_2022_ifrs-full_CategoriesOfRelatedPartiesAxis_cvac_ClarentisSrlMember_srt_TitleOfIndividualAxis_cvac_AntonyBlancMember_GiBB1NZHtU6MtEphFx2MUw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">cvac:ClarentisSrlMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cvac:AntonyBlancMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_9_30_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_SellingAndDistributionExpensesMember_nx7DDIuvEEyD8XuyuNsS6Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cvac:IfrsIncomeStatementLocationAxis">cvac:SellingAndDistributionExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_9_30_2021_cvac_IfrsIncomeStatementLocationAxis_cvac_SellingAndDistributionExpensesMember_-Uy3t4myckOOiYqfNnLrvA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cvac:IfrsIncomeStatementLocationAxis">cvac:SellingAndDistributionExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_9_1_2022_To_9_30_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_srt_ChiefOperatingOfficerMember_fTDjhW41wkulF-dl-PGYYg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:LongTermIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefOperatingOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-09-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_9_1_2022_To_9_30_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ExecutiveBoardMembersMember_hjnyCWqWaUG4U5M-ifsvcQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:LongTermIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cvac:ExecutiveBoardMembersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-09-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_9_1_2022_To_9_30_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ChiefDevelopmentOfficerMember_KVJTFke5SEudjsaztY_vxw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:LongTermIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cvac:ChiefDevelopmentOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-09-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_3_1_2022_To_3_1_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_KeyEmployeesMember_4k0biTJ1L0OjkLnTREDR-w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:LongTermIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cvac:KeyEmployeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-03-01</xbrli:startDate><xbrli:endDate>2022-03-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_5_31_2020_cvac_GovernmentGrantsAxis_cvac_CoalitionForEpidemicPreparednessInnovationsMember_V-hWugM7KEemNT5UugQPwQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cvac:GovernmentGrantsAxis">cvac:CoalitionForEpidemicPreparednessInnovationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_1_31_2020_cvac_GovernmentGrantsAxis_cvac_CoalitionForEpidemicPreparednessInnovationsMember_3sgz0BFjM0OjLj8LLFk2Lg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cvac:GovernmentGrantsAxis">cvac:CoalitionForEpidemicPreparednessInnovationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_9_30_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsResearchAndDevelopmentExpenseMember_u-Q9gJOBkUqQxOVDUX24Hw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cvac:IfrsIncomeStatementLocationAxis">cvac:IfrsResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_9_30_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsGeneralAndAdministrativeExpenseMember_KMYenp1F1EOV1PWLAQFrFw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cvac:IfrsIncomeStatementLocationAxis">cvac:IfrsGeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_9_30_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsCostOfSalesMember_em7QzpMx20e5-T4Zm2ygyA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cvac:IfrsIncomeStatementLocationAxis">cvac:IfrsCostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_9_30_2021_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsResearchAndDevelopmentExpenseMember_0xeLKyJYAEWBhUtu43GF8g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cvac:IfrsIncomeStatementLocationAxis">cvac:IfrsResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_9_30_2021_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsGeneralAndAdministrativeExpenseMember_pxlCrV2ySESTCd1lVbTlfg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cvac:IfrsIncomeStatementLocationAxis">cvac:IfrsGeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_9_30_2021_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsCostOfSalesMember__hz63wg8m0S72b0NYjaYHQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cvac:IfrsIncomeStatementLocationAxis">cvac:IfrsCostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2021_ifrs-full_BorrowingsByNameAxis_cvac_IfrsLineOfCreditMember_lKYOAuZEL0axHg8yeQcJvA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">cvac:IfrsLineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_8_1_2020_To_8_31_2020_ifrs-full_CategoriesOfRelatedPartiesAxis_cvac_DietmarHoppMember_4pr7l6FBv0Cr0BMx5sP5QQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">cvac:DietmarHoppMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-01</xbrli:startDate><xbrli:endDate>2020-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_9_1_2022_To_9_30_2022_cvac_IfrsSaleOfStockAxis_cvac_AtMarketOfferingProgramMember_aEeSD8tWhUqDkvbkYwvYZA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cvac:IfrsSaleOfStockAxis">cvac:AtMarketOfferingProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-09-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2022_To_9_30_2022_pgUlLsnMwE6GuzWOXk2lcg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_ifrs-full_BorrowingsByNameAxis_cvac_IfrsLineOfCreditMember_Zjc-vTBONUWK_U5c-7CI3w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">cvac:IfrsLineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2022_ifrs-full_ProductsAndServicesAxis_cvac_MilestoneRevenuesMember_f7JkTbic-Uq7GDa0pAVbjA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">cvac:MilestoneRevenuesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_7_1_2022_ifrs-full_BusinessCombinationsAxis_cvac_FramePharmaceuticalsB.v.AmsterdamNetherlandsMember_TNMnxy-chEOEtWGU9Rxf9g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">cvac:FramePharmaceuticalsB.v.AmsterdamNetherlandsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_9_30_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_VirtualSharesProgramIMember_8-6ss668qkGhxxIvnx3JTQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:VirtualSharesProgramIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_9_30_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_VirtualSharesProgramIiMember_94K0C2dKwEe87RAK5o3yHg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:VirtualSharesProgramIiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_9_30_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_RestrictedStockUnitForKeyEmployeesMember_dZiMEF-WIUaYDoS6prDgKg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:RestrictedStockUnitForKeyEmployeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_9_30_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_6VLzYOVR1k24GIHsNaoB2A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:LongTermIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_9_30_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_IfrsRestrictedStockUnitMember_XRKL4qJ810SYjrkXptDpGw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:IfrsRestrictedStockUnitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_9_30_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_VirtualSharesProgramIMember_G8wLGie1fkurrNt_KXss3A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:VirtualSharesProgramIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_9_30_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_VirtualSharesProgramIiMember_5phdNMZ4UUa7p62ZO4ZmiQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:VirtualSharesProgramIiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_9_30_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_-7vn4v2-bEuMIEE_cJjuug"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:LongTermIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_9_30_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_IfrsRestrictedStockUnitMember_QgoBjuQOZEO99XfLIWVoQA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:IfrsRestrictedStockUnitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_9_30_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ChiefScientificOfficerMember_UtQLqJhh8UiH4zCtHpD4cQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:LongTermIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cvac:ChiefScientificOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_9_30_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ChiefScientificOfficerMember_Zo3CrV1xc0-l6T3OrHnAhQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:LongTermIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cvac:ChiefScientificOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2022_To_6_30_2022_-gYjaV8XPUKBPSbaN9Qziw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_3_31_2022_LiqLyh4w5EGnOWf_FZQF7Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2022_ifrs-full_BusinessCombinationsAxis_cvac_FramePharmaceuticalsB.v.AmsterdamNetherlandsMember_vR0Bi5R7KE6kPw8J5q5NTA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">cvac:FramePharmaceuticalsB.v.AmsterdamNetherlandsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_9_30_2022_srt_CounterpartyNameAxis_cvac_GlaxosmithklineMember_3G2M3SARj0GkTuTa4M37uw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cvac:GlaxosmithklineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2022_kOEc9a1C10m7Rg-HheHYxg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2022_mqhJpd3F8U63gbp_M5KLaw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_kQVJTWPgRUeESxCd99xt9A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2021_ifrs-full_CategoriesOfRelatedPartiesAxis_cvac_ClarentisSrlMember_Dh91pVmxqEWDD100jMo2Fw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">cvac:ClarentisSrlMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_6_8_2022_To_6_8_2022_ifrs-full_BusinessCombinationsAxis_cvac_FramePharmaceuticalsB.v.AmsterdamNetherlandsMember_1GTamgfVRUOww3XIvpKP3Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">cvac:FramePharmaceuticalsB.v.AmsterdamNetherlandsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-08</xbrli:startDate><xbrli:endDate>2022-06-08</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_9_1_2021_To_9_30_2021_cvac_IfrsSaleOfStockAxis_cvac_AtMarketOfferingProgramMember_UsrXsTjj5kOO1bTEgPYDaA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cvac:IfrsSaleOfStockAxis">cvac:AtMarketOfferingProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-09-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_9_30_2021_5RS16WkLc0uS2ug_bqUm-g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_9_30_2022_ifrs-full_ProductsAndServicesAxis_cvac_MilestoneRevenuesMember_H4PqpAjQEkuxcZ00nka3Eg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">cvac:MilestoneRevenuesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2022_zuGVrjesE0WhwXSGmTqsgA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="Unit_Standard_Option_puBmss6yUE6NakwAOqqzng"><xbrli:measure>cvac:Option</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_tranche__TryzuW6jEmkCnTfvtVlrg"><xbrli:measure>cvac:tranche</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_loan_2Ze7UTdQEkiZKAdZ7o4zlw"><xbrli:measure>cvac:loan</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_CHF_BBNACBTv9k-Ei0YBwsfYBA"><xbrli:measure>iso4217:CHF</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Divide_USD_shares_B3tHpJm3a0ytZJRcE10tTA"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg"><xbrli:measure>iso4217:EUR</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_USD_q8NNp4TBfUC9XydcVDSrpA"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Divide_EUR_shares_6PEZCHC_WE2a7AmZW169oA"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:EUR</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="Unit_Standard_D_Pu_YZcQO3kKxgZxGvGVflA"><xbrli:measure>cvac:D</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_shares_FapG5E6UqkK42IfNNOS6tA"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_Milestone_1ZnSc2qU1UaZ09p9Mr6TGw"><xbrli:measure>cvac:Milestone</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_payment_4W6g8HbU0USZCbuxzWFKng"><xbrli:measure>cvac:payment</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_pure_NsGb2Z3yYka4EicmhvoaQQ"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_employee_-Jetz9Th0ka1WnOToYuqxw"><xbrli:measure>cvac:employee</xbrli:measure></xbrli:unit></ix:resources></ix:header></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;min-height:16.1pt;"><a id="_a3c3fc77_a1d8_4c0a_9429_b7c66ebe7228"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;padding-top:1pt;text-align:center;border-bottom:1px solid #000000;border-top:3.0pt solid #000000;margin:0pt;"><span style="font-size:1pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:4pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:14pt;font-weight:bold;">UNITED STATES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:14pt;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:14pt;font-weight:bold;">Washington, D.C. 20549</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:18pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">FORM </b><ix:nonNumeric contextRef="Duration_1_1_2022_To_9_30_2022_GrYkE3mhHEiRA4fxgfABRg" name="dei:DocumentType" id="Narr_aPaBNMg0nkuUx6vXQB9aZw"><b style="font-weight:bold;">6-K</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:14pt;font-weight:bold;">REPORT OF FOREIGN PRIVATE ISSUER</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:14pt;font-weight:bold;">PURSUANT TO RULE 13a-16 OR 15d-16 OF THE</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:14pt;font-weight:bold;">SECURITIES EXCHANGE ACT OF 1934</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:14pt;">For the month of November, 2022</span></p><div style="font-family:'Times New Roman','Times','serif';font-size:14.0pt;margin-bottom:6pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:14pt;font-weight:bold;">Commission File Number: 001-39446</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:24pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2022_To_9_30_2022_GrYkE3mhHEiRA4fxgfABRg" name="dei:EntityRegistrantName" id="Narr_KL7Q8vqBskCIUumvXQ6fRg"><b style="font-weight:bold;">CureVac N.V.</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(<i style="font-style:italic;">Exact Name of Registrant as Specified in Its Charter</i>)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Friedrich-Miescher-Strasse 15, 72076</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">T&#xFC;bingen, Germany</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">+49 7071 9883 0</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><i style="font-style:italic;">(Address of principal executive office)</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Indicate by check mark whether the registrant files or will file annual reports under cover of Form&#xA0;20-F or Form 40-F:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr><td style="vertical-align:top;width:28.12%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;">Form 20-F</p></td><td style="vertical-align:top;width:15.49%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Segoe UI Symbol';">&#x2612;</span></p></td><td style="vertical-align:top;width:14.83%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#xA0;</p></td><td style="vertical-align:top;width:27.69%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Form 40-F</p></td><td style="vertical-align:top;width:13.84%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 1pt 0pt;"><span style="font-family:'Segoe UI Symbol';">&#x2610;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation&#xA0;S-T&#xA0;Rule&#xA0;101(b)(1):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr><td style="vertical-align:top;width:28.99%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;">Yes</p></td><td style="vertical-align:top;width:14%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 1pt 0pt;"><span style="font-family:'Segoe UI Symbol';">&#x2610;</span></p></td><td style="vertical-align:top;width:15%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#xA0;</p></td><td style="vertical-align:top;width:27.99%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">No</p></td><td style="vertical-align:top;width:14%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Segoe UI Symbol';">&#x2612;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation&#xA0;S-T&#xA0;Rule&#xA0;101(b)(7):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr><td style="vertical-align:top;width:28.99%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;">Yes</p></td><td style="vertical-align:top;width:14%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 1pt 0pt;"><span style="font-family:'Segoe UI Symbol';">&#x2610;</span></p></td><td style="vertical-align:top;width:15%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:27.99%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">No</p></td><td style="vertical-align:top;width:14%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Segoe UI Symbol';">&#x2612;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;padding-top:1pt;border-bottom:3.0pt solid #000000;border-top:1px solid #000000;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-size:0pt;visibility:hidden;">&#x200B;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><a id="_c8c47c16_2cd2_47d3_8b13_2578cca0c07c"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">This Report of Foreign Private Issuer on Form 6-K (this &#x201C;Form 6-K&#x201D;) is being furnished by CureVac N.V. ("CureVac") to the Securities and Exchange Commission (the &#x201C;SEC&#x201D;) for the sole purposes of: (i) furnishing, as Exhibit 99.1 to this Form 6-K, Unaudited Interim Condensed Consolidated Financial Statements announcing CureVac&#x2019;s financial results and business updates as of September 30, 2022 and for the nine month periods ended September 30, 2022 and 2022; (ii) furnishing, as Exhibit 99.2 to this Form 6-K, Management&#x2019;s Discussion and Analysis of Financial Condition and Results of Operations, which discusses and analyzes CureVac's financial condition and results of operations as of September 30, 2022 and for the nine month periods ended September 30, 2022 and 2021; and (iii) furnishing, as Exhibit 99.3 to this Form 6-K, Material Tax Dutch Tax Considerations, which discusses and analyzes certain material Dutch tax consequences of the acquisition, holding and disposal of CureVac's common shares.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The information included in this Form 6-K (including Exhibits 99.1, 99.2 and 99.3) is hereby incorporated by reference into the Company&#x2019;s Registration Statement on Form F-3 (File No. 333-259613).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><a id="_1d775916_982f_43cc_acee_b3a1b69e19c8"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">SIGNATURES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td colspan="2" style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">CUREVAC N.V.</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:3.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:46.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:3.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:bottom;width:46.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Franz-Werner Haas, LLD, LLM</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:3.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:46.94%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">Chief Executive Officer</i></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:3.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:46.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:3.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:46.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date: November 17, 2022</p></td><td style="vertical-align:bottom;width:3.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:46.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><a id="_e02bdaf5_bf7d_4f08_978f_88db7d8ddf60"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">EXHIBIT INDEX</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:13.38%;border-bottom:1px solid #000000;margin:0pt;padding:0.25pt 0.25pt 1.25pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">EXHIBIT NO.</p></td><td style="vertical-align:bottom;width:2.16%;border-bottom:1px solid transparent;margin:0pt;padding:0.25pt 0.25pt 1.25pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#xA0;&#xA0;&#xA0;&#xA0;</p></td><td style="vertical-align:bottom;width:84.44%;border-bottom:1px solid #000000;margin:0pt;padding:0.25pt 0.25pt 1.25pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">DESCRIPTION</p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:13.38%;border-top:1px solid #000000;margin:0pt;padding:0pt 0.25pt 0.25pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">99.1</p></td><td style="vertical-align:bottom;width:2.16%;margin:0pt;padding:0pt 0.25pt 0.25pt 0.25pt;"></td><td style="vertical-align:top;width:84.44%;border-top:1px solid #000000;margin:0pt;padding:0pt 0.25pt 0.25pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="cvac-20220930xex99d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Unaudited Interim Condensed Consolidated Financial Statements as of September 30, 2022 and for the nine month periods ended September 30, 2022 and 2021</span></a></p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:13.38%;margin:0pt;padding:0pt 0.25pt 0.25pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">99.2</p></td><td style="vertical-align:bottom;width:2.16%;margin:0pt;padding:0pt 0.25pt 0.25pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:top;width:84.44%;margin:0pt;padding:0pt 0.25pt 0.25pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="cvac-20220930xex99d2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Management&#x2019;s Discussion and Analysis of Financial Condition and Results of Operations</span></a></p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:13.38%;margin:0pt;padding:0pt 0.25pt 0.25pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">99.3</p></td><td style="vertical-align:bottom;width:2.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.25pt 0.25pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:top;width:84.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.25pt 0.25pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="cvac-20220930xex99d3.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Material Dutch Tax Considerations</span></a></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border:0;"></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>cvac-20220930xex99d1.htm
<DESCRIPTION>EX-99.1
<TEXT>
<XBRL>
<?xml version='1.0' encoding='UTF-8'?>

      <!-- iXBRL document created with: Toppan Merrill Bridge iXBRL 10.1.0.3 -->
      <!-- Based on: iXBRL 1.1 -->
      <!-- Created on: 11/17/2022 10:28:05 PM -->
      <!-- iXBRL Library version: 1.0.8263.24741 -->
      <!-- iXBRL Service Job ID: 751cbc79-9c20-4614-afd6-fc8f8849f06f -->

  <html xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:country="http://xbrl.sec.gov/country/2021" xmlns:cvac="http://www.curevac.com/20220930" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2021" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns="http://www.w3.org/1999/xhtml" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ifrs-full="http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:xbrldi="http://xbrl.org/2006/xbrldi"><head><meta content="text/html" http-equiv="content-type" /><title></title></head><body><div style="margin-top:30pt;"></div><div style="display:none;"><ix:header><ix:hidden><ix:nonFraction unitRef="Unit_Divide_EUR_shares_6PEZCHC_WE2a7AmZW169oA" sign="-" contextRef="Duration_1_1_2021_To_9_30_2021_5RS16WkLc0uS2ug_bqUm-g" decimals="2" name="ifrs-full:DilutedEarningsLossPerShare" id="Hidden_kWSP08hTDU6JsTVRt-1jzQ">2.21</ix:nonFraction><ix:nonFraction unitRef="Unit_Divide_EUR_shares_6PEZCHC_WE2a7AmZW169oA" sign="-" contextRef="Duration_1_1_2022_To_9_30_2022_GrYkE3mhHEiRA4fxgfABRg" decimals="2" name="ifrs-full:DilutedEarningsLossPerShare" id="Hidden_twu7NAo320CgqR-UyIa6xg">0.64</ix:nonFraction><ix:nonNumeric contextRef="Duration_1_1_2022_To_9_30_2022_GrYkE3mhHEiRA4fxgfABRg" name="dei:DocumentPeriodEndDate" id="Tc_o1T0bdebT0eweikTxfjkHg_7_1">2022-09-30</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_9_30_2022_GrYkE3mhHEiRA4fxgfABRg" name="dei:CurrentFiscalYearEndDate" id="Tc_cScBRFFN_kGvmTzC9HmmgA_15_1">--12-31</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_9_30_2022_GrYkE3mhHEiRA4fxgfABRg" name="dei:DocumentFiscalYearFocus" id="Tc_UQeczTIQNUqcmShkx51M5Q_16_1">2022</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_9_30_2022_GrYkE3mhHEiRA4fxgfABRg" name="dei:DocumentFiscalPeriodFocus" id="Tc_W8aHH_3JSkq5TLzjZb8SRA_17_1">Q3</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_9_30_2022_GrYkE3mhHEiRA4fxgfABRg" name="dei:EntityCentralIndexKey" id="Tc_LCuFsyuofEyzuIqi0Sbx0g_18_1">0001809122</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_9_30_2022_GrYkE3mhHEiRA4fxgfABRg" name="dei:AmendmentFlag" id="Tc_48Ap74TDHEahBvHT-qiKKA_19_1">false</ix:nonNumeric><ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="Duration_1_1_2021_To_9_30_2021_5RS16WkLc0uS2ug_bqUm-g" decimals="0" name="ifrs-full:TransfersOutOfLevel2IntoLevel1OfFairValueHierarchyAssets" id="Hidden_PirsTzfz8ESBJFS11fCP4Q">0</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="Duration_1_1_2022_To_9_30_2022_GrYkE3mhHEiRA4fxgfABRg" decimals="0" name="ifrs-full:TransfersOutOfLevel2IntoLevel1OfFairValueHierarchyAssets" id="Hidden_Y0MxeO6rLke55_aaQkLudQ">0</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="Duration_1_1_2021_To_9_30_2021_5RS16WkLc0uS2ug_bqUm-g" decimals="0" name="ifrs-full:TransfersOutOfLevel1IntoLevel2OfFairValueHierarchyLiabilities" id="Hidden_NB6QjTXovEek5POe2TcmUw">0</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="Duration_1_1_2022_To_9_30_2022_GrYkE3mhHEiRA4fxgfABRg" decimals="0" name="ifrs-full:TransfersOutOfLevel1IntoLevel2OfFairValueHierarchyLiabilities" id="Hidden__9uyZNS6lUy8EqQIX9CSkA">0</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="Duration_1_1_2021_To_9_30_2021_5RS16WkLc0uS2ug_bqUm-g" decimals="0" name="ifrs-full:TransfersOutOfLevel2IntoLevel1OfFairValueHierarchyLiabilities" id="Hidden_L0hHurAojU2_aeVDDXvPGA">0</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="Duration_1_1_2022_To_9_30_2022_GrYkE3mhHEiRA4fxgfABRg" decimals="0" name="ifrs-full:TransfersOutOfLevel2IntoLevel1OfFairValueHierarchyLiabilities" id="Hidden_ZpZFbXExjEaiJpkfcLHZQA">0</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="Duration_1_1_2021_To_9_30_2021_5RS16WkLc0uS2ug_bqUm-g" decimals="0" name="ifrs-full:TransfersOutOfLevel3OfFairValueHierarchyAssets" id="Hidden_EyLKUnCsjkqE1Y0Lnu6uXA">0</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="Duration_1_1_2022_To_9_30_2022_GrYkE3mhHEiRA4fxgfABRg" decimals="0" name="ifrs-full:TransfersOutOfLevel3OfFairValueHierarchyAssets" id="Hidden_K-OSXKDmPk6iT1KXoy-UMg">0</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="Duration_1_1_2021_To_9_30_2021_5RS16WkLc0uS2ug_bqUm-g" decimals="0" name="ifrs-full:TransfersIntoLevel3OfFairValueHierarchyLiabilities" id="Hidden_ewhtEuFyckyIHby4z9-g5w">0</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="Duration_1_1_2022_To_9_30_2022_GrYkE3mhHEiRA4fxgfABRg" decimals="0" name="ifrs-full:TransfersIntoLevel3OfFairValueHierarchyLiabilities" id="Hidden_VR0Qmn3c5Ua04jYeohzSDQ">0</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="Duration_1_1_2021_To_9_30_2021_5RS16WkLc0uS2ug_bqUm-g" decimals="0" name="ifrs-full:TransfersOutOfLevel3OfFairValueHierarchyLiabilities" id="Hidden_q-UzAK_rjEmLkZUqgaZtvg">0</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="Duration_1_1_2022_To_9_30_2022_GrYkE3mhHEiRA4fxgfABRg" decimals="0" name="ifrs-full:TransfersOutOfLevel3OfFairValueHierarchyLiabilities" id="Hidden_mvSP4UQRrUi-6cT-ed3wjA">0</ix:nonFraction><ix:nonFraction unitRef="Unit_Divide_EUR_shares_6PEZCHC_WE2a7AmZW169oA" contextRef="As_Of_9_30_2022_ifrs-full_ClassesOfShareCapitalAxis_ifrs-full_OrdinarySharesMember_QerVWaOy8UeUozR8lPK5KA" decimals="2" name="ifrs-full:ParValuePerShare" id="Hidden_Pn4RGe75pUmEplb8tLMDGA">0.12</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_q8NNp4TBfUC9XydcVDSrpA" contextRef="Duration_9_1_2022_To_9_30_2022_UpNYd37lHEq8lbtMmcgfVg" decimals="-5" name="ifrs-full:ProceedsFromIssuingShares" id="Hidden_k6p5zM0iFEqRi29XSeuCWQ">32700000</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="Duration_1_1_2022_To_9_30_2022_srt_CounterpartyNameAxis_cvac_GlaxosmithklineMember_3G2M3SARj0GkTuTa4M37uw" decimals="-3" name="cvac:NetValueOfInventoryTransferred" id="Hidden_N17kRFMeX0inGpkHufA1CQ">98000</ix:nonFraction></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="cvac-20220930.xsd"></link:schemaRef></ix:references><ix:resources></ix:resources></ix:header></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;min-height:75.74pt;"><a id="_1d2250da_9691_48dd_a262_0cc62f2083ed"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 50pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">Exhibit 99.1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><img src="cvac-20220930xex99d1001.jpg" alt="Graphic" style="display:inline-block;height:75.74pt;left:0%;padding-bottom:0pt;position:relative;top:0pt;width:217.47pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 50pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 17pt 0pt;"><b style="font-size:17pt;font-weight:bold;letter-spacing:-0.3pt;">CureVac N.V.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:17pt;font-weight:bold;letter-spacing:-0.2pt;">Unaudited Interim Condensed Consolidated Financial</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 30pt 0pt;"><b style="font-size:17pt;font-weight:bold;letter-spacing:-0.2pt;">Statements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;letter-spacing:-0.2pt;">As of September 30, 2022 and December 31, 2021</b><b style="font-weight:bold;"><br /></b><b style="font-weight:bold;letter-spacing:-0.2pt;">and for the nine months ended</b><b style="font-weight:bold;letter-spacing:-0.2pt;"><br /></b><b style="font-weight:bold;">September 30, 2022 and 2021</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:18pt;margin:0pt;"><span style="font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#x200B;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><span style="font-size:0pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><a id="_74b60fdf_697c_4192_9cd3_cbb2e52ae3c4"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">CureVac N.V.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Interim Condensed Consolidated Statements of Operations and</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Other Comprehensive Income (Loss)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><a id="_da8fe3b7_3ba5_4de4_a879_147f3c3a2419"></a><a id="Tc_rp2AjGL4HUqqywjwxQ6Yjg_1_4"></a><a id="Tc_ne3Eq-EHlUuXHw-5AaEcCw_2_2"></a><a id="Tc_JIxdBx7VuU2xe7ZyWWhW_w_2_4"></a><a id="Tc_pM3XjQw2CkCvQv0jpPL0Tg_2_6"></a><a id="Tc_IjZXh1jarky5T0Ia1Q1Cvw_3_0"></a><a id="Tc_GPvsHTHY0UCw7HGY9E345A_3_4"></a><a id="Tc_DvN5RoPjEESuBZmUIuCInQ_4_0"></a><a id="Tc_I31kpD9EDE2SiheTZOhDLQ_4_2"></a><a id="Tc_1clzTPsc2USHvCagMLruqA_5_0"></a><a id="Tc_NVbyS5s5Kk6VuoKh21AQBg_5_2"></a><a id="Tc_7BMagDqEcEmSLs-9ygp3-g_6_0"></a><a id="Tc_nIxS7wZK60O1zdZMqfN5CA_6_2"></a><a id="Tc_CgbGUm5OaU6cDNP5kjVgGA_7_0"></a><a id="Tc_D2lh-cIWv0u4XwX42_xmXg_7_2"></a><a id="Tc_j1ue93_x-kGQXrtzASJlmA_8_0"></a><a id="Tc_5Ny4GFA9kkKD_yVgywMr4w_8_2"></a><a id="Tc_mNY0pmuCGU63wO5vQZM-5w_9_0"></a><a id="Tc_3mhGvNJ8fUizdKhnct8Q4Q_9_2"></a><a id="Tc_IlG0pRDbl02Aazx9YRvE_A_10_0"></a><a id="Tc_99DTaPZ7cEGeb2eMWkcxtw_11_0"></a><a id="Tc_LRCfQGxQEEiIy4eJDv_niA_12_0"></a><a id="Tc_sY59Sujz2Ue9Ip_3DXwjEw_13_0"></a><a id="Tc_oPZXi8OcPkmAa6hC7JQ9Zg_14_0"></a><a id="Tc_bhT9y5EsJ02EMF4QnHmMvA_15_0"></a><a id="Tc_HflcrE5UhEmzFMfXXhAzeA_15_2"></a><a id="Tc_Sz865yHFiU2cP4qEjjGiPg_16_0"></a><a id="Tc_ReJ5FA9JV020JgoirI0vRw_17_0"></a><a id="Tc_f10e1gt1yUidwGwhtJDP4A_18_0"></a><a id="Tc_h2xJlMMOZkWXwlPCIvKTCQ_19_0"></a><a id="Tc_NK-al9GkSkyyZkz206L_Rw_20_0"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:69.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:69.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#xA0;&#xA0;&#xA0;&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#xA0;&#xA0;&#xA0;&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Nine months ended&#xA0;September 30,</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:69.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#xA0;&#xA0;&#xA0;&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Note</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#xA0;&#xA0;&#xA0;&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#xA0;&#xA0;&#xA0;&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="7" style="padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:69.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">(in thousands of EUR, except per share amounts)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(unaudited)</b></p></td></tr><tr><td style="vertical-align:bottom;width:69.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"> 3.1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="Duration_1_1_2021_To_9_30_2021_5RS16WkLc0uS2ug_bqUm-g" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:RevenueFromContractsWithCustomers" scale="3" id="Tc_zEucKwwuTkeaoX2hZL_fyg_4_4">61,765</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="Duration_1_1_2022_To_9_30_2022_GrYkE3mhHEiRA4fxgfABRg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:RevenueFromContractsWithCustomers" scale="3" id="Tc_lirxWGJcA0WQkRaIH2ZHDw_4_6">55,731</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cost of sales</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"> 3.2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="Duration_1_1_2021_To_9_30_2021_5RS16WkLc0uS2ug_bqUm-g" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:CostOfSales" scale="3" id="Tc_lbi_AEVjhU-kQfUqAvaG9w_5_4">168,177</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="Duration_1_1_2022_To_9_30_2022_GrYkE3mhHEiRA4fxgfABRg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:CostOfSales" scale="3" id="Tc_w69vXYpafEeKRfIvohcDag_5_6">103,992</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:69.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Selling and distribution expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"> 3.3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="Duration_1_1_2021_To_9_30_2021_5RS16WkLc0uS2ug_bqUm-g" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:SalesAndMarketingExpense" scale="3" id="Tc_1gHjva0ySEqfHUx2ESiTDQ_6_4">1,232</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="Duration_1_1_2022_To_9_30_2022_GrYkE3mhHEiRA4fxgfABRg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:SalesAndMarketingExpense" scale="3" id="Tc_cngfnt35AUmlSXSGthgpPQ_6_6">1,825</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:69.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Research and development expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"> 3.4</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="Duration_1_1_2021_To_9_30_2021_5RS16WkLc0uS2ug_bqUm-g" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ResearchAndDevelopmentExpense" scale="3" id="Tc_8EDBJ5uJc0mYdR6OJe47RA_7_4">284,728</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="Duration_1_1_2022_To_9_30_2022_GrYkE3mhHEiRA4fxgfABRg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ResearchAndDevelopmentExpense" scale="3" id="Tc_tbNRuXkVi02QCplsMbeHjQ_7_6">34,934</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:69.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">General and administrative expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"> 3.5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="Duration_1_1_2021_To_9_30_2021_5RS16WkLc0uS2ug_bqUm-g" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:GeneralAndAdministrativeExpense" scale="3" id="Tc_z5MD4GWdUkCGi1iAbPY-Sw_8_4">80,787</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="Duration_1_1_2022_To_9_30_2022_GrYkE3mhHEiRA4fxgfABRg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:GeneralAndAdministrativeExpense" scale="3" id="Tc_P7VuikDyn0mI0ZRT652k2Q_8_6">78,019</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:69.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other operating income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"> 3.6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="Duration_1_1_2021_To_9_30_2021_5RS16WkLc0uS2ug_bqUm-g" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:MiscellaneousOtherOperatingIncome" scale="3" id="Tc_VMK2QGOb5EudnmdDwGs99Q_9_4">66,746</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="Duration_1_1_2022_To_9_30_2022_GrYkE3mhHEiRA4fxgfABRg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:MiscellaneousOtherOperatingIncome" scale="3" id="Tc_ySiD8AYzBU6zf8o0DzRWCw_9_6">35,901</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other operating expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="Duration_1_1_2021_To_9_30_2021_5RS16WkLc0uS2ug_bqUm-g" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:MiscellaneousOtherOperatingExpense" scale="3" id="Tc_Bz5E8XFj1EGe8LvULFlOlQ_10_4">339</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="Duration_1_1_2022_To_9_30_2022_GrYkE3mhHEiRA4fxgfABRg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:MiscellaneousOtherOperatingExpense" scale="3" id="Tc_XOIon8PBq0i8NTbo5BJuzw_10_6">809</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:69.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Operating loss</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#xA0;&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="Duration_1_1_2021_To_9_30_2021_5RS16WkLc0uS2ug_bqUm-g" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ProfitLossFromOperatingActivities" sign="-" scale="3" id="Tc_wFFBe3qptUm_7DDrEZWMew_11_4">406,752</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="Duration_1_1_2022_To_9_30_2022_GrYkE3mhHEiRA4fxgfABRg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ProfitLossFromOperatingActivities" sign="-" scale="3" id="Tc_N81gR9dvAU6VAUOLLhjf6g_11_6">127,947</ix:nonFraction>)</b></p></td></tr><tr><td style="vertical-align:bottom;width:69.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Finance income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#xA0;&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="Duration_1_1_2021_To_9_30_2021_5RS16WkLc0uS2ug_bqUm-g" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:FinanceIncome" scale="3" id="Tc_NlnHcSvWT0iJf4C0Bxqonw_12_4">8,828</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="Duration_1_1_2022_To_9_30_2022_GrYkE3mhHEiRA4fxgfABRg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:FinanceIncome" scale="3" id="Tc_RlYIqtPn_k-AtEDmWaVoxA_12_6">10,619</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Finance expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#xA0;&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="Duration_1_1_2021_To_9_30_2021_5RS16WkLc0uS2ug_bqUm-g" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:FinanceCosts" scale="3" id="Tc_d6eJzyS6T0G28RbaN70A9w_13_4">10,015</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="Duration_1_1_2022_To_9_30_2022_GrYkE3mhHEiRA4fxgfABRg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:FinanceCosts" scale="3" id="Tc_8pro4nvUYUu5BHHOKLTrEQ_13_6">3,077</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:69.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Loss before income tax</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#xA0;&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="Duration_1_1_2021_To_9_30_2021_5RS16WkLc0uS2ug_bqUm-g" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ProfitLossBeforeTax" sign="-" scale="3" id="Tc_fkYjIjHNzk2LPkCdr7uWWA_14_4">407,939</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="Duration_1_1_2022_To_9_30_2022_GrYkE3mhHEiRA4fxgfABRg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ProfitLossBeforeTax" sign="-" scale="3" id="Tc_zWeAI9CBF0-21blUqnUsZA_14_6">120,405</ix:nonFraction>)</b></p></td></tr><tr><td style="vertical-align:bottom;width:69.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Income tax benefit/ (expense)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"> 14</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="Duration_1_1_2021_To_9_30_2021_5RS16WkLc0uS2ug_bqUm-g" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:IncomeTaxExpenseContinuingOperations" scale="3" id="Tc_6NSyBwj550afS1cYQ2M50Q_15_4">1,841</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="Duration_1_1_2022_To_9_30_2022_GrYkE3mhHEiRA4fxgfABRg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:IncomeTaxExpenseContinuingOperations" sign="-" scale="3" id="Tc_jiP94FJDzUyy_h8BDKRmLQ_15_6">160</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Net loss for the period</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">&#xA0;&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="Duration_1_1_2021_To_9_30_2021_5RS16WkLc0uS2ug_bqUm-g" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ProfitLoss" sign="-" scale="3" id="Tc_N4Eq-J2yH02U_EmR75Ubog_16_4">409,780</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="Duration_1_1_2022_To_9_30_2022_GrYkE3mhHEiRA4fxgfABRg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ProfitLoss" sign="-" scale="3" id="Tc_lU8AuZcKX0O9EMjHZ5Brog_16_6">120,245</ix:nonFraction>)</b></p></td></tr><tr><td style="vertical-align:bottom;width:69.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Other comprehensive income (loss):</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#xA0;&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Foreign currency adjustments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#xA0;&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="Duration_1_1_2021_To_9_30_2021_5RS16WkLc0uS2ug_bqUm-g" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" sign="-" scale="3" id="Tc_eA2QhpDb-k6r0lhKA2V6mg_18_4">62</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="Duration_1_1_2022_To_9_30_2022_GrYkE3mhHEiRA4fxgfABRg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" sign="-" scale="3" id="Tc_-vKk2GvvvEqxDCxu31v6DA_18_6">364</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:69.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total comprehensive loss for the period</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">&#xA0;&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="Duration_1_1_2021_To_9_30_2021_5RS16WkLc0uS2ug_bqUm-g" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ComprehensiveIncome" sign="-" scale="3" id="Tc_l5CLrlYJCUC5LU3SLO3ROg_19_4">409,842</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="Duration_1_1_2022_To_9_30_2022_GrYkE3mhHEiRA4fxgfABRg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ComprehensiveIncome" sign="-" scale="3" id="Tc_ulFJczOVXEmAfaIj9rlc_g_19_6">120,609</ix:nonFraction>)</b></p></td></tr><tr><td style="vertical-align:bottom;width:69.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Net loss per share (basic and diluted)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">&#xA0;&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Divide_EUR_shares_6PEZCHC_WE2a7AmZW169oA" contextRef="Duration_1_1_2021_To_9_30_2021_5RS16WkLc0uS2ug_bqUm-g" decimals="2" format="ixt:numdotdecimal" name="ifrs-full:BasicEarningsLossPerShare" sign="-" scale="0" id="Tc_LgUmce25pEyXmxciNFKT_g_20_4">2.21</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Divide_EUR_shares_6PEZCHC_WE2a7AmZW169oA" contextRef="Duration_1_1_2022_To_9_30_2022_GrYkE3mhHEiRA4fxgfABRg" decimals="2" format="ixt:numdotdecimal" name="ifrs-full:BasicEarningsLossPerShare" sign="-" scale="0" id="Tc_cEvCl_LFkkCHeeSHcPjdiA_20_6">0.64</ix:nonFraction>)</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><a id="_7b8871bd_1cf1_437a_9175_e98c0d581fbd"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">CureVac N.V.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Interim Condensed Consolidated Statements of Financial Position</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><a id="_6e74aabb_0b12_4803_9703_0900f19ee9c2"></a><a id="Tc_fR9uxc9yGk-U3qx5qUZNRw_1_4"></a><a id="Tc_4QlPT3RdG02oDP1tvgAG5w_1_6"></a><a id="Tc_AORV7MMaoEe77P1_aGDsgw_2_2"></a><a id="Tc_VU3S7ifcLUiwnc2a2he40w_2_4"></a><a id="Tc__pzMqTCydU2bhcnEfSw_sQ_2_6"></a><a id="Tc_yo1ZMe-IC0GRhtsQ9OT6Xg_3_0"></a><a id="Tc_MoLrDqYszUijRz7Nix9Dow_3_6"></a><a id="Tc_KhQeuek2x027aMxeCgMqSw_4_0"></a><a id="Tc_i7RpbpKP40-r_ixttfNzGQ_5_0"></a><a id="Tc_XKCCz4-s4EKl1ywnaYv3xQ_6_0"></a><a id="Tc_YmA53yAZ706eOKC1r7pyRw_6_2"></a><a id="Tc_V7Hvy2QxwE6w079oAuZ_zg_7_0"></a><a id="Tc_hqSXV_hbGEuYhoOcBG_ukQ_7_2"></a><a id="Tc_JsQ5PsSpbUeSMK6_zLXC3Q_8_0"></a><a id="Tc_ETjoc7TZ-0i5wXYD8g_O0w_9_0"></a><a id="Tc_NbxHEUqY8k6LQA6qKi0r_Q_10_0"></a><a id="Tc_gQePlMamf0S65pSF9AwUZg_10_2"></a><a id="Tc_vimdo6_N_0qhqEn2USy1FA_11_0"></a><a id="Tc_STTj6KxD1kmfoQrmI6bwsA_12_0"></a><a id="Tc_LxwfYiP3BE6RsW3py6scDw_13_0"></a><a id="Tc_ITqb8IhsoEO70veXx7iTJQ_13_2"></a><a id="Tc_4RCy0lHRO0GD6I6as8PDAw_13_4"></a><a id="Tc_iWtMGjmeK0-GA2u2Gjg4Ew_14_0"></a><a id="Tc_bj_eAqKY8EuTfVnTEAFakQ_14_2"></a><a id="Tc_kHYFxmDbHUeVGmjh7P3oxQ_15_0"></a><a id="Tc_nY2AMx5y1kG4sQs_KxM3hg_15_2"></a><a id="Tc_faGD4mEW5EObIHikACPuHg_16_0"></a><a id="Tc_q7pcLt19ZkKD8Btm6bVL8g_16_2"></a><a id="Tc_23EVbupqrk6v06UKR6Wc2A_17_0"></a><a id="Tc_YPV9SFWZtEWMFvEw--20dA_17_2"></a><a id="Tc_BXBges0X-0iRbGP64dtOLQ_18_0"></a><a id="Tc_TmxaUQOXokKkJaA7qorDjg_18_2"></a><a id="Tc_o_iFOU9z6USnzJZG1e_aXw_19_0"></a><a id="Tc_l5XhKlURK06AgB2WJ71CUg_20_0"></a><a id="Tc_2mOG7nUQ00qwZCKtePdACg_21_0"></a><a id="Tc_gSDingPVX0uOBmUrT114sw_22_0"></a><a id="Tc_Y6kVD75bbk-sNjPpkh7nLQ_22_2"></a><a id="Tc_wmhiB2QRsUyFh0BiDVw91w_23_0"></a><a id="Tc_4cwmFZIfZUaOtyPhuev2Cg_24_0"></a><a id="Tc_zNyqqJIbAEGgJk7ggJW1Fg_25_0"></a><a id="Tc_yL9LqMDickOvPbI10MZrXQ_26_0"></a><a id="Tc_n2mC6XSgo0aqrOP4nROhmA_27_0"></a><a id="Tc_1oISmGtWpEKQ0tIbD7aZ-A_28_0"></a><a id="Tc_zF4MT8H0bUOfDYyWCgJBjA_29_0"></a><a id="Tc_2FBZidn6CkCnMvyYiDToAw_30_0"></a><a id="Tc_sRMMczSTC0C6cklNmaQwGQ_31_0"></a><a id="Tc_LbNI4OwWI0aHsaznxdTeUg_31_2"></a><a id="Tc_vIEFCODK00-s34y-44_VEw_32_0"></a><a id="Tc_RrZbZr3fdkOOtVG6a9QiJw_33_0"></a><a id="Tc_OQDe9A1UgUyeqS0RqDdBVQ_34_0"></a><a id="Tc_2LwFhE2E4EyGHJ_3xay_WQ_35_0"></a><a id="Tc_G8YJZ9ZQzEu6feqvjjx5VA_36_0"></a><a id="Tc_tPBY_iOtfEmzdP3QpULYpA_36_2"></a><a id="Tc_Ze-fLAP-HUmB9iV1KPfWLg_37_0"></a><a id="Tc_nbOZWHvxAkKkxI4aZRg4QA_37_2"></a><a id="Tc_lWKrsJ2Nl0ewMvPI8RzzLQ_38_0"></a><a id="Tc_omPPA3gICEmLo1PwkrI-4A_38_2"></a><a id="Tc_pRllUVt_JkyJgBpxCwumHw_39_0"></a><a id="Tc_Xj5QwmFKJ0aPQzWSikTj2Q_39_2"></a><a id="Tc_huRCnjaE1EGXtjRak6htLQ_40_0"></a><a id="Tc_JEBHTozf4k-znnXkTzOBWw_41_0"></a><a id="Tc_F4JQTky-TkCML3OY2gDqzg_42_0"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:70.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:70.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#xA0;&#xA0;&#xA0;&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September 30, </b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:70.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#xA0;&#xA0;&#xA0;&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Note</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#xA0;&#xA0;&#xA0;&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#xA0;&#xA0;&#xA0;&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(in thousands of EUR)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(unaudited)</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#xA0;&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#xA0;&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Non-current assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#xA0;&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Intangible assets and goodwill</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"> 6.1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="As_Of_12_31_2021_kQVJTWPgRUeESxCd99xt9A" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:IntangibleAssetsAndGoodwill" scale="3" id="Tc_DNBEX5giv0y97C9_B6pQbA_6_4">13,238</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="As_Of_9_30_2022_zuGVrjesE0WhwXSGmTqsgA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:IntangibleAssetsAndGoodwill" scale="3" id="Tc_iRcTv7ooRUuVao76JMzG8A_6_6">33,775</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Property, plant and equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"> 6.2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="As_Of_12_31_2021_kQVJTWPgRUeESxCd99xt9A" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:PropertyPlantAndEquipment" scale="3" id="Tc_LuAXDuP8Rk20tLFanKGdXg_7_4">168,264</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="As_Of_9_30_2022_zuGVrjesE0WhwXSGmTqsgA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:PropertyPlantAndEquipment" scale="3" id="Tc_Esz_mKCwhkG-pNcsnsNKsg_7_6">207,660</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Right-of-use assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="As_Of_12_31_2021_kQVJTWPgRUeESxCd99xt9A" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:RightofuseAssets" scale="3" id="Tc_P6fz3A2kKUCeRddMjQC6vQ_8_4">32,129</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="As_Of_9_30_2022_zuGVrjesE0WhwXSGmTqsgA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:RightofuseAssets" scale="3" id="Tc_3E9az2w910O0mksSFbl-cg_8_6">43,801</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Other assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="As_Of_12_31_2021_kQVJTWPgRUeESxCd99xt9A" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:OtherNoncurrentAssets" scale="3" id="Tc_RyVHNud7zES9EprS23XFhA_9_4">1,731</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="As_Of_9_30_2022_zuGVrjesE0WhwXSGmTqsgA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:OtherNoncurrentAssets" scale="3" id="Tc_Fqy3SPG3jU2y1miZKRyoAg_9_6">1,688</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Deferred tax assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"> 14</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="As_Of_12_31_2021_kQVJTWPgRUeESxCd99xt9A" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:NetDeferredTaxAssets" scale="3" id="Tc_CxMCXJVP4kiULx_VsjiOCg_10_4">2,861</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="As_Of_9_30_2022_zuGVrjesE0WhwXSGmTqsgA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:NetDeferredTaxAssets" scale="3" id="Tc_mgV65iXqm02k5Kx03eyVAQ_10_6">1,306</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total non-current assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="As_Of_12_31_2021_kQVJTWPgRUeESxCd99xt9A" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:NoncurrentAssets" scale="3" id="Tc_fKXBMsnQp0Gois5AnH-9ug_11_4">218,223</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="As_Of_9_30_2022_zuGVrjesE0WhwXSGmTqsgA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:NoncurrentAssets" scale="3" id="Tc_7Jf1lnexw0-QdXsvOgLztA_11_6">288,230</ix:nonFraction></b></p></td></tr><tr><td style="vertical-align:bottom;width:70.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Current assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Assets held for sale</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"> 7</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#x2014;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="As_Of_9_30_2022_zuGVrjesE0WhwXSGmTqsgA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners" scale="3" id="Tc_VBxpl3RS_kqpcyebnSgN_A_13_6">3,828</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Inventories</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"> 8</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="As_Of_12_31_2021_kQVJTWPgRUeESxCd99xt9A" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:Inventories" scale="3" id="Tc_l4twpXISc06qEw3I4F9VPQ_14_4">56,159</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="As_Of_9_30_2022_zuGVrjesE0WhwXSGmTqsgA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:Inventories" scale="3" id="Tc_6ka9Tltje0yY_VT_gLKETQ_14_6">7,868</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Trade receivables</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"> 3.1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="As_Of_12_31_2021_kQVJTWPgRUeESxCd99xt9A" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:CurrentTradeReceivables" scale="3" id="Tc_w6R-sfgDgkKUM7V84F5wGw_15_4">18,504</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="As_Of_9_30_2022_zuGVrjesE0WhwXSGmTqsgA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:CurrentTradeReceivables" scale="3" id="Tc_IwXbelnYFEmF0q0iTbrt6g_15_6">6,170</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Other financial assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">10</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="As_Of_12_31_2021_kQVJTWPgRUeESxCd99xt9A" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:OtherCurrentFinancialAssets" scale="3" id="Tc_4WmOt9OVD0Ct_FklS647Rw_16_4">4,648</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="As_Of_9_30_2022_zuGVrjesE0WhwXSGmTqsgA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:OtherCurrentFinancialAssets" scale="3" id="Tc_Yo5ZvW9RsUuFWPPmd7DaoQ_16_6">2,599</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Prepaid expenses and other assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"> 9</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="As_Of_12_31_2021_kQVJTWPgRUeESxCd99xt9A" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:CurrentPrepaymentsAndOtherCurrentAssets" scale="3" id="Tc_O7sc30e0_kuC1uXPJu8Nnw_17_4">49,244</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="As_Of_9_30_2022_zuGVrjesE0WhwXSGmTqsgA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:CurrentPrepaymentsAndOtherCurrentAssets" scale="3" id="Tc_amyaa4AvkE6kSJWwUhaBrQ_17_6">60,952</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">10</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="As_Of_12_31_2021_kQVJTWPgRUeESxCd99xt9A" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:CashAndCashEquivalents" scale="3" id="Tc_VfzBnGLZikCZKTmRrwrH-w_18_4">811,464</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="As_Of_9_30_2022_zuGVrjesE0WhwXSGmTqsgA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:CashAndCashEquivalents" scale="3" id="Tc_kS5alvNdrUugoB4z7sD_EA_18_6">540,865</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total current assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="As_Of_12_31_2021_kQVJTWPgRUeESxCd99xt9A" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:CurrentAssets" scale="3" id="Tc_hD9tUh_zQUmHpNCK5vCUnQ_19_4">940,019</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="As_Of_9_30_2022_zuGVrjesE0WhwXSGmTqsgA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:CurrentAssets" scale="3" id="Tc_k9n_0YMW1EW358CkE4z6wg_19_6">622,282</ix:nonFraction></b></p></td></tr><tr><td style="vertical-align:bottom;width:70.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="As_Of_12_31_2021_kQVJTWPgRUeESxCd99xt9A" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:Assets" scale="3" id="Tc_L2qWrASfNk2c_ekiHF1X3w_20_4">1,158,242</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="As_Of_9_30_2022_zuGVrjesE0WhwXSGmTqsgA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:Assets" scale="3" id="Tc_TZcny92APEWk57FRKY0rrA_20_6">910,512</ix:nonFraction></b></p></td></tr><tr><td style="vertical-align:bottom;width:70.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Equity and liabilities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Equity</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"> 4</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Issued capital</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="As_Of_12_31_2021_kQVJTWPgRUeESxCd99xt9A" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:IssuedCapital" scale="3" id="Tc_UkDDuIayF0q_lXBpzGXVAQ_23_4">22,454</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="As_Of_9_30_2022_zuGVrjesE0WhwXSGmTqsgA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:IssuedCapital" scale="3" id="Tc_JL3uLD9YXUWaxfbxFrF1pA_23_6">22,834</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Capital reserve</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="As_Of_12_31_2021_kQVJTWPgRUeESxCd99xt9A" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:CapitalReserve" scale="3" id="Tc_A_8nIeHw0EihqGB4hmIVLw_24_4">1,728,658</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="As_Of_9_30_2022_zuGVrjesE0WhwXSGmTqsgA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:CapitalReserve" scale="3" id="Tc_EQLj9_T9W0ut_QHMRoRBoQ_24_6">1,781,316</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Treasury Shares</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="As_Of_12_31_2021_kQVJTWPgRUeESxCd99xt9A" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:TreasuryShares" scale="3" id="Tc_pWITyAyvykOT1D27946-0Q_25_4">5,817</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="As_Of_9_30_2022_zuGVrjesE0WhwXSGmTqsgA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:TreasuryShares" scale="3" id="Tc_iPO8J_uqpke0PaOWNbxttQ_25_6">1,734</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:70.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Accumulated deficit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="As_Of_12_31_2021_kQVJTWPgRUeESxCd99xt9A" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:RetainedEarnings" sign="-" scale="3" id="Tc_1C_-OsvD7kStAfFuZj2E6Q_26_4">1,056,785</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="As_Of_9_30_2022_zuGVrjesE0WhwXSGmTqsgA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:RetainedEarnings" sign="-" scale="3" id="Tc_nePppeejgkCR38f4UM2Bpg_26_6">1,177,030</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:70.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Other comprehensive income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="As_Of_12_31_2021_kQVJTWPgRUeESxCd99xt9A" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:AccumulatedOtherComprehensiveIncome" sign="-" scale="3" id="Tc_WE9CK-jZa0mCyIUDyJs_cQ_27_4">34</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="As_Of_9_30_2022_zuGVrjesE0WhwXSGmTqsgA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:AccumulatedOtherComprehensiveIncome" sign="-" scale="3" id="Tc_SYMi5bAhE0ujZxuXArOgYA_27_6">398</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:70.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total equity</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="As_Of_12_31_2021_kQVJTWPgRUeESxCd99xt9A" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:Equity" scale="3" id="Tc_fchTP3crrUaM5oMdHPn8Jg_28_4">688,476</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="As_Of_9_30_2022_zuGVrjesE0WhwXSGmTqsgA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:Equity" scale="3" id="Tc_xqsQxGCsC0uGl0jpHzIpBQ_28_6">624,988</ix:nonFraction></b></p></td></tr><tr><td style="vertical-align:bottom;width:70.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Non-current liabilities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="As_Of_12_31_2021_kQVJTWPgRUeESxCd99xt9A" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:NoncurrentLeaseLiabilities" scale="3" id="Tc_yGIgEZym9kCYDQPaiCiu2A_30_4">25,423</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="As_Of_9_30_2022_zuGVrjesE0WhwXSGmTqsgA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:NoncurrentLeaseLiabilities" scale="3" id="Tc__UM_2tMBXEOBBb0cJ_OunQ_30_6">36,609</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Contract liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"> 3.1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="As_Of_12_31_2021_kQVJTWPgRUeESxCd99xt9A" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:NoncurrentContractLiabilities" scale="3" id="Tc_a6HwNXFwcUuGR-fQf60E_A_31_4">86,345</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="As_Of_9_30_2022_zuGVrjesE0WhwXSGmTqsgA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:NoncurrentContractLiabilities" scale="3" id="Tc_pj4tWOfockWszn0UCpc6OA_31_6">76,279</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Other liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="As_Of_12_31_2021_kQVJTWPgRUeESxCd99xt9A" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:OtherNoncurrentLiabilities" scale="3" id="Tc_pHVRBbqZcEe_2aK8T7_Pqg_32_4">264</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="As_Of_9_30_2022_zuGVrjesE0WhwXSGmTqsgA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:OtherNoncurrentLiabilities" scale="3" id="Tc_2j5VScEcOUS60pD73SUusQ_32_6">284</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total non-current liabilities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="As_Of_12_31_2021_kQVJTWPgRUeESxCd99xt9A" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:NoncurrentLiabilities" scale="3" id="Tc_7SeJQVyZBUmHyA19cPqVlQ_33_4">112,032</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="As_Of_9_30_2022_zuGVrjesE0WhwXSGmTqsgA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:NoncurrentLiabilities" scale="3" id="Tc_ROxKG3X0FEaC3L5hyD-hLQ_33_6">113,172</ix:nonFraction></b></p></td></tr><tr><td style="vertical-align:bottom;width:70.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Current liabilities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="As_Of_12_31_2021_kQVJTWPgRUeESxCd99xt9A" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:CurrentLeaseLiabilities" scale="3" id="Tc_0Xv_P0kmmEm5967L41ITLg_35_4">3,469</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="As_Of_9_30_2022_zuGVrjesE0WhwXSGmTqsgA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:CurrentLeaseLiabilities" scale="3" id="Tc_wD99Opfxukiege2di5Od8A_35_6">4,652</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Trade and other payables</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"> 11</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="As_Of_12_31_2021_kQVJTWPgRUeESxCd99xt9A" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:TradeAndOtherCurrentPayables" scale="3" id="Tc_s6EZjOd_B02QHovJ1w7AtQ_36_4">127,703</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="As_Of_9_30_2022_zuGVrjesE0WhwXSGmTqsgA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:TradeAndOtherCurrentPayables" scale="3" id="Tc_XZfGo9lfBUWm3hAL1hXCMg_36_6">52,608</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Other liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"> 12</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="As_Of_12_31_2021_kQVJTWPgRUeESxCd99xt9A" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:OtherCurrentLiabilities" scale="3" id="Tc_dwvtAfXy4kunnlz3yDzOqA_37_4">170,073</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="As_Of_9_30_2022_zuGVrjesE0WhwXSGmTqsgA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:OtherCurrentLiabilities" scale="3" id="Tc_QBfczfDQMkiMVEz0MXSXJA_37_6">78,967</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Income taxes payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"> 14</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="As_Of_12_31_2021_kQVJTWPgRUeESxCd99xt9A" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:CurrentTaxLiabilities" scale="3" id="Tc_AsuGALuNIUaIQhoGA65Q7A_38_4">739</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="As_Of_9_30_2022_zuGVrjesE0WhwXSGmTqsgA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:CurrentTaxLiabilities" scale="3" id="Tc_Wph6xEbkIkOQnpeWgkK-cA_38_6">587</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Contract liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"> 3.1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="As_Of_12_31_2021_kQVJTWPgRUeESxCd99xt9A" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:CurrentContractLiabilities" scale="3" id="Tc_k8Dcg1aQZkGbymrbr1aQIA_39_4">55,750</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="As_Of_9_30_2022_zuGVrjesE0WhwXSGmTqsgA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:CurrentContractLiabilities" scale="3" id="Tc_uxA-bgfwUU2gVKILzMl5DQ_39_6">35,538</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total current liabilities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="As_Of_12_31_2021_kQVJTWPgRUeESxCd99xt9A" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:CurrentLiabilities" scale="3" id="Tc_Mqm9sF9V2k2YVeAasvGQeQ_40_4">357,734</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="As_Of_9_30_2022_zuGVrjesE0WhwXSGmTqsgA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:CurrentLiabilities" scale="3" id="Tc_5BItdrDRIkuYDYgORZJp_A_40_6">172,352</ix:nonFraction></b></p></td></tr><tr><td style="vertical-align:bottom;width:70.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total liabilities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="As_Of_12_31_2021_kQVJTWPgRUeESxCd99xt9A" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:Liabilities" scale="3" id="Tc_5pS90K-OV0qvh03gjMRjkg_41_4">469,766</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="As_Of_9_30_2022_zuGVrjesE0WhwXSGmTqsgA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:Liabilities" scale="3" id="Tc_r6hNMsx9B0SBj87ZLWhPNg_41_6">285,524</ix:nonFraction></b></p></td></tr><tr><td style="vertical-align:bottom;width:70.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total equity and liabilities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="As_Of_12_31_2021_kQVJTWPgRUeESxCd99xt9A" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:EquityAndLiabilities" scale="3" id="Tc_T9A-nA1AbEi62f7NFalQIQ_42_4">1,158,242</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="As_Of_9_30_2022_zuGVrjesE0WhwXSGmTqsgA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:EquityAndLiabilities" scale="3" id="Tc_lX-ZMBAxeEuJKqanicf3RA_42_6">910,512</ix:nonFraction></b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#x200B;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#x200B;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><a id="_e1b65fe7_758a_46be_8ba5_23f6e11b3d81"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">CureVac N.V.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Interim Condensed Consolidated Statements of Changes in Shareholders&#x2019; Equity </b><b style="font-weight:bold;"><br /></b><b style="font-weight:bold;">for the nine months ended September 30, 2022 and 2021</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><a id="_8affb9f5_7a37_4d0e_97bd_0bd3dcd38810"></a><a id="Tc_kHuhYtEqb0K5NXzmQ-z1Gw_1_10"></a><a id="Tc_BaDkjgb-H0y2gblM7pcGUg_2_2"></a><a id="Tc_T1sUn3B7h0q_D9yEqak-fA_2_4"></a><a id="Tc_mp-ypemc9U2SJGISJrGLyA_2_6"></a><a id="Tc_oM8aGeA2P0WRGXPHjFqWHQ_2_8"></a><a id="Tc_v6nuXezRPUGq5GuMXPzS2A_2_10"></a><a id="Tc_W1d1_aXByUGdXFPOidxYYQ_2_12"></a><a id="Tc_KMQBEUNgYkCoVPcyMeZCmA_3_0"></a><a id="Tc_EYbOXgv0TkC4jTvsn2ujvw_3_2"></a><a id="Tc_Ifu7GNeUdU2Tc5N73E1KCw_3_4"></a><a id="Tc_97wv1jbFdEa4S15n-5WDJg_3_6"></a><a id="Tc_npg-V-vK60KW7wp2xt_kjw_3_8"></a><a id="Tc_TyUIK3EQbkuaiy5FMvbSRA_3_10"></a><a id="Tc_pK7iqIPZDUqrl9qBLERRJg_3_12"></a><a id="Tc_n-_G7-29bUaMtkksbYfz9A_4_0"></a><a id="Tc_0KWS27xmXUGNpb11ba22iA_4_6"></a><a id="Tc_8pu416KRM0KbfV6_MpH07A_5_0"></a><a id="Tc_G4MjMtrTJkyTVQjuGgcEIw_5_2"></a><a id="Tc_waCMVIONhk6Z2VSfp_fW5w_5_4"></a><a id="Tc_8cbE1qq_qkK4QoBEPghveQ_5_6"></a><a id="Tc_xRPbRyq2h02M6dvFrZLtxQ_5_10"></a><a id="Tc_CMt1wbTsIkyfZhZbqQKCHw_6_0"></a><a id="Tc_amjid3q4pUmE_cSdbTDzxA_6_2"></a><a id="Tc_GF17X6gV8U2y1CeAbNsQEQ_6_4"></a><a id="Tc_iGPdJcb8x06PFsaMVOpeHA_6_6"></a><a id="Tc_6xWQqrN5-Em1DW2ypD3L9Q_6_8"></a><a id="Tc_eSSKBL6WvU254NobcjGWeg_7_0"></a><a id="Tc_CA0frNqm8USDKMY4ci14kQ_7_2"></a><a id="Tc_X1A5U1sz30ybOxlLCWa-6A_7_4"></a><a id="Tc_I10y0YnOckeYXlmCyrX0xA_7_6"></a><a id="Tc_gJtohhLEXE-JoZKcMVKYvQ_8_0"></a><a id="Tc_WcGMTIlGdUmH_vCG24w8EQ_8_2"></a><a id="Tc_m8t3I7mCBUWFmXKO63YwFA_8_6"></a><a id="Tc_eSBpVhiDWEe_jZmCbGJzEQ_8_8"></a><a id="Tc_xVXUAzGG0kChnGMmFyBOTw_8_10"></a><a id="Tc_fNSlnCu-sEK-q5fYA5INVQ_9_0"></a><a id="Tc_kaDFE8r8SUCOo62ffNNVTg_9_6"></a><a id="Tc_WGejPTLnCkOOWu_XOoZ1TA_9_8"></a><a id="Tc_b4NPH2DxqkC0-HHkZVY2Sw_9_10"></a><a id="Tc_uQJ6Sf67tE25KQGMd_g4NA_10_0"></a><a id="Tc_zJgLd3E0dE-0stHw_4vdoQ_10_6"></a><a id="Tc_L5F6WWdPv02T6Mhfbz6Oaw_10_8"></a><a id="Tc_XUkBpiAdekORaDbEEdCgVg_10_10"></a><a id="Tc_PI-5DjPPNkaLvmx5uuUfIQ_11_0"></a><a id="Tc_6uvPEGacI0ubMB-an9xtUw_11_2"></a><a id="Tc_fK1azvGLFEiOQXmDwNz-Lg_11_8"></a><a id="Tc_IDoqbvd810SiR70kpRuyxQ_11_10"></a><a id="Tc_PL7kcajDWU-UzLdg-ZUIuw_12_0"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:46.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:46.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#xA0;&#xA0;&#xA0;&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#xA0;&#xA0;&#xA0;&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#xA0;&#xA0;&#xA0;&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#xA0;&#xA0;&#xA0;&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#xA0;&#xA0;&#xA0;&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Currency</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#xA0;&#xA0;&#xA0;&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:46.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Issued&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Capital&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Treasury</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Accumulated&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">translation</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:46.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">(in thousands of EUR)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">capital</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">reserve</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">deficit</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">reserve</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#xA0;equity</b></p></td></tr><tr><td style="vertical-align:bottom;width:46.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Balance as of January 1, 2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="As_Of_12_31_2020_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_ZWlHBf5sd0u18E_i-Im1zQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:Equity" scale="3" id="Tc_I-Hjzpm6nkO5qRtZa3-3fQ_4_2">21,655</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="As_Of_12_31_2020_ifrs-full_ComponentsOfEquityAxis_ifrs-full_CapitalReserveMember_VibTw9zPlkmYxEg1Vcd6Nw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:Equity" scale="3" id="Tc_YqkhWmm9K0W-m9ua453ETQ_4_4">1,334,704</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.85%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> &#x2014;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="As_Of_12_31_2020_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember_ZhVYR0CYCU-n8fXSTddhVA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:Equity" sign="-" scale="3" id="Tc_G3nf4innJkiS4ITV-Zh-3A_4_8">645,069</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.91%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="As_Of_12_31_2020_ifrs-full_ComponentsOfEquityAxis_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_4SMzjwIAMEaHB7TnvYKL-g" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:Equity" scale="3" id="Tc_mn4dicwwZk-fHMHWWeqN6w_4_10">57</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="As_Of_12_31_2020_gDhEGYRPKEaVXa-xMDWqsw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:Equity" scale="3" id="Tc_V1YzF3qFO0Wn1RUa_alIcg_4_12">711,347</ix:nonFraction></b></p></td></tr><tr><td style="vertical-align:bottom;width:46.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#x2014;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#x2014;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#x2014;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="Duration_1_1_2021_To_9_30_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember_dCKGn2XnRk6SRLx6s50FAw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ProfitLoss" sign="-" scale="3" id="Tc_AWh8TyTevE-QCCZ9gyKLQg_5_8">409,780</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#x2014;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="Duration_1_1_2021_To_9_30_2021_5RS16WkLc0uS2ug_bqUm-g" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ProfitLoss" sign="-" scale="3" id="Tc_FMymM68EkkaJzdy_Xboohg_5_12">409,780</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:46.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other comprehensive income (loss)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#x2014;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#x2014;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.85%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#x2014;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#x2014;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="Duration_1_1_2021_To_9_30_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_N1rU63L0z0CKfWKFMPE8ug" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:OtherComprehensiveIncome" sign="-" scale="3" id="Tc_5O42z2Yzd0iZ6Yp-meUp9w_6_10">62</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="Duration_1_1_2021_To_9_30_2021_5RS16WkLc0uS2ug_bqUm-g" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:OtherComprehensiveIncome" sign="-" scale="3" id="Tc_7gJ_xY80nU685EUoQxxjUw_6_12">62</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:46.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total comprehensive income (loss)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> &#x2014;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> &#x2014;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> &#x2014;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="Duration_1_1_2021_To_9_30_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember_dCKGn2XnRk6SRLx6s50FAw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ComprehensiveIncome" sign="-" scale="3" id="Tc_FoNTPkmX7EipxdPsvy56LQ_7_8">409,780</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="Duration_1_1_2021_To_9_30_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_N1rU63L0z0CKfWKFMPE8ug" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ComprehensiveIncome" sign="-" scale="3" id="Tc_YrEIjXGv2EKZW3x2ieF34w_7_10">62</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="Duration_1_1_2021_To_9_30_2021_5RS16WkLc0uS2ug_bqUm-g" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ComprehensiveIncome" sign="-" scale="3" id="Tc_-7IzO7p2dU-w8R9QQcsjtQ_7_12">409,842</ix:nonFraction>)</b></p></td></tr><tr><td style="vertical-align:bottom;width:46.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Share-based payments (net of taxes)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#x2014;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="Duration_1_1_2021_To_9_30_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_CapitalReserveMember_cVl-lTMdZ0SyIz4MzbLhUA" decimals="3" format="ixt:numdotdecimal" name="cvac:ShareBasedPaymentExpenseIncl.DeferredTaxes" scale="3" id="Tc_qAEaYzp7xUypMUr2jlxjFA_8_4">12,965</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#x2014;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#x2014;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#x2014;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="Duration_1_1_2021_To_9_30_2021_5RS16WkLc0uS2ug_bqUm-g" decimals="-3" format="ixt:numdotdecimal" name="cvac:ShareBasedPaymentExpenseIncl.DeferredTaxes" scale="3" id="Tc_b_APNKUWk0etC5j7wyuUlA_8_12">12,965</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:46.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Issuance of share capital (net of transaction costs)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="Duration_1_1_2021_To_9_30_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_H-Nfcg0EfkKBQso-1E13qw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:IssueOfEquity" scale="3" id="Tc_GoovFcUcaE6WMfaSl_FGkA_9_2">690</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="Duration_1_1_2021_To_9_30_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_CapitalReserveMember_cVl-lTMdZ0SyIz4MzbLhUA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:IssueOfEquity" scale="3" id="Tc_a8mTJiu6Y0K8RdqiL37QQw_9_4">403,372</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#x2014;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#x2014;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#x2014;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="Duration_1_1_2021_To_9_30_2021_5RS16WkLc0uS2ug_bqUm-g" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:IssueOfEquity" scale="3" id="Tc_1QlJEouhHUa8Laj2qLRwVA_9_12">404,062</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:46.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Exercise of options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="Duration_1_1_2021_To_9_30_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_H-Nfcg0EfkKBQso-1E13qw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:IncreaseDecreaseThroughExerciseOfOptions" scale="3" id="Tc_yN7CNqsDc0S2BtBNjyrG9A_10_2">101</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="Duration_1_1_2021_To_9_30_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_CapitalReserveMember_cVl-lTMdZ0SyIz4MzbLhUA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:IncreaseDecreaseThroughExerciseOfOptions" scale="3" id="Tc_aL-qvJpKfU-EP0cx3kujFg_10_4">2,422</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#x2014;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#x2014;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#x2014;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="Duration_1_1_2021_To_9_30_2021_5RS16WkLc0uS2ug_bqUm-g" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:IncreaseDecreaseThroughExerciseOfOptions" scale="3" id="Tc_fAkHbh1Ta0ePhjT8PFvOVA_10_12">2,523</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:46.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Repurchase of common shares </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#x2014;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="Duration_1_1_2021_To_9_30_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_CapitalReserveMember_cVl-lTMdZ0SyIz4MzbLhUA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:IncreaseDecreaseThroughTreasuryShareTransactions" sign="-" scale="3" id="Tc_GpCt6S8dFkCttoUiyUifCA_11_4">25,550</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="Duration_1_1_2021_To_9_30_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_TreasurySharesMember_kiA0yBP5YEWvkTpVKfGscg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:IncreaseDecreaseThroughTreasuryShareTransactions" sign="-" scale="3" id="Tc_VU0GXhwIrUapt2Tqt9LiYg_11_6">211</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#x2014;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#x2014;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="Duration_1_1_2021_To_9_30_2021_5RS16WkLc0uS2ug_bqUm-g" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:IncreaseDecreaseThroughTreasuryShareTransactions" sign="-" scale="3" id="Tc_V0jVWNpIc0KtH3o_VPsSaQ_11_12">25,761</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:46.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Balance as of September 30, 2021 (unaudited)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="As_Of_9_30_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_25XvQwjzSUOoEVBaH6bxAA" decimals="3" format="ixt:numdotdecimal" name="ifrs-full:Equity" scale="3" id="Tc_luszhGJq6UaQhrzW5d6ZdQ_12_2">22,446</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="As_Of_9_30_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_CapitalReserveMember_uETolOLN8EO7z8AXUFUrdg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:Equity" scale="3" id="Tc_uP_nfr9yxEeYnoDQIXYKmw_12_4">1,727,913</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.85%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="As_Of_9_30_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_TreasurySharesMember_1xV3xniJzEa6h2UaD4ZV8A" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:Equity" sign="-" scale="3" id="Tc_-qGlGog0B0SquzOXFzEkSw_12_6">211</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="As_Of_9_30_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember_S8HeFlbOnEmNPym3RRCQYQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:Equity" sign="-" scale="3" id="Tc_SE9QIG3pkUagD2w21XHwRw_12_8">1,054,849</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.91%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="As_Of_9_30_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_A7iYghLG40G30BtbFyy3Fw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:Equity" sign="-" scale="3" id="Tc_rOsuE9zt_0SRo4gf5Q1-Ow_12_10">5</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="As_Of_9_30_2021_wVcf5oroJEG4KeEdh1LnEw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:Equity" scale="3" id="Tc_RTuiTatZ90GUOBBhxiLlEQ_12_12">695,294</ix:nonFraction></b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#x200B;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><a id="_53791026_d2a8_485c_af8f_0dafa30aee62"></a><a id="Tc_PPsla7RleE69sXukWJjw1g_1_10"></a><a id="Tc_6UOsFmLjN0q8BygHuAOFGA_2_2"></a><a id="Tc_LqWuZhgis0qeFXiEwh13Tw_2_4"></a><a id="Tc_BYoJwDpBqkO75A2OnKk_IQ_2_6"></a><a id="Tc_-R6EEgBExUGMkMtFWs8sKw_2_8"></a><a id="Tc_M88xGEWvFE2NB_Q6tk0Www_2_10"></a><a id="Tc_0ujHq8FwnUaFSboiJkwp7A_2_12"></a><a id="Tc_A2zYScYT5U-KqOk5n7e0YQ_3_0"></a><a id="Tc_EfjL_h-D-UeEpa6rvh-Y0A_3_2"></a><a id="Tc_HBg8pHFr50Sy3tLoedd3iQ_3_4"></a><a id="Tc_8-ww0DAnFUGqaBaHEyHwPw_3_6"></a><a id="Tc_yAhzmMgDrUWRpl6s8KmBJw_3_8"></a><a id="Tc_oSMgLdqye0y2cwnEznY7Yw_3_10"></a><a id="Tc_SUGSCpjW2kKyQS7s0Mvhkw_3_12"></a><a id="Tc_CPwAAWbRSkqP5VG6TXJ41g_4_0"></a><a id="Tc_3AezfgEw3UaJbAwlC4ZVLQ_5_0"></a><a id="Tc_xu71GUaxy0S_V6ctJdQ7uw_5_2"></a><a id="Tc_tYKBPJaKmECB_EBZodKKxQ_5_4"></a><a id="Tc_hGgG8rPjr0-s_41crw3PZQ_5_6"></a><a id="Tc_037aCCvDnkuxom7iWCpPPQ_5_10"></a><a id="Tc_Lw_NL7R-pEGODKctduY3ZQ_6_0"></a><a id="Tc_yOeRN682R0uz6OECBMmtvA_6_2"></a><a id="Tc_LhmDc8WK9k268d9GFBiIhA_6_4"></a><a id="Tc_U5O7zxFJY0qvJPlBb91Mlw_6_6"></a><a id="Tc_eJyCj2OWP0iMiuum9G4K8w_6_8"></a><a id="Tc_WqZB3S4-SEuCvSnx-1Fqgg_7_0"></a><a id="Tc_WTU5g-dNik2yNJLvzhhi1A_7_2"></a><a id="Tc_kTgLNaMv2kOMkiGD7glMug_7_4"></a><a id="Tc_a4CPvyIidkm-6sH9UhDZsQ_7_6"></a><a id="Tc_j8Fe9QwaAk6lUjzyv6Oogg_8_0"></a><a id="Tc_TTE3dOwj1USeodsaiddU-w_8_2"></a><a id="Tc_WPmDEJWtkEeAHd13dT-Mvg_8_6"></a><a id="Tc_lJHbT7Wva0OqJgW2wiCJ1w_8_8"></a><a id="Tc_Dq4Zs5ZigU2gDfyw3SWUKQ_8_10"></a><a id="Tc_tm01ntG-EkuPIt-WTwjSmg_9_0"></a><a id="Tc_phIIRfvP_E-Fz6D1CnYKGA_10_0"></a><a id="Tc_xLNV7n-PKUSY23zBoNLCFw_11_0"></a><a id="Tc_Ftx09h46JEeGYC9TjvwmRg_11_6"></a><a id="Tc_iZa3ZoUV10uRljd_kfkrVA_11_8"></a><a id="Tc_LdPb97u9jU-hfpPh25l-jA_11_10"></a><a id="Tc_O-X3cBZdFEa1YscA98LAOA_12_0"></a><a id="Tc_0ZOvOGeHVEabJf3iyZeMyQ_12_2"></a><a id="Tc_va9dG_tYnUikusocuz7UNg_12_8"></a><a id="Tc_l4Zst2y6e0SIoIkdJARtnQ_12_10"></a><a id="Tc_tMzUAuqllUqHBlki4QM3gg_13_0"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:46.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:46.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#xA0;&#xA0;&#xA0;&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#xA0;&#xA0;&#xA0;&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#xA0;&#xA0;&#xA0;&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#xA0;&#xA0;&#xA0;&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#xA0;&#xA0;&#xA0;&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Currency&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#xA0;&#xA0;&#xA0;&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:46.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Issued&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Capital&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Treasury</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Accumulated&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">translation&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:46.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">(in thousands of EUR)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">capital</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">reserve</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">deficit</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">reserve</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#xA0;equity</b></p></td></tr><tr><td style="vertical-align:bottom;width:46.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Balance as of January 1, 2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="As_Of_12_31_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_spYNfmXLlkKn0qRrA7DHrQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:Equity" scale="3" id="Tc_Nv_exT6awEeYItzkz8Sw7Q_4_2">22,454</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="As_Of_12_31_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_CapitalReserveMember_hKeYNzP2pkyRPXTqS3GOeg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:Equity" scale="3" id="Tc_ulE_scn0FE2c1-qDH8A2wA_4_4">1,728,658</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="As_Of_12_31_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_TreasurySharesMember_LnSXiw4SC0GJbguDola8gw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:Equity" sign="-" scale="3" id="Tc_ge7wi2owX0qWjMwOjMUAgA_4_6">5,817</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="As_Of_12_31_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember_obI4hBRbIk6bCNEX25ONyQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:Equity" sign="-" scale="3" id="Tc_tiMYDjfacEqYtEbEP_wfNg_4_8">1,056,785</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="As_Of_12_31_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_0fN-yvhfRke2bER127GqTw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:Equity" sign="-" scale="3" id="Tc_-FbwxWp2SUWI2eySPAySmQ_4_10">34</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="As_Of_12_31_2021_kQVJTWPgRUeESxCd99xt9A" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:Equity" scale="3" id="Tc_HmS22zenmEWjtY1hSlUjpw_4_12">688,476</ix:nonFraction></b></p></td></tr><tr><td style="vertical-align:bottom;width:46.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#x2014;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#x2014;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#x2014;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="Duration_1_1_2022_To_9_30_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember_LBd2SxQlf0unc-mzWThKow" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ProfitLoss" sign="-" scale="3" id="Tc_6bcm7RdWzE2uvXTnRW_2mA_5_8">120,245</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#x2014;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="Duration_1_1_2022_To_9_30_2022_GrYkE3mhHEiRA4fxgfABRg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ProfitLoss" sign="-" scale="3" id="Tc_3mcy3rhEi0Ka5_Rx5DdGnw_5_12">120,245</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:46.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other comprehensive income (loss)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#x2014;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#x2014;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#x2014;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#x2014;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="Duration_1_1_2022_To_9_30_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_pqJl73EEck6icL9CscAZ9w" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:OtherComprehensiveIncome" sign="-" scale="3" id="Tc_B9h4zoGrq0CgJItWKL9exg_6_10">364</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="Duration_1_1_2022_To_9_30_2022_GrYkE3mhHEiRA4fxgfABRg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:OtherComprehensiveIncome" sign="-" scale="3" id="Tc_28PpIX_Pf0-48Tz6klqz1A_6_12">364</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:46.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total comprehensive income (loss)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> &#x2014;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> &#x2014;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> &#x2014;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="Duration_1_1_2022_To_9_30_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember_LBd2SxQlf0unc-mzWThKow" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ComprehensiveIncome" sign="-" scale="3" id="Tc_YqTZJ2QfOUmSQu6UeOzA3A_7_8">120,245</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="Duration_1_1_2022_To_9_30_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_pqJl73EEck6icL9CscAZ9w" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ComprehensiveIncome" sign="-" scale="3" id="Tc_JWS_PhearUqv9sRqv0e9Zw_7_10">364</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="Duration_1_1_2022_To_9_30_2022_GrYkE3mhHEiRA4fxgfABRg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ComprehensiveIncome" sign="-" scale="3" id="Tc_3HhFk_ed00OV6VWTboheZw_7_12">120,609</ix:nonFraction>)</b></p></td></tr><tr><td style="vertical-align:bottom;width:46.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Share-based payments (net of taxes)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#x2014;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="Duration_1_1_2022_To_9_30_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_CapitalReserveMember_g_0bQScme0WTxJwAia-iSA" decimals="-3" format="ixt:numdotdecimal" name="cvac:ShareBasedPaymentExpenseIncl.DeferredTaxes" scale="3" id="Tc_r4al29UrIU6jB5RcT__-pg_8_4">5,372</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#x2014;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#x2014;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#x2014;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="Duration_1_1_2022_To_9_30_2022_GrYkE3mhHEiRA4fxgfABRg" decimals="-3" format="ixt:numdotdecimal" name="cvac:ShareBasedPaymentExpenseIncl.DeferredTaxes" scale="3" id="Tc_x-zXvNdChUW8kKBl5IeFTg_8_12">5,372</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:46.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Issuance of share capital (net of transaction costs)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="Duration_1_1_2022_To_9_30_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_jUcA_4Uo70GmthvPRsVfbA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:IssueOfEquity" scale="3" id="Tc_4rARNl1ZHkCZ_CTozndVzg_9_2">378</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="Duration_1_1_2022_To_9_30_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_CapitalReserveMember_g_0bQScme0WTxJwAia-iSA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:IssueOfEquity" scale="3" id="Tc_sg__P3Tk70663ygrdv0LmA_9_4">31,948</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="Duration_1_1_2022_To_9_30_2022_GrYkE3mhHEiRA4fxgfABRg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:IssueOfEquity" scale="3" id="Tc_lsXtPqDS50acQrIyG6FQmw_9_12">32,326</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:46.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Capital Increase from Business Combinations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="Duration_1_1_2022_To_9_30_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_CapitalReserveMember_g_0bQScme0WTxJwAia-iSA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:IncreaseDecreaseThroughAcquisitionOfSubsidiary" scale="3" id="Tc_ogm0HiYWEk-gr3G6FaJHCQ_10_4">18,789</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="Duration_1_1_2022_To_9_30_2022_GrYkE3mhHEiRA4fxgfABRg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:IncreaseDecreaseThroughAcquisitionOfSubsidiary" scale="3" id="Tc_oWS6MDw-BUuuENtPKn57wA_10_12">18,789</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:46.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Exercise of options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="Duration_1_1_2022_To_9_30_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_jUcA_4Uo70GmthvPRsVfbA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:IncreaseDecreaseThroughExerciseOfOptions" scale="3" id="Tc_aLqXj2sd2kmpGdZI1nR5FA_11_2">2</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="Duration_1_1_2022_To_9_30_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_CapitalReserveMember_g_0bQScme0WTxJwAia-iSA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:IncreaseDecreaseThroughExerciseOfOptions" sign="-" scale="3" id="Tc_PzqnNmbczkqF364CX8lADQ_11_4">358</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#x2014;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#x2014;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#x2014;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="Duration_1_1_2022_To_9_30_2022_GrYkE3mhHEiRA4fxgfABRg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:IncreaseDecreaseThroughExerciseOfOptions" sign="-" scale="3" id="Tc_QhaJaVcwO0iagnU2MnQikw_11_12">356</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:46.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Settlement of share-based payment awards</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#x2014;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="Duration_1_1_2022_To_9_30_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_CapitalReserveMember_g_0bQScme0WTxJwAia-iSA" decimals="-3" format="ixt:numdotdecimal" name="cvac:SettlementOfShareBasedPaymentAwardsAmount" sign="-" scale="3" id="Tc_rkop_K6BqUWnuDY-merR4g_12_4">3,093</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="Duration_1_1_2022_To_9_30_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_TreasurySharesMember_hUbz0huuf0-lvXUrSj2p7w" decimals="-3" format="ixt:numdotdecimal" name="cvac:SettlementOfShareBasedPaymentAwardsAmount" scale="3" id="Tc_1bAki70g30SGyh-wPtjkzA_12_6">4,083</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#x2014;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#x2014;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="Duration_1_1_2022_To_9_30_2022_GrYkE3mhHEiRA4fxgfABRg" decimals="-3" format="ixt:numdotdecimal" name="cvac:SettlementOfShareBasedPaymentAwardsAmount" scale="3" id="Tc_-pUG72WJhUOwMu3BubrE1g_12_12">990</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:46.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Balance as of September 30, 2022 (unaudited)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="As_Of_9_30_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_6KA0EJhWSE603b7Uov1rMg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:Equity" scale="3" id="Tc_olDy6br2dEO5puNXtj-hvg_13_2">22,834</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="As_Of_9_30_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_CapitalReserveMember_DnDn5AHz-0-rleJrp9WdNg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:Equity" scale="3" id="Tc_RstJN_y07ESe0MbqIC2p8A_13_4">1,781,316</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="As_Of_9_30_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_TreasurySharesMember_QUC-XwhKoEK4nQE0wgA-OA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:Equity" sign="-" scale="3" id="Tc_UWFngXgLGUaUYRapbOuYxQ_13_6">1,734</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="As_Of_9_30_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember_hG_33slvv0iz_A0sabMEBA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:Equity" sign="-" scale="3" id="Tc_KEuAs4WVlEyw3VkpJGBHtg_13_8">1,177,030</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="As_Of_9_30_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_pOxIHb_0lkKnDUS8JXZwmg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:Equity" sign="-" scale="3" id="Tc_1JofZsH1vkiw6ZWnypGw9Q_13_10">398</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="As_Of_9_30_2022_zuGVrjesE0WhwXSGmTqsgA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:Equity" scale="3" id="Tc_jWvnpH_jYkCFaGavX4lAfA_13_12">624,988</ix:nonFraction></b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#x200B;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><span style="font-size:1pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#x200B;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#x200B;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><a id="_59715005_54b0_4593_aa65_2d0ed8ac01b3"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">CureVac N.V.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Interim Condensed Consolidated Statements of Cash Flows</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><span style="font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#x200B;</span></p><a id="_c0e2a4b1_ab2f_4c85_b08c_3a239209dafc"></a><a id="Tc_pjvOyJv5xEmlU8Y4qILWMQ_1_2"></a><a id="Tc_mUO1c8V04kyhd5sU1z9W_Q_2_2"></a><a id="Tc_xIbHJQliE0-8aW99UAZUWQ_2_4"></a><a id="Tc_SZ1NoHAYr0u1WOcrbrMxig_3_0"></a><a id="Tc_qa79a-OAREqcsVEQXwPUJQ_3_2"></a><a id="Tc_pCwXVSgZlkWv18PA1tFb2Q_4_0"></a><a id="Tc_PIWVQMALfk2WwLwt0ydNIw_5_0"></a><a id="Tc_srgcyxhyNE-PBvfCR0fCDw_6_0"></a><a id="Tc_u2e6a9GKJUOdY2MSmpqxwQ_7_0"></a><a id="Tc_NAOj6Pg-CUeSOD2YXsv4aA_8_0"></a><a id="Tc_kj5uLHH-fkKBum494Lhsgg_9_0"></a><a id="Tc_jZWXl8at3kKK4aWhP8RYsg_10_0"></a><a id="Tc_0n1fIPpL1Eq8X0ArecL-mg_10_2"></a><a id="Tc_M1XMxGbwsEyTLGR5vilcQw_11_0"></a><a id="Tc_JFhV5VV8wU64Iy1FQGg_Ig_12_0"></a><a id="Tc_os3YKWgT80KC3KZkJWSOrQ_13_0"></a><a id="Tc_YfWKaXbX1EKlaLJ4F9Cr5A_13_2"></a><a id="Tc_IO6fR25PhUivzYewbp7yUQ_15_0"></a><a id="Tc_BhNoUHEKHkSfNfNMeHvkLQ_16_0"></a><a id="Tc_O20YIgw7OkCw8jelycV4kg_17_0"></a><a id="Tc_sCyoJz1iYUO83qzAePq-QA_18_0"></a><a id="Tc_w6IFaQ0CkU679C-Ec0CxOg_19_0"></a><a id="Tc_9KTCNjCipk2GOatMQRBKHg_19_4"></a><a id="Tc_TtwW-79yHUalcB_6VqOtAA_20_0"></a><a id="Tc_DDpUK6h380ewEeKtnF7iLQ_21_0"></a><a id="Tc_i9SwalB_1EGAoBxoe1LHOg_21_4"></a><a id="Tc_R6QSppWNEkecN2dkg4-eCA_22_0"></a><a id="Tc_8ylPo82WJUylZxXItmv82w_23_0"></a><a id="Tc_NNq9U1OEF0iCXELFOr4-pA_24_0"></a><a id="Tc_G80whQyjUkOjmybqCuLWnQ_24_4"></a><a id="Tc_7yunpVgda0G0f0B1w6FSig_25_0"></a><a id="Tc_Kmey5ptIDkqBEhD0rTfCig_26_0"></a><a id="Tc_nc34S38FQE2hTNWCZX7fcw_28_0"></a><a id="Tc_fixpPsJSa0yS7droDFaOuw_29_0"></a><a id="Tc_X2x7wLncBUSZrGTWShVpow_30_0"></a><a id="Tc_u3sQ3piAYUWU0O1W39AtmQ_31_0"></a><a id="Tc_3mDuo1uj_0CrJu8mQQfdYg_33_0"></a><a id="Tc_cPiC4hvQFkmOYaRyaZJlJg_34_0"></a><a id="Tc_MdnNe1_5WU-AZY6kctYygw_35_0"></a><a id="Tc_Kh8mMvrTf0CPKXPei7Azow_36_0"></a><a id="Tc_Tf3W18wDeEyCCbm0IiSbCg_36_2"></a><a id="Tc_BlglNFGfC02fTHcZB34pTw_37_0"></a><a id="Tc_bnhLfv_c7kq_UXbnWKftPA_37_2"></a><a id="Tc_55oGypSUIEuw0F3zVf5_CQ_38_0"></a><a id="Tc_jPc8Ujp6dkeLpC2x4rVLDA_38_4"></a><a id="Tc_QcKBQ6PW0k-L5Pzq9B0srw_39_0"></a><a id="Tc_69XaH9Owd0ueWWxjTdzuqw_40_0"></a><a id="Tc_40kI-JL-WEeVu1kbP8Phug_41_0"></a><a id="Tc_3XaIAadEO0uqeToeme2RXQ_42_0"></a><a id="Tc_0EWTE7NYN0eYO5uAfLySgg_43_0"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:71.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:71.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#xA0;&#xA0;&#xA0;&#xA0;</b></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:26.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">For the nine months ended September 30,</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:71.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#xA0;&#xA0;&#xA0;&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#xA0;&#xA0;&#xA0;&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="5" style="padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:71.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">(in thousands of EUR)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:26.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(unaudited)</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Operating activities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Loss before income tax</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="Duration_1_1_2021_To_9_30_2021_5RS16WkLc0uS2ug_bqUm-g" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ProfitLossBeforeTax" sign="-" scale="3" id="Tc_Z_GszAbqSE2i4jnyrBW1gg_5_2">407,939</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="Duration_1_1_2022_To_9_30_2022_GrYkE3mhHEiRA4fxgfABRg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ProfitLossBeforeTax" sign="-" scale="3" id="Tc_JxbFS3xejk2iLjyLytsaug_5_4">120,405</ix:nonFraction>)</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Adjustments to reconcile loss before tax to net cash flows</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> <span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> <span style="visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Finance income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="Duration_1_1_2021_To_9_30_2021_5RS16WkLc0uS2ug_bqUm-g" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:AdjustmentsForFinanceIncome" scale="3" id="Tc_fK9brRGD5EaK0Rc6Xi57wg_7_2">8,828</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="Duration_1_1_2022_To_9_30_2022_GrYkE3mhHEiRA4fxgfABRg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:AdjustmentsForFinanceIncome" scale="3" id="Tc_oE0h213itUKepZTJKC_peQ_7_4">10,619</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:71.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Finance expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="Duration_1_1_2021_To_9_30_2021_5RS16WkLc0uS2ug_bqUm-g" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:AdjustmentsForFinanceCosts" scale="3" id="Tc_J3uX8YvDsEWI1kvjawEh1A_8_2">10,015</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="Duration_1_1_2022_To_9_30_2022_GrYkE3mhHEiRA4fxgfABRg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:AdjustmentsForFinanceCosts" scale="3" id="Tc_PmP0LZKiqEWJKMAWDcdVPg_8_4">3,077</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Depreciation and impairment of property, plant and equipment and right-of-use assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="Duration_1_1_2021_To_9_30_2021_5RS16WkLc0uS2ug_bqUm-g" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense" scale="3" id="Tc_m06kDl6pt0Cb2pY33lKF1A_9_2">11,342</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="Duration_1_1_2022_To_9_30_2022_GrYkE3mhHEiRA4fxgfABRg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense" scale="3" id="Tc_c2wlyTa3k0uoMB3dBVQd_Q_9_4">23,349</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Loss on disposal of fixed assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#x2014;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="Duration_1_1_2022_To_9_30_2022_GrYkE3mhHEiRA4fxgfABRg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets" scale="3" id="Tc_J4FwOHlCPk2nBPqI-EELMw_10_4">6,428</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Impairment of inventory and prepayments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="Duration_1_1_2021_To_9_30_2021_5RS16WkLc0uS2ug_bqUm-g" decimals="-3" format="ixt:numdotdecimal" name="cvac:ImpairmentsOfInventoryAndPrepayments" scale="3" id="Tc_SlgQ7eWlGEq4EddwzdoScw_11_2">39,142</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="Duration_1_1_2022_To_9_30_2022_GrYkE3mhHEiRA4fxgfABRg" decimals="-3" format="ixt:numdotdecimal" name="cvac:ImpairmentsOfInventoryAndPrepayments" scale="3" id="Tc_92k9qitDiEiFmzOt83Elrg_11_4">41,295</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Share-based payment expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="Duration_1_1_2021_To_9_30_2021_5RS16WkLc0uS2ug_bqUm-g" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:AdjustmentsForSharebasedPayments" scale="3" id="Tc_ZxIVM1kuwkGekL6F5Zzr5A_12_2">11,470</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="Duration_1_1_2022_To_9_30_2022_GrYkE3mhHEiRA4fxgfABRg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:AdjustmentsForSharebasedPayments" scale="3" id="Tc_DgUw-rBDY066ZMFkxK5LIQ_12_4">6,455</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Non-cash income from release of provisions</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#x2014;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="Duration_1_1_2022_To_9_30_2022_GrYkE3mhHEiRA4fxgfABRg" decimals="-3" format="ixt:numdotdecimal" name="cvac:AdjustmentsForNonCashIncomeFromReleaseOfProvisions" scale="3" id="Tc_8hqMQCKrf0Kak-XaUCZ_6Q_13_4">61,102</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:71.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Working capital changes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  <span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Decrease / (increase) in trade receivables and contract assets </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="Duration_1_1_2021_To_9_30_2021_5RS16WkLc0uS2ug_bqUm-g" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables" sign="-" scale="3" id="Tc_ox7-zNcuUkK7hE1ttogxCQ_16_2">7,810</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="Duration_1_1_2022_To_9_30_2022_GrYkE3mhHEiRA4fxgfABRg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables" scale="3" id="Tc_pGWMlrE3MUm_sRE83hw-Iw_16_4">12,334</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Decrease / (increase) in inventory</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="Duration_1_1_2021_To_9_30_2021_5RS16WkLc0uS2ug_bqUm-g" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:AdjustmentsForDecreaseIncreaseInInventories" sign="-" scale="3" id="Tc_tT7FWJO6cEiNOy7xpeLqWA_17_2">143,638</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="Duration_1_1_2022_To_9_30_2022_GrYkE3mhHEiRA4fxgfABRg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:AdjustmentsForDecreaseIncreaseInInventories" scale="3" id="Tc_YjkpuBINkUexxaLiGrv6Pw_17_4">6,996</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Decrease / (increase) in other assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="Duration_1_1_2021_To_9_30_2021_5RS16WkLc0uS2ug_bqUm-g" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:AdjustmentsForDecreaseIncreaseInOtherAssets" sign="-" scale="3" id="Tc_KXNreD45NU--xECiW7HI-Q_18_2">214,621</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="Duration_1_1_2022_To_9_30_2022_GrYkE3mhHEiRA4fxgfABRg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:AdjustmentsForDecreaseIncreaseInOtherAssets" sign="-" scale="3" id="Tc_fH3VOhARtEyjFcYYzFJJ8g_18_4">9,724</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:71.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Receipts from grants from government agencies and similar bodies</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="Duration_1_1_2021_To_9_30_2021_5RS16WkLc0uS2ug_bqUm-g" decimals="-3" format="ixt:numdotdecimal" name="cvac:ReceiptsFromGovernmentGrantsClassifiedAsOperatingActivities" scale="3" id="Tc_bOAt-AZ2T0C84t4gMirYLA_19_2">38,349</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#x2014;</p></td></tr><tr><td style="vertical-align:bottom;width:71.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">(Decrease) / increase in trade and other payables, other liabilities and contract liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="Duration_1_1_2021_To_9_30_2021_5RS16WkLc0uS2ug_bqUm-g" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" scale="3" id="Tc_DZ3cL22zMEW-KSv6Uhd3Qw_20_2">130,022</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="Duration_1_1_2022_To_9_30_2022_GrYkE3mhHEiRA4fxgfABRg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" sign="-" scale="3" id="Tc_MpCM0RIcdkiJZqsfE_taZg_20_4">131,746</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:71.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">(Decrease) / increase in other current financial liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="Duration_1_1_2021_To_9_30_2021_5RS16WkLc0uS2ug_bqUm-g" decimals="-3" format="ixt:numdotdecimal" name="cvac:AdjustmentsForIncreaseDecreaseInOtherCurrentFinancialAndOtherLiabilities" scale="3" id="Tc_OGRU1X_WS0SZ-XiJi1lweQ_21_2">78</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#x2014;</p></td></tr><tr><td style="vertical-align:bottom;width:71.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Decrease / (increase) in deferred taxes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="Duration_1_1_2021_To_9_30_2021_5RS16WkLc0uS2ug_bqUm-g" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:AdjustmentsForDeferredTaxExpense" sign="-" scale="3" id="Tc_FpixhTlnWEqtzbT1zCQIew_22_2">100</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="Duration_1_1_2022_To_9_30_2022_GrYkE3mhHEiRA4fxgfABRg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:AdjustmentsForDeferredTaxExpense" scale="3" id="Tc_R9OdQqHUtkCTzkqsiesb-w_22_4">49</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Income taxes paid</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="Duration_1_1_2021_To_9_30_2021_5RS16WkLc0uS2ug_bqUm-g" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:IncomeTaxesPaidClassifiedAsOperatingActivities" scale="3" id="Tc_Mt14MZbkZk29nIiGKCcxmQ_23_2">352</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="Duration_1_1_2022_To_9_30_2022_GrYkE3mhHEiRA4fxgfABRg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:IncomeTaxesPaidClassifiedAsOperatingActivities" scale="3" id="Tc_EpnVRdDTskONrIT5tgAZFQ_23_4">152</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:71.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Interest received</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="Duration_1_1_2021_To_9_30_2021_5RS16WkLc0uS2ug_bqUm-g" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:InterestReceivedClassifiedAsOperatingActivities" scale="3" id="Tc_qBiN3ESb1UuByzMmRIsriA_24_2">25</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#x2014;</p></td></tr><tr><td style="vertical-align:bottom;width:71.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Interest paid</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="Duration_1_1_2021_To_9_30_2021_5RS16WkLc0uS2ug_bqUm-g" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:InterestPaidClassifiedAsOperatingActivities" scale="3" id="Tc_9BdgEe5oO0S9_HoJhI1NlQ_25_2">7,212</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="Duration_1_1_2022_To_9_30_2022_GrYkE3mhHEiRA4fxgfABRg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:InterestPaidClassifiedAsOperatingActivities" scale="3" id="Tc_UiWulRuAaUuvEq2uUZMmvw_25_4">3,326</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:71.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Net cash flow (used in) operating activities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="Duration_1_1_2021_To_9_30_2021_5RS16WkLc0uS2ug_bqUm-g" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:CashFlowsFromUsedInOperatingActivities" sign="-" scale="3" id="Tc_stgfy11zg0GOSRw6LIXt7A_26_2">550,057</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="Duration_1_1_2022_To_9_30_2022_GrYkE3mhHEiRA4fxgfABRg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:CashFlowsFromUsedInOperatingActivities" sign="-" scale="3" id="Tc_LypwqQUStUCh-RsqV46l6w_26_4">237,091</ix:nonFraction>)</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Investing activities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  <span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Purchase of property, plant and equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="Duration_1_1_2021_To_9_30_2021_5RS16WkLc0uS2ug_bqUm-g" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" scale="3" id="Tc_HkhjX2o-vUeFpaj_-i4JRw_29_2">91,032</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="Duration_1_1_2022_To_9_30_2022_GrYkE3mhHEiRA4fxgfABRg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" scale="3" id="Tc_o6wEzyccgkSUkB6fHPxbMw_29_4">67,124</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:71.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Purchase of intangible assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="Duration_1_1_2021_To_9_30_2021_5RS16WkLc0uS2ug_bqUm-g" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" scale="3" id="Tc_or7YbEv2-UqMoBTMiaa_JQ_30_2">2,273</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="Duration_1_1_2022_To_9_30_2022_GrYkE3mhHEiRA4fxgfABRg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" scale="3" id="Tc_jpZq5_zyQU6DW_pKN8Vi4g_30_4">5,435</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:71.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Net cash flow (used in) investing activities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="Duration_1_1_2021_To_9_30_2021_5RS16WkLc0uS2ug_bqUm-g" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:CashFlowsFromUsedInInvestingActivities" sign="-" scale="3" id="Tc_qtBoZPn1cUWYdSqwtnZeGg_31_2">93,305</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="Duration_1_1_2022_To_9_30_2022_GrYkE3mhHEiRA4fxgfABRg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:CashFlowsFromUsedInInvestingActivities" sign="-" scale="3" id="Tc_I9klsE7wKkCy6mmq8eMXkg_31_4">72,559</ix:nonFraction>)</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Financing activities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#xA0;&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Payments on lease obligations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="Duration_1_1_2021_To_9_30_2021_5RS16WkLc0uS2ug_bqUm-g" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" scale="3" id="Tc_fV_pmxBU7kOQGz5tUQvtZQ_34_2">2,346</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="Duration_1_1_2022_To_9_30_2022_GrYkE3mhHEiRA4fxgfABRg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" scale="3" id="Tc_xjrn4TSmUkuespb-OzGwDw_34_4">3,087</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:71.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Payment on / Proceeds from Treasury Shares</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="Duration_1_1_2021_To_9_30_2021_5RS16WkLc0uS2ug_bqUm-g" decimals="-3" format="ixt:numdotdecimal" name="cvac:ProceedFromIssuingOtherEquityInstrument" sign="-" scale="3" id="Tc_BpcZbfO4WUCtqrhmRzyLyA_35_2">23,339</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="Duration_1_1_2022_To_9_30_2022_GrYkE3mhHEiRA4fxgfABRg" decimals="-3" format="ixt:numdotdecimal" name="cvac:ProceedFromIssuingOtherEquityInstrument" scale="3" id="Tc_Cfmnplm42EuGgpleobcTwA_35_4">991</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Proceeds from at-the-market offering program (net of transaction costs) - Note 4</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#x2014;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="Duration_1_1_2022_To_9_30_2022_GrYkE3mhHEiRA4fxgfABRg" decimals="-3" format="ixt:numdotdecimal" name="cvac:IfrsStockIssuedDuringPeriodValueNewIssues" sign="-" scale="3" id="Tc_eFjwvf5dXUuGJ2Pu0sLUoA_36_4">32,325</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Payments from the exercise of options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#x2014;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="Duration_1_1_2022_To_9_30_2022_GrYkE3mhHEiRA4fxgfABRg" decimals="-3" format="ixt:numdotdecimal" name="cvac:ProceedsOrPaymentsFromExerciseOfOptions" scale="3" id="Tc_6UnRoccNLU2gHyp1NGgbVQ_37_4">356</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:71.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Proceeds from the issuance of shares (net of transaction costs)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="Duration_1_1_2021_To_9_30_2021_5RS16WkLc0uS2ug_bqUm-g" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ProceedsFromIssuingShares" scale="3" id="Tc_r2dchFuoeUmSP5j-wYMKcw_38_2">404,164</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#x2014;</p></td></tr><tr><td style="vertical-align:bottom;width:71.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Net cash flow provided by financing activities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="Duration_1_1_2021_To_9_30_2021_5RS16WkLc0uS2ug_bqUm-g" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:CashFlowsFromUsedInFinancingActivities" scale="3" id="Tc_2B8x45D5q06kUr2zr5W34w_39_2">378,479</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="Duration_1_1_2022_To_9_30_2022_GrYkE3mhHEiRA4fxgfABRg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:CashFlowsFromUsedInFinancingActivities" scale="3" id="Tc_qKR_Hk-sREanL7cfjaTjDg_39_4">29,873</ix:nonFraction></b></p></td></tr><tr><td style="vertical-align:bottom;width:71.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net increase (decrease) in cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="Duration_1_1_2021_To_9_30_2021_5RS16WkLc0uS2ug_bqUm-g" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" sign="-" scale="3" id="Tc_h3wG5VEtL0qTZaWqOI9FhA_40_2">264,883</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="Duration_1_1_2022_To_9_30_2022_GrYkE3mhHEiRA4fxgfABRg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" sign="-" scale="3" id="Tc_-cMqb6yaS0e1qsGS17EEmg_40_4">279,777</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:71.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Currency translation gains (losses) on cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="Duration_1_1_2021_To_9_30_2021_5RS16WkLc0uS2ug_bqUm-g" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents" scale="3" id="Tc_t88ahNfsbEuZ16KAjK8qEQ_41_2">3,261</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="Duration_1_1_2022_To_9_30_2022_GrYkE3mhHEiRA4fxgfABRg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents" scale="3" id="Tc_vzgMkBuVYEGHlvOVYIYQ2A_41_4">9,178</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cash and cash equivalents, beginning of period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="As_Of_12_31_2020_gDhEGYRPKEaVXa-xMDWqsw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:CashAndCashEquivalents" scale="3" id="Tc_QvGJymfzS0-o_U6_V8Bx2Q_42_2">1,322,593</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="As_Of_12_31_2021_kQVJTWPgRUeESxCd99xt9A" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:CashAndCashEquivalents" scale="3" id="Tc_Hp_w-_Avmkqd1DOK0yy5XQ_42_4">811,464</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Cash and cash equivalents, end of period</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="As_Of_9_30_2021_wVcf5oroJEG4KeEdh1LnEw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:CashAndCashEquivalents" scale="3" id="Tc_JXccl3zAGkGgyfSrvn2rng_43_2">1,060,971</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="As_Of_9_30_2022_zuGVrjesE0WhwXSGmTqsgA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:CashAndCashEquivalents" scale="3" id="Tc_RU2xFtiiEkmoQRDtpda2lA_43_4">540,865</ix:nonFraction></b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#x200B;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><ix:nonNumeric contextRef="Duration_1_1_2022_To_9_30_2022_GrYkE3mhHEiRA4fxgfABRg" name="cvac:CorporateInformationTextBlock" id="Tb_kkrBNcAzkUGEMZhWqPqL2w" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">1. Corporate Information</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">CureVac N.V. (&#x201C;CureVac&#x201D; or &#x201C;CV&#x201D; or the &#x201C;Company&#x201D;) is the parent company of CureVac Group (&#x201C;Group&#x201D;) and, along with its subsidiaries, is a global biopharmaceutical company developing a new class of transformative medicines based on the messenger ribonucleic acid (mRNA) that has the potential to improve the lives of people.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">The Company is incorporated in the Netherlands and is registered in the commercial register at the Netherlands Chamber of Commerce under 77798031. The Company&#x2019;s registered headquarters is Friedrich-Miescher-Strasse 15, 72076 Tuebingen, Germany. During 2021 until now, Dievini Hopp BioTech holding GmbH &amp; Co. KG (dievini), which is an investment company dedicated to the support of companies in health and life sciences, is the largest shareholder of CureVac. Together with its related parties, dievini has held shares and voting rights in CureVac between appr. 45 &#x2013; 49 % during that period. dievini is thus considered to be the de facto parent of the Group. Dietmar Hopp, Daniel Hopp and Oliver Hopp are the ultimate controlling persons (of the main shareholders) of dievini, and, therefore, control the voting and investment decisions of dievini.</p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><ix:nonNumeric contextRef="Duration_1_1_2022_To_9_30_2022_GrYkE3mhHEiRA4fxgfABRg" name="cvac:DisclosureOfBasisOfPreparationExplanatoryTextBlock" id="Tb_ilauMsZcMUmLn_tWPxvlmA" continuedAt="Tb_ilauMsZcMUmLn_tWPxvlmA_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">2. Basis of preparation</p><ix:nonNumeric contextRef="Duration_1_1_2022_To_9_30_2022_GrYkE3mhHEiRA4fxgfABRg" name="ifrs-full:DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory" id="Tb_Kd6tlYvOvUmVfRtzdfqmhQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The interim condensed consolidated financial statements for the nine months ended September 30, 2022, have been prepared in accordance with IAS 34 Interim Financial Reporting.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The interim condensed consolidated financial statements do not include all the information and disclosures required in the annual consolidated financial statements and should be read in conjunction with the Group&#x2019;s annual consolidated financial statements as of December 31, 2021 and 2020 and for the three years in the period ended December 31, 2021. The interim condensed consolidated financial statements were authorized by the Management Board for presentation to the Supervisory Board on November 16, 2022. The Group&#x2019;s interim condensed consolidated financial statements are presented in Euros (&#x201C;EUR&#x201D;). Unless otherwise stated, amounts are rounded to thousands of Euros, except per share amounts.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_9_30_2022_GrYkE3mhHEiRA4fxgfABRg" name="cvac:DescriptionOfAccountingPolicyOfNewStandardsInterpretationsAndAmendmentsAdoptedTextBlock" id="Tb_3SkoRjI0REuhB3iNkLToEQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">New standards, interpretations and amendments adopted by the Group</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The accounting policies adopted in the preparation of the interim condensed consolidated financial statements are consistent with those followed in the preparation of the Group&#x2019;s annual consolidated financial statements for the year ended December 31, 2021. The new and amended standards and interpretations applied for the first time as of January 1, 2022, as disclosed in the notes to the consolidated financial statements as of December 31, 2021, had no impact on the interim condensed consolidated financial statements of the Group as of and for the nine months ended September 30, 2022. The Group has not early adopted any standard, interpretation or amendment that has been issued but is not yet effective.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_9_30_2022_GrYkE3mhHEiRA4fxgfABRg" name="cvac:DescriptionOfAccountingPolicyForCovid19ImpactExplanatory" id="Tb_42roIoWD5EKsZipFoBYKsg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">Impact of COVID-19 and the Russia-Ukraine Conflict</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As the Group is currently devoting significant resources to the development of COVID vaccines, such development may impair the ability to timely progress other product candidates in clinical trials or into clinical trials from their current preclinical stage. In addition, enrollment in other programs may be delayed as a result of the COVID-19 pandemic and our focus on developing a COVID vaccine could have a negative impact on our progress on and associated revenue recognition from our non-COVID-19 collaborations. The partial disruption, even temporary, may negatively impact the Company&#x2019;s operations and overall business by delaying the progress of its clinical trials and preclinical studies. The Group&#x2019;s operations, including research and manufacturing, could also be disrupted due to the potential of the impact of staff absences as a result of self-isolation procedures or extended illness. However, the Group has taken a series of actions aimed at safeguarding its employees and business associates, including implementing a work-from-home policy for employees except for those related to its laboratory and production operations. The Group is running COVID antigen tests on a weekly basis for employees on the premises.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The ongoing military conflict between Russia and Ukraine has not and is not expected to have a material direct or indirect effect on the Group&#x2019;s operations or financial condition: however, the Group is currently operating in a period of economic uncertainty and capital markets disruption, which has been significantly impacted by geopolitical instability due to the ongoing military conflict between Russia and Ukraine. As a result of this instability and responding actions taken by the United States, Russia, EU, and other Foreign Governments, this may limit or prevent filing, prosecuting, and maintaining of patient applications in Russia. Government actions may also prevent maintenance of issued patents in Russia. These actions could result in abandonment or lapse of our patents or patent applications in Russia, resulting in partial or complete loss of patent rights in Russia. In addition, a decree was adopted by the Russian government in March 2022, allowing Russian companies and individuals to exploit, without consent or compensation, inventions owned by patentees that have citizenship or nationality in, are registered in, or have predominately primary place of business or profit-making activities in countries that Russia has deemed unfriendly. Consequently, we would not be able to prevent third parties from using our inventions in Russia or from selling or importing products made using our inventions in and into Russia. Accordingly, our competitive position may be impaired, and our business, financial condition, results of operations and prospects may be materially adversely affected.</p></ix:nonNumeric></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;min-height:5.75pt;"><ix:continuation id="Tb_ilauMsZcMUmLn_tWPxvlmA_cont1"></ix:continuation><a id="Tc_l7ozijdHSkCd0wjJNA1Umw_1_2"></a><a id="Tc_l5Gebh1dl0KJrVfSMrhKvg_2_2"></a><a id="Tc_3cvKDItQ8USTlnTDtB_jug_2_4"></a><a id="Tc_mR7C-cAzyE6jDo2QPwFkJg_3_2"></a><a id="Tc_441ZTEMX6ke_RqL6r3bsRA_3_4"></a><a id="Tc_SFavzwBy4UObylSZXM8afQ_4_0"></a><a id="Tc_E3ht_oSaU0yOXFzdU0xN9A_5_0"></a><a id="Tc_4xxNtx-ZYkaGc6bGBmSYdw_6_0"></a><a id="Tc_kwpqxbuDz0qp7T6dk5FXRQ_7_0"></a><a id="Tc_FxgHoIcR-0-aEHShG-wj7Q_7_4"></a><a id="Tc_iDoFMBirkE2YKCS0V-5VCA_8_0"></a><a id="Tc_Ydnb7DUXPUS7WStaxl8XHA_9_0"></a><a id="Tc_1DW9c6xN3Eq4MNeuI6TCOg_10_0"></a><a id="Tc_mzkcGJGDO0iyVGsBIwNtnw_11_0"></a><a id="Tc_DPzmOEC-tU65WDv_OjtOrQ_12_0"></a><a id="_e90e3f68_b522_416b_8175_63d388a14daf"></a><a id="Tc_F-v0wCaj4kqJEQMQlZ7QwA_1_4"></a><a id="Tc_wXkR1gDUJEWBTILz9IzmeA_1_6"></a><a id="Tc_CZgJ0GEI3EWRVh8z_adH0g_1_8"></a><a id="Tc_naxkSKepbE2hCP2xF3GFDw_2_4"></a><a id="Tc_5qYJw8YOlky1YLAHrFATDw_2_6"></a><a id="Tc_f-zS48cpF0u4tJKQsSofKw_2_8"></a><a id="Tc_t8WHHPsjTUyyhhnDcDgS9Q_3_2"></a><a id="Tc_iXmIPjbamEa_9uB4xopEDg_3_4"></a><a id="Tc_sulYJQ9gX0WdOGgdVtkAGw_3_6"></a><a id="Tc_ABHOsoWuIUOnFZsWBTlvjg_3_8"></a><a id="Tc_K-yFEWXjsE-MODfAlqQ0-Q_4_2"></a><a id="Tc_eY2mufTZxESUuS42qkIuhQ_4_4"></a><a id="Tc_0RPnJLT1OE2mHuP3-CBJlg_4_6"></a><a id="Tc_B3kVm732p0CakdrMtFnd-g_4_8"></a><a id="Tc_gGtczdT5M0-cUGYaqAoSag_5_0"></a><a id="Tc_YYhNiNIk-E2xYdetLa-3wA_5_2"></a><a id="Tc_Zdrppiaoj0GRSkOaNqrRsQ_5_4"></a><a id="Tc_pux_vdRcuU2CkfFTNy1z5A_5_6"></a><a id="Tc_eFzGxVRsqE2hjwBoeUsMZQ_5_8"></a><a id="Tc_2BaTKqglgk67eKu06B4d5w_5_10"></a><a id="Tc_Nj58uaCbKUGWTIdCgW2suw_6_4"></a><a id="Tc_ZjpNJjV8j060jm05U5BGVg_6_6"></a><a id="Tc_ea0Eo4O5bU2nxnDlPh0evQ_6_8"></a><a id="Tc_QpEnJPPGRUyh2K6kcOzofg_7_0"></a><a id="Tc_0PZzVHmeP0ewBQb48gTbPQ_7_2"></a><a id="Tc_M3shS68ySU-NHmGtP4emGA_8_0"></a><a id="Tc_0x2AvF7S4020HgQd50Hxdw_8_2"></a><a id="Tc_2gOcc6wBCUGlcOb1e94PJw_9_0"></a><a id="Tc_CR8nsZ_CWEOkbDeUSIUeHQ_9_2"></a><a id="Tc_NN6wRTDWXkq8TsoBUA-1wQ_9_4"></a><a id="Tc_RoP2rcUhjkWC4QSm3xdp9w_9_6"></a><a id="Tc_zB-JA1Bcm065vO9MsaeXkg_9_10"></a><a id="Tc_Vzkhb4h4Fkuo4HVqSZGPpQ_10_0"></a><a id="Tc_OVPYPyRWo029KVXzEhj1VQ_10_2"></a><a id="Tc_Jttzg9KXbU6xS7hkXgsxpA_11_0"></a><ix:nonNumeric contextRef="Duration_1_1_2022_To_9_30_2022_GrYkE3mhHEiRA4fxgfABRg" name="ifrs-full:DisclosureOfNotesAndOtherExplanatoryInformationExplanatory" id="Tb_bjSJ6MGdEU6Hl25QLMb2og" continuedAt="Tb_bjSJ6MGdEU6Hl25QLMb2og_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">3. Notes to the consolidated financial statements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">3.1 Revenue from contract with customers</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Group recognized the following revenues:</p><ix:nonNumeric contextRef="Duration_1_1_2022_To_9_30_2022_GrYkE3mhHEiRA4fxgfABRg" name="ifrs-full:DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory" id="Tb_ElnYnKEQQUeTq9cHvgBPRQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#x200B;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:71.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#xA0;&#xA0;&#xA0;&#xA0;</b></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:26.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Nine months ended September 30</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#xA0;&#xA0;&#xA0;&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR k</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR k</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Belgium</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">GSK</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="Duration_1_1_2021_To_9_30_2021_ifrs-full_GeographicalAreasAxis_country_BE_ifrs-full_MajorCustomersAxis_cvac_GlaxosmithklineMember_eVwoaEVfAUKlb5HYdjxaQw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:RevenueFromContractsWithCustomers" scale="3" id="Tc_1Sv9apT_I0mNENmMI8rVQw_5_2">49,621</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="Duration_1_1_2022_To_9_30_2022_ifrs-full_GeographicalAreasAxis_country_BE_ifrs-full_MajorCustomersAxis_cvac_GlaxosmithklineMember_shjcQ9gwY0mzJMJm_89JCQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:RevenueFromContractsWithCustomers" scale="3" id="Tc_-F5nKDg8MEyeheFjLeSi1g_5_4">52,746</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Germany</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> <span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> <span style="visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Boehringer Ingelheim</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="Duration_1_1_2021_To_9_30_2021_ifrs-full_GeographicalAreasAxis_country_DE_ifrs-full_MajorCustomersAxis_cvac_BoehringerIngelheimMember_GLkAvVsjY0iIfdOVguCCiQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:RevenueFromContractsWithCustomers" scale="3" id="Tc_8LlaAZ_ZbEy9v8pfTZ3NHA_7_2">9,990</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#x2014;</p></td></tr><tr><td style="vertical-align:bottom;width:71.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Switzerland</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#xA0;&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">CRISPR</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="Duration_1_1_2021_To_9_30_2021_ifrs-full_GeographicalAreasAxis_country_CH_ifrs-full_MajorCustomersAxis_cvac_CrisprMember_H5jO5eGbWE6vAapf30CSfw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:RevenueFromContractsWithCustomers" scale="3" id="Tc_7XVtUGEh_ESHmVtV57u2hg_9_2">831</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="Duration_1_1_2022_To_9_30_2022_ifrs-full_GeographicalAreasAxis_country_CH_ifrs-full_MajorCustomersAxis_cvac_CrisprMember_HR3g4DsNXU-KQMdhdtvSTQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:RevenueFromContractsWithCustomers" scale="3" id="Tc_LWQy97oUE0G8h-5ZuN9oJA_9_4">1,646</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Netherlands</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Genmab</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="Duration_1_1_2021_To_9_30_2021_ifrs-full_GeographicalAreasAxis_country_NL_ifrs-full_MajorCustomersAxis_cvac_GenmabMember_SSbVK8fnGE6ChnWCps9ySQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:RevenueFromContractsWithCustomers" scale="3" id="Tc_yBWmyTjzo02-nmoeygNF8A_11_2">1,323</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="Duration_1_1_2022_To_9_30_2022_ifrs-full_GeographicalAreasAxis_country_NL_ifrs-full_MajorCustomersAxis_cvac_GenmabMember_7itxWD0v3UC7-_TEXbaZxQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:RevenueFromContractsWithCustomers" scale="3" id="Tc_QpRWgC65H0uD41OYdLKizg_11_4">1,339</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="Duration_1_1_2021_To_9_30_2021_5RS16WkLc0uS2ug_bqUm-g" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:RevenueFromContractsWithCustomers" scale="3" id="Tc_bPOmPYl4_E6KHw234sz15g_12_2">61,765</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="Duration_1_1_2022_To_9_30_2022_GrYkE3mhHEiRA4fxgfABRg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:RevenueFromContractsWithCustomers" scale="3" id="Tc_pXuvneSZoUa4H-bJb4v_eA_12_4">55,731</ix:nonFraction></b></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#x200B;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Of these revenues, all of which were recognized over time as part of collaboration agreements, during the nine months ended September 30, 2022 EUR <ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="Duration_1_1_2022_To_9_30_2022_ifrs-full_ProductsAndServicesAxis_cvac_ResearchServicesCombinedWithIpLicenseMember_JmxbMa7EOkGM2UmzZvcaYA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:RevenueFromContractsWithCustomers" scale="3" id="Narr_mvA1F8EEtk-DLVqhePwwbQ">40,278</ix:nonFraction>k (September 30, 2021: EUR <ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="Duration_1_1_2021_To_9_30_2021_ifrs-full_ProductsAndServicesAxis_cvac_ResearchServicesCombinedWithIpLicenseMember_w9Lhj-1fbUylhw2h1TnuCA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:RevenueFromContractsWithCustomers" scale="3" id="Narr_Nblu8ZU1rEyznyBAn43pgg">49,878</ix:nonFraction>k) related to (i) delivery of research services combined with an IP license (recognized from the upfront payments as further illustrated in the table below) and the reaching of a milestone, (ii) EUR <ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="Duration_1_1_2022_To_9_30_2022_ifrs-full_ProductsAndServicesAxis_cvac_IfrsProductMember_ykNdeTyQ_U6ifIHGuP-a8Q" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:RevenueFromContractsWithCustomers" scale="3" id="Narr_OEt_7C2_jkiq08NYdAl2rw">1,413</ix:nonFraction>k (September 30, 2021: EUR <ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="Duration_1_1_2021_To_9_30_2021_ifrs-full_ProductsAndServicesAxis_cvac_IfrsProductMember_WafA2PzZ0kOs4a0LCkTNpg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:RevenueFromContractsWithCustomers" scale="3" id="Narr_KsHoDduexUOH7ZmyyVNhqQ">1,400</ix:nonFraction>k) related to delivery of products and (iii) EUR <ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="Duration_1_1_2022_To_9_30_2022_ifrs-full_ProductsAndServicesAxis_cvac_ResearchAndDevelopmentServicesMember_xgWEhIWVP0aG8Oi39YdQdg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:RevenueFromContractsWithCustomers" scale="3" id="Narr_cR74iiZIl0K09OreMQyIXw">14,040</ix:nonFraction>k (September 30, 2021: EUR <ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="Duration_1_1_2021_To_9_30_2021_ifrs-full_ProductsAndServicesAxis_cvac_ResearchAndDevelopmentServicesMember_FqOeAMlR502ph1Wxt4STrA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:RevenueFromContractsWithCustomers" scale="3" id="Narr_tPJZEdI9wkuR7khqgDA2Ag">10,489</ix:nonFraction>k) were recognized from those research and development services considered distinct within the agreements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Of the total revenues recognized, in the nine months ended September 30, 2022, EUR <ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="Duration_1_1_2022_To_9_30_2022_ifrs-full_GeographicalAreasAxis_country_BE_ifrs-full_MajorCustomersAxis_cvac_GlaxosmithklineMember_shjcQ9gwY0mzJMJm_89JCQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:RevenueFromContractsWithCustomers" scale="3" id="Narr_hcHmR0pVEE2qD1vriiDFKA">52,746</ix:nonFraction>k in revenue was recognized under the collaboration agreements with GSK, entered into in July 2020, for the research, development, manufacturing and commercialization of mRNA-based vaccines and monoclonal antibodies targeting infectious disease pathogens (&#x201C;GSK I&#x201D;) and in April 2021 for research, development and manufacturing of next-generation mRNA vaccines targeting the original SARS-CoV-2 strain as well as emerging variants, including multivalent and monovalent approaches, such as CureVac&#x2019;s second-generation COVID-19 vaccine candidate, CV2CoV (&#x201C;GSK II&#x201D;). In the first quarter of 2022, the Company reached a development milestone of EUR <ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="Duration_1_1_2022_To_9_30_2022_ifrs-full_ProductsAndServicesAxis_cvac_MilestoneRevenuesMember_H4PqpAjQEkuxcZ00nka3Eg" decimals="-3" format="ixt:numdotdecimal" name="cvac:AdditionalDevelopmentMilestonePaymentsReceived" scale="3" id="Narr_CLTjMLqZrUaRYUa5e_mS2w">10,000</ix:nonFraction>k under the GSK I collaboration. Therefore, revenue for the nine months ending September 30, 2022, also includes recognition of EUR <ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="Duration_1_1_2022_To_9_30_2022_ifrs-full_ProductsAndServicesAxis_cvac_MilestoneRevenuesMember_H4PqpAjQEkuxcZ00nka3Eg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:RevenueFromContractsWithCustomers" scale="3" id="Narr_9ZlXWG4KnUK5hmCqiCdbRQ">5,789</ix:nonFraction>k of the milestone amount. The remaining EUR <ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="As_Of_9_30_2022_ifrs-full_ProductsAndServicesAxis_cvac_MilestoneRevenuesMember_f7JkTbic-Uq7GDa0pAVbjA" decimals="-3" format="ixt:numdotdecimal" name="cvac:IfrsDevelopmentMilestonePaymentIncludedInContractLiabilities" scale="3" id="Narr_YHe4uvtJw06PHukRIx-1EA">4,211</ix:nonFraction>k of the milestone amount is deferred as contract liability and will be recognized into revenue through the estimated completion date of Phase 1 clinical trials, which represents the period of time during which CureVac is responsible for development as, subsequent to this period, GSK will be responsible for further development and commercialization. In the nine months ended September 30, 2021, revenue from the collaborations with GSK consisted of EUR <ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="Duration_1_1_2021_To_9_30_2021_ifrs-full_GeographicalAreasAxis_country_BE_ifrs-full_MajorCustomersAxis_cvac_GlaxosmithklineMember_eVwoaEVfAUKlb5HYdjxaQw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:RevenueFromContractsWithCustomers" scale="3" id="Narr_QYIri_3M_0Cw3DBguGMhkQ">49,621</ix:nonFraction>k primarily recognized from the amortization of upfront and milestone payments.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">The Group has received upfront payments which were initially deferred and are subsequently recognized as revenue as the Group renders services over the performance period. Below is a summary of such payments and the related revenues recognized:</p><ix:nonNumeric contextRef="Duration_1_1_2022_To_9_30_2022_GrYkE3mhHEiRA4fxgfABRg" name="cvac:DisclosureOfUpfrontPaymentsAndRelatedRevenuesRecognizedExplanatory" id="Tb_RTF5Lo-bHEmm3DT1JOJvJQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#x200B;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:16.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:18.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:18.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:18.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:16.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Upfront and</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Upfront and</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Revenue&#xA0;recognized from</b></p></td></tr><tr><td style="vertical-align:bottom;width:16.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">milestones payments included</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">milestones payments included</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#xA0;upfront and milestones payments </b></p></td></tr><tr><td style="vertical-align:bottom;width:16.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Upfront and milestone&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">in contract</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">in contract</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">for nine months ended</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:16.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#xA0;&#xA0;&#xA0;&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">payments</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#xA0;&#xA0;&#xA0;&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#xA0;liabilities&#xA0;at</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#xA0;&#xA0;&#xA0;&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#xA0;liabilities&#xA0;at</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#xA0;&#xA0;&#xA0;&#xA0;</b></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September 30,</b></p></td></tr><tr><td style="vertical-align:bottom;width:16.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Customer</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September 30, 2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, 2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September 30, 2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#xA0;&#xA0;&#xA0;&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="11" style="padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:16.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(EUR k)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(EUR k)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(EUR k)</b></p></td></tr><tr><td style="vertical-align:bottom;width:16.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">GSK  </span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;width:18.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">EUR <ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="As_Of_9_30_2022_ifrs-full_MajorCustomersAxis_cvac_GlaxosmithklineMember_ifrs-full_ProductsAndServicesAxis_cvac_ResearchServicesCombinedWithIpLicenseMember_0AbiwODFUEmyJLdIgNcTfg" decimals="-3" format="ixt:numdotdecimal" name="cvac:UpfrontPaymentsReceivedOrReceivable" scale="3" id="Narr_eB90QURYOESOAwdocVxhBg">205,000</ix:nonFraction>k (EUR <ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="As_Of_9_30_2022_ifrs-full_MajorCustomersAxis_cvac_GlaxosmithklineMember_ifrs-full_ProductsAndServicesAxis_cvac_ResearchServicesCombinedWithIpLicenseMember_ifrs-full_RangeAxis_ifrs-full_BottomOfRangeMember_7jTi8_0PcEeLFJbzx_wjrQ" decimals="-3" format="ixt:numdotdecimal" name="cvac:UpfrontPaymentsReceivedOrReceivable" scale="3" id="Narr_rsY1v8iI0Uu5-xh_m4VQdQ">10,000</ix:nonFraction>k milestone payment included)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="As_Of_12_31_2021_ifrs-full_MajorCustomersAxis_cvac_GlaxosmithklineMember_ifrs-full_ProductsAndServicesAxis_cvac_ResearchServicesCombinedWithIpLicenseMember_PJOVtNdDh0SBq-RS-4qaSw" decimals="-3" format="ixt:numdotdecimal" name="cvac:UpfrontPaymentsIncludedInContractLiabilities" scale="3" id="Tc_cMQO7DIYi0WNxVh2iuVr8Q_7_4">135,494</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="As_Of_9_30_2022_ifrs-full_MajorCustomersAxis_cvac_GlaxosmithklineMember_ifrs-full_ProductsAndServicesAxis_cvac_ResearchServicesCombinedWithIpLicenseMember_0AbiwODFUEmyJLdIgNcTfg" decimals="-3" format="ixt:numdotdecimal" name="cvac:UpfrontPaymentsIncludedInContractLiabilities" scale="3" id="Tc_EVAYlKDkoE63TlHH8Y1svg_7_6">106,788</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="Duration_1_1_2021_To_9_30_2021_ifrs-full_MajorCustomersAxis_cvac_GlaxosmithklineMember_ifrs-full_ProductsAndServicesAxis_cvac_ResearchServicesCombinedWithIpLicenseMember_xJi4YZnmz0Wq6SdDwRVxBA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod" scale="3" id="Tc_j1OjYsef9kCuJ8EdYJY6MQ_7_8">38,315</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="Duration_1_1_2022_To_9_30_2022_ifrs-full_MajorCustomersAxis_cvac_GlaxosmithklineMember_ifrs-full_ProductsAndServicesAxis_cvac_ResearchServicesCombinedWithIpLicenseMember_CAXgAqyHKkO0WaEKjGrFrA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod" scale="3" id="Tc_S-BE3KbvxEGu67CsoWn69w_7_10">38,705</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:16.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">CRISPR  </span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;width:18.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">USD <ix:nonFraction unitRef="Unit_Standard_USD_q8NNp4TBfUC9XydcVDSrpA" contextRef="As_Of_9_30_2022_ifrs-full_MajorCustomersAxis_cvac_CrisprMember_ifrs-full_ProductsAndServicesAxis_cvac_ResearchServicesCombinedWithIpLicenseMember_N0CWO_7EbUeynG_1C6XLwA" decimals="-3" format="ixt:numdotdecimal" name="cvac:UpfrontPaymentsReceivedOrReceivable" scale="3" id="Narr_LQ7WKbf_FECawBGoTwwCvg">3,000</ix:nonFraction>k (EUR <ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="As_Of_9_30_2022_ifrs-full_MajorCustomersAxis_cvac_CrisprMember_ifrs-full_ProductsAndServicesAxis_cvac_ResearchServicesCombinedWithIpLicenseMember_N0CWO_7EbUeynG_1C6XLwA" decimals="-3" format="ixt:numdotdecimal" name="cvac:UpfrontPaymentsReceivedOrReceivable" scale="3" id="Narr_XmVBfDeLNE6NoRjaKw2RTQ">2,524</ix:nonFraction>k)*</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="As_Of_12_31_2021_ifrs-full_MajorCustomersAxis_cvac_CrisprMember_ifrs-full_ProductsAndServicesAxis_cvac_ResearchServicesCombinedWithIpLicenseMember_lhcV_FVDUEqAgO5rXoI-qw" decimals="-3" format="ixt:numdotdecimal" name="cvac:UpfrontPaymentsIncludedInContractLiabilities" scale="3" id="Tc_hVg6pXSd00KJuhCI_VHhKA_8_4">1,239</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="As_Of_9_30_2022_ifrs-full_MajorCustomersAxis_cvac_CrisprMember_ifrs-full_ProductsAndServicesAxis_cvac_ResearchServicesCombinedWithIpLicenseMember_N0CWO_7EbUeynG_1C6XLwA" decimals="-3" format="ixt:numdotdecimal" name="cvac:UpfrontPaymentsIncludedInContractLiabilities" scale="3" id="Tc_6GlJJREVkE6UJlyVzamPUw_8_6">1,007</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="Duration_1_1_2021_To_9_30_2021_ifrs-full_MajorCustomersAxis_cvac_CrisprMember_ifrs-full_ProductsAndServicesAxis_cvac_ResearchServicesCombinedWithIpLicenseMember_PH-MVv0gkEKmWXldRQgZBA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod" scale="3" id="Tc_SVrvU0Aia0-3JuWayn09BA_8_8">232</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="Duration_1_1_2022_To_9_30_2022_ifrs-full_MajorCustomersAxis_cvac_CrisprMember_ifrs-full_ProductsAndServicesAxis_cvac_ResearchServicesCombinedWithIpLicenseMember_khvMaOJtOkK4x-wZSKmcOQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod" scale="3" id="Tc_g_nI_pJ74EOEJPqXgFgLGw_8_10">232</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:16.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Boehringer Ingelheim</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;width:18.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">EUR <ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="As_Of_9_30_2022_ifrs-full_MajorCustomersAxis_cvac_BoehringerIngelheimMember_ifrs-full_ProductsAndServicesAxis_cvac_ResearchServicesCombinedWithIpLicenseMember_k3sZmRwsjkSNWebj2XPVlg" decimals="-3" format="ixt:numdotdecimal" name="cvac:UpfrontPaymentsReceivedOrReceivable" scale="3" id="Narr_VRen4LrdqUO2yXzAkjlEVA">30,000</ix:nonFraction>k</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#x2014;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#x2014;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="Duration_1_1_2021_To_9_30_2021_ifrs-full_MajorCustomersAxis_cvac_BoehringerIngelheimMember_ifrs-full_ProductsAndServicesAxis_cvac_ResearchServicesCombinedWithIpLicenseMember_2uKPlzeQMkesCPFChkjwGg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod" scale="3" id="Tc_D4vXE1YdakWAfJh79NNmkQ_9_8">9,990</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#x2014;</p></td></tr><tr><td style="vertical-align:bottom;width:16.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">Genmab  </span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;width:18.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">USD <ix:nonFraction unitRef="Unit_Standard_USD_q8NNp4TBfUC9XydcVDSrpA" contextRef="As_Of_9_30_2022_ifrs-full_MajorCustomersAxis_cvac_GenmabMember_ifrs-full_ProductsAndServicesAxis_cvac_ResearchServicesCombinedWithIpLicenseMember_yfdi7QFOIken6nwnl1VeyA" decimals="-3" format="ixt:numdotdecimal" name="cvac:UpfrontPaymentsReceivedOrReceivable" scale="3" id="Narr_DOyymkFjjEmdEvaYrE0-VQ">10,000</ix:nonFraction>k (EUR <ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="As_Of_9_30_2022_ifrs-full_MajorCustomersAxis_cvac_GenmabMember_ifrs-full_ProductsAndServicesAxis_cvac_ResearchServicesCombinedWithIpLicenseMember_yfdi7QFOIken6nwnl1VeyA" decimals="-3" format="ixt:numdotdecimal" name="cvac:UpfrontPaymentsReceivedOrReceivable" scale="3" id="Narr_H9IZE8nyakyx1GI-UOMKZA">8,937</ix:nonFraction>k)*</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="As_Of_12_31_2021_ifrs-full_MajorCustomersAxis_cvac_GenmabMember_ifrs-full_ProductsAndServicesAxis_cvac_ResearchServicesCombinedWithIpLicenseMember_g3gSYGvJiUWtJe5m702osQ" decimals="-3" format="ixt:numdotdecimal" name="cvac:UpfrontPaymentsIncludedInContractLiabilities" scale="3" id="Tc_5kd5IemQvECXpYRJMrdUAw_10_4">5,362</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="As_Of_9_30_2022_ifrs-full_MajorCustomersAxis_cvac_GenmabMember_ifrs-full_ProductsAndServicesAxis_cvac_ResearchServicesCombinedWithIpLicenseMember_yfdi7QFOIken6nwnl1VeyA" decimals="-3" format="ixt:numdotdecimal" name="cvac:UpfrontPaymentsIncludedInContractLiabilities" scale="3" id="Tc_7DErYQzrRki-7j3gb5KDSQ_10_6">4,022</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="Duration_1_1_2021_To_9_30_2021_ifrs-full_MajorCustomersAxis_cvac_GenmabMember_ifrs-full_ProductsAndServicesAxis_cvac_ResearchServicesCombinedWithIpLicenseMember_awc6N7gG0USv7ZRK4TKDjw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod" scale="3" id="Tc_TtoNlvpcsUiv01uaCs6wEg_10_8">1,341</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="Duration_1_1_2022_To_9_30_2022_ifrs-full_MajorCustomersAxis_cvac_GenmabMember_ifrs-full_ProductsAndServicesAxis_cvac_ResearchServicesCombinedWithIpLicenseMember_72wIU7VnlkKKba3jsZpOBg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod" scale="3" id="Tc_twhOFT6kNk6oWGn87kdwmQ_10_10">1,341</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:16.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.86%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="As_Of_12_31_2021_ifrs-full_ProductsAndServicesAxis_cvac_ResearchServicesCombinedWithIpLicenseMember_SuxVutvjF02TZJEYT5xAUg" decimals="-3" format="ixt:numdotdecimal" name="cvac:UpfrontPaymentsIncludedInContractLiabilities" scale="3" id="Tc__-f4KpHHMk-c2XMPaDSThA_11_4">142,095</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.86%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="As_Of_9_30_2022_ifrs-full_ProductsAndServicesAxis_cvac_ResearchServicesCombinedWithIpLicenseMember_LDTxHzpQykydqGAuWhIjZQ" decimals="-3" format="ixt:numdotdecimal" name="cvac:UpfrontPaymentsIncludedInContractLiabilities" scale="3" id="Tc_1OSDc_2lFkOGJP7H568UXg_11_6">111,817</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="Duration_1_1_2021_To_9_30_2021_ifrs-full_ProductsAndServicesAxis_cvac_ResearchServicesCombinedWithIpLicenseMember_w9Lhj-1fbUylhw2h1TnuCA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod" scale="3" id="Tc_i4yy5FLZDESpa8g3v2qPHg_11_8">49,878</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="Duration_1_1_2022_To_9_30_2022_ifrs-full_ProductsAndServicesAxis_cvac_ResearchServicesCombinedWithIpLicenseMember_JmxbMa7EOkGM2UmzZvcaYA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod" scale="3" id="Tc_ECM65wz65kGpWNYhaE_LAQ_11_10">40,278</ix:nonFraction></b></p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:5.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1px;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">* Translated at the currency exchange rate prevailing on the transaction date.</p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><a id="Tc_8Xzxtplo0kaDx1mlAGfOpw_1_2"></a><a id="Tc_X5kerYBXeUiC5rOfLsggiA_1_4"></a><a id="Tc_058CXIUWm0KfMQu5QWyVLQ_2_2"></a><a id="Tc_gllnsCc4JUKnksgyMy0Y3g_2_4"></a><a id="Tc_e_gMZ7Dps0ivGl0X2e0rrA_3_2"></a><a id="Tc_p28SGhahfkW4IIP0Tl9e9g_3_4"></a><a id="Tc_V2qQoSqZhEWg8PFSLjnR6w_4_0"></a><a id="Tc_u3EcF7QjfE-tPVB_tRuJrg_5_0"></a><a id="_a57e6c2d_85a8_49ce_b083_2cd0093d1b8c"></a><a id="Tc_q5yk_0DJf0WqydMT4tmk7g_1_2"></a><a id="Tc_-VghbAuBdkuNd_8r1QX9IA_2_2"></a><a id="Tc_GLJXwXvvJ0-wW3MS9heWxw_2_4"></a><a id="Tc_JXEALicKX0ObRstND4WlPg_3_2"></a><a id="Tc_p-NwRUeEA0yh64JhbVMoCg_3_4"></a><a id="Tc_G6n5XGM3lUeWLs7mvbnQ7w_4_0"></a><a id="Tc_tIkwqOROyUS38YEA6NmBPQ_5_0"></a><a id="Tc_rwCQ9IaiqUmXQwoIU5j8FA_6_0"></a><a id="Tc_V3cARJ_Hn0Oui92D6dsD0g_7_0"></a><a id="Tc_urcTqUDTTEyNvbQ7a91Ygg_8_0"></a><a id="Tc_FyeetQSEJUqzXeaqVz7vOw_9_0"></a><a id="Tc_hekvg8A3NkGxCVOTaJs61g_10_0"></a><a id="_b8cc9470_7330_458c_a4e5_9e6eb4e16312"></a><a id="Tc_Xc0YHruNjUSVc2825Re-aQ_1_2"></a><a id="Tc_LfGehbsj-Ue0T6Ke2aa4xQ_2_2"></a><a id="Tc_s-jRQ33jr0mXD3_Z5ZKU4g_2_4"></a><a id="Tc_vu_PCOTF-EiyATaXq8Sn8A_3_2"></a><a id="Tc_h-yROg3CP0m_pjWS85bU2A_3_4"></a><a id="Tc_nT9KEfVk80efHBf7krZhQw_4_0"></a><a id="Tc_HW-gAnQonU-CvyRgrXhy8Q_5_0"></a><a id="Tc_nui2mGMJ10Sf4uxIUur68g_6_0"></a><a id="Tc_0ZPxMj5Uz0q-hx3LMky2mA_7_0"></a><ix:continuation id="Tb_bjSJ6MGdEU6Hl25QLMb2og_cont1" continuedAt="Tb_bjSJ6MGdEU6Hl25QLMb2og_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">Contract balances:</p><ix:nonNumeric contextRef="Duration_1_1_2022_To_9_30_2022_GrYkE3mhHEiRA4fxgfABRg" name="ifrs-full:ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory" id="Tb_bMLmEhD9vkKSLANGOYHYdg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:74.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#xA0;&#xA0;&#xA0;&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#xA0;&#xA0;&#xA0;&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September 30, </b></p></td></tr><tr><td style="vertical-align:bottom;width:74.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR k</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR k</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Trade receivables</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="As_Of_12_31_2021_kQVJTWPgRUeESxCd99xt9A" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:CurrentTradeReceivables" scale="3" id="Tc_h-NnX8qxLU-Ygk4nDTKw1w_4_2">18,504</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="As_Of_9_30_2022_zuGVrjesE0WhwXSGmTqsgA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:CurrentTradeReceivables" scale="3" id="Tc_0GAKBR1hlUOSikyktRAjkA_4_4">6,170</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:74.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Contract liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="As_Of_12_31_2021_kQVJTWPgRUeESxCd99xt9A" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ContractLiabilities" scale="3" id="Tc_OON6KzFoiEe9sFglNj2I7g_5_2">142,095</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="As_Of_9_30_2022_zuGVrjesE0WhwXSGmTqsgA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ContractLiabilities" scale="3" id="Tc_SBhnVCZOOUOlDTvd2ZIlJQ_5_4">111,817</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Trade receivables are non-interest bearing and are generally settled within 30 to 45 days. The contract liabilities contain upfront payments and milestone payments from Collaboration agreements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">3.2 Cost of sales</span></p><ix:nonNumeric contextRef="Duration_1_1_2022_To_9_30_2022_GrYkE3mhHEiRA4fxgfABRg" name="ifrs-full:DisclosureOfExpensesByNatureExplanatory" id="Group_GxE3bduSwEWI74TGKMZFrw" continuedAt="Group_GxE3bduSwEWI74TGKMZFrw_2" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">The cost of sales consists of the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#x200B;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:71.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#xA0;&#xA0;&#xA0;&#xA0;</b></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:27.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Nine months ended September 30,</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#xA0;&#xA0;&#xA0;&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR&#xA0;k</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR k</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Personnel</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="Duration_1_1_2021_To_9_30_2021_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsCostOfSalesMember__hz63wg8m0S72b0NYjaYHQ" decimals="-3" format="ixt:numdotdecimal" name="cvac:PersonnelExpenses" scale="3" id="Tc_ySrE3ba2xEumGtIBvdolMA_4_2">14,897</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="Duration_1_1_2022_To_9_30_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsCostOfSalesMember_em7QzpMx20e5-T4Zm2ygyA" decimals="-3" format="ixt:numdotdecimal" name="cvac:PersonnelExpenses" scale="3" id="Tc_VS7pPFQXHEaaocbBSV6Svw_4_4">19,076</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:71.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Materials</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="Duration_1_1_2021_To_9_30_2021_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsCostOfSalesMember__hz63wg8m0S72b0NYjaYHQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:RawMaterialsAndConsumablesUsed" scale="3" id="Tc_zJPppj0Bg06RlXc2jHIiUw_5_2">13,945</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="Duration_1_1_2022_To_9_30_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsCostOfSalesMember_em7QzpMx20e5-T4Zm2ygyA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:RawMaterialsAndConsumablesUsed" scale="3" id="Tc_ydWbSDbz3Uq1zZK5CdcBsQ_5_4">48,962</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:71.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Third-party services</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="Duration_1_1_2021_To_9_30_2021_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsCostOfSalesMember__hz63wg8m0S72b0NYjaYHQ" decimals="-3" format="ixt:numdotdecimal" name="cvac:ThirdPartyServiceExpenses" scale="3" id="Tc_idWlHa2g5Ue-QqexuDzikw_6_2">130,795</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="Duration_1_1_2022_To_9_30_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsCostOfSalesMember_em7QzpMx20e5-T4Zm2ygyA" decimals="-3" format="ixt:numdotdecimal" name="cvac:ThirdPartyServiceExpenses" scale="3" id="Tc_fho0Ij1drUiWSn4BJ5trLg_6_4">24,030</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:71.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Maintenance and lease</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="Duration_1_1_2021_To_9_30_2021_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsCostOfSalesMember__hz63wg8m0S72b0NYjaYHQ" decimals="-3" format="ixt:numdotdecimal" name="cvac:MaintenanceAndLeaseExpenses" scale="3" id="Tc_7h7QM2ejxUCFdxQIligl7A_7_2">3,227</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="Duration_1_1_2022_To_9_30_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsCostOfSalesMember_em7QzpMx20e5-T4Zm2ygyA" decimals="-3" format="ixt:numdotdecimal" name="cvac:MaintenanceAndLeaseExpenses" scale="3" id="Tc_MFBSeYa-3UaOvCUQ1J0wMw_7_4">1,479</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:71.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Amortization and depreciation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="Duration_1_1_2021_To_9_30_2021_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsCostOfSalesMember__hz63wg8m0S72b0NYjaYHQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:DepreciationAndAmortisationExpense" scale="3" id="Tc_HZmu1pNorkmRA1W41R8yyA_8_2">2,944</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="Duration_1_1_2022_To_9_30_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsCostOfSalesMember_em7QzpMx20e5-T4Zm2ygyA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:DepreciationAndAmortisationExpense" scale="3" id="Tc_uLTT3Uc5bken7O24YwHOYw_8_4">9,757</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:71.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="Duration_1_1_2021_To_9_30_2021_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsCostOfSalesMember__hz63wg8m0S72b0NYjaYHQ" decimals="-3" format="ixt:numdotdecimal" name="cvac:OtherExpense" scale="3" id="Tc_ZtLd2gVNG0aTugHrmtzlWg_9_2">2,369</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="Duration_1_1_2022_To_9_30_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsCostOfSalesMember_em7QzpMx20e5-T4Zm2ygyA" decimals="-3" format="ixt:numdotdecimal" name="cvac:OtherExpense" scale="3" id="Tc_GhFVGaadkUi0H3ngwNEgOA_9_4">688</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:71.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.66%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="Duration_1_1_2021_To_9_30_2021_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsCostOfSalesMember__hz63wg8m0S72b0NYjaYHQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ExpenseByNature" scale="3" id="Tc_atgHK84fakCsyz0YpI3l1Q_10_2">168,177</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.66%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="Duration_1_1_2022_To_9_30_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsCostOfSalesMember_em7QzpMx20e5-T4Zm2ygyA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ExpenseByNature" scale="3" id="Tc_pz02VFLU5kGBvb2a4y3LXg_10_4">103,992</ix:nonFraction>)</b></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#x200B;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">During the nine months ended September 30, 2022, cost of sales mainly decreased compared to the same period of 2021 due to Third-Party Services having been higher last year for set-up activities for the CVnCoV production process. This decrease was partially offset by increased write-offs for raw materials amounting to EUR <ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="Duration_1_1_2022_To_9_30_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsCostOfSalesMember_em7QzpMx20e5-T4Zm2ygyA" decimals="-3" format="ixt:numdotdecimal" name="cvac:WriteOffOfRawMaterials" scale="3" id="Narr_gHjndlsm3kWTve4HDRZLPA">41,295</ix:nonFraction>k, which were procured for manufacturing of products to sell to GSK that are now no longer expected to be purchased.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">3.3 Selling and distribution expenses</span></p><ix:continuation id="Group_GxE3bduSwEWI74TGKMZFrw_2" continuedAt="Group_GxE3bduSwEWI74TGKMZFrw_3"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:16.75pt;margin:0pt;">Selling and distribution expenses consist of the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#x200B;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:71.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#xA0;&#xA0;&#xA0;&#xA0;</b></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:27.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Nine months ended September 30,</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#xA0;&#xA0;&#xA0;&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR&#xA0;k</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR k</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Personnel</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="Duration_1_1_2021_To_9_30_2021_cvac_IfrsIncomeStatementLocationAxis_cvac_SellingAndDistributionExpensesMember_-Uy3t4myckOOiYqfNnLrvA" decimals="-3" format="ixt:numdotdecimal" name="cvac:PersonnelExpenses" scale="3" id="Tc_EH9RoSSrREC-FT4GmVJGsw_4_2">943</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="Duration_1_1_2022_To_9_30_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_SellingAndDistributionExpensesMember_nx7DDIuvEEyD8XuyuNsS6Q" decimals="-3" format="ixt:numdotdecimal" name="cvac:PersonnelExpenses" scale="3" id="Tc_aN6fkIxqCUaAemELS2ZmkQ_4_4">1,467</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:71.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Amortization and depreciation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="Duration_1_1_2021_To_9_30_2021_cvac_IfrsIncomeStatementLocationAxis_cvac_SellingAndDistributionExpensesMember_-Uy3t4myckOOiYqfNnLrvA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:DepreciationAndAmortisationExpense" scale="3" id="Tc_RGsA7SCRjk2s1MTyLSjyTA_5_2">65</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="Duration_1_1_2022_To_9_30_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_SellingAndDistributionExpensesMember_nx7DDIuvEEyD8XuyuNsS6Q" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:DepreciationAndAmortisationExpense" scale="3" id="Tc__aEDp2VCkUKS02W_4NPc2Q_5_4">38</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:71.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="Duration_1_1_2021_To_9_30_2021_cvac_IfrsIncomeStatementLocationAxis_cvac_SellingAndDistributionExpensesMember_-Uy3t4myckOOiYqfNnLrvA" decimals="-3" format="ixt:numdotdecimal" name="cvac:OtherExpense" scale="3" id="Tc_DHxXJapsGkGcOgNevu-i3A_6_2">224</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="Duration_1_1_2022_To_9_30_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_SellingAndDistributionExpensesMember_nx7DDIuvEEyD8XuyuNsS6Q" decimals="-3" format="ixt:numdotdecimal" name="cvac:OtherExpense" scale="3" id="Tc_QNplw96MWUSNMIC6rrJS3A_6_4">320</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:71.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="Duration_1_1_2021_To_9_30_2021_cvac_IfrsIncomeStatementLocationAxis_cvac_SellingAndDistributionExpensesMember_-Uy3t4myckOOiYqfNnLrvA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ExpenseByNature" scale="3" id="Tc_pAs3_m7fU0uybArsYJSjFg_7_2">1,232</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="Duration_1_1_2022_To_9_30_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_SellingAndDistributionExpensesMember_nx7DDIuvEEyD8XuyuNsS6Q" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ExpenseByNature" scale="3" id="Tc_YhHSZxNuNEqdD-SRg-eauQ_7_4">1,825</ix:nonFraction>)</b></p></td></tr></table></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#x200B;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Personnel expenses mainly include salary and salary-related expenses, during the nine months ended September 30, 2022 of EUR <ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="Duration_1_1_2022_To_9_30_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_SellingAndDistributionExpensesMember_nx7DDIuvEEyD8XuyuNsS6Q" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ShorttermEmployeeBenefitsExpense" scale="3" id="Narr_Fo9WJrim9U6QzmcQ60WIaQ">1,315</ix:nonFraction>k (September 30, 2021: <ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="Duration_1_1_2021_To_9_30_2021_cvac_IfrsIncomeStatementLocationAxis_cvac_SellingAndDistributionExpensesMember_-Uy3t4myckOOiYqfNnLrvA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ShorttermEmployeeBenefitsExpense" scale="3" id="Narr_metJN2F5Zk-94A4ZbxPIOA">777</ix:nonFraction>k) and share-based payment expense of EUR <ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="Duration_1_1_2022_To_9_30_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_SellingAndDistributionExpensesMember_nx7DDIuvEEyD8XuyuNsS6Q" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" scale="3" id="Narr_VpSrMVL8EUCfwINCFWvV_A">152</ix:nonFraction>k (September 30, 2021: <ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="Duration_1_1_2021_To_9_30_2021_cvac_IfrsIncomeStatementLocationAxis_cvac_SellingAndDistributionExpensesMember_-Uy3t4myckOOiYqfNnLrvA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" scale="3" id="Narr_ptk85Gecc02mE9Fuf1TCRA">166</ix:nonFraction>k).</p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><a id="_7ed042bf_5bb6_4c25_90ed_255d0d66ff45"></a><a id="Tc_zlSQCicPxUKyd1M1uv8YRg_1_2"></a><a id="Tc_tleNpHbqE0yZbsgU3Uk0Sg_2_2"></a><a id="Tc_w1wAIfCJaE21gUMZy94UeA_2_4"></a><a id="Tc_RQO1OQmHcEOyTVwvtrLtUw_3_2"></a><a id="Tc_luUSaKUD_ESgYNzMyKZ9Fw_3_4"></a><a id="Tc_9jLJ32lyoUGUtP84frKXSQ_4_0"></a><a id="Tc_68WpXJBH10WUbUqSrxgiiw_5_0"></a><a id="Tc_L1uzLW7ArEKRAk1l7SPcgg_6_0"></a><a id="Tc_-sQBKWBHGU6k6USgfGbb9A_7_0"></a><a id="Tc_bz1L6ST3fk6yjN077bBavg_8_0"></a><a id="Tc_JQuGla-kdEeSjelZMd3yXQ_9_0"></a><a id="Tc_nphj01VIVk6jJYxR1dUT5w_10_0"></a><a id="Tc_Q6rZqNp-oUSq03vFwNQ-PA_11_0"></a><a id="_4327f95d_500a_46c4_8df7_d7cca2e714e3"></a><a id="Tc_KOY_q83bMUWYNhCuhLsWkw_1_2"></a><a id="Tc_ObIK315uk0SyEj6OrzGnJA_2_2"></a><a id="Tc_sEYFXk4RBkWWCIuayAOxLg_2_4"></a><a id="Tc_TUQYTtKUmkyTnB9hk7k5bQ_3_2"></a><a id="Tc_UN6Hn2bPDkKQk5xav8s7XA_3_4"></a><a id="Tc_dfN8HpLNUEaYmwE65yo01A_4_0"></a><a id="Tc_xx67H3QxGECJXnSGBIsJMg_5_0"></a><a id="Tc_2RRmVJJL9EOn9DwJQOgWBQ_6_0"></a><a id="Tc_o23PxBBw6EKpRDgKiy5zcg_7_0"></a><a id="Tc_FBhMrdnaikCPgLXoIxj6EA_8_0"></a><a id="Tc_1OTwiHGIIUmsn-XZgCsGzQ_9_0"></a><a id="Tc_xih0LE9rlkqGugLmSwI_sg_10_0"></a><ix:continuation id="Tb_bjSJ6MGdEU6Hl25QLMb2og_cont2" continuedAt="Tb_bjSJ6MGdEU6Hl25QLMb2og_cont3"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">3.4 Research and development expenses</span></p><ix:continuation id="Group_GxE3bduSwEWI74TGKMZFrw_3" continuedAt="Group_GxE3bduSwEWI74TGKMZFrw_4"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">R&amp;D expenses consists of the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:71.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#xA0;&#xA0;&#xA0;&#xA0;</b></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:27.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Nine months ended September 30,</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#xA0;&#xA0;&#xA0;&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR&#xA0;k</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR k</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Materials</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="Duration_1_1_2021_To_9_30_2021_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsResearchAndDevelopmentExpenseMember_0xeLKyJYAEWBhUtu43GF8g" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:RawMaterialsAndConsumablesUsed" scale="3" id="Tc__EEOUFAdz0KOiJe6K5GumQ_4_2">5,893</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="Duration_1_1_2022_To_9_30_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsResearchAndDevelopmentExpenseMember_u-Q9gJOBkUqQxOVDUX24Hw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:RawMaterialsAndConsumablesUsed" scale="3" id="Tc_I7wGEB9VX0GX-WXoJTEwFg_4_4">29,618</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:71.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Personnel</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="Duration_1_1_2021_To_9_30_2021_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsResearchAndDevelopmentExpenseMember_0xeLKyJYAEWBhUtu43GF8g" decimals="-3" format="ixt:numdotdecimal" name="cvac:PersonnelExpenses" scale="3" id="Tc_OT_T_K5yJU2uTIOhy8CSFg_5_2">25,209</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="Duration_1_1_2022_To_9_30_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsResearchAndDevelopmentExpenseMember_u-Q9gJOBkUqQxOVDUX24Hw" decimals="-3" format="ixt:numdotdecimal" name="cvac:PersonnelExpenses" scale="3" id="Tc_sCx4rIWlP0mNch_ErPpoew_5_4">24,326</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:71.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Amortization and depreciation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="Duration_1_1_2021_To_9_30_2021_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsResearchAndDevelopmentExpenseMember_0xeLKyJYAEWBhUtu43GF8g" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:DepreciationAndAmortisationExpense" scale="3" id="Tc_PJuEcGfPHUm-rj7V1Mtnig_6_2">3,051</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="Duration_1_1_2022_To_9_30_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsResearchAndDevelopmentExpenseMember_u-Q9gJOBkUqQxOVDUX24Hw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:DepreciationAndAmortisationExpense" scale="3" id="Tc_RMKNkRgB2UGsnbkxOMzzqA_6_4">3,866</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:71.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Patents and fees to register a legal right</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="Duration_1_1_2021_To_9_30_2021_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsResearchAndDevelopmentExpenseMember_0xeLKyJYAEWBhUtu43GF8g" decimals="-3" format="ixt:numdotdecimal" name="cvac:PatentsAndFeesToRegisterLegalRight" scale="3" id="Tc_Z3lw779MZkSTvpJwhTrXNg_7_2">2,372</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="Duration_1_1_2022_To_9_30_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsResearchAndDevelopmentExpenseMember_u-Q9gJOBkUqQxOVDUX24Hw" decimals="-3" format="ixt:numdotdecimal" name="cvac:PatentsAndFeesToRegisterLegalRight" scale="3" id="Tc_pr2KSBLdbk-n4zztmtxyRg_7_4">2,536</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:71.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Third-party services</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="Duration_1_1_2021_To_9_30_2021_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsResearchAndDevelopmentExpenseMember_0xeLKyJYAEWBhUtu43GF8g" decimals="-3" format="ixt:numdotdecimal" name="cvac:ThirdPartyServiceExpenses" scale="3" id="Tc_rY1FtAzcV0Wlb_m6bayesQ_8_2">246,185</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="Duration_1_1_2022_To_9_30_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsResearchAndDevelopmentExpenseMember_u-Q9gJOBkUqQxOVDUX24Hw" decimals="-3" format="ixt:numdotdecimal" name="cvac:ThirdPartyServiceExpenses" sign="-" scale="3" id="Tc_2IHYOTdbJk6E9-Iqx8hMbA_8_4">28,525</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Maintenance and lease </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="Duration_1_1_2021_To_9_30_2021_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsResearchAndDevelopmentExpenseMember_0xeLKyJYAEWBhUtu43GF8g" decimals="-3" format="ixt:numdotdecimal" name="cvac:MaintenanceAndLeaseExpenses" scale="3" id="Tc_Nci8AzWL8EGYmwDs2oA5Gw_9_2">291</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="Duration_1_1_2022_To_9_30_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsResearchAndDevelopmentExpenseMember_u-Q9gJOBkUqQxOVDUX24Hw" decimals="-3" format="ixt:numdotdecimal" name="cvac:MaintenanceAndLeaseExpenses" scale="3" id="Tc_yq31NmGyxE6VZyQ5gg-w-w_9_4">789</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:71.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="Duration_1_1_2021_To_9_30_2021_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsResearchAndDevelopmentExpenseMember_0xeLKyJYAEWBhUtu43GF8g" decimals="-3" format="ixt:numdotdecimal" name="cvac:OtherExpense" scale="3" id="Tc_Dfx0C22ye0OxR_oN0ciR4w_10_2">1,727</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="Duration_1_1_2022_To_9_30_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsResearchAndDevelopmentExpenseMember_u-Q9gJOBkUqQxOVDUX24Hw" decimals="-3" format="ixt:numdotdecimal" name="cvac:OtherExpense" scale="3" id="Tc_CFe0Hu1vSkCAV2h_WRqJKw_10_4">2,324</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:71.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="Duration_1_1_2021_To_9_30_2021_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsResearchAndDevelopmentExpenseMember_0xeLKyJYAEWBhUtu43GF8g" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ExpenseByNature" scale="3" id="Tc_rsx_serQ0EKe6fpWUAy1Tw_11_2">284,728</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="Duration_1_1_2022_To_9_30_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsResearchAndDevelopmentExpenseMember_u-Q9gJOBkUqQxOVDUX24Hw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ExpenseByNature" scale="3" id="Tc_sgiLdFDcLUKb3d1-xkqtHA_11_4">34,934</ix:nonFraction>)</b></p></td></tr></table></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">During the nine months ended September 30, 2022, research and development expenses decreased significantly in comparison to the same period of 2021, as the prior period was largely impacted by the Group&#xB4;s CVnCoV program in 2021. In the prior year, these expenses consist primarily of cost incurred to CROs involved in the CVnCoV development as well as materials used in the administration of clinical trials. As a result of more participants leaving the clinical trials, prior to completion, than originally estimated and of renegotiations of contracts with CROs, in the nine months ended September 30, 2022, the estimated outstanding costs for the CVnCoV studies decreased, due primarily to re-negotiations of contracts, and resulted in the reversal of provision for onerous contracts in the amount of EUR <ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="As_Of_9_30_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsResearchAndDevelopmentExpenseMember_GiIhuFW_ukOtSf0Bvkce7w" decimals="-3" format="ixt:numdotdecimal" name="cvac:ReversalOfProvisionForOnerousContracts" scale="3" id="Narr_H572OwJbbUu7BCIaCkGJbw">36,769</ix:nonFraction>k. Additionally, a net gain for a change of estimate in the contract termination provisions resulted primarily from GSK taking over, from the Group, committed capacity at Novartis (see Note 3.6 for additional information). The net effect of these two events resulted in an overall gain within the Third-party services category.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Further, in the nine months ended on September 30, 2022, the balance was impacted by an increase in material consumed in research and development. As of September 30, 2022, the Group had no development expenditures which met the requirements for capitalization and thus none have been capitalized. In 2021, according to the terms and conditions of the grant from BMBF, the Group earned income (recognized in other operating income) for certain eligible expenses incurred for the COVID-19 vaccine development; refer to Note 3.6 for more information on amounts recognized from this grant in the nine months ended September 30, 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Personnel expenses mainly include salary and salary-related expenses, during the nine months ended September 30, 2022 of EUR <ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="Duration_1_1_2022_To_9_30_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsResearchAndDevelopmentExpenseMember_u-Q9gJOBkUqQxOVDUX24Hw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ShorttermEmployeeBenefitsExpense" scale="3" id="Narr_TkhXmc2ZtUKhMjPdOPAuFw">23,846</ix:nonFraction>k (September 30, 2021: EUR <ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="Duration_1_1_2021_To_9_30_2021_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsResearchAndDevelopmentExpenseMember_0xeLKyJYAEWBhUtu43GF8g" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ShorttermEmployeeBenefitsExpense" scale="3" id="Narr_IcEIIh9y3Em64IASZUfXrw">24,637</ix:nonFraction>k) and share-based payment expense of EUR <ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="Duration_1_1_2022_To_9_30_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsResearchAndDevelopmentExpenseMember_u-Q9gJOBkUqQxOVDUX24Hw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" scale="3" id="Narr_ZFbfv6WjnEuoxa_JcSQ2_A">480</ix:nonFraction>k (September 30, 2021: <ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="Duration_1_1_2021_To_9_30_2021_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsResearchAndDevelopmentExpenseMember_0xeLKyJYAEWBhUtu43GF8g" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" scale="3" id="Narr_huMSulLDRUWS96fINzbdgQ">572</ix:nonFraction>k).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">3.5 General and administrative expenses</span></p><ix:continuation id="Group_GxE3bduSwEWI74TGKMZFrw_4"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">General and administrative expenses consist of the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#x200B;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:71.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:27.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Nine months ended September 30,</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#xA0;&#xA0;&#xA0;&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#xA0;&#xA0;&#xA0;&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR&#xA0;k</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#xA0;&#xA0;&#xA0;&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR k</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Personnel</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="Duration_1_1_2021_To_9_30_2021_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsGeneralAndAdministrativeExpenseMember_pxlCrV2ySESTCd1lVbTlfg" decimals="-3" format="ixt:numdotdecimal" name="cvac:PersonnelExpenses" scale="3" id="Tc_WRRNwgkY6EaCtVtOT9ZNvQ_4_2">30,039</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="Duration_1_1_2022_To_9_30_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsGeneralAndAdministrativeExpenseMember_KMYenp1F1EOV1PWLAQFrFw" decimals="-3" format="ixt:numdotdecimal" name="cvac:PersonnelExpenses" scale="3" id="Tc_wS5HHqfygk-kYA-t9eJ8bw_4_4">27,971</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:71.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Maintenance and lease </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="Duration_1_1_2021_To_9_30_2021_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsGeneralAndAdministrativeExpenseMember_pxlCrV2ySESTCd1lVbTlfg" decimals="-3" format="ixt:numdotdecimal" name="cvac:MaintenanceAndLeaseExpenses" scale="3" id="Tc_7CEGF7EAQUCBf3yEdCJWqg_5_2">2,106</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="Duration_1_1_2022_To_9_30_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsGeneralAndAdministrativeExpenseMember_KMYenp1F1EOV1PWLAQFrFw" decimals="-3" format="ixt:numdotdecimal" name="cvac:MaintenanceAndLeaseExpenses" scale="3" id="Tc_ciVyAOHyXEykjbN2qoioow_5_4">4,614</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:71.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Third-party services</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="Duration_1_1_2021_To_9_30_2021_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsGeneralAndAdministrativeExpenseMember_pxlCrV2ySESTCd1lVbTlfg" decimals="-3" format="ixt:numdotdecimal" name="cvac:ThirdPartyServiceExpenses" scale="3" id="Tc_xKVliXbwvUqdh2RS2UH7Gw_6_2">28,699</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="Duration_1_1_2022_To_9_30_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsGeneralAndAdministrativeExpenseMember_KMYenp1F1EOV1PWLAQFrFw" decimals="-3" format="ixt:numdotdecimal" name="cvac:ThirdPartyServiceExpenses" scale="3" id="Tc_vbUA99jxu0q7E_gADCqy5g_6_4">19,607</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:71.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Legal and other professional services</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="Duration_1_1_2021_To_9_30_2021_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsGeneralAndAdministrativeExpenseMember_pxlCrV2ySESTCd1lVbTlfg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ProfessionalFeesExpense" scale="3" id="Tc_2az495MY20WSnokNkXhZZQ_7_2">6,394</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="Duration_1_1_2022_To_9_30_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsGeneralAndAdministrativeExpenseMember_KMYenp1F1EOV1PWLAQFrFw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ProfessionalFeesExpense" scale="3" id="Tc_q6K1PlGC8UaoEIFr1Qn8Fw_7_4">7,215</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:71.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Amortization and depreciation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="Duration_1_1_2021_To_9_30_2021_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsGeneralAndAdministrativeExpenseMember_pxlCrV2ySESTCd1lVbTlfg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:DepreciationAndAmortisationExpense" scale="3" id="Tc_WJ0jA7_vsUKD1ZjY3OxGgw_8_2">5,575</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="Duration_1_1_2022_To_9_30_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsGeneralAndAdministrativeExpenseMember_KMYenp1F1EOV1PWLAQFrFw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:DepreciationAndAmortisationExpense" scale="3" id="Tc_K9gg6daWn02EjLDziHDjCw_8_4">9,444</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:71.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="Duration_1_1_2021_To_9_30_2021_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsGeneralAndAdministrativeExpenseMember_pxlCrV2ySESTCd1lVbTlfg" decimals="-3" format="ixt:numdotdecimal" name="cvac:OtherExpense" scale="3" id="Tc_5konuDMRe0iaTBm4TuPPfg_9_2">7,974</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="Duration_1_1_2022_To_9_30_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsGeneralAndAdministrativeExpenseMember_KMYenp1F1EOV1PWLAQFrFw" decimals="-3" format="ixt:numdotdecimal" name="cvac:OtherExpense" scale="3" id="Tc_hzEz8S69JUq4xfIJEQifiw_9_4">9,168</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:71.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.1%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="Duration_1_1_2021_To_9_30_2021_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsGeneralAndAdministrativeExpenseMember_pxlCrV2ySESTCd1lVbTlfg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ExpenseByNature" scale="3" id="Tc_JTJ4uxW6bkKFF7QuYwNaBQ_10_2">80,787</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.14%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="Duration_1_1_2022_To_9_30_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsGeneralAndAdministrativeExpenseMember_KMYenp1F1EOV1PWLAQFrFw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ExpenseByNature" scale="3" id="Tc_va30oP7GAUiXOUSfAlHUFw_10_4">78,019</ix:nonFraction>)</b></p></td></tr></table></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#x200B;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Personnel expenses mainly include salary and salary-related expenses, during the nine months ended September 30, 2022, of EUR <ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="Duration_1_1_2022_To_9_30_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsGeneralAndAdministrativeExpenseMember_KMYenp1F1EOV1PWLAQFrFw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ShorttermEmployeeBenefitsExpense" scale="3" id="Narr_iVkyR7jUrkS9kXPu01ziAg">21,621</ix:nonFraction>k (September 30, 2021: EUR <ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="Duration_1_1_2021_To_9_30_2021_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsGeneralAndAdministrativeExpenseMember_pxlCrV2ySESTCd1lVbTlfg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ShorttermEmployeeBenefitsExpense" scale="3" id="Narr_e2MFnCtBwE2gTpTbt69raA">19,492</ix:nonFraction>k) and share-based payment expense of EUR <ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="Duration_1_1_2022_To_9_30_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsGeneralAndAdministrativeExpenseMember_KMYenp1F1EOV1PWLAQFrFw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" scale="3" id="Narr_uA9qKpN1RkqTqTTJpVd7FQ">5,823</ix:nonFraction>k (September 30, 2021: EUR <ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="Duration_1_1_2021_To_9_30_2021_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsGeneralAndAdministrativeExpenseMember_pxlCrV2ySESTCd1lVbTlfg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" scale="3" id="Narr_MKI3vV8QrUmMbNiXEfqaFg">10,547</ix:nonFraction>k). During the nine months ended September 30, 2022, third-party services expenses decreased, compared to the same period of 2021, mainly due to less consulting services. The &#x201C;Other&#x201D; mainly results from insurance costs related to the D&amp;O insurance EUR <ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="Duration_1_1_2022_To_9_30_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsGeneralAndAdministrativeExpenseMember_KMYenp1F1EOV1PWLAQFrFw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:InsuranceExpense" scale="3" id="Narr_WbSeF3r2m0e6hwB7c9Bg9g">4,150</ix:nonFraction>k, (September 30, 2021: EUR <ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="Duration_1_1_2021_To_9_30_2021_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsGeneralAndAdministrativeExpenseMember_pxlCrV2ySESTCd1lVbTlfg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:InsuranceExpense" scale="3" id="Narr_2Dgjdayl9E6RSDDffGnLiw">4,073</ix:nonFraction>k).</p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><a id="Tc_-Cv8GXc1OkaIrrI_kIIb-Q_1_2"></a><a id="Tc_QHVwlnWz3E-r__fNP-IFxg_2_2"></a><a id="Tc_HPlW-KOAmkWmmiHaZyRuzQ_2_4"></a><a id="Tc_QYOUMkNuPEyFaqOqk2Yn-Q_3_2"></a><a id="Tc_wFC8mXqFQEyQbOzUSnqxSA_3_4"></a><a id="Tc_QA-kytj6o0KKnPmAFEdAIQ_4_0"></a><a id="Tc_-OoJl1cozEiTUr50BtP65A_4_2"></a><a id="Tc_xmLGCHsiqUyzv8orkoFHmQ_5_0"></a><a id="Tc_dUOqSFG7yUu2eZ63zXT-zA_5_2"></a><a id="Tc_E2twZlaiREmhEHzuV4DgIA_6_0"></a><a id="Tc_MBf5FMMAoUGZsxnTDks4QA_6_2"></a><a id="Tc_omZOGzb6NEWLs13hF1Iajw_7_0"></a><a id="Tc_O0Qz1_m0_UesWCQb_xMDnA_8_0"></a><a id="Tc_QFZN3uXRfkWXcBQ4J8OyyA_9_0"></a><ix:continuation id="Tb_bjSJ6MGdEU6Hl25QLMb2og_cont3"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">3.6 Other operating income</span></p><ix:nonNumeric contextRef="Duration_1_1_2022_To_9_30_2022_GrYkE3mhHEiRA4fxgfABRg" name="ifrs-full:DisclosureOfOtherOperatingIncomeExplanatory" id="Tb_fg8RAfbD2k2mRwTNYmZ7Gw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#x200B;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:71.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:27.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Nine months ended September 30,</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#xA0;&#xA0;&#xA0;&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#xA0;&#xA0;&#xA0;&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR&#xA0;k</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#xA0;&#xA0;&#xA0;&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR k</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Compensation for CMO/Material transfer</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#x2014;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="Duration_1_1_2022_To_9_30_2022_GrYkE3mhHEiRA4fxgfABRg" decimals="-3" format="ixt:numdotdecimal" name="cvac:CompensationForContractManufacturingOrganizationsTransfer" scale="3" id="Tc_KxtqA1q93EG3rw6VFdnUyw_4_4">34,379</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Reimbursement claim</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#x2014;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="Duration_1_1_2022_To_9_30_2022_GrYkE3mhHEiRA4fxgfABRg" decimals="-3" format="ixt:numdotdecimal" name="cvac:CostOfReimbursementClaim" scale="3" id="Tc_pIrCWRk4b0mE77cI_TZBmA_5_4">610</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Sale of equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#x2014;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="Duration_1_1_2022_To_9_30_2022_GrYkE3mhHEiRA4fxgfABRg" decimals="-3" format="ixt:numdotdecimal" name="cvac:SaleOfEquipment" scale="3" id="Tc_F0uQtZIFoEWtaIavuwqS8A_6_4">310</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Grants and other cost reimbursements from government agencies and similar bodies</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="Duration_1_1_2021_To_9_30_2021_5RS16WkLc0uS2ug_bqUm-g" decimals="-3" format="ixt:numdotdecimal" name="cvac:OtherOperatingIncomeGovernmentGrants" scale="3" id="Tc_sEeppZoF6kGgzhkRSo5XHA_7_2">64,307</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="Duration_1_1_2022_To_9_30_2022_GrYkE3mhHEiRA4fxgfABRg" decimals="-3" format="ixt:numdotdecimal" name="cvac:OtherOperatingIncomeGovernmentGrants" scale="3" id="Tc_K_0G_946JUasP0rLmbketA_7_4">377</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="Duration_1_1_2021_To_9_30_2021_5RS16WkLc0uS2ug_bqUm-g" decimals="-3" format="ixt:numdotdecimal" name="cvac:MiscellaneousOtherOperatingIncomeOther" scale="3" id="Tc_6kx-vx3JVUqaB1Aw-Xp5dA_8_2">2,439</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="Duration_1_1_2022_To_9_30_2022_GrYkE3mhHEiRA4fxgfABRg" decimals="-3" format="ixt:numdotdecimal" name="cvac:MiscellaneousOtherOperatingIncomeOther" scale="3" id="Tc_4HHifBwiHkuAyt2LOs7NCA_8_4">225</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="Duration_1_1_2021_To_9_30_2021_5RS16WkLc0uS2ug_bqUm-g" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:MiscellaneousOtherOperatingIncome" scale="3" id="Tc_0DMSoCK0a0WUjfgeQl7Ghg_9_2">66,746</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="Duration_1_1_2022_To_9_30_2022_GrYkE3mhHEiRA4fxgfABRg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:MiscellaneousOtherOperatingIncome" scale="3" id="Tc_t_xgKQB3C0GdpIcrREIbOg_9_4">35,901</ix:nonFraction></b></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#x200B;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In March 2022, CureVac AG and GlaxoSmithKline Biologicals SA amended and restated the 2020 GSK agreement and the GSK COVID Agreement in connection with GSK entering into a direct agreement with Novartis for use of Novartis as a CMO at the same time as CureVac exited its CMO agreement with Novartis. Additionally, under the restated agreement, CureVac is entitled to further compensation by GSK. The compensations mainly consist of a consideration for set-up activities undertaken by CureVac (EUR <ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="Duration_1_1_2022_To_9_30_2022_srt_CounterpartyNameAxis_cvac_GlaxosmithklineMember_3G2M3SARj0GkTuTa4M37uw" decimals="-3" format="ixt:numdotdecimal" name="cvac:CompensationForContractManufacturingOrganizationsTransferConsiderationForSetUpActivities" scale="3" id="Narr_KE8v_hwqEUWyQnaljktb0Q">20,500</ix:nonFraction>k) and for reimbursement of prepayments (EUR <ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="Duration_1_1_2022_To_9_30_2022_srt_CounterpartyNameAxis_cvac_GlaxosmithklineMember_3G2M3SARj0GkTuTa4M37uw" decimals="-3" format="ixt:numdotdecimal" name="cvac:CompensationForContractManufacturingOrganizationsTransferManufacturingInterimPeriodReimbursableExpenses" scale="3" id="Narr_IMSIeF61TU6n8eQ-_Zgv6w">12,000</ix:nonFraction>k), which were recognized in other operating income in the nine months ended September 30, 2022. As an additional result of this agreement, certain reserved capacity at Novartis was also taken over from the Group by GSK, which resulted in the reversal of provisions of EUR <ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="Duration_1_1_2021_To_12_31_2021_jm3ww8f3H0egT8wSnNVZZw" decimals="-3" format="ixt:numdotdecimal" name="cvac:ReversalOfProvisionRecognizedDueToCertainReservedCapacityTakenOver" scale="3" id="Narr_hJbdW8Vhmk-UxKkuFNTmdA">25,059</ix:nonFraction>k which had been recognized as of December 31, 2021, and the recognition of a corresponding gain in research and development expenses in the nine months ended September 30, 2022 (see Note 3.4).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">During the nine months ended September 30, 2022 and 2021, income from grants with government agencies and similar bodies resulted from the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">German Federal Ministry of Education and Research (BMBF)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In 2020, the Company received a grant from BMBF to support the development of its COVID-19 vaccine candidate for which it was determined that the arrangement contained two components: a grant component (in the scope of IAS 20) and a supply component (in the scope of IFRS 15). The grant was terminated in 2021. With regard to the grant component, during the nine months ended September 30, 2021, the Group has recognized grant income in the amount of EUR <ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="As_Of_9_30_2021_cvac_GovernmentGrantsAxis_cvac_GermanFederalMinistryOfEducationAndResearchMember_f9iNDb6krUGTFEUGF-sh0Q" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:GovernmentGrants" scale="3" id="Narr_qxgFZ81mWE-OF9Uh77QYwg">64,031</ix:nonFraction>k (September 30, 2022: EUR <ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="As_Of_9_30_2022_cvac_GovernmentGrantsAxis_cvac_GermanFederalMinistryOfEducationAndResearchMember_fN4famsHHEKl4JoAfEVlag" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:GovernmentGrants" scale="3" id="Narr_axf0eD3R_k-3Lkc0eaK2fA">0</ix:nonFraction>).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Coalition for Epidemic Preparedness Innovations (CEPI)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In January 2020, CureVac and CEPI entered into a collaboration to develop a vaccine against the new coronavirus SARS-CoV-2. The aim of the cooperation is to safely advance vaccine candidates into clinical testing as quickly as possible. The agreement builds upon the existing partnership between CureVac and CEPI to develop a rapid-response vaccine platform and included additional initial funding of up to USD <ix:nonFraction unitRef="Unit_Standard_USD_q8NNp4TBfUC9XydcVDSrpA" contextRef="As_Of_1_31_2020_cvac_GovernmentGrantsAxis_cvac_CoalitionForEpidemicPreparednessInnovationsMember_3sgz0BFjM0OjLj8LLFk2Lg" decimals="-3" format="ixt:numdotdecimal" name="cvac:MaximumGrantToBeReceived" scale="3" id="Narr_icdWzYJ2CEKXumpSOTZ6OA">8,300</ix:nonFraction>k. In May 2020, CEPI increased its grant award to the Group for SARS-CoV-2 vaccine development to up to USD <ix:nonFraction unitRef="Unit_Standard_USD_q8NNp4TBfUC9XydcVDSrpA" contextRef="As_Of_5_31_2020_cvac_GovernmentGrantsAxis_cvac_CoalitionForEpidemicPreparednessInnovationsMember_V-hWugM7KEemNT5UugQPwQ" decimals="-3" format="ixt:numdotdecimal" name="cvac:MaximumGrantToBeReceived" scale="3" id="Narr_j63tohHr3U-35Y1diptlEQ">15,300</ix:nonFraction>k.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">For the nine months ended September 30, 2022, CureVac recognized the reimbursement by CEPI of approved expenses of EUR <ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="Duration_1_1_2022_To_9_30_2022_cvac_GovernmentGrantsAxis_cvac_CoalitionForEpidemicPreparednessInnovationsMember_QaC72j_xJU248NAuCm-NTA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:RevenueFromGovernmentGrants" scale="3" id="Narr_weSQ-HXwQEimYAVhynKr4g">26</ix:nonFraction>k (September 30, 2021: EUR <ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="Duration_1_1_2021_To_9_30_2021_cvac_GovernmentGrantsAxis_cvac_CoalitionForEpidemicPreparednessInnovationsMember_-JHShxg3uU65FRp662VaIA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:RevenueFromGovernmentGrants" scale="3" id="Narr_QHCvOg9CMUeVu3ADneIb-g">30</ix:nonFraction>k) as &#x201C;other operating income&#x201D;. As of September 30, 2022, EUR <ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="As_Of_9_30_2022_cvac_GovernmentGrantsAxis_cvac_CoalitionForEpidemicPreparednessInnovationsMember_62kXYP2DG0q3hObonbIX3w" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:GovernmentGrants" scale="3" id="Narr_vdXrnuH9XEGGbJ67vp5t9Q">1,263</ix:nonFraction>k in grant funds received have been deferred and are presented within other liabilities (December 31, 2021: EUR <ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="As_Of_12_31_2021_cvac_GovernmentGrantsAxis_cvac_CoalitionForEpidemicPreparednessInnovationsMember_Vs0aCSCnvE2bQnX-4agCZg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:GovernmentGrants" scale="3" id="Narr_Q1gGgUQaS0SIxrtWKVZZ7A">1,288</ix:nonFraction>k). </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Bill &amp; Melinda Gates Foundation (BMGF)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">For the nine months ended September 30, 2022, CureVac recognized EUR <ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="Duration_1_1_2022_To_9_30_2022_cvac_GovernmentGrantsAxis_cvac_BillAndMelindaGatesFoundationBmgfMember_fYCkAgnPgkW1HP0kse2SZQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:RevenueFromGovernmentGrants" scale="3" id="Narr_qi5Wbs4kSEiUb6bzcnrICg">132</ix:nonFraction>k (September 30, 2021: EUR <ix:nonFraction unitRef="Unit_Standard_USD_q8NNp4TBfUC9XydcVDSrpA" contextRef="Duration_1_1_2021_To_9_30_2021_cvac_GovernmentGrantsAxis_cvac_BillAndMelindaGatesFoundationBmgfMember_Mbzwa-uYGkGbrTexrLia1w" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:RevenueFromGovernmentGrants" scale="3" id="Narr_o1U-MPsJ60OTajI1z4Fyzw">246</ix:nonFraction>k) from the amortization of the grants on a straight-line basis into other operating income. As of September 30, 2022, EUR <ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="As_Of_9_30_2022_cvac_GovernmentGrantsAxis_cvac_BillAndMelindaGatesFoundationBmgfMember_Ws8aHSUk1UC3pLQKXdVR0g" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:GovernmentGrants" scale="3" id="Narr_hi1jcc9qKEG120wbaR3Wjg">1,747</ix:nonFraction>k in grant funds received have been deferred and presented within other liabilities (December 31, 2021: EUR <ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="As_Of_12_31_2021_cvac_GovernmentGrantsAxis_cvac_BillAndMelindaGatesFoundationBmgfMember_nd5DnUyNxE69QH5CpJLGZw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:GovernmentGrants" scale="3" id="Narr_KCe5JyEvJ0W6ArYlwcB7LA">1,879</ix:nonFraction>k). </p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><ix:nonNumeric contextRef="Duration_1_1_2022_To_9_30_2022_GrYkE3mhHEiRA4fxgfABRg" name="ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory" id="Tb_WdaEjK7fiEeQn5nKd2BgUg" continuedAt="Tb_WdaEjK7fiEeQn5nKd2BgUg_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">4. Issued Capital and Reserves</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">According to the Company&#x2019;s articles of association, the Company&#x2019;s authorized shares are divided into <ix:nonFraction unitRef="Unit_Standard_shares_FapG5E6UqkK42IfNNOS6tA" contextRef="As_Of_9_30_2022_ifrs-full_ClassesOfShareCapitalAxis_ifrs-full_OrdinarySharesMember_QerVWaOy8UeUozR8lPK5KA" decimals="INF" format="ixt:numdotdecimal" name="ifrs-full:NumberOfSharesAuthorised" scale="0" id="Narr_8NuGPpOlhEaKiXymKDYMDw">386,250,000</ix:nonFraction> common shares and <ix:nonFraction unitRef="Unit_Standard_shares_FapG5E6UqkK42IfNNOS6tA" contextRef="As_Of_9_30_2022_ifrs-full_ClassesOfShareCapitalAxis_ifrs-full_PreferenceSharesMember_hPye6EgKFUuclVhFCyaxog" decimals="INF" format="ixt:numdotdecimal" name="ifrs-full:NumberOfSharesAuthorised" scale="0" id="Narr_bUrAZmlCf0KYt9NNaweWoQ">386,250,000</ix:nonFraction> preferred shares, each having a <span style="-sec-ix-hidden:Hidden_Pn4RGe75pUmEplb8tLMDGA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">nominal</span></span> value of EUR <ix:nonFraction unitRef="Unit_Divide_EUR_shares_6PEZCHC_WE2a7AmZW169oA" contextRef="As_Of_9_30_2022_ifrs-full_ClassesOfShareCapitalAxis_ifrs-full_PreferenceSharesMember_hPye6EgKFUuclVhFCyaxog" decimals="2" format="ixt:numdotdecimal" name="ifrs-full:ParValuePerShare" scale="0" id="Narr_yHEhLLJfdkyle4kRoy_y7g">0.12</ix:nonFraction>. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of September 30, 2022, <ix:nonFraction unitRef="Unit_Standard_shares_FapG5E6UqkK42IfNNOS6tA" contextRef="As_Of_9_30_2022_ifrs-full_ClassesOfShareCapitalAxis_ifrs-full_PreferenceSharesMember_hPye6EgKFUuclVhFCyaxog" decimals="0" format="ixt-sec:numwordsen" name="ifrs-full:NumberOfSharesIssued" scale="0" id="Narr_y4os6g_7K0ubYcewFZlT4g">no</ix:nonFraction> preferred shares had been issued and all issued common shares issued and outstanding were fully paid.</p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><a id="Tc_skllpadDxkyykn0OylIgcA_1_0"></a><a id="Tc_E2kwHRsvIUm81KS1QPAG_g_2_0"></a><a id="Tc_o4EIvjHlgEKhGSLBfhz-qg_3_0"></a><a id="Tc__JYEg2Q5YkaEotOvLQtTQg_4_0"></a><a id="Tc_CRzap8eaKUGT-oCecN4-mg_5_0"></a><a id="Tc_BQh_bNdj3kmjz1lfobQUlQ_6_0"></a><a id="Tc_kHpIvhjUyEmPD4C1bVpc-w_7_0"></a><a id="Tc_sKBLylbb8E-or5KEJSzmHQ_8_0"></a><a id="Tc_z6SCHpzVqkuGlnbMe0EAfg_9_0"></a><a id="Tc_yMTOSqwP0kqT5kOBmyKPgA_10_0"></a><a id="Tc_R_sXA9WhHUqLa_Cci0LF1Q_11_0"></a><a id="Tc_AOvHkbs3GUq1gTKnT8fFQQ_12_0"></a><a id="Tc_KRKfjuvL50CnJFD3CmMB-A_13_0"></a><ix:continuation id="Tb_WdaEjK7fiEeQn5nKd2BgUg_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">All payments received from shareholders in excess of the nominal value of the shares issued and net of transaction costs are recognized in capital reserves. Capital reserves also consists of recognition of share-based payments and the equity components of convertible loans. The Company may only make distributions, whether a distribution of profits or of freely distributable reserves, to shareholders to the extent shareholders&#x2019; equity exceeds the sum of the paid-in and called-up share capital plus any reserves required by Dutch law or by the Company&#x2019;s articles of association.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In September 2021, the Company entered into a sales agreement, the Open Sale Agreement, with Jefferies LLC and SVB Leerink LLC, as sales agents, to establish an at-the-market (ATM) offering program, pursuant to which it may sell, from time to time, ordinary shares for aggregate gross proceeds of up to $<ix:nonFraction unitRef="Unit_Standard_USD_q8NNp4TBfUC9XydcVDSrpA" contextRef="Duration_9_1_2021_To_9_30_2021_cvac_IfrsSaleOfStockAxis_cvac_AtMarketOfferingProgramMember_UsrXsTjj5kOO1bTEgPYDaA" decimals="-5" format="ixt:numdotdecimal" name="cvac:AggregateGrossProceedsReceivableFromIssuingShares" scale="6" id="Narr_5NiOBIrMjkWERvMyUg8vCA">600.0</ix:nonFraction> million. As of September 30, 2022, <ix:nonFraction unitRef="Unit_Standard_shares_FapG5E6UqkK42IfNNOS6tA" contextRef="Duration_9_1_2022_To_9_30_2022_cvac_IfrsSaleOfStockAxis_cvac_AtMarketOfferingProgramMember_aEeSD8tWhUqDkvbkYwvYZA" decimals="INF" format="ixt:numdotdecimal" name="cvac:IfrsStockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_NwckqOvMgEWlsHo0gUrpzQ">2,288,055</ix:nonFraction> shares were issued under the ATM program, raising <span style="-sec-ix-hidden:Hidden_k6p5zM0iFEqRi29XSeuCWQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$31.7</span></span> million in net proceeds, after deducting $<ix:nonFraction unitRef="Unit_Standard_USD_q8NNp4TBfUC9XydcVDSrpA" contextRef="Duration_1_1_2022_To_9_30_2022_GrYkE3mhHEiRA4fxgfABRg" decimals="-5" format="ixt:numdotdecimal" name="ifrs-full:ShareIssueRelatedCost" scale="6" id="Narr_zp0HQRLAJEmT0fhGo__fKg">1.0</ix:nonFraction> million in transaction costs; related offering expenses were recorded against the proceeds in equity. Following these issuances, the remaining value authorized for sale under the at-the-market program as of September 30, 2022 amounts to $<ix:nonFraction unitRef="Unit_Standard_USD_q8NNp4TBfUC9XydcVDSrpA" contextRef="As_Of_9_30_2022_zuGVrjesE0WhwXSGmTqsgA" decimals="-5" format="ixt:numdotdecimal" name="cvac:RemainingAuthorizedForSaleValue" scale="6" id="Narr__lzBgzUdvkekPnVwpMBTIQ">567.3</ix:nonFraction> million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">The number of shares issued and outstanding developed as follows:</p><ix:nonNumeric contextRef="Duration_1_1_2022_To_9_30_2022_GrYkE3mhHEiRA4fxgfABRg" name="ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory" id="Tb_blfjgBRTqUe1_m9upx1ypw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#x200B;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:79.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:79.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Common shares issued and outstanding at December 31, 2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#xA0;&#xA0;&#xA0;&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_shares_FapG5E6UqkK42IfNNOS6tA" contextRef="As_Of_12_31_2021_kQVJTWPgRUeESxCd99xt9A" decimals="INF" format="ixt:numdotdecimal" name="cvac:CommonSharesIssuedAndOutstanding" scale="0" id="Tc_8f9Pj4mkVEGPgtL5rTYXcA_1_2">187,120,728</ix:nonFraction></b></p></td></tr><tr><td style="vertical-align:bottom;width:79.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Share option exercises between Jan and March 2022</p></td><td style="vertical-align:bottom;width:3.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_FapG5E6UqkK42IfNNOS6tA" contextRef="Duration_1_1_2022_To_3_31_2022_LiqLyh4w5EGnOWf_FZQF7Q" decimals="INF" format="ixt:numdotdecimal" name="cvac:ShareOptionExercises" scale="0" id="Tc_Ns7tNpNvD02P4OF62zoEzA_2_2">78,732</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:79.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Treasury shares</p></td><td style="vertical-align:bottom;width:3.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_FapG5E6UqkK42IfNNOS6tA" contextRef="Duration_1_1_2022_To_3_31_2022_LiqLyh4w5EGnOWf_FZQF7Q" decimals="INF" format="ixt:numdotdecimal" name="cvac:DecreaseInNumberOfSharesDueToTreasuryOfShares" sign="-" scale="0" id="Tc_rKHAoG5bMk6N5GzaTbGfmQ_3_2">78,732</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:79.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Common shares issued and outstanding at March 31, 2022</b></p></td><td style="vertical-align:bottom;width:3.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_shares_FapG5E6UqkK42IfNNOS6tA" contextRef="As_Of_3_31_2022_mqhJpd3F8U63gbp_M5KLaw" decimals="INF" format="ixt:numdotdecimal" name="cvac:CommonSharesIssuedAndOutstanding" scale="0" id="Tc_-fV9hqsBTkOQsCRNhLohqA_4_2">187,120,728</ix:nonFraction></b></p></td></tr><tr><td style="vertical-align:bottom;width:79.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">At-the-market offering program issuances</p></td><td style="vertical-align:bottom;width:3.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_FapG5E6UqkK42IfNNOS6tA" contextRef="Duration_4_1_2022_To_6_30_2022_-gYjaV8XPUKBPSbaN9Qziw" decimals="INF" format="ixt:numdotdecimal" name="cvac:IfrsStockIssuedDuringPeriodSharesNewIssues" scale="0" id="Tc_WP62pLqBzEavPv6xteAx1A_5_2">340,015</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:79.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Share issuances for exercises between Apr to June 2022</p></td><td style="vertical-align:bottom;width:3.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_FapG5E6UqkK42IfNNOS6tA" contextRef="Duration_4_1_2022_To_6_30_2022_-gYjaV8XPUKBPSbaN9Qziw" decimals="INF" format="ixt:numdotdecimal" name="cvac:StockIssuedDuringPeriodForExercises" scale="0" id="Tc_pFy-A8bBYUWmjBFJ33f-nA_6_2">6,211</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:79.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Share option exercises between Apr and June 2022</p></td><td style="vertical-align:bottom;width:3.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_FapG5E6UqkK42IfNNOS6tA" contextRef="Duration_4_1_2022_To_6_30_2022_-gYjaV8XPUKBPSbaN9Qziw" decimals="INF" format="ixt:numdotdecimal" name="cvac:ShareOptionExercises" scale="0" id="Tc_Lrffp3iKdEWui9wRMO-o6A_7_2">39,418</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:79.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Treasury shares</p></td><td style="vertical-align:bottom;width:3.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_FapG5E6UqkK42IfNNOS6tA" contextRef="Duration_4_1_2022_To_6_30_2022_-gYjaV8XPUKBPSbaN9Qziw" decimals="INF" format="ixt:numdotdecimal" name="cvac:DecreaseInNumberOfSharesDueToTreasuryOfShares" sign="-" scale="0" id="Tc_A1DKIsBsKk6Meu414iHX0g_8_2">39,418</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:79.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Common shares issued and outstanding at June 30, 2022</b></p></td><td style="vertical-align:bottom;width:3.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_shares_FapG5E6UqkK42IfNNOS6tA" contextRef="As_Of_6_30_2022_kOEc9a1C10m7Rg-HheHYxg" decimals="INF" format="ixt:numdotdecimal" name="cvac:CommonSharesIssuedAndOutstanding" scale="0" id="Tc_eFk5DOLE0UCcBK5eHGgpfw_9_2">187,466,954</ix:nonFraction></b></p></td></tr><tr><td style="vertical-align:bottom;width:79.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">At-the-market offering program issuances</p></td><td style="vertical-align:bottom;width:3.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_FapG5E6UqkK42IfNNOS6tA" contextRef="Duration_7_1_2022_To_9_30_2022_pgUlLsnMwE6GuzWOXk2lcg" decimals="INF" format="ixt:numdotdecimal" name="cvac:IfrsStockIssuedDuringPeriodSharesNewIssues" scale="0" id="Tc_0O50GDCjq0iiW1StftWtMA_10_2">1,948,040</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:79.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Share issuances for exercises between July to Sept 2022</p></td><td style="vertical-align:bottom;width:3.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_FapG5E6UqkK42IfNNOS6tA" contextRef="Duration_7_1_2022_To_9_30_2022_pgUlLsnMwE6GuzWOXk2lcg" decimals="INF" format="ixt:numdotdecimal" name="cvac:StockIssuedDuringPeriodForExercises" scale="0" id="Tc_vYggyswBjU2_O98a8QXVjA_11_2">9,746</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:79.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Share issuances to former shareholders of Frame Pharmaceuticals</p></td><td style="vertical-align:bottom;width:3.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_FapG5E6UqkK42IfNNOS6tA" contextRef="Duration_7_1_2022_To_9_30_2022_pgUlLsnMwE6GuzWOXk2lcg" decimals="INF" format="ixt:numdotdecimal" name="cvac:StockIssuanceDuringPeriodForExistingShareholders" scale="0" id="Tc_F68tJCEiHEqruQdj-R5a0w_12_2">858,496</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:79.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Common shares issued and outstanding at September 30, 2022</b></p></td><td style="vertical-align:bottom;width:3.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_shares_FapG5E6UqkK42IfNNOS6tA" contextRef="As_Of_9_30_2022_zuGVrjesE0WhwXSGmTqsgA" decimals="INF" format="ixt:numdotdecimal" name="cvac:CommonSharesIssuedAndOutstanding" scale="0" id="Tc_GlvNpnyiH0qC75DXz4q68A_13_2">190,283,236</ix:nonFraction></b></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><a id="_03bf7b14_b737_4a4d_8eba_4fe934d6b53f"></a><a id="Tc_L8Gm7Qe8M0a-qvTXL8BDmg_1_2"></a><a id="Tc_aNOolr4YckyBJ0iKveLAaQ_1_4"></a><a id="Tc_lwRbtVz_g0CB9tcjOV40iQ_2_2"></a><a id="Tc_3MrEvDhOoE68QDK0vUbTVg_2_4"></a><a id="Tc_xS-Q7v8Qv0iNOygkpis9JA_3_0"></a><a id="Tc_0VtxuVzgPkqB9sgRiTbr_A_4_0"></a><a id="Tc_a91lqcFlDUmEp-uFGHZ4Gw_5_0"></a><a id="Tc_SpSVxFV4LEyh--pJu3kHAw_6_0"></a><a id="_3abf0353_fdeb_45f9_88e5_72c70aa14878"></a><a id="Tc_0v3777gLCEqwEGTW73VkIw_1_0"></a><a id="Tc_B5t2J5kz2EqTje7z4fUmrA_1_2"></a><a id="Tc_Vu1PaI2zykaZbnRiHd3kIA_1_4"></a><a id="Tc_v5Q4FkjqgESRl8h4GbMNqQ_2_2"></a><a id="Tc_5gnS6Bz6skOAcjC-yiofug_2_4"></a><a id="Tc_1xwR-Wsbt0Ss8gZxc2UIyw_3_0"></a><a id="Tc_joS1tqZLCUmr8Jux1w31VA_4_0"></a><a id="Tc_4H54IoDU7UaxBy8SUvySzQ_5_0"></a><a id="Tc_UFlUCa_BHU-jfBR7cOD8kw_6_0"></a><a id="Tc_C1WBTe6qcEGHBXNGKao-Jg_7_0"></a><a id="Tc_Byv92qD2uE-0vME0eMFdZg_7_2"></a><a id="Tc_WBUfGHqCHEatx3L1T-rAag_8_0"></a><ix:nonNumeric contextRef="Duration_1_1_2022_To_9_30_2022_GrYkE3mhHEiRA4fxgfABRg" name="ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory" id="Tb_kcScwj880063aYxVhtrhXg" continuedAt="Tb_kcScwj880063aYxVhtrhXg_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">5. Share-based payments</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">During the nine months ended September 30, 2022 and 2021, the Group recognized share-based based payments expenses of EUR <ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="Duration_1_1_2022_To_9_30_2022_GrYkE3mhHEiRA4fxgfABRg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" scale="3" id="Narr_q_0mq82ioEew77nao29g5g">6,455</ix:nonFraction>k and EUR <ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="Duration_1_1_2021_To_9_30_2021_5RS16WkLc0uS2ug_bqUm-g" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" scale="3" id="Narr_kRXF54_DyESVNISqejftRQ">11,285</ix:nonFraction>k, respectively, as follows:</p><ix:nonNumeric contextRef="Duration_1_1_2022_To_9_30_2022_GrYkE3mhHEiRA4fxgfABRg" name="cvac:DisclosureOfExpenseRecognizedForEmployeeServicesExplanatory" id="Tb_V2vjtKM59ESorVeIpLaMpg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">Nine months ended September 30,</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#x200B;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:77.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:77.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#xA0;&#xA0;&#xA0;&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#xA0;&#xA0;&#xA0;&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:77.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR&#xA0;k</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR&#xA0;k</b></p></td></tr><tr><td style="vertical-align:bottom;width:77.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Research and development expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="Duration_1_1_2021_To_9_30_2021_5RS16WkLc0uS2ug_bqUm-g" decimals="-3" format="ixt:numdotdecimal" name="cvac:ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInResearchAndDevelopmentExpenses" scale="3" id="Tc_4t-GpgkoHEuJzQwoF0A_XQ_3_2">572</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="Duration_1_1_2022_To_9_30_2022_GrYkE3mhHEiRA4fxgfABRg" decimals="-3" format="ixt:numdotdecimal" name="cvac:ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInResearchAndDevelopmentExpenses" scale="3" id="Tc_icOww8P4D0C42JhKNpuWjg_3_4">480</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:77.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Sales and marketing expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="Duration_1_1_2021_To_9_30_2021_5RS16WkLc0uS2ug_bqUm-g" decimals="-3" format="ixt:numdotdecimal" name="cvac:ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInSellingAndDistributionExpenses" scale="3" id="Tc_Vks5nIeCDEiczQbXxZ1lRw_4_2">166</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="Duration_1_1_2022_To_9_30_2022_GrYkE3mhHEiRA4fxgfABRg" decimals="-3" format="ixt:numdotdecimal" name="cvac:ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInSellingAndDistributionExpenses" scale="3" id="Tc_OyqepjNZkEG3ljtXNlKrqg_4_4">152</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:77.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">General and administrative expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="Duration_1_1_2021_To_9_30_2021_5RS16WkLc0uS2ug_bqUm-g" decimals="-3" format="ixt:numdotdecimal" name="cvac:ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInGeneralAndAdministrativeExpenses" scale="3" id="Tc_dipF1ABjAU2PRpadcKpsKw_5_2">10,547</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="Duration_1_1_2022_To_9_30_2022_GrYkE3mhHEiRA4fxgfABRg" decimals="-3" format="ixt:numdotdecimal" name="cvac:ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInGeneralAndAdministrativeExpenses" scale="3" id="Tc_zmELOFYMrEC4fsWuebdljg_5_4">5,823</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:77.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="Duration_1_1_2021_To_9_30_2021_5RS16WkLc0uS2ug_bqUm-g" decimals="-3" format="ixt:numdotdecimal" name="cvac:BenefitExpenseRecognizedForShareBasedPayment" scale="3" id="Tc_O4msm3ivNUKzxvAaDKQpww_6_2">11,285</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="Duration_1_1_2022_To_9_30_2022_GrYkE3mhHEiRA4fxgfABRg" decimals="-3" format="ixt:numdotdecimal" name="cvac:BenefitExpenseRecognizedForShareBasedPayment" scale="3" id="Tc_pgRekpCwvkaKgloy00bzxw_6_4">6,455</ix:nonFraction></b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Expense recognized for the equity-settled programs was as follows:</p><ix:nonNumeric contextRef="Duration_1_1_2022_To_9_30_2022_GrYkE3mhHEiRA4fxgfABRg" name="cvac:ScheduleOfExpenseRecognizedForProgramsTableTextBlock" id="Tb_0rkc7Mi14EOU4Z-7BCcu2Q" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">Nine months ended September 30:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#x200B;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:77.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:77.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Program</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;&#xA0;&#xA0;&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;&#xA0;&#xA0;&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:77.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">EUR&#xA0;k</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">EUR k</b></p></td></tr><tr><td style="vertical-align:bottom;width:77.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">LTIP</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="Duration_1_1_2021_To_9_30_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_-7vn4v2-bEuMIEE_cJjuug" decimals="-3" format="ixt:numdotdecimal" name="cvac:ExpenseRecognizedForEmployeeServices" scale="3" id="Tc_DXAcXqustUuqpxxXBLxE6A_3_2">10,075</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="Duration_1_1_2022_To_9_30_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_6VLzYOVR1k24GIHsNaoB2A" decimals="-3" format="ixt:numdotdecimal" name="cvac:ExpenseRecognizedForEmployeeServices" scale="3" id="Tc_FFf8zFVGjEykehqdGT3Nog_3_4">4,430</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:77.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">RSU</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="Duration_1_1_2021_To_9_30_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_IfrsRestrictedStockUnitMember_QgoBjuQOZEO99XfLIWVoQA" decimals="-3" format="ixt:numdotdecimal" name="cvac:ExpenseRecognizedForEmployeeServices" scale="3" id="Tc_htbki9qpBEm7YXRw6cSyyQ_4_2">250</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="Duration_1_1_2022_To_9_30_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_IfrsRestrictedStockUnitMember_XRKL4qJ810SYjrkXptDpGw" decimals="-3" format="ixt:numdotdecimal" name="cvac:ExpenseRecognizedForEmployeeServices" scale="3" id="Tc_AS8Ace9S2E-OvtCFvQdUFA_4_4">275</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:77.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">New VSOP</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="Duration_1_1_2021_To_9_30_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_VirtualSharesProgramIiMember_5phdNMZ4UUa7p62ZO4ZmiQ" decimals="-3" format="ixt:numdotdecimal" name="cvac:ExpenseRecognizedForEmployeeServices" scale="3" id="Tc_t2lHMRQNWU25TGVZHQevow_5_2">441</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="Duration_1_1_2022_To_9_30_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_VirtualSharesProgramIiMember_94K0C2dKwEe87RAK5o3yHg" decimals="-3" format="ixt:numdotdecimal" name="cvac:ExpenseRecognizedForEmployeeServices" sign="-" scale="3" id="Tc_d1J0JtE6RUGlDDq-xwLUlg_5_4">96</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:77.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Prior VSOP</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="Duration_1_1_2021_To_9_30_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_VirtualSharesProgramIMember_G8wLGie1fkurrNt_KXss3A" decimals="-3" format="ixt:numdotdecimal" name="cvac:ExpenseRecognizedForEmployeeServices" scale="3" id="Tc_Vw_1XbcwkUG0Go_TX9PyIg_6_2">519</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="Duration_1_1_2022_To_9_30_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_VirtualSharesProgramIMember_8-6ss668qkGhxxIvnx3JTQ" decimals="-3" format="ixt:numdotdecimal" name="cvac:ExpenseRecognizedForEmployeeServices" scale="3" id="Tc_werTFo5zjk-XbC3OMrd3Gw_6_4">99</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:77.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">RSU for key employees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#x2014;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="Duration_1_1_2022_To_9_30_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_RestrictedStockUnitForKeyEmployeesMember_dZiMEF-WIUaYDoS6prDgKg" decimals="-3" format="ixt:numdotdecimal" name="cvac:ExpenseRecognizedForEmployeeServices" scale="3" id="Tc_tfn8tqQUN0qo9ReH51kVZg_7_4">1,746</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:77.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="Duration_1_1_2021_To_9_30_2021_5RS16WkLc0uS2ug_bqUm-g" decimals="-3" format="ixt:numdotdecimal" name="cvac:ExpenseRecognizedForEmployeeServices" scale="3" id="Tc_AZfBebEZ3kCZthTtcNt2yw_8_2">11,825</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="Duration_1_1_2022_To_9_30_2022_GrYkE3mhHEiRA4fxgfABRg" decimals="-3" format="ixt:numdotdecimal" name="cvac:ExpenseRecognizedForEmployeeServices" scale="3" id="Tc_Dsb_N3ipS02lufHltU339A_8_4">6,455</ix:nonFraction></b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#x200B;</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">On November 16, 2020, CureVac granted <ix:nonFraction unitRef="Unit_Standard_Option_puBmss6yUE6NakwAOqqzng" contextRef="Duration_11_16_2020_To_11_16_2020_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ChiefScientificOfficerMember_YqQecowO2kuyd-MSikFagg" decimals="INF" format="ixt:numdotdecimal" name="ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" scale="0" id="Narr_VeoqoyI810KbxHgF5KBP1g">266,155</ix:nonFraction> options to the Chief Scientific Officer (CSO). Furthermore, on December 1, 2020, CureVac granted <ix:nonFraction unitRef="Unit_Standard_Option_puBmss6yUE6NakwAOqqzng" contextRef="Duration_12_1_2020_To_12_1_2020_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ChiefBusinessOfficerAndChiefCommercialOfficerMember_T3JjiYhNB0mcje4uQOSblw" decimals="INF" format="ixt:numdotdecimal" name="ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" scale="0" id="Narr_4zrojxpjCkmtFWswVrXAaQ">266,156</ix:nonFraction> options (in 3 tranches) to the company`s Chief Business Officer (CBO) and Chief Commercial Officer (CCO). All grants were made at no cost under the terms of a new long-term incentive plan (LTIP) put in place by CureVac N.V. Options </p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_kcScwj880063aYxVhtrhXg_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">will be settled in shares of CureVac N.V. On September 30, 2022, none of the options granted to the CBO/CCO under the LTIP were exercised at that date. The CSO exercised <ix:nonFraction unitRef="Unit_Standard_Option_puBmss6yUE6NakwAOqqzng" contextRef="Duration_5_1_2022_To_5_31_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ChiefScientificOfficerMember_v1kWVxI7sE-mtWe59zilhg" decimals="INF" format="ixt:numdotdecimal" name="ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" scale="0" id="Narr_QMUyydDpFUifiSeZpdU-SA">6,303</ix:nonFraction> of his options in May 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On July 1, 2021, CureVac granted <ix:nonFraction unitRef="Unit_Standard_Option_puBmss6yUE6NakwAOqqzng" contextRef="Duration_7_1_2021_To_7_1_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_srt_ChiefOperatingOfficerMember_lTsgjULrh0unxpPIyz1Ojw" decimals="INF" format="ixt:numdotdecimal" name="ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" scale="0" id="Narr_4mlwvlcnYk2G6a1TymHCrA">20,000</ix:nonFraction> options to the Chief Operations Officer (COO). Furthermore, on August 1, 2021, CureVac granted <ix:nonFraction unitRef="Unit_Standard_Option_puBmss6yUE6NakwAOqqzng" contextRef="Duration_8_1_2021_To_8_1_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ChiefDevelopmentOfficerMember_Sovw0LhIOky6A14jJLrI2g" decimals="INF" format="ixt:numdotdecimal" name="ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" scale="0" id="Narr_56mqKOX_gUqDqgMGIyWUVA">30,000</ix:nonFraction> options to the Chief Development Officer (CDO). All grants were made at no cost under the terms of the new long-term incentive plan (LTIP) put in place by CureVac N.V. Options will be settled in shares of CureVac N.V. As of September 30, 2022, <ix:nonFraction unitRef="Unit_Standard_Option_puBmss6yUE6NakwAOqqzng" contextRef="Duration_9_1_2022_To_9_30_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_srt_ChiefOperatingOfficerMember_fTDjhW41wkulF-dl-PGYYg" decimals="INF" format="ixt-sec:numwordsen" name="cvac:NumberOfShareOptionsVestedInShareBasedPaymentArrangement" scale="0" id="Narr_aFjOGZrR6UKtR-o7tB8XLg">none</ix:nonFraction> of the options granted to the COO under the LTIP were vested and hence, were not exercisable at that date. On September 30, 2022, <ix:nonFraction unitRef="Unit_Standard_Option_puBmss6yUE6NakwAOqqzng" contextRef="Duration_9_1_2022_To_9_30_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ChiefDevelopmentOfficerMember_KVJTFke5SEudjsaztY_vxw" decimals="INF" format="ixt-sec:numwordsen" name="cvac:NumberOfShareOptionsVestedInShareBasedPaymentArrangement" scale="0" id="Narr_M1PD1MAJNkCJ8cLz2W2rnA">none</ix:nonFraction> of the options granted to the CDO under the LTIP were vested and hence, were not exercisable at the date. As the CDO left CureVac in June 2022, all of his options were forfeited. All expenses recognized up to him leaving were reversed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On March 1, 2022, CureVac granted <ix:nonFraction unitRef="Unit_Standard_Option_puBmss6yUE6NakwAOqqzng" contextRef="Duration_3_1_2022_To_3_1_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_KeyEmployeesMember_4k0biTJ1L0OjkLnTREDR-w" decimals="INF" format="ixt:numdotdecimal" name="ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" scale="0" id="Narr_nzXq85jng0ahNaGxKArxNg">11,500</ix:nonFraction> options to <ix:nonFraction unitRef="Unit_Standard_employee_-Jetz9Th0ka1WnOToYuqxw" contextRef="Duration_3_1_2022_To_3_1_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_KeyEmployeesMember_4k0biTJ1L0OjkLnTREDR-w" decimals="INF" format="ixt-sec:numwordsen" name="cvac:NumberOfKeyEmployees" scale="0" id="Narr_d9wN0tFWv0OCFq4-YA2ETA">two</ix:nonFraction> key employees. All grants were made at no cost under the terms of the new long-term incentive plan (LTIP) put in place by CureVac N.V. Options will be settled in shares of CureVac N.V.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On June 22, 2022, CureVac granted <ix:nonFraction unitRef="Unit_Standard_Option_puBmss6yUE6NakwAOqqzng" contextRef="Duration_6_22_2022_To_6_22_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ExecutiveBoardMembersMember_HGJGQ29fb0mCC_uf2baYzw" decimals="INF" format="ixt:numdotdecimal" name="ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" scale="0" id="Narr_TOQddotQvki89BlaWBYQKw">130,000</ix:nonFraction> options to the executive board. All grants were made at no cost under the terms of the new long-term incentive plan (LTIP) put in place by CureVac N.V. Options will be settled in shares of CureVac N.V. As of September 30, 2022, <ix:nonFraction unitRef="Unit_Standard_Option_puBmss6yUE6NakwAOqqzng" contextRef="Duration_9_1_2022_To_9_30_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ExecutiveBoardMembersMember_hjnyCWqWaUG4U5M-ifsvcQ" decimals="INF" format="ixt-sec:numwordsen" name="cvac:NumberOfShareOptionsVestedInShareBasedPaymentArrangement" scale="0" id="Narr_i5KCBMlrdkOW9qFWOhhLvw">none</ix:nonFraction> of the options granted to the executive board under the LTIP were vested and hence, were not exercisable at that date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The expenses recognized for employee services received under the LTIP during the nine months ended September 30, 2022, is in an amount of EUR <ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="Duration_1_1_2022_To_9_30_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ChiefScientificOfficerMember_UtQLqJhh8UiH4zCtHpD4cQ" decimals="-3" format="ixt:numdotdecimal" name="cvac:ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInGeneralAndAdministrativeExpenses" scale="3" id="Narr_h_6bcD2AoUOHCnuzofXPdg">4,430</ix:nonFraction>k (2021; EUR <ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="Duration_1_1_2021_To_9_30_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ChiefScientificOfficerMember_Zo3CrV1xc0-l6T3OrHnAhQ" decimals="-3" format="ixt:numdotdecimal" name="cvac:ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInGeneralAndAdministrativeExpenses" scale="3" id="Narr_K_PUV4qSlkesDx1_DN7RXA">10,075</ix:nonFraction>k) and is included in general and administrative expenses and sales and marketing expenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In 2021, as part of the LTIP program, CureVac awarded RSUs (restricted stock units) to senior executives as well as supervisory board members. On June 24, 2021, CureVac awarded <ix:nonFraction unitRef="Unit_Standard_Option_puBmss6yUE6NakwAOqqzng" contextRef="Duration_6_24_2021_To_6_24_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_SupervisoryBoardMembersMember_WzScVvwhuUOXBAORYNGw1A" decimals="INF" format="ixt:numdotdecimal" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" scale="0" id="Narr_7phhPaJMjUeC4fFgOw2jIg">10,956</ix:nonFraction> RSUs to supervisory board members and on December 23, 2021, CureVac awarded <ix:nonFraction unitRef="Unit_Standard_Option_puBmss6yUE6NakwAOqqzng" contextRef="Duration_12_23_2021_To_12_23_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_MembersOfExecutiveBoardAndVariousKeyEmployeesMember_sPT0TmgA5UyfJUOLzYAeKg" decimals="INF" format="ixt:numdotdecimal" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" scale="0" id="Narr_2mUE_8EuakmaqCpYAaKikA">63,095</ix:nonFraction> RSUs to the executive board and various key employees. Up to September 30, 2022, <ix:nonFraction unitRef="Unit_Standard_shares_FapG5E6UqkK42IfNNOS6tA" contextRef="Duration_1_1_2022_To_9_30_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_6VLzYOVR1k24GIHsNaoB2A" decimals="INF" format="ixt:numdotdecimal" name="cvac:NumberOfOtherEquityInstrumentsSettledInShareBasedPaymentArrangement" scale="0" id="Narr_6OLpXAUg_U60kRfA5xb73g">17,887</ix:nonFraction> RSU&#x2019;s were settled. The related RSU expense is recorded in the functional cost category to which the award recipient&#x2019;s costs are classified.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On February 10, 2022, CureVac awarded <ix:nonFraction unitRef="Unit_Standard_Option_puBmss6yUE6NakwAOqqzng" contextRef="Duration_2_10_2022_To_2_10_2022_srt_TitleOfIndividualAxis_srt_ChiefOperatingOfficerMember_iNHQybO4Pk2sc9tkHPztxA" decimals="INF" format="ixt:numdotdecimal" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" scale="0" id="Narr_UXvLGapbEku3tcT1kUQ0Dg">5,000</ix:nonFraction> options to the Chief Operations Officer (COO). The related RSU expense is included in general and administrative expenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On June 22, 2022, CureVac awarded <ix:nonFraction unitRef="Unit_Standard_Option_puBmss6yUE6NakwAOqqzng" contextRef="Duration_6_22_2022_To_6_22_2022_srt_TitleOfIndividualAxis_cvac_SupervisoryBoardMembersMember_8ClvViKS_0mYv0ZZa7FsSA" decimals="INF" format="ixt:numdotdecimal" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" scale="0" id="Narr_1tN673pQbky8CmfGhFDbtw">37,868</ix:nonFraction> RSUs to supervisory board members and <ix:nonFraction unitRef="Unit_Standard_Option_puBmss6yUE6NakwAOqqzng" contextRef="Duration_6_22_2022_To_6_22_2022_srt_TitleOfIndividualAxis_cvac_ExecutiveBoardMembersMember_hf65wxXOEECOwq5tEDpNWQ" decimals="INF" format="ixt:numdotdecimal" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" scale="0" id="Narr_h2o5pGQRREy5cHUAhTwWag">193,340</ix:nonFraction> RSUs to the executive board and various key employees. The related RSU expense is recorded in the functional cost category to which the award recipient&#x2019;s costs are classified.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On June 22, 2022, CureVac awarded <ix:nonFraction unitRef="Unit_Standard_Option_puBmss6yUE6NakwAOqqzng" contextRef="Duration_6_22_2022_To_6_22_2022_srt_TitleOfIndividualAxis_cvac_ThenChiefExecutiveOfficerMember_MEmTtrB-PEWG-6nmSb4NZw" decimals="INF" format="ixt:numdotdecimal" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" scale="0" id="Narr_es4Q5jYZDEaGFdTWcZsGyQ">36,000</ix:nonFraction> RSUs to the Chief Executive Officer (CEO). The related RSU expense is included in general and administrative expenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On September 22, 2022, CureVac awarded <ix:nonFraction unitRef="Unit_Standard_Option_puBmss6yUE6NakwAOqqzng" contextRef="Duration_9_22_2022_To_9_22_2022_srt_TitleOfIndividualAxis_cvac_ChiefBusinessOfficerMember_GRzsO5WyQEanIaFIpuw0tg" decimals="INF" format="ixt:numdotdecimal" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" scale="0" id="Narr_bufsV0qB002Du8VulfSkfA">30,000</ix:nonFraction> RSUs to the Chief Business Officer (CBO). The related RSU expense is included in general and administrative expenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On July 1, 2022, CureVac awarded <ix:nonFraction unitRef="Unit_Standard_Option_puBmss6yUE6NakwAOqqzng" contextRef="Duration_7_1_2022_To_7_1_2022_srt_TitleOfIndividualAxis_cvac_FormerFrameEmployeesMember_sBysEqLlSUqSMftPMXcxQQ" decimals="INF" format="ixt:numdotdecimal" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" scale="0" id="Narr_75v354gjSkWU_7A_db9gFQ">89,655</ix:nonFraction> RSUs to the former Frame employees, now CureVac Netherlands. The related RSU expense is recorded in the functional cost category to which the award recipients&#x2019; costs are classified.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The remaining expense results from additional grants under the New VSOP and continued vesting of grants under the Prior VSOP. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Exercise of share-based payments</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">For the New VSOP plan, the IPO was a triggering event, by which all vested options, under the plan, became exercisable; <ix:nonFraction unitRef="Unit_Standard_Option_puBmss6yUE6NakwAOqqzng" contextRef="As_Of_9_30_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_VirtualSharesProgramIiMember_-aEvT6TgvU2aaNALbBrVfw" decimals="INF" format="ixt:numdotdecimal" name="ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" scale="0" id="Narr_21wUJZN9GkG3FhUXL7YGeA">109,917</ix:nonFraction> options were exercised within the first nine months of 2022 at a weighted average share price of USD <ix:nonFraction unitRef="Unit_Divide_USD_shares_B3tHpJm3a0ytZJRcE10tTA" contextRef="Duration_4_1_2021_To_9_30_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_VirtualSharesProgramIiMember_H9asqvfrLUqv97coIp3GBQ" decimals="2" format="ixt:numdotdecimal" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019" scale="6" id="Narr_-DyjcK5gzkKD306y22O55w">18.75</ix:nonFraction>.</p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p><ix:nonNumeric contextRef="Duration_1_1_2022_To_9_30_2022_GrYkE3mhHEiRA4fxgfABRg" name="cvac:DisclosureOfFixedAssetsExplanatory" id="Tb_sBUouVkIKUae2H-q1QoNhQ" continuedAt="Tb_sBUouVkIKUae2H-q1QoNhQ_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">6. Fixed Assets</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">6.1 Intangible assets</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">During the nine months ended September 30, 2022, the Group acquired intangible assets of EUR <ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="Duration_1_1_2022_To_9_30_2022_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_ifrs-full_GrossCarryingAmountMember_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_cvac_LicensesSoftwareAndPrepaymentsMember_zeXSak6OQ0iEmjYXe9qo9w" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" scale="3" id="Narr_pl1wyBC_3ke4uc19KesI7A">24,224</ix:nonFraction>k (Nine months ended September 30, 2021: EUR <ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="Duration_1_1_2021_To_9_30_2021_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_ifrs-full_GrossCarryingAmountMember_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_cvac_LicensesSoftwareAndPrepaymentsMember_CzUp1LGslUSZTIy-JKWdLw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" scale="3" id="Narr_jYxNM6ESak-GKscOZYC_UA">2,273</ix:nonFraction>k). Acquired intangibles mainly related to licenses, software and prepayments made to acquire those and, for the nine months ended September 30, 2022, include technology and goodwill acquired in the Frame acquisition. For more details, refer to Note 18.</p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_sBUouVkIKUae2H-q1QoNhQ_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">6.2 Property, plant and equipment</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">During the nine months ended September 30, 2022, the increase in property, plant and equipment was due primarily to the purchase of technical equipment and machines and other equipment of EUR <ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="Duration_1_1_2022_To_9_30_2022_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_ifrs-full_GrossCarryingAmountMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_cvac_TechnicalEquipmentAndMachinesAndOtherEquipmentMember_fDP_vLfur0CDvezFllAP3w" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" scale="3" id="Narr_aoE5R-cfIkCCgxbTt0jjVw">8,661</ix:nonFraction>k (September 30, 2021: EUR <ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="Duration_1_1_2021_To_9_30_2021_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_ifrs-full_GrossCarryingAmountMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_cvac_TechnicalEquipmentAndMachinesAndOtherEquipmentMember_4EQ5xotfIUujKtdlrzbPVQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" scale="3" id="Narr_igqIY1cu40Gxqgt4-qe5Sw">8,907</ix:nonFraction>k) as well as additional amounts recognized as construction in progress of EUR <ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="Duration_1_1_2022_To_9_30_2022_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_ConstructionInProgressMember_BqU3Y93BzU-k13235fXn4g" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" scale="3" id="Narr_AhHJJsr0BEmN7dn6r_pF1g">56,746</ix:nonFraction>k for Company-owned GMP IV facility (EUR <ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="Duration_1_1_2022_To_9_30_2022_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_cvac_CompanyOwnedGmpIvFacilityMember_ZPOcXZnMYk-Um0cwVb1ZHw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" scale="3" id="Narr_KtoCH9YZZ0qa_HDaXdhDnA">49,366</ix:nonFraction>k) and equipment physically located at the CMO facilities (EUR <ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="Duration_1_1_2022_To_9_30_2022_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_cvac_EquipmentPhysicallyLocatedAtCmoFacilitiesMember_7vsnG93SaE-EN8D8ClkcNA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" scale="3" id="Narr_cVInoADr2UWpRA1ZhcYFEw">3,616</ix:nonFraction>k) and the remaining amount mainly for Company&#x2019;s GMP facilities. The increase was partially offset by EUR <ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="Duration_1_1_2022_To_9_30_2022_GrYkE3mhHEiRA4fxgfABRg" decimals="-3" format="ixt:numdotdecimal" name="cvac:IncreaseInPropertyAndEquipmentOffSetByImpairmentOfEquipment" scale="3" id="Narr_V5EelMGCo0SxghuJsD1mvA">5,854</ix:nonFraction>k impairment of equipment located at a CMO facility, which was recognized in cost of sales.</p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2022_To_9_30_2022_GrYkE3mhHEiRA4fxgfABRg" name="ifrs-full:DisclosureOfNoncurrentAssetsHeldForSaleAndDiscontinuedOperationsExplanatory" id="Tb_tj_fwEAcFUShSTkfxVXV4A" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">7. Assets held for sale</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In the second quarter 2022, CureVac signed a sales agreement with a global pharmaceutical contract development and manufacturing organization for the sale of Ultra-Low Temperature freezers for a total price of EUR <ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="As_Of_6_30_2022_kOEc9a1C10m7Rg-HheHYxg" decimals="-3" format="ixt:numdotdecimal" name="cvac:IfrsDisposalGroupIncludingDiscontinuedOperationConsideration" scale="3" id="Narr_k5emFVGq-U2C1ymm1biOmA">865</ix:nonFraction>k. The sale of the assets occurred in July 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In the third quarter 2022, CureVac listed lab equipment for sale on the internet portal of a service provider. Additionally, in fourth quarter 2022, CureVac sold equipment to a CMO.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Group classifies non-current assets as held for sale if their carrying amounts will be recovered principally through a sale transaction rather than through continuing use. Non-current assets classified as held for sale are measured at the lower of their carrying amount and fair value less costs to sell. Costs to sell are the incremental costs directly attributable to the disposal of an asset, excluding finance costs and income tax expense.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The criteria for held for sale classification is regarded as met only when the sale is highly probable, and the asset is available for immediate sale in its present condition. Actions required to complete the sale should indicate that it is unlikely that significant changes to the sale will be made or that the decision to sell will be withdrawn. Management must be committed to the plan to sell the asset and the sale expected to be completed within one year from the date of the classification.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Property, plant and equipment and intangible assets are not depreciated or amortized once classified as held for sale.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Assets and liabilities classified as held for sale are presented separately as current items in the statement of financial position.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_9_30_2022_GrYkE3mhHEiRA4fxgfABRg" name="ifrs-full:DisclosureOfInventoriesExplanatory" id="Tb_RcZcN9nn_EGkV9EQzNfk5A" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">8. Inventories</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The inventories include only raw materials. During the nine months ended September 30, 2022, the decrease in inventory of EUR <ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="Duration_1_1_2022_To_9_30_2022_srt_CounterpartyNameAxis_cvac_GlaxosmithklineMember_3G2M3SARj0GkTuTa4M37uw" decimals="-3" format="ixt:numdotdecimal" name="cvac:IncreaseDecreaseInInventory" scale="3" id="Narr_UXOmGurfDEOZA5bv46jEEQ">48,291</ix:nonFraction>k is due primarily to transfer of inventory EUR <span style="-sec-ix-hidden:Hidden_N17kRFMeX0inGpkHufA1CQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">9,800</span></span>k (net value) to GSK in connection with an agreement into which it entered with Novartis (see Note 3.6 for additional information) and due to further write-offs of EUR <ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="Duration_1_1_2022_To_9_30_2022_srt_CounterpartyNameAxis_cvac_GlaxosmithklineMember_3G2M3SARj0GkTuTa4M37uw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:InventoryWritedown2011" scale="3" id="Narr_Md3EXrt-UkOxv6Eb2nXmwQ">41,295</ix:nonFraction>k as certain raw materials, which had been procured for manufacture into products to sell to GSK, but which are now no longer expected to be purchased.</p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p><ix:nonNumeric contextRef="Duration_1_1_2022_To_9_30_2022_GrYkE3mhHEiRA4fxgfABRg" name="cvac:DisclosureOfPrepaidExpensesAndOtherCurrentAssetsExplanatory" id="Tb_cUA_pTJKE0SrCQjD9ahsdw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">9. Prepaid expenses and other assets (current)</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">Prepaid expenses and other current assets as of September 30, 2022 amounted to EUR <ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="As_Of_9_30_2022_zuGVrjesE0WhwXSGmTqsgA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:CurrentPrepaymentsAndOtherCurrentAssets" scale="3" id="Narr_l81-a4_C2ESMDnq_YsJVkw">60,952</ix:nonFraction>k (December 31, 2021: <ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="As_Of_12_31_2021_kQVJTWPgRUeESxCd99xt9A" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:CurrentPrepaymentsAndOtherCurrentAssets" scale="3" id="Narr_aWSrTY9Z9EG6lJOc20CUdQ">49,244</ix:nonFraction>k) and mainly include receivables for the GSK compensation of EUR <ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="As_Of_9_30_2022_zuGVrjesE0WhwXSGmTqsgA" decimals="-3" format="ixt:numdotdecimal" name="cvac:PrepaidCompensationForContractManufacturingOrganizationsTransfer" scale="3" id="Narr_igwnn0TeUUWJ0iF7iPU2LQ">12,678</ix:nonFraction>k (December 31, 2021: EUR <ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="As_Of_12_31_2021_kQVJTWPgRUeESxCd99xt9A" decimals="-3" format="ixt:numdotdecimal" name="cvac:PrepaidCompensationForContractManufacturingOrganizationsTransfer" scale="3" id="Narr_vkeZUdNzNk6yfpHdWR1LNw">0</ix:nonFraction>k). For more details, refer to Note&#xA0;3.6. In addition, other assets include further prepayments for material and CRO costs in the amount of EUR <ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="As_Of_9_30_2022_zuGVrjesE0WhwXSGmTqsgA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:CurrentAdvancesToSuppliers" scale="3" id="Narr_QtGjI0sHgkayypCno3tbaw">21,999</ix:nonFraction>k (December 31, 2021: EUR <ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="As_Of_12_31_2021_kQVJTWPgRUeESxCd99xt9A" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:CurrentAdvancesToSuppliers" scale="3" id="Narr_m7k0W4xQbEyQiogsIjjqKg">5,724</ix:nonFraction>k) and tax claims against the tax authorities of EUR <ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="As_Of_9_30_2022_zuGVrjesE0WhwXSGmTqsgA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ReceivablesFromTaxesOtherThanIncomeTax" scale="3" id="Narr_pB2b29kOUkOr2ol53WrmtA">18,009</ix:nonFraction>k (December 31, 2021: EUR <ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="As_Of_12_31_2021_kQVJTWPgRUeESxCd99xt9A" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ReceivablesFromTaxesOtherThanIncomeTax" scale="3" id="Narr_bb_g3Wgjb0uvHIrcIG7aKA">35,234</ix:nonFraction>k). These net amounts of VAT refund claims and VAT payables do not bear interest and are reported to the tax authorities on a monthly basis.</p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><a id="_02a1d70c_6cca_45d0_948a_8c3886c973fc"></a><a id="_02a1d70c_6cca_45d0_948a_8c3886c973fc_2"></a><a id="_02a1d70c_6cca_45d0_948a_8c3886c973fc_3"></a><a id="_ec29a6e8_7b25_4a90_b136_7c4f28c03348"></a><a id="_ec29a6e8_7b25_4a90_b136_7c4f28c03348_2"></a><a id="_ec29a6e8_7b25_4a90_b136_7c4f28c03348_3"></a><a id="_afddda3e_9eb8_46a9_8691_20508bb72644"></a><a id="_afddda3e_9eb8_46a9_8691_20508bb72644_2"></a><a id="_afddda3e_9eb8_46a9_8691_20508bb72644_3"></a><a id="_d5285e3e_9506_4783_9d6a_59ed1e883cd0"></a><a id="_d5285e3e_9506_4783_9d6a_59ed1e883cd0_2"></a><a id="_d5285e3e_9506_4783_9d6a_59ed1e883cd0_3"></a><a id="_566cb5e0_f606_4f9b_b964_ee1dbb9e5626"></a><a id="_566cb5e0_f606_4f9b_b964_ee1dbb9e5626_2"></a><a id="_566cb5e0_f606_4f9b_b964_ee1dbb9e5626_3"></a><a id="_c2218b15_f9b8_4a8e_83b9_a6feea5e9101"></a><a id="_c2218b15_f9b8_4a8e_83b9_a6feea5e9101_2"></a><a id="_c2218b15_f9b8_4a8e_83b9_a6feea5e9101_3"></a><ix:nonNumeric contextRef="Duration_1_1_2022_To_9_30_2022_GrYkE3mhHEiRA4fxgfABRg" name="ifrs-full:DisclosureOfFinancialInstrumentsExplanatory" id="Tb_7iZBc8YDRECNSfusUlgbTg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">10. Financial assets and financial liabilities</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Fair values of cash and cash equivalents, trade receivables, trade payables, and other current liabilities approximate their carrying amounts largely due to the short-term maturities of these instruments. Cash and cash equivalents compromise cash at banks and term deposits.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">Cash and cash equivalents compromise cash at banks and term deposits. There were <ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="Duration_1_1_2021_To_9_30_2021_5RS16WkLc0uS2ug_bqUm-g" decimals="0" format="ixt-sec:numwordsen" name="ifrs-full:TransfersOutOfLevel1IntoLevel2OfFairValueHierarchyAssets" scale="0" id="Narr_MbZpJQeIOEuHTPXuUdNaPQ"><ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="Duration_1_1_2022_To_9_30_2022_GrYkE3mhHEiRA4fxgfABRg" decimals="0" format="ixt-sec:numwordsen" name="ifrs-full:TransfersOutOfLevel1IntoLevel2OfFairValueHierarchyAssets" scale="0" id="Narr_PqH7lVike0O0VecC-vkDjA">no</ix:nonFraction></ix:nonFraction> transfers between Level 1 and Level 2 fair value measurements and <ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="Duration_1_1_2021_To_9_30_2021_5RS16WkLc0uS2ug_bqUm-g" decimals="0" format="ixt-sec:numwordsen" name="ifrs-full:TransfersIntoLevel3OfFairValueHierarchyAssets" scale="0" id="Narr_JDvbOTqxYEKe68grU_mk9w"><ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="Duration_1_1_2022_To_9_30_2022_GrYkE3mhHEiRA4fxgfABRg" decimals="0" format="ixt-sec:numwordsen" name="ifrs-full:TransfersIntoLevel3OfFairValueHierarchyAssets" scale="0" id="Narr_aXr3ekyUPEWzPCHGtBPZJg">no</ix:nonFraction></ix:nonFraction> transfers into or out of Level 3 fair value measurements during the nine months ended September 30, 2022 and 2021.</p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><ix:nonNumeric contextRef="Duration_1_1_2022_To_9_30_2022_GrYkE3mhHEiRA4fxgfABRg" name="ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory" id="Tb_1dxviq-c0kmFX9pc_huKhg" continuedAt="Tb_1dxviq-c0kmFX9pc_huKhg_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">11. Trade and other payables</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">During the nine months ended September 30, 2022, the decrease of EUR <ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="Duration_1_1_2022_To_9_30_2022_GrYkE3mhHEiRA4fxgfABRg" decimals="-3" format="ixt:numdotdecimal" name="cvac:ChangeInTradeAndOtherPayables" scale="3" id="Narr_LwkuFXQamE6IafehDf5UZA">75,095</ix:nonFraction>k in trade and other payables was primarily due to less payables to suppliers following the withdrawal of the EMA approval application for CVnCoV in Q4 2021.</p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_1dxviq-c0kmFX9pc_huKhg_cont1"></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><ix:nonNumeric contextRef="Duration_1_1_2022_To_9_30_2022_GrYkE3mhHEiRA4fxgfABRg" name="ifrs-full:DisclosureOfOtherLiabilitiesExplanatory" id="Tb_Z5CVGaQLf0ioJpZyv8uIfg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">12. Other liabilities</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">During the nine months ended September 30, 2022, the decrease of EUR <ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="Duration_1_1_2022_To_9_30_2022_GrYkE3mhHEiRA4fxgfABRg" decimals="-3" format="ixt:numdotdecimal" name="cvac:ChangeInOtherLiabilities" scale="3" id="Narr_Phn6icGUn02zPB3Km2xUQw">91,106</ix:nonFraction>k in other liabilities was primarily due to a net decrease of contract termination provisions (see Note 3.6), due to a reversal of a portion of the provision for onerous contracts relating to CRO arrangements due to a change in estimate (see Note 3.4), due to a consumption of the CRO provision for onerous losses and due to lower accruals for outstanding invoices. </p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><ix:nonNumeric contextRef="Duration_1_1_2022_To_9_30_2022_GrYkE3mhHEiRA4fxgfABRg" name="ifrs-full:DisclosureOfDetailedInformationAboutBorrowingsExplanatory" id="Tb_2FFsVI_txU6ALpL9cQbJCw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">13. Loans</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of September 30, 2021, CureVac had drawn the first of the three tranches of the EIB loan received in December 2020 and, thus, EUR <ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="Duration_1_1_2021_To_9_30_2021_ifrs-full_BorrowingsByNameAxis_cvac_IfrsLineOfCreditMember_w0otbseHCk-9ZLH1m6FDbA" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities" scale="6" id="Narr_bHcJV6fChUuTbJNUJ64Ckg">25</ix:nonFraction> million (plus accrued interest of EUR <ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="As_Of_9_30_2021_ifrs-full_BorrowingsByNameAxis_cvac_IfrsLineOfCreditMember_lKYOAuZEL0axHg8yeQcJvA" decimals="-3" format="ixt:numdotdecimal" name="cvac:LineOfCreditAccruedInterestPayable" scale="3" id="Narr_6sOO03p0K06XA5bLbpnS-w">2,543</ix:nonFraction>k) was outstanding on the loan as of that date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">During the year ended December 31, 2021, CureVac decided to early terminate the EIB loan for a total cash consideration of EUR <ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="Duration_1_1_2021_To_12_31_2021_ifrs-full_BorrowingsByNameAxis_cvac_IfrsLineOfCreditMember_Zjc-vTBONUWK_U5c-7CI3w" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:RepaymentsOfBorrowingsClassifiedAsFinancingActivities" scale="3" id="Narr_RmJmyHZfg0mdk7AIfspCIw">26,633</ix:nonFraction>k, which comprises of EUR <ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="Duration_1_1_2021_To_12_31_2021_ifrs-full_BorrowingsByNameAxis_cvac_IfrsLineOfCreditMember_Zjc-vTBONUWK_U5c-7CI3w" decimals="-3" format="ixt:numdotdecimal" name="cvac:RepaymentsOfPrincipalAmountOfBorrowings" scale="3" id="Narr_ixPPqNIKjEqj9xqmXGkW_w">25,000</ix:nonFraction>k repayment of the loan and <ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="Duration_1_1_2021_To_12_31_2021_ifrs-full_BorrowingsByNameAxis_cvac_IfrsLineOfCreditMember_Zjc-vTBONUWK_U5c-7CI3w" decimals="-3" format="ixt:numdotdecimal" name="cvac:IfrsRepaymentsOfAccruedInterestAndFeesOfBorrowings" scale="3" id="Narr_q2zSwRHrHUa8xGXTMvzOmA">1,633</ix:nonFraction>k interest and fees. As of December 31, 2021, the EIB loan was fully repaid.</p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><ix:nonNumeric contextRef="Duration_1_1_2022_To_9_30_2022_GrYkE3mhHEiRA4fxgfABRg" name="ifrs-full:DisclosureOfIncomeTaxExplanatory" id="Tb_9qn5VpEfrkOKmziJW-Nhvg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">14. Income tax</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Group booked the expected tax benefits or expenses based on a best estimate for a period of nine months ended September 30, 2022. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">For the nine months ended September 30, 2022 and 2021, the Group recorded a consolidated income tax benefit of EUR <ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="Duration_1_1_2022_To_9_30_2022_GrYkE3mhHEiRA4fxgfABRg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:IncomeTaxExpenseContinuingOperations" sign="-" scale="3" id="Narr_7jRVj4aimkGuuCw1LATJxw">160</ix:nonFraction>k (September 30, 2021: income tax expense of EUR -<ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="Duration_1_1_2021_To_9_30_2021_5RS16WkLc0uS2ug_bqUm-g" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:IncomeTaxExpenseContinuingOperations" scale="3" id="Narr_-b9u8TIhGkW4DpmGohG8-Q">1,841</ix:nonFraction>k), respectively. The consolidated income tax benefit (September 30, 2021: income tax expense) for the nine months ended September 30, 2022, resulted from income tax benefit from CureVac Inc of EUR <ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="Duration_1_1_2022_To_9_30_2022_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_cvac_CurevacCorporateServiceGmbhMember_w8u7qadVykiL43suHZX4cQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:CurrentTaxExpenseIncome" scale="3" id="Narr_IkoWRR8bhUGqj6GagqmmLw">235</ix:nonFraction>k for current tax and tax expenses from CureVac Corporate Service and CureVac Swiss AG of EUR <ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="Duration_1_1_2022_To_9_30_2022_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_cvac_CurevacSwissAgMember_uQhhLoLXmEqQ0Uh4SUqsVA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:CurrentTaxExpenseIncome" scale="3" id="Narr_pUKP_FrJHEW54LclzqeP-Q">94</ix:nonFraction>k. CureVac Corporate Service has a deferred tax benefit of EUR <ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="Duration_1_1_2022_To_9_30_2022_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_cvac_CurevacCorporateServiceGmbhMember_w8u7qadVykiL43suHZX4cQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:DeferredTaxExpenseIncome" scale="3" id="Narr_7-PEJ4824k-x7hL_o33Zog">21</ix:nonFraction>k for the nine months ended September 30, 2022.</p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><ix:nonNumeric contextRef="Duration_1_1_2022_To_9_30_2022_GrYkE3mhHEiRA4fxgfABRg" name="ifrs-full:DisclosureOfFinancialRiskManagementExplanatory" id="Tb_4zYgedxufk-z7YSdSqrBIA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">15. Disclosure of financial instruments and risk management</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As the Group requires significant liquid funds available for the financing of its COVID-19 and influenza research and development activities, during the nine months ended September 30, 2022, it has maintained funds as cash and cash equivalents and not in less liquid financial instruments. The Group has distributed the cash amongst several banks and amongst the legal entities in the Group in order to reduce negative interest penalties.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">Refer to Note 15 to the consolidated financial statements as of December&#xA0;31, 2021 for additional information on the Group&#x2019;s risk management activities. As of September 30, 2022, the Group held cash and cash equivalents of USD <ix:nonFraction unitRef="Unit_Standard_USD_q8NNp4TBfUC9XydcVDSrpA" contextRef="As_Of_9_30_2022_ifrs-full_ClassesOfFinancialInstrumentsAxis_cvac_IfrsCashAndCashEquivalentsMember_ifrs-full_TypesOfRisksAxis_ifrs-full_CurrencyRiskMember_srt_CurrencyAxis_currency_USD_GbIyOSI9fU6k0lhzbRaN6Q" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:RiskExposureAssociatedWithInstrumentsSharingCharacteristic" scale="3" id="Narr_8FegT2ZRn0K4KkONCNEicg">82,577</ix:nonFraction>k and CHF <ix:nonFraction unitRef="Unit_Standard_CHF_BBNACBTv9k-Ei0YBwsfYBA" contextRef="As_Of_9_30_2022_ifrs-full_ClassesOfFinancialInstrumentsAxis_cvac_IfrsCashAndCashEquivalentsMember_ifrs-full_TypesOfRisksAxis_ifrs-full_CurrencyRiskMember_srt_CurrencyAxis_currency_CHF_GzG5BBakVUCREUh5rLOPgw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:RiskExposureAssociatedWithInstrumentsSharingCharacteristic" scale="3" id="Narr_SGEr6-QtfEO7-Z21DwQqPA">117</ix:nonFraction>k, which are exposed to foreign currency exchange risk. The Group intends to settle expenses arising in US dollars using these US dollar funds. </p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><ix:nonNumeric contextRef="Duration_1_1_2022_To_9_30_2022_GrYkE3mhHEiRA4fxgfABRg" name="ifrs-full:EarningsPerShareExplanatory" id="Tb_fb4X7p3CCEqXzFJpp8nbEA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">16. Earnings per share</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18.2pt;margin:0pt 0pt 12pt 0pt;">Earnings per share is calculated pursuant to <i style="font-style:italic;">IAS 33 Earnings per Share</i> by dividing the consolidated net loss in CureVac N.V. by the average weighted number of shares outstanding in the fiscal period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18.2pt;margin:0pt;">The weighted number of shares outstanding for the nine months ended September 30, 2022 was <ix:nonFraction unitRef="Unit_Standard_shares_FapG5E6UqkK42IfNNOS6tA" contextRef="Duration_1_1_2022_To_9_30_2022_GrYkE3mhHEiRA4fxgfABRg" decimals="INF" format="ixt:numdotdecimal" name="ifrs-full:WeightedAverageShares" scale="0" id="Narr_oY9fEKQrUUG2-ME6SC4iJw">188,020,542</ix:nonFraction> (September 30, 2021: <ix:nonFraction unitRef="Unit_Standard_shares_FapG5E6UqkK42IfNNOS6tA" contextRef="Duration_1_1_2021_To_9_30_2021_5RS16WkLc0uS2ug_bqUm-g" decimals="INF" format="ixt:numdotdecimal" name="ifrs-full:WeightedAverageShares" scale="0" id="Narr_SfKxzmH040qS50d50Qj1Hg">185,702,736</ix:nonFraction>). This has led to a basic loss per share for the nine months ended September 30, 2022 and 2021 of EUR <ix:nonFraction unitRef="Unit_Divide_EUR_shares_6PEZCHC_WE2a7AmZW169oA" contextRef="Duration_1_1_2022_To_9_30_2022_GrYkE3mhHEiRA4fxgfABRg" decimals="2" format="ixt:numdotdecimal" name="ifrs-full:BasicEarningsLossPerShare" sign="-" scale="0" id="Narr_QOtD-UE1jk2lIvQrWn87mQ">0.64</ix:nonFraction> and EUR <ix:nonFraction unitRef="Unit_Divide_EUR_shares_6PEZCHC_WE2a7AmZW169oA" contextRef="Duration_1_1_2021_To_9_30_2021_5RS16WkLc0uS2ug_bqUm-g" decimals="2" format="ixt:numdotdecimal" name="ifrs-full:BasicEarningsLossPerShare" sign="-" scale="0" id="Narr_hdI2-f74x0O9IdSa6ChOdQ">2.21</ix:nonFraction>, respectively. Since the conversion of options to ordinary shares would decrease loss per share, they are considered antidilutive. Therefore, the diluted earnings per share equals basic earnings per share for the nine months ended September 30, 2022 and 2021. </p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><ix:nonNumeric contextRef="Duration_1_1_2022_To_9_30_2022_GrYkE3mhHEiRA4fxgfABRg" name="ifrs-full:DisclosureOfRelatedPartyExplanatory" id="Tb_WyUIOHu1YEGdqByE06Xb-w" continuedAt="Tb_WyUIOHu1YEGdqByE06Xb-w_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">17. Related party disclosures</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Dietmar Hopp</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18.2pt;margin:0pt 0pt 10pt 0pt;">During fiscal 2019, Dietmar Hopp, principal of dievini Hopp BioTech holding GmbH &amp; Co. KG (dievini), the largest shareholder of the Group, granted <ix:nonFraction unitRef="Unit_Standard_loan_2Ze7UTdQEkiZKAdZ7o4zlw" contextRef="Duration_1_1_2019_To_12_31_2019_ifrs-full_CategoriesOfRelatedPartiesAxis_cvac_DietmarHoppMember_vhtIRbibYkK_L7RHLy0f_A" decimals="INF" format="ixt-sec:numwordsen" name="cvac:RelatedPartyTransactionNumberOfLoansReceived" scale="0" id="Narr_sVFHaEk71kCG5mK5v4wUlw">two</ix:nonFraction> convertible loans to the Group, which were repaid in 2020. Additionally, in August 2020, DH-LT Investments GmbH, a company beneficially owned by Dietmar Hopp, managing director of dievini, the Group<span style="font-family:'Arial','Helvetica','sans-serif';">&#x2019;</span>s largest shareholder, purchased EUR <ix:nonFraction unitRef="Unit_Standard_shares_FapG5E6UqkK42IfNNOS6tA" contextRef="Duration_8_1_2020_To_8_31_2020_ifrs-full_CategoriesOfRelatedPartiesAxis_cvac_DietmarHoppMember_4pr7l6FBv0Cr0BMx5sP5QQ" decimals="INF" format="ixt:numdotdecimal" name="cvac:IncreaseInNumberOfSharesOutstanding" scale="0" id="Narr__5smC5F-vk-RcdePLpm_VA">100,000</ix:nonFraction>k of the Group<span style="font-family:'Arial','Helvetica','sans-serif';">&#x2019;</span>s common shares at a price of USD <ix:nonFraction unitRef="Unit_Divide_USD_shares_B3tHpJm3a0ytZJRcE10tTA" contextRef="Duration_8_1_2020_To_8_31_2020_ifrs-full_CategoriesOfRelatedPartiesAxis_cvac_DietmarHoppMember_4pr7l6FBv0Cr0BMx5sP5QQ" decimals="2" format="ixt:numdotdecimal" name="ifrs-full:WeightedAverageSharePrice2019" scale="0" id="Narr_EcV4HnwmX026XZhVXlZcQQ">16.00</ix:nonFraction> per share.</p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_WyUIOHu1YEGdqByE06Xb-w_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Antony Blanc</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18.2pt;margin:0pt 0pt 11pt 0pt;">In 2020, a consulting agreement between CureVac AG and Clarentis SRL was made. Clarentis SRL is a wholly owned consulting company of Antony Blanc, PhD, the CBO of CureVac. After the transition of Antony Blanc to the Management Board in February 2021, the contract was no longer active, and no new orders were placed. In Q3 2021, a milestone payment, which related to the submission of the EMA dossier for CVnCoV and which amounted to EUR <ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="As_Of_9_30_2021_ifrs-full_CategoriesOfRelatedPartiesAxis_cvac_ClarentisSrlMember_Dh91pVmxqEWDD100jMo2Fw" decimals="-3" format="ixt:numdotdecimal" name="cvac:CollaborationAgreementMilestonePayment" scale="3" id="Narr_nyURrB63rUWgDnF91vLHog">100</ix:nonFraction>k was made to fulfil a contractual obligation from the consulting agreement in place before Antony Blanc joined the Management Board. In addition to his Management Board position at CureVac NV, Antony also took over the role as Management Director at CureVac Belgium SA. He executes this function by using Clarentis SRL. As it relates to these services, CureVac paid until September 2022 an amount of EUR <ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="Duration_1_1_2022_To_9_30_2022_ifrs-full_CategoriesOfRelatedPartiesAxis_cvac_ClarentisSrlMember_srt_TitleOfIndividualAxis_cvac_AntonyBlancMember_GiBB1NZHtU6MtEphFx2MUw" decimals="-3" format="ixt:numdotdecimal" name="cvac:PaymentsToRelatedPartyForServices" scale="3" id="Narr_yGjjClstHUS8XaFC1W3MDA">48</ix:nonFraction>k. The amounts invoiced for this function/services will be offset/deducted from his base compensation for his function on the Board of Management of CureVac N.V.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 11pt 0pt;"><span style="font-style:italic;font-weight:bold;">BePharBel Manufacturing S.A.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">In December 2020, CureVac Real Estate GmbH and BePharBel Manufacturing S.A., entered into a commercial supply agreement to develop and manufacture the diluent that was expected to be used to dilute the Group&#x2019;s first concentrated COVID-19 vaccine candidate, CVnCoV, to the amount specified by each dose level. Pursuant to the terms of the agreement, it was intended that BePharBel Manufacturing would manufacture and deliver to CureVac Real Estate GmbH a low seven figure amount of commercial batches of diluent per year, in 2021 and 2022. Following the withdrawal of the CVnCoV in October 2021 due to COVID-19 virus drift, WHO COVID vaccine efficiency recommendation and market expectations, CureVac Real Estate GmbH terminated the commercial and supply agreement with BePahrBel and entered into negotiations on a structured and rapid wind-down of the ordered production. The Parties agreed on a settlement in May 2022 of all claims resulting from the commercial and supply agreement for an amount of EUR <ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="Duration_5_1_2022_To_5_31_2022_ifrs-full_CategoriesOfRelatedPartiesAxis_cvac_BepharbelManufacturingS.aMember_OIxhC3wEcEmjhA5CfZ3lqQ" decimals="-5" format="ixt:numdotdecimal" name="ifrs-full:CommitmentsMadeByEntityRelatedPartyTransactions" scale="6" id="Narr_xgBx6IuwYkmcNb96VZZdaQ">3,900</ix:nonFraction>k, which had been already recognized in provisions, based on an estimate, as of December 31, 2021. Baron Jean St&#xE9;phenne, our supervisory board member, holds directly and indirectly <ix:nonFraction unitRef="Unit_Standard_pure_NsGb2Z3yYka4EicmhvoaQQ" contextRef="Duration_1_1_2022_To_9_30_2022_srt_TitleOfIndividualAxis_cvac_BaronJeanStephenneMember_xZT627rXM0CHsP6C5sklyg" decimals="4" format="ixt:numdotdecimal" name="ifrs-full:ProportionOfOwnershipInterestInAssociate" scale="-2" id="Narr_KEmy-Zasn0Wi4ApuaxKQlA">15.61</ix:nonFraction>% of BePharBel Manufacturing&#x2019;s equity and is a director of BePharBel Manufacturing, and Baron Jean St&#xE9;phenne&#x2019;s son, Vincent St&#xE9;phenne, holds <ix:nonFraction unitRef="Unit_Standard_pure_NsGb2Z3yYka4EicmhvoaQQ" contextRef="Duration_1_1_2022_To_9_30_2022_srt_TitleOfIndividualAxis_cvac_VincentStphenneMember_PA_nLHYdokKpQK-0_a7lSg" decimals="4" format="ixt:numdotdecimal" name="ifrs-full:ProportionOfOwnershipInterestInAssociate" scale="-2" id="Narr_j5yTNAV6lECjrBDZtMwP0g">1.43</ix:nonFraction>% of BePharBel Manufacturing&#x2019;s equity and is a managing director of BePharBel Manufacturing.</p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><ix:nonNumeric contextRef="Duration_1_1_2022_To_9_30_2022_GrYkE3mhHEiRA4fxgfABRg" name="ifrs-full:DisclosureOfBusinessCombinationsExplanatory" id="Tb__PlzDS7D-0m3TofHmnuL5Q" continuedAt="Tb__PlzDS7D-0m3TofHmnuL5Q_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">18. Significant transactions and events</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Business Combination and Goodwill &#x2013; Frame Acquisition</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18.2pt;margin:0pt 0pt 12pt 0pt;">Effective July 1, 2022 (&#x2018;closing date&#x2019;), CureVac N.V. acquired all shares of Frame Pharmaceuticals B.V., Amsterdam, Netherlands (&#x2018;Frame Pharmaceuticals&#x2019;). Frame Pharmaceuticals focuses on the development of a proprietary platform enabling the identification of structural changes within the cancer genome and has strong competencies in antigen discovery as well as validation for personalized cancer vaccines. CureVac&#x2019;s management and supervisory board expect that the acquisition will contribute several key elements for the required end-to-end building blocks for CureVac&#x2019;s broader oncology strategy.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18.2pt;margin:0pt 0pt 12pt 0pt;">Frame Pharmaceuticals contributed <ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="Duration_1_1_2022_To_9_30_2022_ifrs-full_BusinessCombinationsAxis_cvac_FramePharmaceuticalsB.v.AmsterdamNetherlandsMember_APxhOynMm0ePvj-djFEXLQ" decimals="0" format="ixt-sec:numwordsen" name="ifrs-full:RevenueOfAcquiree" scale="0" id="Narr_vTUrBh-rakShkE-WqTNL4g">no</ix:nonFraction> revenues and a loss of EUR <ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="Duration_1_1_2022_To_9_30_2022_ifrs-full_BusinessCombinationsAxis_cvac_FramePharmaceuticalsB.v.AmsterdamNetherlandsMember_APxhOynMm0ePvj-djFEXLQ" decimals="-5" format="ixt:numdotdecimal" name="ifrs-full:ProfitLossOfAcquiree" scale="6" id="Narr_Cjqc6NKHQUSgVrplz-zx7A">0.6</ix:nonFraction> million to the consolidated result for the current reporting period. Assuming an initial consolidation of Frame Pharmaceuticals on January 1, 2022, the Group's revenue would be unchanged and the loss would have been EUR <ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="Duration_1_1_2022_To_9_30_2022_ifrs-full_BusinessCombinationsAxis_cvac_FramePharmaceuticalsB.v.AmsterdamNetherlandsMember_APxhOynMm0ePvj-djFEXLQ" decimals="-5" format="ixt:numdotdecimal" name="ifrs-full:ProfitLossOfCombinedEntity" scale="6" id="Narr_EVCEYHbbTkqXKLs63VAEBw">3.0</ix:nonFraction> million higher, respectively, than reported (estimate based on the purchase price allocation). In determining these amounts, management has assumed that the fair value adjustments made at the acquisition date would also have applied on January 1, 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18.2pt;margin:0pt 0pt 12pt 0pt;">In the purchase price agreement (&#x2018;SPA&#x2019;) dated June 8, 2022, a total consideration of up to EUR <ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="As_Of_6_8_2022_ifrs-full_BusinessCombinationsAxis_cvac_FramePharmaceuticalsB.v.AmsterdamNetherlandsMember_VaKO9irU5EuHdCnXXdyNiw" decimals="-5" format="ixt:numdotdecimal" name="ifrs-full:AcquisitiondateFairValueOfTotalConsiderationTransferred" scale="6" id="Narr_dasTdkCe4kiZF9LNOxYe4w">32.0</ix:nonFraction> million, subject to certain adjustments for vested and non-vested employee options of the acquiree plus an amount of EUR <ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="As_Of_6_8_2022_ifrs-full_BusinessCombinationsAxis_cvac_FramePharmaceuticalsB.v.AmsterdamNetherlandsMember_VaKO9irU5EuHdCnXXdyNiw" decimals="-4" format="ixt:numdotdecimal" name="ifrs-full:LiabilitiesIncurred" scale="6" id="Narr_TUY6RfeEo0aOf5UwdZNLmQ">1.56</ix:nonFraction> million for the assumption of an outstanding obligation resulting from advisory services was agreed. The consideration consisted of minor cash payments and the transfer of shares in CureVac N.V. (&#x2018;CureVac Shares&#x2019;). The number of CureVac Shares to be issued as part of the different consideration payments were agreed in the SPA and based on the <ix:nonFraction unitRef="Unit_Standard_D_Pu_YZcQO3kKxgZxGvGVflA" contextRef="Duration_6_8_2022_To_6_8_2022_ifrs-full_BusinessCombinationsAxis_cvac_FramePharmaceuticalsB.v.AmsterdamNetherlandsMember_1GTamgfVRUOww3XIvpKP3Q" decimals="INF" format="ixt:numdotdecimal" name="cvac:BusinessAcquisitionSigningSharePriceNumberOfTradingDaysConsidered" scale="0" id="Narr_eGOlbzfRmUKNn-MDPK1zag">60</ix:nonFraction>-trading day volume weighted average price until June 3, 2022, based on a Signing Share Price (&#x2018;Signing Share Price&#x2019;) at EUR <ix:nonFraction unitRef="Unit_Divide_EUR_shares_6PEZCHC_WE2a7AmZW169oA" contextRef="Duration_6_8_2022_To_6_8_2022_ifrs-full_BusinessCombinationsAxis_cvac_FramePharmaceuticalsB.v.AmsterdamNetherlandsMember_1GTamgfVRUOww3XIvpKP3Q" decimals="2" format="ixt:numdotdecimal" name="cvac:BusinessAcquisitionSigningSharePrice" scale="0" id="Narr_xD_pOjJ74km_i9_5Gv4RUw">16.44</ix:nonFraction>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18.2pt;margin:0pt 0pt 12pt 0pt;">The total consideration is split into <ix:nonFraction unitRef="Unit_Standard_payment_4W6g8HbU0USZCbuxzWFKng" contextRef="As_Of_9_30_2022_ifrs-full_BusinessCombinationsAxis_cvac_FramePharmaceuticalsB.v.AmsterdamNetherlandsMember_vR0Bi5R7KE6kPw8J5q5NTA" decimals="INF" format="ixt-sec:numwordsen" name="cvac:NumberOfPaymentsInWhichTotalConsiderationIsToBePaid" scale="0" id="Narr_fsKiXg0wqkuPPeWrCLbWzQ">three</ix:nonFraction> payments, <ix:nonFraction unitRef="Unit_Standard_payment_4W6g8HbU0USZCbuxzWFKng" contextRef="As_Of_9_30_2022_ifrs-full_BusinessCombinationsAxis_cvac_FramePharmaceuticalsB.v.AmsterdamNetherlandsMember_vR0Bi5R7KE6kPw8J5q5NTA" decimals="INF" format="ixt-sec:numwordsen" name="cvac:ContingentConsiderationNumberOfPaymentsConsidered" scale="0" id="Narr_jZQAvqVnhEu7An1MmwVaGA">two</ix:nonFraction> of which are contingent upon the achievement of defined milestones (contingent consideration). At the closing date, CureVac had to pay <ix:nonFraction unitRef="Unit_Standard_pure_NsGb2Z3yYka4EicmhvoaQQ" contextRef="As_Of_7_1_2022_ifrs-full_BusinessCombinationsAxis_cvac_FramePharmaceuticalsB.v.AmsterdamNetherlandsMember_TNMnxy-chEOEtWGU9Rxf9g" decimals="2" format="ixt:numdotdecimal" name="cvac:FirstPortionOfTotalConsiderationTransferredPercentage" scale="-2" id="Narr_xUJ44-54w0qlBAH_ZaCz1Q">50</ix:nonFraction> % of the total consideration, i. e. EUR <ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="As_Of_7_1_2022_ifrs-full_BusinessCombinationsAxis_cvac_FramePharmaceuticalsB.v.AmsterdamNetherlandsMember_TNMnxy-chEOEtWGU9Rxf9g" decimals="-5" format="ixt:numdotdecimal" name="cvac:FirstPortionOfTotalConsiderationTransferredAmount" scale="6" id="Narr_YgCHI378vEqB3KJPLxiyeg">16.0</ix:nonFraction> million plus the consideration for the outstanding obligation of EUR <ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="As_Of_9_30_2022_zuGVrjesE0WhwXSGmTqsgA" decimals="-4" format="ixt:numdotdecimal" name="cvac:FirstPortionOfTotalConsiderationTransferredAmount" scale="6" id="Narr_vOHtj26vbk-XQ1FapUdY2Q">1.56</ix:nonFraction> million as follows:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#x25CF;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Issuance and transfer of </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"><ix:nonFraction unitRef="Unit_Standard_shares_FapG5E6UqkK42IfNNOS6tA" contextRef="As_Of_9_30_2022_zuGVrjesE0WhwXSGmTqsgA" decimals="INF" format="ixt:numdotdecimal" name="cvac:NumberOfInstrumentsOrInterestsIssuedOrIssuableAsConsiderationToFormerShareholders" scale="0" id="Narr_YaegueP0UkqpmxgyXAaYDg">810,242</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> shares (worth EUR </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"><ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="As_Of_9_30_2022_zuGVrjesE0WhwXSGmTqsgA" decimals="-3" format="ixt:numdotdecimal" name="cvac:ValueOfInstrumentsOrInterestsIssuedOrIssuableAsConsiderationToFormerShareholders" scale="3" id="Narr_JAxXyeIFkUW8RdPQ8QvS_Q">11,040</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">k) to former Frame shareholders. The respective share price of one CureVac Share was EUR </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"><ix:nonFraction unitRef="Unit_Divide_EUR_shares_6PEZCHC_WE2a7AmZW169oA" contextRef="As_Of_9_30_2022_zuGVrjesE0WhwXSGmTqsgA" decimals="2" format="ixt:numdotdecimal" name="cvac:IfrsBusinessAcquisitionSharePrice" scale="0" id="Narr_Ev3fwGsTOky2uSXRASMhhA">13.63</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> (&#x2018;Closing Share Price&#x2019;).</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#x25CF;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Issuance and transfer of further </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"><ix:nonFraction unitRef="Unit_Standard_shares_FapG5E6UqkK42IfNNOS6tA" contextRef="As_Of_9_30_2022_zuGVrjesE0WhwXSGmTqsgA" decimals="INF" format="ixt:numdotdecimal" name="cvac:NumberOfInstrumentsOrInterestsIssuedOrIssuableAsConsiderationForDischargingContractualObligations" scale="0" id="Narr_7A4zUZEc3EColsqg0_z1qg">48,254</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> shares (worth EUR </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"><ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="As_Of_9_30_2022_zuGVrjesE0WhwXSGmTqsgA" decimals="-3" format="ixt:numdotdecimal" name="cvac:ValueOfInstrumentsOrInterestsIssuedOrIssuableAsConsiderationForDischargingContractualObligations" scale="3" id="Narr_u8BOlrFyvUevCy5QbzIj4g">657</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">k, valued at the Closing Share Price) as consideration for discharging the contractual obligations for the outstanding advisory agreements of EUR </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"><ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="As_Of_9_30_2022_ifrs-full_BusinessCombinationsAxis_cvac_FramePharmaceuticalsB.v.AmsterdamNetherlandsMember_vR0Bi5R7KE6kPw8J5q5NTA" decimals="-3" format="ixt:numdotdecimal" name="cvac:ValueOfInstrumentsOrInterestsIssuedOrIssuableAsConsiderationForDischargingContractualObligations" scale="3" id="Narr_5oUP12Ov90Wy-TRuvIqc7A">1,560</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">k (adjusted by the strike price of EUR </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"><ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="As_Of_9_30_2022_zuGVrjesE0WhwXSGmTqsgA" decimals="-3" format="ixt:numdotdecimal" name="cvac:StrikePriceForExistingShareBasedPayment" scale="3" id="Narr_bF8fvBGO2E-i1DaANUAsRg">767</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">k for the existing share-based payment). </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#x25CF;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Payment of EUR </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"><ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="As_Of_9_30_2022_zuGVrjesE0WhwXSGmTqsgA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:CashTransferred" scale="3" id="Narr_A9kRjS9EdEaiLuch7e3s_w">585</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">k in cash, consisting of EUR </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"><ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="As_Of_9_30_2022_zuGVrjesE0WhwXSGmTqsgA" decimals="-3" format="ixt:numdotdecimal" name="cvac:CashTransferredForSettlementOfVestedEmployeeOptions" scale="3" id="Narr_Grou3YawokepRPzjjIkNmg">335</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">k being the consideration for the settlement of the vested employee options, and an additional EUR </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"><ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="As_Of_9_30_2022_zuGVrjesE0WhwXSGmTqsgA" decimals="-3" format="ixt:numdotdecimal" name="cvac:AdditionalCashTransferred" scale="3" id="Narr_LTY7nswcsE6PNLEzLo6Hvg">250</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">k.</span></td></tr></table><div style="margin-top:12pt;"></div></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><a id="_e64a247c_268e_45c9_9e01_900e3dcc4bcc"></a><a id="Tc_YgzXe1vrek2TiEZmzKQjGA_1_0"></a><a id="Tc_eBwvtCWfh0CpVfPALX54ow_1_2"></a><a id="Tc_2pdngv_yjEaNrmVKx32O_g_2_0"></a><a id="Tc_T-fuI1ujv023ppqGDt0vHA_3_0"></a><a id="Tc_sCCOao_IE0iVwLmaMyRCWQ_4_0"></a><a id="Tc_LQkKdAseCUOSeNanQrwNdg_5_0"></a><a id="Tc_UUbR43BdukWuy-y65AAV_Q_6_0"></a><a id="Tc_yjsK1qUUMEOkYwIapNckng_7_0"></a><a id="Tc_7HDpP2-9WUSU7uGNHGxumw_8_0"></a><a id="Tc_mkgbU7Wkw0WYxNshQZsPLg_9_0"></a><a id="Tc_Dr5cuC7Ozkix-_tAEEyLcg_10_0"></a><a id="Tc_VDkvo9vEJkSwst-Lyc_YoA_11_0"></a><a id="Tc_RluXNE_wxkuq-_ClhZHxUw_12_0"></a><a id="Tc_7IAqCrIMXEOz96M6E8WCag_13_0"></a><a id="Tc_XGj4ApE-BEiDkjacFVE2Aw_14_0"></a><a id="Tc_B7X_maUmwE62nkopw79DyQ_15_0"></a><a id="Tc_5Lg9o7M0nk-0cuuf1af0zQ_16_0"></a><a id="Tc_quYKVkm7jUeSK8_GWa4IRg_17_0"></a><a id="Tc_JZrqaxn18UKQqG_XrJ2_GQ_18_0"></a><ix:continuation id="Tb__PlzDS7D-0m3TofHmnuL5Q_cont1" continuedAt="Tb__PlzDS7D-0m3TofHmnuL5Q_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Payment of the remaining <ix:nonFraction unitRef="Unit_Standard_pure_NsGb2Z3yYka4EicmhvoaQQ" contextRef="As_Of_9_30_2022_zuGVrjesE0WhwXSGmTqsgA" decimals="2" format="ixt:numdotdecimal" name="cvac:ContingentConsiderationPercentageOfTotalConsideration" scale="-2" id="Narr_6NBRyHAqJUWyIGeReB8WsA">50</ix:nonFraction>% of the total consideration is contingent upon the achievement of <ix:nonFraction unitRef="Unit_Standard_Milestone_1ZnSc2qU1UaZ09p9Mr6TGw" contextRef="As_Of_9_30_2022_zuGVrjesE0WhwXSGmTqsgA" decimals="INF" format="ixt-sec:numwordsen" name="cvac:ContingentConsiderationNumberOfMilestones" scale="0" id="Narr_r1AbDnx2ykGHnNH7dvB9HA">two</ix:nonFraction> milestones. A further <ix:nonFraction unitRef="Unit_Standard_shares_FapG5E6UqkK42IfNNOS6tA" contextRef="As_Of_9_30_2022_zuGVrjesE0WhwXSGmTqsgA" decimals="INF" format="ixt:numdotdecimal" name="cvac:NumberOfInstrumentsOrInterestsIssuedOrIssuableUponAchievementOfFirstMilestone" scale="0" id="Narr_Bw9h_TSpmEa9ZFDXTnwTnw">194,647</ix:nonFraction> shares (representing <ix:nonFraction unitRef="Unit_Standard_pure_NsGb2Z3yYka4EicmhvoaQQ" contextRef="As_Of_9_30_2022_zuGVrjesE0WhwXSGmTqsgA" decimals="2" format="ixt:numdotdecimal" name="cvac:PercentageOfConsiderationTransferredUponAchievementOfFirstMilestone" scale="-2" id="Narr_DdeV3NiT4ECo2aLBuVtkjg">10</ix:nonFraction>% of EUR <ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="As_Of_9_30_2022_zuGVrjesE0WhwXSGmTqsgA" decimals="-5" format="ixt:numdotdecimal" name="cvac:ValueOfInstrumentsOrInterestsIssuedOrIssuableUponAchievementOfFirstMilestone" scale="6" id="Narr__Jn5jg-xZ0mXdt1nu4UwmQ">32.0</ix:nonFraction> million divided by the Signing Share Price, i. e. EUR <ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="As_Of_9_30_2022_zuGVrjesE0WhwXSGmTqsgA" decimals="-3" format="ixt:numdotdecimal" name="cvac:SigningSharePriceRepresenting10" scale="3" id="Narr_HD8VsOoX4kejijxlmaYR8Q">1,831</ix:nonFraction>k) are issuable upon the achievement of the successful investigational new drug application filing and a further <ix:nonFraction unitRef="Unit_Standard_shares_FapG5E6UqkK42IfNNOS6tA" contextRef="As_Of_9_30_2022_zuGVrjesE0WhwXSGmTqsgA" decimals="INF" format="ixt:numdotdecimal" name="cvac:NumberOfInstrumentsOrInterestsIssuedOrIssuableUponAchievementOfSecondMilestone" scale="0" id="Narr_9sjaNog3e02SRiFdgfBlwg">778,589</ix:nonFraction> shares (representing <ix:nonFraction unitRef="Unit_Standard_pure_NsGb2Z3yYka4EicmhvoaQQ" contextRef="As_Of_9_30_2022_zuGVrjesE0WhwXSGmTqsgA" decimals="2" format="ixt:numdotdecimal" name="cvac:PercentageOfConsiderationTransferredUponAchievementOfSecondMilestone" scale="-2" id="Narr_cTr_vf7n7E6Q1UVHjMbLTw">40</ix:nonFraction>% of EUR <ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="As_Of_9_30_2022_zuGVrjesE0WhwXSGmTqsgA" decimals="-5" format="ixt:numdotdecimal" name="cvac:ValueOfInstrumentsOrInterestsIssuedOrIssuableUponAchievementOfSecondMilestone" scale="6" id="Narr_-Pj1WbWBSk6jaWc6pU_s9A">32.0</ix:nonFraction> million divided by the Signing Share Price, i. e. EUR <ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="As_Of_9_30_2022_zuGVrjesE0WhwXSGmTqsgA" decimals="-3" format="ixt:numdotdecimal" name="cvac:SigningSharePriceRepresenting40" scale="3" id="Narr_FlG3lKxUQEqVwle62VMdeg">5,367</ix:nonFraction>k) are issuable upon successful proof of mechanism in humans. The fair value of these contingent payments was determined by considering the likelihood of the events occurring and totaled, based on the Closing Share Price, to a total fair value of EUR <ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="As_Of_9_30_2022_zuGVrjesE0WhwXSGmTqsgA" decimals="-3" format="ixt:numdotdecimal" name="cvac:ClosingSharePriceRepresentingTotalFairValue" scale="3" id="Narr_jcL7m3oEqECImxm4VlH4nQ">7,198</ix:nonFraction>k.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Consequently, the total consideration transferred for the business combination was determined to be EUR <ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="As_Of_9_30_2022_zuGVrjesE0WhwXSGmTqsgA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ContingentConsiderationRecognisedAsOfAcquisitionDate" scale="3" id="Narr_PMH1ym4a-ECCv6B66d-Vyw">19,481</ix:nonFraction>k, consisting of:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#x25CF;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Issuance and transfer of </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"><ix:nonFraction unitRef="Unit_Standard_shares_FapG5E6UqkK42IfNNOS6tA" contextRef="As_Of_9_30_2022_zuGVrjesE0WhwXSGmTqsgA" decimals="INF" format="ixt:numdotdecimal" name="cvac:NumberOfInstrumentsOrInterestIssuedOrIssuable" scale="0" id="Narr_u0EsbzsENUSUO5iey-qGjQ">858,496</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> CureVac shares with a fair value of EUR </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"><ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="Duration_1_1_2022_To_9_30_2022_GrYkE3mhHEiRA4fxgfABRg" decimals="-3" format="ixt:numdotdecimal" name="cvac:FairValueOfTotalConsiderationTransferred" scale="3" id="Narr_Zik1HKz84UKiY4tirr8PRQ">11,697</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">k,</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#x25CF;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Payment of EUR </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"><ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="As_Of_9_30_2022_zuGVrjesE0WhwXSGmTqsgA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:CashTransferred" scale="3" id="Narr_YSY59N7SS02kLAMeiNiZ2Q">585</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">k in cash, and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#x25CF;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Contingent consideration, classified as equity, with a fair value of EUR </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"><ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="As_Of_9_30_2022_zuGVrjesE0WhwXSGmTqsgA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:EquityInterestsOfAcquirer" scale="3" id="Narr_yTg2aRUHME6seW_G7rfT7Q">7,198</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">k. The contingent consideration will be settled by the issuance of a maximum of further </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"><ix:nonFraction unitRef="Unit_Standard_shares_FapG5E6UqkK42IfNNOS6tA" contextRef="As_Of_9_30_2022_zuGVrjesE0WhwXSGmTqsgA" decimals="INF" format="ixt:numdotdecimal" name="cvac:ContingentConsiderationMaximumSharesIssuable" scale="0" id="Narr_kJ9X3Mk3TEm1a9z2pCD4nw">973,236</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> CureVac shares.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition, <ix:nonFraction unitRef="Unit_Standard_Option_puBmss6yUE6NakwAOqqzng" contextRef="Duration_1_1_2022_To_9_30_2022_GrYkE3mhHEiRA4fxgfABRg" decimals="INF" format="ixt:numdotdecimal" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" scale="0" id="Narr_f3cw95tRGEC8kG3zFy4gWw">89,655</ix:nonFraction> restricted stock units (RSUs) were issued to certain employees to replace existing share-based payment awards of the target. This element will be accounted for as a separate transaction from the business combination and accounted for as an equity-settled share-based transaction according to IFRS 2. The total fair value of the grant was determined to be EUR <ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="As_Of_9_30_2022_zuGVrjesE0WhwXSGmTqsgA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted" scale="3" id="Narr_n_Sg7yImrUaYgcyHnYxKMg">1,218</ix:nonFraction>k and will be expensed in the functional cost category to which the award recipient&#x2019;s costs are classified (general and administrative expenses and research and development expenses) over the individual vesting periods for the <ix:nonFraction unitRef="Unit_Standard_tranche__TryzuW6jEmkCnTfvtVlrg" contextRef="Duration_1_1_2022_To_9_30_2022_GrYkE3mhHEiRA4fxgfABRg" decimals="INF" format="ixt:numdotdecimal" name="cvac:NumberOfTranchesForVestingOfInstrumentsGrantedInShareBasedPaymentArrangement" scale="0" id="Narr_nBhXtXm6xEy2SGHwfHpecg">3</ix:nonFraction> tranches, which run through June 30, 2023, June 30, 2024, and June 30, 2025.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Transactions costs in relation to the business combination amounting to total EUR <ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="Duration_1_1_2022_To_9_30_2022_GrYkE3mhHEiRA4fxgfABRg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:AcquisitionrelatedCostsForTransactionRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombination" scale="3" id="Narr__1QTI7Fm-Em7FhyQFDEbng">500</ix:nonFraction>k were expensed and recognized within general and administrative expenses. </p><ix:nonNumeric contextRef="Duration_1_1_2022_To_9_30_2022_GrYkE3mhHEiRA4fxgfABRg" name="ifrs-full:DisclosureOfDetailedInformationAboutBusinessCombinationsExplanatory" id="Tb_6c_hikYie0CPkupXoED9hA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">The purchase price allocation for the assets acquired and liabilities assumed has not been completed as of the date of issuance of these interim financial statements. This is especially due to ongoing identification and measurement of Intangible Assets acquired. The provisional amounts at the acquisition date were determined as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#x200B;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:57.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:38.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:57.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">in EUR thousands</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#xA0;&#xA0;&#xA0;&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:38.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;">Provisional&#xA0;amounts&#xA0;at&#xA0;acquisition&#xA0;date</b></p></td></tr><tr><td style="vertical-align:bottom;width:57.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Non-current assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:38.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="As_Of_9_30_2022_ifrs-full_BusinessCombinationsAxis_cvac_FramePharmaceuticalsB.v.AmsterdamNetherlandsMember_vR0Bi5R7KE6kPw8J5q5NTA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:NoncurrentAssetsRecognisedAsOfAcquisitionDate" scale="3" id="Tc_yfcrMPIm10u6APgoS2NB1w_2_2">6,592</ix:nonFraction></b></p></td></tr><tr><td style="vertical-align:bottom;width:57.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Property, plant and equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:38.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="As_Of_9_30_2022_ifrs-full_BusinessCombinationsAxis_cvac_FramePharmaceuticalsB.v.AmsterdamNetherlandsMember_vR0Bi5R7KE6kPw8J5q5NTA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDate" scale="3" id="Tc_YWOvHbKk606J9l5v9Dv_Bg_3_2">206</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:57.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Right-of-use assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:38.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="As_Of_9_30_2022_ifrs-full_BusinessCombinationsAxis_cvac_FramePharmaceuticalsB.v.AmsterdamNetherlandsMember_vR0Bi5R7KE6kPw8J5q5NTA" decimals="-3" format="ixt:numdotdecimal" name="cvac:RightOfUseAssetsRecognisedAsOfAcquisitionDate" scale="3" id="Tc_jOQ7I2Ew0kKFrzLU6JpLOA_4_2">170</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:57.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Intangible assets (Technology)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:38.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="As_Of_9_30_2022_ifrs-full_BusinessCombinationsAxis_cvac_FramePharmaceuticalsB.v.AmsterdamNetherlandsMember_vR0Bi5R7KE6kPw8J5q5NTA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:TechnologybasedIntangibleAssetsRecognisedAsOfAcquisitionDate" scale="3" id="Tc_Xqf546yZw0eMusaqpJ185Q_5_2">6,216</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:57.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Current assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:38.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="As_Of_9_30_2022_ifrs-full_BusinessCombinationsAxis_cvac_FramePharmaceuticalsB.v.AmsterdamNetherlandsMember_vR0Bi5R7KE6kPw8J5q5NTA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:CurrentAssetsRecognisedAsOfAcquisitionDate" scale="3" id="Tc__r3elxF5GU-g9pE_SPrTZQ_6_2">966</ix:nonFraction></b></p></td></tr><tr><td style="vertical-align:bottom;width:57.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Trade and other receivables</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:38.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="As_Of_9_30_2022_ifrs-full_BusinessCombinationsAxis_cvac_FramePharmaceuticalsB.v.AmsterdamNetherlandsMember_vR0Bi5R7KE6kPw8J5q5NTA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:FairValueOfAcquiredReceivables" scale="3" id="Tc_vp_-mrA1Qk6qogYjb8M4MA_7_2">658</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:57.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:38.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="As_Of_9_30_2022_ifrs-full_BusinessCombinationsAxis_cvac_FramePharmaceuticalsB.v.AmsterdamNetherlandsMember_vR0Bi5R7KE6kPw8J5q5NTA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:CashAndCashEquivalentsRecognisedAsOfAcquisitionDate" scale="3" id="Tc_DpJiEJtmokeC_nRNP5Ds8A_8_2">308</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:57.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:38.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="As_Of_9_30_2022_ifrs-full_BusinessCombinationsAxis_cvac_FramePharmaceuticalsB.v.AmsterdamNetherlandsMember_vR0Bi5R7KE6kPw8J5q5NTA" decimals="-3" format="ixt:numdotdecimal" name="cvac:TotalAssetsRecognisedAsOfAcquisitionDate" scale="3" id="Tc_05GoYEPyrEaFehRsBhP1WA_9_2">7,558</ix:nonFraction></b></p></td></tr><tr><td style="vertical-align:bottom;width:57.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Non-current liabilities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:38.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="As_Of_9_30_2022_ifrs-full_BusinessCombinationsAxis_cvac_FramePharmaceuticalsB.v.AmsterdamNetherlandsMember_vR0Bi5R7KE6kPw8J5q5NTA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:NoncurrentLiabilitiesRecognisedAsOfAcquisitionDate" scale="3" id="Tc_d5NBXsR_zkiIYphbxpo1UQ_10_2">134</ix:nonFraction></b></p></td></tr><tr><td style="vertical-align:bottom;width:57.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:38.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="As_Of_9_30_2022_ifrs-full_BusinessCombinationsAxis_cvac_FramePharmaceuticalsB.v.AmsterdamNetherlandsMember_vR0Bi5R7KE6kPw8J5q5NTA" decimals="-3" format="ixt:numdotdecimal" name="cvac:NoncurrentLeaseLiabilitiesRecognisedAsOfAcquisitionDate" scale="3" id="Tc_k8dlaB_OuUuvRARjIg4vwQ_11_2">114</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:57.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Deferred tax liabilities (net of deferred tax assets)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:38.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="As_Of_9_30_2022_ifrs-full_BusinessCombinationsAxis_cvac_FramePharmaceuticalsB.v.AmsterdamNetherlandsMember_vR0Bi5R7KE6kPw8J5q5NTA" decimals="-3" format="ixt:numdotdecimal" name="cvac:NetDeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate" scale="3" id="Tc_6s6rmNFjpUegxH4Hvrngtw_12_2">20</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:57.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Current liabilities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:38.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="As_Of_9_30_2022_ifrs-full_BusinessCombinationsAxis_cvac_FramePharmaceuticalsB.v.AmsterdamNetherlandsMember_vR0Bi5R7KE6kPw8J5q5NTA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:CurrentLiabilitiesRecognisedAsOfAcquisitionDate" scale="3" id="Tc_hlYrGExAoEuJRB2BsQYRhw_13_2">406</ix:nonFraction></b></p></td></tr><tr><td style="vertical-align:bottom;width:57.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:38.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="As_Of_9_30_2022_ifrs-full_BusinessCombinationsAxis_cvac_FramePharmaceuticalsB.v.AmsterdamNetherlandsMember_vR0Bi5R7KE6kPw8J5q5NTA" decimals="-3" format="ixt:numdotdecimal" name="cvac:CurrentLeaseLiabilitiesRecognisedAsOfAcquisitionDate" scale="3" id="Tc_Zw9wAwoGJEe0S0qSBdEp9A_14_2">55</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:57.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accounts Payables</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:38.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="As_Of_9_30_2022_ifrs-full_BusinessCombinationsAxis_cvac_FramePharmaceuticalsB.v.AmsterdamNetherlandsMember_vR0Bi5R7KE6kPw8J5q5NTA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:TradeAndOtherPayablesRecognisedAsOfAcquisitionDate" scale="3" id="Tc_YenaO_jXjUSRD09pzbyWIw_15_2">346</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:57.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other current liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:38.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="As_Of_9_30_2022_ifrs-full_BusinessCombinationsAxis_cvac_FramePharmaceuticalsB.v.AmsterdamNetherlandsMember_vR0Bi5R7KE6kPw8J5q5NTA" decimals="-3" format="ixt:numdotdecimal" name="cvac:OtherCurrentLiabilitiesRecognisedAsOfAcquisitionDate" scale="3" id="Tc_mQcoIiJFrku_Qet7xekc1Q_16_2">5</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:57.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total liabilities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:38.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="As_Of_9_30_2022_ifrs-full_BusinessCombinationsAxis_cvac_FramePharmaceuticalsB.v.AmsterdamNetherlandsMember_vR0Bi5R7KE6kPw8J5q5NTA" decimals="-3" format="ixt:numdotdecimal" name="cvac:LiabilitiesRecognisedAsOfAcquisitionDate" scale="3" id="Tc_t2n_25_Yf0GffV962eN-5Q_17_2">540</ix:nonFraction></b></p></td></tr><tr><td style="vertical-align:bottom;width:57.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Net assets acquired</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:38.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="As_Of_9_30_2022_ifrs-full_BusinessCombinationsAxis_cvac_FramePharmaceuticalsB.v.AmsterdamNetherlandsMember_vR0Bi5R7KE6kPw8J5q5NTA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:IdentifiableAssetsAcquiredLiabilitiesAssumed" scale="3" id="Tc_rUH_l6g9Dk28q1NJH6FZhw_18_2">7,018</ix:nonFraction></b></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The acquired receivables are expected to be collected in full.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The (provisional) fair value of the technology of EUR <ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="Duration_1_1_2022_To_9_30_2022_GrYkE3mhHEiRA4fxgfABRg" decimals="-3" format="ixt:numdotdecimal" name="cvac:ProvisionalFairValue" scale="3" id="Narr_8YOMUTBnFkyqw2btjNEYEg">6,216</ix:nonFraction>k was determined by applying the replacement cost approach. The replacement cost was derived from historical costs incurred from 2019 to June 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As per July 1, 2022, a net deferred tax liability of EUR <ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="As_Of_9_30_2022_zuGVrjesE0WhwXSGmTqsgA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:DeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate" scale="3" id="Narr_0aAInHCsXEugzUCrpHhPvg">20</ix:nonFraction>k has been recognized for the excess of deferred tax liabilities of EUR <ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="As_Of_9_30_2022_zuGVrjesE0WhwXSGmTqsgA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:DeferredTaxAssetsRecognisedAsOfAcquisitionDate" scale="3" id="Narr_ycXnqFEIn0KqUI84DHpt-g">1,550</ix:nonFraction>k on taxable temporary differences over deferred tax assets of EUR <ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="As_Of_9_30_2022_zuGVrjesE0WhwXSGmTqsgA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised" scale="3" id="Narr_zOcrCWaVbUi2v80Dd_F0kg">1,530</ix:nonFraction>k arising mainly from tax loss carry forwards (of approximately EUR <ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="As_Of_9_30_2022_ifrs-full_BusinessCombinationsAxis_cvac_FramePharmaceuticalsB.v.AmsterdamNetherlandsMember_vR0Bi5R7KE6kPw8J5q5NTA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised" scale="3" id="Narr_xOCOqtiKd0Wwt2LJYkdArg">5,800</ix:nonFraction>k). </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If, within one year of the acquisition date, new information becomes known about facts and circumstances that existed at the acquisition date and that would have resulted in adjustments to the amounts above, the allocation of the purchase price shall be adjusted. </p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><a id="Tc_7oYxBqe-rkOKSzoAKaw-Sw_1_0"></a><a id="Tc_NL8SveBQOUuOeQmISefpfQ_2_0"></a><a id="Tc_Q9KOp5h_UUCrJwNXtb3yLw_3_0"></a><a id="Tc_w9NyAyk9F0is_VIDcUJnLw_4_0"></a><a id="Tc_iUizpchOXUKMyMQSZ4Aihg_1_0"></a><a id="Tc_FolnkEVn8Uq-kFZo8ATPqA_1_2"></a><a id="Tc_WY-WBKhp8kS2FCsfDeM00Q_2_0"></a><ix:continuation id="Tb__PlzDS7D-0m3TofHmnuL5Q_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">Goodwill was provisionally recognized as a result of the acquisition as follows:</p><ix:nonNumeric contextRef="Duration_1_1_2022_To_9_30_2022_GrYkE3mhHEiRA4fxgfABRg" name="cvac:DisclosureOfGoodwillRecognizedAsResultOfAcquisitionExplanatoryTableTextBlock" id="Tb_hkkKaFfacEiHKDQMda426g" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 2pt 0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#x200B;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:86.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:86.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">in EURk</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#xA0;&#xA0;&#xA0;&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#xA0;&#xA0;</p></td></tr><tr><td style="vertical-align:bottom;width:86.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Consideration transferred</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="As_Of_9_30_2022_ifrs-full_BusinessCombinationsAxis_cvac_FramePharmaceuticalsB.v.AmsterdamNetherlandsMember_vR0Bi5R7KE6kPw8J5q5NTA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:AcquisitiondateFairValueOfTotalConsiderationTransferred" scale="3" id="Tc_7dhGA7n3C0mG7f5D-r0DjA_2_2">19,481</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:86.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net Assets acquired</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="As_Of_9_30_2022_ifrs-full_BusinessCombinationsAxis_cvac_FramePharmaceuticalsB.v.AmsterdamNetherlandsMember_vR0Bi5R7KE6kPw8J5q5NTA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:IdentifiableAssetsAcquiredLiabilitiesAssumed" scale="3" id="Tc_5TNjR6Uz2kmlpq2WmjrcmQ_3_2">7,018</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:86.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Preliminary Goodwill</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="As_Of_9_30_2022_ifrs-full_BusinessCombinationsAxis_cvac_FramePharmaceuticalsB.v.AmsterdamNetherlandsMember_vR0Bi5R7KE6kPw8J5q5NTA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:GoodwillRecognisedAsOfAcquisitionDate" sign="-" scale="3" id="Tc_AcVGvQJW60aAF3mtSoAX7g_4_2">12,463</ix:nonFraction></b></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#x200B;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">The preliminary goodwill is mainly attributable to the synergies and an assembled workforce as well as the strategic benefits to the Group. The preliminary goodwill is not deductible for tax purposes.</p><ix:nonNumeric contextRef="Duration_1_1_2022_To_9_30_2022_GrYkE3mhHEiRA4fxgfABRg" name="cvac:DisclosureOfAnalysisOfCashFlowsOnAcquisitionExplanatoryTableTextBlock" id="Tb_R2pZvURcGESbgEQt0q5GVw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#x200B;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:86.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:86.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Analyses of cash flows on acquisition:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#xA0;&#xA0;&#xA0;&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">EURk</b></p></td></tr><tr><td style="vertical-align:bottom;width:86.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Payment of consideration in cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg" contextRef="As_Of_9_30_2022_ifrs-full_BusinessCombinationsAxis_cvac_FramePharmaceuticalsB.v.AmsterdamNetherlandsMember_vR0Bi5R7KE6kPw8J5q5NTA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:CashTransferred" scale="3" id="Tc_rzVNnQKLfEayuzucjw8uNg_2_2">585</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:86.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#x200B;</span></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"><span style="font-size:1pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#x200B;</span></p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#x200B;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border:0;"></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.2
<SEQUENCE>3
<FILENAME>cvac-20220930xex99d2.htm
<DESCRIPTION>EX-99.2
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.14.0.96--><!--Created on: 11/17/2022 10:27:54 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;"><font style="font-weight:normal;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Exhibit 99.2</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">FINANCIAL CONDITION AND RESULTS OF OPERATIONS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">The following discussion and analysis of our financial condition and results of operations provides information that we believe to be relevant to an assessment and understanding of our results of operations and financial condition for the periods described. This discussion should be read in conjunction with our unaudited interim condensed consolidated financial statements and the notes to the financial statements, which are included in this Report of Foreign Private Issuer on Form&#160;6-K. In addition, this information should also be read in conjunction with the information contained in our Annual Report on Form&#160;20-F for the&#160;year ended December&#160;31, 2021, filed with the Securities and Exchange Commission on April&#160;28, 2022, or the Annual Report, including the consolidated annual financial statements as of and for the&#160;year ended December&#160;31, 2021 and their accompanying notes included therein.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Forward-Looking Statements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">This Report of Foreign Private Issuer on Form&#160;6-K contains historical information and forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995 with respect to the business, financial condition and results of operations of CureVac N.V. The words &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;could,&#8221; &#8220;expect,&#8221; &#8220;should,&#8221; &#8220;plan,&#8221; &#8220;intend,&#8221; &#8220;estimate&#8221; and &#8220;potential,&#8221; and similar expressions are intended to identify forward-looking statements. Such statements reflect the current views, assumptions and expectations of CureVac N.V. with respect to future events and are subject to risks and uncertainties. Many factors could cause the actual results, performance or achievements of CureVac N.V. to be materially different from any future results, performance or achievements that may be expressed or implied by such forward-looking statements, or financial information, including, among others, our ability to obtain funding for our operations necessary to complete further development and commercialization of our product candidates, the initiation, timing, progress, results, and cost of our research and development programs and our current and future preclinical studies and clinical trials, including statements regarding the timing of initiation and completion of studies or trials and related preparatory work, the period during which the results of the trials will become available and our research and development programs, the timing of and our ability to obtain and maintain regulatory approval for our product candidates, the ability and willingness of our third-party collaborators to continue research and development activities relating to our product candidates and cost associated with cancellation of manufacture and supply agreements in the event of termination of our research and development programs, the exercise by the Bill&#160;&amp; Melinda Gates Foundation of withdrawal rights, our and our collaborators&#8217; ability to obtain, maintain, defend and enforce our intellectual property protection for our proprietary and collaborative product candidates, and the scope of such protection, the rate and degree of market acceptance of our products, our ability to commercialize our product candidates, if approved, our ability and the potential to successfully manufacture our drug substances and delivery vehicles for preclinical use, for clinical trials and on a larger scale for commercial use, if approved, general economic, political, demographic and business conditions in the United States and Europe, fluctuations in inflation and exchange rates in Europe, our ability to implement our growth strategy, our ability to compete and conduct our business in the future, our ability to enroll patients for our clinical trials, the availability of qualified personnel and the ability to retain such personnel, regulatory developments and changes in the United States, Europe and countries outside of Europe including tax matters, our ability to overcome the challenges posed by the COVID-19 pandemic to the conduct of our business and other various other factors, whether referenced or not referenced in this Report of Foreign Private Issuer on Form&#160;6-K, that may affect our financial condition, liquidity and results of operations. Various other risks and uncertainties may affect CureVac and its results of operations, as described in reports filed by CureVac with the Securities and Exchange Commission from time to time, including its Annual Report. CureVac does not assume any obligation to update these forward-looking statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Unless otherwise indicated or the context otherwise requires, all references in this Report of Foreign Private Issuer on Form&#160;6-K to &#8220;CureVac&#8221; or the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;our,&#8221; &#8220;ours,&#8221; &#8220;ourselves,&#8221; &#8220;us&#8221; or similar terms refer to CureVac N.V. together with its subsidiaries.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Overview</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">We are a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid that has the potential to improve the lives of people. Our vision is to revolutionize medicine and open new avenues for developing therapies by enabling the body to make its own drugs. Messenger ribonucleic acid, or mRNA, plays a central role in cellular biology in the production of proteins in every living cell. We are the pioneers in successfully harnessing mRNAs designed to prevent infections and to treat diseases by mimicking human biology to synthesize the desired proteins. Our technology platform is based on a targeted approach to optimize mRNA constructs that encode functional proteins that either induce a desired immune response or replace defective or missing proteins using the cell&#8217;s intrinsic translation machinery. Our current product portfolio includes clinical and preclinical candidates across multiple disease indications in prophylactic vaccines, oncology and molecular therapy.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In prophylactic vaccines, we are advancing our second-generation mRNA backbone against coronavirus (SARS-CoV-2) and a range of infectious diseases including influenza in collaboration with GlaxoSmithKline Biologicals SA, or GSK.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The collaboration on COVID-19 vaccine candidates with GSK was initiated in April&#160;2021, and aims to research, develop and manufacture mRNA vaccines targeting the original SARS-CoV-2 strain as well as emerging variants. The collaboration extends the initial partnership we started with GSK in July&#160;2020, which focuses on the development of new products based on our second-generation mRNA backbone for different targets in the field of infectious diseases of which influenza was disclosed as the first indication. The improved second-generation mRNA backbone that is being used in this collaboration features targeted optimizations designed to improve intracellular mRNA stability and translation for increased and extended protein expression. These optimizations potentially allow for strong and early immune responses at low doses, which is intended to also support the development of multivalent vaccines to target rapidly spreading COVID-19 variants or different influenza strains as well as combination vaccines against different viral diseases.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">CV2CoV was introduced as the first representative of our joint COVID-19 vaccine program based on our second-generation backbone. The vaccine candidate is a non-chemically modified mRNA, encoding the prefusion stabilized full-length spike protein of the original SARS-CoV-2 virus, formulated within Lipid Nanoparticles, or LNPs. On May&#160;13, 2021, we announced a manuscript on the bioRxiv preprint server from a preclinical study in rats, showing that CV2CoV is able to induce high levels of antigen production in an in vitro setup as well as strong and dose-dependent immune responses. The data were published in the journal Vaccines on August 4, 2022. The data were further complemented in June 2021, by preclinical data published in Nature Communications demonstrating full protection by CV2CoV and our first-generation vaccine candidate CVnCoV, from lethal infection caused by SARS-CoV-2 ancestral strain BavPat1 or the Beta variant (B.1.351) in a transgenic mouse model, expressing the human ACE2 receptor. In a preprint manuscript announced on August&#160;16, 2021, and a subsequent Nature publication issued on November&#160;18, 2021, we further presented preclinical data investigating immune responses as well as the protective efficacy of CV2CoV in comparison to CVnCoV, against SARS-CoV-2 challenge in non-human primates. The study, conducted in collaboration with Dan Barouch, MD, Ph.D., of Beth Israel Deaconess Medical Center, assessed cynomolgus macaques vaccinated with 12&#181;g of either the first or second-generation vaccine candidate. Better activation of innate and adaptive immune responses was achieved with CV2CoV, resulting in faster response onset, higher titers of antibodies and stronger memory B and T cell activation as compared to our first-generation candidate, CVnCoV. Higher antibody neutralizing capacity was observed with CV2CoV across a broad range of variants, including the Beta, Delta and Lambda variants. During challenge with the original SARS-CoV-2 virus, animals vaccinated with CV2CoV were found to be better protected compared to CVnCoV based on effective clearance of the virus in the lungs and nasal passages. A direct comparison of CV2CoV with a licensed mRNA vaccine in non-human primates was able to show that neutralizing antibody levels measured following full vaccination of animals with either 12&#181;g of CV2CoV or a 30&#181;g standard dose of the licensed mRNA vaccine were highly comparable. Following these preclinical data, we announced the start of a Phase 1 clinical trial with CV2CoV on March&#160;30, 2022. The Phase 1 dose-escalation study is being conducted at clinical sites in the U.S. and evaluates the safety, reactogenicity and immunogenicity of a single booster dose of CV2CoV in the dose range of 2&#181;g to 20&#181;g.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Within the joint vaccine program with GSK, we also extended our technology platform to chemically modified mRNA constructs to allow for data-driven selection of the best candidate. We announced the start of a Phase 1 clinical trial with a chemically modified COVID-19 mRNA vaccine candidate based on our second-generation backbone, CV0501, on August 18, 2022. CV0501 specifically targets the Omicron variant. The study is being conducted at clinical sites in the U.S., Australia, and the Philippines and evaluates the safety, reactogenicity and immunogenicity of a single booster dose of CV0501 in the dose range of 12&#181;g to 50&#181;g. Additional dose levels below 12&#181;g and above 50&#181;g may be evaluated if supported by safety and immunogenicity data at these dose levels. Based on the results of both Phase 1 studies, selection of the best performing candidate for a subsequent pivotal study for advanced clinical development is expected to be made in the fourth quarter of 2022 or early in the first quarter of 2023. The pivotal trial may be initiated in the first half of 2023, contingent on discussion with regulatory authorities. Candidates further addressing relevant COVID-19 variants featuring the same second-generation mRNA backbone are currently in preclinical testing. On April&#160;21, 2022, the preclinical data for the second-generation mRNA backbone was extended by a study conducted in collaboration with the Friedrich-Loeffler-Institut, comparing immune responses and protective efficacy of monovalent and bivalent mRNA vaccines encoding Beta and/or Delta variants, primarily in a transgenic mouse model and a Wistar rat model.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On October&#160;12, 2021, we announced the strategic decision to withdraw our first-generation COVID-19 vaccine candidate, CVnCoV, from the approval process with the European Medicines Agency, or EMA, and to focus our COVID-19 vaccine program on the development of mRNA vaccine candidates based on our second-generation backbone in collaboration with GSK. The decision was aligned with the evolving dynamics of the pandemic response toward greater need for more differentiated vaccines. The rolling submission with the EMA was originally initiated in February&#160;2021 to assess CVnCoV&#8217;s compliance with standards for vaccine efficacy, safety and pharmaceutical quality as a prerequisite for a formal market authorization application. Later in 2021, the EMA informed us that it would not start reviewing the provided CVnCoV data packages before 2022. As a result, we estimated that the earliest possible approval of CVnCoV would come in the second quarter of 2022. By this time, we expected candidates featuring the second-generation backbone to be progressing through clinical development. Consequently, CVnCoV was also withdrawn from a rolling submission with Swissmedic, Switzerland&#8217;s authority responsible for the authorization and supervision of therapeutic products, initiated in April&#160;2021, to review the safety, efficacy and pharmaceutical quality of CVnCoV as a prerequisite for market authorization.</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">All clinical studies with first-generation candidate, CVnCoV, have completed the scheduled safety follow-up times for all trial participants as per the respective trial protocols. These include a Phase 1 study in Germany (initiated in June&#160;2020), a Phase 2a study in Peru and Panama (initiated in September&#160;2020), the Phase 2b/3 (HERALD) study in Europe and Latin America (initiated in December&#160;2020), a Phase 3 study in healthcare workers in Germany (initiated in December&#160;2020), and a Phase 3 study in participants with comorbidities in Belgium (initiated in April&#160;2021).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Phase 2b/3 (HERALD) study and Phase 3 study in healthcare workers in Germany are under final data analysis. Primary data of the Phase 2b/3 (HERALD) trial was published in The Lancet Infectious Diseases on November&#160;23, 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Data of an interim analysis of the Phase 1 trial in Germany was published in Wiener klinische Wochenschrift on August&#160;10, 2021. Safety and immunogenicity data of the Phase 2a clinical trial in Peru and Panama was uploaded to the SSRN preprint server on December 10, 2021 and published in Vaccine: X on July 1, 2022. Neutralizing antibody data against the ancestral strain and the beta variant after a third dose of CVnCoV in the same trial were posted on the MedRxiv preprint server on February 24, 2022 and published in Vaccines on March 25, 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Previously announced studies to be initiated with CVnCoV, including a Phase 2 clinical trial, focusing on immunogenicity in older adults above the age of 65&#160;years old compared to younger adults and a flu-co-administration study, planned to be initiated together with Bayer AG to assess compatibility with established seasonal vaccines in an older population, were cancelled.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">To assess the benefit of booster vaccinations, CVnCoV was also included in the Cov-Boost trial sponsored by the University of Southampton, UK, which is evaluating several COVID-19 vaccines and vaccine candidates as booster vaccines. Each participant in the Cov-Boost trial received one booster vaccine 84 or 70&#160;days respectively after they completed their primary vaccination with two doses of either Comirnaty or Vaxzervia. The Cov-Boost trial started in June&#160;2021 across 18 sites in the United Kingdom and dosed overall 2,878 participants with a third dose vaccine. Initial results from the Cov-Boost trial were published in The Lancet on December&#160;2, 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our pivotal Phase 2b/3 trial for CVnCoV, which included approximately 40,000 participants, reported interim analysis outcomes following a first interim analysis on May&#160;28, 2021, based on 59 adjudicated COVID-19 cases and a second interim analysis on June&#160;16, 2021, based on 134 adjudicated COVID-19 cases in the unprecedented context of at least 13 variants circulating within the assessed study population subset. In the highly dynamic variant environment, the HERALD trial met the prespecified success criteria for efficacy against symptomatic COVID-19 of any severity and for efficacy against moderate-to-severe COVID-19, as defined in the protocol. The primary efficacy analysis included 12,851 participants in the CVnCoV group and 12,211 in the placebo group. The mean observation period, starting 15&#160;days after administration of the second dose, was 48.2&#160;days. Vaccine efficacy against COVID-19 of any severity was 48.2% in the overall primary efficacy analysis set of SARS-CoV-2-naive participants, and 52.5% in those aged 18&#8211;60&#160;years. Vaccine efficacy against moderate-to-severe COVID-19 was 70.7% overall and 77.2% in participants aged 18&#8211;60&#160;years. There were too few participants aged 61&#160;years or older who developed COVID-19 to allow a meaningful estimate of efficacy in this age group.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">HERALD was conducted in an unprecedented evolving landscape that reflects the changing reality of the global COVID-19 pandemic, with an increasing number of SARS-CoV-2 variants adding additional challenges to the assessment of COVID-19 vaccine candidates. Sequence data were available for 184 of 207 adjudicated cases in people aged 18&#8211;60&#160;years. About 50% of cases of COVID-19 in our trial were caused by variants of concern, 35% were caused by variants of interest, as classified by WHO in September&#160;2021, and about 3% were caused by wild-type, with the remaining 11% caused by other variants. Although we were only able to evaluate vaccine efficacy against these variants in participants aged 18&#8211;60&#160;years, the results indicate that the vaccine had similar efficacies against Alpha, Gamma, and Lambda variants. Many newly emerged strains that have shown increased transmissibility, and differences in neutralizing antibody activity against these strains might alter vaccine efficacy.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The first non-COVID-19 vaccine candidate within the broader infectious disease program applying our second-generation backbone we are developing in collaboration with GSK is the influenza candidate, CVSQIV, a differentiated multivalent vaccine candidate featuring multiple non-chemically modified mRNA constructs to induce immune responses against relevant targets of four different influenza strains. On February&#160;10, 2022, we announced the start of a Phase 1 dose-escalation study in Panama evaluating the safety, reactogenicity and immunogenicity of CVSQIV in the dose range of 3&#181;g to 28&#181;g. In line with the mRNA development strategy to also test chemically modified mRNA and similar to the setup of the COVID-19 vaccine program, CureVac and GSK announced the start of a Phase 1 dose-escalation study with a chemically modified influenza vaccine candidate, Flu SV mRNA, on August 18, 2022. The candidate is a monovalent candidate. The Phase 1 dose-escalation study will be conducted in Canada, Spain, and Belgium to evaluate the safety, reactogenicity and immunogenicity of FLU SV mRNA.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Beyond the GSK COVID-19 and general infectious disease collaboration, our next advanced prophylactic vaccine program, CV7202, is being developed for prophylactic vaccination against rabies. CV7202 is an mRNA based on our first-generation backbone that encodes the rabies virus glycoprotein, RABV-G, formulated with Lipid Nanoparticles. Safety, reactogenicity, and immunogenicity of CV7202 was investigated in a Phase 1 clinical trial that has completed the scheduled follow-up time for all trial participants as per trial protocol. In January&#160;2021, we published data from our Phase 1 trial of CV7202 in rabies. CV7202 induced </p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">adaptive immune response as shown by rabies-specific virus-neutralizing antibodies above the World Health Organization thresholds considered to be protective, after the second dose in all subjects, at the lowest 1&#956;g and 2&#956;g dose levels. We also showed that the lowest dose levels (1&#956;g and 2&#956;g mRNA) were generally well tolerated. We are currently assessing the path forward for advancing CV7202.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In oncology, we plan to build a meaningful portfolio and create long-term value to accelerate growth beyond the recent progress in prophylactic vaccines. Developing new oncology candidates is characterized by similar medical challenges as in infectious diseases, including selection and accessibility of disease-relevant antigens, enhancing antigen-induced immune activation, and triggering immune responses led by a strong induction of tumor-killing T cells. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our oncology candidate, CV8102, is a complex of single-stranded non-coding RNA, which has been optimized to maximize activation of cellular receptors that normally detect viral pathogens entering the cells (such as toll-like receptor 7, or TLR7, toll-like receptor 8, or TLR8, and retinoic acid inducible gene I, or RIG-I pathways), mimicking a viral infection of the tumor. CV8102 is designed to recruit and activate antigen-presenting cells at the site of injection to present tumor antigens released from tumor cells to T cells in the draining lymph node. This potentially leads to activation of tumor-specific T cells, which can kill tumor cells at the injected site, but also at distant non-injected tumor lesions or metastases. CV8102 is currently being evaluated in a Phase 1 clinical trial as a single agent and in combination with anti-PD-1 antibodies. The trial consists of two parts. The first dose-escalating part assesses CV8102 in patients with solid tumors, namely&#8201;cutaneous melanoma, adenoidcystic carcinoma, squamous cell carcinoma of skin, and squamous cell carcinoma of head and neck, or HNSCC. The trial is fully recruited with 58 patients, 33 in the single-agent cohort and 25 in the combination cohort with anti-PD-1 antibodies. Preliminary safety and efficacy observed in this part of the trial were reported at ESMO 2021. As of June 21, 2021, in the single-agent cohort, we observed one patient with a complete response and two patients with a partial response according to RECIST 1.1. In addition, twelve patients experienced a best response of stable disease. In the PD-1 dose-escalation combination cohort, one PD-1 refractory melanoma patient experienced a partial response according to RECIST 1.1. In addition, three patients experienced a best response of stable disease.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On November&#160;10, 2021, at the Society for Immunotherapy of Cancer, or the SITC conference, we extended the ESMO update with an extensive analysis of immune cell activation to better understand the mobilization of the immune system against CV8102-injected as well as non-injected tumors. The data showed efficient stimulation of the immune system characterized by the induction of interferon alpha and interferon gamma. Serial tumor biopsies from individual patients demonstrated increased infiltration of T cells in the micro-environment of injected as well as non-injected tumors. Both observations support the hypothesis that local injection of the RNA immuno-modulator into a single tumor lesion can induce a systemic response leading to immune attack against both injected and non-injected tumors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In February&#160;2021, we initiated an expansion of our Phase 1 study to confirm the safety, tolerability and efficacy of CV8102 at a 600&#956;g dose. This second part of the Phase 1 trial completed enrollment in October&#160;2021 and involves 40 trial participants, with 10 patients in the single-agent cohort and 30 patients in the combination cohort with anti-PD-1 antibodies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:17.85pt;margin:0pt 0pt 12pt 0pt;">On November 11, 2022, at the Society for Immunotherapy of Cancer, or the SITC conference, we presented preliminary data from the expansion study. As of August 30, 2022, preliminary efficacy was observed in the cohort of 30 patients treated in combination with anti-PD-1 antibodies, 40% of whom were pretreated with anti-CTLA-4 antibodies. In this anti-PD-1 combination cohort, five out of 30 patients (17%) experienced a partial response according to RECIST 1.1. Responses appeared durable for up to one year from the start of treatment. No objective responses were observed in the 10 patients of the single-agent cohort, 50% of whom were pretreated with anti-CTLA-4 antibodies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:17.85pt;margin:0pt 0pt 12pt 0pt;">Extensive analysis of immune cell activation confirmed that CV8102 single agent or combination treatment, after the first dose, activated systemic pathways of immune response. Preliminary analysis of the tumor microenvironment in a subgroup of patients showed the positive outcome of increased infiltration of T cells, following intra-tumoral injection in 4 out of 8 (single agent cohort) and 10 out of 18 (anti- PD1 combination cohort) analyzed paired biopsy samples.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:17.85pt;margin:0pt 0pt 12pt 0pt;">Final study results are expected to be submitted for publication in a peer reviewed journal in H1 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On November 2, 2022, we published a paper in Cancer Immunology, Immunotherapy, assessing the mode of action and efficacy of CV8102 for local immunotherapy in preclinical models. Intratumoral administration of CV8102 was shown to activate innate immune responses in the tumor microenvironment and draining lymph nodes, resulting in a dose-dependent anti-tumoral response. Combining CV8102 with systemic anti- PD-1 treatment further enhanced anti-tumoral responses, inducing tumor infiltration and activation of CD8+ T cells. The resulting memory response prevented tumor growth in rechallenged animals and impaired the growth of non-injected distal tumors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:17.85pt;margin:0pt 0pt 12pt 0pt;">Taking advantage of recent technology platform advances, particularly our second-generation mRNA backbone in COVID-19 and infectious diseases, we are evaluating targeted expansions of our unique mRNA approaches for the development of cancer vaccines. This targeted expansion is based on three strategic pillars:</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">1.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Validation and optimization of our broad mRNA technology approach for T cell mediated tumor control</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">2.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Build-up of a pipeline of cancer vaccine candidates targeting antigens predicted to be immuno&#173;genic and presented on tumors in cancer patients</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">3.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Addition of comple&#173;mentary platform technologies for improved antigen discovery, validation and optimization of vaccine design focusing on T cell activation</font></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">To deliver on this strategy, we announced a partnership with Belgium-based company myNEO on May 25, 2022, and the acquisition of Netherland-based Frame Cancer Therapeutics on June 8, 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Together with immunotherapy company myNEO, we aim to identify specific antigens found on the surface of tumors for the development of novel mRNA immunotherapies.&#160;myNEO utilizes a broad range of underlying genomic alterations to identify constantly emerging, novel classes of antigens of defined tumor types. Incorporating new ranking methodologies based on tumor cell antigen processing and presentation is expected to allow for selection of antigens with the highest confidence of success for potential clinical testing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">With the acquisition of Frame Cancer Therapeutics, a private company focused on advanced genomics and bioinformatics, to identify both shared and unique neoantigens across different cancer types, we complement existing inhouse expertise to identify and validate promising neoantigens for mRNA cancer vaccine candidates. The former Frame Cancer Therapeutics site was inaugurated as CureVac Netherlands and will further develop the proprietary technology platform, which has the potential to identify a broad panel of neoantigens and tumor-associated antigens that go beyond conventional approaches and could strongly increase the likelihood of developing highly effective cancer vaccines that activate the human immune system against cancer.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The highly synergistic technologies of Frame Cancer Therapeutics and myNEO are expected to accelerate CureVac&#8217;s oncology strategy to build a meaningful portfolio of new cancer vaccine candidates. Within this strategy, we follow two approaches. The first approach assesses tumor antigens shared by different cancer patients for the development of off-the-shelf cancer vaccines. The second approach is tailored to the individual tumor setup of a patient for personalized therapy.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:21.6pt;margin:0pt 0pt 12pt 0pt;">In this context, we are committed to drive innovation by leveraging The RNA Printer<sup style="font-size:7.5pt;vertical-align:top;">&#174;</sup>, CureVac&#8217;s automated end-to-end manufacturing solution for GMP-grade mRNA vaccines and thera&#173;peutics. The highly standardized system is expected to allow for rapid and highly flexible availability of mRNA to screen new targets and transition promising mRNA product candidates more efficiently into the clinic. Designed for small-scale quantities, the automated GMP-grade output of The RNA Printer<sup style="font-size:7.5pt;vertical-align:top;">&#174;</sup> is designed to open avenues for personalized mRNA-based cancer therapies. The system is currently undergoing regulatory approval processes to obtain its first manufacturing licenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On June&#160;16, 2021, Boehringer Ingelheim expressed its intention to terminate the 2014 collaboration agreement on BI1361849 (previously CV9202). The termination became effective on November&#160;17, 2021. The legacy program, targeting specific immune responses against tumor-associated antigens frequently overexpressed in patients with non-small cell lung cancer, or NSCLC, applies an older protamine formulation technology, which reflected the state of the technology development at the time. A Phase 1/2 clinical trial in NSCLC applying BI1361849 as a combination therapy is ongoing. Both companies are currently assessing options to continue a collaboration on our RNA technology platform based on state-of-the-art LNP-based formulations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In molecular therapies, we published preclinical mouse data in liver fibrosis in the Journal of Hepatology in August&#160;2021. Progression of liver fibrosis is associated with the gradual decrease of hepatocyte nuclear factor 4 alpha, or HNF4 alpha, an important regulator and key factor in liver metabolism. In the published study, four independent mouse models of the disease were treated with mRNA encoding HNF4A. The treatment was able to restore HNF4A levels and thereby significantly reduced liver injury. The study was conducted in collaboration with the REBIRTH-Research Center for Translational Regenerative Medicine and Department of Gastroenterology, Hepatology and Endocrinology at the Hannover Medical School, Hannover (Germany). It provides the first preclinical data demonstrating the therapeutic applicability of mRNA encoded HNF4A in the treatment of liver fibrosis and cirrhosis.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">We further expect to publish data from our collaboration with the Schepens Eye Research Institute.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><font style="margin-bottom:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On September 26, 2022, CureVac AG entered into a plan of merger with CureVac Beteiligungsverwaltungs AG, with CureVac SE as the surviving entity and both CureVac AG and CureVac Beteiligungsverwaltungs AG as disappearing entities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Key Factors Affecting Our Results of Operations</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We believe that the most significant factors affecting our results of operations include:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 9.35pt;">Research and Development Expenses</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our ability to successfully pioneer a robust mRNA technology platform and develop innovative product candidates will be the primary factor affecting our future growth and development. Our approach to the discovery and development of product candidates based on mRNA technology is still being demonstrated. As such, we do not know whether we will be able to successfully develop any products. Developing novel product candidates requires a significant investment of resources over a prolonged period of time, and a core part of our strategy is to continue making sustained investments in this area. We have chosen to leverage our platform to initially focus on advancing our product candidates in the areas of prophylactic vaccines, oncology and molecular therapy.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">All of the product candidates are still in development, and we have incurred and will continue to incur significant research and development costs for preclinical studies and clinical trials. We expect that our research and development expenses will constitute the most substantial part of our expenses in future periods in line with the advance and expansion of the development of our product candidates. Due to our accelerated efforts to develop our first-generation backbone COVID-19 vaccine candidate, CVnCoV, we incurred research and development expenses that significantly exceeded our historical levels of research and developments expenses. Additionally, our October 2021 notification to the European Commission of the withdrawal of our regulatory approval application for CVnCoV resulted in our recognition of several expenses, which have contributed to our increased expense levels, but which we do not expect to recur in future periods. In April 2021, we entered into a collaboration agreement with GSK for the development of a broad COVID-19 vaccine program based on our second-generation backbone. CV2CoV, a non-chemically modified mRNA, encoding the prefusion stabilized full-length spike protein of the SARS-CoV-2 virus, and formulated within LNPs, is the first representative of our COVID-19 vaccine program based on the second-generation backbone and presently in the Phase 1 clinical trial, as announced on March 30, 2022. Within this COVID-19 vaccine program, we plan to extend our technology platform also to chemically modified mRNA constructs to allow for data-driven selection of the best candidate. We expect to incur significant expenses related to such second-generation backbone vaccine candidates. But, as we and GSK agreed to equally share the development costs for GSK COVID products, our current level of research and development expenses will not continue to increase in the level as it did from 2020 to 2021. Once we conclude our research and development efforts related to a selected second-generation backbone vaccine candidate, we expect that our research and development expenses shall be consistent with our past trends before the COVID-19 pandemic, but we may find it necessary to continue such current trend with respect to our research and developments expenses or we may continue to increase further our research and development expenses. For example, we may continue to increase our research and development expenses for future research and development related to the next generation backbone for our COVID-19 vaccine candidates, such as for our second-generation backbone COVID-19 vaccine candidates or may pursue new indications with our technology platform.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We have historically funded the research and development expenses primarily through public offerings of our common stock, private placements of equity securities, convertible loans, grants from government agencies and similar bodies and payments for collaborative research and development services with strategic partners. In addition, we signed an advance purchase agreement, or APA, with the EC that provided substantial support for our efforts to advance our first-generation backbone vaccine candidate, CVnCoV. In October 2021, we notified the European Commission of the withdrawal of our regulatory approval application for CVnCoV, which automatically terminated the APA.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 9.35pt;">Our and Our Collaborators&#8217; Ability to Commercialize Our Product Candidates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our ability to generate revenue from our product candidates depends on our and our collaborators&#8217; ability to successfully advance clinical trials for our product candidates and receive regulatory approval, particularly in the United States, Europe, and other major markets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We believe that our broad portfolio of product candidates with both novel and validated targets enhances the likelihood that our research and development efforts will yield successful product candidates. Nonetheless, we cannot be certain if any of our product candidates will receive regulatory approvals. Even if such approvals are granted, we will thereafter need to maintain manufacturing and supply arrangements and engage in extensive marketing prior to generating any revenue from such products, and the ultimate commercial success of our products will depend on their acceptance by patients, the medical community and third-party payors and their ability to compete effectively with other therapies on the market.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The competitive environment is also an important factor with the commercial success of our product candidates, and our ability to successfully commercialize a product candidate will depend on whether there are competing product candidates being developed or already marketed by other companies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">We currently do not have any product candidates that have received regulatory approval. As such, we have not incurred any material commercialization expenses in connection with an approved product candidate. In February&#160;2021, we initiated a rolling submission for our first generation COVID-19 vaccine candidate, CVnCoV, with the EMA, which was designed to allow the EMA to </p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">assess CVnCoV&#8217;s compliance with standards for vaccine efficacy, safety and pharmaceutical quality as a prerequisite for a formal market authorization application. Later in 2021, EMA informed us that the EMA would not start reviewing our submission for CVnCoV before the beginning of 2022. As a result, we estimated that the earliest possible approval of CVnCoV would come in the second quarter of 2022. Data on the efficacy of CVnCoV was generated and published in June&#160;2021. This efficacy data did not live up to our pre-trial expectations and fell behind the efficacy of competing COVID-19 vaccine products. The application for the marketing authorization for CVnCoV was withdrawn in early October&#160;2021, as a necessary reaction to the efficacy data as well as the concerns and uncertainties resulting from such data on the granting of a marketing authorization and the expected concerns of prescribers and patients to use a COVID-19 vaccine with a lower efficacy compared to the vaccines already available on the market. After the withdrawal of the application for a marketing authorization for CVnCoV, we have focused our efforts on second-generation mRNA vaccines. The decision is aligned with the evolving dynamics of the pandemic response toward greater need for differentiated vaccines with the gradual transition from an acute pandemic to an endemic SARS-CoV-2 environment. In connection with the regulatory approval process, and in preparation for the commercialization of a second-generation COVID-19 vaccine, we expect our expenses related to commercialization to significantly decrease in the short-term due to our past commercialization efforts for CVnCoV. However, we expect that our expenses related to commercialization will significantly increase in the long-term if a second-generation COVID-19 vaccine candidate reaches late clinical stages, but we expect that this increase in expenses will be mitigated by the GSK COVID Agreement, as described below. As part of the commercialization process of CVnCoV, we also entered into strategic partnerships with Bayer for the development, production and distribution of CVnCoV. In addition, pursuant to a preliminary agreement regarding the secondary manufacturing of CVnCoV we entered into with GSK, GSK would have supported the secondary manufacturing of up to 100 million doses of CVnCoV in 2021. Additionally, we also partnered with Fareva, Rentschler Biopharma SE, and Novartis AG, among others, to develop an integrated European manufacturing network. Due to our decision to withdraw CVnCoV from the regulatory approval process and focus our efforts on second-generation mRNA vaccine, separate agreements with Celonic and Wacker were terminated.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 9.35pt;">Our Collaborations, Related License Agreements and Advance Purchase Agreements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our results of operations have been, and we expect them to continue to be, affected by our contractual collaborations with third parties for the development and commercialization of certain of our product candidates. In addition, our future results of operation may be affected by future advance purchase agreements for our COVID-19 vaccine candidates. To date, our revenues have been recognized pursuant to license and collaboration agreements, which include up-front payments for licenses or options to obtain licenses, milestone payments, payments for product sales and payments for research and development services. Grants from government agencies or similar bodies are recognized as other operating income or as a reduction to depreciation and amortization expense recognized from assets purchased under the associated arrangements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We have entered into strategic collaborations and license agreements with third parties. In addition, on November&#160;30, 2020, we entered into an advance purchase agreement, or APA, with the European Commission, or EC, which provided for the advance purchase by the commission of our first-generation vaccine candidate, CVnCoV. In October&#160;2021, we notified the EC of the withdrawal of our regulatory approval application for CVnCoV, which automatically terminated the APA. As part of our business development strategy, we aim to increase the number of our strategic collaborations in order to derive further value from our platform and more fully exploit the potential of our collaborations and license agreements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Certain key terms of our current material collaboration and license agreements, as well as our advance purchase agreement with the EC are summarized below.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 18pt;">Research and Option Agreement with myNEO</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On May&#160;12, 2022, we entered into a Research and Option Agreement (&#8220;R&amp;O&#8221;) with myNEO NV (&#8220;myNEO&#8221;), pursuant to which we will both collaborate in research to identify specific antigens found on the surface of tumors for the development of novel mRNA immunotherapies. To achieve this goal, myNEO will leverage its biological datasets, its integrated machine learning and bioinformatics platform to identify and validate specific antigen targets predicted to elicit a strong immune response. Under the R&amp;O, we aim to develop and commercialize at least two new medicinal products for the treatment of non-small cell lung cancer, melanoma and potentially other indications. Under the R&amp;O, we paid myNEO an up-front one-time technology access fee of &#8364;138,000 and myNEO is eligible to receive up to &#8364;17.5 million in research and development milestone payments and &#8364;37.5 million in commercial milestone payments.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 18pt;">GlaxoSmithKline</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In July&#160;2020, we entered into a Collaboration and License Agreement with GSK, which we refer to as the 2020 GSK Agreement, pursuant to which we are collaborating with GSK to research, develop and commercialize prophylactic and therapeutic non-replicating mRNA-based vaccines and antibodies targeting infectious disease pathogens. The 2020 GSK Agreement was amended and restated in April&#160;2021, September&#160;2021, February&#160;2022 and March&#160;2022.</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">GSK paid us an up-front payment of &#8364;120 million and is required to pay us a manufacturing capacity reservation fee of &#8364;30 million following a certain regulatory milestone event, which is creditable against future milestone payments. We are eligible to receive up to between &#8364;28 million to &#8364;45 million in development milestone payments, &#8364;32 million to &#8364;35 million in regulatory milestone payments and &#8364;70 million to &#8364;100 million in commercial milestone payments, depending on the product. Under the 2020 GSK Agreement, we granted GSK an exclusive option to add additional products in the field of infectious diseases to the license granted under the 2020 GSK Agreement and, upon each exercise of such option, GSK is required to compensate us for certain development costs and pay any accrued milestone payments. Additionally, GSK has the right to replace products licensed under the 2020 GSK Agreement and, if the replacement product was already under development by us, GSK must compensate us for certain development costs and pay any accrued milestone payments. We are additionally eligible to receive tiered royalty payments ranging from a single-digit&#160;percentage to a low teens&#160;percentage on net sales, subject to certain customary reductions. GSK is required to compensate us for certain development and regulatory costs we may incur in connection with performing our obligations under the 2020 GSK Agreement, and we are eligible to receive up to &#8364;20,000 in reimbursements for expenses incurred by recording or registering the licenses granted under the 2020 GSK Agreement. We retain the right to commercialize products developed under the 2020 GSK Agreement in Germany, Austria and Switzerland, as GSK&#8217;s exclusive distributor in these markets. Under any such distribution agreement to be entered into between us and GSK, we will be required to purchase supply from GSK and pay GSK a low thirties&#160;percentage royalty on net sales. Pursuant to the amendment in September&#160;2021, we and GSK are required to complete certain development activities set forth in updated development plans. We and GSK agree to decide whether the products required for clinical studies will be manufactured by us, GSK or jointly.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Additionally, in April&#160;2021, we entered into a new collaboration agreement with GSK, which we refer to as the GSK COVID Agreement, pursuant to which we are collaborating with GSK to research, develop and manufacture next-generation mRNA vaccines targeting the original SARS-CoV-2 strain as well as emerging variants, including multivalent and monovalent approaches, such as our second-generation COVID-19 vaccine candidate, CV2CoV. These vaccine candidates may either be used to protect unvaccinated individuals or to serve as boosters in the event that SARS-CoV-2 immunity gained from an initial vaccination reduces over time. The GSK COVID Agreement was amended and restated in September&#160;2021 and March&#160;2022. Pursuant to the amendment in September&#160;2021, we and GSK are required to complete certain development activities with respect to the GSK COVID products set forth in updated development plans. We and GSK agree to decide whether the GSK COVID products required for clinical studies will be manufactured by us, GSK or jointly.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Under the GSK COVID Agreement, GSK has paid us an up-front payment of &#8364;75 million. We and GSK agreed to equally share all development costs for GSK COVID products, subject to certain exceptions. We and GSK will share all net profits generated from sales of GSK COVID products, other than Combination Products (as defined therein), under profit sharing arrangements that in certain cases vary depending upon the GSK COVID product in question, the time of sale, the number of doses sold and the party to whom the sale is made. We are eligible to receive tiered royalty payments ranging from a sub-teen&#160;percentage to a mid-teen&#160;percentage on net sales of Combination Products, subject to certain customary reductions. Under the GSK COVID Agreement we have the right to commercialize GSK COVID products in Austria, Germany and Switzerland and if we exercise such right, our sales of GSK COVID products, other than Combination Products will be subject to the profit share and we will be required to pay GSK a high-teen&#160;percentage royalty on net sales of all Combination Products in such countries.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 18pt;">Genmab</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In December&#160;2019, we entered into a Collaboration and License Agreement, which we refer to as the Genmab Agreement, with Genmab to research and develop up to four potential differentiated mRNA-based antibody products, to be selected by Genmab, based on the combination of our proprietary RNAntibody technology with Genmab&#8217;s proprietary antibody technology for the treatment of human diseases. We will collaborate on research to identify an initial product candidate designed to express a certain Genmab proprietary antibody, and we will contribute a portion of the overall costs for the development of such product candidate, until submission of an IND. Genmab will thereafter be responsible for the development and commercialization of the product candidate. Under the Genmab Agreement, we further grant Genmab a license for the preclinical development of up to four additional mRNA antibody product concepts and options to obtain commercial licenses under our mRNA technology to develop, manufacture and commercialize product candidates for up to three of such product concepts.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Under the terms of the Genmab Agreement, Genmab paid us a $10 million up-front fee and made a &#8364;20 million equity investment in March&#160;2020. Genmab will be obligated to pay us a $0.5 million reservation fee upon the selection of each additional product concept for development under the Genmab Agreement and $5 million upon selection of a product targeting Genmab&#8217;s proprietary antibody for further development and commercialization. Genmab is additionally required to pay us up to $30 million in option exercise fees. If Genmab exercises any of its options to obtain commercial licenses for the additional mRNA antibody concepts, Genmab would fund all research and would develop and commercialize any resulting product candidates. We are additionally eligible to receive up to between $25 million and $43 million in development milestone payments, $100 million and $125 million in regulatory milestone payments and $150 million and $200 million in commercial milestone payments for each product, depending on the specific product concept. In addition, we are eligible to receive a mid single-digit to low teens&#160;percentage tiered royalty on aggregate net sales of licensed products, on a per-product basis and subject to certain customary reductions. If Genmab grants a sublicense to the initial product candidate developed under the Genmab Agreement before a certain milestone event, Genmab must </p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">pay us a one-time $10 million payment. We are responsible for any payments to third parties related to the LNP technology we license to Genmab for use in relation to the initial product candidate developed under the Genmab Agreement and a portion of such payments with respect to LNP technology used in the additional product concepts. We retain an option to participate in development and commercialization of one of the potential additional mRNA antibody product concepts under predefined terms and conditions. In the event we exercise such right, we must pay Genmab a one-time payment of $3 million and refund any option fee paid by Genmab with respect to such product. As of September&#160;30, 2022, we have received $1 million in development cost reimbursements and we have not received any reservation, product selection, option exercise or sublicense fees or milestone or royalty payments.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 18pt;">Arcturus</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In January&#160;2018, we entered into a Development and Option Agreement, which we refer to as the Arcturus Agreement, with Arcturus, which provides us with access to Arcturus LNP formulation technology which we use in combination with our mRNA technology. We paid Arcturus an up-front fee of $5 million and must pay an extension fee of $1 million if we exercise our option to extend the initial term of the Arcturus Agreement beyond July&#160;2023. We are required to reimburse Arcturus for certain costs incurred in connection with development activities and provide certain FTE funding. We are additionally required to pay up to an aggregate of $5 million in connection with our acceptance of the irrevocable offer to obtain licenses for further development and commercialization of selected targets. As of September&#160;30, 2022, we have not accepted any such irrevocable offer. Under each license agreement to be entered into in connection with our acceptance of the irrevocable offer, to the extent applicable, we will additionally be required to make certain royalty payments, which are not in excess of 10% on net sales of licensed products, and pay Arcturus up to $6 million in development milestone payments, $9 million in regulatory milestone payments and $8 million in commercial milestone payments. As of September&#160;30, 2022, we have made payments totaling $5.5 million to Arcturus reimbursing Arcturus for development costs and in connection with our FTE funding obligations, and we have not accepted the irrevocable offer with respect to any target and therefore have not paid any acceptance fees or made any milestone or royalty payments to Arcturus.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 18pt;">Acuitas</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In April&#160;2016, we entered into a Development and Option Agreement, which as amended we refer to as the Acuitas Agreement, with Acuitas, which provides us with access to Acuitas LNP formulation technology that we use in combination with our mRNA technology. We are required to pay Acuitas annual target reservation and maintenance fees of up to $1.4 million if we reserve the maximum number of targets permitted under the Acuitas Agreement and to reimburse Acuitas for certain costs incurred in connection with development activities and certain FTE costs. We are additionally required to pay an option exercise fee ranging from $50,000 to $2 million upon each exercise of our option to obtain a license for further development and commercialization with respect to a selected target, subject to certain additional fees ranging from $10,000 to $200,000 for the exercise of our option for certain other vaccine targets. We paid Acuitas a $5 million up-front fee in connection with an amendment to the Acuitas Agreement dated July&#160;2020 and, upon each exercise of our option to exchange a vaccine target licensed under any non-exclusive license, we are required to pay an exchange fee of $3 million. We additionally paid Acuitas a $3 million up-front fee in connection with an amendment to the Acuitas Agreement dated December&#160;2020 and are required to pay an additional $250,000 in April&#160;2022 and April&#160;2023 for each of certain options not yet exercised. Under each license agreement in connection with our exercise of our option, we will additionally be required to make low single-digit&#160;percentage tiered royalty payments and must pay up to between $1.1 million and $9 million in development milestone payments, $1.3 million and $7 million in regulatory milestone payments and $1.3 million and $7 million in commercial milestone payments, depending on whether the license is exclusive or non-exclusive and the number of options exercised to date. As of September&#160;30, 2022, we have exercised our option to obtain a non-exclusive license to seventeen targets, subject to customary closing conditions. As of September&#160;30, 2022, we have paid Acuitas $3.7 million in reservation and option exercise fees and have made payments totaling $8.6 million reimbursing Acuitas for development costs and LNP batches and in connection with our FTE funding obligations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">For each option that we have exercised under the Acuitas Agreement, we have entered into a non-exclusive license agreement with Acuitas with respect to such optioned target, all based on the same form agreement, which we refer to as the Acuitas License Agreements. We are required to pay Acuitas up to between $1.1 million and $1.6 million in development milestone payments, $1.3 million and $1.8 million in regulatory milestone payments and between $1.3 million and $1.8 million in commercial milestone payments under each Acuitas License Agreement. We must pay Acuitas annual fees ranging from $5,000 to $10,000 for any additional protein targeted by a vaccine product licensed under each Acuitas License Agreement after a certain milestone event. Additionally, we are obligated to pay Acuitas a low single-digit&#160;percentage royalty on net sales of licensed products. As of September&#160;30, 2022, we have made $100,000 in development milestone payments to Acuitas with respect to the license agreement relating to Rabies RAV-G, we have made $1.4 million in development milestone payments (Phase I, Phase II and Phase III milestone payments) to Acuitas with respect to the license agreement relating to the SARS-CoV-2 Spike protein S, and we have made $100,000 in development milestone payments to Acuitas with respect to the license agreement relating to the Influenza hemagglutinin (HA) antigen, and have not made any royalty payments.</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 18pt;">CRISPR Therapeutics</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In November&#160;2017, we entered into a Development and License Agreement with CRISPR Therapeutics which, as amended by an amendment entered into in June&#160;2020, we refer to as the CRISPR Therapeutics Agreement, pursuant to which we will develop novel Cas9 mRNA constructs for use in gene editing therapeutics. Under the CRISPR Therapeutics Agreement, we granted CRISPR Therapeutics an exclusive worldwide license to use our improved Cas9 constructs for the development and commercialization of three of its in vivo gene-editing programs for certain diseases.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">CRISPR Therapeutics has paid us an up-front one-time technology access fee of $3 million, and we are eligible to receive up to $13 million in development milestone payments, $33 million in regulatory milestone payments and $133 million in commercial milestone payments, as well as mid-single-digit&#160;percentage royalties from CRISPR Therapeutics on the net sales of licensed products on a product-by-product and country-by-country basis, subject to certain potential customary reductions. Additionally, CRISPR Therapeutics will make payments to us for services provided by us in conjunction with research programs under the CRISPR Therapeutics Agreement. In the event CRISPR Therapeutics exercises its right to sublicense under the CRISPR Therapeutics Agreement, CRISPR Therapeutics must pay us a low teens to mid-twenties&#160;percentage of any non-royalty sublicense income, depending on the timing of the sublicense and whether the sublicense is granted through an affiliate of CRISPR Therapeutics. As of September&#160;30, 2022, we have received &#8364;3.6 million in payments and we have invoiced &#8364;0.6 million for the supply of materials and FTE cost, development reimbursements and up-front one-time technology access fee and no milestone, royalty or sublicense fee payments.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 18pt;">Boehringer Ingelheim</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In August&#160;2014, we entered into an Exclusive Collaboration and License Agreement with Boehringer Ingelheim GmbH, or Boehringer Ingelheim, which we refer to as the Boehringer Agreement, whereby we granted Boehringer Ingelheim exclusive global rights for development and commercialization of our investigational therapeutic mRNA vaccine BI 1361849 (formerly CV9202) formulated with our protamine technology. We received an up-front payment of &#8364;30 million as well as an option fee payment of &#8364;5 million and an additional &#8364;7 million in development milestone payments and, as of September&#160;30, 2022, we received &#8364;7.6 million for the supply of materials and reimbursing us for development costs. In June&#160;2021, Boehringer Ingelheim provided notice of its intention to terminate the Boehringer Agreement, whereby such termination became effective on November&#160;17, 2021. Upon termination of the Boehringer Agreement, the rights and licenses granted by us to Boehringer Ingelheim reverted back to us, provided that Boehringer Ingelheim has the right to sell off existing inventory of BI 1361849 (formerly CV9202) for a certain period. In addition, Boehringer Ingelheim must assign to us all regulatory approvals or applications and grant us a non-exclusive, cost-free, perpetual and worldwide license to intellectual property held by Boehringer Ingelheim that has been used in the development, manufacture or commercialization of BI 1361849 (formerly CV9202), along with any other product developed under the Boehringer Agreement. We and Boehringer Ingelheim are currently assessing options to continue a collaboration based on state-of-the-art LNP-based formulations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 18pt;">Bill&#160;&amp; Melinda Gates Foundation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In May&#160;2014, we were awarded a grant from the Bill&#160;&amp; Melinda Gates Foundation for the development of a vaccine for rotaviruses, as amended in November&#160;2020, for up to $2.8 million in funding. As of September&#160;30, 2022, we have received $2.8 million in funding under the agreement. In March&#160;2015, the Bill&#160;&amp; Melinda Gates Foundation made an equity investment of $40 million to support continued development of our RNA technology platform and the construction of an industrial-scale cGMP production facility. In February&#160;2015, we entered into a Global Access Commitments Agreement with the Bill&#160;&amp; Melinda Gates Foundation pursuant to which we are required to take certain actions to support the Bill&#160;&amp; Melinda Gates Foundation mission. In connection with the investment by the Bill&#160;&amp; Melinda Gates Foundation, we are required to conduct development activities for up to three concurrent projects to be proposed by the Bill&#160;&amp; Melinda Gates Foundation. The costs of such projects will be allocated on a project-by-project basis in proportion to the allocation of the expected benefits.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In November&#160;2016, in connection with the Global Access Commitments Agreement, we were awarded a grant for up to $0.9 million in funding from the Bill&#160;&amp; Melinda Gates Foundation for the development of a vaccine for picornaviruses. As of September&#160;30, 2022, we have received $0.7 million in funding under the picornaviruses grant agreement. In November&#160;2017, we were awarded two additional grants each for up to $1.9 million and $1.5 million in funding from the Bill&#160;&amp; Melinda Gates Foundation for the development of a universal influenza and a malaria vaccine, respectively. By an amendment entered into November&#160;2020, our grant for the development of a malaria vaccine was increased by an additional $0.8 million. As of September&#160;30, 2022, we have received $1.9 million and $2.2 million, respectively, in funding under each grant agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 18pt;">Coalition for Epidemic Preparedness Innovations</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">In February&#160;2019, we entered into a framework partnership agreement, which as amended we refer to as the CEPI Agreement, with the Coalition for Epidemic Preparedness, or CEPI, to develop our RNA Printer using certain intellectual property controlled by us covering the development and manufacture of mRNA products, as well as certain additional intellectual property licensed to us. In </p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">connection with the CEPI Agreement we have entered into work orders for the preclinical development of a Lassa virus vaccine, a yellow fever vaccine and our rabies virus vaccine. In addition, we entered into a work package for the preclinical development and a Phase 1 clinical trial for our first-generation COVID-19 vaccine candidate, CVnCoV. The CEPI Agreement terminated in Feburary 2022, except with respect to certain ongoing projects, which are contemplated to be completed in March&#160;2023. CEPI agreed to contribute up to $34 million in funding for projects undertaken under the CEPI Agreement and an additional $15.3 million in connection with development of CVnCoV. As of September&#160;30, 2022, we have received &#8364;27.1 million in funding for projects undertaken under the CEPI Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 18pt;">Tesla Automation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In November&#160;2015, we entered into a development and intellectual property agreement with Tesla Automation, formerly trading under the name of Tesla Grohmann Automation, which we refer to as the Tesla Automation Agreement, pursuant to which Tesla Automation agreed to design, develop and manufacture certain automated manufacturing machines on our behalf. We are obligated to pay Tesla Automation a fee for each machine delivered by Tesla Automation and up to $50 million to $60 million in commercial milestone payments as well as certain development costs under each associated work order. As of September&#160;30, 2022, we have paid Tesla Automation &#8364;18 million to &#8364;19 million in development costs under various work orders, and we have not paid any fees for machines provided under the Tesla Automation Agreement or made any milestone payments.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 18pt;">Advance Purchase Agreement for our First-Generation COVID-19 Vaccine Candidate</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On November&#160;30, 2020, we entered into an APA with the EC, acting on behalf and in the name of all Member States of the European Union, which provided for the advance purchase by the Member States of 225 million doses of the vaccine to be allocated among the Member States and the option to purchase up to an additional 180 million doses. Pursuant to the APA, we received an up-front payment of &#8364;450 million. Such up-front payment had to be used solely for the development and commercial supply of CVnCoV. We are required to return any unspent amounts of the up-front payment if, among others, we fail to successfully develop CVnCoV or if we successfully develop CVnCoV, but we do not receive EU marketing authorization or fail to supply any doses of CVnCoV to any of the Member States by late 2021, unless we and the EC mutually agree to a later date. In October&#160;2021, we notified the EC of the withdrawal of our regulatory approval application for CVnCoV, which notification automatically terminated the APA. According to the APA, in such case of termination, CureVac would only return the unspent amount of the up-front payment. In the context of the APA, &#8220;spent&#8221; means either costs incurred or commitments made in connection with the purposes set forth in the APA. On March&#160;8, 2022, we received a letter signed by the EC acknowledging and outlining that we will not be required to return any portion of the up-front payment. Due to the termination of the APA, we will not receive any further payments related to the APA.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In other respects, upon the EC&#8217;s request, we will transfer any raw materials and/or primary components paid for with the up-front payment that were not used as of the termination date. Additionally, should the EC request, or should we successfully sell, any raw materials and/or primary components, then an applicable portion of such raw materials, primary components or proceeds, as the case may be, will be remitted to the EC. This repayment agreement expires at the end of 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 18pt;">Acquisition of Frame Pharmaceuticals</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On June&#160;8, 2022, we entered into a Share Purchase Agreement (&#8220;SPA&#8221;), to acquire all of the issued and outstanding shares of Frame Pharmaceuticals B.V., domiciled in Amsterdam, the Netherlands, a private company with limited liability (<i style="font-style:italic;">besloten vennootschap met beperkte aansprakelijkheid</i>), organized and existing under the laws of the Netherlands, focused on advanced genomics and bioinformatics to identify both unique and shared neoantigens across different cancer types. Under the SPA, the total consideration for the purchase was &#8364;34 million, conditioned on certain development milestone payments, as described therein. This acquisition serves to complement and strengthen our discovery capabilities to identify and validate promising neoantigens for our mRNA cancer vaccine programs and could strongly increase the likelihood of developing highly effective cancer vaccines for patients.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Financial Operations Overview</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 9.35pt;">Revenue</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">To date, our revenues have consisted of up-front licensing payments, milestone payments, product sales and compensation for research and development services, all of which relate to our license and collaboration agreements. Certain of these payments are initially recorded on our statement of financial position and are subsequently recognized as revenue in accordance with our accounting policy as described further in Note 3 to our audited consolidated financial statements included in the Annual Report.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 9.35pt;">Cost of Sales</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Cost of sales consists primarily of personnel costs, costs for materials and third party services, including any relating to written-off inventory, as well as maintenance and lease costs, and depreciation and amortization. Costs of sales includes costs of product sales, idle production costs and costs from set-up and quality assurance activities for our production processes, including those relating to </p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">pharmaceutical products which are under development in our collaboration agreements and for which we have not yet generated revenues. See &#8220;Research and Development Expenses&#8221; below for additional information on recognition of costs relating to pre-launch products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 9.35pt;">Selling and Distribution Expenses</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Selling and distribution expenses primarily consist of personnel expenses which include salary and salary-related expenses and expenses from share-based compensation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 9.35pt;">Research and Development Expenses</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Research and development expenses consist primarily of costs incurred for our research and preclinical and clinical development activities, including our product discovery efforts and certain activities relating to the design of GMP-manufacturing facilities. Research and development expenses contain wages and salaries, share-based compensation, fringe benefits and other personnel costs, the costs of clinical testing and the associated clinical production costs, research material production costs, fees for contractual partners, consultants and other third parties, fees to register legal rights, amortization of licensed software and intellectual property as well as costs for plant and facilities. Research and development expenses contain costs for independent research and development work as well as work carried out in the context of collaboration and licensing agreements; such expenses include all costs related to research and development services delivered under our collaboration arrangements. Additionally, prior to initial regulatory approval, if any, costs relating to production of products are expensed as research and development expenses in the period incurred. If pre-launch products are sold, the respective product gross margin may be higher compared to the expected recurring margin, as the underlying costs will not be included in cost of sales as they will have been recognized in research and development expense in the period incurred.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We expense research and development expenses as incurred. We recognize costs for certain development activities, such as preclinical studies and clinical trials, based on an evaluation of the progress to completion of specific tasks. We use information provided to us by our vendors such as patient enrollment or clinical site activations for services received and efforts expended. We expect to incur significant expenses related to such second-generation vaccine candidates. But, as we and GSK agreed to equally share the development costs for GSK COVID products, our current level of research and development expenses will not continue to increase in the level as it did from 2020 to 2021. Once we conclude our research and development efforts related to a selected second-generation vaccine candidate, we expect that our research and development expenses shall be consistent with our past trends before the COVID-19 pandemic, but we may find it necessary to continue such current trend with respect to our research and developments expenses or we may continue to increase further our research and development expenses. For example, we may continue to increase our research and development expenses for future research and development related to the next generations of our COVID-19 vaccine candidates, such as for our second-generation COVID-19 vaccine candidates or may pursue new indications with our technology platform.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 9.35pt;">General and Administrative Expenses</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">General and administrative expenses generally include wages and salaries, share-based compensation, fringe benefits and other personnel costs of our senior management and administrative personnel, costs for professional services, including legal, audit and consulting services and costs of facilities and office expenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Results of Operations</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 9.35pt;">Comparison of the Nine&#160;Months Ended September&#160;30, 2021 to the Nine&#160;Months Ended September&#160;30, 2022</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We have based the following discussion of our financial condition and results of operations on our unaudited interim condensed consolidated financial statements for the nine&#160;months ended September&#160;30, 2021 and 2022 and the notes thereto, included elsewhere in this Report of Foreign Private Issuer on Form&#160;6-K.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our historical results for the nine&#160;months ended September&#160;30, 2021 and 2022 are not necessarily indicative of results to be expected for a full&#160;year or any other interim period.</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The following table summarizes our consolidated results of operations for the nine&#160;months ended September&#160;30, 2021 and 2022:</p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">For the Nine Months Ended</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September&#160;30,</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="5" style="padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(in&#160;thousands&#160;of&#160;euros,&#160;except per&#160;share&#160;data)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(unaudited)</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Statement of Operations and Comprehensive Income (Loss) Data:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 61,765</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 55,731</font></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cost of sales</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> (168,177)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> (103,992)</font></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Selling and distribution expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> (1,232)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> (1,825)</font></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Research and development expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> (284,728)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> (34,934)</font></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">General and administrative expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> (80,787)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> (78,019)</font></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other operating income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 66,746</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 35,901</font></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other operating expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> (339)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> (809)</font></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Operating loss</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> (406,752)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> (127,947)</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Finance income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 8,828</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 10,619</font></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Finance expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> (10,015)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> (3,077)</font></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Loss before income tax</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> (407,939)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> (120,405)</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Income tax benefit (expense)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> (1,841)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 160</font></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Net loss</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> (409,780)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> (120,245)</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Other comprehensive income/loss:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  <font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  <font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><i style="font-style:italic;">Items that may be subsequently reclassified to profit or loss</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  <font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  <font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Foreign currency adjustments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> (62)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> (364)</font></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total comprehensive loss</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> (409,842)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> (120,609)</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Net loss per share (basic and diluted)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> (2.21)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> (0.64)</b></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><font style="margin-bottom:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 18pt;">Revenue</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Revenue was &#8364;55.7 million for the nine months ended September 30, 2022, representing a decrease of &#8364;6.0 million, or 10%, from &#8364;61.8 million for the nine months ended September 30, 2021. The decrease was primarily driven by the termination of the Boehringer Ingelheim cooperation in 2021, which led to a recognition of &#8364;10.0 million for the nine months ended September&#160;30, 2021. In the nine months ended September 30, 2022 and 2021, &#8364;52.7 million and &#8364;49.6 million, respectively, in revenue was recognized under the collaboration agreements with GSK, for both the 2020 GSK agreement and the GSK COVID Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 18pt;">Cost of Sales</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Cost of sales was &#8364;104.0 million for the nine months ended September 30, 2022, representing a decrease of &#8364;64.2 million, or 38%, from &#8364;168.2 million for the nine months ended September 30, 2021. The decrease was primarily attributable to less expenses on CMO services (fiscal year 2021 was highly impacted by significant expenses for the set-up of a CMO network), partially offset by an increased write-off for raw materials which were procured for manufacturing products to sell to GSK and which are now no longer expected to be used due to a decline in production planning following the transfer of reserved production capacity at a CMO to GSK (as described in the &#8220;Other Operating Income&#8221; section below). We recognize in Cost of Sales costs related to all R&amp;D-services that we provide to GSK and all other collaboration partners.</p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">For&#160;the&#160;Nine&#160;Months&#160;Ended</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September&#160;30,</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="5" style="padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(in&#160;thousands&#160;of&#160;euros)</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(unaudited)</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Personnel</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> (14,897)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> (19,076)</font></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Materials</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> (13,945)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> (48,962)</font></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Third party services</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> (130,795)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> (24,030)</font></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Maintenance and lease</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> (3,227)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> (1,479)</font></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Amortization, depreciation and derecognition</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> (2,944)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> (9,757)</font></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> (2,369)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> (688)</font></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> (168,177)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> (103,992)</b></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><font style="margin-bottom:12pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 18pt;">Selling and Distribution Expenses</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Selling and distribution expenses were &#8364;1.8 million for the nine&#160;months ended September&#160;30, 2022 and were relatively unchanged compared to the nine&#160;months ended September&#160;30, 2021.</p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">For&#160;the&#160;Nine&#160;Months&#160;Ended</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September&#160;30,</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="5" style="padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(in&#160;thousands&#160;of&#160;euros)</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(unaudited)</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Personnel</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> (943)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> (1,467)</font></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Amortization and depreciation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> (65)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> (38)</font></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> (224)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> (320)</font></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> (1,232)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> (1,825)</b></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><font style="margin-bottom:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 18pt;">Research and Development Expenses</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Research and development costs were &#8364;34.9 million for the nine months ended September 30, 2022, representing a decrease of &#8364;249.8 million, or 88%, from &#8364;284.7 million for the nine months ended September 30, 2021. The decrease was primarily attributable to significantly lower research and development costs. Fiscal year 2021 was highly impacted from the start of our Phase 2/3 clinical trial for CVnCoV. As of December 2021, we recognized a provision for all remaining costs related to the CVnCoV clinical trials. During the first nine months of 2022, we were able to renegotiate the existing contracts such that our estimated remaining costs decreased and more participants exited the trials earlier than originally estimated. As a result of these changes, our estimated remaining costs decreased and, thus, we recognized a gain from the reversal of &#8364;36.8 million of the provision. Additionally, during this period, we recognized a net gain for a change of estimate in the contract termination provisions as a result from GSK taking over our committed capacity at a CMO.</p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">For the Nine Months Ended</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September 30,</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="5" style="padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in thousands of euros)</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(unaudited)</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Materials</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> (5,893)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> (29,618)</font></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Personnel</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> (25,209)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> (24,326)</font></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Amortization and depreciation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> (3,051)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> (3,866)</font></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Patents and fees to register a legal right</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> (2,372)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> (2,536)</font></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Third party services</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> (246,185)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 28,525</font></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Maintenance and lease</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> (291)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> (789)</font></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> (1,727)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> (2,324)</font></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> (284,728)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> (34,934)</b></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The following table reflects our research and development costs for each of our programs for the nine&#160;months ended September&#160;30, 2021 and 2022:</p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">For&#160;the&#160;Nine&#160;Months&#160;Ended</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September&#160;30,</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="5" style="padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(in&#160;thousands&#160;of&#160;euros)</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(unaudited)</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Key Programs (CV8102, CV7202, CV2CoV and CVnCoV)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">CV8102</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> (5,126)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> (2,278)</font></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">CV7202</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> (239)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> (187)</font></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Second Generation Covid (CV2CoV and CV0501)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> (5,653)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> (18,067)</font></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">CVnCoV</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> (243,213)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 33,688</font></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other Research and Development Programs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> (1,407)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> (7,741)</font></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Unallocated costs(1)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> (29,090)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> (40,349)</font></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> (284,728)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> (34,934)</b></p></td></tr></table></div><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><hr noshade="true" color="#000000" size="1" width="25.0%" style="background-color:#000000;color:#000000;height:1pt;position:relative;top:0.6em;border:none;margin:0pt;" align="left"></div><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Unallocated costs primarily consist of costs associated with personnel expenses, patents and fees to register a legal right, amortization and depreciation, maintenance and lease expenses, certain third-party service expenses and certain material expenses.</font></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We expect that our research and development expenses will constitute the most substantial part of our expenses in future periods in line with the advance and expansion of the development of our product candidates.</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Due to our accelerated efforts in 2021 to develop CVnCoV our COVID-19 vaccine candidate based on our first-generation mRNA backbone, we incurred research and development expenses that significantly exceeded our historical levels of research and developments expenses. Additionally, our October&#160;2021 notification to the European Commission of the withdrawal of our regulatory approval application for CVnCoV resulted in our recognition of several expenses, which have contributed to our increased expense levels, but which we do not expect to recur in future periods. In April&#160;2021, we entered into a collaboration agreement with GSK for the development of a broad COVID-19 vaccine program based on our improved second-generation mRNA backbone. CV2CoV, a non-chemically modified mRNA, encoding the prefusion stabilized full-length spike protein of the SARS-CoV-2 virus, and formulated within LNPs, is the first representative of this COVID-19 vaccine program. Within the COVID-19 vaccine program applying our second-generation mRNA backbone, we extended our technology platform also to chemically modified mRNA constructs to allow for the data-driven selection of the best candidate. We expect to incur significant expenses related to such second-generation mRNA backbone vaccine candidates. But, as we and GSK agreed to equally share the development costs for GSK COVID products, our current level of research and development expenses will not continue to increase in the level as it did from 2020 to 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 18pt;">Considering that, our research and development expenses primarily relate to the following key programs:</p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Our unmodified mRNA vaccine candidate based on our second-generation backbone, CV2CoV against SARS-CoV2, which is being co-developed with GSK. On March 30, 2022, we announced the start of a Phase 1 clinical trial for CV2CoV, with a study of a modified mRNA candidate expected to follow. We announced the start of this Phase 1 trial for a modified mRNA vaccine candidate based on our second-generation backbone, CV0501, on August 18, 2022.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Our oncology program, CV8102, which is currently in a Phase 1 dose escalating clinical trial for four types of solid tumors as a monotherapy and in combination with anti-PD1 and an expansion of the Phase 1 study to evaluate the safety, tolerability and efficacy of CV8102 at a 600&#956;g dose in patients with PD-1 refractory melanoma &#8211; also as a monotherapy and in combinations with anti-PD-1 antibodies.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Our vaccine program, CV7202, which is currently in a Phase&#160;1 clinical trial as a vaccine candidate for rabies.</font></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 18pt;">General and Administrative Expenses</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">General and administrative expenses were &#8364;78.0 million for the nine&#160;months ended September&#160;30, 2022, representing a decrease of &#8364;2.8 million, or 3%, from &#8364;80.8 million for the nine&#160;months ended September&#160;30, 2021. The decrease was primarily attributable to less third-party services partially offset by increases in amortization and depreciation and legal and other professional services.</p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">For&#160;the&#160;Nine&#160;Months&#160;Ended</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September&#160;30,</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="5" style="padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in&#160;thousands&#160;of&#160;euros)</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(unaudited)</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Personnel</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> (30,039)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> (27,971)</font></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Maintenance and lease costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> (2,106)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> (4,614)</font></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Third party services</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> (28,699)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> (19,607)</font></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Legal and other professional services</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> (6,394)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> (7,215)</font></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Amortization and depreciation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> (5,575)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> (9,444)</font></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> (7,974)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> (9,168)</font></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> (80,787)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> (78,019)</b></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 18pt;">Other Operating Income</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Other operating income was &#8364;35.9 million for the nine&#160;months ended September&#160;30, 2022, representing a decrease of &#8364;30.8 million, or 46%, from &#8364;66.7 million for the nine&#160;months ended September&#160;30, 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In March 2022, CureVac SE (as the surviving entity from the merger of CureVac AG and CureVac Beteiligungsverwaltungs AG) and GlaxoSmithKline Biologicals SA amended and restated the 2020 GSK Agreement and the GSK COVID Agreement in connection with GSK entering into a direct Agreement with Novartis relating to the use of Novartis as CMO at the same time as CureVac exits its CMO agreement with Novartis and is released from its pre-existing capacity commitments under the agreement. As a result, the Company will avoid an outflow of resources. Additionally, under the restated agreement, CureVac was entitled to further compensation by GSK. The compensation mainly consists of consideration for set-up activities undertaken by CureVac (&#8364;20.5 million) and for reimbursement of prepayments (&#8364;12.0 million). In 2021 the other operating income was primarily attributable to amounts recognized from grants from government agencies and similar bodies, primarily the German Federal Ministry of Education and Research, or BMBF.</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 18pt;">Other Operating Expense</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Other operating expense was &#8364;0.8 million for the nine&#160;months ended September&#160;30, 2022, relatively unchanged compared to the nine&#160;months ended September&#160;30, 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 18pt;">Finance Income</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Finance income was &#8364;10.6 million for the nine&#160;months ended September&#160;30, 2022, representing an increase of &#8364;1.8 million, or 20%, from &#8364;8.8 million for the nine&#160;months ended September&#160;30, 2021. The increase was attributable to higher foreign exchange gains and positive interest on cash investments.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 18pt;">Finance Expenses</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Finance expenses were &#8364;3.1 million for the nine&#160;months ended September&#160;30, 2022, representing a decrease of &#8364;6.9 million, or 69%, from &#8364;10.0 million for the nine&#160;months ended September&#160;30, 2021. The decrease was mainly attributable to less negative interest on cash, which is being held in liquid funds available for use for CV2CoV development and other manufacturing activities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 18pt;">Income Tax Benefit (Expense)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">An income tax benefit of &#8364;0.2&#160;million was generated for the nine&#160;months ended September&#160;30, 2022, representing a decrease of &#8364;2.0 million, from an income tax expense of &#8364;1.8 million generated for the nine&#160;months ended September&#160;30, 2021. The decrease to a benefit was primarily attributable to deferred tax income on temporary differences.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Liquidity and Capital Resources</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our financial condition and liquidity is and will continue to be influenced by a variety of factors, including:</p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to generate cash flows from our operations;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">future indebtedness and the interest we are obligated to pay on this indebtedness;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the availability of public and private debt and equity financing;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">changes in exchange rates which will impact our generation of cash flows from operations when measured in euros; and</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our capital expenditure requirements.</font></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 9.35pt;">Overview</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Since inception, we have incurred significant operating losses. For the nine&#160;months ended September&#160;30, 2021 and 2022, we incurred net losses of &#8364;409.8 million and &#8364;120.2 million, respectively. To date, we have financed our operations primarily through the IPO in August&#160;2020, the public offering in February&#160;2021, private placements of equity securities, issuance of convertible debt, grants from government agencies and similar bodies and payments for collaborative research and development services. Our cash and cash equivalents as of September&#160;30, 2022 were &#8364;540.9 million. Our primary cash needs are to fund our non-clinical and clinical development programs, for working capital requirements and for capital expenditures. We believe our existing cash, cash equivalents, borrowings available to us, receipts from grants and short-term investments will enable us to fund our operating expenses and capital expenditure requirements at least through the end of 2023. We have based this estimate on assumptions that may prove to be wrong, and we could exhaust our available capital resources sooner than we expect.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In September&#160;2021, we entered into a sales agreement, the Open Sale Agreement, with Jefferies LLC and SVB Securities LLC, as sales agents, to establish an at-the-market offering program (&#8220;ATM Program&#8221;), pursuant to which we may sell, from time to time, ordinary shares for aggregate gross proceeds of up to $600.0 million. For the nine&#160;months ended September&#160;30, 2022, 2,288,055 shares were issued for the ATM and expenses in connection with the ATM were booked against equity. Following these issuances, the remaining value authorized for sale under the at-the-market program as of September 30, 2022 amounts to $567.3 million.</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 9.35pt;">Comparative Cash Flows</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 18pt;">Comparison of the nine&#160;months ended September&#160;30, 2021 and 2022</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The following table summarizes our cash flows from operating, investing and financing activities for the periods indicated:</p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">For&#160;the&#160;Nine&#160;Months&#160;Ended</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September&#160;30,</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="5" style="padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(in&#160;thousands&#160;of&#160;euros)</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(unaudited)</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net cash flow from (used in):</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Operating activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> (550,057)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> (237,091)</font></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Investing activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> (93,305)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> (72,559)</font></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Financing activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 378,479</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 29,873</font></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Effect of currency translation gains on cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 3,261</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 9,178</font></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Overall cash inflow</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> (261,622)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> (270,599)</b></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><font style="margin-bottom:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 18pt;">Operating Activities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Net cash used in operating activities for the nine&#160;months ended September&#160;30, 2022 was &#8364;237.1 million as compared to net cash used in operating activities of &#8364;550.1 million for the nine&#160;months ended September&#160;30, 2021. The decrease in net cash in operating activities was primarily attributable to less prepayments for service agreements with Contract Research Organizations and Contract Manufacturing Organizations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 18pt;">Investing Activities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Net cash used in investing activities for the nine&#160;months ended September&#160;30, 2022 was &#8364;72.6 million as compared to net cash used in investing activities of &#8364;93.3 million for the nine&#160;months ended September&#160;30, 2021. The change in cash flows from investing activities was primarily attributable to decreased purchases of property, plant and equipment for contract manufacturing facilities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 18pt;">Financing Activities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Net cash used by financing activities was &#8364;29.9 million for the nine&#160;months ended September&#160;30, 2022 as compared to cash provided by financing activities of &#8364;378.5 million for the nine&#160;months ended September&#160;30, 2021. The decrease in cash flow provided by financing activities was mainly attributable to the raising of cash in the follow-on public offering, which closed in February&#160;2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Off-Balance Sheet Arrangements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We did not have during the periods presented, and we do not currently have, any off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources, except for those noncancellable contractual obligations from certain of our arrangements with contract manufacturing organizations disclosed in &#8220;Liquidity and Capital Resources&#8221; and &#8220;Contractual Obligations and Commitments.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Safe Harbor</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">See &#8220;Forward-Looking Statements.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Critical Accounting Policies and Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our consolidated financial statements are prepared in accordance with International Financial Reporting Standards, or the IFRS, as issued by the International Accounting Standards Board, or IASB. Some of the accounting methods and policies used in preparing the financial statements under IFRS are based on complex and subjective assessments by our management or on estimates based on past experience and assumptions deemed realistic and reasonable based on the circumstances concerned. The actual value of our assets, liabilities and shareholders&#8217; equity and of our earnings could differ from the value derived from these estimates if conditions changed and these changes had an impact on the assumptions adopted.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our significant accounting policies that we believe to be critical to the judgments and estimates used in the preparation of our financial statements are included in &#8220;Note 3&#8201;&#8212; Basis of preparation&#8221; to our audited consolidated financial statements included in the Annual Report.</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Recent Accounting Pronouncements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We have applied, in our audited consolidated financial statements for the&#160;year ended December&#160;31, 2021, new standards and amendments as issued by IASB and that are mandatory as of January&#160;1, 2021. See Note 2 to our audited consolidated financial statements included in the Annual Report.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">We have applied, in our unaudited interim condensed consolidated financial statements for the nine&#160;months ended September&#160;30, 2022, new standards and amendments as issued by IASB and as issued by IASB and that are mandatory as of January&#160;1, 2021. See Note 2 to our unaudited interim condensed consolidated financial statements included elsewhere in this Report of Foreign Private Issuer on Form&#160;6-K for further information on these new standards and amendments.</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.3
<SEQUENCE>4
<FILENAME>cvac-20220930xex99d3.htm
<DESCRIPTION>EX-99.3
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.14.0.96--><!--Created on: 11/17/2022 10:27:53 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Exhibit 99.3</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><font style="font-style:italic;font-weight:bold;">EXPLANATORY NOTE</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">This &#8220;Material Dutch Tax Considerations&#8221; section is being provided to update the disclosure in CureVac&#8217;s Annual Report on Form 20-F for the year ended December 31, 2021 as filed with the U.S. Securities and Exchange Commission on April 28, 2022 as a result of subsequent changes in Dutch tax law. This section shall be deemed to be incorporated by reference into CureVac&#8217;s Annual Report on Form 20-F for the year ended December 31, 2021 and to be a part thereof from the date on which this report is submitted, to the extent not superseded by documents or reports subsequently filed or furnished. </i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">MATERIAL DUTCH TAX CONSIDERATIONS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 9.35pt;"><font style="font-style:italic;font-weight:bold;">General</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The following is a general summary of certain material Dutch tax consequences of the acquisition, holding and disposal of our common shares. This summary does not purport to set forth all possible tax considerations or consequences that may be relevant to a holder or prospective holder of our common shares and does not purport to deal with the tax consequences applicable to all categories of investors, some of which (such as trusts or similar arrangements) may be subject to special rules. In view of its general nature, it should be treated with corresponding caution.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">This summary is based on the tax laws of the Netherlands, published regulations thereunder and published authoritative case law, all as in effect on the date hereof, and all of which are subject to change, possibly with retroactive effect. Where the summary refers to &#8220;the Netherlands&#8221; or &#8220;Dutch&#8221; it refers only to the part of the Kingdom of the Netherlands located in Europe.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">This discussion is for general information purposes and is not Dutch tax advice or a complete description of all Dutch tax consequences relating to the acquisition, holding and disposal of our common shares. Holders or prospective holders of our common shares should consult their own tax advisor regarding the Dutch tax consequences relating to the acquisition, holding and disposal of our common shares in light of their particular circumstances.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Please note that this section does not set forth the Dutch tax considerations for:</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">(i)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">holders of common shares if such holders have a substantial interest (<i style="font-style:italic;">aanmerkelijk belang</i>) or deemed substantial interest (<i style="font-style:italic;">fictief aanmerkelijk belang</i>) under the Dutch Income Tax Act 2001 (<i style="font-style:italic;">Wet inkomstenbelasting 2001</i>). Generally, a holder of securities in a company is considered to hold a substantial interest in such company if such holder alone or, in the case of individuals, together with such holder&#8217;s partner for Dutch income tax purposes, or any relatives by blood or marriage in the direct line (including foster children) directly or indirectly holds (i)&#160;an interest of 5% or more of the total issued and outstanding capital of that company or of 5% or more of the issued and outstanding capital of a certain class of shares of that company; or (ii)&#160;rights to acquire, directly or indirectly, such interest; or (iii)&#160;certain profit sharing rights in that company that relate to 5% or more of the company&#8217;s annual profits and/or to 5% or more of the company&#8217;s liquidation proceeds. A deemed substantial interest exists if a substantial interest (or part thereof) in a company has been disposed of, or is deemed to have been disposed of, on a non-recognition basis;</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">(ii)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">holders of common shares for which the common shares qualify or qualified as a participation (<i style="font-style:italic;">deelneming</i>) for purposes of the Dutch Corporate Income Tax Act 1969 (<i style="font-style:italic;">Wet op de vennootschapsbelasting 1969</i>). Generally, a holder&#8217;s shareholding of 5% or more in a company&#8217;s nominal paid-up share capital qualifies as a participation. A holder may also have a participation if (a) such holder does not have a shareholding of 5% or more but a related entity (statutorily defined term) has a participation or (b) the company in which the shares are held is a related entity (statutorily defined term);</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">(iii)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">pension funds, investment institutions (<i style="font-style:italic;">fiscale beleggingsinstellingen</i>), exempt investment institutions (<i style="font-style:italic;">vrijgestelde beleggingsinstellingen</i>) (as defined in the Dutch Corporate Income Tax Act 1969) and other entities that are, in whole or in part, not subject to or exempt from Dutch corporate income tax as well as entities that are exempt from corporate income tax in their country of residence, such country of residence being another state of the European Union, Norway, Liechtenstein, Iceland or any other state with which the Netherlands has agreed to exchange information in line with international standards; and</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">(iv)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">holders of common shares who are individuals and for whom the common shares or any benefit derived from the common shares are a remuneration or deemed to be a remuneration for (employment) activities performed by such holders or certain individuals related to such holders (as defined in the Dutch Income Tax Act 2001).</p></td></tr></table></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 9.35pt;"><font style="font-style:italic;font-weight:bold;">Dividend Withholding Tax</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Dividends distributed by us generally are subject to Dutch dividend withholding tax at a rate of 15%. Generally, we are responsible for the withholding of such dividend withholding tax at source; the Dutch dividend withholding tax is for the account of the holder of our common shares.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The expression &#8220;dividends distributed&#8221; includes, among other things:</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">(i)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">distributions in cash or in kind, deemed and constructive distributions and repayments of paid-in capital not recognized for Dutch dividend withholding tax purposes;</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">(ii)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">liquidation proceeds, proceeds from the redemption of common shares, or proceeds from the repurchase of common shares (other than as temporary portfolio investment; <i style="font-style:italic;">tijdelijke belegging</i>) by us or one of our subsidiaries or other affiliated entities to the extent such proceeds exceed the average paid-in capital of those common shares as recognized for Dutch dividend withholding tax purposes;</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">(iii)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">an amount equal to the par value of common shares issued or an increase of the par value of common shares, to the extent that it does not appear that a contribution, recognized for Dutch dividend withholding tax purposes, has been made or will be made; and</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">(iv)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">partial repayment of the paid-in capital, recognized for Dutch dividend withholding tax purposes, if and to the extent that we have net profits (<i style="font-style:italic;">zuivere winst</i>), unless (i)&#160;the general meeting has resolved in advance to make such repayment and (ii)&#160;the par value of the common shares concerned has been reduced by an equal amount by way of an amendment of our articles of association. The term &#8220;net profits&#8221; includes anticipated profits that have yet to be realized.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Corporate legal entities that are resident or deemed to be resident of the Netherlands for Dutch corporate income tax purposes (&#8220;Dutch Resident Entities&#8221;) generally are entitled to an exemption from, or a credit for, any Dutch dividend withholding tax against their Dutch corporate income tax liability. The credit in any given year is, however, limited to the amount of Dutch corporate income tax payable in respect of the relevant year with an indefinite carry forward of any excess amount. Individuals who are resident or deemed to be resident of the Netherlands for Dutch personal income tax purposes (&#8220;Dutch Resident Individuals&#8221;) generally are entitled to a credit for any Dutch dividend withholding tax against their Dutch personal income tax liability and to a refund of any residual Dutch dividend withholding tax. The above generally also applies to holders of our common shares that are neither resident nor deemed to be resident of the Netherlands (&#8220;Non-Resident Holders&#8221;) if the common shares are attributable to a Dutch permanent establishment of such Non-Resident Holder.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">A holder of common shares resident of a country other than the Netherlands may, depending on such holder&#8217;s specific circumstances, be entitled to exemptions from, reduction of, or full or partial refund of, Dutch dividend withholding tax under Dutch domestic tax law, EU law, or treaties for the avoidance of double taxation in effect between the Netherlands and such other country.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 9.35pt;"><i style="font-style:italic;">Dividend Stripping</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">According to Dutch domestic anti-dividend stripping rules, no credit against Dutch tax, exemption from, reduction, or refund of Dutch dividend withholding tax will be granted if the recipient of the dividends we paid is not considered the beneficial owner (<i style="font-style:italic;">uiteindelijk gerechtigde</i>; as described in the Dutch Dividend Withholding Tax Act 1965) of those dividends. This legislation generally targets situations in which a shareholder retains its economic interest in shares but reduces the withholding tax costs on dividends by a transaction with another party. It is not required for these rules to apply that the recipient of the dividends is aware that a dividend stripping transaction took place. The Dutch State Secretary of Finance takes the position that the definition of beneficial ownership introduced by this legislation will also be applied in the context of a double taxation convention.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 9.35pt;"><i style="font-style:italic;">Conditional withholding tax on dividends (as of January 1, 2024)</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of January 1, 2024, a Dutch conditional withholding tax will be imposed on dividends distributed by us to entities related (<i style="font-style:italic;">gelieerd</i>) to us (within the meaning of the Dutch Withholding Tax Act 2021; <i style="font-style:italic;">Wet bronbelasting 2021</i>), if such related entity:</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">(i)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">is considered to be resident (<i style="font-style:italic;">gevestigd</i>) in a jurisdiction that is listed in the yearly updated Dutch Regulation on low-taxing states and non-cooperative jurisdictions for tax purposes (<i style="font-style:italic;">Regeling laagbelastende staten en niet-co&#246;peratieve rechtsgebieden voor belastingdoeleinden</i>) (a &#8220;Listed Jurisdiction&#8221;); or</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">(ii)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">has a permanent establishment located in a Listed Jurisdiction to which the Shares are attributable; or</p></td></tr></table></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">(iii)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">holds the common shares with the main purpose or one of the main purposes of avoiding taxation for another person or entity and there is an artificial arrangement or transaction or a series of artificial arrangements or transactions; or</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">(iv)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">is not considered to be the beneficial owner of the common shares in its jurisdiction of residence because such jurisdiction treats another entity as the beneficial owner of the common shares (a hybrid mismatch); or</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">(v)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">is not resident in any jurisdiction (also a hybrid mismatch); or</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">(vi)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">is a reverse hybrid (within the meaning of Article 2(12) of the Dutch Corporate Income Tax Act 1969), if and to the extent (x) there is a participant in the reverse hybrid which is related (<i style="font-style:italic;">gelieerd</i>) to the reverse hybrid, (y) the jurisdiction of residence of such participant treats the reverse hybrid as transparent for tax purposes and (z) such participant would have been subject to the Dutch conditional withholding tax in respect of dividends distributed by us without the interposition of the reverse hybrid,</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">all within the meaning of the Dutch Withholding Tax Act 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Dutch conditional withholding tax on dividends will be imposed at the highest Dutch corporate income tax rate in effect at the time of the distribution 2022: 25.8%). The Dutch conditional withholding tax on dividends will be reduced, but not below zero, by any regular Dutch dividend withholding tax withheld in respect of the same dividend distribution. As such, based on the currently applicable rates, the overall effective tax rate of withholding the regular Dutch dividend withholding tax (as described above) and the Dutch conditional withholding tax on dividends will not exceed the highest corporate income tax rate in effect at the time of the distribution (2022: 25.8%).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Dual Tax Residency</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We are incorporated under the laws of the Netherlands, and we are therefore a Dutch tax resident for Dutch domestic tax law purposes, including the Dutch Dividend Withholding Tax Act 1969. We are also treated as a German tax resident for German domestic tax law purposes, since our place of effective management is located in Germany. Based on the so-called tie-breaker provision (the &#8220;Tie-Breaker Provision&#8221;) included in Section 4(3) of the 2012 Convention between the Federal Republic of Germany and the Kingdom of the Netherlands for the avoidance of double taxation with respect to taxes on income (the &#8220;double tax treaty between Germany and the Netherlands&#8221;) as in effect on the date hereof, our tax residence in either the Netherlands or Germany for the purposes of the double tax treaty between Germany and the Netherlands should be determined on our place of effective management. As long as our place of effective management is in Germany, and the Tie-Breaker Provision and the reservation made by Germany with respect to the Tie-Breaker Provision as part of the Multilateral Convention to Implement Tax Treaty Related Measures to Prevent Base Erosion and Profit Shifting are not changed, we should exclusively be a tax resident of Germany for purposes of the double tax treaty between Germany and the Netherlands. As a consequence, the Netherlands will be restricted to impose Dutch dividend withholding tax on dividends distributed by us pursuant to Section 10(5) of the double tax treaty between Germany and the Netherlands, except for dividends distributed to Dutch Resident Entities, Dutch Resident Individuals and Non-Resident Holders if the common shares are attributable to a permanent establishment in the Netherlands of such Non-Resident Holder.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 9.35pt;"><font style="font-style:italic;font-weight:bold;">Taxes on Income and Capital Gains</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;"><i style="font-style:italic;">Dutch Resident Entities</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Generally speaking, if the holder of common shares is a Dutch Resident Entity, any benefits derived or deemed to be derived from the common shares or any capital gains realized on the disposal or deemed disposal of the common shares is subject to Dutch corporate income tax at a rate of 15% with respect to taxable profits up to &#8364;395,000 and 25.8% with respect to taxable profits in excess of that amount (rates and brackets for 2022).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;"><i style="font-style:italic;">Dutch Resident Individuals</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If the holder of common shares is a Dutch Resident Individual, any benefits derived or deemed to be derived from the common shares or any capital gains realized on the disposal or deemed disposal of the common shares is taxable at the progressive Dutch income tax rates (with a maximum of 49.5% in 2022), if:</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">(i)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">the common shares are attributable to an enterprise from which the holder of common shares derives a share of the profit, whether as an entrepreneur (<i style="font-style:italic;">ondernemer</i>) or as a person who has a co-entitlement to the net worth (<i style="font-style:italic;">medegerechtigd tot het vermogen</i>) of such enterprise without being a shareholder (as defined in the Dutch Income Tax Act 2001); or</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">(ii)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">the holder of common shares is considered to perform activities with respect to the common shares that go beyond ordinary asset management (<i style="font-style:italic;">normaal, actief vermogensbeheer</i>) or otherwise derives benefits from the common shares that are taxable as benefits from miscellaneous activities (<i style="font-style:italic;">resultaat uit overige werkzaamheden</i>).</p></td></tr></table></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;"><i style="font-style:italic;">Taxation of savings and investments</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If the above-mentioned conditions (i) and (ii) do not apply to the Dutch Resident Individual, the Dutch Resident Individual&#8217;s net investment assets (<i style="font-style:italic;">rendementsgrondslag</i>) for the year will be subject to an annual Dutch income tax on a deemed return under the regime for savings and investments (<i style="font-style:italic;">inkomen uit sparen en beleggen</i>), insofar the Dutch Resident Individual&#8217;s net investment assets for the year exceed a statutory threshold (<i style="font-style:italic;">heffingvrij vermogen</i>). The net investment assets for the year are the fair market value of the investment assets less the allowable liabilities on January 1 of the relevant calendar year. The common shares are included as investment assets. The deemed return on the Dutch Resident Individual&#8217;s net investment assets for the year is taxed at a flat rate of 31% (rate for 2022). Actual income or capital gains realized in respect of the common shares are as such not subject to Dutch income tax.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Based on a decision of the Dutch Supreme Court (<i style="font-style:italic;">Hoge Raad</i>) of 24 December 2021 (ECLI:NL:HR:2021:1963), the system of taxation for savings and investments based on a deemed return may under specific circumstances contravene with Section 1 of the First Protocol to the European Convention on Human Rights in combination with Section 14 of the European Convention on Human Rights. On June 28, 2022 the Dutch State Secretary of Finance has issued a decree amending the regime for taxation of savings and investments as in effect on the date hereof to comply with this Dutch Supreme Court ruling. This decree will be implement in Dutch tax law pursuant to the &#8216;Law on the restoration of rights box 3&#8217; (<i style="font-style:italic;">Wet rechtsherstel box 3</i>), which applies to calendar year 2022. On the basis of the decree as published on June 28, 2022 and the aforementioned new law the tax will be levied at the lowest outcome of the following two calculation methods:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Method 1. Under Method 1, the annual taxable benefit from a Dutch Resident Individual&#8217;s assets and liabilities taxed under this regime, including the common shares, is based on a deemed return (ranging from 1.82% and 5.53% in 2022) of the positive balance of the fair market value of those assets, including the common shares, and the fair market value of those liabilities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Method 2. Under Method 2, the annual taxable benefit from a Dutch Resident Individual&#8217;s assets and liabilities taxed under this regime, including the common shares, is based on the actual allocation of the Dutch Resident Individual&#8217;s assets and liabilities over the following three categories: (i) bank savings, (ii) other investments, including the common shares, and (iii) liabilities. The tax is calculated as follows:</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">(i)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">a deemed return on the fair market value of the actual amount of bank savings; <i style="font-style:italic;">plus</i></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">(ii)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">a deemed return on the fair market value of the actual amount of other investments, including the common shares; <i style="font-style:italic;">minus</i></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">(iii)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">a deemed return on the fair market value of the actual amount of liabilities.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Under Method 2, the statutory threshold is divided pro-rata over the three assets and liabilities categories mentioned above. At the date hereof, the deemed returns under (i) to (iii) above have not yet been definitively published for the calendar year 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Holders of common shares are advised to consult their own tax advisor to ensure that the tax is levied in accordance with the decision of the Dutch Supreme Court.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;"><i style="font-style:italic;">Non-residents of the Netherlands</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">A holder of common shares that is neither a Dutch Resident Entity nor a Dutch Resident Individual will not be subject to Dutch (corporate) income tax in respect of income derived or deemed to be derived from the common shares or in respect of capital gains realized on the disposal or deemed disposal of the common shares, provided that:</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">(i)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">such holder does not have an interest in an enterprise or deemed enterprise (as defined in the Dutch Income Tax Act 2001 and the Dutch Corporate Income Tax Act 1969) which, in whole or in part, is either effectively managed in the Netherlands or carried on through a permanent establishment, a deemed permanent establishment or a permanent representative in the Netherlands and to which enterprise or part of an enterprise the common shares are attributable; and</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">(ii)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">in the event the holder is an individual, such holder does not carry out any activities in the Netherlands with respect to the common shares that go beyond ordinary asset management and does not otherwise derive benefits from the common shares that are taxable as benefits from miscellaneous activities in the Netherlands.</p></td></tr></table></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 9.35pt;"><font style="font-style:italic;font-weight:bold;">Gift and Inheritance Taxes</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;"><i style="font-style:italic;">Residents of the Netherlands</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Gift or inheritance taxes will arise in the Netherlands with respect to a transfer of common shares by way of a gift by, or on the death of, a holder of such common shares who is resident or deemed resident of the Netherlands at the time of the gift or the holder&#8217;s death.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;"><i style="font-style:italic;">Non-residents of the Netherlands</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">No gift or inheritance taxes will arise in the Netherlands with respect to a transfer of common shares by way of gift by, or on the death of, a holder of common shares who is neither resident nor deemed to be resident of the Netherlands, unless:</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">(i)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">in the case of a gift of common shares by an individual who at the date of the gift was neither resident nor deemed to be resident of the Netherlands, such individual dies within 180&#160;days after the date of the gift, while being resident or deemed to be resident of the Netherlands; or</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">(ii)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">in the case of a gift of common shares is made under a condition precedent, the holder of common shares is resident or is deemed to be resident of the Netherlands at the time the condition is fulfilled; or</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">(iii)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">the transfer is otherwise construed as a gift or inheritance made by, or on behalf of, a person who, at the time of the gift or death, is or is deemed to be resident of the Netherlands.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">For purposes of Dutch gift and inheritance taxes, among others, a person that holds the Dutch nationality will be deemed to be resident of the Netherlands if such person has been resident in the Netherlands at any time during the ten (10) years preceding the date of the gift or such person&#8217;s death. Additionally, for purposes of Dutch gift tax, amongst others, a person not holding the Dutch nationality will be deemed to be resident of the Netherlands if such person has been resident in the Netherlands at any time during the twelve (12) months preceding the date of the gift. Applicable tax treaties may override deemed residency.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 9.35pt;"><font style="font-style:italic;font-weight:bold;">Value Added Tax (VAT)</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">No Dutch VAT will be payable by a holder of common shares in respect of any payment in consideration for the holding or disposal of the common shares.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;"><i style="font-style:italic;">Other Taxes and Duties</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">No Dutch registration tax, stamp duty or any other similar documentary tax or duty will be payable by a holder of common shares in respect of any payment in consideration for the holding or disposal of the common shares.</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>cvac-20220930xex99d1001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 cvac-20220930xex99d1001.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" !E 2(# 2(  A$! Q$!_\0
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M2?VMT..?[0M>/^V451FN+J8.-)T_M347Z,UR3 T<?.LJVT(2DM;:JUCZ]!R
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MA0O&-91NGJU=V.9U#]KCPK;7;Q6NGZI>Q*<":.) K?0,X/YBJ_\ PV#X=_Z
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M:%IZ1K:Q8'V9#_ .22,D^YK;_P"$*T ?\P33\_\ 7JG^%=+J8&+:]D_O_P"
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M7;R:+XKNM.B?JKP[FQV&Y67^5,_X96UO'_(^W/\ X#O_ /':XL-AJU"E&E/
MQDXJU[QU\]5<]+%XK#XJM.O3S*4(R=U&T]+]-';0]<\*?"[PIX)U%[[1M,CL
MKMXS$TBS.Y*$@D89B.H'Y5UYR<>E?.O_  RMK7?Q]<C_ +=W_P#CM?0EE;FT
MM((2QD*(JES_ !8'6OHL!*I9PE0]FEM9II_<?)9G"ES*<,2ZTGNVFFNVKW/D
MC]M+X'^:O_">:-;9D7":G%$.HZ+-C\E;_@)[&OF34OB?X@UCP%IG@ZYNR^C6
M$[311\[LGHI.>57+$#MN/MC]3[ZRAU2SGM+J))[:=&CDC<95E(P01Z$&OE7P
M/^Q\-"^.-UJ%XBS>$+ K>6*NP8S.2=D3#_8(R2>N%]3C]"P&8TXT7#$:N&L?
M\C\)XAX;Q%3&JME^BK>[.VRZMOR=OO.X_9-^"?\ PK3P<-8U*'R]?U=%DD#C
MYK>'JD?L3]YO? [5Y;^U7\3-2^)/BVV^&7A!)+_RY<7B0=9YQ_RSSTVI@DGI
MG_=KZX\2V%]J.@7MII=\NFWTT1CANVB\P0L>-VW(R1VYZXKR;X%_LT67P@UK
M4=9O-4/B#5[H;([EX/+\E2<OC+,2S'&3GH/<UYU'%P]K/%5G>7V5Y_\  /H<
M9E%=86CE.#CRTG\<KJ]NJMNVV>.> 8_V@/AMX:MM!T3P38PV<&YLLL9>1B<E
MF;S>3_0 =JR_BEX;^.OQ=TNVM-?\%6N+20RQSVRQ)*O&" WFG@\<>H'I7W-B
MAEP*:S-QG[14X\W>SN.7"L)T/JSQ-1PM:UU:RVTL?+W['?QCEU;3I/ 6NNR:
MQI886GG'#21*?FC/^TA[?W?]VN9_X* D_;_ _P#N7?\ Z%#7I/CO]EH:_P#%
M&'QQX=\1'PUJ:R).Z+:><K2KU<?.N-PZCG//J:[OXM?!K1OC+X>M]-UII([B
MV;S(+VUPKQ.1AL Y!4]P?0=Q6D<5AZ6+CB8;/==FU8Y)Y;F.(RBKEE57E&RC
M)M6DDTUZ.RMJ=3X0NX+KPOI,D,\<L36D162-P5/R#H16SYB'^)?SKY03]A_4
MK(>5IWQ&O+2T'W8A:-QZ])0/TIW_  Q1K_\ T5"]_P# 63_X]7/+#X1R;5?_
M ,E9Z5/,<VA!0>!>G]^)]6AU)&&!/IFE)R/K7@7PF_9GU7X:^,[;7;OQQ<ZY
M##&\9LY('0-N4C.3*W3.>G:O?3QSGI7GUH4Z<K4Y<R[VL?18*OB*])SQ%+V<
MK[73T[W08Y&.M-)5><@ 5S?C3XC^'/AYIYN_$.KVVG1G[BR-EY#Z*@^9C]!7
MR%\5_P!J7Q'\7+E_"O@#3;RUL[HF,R0@M=W*G@C"_<7GG!)]2!D5OAL%6Q+N
ME:/5O8\W,\\PF61M*7-4>T5JV_3H<E^U]\3;7XB?$J.RTIQ<6&CQFT65.1)*
M6S(5/<9PO_ <]Z^L_P!EWP!=_#[X0Z;:7Z-%?7C/?30N,&,OC:I'8A0N??->
M9?L^?L@IX9N[3Q%XT2*ZU*,K+;:8IW1V[#D-(>C,..!P#Z]OJH<<"O1S#$TO
M91PE#6,=WW/GN'LJQ3Q53-\>N6=3:/9.V_W(=2T45X!^B!1110 5')$DR,CH
MKJPP0PR"*DHI-7W&G;8\F\<?LW^$O&'F3Q6QTB^<Y,UEA5)]T/R_E@^]>%^*
M_P!E'Q5H9DETB:'68%Y41MY4A'^ZQQ^3&OLND[&OGL7D6"QEY2ARR[K3_@'T
M^!XES' )1C4YHKI+7_@_B? =OX@^(/PQF""XU32 IP(IPWEG_@+#:>GI7=:!
M^UUXIT\A-3LK34TSUP8G_,<?^.U]=W-E!>PM%/!'-&W59%!!_ UPFN? 7P/K
MY=IM!@MI7ZO9DPG\E('Z5X_]B8_"?[GB7;L]OU_(^A_UCRO'+_A0P:OWC:_Z
M/\6=3X1U_P#X2CPOI>L>3]G:]MXY_*W;MFY0<9XSC-;>169X?T2W\.:)8Z7:
M[OLUI"L$6]MS;5&!D]^!6E@5]K24E"*J;V5_4_.JKBZDG#X;NWIT%I:**U,P
MHHHH ***89$!P64'ZT";2W'T4WS4_OK^=&]?[P_.G87,NXZBF[U_O#\Z/,3^
M\OYTK!S+N.IN1FCS$_O+^=5YKZWMTW2W$<2],NX S^--)LESBMV6.?2CD5B7
MGC7P_IZYN=:T^W&=N9+I%Y].36'?_&OP%ISB.X\7:/$Y&0#>(>/P-:1I5);1
M;^1SSQF&I_'4BO5I';\F@G\:\BU+]JOX8Z8C$^)4N&7C;:P2R$_3"XKD]2_;
M@\!VN19VVJZ@^#@1VZH"?^!,#^E;QP6)GM!_<>?4SS+:7Q5X_)W_ "/HD"C'
MXU\OS_M>^(=98)X;^&6JWV_:$EFWXW$],)&?YU!_PG?[17B]A_9OA2S\/0-T
MDN$56 ]_,<G_ ,=K=9?57QM1]6CB?$6$E_ C.I_AB_S:2/J=B .H'UKG_$'C
MSPYX2B9]8UNQTY5'/VFX5#^1.37SG_PHCXU>-@%\3_$8Z? _#QV4C]/]V,(I
M[=ZUM"_88\*V\GGZ[K6J:Y.W+C<L*,?PRW_CU4L-AJ?\6K?RBK_B]#-YEF>(
M_P!VPCBN\VE^"NS4\8?MJ^ _#Y:/2S=^()P,#[+%Y<6?]Y\'\@:\YG^-?QL^
M,;?9_!WAE]"T^7@7BQ]%/?SI,+_WR,U]%^%?@;X%\&R+)I?AFPBG48$\D?FR
M?]]/DC\*[M46-0J@*!Q@=*I8G"T?X-.[[R=_P6AD\MS7&_[YB>2/\M-6_%ZG
MR-X4_8IU/Q!?C5?B)XFGOKAR&DMK61I'<^C3/_0?C7TCX'^&GAKX<V'V3P_H
M]OIZD /*BYED]W<_,WXFNJYSZTFW/%<M?&5L1I.6G9:+[CU,#DN"R]\U&'O=
M9/5OYO\ 0<*6BBN(]X**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M!F>!BO&O'/[,>B^.O$=WK=QKVO6=Y=,"XMKM0H   105X48Z5[+C-<9\-/BG
MHWQ5M_$,NB^=Y>AZU=:%=>>FW-Q;L%D*\G*Y/!K6G5G2ES4W9G%B<)1QD%"O
M'F2U^9Y>W['.E* (O&_BN%!_"MZF/_0*0_LFW-G&J:9\3/%UD"VYPUX65OP7
M;S[\U?\ VW?&'B#P1^S-XOU#PGJ$^F>*)1:V>FW-J<2K/-<Q1*$/8G>1GWKV
M?0[>[L]&L(+ZX^UWT5O&EQ<8QYL@4!FQVR<G\:Z?KV(_F_!?Y'F?V#E_2G;T
M;7Y,\%D_93UJ5&1_BSXI=&&&5IW((]/]95.']C:194,OQ&\1/&#\RH^UB/8E
MCC\C7TJ![T9 JEC\0MI?@O\ (A\/Y=)W=.__ &]+_,^=6_8RTJ1]S^-O%3GU
M:[0G_P! HC_8C\'F0M<ZSKMVAY*27$?)]<[*^A+B=;>&25@=D:ECM!)P!G@#
MK7S=IW[9>I>*KR6+PO\  KXGZQ:I(8TO[G2HM/@D(.,@SRJ<?44OK^)Z392R
M#+>M%/UN_P V;EM^Q3\.(,>9!J5P0<Y>\89_[Y K;L_V3?AA9HB_\([YY48W
M2W4S$_7YJIZE^T5J7@W29]8\;_##Q1X4T*UB::[U0/:7\-I&HRTDHMYG=449
M)(4X ->P:7J5KK6FVFH6,Z75E=0I/!/&<K)&RAE8'T((-0\;B7O4?WFT<DRV
M&V'C]R.*T_X!?#S393)!X.TD.1C]Y;+(/R;(KJ=.\(:'HZ*MAH]A9JHPH@MD
M3 ]L"J7Q&\91?#GX?^)/%,UG/J,.B:=<:B]I:X\V98HV<HF>,D+@9JM\*/B=
MHGQD^'>@^-/#LYGT?6;5;F$MPZ9X9&'9E8,I'JIK"56I/>3?S.^G@\/2_ATX
MKT21UHC11P@'T%.P/2N#^+GQK\(_ WP]%K/B[4VL;::0Q00P6\ES<3L 6;RX
M8E9V"J"S$#"J"3BNE\+>*=)\;>'-/U[0K^#5-'U&!;FTO+=]T<T;#(8'_.*R
M.M)+8U\4M%% PHHHH **** &DA023@#N:RO#OB72/%NF#4=#U*UU:P,CQ+=6
M<JRQ,Z,5<!ER#A@0<=Q6)\9(+NY^$7CB&PE:"^DT*^2WE4X*2&W<*P^AP:Q?
MV:?"UCX+_9\^'&BZ=%Y5K;:!987N6:%6=C[EF8GW- 'IE0?:X?M'D>='Y^,^
M5N&['KCK7GO[0?BG5?"/PLU.[T:Z_L_4[F>UT^'4&4,+,W%Q' 9R#Q\@D+#/
M&0,U\F>$O"&AZY\>KOX?S:% MK'K.H6/_"17,#1:FXM[6&19X=5\SSI+P2RA
MFCQMV$G  Q0!]^45^6WB3_@I=\2/ASXBU7PF^FZ?X@?0;J72SJ[Q-NOC YB\
M\[>,OLW<<?-Q10!^I-%%% !1110 4444 %%%% !1110 4444 </\6OBE:?"#
MPBVO76BZWXB+7$=K!IOA^Q:[NYY7R%54& !QRS$ =S7SG\"/B1XH\,_$;XA^
M!]/^%]UI>J:MJLOC""#Q!J]O9N;:[" L%3S2VV6-U;83M+*#@FOL2N"^*'P=
MT'XK0V$FH->Z9K.F.TNF:[H]P;:_L'888Q2CLPX9&!5AU!H \?\ V@O&.JZ#
MX+\#W?Q+LM!T.QN/'VC1.UK?M-;6\*RF423RRQQ@8:(=L#(YKH=0^-WC3XER
M3O\ !30=&U_1K/)E\2^(KF6WL+]UZP67EJ6E.>#-_JU/3?SCK?#_ ,$8/^$=
MU+1O'&OW_P 4+&_="UOXJM[:6%%0Y4+$D2KG/)8@DX'2O1;*RM]-M(;6T@CM
M;:%!'%!"@1(U P%51P !V% 'D,/[36@WG[.6H_%BW@(@T^PEGN]+EE42VEU&
M2DEM,1]PK*"K$C@#=C%>/?#/P-\:?&_[3]KXKUWQCX@MO VA6S&[A5TM]*UF
M[D3*Q6-NN2UK&&'[^0EI&7(QV]S\/_LR?#CPUXH\>Z[9>'HOM/CE0FO6TKM)
M:W0P0_[DG8N_<2V!R3FF_"K]GK2O@Q=1Q>&/$?B>+P["C1P>&;[4OM>GVZG.
M!$)%:1 ,\*'P, 8Q0!ZQ7A6F>(M6TG]L_7M N[V9]%UGP7::C86C2,4CFMKN
M:.<JO0$B>+..N%KW6L6Z\*:5>>)K#Q#-91OK-C;S6EO>'.^.&4HTB>X)C0\_
MW: /CKP_\4K/]K'XE^,/A[\4=<;X=Z=I%^UHGPTED-E=:Y;@C;/<7+$&:)SG
M]S#@8 W%@:^A?CKXXC^%?P7U@>&I[6RU=(K?1-&ACP5M[JX9;>U&P=E9U;'<
M(:Z?XA_!SP-\6;6.W\9>$M(\2)%_JFU&T25X_P#<<C<OX$5PP_9$^&]A)X:7
M0]%7P]INC:[%XC;3],.R&^O(HV2!Y\Y+B/<&49ZJ* .@^"GB*_\ '7POM[/Q
M8(KCQ)IXET3Q!#M^1[J']W*VW^[(,2#L5D6OE#]DOXK:-^RY^RG\4=6\0"9?
M"OA7QKJ^G:);I_K;Q1,%C@BSU+2;E]!\Q/0U]/?%#]GNT^(NNKK>F^+_ !3X
M!U>54AO[KPK?BV.H1+]U9E9&4LHR%< . <9Q@#?M?@=X$A\)>'/#+>&K*YT3
MP_=1WVG6MRGF+%<H6*SG/WI-S,Q9LDLQ)YH ^0/A'^T!9Z+XSU+Q5\0=(\0>
M//CGJT2A/!WA329;W_A%-.D >*RW';%"[*5>5F8,Q(!Z5I_ KXB^*/@5\:9M
M"U_X<:S\/?@]X^U(_P#"/1:M<02C2=6D!9X-L+,(8;ALLJ-]U\@<$X^X+>QM
M[.2>2"WCADG;?*T:!3(V,98CJ< <FB[LX+Z+R[B&.>,,'"2H&&X'(.#W!&10
M!:KQ+XL_$?7K[Q3?^"?"&O:3X/N-/T^#4-8\5:S")H=/6>5H[>*.)F5'ED9'
M/SMM  X8L!7MM> ZE9Z++^U9KGAC6[:TO[#QCX+@G?3[V%9([EK.ZD1P0V0<
M)<H<>V: //?"_P"T7X[^$=E\;K7XD:KIWQ M? %O9W-GXATNT6Q^US7*G993
M(I*)(K&+)7H) 37/>&1\?-3_ &C[#4[OQ3XB;PKX?66Y\6^=IL=KH$P\K<ME
MI<.TS7)7.#<,W) /L?K.Z^%?A&[\":AX+?P]8)X6OH'MKG2H81'#(CC# A<<
MGUZ].:SOA?\ ".T^%5A'86'B+Q'JVGP1""WM=:U(W:6\8QM1"PW84  %B3CO
M0!\D>#/VA;KX]>%+_P 8_$/Q?X7T?P+JD4J^&_!GAFZDD\417BOM@??&X?[1
MD']VJE<N,@ 5[3K/Q:\3>'],T3PCK&N6?A77-/\ "$?B'Q5XIU"W%PE@@(B.
MR,$(TC2"0EC\JA"<'(KUGP_\&O GA3Q)<^(=%\&:#I6NW)9I=2L].BBN'+?>
M)=5!Y[\\UPOQ)ET[PA^T!\/]9O\ RC:^*[.[\'W"3H"CN1]JMU.>N3%.F#UW
MT <7X"^+.O:O#\3]#G\86'Q.T#3?#@U>P\7:;:1PH&ECFS:2F$F)W41JX*8.
MU_F&<5F:U\4Y&\'?#[P#!>ZQ8S7?@.'7YH?#H U754CCAC%E8L<;78L6=E.Y
M5 P5R6'TNO@W1(O#%WX=M-,M=.T6Y@DMWL[&)8(PCJ5;"H !D$\BN'\5_LS_
M  _\:^!?#7A35M'DN++PW#%#H]]'=217UAY:!%>*Y1A(K849(/..: /,OV2O
MV?-?\/\ P&\3^'?B>M]=Q>*=3N[Q= U;4WU"73+&4*(K9IR23(H7<64\,01R
M*Z.3]G#Q.]L-)/Q&!T(7?VU;HZ!;G6EEV[/,%[G'G^6-GG^5YF.^>:]<\$>$
M#X(T!-*&N:OKZ1N6CNM;N1<7"J<80R;06 QP6R>>2:Z2@#A=(^"_@?0]*LM-
MM?"^F?9K.!+>+SK99'V(H5=SMDL< 9).3U-%=U10 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %<'XB^$6E^
M(OBWX/\ B!+<7$&L>&K6]LX8XR/+GBN50,KC_9,:D8[YHHH [RBBB@ KYT_;
M@\)CQ#\,O"VJ17DEAJ'A_P 8:+J=I-&,D2?:TA(ZC@K,U%% 'T71110 4444
' %%%% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>6
<FILENAME>cvac-20220930.xsd
<DESCRIPTION>EX-101.SCH
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  10.1.0.3 -->
<!--Based on XBRL 2.1-->
<!--Created on: 11/17/2022 10:28:01 PM-->
<!--Modified on: 11/17/2022 10:28:01 PM-->
<xsd:schema targetNamespace="http://www.curevac.com/20220930" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:cvac="http://www.curevac.com/20220930" xmlns:deprecated="http://www.xbrl.org/2009/role/deprecated" xmlns:currency="http://xbrl.sec.gov/currency/2021" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:fact-explanatoryFact="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:ifrs-full="http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full" xmlns:srt-roles="http://fasb.org/srt-roles/2021-01-31" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:stpr="http://xbrl.sec.gov/stpr/2021" xmlns:sic="http://xbrl.sec.gov/sic/2021" xmlns:srt-types="http://fasb.org/srt-types/2021-01-31" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:country="http://xbrl.sec.gov/country/2021" xmlns:net="http://www.xbrl.org/2009/role/net" xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:naics="http://xbrl.sec.gov/naics/2021" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:exch="http://xbrl.sec.gov/exch/2021" xmlns:attributeFormDefault="unqualified" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:srt="http://fasb.org/srt/2021-01-31">
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfOperationsAndOtherComprehensiveIncomeLoss" id="StatementInterimCondensedConsolidatedStatementsOfOperationsAndOtherComprehensiveIncomeLoss">
        <link:definition>00100 - Statement - Interim Condensed Consolidated Statements of Operations and Other Comprehensive Income (Loss)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition" id="StatementInterimCondensedConsolidatedStatementsOfFinancialPosition">
        <link:definition>00200 - Statement - Interim Condensed Consolidated Statements of Financial Position</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows" id="StatementInterimCondensedConsolidatedStatementsOfCashFlows">
        <link:definition>00400 - Statement - Interim Condensed Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsCostOfSalesDetails" id="DisclosureNotesToConsolidatedFinancialStatementsCostOfSalesDetails">
        <link:definition>40304 - Disclosure - Notes to the consolidated financial statements - Cost of sales (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsOtherOperatingIncomeDetails" id="DisclosureNotesToConsolidatedFinancialStatementsOtherOperatingIncomeDetails">
        <link:definition>40308 - Disclosure - Notes to the consolidated financial statements - Other operating income (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.curevac.com/role/DisclosureShareBasedPaymentsExpensesDetails" id="DisclosureShareBasedPaymentsExpensesDetails">
        <link:definition>40501 - Disclosure - Share-based payments - Expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.curevac.com/role/DisclosureSignificantTransactionsAndEventsFrameAcquisitionPurchasePriceAllocationDetails" id="DisclosureSignificantTransactionsAndEventsFrameAcquisitionPurchasePriceAllocationDetails">
        <link:definition>41802 - Disclosure - Significant transactions and events - Frame Acquisition - Purchase Price Allocation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.curevac.com/role/DisclosureSignificantTransactionsAndEventsGoodwillRecognizedOnFrameAcquisitionDetails" id="DisclosureSignificantTransactionsAndEventsGoodwillRecognizedOnFrameAcquisitionDetails">
        <link:definition>41803 - Disclosure - Significant transactions and events - Goodwill Recognized On Frame Acquisition (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.curevac.com/role/DisclosureSignificantTransactionsAndEventsAnalysesOfCashFlowsOnFrameAcquisitionDetails" id="DisclosureSignificantTransactionsAndEventsAnalysesOfCashFlowsOnFrameAcquisitionDetails">
        <link:definition>41804 - Disclosure - Significant transactions and events - Analyses of cash flows on Frame Acquisition (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.curevac.com/role/DocumentDocumentAndEntityInformation" id="DocumentDocumentAndEntityInformation">
        <link:definition>00090 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfChangesInShareholdersEquity" id="StatementInterimCondensedConsolidatedStatementsOfChangesInShareholdersEquity">
        <link:definition>00300 - Statement - Interim Condensed Consolidated Statements of Changes in Shareholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.curevac.com/role/DisclosureShareBasedPaymentsTables" id="DisclosureShareBasedPaymentsTables">
        <link:definition>30503 - Disclosure - Share-based payments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.curevac.com/role/DisclosureCorporateInformationDetails" id="DisclosureCorporateInformationDetails">
        <link:definition>40101 - Disclosure - Corporate Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsRevenueFromContractWithCustomersDetails" id="DisclosureNotesToConsolidatedFinancialStatementsRevenueFromContractWithCustomersDetails">
        <link:definition>40301 - Disclosure - Notes to the consolidated financial statements - Revenue from contract with customers (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsSummaryOfUpfrontPaymentsAndRelatedRevenuesRecognizedDetails" id="DisclosureNotesToConsolidatedFinancialStatementsSummaryOfUpfrontPaymentsAndRelatedRevenuesRecognizedDetails">
        <link:definition>40302 - Disclosure - Notes to the consolidated financial statements - Summary of upfront payments and related revenues recognized (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsContractLiabilitiesAllocatedToRemainingPerformanceObligationsDetails" id="DisclosureNotesToConsolidatedFinancialStatementsContractLiabilitiesAllocatedToRemainingPerformanceObligationsDetails">
        <link:definition>40303 - Disclosure - Notes to the consolidated financial statements - Contract liabilities allocated to the remaining performance obligations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsSellingAndDistributionExpensesDetails" id="DisclosureNotesToConsolidatedFinancialStatementsSellingAndDistributionExpensesDetails">
        <link:definition>40305 - Disclosure - Notes to the consolidated financial statements - Selling and distribution expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsResearchAndDevelopmentExpensesDetails" id="DisclosureNotesToConsolidatedFinancialStatementsResearchAndDevelopmentExpensesDetails">
        <link:definition>40306 - Disclosure - Notes to the consolidated financial statements - Research and development expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsGeneralAndAdministrativeExpensesDetails" id="DisclosureNotesToConsolidatedFinancialStatementsGeneralAndAdministrativeExpensesDetails">
        <link:definition>40307 - Disclosure - Notes to the consolidated financial statements - General and administrative expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsGrantsWithGovernmentAgenciesAndSimilarBodiesDetails" id="DisclosureNotesToConsolidatedFinancialStatementsGrantsWithGovernmentAgenciesAndSimilarBodiesDetails">
        <link:definition>40309 - Disclosure - Notes to the consolidated financial statements - Grants with government agencies and similar bodies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.curevac.com/role/DisclosureIssuedCapitalAndReservesOverviewAndGeneralRemarksDetails" id="DisclosureIssuedCapitalAndReservesOverviewAndGeneralRemarksDetails">
        <link:definition>40401 - Disclosure - Issued Capital and Reserves - Overview and General Remarks (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.curevac.com/role/DisclosureIssuedCapitalAndReservesImpactOfShareSplitDetails" id="DisclosureIssuedCapitalAndReservesImpactOfShareSplitDetails">
        <link:definition>40402 - Disclosure - Issued Capital and Reserves - Impact of share split (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.curevac.com/role/DisclosureShareBasedPaymentsExpenseRecognizedForProgramDetails" id="DisclosureShareBasedPaymentsExpenseRecognizedForProgramDetails">
        <link:definition>40502 - Disclosure - Share-based payments - Expense recognized for the program (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.curevac.com/role/DisclosureShareBasedPaymentsDetails" id="DisclosureShareBasedPaymentsDetails">
        <link:definition>40503 - Disclosure - Share-based payments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.curevac.com/role/DisclosureFixedAssetsIntangibleAssetsDetails" id="DisclosureFixedAssetsIntangibleAssetsDetails">
        <link:definition>40601 - Disclosure - Fixed Assets - Intangible assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.curevac.com/role/DisclosureFixedAssetsPropertyPlantAndEquipmentDetails" id="DisclosureFixedAssetsPropertyPlantAndEquipmentDetails">
        <link:definition>40602 - Disclosure - Fixed Assets - Property, plant and equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.curevac.com/role/DisclosureInventoriesDetails" id="DisclosureInventoriesDetails">
        <link:definition>40801 - Disclosure - Inventories (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.curevac.com/role/DisclosureOtherLiabilitiesDetails" id="DisclosureOtherLiabilitiesDetails">
        <link:definition>41201 - Disclosure - Other liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.curevac.com/role/DisclosureLoansDetails" id="DisclosureLoansDetails">
        <link:definition>41301 - Disclosure - Loans (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.curevac.com/role/DisclosureIncomeTaxDetails" id="DisclosureIncomeTaxDetails">
        <link:definition>41401 - Disclosure - Income tax (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.curevac.com/role/DisclosureDisclosureOfFinancialInstrumentsAndRiskManagementDetails" id="DisclosureDisclosureOfFinancialInstrumentsAndRiskManagementDetails">
        <link:definition>41501 - Disclosure - Disclosure of financial instruments and risk management (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.curevac.com/role/DisclosureRelatedPartyDisclosuresDetails" id="DisclosureRelatedPartyDisclosuresDetails">
        <link:definition>41701 - Disclosure - Related party disclosures (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.curevac.com/role/DisclosureSignificantTransactionsAndEventsDetails" id="DisclosureSignificantTransactionsAndEventsDetails">
        <link:definition>41801 - Disclosure - Significant transactions and events (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.curevac.com/role/DisclosureCorporateInformation" id="DisclosureCorporateInformation">
        <link:definition>10101 - Disclosure - Corporate Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.curevac.com/role/DisclosureBasisOfPreparation" id="DisclosureBasisOfPreparation">
        <link:definition>10201 - Disclosure - Basis of preparation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatements" id="DisclosureNotesToConsolidatedFinancialStatements">
        <link:definition>10301 - Disclosure - Notes to the consolidated financial statements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.curevac.com/role/DisclosureIssuedCapitalAndReserves" id="DisclosureIssuedCapitalAndReserves">
        <link:definition>10401 - Disclosure - Issued Capital and Reserves</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.curevac.com/role/DisclosureShareBasedPayments" id="DisclosureShareBasedPayments">
        <link:definition>10501 - Disclosure - Share-based payments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.curevac.com/role/DisclosureFixedAssets" id="DisclosureFixedAssets">
        <link:definition>10601 - Disclosure - Fixed Assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.curevac.com/role/DisclosureAssetsHeldForSale" id="DisclosureAssetsHeldForSale">
        <link:definition>10701 - Disclosure - Assets held for sale</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.curevac.com/role/DisclosureInventories" id="DisclosureInventories">
        <link:definition>10801 - Disclosure - Inventories</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.curevac.com/role/DisclosurePrepaidExpensesAndOtherAssetsCurrent" id="DisclosurePrepaidExpensesAndOtherAssetsCurrent">
        <link:definition>10901 - Disclosure - Prepaid expenses and other assets (current)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.curevac.com/role/DisclosureFinancialAssetsAndFinancialLiabilities" id="DisclosureFinancialAssetsAndFinancialLiabilities">
        <link:definition>11001 - Disclosure - Financial assets and financial liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.curevac.com/role/DisclosureTradeAndOtherPayables" id="DisclosureTradeAndOtherPayables">
        <link:definition>11101 - Disclosure - Trade and other payables</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.curevac.com/role/DisclosureOtherLiabilities" id="DisclosureOtherLiabilities">
        <link:definition>11201 - Disclosure - Other liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.curevac.com/role/DisclosureLoans" id="DisclosureLoans">
        <link:definition>11301 - Disclosure - Loans</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.curevac.com/role/DisclosureIncomeTax" id="DisclosureIncomeTax">
        <link:definition>11401 - Disclosure - Income tax</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.curevac.com/role/DisclosureDisclosureOfFinancialInstrumentsAndRiskManagement" id="DisclosureDisclosureOfFinancialInstrumentsAndRiskManagement">
        <link:definition>11501 - Disclosure - Disclosure of financial instruments and risk management</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.curevac.com/role/DisclosureEarningsPerShare" id="DisclosureEarningsPerShare">
        <link:definition>11601 - Disclosure - Earnings per share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.curevac.com/role/DisclosureRelatedPartyDisclosures" id="DisclosureRelatedPartyDisclosures">
        <link:definition>11701 - Disclosure - Related party disclosures</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.curevac.com/role/DisclosureSignificantTransactionsAndEvents" id="DisclosureSignificantTransactionsAndEvents">
        <link:definition>11801 - Disclosure - Significant transactions and events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.curevac.com/role/DisclosureSubsequentEvents" id="DisclosureSubsequentEvents">
        <link:definition>11901 - Disclosure - Subsequent events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.curevac.com/role/DisclosureBasisOfPreparationPolicies" id="DisclosureBasisOfPreparationPolicies">
        <link:definition>20202 - Disclosure - Basis of preparation (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsTables" id="DisclosureNotesToConsolidatedFinancialStatementsTables">
        <link:definition>30303 - Disclosure - Notes to the consolidated financial statements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.curevac.com/role/DisclosureIssuedCapitalAndReservesTables" id="DisclosureIssuedCapitalAndReservesTables">
        <link:definition>30403 - Disclosure - Issued Capital and Reserves (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.curevac.com/role/DisclosureSignificantTransactionsAndEventsTables" id="DisclosureSignificantTransactionsAndEventsTables">
        <link:definition>31803 - Disclosure - Significant transactions and events (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.curevac.com/role/DisclosureAssetsHeldForSaleDetails" id="DisclosureAssetsHeldForSaleDetails">
        <link:definition>40701 - Disclosure - Assets held for sale (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.curevac.com/role/DisclosurePrepaidExpensesAndOtherAssetsCurrentDetails" id="DisclosurePrepaidExpensesAndOtherAssetsCurrentDetails">
        <link:definition>40901 - Disclosure - Prepaid expenses and other assets (current) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.curevac.com/role/DisclosureFinancialAssetsAndFinancialLiabilitiesDetails" id="DisclosureFinancialAssetsAndFinancialLiabilitiesDetails">
        <link:definition>41001 - Disclosure - Financial assets and financial liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.curevac.com/role/DisclosureTradeAndOtherPayablesDetails" id="DisclosureTradeAndOtherPayablesDetails">
        <link:definition>41101 - Disclosure - Trade and other payables (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.curevac.com/role/DisclosureEarningsPerShareDetails" id="DisclosureEarningsPerShareDetails">
        <link:definition>41601 - Disclosure - Earnings per share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:type="simple" xlink:href="cvac-20220930_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="cvac-20220930_cal.xml" xlink:title="Calculation Links, all" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="cvac-20220930_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="cvac-20220930_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:roleType roleURI="http://www.curevac.com/role/DisclosureStandardAndCustomAxisDomainDefaults" id="DisclosureStandardAndCustomAxisDomainDefaults">
        <link:definition>99900 - Disclosure - Standard And Custom Axis Domain Defaults</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:import namespace="http://xbrl.sec.gov/dei/2021q4" schemaLocation="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/country/2021" schemaLocation="https://xbrl.sec.gov/country/2021/country-2021.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/currency/2021" schemaLocation="https://xbrl.sec.gov/currency/2021/currency-2021.xsd" />
  <xsd:import namespace="http://fasb.org/srt/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd" />
  <xsd:import namespace="http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full" schemaLocation="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd" />
  <xsd:element name="CorporateInformationAbstract" id="cvac_CorporateInformationAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="CorporateInformationTextBlock" id="cvac_CorporateInformationTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="CurevacN.v.Member" id="cvac_CurevacN.v.Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="CorporateReorganizationStockSplitRatio" id="cvac_CorporateReorganizationStockSplitRatio" type="xbrli:pureItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ChangesInWorkingCapitalAbstract" id="cvac_ChangesInWorkingCapitalAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ReceiptsFromGovernmentGrantsClassifiedAsOperatingActivities" id="cvac_ReceiptsFromGovernmentGrantsClassifiedAsOperatingActivities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="IfrsProductMember" id="cvac_IfrsProductMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="DisclosureOfNotesToConsolidatedFinancialStatementsAbstract" id="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="DisclosureOfUpfrontPaymentsAndRelatedRevenuesRecognizedExplanatory" id="cvac_DisclosureOfUpfrontPaymentsAndRelatedRevenuesRecognizedExplanatory" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="EliLillyAndCompanyMember" id="cvac_EliLillyAndCompanyMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="BoehringerIngelheimMember" id="cvac_BoehringerIngelheimMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="OtherCustomersMember" id="cvac_OtherCustomersMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="CrisprMember" id="cvac_CrisprMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ResearchServicesCombinedWithIpLicenseMember" id="cvac_ResearchServicesCombinedWithIpLicenseMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ResearchAndDevelopmentServicesMember" id="cvac_ResearchAndDevelopmentServicesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="GenmabMember" id="cvac_GenmabMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="UpfrontPaymentsReceivedOrReceivable" id="cvac_UpfrontPaymentsReceivedOrReceivable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element name="UpfrontPaymentsIncludedInContractLiabilities" id="cvac_UpfrontPaymentsIncludedInContractLiabilities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element name="IfrsIncomeStatementLocationAxis" id="cvac_IfrsIncomeStatementLocationAxis" type="xbrli:stringItemType" substitutionGroup="xbrldt:dimensionItem" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="IfrsIncomeStatementLocationDomain" id="cvac_IfrsIncomeStatementLocationDomain" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="IfrsCostOfSalesMember" id="cvac_IfrsCostOfSalesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="PersonnelExpenses" id="cvac_PersonnelExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="ThirdPartyServiceExpenses" id="cvac_ThirdPartyServiceExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="MaintenanceAndLeaseExpenses" id="cvac_MaintenanceAndLeaseExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="SellingAndDistributionExpensesMember" id="cvac_SellingAndDistributionExpensesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="IfrsResearchAndDevelopmentExpenseMember" id="cvac_IfrsResearchAndDevelopmentExpenseMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="PatentsAndFeesToRegisterLegalRight" id="cvac_PatentsAndFeesToRegisterLegalRight" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="ReversalOfProvisionsForPersonnelExpenses" id="cvac_ReversalOfProvisionsForPersonnelExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element name="IfrsGeneralAndAdministrativeExpenseMember" id="cvac_IfrsGeneralAndAdministrativeExpenseMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="MiscellaneousOtherOperatingIncomeOther" id="cvac_MiscellaneousOtherOperatingIncomeOther" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element name="DisclosureOfGovernmentGrantsTable" id="cvac_DisclosureOfGovernmentGrantsTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="GovernmentGrantsAxis" id="cvac_GovernmentGrantsAxis" type="xbrli:stringItemType" substitutionGroup="xbrldt:dimensionItem" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="GovernmentGrantsDomain" id="cvac_GovernmentGrantsDomain" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="CoalitionForEpidemicPreparednessInnovationsMember" id="cvac_CoalitionForEpidemicPreparednessInnovationsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="BillAndMelindaGatesFoundationBmgfMember" id="cvac_BillAndMelindaGatesFoundationBmgfMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="BillMelindaGatesFoundationBmgfGrantForDevelopmentOfUniversalInfluenzaVaccineMember" id="cvac_BillMelindaGatesFoundationBmgfGrantForDevelopmentOfUniversalInfluenzaVaccineMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="BillMelindaGatesFoundationBmgfGrantForMalariaVaccineMember" id="cvac_BillMelindaGatesFoundationBmgfGrantForMalariaVaccineMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="DisclosureOfGovernmentGrantsLineItems" id="cvac_DisclosureOfGovernmentGrantsLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="PartnershipAgreementMaximumAmount" id="cvac_PartnershipAgreementMaximumAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element name="PartnershipAgreementTerm" id="cvac_PartnershipAgreementTerm" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="PartnershipAgreementPeriodOfCostsToBeCovered" id="cvac_PartnershipAgreementPeriodOfCostsToBeCovered" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="AmountDeductedFromCarryingAmountOfQualifyingAssets" id="cvac_AmountDeductedFromCarryingAmountOfQualifyingAssets" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element name="NumberOfAdditionalGrantsReceived" id="cvac_NumberOfAdditionalGrantsReceived" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="DisclosureOfFixedAssetsAbstract" id="cvac_DisclosureOfFixedAssetsAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="DisclosureOfFixedAssetsExplanatory" id="cvac_DisclosureOfFixedAssetsExplanatory" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="DisclosureOfPrepaidExpensesAndOtherCurrentAssetsAbstract" id="cvac_DisclosureOfPrepaidExpensesAndOtherCurrentAssetsAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="DisclosureOfPrepaidExpensesAndOtherCurrentAssetsExplanatory" id="cvac_DisclosureOfPrepaidExpensesAndOtherCurrentAssetsExplanatory" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="SeriesSharesMember" id="cvac_SeriesSharesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="SeriesCSharesMember" id="cvac_SeriesCSharesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="VirtualSharesProgramIMember" id="cvac_VirtualSharesProgramIMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="VirtualSharesProgramIiMember" id="cvac_VirtualSharesProgramIiMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="OptionsGrantedToThenChiefExecutiveOfficerMember" id="cvac_OptionsGrantedToThenChiefExecutiveOfficerMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInResearchAndDevelopmentExpenses" id="cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInResearchAndDevelopmentExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInGeneralAndAdministrativeExpenses" id="cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInGeneralAndAdministrativeExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="IfrsVestingAxis" id="cvac_IfrsVestingAxis" type="xbrli:stringItemType" substitutionGroup="xbrldt:dimensionItem" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="IfrsVestingDomain" id="cvac_IfrsVestingDomain" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="IfrsShareBasedPaymentArrangementTrancheOneMember" id="cvac_IfrsShareBasedPaymentArrangementTrancheOneMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInSellingAndDistributionExpenses" id="cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInSellingAndDistributionExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="BenefitExpenseRecognizedForShareBasedPayment" id="cvac_BenefitExpenseRecognizedForShareBasedPayment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="ExpenseRecognizedForEmployeeServices" id="cvac_ExpenseRecognizedForEmployeeServices" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="DisclosureOfExpenseRecognizedForEmployeeServicesExplanatory" id="cvac_DisclosureOfExpenseRecognizedForEmployeeServicesExplanatory" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="RittershausRechtsanwaelteMember" id="cvac_RittershausRechtsanwaelteMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="Dr.IngmarHoerrMember" id="cvac_Dr.IngmarHoerrMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="DietmarHoppMember" id="cvac_DietmarHoppMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="RelatedPartyTransactionNoticePeriodForTerminationOfAgreement" id="cvac_RelatedPartyTransactionNoticePeriodForTerminationOfAgreement" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="RelatedPartyTransactionConsultingFees" id="cvac_RelatedPartyTransactionConsultingFees" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="RelatedPartyTransactionAdvisoryFees" id="cvac_RelatedPartyTransactionAdvisoryFees" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="RelatedPartyTransactionNumberOfLoansReceived" id="cvac_RelatedPartyTransactionNumberOfLoansReceived" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ManagementBoardMember" id="cvac_ManagementBoardMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="OtherOperatingIncomeGovernmentGrants" id="cvac_OtherOperatingIncomeGovernmentGrants" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element name="FinancialInstrumentsAndRiskManagementAbstract" id="cvac_FinancialInstrumentsAndRiskManagementAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="IfrsCashAndCashEquivalentsMember" id="cvac_IfrsCashAndCashEquivalentsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="OtherExpense" id="cvac_OtherExpense" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="AdjustmentsForIncreaseDecreaseInOtherCurrentFinancialAndOtherLiabilities" id="cvac_AdjustmentsForIncreaseDecreaseInOtherCurrentFinancialAndOtherLiabilities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="IfrsOtherLiabilitiesAbstract" id="cvac_IfrsOtherLiabilitiesAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="DescriptionOfAccountingPolicyForPreLaunchProductsExplanatory" id="cvac_DescriptionOfAccountingPolicyForPreLaunchProductsExplanatory" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="DescriptionOfAccountingPolicyForCovid19ImpactExplanatory" id="cvac_DescriptionOfAccountingPolicyForCovid19ImpactExplanatory" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="IfrsIncreaseDecreaseInPrepaidExpenseAndOtherAssets" id="cvac_IfrsIncreaseDecreaseInPrepaidExpenseAndOtherAssets" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element name="GlaxosmithklineMember" id="cvac_GlaxosmithklineMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="GermanFederalMinistryOfEducationAndResearchMember" id="cvac_GermanFederalMinistryOfEducationAndResearchMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="EuropeanCommissionMember" id="cvac_EuropeanCommissionMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="NumberOfDosesOfSarsCov2CanBePurchasedByMemberStatesUnderAdvancePurchaseAgreement" id="cvac_NumberOfDosesOfSarsCov2CanBePurchasedByMemberStatesUnderAdvancePurchaseAgreement" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="RealEstateTransferTaxes" id="cvac_RealEstateTransferTaxes" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="MaximumGrantToBeReceived" id="cvac_MaximumGrantToBeReceived" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element name="IfrsStockholdersEquityNoteStockSplitConversionRatio" id="cvac_IfrsStockholdersEquityNoteStockSplitConversionRatio" type="xbrli:pureItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="IfrsSaleOfStockAxis" id="cvac_IfrsSaleOfStockAxis" type="xbrli:stringItemType" substitutionGroup="xbrldt:dimensionItem" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="IfrsSaleOfStockDomain" id="cvac_IfrsSaleOfStockDomain" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="CapitalIncreaseByGenmabMember" id="cvac_CapitalIncreaseByGenmabMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="PrivatePlacementIsa2020Member" id="cvac_PrivatePlacementIsa2020Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ExerciseOfGreenshoeMember" id="cvac_ExerciseOfGreenshoeMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ExerciseOfOptionsMember" id="cvac_ExerciseOfOptionsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="IncreaseInNumberOfSharesOutstanding" id="cvac_IncreaseInNumberOfSharesOutstanding" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="IfrsOverAllotmentOptionMember" id="cvac_IfrsOverAllotmentOptionMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="BepharbelManufacturingS.aMember" id="cvac_BepharbelManufacturingS.aMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="BaronJeanStephenneMember" id="cvac_BaronJeanStephenneMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="VincentStphenneMember" id="cvac_VincentStphenneMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="AmountPaidAtSigningOfAgreementRelatedPartyTransactions" id="cvac_AmountPaidAtSigningOfAgreementRelatedPartyTransactions" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="TerminationFeeRelatedPartyTransactions" id="cvac_TerminationFeeRelatedPartyTransactions" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="RepaymentsOfPrincipalAmountOfBorrowings" id="cvac_RepaymentsOfPrincipalAmountOfBorrowings" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element name="IfrsLineOfCreditMember" id="cvac_IfrsLineOfCreditMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="CollaborationAgreementMilestonePayment" id="cvac_CollaborationAgreementMilestonePayment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element name="RightToExercisePercentageOfVestedVirtualShares" id="cvac_RightToExercisePercentageOfVestedVirtualShares" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ProvisionForEmployerTaxes" id="cvac_ProvisionForEmployerTaxes" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="LockUpPeriodAfterInitialListing" id="cvac_LockUpPeriodAfterInitialListing" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="LongTermIncentivePlanMember" id="cvac_LongTermIncentivePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ChiefScientificOfficerMember" id="cvac_ChiefScientificOfficerMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ChiefBusinessOfficerAndChiefCommercialOfficerMember" id="cvac_ChiefBusinessOfficerAndChiefCommercialOfficerMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ThenChiefExecutiveOfficerMember" id="cvac_ThenChiefExecutiveOfficerMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="NumberOfShareOptionsVestedInShareBasedPaymentArrangement" id="cvac_NumberOfShareOptionsVestedInShareBasedPaymentArrangement" type="xbrli:decimalItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="InitialPublicOfferingAndPrivatePlacementMember" id="cvac_InitialPublicOfferingAndPrivatePlacementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="CommonSharesIssuedAndOutstanding" id="cvac_CommonSharesIssuedAndOutstanding" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" />
  <xsd:element name="ShareOptionExercises" id="cvac_ShareOptionExercises" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="LineOfCreditAccruedInterestPayable" id="cvac_LineOfCreditAccruedInterestPayable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element name="DisclosureOfBasisOfPreparationAbstract" id="cvac_DisclosureOfBasisOfPreparationAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="DisclosureOfBasisOfPreparationExplanatoryTextBlock" id="cvac_DisclosureOfBasisOfPreparationExplanatoryTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="DescriptionOfAccountingPolicyOfNewStandardsInterpretationsAndAmendmentsAdoptedTextBlock" id="cvac_DescriptionOfAccountingPolicyOfNewStandardsInterpretationsAndAmendmentsAdoptedTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="EuropeanUnionAdvancePurchaseAgreementMember" id="cvac_EuropeanUnionAdvancePurchaseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="FollowOnPublicOfferingMember" id="cvac_FollowOnPublicOfferingMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ShareBasedPaymentExpenseIncl.DeferredTaxes" id="cvac_ShareBasedPaymentExpenseIncl.DeferredTaxes" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element name="ScheduleOfExpenseRecognizedForProgramsTableTextBlock" id="cvac_ScheduleOfExpenseRecognizedForProgramsTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ChangeInTradeAndOtherPayables" id="cvac_ChangeInTradeAndOtherPayables" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="TechnicalEquipmentAndMachinesAndOtherEquipmentMember" id="cvac_TechnicalEquipmentAndMachinesAndOtherEquipmentMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="LicensesSoftwareAndPrepaymentsMember" id="cvac_LicensesSoftwareAndPrepaymentsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="AmountOfLiabilityCashClaimAwards" id="cvac_AmountOfLiabilityCashClaimAwards" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element name="UpfrontPaymentReceived" id="cvac_UpfrontPaymentReceived" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element name="AdditionalDevelopmentMilestonePaymentsReceived" id="cvac_AdditionalDevelopmentMilestonePaymentsReceived" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element name="Gsk2ndGenMember" id="cvac_Gsk2ndGenMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="AmountOfRestrictedStockUnitsReceived" id="cvac_AmountOfRestrictedStockUnitsReceived" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element name="ComprehensiveIncomeLoss" id="cvac_ComprehensiveIncomeLoss" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element name="NetLoss" id="cvac_NetLoss" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element name="ChangeInExpenseByNature" id="cvac_ChangeInExpenseByNature" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element name="ClarentisSrlMember" id="cvac_ClarentisSrlMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ImpairmentsOfInventoryAndPrepayments" id="cvac_ImpairmentsOfInventoryAndPrepayments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="BmbfMember" id="cvac_BmbfMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="IfrsRepaymentsOfAccruedInterestAndFeesOfBorrowings" id="cvac_IfrsRepaymentsOfAccruedInterestAndFeesOfBorrowings" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="PlanNameAxis" id="cvac_PlanNameAxis" type="xbrli:stringItemType" substitutionGroup="xbrldt:dimensionItem" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="PlanNameDomain" id="cvac_PlanNameDomain" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="IfrsNumberOfSharesOutstandingThroughTransferFromShareholdersToEntity" id="cvac_IfrsNumberOfSharesOutstandingThroughTransferFromShareholdersToEntity" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="ChiefDevelopmentOfficerMember" id="cvac_ChiefDevelopmentOfficerMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="IfrsContractualObligation" id="cvac_IfrsContractualObligation" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="ContractResearchOrganizationAgreementMember" id="cvac_ContractResearchOrganizationAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="DisclosureOfOtherLiabilitiesTable" id="cvac_DisclosureOfOtherLiabilitiesTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="DisclosureOfOtherLiabilitiesLineItems" id="cvac_DisclosureOfOtherLiabilitiesLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="ContractManufacturingOrganizationAgreementMember" id="cvac_ContractManufacturingOrganizationAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="RestrictedStockUnitsMember" id="cvac_RestrictedStockUnitsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="MembersOfExecutiveBoardAndVariousKeyEmployeesMember" id="cvac_MembersOfExecutiveBoardAndVariousKeyEmployeesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="TypeOfArrangementAxis" id="cvac_TypeOfArrangementAxis" type="xbrli:stringItemType" substitutionGroup="xbrldt:dimensionItem" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="ArrangementsAndNonArrangementTransactionsMember" id="cvac_ArrangementsAndNonArrangementTransactionsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="CrisprTherapeuticsMember" id="cvac_CrisprTherapeuticsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="EliLillyMember" id="cvac_EliLillyMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="IfrsDevelopmentMilestonePaymentIncludedInContractLiabilities" id="cvac_IfrsDevelopmentMilestonePaymentIncludedInContractLiabilities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="IfrsIncreaseInExpenseRelatedToIneffectiveSetUpActivitiesAndSettlementCosts" id="cvac_IfrsIncreaseInExpenseRelatedToIneffectiveSetUpActivitiesAndSettlementCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="AdvancedPurchaseAgreementWithEuropeanCommissionMember" id="cvac_AdvancedPurchaseAgreementWithEuropeanCommissionMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="IfrsMilestonePaymentReceived" id="cvac_IfrsMilestonePaymentReceived" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="IfrsRemainingGrantIncome" id="cvac_IfrsRemainingGrantIncome" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis" id="cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis" type="xbrli:stringItemType" substitutionGroup="xbrldt:dimensionItem" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountDomain" id="cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountDomain" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="ProceedsFromRepaymentsOfBorrowingsClassifiedAsFinancingActivities" id="cvac_ProceedsFromRepaymentsOfBorrowingsClassifiedAsFinancingActivities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="GskAgreement2020Member" id="cvac_GskAgreement2020Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="DecreaseInNumberOfSharesDueToTreasuryOfShares" id="cvac_DecreaseInNumberOfSharesDueToTreasuryOfShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="CompanyOwnedGmpIvFacilityMember" id="cvac_CompanyOwnedGmpIvFacilityMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="EquipmentPhysicallyLocatedAtCmoFacilitiesMember" id="cvac_EquipmentPhysicallyLocatedAtCmoFacilitiesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="PrepaidCompensationForContractManufacturingOrganizationsTransfer" id="cvac_PrepaidCompensationForContractManufacturingOrganizationsTransfer" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="debit" />
  <xsd:element name="ChangeInOtherLiabilities" id="cvac_ChangeInOtherLiabilities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="IfrsRestrictedStockUnitMember" id="cvac_IfrsRestrictedStockUnitMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="NumberOfKeyEmployees" id="cvac_NumberOfKeyEmployees" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="MilestoneRevenuesMember" id="cvac_MilestoneRevenuesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="CompensationForContractManufacturingOrganizationsTransfer" id="cvac_CompensationForContractManufacturingOrganizationsTransfer" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="ReversalOfProvisionForOnerousContracts" id="cvac_ReversalOfProvisionForOnerousContracts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="CompensationForContractManufacturingOrganizationsTransferConsiderationForSetUpActivities" id="cvac_CompensationForContractManufacturingOrganizationsTransferConsiderationForSetUpActivities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="CompensationForContractManufacturingOrganizationsTransferManufacturingInterimPeriodReimbursableExpenses" id="cvac_CompensationForContractManufacturingOrganizationsTransferManufacturingInterimPeriodReimbursableExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="ProceedsOnExerciseOfOptions" id="cvac_ProceedsOnExerciseOfOptions" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="SettlementOfShareBasedPaymentAwardsAmount" id="cvac_SettlementOfShareBasedPaymentAwardsAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="AdjustmentsForNonCashIncomeFromReleaseOfProvisions" id="cvac_AdjustmentsForNonCashIncomeFromReleaseOfProvisions" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="ReversalOfProvisionRecognizedDueToCertainReservedCapacityTakenOver" id="cvac_ReversalOfProvisionRecognizedDueToCertainReservedCapacityTakenOver" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="IncreaseInPropertyAndEquipmentOffSetByImpairmentOfEquipment" id="cvac_IncreaseInPropertyAndEquipmentOffSetByImpairmentOfEquipment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="IfrsDisposalGroupIncludingDiscontinuedOperationConsideration" id="cvac_IfrsDisposalGroupIncludingDiscontinuedOperationConsideration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="debit" />
  <xsd:element name="CostOfReimbursementClaim" id="cvac_CostOfReimbursementClaim" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="SaleOfEquipment" id="cvac_SaleOfEquipment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="AntonyBlancMember" id="cvac_AntonyBlancMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="PaymentsToRelatedPartyForServices" id="cvac_PaymentsToRelatedPartyForServices" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="IncomeTaxDisclosureTable" id="cvac_IncomeTaxDisclosureTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="IncomeTaxDisclosureLineItems" id="cvac_IncomeTaxDisclosureLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="CurevacCorporateServiceGmbhMember" id="cvac_CurevacCorporateServiceGmbhMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="CurevacSwissAgMember" id="cvac_CurevacSwissAgMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="WriteOffOfRawMaterials" id="cvac_WriteOffOfRawMaterials" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="InventoriesTable" id="cvac_InventoriesTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="InventoriesLineItem" id="cvac_InventoriesLineItem" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="IncreaseDecreaseInInventory" id="cvac_IncreaseDecreaseInInventory" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="NetValueOfInventoryTransferred" id="cvac_NetValueOfInventoryTransferred" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="AtMarketOfferingProgramMember" id="cvac_AtMarketOfferingProgramMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="AggregateGrossProceedsReceivableFromIssuingShares" id="cvac_AggregateGrossProceedsReceivableFromIssuingShares" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="IfrsStockIssuedDuringPeriodSharesNewIssues" id="cvac_IfrsStockIssuedDuringPeriodSharesNewIssues" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="StockIssuedDuringPeriodForExercises" id="cvac_StockIssuedDuringPeriodForExercises" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="RestrictedStockUnitForKeyEmployeesMember" id="cvac_RestrictedStockUnitForKeyEmployeesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="KeyEmployeesMember" id="cvac_KeyEmployeesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="ExecutiveBoardMembersMember" id="cvac_ExecutiveBoardMembersMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="SupervisoryBoardMembersMember" id="cvac_SupervisoryBoardMembersMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="NumberOfOtherEquityInstrumentsSettledInShareBasedPaymentArrangement" id="cvac_NumberOfOtherEquityInstrumentsSettledInShareBasedPaymentArrangement" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="FramePharmaceuticalsB.v.AmsterdamNetherlandsMember" id="cvac_FramePharmaceuticalsB.v.AmsterdamNetherlandsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="AssetsHeldForSaleAxis" id="cvac_AssetsHeldForSaleAxis" type="xbrli:stringItemType" substitutionGroup="xbrldt:dimensionItem" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="AssetsHeldForSaleDomain" id="cvac_AssetsHeldForSaleDomain" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="ProceedFromIssuingOtherEquityInstrument" id="cvac_ProceedFromIssuingOtherEquityInstrument" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="IfrsStockIssuedDuringPeriodValueNewIssues" id="cvac_IfrsStockIssuedDuringPeriodValueNewIssues" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="ChiefOperatingOfficerAndChiefDevelopmentOfficerMember" id="cvac_ChiefOperatingOfficerAndChiefDevelopmentOfficerMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="DisclosureOfGoodwillRecognizedAsResultOfAcquisitionExplanatoryTableTextBlock" id="cvac_DisclosureOfGoodwillRecognizedAsResultOfAcquisitionExplanatoryTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="DisclosureOfAnalysisOfCashFlowsOnAcquisitionExplanatoryTableTextBlock" id="cvac_DisclosureOfAnalysisOfCashFlowsOnAcquisitionExplanatoryTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="BusinessAcquisitionSigningSharePriceNumberOfTradingDaysConsidered" id="cvac_BusinessAcquisitionSigningSharePriceNumberOfTradingDaysConsidered" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="BusinessAcquisitionSigningSharePrice" id="cvac_BusinessAcquisitionSigningSharePrice" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="NumberOfPaymentsInWhichTotalConsiderationIsToBePaid" id="cvac_NumberOfPaymentsInWhichTotalConsiderationIsToBePaid" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" />
  <xsd:element name="ContingentConsiderationNumberOfPaymentsConsidered" id="cvac_ContingentConsiderationNumberOfPaymentsConsidered" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" />
  <xsd:element name="FirstPortionOfTotalConsiderationTransferredPercentage" id="cvac_FirstPortionOfTotalConsiderationTransferredPercentage" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" />
  <xsd:element name="FirstPortionOfTotalConsiderationTransferredAmount" id="cvac_FirstPortionOfTotalConsiderationTransferredAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="IfrsBusinessAcquisitionSharePrice" id="cvac_IfrsBusinessAcquisitionSharePrice" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" />
  <xsd:element name="NumberOfInstrumentsOrInterestsIssuedOrIssuableAsConsiderationForDischargingContractualObligations" id="cvac_NumberOfInstrumentsOrInterestsIssuedOrIssuableAsConsiderationForDischargingContractualObligations" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" />
  <xsd:element name="ValueOfInstrumentsOrInterestsIssuedOrIssuableAsConsiderationForDischargingContractualObligations" id="cvac_ValueOfInstrumentsOrInterestsIssuedOrIssuableAsConsiderationForDischargingContractualObligations" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="StrikePriceForExistingShareBasedPayment" id="cvac_StrikePriceForExistingShareBasedPayment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="CashTransferredForSettlementOfVestedEmployeeOptions" id="cvac_CashTransferredForSettlementOfVestedEmployeeOptions" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="AdditionalCashTransferred" id="cvac_AdditionalCashTransferred" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="ContingentConsiderationPercentageOfTotalConsideration" id="cvac_ContingentConsiderationPercentageOfTotalConsideration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" />
  <xsd:element name="ContingentConsiderationNumberOfMilestones" id="cvac_ContingentConsiderationNumberOfMilestones" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" />
  <xsd:element name="NumberOfInstrumentsOrInterestsIssuedOrIssuableAsConsiderationToFormerShareholders" id="cvac_NumberOfInstrumentsOrInterestsIssuedOrIssuableAsConsiderationToFormerShareholders" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" />
  <xsd:element name="ValueOfInstrumentsOrInterestsIssuedOrIssuableAsConsiderationToFormerShareholders" id="cvac_ValueOfInstrumentsOrInterestsIssuedOrIssuableAsConsiderationToFormerShareholders" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="NumberOfInstrumentsOrInterestsIssuedOrIssuableUponAchievementOfFirstMilestone" id="cvac_NumberOfInstrumentsOrInterestsIssuedOrIssuableUponAchievementOfFirstMilestone" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" />
  <xsd:element name="PercentageOfConsiderationTransferredUponAchievementOfFirstMilestone" id="cvac_PercentageOfConsiderationTransferredUponAchievementOfFirstMilestone" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" />
  <xsd:element name="ValueOfInstrumentsOrInterestsIssuedOrIssuableUponAchievementOfFirstMilestone" id="cvac_ValueOfInstrumentsOrInterestsIssuedOrIssuableUponAchievementOfFirstMilestone" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="NumberOfInstrumentsOrInterestsIssuedOrIssuableUponAchievementOfSecondMilestone" id="cvac_NumberOfInstrumentsOrInterestsIssuedOrIssuableUponAchievementOfSecondMilestone" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" />
  <xsd:element name="PercentageOfConsiderationTransferredUponAchievementOfSecondMilestone" id="cvac_PercentageOfConsiderationTransferredUponAchievementOfSecondMilestone" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" />
  <xsd:element name="ValueOfInstrumentsOrInterestsIssuedOrIssuableUponAchievementOfSecondMilestone" id="cvac_ValueOfInstrumentsOrInterestsIssuedOrIssuableUponAchievementOfSecondMilestone" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="ContingentConsiderationMaximumSharesIssuable" id="cvac_ContingentConsiderationMaximumSharesIssuable" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" />
  <xsd:element name="NumberOfTranchesForVestingOfInstrumentsGrantedInShareBasedPaymentArrangement" id="cvac_NumberOfTranchesForVestingOfInstrumentsGrantedInShareBasedPaymentArrangement" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="RightOfUseAssetsRecognisedAsOfAcquisitionDate" id="cvac_RightOfUseAssetsRecognisedAsOfAcquisitionDate" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="debit" />
  <xsd:element name="TotalAssetsRecognisedAsOfAcquisitionDate" id="cvac_TotalAssetsRecognisedAsOfAcquisitionDate" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="debit" />
  <xsd:element name="NoncurrentLeaseLiabilitiesRecognisedAsOfAcquisitionDate" id="cvac_NoncurrentLeaseLiabilitiesRecognisedAsOfAcquisitionDate" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="NetDeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate" id="cvac_NetDeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="CurrentLeaseLiabilitiesRecognisedAsOfAcquisitionDate" id="cvac_CurrentLeaseLiabilitiesRecognisedAsOfAcquisitionDate" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="ChiefBusinessOfficerMember" id="cvac_ChiefBusinessOfficerMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="FormerFrameEmployeesMember" id="cvac_FormerFrameEmployeesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="ProceedsOrPaymentsFromExerciseOfOptions" id="cvac_ProceedsOrPaymentsFromExerciseOfOptions" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="DisclosureOfNotesToConsolidatedFinancialStatementsTable" id="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="DisclosureOfNotesToConsolidatedFinancialStatementsLineItems" id="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="IfrsCashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities" id="cvac_IfrsCashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="NumberOfInstrumentsOrInterestIssuedOrIssuable" id="cvac_NumberOfInstrumentsOrInterestIssuedOrIssuable" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" />
  <xsd:element name="SigningSharePriceRepresenting10" id="cvac_SigningSharePriceRepresenting10" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="debit" />
  <xsd:element name="SigningSharePriceRepresenting40" id="cvac_SigningSharePriceRepresenting40" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="debit" />
  <xsd:element name="ClosingSharePriceRepresentingTotalFairValue" id="cvac_ClosingSharePriceRepresentingTotalFairValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="debit" />
  <xsd:element name="FairValueOfTotalConsiderationTransferred" id="cvac_FairValueOfTotalConsiderationTransferred" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="ProvisionalFairValue" id="cvac_ProvisionalFairValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="OtherCurrentLiabilitiesRecognisedAsOfAcquisitionDate" id="cvac_OtherCurrentLiabilitiesRecognisedAsOfAcquisitionDate" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="LiabilitiesRecognisedAsOfAcquisitionDate" id="cvac_LiabilitiesRecognisedAsOfAcquisitionDate" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="RemainingAuthorizedForSaleValue" id="cvac_RemainingAuthorizedForSaleValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="StockIssuanceDuringPeriodForExistingShareholders" id="cvac_StockIssuanceDuringPeriodForExistingShareholders" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>7
<FILENAME>cvac-20220930_cal.xml
<DESCRIPTION>EX-101.CAL
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  10.1.0.3 -->
<!--Based on XBRL 2.1-->
<!--Created on: 11/17/2022 10:28:01 PM-->
<!--Modified on: 11/17/2022 10:28:01 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink">
  <roleRef xlink:type="simple" xlink:href="cvac-20220930.xsd#StatementInterimCondensedConsolidatedStatementsOfOperationsAndOtherComprehensiveIncomeLoss" roleURI="http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfOperationsAndOtherComprehensiveIncomeLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20220930.xsd#StatementInterimCondensedConsolidatedStatementsOfFinancialPosition" roleURI="http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20220930.xsd#StatementInterimCondensedConsolidatedStatementsOfCashFlows" roleURI="http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20220930.xsd#DisclosureNotesToConsolidatedFinancialStatementsCostOfSalesDetails" roleURI="http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsCostOfSalesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20220930.xsd#DisclosureNotesToConsolidatedFinancialStatementsOtherOperatingIncomeDetails" roleURI="http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsOtherOperatingIncomeDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20220930.xsd#DisclosureShareBasedPaymentsExpensesDetails" roleURI="http://www.curevac.com/role/DisclosureShareBasedPaymentsExpensesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20220930.xsd#DisclosureSignificantTransactionsAndEventsFrameAcquisitionPurchasePriceAllocationDetails" roleURI="http://www.curevac.com/role/DisclosureSignificantTransactionsAndEventsFrameAcquisitionPurchasePriceAllocationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20220930.xsd#DisclosureSignificantTransactionsAndEventsGoodwillRecognizedOnFrameAcquisitionDetails" roleURI="http://www.curevac.com/role/DisclosureSignificantTransactionsAndEventsGoodwillRecognizedOnFrameAcquisitionDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20220930.xsd#DisclosureSignificantTransactionsAndEventsAnalysesOfCashFlowsOnFrameAcquisitionDetails" roleURI="http://www.curevac.com/role/DisclosureSignificantTransactionsAndEventsAnalysesOfCashFlowsOnFrameAcquisitionDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <calculationLink xlink:role="http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfOperationsAndOtherComprehensiveIncomeLoss" xlink:type="extended" xlink:title="00100 - Statement - Interim Condensed Consolidated Statements of Operations and Other Comprehensive Income (Loss)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ComprehensiveIncome" xlink:label="ComprehensiveIncome" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" xlink:label="ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation_638043208767419481" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ComprehensiveIncome" xlink:to="ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation_638043208767419481" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProfitLoss" xlink:label="ifrs-full_ProfitLoss_638043208767419481" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ComprehensiveIncome" xlink:to="ifrs-full_ProfitLoss_638043208767419481" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProfitLossBeforeTax" xlink:label="ifrs-full_ProfitLossBeforeTax_638043208767419481" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ProfitLoss_638043208767419481" xlink:to="ifrs-full_ProfitLossBeforeTax_638043208767419481" order="1" use="optional" weight="1" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_FinanceIncome" xlink:label="ifrs-full_FinanceIncome_638043208767419481" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ProfitLossBeforeTax_638043208767419481" xlink:to="ifrs-full_FinanceIncome_638043208767419481" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_FinanceCosts" xlink:label="ifrs-full_FinanceCosts_638043208767419481" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ProfitLossBeforeTax_638043208767419481" xlink:to="ifrs-full_FinanceCosts_638043208767419481" order="2" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProfitLossFromOperatingActivities" xlink:label="ifrs-full_ProfitLossFromOperatingActivities_638043208767419481" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ProfitLossBeforeTax_638043208767419481" xlink:to="ifrs-full_ProfitLossFromOperatingActivities_638043208767419481" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RevenueFromContractsWithCustomers" xlink:label="ifrs-full_RevenueFromContractsWithCustomers_638043208767419481" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ProfitLossFromOperatingActivities_638043208767419481" xlink:to="ifrs-full_RevenueFromContractsWithCustomers_638043208767419481" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CostOfSales" xlink:label="ifrs-full_CostOfSales_638043208767419481" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ProfitLossFromOperatingActivities_638043208767419481" xlink:to="ifrs-full_CostOfSales_638043208767419481" order="2" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_SalesAndMarketingExpense" xlink:label="ifrs-full_SalesAndMarketingExpense_638043208767419481" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ProfitLossFromOperatingActivities_638043208767419481" xlink:to="ifrs-full_SalesAndMarketingExpense_638043208767419481" order="3" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ResearchAndDevelopmentExpense" xlink:label="ifrs-full_ResearchAndDevelopmentExpense_638043208767429479" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ProfitLossFromOperatingActivities_638043208767419481" xlink:to="ifrs-full_ResearchAndDevelopmentExpense_638043208767429479" order="4" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_GeneralAndAdministrativeExpense" xlink:label="ifrs-full_GeneralAndAdministrativeExpense_638043208767429479" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ProfitLossFromOperatingActivities_638043208767419481" xlink:to="ifrs-full_GeneralAndAdministrativeExpense_638043208767429479" order="5" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_MiscellaneousOtherOperatingIncome" xlink:label="ifrs-full_MiscellaneousOtherOperatingIncome_638043208767429479" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ProfitLossFromOperatingActivities_638043208767419481" xlink:to="ifrs-full_MiscellaneousOtherOperatingIncome_638043208767429479" order="6" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_MiscellaneousOtherOperatingExpense" xlink:label="ifrs-full_MiscellaneousOtherOperatingExpense_638043208767429479" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ProfitLossFromOperatingActivities_638043208767419481" xlink:to="ifrs-full_MiscellaneousOtherOperatingExpense_638043208767429479" order="7" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:label="ifrs-full_IncomeTaxExpenseContinuingOperations_638043208767429479" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ProfitLoss_638043208767419481" xlink:to="ifrs-full_IncomeTaxExpenseContinuingOperations_638043208767429479" order="2" use="optional" weight="-1" priority="3" />
  </calculationLink>
  <calculationLink xlink:role="http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition" xlink:type="extended" xlink:title="00200 - Statement - Interim Condensed Consolidated Statements of Financial Position" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_Assets" xlink:label="Assets" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NoncurrentAssets" xlink:label="ifrs-full_NoncurrentAssets_638043208767429479" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Assets" xlink:to="ifrs-full_NoncurrentAssets_638043208767429479" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwill" xlink:label="ifrs-full_IntangibleAssetsOtherThanGoodwill_638043208767429479" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_NoncurrentAssets_638043208767429479" xlink:to="ifrs-full_IntangibleAssetsOtherThanGoodwill_638043208767429479" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IntangibleAssetsAndGoodwill" xlink:label="ifrs-full_IntangibleAssetsAndGoodwill_638043208767439479" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_NoncurrentAssets_638043208767429479" xlink:to="ifrs-full_IntangibleAssetsAndGoodwill_638043208767439479" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_PropertyPlantAndEquipment" xlink:label="ifrs-full_PropertyPlantAndEquipment_638043208767439479" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_NoncurrentAssets_638043208767429479" xlink:to="ifrs-full_PropertyPlantAndEquipment_638043208767439479" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OtherNoncurrentAssets" xlink:label="ifrs-full_OtherNoncurrentAssets_638043208767439479" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_NoncurrentAssets_638043208767429479" xlink:to="ifrs-full_OtherNoncurrentAssets_638043208767439479" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NetDeferredTaxAssets" xlink:label="ifrs-full_NetDeferredTaxAssets_638043208767439479" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_NoncurrentAssets_638043208767429479" xlink:to="ifrs-full_NetDeferredTaxAssets_638043208767439479" order="5" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RightofuseAssets" xlink:label="ifrs-full_RightofuseAssets_638043208767439479" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_NoncurrentAssets_638043208767429479" xlink:to="ifrs-full_RightofuseAssets_638043208767439479" order="6" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CurrentAssets" xlink:label="ifrs-full_CurrentAssets_638043208767439479" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Assets" xlink:to="ifrs-full_CurrentAssets_638043208767439479" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_Inventories" xlink:label="ifrs-full_Inventories_638043208767439479" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CurrentAssets_638043208767439479" xlink:to="ifrs-full_Inventories_638043208767439479" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CurrentTradeReceivables" xlink:label="ifrs-full_CurrentTradeReceivables_638043208767439479" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CurrentAssets_638043208767439479" xlink:to="ifrs-full_CurrentTradeReceivables_638043208767439479" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CurrentContractAssets" xlink:label="ifrs-full_CurrentContractAssets_638043208767439479" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CurrentAssets_638043208767439479" xlink:to="ifrs-full_CurrentContractAssets_638043208767439479" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CurrentPrepaymentsAndOtherCurrentAssets" xlink:label="ifrs-full_CurrentPrepaymentsAndOtherCurrentAssets_638043208767449479" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CurrentAssets_638043208767439479" xlink:to="ifrs-full_CurrentPrepaymentsAndOtherCurrentAssets_638043208767449479" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OtherCurrentFinancialAssets" xlink:label="ifrs-full_OtherCurrentFinancialAssets_638043208767449479" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CurrentAssets_638043208767439479" xlink:to="ifrs-full_OtherCurrentFinancialAssets_638043208767449479" order="5" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CashAndCashEquivalents" xlink:label="ifrs-full_CashAndCashEquivalents_638043208767449479" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CurrentAssets_638043208767439479" xlink:to="ifrs-full_CashAndCashEquivalents_638043208767449479" order="6" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners" xlink:label="ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners_638043208767449479" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CurrentAssets_638043208767439479" xlink:to="ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners_638043208767449479" order="7" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_EquityAndLiabilities" xlink:label="EquityAndLiabilities" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_Equity" xlink:label="ifrs-full_Equity_638043208767449479" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="EquityAndLiabilities" xlink:to="ifrs-full_Equity_638043208767449479" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IssuedCapital" xlink:label="ifrs-full_IssuedCapital_638043208767449479" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_Equity_638043208767449479" xlink:to="ifrs-full_IssuedCapital_638043208767449479" order="1" use="optional" weight="1" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TreasuryShares" xlink:label="ifrs-full_TreasuryShares_638043208767459479" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_Equity_638043208767449479" xlink:to="ifrs-full_TreasuryShares_638043208767459479" order="2" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CapitalReserve" xlink:label="ifrs-full_CapitalReserve_638043208767459479" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_Equity_638043208767449479" xlink:to="ifrs-full_CapitalReserve_638043208767459479" order="3" use="optional" weight="1" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RetainedEarnings" xlink:label="ifrs-full_RetainedEarnings_638043208767459479" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_Equity_638043208767449479" xlink:to="ifrs-full_RetainedEarnings_638043208767459479" order="4" use="optional" weight="1" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AccumulatedOtherComprehensiveIncome" xlink:label="ifrs-full_AccumulatedOtherComprehensiveIncome_638043208767459479" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_Equity_638043208767449479" xlink:to="ifrs-full_AccumulatedOtherComprehensiveIncome_638043208767459479" order="5" use="optional" weight="1" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_Liabilities" xlink:label="ifrs-full_Liabilities_638043208767459479" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="EquityAndLiabilities" xlink:to="ifrs-full_Liabilities_638043208767459479" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NoncurrentLiabilities" xlink:label="ifrs-full_NoncurrentLiabilities_638043208767459479" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_Liabilities_638043208767459479" xlink:to="ifrs-full_NoncurrentLiabilities_638043208767459479" order="1" use="optional" weight="1" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NoncurrentLeaseLiabilities" xlink:label="ifrs-full_NoncurrentLeaseLiabilities_638043208767459479" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_NoncurrentLiabilities_638043208767459479" xlink:to="ifrs-full_NoncurrentLeaseLiabilities_638043208767459479" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NoncurrentContractLiabilities" xlink:label="ifrs-full_NoncurrentContractLiabilities_638043208767469480" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_NoncurrentLiabilities_638043208767459479" xlink:to="ifrs-full_NoncurrentContractLiabilities_638043208767469480" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NoncurrentFinancialLiabilities" xlink:label="ifrs-full_NoncurrentFinancialLiabilities_638043208767469480" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_NoncurrentLiabilities_638043208767459479" xlink:to="ifrs-full_NoncurrentFinancialLiabilities_638043208767469480" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OtherNoncurrentLiabilities" xlink:label="ifrs-full_OtherNoncurrentLiabilities_638043208767469480" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_NoncurrentLiabilities_638043208767459479" xlink:to="ifrs-full_OtherNoncurrentLiabilities_638043208767469480" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CurrentLiabilities" xlink:label="ifrs-full_CurrentLiabilities_638043208767469480" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_Liabilities_638043208767459479" xlink:to="ifrs-full_CurrentLiabilities_638043208767469480" order="2" use="optional" weight="1" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OtherCurrentFinancialLiabilities" xlink:label="ifrs-full_OtherCurrentFinancialLiabilities_638043208767469480" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CurrentLiabilities_638043208767469480" xlink:to="ifrs-full_OtherCurrentFinancialLiabilities_638043208767469480" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CurrentLeaseLiabilities" xlink:label="ifrs-full_CurrentLeaseLiabilities_638043208767469480" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CurrentLiabilities_638043208767469480" xlink:to="ifrs-full_CurrentLeaseLiabilities_638043208767469480" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TradeAndOtherCurrentPayables" xlink:label="ifrs-full_TradeAndOtherCurrentPayables_638043208767469480" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CurrentLiabilities_638043208767469480" xlink:to="ifrs-full_TradeAndOtherCurrentPayables_638043208767469480" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OtherCurrentLiabilities" xlink:label="ifrs-full_OtherCurrentLiabilities_638043208767479480" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CurrentLiabilities_638043208767469480" xlink:to="ifrs-full_OtherCurrentLiabilities_638043208767479480" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CurrentTaxLiabilities" xlink:label="ifrs-full_CurrentTaxLiabilities_638043208767479480" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CurrentLiabilities_638043208767469480" xlink:to="ifrs-full_CurrentTaxLiabilities_638043208767479480" order="5" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CurrentContractLiabilities" xlink:label="ifrs-full_CurrentContractLiabilities_638043208767479480" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CurrentLiabilities_638043208767469480" xlink:to="ifrs-full_CurrentContractLiabilities_638043208767479480" order="6" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows" xlink:type="extended" xlink:title="00400 - Statement - Interim Condensed Consolidated Statements of Cash Flows" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" xlink:label="IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivities_638043208767479480" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" xlink:to="ifrs-full_CashFlowsFromUsedInOperatingActivities_638043208767479480" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProfitLossBeforeTax" xlink:label="ifrs-full_ProfitLossBeforeTax_638043208767489479" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivities_638043208767479480" xlink:to="ifrs-full_ProfitLossBeforeTax_638043208767489479" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AdjustmentsForFinanceIncome" xlink:label="ifrs-full_AdjustmentsForFinanceIncome_638043208767489479" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivities_638043208767479480" xlink:to="ifrs-full_AdjustmentsForFinanceIncome_638043208767489479" order="2" use="optional" weight="-1" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets" xlink:label="ifrs-full_AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets_638043208767489479" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivities_638043208767479480" xlink:to="ifrs-full_AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets_638043208767489479" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AdjustmentsForGainLossOnDisposalsPropertyPlantAndEquipment" xlink:label="ifrs-full_AdjustmentsForGainLossOnDisposalsPropertyPlantAndEquipment_638043208767489479" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivities_638043208767479480" xlink:to="ifrs-full_AdjustmentsForGainLossOnDisposalsPropertyPlantAndEquipment_638043208767489479" order="4" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AdjustmentsForFinanceCosts" xlink:label="ifrs-full_AdjustmentsForFinanceCosts_638043208767489479" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivities_638043208767479480" xlink:to="ifrs-full_AdjustmentsForFinanceCosts_638043208767489479" order="5" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_AdjustmentsForNonCashIncomeFromReleaseOfProvisions" xlink:label="cvac_AdjustmentsForNonCashIncomeFromReleaseOfProvisions_638043208767489479" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivities_638043208767479480" xlink:to="cvac_AdjustmentsForNonCashIncomeFromReleaseOfProvisions_638043208767489479" order="6" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" xlink:label="ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment_638043208767489479" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivities_638043208767479480" xlink:to="ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment_638043208767489479" order="7" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_ImpairmentsOfInventoryAndPrepayments" xlink:label="cvac_ImpairmentsOfInventoryAndPrepayments_638043208767489479" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivities_638043208767479480" xlink:to="cvac_ImpairmentsOfInventoryAndPrepayments_638043208767489479" order="8" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense" xlink:label="ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense_638043208767489479" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivities_638043208767479480" xlink:to="ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense_638043208767489479" order="9" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInOtherAssets" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInOtherAssets_638043208767499476" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivities_638043208767479480" xlink:to="ifrs-full_AdjustmentsForDecreaseIncreaseInOtherAssets_638043208767499476" order="10" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AdjustmentsForSharebasedPayments" xlink:label="ifrs-full_AdjustmentsForSharebasedPayments_638043208767499476" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivities_638043208767479480" xlink:to="ifrs-full_AdjustmentsForSharebasedPayments_638043208767499476" order="11" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables_638043208767499476" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivities_638043208767479480" xlink:to="ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables_638043208767499476" order="12" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInInventories" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInInventories_638043208767499476" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivities_638043208767479480" xlink:to="ifrs-full_AdjustmentsForDecreaseIncreaseInInventories_638043208767499476" order="13" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_AdjustmentsForIncreaseDecreaseInOtherCurrentFinancialAndOtherLiabilities" xlink:label="cvac_AdjustmentsForIncreaseDecreaseInOtherCurrentFinancialAndOtherLiabilities_638043208767499476" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivities_638043208767479480" xlink:to="cvac_AdjustmentsForIncreaseDecreaseInOtherCurrentFinancialAndOtherLiabilities_638043208767499476" order="14" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_ReceiptsFromGovernmentGrantsClassifiedAsOperatingActivities" xlink:label="cvac_ReceiptsFromGovernmentGrantsClassifiedAsOperatingActivities_638043208767499476" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivities_638043208767479480" xlink:to="cvac_ReceiptsFromGovernmentGrantsClassifiedAsOperatingActivities_638043208767499476" order="15" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" xlink:label="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables_638043208767499476" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivities_638043208767479480" xlink:to="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables_638043208767499476" order="16" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IncomeTaxesPaidClassifiedAsOperatingActivities" xlink:label="ifrs-full_IncomeTaxesPaidClassifiedAsOperatingActivities_638043208767499476" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivities_638043208767479480" xlink:to="ifrs-full_IncomeTaxesPaidClassifiedAsOperatingActivities_638043208767499476" order="17" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_InterestReceivedClassifiedAsOperatingActivities" xlink:label="ifrs-full_InterestReceivedClassifiedAsOperatingActivities_638043208767509481" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivities_638043208767479480" xlink:to="ifrs-full_InterestReceivedClassifiedAsOperatingActivities_638043208767509481" order="18" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_InterestPaidClassifiedAsOperatingActivities" xlink:label="ifrs-full_InterestPaidClassifiedAsOperatingActivities_638043208767509481" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivities_638043208767479480" xlink:to="ifrs-full_InterestPaidClassifiedAsOperatingActivities_638043208767509481" order="19" use="optional" weight="-1" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AdjustmentsForDeferredTaxExpense" xlink:label="ifrs-full_AdjustmentsForDeferredTaxExpense_638043208767509481" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivities_638043208767479480" xlink:to="ifrs-full_AdjustmentsForDeferredTaxExpense_638043208767509481" order="20" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_IfrsIncreaseDecreaseInPrepaidExpenseAndOtherAssets" xlink:label="cvac_IfrsIncreaseDecreaseInPrepaidExpenseAndOtherAssets_638043208767509481" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivities_638043208767479480" xlink:to="cvac_IfrsIncreaseDecreaseInPrepaidExpenseAndOtherAssets_638043208767509481" order="21" use="optional" weight="-1" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:label="ifrs-full_CashFlowsFromUsedInInvestingActivities_638043208767509481" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" xlink:to="ifrs-full_CashFlowsFromUsedInInvestingActivities_638043208767509481" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:label="ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_638043208767509481" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivities_638043208767509481" xlink:to="ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_638043208767509481" order="1" use="optional" weight="-1" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" xlink:label="ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities_638043208767509481" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivities_638043208767509481" xlink:to="ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities_638043208767509481" order="2" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_PurchaseOfOtherLongtermAssetsClassifiedAsInvestingActivities" xlink:label="ifrs-full_PurchaseOfOtherLongtermAssetsClassifiedAsInvestingActivities_638043208767519477" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivities_638043208767509481" xlink:to="ifrs-full_PurchaseOfOtherLongtermAssetsClassifiedAsInvestingActivities_638043208767519477" order="3" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivities_638043208767519477" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" xlink:to="ifrs-full_CashFlowsFromUsedInFinancingActivities_638043208767519477" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" xlink:label="ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities_638043208767519477" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivities_638043208767519477" xlink:to="ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities_638043208767519477" order="1" use="optional" weight="-1" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProceedsFromIssueOfBondsNotesAndDebentures" xlink:label="ifrs-full_ProceedsFromIssueOfBondsNotesAndDebentures_638043208767519477" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivities_638043208767519477" xlink:to="ifrs-full_ProceedsFromIssueOfBondsNotesAndDebentures_638043208767519477" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProceedsFromIssuingOtherEquityInstruments" xlink:label="ifrs-full_ProceedsFromIssuingOtherEquityInstruments_638043208767519477" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivities_638043208767519477" xlink:to="ifrs-full_ProceedsFromIssuingOtherEquityInstruments_638043208767519477" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_ProceedsFromRepaymentsOfBorrowingsClassifiedAsFinancingActivities" xlink:label="cvac_ProceedsFromRepaymentsOfBorrowingsClassifiedAsFinancingActivities_638043208767519477" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivities_638043208767519477" xlink:to="cvac_ProceedsFromRepaymentsOfBorrowingsClassifiedAsFinancingActivities_638043208767519477" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProceedsFromIssuingShares" xlink:label="ifrs-full_ProceedsFromIssuingShares_638043208767529484" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivities_638043208767519477" xlink:to="ifrs-full_ProceedsFromIssuingShares_638043208767529484" order="5" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProceedsFromExerciseOfOptions" xlink:label="ifrs-full_ProceedsFromExerciseOfOptions_638043208767529484" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivities_638043208767519477" xlink:to="ifrs-full_ProceedsFromExerciseOfOptions_638043208767529484" order="6" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_ProceedsOrPaymentsFromExerciseOfOptions" xlink:label="cvac_ProceedsOrPaymentsFromExerciseOfOptions_638043208767529484" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivities_638043208767519477" xlink:to="cvac_ProceedsOrPaymentsFromExerciseOfOptions_638043208767529484" order="7" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_ProceedsOnExerciseOfOptions" xlink:label="cvac_ProceedsOnExerciseOfOptions_638043208767529484" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivities_638043208767519477" xlink:to="cvac_ProceedsOnExerciseOfOptions_638043208767529484" order="8" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_IfrsStockIssuedDuringPeriodValueNewIssues" xlink:label="cvac_IfrsStockIssuedDuringPeriodValueNewIssues_638043208767529484" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivities_638043208767519477" xlink:to="cvac_IfrsStockIssuedDuringPeriodValueNewIssues_638043208767529484" order="9" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RepaymentsOfBondsNotesAndDebentures" xlink:label="ifrs-full_RepaymentsOfBondsNotesAndDebentures_638043208767529484" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivities_638043208767519477" xlink:to="ifrs-full_RepaymentsOfBondsNotesAndDebentures_638043208767529484" order="10" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_ProceedFromIssuingOtherEquityInstrument" xlink:label="cvac_ProceedFromIssuingOtherEquityInstrument_638043208767539531" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivities_638043208767519477" xlink:to="cvac_ProceedFromIssuingOtherEquityInstrument_638043208767539531" order="11" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsCostOfSalesDetails" xlink:type="extended" xlink:title="40304 - Disclosure - Notes to the consolidated financial statements - Cost of sales (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ExpenseByNature" xlink:label="ExpenseByNature" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_PersonnelExpenses" xlink:label="cvac_PersonnelExpenses_638043208767539531" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ExpenseByNature" xlink:to="cvac_PersonnelExpenses_638043208767539531" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RawMaterialsAndConsumablesUsed" xlink:label="ifrs-full_RawMaterialsAndConsumablesUsed_638043208767539531" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ExpenseByNature" xlink:to="ifrs-full_RawMaterialsAndConsumablesUsed_638043208767539531" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_ThirdPartyServiceExpenses" xlink:label="cvac_ThirdPartyServiceExpenses_638043208767539531" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ExpenseByNature" xlink:to="cvac_ThirdPartyServiceExpenses_638043208767539531" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_MaintenanceAndLeaseExpenses" xlink:label="cvac_MaintenanceAndLeaseExpenses_638043208767539531" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ExpenseByNature" xlink:to="cvac_MaintenanceAndLeaseExpenses_638043208767539531" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DepreciationAndAmortisationExpense" xlink:label="ifrs-full_DepreciationAndAmortisationExpense_638043208767549480" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ExpenseByNature" xlink:to="ifrs-full_DepreciationAndAmortisationExpense_638043208767549480" order="5" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProfessionalFeesExpense" xlink:label="ifrs-full_ProfessionalFeesExpense_638043208767549480" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ExpenseByNature" xlink:to="ifrs-full_ProfessionalFeesExpense_638043208767549480" order="6" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_PatentsAndFeesToRegisterLegalRight" xlink:label="cvac_PatentsAndFeesToRegisterLegalRight_638043208767549480" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ExpenseByNature" xlink:to="cvac_PatentsAndFeesToRegisterLegalRight_638043208767549480" order="7" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_OtherExpense" xlink:label="cvac_OtherExpense_638043208767549480" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ExpenseByNature" xlink:to="cvac_OtherExpense_638043208767549480" order="8" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsOtherOperatingIncomeDetails" xlink:type="extended" xlink:title="40308 - Disclosure - Notes to the consolidated financial statements - Other operating income (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_MiscellaneousOtherOperatingIncome" xlink:label="MiscellaneousOtherOperatingIncome" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_SaleOfEquipment" xlink:label="cvac_SaleOfEquipment_638043208767549480" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="MiscellaneousOtherOperatingIncome" xlink:to="cvac_SaleOfEquipment_638043208767549480" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_CostOfReimbursementClaim" xlink:label="cvac_CostOfReimbursementClaim_638043208767549480" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="MiscellaneousOtherOperatingIncome" xlink:to="cvac_CostOfReimbursementClaim_638043208767549480" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_CompensationForContractManufacturingOrganizationsTransfer" xlink:label="cvac_CompensationForContractManufacturingOrganizationsTransfer_638043208767549480" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="MiscellaneousOtherOperatingIncome" xlink:to="cvac_CompensationForContractManufacturingOrganizationsTransfer_638043208767549480" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_ReversalOfProvisionsForPersonnelExpenses" xlink:label="cvac_ReversalOfProvisionsForPersonnelExpenses_638043208767549480" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="MiscellaneousOtherOperatingIncome" xlink:to="cvac_ReversalOfProvisionsForPersonnelExpenses_638043208767549480" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_OtherOperatingIncomeGovernmentGrants" xlink:label="cvac_OtherOperatingIncomeGovernmentGrants_638043208767559481" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="MiscellaneousOtherOperatingIncome" xlink:to="cvac_OtherOperatingIncomeGovernmentGrants_638043208767559481" order="5" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_MiscellaneousOtherOperatingIncomeOther" xlink:label="cvac_MiscellaneousOtherOperatingIncomeOther_638043208767559481" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="MiscellaneousOtherOperatingIncome" xlink:to="cvac_MiscellaneousOtherOperatingIncomeOther_638043208767559481" order="6" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.curevac.com/role/DisclosureShareBasedPaymentsExpensesDetails" xlink:type="extended" xlink:title="40501 - Disclosure - Share-based payments - Expenses (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_BenefitExpenseRecognizedForShareBasedPayment" xlink:label="BenefitExpenseRecognizedForShareBasedPayment" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInGeneralAndAdministrativeExpenses" xlink:label="cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInGeneralAndAdministrativeExpenses_638043208767559481" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="BenefitExpenseRecognizedForShareBasedPayment" xlink:to="cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInGeneralAndAdministrativeExpenses_638043208767559481" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInResearchAndDevelopmentExpenses" xlink:label="cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInResearchAndDevelopmentExpenses_638043208767559481" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="BenefitExpenseRecognizedForShareBasedPayment" xlink:to="cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInResearchAndDevelopmentExpenses_638043208767559481" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInSellingAndDistributionExpenses" xlink:label="cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInSellingAndDistributionExpenses_638043208767559481" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="BenefitExpenseRecognizedForShareBasedPayment" xlink:to="cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInSellingAndDistributionExpenses_638043208767559481" order="3" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.curevac.com/role/DisclosureSignificantTransactionsAndEventsFrameAcquisitionPurchasePriceAllocationDetails" xlink:type="extended" xlink:title="41802 - Disclosure - Significant transactions and events - Frame Acquisition - Purchase Price Allocation (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed" xlink:label="ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_TotalAssetsRecognisedAsOfAcquisitionDate" xlink:label="cvac_TotalAssetsRecognisedAsOfAcquisitionDate_638043208767559481" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed" xlink:to="cvac_TotalAssetsRecognisedAsOfAcquisitionDate_638043208767559481" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NoncurrentAssetsRecognisedAsOfAcquisitionDate" xlink:label="ifrs-full_NoncurrentAssetsRecognisedAsOfAcquisitionDate_638043208767559481" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="cvac_TotalAssetsRecognisedAsOfAcquisitionDate_638043208767559481" xlink:to="ifrs-full_NoncurrentAssetsRecognisedAsOfAcquisitionDate_638043208767559481" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TechnologybasedIntangibleAssetsRecognisedAsOfAcquisitionDate" xlink:label="ifrs-full_TechnologybasedIntangibleAssetsRecognisedAsOfAcquisitionDate_638043208767569484" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_NoncurrentAssetsRecognisedAsOfAcquisitionDate_638043208767559481" xlink:to="ifrs-full_TechnologybasedIntangibleAssetsRecognisedAsOfAcquisitionDate_638043208767569484" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_RightOfUseAssetsRecognisedAsOfAcquisitionDate" xlink:label="cvac_RightOfUseAssetsRecognisedAsOfAcquisitionDate_638043208767569484" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_NoncurrentAssetsRecognisedAsOfAcquisitionDate_638043208767559481" xlink:to="cvac_RightOfUseAssetsRecognisedAsOfAcquisitionDate_638043208767569484" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDate" xlink:label="ifrs-full_PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDate_638043208767569484" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_NoncurrentAssetsRecognisedAsOfAcquisitionDate_638043208767559481" xlink:to="ifrs-full_PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDate_638043208767569484" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CurrentAssetsRecognisedAsOfAcquisitionDate" xlink:label="ifrs-full_CurrentAssetsRecognisedAsOfAcquisitionDate_638043208767569484" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="cvac_TotalAssetsRecognisedAsOfAcquisitionDate_638043208767559481" xlink:to="ifrs-full_CurrentAssetsRecognisedAsOfAcquisitionDate_638043208767569484" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CashAndCashEquivalentsRecognisedAsOfAcquisitionDate" xlink:label="ifrs-full_CashAndCashEquivalentsRecognisedAsOfAcquisitionDate_638043208767569484" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CurrentAssetsRecognisedAsOfAcquisitionDate_638043208767569484" xlink:to="ifrs-full_CashAndCashEquivalentsRecognisedAsOfAcquisitionDate_638043208767569484" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_FairValueOfAcquiredReceivables" xlink:label="ifrs-full_FairValueOfAcquiredReceivables_638043208767569484" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CurrentAssetsRecognisedAsOfAcquisitionDate_638043208767569484" xlink:to="ifrs-full_FairValueOfAcquiredReceivables_638043208767569484" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_LiabilitiesRecognisedAsOfAcquisitionDate" xlink:label="cvac_LiabilitiesRecognisedAsOfAcquisitionDate_638043208767569484" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed" xlink:to="cvac_LiabilitiesRecognisedAsOfAcquisitionDate_638043208767569484" order="2" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CurrentLiabilitiesRecognisedAsOfAcquisitionDate" xlink:label="ifrs-full_CurrentLiabilitiesRecognisedAsOfAcquisitionDate_638043208767569484" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="cvac_LiabilitiesRecognisedAsOfAcquisitionDate_638043208767569484" xlink:to="ifrs-full_CurrentLiabilitiesRecognisedAsOfAcquisitionDate_638043208767569484" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_CurrentLeaseLiabilitiesRecognisedAsOfAcquisitionDate" xlink:label="cvac_CurrentLeaseLiabilitiesRecognisedAsOfAcquisitionDate_638043208767569484" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CurrentLiabilitiesRecognisedAsOfAcquisitionDate_638043208767569484" xlink:to="cvac_CurrentLeaseLiabilitiesRecognisedAsOfAcquisitionDate_638043208767569484" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TradeAndOtherPayablesRecognisedAsOfAcquisitionDate" xlink:label="ifrs-full_TradeAndOtherPayablesRecognisedAsOfAcquisitionDate_638043208767579482" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CurrentLiabilitiesRecognisedAsOfAcquisitionDate_638043208767569484" xlink:to="ifrs-full_TradeAndOtherPayablesRecognisedAsOfAcquisitionDate_638043208767579482" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_OtherCurrentLiabilitiesRecognisedAsOfAcquisitionDate" xlink:label="cvac_OtherCurrentLiabilitiesRecognisedAsOfAcquisitionDate_638043208767579482" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CurrentLiabilitiesRecognisedAsOfAcquisitionDate_638043208767569484" xlink:to="cvac_OtherCurrentLiabilitiesRecognisedAsOfAcquisitionDate_638043208767579482" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NoncurrentLiabilitiesRecognisedAsOfAcquisitionDate" xlink:label="ifrs-full_NoncurrentLiabilitiesRecognisedAsOfAcquisitionDate_638043208767579482" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="cvac_LiabilitiesRecognisedAsOfAcquisitionDate_638043208767569484" xlink:to="ifrs-full_NoncurrentLiabilitiesRecognisedAsOfAcquisitionDate_638043208767579482" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_NoncurrentLeaseLiabilitiesRecognisedAsOfAcquisitionDate" xlink:label="cvac_NoncurrentLeaseLiabilitiesRecognisedAsOfAcquisitionDate_638043208767579482" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_NoncurrentLiabilitiesRecognisedAsOfAcquisitionDate_638043208767579482" xlink:to="cvac_NoncurrentLeaseLiabilitiesRecognisedAsOfAcquisitionDate_638043208767579482" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_NetDeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate" xlink:label="cvac_NetDeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate_638043208767579482" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_NoncurrentLiabilitiesRecognisedAsOfAcquisitionDate_638043208767579482" xlink:to="cvac_NetDeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate_638043208767579482" order="2" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.curevac.com/role/DisclosureSignificantTransactionsAndEventsGoodwillRecognizedOnFrameAcquisitionDetails" xlink:type="extended" xlink:title="41803 - Disclosure - Significant transactions and events - Goodwill Recognized On Frame Acquisition (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_GoodwillRecognisedAsOfAcquisitionDate" xlink:label="ifrs-full_GoodwillRecognisedAsOfAcquisitionDate" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred" xlink:label="ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred_638043208767579482" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_GoodwillRecognisedAsOfAcquisitionDate" xlink:to="ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred_638043208767579482" order="1" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed" xlink:label="ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed_638043208767589481" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_GoodwillRecognisedAsOfAcquisitionDate" xlink:to="ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed_638043208767589481" order="2" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.curevac.com/role/DisclosureSignificantTransactionsAndEventsAnalysesOfCashFlowsOnFrameAcquisitionDetails" xlink:type="extended" xlink:title="41804 - Disclosure - Significant transactions and events - Analyses of cash flows on Frame Acquisition (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_IfrsCashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities" xlink:label="cvac_IfrsCashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CashTransferred" xlink:label="ifrs-full_CashTransferred_638043208767589481" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="cvac_IfrsCashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities" xlink:to="ifrs-full_CashTransferred_638043208767589481" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CashAndCashEquivalentsRecognisedAsOfAcquisitionDate" xlink:label="ifrs-full_CashAndCashEquivalentsRecognisedAsOfAcquisitionDate_638043208767589481" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="cvac_IfrsCashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities" xlink:to="ifrs-full_CashAndCashEquivalentsRecognisedAsOfAcquisitionDate_638043208767589481" order="2" use="optional" weight="-1" />
  </calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>8
<FILENAME>cvac-20220930_def.xml
<DESCRIPTION>EX-101.DEF
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  10.1.0.3 -->
<!--Based on XBRL 2.1-->
<!--Created on: 11/17/2022 10:28:01 PM-->
<!--Modified on: 11/17/2022 10:28:01 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink">
  <roleRef xlink:type="simple" xlink:href="cvac-20220930.xsd#DocumentDocumentAndEntityInformation" roleURI="http://www.curevac.com/role/DocumentDocumentAndEntityInformation" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20220930.xsd#StatementInterimCondensedConsolidatedStatementsOfChangesInShareholdersEquity" roleURI="http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfChangesInShareholdersEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20220930.xsd#DisclosureShareBasedPaymentsTables" roleURI="http://www.curevac.com/role/DisclosureShareBasedPaymentsTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20220930.xsd#DisclosureCorporateInformationDetails" roleURI="http://www.curevac.com/role/DisclosureCorporateInformationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20220930.xsd#DisclosureNotesToConsolidatedFinancialStatementsRevenueFromContractWithCustomersDetails" roleURI="http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsRevenueFromContractWithCustomersDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20220930.xsd#DisclosureNotesToConsolidatedFinancialStatementsSummaryOfUpfrontPaymentsAndRelatedRevenuesRecognizedDetails" roleURI="http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsSummaryOfUpfrontPaymentsAndRelatedRevenuesRecognizedDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20220930.xsd#DisclosureNotesToConsolidatedFinancialStatementsContractLiabilitiesAllocatedToRemainingPerformanceObligationsDetails" roleURI="http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsContractLiabilitiesAllocatedToRemainingPerformanceObligationsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20220930.xsd#DisclosureNotesToConsolidatedFinancialStatementsCostOfSalesDetails" roleURI="http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsCostOfSalesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20220930.xsd#DisclosureNotesToConsolidatedFinancialStatementsSellingAndDistributionExpensesDetails" roleURI="http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsSellingAndDistributionExpensesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20220930.xsd#DisclosureNotesToConsolidatedFinancialStatementsResearchAndDevelopmentExpensesDetails" roleURI="http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsResearchAndDevelopmentExpensesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20220930.xsd#DisclosureNotesToConsolidatedFinancialStatementsGeneralAndAdministrativeExpensesDetails" roleURI="http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsGeneralAndAdministrativeExpensesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20220930.xsd#DisclosureNotesToConsolidatedFinancialStatementsGrantsWithGovernmentAgenciesAndSimilarBodiesDetails" roleURI="http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsGrantsWithGovernmentAgenciesAndSimilarBodiesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20220930.xsd#DisclosureIssuedCapitalAndReservesOverviewAndGeneralRemarksDetails" roleURI="http://www.curevac.com/role/DisclosureIssuedCapitalAndReservesOverviewAndGeneralRemarksDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20220930.xsd#DisclosureIssuedCapitalAndReservesImpactOfShareSplitDetails" roleURI="http://www.curevac.com/role/DisclosureIssuedCapitalAndReservesImpactOfShareSplitDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20220930.xsd#DisclosureShareBasedPaymentsExpensesDetails" roleURI="http://www.curevac.com/role/DisclosureShareBasedPaymentsExpensesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20220930.xsd#DisclosureShareBasedPaymentsExpenseRecognizedForProgramDetails" roleURI="http://www.curevac.com/role/DisclosureShareBasedPaymentsExpenseRecognizedForProgramDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20220930.xsd#DisclosureShareBasedPaymentsDetails" roleURI="http://www.curevac.com/role/DisclosureShareBasedPaymentsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20220930.xsd#DisclosureFixedAssetsIntangibleAssetsDetails" roleURI="http://www.curevac.com/role/DisclosureFixedAssetsIntangibleAssetsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20220930.xsd#DisclosureFixedAssetsPropertyPlantAndEquipmentDetails" roleURI="http://www.curevac.com/role/DisclosureFixedAssetsPropertyPlantAndEquipmentDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20220930.xsd#DisclosureInventoriesDetails" roleURI="http://www.curevac.com/role/DisclosureInventoriesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20220930.xsd#DisclosureOtherLiabilitiesDetails" roleURI="http://www.curevac.com/role/DisclosureOtherLiabilitiesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20220930.xsd#DisclosureLoansDetails" roleURI="http://www.curevac.com/role/DisclosureLoansDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20220930.xsd#DisclosureIncomeTaxDetails" roleURI="http://www.curevac.com/role/DisclosureIncomeTaxDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20220930.xsd#DisclosureDisclosureOfFinancialInstrumentsAndRiskManagementDetails" roleURI="http://www.curevac.com/role/DisclosureDisclosureOfFinancialInstrumentsAndRiskManagementDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20220930.xsd#DisclosureRelatedPartyDisclosuresDetails" roleURI="http://www.curevac.com/role/DisclosureRelatedPartyDisclosuresDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20220930.xsd#DisclosureSignificantTransactionsAndEventsDetails" roleURI="http://www.curevac.com/role/DisclosureSignificantTransactionsAndEventsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20220930.xsd#DisclosureSignificantTransactionsAndEventsFrameAcquisitionPurchasePriceAllocationDetails" roleURI="http://www.curevac.com/role/DisclosureSignificantTransactionsAndEventsFrameAcquisitionPurchasePriceAllocationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20220930.xsd#DisclosureSignificantTransactionsAndEventsGoodwillRecognizedOnFrameAcquisitionDetails" roleURI="http://www.curevac.com/role/DisclosureSignificantTransactionsAndEventsGoodwillRecognizedOnFrameAcquisitionDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20220930.xsd#DisclosureSignificantTransactionsAndEventsAnalysesOfCashFlowsOnFrameAcquisitionDetails" roleURI="http://www.curevac.com/role/DisclosureSignificantTransactionsAndEventsAnalysesOfCashFlowsOnFrameAcquisitionDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <link:roleRef roleURI="http://www.curevac.com/role/DisclosureStandardAndCustomAxisDomainDefaults" xlink:type="simple" xlink:href="cvac-20220930.xsd#DisclosureStandardAndCustomAxisDomainDefaults" />
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="simple" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd#eedm" />
  <link:arcroleRef arcroleURI="http://www.esma.europa.eu/xbrl/esef/arcrole/wider-narrower" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd#wider-narrower" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" />
  <link:definitionLink xlink:type="extended" xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:title="Extensible Enumeration Domain Members" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.curevac.com/role/DisclosureStandardAndCustomAxisDomainDefaults">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressesAddressTypeAxis" xlink:label="EntityAddressesAddressTypeAxis" xlink:title="EntityAddressesAddressTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AddressTypeDomain" xlink:label="AddressTypeDomain" xlink:title="AddressTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="EntityAddressesAddressTypeAxis" xlink:to="AddressTypeDomain" xlink:title="definition: EntityAddressesAddressTypeAxis to AddressTypeDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:label="RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:title="RetrospectiveApplicationAndRetrospectiveRestatementAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RestatedMember" xlink:label="RestatedMember" xlink:title="RestatedMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:to="RestatedMember" xlink:title="definition: RetrospectiveApplicationAndRetrospectiveRestatementAxis to RestatedMember" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ComponentsOfEquityAxis" xlink:label="ComponentsOfEquityAxis" xlink:title="ComponentsOfEquityAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_EquityMember" xlink:label="EquityMember" xlink:title="EquityMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ComponentsOfEquityAxis" xlink:to="EquityMember" xlink:title="definition: ComponentsOfEquityAxis to EquityMember" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:label="TypesOfSharebasedPaymentArrangementsAxis" xlink:title="TypesOfSharebasedPaymentArrangementsAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_SharebasedPaymentArrangementsMember" xlink:label="SharebasedPaymentArrangementsMember" xlink:title="SharebasedPaymentArrangementsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="TypesOfSharebasedPaymentArrangementsAxis" xlink:to="SharebasedPaymentArrangementsMember" xlink:title="definition: TypesOfSharebasedPaymentArrangementsAxis to SharebasedPaymentArrangementsMember" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_IfrsSaleOfStockAxis" xlink:label="IfrsSaleOfStockAxis" xlink:title="IfrsSaleOfStockAxis" />
    <link:loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_IfrsSaleOfStockDomain" xlink:label="IfrsSaleOfStockDomain" xlink:title="IfrsSaleOfStockDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="IfrsSaleOfStockAxis" xlink:to="IfrsSaleOfStockDomain" xlink:title="definition: IfrsSaleOfStockAxis to IfrsSaleOfStockDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="TitleOfIndividualAxis" xlink:title="TitleOfIndividualAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="TitleOfIndividualWithRelationshipToEntityDomain" xlink:title="TitleOfIndividualWithRelationshipToEntityDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="TitleOfIndividualAxis" xlink:to="TitleOfIndividualWithRelationshipToEntityDomain" xlink:title="definition: TitleOfIndividualAxis to TitleOfIndividualWithRelationshipToEntityDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RangeAxis" xlink:label="RangeAxis" xlink:title="RangeAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RangesMember" xlink:label="RangesMember" xlink:title="RangesMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="RangeAxis" xlink:to="RangesMember" xlink:title="definition: RangeAxis to RangesMember" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis" xlink:label="StatementScenarioAxis" xlink:title="StatementScenarioAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="ScenarioUnspecifiedDomain" xlink:title="ScenarioUnspecifiedDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="StatementScenarioAxis" xlink:to="ScenarioUnspecifiedDomain" xlink:title="definition: StatementScenarioAxis to ScenarioUnspecifiedDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_MaturityAxis" xlink:label="MaturityAxis" xlink:title="MaturityAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AggregatedTimeBandsMember" xlink:label="AggregatedTimeBandsMember" xlink:title="AggregatedTimeBandsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="MaturityAxis" xlink:to="AggregatedTimeBandsMember" xlink:title="definition: MaturityAxis to AggregatedTimeBandsMember" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_IfrsVestingAxis" xlink:label="IfrsVestingAxis" xlink:title="IfrsVestingAxis" />
    <link:loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_IfrsVestingDomain" xlink:label="IfrsVestingDomain" xlink:title="IfrsVestingDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="IfrsVestingAxis" xlink:to="IfrsVestingDomain" xlink:title="definition: IfrsVestingAxis to IfrsVestingDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:label="NonadjustingEventsAfterReportingPeriodAxis" xlink:title="NonadjustingEventsAfterReportingPeriodAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NonadjustingEventsMember" xlink:label="NonadjustingEventsMember" xlink:title="NonadjustingEventsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="NonadjustingEventsAfterReportingPeriodAxis" xlink:to="NonadjustingEventsMember" xlink:title="definition: NonadjustingEventsAfterReportingPeriodAxis to NonadjustingEventsMember" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_BusinessCombinationsAxis" xlink:label="BusinessCombinationsAxis" xlink:title="BusinessCombinationsAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_EntitysTotalForBusinessCombinationsMember" xlink:label="EntitysTotalForBusinessCombinationsMember" xlink:title="EntitysTotalForBusinessCombinationsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="BusinessCombinationsAxis" xlink:to="EntitysTotalForBusinessCombinationsMember" xlink:title="definition: BusinessCombinationsAxis to EntitysTotalForBusinessCombinationsMember" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="ConsolidatedEntitiesAxis" xlink:title="ConsolidatedEntitiesAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="ConsolidatedEntitiesDomain" xlink:title="ConsolidatedEntitiesDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ConsolidatedEntitiesAxis" xlink:to="ConsolidatedEntitiesDomain" xlink:title="definition: ConsolidatedEntitiesAxis to ConsolidatedEntitiesDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProductsAndServicesAxis" xlink:label="ProductsAndServicesAxis" xlink:title="ProductsAndServicesAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProductsAndServicesMember" xlink:label="ProductsAndServicesMember" xlink:title="ProductsAndServicesMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ProductsAndServicesAxis" xlink:to="ProductsAndServicesMember" xlink:title="definition: ProductsAndServicesAxis to ProductsAndServicesMember" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TimingOfTransferOfGoodsOrServicesAxis" xlink:label="TimingOfTransferOfGoodsOrServicesAxis" xlink:title="TimingOfTransferOfGoodsOrServicesAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TimingOfTransferOfGoodsOrServicesMember" xlink:label="TimingOfTransferOfGoodsOrServicesMember" xlink:title="TimingOfTransferOfGoodsOrServicesMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="TimingOfTransferOfGoodsOrServicesAxis" xlink:to="TimingOfTransferOfGoodsOrServicesMember" xlink:title="definition: TimingOfTransferOfGoodsOrServicesAxis to TimingOfTransferOfGoodsOrServicesMember" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ClassesOfAssetsAxis" xlink:label="ClassesOfAssetsAxis" xlink:title="ClassesOfAssetsAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ClassesOfAssetsMember" xlink:label="ClassesOfAssetsMember" xlink:title="ClassesOfAssetsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ClassesOfAssetsAxis" xlink:to="ClassesOfAssetsMember" xlink:title="definition: ClassesOfAssetsAxis to ClassesOfAssetsMember" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_InitiallyAppliedIFRSsAxis" xlink:label="InitiallyAppliedIFRSsAxis" xlink:title="InitiallyAppliedIFRSsAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_InitiallyAppliedIFRSsMember" xlink:label="InitiallyAppliedIFRSsMember" xlink:title="InitiallyAppliedIFRSsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="InitiallyAppliedIFRSsAxis" xlink:to="InitiallyAppliedIFRSsMember" xlink:title="definition: InitiallyAppliedIFRSsAxis to InitiallyAppliedIFRSsMember" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ConcentrationsOfRiskAxis" xlink:label="ConcentrationsOfRiskAxis" xlink:title="ConcentrationsOfRiskAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ConcentrationsOfRiskMember" xlink:label="ConcentrationsOfRiskMember" xlink:title="ConcentrationsOfRiskMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ConcentrationsOfRiskAxis" xlink:to="ConcentrationsOfRiskMember" xlink:title="definition: ConcentrationsOfRiskAxis to ConcentrationsOfRiskMember" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis" xlink:label="ClassesOfIntangibleAssetsOtherThanGoodwillAxis" xlink:title="ClassesOfIntangibleAssetsOtherThanGoodwillAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwillMember" xlink:label="IntangibleAssetsOtherThanGoodwillMember" xlink:title="IntangibleAssetsOtherThanGoodwillMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ClassesOfIntangibleAssetsOtherThanGoodwillAxis" xlink:to="IntangibleAssetsOtherThanGoodwillMember" xlink:title="definition: ClassesOfIntangibleAssetsOtherThanGoodwillAxis to IntangibleAssetsOtherThanGoodwillMember" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:label="CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:title="CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CarryingAmountMember" xlink:label="CarryingAmountMember" xlink:title="CarryingAmountMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:to="CarryingAmountMember" xlink:title="definition: CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis to CarryingAmountMember" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:label="ClassesOfPropertyPlantAndEquipmentAxis" xlink:title="ClassesOfPropertyPlantAndEquipmentAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_PropertyPlantAndEquipmentMember" xlink:label="PropertyPlantAndEquipmentMember" xlink:title="PropertyPlantAndEquipmentMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ClassesOfPropertyPlantAndEquipmentAxis" xlink:to="PropertyPlantAndEquipmentMember" xlink:title="definition: ClassesOfPropertyPlantAndEquipmentAxis to PropertyPlantAndEquipmentMember" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_GeographicalAreasAxis" xlink:label="GeographicalAreasAxis" xlink:title="GeographicalAreasAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_GeographicalAreasMember" xlink:label="GeographicalAreasMember" xlink:title="GeographicalAreasMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="GeographicalAreasAxis" xlink:to="GeographicalAreasMember" xlink:title="definition: GeographicalAreasAxis to GeographicalAreasMember" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_MajorCustomersAxis" xlink:label="MajorCustomersAxis" xlink:title="MajorCustomersAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_MajorCustomersMember" xlink:label="MajorCustomersMember" xlink:title="MajorCustomersMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="MajorCustomersAxis" xlink:to="MajorCustomersMember" xlink:title="definition: MajorCustomersAxis to MajorCustomersMember" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_GovernmentGrantsAxis" xlink:label="GovernmentGrantsAxis" xlink:title="GovernmentGrantsAxis" />
    <link:loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_GovernmentGrantsDomain" xlink:label="GovernmentGrantsDomain" xlink:title="GovernmentGrantsDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="GovernmentGrantsAxis" xlink:to="GovernmentGrantsDomain" xlink:title="definition: GovernmentGrantsAxis to GovernmentGrantsDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_IfrsIncomeStatementLocationAxis" xlink:label="IfrsIncomeStatementLocationAxis" xlink:title="IfrsIncomeStatementLocationAxis" />
    <link:loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_IfrsIncomeStatementLocationDomain" xlink:label="IfrsIncomeStatementLocationDomain" xlink:title="IfrsIncomeStatementLocationDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="IfrsIncomeStatementLocationAxis" xlink:to="IfrsIncomeStatementLocationDomain" xlink:title="definition: IfrsIncomeStatementLocationAxis to IfrsIncomeStatementLocationDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ClassesOfShareCapitalAxis" xlink:label="ClassesOfShareCapitalAxis" xlink:title="ClassesOfShareCapitalAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ClassesOfShareCapitalMember" xlink:label="ClassesOfShareCapitalMember" xlink:title="ClassesOfShareCapitalMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ClassesOfShareCapitalAxis" xlink:to="ClassesOfShareCapitalMember" xlink:title="definition: ClassesOfShareCapitalAxis to ClassesOfShareCapitalMember" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="CategoriesOfRelatedPartiesAxis" xlink:title="CategoriesOfRelatedPartiesAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="EntitysTotalForRelatedPartiesMember" xlink:title="EntitysTotalForRelatedPartiesMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="CategoriesOfRelatedPartiesAxis" xlink:to="EntitysTotalForRelatedPartiesMember" xlink:title="definition: CategoriesOfRelatedPartiesAxis to EntitysTotalForRelatedPartiesMember" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_BorrowingsByNameAxis" xlink:label="BorrowingsByNameAxis" xlink:title="BorrowingsByNameAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_BorrowingsByNameMember" xlink:label="BorrowingsByNameMember" xlink:title="BorrowingsByNameMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="BorrowingsByNameAxis" xlink:to="BorrowingsByNameMember" xlink:title="definition: BorrowingsByNameAxis to BorrowingsByNameMember" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" xlink:label="TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" xlink:title="TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember" xlink:label="TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember" xlink:title="TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" xlink:to="TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember" xlink:title="definition: TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis to TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CurrencyAxis" xlink:label="CurrencyAxis" xlink:title="CurrencyAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2021/currency-2021.xsd#currency_AllCurrenciesDomain" xlink:label="AllCurrenciesDomain" xlink:title="AllCurrenciesDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="CurrencyAxis" xlink:to="AllCurrenciesDomain" xlink:title="definition: CurrencyAxis to AllCurrenciesDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TypesOfRisksAxis" xlink:label="TypesOfRisksAxis" xlink:title="TypesOfRisksAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TypesOfRisksMember" xlink:label="TypesOfRisksMember" xlink:title="TypesOfRisksMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="TypesOfRisksAxis" xlink:to="TypesOfRisksMember" xlink:title="definition: TypesOfRisksAxis to TypesOfRisksMember" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:label="ClassesOfFinancialInstrumentsAxis" xlink:title="ClassesOfFinancialInstrumentsAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ClassesOfFinancialInstrumentsMember" xlink:label="ClassesOfFinancialInstrumentsMember" xlink:title="ClassesOfFinancialInstrumentsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ClassesOfFinancialInstrumentsAxis" xlink:to="ClassesOfFinancialInstrumentsMember" xlink:title="definition: ClassesOfFinancialInstrumentsAxis to ClassesOfFinancialInstrumentsMember" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_LevelsOfFairValueHierarchyAxis" xlink:label="LevelsOfFairValueHierarchyAxis" xlink:title="LevelsOfFairValueHierarchyAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AllLevelsOfFairValueHierarchyMember" xlink:label="AllLevelsOfFairValueHierarchyMember" xlink:title="AllLevelsOfFairValueHierarchyMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="LevelsOfFairValueHierarchyAxis" xlink:to="AllLevelsOfFairValueHierarchyMember" xlink:title="definition: LevelsOfFairValueHierarchyAxis to AllLevelsOfFairValueHierarchyMember" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis" xlink:label="LiabilitiesArisingFromFinancingActivitiesAxis" xlink:title="LiabilitiesArisingFromFinancingActivitiesAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_LiabilitiesArisingFromFinancingActivitiesMember" xlink:label="LiabilitiesArisingFromFinancingActivitiesMember" xlink:title="LiabilitiesArisingFromFinancingActivitiesMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="LiabilitiesArisingFromFinancingActivitiesAxis" xlink:to="LiabilitiesArisingFromFinancingActivitiesMember" xlink:title="definition: LiabilitiesArisingFromFinancingActivitiesAxis to LiabilitiesArisingFromFinancingActivitiesMember" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_PlanNameAxis" xlink:label="cvac_PlanNameAxis_1" xlink:title="cvac_PlanNameAxis_1" />
    <link:loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_PlanNameDomain" xlink:label="cvac_PlanNameDomain_1" xlink:title="cvac_PlanNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="cvac_PlanNameAxis_1" xlink:to="cvac_PlanNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:cvac_PlanNameAxis_1 To cvac_PlanNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TypesOfContractsAxis" xlink:label="ifrs-full_TypesOfContractsAxis_1" xlink:title="ifrs-full_TypesOfContractsAxis_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TypesOfContractsMember" xlink:label="ifrs-full_TypesOfContractsMember_1" xlink:title="ifrs-full_TypesOfContractsMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="ifrs-full_TypesOfContractsAxis_1" xlink:to="ifrs-full_TypesOfContractsMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:ifrs-full_TypesOfContractsAxis_1 To ifrs-full_TypesOfContractsMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_TypeOfArrangementAxis" xlink:label="cvac_TypeOfArrangementAxis_1" xlink:title="cvac_TypeOfArrangementAxis_1" />
    <link:loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_ArrangementsAndNonArrangementTransactionsMember" xlink:label="cvac_ArrangementsAndNonArrangementTransactionsMember_1" xlink:title="cvac_ArrangementsAndNonArrangementTransactionsMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="cvac_TypeOfArrangementAxis_1" xlink:to="cvac_ArrangementsAndNonArrangementTransactionsMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:cvac_TypeOfArrangementAxis_1 To cvac_ArrangementsAndNonArrangementTransactionsMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_1" xlink:title="srt_CounterpartyNameAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_1" xlink:title="srt_RepurchaseAgreementCounterpartyNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_CounterpartyNameAxis_1" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_CounterpartyNameAxis_1 To srt_RepurchaseAgreementCounterpartyNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis" xlink:label="cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_1" xlink:title="cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_1" />
    <link:loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountDomain" xlink:label="cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountDomain_1" xlink:title="cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_1" xlink:to="cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_1 To cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CounterpartiesAxis" xlink:label="ifrs-full_CounterpartiesAxis_1" xlink:title="ifrs-full_CounterpartiesAxis_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CounterpartiesMember" xlink:label="ifrs-full_CounterpartiesMember_1" xlink:title="ifrs-full_CounterpartiesMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="ifrs-full_CounterpartiesAxis_1" xlink:to="ifrs-full_CounterpartiesMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:ifrs-full_CounterpartiesAxis_1 To ifrs-full_CounterpartiesMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AssetsAndLiabilitiesClassifiedAsHeldForSaleAxis" xlink:label="ifrs-full_AssetsAndLiabilitiesClassifiedAsHeldForSaleAxis_1" xlink:title="ifrs-full_AssetsAndLiabilitiesClassifiedAsHeldForSaleAxis_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AssetsAndLiabilitiesNotClassifiedAsHeldForSaleMember" xlink:label="ifrs-full_AssetsAndLiabilitiesNotClassifiedAsHeldForSaleMember_1" xlink:title="ifrs-full_AssetsAndLiabilitiesNotClassifiedAsHeldForSaleMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="ifrs-full_AssetsAndLiabilitiesClassifiedAsHeldForSaleAxis_1" xlink:to="ifrs-full_AssetsAndLiabilitiesNotClassifiedAsHeldForSaleMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:ifrs-full_AssetsAndLiabilitiesClassifiedAsHeldForSaleAxis_1 To ifrs-full_AssetsAndLiabilitiesNotClassifiedAsHeldForSaleMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_SignificantInvestmentsInSubsidiariesAxis" xlink:label="ifrs-full_SignificantInvestmentsInSubsidiariesAxis_1" xlink:title="ifrs-full_SignificantInvestmentsInSubsidiariesAxis_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_EntitysTotalForSubsidiariesMember" xlink:label="ifrs-full_EntitysTotalForSubsidiariesMember_1" xlink:title="ifrs-full_EntitysTotalForSubsidiariesMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="ifrs-full_SignificantInvestmentsInSubsidiariesAxis_1" xlink:to="ifrs-full_EntitysTotalForSubsidiariesMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:ifrs-full_SignificantInvestmentsInSubsidiariesAxis_1 To ifrs-full_EntitysTotalForSubsidiariesMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ClassesOfContingentLiabilitiesAxis" xlink:label="ifrs-full_ClassesOfContingentLiabilitiesAxis_1" xlink:title="ifrs-full_ClassesOfContingentLiabilitiesAxis_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ContingentLiabilitiesMember" xlink:label="ifrs-full_ContingentLiabilitiesMember_1" xlink:title="ifrs-full_ContingentLiabilitiesMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="ifrs-full_ClassesOfContingentLiabilitiesAxis_1" xlink:to="ifrs-full_ContingentLiabilitiesMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:ifrs-full_ClassesOfContingentLiabilitiesAxis_1 To ifrs-full_ContingentLiabilitiesMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_AssetsHeldForSaleAxis" xlink:label="cvac_AssetsHeldForSaleAxis_1" xlink:title="cvac_AssetsHeldForSaleAxis_1" />
    <link:loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_AssetsHeldForSaleDomain" xlink:label="cvac_AssetsHeldForSaleDomain_1" xlink:title="cvac_AssetsHeldForSaleDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="cvac_AssetsHeldForSaleAxis_1" xlink:to="cvac_AssetsHeldForSaleDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:cvac_AssetsHeldForSaleAxis_1 To cvac_AssetsHeldForSaleDomain_1" order="1" />
  </link:definitionLink>
  <definitionLink xlink:role="http://www.curevac.com/role/DocumentDocumentAndEntityInformation" xlink:type="extended" xlink:title="00090 - Document - Document and Entity Information" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressesAddressTypeAxis" xlink:label="dei_EntityAddressesAddressTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="dei_DocumentInformationTable" xlink:to="dei_EntityAddressesAddressTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AddressTypeDomain" xlink:label="dei_AddressTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="dei_EntityAddressesAddressTypeAxis" xlink:to="dei_AddressTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_BusinessContactMember" xlink:label="dei_BusinessContactMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="dei_AddressTypeDomain" xlink:to="dei_BusinessContactMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentRegistrationStatement" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentAnnualReport" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentTransitionReport" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentShellCompanyReport" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine2" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCityOrTown" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressStateOrProvince" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCountry" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressPostalZipCode" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="16" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CityAreaCode" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="17" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_LocalPhoneNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_ContactPersonnelName" xlink:label="dei_ContactPersonnelName" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="18" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_ContactPersonnelName" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="19" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CountryRegion" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_ContactPersonnelEmailAddress" xlink:label="dei_ContactPersonnelEmailAddress" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="20" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_ContactPersonnelEmailAddress" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="21" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_Security12bTitle" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="22" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_TradingSymbol" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="23" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_SecurityExchangeName" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="24" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFileNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="25" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityWellKnownSeasonedIssuer" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="26" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCurrentReportingStatus" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="27" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFilerCategory" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="28" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityInteractiveDataCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="29" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="30" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityExTransitionPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="31" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentAccountingStandard" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="32" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityShellCompany" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="33" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCommonStockSharesOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="34" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CurrentFiscalYearEndDate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="35" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalYearFocus" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="36" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalPeriodFocus" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="37" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="38" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="39" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_IcfrAuditorAttestationFlag" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="40" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentDescription" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="41" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityVoluntaryFilers" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="42" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityPublicFloat" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorName" xlink:label="dei_AuditorName" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="43" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorName" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="44" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorFirmId" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="45" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorLocation" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfChangesInShareholdersEquity" xlink:type="extended" xlink:title="00300 - Statement - Interim Condensed Consolidated Statements of Changes in Shareholders' Equity" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_StatementOfChangesInEquityTable" xlink:label="ifrs-full_StatementOfChangesInEquityTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:label="ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="ifrs-full_StatementOfChangesInEquityTable" xlink:to="ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RestatedMember" xlink:label="ifrs-full_RestatedMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:to="ifrs-full_RestatedMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_InAccordanceWithIFRS9Member" xlink:label="ifrs-full_InAccordanceWithIFRS9Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_RestatedMember" xlink:to="ifrs-full_InAccordanceWithIFRS9Member" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IncreaseDecreaseDueToApplicationOfIFRS15Member" xlink:label="ifrs-full_IncreaseDecreaseDueToApplicationOfIFRS15Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_RestatedMember" xlink:to="ifrs-full_IncreaseDecreaseDueToApplicationOfIFRS15Member" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_PreviouslyStatedMember" xlink:label="ifrs-full_PreviouslyStatedMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="ifrs-full_RestatedMember" xlink:to="ifrs-full_PreviouslyStatedMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ComponentsOfEquityAxis" xlink:label="ifrs-full_ComponentsOfEquityAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="ifrs-full_StatementOfChangesInEquityTable" xlink:to="ifrs-full_ComponentsOfEquityAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_EquityMember" xlink:label="ifrs-full_EquityMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="ifrs-full_EquityMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IssuedCapitalMember" xlink:label="ifrs-full_IssuedCapitalMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_EquityMember" xlink:to="ifrs-full_IssuedCapitalMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CapitalReserveMember" xlink:label="ifrs-full_CapitalReserveMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_EquityMember" xlink:to="ifrs-full_CapitalReserveMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TreasurySharesMember" xlink:label="ifrs-full_TreasurySharesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="ifrs-full_EquityMember" xlink:to="ifrs-full_TreasurySharesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RetainedEarningsMember" xlink:label="ifrs-full_RetainedEarningsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="ifrs-full_EquityMember" xlink:to="ifrs-full_RetainedEarningsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember" xlink:label="ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="ifrs-full_EquityMember" xlink:to="ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_StatementOfChangesInEquityLineItems" xlink:label="ifrs-full_StatementOfChangesInEquityLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_StatementOfChangesInEquityTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_Equity" xlink:label="ifrs-full_Equity" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_Equity" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_NetLoss" xlink:label="cvac_NetLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="cvac_NetLoss" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProfitLoss" xlink:label="ifrs-full_ProfitLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_ProfitLoss" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OtherComprehensiveIncome" xlink:label="ifrs-full_OtherComprehensiveIncome" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_OtherComprehensiveIncome" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_ComprehensiveIncomeLoss" xlink:label="cvac_ComprehensiveIncomeLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="cvac_ComprehensiveIncomeLoss" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ComprehensiveIncome" xlink:label="ifrs-full_ComprehensiveIncome" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_ComprehensiveIncome" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_ShareBasedPaymentExpenseIncl.DeferredTaxes" xlink:label="cvac_ShareBasedPaymentExpenseIncl.DeferredTaxes" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="cvac_ShareBasedPaymentExpenseIncl.DeferredTaxes" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IssueOfEquity" xlink:label="ifrs-full_IssueOfEquity" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_IssueOfEquity" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IncreaseDecreaseThroughConversionOfConvertibleInstruments" xlink:label="ifrs-full_IncreaseDecreaseThroughConversionOfConvertibleInstruments" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_IncreaseDecreaseThroughConversionOfConvertibleInstruments" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DecreaseIncreaseThroughTaxOnSharebasedPaymentTransactions" xlink:label="ifrs-full_DecreaseIncreaseThroughTaxOnSharebasedPaymentTransactions" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_DecreaseIncreaseThroughTaxOnSharebasedPaymentTransactions" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IncreaseDecreaseThroughExerciseOfOptions" xlink:label="ifrs-full_IncreaseDecreaseThroughExerciseOfOptions" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_IncreaseDecreaseThroughExerciseOfOptions" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_SettlementOfShareBasedPaymentAwardsAmount" xlink:label="cvac_SettlementOfShareBasedPaymentAwardsAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="cvac_SettlementOfShareBasedPaymentAwardsAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IncreaseDecreaseThroughTreasuryShareTransactions" xlink:label="ifrs-full_IncreaseDecreaseThroughTreasuryShareTransactions" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_IncreaseDecreaseThroughTreasuryShareTransactions" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IncreaseDecreaseThroughAcquisitionOfSubsidiary" xlink:label="ifrs-full_IncreaseDecreaseThroughAcquisitionOfSubsidiary" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_IncreaseDecreaseThroughAcquisitionOfSubsidiary" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NumberOfSharesOutstanding" xlink:label="ifrs-full_NumberOfSharesOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="16" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_NumberOfSharesOutstanding" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.curevac.com/role/DisclosureShareBasedPaymentsTables" xlink:type="extended" xlink:title="30503 - Disclosure - Share-based payments (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:label="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:to="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_SharebasedPaymentArrangementsMember" xlink:label="ifrs-full_SharebasedPaymentArrangementsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:to="ifrs-full_SharebasedPaymentArrangementsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_VirtualSharesProgramIMember" xlink:label="cvac_VirtualSharesProgramIMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_SharebasedPaymentArrangementsMember" xlink:to="cvac_VirtualSharesProgramIMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_VirtualSharesProgramIiMember" xlink:label="cvac_VirtualSharesProgramIiMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_SharebasedPaymentArrangementsMember" xlink:to="cvac_VirtualSharesProgramIiMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_OptionsGrantedToThenChiefExecutiveOfficerMember" xlink:label="cvac_OptionsGrantedToThenChiefExecutiveOfficerMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="ifrs-full_SharebasedPaymentArrangementsMember" xlink:to="cvac_OptionsGrantedToThenChiefExecutiveOfficerMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_RestrictedStockUnitsMember" xlink:label="cvac_RestrictedStockUnitsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="ifrs-full_SharebasedPaymentArrangementsMember" xlink:to="cvac_RestrictedStockUnitsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory" xlink:label="ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory" xlink:label="ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_DisclosureOfExpenseRecognizedForEmployeeServicesExplanatory" xlink:label="cvac_DisclosureOfExpenseRecognizedForEmployeeServicesExplanatory" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="cvac_DisclosureOfExpenseRecognizedForEmployeeServicesExplanatory" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_ScheduleOfExpenseRecognizedForProgramsTableTextBlock" xlink:label="cvac_ScheduleOfExpenseRecognizedForProgramsTableTextBlock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="cvac_ScheduleOfExpenseRecognizedForProgramsTableTextBlock" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.curevac.com/role/DisclosureCorporateInformationDetails" xlink:type="extended" xlink:title="40101 - Disclosure - Corporate Information (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfBusinessCombinationsTable" xlink:label="ifrs-full_DisclosureOfBusinessCombinationsTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_BusinessCombinationsAxis" xlink:label="ifrs-full_BusinessCombinationsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsTable" xlink:to="ifrs-full_BusinessCombinationsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_EntitysTotalForBusinessCombinationsMember" xlink:label="ifrs-full_EntitysTotalForBusinessCombinationsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_BusinessCombinationsAxis" xlink:to="ifrs-full_EntitysTotalForBusinessCombinationsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_CurevacN.v.Member" xlink:label="cvac_CurevacN.v.Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_EntitysTotalForBusinessCombinationsMember" xlink:to="cvac_CurevacN.v.Member" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="srt_ConsolidatedEntitiesAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsTable" xlink:to="srt_ConsolidatedEntitiesAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="srt_ConsolidatedEntitiesDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_ConsolidatedEntitiesAxis" xlink:to="srt_ConsolidatedEntitiesDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ParentCompanyMember" xlink:label="srt_ParentCompanyMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_ConsolidatedEntitiesDomain" xlink:to="srt_ParentCompanyMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:label="ifrs-full_DisclosureOfBusinessCombinationsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:to="ifrs-full_DisclosureOfBusinessCombinationsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_PercentageOfVotingEquityInterestsAcquired" xlink:label="ifrs-full_PercentageOfVotingEquityInterestsAcquired" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:to="ifrs-full_PercentageOfVotingEquityInterestsAcquired" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_CorporateReorganizationStockSplitRatio" xlink:label="cvac_CorporateReorganizationStockSplitRatio" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:to="cvac_CorporateReorganizationStockSplitRatio" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProportionOfOwnershipInterestInSubsidiary" xlink:label="ifrs-full_ProportionOfOwnershipInterestInSubsidiary" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:to="ifrs-full_ProportionOfOwnershipInterestInSubsidiary" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsRevenueFromContractWithCustomersDetails" xlink:type="extended" xlink:title="40301 - Disclosure - Notes to the consolidated financial statements - Revenue from contract with customers (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_DisclosureOfNotesToConsolidatedFinancialStatementsTable" xlink:label="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_GeographicalAreasAxis" xlink:label="ifrs-full_GeographicalAreasAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsTable" xlink:to="ifrs-full_GeographicalAreasAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_GeographicalAreasMember" xlink:label="ifrs-full_GeographicalAreasMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_GeographicalAreasAxis" xlink:to="ifrs-full_GeographicalAreasMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_BE" xlink:label="country_BE" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_GeographicalAreasMember" xlink:to="country_BE" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_DE" xlink:label="country_DE" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_GeographicalAreasMember" xlink:to="country_DE" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_CH" xlink:label="country_CH" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="ifrs-full_GeographicalAreasMember" xlink:to="country_CH" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_NL" xlink:label="country_NL" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="ifrs-full_GeographicalAreasMember" xlink:to="country_NL" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US" xlink:label="country_US" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="ifrs-full_GeographicalAreasMember" xlink:to="country_US" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_MajorCustomersAxis" xlink:label="ifrs-full_MajorCustomersAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsTable" xlink:to="ifrs-full_MajorCustomersAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_MajorCustomersMember" xlink:label="ifrs-full_MajorCustomersMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_MajorCustomersAxis" xlink:to="ifrs-full_MajorCustomersMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_GlaxosmithklineMember" xlink:label="cvac_GlaxosmithklineMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_MajorCustomersMember" xlink:to="cvac_GlaxosmithklineMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_BoehringerIngelheimMember" xlink:label="cvac_BoehringerIngelheimMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_MajorCustomersMember" xlink:to="cvac_BoehringerIngelheimMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_CrisprMember" xlink:label="cvac_CrisprMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="ifrs-full_MajorCustomersMember" xlink:to="cvac_CrisprMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_GenmabMember" xlink:label="cvac_GenmabMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="ifrs-full_MajorCustomersMember" xlink:to="cvac_GenmabMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_EliLillyAndCompanyMember" xlink:label="cvac_EliLillyAndCompanyMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="ifrs-full_MajorCustomersMember" xlink:to="cvac_EliLillyAndCompanyMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_OtherCustomersMember" xlink:label="cvac_OtherCustomersMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="ifrs-full_MajorCustomersMember" xlink:to="cvac_OtherCustomersMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProductsAndServicesAxis" xlink:label="ifrs-full_ProductsAndServicesAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsTable" xlink:to="ifrs-full_ProductsAndServicesAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProductsAndServicesMember" xlink:label="ifrs-full_ProductsAndServicesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_ProductsAndServicesAxis" xlink:to="ifrs-full_ProductsAndServicesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_ResearchServicesCombinedWithIpLicenseMember" xlink:label="cvac_ResearchServicesCombinedWithIpLicenseMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_ProductsAndServicesMember" xlink:to="cvac_ResearchServicesCombinedWithIpLicenseMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_IfrsProductMember" xlink:label="cvac_IfrsProductMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_ProductsAndServicesMember" xlink:to="cvac_IfrsProductMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_MilestoneRevenuesMember" xlink:label="cvac_MilestoneRevenuesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="ifrs-full_ProductsAndServicesMember" xlink:to="cvac_MilestoneRevenuesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_ResearchAndDevelopmentServicesMember" xlink:label="cvac_ResearchAndDevelopmentServicesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="ifrs-full_ProductsAndServicesMember" xlink:to="cvac_ResearchAndDevelopmentServicesMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems" xlink:label="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems" xlink:to="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RevenueFromContractsWithCustomers" xlink:label="ifrs-full_RevenueFromContractsWithCustomers" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems" xlink:to="ifrs-full_RevenueFromContractsWithCustomers" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_AdditionalDevelopmentMilestonePaymentsReceived" xlink:label="cvac_AdditionalDevelopmentMilestonePaymentsReceived" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems" xlink:to="cvac_AdditionalDevelopmentMilestonePaymentsReceived" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_IfrsDevelopmentMilestonePaymentIncludedInContractLiabilities" xlink:label="cvac_IfrsDevelopmentMilestonePaymentIncludedInContractLiabilities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems" xlink:to="cvac_IfrsDevelopmentMilestonePaymentIncludedInContractLiabilities" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsSummaryOfUpfrontPaymentsAndRelatedRevenuesRecognizedDetails" xlink:type="extended" xlink:title="40302 - Disclosure - Notes to the consolidated financial statements - Summary of upfront payments and related revenues recognized (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_DisclosureOfNotesToConsolidatedFinancialStatementsTable" xlink:label="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProductsAndServicesAxis" xlink:label="ifrs-full_ProductsAndServicesAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsTable" xlink:to="ifrs-full_ProductsAndServicesAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProductsAndServicesMember" xlink:label="ifrs-full_ProductsAndServicesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_ProductsAndServicesAxis" xlink:to="ifrs-full_ProductsAndServicesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_ResearchServicesCombinedWithIpLicenseMember" xlink:label="cvac_ResearchServicesCombinedWithIpLicenseMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_ProductsAndServicesMember" xlink:to="cvac_ResearchServicesCombinedWithIpLicenseMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RangeAxis" xlink:label="ifrs-full_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsTable" xlink:to="ifrs-full_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RangesMember" xlink:label="ifrs-full_RangesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_RangesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_BottomOfRangeMember" xlink:label="ifrs-full_BottomOfRangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_RangesMember" xlink:to="ifrs-full_BottomOfRangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_MajorCustomersAxis" xlink:label="ifrs-full_MajorCustomersAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsTable" xlink:to="ifrs-full_MajorCustomersAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_MajorCustomersMember" xlink:label="ifrs-full_MajorCustomersMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_MajorCustomersAxis" xlink:to="ifrs-full_MajorCustomersMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_EliLillyAndCompanyMember" xlink:label="cvac_EliLillyAndCompanyMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_MajorCustomersMember" xlink:to="cvac_EliLillyAndCompanyMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_CrisprMember" xlink:label="cvac_CrisprMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_MajorCustomersMember" xlink:to="cvac_CrisprMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_BoehringerIngelheimMember" xlink:label="cvac_BoehringerIngelheimMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="ifrs-full_MajorCustomersMember" xlink:to="cvac_BoehringerIngelheimMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_GenmabMember" xlink:label="cvac_GenmabMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="ifrs-full_MajorCustomersMember" xlink:to="cvac_GenmabMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_GlaxosmithklineMember" xlink:label="cvac_GlaxosmithklineMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="ifrs-full_MajorCustomersMember" xlink:to="cvac_GlaxosmithklineMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_Gsk2ndGenMember" xlink:label="cvac_Gsk2ndGenMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="ifrs-full_MajorCustomersMember" xlink:to="cvac_Gsk2ndGenMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_BmbfMember" xlink:label="cvac_BmbfMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="ifrs-full_MajorCustomersMember" xlink:to="cvac_BmbfMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_GermanFederalMinistryOfEducationAndResearchMember" xlink:label="cvac_GermanFederalMinistryOfEducationAndResearchMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="ifrs-full_MajorCustomersMember" xlink:to="cvac_GermanFederalMinistryOfEducationAndResearchMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_EuropeanUnionAdvancePurchaseAgreementMember" xlink:label="cvac_EuropeanUnionAdvancePurchaseAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="ifrs-full_MajorCustomersMember" xlink:to="cvac_EuropeanUnionAdvancePurchaseAgreementMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_EuropeanCommissionMember" xlink:label="cvac_EuropeanCommissionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="ifrs-full_MajorCustomersMember" xlink:to="cvac_EuropeanCommissionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems" xlink:label="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems" xlink:to="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_UpfrontPaymentsReceivedOrReceivable" xlink:label="cvac_UpfrontPaymentsReceivedOrReceivable" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems" xlink:to="cvac_UpfrontPaymentsReceivedOrReceivable" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_UpfrontPaymentsIncludedInContractLiabilities" xlink:label="cvac_UpfrontPaymentsIncludedInContractLiabilities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems" xlink:to="cvac_UpfrontPaymentsIncludedInContractLiabilities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod" xlink:label="ifrs-full_RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems" xlink:to="ifrs-full_RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsContractLiabilitiesAllocatedToRemainingPerformanceObligationsDetails" xlink:type="extended" xlink:title="40303 - Disclosure - Notes to the consolidated financial statements - Contract liabilities allocated to the remaining performance obligations (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_DisclosureOfNotesToConsolidatedFinancialStatementsTable" xlink:label="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsTable" xlink:to="srt_StatementScenarioAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems" xlink:label="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems" xlink:to="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CurrentTradeReceivables" xlink:label="ifrs-full_CurrentTradeReceivables" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems" xlink:to="ifrs-full_CurrentTradeReceivables" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CurrentContractAssets" xlink:label="ifrs-full_CurrentContractAssets" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems" xlink:to="ifrs-full_CurrentContractAssets" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ContractLiabilities" xlink:label="ifrs-full_ContractLiabilities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems" xlink:to="ifrs-full_ContractLiabilities" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsCostOfSalesDetails" xlink:type="extended" xlink:title="40304 - Disclosure - Notes to the consolidated financial statements - Cost of sales (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_DisclosureOfNotesToConsolidatedFinancialStatementsTable" xlink:label="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsTable" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_IfrsIncomeStatementLocationAxis" xlink:label="cvac_IfrsIncomeStatementLocationAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsTable" xlink:to="cvac_IfrsIncomeStatementLocationAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_IfrsIncomeStatementLocationDomain" xlink:label="cvac_IfrsIncomeStatementLocationDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="cvac_IfrsIncomeStatementLocationAxis" xlink:to="cvac_IfrsIncomeStatementLocationDomain" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_IfrsCostOfSalesMember" xlink:label="cvac_IfrsCostOfSalesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="cvac_IfrsIncomeStatementLocationDomain" xlink:to="cvac_IfrsCostOfSalesMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems" xlink:label="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems" xlink:to="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_PersonnelExpenses" xlink:label="cvac_PersonnelExpenses" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems" xlink:to="cvac_PersonnelExpenses" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RawMaterialsAndConsumablesUsed" xlink:label="ifrs-full_RawMaterialsAndConsumablesUsed" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems" xlink:to="ifrs-full_RawMaterialsAndConsumablesUsed" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_ThirdPartyServiceExpenses" xlink:label="cvac_ThirdPartyServiceExpenses" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems" xlink:to="cvac_ThirdPartyServiceExpenses" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_MaintenanceAndLeaseExpenses" xlink:label="cvac_MaintenanceAndLeaseExpenses" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems" xlink:to="cvac_MaintenanceAndLeaseExpenses" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DepreciationAndAmortisationExpense" xlink:label="ifrs-full_DepreciationAndAmortisationExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems" xlink:to="ifrs-full_DepreciationAndAmortisationExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_OtherExpense" xlink:label="cvac_OtherExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems" xlink:to="cvac_OtherExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ExpenseByNature" xlink:label="ifrs-full_ExpenseByNature" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems" xlink:to="ifrs-full_ExpenseByNature" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DecreaseThroughDerecognitionFinancialAssets" xlink:label="ifrs-full_DecreaseThroughDerecognitionFinancialAssets" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems" xlink:to="ifrs-full_DecreaseThroughDerecognitionFinancialAssets" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_ChangeInExpenseByNature" xlink:label="cvac_ChangeInExpenseByNature" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems" xlink:to="cvac_ChangeInExpenseByNature" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_WriteOffOfRawMaterials" xlink:label="cvac_WriteOffOfRawMaterials" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems" xlink:to="cvac_WriteOffOfRawMaterials" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsSellingAndDistributionExpensesDetails" xlink:type="extended" xlink:title="40305 - Disclosure - Notes to the consolidated financial statements - Selling and distribution expenses (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_DisclosureOfNotesToConsolidatedFinancialStatementsTable" xlink:label="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsTable" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_IfrsIncomeStatementLocationAxis" xlink:label="cvac_IfrsIncomeStatementLocationAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsTable" xlink:to="cvac_IfrsIncomeStatementLocationAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_IfrsIncomeStatementLocationDomain" xlink:label="cvac_IfrsIncomeStatementLocationDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="cvac_IfrsIncomeStatementLocationAxis" xlink:to="cvac_IfrsIncomeStatementLocationDomain" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_SellingAndDistributionExpensesMember" xlink:label="cvac_SellingAndDistributionExpensesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="cvac_IfrsIncomeStatementLocationDomain" xlink:to="cvac_SellingAndDistributionExpensesMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems" xlink:label="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems" xlink:to="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_PersonnelExpenses" xlink:label="cvac_PersonnelExpenses" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems" xlink:to="cvac_PersonnelExpenses" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DepreciationAndAmortisationExpense" xlink:label="ifrs-full_DepreciationAndAmortisationExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems" xlink:to="ifrs-full_DepreciationAndAmortisationExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_OtherExpense" xlink:label="cvac_OtherExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems" xlink:to="cvac_OtherExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ExpenseByNature" xlink:label="ifrs-full_ExpenseByNature" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems" xlink:to="ifrs-full_ExpenseByNature" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ShorttermEmployeeBenefitsExpense" xlink:label="ifrs-full_ShorttermEmployeeBenefitsExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems" xlink:to="ifrs-full_ShorttermEmployeeBenefitsExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" xlink:label="ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems" xlink:to="ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsResearchAndDevelopmentExpensesDetails" xlink:type="extended" xlink:title="40306 - Disclosure - Notes to the consolidated financial statements - Research and development expenses (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_DisclosureOfNotesToConsolidatedFinancialStatementsTable" xlink:label="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsTable" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_IfrsIncomeStatementLocationAxis" xlink:label="cvac_IfrsIncomeStatementLocationAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsTable" xlink:to="cvac_IfrsIncomeStatementLocationAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_IfrsIncomeStatementLocationDomain" xlink:label="cvac_IfrsIncomeStatementLocationDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="cvac_IfrsIncomeStatementLocationAxis" xlink:to="cvac_IfrsIncomeStatementLocationDomain" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_IfrsResearchAndDevelopmentExpenseMember" xlink:label="cvac_IfrsResearchAndDevelopmentExpenseMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="cvac_IfrsIncomeStatementLocationDomain" xlink:to="cvac_IfrsResearchAndDevelopmentExpenseMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems" xlink:label="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems" xlink:to="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RawMaterialsAndConsumablesUsed" xlink:label="ifrs-full_RawMaterialsAndConsumablesUsed" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems" xlink:to="ifrs-full_RawMaterialsAndConsumablesUsed" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_PersonnelExpenses" xlink:label="cvac_PersonnelExpenses" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems" xlink:to="cvac_PersonnelExpenses" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DepreciationAndAmortisationExpense" xlink:label="ifrs-full_DepreciationAndAmortisationExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems" xlink:to="ifrs-full_DepreciationAndAmortisationExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_PatentsAndFeesToRegisterLegalRight" xlink:label="cvac_PatentsAndFeesToRegisterLegalRight" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems" xlink:to="cvac_PatentsAndFeesToRegisterLegalRight" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_ThirdPartyServiceExpenses" xlink:label="cvac_ThirdPartyServiceExpenses" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems" xlink:to="cvac_ThirdPartyServiceExpenses" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_MaintenanceAndLeaseExpenses" xlink:label="cvac_MaintenanceAndLeaseExpenses" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems" xlink:to="cvac_MaintenanceAndLeaseExpenses" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_OtherExpense" xlink:label="cvac_OtherExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems" xlink:to="cvac_OtherExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ExpenseByNature" xlink:label="ifrs-full_ExpenseByNature" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems" xlink:to="ifrs-full_ExpenseByNature" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ShorttermEmployeeBenefitsExpense" xlink:label="ifrs-full_ShorttermEmployeeBenefitsExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems" xlink:to="ifrs-full_ShorttermEmployeeBenefitsExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" xlink:label="ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems" xlink:to="ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_ReversalOfProvisionForOnerousContracts" xlink:label="cvac_ReversalOfProvisionForOnerousContracts" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems" xlink:to="cvac_ReversalOfProvisionForOnerousContracts" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_IfrsIncreaseInExpenseRelatedToIneffectiveSetUpActivitiesAndSettlementCosts" xlink:label="cvac_IfrsIncreaseInExpenseRelatedToIneffectiveSetUpActivitiesAndSettlementCosts" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems" xlink:to="cvac_IfrsIncreaseInExpenseRelatedToIneffectiveSetUpActivitiesAndSettlementCosts" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsGeneralAndAdministrativeExpensesDetails" xlink:type="extended" xlink:title="40307 - Disclosure - Notes to the consolidated financial statements - General and administrative expenses (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_DisclosureOfNotesToConsolidatedFinancialStatementsTable" xlink:label="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsTable" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_IfrsIncomeStatementLocationAxis" xlink:label="cvac_IfrsIncomeStatementLocationAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsTable" xlink:to="cvac_IfrsIncomeStatementLocationAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_IfrsIncomeStatementLocationDomain" xlink:label="cvac_IfrsIncomeStatementLocationDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="cvac_IfrsIncomeStatementLocationAxis" xlink:to="cvac_IfrsIncomeStatementLocationDomain" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_IfrsGeneralAndAdministrativeExpenseMember" xlink:label="cvac_IfrsGeneralAndAdministrativeExpenseMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="cvac_IfrsIncomeStatementLocationDomain" xlink:to="cvac_IfrsGeneralAndAdministrativeExpenseMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems" xlink:label="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems" xlink:to="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_PersonnelExpenses" xlink:label="cvac_PersonnelExpenses" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems" xlink:to="cvac_PersonnelExpenses" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_MaintenanceAndLeaseExpenses" xlink:label="cvac_MaintenanceAndLeaseExpenses" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems" xlink:to="cvac_MaintenanceAndLeaseExpenses" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_ThirdPartyServiceExpenses" xlink:label="cvac_ThirdPartyServiceExpenses" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems" xlink:to="cvac_ThirdPartyServiceExpenses" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProfessionalFeesExpense" xlink:label="ifrs-full_ProfessionalFeesExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems" xlink:to="ifrs-full_ProfessionalFeesExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DepreciationAndAmortisationExpense" xlink:label="ifrs-full_DepreciationAndAmortisationExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems" xlink:to="ifrs-full_DepreciationAndAmortisationExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_OtherExpense" xlink:label="cvac_OtherExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems" xlink:to="cvac_OtherExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ExpenseByNature" xlink:label="ifrs-full_ExpenseByNature" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems" xlink:to="ifrs-full_ExpenseByNature" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ShorttermEmployeeBenefitsExpense" xlink:label="ifrs-full_ShorttermEmployeeBenefitsExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems" xlink:to="ifrs-full_ShorttermEmployeeBenefitsExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" xlink:label="ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems" xlink:to="ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TravelExpense" xlink:label="ifrs-full_TravelExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems" xlink:to="ifrs-full_TravelExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_InsuranceExpense" xlink:label="ifrs-full_InsuranceExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems" xlink:to="ifrs-full_InsuranceExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_RealEstateTransferTaxes" xlink:label="cvac_RealEstateTransferTaxes" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems" xlink:to="cvac_RealEstateTransferTaxes" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsGrantsWithGovernmentAgenciesAndSimilarBodiesDetails" xlink:type="extended" xlink:title="40309 - Disclosure - Notes to the consolidated financial statements - Grants with government agencies and similar bodies (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_DisclosureOfGovernmentGrantsTable" xlink:label="cvac_DisclosureOfGovernmentGrantsTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="cvac_DisclosureOfGovernmentGrantsTable" xlink:to="srt_StatementScenarioAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_GovernmentGrantsAxis" xlink:label="cvac_GovernmentGrantsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="cvac_DisclosureOfGovernmentGrantsTable" xlink:to="cvac_GovernmentGrantsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_GovernmentGrantsDomain" xlink:label="cvac_GovernmentGrantsDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="cvac_GovernmentGrantsAxis" xlink:to="cvac_GovernmentGrantsDomain" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_GermanFederalMinistryOfEducationAndResearchMember" xlink:label="cvac_GermanFederalMinistryOfEducationAndResearchMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="cvac_GovernmentGrantsDomain" xlink:to="cvac_GermanFederalMinistryOfEducationAndResearchMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_CoalitionForEpidemicPreparednessInnovationsMember" xlink:label="cvac_CoalitionForEpidemicPreparednessInnovationsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="cvac_GovernmentGrantsDomain" xlink:to="cvac_CoalitionForEpidemicPreparednessInnovationsMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_BillAndMelindaGatesFoundationBmgfMember" xlink:label="cvac_BillAndMelindaGatesFoundationBmgfMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="cvac_GovernmentGrantsDomain" xlink:to="cvac_BillAndMelindaGatesFoundationBmgfMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_BillMelindaGatesFoundationBmgfGrantForDevelopmentOfUniversalInfluenzaVaccineMember" xlink:label="cvac_BillMelindaGatesFoundationBmgfGrantForDevelopmentOfUniversalInfluenzaVaccineMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="cvac_BillAndMelindaGatesFoundationBmgfMember" xlink:to="cvac_BillMelindaGatesFoundationBmgfGrantForDevelopmentOfUniversalInfluenzaVaccineMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_BillMelindaGatesFoundationBmgfGrantForMalariaVaccineMember" xlink:label="cvac_BillMelindaGatesFoundationBmgfGrantForMalariaVaccineMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="cvac_BillAndMelindaGatesFoundationBmgfMember" xlink:to="cvac_BillMelindaGatesFoundationBmgfGrantForMalariaVaccineMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="cvac_DisclosureOfGovernmentGrantsTable" xlink:to="srt_CounterpartyNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_GlaxosmithklineMember" xlink:label="cvac_GlaxosmithklineMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="cvac_GlaxosmithklineMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_GskAgreement2020Member" xlink:label="cvac_GskAgreement2020Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="cvac_GskAgreement2020Member" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_BoehringerIngelheimMember" xlink:label="cvac_BoehringerIngelheimMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="cvac_BoehringerIngelheimMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_CrisprTherapeuticsMember" xlink:label="cvac_CrisprTherapeuticsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="cvac_CrisprTherapeuticsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_GenmabMember" xlink:label="cvac_GenmabMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="cvac_GenmabMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_EliLillyMember" xlink:label="cvac_EliLillyMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="cvac_EliLillyMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_TypeOfArrangementAxis" xlink:label="cvac_TypeOfArrangementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="cvac_DisclosureOfGovernmentGrantsTable" xlink:to="cvac_TypeOfArrangementAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_ArrangementsAndNonArrangementTransactionsMember" xlink:label="cvac_ArrangementsAndNonArrangementTransactionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="cvac_TypeOfArrangementAxis" xlink:to="cvac_ArrangementsAndNonArrangementTransactionsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_AdvancedPurchaseAgreementWithEuropeanCommissionMember" xlink:label="cvac_AdvancedPurchaseAgreementWithEuropeanCommissionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="cvac_ArrangementsAndNonArrangementTransactionsMember" xlink:to="cvac_AdvancedPurchaseAgreementWithEuropeanCommissionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_DisclosureOfGovernmentGrantsLineItems" xlink:label="cvac_DisclosureOfGovernmentGrantsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="cvac_DisclosureOfGovernmentGrantsLineItems" xlink:to="cvac_DisclosureOfGovernmentGrantsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_NumberOfDosesOfSarsCov2CanBePurchasedByMemberStatesUnderAdvancePurchaseAgreement" xlink:label="cvac_NumberOfDosesOfSarsCov2CanBePurchasedByMemberStatesUnderAdvancePurchaseAgreement" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="cvac_DisclosureOfGovernmentGrantsLineItems" xlink:to="cvac_NumberOfDosesOfSarsCov2CanBePurchasedByMemberStatesUnderAdvancePurchaseAgreement" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_MaximumGrantToBeReceived" xlink:label="cvac_MaximumGrantToBeReceived" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="cvac_DisclosureOfGovernmentGrantsLineItems" xlink:to="cvac_MaximumGrantToBeReceived" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_UpfrontPaymentReceived" xlink:label="cvac_UpfrontPaymentReceived" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="cvac_DisclosureOfGovernmentGrantsLineItems" xlink:to="cvac_UpfrontPaymentReceived" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RevenueFromGovernmentGrants" xlink:label="ifrs-full_RevenueFromGovernmentGrants" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="cvac_DisclosureOfGovernmentGrantsLineItems" xlink:to="ifrs-full_RevenueFromGovernmentGrants" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_IfrsMilestonePaymentReceived" xlink:label="cvac_IfrsMilestonePaymentReceived" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="cvac_DisclosureOfGovernmentGrantsLineItems" xlink:to="cvac_IfrsMilestonePaymentReceived" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_IfrsRemainingGrantIncome" xlink:label="cvac_IfrsRemainingGrantIncome" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="cvac_DisclosureOfGovernmentGrantsLineItems" xlink:to="cvac_IfrsRemainingGrantIncome" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_GovernmentGrants" xlink:label="ifrs-full_GovernmentGrants" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="cvac_DisclosureOfGovernmentGrantsLineItems" xlink:to="ifrs-full_GovernmentGrants" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_PartnershipAgreementMaximumAmount" xlink:label="cvac_PartnershipAgreementMaximumAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="cvac_DisclosureOfGovernmentGrantsLineItems" xlink:to="cvac_PartnershipAgreementMaximumAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_PartnershipAgreementTerm" xlink:label="cvac_PartnershipAgreementTerm" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="cvac_DisclosureOfGovernmentGrantsLineItems" xlink:to="cvac_PartnershipAgreementTerm" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_PartnershipAgreementPeriodOfCostsToBeCovered" xlink:label="cvac_PartnershipAgreementPeriodOfCostsToBeCovered" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="cvac_DisclosureOfGovernmentGrantsLineItems" xlink:to="cvac_PartnershipAgreementPeriodOfCostsToBeCovered" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProceedsFromGovernmentGrantsClassifiedAsFinancingActivities" xlink:label="ifrs-full_ProceedsFromGovernmentGrantsClassifiedAsFinancingActivities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="cvac_DisclosureOfGovernmentGrantsLineItems" xlink:to="ifrs-full_ProceedsFromGovernmentGrantsClassifiedAsFinancingActivities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_AmountDeductedFromCarryingAmountOfQualifyingAssets" xlink:label="cvac_AmountDeductedFromCarryingAmountOfQualifyingAssets" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="cvac_DisclosureOfGovernmentGrantsLineItems" xlink:to="cvac_AmountDeductedFromCarryingAmountOfQualifyingAssets" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_NumberOfAdditionalGrantsReceived" xlink:label="cvac_NumberOfAdditionalGrantsReceived" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="cvac_DisclosureOfGovernmentGrantsLineItems" xlink:to="cvac_NumberOfAdditionalGrantsReceived" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_ReceiptsFromGovernmentGrantsClassifiedAsOperatingActivities" xlink:label="cvac_ReceiptsFromGovernmentGrantsClassifiedAsOperatingActivities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="cvac_DisclosureOfGovernmentGrantsLineItems" xlink:to="cvac_ReceiptsFromGovernmentGrantsClassifiedAsOperatingActivities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_CompensationForContractManufacturingOrganizationsTransferConsiderationForSetUpActivities" xlink:label="cvac_CompensationForContractManufacturingOrganizationsTransferConsiderationForSetUpActivities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="16" xlink:from="cvac_DisclosureOfGovernmentGrantsLineItems" xlink:to="cvac_CompensationForContractManufacturingOrganizationsTransferConsiderationForSetUpActivities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_CompensationForContractManufacturingOrganizationsTransferManufacturingInterimPeriodReimbursableExpenses" xlink:label="cvac_CompensationForContractManufacturingOrganizationsTransferManufacturingInterimPeriodReimbursableExpenses" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="17" xlink:from="cvac_DisclosureOfGovernmentGrantsLineItems" xlink:to="cvac_CompensationForContractManufacturingOrganizationsTransferManufacturingInterimPeriodReimbursableExpenses" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_ReversalOfProvisionRecognizedDueToCertainReservedCapacityTakenOver" xlink:label="cvac_ReversalOfProvisionRecognizedDueToCertainReservedCapacityTakenOver" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="18" xlink:from="cvac_DisclosureOfGovernmentGrantsLineItems" xlink:to="cvac_ReversalOfProvisionRecognizedDueToCertainReservedCapacityTakenOver" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.curevac.com/role/DisclosureIssuedCapitalAndReservesOverviewAndGeneralRemarksDetails" xlink:type="extended" xlink:title="40401 - Disclosure - Issued Capital and Reserves - Overview and General Remarks (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalTable" xlink:label="ifrs-full_DisclosureOfClassesOfShareCapitalTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:label="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalTable" xlink:to="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_SharebasedPaymentArrangementsMember" xlink:label="ifrs-full_SharebasedPaymentArrangementsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:to="ifrs-full_SharebasedPaymentArrangementsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_VirtualSharesProgramIMember" xlink:label="cvac_VirtualSharesProgramIMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_SharebasedPaymentArrangementsMember" xlink:to="cvac_VirtualSharesProgramIMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ClassesOfShareCapitalAxis" xlink:label="ifrs-full_ClassesOfShareCapitalAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalTable" xlink:to="ifrs-full_ClassesOfShareCapitalAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ClassesOfShareCapitalMember" xlink:label="ifrs-full_ClassesOfShareCapitalMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_ClassesOfShareCapitalAxis" xlink:to="ifrs-full_ClassesOfShareCapitalMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OrdinarySharesMember" xlink:label="ifrs-full_OrdinarySharesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_ClassesOfShareCapitalMember" xlink:to="ifrs-full_OrdinarySharesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_PreferenceSharesMember" xlink:label="ifrs-full_PreferenceSharesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_ClassesOfShareCapitalMember" xlink:to="ifrs-full_PreferenceSharesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_IfrsSaleOfStockAxis" xlink:label="cvac_IfrsSaleOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalTable" xlink:to="cvac_IfrsSaleOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_IfrsSaleOfStockDomain" xlink:label="cvac_IfrsSaleOfStockDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="cvac_IfrsSaleOfStockAxis" xlink:to="cvac_IfrsSaleOfStockDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_FollowOnPublicOfferingMember" xlink:label="cvac_FollowOnPublicOfferingMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="cvac_IfrsSaleOfStockDomain" xlink:to="cvac_FollowOnPublicOfferingMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_IfrsOverAllotmentOptionMember" xlink:label="cvac_IfrsOverAllotmentOptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="cvac_IfrsSaleOfStockDomain" xlink:to="cvac_IfrsOverAllotmentOptionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ComponentsOfEquityAxis" xlink:label="ifrs-full_ComponentsOfEquityAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalTable" xlink:to="ifrs-full_ComponentsOfEquityAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_EquityMember" xlink:label="ifrs-full_EquityMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="ifrs-full_EquityMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TreasurySharesMember" xlink:label="ifrs-full_TreasurySharesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_EquityMember" xlink:to="ifrs-full_TreasurySharesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:label="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="ifrs-full_DisclosureOfClassesOfShareCapitalTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NumberOfSharesAuthorised" xlink:label="ifrs-full_NumberOfSharesAuthorised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="ifrs-full_NumberOfSharesAuthorised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ParValuePerShare" xlink:label="ifrs-full_ParValuePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="ifrs-full_ParValuePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NumberOfSharesIssued" xlink:label="ifrs-full_NumberOfSharesIssued" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="ifrs-full_NumberOfSharesIssued" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ShareIssueRelatedCost" xlink:label="ifrs-full_ShareIssueRelatedCost" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="ifrs-full_ShareIssueRelatedCost" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_RemainingAuthorizedForSaleValue" xlink:label="cvac_RemainingAuthorizedForSaleValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="cvac_RemainingAuthorizedForSaleValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_IfrsStockholdersEquityNoteStockSplitConversionRatio" xlink:label="cvac_IfrsStockholdersEquityNoteStockSplitConversionRatio" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="cvac_IfrsStockholdersEquityNoteStockSplitConversionRatio" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.curevac.com/role/DisclosureIssuedCapitalAndReservesImpactOfShareSplitDetails" xlink:type="extended" xlink:title="40402 - Disclosure - Issued Capital and Reserves - Impact of share split (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalTable" xlink:label="ifrs-full_DisclosureOfClassesOfShareCapitalTable" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_IfrsSaleOfStockAxis" xlink:label="cvac_IfrsSaleOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalTable" xlink:to="cvac_IfrsSaleOfStockAxis" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_IfrsSaleOfStockDomain" xlink:label="cvac_IfrsSaleOfStockDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="cvac_IfrsSaleOfStockAxis" xlink:to="cvac_IfrsSaleOfStockDomain" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_CapitalIncreaseByGenmabMember" xlink:label="cvac_CapitalIncreaseByGenmabMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="cvac_IfrsSaleOfStockDomain" xlink:to="cvac_CapitalIncreaseByGenmabMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_PrivatePlacementIsa2020Member" xlink:label="cvac_PrivatePlacementIsa2020Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="cvac_IfrsSaleOfStockDomain" xlink:to="cvac_PrivatePlacementIsa2020Member" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_InitialPublicOfferingAndPrivatePlacementMember" xlink:label="cvac_InitialPublicOfferingAndPrivatePlacementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="cvac_IfrsSaleOfStockDomain" xlink:to="cvac_InitialPublicOfferingAndPrivatePlacementMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_ExerciseOfGreenshoeMember" xlink:label="cvac_ExerciseOfGreenshoeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="cvac_IfrsSaleOfStockDomain" xlink:to="cvac_ExerciseOfGreenshoeMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_FollowOnPublicOfferingMember" xlink:label="cvac_FollowOnPublicOfferingMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="cvac_IfrsSaleOfStockDomain" xlink:to="cvac_FollowOnPublicOfferingMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_AtMarketOfferingProgramMember" xlink:label="cvac_AtMarketOfferingProgramMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="cvac_IfrsSaleOfStockDomain" xlink:to="cvac_AtMarketOfferingProgramMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ClassesOfShareCapitalAxis" xlink:label="ifrs-full_ClassesOfShareCapitalAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalTable" xlink:to="ifrs-full_ClassesOfShareCapitalAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ClassesOfShareCapitalMember" xlink:label="ifrs-full_ClassesOfShareCapitalMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_ClassesOfShareCapitalAxis" xlink:to="ifrs-full_ClassesOfShareCapitalMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_SeriesSharesMember" xlink:label="cvac_SeriesSharesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_ClassesOfShareCapitalMember" xlink:to="cvac_SeriesSharesMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_SeriesCSharesMember" xlink:label="cvac_SeriesCSharesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_ClassesOfShareCapitalMember" xlink:to="cvac_SeriesCSharesMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:label="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalTable" xlink:to="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NonadjustingEventsMember" xlink:label="ifrs-full_NonadjustingEventsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:to="ifrs-full_NonadjustingEventsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_MajorOrdinaryShareTransactionsMember" xlink:label="ifrs-full_MajorOrdinaryShareTransactionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_NonadjustingEventsMember" xlink:to="ifrs-full_MajorOrdinaryShareTransactionsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:label="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="ifrs-full_DisclosureOfClassesOfShareCapitalTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_CommonSharesIssuedAndOutstanding" xlink:label="cvac_CommonSharesIssuedAndOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="cvac_CommonSharesIssuedAndOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_IncreaseInNumberOfSharesOutstanding" xlink:label="cvac_IncreaseInNumberOfSharesOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="cvac_IncreaseInNumberOfSharesOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_ShareOptionExercises" xlink:label="cvac_ShareOptionExercises" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="cvac_ShareOptionExercises" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_DecreaseInNumberOfSharesDueToTreasuryOfShares" xlink:label="cvac_DecreaseInNumberOfSharesDueToTreasuryOfShares" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="cvac_DecreaseInNumberOfSharesDueToTreasuryOfShares" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_StockIssuedDuringPeriodForExercises" xlink:label="cvac_StockIssuedDuringPeriodForExercises" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="cvac_StockIssuedDuringPeriodForExercises" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_StockIssuanceDuringPeriodForExistingShareholders" xlink:label="cvac_StockIssuanceDuringPeriodForExistingShareholders" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="cvac_StockIssuanceDuringPeriodForExistingShareholders" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_IfrsStockIssuedDuringPeriodSharesNewIssues" xlink:label="cvac_IfrsStockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="cvac_IfrsStockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_AggregateGrossProceedsReceivableFromIssuingShares" xlink:label="cvac_AggregateGrossProceedsReceivableFromIssuingShares" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="cvac_AggregateGrossProceedsReceivableFromIssuingShares" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProceedsFromIssuingShares" xlink:label="ifrs-full_ProceedsFromIssuingShares" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="ifrs-full_ProceedsFromIssuingShares" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ShareIssueRelatedCost" xlink:label="ifrs-full_ShareIssueRelatedCost" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="ifrs-full_ShareIssueRelatedCost" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.curevac.com/role/DisclosureShareBasedPaymentsExpensesDetails" xlink:type="extended" xlink:title="40501 - Disclosure - Share-based payments - Expenses (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:label="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:to="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_SharebasedPaymentArrangementsMember" xlink:label="ifrs-full_SharebasedPaymentArrangementsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:to="ifrs-full_SharebasedPaymentArrangementsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_VirtualSharesProgramIMember" xlink:label="cvac_VirtualSharesProgramIMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_SharebasedPaymentArrangementsMember" xlink:to="cvac_VirtualSharesProgramIMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInResearchAndDevelopmentExpenses" xlink:label="cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInResearchAndDevelopmentExpenses" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInResearchAndDevelopmentExpenses" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInSellingAndDistributionExpenses" xlink:label="cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInSellingAndDistributionExpenses" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInSellingAndDistributionExpenses" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInGeneralAndAdministrativeExpenses" xlink:label="cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInGeneralAndAdministrativeExpenses" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInGeneralAndAdministrativeExpenses" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_BenefitExpenseRecognizedForShareBasedPayment" xlink:label="cvac_BenefitExpenseRecognizedForShareBasedPayment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="cvac_BenefitExpenseRecognizedForShareBasedPayment" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.curevac.com/role/DisclosureShareBasedPaymentsExpenseRecognizedForProgramDetails" xlink:type="extended" xlink:title="40502 - Disclosure - Share-based payments - Expense recognized for the program (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:label="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:to="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_SharebasedPaymentArrangementsMember" xlink:label="ifrs-full_SharebasedPaymentArrangementsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:to="ifrs-full_SharebasedPaymentArrangementsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_LongTermIncentivePlanMember" xlink:label="cvac_LongTermIncentivePlanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_SharebasedPaymentArrangementsMember" xlink:to="cvac_LongTermIncentivePlanMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_IfrsRestrictedStockUnitMember" xlink:label="cvac_IfrsRestrictedStockUnitMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_SharebasedPaymentArrangementsMember" xlink:to="cvac_IfrsRestrictedStockUnitMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_RestrictedStockUnitForKeyEmployeesMember" xlink:label="cvac_RestrictedStockUnitForKeyEmployeesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="ifrs-full_SharebasedPaymentArrangementsMember" xlink:to="cvac_RestrictedStockUnitForKeyEmployeesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_OptionsGrantedToThenChiefExecutiveOfficerMember" xlink:label="cvac_OptionsGrantedToThenChiefExecutiveOfficerMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="ifrs-full_SharebasedPaymentArrangementsMember" xlink:to="cvac_OptionsGrantedToThenChiefExecutiveOfficerMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_VirtualSharesProgramIiMember" xlink:label="cvac_VirtualSharesProgramIiMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="ifrs-full_SharebasedPaymentArrangementsMember" xlink:to="cvac_VirtualSharesProgramIiMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_VirtualSharesProgramIMember" xlink:label="cvac_VirtualSharesProgramIMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="ifrs-full_SharebasedPaymentArrangementsMember" xlink:to="cvac_VirtualSharesProgramIMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_ExpenseRecognizedForEmployeeServices" xlink:label="cvac_ExpenseRecognizedForEmployeeServices" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="cvac_ExpenseRecognizedForEmployeeServices" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.curevac.com/role/DisclosureShareBasedPaymentsDetails" xlink:type="extended" xlink:title="40503 - Disclosure - Share-based payments (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_IfrsSaleOfStockAxis" xlink:label="cvac_IfrsSaleOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:to="cvac_IfrsSaleOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_IfrsSaleOfStockDomain" xlink:label="cvac_IfrsSaleOfStockDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="cvac_IfrsSaleOfStockAxis" xlink:to="cvac_IfrsSaleOfStockDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_ExerciseOfOptionsMember" xlink:label="cvac_ExerciseOfOptionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="cvac_IfrsSaleOfStockDomain" xlink:to="cvac_ExerciseOfOptionsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:to="srt_TitleOfIndividualAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_ChiefScientificOfficerMember" xlink:label="cvac_ChiefScientificOfficerMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="cvac_ChiefScientificOfficerMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_ChiefOperatingOfficerAndChiefDevelopmentOfficerMember" xlink:label="cvac_ChiefOperatingOfficerAndChiefDevelopmentOfficerMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="cvac_ChiefOperatingOfficerAndChiefDevelopmentOfficerMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_ChiefBusinessOfficerAndChiefCommercialOfficerMember" xlink:label="cvac_ChiefBusinessOfficerAndChiefCommercialOfficerMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="cvac_ChiefBusinessOfficerAndChiefCommercialOfficerMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ChiefOperatingOfficerMember" xlink:label="srt_ChiefOperatingOfficerMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_ChiefOperatingOfficerMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_ChiefDevelopmentOfficerMember" xlink:label="cvac_ChiefDevelopmentOfficerMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="cvac_ChiefDevelopmentOfficerMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_ThenChiefExecutiveOfficerMember" xlink:label="cvac_ThenChiefExecutiveOfficerMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="cvac_ThenChiefExecutiveOfficerMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_ManagementBoardMember" xlink:label="cvac_ManagementBoardMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="cvac_ManagementBoardMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_MembersOfExecutiveBoardAndVariousKeyEmployeesMember" xlink:label="cvac_MembersOfExecutiveBoardAndVariousKeyEmployeesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="cvac_MembersOfExecutiveBoardAndVariousKeyEmployeesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_KeyEmployeesMember" xlink:label="cvac_KeyEmployeesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="cvac_KeyEmployeesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_ExecutiveBoardMembersMember" xlink:label="cvac_ExecutiveBoardMembersMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="cvac_ExecutiveBoardMembersMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_SupervisoryBoardMembersMember" xlink:label="cvac_SupervisoryBoardMembersMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="cvac_SupervisoryBoardMembersMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_ChiefBusinessOfficerMember" xlink:label="cvac_ChiefBusinessOfficerMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="cvac_ChiefBusinessOfficerMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_FormerFrameEmployeesMember" xlink:label="cvac_FormerFrameEmployeesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="cvac_FormerFrameEmployeesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RangeAxis" xlink:label="ifrs-full_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:to="ifrs-full_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RangesMember" xlink:label="ifrs-full_RangesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_RangesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:to="srt_StatementScenarioAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_MaturityAxis" xlink:label="ifrs-full_MaturityAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="5" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:to="ifrs-full_MaturityAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AggregatedTimeBandsMember" xlink:label="ifrs-full_AggregatedTimeBandsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_MaturityAxis" xlink:to="ifrs-full_AggregatedTimeBandsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NotLaterThanOneYearMember" xlink:label="ifrs-full_NotLaterThanOneYearMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_AggregatedTimeBandsMember" xlink:to="ifrs-full_NotLaterThanOneYearMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember" xlink:label="ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_AggregatedTimeBandsMember" xlink:to="ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_IfrsVestingAxis" xlink:label="cvac_IfrsVestingAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="6" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:to="cvac_IfrsVestingAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_IfrsVestingDomain" xlink:label="cvac_IfrsVestingDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="cvac_IfrsVestingAxis" xlink:to="cvac_IfrsVestingDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_IfrsShareBasedPaymentArrangementTrancheOneMember" xlink:label="cvac_IfrsShareBasedPaymentArrangementTrancheOneMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="cvac_IfrsVestingDomain" xlink:to="cvac_IfrsShareBasedPaymentArrangementTrancheOneMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:label="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="7" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:to="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_SharebasedPaymentArrangementsMember" xlink:label="ifrs-full_SharebasedPaymentArrangementsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:to="ifrs-full_SharebasedPaymentArrangementsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_LongTermIncentivePlanMember" xlink:label="cvac_LongTermIncentivePlanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_SharebasedPaymentArrangementsMember" xlink:to="cvac_LongTermIncentivePlanMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_OptionsGrantedToThenChiefExecutiveOfficerMember" xlink:label="cvac_OptionsGrantedToThenChiefExecutiveOfficerMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_SharebasedPaymentArrangementsMember" xlink:to="cvac_OptionsGrantedToThenChiefExecutiveOfficerMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_VirtualSharesProgramIMember" xlink:label="cvac_VirtualSharesProgramIMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="ifrs-full_SharebasedPaymentArrangementsMember" xlink:to="cvac_VirtualSharesProgramIMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_VirtualSharesProgramIiMember" xlink:label="cvac_VirtualSharesProgramIiMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="ifrs-full_SharebasedPaymentArrangementsMember" xlink:to="cvac_VirtualSharesProgramIiMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees" xlink:label="ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" xlink:label="ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" xlink:label="ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NumberOfInstrumentsGrantedInSharebasedPaymentArrangement" xlink:label="ifrs-full_NumberOfInstrumentsGrantedInSharebasedPaymentArrangement" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_NumberOfInstrumentsGrantedInSharebasedPaymentArrangement" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInGeneralAndAdministrativeExpenses" xlink:label="cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInGeneralAndAdministrativeExpenses" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInGeneralAndAdministrativeExpenses" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_RightToExercisePercentageOfVestedVirtualShares" xlink:label="cvac_RightToExercisePercentageOfVestedVirtualShares" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="cvac_RightToExercisePercentageOfVestedVirtualShares" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_LockUpPeriodAfterInitialListing" xlink:label="cvac_LockUpPeriodAfterInitialListing" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="cvac_LockUpPeriodAfterInitialListing" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" xlink:label="ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_NumberOfKeyEmployees" xlink:label="cvac_NumberOfKeyEmployees" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="cvac_NumberOfKeyEmployees" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted" xlink:label="ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_ProvisionForEmployerTaxes" xlink:label="cvac_ProvisionForEmployerTaxes" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="cvac_ProvisionForEmployerTaxes" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_AmountOfLiabilityCashClaimAwards" xlink:label="cvac_AmountOfLiabilityCashClaimAwards" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="cvac_AmountOfLiabilityCashClaimAwards" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_AmountOfRestrictedStockUnitsReceived" xlink:label="cvac_AmountOfRestrictedStockUnitsReceived" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="cvac_AmountOfRestrictedStockUnitsReceived" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_NumberOfShareOptionsVestedInShareBasedPaymentArrangement" xlink:label="cvac_NumberOfShareOptionsVestedInShareBasedPaymentArrangement" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="16" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="cvac_NumberOfShareOptionsVestedInShareBasedPaymentArrangement" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_NumberOfOtherEquityInstrumentsSettledInShareBasedPaymentArrangement" xlink:label="cvac_NumberOfOtherEquityInstrumentsSettledInShareBasedPaymentArrangement" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="17" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="cvac_NumberOfOtherEquityInstrumentsSettledInShareBasedPaymentArrangement" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.curevac.com/role/DisclosureFixedAssetsIntangibleAssetsDetails" xlink:type="extended" xlink:title="40601 - Disclosure - Fixed Assets - Intangible assets (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfIntangibleAssetsTable" xlink:label="ifrs-full_DisclosureOfIntangibleAssetsTable" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis" xlink:label="cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="ifrs-full_DisclosureOfIntangibleAssetsTable" xlink:to="cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountDomain" xlink:label="cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis" xlink:to="cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_GrossCarryingAmountMember" xlink:label="ifrs-full_GrossCarryingAmountMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountDomain" xlink:to="ifrs-full_GrossCarryingAmountMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis" xlink:label="ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="ifrs-full_DisclosureOfIntangibleAssetsTable" xlink:to="ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwillMember" xlink:label="ifrs-full_IntangibleAssetsOtherThanGoodwillMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis" xlink:to="ifrs-full_IntangibleAssetsOtherThanGoodwillMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_LicensesSoftwareAndPrepaymentsMember" xlink:label="cvac_LicensesSoftwareAndPrepaymentsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_IntangibleAssetsOtherThanGoodwillMember" xlink:to="cvac_LicensesSoftwareAndPrepaymentsMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:label="ifrs-full_DisclosureOfIntangibleAssetsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:to="ifrs-full_DisclosureOfIntangibleAssetsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" xlink:label="ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:to="ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.curevac.com/role/DisclosureFixedAssetsPropertyPlantAndEquipmentDetails" xlink:type="extended" xlink:title="40602 - Disclosure - Fixed Assets - Property, plant and equipment (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable" xlink:label="ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis" xlink:label="cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable" xlink:to="cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountDomain" xlink:label="cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis" xlink:to="cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_GrossCarryingAmountMember" xlink:label="ifrs-full_GrossCarryingAmountMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountDomain" xlink:to="ifrs-full_GrossCarryingAmountMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:label="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable" xlink:to="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_PropertyPlantAndEquipmentMember" xlink:label="ifrs-full_PropertyPlantAndEquipmentMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:to="ifrs-full_PropertyPlantAndEquipmentMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_TechnicalEquipmentAndMachinesAndOtherEquipmentMember" xlink:label="cvac_TechnicalEquipmentAndMachinesAndOtherEquipmentMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_PropertyPlantAndEquipmentMember" xlink:to="cvac_TechnicalEquipmentAndMachinesAndOtherEquipmentMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ConstructionInProgressMember" xlink:label="ifrs-full_ConstructionInProgressMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_PropertyPlantAndEquipmentMember" xlink:to="ifrs-full_ConstructionInProgressMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_CompanyOwnedGmpIvFacilityMember" xlink:label="cvac_CompanyOwnedGmpIvFacilityMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="ifrs-full_PropertyPlantAndEquipmentMember" xlink:to="cvac_CompanyOwnedGmpIvFacilityMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_EquipmentPhysicallyLocatedAtCmoFacilitiesMember" xlink:label="cvac_EquipmentPhysicallyLocatedAtCmoFacilitiesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="ifrs-full_PropertyPlantAndEquipmentMember" xlink:to="cvac_EquipmentPhysicallyLocatedAtCmoFacilitiesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:label="ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:to="ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" xlink:label="ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:to="ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_IncreaseInPropertyAndEquipmentOffSetByImpairmentOfEquipment" xlink:label="cvac_IncreaseInPropertyAndEquipmentOffSetByImpairmentOfEquipment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:to="cvac_IncreaseInPropertyAndEquipmentOffSetByImpairmentOfEquipment" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.curevac.com/role/DisclosureInventoriesDetails" xlink:type="extended" xlink:title="40801 - Disclosure - Inventories (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_InventoriesTable" xlink:label="cvac_InventoriesTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="cvac_InventoriesTable" xlink:to="srt_CounterpartyNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_GlaxosmithklineMember" xlink:label="cvac_GlaxosmithklineMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="cvac_GlaxosmithklineMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_InventoriesLineItem" xlink:label="cvac_InventoriesLineItem" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="cvac_InventoriesLineItem" xlink:to="cvac_InventoriesTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_IncreaseDecreaseInInventory" xlink:label="cvac_IncreaseDecreaseInInventory" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="cvac_InventoriesLineItem" xlink:to="cvac_IncreaseDecreaseInInventory" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_NetValueOfInventoryTransferred" xlink:label="cvac_NetValueOfInventoryTransferred" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="cvac_InventoriesLineItem" xlink:to="cvac_NetValueOfInventoryTransferred" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_InventoryWritedown2011" xlink:label="ifrs-full_InventoryWritedown2011" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="cvac_InventoriesLineItem" xlink:to="ifrs-full_InventoryWritedown2011" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.curevac.com/role/DisclosureOtherLiabilitiesDetails" xlink:type="extended" xlink:title="41201 - Disclosure - Other liabilities (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_DisclosureOfOtherLiabilitiesTable" xlink:label="cvac_DisclosureOfOtherLiabilitiesTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TypesOfContractsAxis" xlink:label="ifrs-full_TypesOfContractsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="cvac_DisclosureOfOtherLiabilitiesTable" xlink:to="ifrs-full_TypesOfContractsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TypesOfContractsMember" xlink:label="ifrs-full_TypesOfContractsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_TypesOfContractsAxis" xlink:to="ifrs-full_TypesOfContractsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_ContractResearchOrganizationAgreementMember" xlink:label="cvac_ContractResearchOrganizationAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_TypesOfContractsMember" xlink:to="cvac_ContractResearchOrganizationAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_ContractManufacturingOrganizationAgreementMember" xlink:label="cvac_ContractManufacturingOrganizationAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_TypesOfContractsMember" xlink:to="cvac_ContractManufacturingOrganizationAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_DisclosureOfOtherLiabilitiesLineItems" xlink:label="cvac_DisclosureOfOtherLiabilitiesLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="cvac_DisclosureOfOtherLiabilitiesLineItems" xlink:to="cvac_DisclosureOfOtherLiabilitiesTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_ChangeInOtherLiabilities" xlink:label="cvac_ChangeInOtherLiabilities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="cvac_DisclosureOfOtherLiabilitiesLineItems" xlink:to="cvac_ChangeInOtherLiabilities" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.curevac.com/role/DisclosureLoansDetails" xlink:type="extended" xlink:title="41301 - Disclosure - Loans (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable" xlink:label="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_BorrowingsByNameAxis" xlink:label="ifrs-full_BorrowingsByNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable" xlink:to="ifrs-full_BorrowingsByNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_BorrowingsByNameMember" xlink:label="ifrs-full_BorrowingsByNameMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_BorrowingsByNameAxis" xlink:to="ifrs-full_BorrowingsByNameMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_IfrsLineOfCreditMember" xlink:label="cvac_IfrsLineOfCreditMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_BorrowingsByNameMember" xlink:to="cvac_IfrsLineOfCreditMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:label="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:to="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities" xlink:label="ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:to="ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_LineOfCreditAccruedInterestPayable" xlink:label="cvac_LineOfCreditAccruedInterestPayable" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:to="cvac_LineOfCreditAccruedInterestPayable" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities" xlink:label="ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:to="ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_RepaymentsOfPrincipalAmountOfBorrowings" xlink:label="cvac_RepaymentsOfPrincipalAmountOfBorrowings" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:to="cvac_RepaymentsOfPrincipalAmountOfBorrowings" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_IfrsRepaymentsOfAccruedInterestAndFeesOfBorrowings" xlink:label="cvac_IfrsRepaymentsOfAccruedInterestAndFeesOfBorrowings" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:to="cvac_IfrsRepaymentsOfAccruedInterestAndFeesOfBorrowings" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.curevac.com/role/DisclosureIncomeTaxDetails" xlink:type="extended" xlink:title="41401 - Disclosure - Income tax (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_IncomeTaxDisclosureTable" xlink:label="cvac_IncomeTaxDisclosureTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_SignificantInvestmentsInSubsidiariesAxis" xlink:label="ifrs-full_SignificantInvestmentsInSubsidiariesAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="cvac_IncomeTaxDisclosureTable" xlink:to="ifrs-full_SignificantInvestmentsInSubsidiariesAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_EntitysTotalForSubsidiariesMember" xlink:label="ifrs-full_EntitysTotalForSubsidiariesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_SignificantInvestmentsInSubsidiariesAxis" xlink:to="ifrs-full_EntitysTotalForSubsidiariesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_CurevacCorporateServiceGmbhMember" xlink:label="cvac_CurevacCorporateServiceGmbhMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_EntitysTotalForSubsidiariesMember" xlink:to="cvac_CurevacCorporateServiceGmbhMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_CurevacSwissAgMember" xlink:label="cvac_CurevacSwissAgMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_EntitysTotalForSubsidiariesMember" xlink:to="cvac_CurevacSwissAgMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_IncomeTaxDisclosureLineItems" xlink:label="cvac_IncomeTaxDisclosureLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="cvac_IncomeTaxDisclosureLineItems" xlink:to="cvac_IncomeTaxDisclosureTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:label="ifrs-full_IncomeTaxExpenseContinuingOperations" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="cvac_IncomeTaxDisclosureLineItems" xlink:to="ifrs-full_IncomeTaxExpenseContinuingOperations" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CurrentTaxExpenseIncome" xlink:label="ifrs-full_CurrentTaxExpenseIncome" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="cvac_IncomeTaxDisclosureLineItems" xlink:to="ifrs-full_CurrentTaxExpenseIncome" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DeferredTaxExpenseIncome" xlink:label="ifrs-full_DeferredTaxExpenseIncome" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="cvac_IncomeTaxDisclosureLineItems" xlink:to="ifrs-full_DeferredTaxExpenseIncome" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.curevac.com/role/DisclosureDisclosureOfFinancialInstrumentsAndRiskManagementDetails" xlink:type="extended" xlink:title="41501 - Disclosure - Disclosure of financial instruments and risk management (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable" xlink:label="ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CurrencyAxis" xlink:label="srt_CurrencyAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable" xlink:to="srt_CurrencyAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2021/currency-2021.xsd#currency_AllCurrenciesDomain" xlink:label="currency_AllCurrenciesDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_CurrencyAxis" xlink:to="currency_AllCurrenciesDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2021/currency-2021.xsd#currency_USD" xlink:label="currency_USD" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="currency_AllCurrenciesDomain" xlink:to="currency_USD" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2021/currency-2021.xsd#currency_CHF" xlink:label="currency_CHF" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="currency_AllCurrenciesDomain" xlink:to="currency_CHF" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TypesOfRisksAxis" xlink:label="ifrs-full_TypesOfRisksAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable" xlink:to="ifrs-full_TypesOfRisksAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TypesOfRisksMember" xlink:label="ifrs-full_TypesOfRisksMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_TypesOfRisksAxis" xlink:to="ifrs-full_TypesOfRisksMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CurrencyRiskMember" xlink:label="ifrs-full_CurrencyRiskMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_TypesOfRisksMember" xlink:to="ifrs-full_CurrencyRiskMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:label="ifrs-full_ClassesOfFinancialInstrumentsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable" xlink:to="ifrs-full_ClassesOfFinancialInstrumentsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ClassesOfFinancialInstrumentsMember" xlink:label="ifrs-full_ClassesOfFinancialInstrumentsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:to="ifrs-full_ClassesOfFinancialInstrumentsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_IfrsCashAndCashEquivalentsMember" xlink:label="cvac_IfrsCashAndCashEquivalentsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsMember" xlink:to="cvac_IfrsCashAndCashEquivalentsMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems" xlink:label="ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems" xlink:to="ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RiskExposureAssociatedWithInstrumentsSharingCharacteristic" xlink:label="ifrs-full_RiskExposureAssociatedWithInstrumentsSharingCharacteristic" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems" xlink:to="ifrs-full_RiskExposureAssociatedWithInstrumentsSharingCharacteristic" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.curevac.com/role/DisclosureRelatedPartyDisclosuresDetails" xlink:type="extended" xlink:title="41701 - Disclosure - Related party disclosures (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:label="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RangeAxis" xlink:label="ifrs-full_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:to="ifrs-full_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RangesMember" xlink:label="ifrs-full_RangesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_RangesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_BottomOfRangeMember" xlink:label="ifrs-full_BottomOfRangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_RangesMember" xlink:to="ifrs-full_BottomOfRangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TopOfRangeMember" xlink:label="ifrs-full_TopOfRangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_RangesMember" xlink:to="ifrs-full_TopOfRangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:to="srt_TitleOfIndividualAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_BaronJeanStephenneMember" xlink:label="cvac_BaronJeanStephenneMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="cvac_BaronJeanStephenneMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_VincentStphenneMember" xlink:label="cvac_VincentStphenneMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="cvac_VincentStphenneMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_AntonyBlancMember" xlink:label="cvac_AntonyBlancMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="cvac_AntonyBlancMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:to="ifrs-full_CategoriesOfRelatedPartiesAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="ifrs-full_EntitysTotalForRelatedPartiesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_EntitysTotalForRelatedPartiesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_RittershausRechtsanwaelteMember" xlink:label="cvac_RittershausRechtsanwaelteMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="cvac_RittershausRechtsanwaelteMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_Dr.IngmarHoerrMember" xlink:label="cvac_Dr.IngmarHoerrMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="cvac_Dr.IngmarHoerrMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_DietmarHoppMember" xlink:label="cvac_DietmarHoppMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="cvac_DietmarHoppMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_BepharbelManufacturingS.aMember" xlink:label="cvac_BepharbelManufacturingS.aMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="cvac_BepharbelManufacturingS.aMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_ClarentisSrlMember" xlink:label="cvac_ClarentisSrlMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="cvac_ClarentisSrlMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:label="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:to="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_SharebasedPaymentArrangementsMember" xlink:label="ifrs-full_SharebasedPaymentArrangementsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:to="ifrs-full_SharebasedPaymentArrangementsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_VirtualSharesProgramIMember" xlink:label="cvac_VirtualSharesProgramIMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_SharebasedPaymentArrangementsMember" xlink:to="cvac_VirtualSharesProgramIMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:label="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_RelatedPartyTransactionNumberOfLoansReceived" xlink:label="cvac_RelatedPartyTransactionNumberOfLoansReceived" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="cvac_RelatedPartyTransactionNumberOfLoansReceived" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_IncreaseInNumberOfSharesOutstanding" xlink:label="cvac_IncreaseInNumberOfSharesOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="cvac_IncreaseInNumberOfSharesOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_WeightedAverageSharePrice2019" xlink:label="ifrs-full_WeightedAverageSharePrice2019" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="ifrs-full_WeightedAverageSharePrice2019" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_CollaborationAgreementMilestonePayment" xlink:label="cvac_CollaborationAgreementMilestonePayment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="cvac_CollaborationAgreementMilestonePayment" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_PaymentsToRelatedPartyForServices" xlink:label="cvac_PaymentsToRelatedPartyForServices" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="cvac_PaymentsToRelatedPartyForServices" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CommitmentsMadeByEntityRelatedPartyTransactions" xlink:label="ifrs-full_CommitmentsMadeByEntityRelatedPartyTransactions" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="ifrs-full_CommitmentsMadeByEntityRelatedPartyTransactions" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProportionOfOwnershipInterestInAssociate" xlink:label="ifrs-full_ProportionOfOwnershipInterestInAssociate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="ifrs-full_ProportionOfOwnershipInterestInAssociate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TransfersOfResearchAndDevelopmentToEntityRelatedPartyTransactions" xlink:label="ifrs-full_TransfersOfResearchAndDevelopmentToEntityRelatedPartyTransactions" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="ifrs-full_TransfersOfResearchAndDevelopmentToEntityRelatedPartyTransactions" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_RelatedPartyTransactionNoticePeriodForTerminationOfAgreement" xlink:label="cvac_RelatedPartyTransactionNoticePeriodForTerminationOfAgreement" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="cvac_RelatedPartyTransactionNoticePeriodForTerminationOfAgreement" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_RelatedPartyTransactionConsultingFees" xlink:label="cvac_RelatedPartyTransactionConsultingFees" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="cvac_RelatedPartyTransactionConsultingFees" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_RelatedPartyTransactionAdvisoryFees" xlink:label="cvac_RelatedPartyTransactionAdvisoryFees" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="cvac_RelatedPartyTransactionAdvisoryFees" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_AmountPaidAtSigningOfAgreementRelatedPartyTransactions" xlink:label="cvac_AmountPaidAtSigningOfAgreementRelatedPartyTransactions" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="cvac_AmountPaidAtSigningOfAgreementRelatedPartyTransactions" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_PurchasesOfGoodsRelatedPartyTransactions" xlink:label="ifrs-full_PurchasesOfGoodsRelatedPartyTransactions" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="ifrs-full_PurchasesOfGoodsRelatedPartyTransactions" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_TerminationFeeRelatedPartyTransactions" xlink:label="cvac_TerminationFeeRelatedPartyTransactions" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="cvac_TerminationFeeRelatedPartyTransactions" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_IfrsNumberOfSharesOutstandingThroughTransferFromShareholdersToEntity" xlink:label="cvac_IfrsNumberOfSharesOutstandingThroughTransferFromShareholdersToEntity" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="16" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="cvac_IfrsNumberOfSharesOutstandingThroughTransferFromShareholdersToEntity" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_IfrsContractualObligation" xlink:label="cvac_IfrsContractualObligation" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="17" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="cvac_IfrsContractualObligation" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.curevac.com/role/DisclosureSignificantTransactionsAndEventsDetails" xlink:type="extended" xlink:title="41801 - Disclosure - Significant transactions and events (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfBusinessCombinationsTable" xlink:label="ifrs-full_DisclosureOfBusinessCombinationsTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_BusinessCombinationsAxis" xlink:label="ifrs-full_BusinessCombinationsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsTable" xlink:to="ifrs-full_BusinessCombinationsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_EntitysTotalForBusinessCombinationsMember" xlink:label="ifrs-full_EntitysTotalForBusinessCombinationsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_BusinessCombinationsAxis" xlink:to="ifrs-full_EntitysTotalForBusinessCombinationsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_FramePharmaceuticalsB.v.AmsterdamNetherlandsMember" xlink:label="cvac_FramePharmaceuticalsB.v.AmsterdamNetherlandsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_EntitysTotalForBusinessCombinationsMember" xlink:to="cvac_FramePharmaceuticalsB.v.AmsterdamNetherlandsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:label="ifrs-full_DisclosureOfBusinessCombinationsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:to="ifrs-full_DisclosureOfBusinessCombinationsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RevenueOfAcquiree" xlink:label="ifrs-full_RevenueOfAcquiree" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:to="ifrs-full_RevenueOfAcquiree" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProfitLossOfAcquiree" xlink:label="ifrs-full_ProfitLossOfAcquiree" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:to="ifrs-full_ProfitLossOfAcquiree" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RevenueOfCombinedEntity" xlink:label="ifrs-full_RevenueOfCombinedEntity" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:to="ifrs-full_RevenueOfCombinedEntity" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProfitLossOfCombinedEntity" xlink:label="ifrs-full_ProfitLossOfCombinedEntity" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:to="ifrs-full_ProfitLossOfCombinedEntity" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred" xlink:label="ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:to="ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_LiabilitiesIncurred" xlink:label="ifrs-full_LiabilitiesIncurred" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:to="ifrs-full_LiabilitiesIncurred" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_BusinessAcquisitionSigningSharePriceNumberOfTradingDaysConsidered" xlink:label="cvac_BusinessAcquisitionSigningSharePriceNumberOfTradingDaysConsidered" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:to="cvac_BusinessAcquisitionSigningSharePriceNumberOfTradingDaysConsidered" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_BusinessAcquisitionSigningSharePrice" xlink:label="cvac_BusinessAcquisitionSigningSharePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:to="cvac_BusinessAcquisitionSigningSharePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_NumberOfPaymentsInWhichTotalConsiderationIsToBePaid" xlink:label="cvac_NumberOfPaymentsInWhichTotalConsiderationIsToBePaid" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:to="cvac_NumberOfPaymentsInWhichTotalConsiderationIsToBePaid" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_ContingentConsiderationNumberOfPaymentsConsidered" xlink:label="cvac_ContingentConsiderationNumberOfPaymentsConsidered" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:to="cvac_ContingentConsiderationNumberOfPaymentsConsidered" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_FirstPortionOfTotalConsiderationTransferredPercentage" xlink:label="cvac_FirstPortionOfTotalConsiderationTransferredPercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:to="cvac_FirstPortionOfTotalConsiderationTransferredPercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_FirstPortionOfTotalConsiderationTransferredAmount" xlink:label="cvac_FirstPortionOfTotalConsiderationTransferredAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:to="cvac_FirstPortionOfTotalConsiderationTransferredAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_NumberOfInstrumentsOrInterestsIssuedOrIssuableAsConsiderationToFormerShareholders" xlink:label="cvac_NumberOfInstrumentsOrInterestsIssuedOrIssuableAsConsiderationToFormerShareholders" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:to="cvac_NumberOfInstrumentsOrInterestsIssuedOrIssuableAsConsiderationToFormerShareholders" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_ValueOfInstrumentsOrInterestsIssuedOrIssuableAsConsiderationToFormerShareholders" xlink:label="cvac_ValueOfInstrumentsOrInterestsIssuedOrIssuableAsConsiderationToFormerShareholders" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:to="cvac_ValueOfInstrumentsOrInterestsIssuedOrIssuableAsConsiderationToFormerShareholders" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_EquityInterestsOfAcquirer" xlink:label="ifrs-full_EquityInterestsOfAcquirer" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="16" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:to="ifrs-full_EquityInterestsOfAcquirer" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_NumberOfInstrumentsOrInterestIssuedOrIssuable" xlink:label="cvac_NumberOfInstrumentsOrInterestIssuedOrIssuable" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="17" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:to="cvac_NumberOfInstrumentsOrInterestIssuedOrIssuable" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_IfrsBusinessAcquisitionSharePrice" xlink:label="cvac_IfrsBusinessAcquisitionSharePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="18" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:to="cvac_IfrsBusinessAcquisitionSharePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_NumberOfInstrumentsOrInterestsIssuedOrIssuableAsConsiderationForDischargingContractualObligations" xlink:label="cvac_NumberOfInstrumentsOrInterestsIssuedOrIssuableAsConsiderationForDischargingContractualObligations" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="19" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:to="cvac_NumberOfInstrumentsOrInterestsIssuedOrIssuableAsConsiderationForDischargingContractualObligations" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_ValueOfInstrumentsOrInterestsIssuedOrIssuableAsConsiderationForDischargingContractualObligations" xlink:label="cvac_ValueOfInstrumentsOrInterestsIssuedOrIssuableAsConsiderationForDischargingContractualObligations" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="20" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:to="cvac_ValueOfInstrumentsOrInterestsIssuedOrIssuableAsConsiderationForDischargingContractualObligations" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_StrikePriceForExistingShareBasedPayment" xlink:label="cvac_StrikePriceForExistingShareBasedPayment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="21" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:to="cvac_StrikePriceForExistingShareBasedPayment" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CashTransferred" xlink:label="ifrs-full_CashTransferred" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="22" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:to="ifrs-full_CashTransferred" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_CashTransferredForSettlementOfVestedEmployeeOptions" xlink:label="cvac_CashTransferredForSettlementOfVestedEmployeeOptions" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="23" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:to="cvac_CashTransferredForSettlementOfVestedEmployeeOptions" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_AdditionalCashTransferred" xlink:label="cvac_AdditionalCashTransferred" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="24" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:to="cvac_AdditionalCashTransferred" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_ContingentConsiderationPercentageOfTotalConsideration" xlink:label="cvac_ContingentConsiderationPercentageOfTotalConsideration" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="25" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:to="cvac_ContingentConsiderationPercentageOfTotalConsideration" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_ContingentConsiderationNumberOfMilestones" xlink:label="cvac_ContingentConsiderationNumberOfMilestones" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="26" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:to="cvac_ContingentConsiderationNumberOfMilestones" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_NumberOfInstrumentsOrInterestsIssuedOrIssuableUponAchievementOfFirstMilestone" xlink:label="cvac_NumberOfInstrumentsOrInterestsIssuedOrIssuableUponAchievementOfFirstMilestone" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="27" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:to="cvac_NumberOfInstrumentsOrInterestsIssuedOrIssuableUponAchievementOfFirstMilestone" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_PercentageOfConsiderationTransferredUponAchievementOfFirstMilestone" xlink:label="cvac_PercentageOfConsiderationTransferredUponAchievementOfFirstMilestone" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="28" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:to="cvac_PercentageOfConsiderationTransferredUponAchievementOfFirstMilestone" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_ValueOfInstrumentsOrInterestsIssuedOrIssuableUponAchievementOfFirstMilestone" xlink:label="cvac_ValueOfInstrumentsOrInterestsIssuedOrIssuableUponAchievementOfFirstMilestone" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="29" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:to="cvac_ValueOfInstrumentsOrInterestsIssuedOrIssuableUponAchievementOfFirstMilestone" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_NumberOfInstrumentsOrInterestsIssuedOrIssuableUponAchievementOfSecondMilestone" xlink:label="cvac_NumberOfInstrumentsOrInterestsIssuedOrIssuableUponAchievementOfSecondMilestone" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="30" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:to="cvac_NumberOfInstrumentsOrInterestsIssuedOrIssuableUponAchievementOfSecondMilestone" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_PercentageOfConsiderationTransferredUponAchievementOfSecondMilestone" xlink:label="cvac_PercentageOfConsiderationTransferredUponAchievementOfSecondMilestone" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="31" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:to="cvac_PercentageOfConsiderationTransferredUponAchievementOfSecondMilestone" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_ValueOfInstrumentsOrInterestsIssuedOrIssuableUponAchievementOfSecondMilestone" xlink:label="cvac_ValueOfInstrumentsOrInterestsIssuedOrIssuableUponAchievementOfSecondMilestone" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="32" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:to="cvac_ValueOfInstrumentsOrInterestsIssuedOrIssuableUponAchievementOfSecondMilestone" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ContingentConsiderationRecognisedAsOfAcquisitionDate" xlink:label="ifrs-full_ContingentConsiderationRecognisedAsOfAcquisitionDate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="33" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:to="ifrs-full_ContingentConsiderationRecognisedAsOfAcquisitionDate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NumberOfInstrumentsOrInterestsIssuedOrIssuable" xlink:label="ifrs-full_NumberOfInstrumentsOrInterestsIssuedOrIssuable" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="34" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:to="ifrs-full_NumberOfInstrumentsOrInterestsIssuedOrIssuable" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_ContingentConsiderationMaximumSharesIssuable" xlink:label="cvac_ContingentConsiderationMaximumSharesIssuable" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="35" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:to="cvac_ContingentConsiderationMaximumSharesIssuable" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted" xlink:label="ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="36" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:to="ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted" xlink:label="ifrs-full_WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="37" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:to="ifrs-full_WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_NumberOfTranchesForVestingOfInstrumentsGrantedInShareBasedPaymentArrangement" xlink:label="cvac_NumberOfTranchesForVestingOfInstrumentsGrantedInShareBasedPaymentArrangement" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="38" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:to="cvac_NumberOfTranchesForVestingOfInstrumentsGrantedInShareBasedPaymentArrangement" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AcquisitionrelatedCostsForTransactionRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombination" xlink:label="ifrs-full_AcquisitionrelatedCostsForTransactionRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombination" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="39" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:to="ifrs-full_AcquisitionrelatedCostsForTransactionRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombination" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_ProvisionalFairValue" xlink:label="cvac_ProvisionalFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="40" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:to="cvac_ProvisionalFairValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_FairValueOfTotalConsiderationTransferred" xlink:label="cvac_FairValueOfTotalConsiderationTransferred" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="41" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:to="cvac_FairValueOfTotalConsiderationTransferred" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_SigningSharePriceRepresenting10" xlink:label="cvac_SigningSharePriceRepresenting10" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="42" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:to="cvac_SigningSharePriceRepresenting10" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_SigningSharePriceRepresenting40" xlink:label="cvac_SigningSharePriceRepresenting40" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="43" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:to="cvac_SigningSharePriceRepresenting40" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_ClosingSharePriceRepresentingTotalFairValue" xlink:label="cvac_ClosingSharePriceRepresentingTotalFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="44" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:to="cvac_ClosingSharePriceRepresentingTotalFairValue" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.curevac.com/role/DisclosureSignificantTransactionsAndEventsFrameAcquisitionPurchasePriceAllocationDetails" xlink:type="extended" xlink:title="41802 - Disclosure - Significant transactions and events - Frame Acquisition - Purchase Price Allocation (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfBusinessCombinationsTable" xlink:label="ifrs-full_DisclosureOfBusinessCombinationsTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_BusinessCombinationsAxis" xlink:label="ifrs-full_BusinessCombinationsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsTable" xlink:to="ifrs-full_BusinessCombinationsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_EntitysTotalForBusinessCombinationsMember" xlink:label="ifrs-full_EntitysTotalForBusinessCombinationsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_BusinessCombinationsAxis" xlink:to="ifrs-full_EntitysTotalForBusinessCombinationsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_FramePharmaceuticalsB.v.AmsterdamNetherlandsMember" xlink:label="cvac_FramePharmaceuticalsB.v.AmsterdamNetherlandsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_EntitysTotalForBusinessCombinationsMember" xlink:to="cvac_FramePharmaceuticalsB.v.AmsterdamNetherlandsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:label="ifrs-full_DisclosureOfBusinessCombinationsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:to="ifrs-full_DisclosureOfBusinessCombinationsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NoncurrentAssetsRecognisedAsOfAcquisitionDate" xlink:label="ifrs-full_NoncurrentAssetsRecognisedAsOfAcquisitionDate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:to="ifrs-full_NoncurrentAssetsRecognisedAsOfAcquisitionDate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDate" xlink:label="ifrs-full_PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:to="ifrs-full_PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_RightOfUseAssetsRecognisedAsOfAcquisitionDate" xlink:label="cvac_RightOfUseAssetsRecognisedAsOfAcquisitionDate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:to="cvac_RightOfUseAssetsRecognisedAsOfAcquisitionDate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TechnologybasedIntangibleAssetsRecognisedAsOfAcquisitionDate" xlink:label="ifrs-full_TechnologybasedIntangibleAssetsRecognisedAsOfAcquisitionDate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:to="ifrs-full_TechnologybasedIntangibleAssetsRecognisedAsOfAcquisitionDate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CurrentAssetsRecognisedAsOfAcquisitionDate" xlink:label="ifrs-full_CurrentAssetsRecognisedAsOfAcquisitionDate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:to="ifrs-full_CurrentAssetsRecognisedAsOfAcquisitionDate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_FairValueOfAcquiredReceivables" xlink:label="ifrs-full_FairValueOfAcquiredReceivables" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:to="ifrs-full_FairValueOfAcquiredReceivables" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CashAndCashEquivalentsRecognisedAsOfAcquisitionDate" xlink:label="ifrs-full_CashAndCashEquivalentsRecognisedAsOfAcquisitionDate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:to="ifrs-full_CashAndCashEquivalentsRecognisedAsOfAcquisitionDate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_TotalAssetsRecognisedAsOfAcquisitionDate" xlink:label="cvac_TotalAssetsRecognisedAsOfAcquisitionDate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:to="cvac_TotalAssetsRecognisedAsOfAcquisitionDate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NoncurrentLiabilitiesRecognisedAsOfAcquisitionDate" xlink:label="ifrs-full_NoncurrentLiabilitiesRecognisedAsOfAcquisitionDate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:to="ifrs-full_NoncurrentLiabilitiesRecognisedAsOfAcquisitionDate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_NoncurrentLeaseLiabilitiesRecognisedAsOfAcquisitionDate" xlink:label="cvac_NoncurrentLeaseLiabilitiesRecognisedAsOfAcquisitionDate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:to="cvac_NoncurrentLeaseLiabilitiesRecognisedAsOfAcquisitionDate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_NetDeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate" xlink:label="cvac_NetDeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:to="cvac_NetDeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CurrentLiabilitiesRecognisedAsOfAcquisitionDate" xlink:label="ifrs-full_CurrentLiabilitiesRecognisedAsOfAcquisitionDate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:to="ifrs-full_CurrentLiabilitiesRecognisedAsOfAcquisitionDate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_CurrentLeaseLiabilitiesRecognisedAsOfAcquisitionDate" xlink:label="cvac_CurrentLeaseLiabilitiesRecognisedAsOfAcquisitionDate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:to="cvac_CurrentLeaseLiabilitiesRecognisedAsOfAcquisitionDate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TradeAndOtherPayablesRecognisedAsOfAcquisitionDate" xlink:label="ifrs-full_TradeAndOtherPayablesRecognisedAsOfAcquisitionDate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:to="ifrs-full_TradeAndOtherPayablesRecognisedAsOfAcquisitionDate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_OtherCurrentLiabilitiesRecognisedAsOfAcquisitionDate" xlink:label="cvac_OtherCurrentLiabilitiesRecognisedAsOfAcquisitionDate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="16" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:to="cvac_OtherCurrentLiabilitiesRecognisedAsOfAcquisitionDate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_LiabilitiesRecognisedAsOfAcquisitionDate" xlink:label="cvac_LiabilitiesRecognisedAsOfAcquisitionDate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="17" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:to="cvac_LiabilitiesRecognisedAsOfAcquisitionDate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed" xlink:label="ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="18" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:to="ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate" xlink:label="ifrs-full_DeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="19" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:to="ifrs-full_DeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DeferredTaxAssetsRecognisedAsOfAcquisitionDate" xlink:label="ifrs-full_DeferredTaxAssetsRecognisedAsOfAcquisitionDate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="20" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:to="ifrs-full_DeferredTaxAssetsRecognisedAsOfAcquisitionDate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised" xlink:label="ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="21" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:to="ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.curevac.com/role/DisclosureSignificantTransactionsAndEventsGoodwillRecognizedOnFrameAcquisitionDetails" xlink:type="extended" xlink:title="41803 - Disclosure - Significant transactions and events - Goodwill Recognized On Frame Acquisition (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfBusinessCombinationsTable" xlink:label="ifrs-full_DisclosureOfBusinessCombinationsTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_BusinessCombinationsAxis" xlink:label="ifrs-full_BusinessCombinationsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsTable" xlink:to="ifrs-full_BusinessCombinationsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_EntitysTotalForBusinessCombinationsMember" xlink:label="ifrs-full_EntitysTotalForBusinessCombinationsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_BusinessCombinationsAxis" xlink:to="ifrs-full_EntitysTotalForBusinessCombinationsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_FramePharmaceuticalsB.v.AmsterdamNetherlandsMember" xlink:label="cvac_FramePharmaceuticalsB.v.AmsterdamNetherlandsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_EntitysTotalForBusinessCombinationsMember" xlink:to="cvac_FramePharmaceuticalsB.v.AmsterdamNetherlandsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:label="ifrs-full_DisclosureOfBusinessCombinationsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:to="ifrs-full_DisclosureOfBusinessCombinationsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred" xlink:label="ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:to="ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed" xlink:label="ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:to="ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_GoodwillRecognisedAsOfAcquisitionDate" xlink:label="ifrs-full_GoodwillRecognisedAsOfAcquisitionDate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:to="ifrs-full_GoodwillRecognisedAsOfAcquisitionDate" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.curevac.com/role/DisclosureSignificantTransactionsAndEventsAnalysesOfCashFlowsOnFrameAcquisitionDetails" xlink:type="extended" xlink:title="41804 - Disclosure - Significant transactions and events - Analyses of cash flows on Frame Acquisition (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfBusinessCombinationsTable" xlink:label="ifrs-full_DisclosureOfBusinessCombinationsTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_BusinessCombinationsAxis" xlink:label="ifrs-full_BusinessCombinationsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsTable" xlink:to="ifrs-full_BusinessCombinationsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_EntitysTotalForBusinessCombinationsMember" xlink:label="ifrs-full_EntitysTotalForBusinessCombinationsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_BusinessCombinationsAxis" xlink:to="ifrs-full_EntitysTotalForBusinessCombinationsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_FramePharmaceuticalsB.v.AmsterdamNetherlandsMember" xlink:label="cvac_FramePharmaceuticalsB.v.AmsterdamNetherlandsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_EntitysTotalForBusinessCombinationsMember" xlink:to="cvac_FramePharmaceuticalsB.v.AmsterdamNetherlandsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:label="ifrs-full_DisclosureOfBusinessCombinationsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:to="ifrs-full_DisclosureOfBusinessCombinationsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CashTransferred" xlink:label="ifrs-full_CashTransferred" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:to="ifrs-full_CashTransferred" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CashAndCashEquivalentsRecognisedAsOfAcquisitionDate" xlink:label="ifrs-full_CashAndCashEquivalentsRecognisedAsOfAcquisitionDate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:to="ifrs-full_CashAndCashEquivalentsRecognisedAsOfAcquisitionDate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities" xlink:label="ifrs-full_CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:to="ifrs-full_CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_IfrsCashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities" xlink:label="cvac_IfrsCashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:to="cvac_IfrsCashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AcquisitionrelatedCostsForTransactionRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombination" xlink:label="ifrs-full_AcquisitionrelatedCostsForTransactionRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombination" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:to="ifrs-full_AcquisitionrelatedCostsForTransactionRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombination" priority="1" use="optional" />
  </definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>9
<FILENAME>cvac-20220930_lab.xml
<DESCRIPTION>EX-101.LAB
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  10.1.0.3 -->
<!--Based on XBRL 2.1-->
<!--Created on: 11/17/2022 10:28:01 PM-->
<!--Modified on: 11/17/2022 10:28:01 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink">
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xmlns="http://www.xbrl.org/2003/linkbase" />
  <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document and Entity Information</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentInformationTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Information [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressesAddressTypeAxis" xlink:label="dei_EntityAddressesAddressTypeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressesAddressTypeAxis" xlink:to="dei_EntityAddressesAddressTypeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressesAddressTypeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Addresses, Address Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AddressTypeDomain" xlink:label="dei_AddressTypeDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AddressTypeDomain" xlink:to="dei_AddressTypeDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AddressTypeDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Address Type [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_BusinessContactMember" xlink:label="dei_BusinessContactMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_BusinessContactMember" xlink:to="dei_BusinessContactMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_BusinessContactMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Business Contact</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentInformationLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Information [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentInformationLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document and Entity Information</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Type</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Registration Statement</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Annual Report</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Transition Report</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Shell Company Report</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Registrant Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Period End Date</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Incorporation, State or Country Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Address Line One</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Address Line Two</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, City or Town</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, State or Province</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Country</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Postal Zip Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">City Area Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Local Phone Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_ContactPersonnelName" xlink:label="dei_ContactPersonnelName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_ContactPersonnelName" xlink:to="dei_ContactPersonnelName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_ContactPersonnelName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contact Personnel Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Country Region</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_ContactPersonnelEmailAddress" xlink:label="dei_ContactPersonnelEmailAddress" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_ContactPersonnelEmailAddress" xlink:to="dei_ContactPersonnelEmailAddress_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_ContactPersonnelEmailAddress_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contact Personnel Email Address</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Title of 12(b) Security</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Trading Symbol</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Security Exchange Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity File Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Well-known Seasoned Issuer</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Current Reporting Status</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Filer Category</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Interactive Data Current</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Emerging Growth Company</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Ex Transition Period</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Accounting Standard</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Shell Company</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Common Stock, Shares Outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current Fiscal Year End Date</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Fiscal Year Focus</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Fiscal Period Focus</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Central Index Key</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amendment Flag</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_IcfrAuditorAttestationFlag" xlink:to="dei_IcfrAuditorAttestationFlag_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">ICFR Auditor Attestation Flag</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amendment Description</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Voluntary Filers</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Public Float</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorName" xlink:label="dei_AuditorName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorName" xlink:to="dei_AuditorName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Auditor Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorFirmId" xlink:to="dei_AuditorFirmId_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorFirmId_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Auditor Firm ID</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorLocation" xlink:to="dei_AuditorLocation_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorLocation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Auditor Location</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_StatementOfComprehensiveIncomeAbstract" xlink:label="ifrs-full_StatementOfComprehensiveIncomeAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_StatementOfComprehensiveIncomeAbstract" xlink:to="ifrs-full_StatementOfComprehensiveIncomeAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_StatementOfComprehensiveIncomeAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interim Condensed Consolidated Statements of Operations and Other Comprehensive Income (Loss)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RevenueFromContractsWithCustomers" xlink:label="ifrs-full_RevenueFromContractsWithCustomers" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RevenueFromContractsWithCustomers" xlink:to="ifrs-full_RevenueFromContractsWithCustomers_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_RevenueFromContractsWithCustomers_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total revenues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_RevenueFromContractsWithCustomers_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_RevenueFromContractsWithCustomers_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue recognized</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CostOfSales" xlink:label="ifrs-full_CostOfSales" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CostOfSales" xlink:to="ifrs-full_CostOfSales_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CostOfSales_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cost of sales.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_CostOfSales_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cost of sales</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_SalesAndMarketingExpense" xlink:label="ifrs-full_SalesAndMarketingExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_SalesAndMarketingExpense" xlink:to="ifrs-full_SalesAndMarketingExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_SalesAndMarketingExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sales and marketing expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_SalesAndMarketingExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Selling and distribution expenses</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ResearchAndDevelopmentExpense" xlink:label="ifrs-full_ResearchAndDevelopmentExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ResearchAndDevelopmentExpense" xlink:to="ifrs-full_ResearchAndDevelopmentExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and development expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and development expenses</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_GeneralAndAdministrativeExpense" xlink:label="ifrs-full_GeneralAndAdministrativeExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_GeneralAndAdministrativeExpense" xlink:to="ifrs-full_GeneralAndAdministrativeExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">General and administrative expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">General and administrative expenses</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_MiscellaneousOtherOperatingIncome" xlink:label="ifrs-full_MiscellaneousOtherOperatingIncome" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_MiscellaneousOtherOperatingIncome" xlink:to="ifrs-full_MiscellaneousOtherOperatingIncome_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_MiscellaneousOtherOperatingIncome_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Miscellaneous other operating income</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_MiscellaneousOtherOperatingIncome_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other operating income</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_MiscellaneousOtherOperatingIncome_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_MiscellaneousOtherOperatingExpense" xlink:label="ifrs-full_MiscellaneousOtherOperatingExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_MiscellaneousOtherOperatingExpense" xlink:to="ifrs-full_MiscellaneousOtherOperatingExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_MiscellaneousOtherOperatingExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Miscellaneous other operating expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_MiscellaneousOtherOperatingExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other operating expenses</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProfitLossFromOperatingActivities" xlink:label="ifrs-full_ProfitLossFromOperatingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProfitLossFromOperatingActivities" xlink:to="ifrs-full_ProfitLossFromOperatingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ProfitLossFromOperatingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Profit (loss) from operating activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_ProfitLossFromOperatingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating loss</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_FinanceIncome" xlink:label="ifrs-full_FinanceIncome" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FinanceIncome" xlink:to="ifrs-full_FinanceIncome_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_FinanceIncome_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finance income</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_FinanceIncome_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finance income</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_FinanceCosts" xlink:label="ifrs-full_FinanceCosts" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FinanceCosts" xlink:to="ifrs-full_FinanceCosts_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_FinanceCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finance costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_FinanceCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finance expenses</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProfitLossBeforeTax" xlink:label="ifrs-full_ProfitLossBeforeTax" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProfitLossBeforeTax" xlink:to="ifrs-full_ProfitLossBeforeTax_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ProfitLossBeforeTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Profit (loss) before tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ProfitLossBeforeTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loss before income tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_ProfitLossBeforeTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loss before income tax</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:label="ifrs-full_IncomeTaxExpenseContinuingOperations" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:to="ifrs-full_IncomeTaxExpenseContinuingOperations_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IncomeTaxExpenseContinuingOperations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tax expense (income)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_IncomeTaxExpenseContinuingOperations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income tax benefit/ (expense)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProfitLoss" xlink:label="ifrs-full_ProfitLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProfitLoss" xlink:to="ifrs-full_ProfitLoss_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ProfitLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Profit (loss)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_ProfitLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss for the period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_ProfitLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OtherComprehensiveIncomeAbstract" xlink:label="ifrs-full_OtherComprehensiveIncomeAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherComprehensiveIncomeAbstract" xlink:to="ifrs-full_OtherComprehensiveIncomeAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherComprehensiveIncomeAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other comprehensive income [abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_OtherComprehensiveIncomeAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other comprehensive income (loss):</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" xlink:label="ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" xlink:to="ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other comprehensive income, net of tax, exchange differences on translation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Foreign currency adjustments</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ComprehensiveIncome" xlink:label="ifrs-full_ComprehensiveIncome" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ComprehensiveIncome" xlink:to="ifrs-full_ComprehensiveIncome_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ComprehensiveIncome_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Comprehensive income</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ComprehensiveIncome_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total comprehensive income (loss)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_ComprehensiveIncome_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total comprehensive loss for the period</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_BasicEarningsLossPerShare" xlink:label="ifrs-full_BasicEarningsLossPerShare" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_BasicEarningsLossPerShare" xlink:to="ifrs-full_BasicEarningsLossPerShare_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_BasicEarningsLossPerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Basic earnings (loss) per share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_BasicEarningsLossPerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss per share basic</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DilutedEarningsLossPerShare" xlink:label="ifrs-full_DilutedEarningsLossPerShare" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DilutedEarningsLossPerShare" xlink:to="ifrs-full_DilutedEarningsLossPerShare_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DilutedEarningsLossPerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Diluted earnings (loss) per share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DilutedEarningsLossPerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss per share diluted</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_StatementOfFinancialPositionAbstract" xlink:label="ifrs-full_StatementOfFinancialPositionAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_StatementOfFinancialPositionAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interim Condensed Consolidated Statements of Financial Position</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AssetsAbstract" xlink:label="ifrs-full_AssetsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AssetsAbstract" xlink:to="ifrs-full_AssetsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AssetsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">AssetsAbstract</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_AssetsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NoncurrentAssetsAbstract" xlink:label="ifrs-full_NoncurrentAssetsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncurrentAssetsAbstract" xlink:to="ifrs-full_NoncurrentAssetsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NoncurrentAssetsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">NoncurrentAssets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_NoncurrentAssetsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non-current assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IntangibleAssetsAndGoodwill" xlink:label="ifrs-full_IntangibleAssetsAndGoodwill" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IntangibleAssetsAndGoodwill" xlink:to="ifrs-full_IntangibleAssetsAndGoodwill_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IntangibleAssetsAndGoodwill_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Intangible assets and goodwill</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_IntangibleAssetsAndGoodwill_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Intangible assets and goodwill</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwill" xlink:label="ifrs-full_IntangibleAssetsOtherThanGoodwill" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IntangibleAssetsOtherThanGoodwill" xlink:to="ifrs-full_IntangibleAssetsOtherThanGoodwill_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IntangibleAssetsOtherThanGoodwill_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">IntangibleAssetsOtherThanGoodwill</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_IntangibleAssetsOtherThanGoodwill_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Intangible assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_PropertyPlantAndEquipment" xlink:label="ifrs-full_PropertyPlantAndEquipment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PropertyPlantAndEquipment" xlink:to="ifrs-full_PropertyPlantAndEquipment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_PropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, plant and equipment.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_PropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, plant and equipment</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RightofuseAssets" xlink:label="ifrs-full_RightofuseAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RightofuseAssets" xlink:to="ifrs-full_RightofuseAssets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_RightofuseAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">RightofuseAssets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_RightofuseAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Right-of-use assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OtherNoncurrentAssets" xlink:label="ifrs-full_OtherNoncurrentAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherNoncurrentAssets" xlink:to="ifrs-full_OtherNoncurrentAssets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherNoncurrentAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other assets.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_OtherNoncurrentAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NetDeferredTaxAssets" xlink:label="ifrs-full_NetDeferredTaxAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NetDeferredTaxAssets" xlink:to="ifrs-full_NetDeferredTaxAssets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NetDeferredTaxAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net deferred tax assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_NetDeferredTaxAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred tax assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NoncurrentAssets" xlink:label="ifrs-full_NoncurrentAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncurrentAssets" xlink:to="ifrs-full_NoncurrentAssets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NoncurrentAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total non-current assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_NoncurrentAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total non-current assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CurrentAssetsAbstract" xlink:label="ifrs-full_CurrentAssetsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentAssetsAbstract" xlink:to="ifrs-full_CurrentAssetsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentAssetsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">CurrentAssetsAbstract</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CurrentAssetsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners" xlink:label="ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners" xlink:to="ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non-current assets or disposal groups classified as held for sale or as held for distribution to owners</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets held for sale</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_Inventories" xlink:label="ifrs-full_Inventories" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Inventories" xlink:to="ifrs-full_Inventories_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_Inventories_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inventories</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_Inventories_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inventories</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CurrentTradeReceivables" xlink:label="ifrs-full_CurrentTradeReceivables" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentTradeReceivables" xlink:to="ifrs-full_CurrentTradeReceivables_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentTradeReceivables_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current trade receivables</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CurrentTradeReceivables_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Trade receivables</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CurrentContractAssets" xlink:label="ifrs-full_CurrentContractAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentContractAssets" xlink:to="ifrs-full_CurrentContractAssets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentContractAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current contract assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CurrentContractAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contract assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_CurrentContractAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contract assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OtherCurrentFinancialAssets" xlink:label="ifrs-full_OtherCurrentFinancialAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherCurrentFinancialAssets" xlink:to="ifrs-full_OtherCurrentFinancialAssets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherCurrentFinancialAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other current financial assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_OtherCurrentFinancialAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other financial assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CurrentPrepaymentsAndOtherCurrentAssets" xlink:label="ifrs-full_CurrentPrepaymentsAndOtherCurrentAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentPrepaymentsAndOtherCurrentAssets" xlink:to="ifrs-full_CurrentPrepaymentsAndOtherCurrentAssets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentPrepaymentsAndOtherCurrentAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current prepayments and other current assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CurrentPrepaymentsAndOtherCurrentAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid expenses and other assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_CurrentPrepaymentsAndOtherCurrentAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid expenses and other current assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CashAndCashEquivalents" xlink:label="ifrs-full_CashAndCashEquivalents" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashAndCashEquivalents" xlink:to="ifrs-full_CashAndCashEquivalents_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CashAndCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and cash equivalents.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="ifrs-full_CashAndCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and cash equivalents, end of period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="ifrs-full_CashAndCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and cash equivalents, beginning of period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CashAndCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and cash equivalents</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CurrentAssets" xlink:label="ifrs-full_CurrentAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentAssets" xlink:to="ifrs-full_CurrentAssets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_CurrentAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total current assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_Assets" xlink:label="ifrs-full_Assets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Assets" xlink:to="ifrs-full_Assets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_Assets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_Assets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_EquityAndLiabilitiesAbstract" xlink:label="ifrs-full_EquityAndLiabilitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EquityAndLiabilitiesAbstract" xlink:to="ifrs-full_EquityAndLiabilitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_EquityAndLiabilitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">EquityAndLiabilitiesAbstract</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_EquityAndLiabilitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity and liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_EquityAbstract" xlink:label="ifrs-full_EquityAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EquityAbstract" xlink:to="ifrs-full_EquityAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_EquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity [abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_EquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IssuedCapital" xlink:label="ifrs-full_IssuedCapital" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IssuedCapital" xlink:to="ifrs-full_IssuedCapital_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IssuedCapital_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issued capital.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_IssuedCapital_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issued capital</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CapitalReserve" xlink:label="ifrs-full_CapitalReserve" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CapitalReserve" xlink:to="ifrs-full_CapitalReserve_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CapitalReserve_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Capital reserve.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CapitalReserve_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Capital reserve</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TreasuryShares" xlink:label="ifrs-full_TreasuryShares" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TreasuryShares" xlink:to="ifrs-full_TreasuryShares_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TreasuryShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Treasury shares.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_TreasuryShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Treasury Shares</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RetainedEarnings" xlink:label="ifrs-full_RetainedEarnings" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RetainedEarnings" xlink:to="ifrs-full_RetainedEarnings_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_RetainedEarnings_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Retained earnings</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_RetainedEarnings_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated deficit</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AccumulatedOtherComprehensiveIncome" xlink:label="ifrs-full_AccumulatedOtherComprehensiveIncome" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AccumulatedOtherComprehensiveIncome" xlink:to="ifrs-full_AccumulatedOtherComprehensiveIncome_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AccumulatedOtherComprehensiveIncome_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated other comprehensive income</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_AccumulatedOtherComprehensiveIncome_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other comprehensive income</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_Equity" xlink:label="ifrs-full_Equity" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Equity" xlink:to="ifrs-full_Equity_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_Equity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="ifrs-full_Equity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance at the end</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="ifrs-full_Equity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance at the beginning</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_Equity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total equity</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NoncurrentLiabilitiesAbstract" xlink:label="ifrs-full_NoncurrentLiabilitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncurrentLiabilitiesAbstract" xlink:to="ifrs-full_NoncurrentLiabilitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NoncurrentLiabilitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">NoncurrentLiabilitiesAbstract</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_NoncurrentLiabilitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non-current liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NoncurrentFinancialLiabilities" xlink:label="ifrs-full_NoncurrentFinancialLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncurrentFinancialLiabilities" xlink:to="ifrs-full_NoncurrentFinancialLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NoncurrentFinancialLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non-current financial liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_NoncurrentFinancialLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finance Liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NoncurrentLeaseLiabilities" xlink:label="ifrs-full_NoncurrentLeaseLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncurrentLeaseLiabilities" xlink:to="ifrs-full_NoncurrentLeaseLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NoncurrentLeaseLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non-current lease liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_NoncurrentLeaseLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lease liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NoncurrentContractLiabilities" xlink:label="ifrs-full_NoncurrentContractLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncurrentContractLiabilities" xlink:to="ifrs-full_NoncurrentContractLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NoncurrentContractLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non-current contract liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_NoncurrentContractLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contract liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OtherNoncurrentLiabilities" xlink:label="ifrs-full_OtherNoncurrentLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherNoncurrentLiabilities" xlink:to="ifrs-full_OtherNoncurrentLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherNoncurrentLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other non-current liabilities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_OtherNoncurrentLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NoncurrentLiabilities" xlink:label="ifrs-full_NoncurrentLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncurrentLiabilities" xlink:to="ifrs-full_NoncurrentLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NoncurrentLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non-current liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_NoncurrentLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total non-current liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CurrentLiabilitiesAbstract" xlink:label="ifrs-full_CurrentLiabilitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentLiabilitiesAbstract" xlink:to="ifrs-full_CurrentLiabilitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentLiabilitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current liabilities [abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CurrentLiabilitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CurrentLeaseLiabilities" xlink:label="ifrs-full_CurrentLeaseLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentLeaseLiabilities" xlink:to="ifrs-full_CurrentLeaseLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentLeaseLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current lease liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CurrentLeaseLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lease liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TradeAndOtherCurrentPayables" xlink:label="ifrs-full_TradeAndOtherCurrentPayables" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TradeAndOtherCurrentPayables" xlink:to="ifrs-full_TradeAndOtherCurrentPayables_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TradeAndOtherCurrentPayables_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Trade and other current payables</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_TradeAndOtherCurrentPayables_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Trade and other payables</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OtherCurrentLiabilities" xlink:label="ifrs-full_OtherCurrentLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherCurrentLiabilities" xlink:to="ifrs-full_OtherCurrentLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherCurrentLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other current liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_OtherCurrentLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CurrentTaxLiabilities" xlink:label="ifrs-full_CurrentTaxLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentTaxLiabilities" xlink:to="ifrs-full_CurrentTaxLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentTaxLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current tax liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_CurrentTaxLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income taxes payable</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CurrentContractLiabilities" xlink:label="ifrs-full_CurrentContractLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentContractLiabilities" xlink:to="ifrs-full_CurrentContractLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentContractLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current contract liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CurrentContractLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contract liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CurrentLiabilities" xlink:label="ifrs-full_CurrentLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentLiabilities" xlink:to="ifrs-full_CurrentLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_CurrentLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total current liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_Liabilities" xlink:label="ifrs-full_Liabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Liabilities" xlink:to="ifrs-full_Liabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_Liabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_Liabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_EquityAndLiabilities" xlink:label="ifrs-full_EquityAndLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EquityAndLiabilities" xlink:to="ifrs-full_EquityAndLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_EquityAndLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity and liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_EquityAndLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total equity and liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_StatementOfChangesInEquityAbstract" xlink:label="ifrs-full_StatementOfChangesInEquityAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_StatementOfChangesInEquityAbstract" xlink:to="ifrs-full_StatementOfChangesInEquityAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_StatementOfChangesInEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interim Condensed Consolidated Statements of Changes in Shareholders' Equity</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_StatementOfChangesInEquityTable" xlink:label="ifrs-full_StatementOfChangesInEquityTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_StatementOfChangesInEquityTable" xlink:to="ifrs-full_StatementOfChangesInEquityTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_StatementOfChangesInEquityTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statement of changes in equity [table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:label="ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:to="ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Retrospective application and retrospective restatement [axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RestatedMember" xlink:label="ifrs-full_RestatedMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RestatedMember" xlink:to="ifrs-full_RestatedMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_RestatedMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Currently stated [member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_InAccordanceWithIFRS9Member" xlink:label="ifrs-full_InAccordanceWithIFRS9Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_InAccordanceWithIFRS9Member" xlink:to="ifrs-full_InAccordanceWithIFRS9Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_InAccordanceWithIFRS9Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effects from the first-time adoption of IFRS 9</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IncreaseDecreaseDueToApplicationOfIFRS15Member" xlink:label="ifrs-full_IncreaseDecreaseDueToApplicationOfIFRS15Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncreaseDecreaseDueToApplicationOfIFRS15Member" xlink:to="ifrs-full_IncreaseDecreaseDueToApplicationOfIFRS15Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IncreaseDecreaseDueToApplicationOfIFRS15Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effects from the first-time adoption of IFRS 15</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_PreviouslyStatedMember" xlink:label="ifrs-full_PreviouslyStatedMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PreviouslyStatedMember" xlink:to="ifrs-full_PreviouslyStatedMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_PreviouslyStatedMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Previously stated</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ComponentsOfEquityAxis" xlink:label="ifrs-full_ComponentsOfEquityAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="ifrs-full_ComponentsOfEquityAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ComponentsOfEquityAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Components of equity [axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_EquityMember" xlink:label="ifrs-full_EquityMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EquityMember" xlink:to="ifrs-full_EquityMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_EquityMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity [member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IssuedCapitalMember" xlink:label="ifrs-full_IssuedCapitalMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IssuedCapitalMember" xlink:to="ifrs-full_IssuedCapitalMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IssuedCapitalMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issued capital</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CapitalReserveMember" xlink:label="ifrs-full_CapitalReserveMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CapitalReserveMember" xlink:to="ifrs-full_CapitalReserveMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CapitalReserveMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Capital reserve</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TreasurySharesMember" xlink:label="ifrs-full_TreasurySharesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TreasurySharesMember" xlink:to="ifrs-full_TreasurySharesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TreasurySharesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Treasury Shares</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RetainedEarningsMember" xlink:label="ifrs-full_RetainedEarningsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RetainedEarningsMember" xlink:to="ifrs-full_RetainedEarningsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_RetainedEarningsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated deficit</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember" xlink:label="ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember" xlink:to="ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Currency translation reserve</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_StatementOfChangesInEquityLineItems" xlink:label="ifrs-full_StatementOfChangesInEquityLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_StatementOfChangesInEquityLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_StatementOfChangesInEquityLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statement of changes in equity [line items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_StatementOfChangesInEquityLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statement of changes in equity</label>
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_NetLoss" xlink:label="cvac_NetLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_NetLoss" xlink:to="cvac_NetLoss_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_NetLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_NetLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_NetLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OtherComprehensiveIncome" xlink:label="ifrs-full_OtherComprehensiveIncome" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherComprehensiveIncome" xlink:to="ifrs-full_OtherComprehensiveIncome_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherComprehensiveIncome_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other comprehensive income</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_OtherComprehensiveIncome_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other comprehensive income (loss)</label>
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_ComprehensiveIncomeLoss" xlink:label="cvac_ComprehensiveIncomeLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_ComprehensiveIncomeLoss" xlink:to="cvac_ComprehensiveIncomeLoss_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_ComprehensiveIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of income (loss) in equity resulting from transactions and other events, other than those income (loss) resulting from transactions with owners in their capacity as owners.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_ComprehensiveIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Comprehensive Income (Loss)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="cvac_ComprehensiveIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total comprehensive income (loss)</label>
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_ShareBasedPaymentExpenseIncl.DeferredTaxes" xlink:label="cvac_ShareBasedPaymentExpenseIncl.DeferredTaxes" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_ShareBasedPaymentExpenseIncl.DeferredTaxes" xlink:to="cvac_ShareBasedPaymentExpenseIncl.DeferredTaxes_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_ShareBasedPaymentExpenseIncl.DeferredTaxes_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of Share-based payment expense (incl. deferred taxes)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_ShareBasedPaymentExpenseIncl.DeferredTaxes_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based payment expense (incl. deferred taxes)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_ShareBasedPaymentExpenseIncl.DeferredTaxes_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based payments (net of taxes)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IssueOfEquity" xlink:label="ifrs-full_IssueOfEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IssueOfEquity" xlink:to="ifrs-full_IssueOfEquity_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IssueOfEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issue of equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_IssueOfEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of share capital (net of transaction costs)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IncreaseDecreaseThroughConversionOfConvertibleInstruments" xlink:label="ifrs-full_IncreaseDecreaseThroughConversionOfConvertibleInstruments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncreaseDecreaseThroughConversionOfConvertibleInstruments" xlink:to="ifrs-full_IncreaseDecreaseThroughConversionOfConvertibleInstruments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IncreaseDecreaseThroughConversionOfConvertibleInstruments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (decrease) through conversion of convertible instruments, equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveTerseLabel" xlink:label="ifrs-full_IncreaseDecreaseThroughConversionOfConvertibleInstruments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity component of convertible loans (net of tax)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DecreaseIncreaseThroughTaxOnSharebasedPaymentTransactions" xlink:label="ifrs-full_DecreaseIncreaseThroughTaxOnSharebasedPaymentTransactions" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DecreaseIncreaseThroughTaxOnSharebasedPaymentTransactions" xlink:to="ifrs-full_DecreaseIncreaseThroughTaxOnSharebasedPaymentTransactions_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DecreaseIncreaseThroughTaxOnSharebasedPaymentTransactions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Decrease (increase) through tax on share-based payment transactions, equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_DecreaseIncreaseThroughTaxOnSharebasedPaymentTransactions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred taxes on convertible loan</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IncreaseDecreaseThroughExerciseOfOptions" xlink:label="ifrs-full_IncreaseDecreaseThroughExerciseOfOptions" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncreaseDecreaseThroughExerciseOfOptions" xlink:to="ifrs-full_IncreaseDecreaseThroughExerciseOfOptions_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IncreaseDecreaseThroughExerciseOfOptions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares issued on exercise of option</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_IncreaseDecreaseThroughExerciseOfOptions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise of options</label>
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_SettlementOfShareBasedPaymentAwardsAmount" xlink:label="cvac_SettlementOfShareBasedPaymentAwardsAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_SettlementOfShareBasedPaymentAwardsAmount" xlink:to="cvac_SettlementOfShareBasedPaymentAwardsAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_SettlementOfShareBasedPaymentAwardsAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of share based payment awards settled in cash.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_SettlementOfShareBasedPaymentAwardsAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Settlement Of Share Based Payment Awards , Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_SettlementOfShareBasedPaymentAwardsAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Settlement of share-based payment awards</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IncreaseDecreaseThroughTreasuryShareTransactions" xlink:label="ifrs-full_IncreaseDecreaseThroughTreasuryShareTransactions" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncreaseDecreaseThroughTreasuryShareTransactions" xlink:to="ifrs-full_IncreaseDecreaseThroughTreasuryShareTransactions_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IncreaseDecreaseThroughTreasuryShareTransactions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (decrease) through treasury share transactions, equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_IncreaseDecreaseThroughTreasuryShareTransactions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Repurchase of common shares</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IncreaseDecreaseThroughAcquisitionOfSubsidiary" xlink:label="ifrs-full_IncreaseDecreaseThroughAcquisitionOfSubsidiary" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncreaseDecreaseThroughAcquisitionOfSubsidiary" xlink:to="ifrs-full_IncreaseDecreaseThroughAcquisitionOfSubsidiary_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IncreaseDecreaseThroughAcquisitionOfSubsidiary_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (decrease) through acquisition of subsidiary, equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_IncreaseDecreaseThroughAcquisitionOfSubsidiary_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Capital Increase from Business Combinations</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NumberOfSharesOutstanding" xlink:label="ifrs-full_NumberOfSharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfSharesOutstanding" xlink:to="ifrs-full_NumberOfSharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NumberOfSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of shares outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="ifrs-full_NumberOfSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance at the end (in shares)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_StatementOfCashFlowsAbstract" xlink:label="ifrs-full_StatementOfCashFlowsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_StatementOfCashFlowsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interim Condensed Consolidated Statements of Cash Flows</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash flows from (used in) operating activities [abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating activities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AdjustmentsForReconcileProfitLossAbstract" xlink:label="ifrs-full_AdjustmentsForReconcileProfitLossAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForReconcileProfitLossAbstract" xlink:to="ifrs-full_AdjustmentsForReconcileProfitLossAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdjustmentsForReconcileProfitLossAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments to reconcile profit (loss) [abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_AdjustmentsForReconcileProfitLossAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments to reconcile loss before tax to net cash flows</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AdjustmentsForFinanceIncome" xlink:label="ifrs-full_AdjustmentsForFinanceIncome" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForFinanceIncome" xlink:to="ifrs-full_AdjustmentsForFinanceIncome_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdjustmentsForFinanceIncome_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments for finance income</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_AdjustmentsForFinanceIncome_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finance income</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AdjustmentsForFinanceCosts" xlink:label="ifrs-full_AdjustmentsForFinanceCosts" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForFinanceCosts" xlink:to="ifrs-full_AdjustmentsForFinanceCosts_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdjustmentsForFinanceCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments for finance costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_AdjustmentsForFinanceCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finance expense</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense" xlink:label="ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense" xlink:to="ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments for depreciation and amortisation expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Depreciation and impairment of property, plant and equipment and right-of-use assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AdjustmentsForGainLossOnDisposalsPropertyPlantAndEquipment" xlink:label="ifrs-full_AdjustmentsForGainLossOnDisposalsPropertyPlantAndEquipment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForGainLossOnDisposalsPropertyPlantAndEquipment" xlink:to="ifrs-full_AdjustmentsForGainLossOnDisposalsPropertyPlantAndEquipment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdjustmentsForGainLossOnDisposalsPropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments for gain (loss) on disposals, property, plant and equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_AdjustmentsForGainLossOnDisposalsPropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loss on disposal of fixed assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets" xlink:label="ifrs-full_AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets" xlink:to="ifrs-full_AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments for losses (gains) on disposal of non-current assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loss on disposal of fixed assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" xlink:label="ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" xlink:to="ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments for impairment loss (reversal of impairment loss) recognised in profit or loss, property, plant and equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Impairment to property, plant and equipment</label>
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_ImpairmentsOfInventoryAndPrepayments" xlink:label="cvac_ImpairmentsOfInventoryAndPrepayments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_ImpairmentsOfInventoryAndPrepayments" xlink:to="cvac_ImpairmentsOfInventoryAndPrepayments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_ImpairmentsOfInventoryAndPrepayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Impairments of inventory and prepayments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_ImpairmentsOfInventoryAndPrepayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Impairments of inventory and prepayments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_ImpairmentsOfInventoryAndPrepayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Impairment of inventory and prepayments</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AdjustmentsForSharebasedPayments" xlink:label="ifrs-full_AdjustmentsForSharebasedPayments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForSharebasedPayments" xlink:to="ifrs-full_AdjustmentsForSharebasedPayments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdjustmentsForSharebasedPayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments for share-based payments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_AdjustmentsForSharebasedPayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based payment expense</label>
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_AdjustmentsForNonCashIncomeFromReleaseOfProvisions" xlink:label="cvac_AdjustmentsForNonCashIncomeFromReleaseOfProvisions" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_AdjustmentsForNonCashIncomeFromReleaseOfProvisions" xlink:to="cvac_AdjustmentsForNonCashIncomeFromReleaseOfProvisions_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_AdjustmentsForNonCashIncomeFromReleaseOfProvisions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments for non cash income from release of provisions to reconcile profit (loss) to net cash flow from (used in) operating activities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_AdjustmentsForNonCashIncomeFromReleaseOfProvisions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments For Non Cash Income From Release Of Provisions</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="cvac_AdjustmentsForNonCashIncomeFromReleaseOfProvisions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non-cash income from release of provisions</label>
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_ChangesInWorkingCapitalAbstract" xlink:label="cvac_ChangesInWorkingCapitalAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_ChangesInWorkingCapitalAbstract" xlink:to="cvac_ChangesInWorkingCapitalAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_ChangesInWorkingCapitalAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">No definition available.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_ChangesInWorkingCapitalAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Changes in Working Capital [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_ChangesInWorkingCapitalAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Working capital changes</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables" xlink:to="ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments for decrease (increase) in trade and other receivables</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Decrease / (increase) in trade receivables and contract assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInInventories" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInInventories" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForDecreaseIncreaseInInventories" xlink:to="ifrs-full_AdjustmentsForDecreaseIncreaseInInventories_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInInventories_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments for decrease (increase) in inventories</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInInventories_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Decrease / (increase) in inventory</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInOtherAssets" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInOtherAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForDecreaseIncreaseInOtherAssets" xlink:to="ifrs-full_AdjustmentsForDecreaseIncreaseInOtherAssets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInOtherAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments for decrease (increase) in other assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInOtherAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Decrease / (increase) in other assets</label>
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_IfrsIncreaseDecreaseInPrepaidExpenseAndOtherAssets" xlink:label="cvac_IfrsIncreaseDecreaseInPrepaidExpenseAndOtherAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_IfrsIncreaseDecreaseInPrepaidExpenseAndOtherAssets" xlink:to="cvac_IfrsIncreaseDecreaseInPrepaidExpenseAndOtherAssets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_IfrsIncreaseDecreaseInPrepaidExpenseAndOtherAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of increase (decrease) in prepaid expenses, and assets classified as other.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_IfrsIncreaseDecreaseInPrepaidExpenseAndOtherAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ifrs Increase (Decrease) in Prepaid Expense and Other Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="cvac_IfrsIncreaseDecreaseInPrepaidExpenseAndOtherAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Decrease / (increase) in prepaid expenses and other assets</label>
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_ReceiptsFromGovernmentGrantsClassifiedAsOperatingActivities" xlink:label="cvac_ReceiptsFromGovernmentGrantsClassifiedAsOperatingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_ReceiptsFromGovernmentGrantsClassifiedAsOperatingActivities" xlink:to="cvac_ReceiptsFromGovernmentGrantsClassifiedAsOperatingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_ReceiptsFromGovernmentGrantsClassifiedAsOperatingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The cash inflow from government grants and similar bodies.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_ReceiptsFromGovernmentGrantsClassifiedAsOperatingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Receipts from Government Grants Classified as Operating Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_ReceiptsFromGovernmentGrantsClassifiedAsOperatingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Receipts from grants from government agencies and similar bodies</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="cvac_ReceiptsFromGovernmentGrantsClassifiedAsOperatingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Grant amount received/eligible to receive</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" xlink:label="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" xlink:to="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments for increase (decrease) in trade and other payables</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">(Decrease) / increase in trade and other payables, other liabilities and contract liabilities</label>
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_AdjustmentsForIncreaseDecreaseInOtherCurrentFinancialAndOtherLiabilities" xlink:label="cvac_AdjustmentsForIncreaseDecreaseInOtherCurrentFinancialAndOtherLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_AdjustmentsForIncreaseDecreaseInOtherCurrentFinancialAndOtherLiabilities" xlink:to="cvac_AdjustmentsForIncreaseDecreaseInOtherCurrentFinancialAndOtherLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_AdjustmentsForIncreaseDecreaseInOtherCurrentFinancialAndOtherLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments for increase (decrease) in other current financial and other liabilities to reconcile profit(loss) to net cashflow (used in) operating activities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_AdjustmentsForIncreaseDecreaseInOtherCurrentFinancialAndOtherLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments For Increase Decrease In Other Current Financial And Other Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_AdjustmentsForIncreaseDecreaseInOtherCurrentFinancialAndOtherLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">(Decrease) / increase in other current financial liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AdjustmentsForDeferredTaxExpense" xlink:label="ifrs-full_AdjustmentsForDeferredTaxExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForDeferredTaxExpense" xlink:to="ifrs-full_AdjustmentsForDeferredTaxExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdjustmentsForDeferredTaxExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments for deferred tax expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_AdjustmentsForDeferredTaxExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Decrease / (increase) in deferred taxes</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IncomeTaxesPaidClassifiedAsOperatingActivities" xlink:label="ifrs-full_IncomeTaxesPaidClassifiedAsOperatingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncomeTaxesPaidClassifiedAsOperatingActivities" xlink:to="ifrs-full_IncomeTaxesPaidClassifiedAsOperatingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IncomeTaxesPaidClassifiedAsOperatingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income taxes paid, classified as operating activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_IncomeTaxesPaidClassifiedAsOperatingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income taxes paid</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_InterestReceivedClassifiedAsOperatingActivities" xlink:label="ifrs-full_InterestReceivedClassifiedAsOperatingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_InterestReceivedClassifiedAsOperatingActivities" xlink:to="ifrs-full_InterestReceivedClassifiedAsOperatingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_InterestReceivedClassifiedAsOperatingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest received, classified as operating activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_InterestReceivedClassifiedAsOperatingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest received</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_InterestPaidClassifiedAsOperatingActivities" xlink:label="ifrs-full_InterestPaidClassifiedAsOperatingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_InterestPaidClassifiedAsOperatingActivities" xlink:to="ifrs-full_InterestPaidClassifiedAsOperatingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_InterestPaidClassifiedAsOperatingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest paid, classified as operating activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="ifrs-full_InterestPaidClassifiedAsOperatingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest paid</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:to="ifrs-full_CashFlowsFromUsedInOperatingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash flows from (used in) operating activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net cash flow (used in) operating activities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:label="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash flows from (used in) investing activities [abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Investing activities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:label="ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:to="ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Purchase of property, plant and equipment, classified as investing activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Purchase of property, plant and equipment</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" xlink:label="ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" xlink:to="ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Purchase of intangible assets, classified as investing activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Purchase of intangible assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_PurchaseOfOtherLongtermAssetsClassifiedAsInvestingActivities" xlink:label="ifrs-full_PurchaseOfOtherLongtermAssetsClassifiedAsInvestingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PurchaseOfOtherLongtermAssetsClassifiedAsInvestingActivities" xlink:to="ifrs-full_PurchaseOfOtherLongtermAssetsClassifiedAsInvestingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_PurchaseOfOtherLongtermAssetsClassifiedAsInvestingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Purchase of other long-term assets, classified as investing activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_PurchaseOfOtherLongtermAssetsClassifiedAsInvestingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Purchases of financial assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:label="ifrs-full_CashFlowsFromUsedInInvestingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:to="ifrs-full_CashFlowsFromUsedInInvestingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CashFlowsFromUsedInInvestingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash flows from (used in) investing activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_CashFlowsFromUsedInInvestingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net cash flow (used in) investing activities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash flows from (used in) financing activities [abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financing activities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" xlink:label="ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" xlink:to="ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments of lease liabilities, classified as financing activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments on lease obligations</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProceedsFromIssuingOtherEquityInstruments" xlink:label="ifrs-full_ProceedsFromIssuingOtherEquityInstruments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProceedsFromIssuingOtherEquityInstruments" xlink:to="ifrs-full_ProceedsFromIssuingOtherEquityInstruments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ProceedsFromIssuingOtherEquityInstruments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from issuing other equity instruments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ProceedsFromIssuingOtherEquityInstruments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payment on Treasury Shares</label>
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_ProceedFromIssuingOtherEquityInstrument" xlink:label="cvac_ProceedFromIssuingOtherEquityInstrument" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_ProceedFromIssuingOtherEquityInstrument" xlink:to="cvac_ProceedFromIssuingOtherEquityInstrument_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_ProceedFromIssuingOtherEquityInstrument_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of Proceed From Issuing Other Equity Instrument</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_ProceedFromIssuingOtherEquityInstrument_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceed From Issuing Other Equity Instrument</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_ProceedFromIssuingOtherEquityInstrument_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payment on / Proceeds from Treasury Shares</label>
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_IfrsStockIssuedDuringPeriodValueNewIssues" xlink:label="cvac_IfrsStockIssuedDuringPeriodValueNewIssues" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_IfrsStockIssuedDuringPeriodValueNewIssues" xlink:to="cvac_IfrsStockIssuedDuringPeriodValueNewIssues_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_IfrsStockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The cash inflow from at the market shares issued during the period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_IfrsStockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ifrs Stock Issued During Period Value New Issues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="cvac_IfrsStockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from at-the-market offering program (net of transaction costs)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProceedsFromExerciseOfOptions" xlink:label="ifrs-full_ProceedsFromExerciseOfOptions" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProceedsFromExerciseOfOptions" xlink:to="ifrs-full_ProceedsFromExerciseOfOptions_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ProceedsFromExerciseOfOptions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from exercise of options</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ProceedsFromExerciseOfOptions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from the exercise of options</label>
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_ProceedsOrPaymentsFromExerciseOfOptions" xlink:label="cvac_ProceedsOrPaymentsFromExerciseOfOptions" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_ProceedsOrPaymentsFromExerciseOfOptions" xlink:to="cvac_ProceedsOrPaymentsFromExerciseOfOptions_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_ProceedsOrPaymentsFromExerciseOfOptions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The cash inflow or outflow from the exercise of options.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_ProceedsOrPaymentsFromExerciseOfOptions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds Or Payments From Exercise Of Options</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="cvac_ProceedsOrPaymentsFromExerciseOfOptions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments from the exercise of options</label>
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_ProceedsOnExerciseOfOptions" xlink:label="cvac_ProceedsOnExerciseOfOptions" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_ProceedsOnExerciseOfOptions" xlink:to="cvac_ProceedsOnExerciseOfOptions_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_ProceedsOnExerciseOfOptions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds on exercise of options.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_ProceedsOnExerciseOfOptions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds On Exercise Of Options</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="cvac_ProceedsOnExerciseOfOptions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds on exercise of options</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProceedsFromIssuingShares" xlink:label="ifrs-full_ProceedsFromIssuingShares" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProceedsFromIssuingShares" xlink:to="ifrs-full_ProceedsFromIssuingShares_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ProceedsFromIssuingShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from issuing shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ProceedsFromIssuingShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash received from issuance of shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_ProceedsFromIssuingShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from the issuance of shares (net of transaction costs)</label>
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_ProceedsFromRepaymentsOfBorrowingsClassifiedAsFinancingActivities" xlink:label="cvac_ProceedsFromRepaymentsOfBorrowingsClassifiedAsFinancingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_ProceedsFromRepaymentsOfBorrowingsClassifiedAsFinancingActivities" xlink:to="cvac_ProceedsFromRepaymentsOfBorrowingsClassifiedAsFinancingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_ProceedsFromRepaymentsOfBorrowingsClassifiedAsFinancingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The cash inflow from borrowings obtained. [Refer: Borrowings]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_ProceedsFromRepaymentsOfBorrowingsClassifiedAsFinancingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from (Repayments of) borrowings, classified as financing activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_ProceedsFromRepaymentsOfBorrowingsClassifiedAsFinancingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from (repayment of) the EIB loan</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProceedsFromIssueOfBondsNotesAndDebentures" xlink:label="ifrs-full_ProceedsFromIssueOfBondsNotesAndDebentures" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProceedsFromIssueOfBondsNotesAndDebentures" xlink:to="ifrs-full_ProceedsFromIssueOfBondsNotesAndDebentures_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ProceedsFromIssueOfBondsNotesAndDebentures_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from issue of bonds, notes and debentures</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_ProceedsFromIssueOfBondsNotesAndDebentures_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from the convertible loan</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RepaymentsOfBondsNotesAndDebentures" xlink:label="ifrs-full_RepaymentsOfBondsNotesAndDebentures" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RepaymentsOfBondsNotesAndDebentures" xlink:to="ifrs-full_RepaymentsOfBondsNotesAndDebentures_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_RepaymentsOfBondsNotesAndDebentures_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Repayments of bonds, notes and debentures</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_RepaymentsOfBondsNotesAndDebentures_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Repayments of convertible loan</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:to="ifrs-full_CashFlowsFromUsedInFinancingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash flows from (used in) financing activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net cash flow provided by financing activities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" xlink:label="ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" xlink:to="ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (decrease) in cash and cash equivalents before effect of exchange rate changes</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net increase (decrease) in cash and cash equivalents</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents" xlink:label="ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents" xlink:to="ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effect of exchange rate changes on cash and cash equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Currency translation gains (losses) on cash and cash equivalents</label>
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_CorporateInformationAbstract" xlink:label="cvac_CorporateInformationAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_CorporateInformationAbstract" xlink:to="cvac_CorporateInformationAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_CorporateInformationAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">No definition available.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_CorporateInformationAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Corporate Information</label>
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_CorporateInformationTextBlock" xlink:label="cvac_CorporateInformationTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_CorporateInformationTextBlock" xlink:to="cvac_CorporateInformationTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_CorporateInformationTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The entire disclosure on corporate information.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_CorporateInformationTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Corporate Information [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_CorporateInformationTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Corporate Information</label>
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_DisclosureOfBasisOfPreparationAbstract" xlink:label="cvac_DisclosureOfBasisOfPreparationAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_DisclosureOfBasisOfPreparationAbstract" xlink:to="cvac_DisclosureOfBasisOfPreparationAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_DisclosureOfBasisOfPreparationAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The disclosure of the basis used for the preparation of the financial statement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_DisclosureOfBasisOfPreparationAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Basis of preparation</label>
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_DisclosureOfBasisOfPreparationExplanatoryTextBlock" xlink:label="cvac_DisclosureOfBasisOfPreparationExplanatoryTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_DisclosureOfBasisOfPreparationExplanatoryTextBlock" xlink:to="cvac_DisclosureOfBasisOfPreparationExplanatoryTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_DisclosureOfBasisOfPreparationExplanatoryTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The disclosure of the basis used for the preparation of the financial statement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_DisclosureOfBasisOfPreparationExplanatoryTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of Basis of Preparation Explanatory [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_DisclosureOfBasisOfPreparationExplanatoryTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Basis of preparation</label>
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_DisclosureOfNotesToConsolidatedFinancialStatementsAbstract" xlink:label="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsAbstract" xlink:to="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">No definition available.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Notes to the consolidated financial statements</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfNotesAndOtherExplanatoryInformationExplanatory" xlink:label="ifrs-full_DisclosureOfNotesAndOtherExplanatoryInformationExplanatory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfNotesAndOtherExplanatoryInformationExplanatory" xlink:to="ifrs-full_DisclosureOfNotesAndOtherExplanatoryInformationExplanatory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfNotesAndOtherExplanatoryInformationExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of notes and other explanatory information [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfNotesAndOtherExplanatoryInformationExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Notes to the consolidated financial statements</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalAbstract" xlink:label="ifrs-full_DisclosureOfClassesOfShareCapitalAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalAbstract" xlink:to="ifrs-full_DisclosureOfClassesOfShareCapitalAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfClassesOfShareCapitalAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issued Capital and Reserves</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory" xlink:label="ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory" xlink:to="ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of share capital, reserves and other equity interest [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issued Capital and Reserves</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:to="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based payments</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory" xlink:label="ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory" xlink:to="ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of share-based payment arrangements [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based payments</label>
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_DisclosureOfFixedAssetsAbstract" xlink:label="cvac_DisclosureOfFixedAssetsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_DisclosureOfFixedAssetsAbstract" xlink:to="cvac_DisclosureOfFixedAssetsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_DisclosureOfFixedAssetsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">No definition available.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_DisclosureOfFixedAssetsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fixed Assets</label>
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_DisclosureOfFixedAssetsExplanatory" xlink:label="cvac_DisclosureOfFixedAssetsExplanatory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_DisclosureOfFixedAssetsExplanatory" xlink:to="cvac_DisclosureOfFixedAssetsExplanatory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_DisclosureOfFixedAssetsExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The entire disclosure for fixed assets.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_DisclosureOfFixedAssetsExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure Of Fixed Assets, Explanatory</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_DisclosureOfFixedAssetsExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fixed Assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwnersAbstract" xlink:label="ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwnersAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwnersAbstract" xlink:to="ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwnersAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwnersAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets held for sale</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfNoncurrentAssetsHeldForSaleAndDiscontinuedOperationsExplanatory" xlink:label="ifrs-full_DisclosureOfNoncurrentAssetsHeldForSaleAndDiscontinuedOperationsExplanatory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfNoncurrentAssetsHeldForSaleAndDiscontinuedOperationsExplanatory" xlink:to="ifrs-full_DisclosureOfNoncurrentAssetsHeldForSaleAndDiscontinuedOperationsExplanatory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfNoncurrentAssetsHeldForSaleAndDiscontinuedOperationsExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of non-current assets held for sale and discontinued operations [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfNoncurrentAssetsHeldForSaleAndDiscontinuedOperationsExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets held for sale</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ClassesOfInventoriesAbstract" xlink:label="ifrs-full_ClassesOfInventoriesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ClassesOfInventoriesAbstract" xlink:to="ifrs-full_ClassesOfInventoriesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ClassesOfInventoriesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inventories.</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfInventoriesExplanatory" xlink:label="ifrs-full_DisclosureOfInventoriesExplanatory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfInventoriesExplanatory" xlink:to="ifrs-full_DisclosureOfInventoriesExplanatory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfInventoriesExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of inventories [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfInventoriesExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inventories</label>
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_DisclosureOfPrepaidExpensesAndOtherCurrentAssetsAbstract" xlink:label="cvac_DisclosureOfPrepaidExpensesAndOtherCurrentAssetsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_DisclosureOfPrepaidExpensesAndOtherCurrentAssetsAbstract" xlink:to="cvac_DisclosureOfPrepaidExpensesAndOtherCurrentAssetsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_DisclosureOfPrepaidExpensesAndOtherCurrentAssetsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">No definition available.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_DisclosureOfPrepaidExpensesAndOtherCurrentAssetsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid expenses and other assets (current)</label>
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_DisclosureOfPrepaidExpensesAndOtherCurrentAssetsExplanatory" xlink:label="cvac_DisclosureOfPrepaidExpensesAndOtherCurrentAssetsExplanatory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_DisclosureOfPrepaidExpensesAndOtherCurrentAssetsExplanatory" xlink:to="cvac_DisclosureOfPrepaidExpensesAndOtherCurrentAssetsExplanatory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_DisclosureOfPrepaidExpensesAndOtherCurrentAssetsExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The entire disclosure for prepaid expenses and other current assets.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_DisclosureOfPrepaidExpensesAndOtherCurrentAssetsExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure Of Prepaid Expenses And Other Current Assets, Explanatory</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_DisclosureOfPrepaidExpensesAndOtherCurrentAssetsExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid expenses and other assets (current)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfFinancialInstrumentsAbstract" xlink:label="ifrs-full_DisclosureOfFinancialInstrumentsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsAbstract" xlink:to="ifrs-full_DisclosureOfFinancialInstrumentsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfFinancialInstrumentsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financial assets and financial liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfFinancialInstrumentsExplanatory" xlink:label="ifrs-full_DisclosureOfFinancialInstrumentsExplanatory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsExplanatory" xlink:to="ifrs-full_DisclosureOfFinancialInstrumentsExplanatory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfFinancialInstrumentsExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of financial instruments [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfFinancialInstrumentsExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financial assets and financial liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TradeAndOtherCurrentPayablesAbstract" xlink:label="ifrs-full_TradeAndOtherCurrentPayablesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TradeAndOtherCurrentPayablesAbstract" xlink:to="ifrs-full_TradeAndOtherCurrentPayablesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TradeAndOtherCurrentPayablesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Trade and other payables.</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory" xlink:label="ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory" xlink:to="ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of trade and other payables [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Trade and other payables</label>
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_IfrsOtherLiabilitiesAbstract" xlink:label="cvac_IfrsOtherLiabilitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_IfrsOtherLiabilitiesAbstract" xlink:to="cvac_IfrsOtherLiabilitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_IfrsOtherLiabilitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">No definition available.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_IfrsOtherLiabilitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other liabilities.</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfOtherLiabilitiesExplanatory" xlink:label="ifrs-full_DisclosureOfOtherLiabilitiesExplanatory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfOtherLiabilitiesExplanatory" xlink:to="ifrs-full_DisclosureOfOtherLiabilitiesExplanatory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfOtherLiabilitiesExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of other liabilities [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfOtherLiabilitiesExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsAbstract" xlink:label="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsAbstract" xlink:to="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loans</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsExplanatory" xlink:label="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsExplanatory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsExplanatory" xlink:to="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsExplanatory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of detailed information about borrowings [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loans</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract" xlink:label="ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract" xlink:to="ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income tax</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfIncomeTaxExplanatory" xlink:label="ifrs-full_DisclosureOfIncomeTaxExplanatory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfIncomeTaxExplanatory" xlink:to="ifrs-full_DisclosureOfIncomeTaxExplanatory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfIncomeTaxExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of income tax [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfIncomeTaxExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income tax</label>
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_FinancialInstrumentsAndRiskManagementAbstract" xlink:label="cvac_FinancialInstrumentsAndRiskManagementAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_FinancialInstrumentsAndRiskManagementAbstract" xlink:to="cvac_FinancialInstrumentsAndRiskManagementAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_FinancialInstrumentsAndRiskManagementAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">No definition available.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_FinancialInstrumentsAndRiskManagementAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of financial instruments and risk management</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfFinancialRiskManagementExplanatory" xlink:label="ifrs-full_DisclosureOfFinancialRiskManagementExplanatory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfFinancialRiskManagementExplanatory" xlink:to="ifrs-full_DisclosureOfFinancialRiskManagementExplanatory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfFinancialRiskManagementExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of financial risk management [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfFinancialRiskManagementExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of financial instruments and risk management</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_EarningsPerShareAbstract" xlink:label="ifrs-full_EarningsPerShareAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EarningsPerShareAbstract" xlink:to="ifrs-full_EarningsPerShareAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_EarningsPerShareAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnings per share</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_EarningsPerShareExplanatory" xlink:label="ifrs-full_EarningsPerShareExplanatory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EarningsPerShareExplanatory" xlink:to="ifrs-full_EarningsPerShareExplanatory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_EarningsPerShareExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnings per share [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_EarningsPerShareExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnings per share</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract" xlink:label="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract" xlink:to="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related party disclosures</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfRelatedPartyExplanatory" xlink:label="ifrs-full_DisclosureOfRelatedPartyExplanatory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfRelatedPartyExplanatory" xlink:to="ifrs-full_DisclosureOfRelatedPartyExplanatory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfRelatedPartyExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of related party [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfRelatedPartyExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related party disclosures</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfBusinessCombinationsAbstract" xlink:label="ifrs-full_DisclosureOfBusinessCombinationsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsAbstract" xlink:to="ifrs-full_DisclosureOfBusinessCombinationsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfBusinessCombinationsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Significant transactions and events</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfBusinessCombinationsExplanatory" xlink:label="ifrs-full_DisclosureOfBusinessCombinationsExplanatory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsExplanatory" xlink:to="ifrs-full_DisclosureOfBusinessCombinationsExplanatory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfBusinessCombinationsExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of business combinations [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfBusinessCombinationsExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Significant transactions and events</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract" xlink:label="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract" xlink:to="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent events</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory" xlink:label="ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory" xlink:to="ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of events after reporting period [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent events</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory" xlink:label="ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory" xlink:to="ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of basis of preparation of financial statements [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Basis of preparation</label>
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_DescriptionOfAccountingPolicyOfNewStandardsInterpretationsAndAmendmentsAdoptedTextBlock" xlink:label="cvac_DescriptionOfAccountingPolicyOfNewStandardsInterpretationsAndAmendmentsAdoptedTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_DescriptionOfAccountingPolicyOfNewStandardsInterpretationsAndAmendmentsAdoptedTextBlock" xlink:to="cvac_DescriptionOfAccountingPolicyOfNewStandardsInterpretationsAndAmendmentsAdoptedTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_DescriptionOfAccountingPolicyOfNewStandardsInterpretationsAndAmendmentsAdoptedTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The description of the entity's accounting policy for New standards, interpretations and amendments adopted by the Group.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_DescriptionOfAccountingPolicyOfNewStandardsInterpretationsAndAmendmentsAdoptedTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Description of Accounting Policy of New Standards, Interpretations and Amendments Adopted [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_DescriptionOfAccountingPolicyOfNewStandardsInterpretationsAndAmendmentsAdoptedTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">New standards, interpretations and amendments adopted by the Group</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Description of accounting policy for research and development expense [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and Development Expenses</label>
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_DescriptionOfAccountingPolicyForPreLaunchProductsExplanatory" xlink:label="cvac_DescriptionOfAccountingPolicyForPreLaunchProductsExplanatory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_DescriptionOfAccountingPolicyForPreLaunchProductsExplanatory" xlink:to="cvac_DescriptionOfAccountingPolicyForPreLaunchProductsExplanatory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_DescriptionOfAccountingPolicyForPreLaunchProductsExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Description of accounting policy for Pre-launch products.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_DescriptionOfAccountingPolicyForPreLaunchProductsExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Description of Accounting Policy for Pre-Launch Products, Explanatory</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_DescriptionOfAccountingPolicyForPreLaunchProductsExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Pre-launch products</label>
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_DescriptionOfAccountingPolicyForCovid19ImpactExplanatory" xlink:label="cvac_DescriptionOfAccountingPolicyForCovid19ImpactExplanatory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_DescriptionOfAccountingPolicyForCovid19ImpactExplanatory" xlink:to="cvac_DescriptionOfAccountingPolicyForCovid19ImpactExplanatory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_DescriptionOfAccountingPolicyForCovid19ImpactExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Description of accounting policy for Covid-19 impact.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_DescriptionOfAccountingPolicyForCovid19ImpactExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Description of Accounting Policy for Covid-19 Impact, Explanatory</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_DescriptionOfAccountingPolicyForCovid19ImpactExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Impact of COVID-19 and the Russia-Ukraine Conflict</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory" xlink:label="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory" xlink:to="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of disaggregation of revenue from contracts with customers [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of revenue from contract with customers recognized</label>
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_DisclosureOfUpfrontPaymentsAndRelatedRevenuesRecognizedExplanatory" xlink:label="cvac_DisclosureOfUpfrontPaymentsAndRelatedRevenuesRecognizedExplanatory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_DisclosureOfUpfrontPaymentsAndRelatedRevenuesRecognizedExplanatory" xlink:to="cvac_DisclosureOfUpfrontPaymentsAndRelatedRevenuesRecognizedExplanatory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_DisclosureOfUpfrontPaymentsAndRelatedRevenuesRecognizedExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of detailed information about upfront payments and related revenues recognized.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_DisclosureOfUpfrontPaymentsAndRelatedRevenuesRecognizedExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure Of Upfront Payments And Related Revenues Recognized, Explanatory</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_DisclosureOfUpfrontPaymentsAndRelatedRevenuesRecognizedExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of upfront payments and related revenues recognized</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory" xlink:label="ifrs-full_ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory" xlink:to="ifrs-full_ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Explanation of significant changes in contract assets and contract liabilities [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of contract balances</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfTransactionPriceAllocatedToRemainingPerformanceObligationsExplanatory" xlink:label="ifrs-full_DisclosureOfTransactionPriceAllocatedToRemainingPerformanceObligationsExplanatory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfTransactionPriceAllocatedToRemainingPerformanceObligationsExplanatory" xlink:to="ifrs-full_DisclosureOfTransactionPriceAllocatedToRemainingPerformanceObligationsExplanatory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfTransactionPriceAllocatedToRemainingPerformanceObligationsExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of transaction price allocated to remaining performance obligations [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfTransactionPriceAllocatedToRemainingPerformanceObligationsExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Contract liabilities allocated to the remaining performance obligations (unsatisfied or partially unsatisfied) as at year-end</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfExpensesByNatureExplanatory" xlink:label="ifrs-full_DisclosureOfExpensesByNatureExplanatory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfExpensesByNatureExplanatory" xlink:to="ifrs-full_DisclosureOfExpensesByNatureExplanatory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfExpensesByNatureExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of expenses by nature [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfExpensesByNatureExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of cost of sales, selling and distribution expenses, research and development expenses and general and administrative expenses</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfOtherOperatingIncomeExplanatory" xlink:label="ifrs-full_DisclosureOfOtherOperatingIncomeExplanatory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfOtherOperatingIncomeExplanatory" xlink:to="ifrs-full_DisclosureOfOtherOperatingIncomeExplanatory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfOtherOperatingIncomeExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of other operating income [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfOtherOperatingIncomeExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of other operating income</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfOtherOperatingExpenseExplanatory" xlink:label="ifrs-full_DisclosureOfOtherOperatingExpenseExplanatory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfOtherOperatingExpenseExplanatory" xlink:to="ifrs-full_DisclosureOfOtherOperatingExpenseExplanatory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfOtherOperatingExpenseExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of other operating expense [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfOtherOperatingExpenseExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of other operating expenses</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory" xlink:label="ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory" xlink:to="ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of classes of share capital [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of number of shares issued and outstanding</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:to="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of terms and conditions of share-based payment arrangement [table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:label="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:to="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Types of share-based payment arrangements [axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_SharebasedPaymentArrangementsMember" xlink:label="ifrs-full_SharebasedPaymentArrangementsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_SharebasedPaymentArrangementsMember" xlink:to="ifrs-full_SharebasedPaymentArrangementsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_SharebasedPaymentArrangementsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based payment arrangements [member]</label>
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_VirtualSharesProgramIMember" xlink:label="cvac_VirtualSharesProgramIMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_VirtualSharesProgramIMember" xlink:to="cvac_VirtualSharesProgramIMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_VirtualSharesProgramIMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for Virtual shares program I.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_VirtualSharesProgramIMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prior VSOP</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_VirtualSharesProgramIMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prior VSOP</label>
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_VirtualSharesProgramIiMember" xlink:label="cvac_VirtualSharesProgramIiMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_VirtualSharesProgramIiMember" xlink:to="cvac_VirtualSharesProgramIiMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_VirtualSharesProgramIiMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for Virtual shares program II (New VSOP).</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_VirtualSharesProgramIiMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">New VSOP</label>
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_OptionsGrantedToThenChiefExecutiveOfficerMember" xlink:label="cvac_OptionsGrantedToThenChiefExecutiveOfficerMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_OptionsGrantedToThenChiefExecutiveOfficerMember" xlink:to="cvac_OptionsGrantedToThenChiefExecutiveOfficerMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_OptionsGrantedToThenChiefExecutiveOfficerMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for options granted to Dan Menichella, the then Chief Executive Officer (CEO).</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_OptionsGrantedToThenChiefExecutiveOfficerMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Former Chief Executive Officer Grant</label>
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_RestrictedStockUnitsMember" xlink:label="cvac_RestrictedStockUnitsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_RestrictedStockUnitsMember" xlink:to="cvac_RestrictedStockUnitsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_RestrictedStockUnitsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for Restricted stock Units</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_RestrictedStockUnitsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restricted Stock Units</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of terms and conditions of share-based payment arrangement [line items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based payments</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory" xlink:label="ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory" xlink:to="ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of number and weighted average exercise prices of share options [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of reconciliation of outstanding awards</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory" xlink:label="ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory" xlink:to="ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of indirect measurement of fair value of goods or services received, share options granted during period [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of inputs used in the measurement of the fair value at grant date</label>
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_DisclosureOfExpenseRecognizedForEmployeeServicesExplanatory" xlink:label="cvac_DisclosureOfExpenseRecognizedForEmployeeServicesExplanatory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_DisclosureOfExpenseRecognizedForEmployeeServicesExplanatory" xlink:to="cvac_DisclosureOfExpenseRecognizedForEmployeeServicesExplanatory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_DisclosureOfExpenseRecognizedForEmployeeServicesExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of expense recognized for employee services explanatory.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_DisclosureOfExpenseRecognizedForEmployeeServicesExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of Expense Recognized For Employee Services Explanatory</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_DisclosureOfExpenseRecognizedForEmployeeServicesExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of expense recognized for employee services received</label>
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_ScheduleOfExpenseRecognizedForProgramsTableTextBlock" xlink:label="cvac_ScheduleOfExpenseRecognizedForProgramsTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_ScheduleOfExpenseRecognizedForProgramsTableTextBlock" xlink:to="cvac_ScheduleOfExpenseRecognizedForProgramsTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_ScheduleOfExpenseRecognizedForProgramsTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The tabular disclosure of expense recognized for the programs.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_ScheduleOfExpenseRecognizedForProgramsTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Expense Recognized for the Programs [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_ScheduleOfExpenseRecognizedForProgramsTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule for expense recognized for the programs</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBusinessCombinationsExplanatory" xlink:label="ifrs-full_DisclosureOfDetailedInformationAboutBusinessCombinationsExplanatory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBusinessCombinationsExplanatory" xlink:to="ifrs-full_DisclosureOfDetailedInformationAboutBusinessCombinationsExplanatory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfDetailedInformationAboutBusinessCombinationsExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of detailed information about business combination [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfDetailedInformationAboutBusinessCombinationsExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of purchase price allocation</label>
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_DisclosureOfGoodwillRecognizedAsResultOfAcquisitionExplanatoryTableTextBlock" xlink:label="cvac_DisclosureOfGoodwillRecognizedAsResultOfAcquisitionExplanatoryTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_DisclosureOfGoodwillRecognizedAsResultOfAcquisitionExplanatoryTableTextBlock" xlink:to="cvac_DisclosureOfGoodwillRecognizedAsResultOfAcquisitionExplanatoryTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_DisclosureOfGoodwillRecognizedAsResultOfAcquisitionExplanatoryTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The disclosure of detailed information pertaining to goodwill recognized as a result of the acquisition.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_DisclosureOfGoodwillRecognizedAsResultOfAcquisitionExplanatoryTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure Of Goodwill Recognized As A Result Of Acquisition, Explanatory [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_DisclosureOfGoodwillRecognizedAsResultOfAcquisitionExplanatoryTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of goodwill recognized as a result of the acquisition</label>
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_DisclosureOfAnalysisOfCashFlowsOnAcquisitionExplanatoryTableTextBlock" xlink:label="cvac_DisclosureOfAnalysisOfCashFlowsOnAcquisitionExplanatoryTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_DisclosureOfAnalysisOfCashFlowsOnAcquisitionExplanatoryTableTextBlock" xlink:to="cvac_DisclosureOfAnalysisOfCashFlowsOnAcquisitionExplanatoryTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_DisclosureOfAnalysisOfCashFlowsOnAcquisitionExplanatoryTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The disclosure of detailed information pertaining to analysis of cash flows on acquisition.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_DisclosureOfAnalysisOfCashFlowsOnAcquisitionExplanatoryTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure Of Analysis Of Cash Flows On Acquisition, Explanatory [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_DisclosureOfAnalysisOfCashFlowsOnAcquisitionExplanatoryTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of analyses of cash flows on acquisition</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfBusinessCombinationsTable" xlink:label="ifrs-full_DisclosureOfBusinessCombinationsTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsTable" xlink:to="ifrs-full_DisclosureOfBusinessCombinationsTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfBusinessCombinationsTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of detailed information about business combination [table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_BusinessCombinationsAxis" xlink:label="ifrs-full_BusinessCombinationsAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_BusinessCombinationsAxis" xlink:to="ifrs-full_BusinessCombinationsAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_BusinessCombinationsAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Business combinations [axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_EntitysTotalForBusinessCombinationsMember" xlink:label="ifrs-full_EntitysTotalForBusinessCombinationsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EntitysTotalForBusinessCombinationsMember" xlink:to="ifrs-full_EntitysTotalForBusinessCombinationsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_EntitysTotalForBusinessCombinationsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity's total for business combinations [member]</label>
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_CurevacN.v.Member" xlink:label="cvac_CurevacN.v.Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_CurevacN.v.Member" xlink:to="cvac_CurevacN.v.Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_CurevacN.v.Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Member stands for CureVac N.V. , a former holding company to the entity.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_CurevacN.v.Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">CureVac N.V.</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="srt_ConsolidatedEntitiesAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ConsolidatedEntitiesAxis" xlink:to="srt_ConsolidatedEntitiesAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ConsolidatedEntitiesAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Consolidated Entities [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="srt_ConsolidatedEntitiesDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ConsolidatedEntitiesDomain" xlink:to="srt_ConsolidatedEntitiesDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ConsolidatedEntitiesDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Consolidated Entities [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ParentCompanyMember" xlink:label="srt_ParentCompanyMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ParentCompanyMember" xlink:to="srt_ParentCompanyMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ParentCompanyMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cure Vac B.V.</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:label="ifrs-full_DisclosureOfBusinessCombinationsLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:to="ifrs-full_DisclosureOfBusinessCombinationsLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfBusinessCombinationsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of detailed information about business combination</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfBusinessCombinationsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Significant transactions and events</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_DisclosureOfBusinessCombinationsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Significant transactions and events</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_PercentageOfVotingEquityInterestsAcquired" xlink:label="ifrs-full_PercentageOfVotingEquityInterestsAcquired" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PercentageOfVotingEquityInterestsAcquired" xlink:to="ifrs-full_PercentageOfVotingEquityInterestsAcquired_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_PercentageOfVotingEquityInterestsAcquired_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of voting equity interests acquired</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_PercentageOfVotingEquityInterestsAcquired_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Voting interests held</label>
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_CorporateReorganizationStockSplitRatio" xlink:label="cvac_CorporateReorganizationStockSplitRatio" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_CorporateReorganizationStockSplitRatio" xlink:to="cvac_CorporateReorganizationStockSplitRatio_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_CorporateReorganizationStockSplitRatio_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock split ratio upon corporate reorganization for determining the basis for issuance of shares to the holders of the entity.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_CorporateReorganizationStockSplitRatio_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Corporate Reorganization, Stock Split Ratio</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_CorporateReorganizationStockSplitRatio_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share split ratio</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProportionOfOwnershipInterestInSubsidiary" xlink:label="ifrs-full_ProportionOfOwnershipInterestInSubsidiary" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProportionOfOwnershipInterestInSubsidiary" xlink:to="ifrs-full_ProportionOfOwnershipInterestInSubsidiary_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ProportionOfOwnershipInterestInSubsidiary_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proportion of ownership interest in subsidiary</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ProportionOfOwnershipInterestInSubsidiary_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ownership percentage</label>
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_DisclosureOfNotesToConsolidatedFinancialStatementsTable" xlink:label="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsTable" xlink:to="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of information pertaining to disclosure of notes to the consolidated financial statements.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure Of Notes To The Consolidated Financial Statements [Table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_GeographicalAreasAxis" xlink:label="ifrs-full_GeographicalAreasAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_GeographicalAreasAxis" xlink:to="ifrs-full_GeographicalAreasAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_GeographicalAreasAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Geographical areas [axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_GeographicalAreasMember" xlink:label="ifrs-full_GeographicalAreasMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_GeographicalAreasMember" xlink:to="ifrs-full_GeographicalAreasMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_GeographicalAreasMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Geographical areas [member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_BE" xlink:label="country_BE" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_BE" xlink:to="country_BE_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="country_BE_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Belgium</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_DE" xlink:label="country_DE" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_DE" xlink:to="country_DE_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="country_DE_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Germany</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_NL" xlink:label="country_NL" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_NL" xlink:to="country_NL_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="country_NL_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Netherlands</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_CH" xlink:label="country_CH" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_CH" xlink:to="country_CH_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="country_CH_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Switzerland</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US" xlink:label="country_US" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_US" xlink:to="country_US_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="country_US_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">United States</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_MajorCustomersAxis" xlink:label="ifrs-full_MajorCustomersAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_MajorCustomersAxis" xlink:to="ifrs-full_MajorCustomersAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_MajorCustomersAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Major customers [axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_MajorCustomersMember" xlink:label="ifrs-full_MajorCustomersMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_MajorCustomersMember" xlink:to="ifrs-full_MajorCustomersMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_MajorCustomersMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Customers [member]</label>
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_GlaxosmithklineMember" xlink:label="cvac_GlaxosmithklineMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_GlaxosmithklineMember" xlink:to="cvac_GlaxosmithklineMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_GlaxosmithklineMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for GlaxoSmithKline.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_GlaxosmithklineMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">GSK</label>
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_BoehringerIngelheimMember" xlink:label="cvac_BoehringerIngelheimMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_BoehringerIngelheimMember" xlink:to="cvac_BoehringerIngelheimMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_BoehringerIngelheimMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for Boehringer Ingelheim.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_BoehringerIngelheimMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Boehringer Ingelheim</label>
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_OtherCustomersMember" xlink:label="cvac_OtherCustomersMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_OtherCustomersMember" xlink:to="cvac_OtherCustomersMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_OtherCustomersMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for Other customers.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_OtherCustomersMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Others</label>
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_GenmabMember" xlink:label="cvac_GenmabMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_GenmabMember" xlink:to="cvac_GenmabMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_GenmabMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for Genmab.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_GenmabMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Genmab</label>
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_CrisprMember" xlink:label="cvac_CrisprMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_CrisprMember" xlink:to="cvac_CrisprMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_CrisprMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for CRISPR.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_CrisprMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">CRISPR</label>
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_EliLillyAndCompanyMember" xlink:label="cvac_EliLillyAndCompanyMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_EliLillyAndCompanyMember" xlink:to="cvac_EliLillyAndCompanyMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_EliLillyAndCompanyMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for Eli Lilly and Company.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_EliLillyAndCompanyMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Eli Lilly.</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProductsAndServicesAxis" xlink:label="ifrs-full_ProductsAndServicesAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProductsAndServicesAxis" xlink:to="ifrs-full_ProductsAndServicesAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ProductsAndServicesAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Products and services [axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProductsAndServicesMember" xlink:label="ifrs-full_ProductsAndServicesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProductsAndServicesMember" xlink:to="ifrs-full_ProductsAndServicesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ProductsAndServicesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Products and services [member]</label>
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_ResearchServicesCombinedWithIpLicenseMember" xlink:label="cvac_ResearchServicesCombinedWithIpLicenseMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_ResearchServicesCombinedWithIpLicenseMember" xlink:to="cvac_ResearchServicesCombinedWithIpLicenseMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_ResearchServicesCombinedWithIpLicenseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for research services combined with an IP license.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_ResearchServicesCombinedWithIpLicenseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research services combined with an IP license</label>
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_IfrsProductMember" xlink:label="cvac_IfrsProductMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_IfrsProductMember" xlink:to="cvac_IfrsProductMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_IfrsProductMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Article or substance produced by nature, labor or machinery.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_IfrsProductMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Product</label>
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_MilestoneRevenuesMember" xlink:label="cvac_MilestoneRevenuesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_MilestoneRevenuesMember" xlink:to="cvac_MilestoneRevenuesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_MilestoneRevenuesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for milestone revenues.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_MilestoneRevenuesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Milestone revenues</label>
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_ResearchAndDevelopmentServicesMember" xlink:label="cvac_ResearchAndDevelopmentServicesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_ResearchAndDevelopmentServicesMember" xlink:to="cvac_ResearchAndDevelopmentServicesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_ResearchAndDevelopmentServicesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for research and development services.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_ResearchAndDevelopmentServicesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and development services</label>
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems" xlink:label="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems" xlink:to="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents of disclosure of notes to the consolidated financial statements.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure Of Notes To The Consolidated Financial Statements [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Notes to the consolidated financial statements</label>
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_AdditionalDevelopmentMilestonePaymentsReceived" xlink:label="cvac_AdditionalDevelopmentMilestonePaymentsReceived" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_AdditionalDevelopmentMilestonePaymentsReceived" xlink:to="cvac_AdditionalDevelopmentMilestonePaymentsReceived_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_AdditionalDevelopmentMilestonePaymentsReceived_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of additional development milestone payment received.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_AdditionalDevelopmentMilestonePaymentsReceived_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional Development Milestone Payments Received</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_AdditionalDevelopmentMilestonePaymentsReceived_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional development milestone payments</label>
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_IfrsDevelopmentMilestonePaymentIncludedInContractLiabilities" xlink:label="cvac_IfrsDevelopmentMilestonePaymentIncludedInContractLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_IfrsDevelopmentMilestonePaymentIncludedInContractLiabilities" xlink:to="cvac_IfrsDevelopmentMilestonePaymentIncludedInContractLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_IfrsDevelopmentMilestonePaymentIncludedInContractLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of development milestone payment included in contract liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_IfrsDevelopmentMilestonePaymentIncludedInContractLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">IFRS Development Milestone Payment Included In Contract Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_IfrsDevelopmentMilestonePaymentIncludedInContractLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Development milestone payment included in contract liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RangeAxis" xlink:label="ifrs-full_RangeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_RangeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_RangeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Range [axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RangesMember" xlink:label="ifrs-full_RangesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RangesMember" xlink:to="ifrs-full_RangesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_RangesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ranges [member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_BottomOfRangeMember" xlink:label="ifrs-full_BottomOfRangeMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_BottomOfRangeMember" xlink:to="ifrs-full_BottomOfRangeMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_BottomOfRangeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Minimum</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_BottomOfRangeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Minimum</label>
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_Gsk2ndGenMember" xlink:label="cvac_Gsk2ndGenMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_Gsk2ndGenMember" xlink:to="cvac_Gsk2ndGenMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_Gsk2ndGenMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for GSK 2nd Gen.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_Gsk2ndGenMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">GSK 2nd Gen</label>
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_BmbfMember" xlink:label="cvac_BmbfMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_BmbfMember" xlink:to="cvac_BmbfMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_BmbfMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for BMBF</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_BmbfMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">BMBF</label>
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_GermanFederalMinistryOfEducationAndResearchMember" xlink:label="cvac_GermanFederalMinistryOfEducationAndResearchMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_GermanFederalMinistryOfEducationAndResearchMember" xlink:to="cvac_GermanFederalMinistryOfEducationAndResearchMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_GermanFederalMinistryOfEducationAndResearchMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for German Federal Ministry of Education and Research.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_GermanFederalMinistryOfEducationAndResearchMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">German Federal Ministry of Education and Research</label>
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_EuropeanUnionAdvancePurchaseAgreementMember" xlink:label="cvac_EuropeanUnionAdvancePurchaseAgreementMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_EuropeanUnionAdvancePurchaseAgreementMember" xlink:to="cvac_EuropeanUnionAdvancePurchaseAgreementMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_EuropeanUnionAdvancePurchaseAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to EU APA.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_EuropeanUnionAdvancePurchaseAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">EU APA</label>
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_EuropeanCommissionMember" xlink:label="cvac_EuropeanCommissionMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_EuropeanCommissionMember" xlink:to="cvac_EuropeanCommissionMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_EuropeanCommissionMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for European Commission.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_EuropeanCommissionMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">European Commission</label>
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_UpfrontPaymentsReceivedOrReceivable" xlink:label="cvac_UpfrontPaymentsReceivedOrReceivable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_UpfrontPaymentsReceivedOrReceivable" xlink:to="cvac_UpfrontPaymentsReceivedOrReceivable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_UpfrontPaymentsReceivedOrReceivable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of upfront payments received or receivable by the company.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_UpfrontPaymentsReceivedOrReceivable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Upfront Payments Received Or Receivable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_UpfrontPaymentsReceivedOrReceivable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Upfront and milestone payments received or receivable</label>
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_UpfrontPaymentsIncludedInContractLiabilities" xlink:label="cvac_UpfrontPaymentsIncludedInContractLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_UpfrontPaymentsIncludedInContractLiabilities" xlink:to="cvac_UpfrontPaymentsIncludedInContractLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_UpfrontPaymentsIncludedInContractLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of upfront payments of the company included in contract liabilities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_UpfrontPaymentsIncludedInContractLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Upfront Payments Included In Contract Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_UpfrontPaymentsIncludedInContractLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Upfront and milestones payments included in contract liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod" xlink:label="ifrs-full_RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod" xlink:to="ifrs-full_RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue that was included in contract liability balance at beginning of period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue recognized from upfront and milestones payments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_StatementScenarioAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_StatementScenarioAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Scenario [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioUnspecifiedDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ScenarioUnspecifiedDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Scenario [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ContractLiabilities" xlink:label="ifrs-full_ContractLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ContractLiabilities" xlink:to="ifrs-full_ContractLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ContractLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contract liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_ContractLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contract liabilities</label>
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_IfrsIncomeStatementLocationAxis" xlink:label="cvac_IfrsIncomeStatementLocationAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_IfrsIncomeStatementLocationAxis" xlink:to="cvac_IfrsIncomeStatementLocationAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_IfrsIncomeStatementLocationAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Information by location in the income statement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_IfrsIncomeStatementLocationAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ifrs Income Statement Location [Axis]</label>
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_IfrsIncomeStatementLocationDomain" xlink:label="cvac_IfrsIncomeStatementLocationDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_IfrsIncomeStatementLocationDomain" xlink:to="cvac_IfrsIncomeStatementLocationDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_IfrsIncomeStatementLocationDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Location in the income statement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_IfrsIncomeStatementLocationDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ifrs Income Statement Location [Domain]</label>
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_IfrsCostOfSalesMember" xlink:label="cvac_IfrsCostOfSalesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_IfrsCostOfSalesMember" xlink:to="cvac_IfrsCostOfSalesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_IfrsCostOfSalesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Primary financial statement caption encompassing cost of sales.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_IfrsCostOfSalesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cost of sales</label>
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_PersonnelExpenses" xlink:label="cvac_PersonnelExpenses" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_PersonnelExpenses" xlink:to="cvac_PersonnelExpenses_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_PersonnelExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of personnel expenses incurred by the company during the period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_PersonnelExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Personnel Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="cvac_PersonnelExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Personnel</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RawMaterialsAndConsumablesUsed" xlink:label="ifrs-full_RawMaterialsAndConsumablesUsed" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RawMaterialsAndConsumablesUsed" xlink:to="ifrs-full_RawMaterialsAndConsumablesUsed_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_RawMaterialsAndConsumablesUsed_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Raw materials and consumables used</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="ifrs-full_RawMaterialsAndConsumablesUsed_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Materials</label>
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_ThirdPartyServiceExpenses" xlink:label="cvac_ThirdPartyServiceExpenses" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_ThirdPartyServiceExpenses" xlink:to="cvac_ThirdPartyServiceExpenses_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_ThirdPartyServiceExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of expenses incurred by the company for third party services during the period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_ThirdPartyServiceExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Third Party Service Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="cvac_ThirdPartyServiceExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Third-party services</label>
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_MaintenanceAndLeaseExpenses" xlink:label="cvac_MaintenanceAndLeaseExpenses" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_MaintenanceAndLeaseExpenses" xlink:to="cvac_MaintenanceAndLeaseExpenses_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_MaintenanceAndLeaseExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of maintenance and lease expenses incurred by the company during the period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_MaintenanceAndLeaseExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maintenance And Lease Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="cvac_MaintenanceAndLeaseExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maintenance and lease</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DepreciationAndAmortisationExpense" xlink:label="ifrs-full_DepreciationAndAmortisationExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DepreciationAndAmortisationExpense" xlink:to="ifrs-full_DepreciationAndAmortisationExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DepreciationAndAmortisationExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Depreciation and amortisation expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_DepreciationAndAmortisationExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amortization and depreciation</label>
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_OtherExpense" xlink:label="cvac_OtherExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_OtherExpense" xlink:to="cvac_OtherExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_OtherExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of other expense.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_OtherExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="cvac_OtherExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ExpenseByNature" xlink:label="ifrs-full_ExpenseByNature" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ExpenseByNature" xlink:to="ifrs-full_ExpenseByNature_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ExpenseByNature_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expenses, by nature</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="ifrs-full_ExpenseByNature_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DecreaseThroughDerecognitionFinancialAssets" xlink:label="ifrs-full_DecreaseThroughDerecognitionFinancialAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DecreaseThroughDerecognitionFinancialAssets" xlink:to="ifrs-full_DecreaseThroughDerecognitionFinancialAssets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DecreaseThroughDerecognitionFinancialAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Decrease through derecognition, financial assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DecreaseThroughDerecognitionFinancialAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loss on derecognition of fixed assets</label>
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_ChangeInExpenseByNature" xlink:label="cvac_ChangeInExpenseByNature" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_ChangeInExpenseByNature" xlink:to="cvac_ChangeInExpenseByNature_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_ChangeInExpenseByNature_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The increase (decrease) in expense by nature.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_ChangeInExpenseByNature_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Change in Expense By Nature</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_ChangeInExpenseByNature_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase in cost of sales</label>
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_WriteOffOfRawMaterials" xlink:label="cvac_WriteOffOfRawMaterials" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_WriteOffOfRawMaterials" xlink:to="cvac_WriteOffOfRawMaterials_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_WriteOffOfRawMaterials_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of raw materials written off during the period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_WriteOffOfRawMaterials_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Write Off Of Raw Materials</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_WriteOffOfRawMaterials_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Write off of raw materials</label>
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_SellingAndDistributionExpensesMember" xlink:label="cvac_SellingAndDistributionExpensesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_SellingAndDistributionExpensesMember" xlink:to="cvac_SellingAndDistributionExpensesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_SellingAndDistributionExpensesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for selling and distribution expenses.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_SellingAndDistributionExpensesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Selling and distribution expenses</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ShorttermEmployeeBenefitsExpense" xlink:label="ifrs-full_ShorttermEmployeeBenefitsExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ShorttermEmployeeBenefitsExpense" xlink:to="ifrs-full_ShorttermEmployeeBenefitsExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ShorttermEmployeeBenefitsExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Short-term employee benefits expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ShorttermEmployeeBenefitsExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Salary and salary-related expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_ShorttermEmployeeBenefitsExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Salary and salary-related expenses</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" xlink:label="ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" xlink:to="ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expense from share-based payment transactions in which goods or services received did not qualify for recognition as assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expenses from share-based payments</label>
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_IfrsResearchAndDevelopmentExpenseMember" xlink:label="cvac_IfrsResearchAndDevelopmentExpenseMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_IfrsResearchAndDevelopmentExpenseMember" xlink:to="cvac_IfrsResearchAndDevelopmentExpenseMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_IfrsResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Primary financial statement caption in which the reported facts about research and development expense have been included.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_IfrsResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and development expenses</label>
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_PatentsAndFeesToRegisterLegalRight" xlink:label="cvac_PatentsAndFeesToRegisterLegalRight" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_PatentsAndFeesToRegisterLegalRight" xlink:to="cvac_PatentsAndFeesToRegisterLegalRight_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_PatentsAndFeesToRegisterLegalRight_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of expenses incurred by the company for registering a legal right.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_PatentsAndFeesToRegisterLegalRight_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Patents And Fees To Register Legal Right</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="cvac_PatentsAndFeesToRegisterLegalRight_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Patents and fees to register a legal right</label>
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_ReversalOfProvisionForOnerousContracts" xlink:label="cvac_ReversalOfProvisionForOnerousContracts" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_ReversalOfProvisionForOnerousContracts" xlink:to="cvac_ReversalOfProvisionForOnerousContracts_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_ReversalOfProvisionForOnerousContracts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the amount of reversal of provision for onerous contracts which will decrease in research and development expenses.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_ReversalOfProvisionForOnerousContracts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reversal of Provision for Onerous Contracts</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_ReversalOfProvisionForOnerousContracts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reversal of provision of onerous contracts</label>
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_IfrsIncreaseInExpenseRelatedToIneffectiveSetUpActivitiesAndSettlementCosts" xlink:label="cvac_IfrsIncreaseInExpenseRelatedToIneffectiveSetUpActivitiesAndSettlementCosts" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_IfrsIncreaseInExpenseRelatedToIneffectiveSetUpActivitiesAndSettlementCosts" xlink:to="cvac_IfrsIncreaseInExpenseRelatedToIneffectiveSetUpActivitiesAndSettlementCosts_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_IfrsIncreaseInExpenseRelatedToIneffectiveSetUpActivitiesAndSettlementCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The increase in expense related to in-effective set-up activities and settlement costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_IfrsIncreaseInExpenseRelatedToIneffectiveSetUpActivitiesAndSettlementCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">IFRS Increase In Expense Related To Ineffective Set-up activities And Settlement Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_IfrsIncreaseInExpenseRelatedToIneffectiveSetUpActivitiesAndSettlementCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Recognition of expenses related to ineffective set-up activities and settlement costs</label>
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_IfrsGeneralAndAdministrativeExpenseMember" xlink:label="cvac_IfrsGeneralAndAdministrativeExpenseMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_IfrsGeneralAndAdministrativeExpenseMember" xlink:to="cvac_IfrsGeneralAndAdministrativeExpenseMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_IfrsGeneralAndAdministrativeExpenseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Primary financial statement caption encompassing general and administrative expense.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_IfrsGeneralAndAdministrativeExpenseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">General and administrative expenses</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProfessionalFeesExpense" xlink:label="ifrs-full_ProfessionalFeesExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProfessionalFeesExpense" xlink:to="ifrs-full_ProfessionalFeesExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ProfessionalFeesExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Professional fees expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_ProfessionalFeesExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Legal and other professional services</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TravelExpense" xlink:label="ifrs-full_TravelExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TravelExpense" xlink:to="ifrs-full_TravelExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TravelExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Travel expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_TravelExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Travel expenses</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_InsuranceExpense" xlink:label="ifrs-full_InsuranceExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_InsuranceExpense" xlink:to="ifrs-full_InsuranceExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_InsuranceExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Insurance expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_InsuranceExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Insurance expense</label>
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_RealEstateTransferTaxes" xlink:label="cvac_RealEstateTransferTaxes" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_RealEstateTransferTaxes" xlink:to="cvac_RealEstateTransferTaxes_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_RealEstateTransferTaxes_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of real estate transfer taxes.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_RealEstateTransferTaxes_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Real Estate Transfer Taxes</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_RealEstateTransferTaxes_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Real estate transfer taxes</label>
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_CompensationForContractManufacturingOrganizationsTransfer" xlink:label="cvac_CompensationForContractManufacturingOrganizationsTransfer" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_CompensationForContractManufacturingOrganizationsTransfer" xlink:to="cvac_CompensationForContractManufacturingOrganizationsTransfer_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_CompensationForContractManufacturingOrganizationsTransfer_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the amount of income recognised on compensation for contract manufacturing organizations transfer.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_CompensationForContractManufacturingOrganizationsTransfer_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Compensation for Contract Manufacturing organizations Transfer</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_CompensationForContractManufacturingOrganizationsTransfer_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Compensation for CMO/Material transfer</label>
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_CostOfReimbursementClaim" xlink:label="cvac_CostOfReimbursementClaim" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_CostOfReimbursementClaim" xlink:to="cvac_CostOfReimbursementClaim_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_CostOfReimbursementClaim_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of cost of reimbursement claim.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_CostOfReimbursementClaim_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cost of reimbursement claim</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_CostOfReimbursementClaim_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reimbursement claim</label>
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_SaleOfEquipment" xlink:label="cvac_SaleOfEquipment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_SaleOfEquipment" xlink:to="cvac_SaleOfEquipment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_SaleOfEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of sale of equipment in operating income.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_SaleOfEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sale of equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_SaleOfEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sale of equipment</label>
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_OtherOperatingIncomeGovernmentGrants" xlink:label="cvac_OtherOperatingIncomeGovernmentGrants" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_OtherOperatingIncomeGovernmentGrants" xlink:to="cvac_OtherOperatingIncomeGovernmentGrants_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_OtherOperatingIncomeGovernmentGrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of other operating income recognized in relation to government agencies and similar bodies.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_OtherOperatingIncomeGovernmentGrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Operating Income, Government Grants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="cvac_OtherOperatingIncomeGovernmentGrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Grants and other cost reimbursements from government agencies and similar bodies</label>
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_ReversalOfProvisionsForPersonnelExpenses" xlink:label="cvac_ReversalOfProvisionsForPersonnelExpenses" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_ReversalOfProvisionsForPersonnelExpenses" xlink:to="cvac_ReversalOfProvisionsForPersonnelExpenses_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_ReversalOfProvisionsForPersonnelExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of personnel expenses reversed during the period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_ReversalOfProvisionsForPersonnelExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reversal Of Provisions For Personnel Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="cvac_ReversalOfProvisionsForPersonnelExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income from reversal of provisions</label>
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_MiscellaneousOtherOperatingIncomeOther" xlink:label="cvac_MiscellaneousOtherOperatingIncomeOther" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_MiscellaneousOtherOperatingIncomeOther" xlink:to="cvac_MiscellaneousOtherOperatingIncomeOther_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_MiscellaneousOtherOperatingIncomeOther_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of miscellaneous other operating income, classified as other.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_MiscellaneousOtherOperatingIncomeOther_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Miscellaneous Other Operating Income, Other</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_MiscellaneousOtherOperatingIncomeOther_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other</label>
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_DisclosureOfGovernmentGrantsTable" xlink:label="cvac_DisclosureOfGovernmentGrantsTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_DisclosureOfGovernmentGrantsTable" xlink:to="cvac_DisclosureOfGovernmentGrantsTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_DisclosureOfGovernmentGrantsTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of information pertaining to disclosure of government grants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_DisclosureOfGovernmentGrantsTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure Of Government Grants [Table]</label>
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_GovernmentGrantsAxis" xlink:label="cvac_GovernmentGrantsAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_GovernmentGrantsAxis" xlink:to="cvac_GovernmentGrantsAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_GovernmentGrantsAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of information pertaining to government grants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_GovernmentGrantsAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Government Grants [Axis]</label>
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_GovernmentGrantsDomain" xlink:label="cvac_GovernmentGrantsDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_GovernmentGrantsDomain" xlink:to="cvac_GovernmentGrantsDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_GovernmentGrantsDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Information pertaining to government grants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_GovernmentGrantsDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Government Grants [Domain]</label>
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_CoalitionForEpidemicPreparednessInnovationsMember" xlink:label="cvac_CoalitionForEpidemicPreparednessInnovationsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_CoalitionForEpidemicPreparednessInnovationsMember" xlink:to="cvac_CoalitionForEpidemicPreparednessInnovationsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_CoalitionForEpidemicPreparednessInnovationsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for grants related to Coalition for Epidemic Preparedness Innovations.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_CoalitionForEpidemicPreparednessInnovationsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Coalition for Epidemic Preparedness Innovations</label>
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_BillAndMelindaGatesFoundationBmgfMember" xlink:label="cvac_BillAndMelindaGatesFoundationBmgfMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_BillAndMelindaGatesFoundationBmgfMember" xlink:to="cvac_BillAndMelindaGatesFoundationBmgfMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_BillAndMelindaGatesFoundationBmgfMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for grants from Bill &amp; Melinda Gates Foundation (BMGF).</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_BillAndMelindaGatesFoundationBmgfMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Bill &amp; Melinda Gates Foundation (BMGF)</label>
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_BillMelindaGatesFoundationBmgfGrantForDevelopmentOfUniversalInfluenzaVaccineMember" xlink:label="cvac_BillMelindaGatesFoundationBmgfGrantForDevelopmentOfUniversalInfluenzaVaccineMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_BillMelindaGatesFoundationBmgfGrantForDevelopmentOfUniversalInfluenzaVaccineMember" xlink:to="cvac_BillMelindaGatesFoundationBmgfGrantForDevelopmentOfUniversalInfluenzaVaccineMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_BillMelindaGatesFoundationBmgfGrantForDevelopmentOfUniversalInfluenzaVaccineMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for grants from Bill &amp; Melinda Gates Foundation (BMGF) for development of a universal influenza vaccine.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_BillMelindaGatesFoundationBmgfGrantForDevelopmentOfUniversalInfluenzaVaccineMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Bill &amp; Melinda Gates Foundation (BMGF), Grant for development of a universal influenza vaccine</label>
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_BillMelindaGatesFoundationBmgfGrantForMalariaVaccineMember" xlink:label="cvac_BillMelindaGatesFoundationBmgfGrantForMalariaVaccineMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_BillMelindaGatesFoundationBmgfGrantForMalariaVaccineMember" xlink:to="cvac_BillMelindaGatesFoundationBmgfGrantForMalariaVaccineMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_BillMelindaGatesFoundationBmgfGrantForMalariaVaccineMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for grants from Bill &amp; Melinda Gates Foundation (BMGF) for malaria vaccine.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_BillMelindaGatesFoundationBmgfGrantForMalariaVaccineMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Bill &amp; Melinda Gates Foundation (BMGF), Grant for malaria vaccine</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_CounterpartyNameAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_CounterpartyNameAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Counterparty Name [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Counterparty Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_GskAgreement2020Member" xlink:label="cvac_GskAgreement2020Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_GskAgreement2020Member" xlink:to="cvac_GskAgreement2020Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_GskAgreement2020Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for GSK Agreement 2020.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_GskAgreement2020Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2020 GSK AGREEMENT</label>
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_CrisprTherapeuticsMember" xlink:label="cvac_CrisprTherapeuticsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_CrisprTherapeuticsMember" xlink:to="cvac_CrisprTherapeuticsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_CrisprTherapeuticsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for CRISPR Therapeutics</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_CrisprTherapeuticsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">CRISPR Therapeutics</label>
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_EliLillyMember" xlink:label="cvac_EliLillyMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_EliLillyMember" xlink:to="cvac_EliLillyMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_EliLillyMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for Eli Lilly</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_EliLillyMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Eli Lilly</label>
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_TypeOfArrangementAxis" xlink:label="cvac_TypeOfArrangementAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_TypeOfArrangementAxis" xlink:to="cvac_TypeOfArrangementAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_TypeOfArrangementAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_TypeOfArrangementAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Type Of Arrangement [Axis]</label>
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_ArrangementsAndNonArrangementTransactionsMember" xlink:label="cvac_ArrangementsAndNonArrangementTransactionsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_ArrangementsAndNonArrangementTransactionsMember" xlink:to="cvac_ArrangementsAndNonArrangementTransactionsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_ArrangementsAndNonArrangementTransactionsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_ArrangementsAndNonArrangementTransactionsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Arrangements And Non-arrangement Transactions [Member]</label>
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_AdvancedPurchaseAgreementWithEuropeanCommissionMember" xlink:label="cvac_AdvancedPurchaseAgreementWithEuropeanCommissionMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_AdvancedPurchaseAgreementWithEuropeanCommissionMember" xlink:to="cvac_AdvancedPurchaseAgreementWithEuropeanCommissionMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_AdvancedPurchaseAgreementWithEuropeanCommissionMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for Advance Purchase Agreement with European Commission</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_AdvancedPurchaseAgreementWithEuropeanCommissionMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Advance Purchase Agreement with European Commission</label>
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_DisclosureOfGovernmentGrantsLineItems" xlink:label="cvac_DisclosureOfGovernmentGrantsLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_DisclosureOfGovernmentGrantsLineItems" xlink:to="cvac_DisclosureOfGovernmentGrantsLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_DisclosureOfGovernmentGrantsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_DisclosureOfGovernmentGrantsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure Of Government Grants [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="cvac_DisclosureOfGovernmentGrantsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure Of Government Grants</label>
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_NumberOfDosesOfSarsCov2CanBePurchasedByMemberStatesUnderAdvancePurchaseAgreement" xlink:label="cvac_NumberOfDosesOfSarsCov2CanBePurchasedByMemberStatesUnderAdvancePurchaseAgreement" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_NumberOfDosesOfSarsCov2CanBePurchasedByMemberStatesUnderAdvancePurchaseAgreement" xlink:to="cvac_NumberOfDosesOfSarsCov2CanBePurchasedByMemberStatesUnderAdvancePurchaseAgreement_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_NumberOfDosesOfSarsCov2CanBePurchasedByMemberStatesUnderAdvancePurchaseAgreement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of doses of SARS-CoV-2 advance purchase by the Member States under agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_NumberOfDosesOfSarsCov2CanBePurchasedByMemberStatesUnderAdvancePurchaseAgreement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of Doses of SARS-CoV-2 Can be Purchased By Member States under Advance purchase Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_NumberOfDosesOfSarsCov2CanBePurchasedByMemberStatesUnderAdvancePurchaseAgreement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of doses of SARS-CoV-2 advance purchase by the Member States under agreement</label>
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_MaximumGrantToBeReceived" xlink:label="cvac_MaximumGrantToBeReceived" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_MaximumGrantToBeReceived" xlink:to="cvac_MaximumGrantToBeReceived_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_MaximumGrantToBeReceived_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of maximum grant receivable.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_MaximumGrantToBeReceived_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum Grant To Be Received</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_MaximumGrantToBeReceived_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum grant</label>
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_UpfrontPaymentReceived" xlink:label="cvac_UpfrontPaymentReceived" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_UpfrontPaymentReceived" xlink:to="cvac_UpfrontPaymentReceived_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_UpfrontPaymentReceived_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of upfront payment received.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_UpfrontPaymentReceived_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Upfront Payment Received</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RevenueFromGovernmentGrants" xlink:label="ifrs-full_RevenueFromGovernmentGrants" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RevenueFromGovernmentGrants" xlink:to="ifrs-full_RevenueFromGovernmentGrants_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_RevenueFromGovernmentGrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income from government grants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_RevenueFromGovernmentGrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income from release of governmental contract liabilities</label>
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_IfrsMilestonePaymentReceived" xlink:label="cvac_IfrsMilestonePaymentReceived" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_IfrsMilestonePaymentReceived" xlink:to="cvac_IfrsMilestonePaymentReceived_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_IfrsMilestonePaymentReceived_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of milestone payment received.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_IfrsMilestonePaymentReceived_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">IFRS Milestone Payment Received</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_IfrsMilestonePaymentReceived_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Milestone payment received</label>
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_IfrsRemainingGrantIncome" xlink:label="cvac_IfrsRemainingGrantIncome" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_IfrsRemainingGrantIncome" xlink:to="cvac_IfrsRemainingGrantIncome_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_IfrsRemainingGrantIncome_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of remaining grant income classified as other operating income.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_IfrsRemainingGrantIncome_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">IFRS Remaining Grant Income</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_IfrsRemainingGrantIncome_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Remaining grant income</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_GovernmentGrants" xlink:label="ifrs-full_GovernmentGrants" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_GovernmentGrants" xlink:to="ifrs-full_GovernmentGrants_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_GovernmentGrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Government grants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_GovernmentGrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Grants received and deferred</label>
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_PartnershipAgreementMaximumAmount" xlink:label="cvac_PartnershipAgreementMaximumAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_PartnershipAgreementMaximumAmount" xlink:to="cvac_PartnershipAgreementMaximumAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_PartnershipAgreementMaximumAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum amount agreed under the partnership agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_PartnershipAgreementMaximumAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Partnership Agreement, Maximum Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_PartnershipAgreementMaximumAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum amount under the partnership agreement</label>
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_PartnershipAgreementTerm" xlink:label="cvac_PartnershipAgreementTerm" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_PartnershipAgreementTerm" xlink:to="cvac_PartnershipAgreementTerm_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_PartnershipAgreementTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Term of the partnership agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_PartnershipAgreementTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Partnership Agreement, Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_PartnershipAgreementTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Term of the partnership agreement</label>
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_PartnershipAgreementPeriodOfCostsToBeCovered" xlink:label="cvac_PartnershipAgreementPeriodOfCostsToBeCovered" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_PartnershipAgreementPeriodOfCostsToBeCovered" xlink:to="cvac_PartnershipAgreementPeriodOfCostsToBeCovered_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_PartnershipAgreementPeriodOfCostsToBeCovered_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Period for which the costs are to be covered by the funds received under the partnership agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_PartnershipAgreementPeriodOfCostsToBeCovered_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Partnership Agreement, Period Of Costs To Be Covered</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_PartnershipAgreementPeriodOfCostsToBeCovered_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Period for which the costs are to be covered</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProceedsFromGovernmentGrantsClassifiedAsFinancingActivities" xlink:label="ifrs-full_ProceedsFromGovernmentGrantsClassifiedAsFinancingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProceedsFromGovernmentGrantsClassifiedAsFinancingActivities" xlink:to="ifrs-full_ProceedsFromGovernmentGrantsClassifiedAsFinancingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ProceedsFromGovernmentGrantsClassifiedAsFinancingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from government grants, classified as financing activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_ProceedsFromGovernmentGrantsClassifiedAsFinancingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Government grants</label>
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_AmountDeductedFromCarryingAmountOfQualifyingAssets" xlink:label="cvac_AmountDeductedFromCarryingAmountOfQualifyingAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_AmountDeductedFromCarryingAmountOfQualifyingAssets" xlink:to="cvac_AmountDeductedFromCarryingAmountOfQualifyingAssets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_AmountDeductedFromCarryingAmountOfQualifyingAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount pertaining to grants deducted from the carrying amount of qualifying assets.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_AmountDeductedFromCarryingAmountOfQualifyingAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount Deducted From Carrying Amount Of Qualifying Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_AmountDeductedFromCarryingAmountOfQualifyingAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount deducted from the carrying amount of qualifying assets</label>
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_NumberOfAdditionalGrantsReceived" xlink:label="cvac_NumberOfAdditionalGrantsReceived" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_NumberOfAdditionalGrantsReceived" xlink:to="cvac_NumberOfAdditionalGrantsReceived_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_NumberOfAdditionalGrantsReceived_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of additional grants received by the company.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_NumberOfAdditionalGrantsReceived_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number Of Additional Grants Received</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_NumberOfAdditionalGrantsReceived_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of additional grants received</label>
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_CompensationForContractManufacturingOrganizationsTransferConsiderationForSetUpActivities" xlink:label="cvac_CompensationForContractManufacturingOrganizationsTransferConsiderationForSetUpActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_CompensationForContractManufacturingOrganizationsTransferConsiderationForSetUpActivities" xlink:to="cvac_CompensationForContractManufacturingOrganizationsTransferConsiderationForSetUpActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_CompensationForContractManufacturingOrganizationsTransferConsiderationForSetUpActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the amount of income recognized on compensation for contract manufacturing organizations transfer which is mainly for consideration for set-up activities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_CompensationForContractManufacturingOrganizationsTransferConsiderationForSetUpActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Compensation for Contract Manufacturing organizations Transfer, Consideration for Set-up Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_CompensationForContractManufacturingOrganizationsTransferConsiderationForSetUpActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Compensation consist for set-up activities</label>
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_CompensationForContractManufacturingOrganizationsTransferManufacturingInterimPeriodReimbursableExpenses" xlink:label="cvac_CompensationForContractManufacturingOrganizationsTransferManufacturingInterimPeriodReimbursableExpenses" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_CompensationForContractManufacturingOrganizationsTransferManufacturingInterimPeriodReimbursableExpenses" xlink:to="cvac_CompensationForContractManufacturingOrganizationsTransferManufacturingInterimPeriodReimbursableExpenses_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_CompensationForContractManufacturingOrganizationsTransferManufacturingInterimPeriodReimbursableExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the amount of income recognized on compensation for contract manufacturing organizations transfer which is mainly for Manufacturing Interim Period Reimbursable Expenses.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_CompensationForContractManufacturingOrganizationsTransferManufacturingInterimPeriodReimbursableExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Compensation for Contract Manufacturing organizations Transfer, Manufacturing Interim Period Reimbursable Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_CompensationForContractManufacturingOrganizationsTransferManufacturingInterimPeriodReimbursableExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Compensation consist of Manufacturing Interim Period Reimbursable Expenses</label>
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_ReversalOfProvisionRecognizedDueToCertainReservedCapacityTakenOver" xlink:label="cvac_ReversalOfProvisionRecognizedDueToCertainReservedCapacityTakenOver" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_ReversalOfProvisionRecognizedDueToCertainReservedCapacityTakenOver" xlink:to="cvac_ReversalOfProvisionRecognizedDueToCertainReservedCapacityTakenOver_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_ReversalOfProvisionRecognizedDueToCertainReservedCapacityTakenOver_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the amount of provisions reversed due to certain reserved capacity taken over from the group.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_ReversalOfProvisionRecognizedDueToCertainReservedCapacityTakenOver_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reversal Of Provision Recognized Due to Certain Reserved Capacity Taken Over</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_ReversalOfProvisionRecognizedDueToCertainReservedCapacityTakenOver_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reversal of provision recognized</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalTable" xlink:label="ifrs-full_DisclosureOfClassesOfShareCapitalTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalTable" xlink:to="ifrs-full_DisclosureOfClassesOfShareCapitalTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfClassesOfShareCapitalTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of classes of share capital [table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ClassesOfShareCapitalAxis" xlink:label="ifrs-full_ClassesOfShareCapitalAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ClassesOfShareCapitalAxis" xlink:to="ifrs-full_ClassesOfShareCapitalAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ClassesOfShareCapitalAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Classes of share capital [axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ClassesOfShareCapitalMember" xlink:label="ifrs-full_ClassesOfShareCapitalMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ClassesOfShareCapitalMember" xlink:to="ifrs-full_ClassesOfShareCapitalMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ClassesOfShareCapitalMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share capital [member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OrdinarySharesMember" xlink:label="ifrs-full_OrdinarySharesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OrdinarySharesMember" xlink:to="ifrs-full_OrdinarySharesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OrdinarySharesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common shares</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_PreferenceSharesMember" xlink:label="ifrs-full_PreferenceSharesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PreferenceSharesMember" xlink:to="ifrs-full_PreferenceSharesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_PreferenceSharesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred shares</label>
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_IfrsSaleOfStockAxis" xlink:label="cvac_IfrsSaleOfStockAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_IfrsSaleOfStockAxis" xlink:to="cvac_IfrsSaleOfStockAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_IfrsSaleOfStockAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Information by type of sale of the entity's stock.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_IfrsSaleOfStockAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">IFRS Sale of Stock [Axis]</label>
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_IfrsSaleOfStockDomain" xlink:label="cvac_IfrsSaleOfStockDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_IfrsSaleOfStockDomain" xlink:to="cvac_IfrsSaleOfStockDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_IfrsSaleOfStockDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_IfrsSaleOfStockDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">IFRS Sale of Stock [Domain]</label>
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_FollowOnPublicOfferingMember" xlink:label="cvac_FollowOnPublicOfferingMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_FollowOnPublicOfferingMember" xlink:to="cvac_FollowOnPublicOfferingMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_FollowOnPublicOfferingMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to follow on public offering.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_FollowOnPublicOfferingMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Follow-on public offering, incl. Greenshoe</label>
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_IfrsOverAllotmentOptionMember" xlink:label="cvac_IfrsOverAllotmentOptionMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_IfrsOverAllotmentOptionMember" xlink:to="cvac_IfrsOverAllotmentOptionMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_IfrsOverAllotmentOptionMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Right given to the underwriter to sell additional shares over the initial allotment.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_IfrsOverAllotmentOptionMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Over-Allotment Option</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:label="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of classes of share capital [line items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issued Capital and Reserves</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NumberOfSharesAuthorised" xlink:label="ifrs-full_NumberOfSharesAuthorised" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfSharesAuthorised" xlink:to="ifrs-full_NumberOfSharesAuthorised_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NumberOfSharesAuthorised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of shares authorised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_NumberOfSharesAuthorised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of shares authorized</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ParValuePerShare" xlink:label="ifrs-full_ParValuePerShare" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ParValuePerShare" xlink:to="ifrs-full_ParValuePerShare_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ParValuePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Par value per share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_ParValuePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Notional value per share</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NumberOfSharesIssued" xlink:label="ifrs-full_NumberOfSharesIssued" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfSharesIssued" xlink:to="ifrs-full_NumberOfSharesIssued_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NumberOfSharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of shares issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_NumberOfSharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of shares issued</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ShareIssueRelatedCost" xlink:label="ifrs-full_ShareIssueRelatedCost" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ShareIssueRelatedCost" xlink:to="ifrs-full_ShareIssueRelatedCost_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ShareIssueRelatedCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share issue related cost</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ShareIssueRelatedCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Offering costs for legal, accounting, printing and registration fees</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_ShareIssueRelatedCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares issue of transaction costs</label>
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_RemainingAuthorizedForSaleValue" xlink:label="cvac_RemainingAuthorizedForSaleValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_RemainingAuthorizedForSaleValue" xlink:to="cvac_RemainingAuthorizedForSaleValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_RemainingAuthorizedForSaleValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of remaining authorized for sale value.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_RemainingAuthorizedForSaleValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Remaining Authorized For Sale Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_RemainingAuthorizedForSaleValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Remaining authorized for sale value</label>
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_IfrsStockholdersEquityNoteStockSplitConversionRatio" xlink:label="cvac_IfrsStockholdersEquityNoteStockSplitConversionRatio" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_IfrsStockholdersEquityNoteStockSplitConversionRatio" xlink:to="cvac_IfrsStockholdersEquityNoteStockSplitConversionRatio_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_IfrsStockholdersEquityNoteStockSplitConversionRatio_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_IfrsStockholdersEquityNoteStockSplitConversionRatio_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">IFRS Stockholders' Equity Note, Stock Split, Conversion Ratio</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_IfrsStockholdersEquityNoteStockSplitConversionRatio_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share split ratio</label>
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_CapitalIncreaseByGenmabMember" xlink:label="cvac_CapitalIncreaseByGenmabMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_CapitalIncreaseByGenmabMember" xlink:to="cvac_CapitalIncreaseByGenmabMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_CapitalIncreaseByGenmabMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for Genmab, capital increase.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_CapitalIncreaseByGenmabMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Genmab Investment</label>
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_PrivatePlacementIsa2020Member" xlink:label="cvac_PrivatePlacementIsa2020Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_PrivatePlacementIsa2020Member" xlink:to="cvac_PrivatePlacementIsa2020Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_PrivatePlacementIsa2020Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for private Placement "ISA 2020".</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_PrivatePlacementIsa2020Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2020 Private Investment</label>
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_InitialPublicOfferingAndPrivatePlacementMember" xlink:label="cvac_InitialPublicOfferingAndPrivatePlacementMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_InitialPublicOfferingAndPrivatePlacementMember" xlink:to="cvac_InitialPublicOfferingAndPrivatePlacementMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_InitialPublicOfferingAndPrivatePlacementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for initial public offering and private placement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_InitialPublicOfferingAndPrivatePlacementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Initial Public Offering and Private Placement</label>
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_ExerciseOfGreenshoeMember" xlink:label="cvac_ExerciseOfGreenshoeMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_ExerciseOfGreenshoeMember" xlink:to="cvac_ExerciseOfGreenshoeMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_ExerciseOfGreenshoeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for exercise of Greenshoe.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_ExerciseOfGreenshoeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise "Greenshoe"</label>
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_AtMarketOfferingProgramMember" xlink:label="cvac_AtMarketOfferingProgramMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_AtMarketOfferingProgramMember" xlink:to="cvac_AtMarketOfferingProgramMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_AtMarketOfferingProgramMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to at the market offering program.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_AtMarketOfferingProgramMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">ATM Offering Program</label>
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_SeriesSharesMember" xlink:label="cvac_SeriesSharesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_SeriesSharesMember" xlink:to="cvac_SeriesSharesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_SeriesSharesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for Series A shares.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_SeriesSharesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Series A</label>
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_SeriesCSharesMember" xlink:label="cvac_SeriesCSharesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_SeriesCSharesMember" xlink:to="cvac_SeriesCSharesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_SeriesCSharesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for Series C shares.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_SeriesCSharesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Series C</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:label="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:to="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non-adjusting events after reporting period [axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NonadjustingEventsMember" xlink:label="ifrs-full_NonadjustingEventsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NonadjustingEventsMember" xlink:to="ifrs-full_NonadjustingEventsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NonadjustingEventsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non-adjusting events after reporting period [member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_MajorOrdinaryShareTransactionsMember" xlink:label="ifrs-full_MajorOrdinaryShareTransactionsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_MajorOrdinaryShareTransactionsMember" xlink:to="ifrs-full_MajorOrdinaryShareTransactionsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_MajorOrdinaryShareTransactionsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share transaction</label>
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_CommonSharesIssuedAndOutstanding" xlink:label="cvac_CommonSharesIssuedAndOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_CommonSharesIssuedAndOutstanding" xlink:to="cvac_CommonSharesIssuedAndOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_CommonSharesIssuedAndOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The number of shares issued and outstanding for during the period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_CommonSharesIssuedAndOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Shares Issued And Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="cvac_CommonSharesIssuedAndOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common shares issued and outstanding ending</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="cvac_CommonSharesIssuedAndOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common shares issued and outstanding beginning</label>
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_IncreaseInNumberOfSharesOutstanding" xlink:label="cvac_IncreaseInNumberOfSharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_IncreaseInNumberOfSharesOutstanding" xlink:to="cvac_IncreaseInNumberOfSharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_IncreaseInNumberOfSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The increase in the number of shares outstanding.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_IncreaseInNumberOfSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase In Number Of Shares Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_IncreaseInNumberOfSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Capital Investment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="cvac_IncreaseInNumberOfSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Capital increase (in shares)</label>
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_ShareOptionExercises" xlink:label="cvac_ShareOptionExercises" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_ShareOptionExercises" xlink:to="cvac_ShareOptionExercises_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_ShareOptionExercises_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The number of share option exercises.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_ShareOptionExercises_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share Option Exercises</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_ShareOptionExercises_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share option exercises</label>
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_DecreaseInNumberOfSharesDueToTreasuryOfShares" xlink:label="cvac_DecreaseInNumberOfSharesDueToTreasuryOfShares" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_DecreaseInNumberOfSharesDueToTreasuryOfShares" xlink:to="cvac_DecreaseInNumberOfSharesDueToTreasuryOfShares_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_DecreaseInNumberOfSharesDueToTreasuryOfShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This element represents for decrease in number of shares due to treasury of shares.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_DecreaseInNumberOfSharesDueToTreasuryOfShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Decrease In Number Of Shares Due To Treasury Of Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_DecreaseInNumberOfSharesDueToTreasuryOfShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Treasury shares</label>
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_StockIssuedDuringPeriodForExercises" xlink:label="cvac_StockIssuedDuringPeriodForExercises" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_StockIssuedDuringPeriodForExercises" xlink:to="cvac_StockIssuedDuringPeriodForExercises_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_StockIssuedDuringPeriodForExercises_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of new stock issued during the period, upon exercises.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_StockIssuedDuringPeriodForExercises_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, For Exercises</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_StockIssuedDuringPeriodForExercises_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share issuances for exercises</label>
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_StockIssuanceDuringPeriodForExistingShareholders" xlink:label="cvac_StockIssuanceDuringPeriodForExistingShareholders" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_StockIssuanceDuringPeriodForExistingShareholders" xlink:to="cvac_StockIssuanceDuringPeriodForExistingShareholders_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_StockIssuanceDuringPeriodForExistingShareholders_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of new stock issued during the period for existing shareholders.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_StockIssuanceDuringPeriodForExistingShareholders_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issuance During Period For Existing Shareholders</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_StockIssuanceDuringPeriodForExistingShareholders_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share issuances to former shareholders of Frame Pharmaceuticals</label>
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_IfrsStockIssuedDuringPeriodSharesNewIssues" xlink:label="cvac_IfrsStockIssuedDuringPeriodSharesNewIssues" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_IfrsStockIssuedDuringPeriodSharesNewIssues" xlink:to="cvac_IfrsStockIssuedDuringPeriodSharesNewIssues_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_IfrsStockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of new stock issued during the period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_IfrsStockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ifrs Stock Issued During Period, Shares, New Issues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="cvac_IfrsStockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">At-the-market offering program issuances</label>
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_AggregateGrossProceedsReceivableFromIssuingShares" xlink:label="cvac_AggregateGrossProceedsReceivableFromIssuingShares" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_AggregateGrossProceedsReceivableFromIssuingShares" xlink:to="cvac_AggregateGrossProceedsReceivableFromIssuingShares_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_AggregateGrossProceedsReceivableFromIssuingShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum amount of aggregate gross proceeds receivable from issuance of shares.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_AggregateGrossProceedsReceivableFromIssuingShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Aggregate Gross Proceeds Receivable From Issuing Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_AggregateGrossProceedsReceivableFromIssuingShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Aggregate gross proceeds</label>
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInResearchAndDevelopmentExpenses" xlink:label="cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInResearchAndDevelopmentExpenses" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInResearchAndDevelopmentExpenses" xlink:to="cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInResearchAndDevelopmentExpenses_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInResearchAndDevelopmentExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of expense arising from share-based payment transactions in which the goods or services received did not qualify for recognition as assets in research and development expenses.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInResearchAndDevelopmentExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expense From Share-Based Payment Transactions In Which Goods Or Services Received Did Not Qualify For Recognition As Assets In Research And Development Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInResearchAndDevelopmentExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and development expenses</label>
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInSellingAndDistributionExpenses" xlink:label="cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInSellingAndDistributionExpenses" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInSellingAndDistributionExpenses" xlink:to="cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInSellingAndDistributionExpenses_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInSellingAndDistributionExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of expense arising from share-based payment transactions in which the goods or services received did not qualify for recognition as assets in selling and distribution expenses.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInSellingAndDistributionExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expense From Share-Based Payment Transactions In Which Goods Or Services Received Did Not Qualify For Recognition As Assets In Selling And Distribution Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInSellingAndDistributionExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sales and marketing expenses</label>
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInGeneralAndAdministrativeExpenses" xlink:label="cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInGeneralAndAdministrativeExpenses" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInGeneralAndAdministrativeExpenses" xlink:to="cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInGeneralAndAdministrativeExpenses_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInGeneralAndAdministrativeExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of expense arising from share-based payment transactions in which the goods or services received did not qualify for recognition as assets in general and administrative expenses.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInGeneralAndAdministrativeExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expense From Share-Based Payment Transactions In Which Goods Or Services Received Did Not Qualify For Recognition As Assets In General And Administrative Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInGeneralAndAdministrativeExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">General and administrative expenses</label>
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_BenefitExpenseRecognizedForShareBasedPayment" xlink:label="cvac_BenefitExpenseRecognizedForShareBasedPayment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_BenefitExpenseRecognizedForShareBasedPayment" xlink:to="cvac_BenefitExpenseRecognizedForShareBasedPayment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_BenefitExpenseRecognizedForShareBasedPayment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of benefit expense benefit recognized for share-based payment.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_BenefitExpenseRecognizedForShareBasedPayment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Benefit Expense Recognized For Share Based Payment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="cvac_BenefitExpenseRecognizedForShareBasedPayment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total</label>
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_LongTermIncentivePlanMember" xlink:label="cvac_LongTermIncentivePlanMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_LongTermIncentivePlanMember" xlink:to="cvac_LongTermIncentivePlanMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_LongTermIncentivePlanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for Long-Term Incentive Plan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_LongTermIncentivePlanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">LTIP</label>
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_IfrsRestrictedStockUnitMember" xlink:label="cvac_IfrsRestrictedStockUnitMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_IfrsRestrictedStockUnitMember" xlink:to="cvac_IfrsRestrictedStockUnitMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_IfrsRestrictedStockUnitMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member represents for restricted stock unit.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_IfrsRestrictedStockUnitMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">RSU</label>
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_RestrictedStockUnitForKeyEmployeesMember" xlink:label="cvac_RestrictedStockUnitForKeyEmployeesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_RestrictedStockUnitForKeyEmployeesMember" xlink:to="cvac_RestrictedStockUnitForKeyEmployeesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_RestrictedStockUnitForKeyEmployeesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for RSU for key employees.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_RestrictedStockUnitForKeyEmployeesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">RSU for key employees</label>
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_ExpenseRecognizedForEmployeeServices" xlink:label="cvac_ExpenseRecognizedForEmployeeServices" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_ExpenseRecognizedForEmployeeServices" xlink:to="cvac_ExpenseRecognizedForEmployeeServices_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_ExpenseRecognizedForEmployeeServices_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of expense recognized for employee services.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_ExpenseRecognizedForEmployeeServices_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expense Recognized For Employee Services</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="cvac_ExpenseRecognizedForEmployeeServices_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expense Recognized For Employee Services</label>
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_ExerciseOfOptionsMember" xlink:label="cvac_ExerciseOfOptionsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_ExerciseOfOptionsMember" xlink:to="cvac_ExerciseOfOptionsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_ExerciseOfOptionsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for exercise of options.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_ExerciseOfOptionsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise of options</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_TitleOfIndividualAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Title of Individual [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Title of Individual [Domain]</label>
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_ChiefScientificOfficerMember" xlink:label="cvac_ChiefScientificOfficerMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_ChiefScientificOfficerMember" xlink:to="cvac_ChiefScientificOfficerMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_ChiefScientificOfficerMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for Chief Scientific Officer.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_ChiefScientificOfficerMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Chief Scientific Officer</label>
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_ChiefOperatingOfficerAndChiefDevelopmentOfficerMember" xlink:label="cvac_ChiefOperatingOfficerAndChiefDevelopmentOfficerMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_ChiefOperatingOfficerAndChiefDevelopmentOfficerMember" xlink:to="cvac_ChiefOperatingOfficerAndChiefDevelopmentOfficerMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_ChiefOperatingOfficerAndChiefDevelopmentOfficerMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Person with designation of Chief operating officer and Chief development officer.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_ChiefOperatingOfficerAndChiefDevelopmentOfficerMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Chief Operating Officer and Chief Development Officer</label>
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_ChiefBusinessOfficerAndChiefCommercialOfficerMember" xlink:label="cvac_ChiefBusinessOfficerAndChiefCommercialOfficerMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_ChiefBusinessOfficerAndChiefCommercialOfficerMember" xlink:to="cvac_ChiefBusinessOfficerAndChiefCommercialOfficerMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_ChiefBusinessOfficerAndChiefCommercialOfficerMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for Chief Business Officer and Chief Commercial Officer.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_ChiefBusinessOfficerAndChiefCommercialOfficerMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Chief Business Officer and Chief Commercial Officer</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ChiefOperatingOfficerMember" xlink:label="srt_ChiefOperatingOfficerMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ChiefOperatingOfficerMember" xlink:to="srt_ChiefOperatingOfficerMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ChiefOperatingOfficerMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Chief Operating Officer</label>
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_ChiefDevelopmentOfficerMember" xlink:label="cvac_ChiefDevelopmentOfficerMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_ChiefDevelopmentOfficerMember" xlink:to="cvac_ChiefDevelopmentOfficerMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_ChiefDevelopmentOfficerMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for Chief Development Officer</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_ChiefDevelopmentOfficerMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Chief Development Officer</label>
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_ThenChiefExecutiveOfficerMember" xlink:label="cvac_ThenChiefExecutiveOfficerMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_ThenChiefExecutiveOfficerMember" xlink:to="cvac_ThenChiefExecutiveOfficerMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_ThenChiefExecutiveOfficerMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for Dan Menichella, then Chief Executive Officer.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_ThenChiefExecutiveOfficerMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Dan Menichella, then Chief Executive Officer</label>
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_ManagementBoardMember" xlink:label="cvac_ManagementBoardMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_ManagementBoardMember" xlink:to="cvac_ManagementBoardMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_ManagementBoardMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Member stands for management board of the entity's key management personnel.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_ManagementBoardMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Management Board</label>
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_MembersOfExecutiveBoardAndVariousKeyEmployeesMember" xlink:label="cvac_MembersOfExecutiveBoardAndVariousKeyEmployeesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_MembersOfExecutiveBoardAndVariousKeyEmployeesMember" xlink:to="cvac_MembersOfExecutiveBoardAndVariousKeyEmployeesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_MembersOfExecutiveBoardAndVariousKeyEmployeesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for person or persons designated as part of Executive board and various key employees.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_MembersOfExecutiveBoardAndVariousKeyEmployeesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Members of executive board and various key employees</label>
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_KeyEmployeesMember" xlink:label="cvac_KeyEmployeesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_KeyEmployeesMember" xlink:to="cvac_KeyEmployeesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_KeyEmployeesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for key employees.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_KeyEmployeesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Key employees</label>
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_ExecutiveBoardMembersMember" xlink:label="cvac_ExecutiveBoardMembersMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_ExecutiveBoardMembersMember" xlink:to="cvac_ExecutiveBoardMembersMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_ExecutiveBoardMembersMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for executive board members.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_ExecutiveBoardMembersMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Executive board members</label>
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_SupervisoryBoardMembersMember" xlink:label="cvac_SupervisoryBoardMembersMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_SupervisoryBoardMembersMember" xlink:to="cvac_SupervisoryBoardMembersMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_SupervisoryBoardMembersMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for supervisory board members.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_SupervisoryBoardMembersMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Supervisory board members</label>
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_ChiefBusinessOfficerMember" xlink:label="cvac_ChiefBusinessOfficerMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_ChiefBusinessOfficerMember" xlink:to="cvac_ChiefBusinessOfficerMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_ChiefBusinessOfficerMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for Chief Business Officer.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_ChiefBusinessOfficerMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Chief Business Officer [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_ChiefBusinessOfficerMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Chief Business Officer</label>
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_FormerFrameEmployeesMember" xlink:label="cvac_FormerFrameEmployeesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_FormerFrameEmployeesMember" xlink:to="cvac_FormerFrameEmployeesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_FormerFrameEmployeesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Former Frame employee's</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_FormerFrameEmployeesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Former Frame Employee&amp;rsquo;s [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_FormerFrameEmployeesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Former Frame employee's</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_MaturityAxis" xlink:label="ifrs-full_MaturityAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_MaturityAxis" xlink:to="ifrs-full_MaturityAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_MaturityAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maturity [axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AggregatedTimeBandsMember" xlink:label="ifrs-full_AggregatedTimeBandsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AggregatedTimeBandsMember" xlink:to="ifrs-full_AggregatedTimeBandsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AggregatedTimeBandsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Aggregated time bands [member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NotLaterThanOneYearMember" xlink:label="ifrs-full_NotLaterThanOneYearMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NotLaterThanOneYearMember" xlink:to="ifrs-full_NotLaterThanOneYearMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NotLaterThanOneYearMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Within one year</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember" xlink:label="ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember" xlink:to="ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2022</label>
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_IfrsVestingAxis" xlink:label="cvac_IfrsVestingAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_IfrsVestingAxis" xlink:to="cvac_IfrsVestingAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_IfrsVestingAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Information by vesting schedule of award under share-based payment arrangement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_IfrsVestingAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ifrs Vesting [Axis]</label>
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_IfrsVestingDomain" xlink:label="cvac_IfrsVestingDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_IfrsVestingDomain" xlink:to="cvac_IfrsVestingDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_IfrsVestingDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vesting schedule of award under share-based payment arrangement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_IfrsVestingDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ifrs Vesting [Domain]</label>
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_IfrsShareBasedPaymentArrangementTrancheOneMember" xlink:label="cvac_IfrsShareBasedPaymentArrangementTrancheOneMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_IfrsShareBasedPaymentArrangementTrancheOneMember" xlink:to="cvac_IfrsShareBasedPaymentArrangementTrancheOneMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_IfrsShareBasedPaymentArrangementTrancheOneMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">First portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_IfrsShareBasedPaymentArrangementTrancheOneMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">First tranche</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees" xlink:label="ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees" xlink:to="ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expense from share-based payment transactions with employees</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based based payments expenses</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" xlink:label="ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" xlink:to="ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of share options granted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of share options granted</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" xlink:label="ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" xlink:to="ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Options exercisable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Thereof exercisable</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NumberOfInstrumentsGrantedInSharebasedPaymentArrangement" xlink:label="ifrs-full_NumberOfInstrumentsGrantedInSharebasedPaymentArrangement" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfInstrumentsGrantedInSharebasedPaymentArrangement" xlink:to="ifrs-full_NumberOfInstrumentsGrantedInSharebasedPaymentArrangement_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NumberOfInstrumentsGrantedInSharebasedPaymentArrangement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of instruments granted in share-based payment arrangement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_NumberOfInstrumentsGrantedInSharebasedPaymentArrangement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of awards granted</label>
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_RightToExercisePercentageOfVestedVirtualShares" xlink:label="cvac_RightToExercisePercentageOfVestedVirtualShares" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_RightToExercisePercentageOfVestedVirtualShares" xlink:to="cvac_RightToExercisePercentageOfVestedVirtualShares_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_RightToExercisePercentageOfVestedVirtualShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the right to exercise percentage of vested virtual shares.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_RightToExercisePercentageOfVestedVirtualShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Right To Exercise Percentage Of Vested Virtual Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_RightToExercisePercentageOfVestedVirtualShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Right to exercise percentage of vested virtual shares</label>
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_LockUpPeriodAfterInitialListing" xlink:label="cvac_LockUpPeriodAfterInitialListing" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_LockUpPeriodAfterInitialListing" xlink:to="cvac_LockUpPeriodAfterInitialListing_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_LockUpPeriodAfterInitialListing_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the lock-up period, which is days after the initial listing.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_LockUpPeriodAfterInitialListing_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">lock Up Period, After Initial Listing</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_LockUpPeriodAfterInitialListing_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lock-up period</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" xlink:label="ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" xlink:to="ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of share options exercised in share-based payment arrangement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of options exercised</label>
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_NumberOfKeyEmployees" xlink:label="cvac_NumberOfKeyEmployees" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_NumberOfKeyEmployees" xlink:to="cvac_NumberOfKeyEmployees_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_NumberOfKeyEmployees_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the number of key employees.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_NumberOfKeyEmployees_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of Key Employees</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_NumberOfKeyEmployees_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of key employees</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted" xlink:label="ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted" xlink:to="ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of other equity instruments granted in share-based payment arrangement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of RSU's awarded</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">RSUs issued to certain former employees</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019" xlink:to="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average exercise price of share options exercised in share-based payment arrangement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Average share price</label>
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_ProvisionForEmployerTaxes" xlink:label="cvac_ProvisionForEmployerTaxes" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_ProvisionForEmployerTaxes" xlink:to="cvac_ProvisionForEmployerTaxes_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_ProvisionForEmployerTaxes_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of provision for employer taxes arising according to US regulations for future exercises.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_ProvisionForEmployerTaxes_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Provision for Employer Taxes</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="cvac_ProvisionForEmployerTaxes_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Provision for employer taxes</label>
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_AmountOfLiabilityCashClaimAwards" xlink:label="cvac_AmountOfLiabilityCashClaimAwards" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_AmountOfLiabilityCashClaimAwards" xlink:to="cvac_AmountOfLiabilityCashClaimAwards_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_AmountOfLiabilityCashClaimAwards_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of liability recognized in financial statements towards cash claim of Awards.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_AmountOfLiabilityCashClaimAwards_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of Liability, Cash Claim Awards</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_AmountOfLiabilityCashClaimAwards_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of liability, cash claim awards</label>
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_AmountOfRestrictedStockUnitsReceived" xlink:label="cvac_AmountOfRestrictedStockUnitsReceived" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_AmountOfRestrictedStockUnitsReceived" xlink:to="cvac_AmountOfRestrictedStockUnitsReceived_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_AmountOfRestrictedStockUnitsReceived_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of Restricted Stock Units Received.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_AmountOfRestrictedStockUnitsReceived_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of Restricted Stock Units Received</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_AmountOfRestrictedStockUnitsReceived_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of restricted stock units received</label>
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_NumberOfShareOptionsVestedInShareBasedPaymentArrangement" xlink:label="cvac_NumberOfShareOptionsVestedInShareBasedPaymentArrangement" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_NumberOfShareOptionsVestedInShareBasedPaymentArrangement" xlink:to="cvac_NumberOfShareOptionsVestedInShareBasedPaymentArrangement_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_NumberOfShareOptionsVestedInShareBasedPaymentArrangement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The number of share options vested in a share-based payment arrangement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_NumberOfShareOptionsVestedInShareBasedPaymentArrangement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number Of Share Options Vested In Share-Based Payment Arrangement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="cvac_NumberOfShareOptionsVestedInShareBasedPaymentArrangement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of options vested</label>
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_NumberOfOtherEquityInstrumentsSettledInShareBasedPaymentArrangement" xlink:label="cvac_NumberOfOtherEquityInstrumentsSettledInShareBasedPaymentArrangement" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_NumberOfOtherEquityInstrumentsSettledInShareBasedPaymentArrangement" xlink:to="cvac_NumberOfOtherEquityInstrumentsSettledInShareBasedPaymentArrangement_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_NumberOfOtherEquityInstrumentsSettledInShareBasedPaymentArrangement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The number of other equity instruments settled in a share-based payment arrangement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_NumberOfOtherEquityInstrumentsSettledInShareBasedPaymentArrangement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number Of Other Equity Instruments Settled In Share-Based Payment Arrangement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_NumberOfOtherEquityInstrumentsSettledInShareBasedPaymentArrangement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of RSUs settled</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfIntangibleAssetsTable" xlink:label="ifrs-full_DisclosureOfIntangibleAssetsTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfIntangibleAssetsTable" xlink:to="ifrs-full_DisclosureOfIntangibleAssetsTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfIntangibleAssetsTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of detailed information about intangible assets [table]</label>
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis" xlink:label="cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis" xlink:to="cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">NA.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Carrying Amount Accumulated Depreciation Amortisation And Impairments And Gross Carrying Amount [axis]</label>
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountDomain" xlink:label="cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountDomain" xlink:to="cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">NA</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Carrying Amount Accumulated Depreciation Amortisation And Impairments And Gross Carrying Amount [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_GrossCarryingAmountMember" xlink:label="ifrs-full_GrossCarryingAmountMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_GrossCarryingAmountMember" xlink:to="ifrs-full_GrossCarryingAmountMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_GrossCarryingAmountMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Acquisition costs</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis" xlink:label="ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis" xlink:to="ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Classes of intangible assets other than goodwill [axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwillMember" xlink:label="ifrs-full_IntangibleAssetsOtherThanGoodwillMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IntangibleAssetsOtherThanGoodwillMember" xlink:to="ifrs-full_IntangibleAssetsOtherThanGoodwillMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IntangibleAssetsOtherThanGoodwillMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Intangible assets other than goodwill [member]</label>
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_LicensesSoftwareAndPrepaymentsMember" xlink:label="cvac_LicensesSoftwareAndPrepaymentsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_LicensesSoftwareAndPrepaymentsMember" xlink:to="cvac_LicensesSoftwareAndPrepaymentsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_LicensesSoftwareAndPrepaymentsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">licenses, software and prepayments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_LicensesSoftwareAndPrepaymentsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">licenses, software and prepayments</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:label="ifrs-full_DisclosureOfIntangibleAssetsLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:to="ifrs-full_DisclosureOfIntangibleAssetsLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfIntangibleAssetsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of detailed information about intangible assets [line items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfIntangibleAssetsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of detailed information about intangible assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" xlink:label="ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" xlink:to="ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additions other than through business combinations, intangible assets other than goodwill</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additions</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable" xlink:label="ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable" xlink:to="ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of detailed information about property, plant and equipment [table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:label="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:to="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Classes of property, plant and equipment [axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_PropertyPlantAndEquipmentMember" xlink:label="ifrs-full_PropertyPlantAndEquipmentMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PropertyPlantAndEquipmentMember" xlink:to="ifrs-full_PropertyPlantAndEquipmentMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_PropertyPlantAndEquipmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, plant and equipment</label>
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_TechnicalEquipmentAndMachinesAndOtherEquipmentMember" xlink:label="cvac_TechnicalEquipmentAndMachinesAndOtherEquipmentMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_TechnicalEquipmentAndMachinesAndOtherEquipmentMember" xlink:to="cvac_TechnicalEquipmentAndMachinesAndOtherEquipmentMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_TechnicalEquipmentAndMachinesAndOtherEquipmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for technical equipment and machines and other equipment.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_TechnicalEquipmentAndMachinesAndOtherEquipmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Technical equipment and machines</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ConstructionInProgressMember" xlink:label="ifrs-full_ConstructionInProgressMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ConstructionInProgressMember" xlink:to="ifrs-full_ConstructionInProgressMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ConstructionInProgressMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets under construction</label>
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_CompanyOwnedGmpIvFacilityMember" xlink:label="cvac_CompanyOwnedGmpIvFacilityMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_CompanyOwnedGmpIvFacilityMember" xlink:to="cvac_CompanyOwnedGmpIvFacilityMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_CompanyOwnedGmpIvFacilityMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for company-owned GMP IV facility.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_CompanyOwnedGmpIvFacilityMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Company-owned GMP IV facility</label>
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_EquipmentPhysicallyLocatedAtCmoFacilitiesMember" xlink:label="cvac_EquipmentPhysicallyLocatedAtCmoFacilitiesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_EquipmentPhysicallyLocatedAtCmoFacilitiesMember" xlink:to="cvac_EquipmentPhysicallyLocatedAtCmoFacilitiesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_EquipmentPhysicallyLocatedAtCmoFacilitiesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for equipment physically located at the CMO facilities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_EquipmentPhysicallyLocatedAtCmoFacilitiesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equipment physically located at the CMO facilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:label="ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:to="ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of detailed information about property, plant and equipment [line items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of detailed information about property, plant and equipment</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" xlink:label="ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" xlink:to="ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additions other than through business combinations, property, plant and equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additions</label>
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_IncreaseInPropertyAndEquipmentOffSetByImpairmentOfEquipment" xlink:label="cvac_IncreaseInPropertyAndEquipmentOffSetByImpairmentOfEquipment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_IncreaseInPropertyAndEquipmentOffSetByImpairmentOfEquipment" xlink:to="cvac_IncreaseInPropertyAndEquipmentOffSetByImpairmentOfEquipment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_IncreaseInPropertyAndEquipmentOffSetByImpairmentOfEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of increase in PPE off set by impairment in equipment.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_IncreaseInPropertyAndEquipmentOffSetByImpairmentOfEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase In Property and Equipment Off Set By Impairment of Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_IncreaseInPropertyAndEquipmentOffSetByImpairmentOfEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Partial offset of increase in property, plant and equipment</label>
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_IfrsDisposalGroupIncludingDiscontinuedOperationConsideration" xlink:label="cvac_IfrsDisposalGroupIncludingDiscontinuedOperationConsideration" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_IfrsDisposalGroupIncludingDiscontinuedOperationConsideration" xlink:to="cvac_IfrsDisposalGroupIncludingDiscontinuedOperationConsideration_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_IfrsDisposalGroupIncludingDiscontinuedOperationConsideration_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">"
Amount of consideration received or receivable for the disposal of assets and liabilities, including discontinued operation."</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_IfrsDisposalGroupIncludingDiscontinuedOperationConsideration_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ifrs Disposal Group, Including Discontinued Operation, Consideration</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_IfrsDisposalGroupIncludingDiscontinuedOperationConsideration_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total consideration</label>
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_InventoriesTable" xlink:label="cvac_InventoriesTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_InventoriesTable" xlink:to="cvac_InventoriesTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_InventoriesTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">N/A</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_InventoriesTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inventories [Table]</label>
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_InventoriesLineItem" xlink:label="cvac_InventoriesLineItem" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_InventoriesLineItem" xlink:to="cvac_InventoriesLineItem_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_InventoriesLineItem_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">N/A</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_InventoriesLineItem_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inventories [Line item</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_InventoriesLineItem_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inventories</label>
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_IncreaseDecreaseInInventory" xlink:label="cvac_IncreaseDecreaseInInventory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_IncreaseDecreaseInInventory" xlink:to="cvac_IncreaseDecreaseInInventory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_IncreaseDecreaseInInventory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of increase (decrease) in inventory during the period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_IncreaseDecreaseInInventory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) In Inventory</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_IncreaseDecreaseInInventory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Decrease in inventory</label>
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_NetValueOfInventoryTransferred" xlink:label="cvac_NetValueOfInventoryTransferred" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_NetValueOfInventoryTransferred" xlink:to="cvac_NetValueOfInventoryTransferred_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_NetValueOfInventoryTransferred_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net value of inventory transferred during the period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_NetValueOfInventoryTransferred_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Value Of Inventory Transferred</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_NetValueOfInventoryTransferred_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net inventory transferred</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_InventoryWritedown2011" xlink:label="ifrs-full_InventoryWritedown2011" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_InventoryWritedown2011" xlink:to="ifrs-full_InventoryWritedown2011_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_InventoryWritedown2011_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inventory write-down</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_InventoryWritedown2011_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inventory write-offs</label>
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_PrepaidCompensationForContractManufacturingOrganizationsTransfer" xlink:label="cvac_PrepaidCompensationForContractManufacturingOrganizationsTransfer" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_PrepaidCompensationForContractManufacturingOrganizationsTransfer" xlink:to="cvac_PrepaidCompensationForContractManufacturingOrganizationsTransfer_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_PrepaidCompensationForContractManufacturingOrganizationsTransfer_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the amount of prepaid compensation for contract manufacturing organizations transfer.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_PrepaidCompensationForContractManufacturingOrganizationsTransfer_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid Compensation for Contract Manufacturing organizations Transfer</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_PrepaidCompensationForContractManufacturingOrganizationsTransfer_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepayments for compensation</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CurrentAdvancesToSuppliers" xlink:label="ifrs-full_CurrentAdvancesToSuppliers" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentAdvancesToSuppliers" xlink:to="ifrs-full_CurrentAdvancesToSuppliers_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentAdvancesToSuppliers_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current advances to suppliers</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CurrentAdvancesToSuppliers_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepayments for material</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ReceivablesFromTaxesOtherThanIncomeTax" xlink:label="ifrs-full_ReceivablesFromTaxesOtherThanIncomeTax" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ReceivablesFromTaxesOtherThanIncomeTax" xlink:to="ifrs-full_ReceivablesFromTaxesOtherThanIncomeTax_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ReceivablesFromTaxesOtherThanIncomeTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Receivables from taxes other than income tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ReceivablesFromTaxesOtherThanIncomeTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tax claims against the tax authorities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TransfersOutOfLevel1IntoLevel2OfFairValueHierarchyAssets" xlink:label="ifrs-full_TransfersOutOfLevel1IntoLevel2OfFairValueHierarchyAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TransfersOutOfLevel1IntoLevel2OfFairValueHierarchyAssets" xlink:to="ifrs-full_TransfersOutOfLevel1IntoLevel2OfFairValueHierarchyAssets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TransfersOutOfLevel1IntoLevel2OfFairValueHierarchyAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Transfers out of Level 1 into Level 2 of fair value hierarchy, assets held at end of reporting period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_TransfersOutOfLevel1IntoLevel2OfFairValueHierarchyAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Transfer from Level 1 to Level 2, Assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TransfersOutOfLevel2IntoLevel1OfFairValueHierarchyAssets" xlink:label="ifrs-full_TransfersOutOfLevel2IntoLevel1OfFairValueHierarchyAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TransfersOutOfLevel2IntoLevel1OfFairValueHierarchyAssets" xlink:to="ifrs-full_TransfersOutOfLevel2IntoLevel1OfFairValueHierarchyAssets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TransfersOutOfLevel2IntoLevel1OfFairValueHierarchyAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Transfers out of Level 2 into Level 1 of fair value hierarchy, assets held at end of reporting period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_TransfersOutOfLevel2IntoLevel1OfFairValueHierarchyAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Transfer from Level 2 to Level 1, Assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TransfersOutOfLevel1IntoLevel2OfFairValueHierarchyLiabilities" xlink:label="ifrs-full_TransfersOutOfLevel1IntoLevel2OfFairValueHierarchyLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TransfersOutOfLevel1IntoLevel2OfFairValueHierarchyLiabilities" xlink:to="ifrs-full_TransfersOutOfLevel1IntoLevel2OfFairValueHierarchyLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TransfersOutOfLevel1IntoLevel2OfFairValueHierarchyLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Transfers out of Level 1 into Level 2 of fair value hierarchy, liabilities held at end of reporting period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_TransfersOutOfLevel1IntoLevel2OfFairValueHierarchyLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Transfer from Level 1 to Level 2, Liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TransfersOutOfLevel2IntoLevel1OfFairValueHierarchyLiabilities" xlink:label="ifrs-full_TransfersOutOfLevel2IntoLevel1OfFairValueHierarchyLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TransfersOutOfLevel2IntoLevel1OfFairValueHierarchyLiabilities" xlink:to="ifrs-full_TransfersOutOfLevel2IntoLevel1OfFairValueHierarchyLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TransfersOutOfLevel2IntoLevel1OfFairValueHierarchyLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Transfers out of Level 2 into Level 1 of fair value hierarchy, liabilities held at end of reporting period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_TransfersOutOfLevel2IntoLevel1OfFairValueHierarchyLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Transfer from Level 2 to Level 1, Liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TransfersIntoLevel3OfFairValueHierarchyAssets" xlink:label="ifrs-full_TransfersIntoLevel3OfFairValueHierarchyAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TransfersIntoLevel3OfFairValueHierarchyAssets" xlink:to="ifrs-full_TransfersIntoLevel3OfFairValueHierarchyAssets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TransfersIntoLevel3OfFairValueHierarchyAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Transfers into Level 3 of fair value hierarchy, assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_TransfersIntoLevel3OfFairValueHierarchyAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Transfers into Level 3, Assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TransfersOutOfLevel3OfFairValueHierarchyAssets" xlink:label="ifrs-full_TransfersOutOfLevel3OfFairValueHierarchyAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TransfersOutOfLevel3OfFairValueHierarchyAssets" xlink:to="ifrs-full_TransfersOutOfLevel3OfFairValueHierarchyAssets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TransfersOutOfLevel3OfFairValueHierarchyAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Transfers out of Level 3 of fair value hierarchy, assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_TransfersOutOfLevel3OfFairValueHierarchyAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Transfers out of Level 3, Assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TransfersIntoLevel3OfFairValueHierarchyLiabilities" xlink:label="ifrs-full_TransfersIntoLevel3OfFairValueHierarchyLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TransfersIntoLevel3OfFairValueHierarchyLiabilities" xlink:to="ifrs-full_TransfersIntoLevel3OfFairValueHierarchyLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TransfersIntoLevel3OfFairValueHierarchyLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Transfers into Level 3 of fair value hierarchy, liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_TransfersIntoLevel3OfFairValueHierarchyLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Transfers into Level 3, Liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TransfersOutOfLevel3OfFairValueHierarchyLiabilities" xlink:label="ifrs-full_TransfersOutOfLevel3OfFairValueHierarchyLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TransfersOutOfLevel3OfFairValueHierarchyLiabilities" xlink:to="ifrs-full_TransfersOutOfLevel3OfFairValueHierarchyLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TransfersOutOfLevel3OfFairValueHierarchyLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Transfers out of Level 3 of fair value hierarchy, liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_TransfersOutOfLevel3OfFairValueHierarchyLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Transfers out of Level 3, Liabilities</label>
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_ChangeInTradeAndOtherPayables" xlink:label="cvac_ChangeInTradeAndOtherPayables" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_ChangeInTradeAndOtherPayables" xlink:to="cvac_ChangeInTradeAndOtherPayables_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_ChangeInTradeAndOtherPayables_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of change in trade and other payables.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_ChangeInTradeAndOtherPayables_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Change in Trade and Other Payables</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_ChangeInTradeAndOtherPayables_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of decrease in trade and other payables</label>
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_DisclosureOfOtherLiabilitiesTable" xlink:label="cvac_DisclosureOfOtherLiabilitiesTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_DisclosureOfOtherLiabilitiesTable" xlink:to="cvac_DisclosureOfOtherLiabilitiesTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_DisclosureOfOtherLiabilitiesTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule disclosing information related to other liabilities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_DisclosureOfOtherLiabilitiesTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of Other liabilities [table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TypesOfContractsAxis" xlink:label="ifrs-full_TypesOfContractsAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TypesOfContractsAxis" xlink:to="ifrs-full_TypesOfContractsAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TypesOfContractsAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Types of contracts [axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TypesOfContractsMember" xlink:label="ifrs-full_TypesOfContractsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TypesOfContractsMember" xlink:to="ifrs-full_TypesOfContractsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TypesOfContractsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Types of contracts [member]</label>
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_ContractResearchOrganizationAgreementMember" xlink:label="cvac_ContractResearchOrganizationAgreementMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_ContractResearchOrganizationAgreementMember" xlink:to="cvac_ContractResearchOrganizationAgreementMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_ContractResearchOrganizationAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for contract research organization Agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_ContractResearchOrganizationAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">CRO agreement</label>
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_ContractManufacturingOrganizationAgreementMember" xlink:label="cvac_ContractManufacturingOrganizationAgreementMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_ContractManufacturingOrganizationAgreementMember" xlink:to="cvac_ContractManufacturingOrganizationAgreementMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_ContractManufacturingOrganizationAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for contract manufacturing organization Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_ContractManufacturingOrganizationAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">CMO agreement</label>
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_DisclosureOfOtherLiabilitiesLineItems" xlink:label="cvac_DisclosureOfOtherLiabilitiesLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_DisclosureOfOtherLiabilitiesLineItems" xlink:to="cvac_DisclosureOfOtherLiabilitiesLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_DisclosureOfOtherLiabilitiesLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">NA</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_DisclosureOfOtherLiabilitiesLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of Other liabilities [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_DisclosureOfOtherLiabilitiesLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of Other liabilities</label>
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_ChangeInOtherLiabilities" xlink:label="cvac_ChangeInOtherLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_ChangeInOtherLiabilities" xlink:to="cvac_ChangeInOtherLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_ChangeInOtherLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of increase (decrease) in other liabilities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_ChangeInOtherLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Change in Other Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="cvac_ChangeInOtherLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Decrease in other liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable" xlink:label="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable" xlink:to="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of detailed information about borrowings [table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_BorrowingsByNameAxis" xlink:label="ifrs-full_BorrowingsByNameAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_BorrowingsByNameAxis" xlink:to="ifrs-full_BorrowingsByNameAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_BorrowingsByNameAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Borrowings by name [axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_BorrowingsByNameMember" xlink:label="ifrs-full_BorrowingsByNameMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_BorrowingsByNameMember" xlink:to="ifrs-full_BorrowingsByNameMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_BorrowingsByNameMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Borrowings by name [member]</label>
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_IfrsLineOfCreditMember" xlink:label="cvac_IfrsLineOfCreditMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_IfrsLineOfCreditMember" xlink:to="cvac_IfrsLineOfCreditMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_IfrsLineOfCreditMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">A contractual arrangement with a lender under which borrowings can be made up to a specific amount at any point in time, and under which borrowings outstanding may be either short-term or long-term, depending upon the particulars.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_IfrsLineOfCreditMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Line of credit</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:label="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:to="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of detailed information about borrowings [line items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of detailed information about borrowings</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities" xlink:label="ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities" xlink:to="ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from borrowings, classified as financing activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount drawn</label>
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_LineOfCreditAccruedInterestPayable" xlink:label="cvac_LineOfCreditAccruedInterestPayable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_LineOfCreditAccruedInterestPayable" xlink:to="cvac_LineOfCreditAccruedInterestPayable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_LineOfCreditAccruedInterestPayable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lin of credit accrued interest payable.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_LineOfCreditAccruedInterestPayable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Line of Credit Accrued Interest Payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_LineOfCreditAccruedInterestPayable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued interest</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities" xlink:label="ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities" xlink:to="ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Repayments of borrowings, classified as financing activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash consideration</label>
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_RepaymentsOfPrincipalAmountOfBorrowings" xlink:label="cvac_RepaymentsOfPrincipalAmountOfBorrowings" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_RepaymentsOfPrincipalAmountOfBorrowings" xlink:to="cvac_RepaymentsOfPrincipalAmountOfBorrowings_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_RepaymentsOfPrincipalAmountOfBorrowings_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The cash outflow to settle principal amount of borrowings, classified as financing activities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_RepaymentsOfPrincipalAmountOfBorrowings_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Repayments of Principal Amount of Borrowings</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="cvac_RepaymentsOfPrincipalAmountOfBorrowings_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Repayment of principal amount of loan</label>
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_IfrsRepaymentsOfAccruedInterestAndFeesOfBorrowings" xlink:label="cvac_IfrsRepaymentsOfAccruedInterestAndFeesOfBorrowings" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_IfrsRepaymentsOfAccruedInterestAndFeesOfBorrowings" xlink:to="cvac_IfrsRepaymentsOfAccruedInterestAndFeesOfBorrowings_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_IfrsRepaymentsOfAccruedInterestAndFeesOfBorrowings_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The cash outflow to settle accrued interest and fees of borrowings, classified as financing activities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_IfrsRepaymentsOfAccruedInterestAndFeesOfBorrowings_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">IFRS Repayments Of Accrued Interest And Fees Of Borrowings</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_IfrsRepaymentsOfAccruedInterestAndFeesOfBorrowings_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Repayment of accrued interest and fees of loan</label>
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_IncomeTaxDisclosureTable" xlink:label="cvac_IncomeTaxDisclosureTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_IncomeTaxDisclosureTable" xlink:to="cvac_IncomeTaxDisclosureTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_IncomeTaxDisclosureTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule disclosing information related to income tax disclosures.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_IncomeTaxDisclosureTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax Disclosure [Table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_SignificantInvestmentsInSubsidiariesAxis" xlink:label="ifrs-full_SignificantInvestmentsInSubsidiariesAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_SignificantInvestmentsInSubsidiariesAxis" xlink:to="ifrs-full_SignificantInvestmentsInSubsidiariesAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_SignificantInvestmentsInSubsidiariesAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsidiaries [axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_EntitysTotalForSubsidiariesMember" xlink:label="ifrs-full_EntitysTotalForSubsidiariesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EntitysTotalForSubsidiariesMember" xlink:to="ifrs-full_EntitysTotalForSubsidiariesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_EntitysTotalForSubsidiariesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity's total for subsidiaries [member]</label>
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_CurevacCorporateServiceGmbhMember" xlink:label="cvac_CurevacCorporateServiceGmbhMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_CurevacCorporateServiceGmbhMember" xlink:to="cvac_CurevacCorporateServiceGmbhMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_CurevacCorporateServiceGmbhMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for CureVac Corporate Service GmbH.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_CurevacCorporateServiceGmbhMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">CureVac Corporate Service GmbH</label>
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_CurevacSwissAgMember" xlink:label="cvac_CurevacSwissAgMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_CurevacSwissAgMember" xlink:to="cvac_CurevacSwissAgMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_CurevacSwissAgMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for CureVac Swiss AG.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_CurevacSwissAgMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">CureVac Swiss AG</label>
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_IncomeTaxDisclosureLineItems" xlink:label="cvac_IncomeTaxDisclosureLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_IncomeTaxDisclosureLineItems" xlink:to="cvac_IncomeTaxDisclosureLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_IncomeTaxDisclosureLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_IncomeTaxDisclosureLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax Disclosure [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_IncomeTaxDisclosureLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax Disclosure</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CurrentTaxExpenseIncome" xlink:label="ifrs-full_CurrentTaxExpenseIncome" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentTaxExpenseIncome" xlink:to="ifrs-full_CurrentTaxExpenseIncome_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentTaxExpenseIncome_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current tax expense (income)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CurrentTaxExpenseIncome_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current tax expense</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DeferredTaxExpenseIncome" xlink:label="ifrs-full_DeferredTaxExpenseIncome" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DeferredTaxExpenseIncome" xlink:to="ifrs-full_DeferredTaxExpenseIncome_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DeferredTaxExpenseIncome_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred tax expense (income)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DeferredTaxExpenseIncome_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred tax expense (benefit)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable" xlink:label="ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable" xlink:to="ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of nature and extent of risks arising from financial instruments [table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CurrencyAxis" xlink:label="srt_CurrencyAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CurrencyAxis" xlink:to="srt_CurrencyAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_CurrencyAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Currency [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2021/currency-2021.xsd#currency_AllCurrenciesDomain" xlink:label="currency_AllCurrenciesDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="currency_AllCurrenciesDomain" xlink:to="currency_AllCurrenciesDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="currency_AllCurrenciesDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">All Currencies [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2021/currency-2021.xsd#currency_USD" xlink:label="currency_USD" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="currency_USD" xlink:to="currency_USD_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="currency_USD_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">USD</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2021/currency-2021.xsd#currency_CHF" xlink:label="currency_CHF" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="currency_CHF" xlink:to="currency_CHF_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="currency_CHF_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">CHF</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TypesOfRisksAxis" xlink:label="ifrs-full_TypesOfRisksAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TypesOfRisksAxis" xlink:to="ifrs-full_TypesOfRisksAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TypesOfRisksAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Types of risks [axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TypesOfRisksMember" xlink:label="ifrs-full_TypesOfRisksMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TypesOfRisksMember" xlink:to="ifrs-full_TypesOfRisksMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TypesOfRisksMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Risks [member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CurrencyRiskMember" xlink:label="ifrs-full_CurrencyRiskMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrencyRiskMember" xlink:to="ifrs-full_CurrencyRiskMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrencyRiskMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Foreign currency risk</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:label="ifrs-full_ClassesOfFinancialInstrumentsAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:to="ifrs-full_ClassesOfFinancialInstrumentsAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ClassesOfFinancialInstrumentsAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Classes of financial instruments [axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ClassesOfFinancialInstrumentsMember" xlink:label="ifrs-full_ClassesOfFinancialInstrumentsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsMember" xlink:to="ifrs-full_ClassesOfFinancialInstrumentsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ClassesOfFinancialInstrumentsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financial instruments, class [member]</label>
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_IfrsCashAndCashEquivalentsMember" xlink:label="cvac_IfrsCashAndCashEquivalentsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_IfrsCashAndCashEquivalentsMember" xlink:to="cvac_IfrsCashAndCashEquivalentsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_IfrsCashAndCashEquivalentsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for cash and cash equivalents.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_IfrsCashAndCashEquivalentsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and cash equivalents</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems" xlink:label="ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems" xlink:to="ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of nature and extent of risks arising from financial instruments [line items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of nature and extent of risks arising from financial instruments</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RiskExposureAssociatedWithInstrumentsSharingCharacteristic" xlink:label="ifrs-full_RiskExposureAssociatedWithInstrumentsSharingCharacteristic" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RiskExposureAssociatedWithInstrumentsSharingCharacteristic" xlink:to="ifrs-full_RiskExposureAssociatedWithInstrumentsSharingCharacteristic_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_RiskExposureAssociatedWithInstrumentsSharingCharacteristic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Risk exposure associated with instruments sharing characteristic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_RiskExposureAssociatedWithInstrumentsSharingCharacteristic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exposure in (foreign) currency</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_WeightedAverageShares" xlink:label="ifrs-full_WeightedAverageShares" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WeightedAverageShares" xlink:to="ifrs-full_WeightedAverageShares_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_WeightedAverageShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average number of ordinary shares outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_WeightedAverageShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted number of shares outstanding</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:label="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:to="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of transactions between related parties [table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TopOfRangeMember" xlink:label="ifrs-full_TopOfRangeMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TopOfRangeMember" xlink:to="ifrs-full_TopOfRangeMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TopOfRangeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_TopOfRangeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum</label>
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_BaronJeanStephenneMember" xlink:label="cvac_BaronJeanStephenneMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_BaronJeanStephenneMember" xlink:to="cvac_BaronJeanStephenneMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_BaronJeanStephenneMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for Baron Jean Stephenne.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_BaronJeanStephenneMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Baron Jean Stephenne</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_BaronJeanStephenneMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Baron Jean Stephenne</label>
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_VincentStphenneMember" xlink:label="cvac_VincentStphenneMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_VincentStphenneMember" xlink:to="cvac_VincentStphenneMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_VincentStphenneMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for Vincent Stphenne.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_VincentStphenneMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vincent Stphenne</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_VincentStphenneMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vincent Stphenne</label>
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_AntonyBlancMember" xlink:label="cvac_AntonyBlancMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_AntonyBlancMember" xlink:to="cvac_AntonyBlancMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_AntonyBlancMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for Antony Blanc.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_AntonyBlancMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antony Blanc</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_AntonyBlancMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antony Blanc</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_CategoriesOfRelatedPartiesAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Categories of related parties [axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="ifrs-full_EntitysTotalForRelatedPartiesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="ifrs-full_EntitysTotalForRelatedPartiesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_EntitysTotalForRelatedPartiesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity's total for related parties [member]</label>
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_DietmarHoppMember" xlink:label="cvac_DietmarHoppMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_DietmarHoppMember" xlink:to="cvac_DietmarHoppMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_DietmarHoppMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Member stands for Mr. Dietmar Hopp, principal of dievini Hopp BioTech holding GmbH &amp; Co. KG , a majority shareholder of the entity, a related party.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_DietmarHoppMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Dietmar Hopp</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_DietmarHoppMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Dietmar Hopp</label>
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_ClarentisSrlMember" xlink:label="cvac_ClarentisSrlMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_ClarentisSrlMember" xlink:to="cvac_ClarentisSrlMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_ClarentisSrlMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Member stands for Clarentis SRL, wholly owned consulting company of Antony Blanc, Chief business officer, a related party.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_ClarentisSrlMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Clarentis SRL</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_ClarentisSrlMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Clarentis SRL</label>
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_BepharbelManufacturingS.aMember" xlink:label="cvac_BepharbelManufacturingS.aMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_BepharbelManufacturingS.aMember" xlink:to="cvac_BepharbelManufacturingS.aMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_BepharbelManufacturingS.aMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for BePharBel Manufacturing S.A.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_BepharbelManufacturingS.aMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">BePharBel Manufacturing S.A</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_BepharbelManufacturingS.aMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">BePharBel Manufacturing S.A</label>
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_Dr.IngmarHoerrMember" xlink:label="cvac_Dr.IngmarHoerrMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_Dr.IngmarHoerrMember" xlink:to="cvac_Dr.IngmarHoerrMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_Dr.IngmarHoerrMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Member stands for Dr. Ingmar Hoerr, a related party.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_Dr.IngmarHoerrMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Dr. Ingmar Hoerr</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_Dr.IngmarHoerrMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Dr. Ingmar Hoerr</label>
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_RittershausRechtsanwaelteMember" xlink:label="cvac_RittershausRechtsanwaelteMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_RittershausRechtsanwaelteMember" xlink:to="cvac_RittershausRechtsanwaelteMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_RittershausRechtsanwaelteMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Member stands for Rittershaus Rechtsanwaelte , a related party.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_RittershausRechtsanwaelteMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Rittershaus Rechtsanwaelte</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_RittershausRechtsanwaelteMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Rittershaus Rechtsanwaelte</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:label="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of transactions between related parties [line items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related party disclosures</label>
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_RelatedPartyTransactionNumberOfLoansReceived" xlink:label="cvac_RelatedPartyTransactionNumberOfLoansReceived" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_RelatedPartyTransactionNumberOfLoansReceived" xlink:to="cvac_RelatedPartyTransactionNumberOfLoansReceived_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_RelatedPartyTransactionNumberOfLoansReceived_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of loans received from a related party.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_RelatedPartyTransactionNumberOfLoansReceived_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related Party Transaction, Number of Loans Received</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_RelatedPartyTransactionNumberOfLoansReceived_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of convertible loans</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_WeightedAverageSharePrice2019" xlink:label="ifrs-full_WeightedAverageSharePrice2019" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WeightedAverageSharePrice2019" xlink:to="ifrs-full_WeightedAverageSharePrice2019_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_WeightedAverageSharePrice2019_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average share price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_WeightedAverageSharePrice2019_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Price per share</label>
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_CollaborationAgreementMilestonePayment" xlink:label="cvac_CollaborationAgreementMilestonePayment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_CollaborationAgreementMilestonePayment" xlink:to="cvac_CollaborationAgreementMilestonePayment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_CollaborationAgreementMilestonePayment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the amount of milestone payment receivable.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_CollaborationAgreementMilestonePayment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaboration Agreement, Milestone Payment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_CollaborationAgreementMilestonePayment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Milestone payment</label>
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_PaymentsToRelatedPartyForServices" xlink:label="cvac_PaymentsToRelatedPartyForServices" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_PaymentsToRelatedPartyForServices" xlink:to="cvac_PaymentsToRelatedPartyForServices_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_PaymentsToRelatedPartyForServices_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments made to related party by the company for services.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_PaymentsToRelatedPartyForServices_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments To Related Party For Services</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_PaymentsToRelatedPartyForServices_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments to related party for services</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CommitmentsMadeByEntityRelatedPartyTransactions" xlink:label="ifrs-full_CommitmentsMadeByEntityRelatedPartyTransactions" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CommitmentsMadeByEntityRelatedPartyTransactions" xlink:to="ifrs-full_CommitmentsMadeByEntityRelatedPartyTransactions_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CommitmentsMadeByEntityRelatedPartyTransactions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments made by entity, related party transactions</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CommitmentsMadeByEntityRelatedPartyTransactions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum settlement amount</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProportionOfOwnershipInterestInAssociate" xlink:label="ifrs-full_ProportionOfOwnershipInterestInAssociate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProportionOfOwnershipInterestInAssociate" xlink:to="ifrs-full_ProportionOfOwnershipInterestInAssociate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ProportionOfOwnershipInterestInAssociate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proportion of ownership interest in associate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ProportionOfOwnershipInterestInAssociate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity interest held</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TransfersOfResearchAndDevelopmentToEntityRelatedPartyTransactions" xlink:label="ifrs-full_TransfersOfResearchAndDevelopmentToEntityRelatedPartyTransactions" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TransfersOfResearchAndDevelopmentToEntityRelatedPartyTransactions" xlink:to="ifrs-full_TransfersOfResearchAndDevelopmentToEntityRelatedPartyTransactions_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TransfersOfResearchAndDevelopmentToEntityRelatedPartyTransactions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and development expenses.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_TransfersOfResearchAndDevelopmentToEntityRelatedPartyTransactions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and development expense</label>
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_RelatedPartyTransactionNoticePeriodForTerminationOfAgreement" xlink:label="cvac_RelatedPartyTransactionNoticePeriodForTerminationOfAgreement" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_RelatedPartyTransactionNoticePeriodForTerminationOfAgreement" xlink:to="cvac_RelatedPartyTransactionNoticePeriodForTerminationOfAgreement_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_RelatedPartyTransactionNoticePeriodForTerminationOfAgreement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Period of notice for termination of the agreement at the option of the party.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_RelatedPartyTransactionNoticePeriodForTerminationOfAgreement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related Party Transaction, Notice Period for Termination of Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_RelatedPartyTransactionNoticePeriodForTerminationOfAgreement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Notice period for termination at the option</label>
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_RelatedPartyTransactionConsultingFees" xlink:label="cvac_RelatedPartyTransactionConsultingFees" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_RelatedPartyTransactionConsultingFees" xlink:to="cvac_RelatedPartyTransactionConsultingFees_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_RelatedPartyTransactionConsultingFees_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of consulting fees incurred as a part of related party transaction.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_RelatedPartyTransactionConsultingFees_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related Party Transaction, Consulting Fees</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_RelatedPartyTransactionConsultingFees_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">consulting fees</label>
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_RelatedPartyTransactionAdvisoryFees" xlink:label="cvac_RelatedPartyTransactionAdvisoryFees" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_RelatedPartyTransactionAdvisoryFees" xlink:to="cvac_RelatedPartyTransactionAdvisoryFees_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_RelatedPartyTransactionAdvisoryFees_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of advisory fees incurred as a part of related party transaction.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_RelatedPartyTransactionAdvisoryFees_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related Party Transaction, Advisory Fees</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_RelatedPartyTransactionAdvisoryFees_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Advisory fees</label>
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_AmountPaidAtSigningOfAgreementRelatedPartyTransactions" xlink:label="cvac_AmountPaidAtSigningOfAgreementRelatedPartyTransactions" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_AmountPaidAtSigningOfAgreementRelatedPartyTransactions" xlink:to="cvac_AmountPaidAtSigningOfAgreementRelatedPartyTransactions_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_AmountPaidAtSigningOfAgreementRelatedPartyTransactions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount paid at signing of the agreement in related party transactions.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_AmountPaidAtSigningOfAgreementRelatedPartyTransactions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount Paid at Signing of Agreement, Related Party Transactions</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_AmountPaidAtSigningOfAgreementRelatedPartyTransactions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount paid at signing of the agreement</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_PurchasesOfGoodsRelatedPartyTransactions" xlink:label="ifrs-full_PurchasesOfGoodsRelatedPartyTransactions" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PurchasesOfGoodsRelatedPartyTransactions" xlink:to="ifrs-full_PurchasesOfGoodsRelatedPartyTransactions_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_PurchasesOfGoodsRelatedPartyTransactions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Purchases of goods, related party transactions</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_PurchasesOfGoodsRelatedPartyTransactions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total payments</label>
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_TerminationFeeRelatedPartyTransactions" xlink:label="cvac_TerminationFeeRelatedPartyTransactions" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_TerminationFeeRelatedPartyTransactions" xlink:to="cvac_TerminationFeeRelatedPartyTransactions_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_TerminationFeeRelatedPartyTransactions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of termination fee in related party transactions.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_TerminationFeeRelatedPartyTransactions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Termination Fee, Related Party Transactions</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_TerminationFeeRelatedPartyTransactions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Termination fee</label>
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_IfrsNumberOfSharesOutstandingThroughTransferFromShareholdersToEntity" xlink:label="cvac_IfrsNumberOfSharesOutstandingThroughTransferFromShareholdersToEntity" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_IfrsNumberOfSharesOutstandingThroughTransferFromShareholdersToEntity" xlink:to="cvac_IfrsNumberOfSharesOutstandingThroughTransferFromShareholdersToEntity_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_IfrsNumberOfSharesOutstandingThroughTransferFromShareholdersToEntity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of shares received from the participants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_IfrsNumberOfSharesOutstandingThroughTransferFromShareholdersToEntity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">IFRS Number Of Shares Outstanding Through Transfer From Shareholders To Entity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_IfrsNumberOfSharesOutstandingThroughTransferFromShareholdersToEntity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of shares received</label>
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_IfrsContractualObligation" xlink:label="cvac_IfrsContractualObligation" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_IfrsContractualObligation" xlink:to="cvac_IfrsContractualObligation_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_IfrsContractualObligation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of contractual obligation, including but not limited to, long-term debt, capital lease obligations, operating lease obligations, purchase obligations, and other commitments.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_IfrsContractualObligation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">IFRS Contractual Obligation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_IfrsContractualObligation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contractual obligation amount</label>
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_FramePharmaceuticalsB.v.AmsterdamNetherlandsMember" xlink:label="cvac_FramePharmaceuticalsB.v.AmsterdamNetherlandsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_FramePharmaceuticalsB.v.AmsterdamNetherlandsMember" xlink:to="cvac_FramePharmaceuticalsB.v.AmsterdamNetherlandsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_FramePharmaceuticalsB.v.AmsterdamNetherlandsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to Frame Pharmaceuticals B.V., Amsterdam, Netherlands.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_FramePharmaceuticalsB.v.AmsterdamNetherlandsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Frame Pharmaceuticals B.V., Amsterdam, Netherlands</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="cvac_FramePharmaceuticalsB.v.AmsterdamNetherlandsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Frame Pharmaceuticals B.v.Amsterdam Netherlands</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RevenueOfAcquiree" xlink:label="ifrs-full_RevenueOfAcquiree" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RevenueOfAcquiree" xlink:to="ifrs-full_RevenueOfAcquiree_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_RevenueOfAcquiree_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue of acquiree since acquisition date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_RevenueOfAcquiree_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenues contributed to the consolidated result</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProfitLossOfAcquiree" xlink:label="ifrs-full_ProfitLossOfAcquiree" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProfitLossOfAcquiree" xlink:to="ifrs-full_ProfitLossOfAcquiree_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ProfitLossOfAcquiree_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Profit (loss) of acquiree since acquisition date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ProfitLossOfAcquiree_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loss contributed to the consolidated result</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RevenueOfCombinedEntity" xlink:label="ifrs-full_RevenueOfCombinedEntity" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RevenueOfCombinedEntity" xlink:to="ifrs-full_RevenueOfCombinedEntity_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_RevenueOfCombinedEntity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue of combined entity as if combination occurred at beginning of period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_RevenueOfCombinedEntity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue of combined entity as if combination occurred at beginning of period</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProfitLossOfCombinedEntity" xlink:label="ifrs-full_ProfitLossOfCombinedEntity" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProfitLossOfCombinedEntity" xlink:to="ifrs-full_ProfitLossOfCombinedEntity_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ProfitLossOfCombinedEntity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Profit (loss) of combined entity as if combination occurred at beginning of period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ProfitLossOfCombinedEntity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loss of combined entity as if combination occurred at beginning of period</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred" xlink:label="ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred" xlink:to="ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Consideration transferred, acquisition-date fair value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total purchase price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Consideration transferred</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_LiabilitiesIncurred" xlink:label="ifrs-full_LiabilitiesIncurred" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_LiabilitiesIncurred" xlink:to="ifrs-full_LiabilitiesIncurred_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_LiabilitiesIncurred_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities incurred</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_LiabilitiesIncurred_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net amount of discharging contractual obligations</label>
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_BusinessAcquisitionSigningSharePriceNumberOfTradingDaysConsidered" xlink:label="cvac_BusinessAcquisitionSigningSharePriceNumberOfTradingDaysConsidered" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_BusinessAcquisitionSigningSharePriceNumberOfTradingDaysConsidered" xlink:to="cvac_BusinessAcquisitionSigningSharePriceNumberOfTradingDaysConsidered_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_BusinessAcquisitionSigningSharePriceNumberOfTradingDaysConsidered_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of trading days over which the volume weighted average price is considered for determination of Signing Share Price under the business combination.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_BusinessAcquisitionSigningSharePriceNumberOfTradingDaysConsidered_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Business Acquisition, Signing Share Price, Number Of Trading Days Considered</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_BusinessAcquisitionSigningSharePriceNumberOfTradingDaysConsidered_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Signing Share Price, Number of trading days considered</label>
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_BusinessAcquisitionSigningSharePrice" xlink:label="cvac_BusinessAcquisitionSigningSharePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_BusinessAcquisitionSigningSharePrice" xlink:to="cvac_BusinessAcquisitionSigningSharePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_BusinessAcquisitionSigningSharePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The price at which the equity interests are to be issued under the business combination.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_BusinessAcquisitionSigningSharePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Business Acquisition, Signing Share Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_BusinessAcquisitionSigningSharePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Signing Share Price</label>
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_NumberOfPaymentsInWhichTotalConsiderationIsToBePaid" xlink:label="cvac_NumberOfPaymentsInWhichTotalConsiderationIsToBePaid" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_NumberOfPaymentsInWhichTotalConsiderationIsToBePaid" xlink:to="cvac_NumberOfPaymentsInWhichTotalConsiderationIsToBePaid_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_NumberOfPaymentsInWhichTotalConsiderationIsToBePaid_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of payments in which the total consideration is to be paid under the business combination.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_NumberOfPaymentsInWhichTotalConsiderationIsToBePaid_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number Of Payments In Which The Total Consideration Is To Be Paid</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_NumberOfPaymentsInWhichTotalConsiderationIsToBePaid_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of payments in which the total consideration is to be paid</label>
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_ContingentConsiderationNumberOfPaymentsConsidered" xlink:label="cvac_ContingentConsiderationNumberOfPaymentsConsidered" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_ContingentConsiderationNumberOfPaymentsConsidered" xlink:to="cvac_ContingentConsiderationNumberOfPaymentsConsidered_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_ContingentConsiderationNumberOfPaymentsConsidered_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of payments of total consideration under the business combination arrangement, that are subject to the achievement of defined milestones (contingent considerations).</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_ContingentConsiderationNumberOfPaymentsConsidered_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contingent Consideration, Number Of Payments Considered</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_ContingentConsiderationNumberOfPaymentsConsidered_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contingent consideration, Number of payments considered</label>
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_FirstPortionOfTotalConsiderationTransferredPercentage" xlink:label="cvac_FirstPortionOfTotalConsiderationTransferredPercentage" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_FirstPortionOfTotalConsiderationTransferredPercentage" xlink:to="cvac_FirstPortionOfTotalConsiderationTransferredPercentage_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_FirstPortionOfTotalConsiderationTransferredPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of first portion of total consideration transferred under the business combination.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_FirstPortionOfTotalConsiderationTransferredPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">First Portion Of Total Consideration Transferred, Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_FirstPortionOfTotalConsiderationTransferredPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">First portion of total consideration transferred, percentage</label>
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_FirstPortionOfTotalConsiderationTransferredAmount" xlink:label="cvac_FirstPortionOfTotalConsiderationTransferredAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_FirstPortionOfTotalConsiderationTransferredAmount" xlink:to="cvac_FirstPortionOfTotalConsiderationTransferredAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_FirstPortionOfTotalConsiderationTransferredAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of first portion of total consideration transferred under the business combination.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_FirstPortionOfTotalConsiderationTransferredAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">First Portion Of Total Consideration Transferred, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_FirstPortionOfTotalConsiderationTransferredAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">First portion of total consideration transferred, amount</label>
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_NumberOfInstrumentsOrInterestsIssuedOrIssuableAsConsiderationToFormerShareholders" xlink:label="cvac_NumberOfInstrumentsOrInterestsIssuedOrIssuableAsConsiderationToFormerShareholders" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_NumberOfInstrumentsOrInterestsIssuedOrIssuableAsConsiderationToFormerShareholders" xlink:to="cvac_NumberOfInstrumentsOrInterestsIssuedOrIssuableAsConsiderationToFormerShareholders_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_NumberOfInstrumentsOrInterestsIssuedOrIssuableAsConsiderationToFormerShareholders_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The number of instruments or interests issued or issuable at acquisition date for equity interests of the acquirer transferred as consideration to former shareholders in a business combination.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_NumberOfInstrumentsOrInterestsIssuedOrIssuableAsConsiderationToFormerShareholders_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number Of Instruments Or Interests Issued Or Issuable, As Consideration To Former Shareholders</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_NumberOfInstrumentsOrInterestsIssuedOrIssuableAsConsiderationToFormerShareholders_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance and transfer of shares to former Frame shareholders</label>
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_ValueOfInstrumentsOrInterestsIssuedOrIssuableAsConsiderationToFormerShareholders" xlink:label="cvac_ValueOfInstrumentsOrInterestsIssuedOrIssuableAsConsiderationToFormerShareholders" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_ValueOfInstrumentsOrInterestsIssuedOrIssuableAsConsiderationToFormerShareholders" xlink:to="cvac_ValueOfInstrumentsOrInterestsIssuedOrIssuableAsConsiderationToFormerShareholders_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_ValueOfInstrumentsOrInterestsIssuedOrIssuableAsConsiderationToFormerShareholders_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Value of instruments or interests issued or issuable at acquisition date for equity interests of the acquirer transferred as consideration to former shareholders in a business combination.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_ValueOfInstrumentsOrInterestsIssuedOrIssuableAsConsiderationToFormerShareholders_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Value Of Instruments Or Interests Issued Or Issuable, As Consideration To Former Shareholders</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_ValueOfInstrumentsOrInterestsIssuedOrIssuableAsConsiderationToFormerShareholders_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Value of shares issued to former Frame shareholders</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_EquityInterestsOfAcquirer" xlink:label="ifrs-full_EquityInterestsOfAcquirer" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EquityInterestsOfAcquirer" xlink:to="ifrs-full_EquityInterestsOfAcquirer_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_EquityInterestsOfAcquirer_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity interests of acquirer</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_EquityInterestsOfAcquirer_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Value of shares issued to former Frame shareholders</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_EquityInterestsOfAcquirer_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Value of aggregate consideration in shares</label>
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_NumberOfInstrumentsOrInterestIssuedOrIssuable" xlink:label="cvac_NumberOfInstrumentsOrInterestIssuedOrIssuable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_NumberOfInstrumentsOrInterestIssuedOrIssuable" xlink:to="cvac_NumberOfInstrumentsOrInterestIssuedOrIssuable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_NumberOfInstrumentsOrInterestIssuedOrIssuable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The number of instruments or interests issued or issuable at acquisition date for equity interests of the acquirer transferred as consideration to former shareholders in a business combination.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_NumberOfInstrumentsOrInterestIssuedOrIssuable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number Of Instruments Or Interest Issued Or Issuable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_NumberOfInstrumentsOrInterestIssuedOrIssuable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares transferred</label>
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_IfrsBusinessAcquisitionSharePrice" xlink:label="cvac_IfrsBusinessAcquisitionSharePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_IfrsBusinessAcquisitionSharePrice" xlink:to="cvac_IfrsBusinessAcquisitionSharePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_IfrsBusinessAcquisitionSharePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Price of a single share of a number of saleable stocks paid or offered to be paid in a business combination.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_IfrsBusinessAcquisitionSharePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ifrs Business Acquisition, Share Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_IfrsBusinessAcquisitionSharePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Closing Share Price</label>
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_NumberOfInstrumentsOrInterestsIssuedOrIssuableAsConsiderationForDischargingContractualObligations" xlink:label="cvac_NumberOfInstrumentsOrInterestsIssuedOrIssuableAsConsiderationForDischargingContractualObligations" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_NumberOfInstrumentsOrInterestsIssuedOrIssuableAsConsiderationForDischargingContractualObligations" xlink:to="cvac_NumberOfInstrumentsOrInterestsIssuedOrIssuableAsConsiderationForDischargingContractualObligations_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_NumberOfInstrumentsOrInterestsIssuedOrIssuableAsConsiderationForDischargingContractualObligations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The number of instruments or interests issued or issuable at acquisition date for equity interests of the acquirer transferred as consideration for discharging the contractual obligations for the outstanding advisory agreements in a business combination.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_NumberOfInstrumentsOrInterestsIssuedOrIssuableAsConsiderationForDischargingContractualObligations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number Of Instruments Or Interests Issued Or Issuable, As Consideration For Discharging Contractual Obligations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_NumberOfInstrumentsOrInterestsIssuedOrIssuableAsConsiderationForDischargingContractualObligations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance and transfer of shares as consideration for discharging the contractual obligations for the outstanding advisory agreements</label>
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_ValueOfInstrumentsOrInterestsIssuedOrIssuableAsConsiderationForDischargingContractualObligations" xlink:label="cvac_ValueOfInstrumentsOrInterestsIssuedOrIssuableAsConsiderationForDischargingContractualObligations" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_ValueOfInstrumentsOrInterestsIssuedOrIssuableAsConsiderationForDischargingContractualObligations" xlink:to="cvac_ValueOfInstrumentsOrInterestsIssuedOrIssuableAsConsiderationForDischargingContractualObligations_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_ValueOfInstrumentsOrInterestsIssuedOrIssuableAsConsiderationForDischargingContractualObligations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Value of instruments or interests issued or issuable at acquisition date for equity interests of the acquirer transferred as consideration for discharging the contractual obligations for the outstanding advisory agreements in a business combination.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_ValueOfInstrumentsOrInterestsIssuedOrIssuableAsConsiderationForDischargingContractualObligations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Value Of Instruments Or Interests Issued Or Issuable, As Consideration For Discharging Contractual Obligations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_ValueOfInstrumentsOrInterestsIssuedOrIssuableAsConsiderationForDischargingContractualObligations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Value of shares issued as consideration for discharging the contractual obligations for the outstanding advisory agreements</label>
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_StrikePriceForExistingShareBasedPayment" xlink:label="cvac_StrikePriceForExistingShareBasedPayment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_StrikePriceForExistingShareBasedPayment" xlink:to="cvac_StrikePriceForExistingShareBasedPayment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_StrikePriceForExistingShareBasedPayment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Strike price for existing share-based payment considered for payment of consideration under the business combination.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_StrikePriceForExistingShareBasedPayment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Strike Price For Existing Share-Based Payment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_StrikePriceForExistingShareBasedPayment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Strike price for existing share-based payment</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CashTransferred" xlink:label="ifrs-full_CashTransferred" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashTransferred" xlink:to="ifrs-full_CashTransferred_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CashTransferred_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash transferred</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_CashTransferred_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payment of consideration in cash and cash equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CashTransferred_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash payments</label>
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_CashTransferredForSettlementOfVestedEmployeeOptions" xlink:label="cvac_CashTransferredForSettlementOfVestedEmployeeOptions" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_CashTransferredForSettlementOfVestedEmployeeOptions" xlink:to="cvac_CashTransferredForSettlementOfVestedEmployeeOptions_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_CashTransferredForSettlementOfVestedEmployeeOptions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of cash transferred in a business combination for the settlement of the vested employee options.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_CashTransferredForSettlementOfVestedEmployeeOptions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash Transferred For The Settlement Of The Vested Employee Options</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_CashTransferredForSettlementOfVestedEmployeeOptions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Consideration paid in cash for the settlement of the vested employee options</label>
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_AdditionalCashTransferred" xlink:label="cvac_AdditionalCashTransferred" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_AdditionalCashTransferred" xlink:to="cvac_AdditionalCashTransferred_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_AdditionalCashTransferred_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The fair value, at acquisition date, of additional cash transferred as consideration in a business combination.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_AdditionalCashTransferred_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional Cash Transferred</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_AdditionalCashTransferred_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional cash consideration</label>
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_ContingentConsiderationPercentageOfTotalConsideration" xlink:label="cvac_ContingentConsiderationPercentageOfTotalConsideration" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_ContingentConsiderationPercentageOfTotalConsideration" xlink:to="cvac_ContingentConsiderationPercentageOfTotalConsideration_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_ContingentConsiderationPercentageOfTotalConsideration_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of total consideration transferred under the business combination, that are subject to the achievement of defined milestones (contingent considerations).</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_ContingentConsiderationPercentageOfTotalConsideration_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contingent Consideration, Percentage Of Total Consideration</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_ContingentConsiderationPercentageOfTotalConsideration_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contingent consideration, Percentage of total consideration</label>
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_ContingentConsiderationNumberOfMilestones" xlink:label="cvac_ContingentConsiderationNumberOfMilestones" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_ContingentConsiderationNumberOfMilestones" xlink:to="cvac_ContingentConsiderationNumberOfMilestones_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_ContingentConsiderationNumberOfMilestones_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of milestones to be achieved under the contingent consideration arrangement under the business combination.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_ContingentConsiderationNumberOfMilestones_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contingent Consideration, Number Of Milestones</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_ContingentConsiderationNumberOfMilestones_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contingent consideration, Number of milestones</label>
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_NumberOfInstrumentsOrInterestsIssuedOrIssuableUponAchievementOfFirstMilestone" xlink:label="cvac_NumberOfInstrumentsOrInterestsIssuedOrIssuableUponAchievementOfFirstMilestone" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_NumberOfInstrumentsOrInterestsIssuedOrIssuableUponAchievementOfFirstMilestone" xlink:to="cvac_NumberOfInstrumentsOrInterestsIssuedOrIssuableUponAchievementOfFirstMilestone_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_NumberOfInstrumentsOrInterestsIssuedOrIssuableUponAchievementOfFirstMilestone_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The number of instruments or interests issued or issuable at acquisition date for equity interests of the acquirer transferred as consideration upon the achievement of first milestone in a business combination.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_NumberOfInstrumentsOrInterestsIssuedOrIssuableUponAchievementOfFirstMilestone_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number Of Instruments Or Interests Issued Or Issuable, Upon Achievement Of First Milestone</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_NumberOfInstrumentsOrInterestsIssuedOrIssuableUponAchievementOfFirstMilestone_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of shares issued upon the achievement of the successful investigational new drug application filing</label>
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_PercentageOfConsiderationTransferredUponAchievementOfFirstMilestone" xlink:label="cvac_PercentageOfConsiderationTransferredUponAchievementOfFirstMilestone" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_PercentageOfConsiderationTransferredUponAchievementOfFirstMilestone" xlink:to="cvac_PercentageOfConsiderationTransferredUponAchievementOfFirstMilestone_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_PercentageOfConsiderationTransferredUponAchievementOfFirstMilestone_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of total consideration transferred under the business combination, upon the achievement of first milestone.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_PercentageOfConsiderationTransferredUponAchievementOfFirstMilestone_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage Of Consideration Transferred Upon Achievement Of First Milestone</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_PercentageOfConsiderationTransferredUponAchievementOfFirstMilestone_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of consideration transferred upon the achievement of the successful investigational new drug application filing</label>
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_ValueOfInstrumentsOrInterestsIssuedOrIssuableUponAchievementOfFirstMilestone" xlink:label="cvac_ValueOfInstrumentsOrInterestsIssuedOrIssuableUponAchievementOfFirstMilestone" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_ValueOfInstrumentsOrInterestsIssuedOrIssuableUponAchievementOfFirstMilestone" xlink:to="cvac_ValueOfInstrumentsOrInterestsIssuedOrIssuableUponAchievementOfFirstMilestone_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_ValueOfInstrumentsOrInterestsIssuedOrIssuableUponAchievementOfFirstMilestone_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Value of instruments or interests issued or issuable at acquisition date for equity interests of the acquirer transferred as consideration upon the achievement of first milestone in a business combination.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_ValueOfInstrumentsOrInterestsIssuedOrIssuableUponAchievementOfFirstMilestone_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Value Of Instruments Or Interests Issued Or Issuable, Upon Achievement Of First Milestone</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_ValueOfInstrumentsOrInterestsIssuedOrIssuableUponAchievementOfFirstMilestone_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Value of shares issued upon the achievement of the successful investigational new drug application filing</label>
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_NumberOfInstrumentsOrInterestsIssuedOrIssuableUponAchievementOfSecondMilestone" xlink:label="cvac_NumberOfInstrumentsOrInterestsIssuedOrIssuableUponAchievementOfSecondMilestone" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_NumberOfInstrumentsOrInterestsIssuedOrIssuableUponAchievementOfSecondMilestone" xlink:to="cvac_NumberOfInstrumentsOrInterestsIssuedOrIssuableUponAchievementOfSecondMilestone_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_NumberOfInstrumentsOrInterestsIssuedOrIssuableUponAchievementOfSecondMilestone_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The number of instruments or interests issued or issuable at acquisition date for equity interests of the acquirer transferred as consideration upon the achievement of second milestone in a business combination.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_NumberOfInstrumentsOrInterestsIssuedOrIssuableUponAchievementOfSecondMilestone_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number Of Instruments Or Interests Issued Or Issuable, Upon Achievement Of Second Milestone</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_NumberOfInstrumentsOrInterestsIssuedOrIssuableUponAchievementOfSecondMilestone_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of shares issued upon successful proof of mechanism in humans</label>
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_PercentageOfConsiderationTransferredUponAchievementOfSecondMilestone" xlink:label="cvac_PercentageOfConsiderationTransferredUponAchievementOfSecondMilestone" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_PercentageOfConsiderationTransferredUponAchievementOfSecondMilestone" xlink:to="cvac_PercentageOfConsiderationTransferredUponAchievementOfSecondMilestone_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_PercentageOfConsiderationTransferredUponAchievementOfSecondMilestone_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of total consideration transferred under the business combination, upon the achievement of second milestone.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_PercentageOfConsiderationTransferredUponAchievementOfSecondMilestone_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage Of Consideration Transferred Upon Achievement Of Second Milestone</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_PercentageOfConsiderationTransferredUponAchievementOfSecondMilestone_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of consideration transferred upon successful proof of mechanism in humans</label>
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_ValueOfInstrumentsOrInterestsIssuedOrIssuableUponAchievementOfSecondMilestone" xlink:label="cvac_ValueOfInstrumentsOrInterestsIssuedOrIssuableUponAchievementOfSecondMilestone" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_ValueOfInstrumentsOrInterestsIssuedOrIssuableUponAchievementOfSecondMilestone" xlink:to="cvac_ValueOfInstrumentsOrInterestsIssuedOrIssuableUponAchievementOfSecondMilestone_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_ValueOfInstrumentsOrInterestsIssuedOrIssuableUponAchievementOfSecondMilestone_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Value of instruments or interests issued or issuable at acquisition date for equity interests of the acquirer transferred as consideration upon the achievement of second milestone in a business combination.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_ValueOfInstrumentsOrInterestsIssuedOrIssuableUponAchievementOfSecondMilestone_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Value Of Instruments Or Interests Issued Or Issuable, Upon Achievement Of Second Milestone</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_ValueOfInstrumentsOrInterestsIssuedOrIssuableUponAchievementOfSecondMilestone_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Value of shares issued upon successful proof of mechanism in humans</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ContingentConsiderationRecognisedAsOfAcquisitionDate" xlink:label="ifrs-full_ContingentConsiderationRecognisedAsOfAcquisitionDate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ContingentConsiderationRecognisedAsOfAcquisitionDate" xlink:to="ifrs-full_ContingentConsiderationRecognisedAsOfAcquisitionDate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ContingentConsiderationRecognisedAsOfAcquisitionDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contingent consideration recognised as of acquisition date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_ContingentConsiderationRecognisedAsOfAcquisitionDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contingent consideration, fair value</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NumberOfInstrumentsOrInterestsIssuedOrIssuable" xlink:label="ifrs-full_NumberOfInstrumentsOrInterestsIssuedOrIssuable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfInstrumentsOrInterestsIssuedOrIssuable" xlink:to="ifrs-full_NumberOfInstrumentsOrInterestsIssuedOrIssuable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NumberOfInstrumentsOrInterestsIssuedOrIssuable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of instruments or interests issued or issuable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_NumberOfInstrumentsOrInterestsIssuedOrIssuable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Aggregate consideration in shares</label>
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_ContingentConsiderationMaximumSharesIssuable" xlink:label="cvac_ContingentConsiderationMaximumSharesIssuable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_ContingentConsiderationMaximumSharesIssuable" xlink:to="cvac_ContingentConsiderationMaximumSharesIssuable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_ContingentConsiderationMaximumSharesIssuable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum number of shares issuable as contingent consideration in a business combination.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_ContingentConsiderationMaximumSharesIssuable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contingent Consideration, Maximum Shares Issuable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_ContingentConsiderationMaximumSharesIssuable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contingent Consideration, Maximum shares issuable</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted" xlink:label="ifrs-full_WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted" xlink:to="ifrs-full_WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average fair value at measurement date, other equity instruments granted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total fair value of the RSU grant</label>
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_NumberOfTranchesForVestingOfInstrumentsGrantedInShareBasedPaymentArrangement" xlink:label="cvac_NumberOfTranchesForVestingOfInstrumentsGrantedInShareBasedPaymentArrangement" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_NumberOfTranchesForVestingOfInstrumentsGrantedInShareBasedPaymentArrangement" xlink:to="cvac_NumberOfTranchesForVestingOfInstrumentsGrantedInShareBasedPaymentArrangement_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_NumberOfTranchesForVestingOfInstrumentsGrantedInShareBasedPaymentArrangement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The number of tranches for vesting of instruments granted in a share-based payment arrangement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_NumberOfTranchesForVestingOfInstrumentsGrantedInShareBasedPaymentArrangement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number Of Tranches For Vesting Of Instruments Granted In Share-Based Payment Arrangement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_NumberOfTranchesForVestingOfInstrumentsGrantedInShareBasedPaymentArrangement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of tranches for vesting of RSUs granted</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AcquisitionrelatedCostsForTransactionRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombination" xlink:label="ifrs-full_AcquisitionrelatedCostsForTransactionRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombination" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AcquisitionrelatedCostsForTransactionRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombination" xlink:to="ifrs-full_AcquisitionrelatedCostsForTransactionRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombination_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AcquisitionrelatedCostsForTransactionRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombination_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Acquisition-related costs for transaction recognised separately from acquisition of assets and assumption of liabilities in business combination</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_AcquisitionrelatedCostsForTransactionRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombination_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Transaction costs of the acquisition (included in cash flows from operating activities)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_AcquisitionrelatedCostsForTransactionRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombination_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Transactions costs</label>
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_ProvisionalFairValue" xlink:label="cvac_ProvisionalFairValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_ProvisionalFairValue" xlink:to="cvac_ProvisionalFairValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_ProvisionalFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of provisional fair value.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_ProvisionalFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Provisional Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_ProvisionalFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Provisional fair value</label>
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_FairValueOfTotalConsiderationTransferred" xlink:label="cvac_FairValueOfTotalConsiderationTransferred" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_FairValueOfTotalConsiderationTransferred" xlink:to="cvac_FairValueOfTotalConsiderationTransferred_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_FairValueOfTotalConsiderationTransferred_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of fair value of total consideration transferred.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_FairValueOfTotalConsiderationTransferred_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Of Total Consideration Transferred</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_FairValueOfTotalConsiderationTransferred_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of fair value</label>
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_SigningSharePriceRepresenting10" xlink:label="cvac_SigningSharePriceRepresenting10" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_SigningSharePriceRepresenting10" xlink:to="cvac_SigningSharePriceRepresenting10_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_SigningSharePriceRepresenting10_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount represents of signing share price representing 10%.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_SigningSharePriceRepresenting10_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Signing Share Price Representing 10%</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_SigningSharePriceRepresenting10_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Signing share price representing 10%</label>
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_SigningSharePriceRepresenting40" xlink:label="cvac_SigningSharePriceRepresenting40" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_SigningSharePriceRepresenting40" xlink:to="cvac_SigningSharePriceRepresenting40_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_SigningSharePriceRepresenting40_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount represents of signing share price representing 40%.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_SigningSharePriceRepresenting40_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Signing Share Price Representing 40%</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_SigningSharePriceRepresenting40_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Signing share price representing 40%</label>
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_ClosingSharePriceRepresentingTotalFairValue" xlink:label="cvac_ClosingSharePriceRepresentingTotalFairValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_ClosingSharePriceRepresentingTotalFairValue" xlink:to="cvac_ClosingSharePriceRepresentingTotalFairValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_ClosingSharePriceRepresentingTotalFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount represents of closing share price representing total fair value.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_ClosingSharePriceRepresentingTotalFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Closing Share Price Representing Total Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_ClosingSharePriceRepresentingTotalFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Closing share price representing total fair value</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NoncurrentAssetsRecognisedAsOfAcquisitionDate" xlink:label="ifrs-full_NoncurrentAssetsRecognisedAsOfAcquisitionDate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncurrentAssetsRecognisedAsOfAcquisitionDate" xlink:to="ifrs-full_NoncurrentAssetsRecognisedAsOfAcquisitionDate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NoncurrentAssetsRecognisedAsOfAcquisitionDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non-current assets recognised as of acquisition date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_NoncurrentAssetsRecognisedAsOfAcquisitionDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non-current assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDate" xlink:label="ifrs-full_PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDate" xlink:to="ifrs-full_PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, plant and equipment recognised as of acquisition date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, plant and equipment</label>
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_RightOfUseAssetsRecognisedAsOfAcquisitionDate" xlink:label="cvac_RightOfUseAssetsRecognisedAsOfAcquisitionDate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_RightOfUseAssetsRecognisedAsOfAcquisitionDate" xlink:to="cvac_RightOfUseAssetsRecognisedAsOfAcquisitionDate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_RightOfUseAssetsRecognisedAsOfAcquisitionDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount recognised as of the acquisition date for right-of-use assets assumed in a business combination.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_RightOfUseAssetsRecognisedAsOfAcquisitionDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Right Of Use Assets Recognised As Of Acquisition Date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_RightOfUseAssetsRecognisedAsOfAcquisitionDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Right-of-use assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TechnologybasedIntangibleAssetsRecognisedAsOfAcquisitionDate" xlink:label="ifrs-full_TechnologybasedIntangibleAssetsRecognisedAsOfAcquisitionDate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TechnologybasedIntangibleAssetsRecognisedAsOfAcquisitionDate" xlink:to="ifrs-full_TechnologybasedIntangibleAssetsRecognisedAsOfAcquisitionDate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TechnologybasedIntangibleAssetsRecognisedAsOfAcquisitionDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Technology-based intangible assets recognised as of acquisition date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_TechnologybasedIntangibleAssetsRecognisedAsOfAcquisitionDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Intangible assets (Technology)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CurrentAssetsRecognisedAsOfAcquisitionDate" xlink:label="ifrs-full_CurrentAssetsRecognisedAsOfAcquisitionDate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentAssetsRecognisedAsOfAcquisitionDate" xlink:to="ifrs-full_CurrentAssetsRecognisedAsOfAcquisitionDate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentAssetsRecognisedAsOfAcquisitionDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current assets recognised as of acquisition date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_CurrentAssetsRecognisedAsOfAcquisitionDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_FairValueOfAcquiredReceivables" xlink:label="ifrs-full_FairValueOfAcquiredReceivables" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FairValueOfAcquiredReceivables" xlink:to="ifrs-full_FairValueOfAcquiredReceivables_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_FairValueOfAcquiredReceivables_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair value of acquired receivables</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_FairValueOfAcquiredReceivables_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Trade and other receivables</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CashAndCashEquivalentsRecognisedAsOfAcquisitionDate" xlink:label="ifrs-full_CashAndCashEquivalentsRecognisedAsOfAcquisitionDate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashAndCashEquivalentsRecognisedAsOfAcquisitionDate" xlink:to="ifrs-full_CashAndCashEquivalentsRecognisedAsOfAcquisitionDate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CashAndCashEquivalentsRecognisedAsOfAcquisitionDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and cash equivalents recognised as of acquisition date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CashAndCashEquivalentsRecognisedAsOfAcquisitionDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash acquired with the subsidiary (included in cash flows from investing activities)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_CashAndCashEquivalentsRecognisedAsOfAcquisitionDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and cash equivalents</label>
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_TotalAssetsRecognisedAsOfAcquisitionDate" xlink:label="cvac_TotalAssetsRecognisedAsOfAcquisitionDate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_TotalAssetsRecognisedAsOfAcquisitionDate" xlink:to="cvac_TotalAssetsRecognisedAsOfAcquisitionDate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_TotalAssetsRecognisedAsOfAcquisitionDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount recognised as of the acquisition date for total assets assumed in a business combination.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_TotalAssetsRecognisedAsOfAcquisitionDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total Assets Recognised As Of Acquisition Date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="cvac_TotalAssetsRecognisedAsOfAcquisitionDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NoncurrentLiabilitiesRecognisedAsOfAcquisitionDate" xlink:label="ifrs-full_NoncurrentLiabilitiesRecognisedAsOfAcquisitionDate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncurrentLiabilitiesRecognisedAsOfAcquisitionDate" xlink:to="ifrs-full_NoncurrentLiabilitiesRecognisedAsOfAcquisitionDate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NoncurrentLiabilitiesRecognisedAsOfAcquisitionDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non-current liabilities recognised as of acquisition date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_NoncurrentLiabilitiesRecognisedAsOfAcquisitionDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non-current liabilities</label>
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_NoncurrentLeaseLiabilitiesRecognisedAsOfAcquisitionDate" xlink:label="cvac_NoncurrentLeaseLiabilitiesRecognisedAsOfAcquisitionDate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_NoncurrentLeaseLiabilitiesRecognisedAsOfAcquisitionDate" xlink:to="cvac_NoncurrentLeaseLiabilitiesRecognisedAsOfAcquisitionDate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_NoncurrentLeaseLiabilitiesRecognisedAsOfAcquisitionDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount recognised as of the acquisition date for non-current lease liabilities assumed in a business combination.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_NoncurrentLeaseLiabilitiesRecognisedAsOfAcquisitionDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Noncurrent Lease Liabilities Recognised As Of Acquisition Date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_NoncurrentLeaseLiabilitiesRecognisedAsOfAcquisitionDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lease liabilities</label>
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_NetDeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate" xlink:label="cvac_NetDeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_NetDeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate" xlink:to="cvac_NetDeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_NetDeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount recognised as of the acquisition date for deferred tax liabilities net of deferred tax assets assumed in a business combination.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_NetDeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Deferred Tax Liabilities Recognised As Of Acquisition Date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_NetDeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred tax liabilities (net of deferred tax assets)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CurrentLiabilitiesRecognisedAsOfAcquisitionDate" xlink:label="ifrs-full_CurrentLiabilitiesRecognisedAsOfAcquisitionDate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentLiabilitiesRecognisedAsOfAcquisitionDate" xlink:to="ifrs-full_CurrentLiabilitiesRecognisedAsOfAcquisitionDate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentLiabilitiesRecognisedAsOfAcquisitionDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current liabilities recognised as of acquisition date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_CurrentLiabilitiesRecognisedAsOfAcquisitionDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current liabilities</label>
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_CurrentLeaseLiabilitiesRecognisedAsOfAcquisitionDate" xlink:label="cvac_CurrentLeaseLiabilitiesRecognisedAsOfAcquisitionDate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_CurrentLeaseLiabilitiesRecognisedAsOfAcquisitionDate" xlink:to="cvac_CurrentLeaseLiabilitiesRecognisedAsOfAcquisitionDate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_CurrentLeaseLiabilitiesRecognisedAsOfAcquisitionDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount recognised as of the acquisition date for current lease liabilities assumed in a business combination.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_CurrentLeaseLiabilitiesRecognisedAsOfAcquisitionDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current Lease Liabilities Recognised As Of Acquisition Date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_CurrentLeaseLiabilitiesRecognisedAsOfAcquisitionDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lease liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TradeAndOtherPayablesRecognisedAsOfAcquisitionDate" xlink:label="ifrs-full_TradeAndOtherPayablesRecognisedAsOfAcquisitionDate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TradeAndOtherPayablesRecognisedAsOfAcquisitionDate" xlink:to="ifrs-full_TradeAndOtherPayablesRecognisedAsOfAcquisitionDate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TradeAndOtherPayablesRecognisedAsOfAcquisitionDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Trade and other payables recognised as of acquisition date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_TradeAndOtherPayablesRecognisedAsOfAcquisitionDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts Payables</label>
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_OtherCurrentLiabilitiesRecognisedAsOfAcquisitionDate" xlink:label="cvac_OtherCurrentLiabilitiesRecognisedAsOfAcquisitionDate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_OtherCurrentLiabilitiesRecognisedAsOfAcquisitionDate" xlink:to="cvac_OtherCurrentLiabilitiesRecognisedAsOfAcquisitionDate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_OtherCurrentLiabilitiesRecognisedAsOfAcquisitionDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount recognised as of the acquisition date for other liabilities assumed in a business combination.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_OtherCurrentLiabilitiesRecognisedAsOfAcquisitionDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Current Liabilities Recognised As Of Acquisition Date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_OtherCurrentLiabilitiesRecognisedAsOfAcquisitionDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other current liabilities</label>
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_LiabilitiesRecognisedAsOfAcquisitionDate" xlink:label="cvac_LiabilitiesRecognisedAsOfAcquisitionDate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_LiabilitiesRecognisedAsOfAcquisitionDate" xlink:to="cvac_LiabilitiesRecognisedAsOfAcquisitionDate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_LiabilitiesRecognisedAsOfAcquisitionDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount recognised as of the acquisition date for total liabilities assumed in a business combination.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_LiabilitiesRecognisedAsOfAcquisitionDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities Recognised As Of Acquisition Date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="cvac_LiabilitiesRecognisedAsOfAcquisitionDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed" xlink:label="ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed" xlink:to="ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Identifiable assets acquired (liabilities assumed)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Assets acquired</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net assets acquired</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate" xlink:label="ifrs-full_DeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate" xlink:to="ifrs-full_DeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred tax liabilities recognised as of acquisition date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred tax liabilities arising on taxable temporary differences</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DeferredTaxAssetsRecognisedAsOfAcquisitionDate" xlink:label="ifrs-full_DeferredTaxAssetsRecognisedAsOfAcquisitionDate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DeferredTaxAssetsRecognisedAsOfAcquisitionDate" xlink:to="ifrs-full_DeferredTaxAssetsRecognisedAsOfAcquisitionDate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DeferredTaxAssetsRecognisedAsOfAcquisitionDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred tax assets recognised as of acquisition date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DeferredTaxAssetsRecognisedAsOfAcquisitionDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred tax assets arising mainly from tax loss carry forwards</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised" xlink:label="ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised" xlink:to="ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unused tax losses for which no deferred tax asset recognised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tax loss carry forwards</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_GoodwillRecognisedAsOfAcquisitionDate" xlink:label="ifrs-full_GoodwillRecognisedAsOfAcquisitionDate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_GoodwillRecognisedAsOfAcquisitionDate" xlink:to="ifrs-full_GoodwillRecognisedAsOfAcquisitionDate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_GoodwillRecognisedAsOfAcquisitionDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Goodwill recognised as of acquisition date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="ifrs-full_GoodwillRecognisedAsOfAcquisitionDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preliminary Goodwill</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities" xlink:label="ifrs-full_CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities" xlink:to="ifrs-full_CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash flows used in obtaining control of subsidiaries or other businesses, classified as investing activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Included in cash flows from investing activities</label>
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_IfrsCashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities" xlink:label="cvac_IfrsCashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_IfrsCashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities" xlink:to="cvac_IfrsCashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_IfrsCashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The aggregate cash flows used in obtaining control of subsidiaries or other businesses, classified as investing activities. [Refer: Subsidiaries [member]]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_IfrsCashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">IFRS Cash Flows Used In Obtaining Control Of Subsidiaries Or Other Businesses Classified As Investing Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="cvac_IfrsCashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Included in cash flows from investing activities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OtherCurrentFinancialLiabilities" xlink:label="ifrs-full_OtherCurrentFinancialLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherCurrentFinancialLiabilities" xlink:to="ifrs-full_OtherCurrentFinancialLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherCurrentFinancialLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other current financial liabilities</label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>10
<FILENAME>cvac-20220930_pre.xml
<DESCRIPTION>EX-101.PRE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  10.1.0.3 -->
<!--Based on XBRL 2.1-->
<!--Created on: 11/17/2022 10:28:01 PM-->
<!--Modified on: 11/17/2022 10:28:01 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink">
  <roleRef xlink:type="simple" xlink:href="cvac-20220930.xsd#DocumentDocumentAndEntityInformation" roleURI="http://www.curevac.com/role/DocumentDocumentAndEntityInformation" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20220930.xsd#StatementInterimCondensedConsolidatedStatementsOfOperationsAndOtherComprehensiveIncomeLoss" roleURI="http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfOperationsAndOtherComprehensiveIncomeLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20220930.xsd#StatementInterimCondensedConsolidatedStatementsOfFinancialPosition" roleURI="http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20220930.xsd#StatementInterimCondensedConsolidatedStatementsOfChangesInShareholdersEquity" roleURI="http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfChangesInShareholdersEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20220930.xsd#StatementInterimCondensedConsolidatedStatementsOfCashFlows" roleURI="http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20220930.xsd#DisclosureCorporateInformation" roleURI="http://www.curevac.com/role/DisclosureCorporateInformation" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20220930.xsd#DisclosureBasisOfPreparation" roleURI="http://www.curevac.com/role/DisclosureBasisOfPreparation" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20220930.xsd#DisclosureNotesToConsolidatedFinancialStatements" roleURI="http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatements" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20220930.xsd#DisclosureIssuedCapitalAndReserves" roleURI="http://www.curevac.com/role/DisclosureIssuedCapitalAndReserves" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20220930.xsd#DisclosureShareBasedPayments" roleURI="http://www.curevac.com/role/DisclosureShareBasedPayments" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20220930.xsd#DisclosureFixedAssets" roleURI="http://www.curevac.com/role/DisclosureFixedAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20220930.xsd#DisclosureAssetsHeldForSale" roleURI="http://www.curevac.com/role/DisclosureAssetsHeldForSale" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20220930.xsd#DisclosureInventories" roleURI="http://www.curevac.com/role/DisclosureInventories" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20220930.xsd#DisclosurePrepaidExpensesAndOtherAssetsCurrent" roleURI="http://www.curevac.com/role/DisclosurePrepaidExpensesAndOtherAssetsCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20220930.xsd#DisclosureFinancialAssetsAndFinancialLiabilities" roleURI="http://www.curevac.com/role/DisclosureFinancialAssetsAndFinancialLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20220930.xsd#DisclosureTradeAndOtherPayables" roleURI="http://www.curevac.com/role/DisclosureTradeAndOtherPayables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20220930.xsd#DisclosureOtherLiabilities" roleURI="http://www.curevac.com/role/DisclosureOtherLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20220930.xsd#DisclosureLoans" roleURI="http://www.curevac.com/role/DisclosureLoans" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20220930.xsd#DisclosureIncomeTax" roleURI="http://www.curevac.com/role/DisclosureIncomeTax" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20220930.xsd#DisclosureDisclosureOfFinancialInstrumentsAndRiskManagement" roleURI="http://www.curevac.com/role/DisclosureDisclosureOfFinancialInstrumentsAndRiskManagement" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20220930.xsd#DisclosureEarningsPerShare" roleURI="http://www.curevac.com/role/DisclosureEarningsPerShare" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20220930.xsd#DisclosureRelatedPartyDisclosures" roleURI="http://www.curevac.com/role/DisclosureRelatedPartyDisclosures" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20220930.xsd#DisclosureSignificantTransactionsAndEvents" roleURI="http://www.curevac.com/role/DisclosureSignificantTransactionsAndEvents" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20220930.xsd#DisclosureSubsequentEvents" roleURI="http://www.curevac.com/role/DisclosureSubsequentEvents" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20220930.xsd#DisclosureBasisOfPreparationPolicies" roleURI="http://www.curevac.com/role/DisclosureBasisOfPreparationPolicies" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20220930.xsd#DisclosureNotesToConsolidatedFinancialStatementsTables" roleURI="http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20220930.xsd#DisclosureIssuedCapitalAndReservesTables" roleURI="http://www.curevac.com/role/DisclosureIssuedCapitalAndReservesTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20220930.xsd#DisclosureShareBasedPaymentsTables" roleURI="http://www.curevac.com/role/DisclosureShareBasedPaymentsTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20220930.xsd#DisclosureSignificantTransactionsAndEventsTables" roleURI="http://www.curevac.com/role/DisclosureSignificantTransactionsAndEventsTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20220930.xsd#DisclosureCorporateInformationDetails" roleURI="http://www.curevac.com/role/DisclosureCorporateInformationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20220930.xsd#DisclosureNotesToConsolidatedFinancialStatementsRevenueFromContractWithCustomersDetails" roleURI="http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsRevenueFromContractWithCustomersDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20220930.xsd#DisclosureNotesToConsolidatedFinancialStatementsSummaryOfUpfrontPaymentsAndRelatedRevenuesRecognizedDetails" roleURI="http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsSummaryOfUpfrontPaymentsAndRelatedRevenuesRecognizedDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20220930.xsd#DisclosureNotesToConsolidatedFinancialStatementsContractLiabilitiesAllocatedToRemainingPerformanceObligationsDetails" roleURI="http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsContractLiabilitiesAllocatedToRemainingPerformanceObligationsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20220930.xsd#DisclosureNotesToConsolidatedFinancialStatementsCostOfSalesDetails" roleURI="http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsCostOfSalesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20220930.xsd#DisclosureNotesToConsolidatedFinancialStatementsSellingAndDistributionExpensesDetails" roleURI="http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsSellingAndDistributionExpensesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20220930.xsd#DisclosureNotesToConsolidatedFinancialStatementsResearchAndDevelopmentExpensesDetails" roleURI="http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsResearchAndDevelopmentExpensesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20220930.xsd#DisclosureNotesToConsolidatedFinancialStatementsGeneralAndAdministrativeExpensesDetails" roleURI="http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsGeneralAndAdministrativeExpensesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20220930.xsd#DisclosureNotesToConsolidatedFinancialStatementsOtherOperatingIncomeDetails" roleURI="http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsOtherOperatingIncomeDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20220930.xsd#DisclosureNotesToConsolidatedFinancialStatementsGrantsWithGovernmentAgenciesAndSimilarBodiesDetails" roleURI="http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsGrantsWithGovernmentAgenciesAndSimilarBodiesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20220930.xsd#DisclosureIssuedCapitalAndReservesOverviewAndGeneralRemarksDetails" roleURI="http://www.curevac.com/role/DisclosureIssuedCapitalAndReservesOverviewAndGeneralRemarksDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20220930.xsd#DisclosureIssuedCapitalAndReservesImpactOfShareSplitDetails" roleURI="http://www.curevac.com/role/DisclosureIssuedCapitalAndReservesImpactOfShareSplitDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20220930.xsd#DisclosureShareBasedPaymentsExpensesDetails" roleURI="http://www.curevac.com/role/DisclosureShareBasedPaymentsExpensesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20220930.xsd#DisclosureShareBasedPaymentsExpenseRecognizedForProgramDetails" roleURI="http://www.curevac.com/role/DisclosureShareBasedPaymentsExpenseRecognizedForProgramDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20220930.xsd#DisclosureShareBasedPaymentsDetails" roleURI="http://www.curevac.com/role/DisclosureShareBasedPaymentsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20220930.xsd#DisclosureFixedAssetsIntangibleAssetsDetails" roleURI="http://www.curevac.com/role/DisclosureFixedAssetsIntangibleAssetsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20220930.xsd#DisclosureFixedAssetsPropertyPlantAndEquipmentDetails" roleURI="http://www.curevac.com/role/DisclosureFixedAssetsPropertyPlantAndEquipmentDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20220930.xsd#DisclosureAssetsHeldForSaleDetails" roleURI="http://www.curevac.com/role/DisclosureAssetsHeldForSaleDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20220930.xsd#DisclosureInventoriesDetails" roleURI="http://www.curevac.com/role/DisclosureInventoriesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20220930.xsd#DisclosurePrepaidExpensesAndOtherAssetsCurrentDetails" roleURI="http://www.curevac.com/role/DisclosurePrepaidExpensesAndOtherAssetsCurrentDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20220930.xsd#DisclosureFinancialAssetsAndFinancialLiabilitiesDetails" roleURI="http://www.curevac.com/role/DisclosureFinancialAssetsAndFinancialLiabilitiesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20220930.xsd#DisclosureTradeAndOtherPayablesDetails" roleURI="http://www.curevac.com/role/DisclosureTradeAndOtherPayablesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20220930.xsd#DisclosureOtherLiabilitiesDetails" roleURI="http://www.curevac.com/role/DisclosureOtherLiabilitiesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20220930.xsd#DisclosureLoansDetails" roleURI="http://www.curevac.com/role/DisclosureLoansDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20220930.xsd#DisclosureIncomeTaxDetails" roleURI="http://www.curevac.com/role/DisclosureIncomeTaxDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20220930.xsd#DisclosureDisclosureOfFinancialInstrumentsAndRiskManagementDetails" roleURI="http://www.curevac.com/role/DisclosureDisclosureOfFinancialInstrumentsAndRiskManagementDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20220930.xsd#DisclosureEarningsPerShareDetails" roleURI="http://www.curevac.com/role/DisclosureEarningsPerShareDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20220930.xsd#DisclosureRelatedPartyDisclosuresDetails" roleURI="http://www.curevac.com/role/DisclosureRelatedPartyDisclosuresDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20220930.xsd#DisclosureSignificantTransactionsAndEventsDetails" roleURI="http://www.curevac.com/role/DisclosureSignificantTransactionsAndEventsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20220930.xsd#DisclosureSignificantTransactionsAndEventsFrameAcquisitionPurchasePriceAllocationDetails" roleURI="http://www.curevac.com/role/DisclosureSignificantTransactionsAndEventsFrameAcquisitionPurchasePriceAllocationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20220930.xsd#DisclosureSignificantTransactionsAndEventsGoodwillRecognizedOnFrameAcquisitionDetails" roleURI="http://www.curevac.com/role/DisclosureSignificantTransactionsAndEventsGoodwillRecognizedOnFrameAcquisitionDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20220930.xsd#DisclosureSignificantTransactionsAndEventsAnalysesOfCashFlowsOnFrameAcquisitionDetails" roleURI="http://www.curevac.com/role/DisclosureSignificantTransactionsAndEventsAnalysesOfCashFlowsOnFrameAcquisitionDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" />
  <presentationLink xlink:role="http://www.curevac.com/role/DocumentDocumentAndEntityInformation" xlink:type="extended" xlink:title="00090 - Document - Document and Entity Information" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract" xlink:label="CoverAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable_638043208768719495" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_DocumentInformationTable_638043208768719495" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressesAddressTypeAxis" xlink:label="dei_EntityAddressesAddressTypeAxis_638043208768719495" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable_638043208768719495" xlink:to="dei_EntityAddressesAddressTypeAxis_638043208768719495" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AddressTypeDomain" xlink:label="dei_AddressTypeDomain_638043208768719495" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityAddressesAddressTypeAxis_638043208768719495" xlink:to="dei_AddressTypeDomain_638043208768719495" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_BusinessContactMember" xlink:label="dei_BusinessContactMember_638043208768719495" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_AddressTypeDomain_638043208768719495" xlink:to="dei_BusinessContactMember_638043208768719495" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems_638043208768719495" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable_638043208768719495" xlink:to="dei_DocumentInformationLineItems_638043208768719495" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType" xlink:label="dei_DocumentType_638043208768719495" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_638043208768719495" xlink:to="dei_DocumentType_638043208768719495" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement_638043208768729498" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_638043208768719495" xlink:to="dei_DocumentRegistrationStatement_638043208768729498" order="2" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport_638043208768729498" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_638043208768719495" xlink:to="dei_DocumentAnnualReport_638043208768729498" order="3" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport_638043208768729498" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_638043208768719495" xlink:to="dei_DocumentTransitionReport_638043208768729498" order="4" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport_638043208768729498" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_638043208768719495" xlink:to="dei_DocumentShellCompanyReport_638043208768729498" order="5" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName_638043208768729498" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_638043208768719495" xlink:to="dei_EntityRegistrantName_638043208768729498" order="6" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate_638043208768729498" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_638043208768719495" xlink:to="dei_DocumentPeriodEndDate_638043208768729498" order="7" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode_638043208768729498" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_638043208768719495" xlink:to="dei_EntityIncorporationStateCountryCode_638043208768729498" order="8" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1_638043208768729498" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_638043208768719495" xlink:to="dei_EntityAddressAddressLine1_638043208768729498" order="9" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2_638043208768729498" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_638043208768719495" xlink:to="dei_EntityAddressAddressLine2_638043208768729498" order="10" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown_638043208768729498" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_638043208768719495" xlink:to="dei_EntityAddressCityOrTown_638043208768729498" order="11" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince_638043208768729498" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_638043208768719495" xlink:to="dei_EntityAddressStateOrProvince_638043208768729498" order="12" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry_638043208768729498" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_638043208768719495" xlink:to="dei_EntityAddressCountry_638043208768729498" order="13" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode_638043208768739494" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_638043208768719495" xlink:to="dei_EntityAddressPostalZipCode_638043208768739494" order="14" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode_638043208768739494" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_638043208768719495" xlink:to="dei_CityAreaCode_638043208768739494" order="15" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber_638043208768739494" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_638043208768719495" xlink:to="dei_LocalPhoneNumber_638043208768739494" order="16" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_ContactPersonnelName" xlink:label="dei_ContactPersonnelName_638043208768739494" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_638043208768719495" xlink:to="dei_ContactPersonnelName_638043208768739494" order="17" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion_638043208768739494" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_638043208768719495" xlink:to="dei_CountryRegion_638043208768739494" order="18" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_ContactPersonnelEmailAddress" xlink:label="dei_ContactPersonnelEmailAddress_638043208768739494" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_638043208768719495" xlink:to="dei_ContactPersonnelEmailAddress_638043208768739494" order="19" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle_638043208768739494" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_638043208768719495" xlink:to="dei_Security12bTitle_638043208768739494" order="20" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol_638043208768739494" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_638043208768719495" xlink:to="dei_TradingSymbol_638043208768739494" order="21" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName_638043208768739494" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_638043208768719495" xlink:to="dei_SecurityExchangeName_638043208768739494" order="22" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber_638043208768749494" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_638043208768719495" xlink:to="dei_EntityFileNumber_638043208768749494" order="23" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer_638043208768749494" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_638043208768719495" xlink:to="dei_EntityWellKnownSeasonedIssuer_638043208768749494" order="24" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus_638043208768749494" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_638043208768719495" xlink:to="dei_EntityCurrentReportingStatus_638043208768749494" order="25" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory_638043208768749494" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_638043208768719495" xlink:to="dei_EntityFilerCategory_638043208768749494" order="26" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent_638043208768749494" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_638043208768719495" xlink:to="dei_EntityInteractiveDataCurrent_638043208768749494" order="27" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany_638043208768749494" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_638043208768719495" xlink:to="dei_EntityEmergingGrowthCompany_638043208768749494" order="28" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod_638043208768749494" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_638043208768719495" xlink:to="dei_EntityExTransitionPeriod_638043208768749494" order="29" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard_638043208768749494" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_638043208768719495" xlink:to="dei_DocumentAccountingStandard_638043208768749494" order="30" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany_638043208768759496" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_638043208768719495" xlink:to="dei_EntityShellCompany_638043208768759496" order="31" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding_638043208768759496" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_638043208768719495" xlink:to="dei_EntityCommonStockSharesOutstanding_638043208768759496" order="32" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate_638043208768759496" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_638043208768719495" xlink:to="dei_CurrentFiscalYearEndDate_638043208768759496" order="33" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus_638043208768759496" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_638043208768719495" xlink:to="dei_DocumentFiscalYearFocus_638043208768759496" order="34" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus_638043208768759496" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_638043208768719495" xlink:to="dei_DocumentFiscalPeriodFocus_638043208768759496" order="35" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey_638043208768759496" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_638043208768719495" xlink:to="dei_EntityCentralIndexKey_638043208768759496" order="36" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag_638043208768759496" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_638043208768719495" xlink:to="dei_AmendmentFlag_638043208768759496" order="37" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag_638043208768769495" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_638043208768719495" xlink:to="dei_IcfrAuditorAttestationFlag_638043208768769495" order="38" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription_638043208768769495" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_638043208768719495" xlink:to="dei_AmendmentDescription_638043208768769495" order="39" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers_638043208768769495" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_638043208768719495" xlink:to="dei_EntityVoluntaryFilers_638043208768769495" order="40" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat_638043208768769495" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_638043208768719495" xlink:to="dei_EntityPublicFloat_638043208768769495" order="41" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorName" xlink:label="dei_AuditorName_638043208768769495" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_638043208768719495" xlink:to="dei_AuditorName_638043208768769495" order="42" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId_638043208768769495" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_638043208768719495" xlink:to="dei_AuditorFirmId_638043208768769495" order="43" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation_638043208768779503" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_638043208768719495" xlink:to="dei_AuditorLocation_638043208768779503" order="44" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfOperationsAndOtherComprehensiveIncomeLoss" xlink:type="extended" xlink:title="00100 - Statement - Interim Condensed Consolidated Statements of Operations and Other Comprehensive Income (Loss)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_StatementOfComprehensiveIncomeAbstract" xlink:label="StatementOfComprehensiveIncomeAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RevenueFromContractsWithCustomers" xlink:label="ifrs-full_RevenueFromContractsWithCustomers_638043208768779503" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfComprehensiveIncomeAbstract" xlink:to="ifrs-full_RevenueFromContractsWithCustomers_638043208768779503" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CostOfSales" xlink:label="ifrs-full_CostOfSales_638043208768779503" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfComprehensiveIncomeAbstract" xlink:to="ifrs-full_CostOfSales_638043208768779503" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_SalesAndMarketingExpense" xlink:label="ifrs-full_SalesAndMarketingExpense_638043208768779503" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfComprehensiveIncomeAbstract" xlink:to="ifrs-full_SalesAndMarketingExpense_638043208768779503" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ResearchAndDevelopmentExpense" xlink:label="ifrs-full_ResearchAndDevelopmentExpense_638043208768779503" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfComprehensiveIncomeAbstract" xlink:to="ifrs-full_ResearchAndDevelopmentExpense_638043208768779503" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_GeneralAndAdministrativeExpense" xlink:label="ifrs-full_GeneralAndAdministrativeExpense_638043208768779503" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfComprehensiveIncomeAbstract" xlink:to="ifrs-full_GeneralAndAdministrativeExpense_638043208768779503" order="5" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_MiscellaneousOtherOperatingIncome" xlink:label="ifrs-full_MiscellaneousOtherOperatingIncome_638043208768779503" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfComprehensiveIncomeAbstract" xlink:to="ifrs-full_MiscellaneousOtherOperatingIncome_638043208768779503" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_MiscellaneousOtherOperatingExpense" xlink:label="ifrs-full_MiscellaneousOtherOperatingExpense_638043208768779503" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfComprehensiveIncomeAbstract" xlink:to="ifrs-full_MiscellaneousOtherOperatingExpense_638043208768779503" order="7" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProfitLossFromOperatingActivities" xlink:label="ifrs-full_ProfitLossFromOperatingActivities_638043208768789504" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfComprehensiveIncomeAbstract" xlink:to="ifrs-full_ProfitLossFromOperatingActivities_638043208768789504" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_FinanceIncome" xlink:label="ifrs-full_FinanceIncome_638043208768789504" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfComprehensiveIncomeAbstract" xlink:to="ifrs-full_FinanceIncome_638043208768789504" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_FinanceCosts" xlink:label="ifrs-full_FinanceCosts_638043208768789504" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfComprehensiveIncomeAbstract" xlink:to="ifrs-full_FinanceCosts_638043208768789504" order="10" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProfitLossBeforeTax" xlink:label="ifrs-full_ProfitLossBeforeTax_638043208768789504" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfComprehensiveIncomeAbstract" xlink:to="ifrs-full_ProfitLossBeforeTax_638043208768789504" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:label="ifrs-full_IncomeTaxExpenseContinuingOperations_638043208768789504" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfComprehensiveIncomeAbstract" xlink:to="ifrs-full_IncomeTaxExpenseContinuingOperations_638043208768789504" order="12" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="9" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProfitLoss" xlink:label="ifrs-full_ProfitLoss_638043208768789504" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfComprehensiveIncomeAbstract" xlink:to="ifrs-full_ProfitLoss_638043208768789504" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OtherComprehensiveIncomeAbstract" xlink:label="ifrs-full_OtherComprehensiveIncomeAbstract_638043208768789504" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfComprehensiveIncomeAbstract" xlink:to="ifrs-full_OtherComprehensiveIncomeAbstract_638043208768789504" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" xlink:label="ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation_638043208768789504" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_OtherComprehensiveIncomeAbstract_638043208768789504" xlink:to="ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation_638043208768789504" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ComprehensiveIncome" xlink:label="ifrs-full_ComprehensiveIncome_638043208768789504" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfComprehensiveIncomeAbstract" xlink:to="ifrs-full_ComprehensiveIncome_638043208768789504" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_BasicEarningsLossPerShare" xlink:label="ifrs-full_BasicEarningsLossPerShare_638043208768789504" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfComprehensiveIncomeAbstract" xlink:to="ifrs-full_BasicEarningsLossPerShare_638043208768789504" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DilutedEarningsLossPerShare" xlink:label="ifrs-full_DilutedEarningsLossPerShare_638043208768789504" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfComprehensiveIncomeAbstract" xlink:to="ifrs-full_DilutedEarningsLossPerShare_638043208768789504" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition" xlink:type="extended" xlink:title="00200 - Statement - Interim Condensed Consolidated Statements of Financial Position" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_StatementOfFinancialPositionAbstract" xlink:label="StatementOfFinancialPositionAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AssetsAbstract" xlink:label="ifrs-full_AssetsAbstract_638043208768799499" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_AssetsAbstract_638043208768799499" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NoncurrentAssetsAbstract" xlink:label="ifrs-full_NoncurrentAssetsAbstract_638043208768799499" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AssetsAbstract_638043208768799499" xlink:to="ifrs-full_NoncurrentAssetsAbstract_638043208768799499" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IntangibleAssetsAndGoodwill" xlink:label="ifrs-full_IntangibleAssetsAndGoodwill_638043208768799499" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NoncurrentAssetsAbstract_638043208768799499" xlink:to="ifrs-full_IntangibleAssetsAndGoodwill_638043208768799499" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwill" xlink:label="ifrs-full_IntangibleAssetsOtherThanGoodwill_638043208768799499" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NoncurrentAssetsAbstract_638043208768799499" xlink:to="ifrs-full_IntangibleAssetsOtherThanGoodwill_638043208768799499" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_PropertyPlantAndEquipment" xlink:label="ifrs-full_PropertyPlantAndEquipment_638043208768799499" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NoncurrentAssetsAbstract_638043208768799499" xlink:to="ifrs-full_PropertyPlantAndEquipment_638043208768799499" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RightofuseAssets" xlink:label="ifrs-full_RightofuseAssets_638043208768799499" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NoncurrentAssetsAbstract_638043208768799499" xlink:to="ifrs-full_RightofuseAssets_638043208768799499" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OtherNoncurrentAssets" xlink:label="ifrs-full_OtherNoncurrentAssets_638043208768799499" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NoncurrentAssetsAbstract_638043208768799499" xlink:to="ifrs-full_OtherNoncurrentAssets_638043208768799499" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NetDeferredTaxAssets" xlink:label="ifrs-full_NetDeferredTaxAssets_638043208768799499" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NoncurrentAssetsAbstract_638043208768799499" xlink:to="ifrs-full_NetDeferredTaxAssets_638043208768799499" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NoncurrentAssets" xlink:label="ifrs-full_NoncurrentAssets_638043208768799499" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NoncurrentAssetsAbstract_638043208768799499" xlink:to="ifrs-full_NoncurrentAssets_638043208768799499" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CurrentAssetsAbstract" xlink:label="ifrs-full_CurrentAssetsAbstract_638043208768799499" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AssetsAbstract_638043208768799499" xlink:to="ifrs-full_CurrentAssetsAbstract_638043208768799499" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners" xlink:label="ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners_638043208768809494" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentAssetsAbstract_638043208768799499" xlink:to="ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners_638043208768809494" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_Inventories" xlink:label="ifrs-full_Inventories_638043208768809494" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentAssetsAbstract_638043208768799499" xlink:to="ifrs-full_Inventories_638043208768809494" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CurrentTradeReceivables" xlink:label="ifrs-full_CurrentTradeReceivables_638043208768809494" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentAssetsAbstract_638043208768799499" xlink:to="ifrs-full_CurrentTradeReceivables_638043208768809494" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CurrentContractAssets" xlink:label="ifrs-full_CurrentContractAssets_638043208768809494" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentAssetsAbstract_638043208768799499" xlink:to="ifrs-full_CurrentContractAssets_638043208768809494" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OtherCurrentFinancialAssets" xlink:label="ifrs-full_OtherCurrentFinancialAssets_638043208768809494" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentAssetsAbstract_638043208768799499" xlink:to="ifrs-full_OtherCurrentFinancialAssets_638043208768809494" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CurrentPrepaymentsAndOtherCurrentAssets" xlink:label="ifrs-full_CurrentPrepaymentsAndOtherCurrentAssets_638043208768809494" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentAssetsAbstract_638043208768799499" xlink:to="ifrs-full_CurrentPrepaymentsAndOtherCurrentAssets_638043208768809494" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CashAndCashEquivalents" xlink:label="ifrs-full_CashAndCashEquivalents_638043208768809494" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentAssetsAbstract_638043208768799499" xlink:to="ifrs-full_CashAndCashEquivalents_638043208768809494" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CurrentAssets" xlink:label="ifrs-full_CurrentAssets_638043208768809494" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentAssetsAbstract_638043208768799499" xlink:to="ifrs-full_CurrentAssets_638043208768809494" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_Assets" xlink:label="ifrs-full_Assets_638043208768809494" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AssetsAbstract_638043208768799499" xlink:to="ifrs-full_Assets_638043208768809494" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_EquityAndLiabilitiesAbstract" xlink:label="ifrs-full_EquityAndLiabilitiesAbstract_638043208768809494" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_EquityAndLiabilitiesAbstract_638043208768809494" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_EquityAbstract" xlink:label="ifrs-full_EquityAbstract_638043208768819494" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EquityAndLiabilitiesAbstract_638043208768809494" xlink:to="ifrs-full_EquityAbstract_638043208768819494" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IssuedCapital" xlink:label="ifrs-full_IssuedCapital_638043208768819494" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EquityAbstract_638043208768819494" xlink:to="ifrs-full_IssuedCapital_638043208768819494" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CapitalReserve" xlink:label="ifrs-full_CapitalReserve_638043208768819494" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EquityAbstract_638043208768819494" xlink:to="ifrs-full_CapitalReserve_638043208768819494" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TreasuryShares" xlink:label="ifrs-full_TreasuryShares_638043208768819494" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EquityAbstract_638043208768819494" xlink:to="ifrs-full_TreasuryShares_638043208768819494" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RetainedEarnings" xlink:label="ifrs-full_RetainedEarnings_638043208768819494" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EquityAbstract_638043208768819494" xlink:to="ifrs-full_RetainedEarnings_638043208768819494" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AccumulatedOtherComprehensiveIncome" xlink:label="ifrs-full_AccumulatedOtherComprehensiveIncome_638043208768819494" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EquityAbstract_638043208768819494" xlink:to="ifrs-full_AccumulatedOtherComprehensiveIncome_638043208768819494" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_Equity" xlink:label="ifrs-full_Equity_638043208768819494" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EquityAbstract_638043208768819494" xlink:to="ifrs-full_Equity_638043208768819494" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NoncurrentLiabilitiesAbstract" xlink:label="ifrs-full_NoncurrentLiabilitiesAbstract_638043208768819494" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EquityAndLiabilitiesAbstract_638043208768809494" xlink:to="ifrs-full_NoncurrentLiabilitiesAbstract_638043208768819494" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NoncurrentFinancialLiabilities" xlink:label="ifrs-full_NoncurrentFinancialLiabilities_638043208768819494" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NoncurrentLiabilitiesAbstract_638043208768819494" xlink:to="ifrs-full_NoncurrentFinancialLiabilities_638043208768819494" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NoncurrentLeaseLiabilities" xlink:label="ifrs-full_NoncurrentLeaseLiabilities_638043208768829493" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NoncurrentLiabilitiesAbstract_638043208768819494" xlink:to="ifrs-full_NoncurrentLeaseLiabilities_638043208768829493" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NoncurrentContractLiabilities" xlink:label="ifrs-full_NoncurrentContractLiabilities_638043208768829493" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NoncurrentLiabilitiesAbstract_638043208768819494" xlink:to="ifrs-full_NoncurrentContractLiabilities_638043208768829493" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OtherNoncurrentLiabilities" xlink:label="ifrs-full_OtherNoncurrentLiabilities_638043208768829493" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NoncurrentLiabilitiesAbstract_638043208768819494" xlink:to="ifrs-full_OtherNoncurrentLiabilities_638043208768829493" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NoncurrentLiabilities" xlink:label="ifrs-full_NoncurrentLiabilities_638043208768829493" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NoncurrentLiabilitiesAbstract_638043208768819494" xlink:to="ifrs-full_NoncurrentLiabilities_638043208768829493" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CurrentLiabilitiesAbstract" xlink:label="ifrs-full_CurrentLiabilitiesAbstract_638043208768829493" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EquityAndLiabilitiesAbstract_638043208768809494" xlink:to="ifrs-full_CurrentLiabilitiesAbstract_638043208768829493" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CurrentLeaseLiabilities" xlink:label="ifrs-full_CurrentLeaseLiabilities_638043208768829493" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentLiabilitiesAbstract_638043208768829493" xlink:to="ifrs-full_CurrentLeaseLiabilities_638043208768829493" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TradeAndOtherCurrentPayables" xlink:label="ifrs-full_TradeAndOtherCurrentPayables_638043208768829493" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentLiabilitiesAbstract_638043208768829493" xlink:to="ifrs-full_TradeAndOtherCurrentPayables_638043208768829493" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OtherCurrentLiabilities" xlink:label="ifrs-full_OtherCurrentLiabilities_638043208768829493" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentLiabilitiesAbstract_638043208768829493" xlink:to="ifrs-full_OtherCurrentLiabilities_638043208768829493" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CurrentTaxLiabilities" xlink:label="ifrs-full_CurrentTaxLiabilities_638043208768839495" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentLiabilitiesAbstract_638043208768829493" xlink:to="ifrs-full_CurrentTaxLiabilities_638043208768839495" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CurrentContractLiabilities" xlink:label="ifrs-full_CurrentContractLiabilities_638043208768839495" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentLiabilitiesAbstract_638043208768829493" xlink:to="ifrs-full_CurrentContractLiabilities_638043208768839495" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CurrentLiabilities" xlink:label="ifrs-full_CurrentLiabilities_638043208768839495" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentLiabilitiesAbstract_638043208768829493" xlink:to="ifrs-full_CurrentLiabilities_638043208768839495" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_Liabilities" xlink:label="ifrs-full_Liabilities_638043208768839495" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EquityAndLiabilitiesAbstract_638043208768809494" xlink:to="ifrs-full_Liabilities_638043208768839495" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_EquityAndLiabilities" xlink:label="ifrs-full_EquityAndLiabilities_638043208768839495" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EquityAndLiabilitiesAbstract_638043208768809494" xlink:to="ifrs-full_EquityAndLiabilities_638043208768839495" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="5" />
  </presentationLink>
  <presentationLink xlink:role="http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfChangesInShareholdersEquity" xlink:type="extended" xlink:title="00300 - Statement - Interim Condensed Consolidated Statements of Changes in Shareholders' Equity" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_StatementOfChangesInEquityAbstract" xlink:label="StatementOfChangesInEquityAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_StatementOfChangesInEquityTable" xlink:label="ifrs-full_StatementOfChangesInEquityTable_638043208768849502" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfChangesInEquityAbstract" xlink:to="ifrs-full_StatementOfChangesInEquityTable_638043208768849502" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:label="ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis_638043208768849502" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityTable_638043208768849502" xlink:to="ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis_638043208768849502" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_InAccordanceWithIFRS9Member" xlink:label="ifrs-full_InAccordanceWithIFRS9Member_638043208768849502" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis_638043208768849502" xlink:to="ifrs-full_InAccordanceWithIFRS9Member_638043208768849502" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IncreaseDecreaseDueToApplicationOfIFRS15Member" xlink:label="ifrs-full_IncreaseDecreaseDueToApplicationOfIFRS15Member_638043208768849502" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis_638043208768849502" xlink:to="ifrs-full_IncreaseDecreaseDueToApplicationOfIFRS15Member_638043208768849502" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_PreviouslyStatedMember" xlink:label="ifrs-full_PreviouslyStatedMember_638043208768849502" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis_638043208768849502" xlink:to="ifrs-full_PreviouslyStatedMember_638043208768849502" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RestatedMember" xlink:label="ifrs-full_RestatedMember_638043208768849502" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis_638043208768849502" xlink:to="ifrs-full_RestatedMember_638043208768849502" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ComponentsOfEquityAxis" xlink:label="ifrs-full_ComponentsOfEquityAxis_638043208768849502" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityTable_638043208768849502" xlink:to="ifrs-full_ComponentsOfEquityAxis_638043208768849502" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IssuedCapitalMember" xlink:label="ifrs-full_IssuedCapitalMember_638043208768849502" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ComponentsOfEquityAxis_638043208768849502" xlink:to="ifrs-full_IssuedCapitalMember_638043208768849502" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CapitalReserveMember" xlink:label="ifrs-full_CapitalReserveMember_638043208768849502" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ComponentsOfEquityAxis_638043208768849502" xlink:to="ifrs-full_CapitalReserveMember_638043208768849502" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TreasurySharesMember" xlink:label="ifrs-full_TreasurySharesMember_638043208768849502" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ComponentsOfEquityAxis_638043208768849502" xlink:to="ifrs-full_TreasurySharesMember_638043208768849502" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RetainedEarningsMember" xlink:label="ifrs-full_RetainedEarningsMember_638043208768849502" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ComponentsOfEquityAxis_638043208768849502" xlink:to="ifrs-full_RetainedEarningsMember_638043208768849502" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember" xlink:label="ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_638043208768849502" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ComponentsOfEquityAxis_638043208768849502" xlink:to="ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_638043208768849502" order="5" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_EquityMember" xlink:label="ifrs-full_EquityMember_638043208768859497" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ComponentsOfEquityAxis_638043208768849502" xlink:to="ifrs-full_EquityMember_638043208768859497" order="6" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_StatementOfChangesInEquityLineItems" xlink:label="ifrs-full_StatementOfChangesInEquityLineItems_638043208768859497" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityTable_638043208768849502" xlink:to="ifrs-full_StatementOfChangesInEquityLineItems_638043208768859497" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_Equity" xlink:label="ifrs-full_Equity_638043208768859497" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems_638043208768859497" xlink:to="ifrs-full_Equity_638043208768859497" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_NetLoss" xlink:label="cvac_NetLoss_638043208768859497" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems_638043208768859497" xlink:to="cvac_NetLoss_638043208768859497" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProfitLoss" xlink:label="ifrs-full_ProfitLoss_638043208768859497" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems_638043208768859497" xlink:to="ifrs-full_ProfitLoss_638043208768859497" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OtherComprehensiveIncome" xlink:label="ifrs-full_OtherComprehensiveIncome_638043208768859497" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems_638043208768859497" xlink:to="ifrs-full_OtherComprehensiveIncome_638043208768859497" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_ComprehensiveIncomeLoss" xlink:label="cvac_ComprehensiveIncomeLoss_638043208768859497" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems_638043208768859497" xlink:to="cvac_ComprehensiveIncomeLoss_638043208768859497" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ComprehensiveIncome" xlink:label="ifrs-full_ComprehensiveIncome_638043208768859497" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems_638043208768859497" xlink:to="ifrs-full_ComprehensiveIncome_638043208768859497" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_ShareBasedPaymentExpenseIncl.DeferredTaxes" xlink:label="cvac_ShareBasedPaymentExpenseIncl.DeferredTaxes_638043208768859497" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems_638043208768859497" xlink:to="cvac_ShareBasedPaymentExpenseIncl.DeferredTaxes_638043208768859497" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IssueOfEquity" xlink:label="ifrs-full_IssueOfEquity_638043208768859497" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems_638043208768859497" xlink:to="ifrs-full_IssueOfEquity_638043208768859497" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IncreaseDecreaseThroughConversionOfConvertibleInstruments" xlink:label="ifrs-full_IncreaseDecreaseThroughConversionOfConvertibleInstruments_638043208768869497" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems_638043208768859497" xlink:to="ifrs-full_IncreaseDecreaseThroughConversionOfConvertibleInstruments_638043208768869497" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/positiveTerseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DecreaseIncreaseThroughTaxOnSharebasedPaymentTransactions" xlink:label="ifrs-full_DecreaseIncreaseThroughTaxOnSharebasedPaymentTransactions_638043208768869497" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems_638043208768859497" xlink:to="ifrs-full_DecreaseIncreaseThroughTaxOnSharebasedPaymentTransactions_638043208768869497" order="10" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IncreaseDecreaseThroughExerciseOfOptions" xlink:label="ifrs-full_IncreaseDecreaseThroughExerciseOfOptions_638043208768869497" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems_638043208768859497" xlink:to="ifrs-full_IncreaseDecreaseThroughExerciseOfOptions_638043208768869497" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_SettlementOfShareBasedPaymentAwardsAmount" xlink:label="cvac_SettlementOfShareBasedPaymentAwardsAmount_638043208768869497" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems_638043208768859497" xlink:to="cvac_SettlementOfShareBasedPaymentAwardsAmount_638043208768869497" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IncreaseDecreaseThroughTreasuryShareTransactions" xlink:label="ifrs-full_IncreaseDecreaseThroughTreasuryShareTransactions_638043208768899497" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems_638043208768859497" xlink:to="ifrs-full_IncreaseDecreaseThroughTreasuryShareTransactions_638043208768899497" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IncreaseDecreaseThroughAcquisitionOfSubsidiary" xlink:label="ifrs-full_IncreaseDecreaseThroughAcquisitionOfSubsidiary_638043208768899497" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems_638043208768859497" xlink:to="ifrs-full_IncreaseDecreaseThroughAcquisitionOfSubsidiary_638043208768899497" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NumberOfSharesOutstanding" xlink:label="ifrs-full_NumberOfSharesOutstanding_638043208768899497" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems_638043208768859497" xlink:to="ifrs-full_NumberOfSharesOutstanding_638043208768899497" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_Equity" xlink:label="ifrs-full_Equity_638043208768909502" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems_638043208768859497" xlink:to="ifrs-full_Equity_638043208768909502" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows" xlink:type="extended" xlink:title="00400 - Statement - Interim Condensed Consolidated Statements of Cash Flows" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_StatementOfCashFlowsAbstract" xlink:label="StatementOfCashFlowsAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_638043208768909502" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_638043208768909502" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProfitLossBeforeTax" xlink:label="ifrs-full_ProfitLossBeforeTax_638043208768909502" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_638043208768909502" xlink:to="ifrs-full_ProfitLossBeforeTax_638043208768909502" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AdjustmentsForReconcileProfitLossAbstract" xlink:label="ifrs-full_AdjustmentsForReconcileProfitLossAbstract_638043208768909502" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_638043208768909502" xlink:to="ifrs-full_AdjustmentsForReconcileProfitLossAbstract_638043208768909502" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AdjustmentsForFinanceIncome" xlink:label="ifrs-full_AdjustmentsForFinanceIncome_638043208768909502" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AdjustmentsForReconcileProfitLossAbstract_638043208768909502" xlink:to="ifrs-full_AdjustmentsForFinanceIncome_638043208768909502" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AdjustmentsForFinanceCosts" xlink:label="ifrs-full_AdjustmentsForFinanceCosts_638043208768909502" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AdjustmentsForReconcileProfitLossAbstract_638043208768909502" xlink:to="ifrs-full_AdjustmentsForFinanceCosts_638043208768909502" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense" xlink:label="ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense_638043208768909502" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AdjustmentsForReconcileProfitLossAbstract_638043208768909502" xlink:to="ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense_638043208768909502" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AdjustmentsForGainLossOnDisposalsPropertyPlantAndEquipment" xlink:label="ifrs-full_AdjustmentsForGainLossOnDisposalsPropertyPlantAndEquipment_638043208768909502" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AdjustmentsForReconcileProfitLossAbstract_638043208768909502" xlink:to="ifrs-full_AdjustmentsForGainLossOnDisposalsPropertyPlantAndEquipment_638043208768909502" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="9" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets" xlink:label="ifrs-full_AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets_638043208768909502" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AdjustmentsForReconcileProfitLossAbstract_638043208768909502" xlink:to="ifrs-full_AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets_638043208768909502" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" xlink:label="ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment_638043208768919500" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AdjustmentsForReconcileProfitLossAbstract_638043208768909502" xlink:to="ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment_638043208768919500" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AdjustmentsForGainLossOnDisposalsPropertyPlantAndEquipment" xlink:label="ifrs-full_AdjustmentsForGainLossOnDisposalsPropertyPlantAndEquipment_638043208768919500" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AdjustmentsForReconcileProfitLossAbstract_638043208768909502" xlink:to="ifrs-full_AdjustmentsForGainLossOnDisposalsPropertyPlantAndEquipment_638043208768919500" order="7" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="8" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_ImpairmentsOfInventoryAndPrepayments" xlink:label="cvac_ImpairmentsOfInventoryAndPrepayments_638043208768919500" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AdjustmentsForReconcileProfitLossAbstract_638043208768909502" xlink:to="cvac_ImpairmentsOfInventoryAndPrepayments_638043208768919500" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AdjustmentsForSharebasedPayments" xlink:label="ifrs-full_AdjustmentsForSharebasedPayments_638043208768919500" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AdjustmentsForReconcileProfitLossAbstract_638043208768909502" xlink:to="ifrs-full_AdjustmentsForSharebasedPayments_638043208768919500" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_AdjustmentsForNonCashIncomeFromReleaseOfProvisions" xlink:label="cvac_AdjustmentsForNonCashIncomeFromReleaseOfProvisions_638043208768919500" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AdjustmentsForReconcileProfitLossAbstract_638043208768909502" xlink:to="cvac_AdjustmentsForNonCashIncomeFromReleaseOfProvisions_638043208768919500" order="10" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_ChangesInWorkingCapitalAbstract" xlink:label="cvac_ChangesInWorkingCapitalAbstract_638043208768919500" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_638043208768909502" xlink:to="cvac_ChangesInWorkingCapitalAbstract_638043208768919500" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables_638043208768919500" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_ChangesInWorkingCapitalAbstract_638043208768919500" xlink:to="ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables_638043208768919500" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInInventories" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInInventories_638043208768919500" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_ChangesInWorkingCapitalAbstract_638043208768919500" xlink:to="ifrs-full_AdjustmentsForDecreaseIncreaseInInventories_638043208768919500" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInOtherAssets" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInOtherAssets_638043208768919500" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_ChangesInWorkingCapitalAbstract_638043208768919500" xlink:to="ifrs-full_AdjustmentsForDecreaseIncreaseInOtherAssets_638043208768919500" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_IfrsIncreaseDecreaseInPrepaidExpenseAndOtherAssets" xlink:label="cvac_IfrsIncreaseDecreaseInPrepaidExpenseAndOtherAssets_638043208768919500" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_ChangesInWorkingCapitalAbstract_638043208768919500" xlink:to="cvac_IfrsIncreaseDecreaseInPrepaidExpenseAndOtherAssets_638043208768919500" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_ReceiptsFromGovernmentGrantsClassifiedAsOperatingActivities" xlink:label="cvac_ReceiptsFromGovernmentGrantsClassifiedAsOperatingActivities_638043208768919500" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_ChangesInWorkingCapitalAbstract_638043208768919500" xlink:to="cvac_ReceiptsFromGovernmentGrantsClassifiedAsOperatingActivities_638043208768919500" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" xlink:label="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables_638043208768929500" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_ChangesInWorkingCapitalAbstract_638043208768919500" xlink:to="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables_638043208768929500" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_AdjustmentsForIncreaseDecreaseInOtherCurrentFinancialAndOtherLiabilities" xlink:label="cvac_AdjustmentsForIncreaseDecreaseInOtherCurrentFinancialAndOtherLiabilities_638043208768929500" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_ChangesInWorkingCapitalAbstract_638043208768919500" xlink:to="cvac_AdjustmentsForIncreaseDecreaseInOtherCurrentFinancialAndOtherLiabilities_638043208768929500" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AdjustmentsForDeferredTaxExpense" xlink:label="ifrs-full_AdjustmentsForDeferredTaxExpense_638043208768929500" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_ChangesInWorkingCapitalAbstract_638043208768919500" xlink:to="ifrs-full_AdjustmentsForDeferredTaxExpense_638043208768929500" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IncomeTaxesPaidClassifiedAsOperatingActivities" xlink:label="ifrs-full_IncomeTaxesPaidClassifiedAsOperatingActivities_638043208768929500" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_ChangesInWorkingCapitalAbstract_638043208768919500" xlink:to="ifrs-full_IncomeTaxesPaidClassifiedAsOperatingActivities_638043208768929500" order="9" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_InterestReceivedClassifiedAsOperatingActivities" xlink:label="ifrs-full_InterestReceivedClassifiedAsOperatingActivities_638043208768929500" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_ChangesInWorkingCapitalAbstract_638043208768919500" xlink:to="ifrs-full_InterestReceivedClassifiedAsOperatingActivities_638043208768929500" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_InterestPaidClassifiedAsOperatingActivities" xlink:label="ifrs-full_InterestPaidClassifiedAsOperatingActivities_638043208768929500" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_ChangesInWorkingCapitalAbstract_638043208768919500" xlink:to="ifrs-full_InterestPaidClassifiedAsOperatingActivities_638043208768929500" order="11" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" priority="8" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivities_638043208768929500" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_ChangesInWorkingCapitalAbstract_638043208768919500" xlink:to="ifrs-full_CashFlowsFromUsedInOperatingActivities_638043208768929500" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:label="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_638043208768929500" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_638043208768929500" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:label="ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_638043208768929500" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_638043208768929500" xlink:to="ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_638043208768929500" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" xlink:label="ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities_638043208768939499" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_638043208768929500" xlink:to="ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities_638043208768939499" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_PurchaseOfOtherLongtermAssetsClassifiedAsInvestingActivities" xlink:label="ifrs-full_PurchaseOfOtherLongtermAssetsClassifiedAsInvestingActivities_638043208768939499" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_638043208768929500" xlink:to="ifrs-full_PurchaseOfOtherLongtermAssetsClassifiedAsInvestingActivities_638043208768939499" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:label="ifrs-full_CashFlowsFromUsedInInvestingActivities_638043208768939499" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_638043208768929500" xlink:to="ifrs-full_CashFlowsFromUsedInInvestingActivities_638043208768939499" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_638043208768939499" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_638043208768939499" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" xlink:label="ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities_638043208768939499" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_638043208768939499" xlink:to="ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities_638043208768939499" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProceedsFromIssuingOtherEquityInstruments" xlink:label="ifrs-full_ProceedsFromIssuingOtherEquityInstruments_638043208768939499" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_638043208768939499" xlink:to="ifrs-full_ProceedsFromIssuingOtherEquityInstruments_638043208768939499" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_ProceedFromIssuingOtherEquityInstrument" xlink:label="cvac_ProceedFromIssuingOtherEquityInstrument_638043208768939499" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_638043208768939499" xlink:to="cvac_ProceedFromIssuingOtherEquityInstrument_638043208768939499" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_IfrsStockIssuedDuringPeriodValueNewIssues" xlink:label="cvac_IfrsStockIssuedDuringPeriodValueNewIssues_638043208768939499" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_638043208768939499" xlink:to="cvac_IfrsStockIssuedDuringPeriodValueNewIssues_638043208768939499" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProceedsFromExerciseOfOptions" xlink:label="ifrs-full_ProceedsFromExerciseOfOptions_638043208768949498" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_638043208768939499" xlink:to="ifrs-full_ProceedsFromExerciseOfOptions_638043208768949498" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_ProceedsOrPaymentsFromExerciseOfOptions" xlink:label="cvac_ProceedsOrPaymentsFromExerciseOfOptions_638043208768949498" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_638043208768939499" xlink:to="cvac_ProceedsOrPaymentsFromExerciseOfOptions_638043208768949498" order="6" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_ProceedsOnExerciseOfOptions" xlink:label="cvac_ProceedsOnExerciseOfOptions_638043208768949498" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_638043208768939499" xlink:to="cvac_ProceedsOnExerciseOfOptions_638043208768949498" order="7" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProceedsFromIssuingShares" xlink:label="ifrs-full_ProceedsFromIssuingShares_638043208768949498" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_638043208768939499" xlink:to="ifrs-full_ProceedsFromIssuingShares_638043208768949498" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_ProceedsFromRepaymentsOfBorrowingsClassifiedAsFinancingActivities" xlink:label="cvac_ProceedsFromRepaymentsOfBorrowingsClassifiedAsFinancingActivities_638043208768949498" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_638043208768939499" xlink:to="cvac_ProceedsFromRepaymentsOfBorrowingsClassifiedAsFinancingActivities_638043208768949498" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProceedsFromIssueOfBondsNotesAndDebentures" xlink:label="ifrs-full_ProceedsFromIssueOfBondsNotesAndDebentures_638043208768949498" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_638043208768939499" xlink:to="ifrs-full_ProceedsFromIssueOfBondsNotesAndDebentures_638043208768949498" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RepaymentsOfBondsNotesAndDebentures" xlink:label="ifrs-full_RepaymentsOfBondsNotesAndDebentures_638043208768949498" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_638043208768939499" xlink:to="ifrs-full_RepaymentsOfBondsNotesAndDebentures_638043208768949498" order="11" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivities_638043208768959498" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_638043208768939499" xlink:to="ifrs-full_CashFlowsFromUsedInFinancingActivities_638043208768959498" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" xlink:label="ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges_638043208768959498" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges_638043208768959498" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents" xlink:label="ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents_638043208768959498" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents_638043208768959498" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CashAndCashEquivalents" xlink:label="ifrs-full_CashAndCashEquivalents_638043208768959498" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="ifrs-full_CashAndCashEquivalents_638043208768959498" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CashAndCashEquivalents" xlink:label="ifrs-full_CashAndCashEquivalents_6380432087689594981" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="ifrs-full_CashAndCashEquivalents_6380432087689594981" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.curevac.com/role/DisclosureCorporateInformation" xlink:type="extended" xlink:title="10101 - Disclosure - Corporate Information" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_CorporateInformationAbstract" xlink:label="CorporateInformationAbstract" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_CorporateInformationTextBlock" xlink:label="cvac_CorporateInformationTextBlock_638043208768969498" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CorporateInformationAbstract" xlink:to="cvac_CorporateInformationTextBlock_638043208768969498" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.curevac.com/role/DisclosureBasisOfPreparation" xlink:type="extended" xlink:title="10201 - Disclosure - Basis of preparation" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_DisclosureOfBasisOfPreparationAbstract" xlink:label="DisclosureOfBasisOfPreparationAbstract" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_DisclosureOfBasisOfPreparationExplanatoryTextBlock" xlink:label="cvac_DisclosureOfBasisOfPreparationExplanatoryTextBlock_638043208768969498" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfBasisOfPreparationAbstract" xlink:to="cvac_DisclosureOfBasisOfPreparationExplanatoryTextBlock_638043208768969498" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatements" xlink:type="extended" xlink:title="10301 - Disclosure - Notes to the consolidated financial statements" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_DisclosureOfNotesToConsolidatedFinancialStatementsAbstract" xlink:label="DisclosureOfNotesToConsolidatedFinancialStatementsAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfNotesAndOtherExplanatoryInformationExplanatory" xlink:label="ifrs-full_DisclosureOfNotesAndOtherExplanatoryInformationExplanatory_638043208768969498" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfNotesToConsolidatedFinancialStatementsAbstract" xlink:to="ifrs-full_DisclosureOfNotesAndOtherExplanatoryInformationExplanatory_638043208768969498" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.curevac.com/role/DisclosureIssuedCapitalAndReserves" xlink:type="extended" xlink:title="10401 - Disclosure - Issued Capital and Reserves" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalAbstract" xlink:label="DisclosureOfClassesOfShareCapitalAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory" xlink:label="ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory_638043208768969498" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfClassesOfShareCapitalAbstract" xlink:to="ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory_638043208768969498" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
  </presentationLink>
  <presentationLink xlink:role="http://www.curevac.com/role/DisclosureShareBasedPayments" xlink:type="extended" xlink:title="10501 - Disclosure - Share-based payments" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:label="DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory" xlink:label="ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory_638043208768979499" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:to="ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory_638043208768979499" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.curevac.com/role/DisclosureFixedAssets" xlink:type="extended" xlink:title="10601 - Disclosure - Fixed Assets" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_DisclosureOfFixedAssetsAbstract" xlink:label="DisclosureOfFixedAssetsAbstract" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_DisclosureOfFixedAssetsExplanatory" xlink:label="cvac_DisclosureOfFixedAssetsExplanatory_638043208768979499" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfFixedAssetsAbstract" xlink:to="cvac_DisclosureOfFixedAssetsExplanatory_638043208768979499" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.curevac.com/role/DisclosureAssetsHeldForSale" xlink:type="extended" xlink:title="10701 - Disclosure - Assets held for sale" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwnersAbstract" xlink:label="ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwnersAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfNoncurrentAssetsHeldForSaleAndDiscontinuedOperationsExplanatory" xlink:label="ifrs-full_DisclosureOfNoncurrentAssetsHeldForSaleAndDiscontinuedOperationsExplanatory_638043208768979499" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwnersAbstract" xlink:to="ifrs-full_DisclosureOfNoncurrentAssetsHeldForSaleAndDiscontinuedOperationsExplanatory_638043208768979499" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.curevac.com/role/DisclosureInventories" xlink:type="extended" xlink:title="10801 - Disclosure - Inventories" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ClassesOfInventoriesAbstract" xlink:label="ClassesOfInventoriesAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfInventoriesExplanatory" xlink:label="ifrs-full_DisclosureOfInventoriesExplanatory_638043208768979499" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ClassesOfInventoriesAbstract" xlink:to="ifrs-full_DisclosureOfInventoriesExplanatory_638043208768979499" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.curevac.com/role/DisclosurePrepaidExpensesAndOtherAssetsCurrent" xlink:type="extended" xlink:title="10901 - Disclosure - Prepaid expenses and other assets (current)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_DisclosureOfPrepaidExpensesAndOtherCurrentAssetsAbstract" xlink:label="DisclosureOfPrepaidExpensesAndOtherCurrentAssetsAbstract" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_DisclosureOfPrepaidExpensesAndOtherCurrentAssetsExplanatory" xlink:label="cvac_DisclosureOfPrepaidExpensesAndOtherCurrentAssetsExplanatory_638043208768989499" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfPrepaidExpensesAndOtherCurrentAssetsAbstract" xlink:to="cvac_DisclosureOfPrepaidExpensesAndOtherCurrentAssetsExplanatory_638043208768989499" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.curevac.com/role/DisclosureFinancialAssetsAndFinancialLiabilities" xlink:type="extended" xlink:title="11001 - Disclosure - Financial assets and financial liabilities" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfFinancialInstrumentsAbstract" xlink:label="DisclosureOfFinancialInstrumentsAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfFinancialInstrumentsExplanatory" xlink:label="ifrs-full_DisclosureOfFinancialInstrumentsExplanatory_638043208768989499" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfFinancialInstrumentsAbstract" xlink:to="ifrs-full_DisclosureOfFinancialInstrumentsExplanatory_638043208768989499" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.curevac.com/role/DisclosureTradeAndOtherPayables" xlink:type="extended" xlink:title="11101 - Disclosure - Trade and other payables" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TradeAndOtherCurrentPayablesAbstract" xlink:label="TradeAndOtherCurrentPayablesAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory" xlink:label="ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory_638043208768989499" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TradeAndOtherCurrentPayablesAbstract" xlink:to="ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory_638043208768989499" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.curevac.com/role/DisclosureOtherLiabilities" xlink:type="extended" xlink:title="11201 - Disclosure - Other liabilities" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_IfrsOtherLiabilitiesAbstract" xlink:label="IfrsOtherLiabilitiesAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfOtherLiabilitiesExplanatory" xlink:label="ifrs-full_DisclosureOfOtherLiabilitiesExplanatory_638043208768989499" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IfrsOtherLiabilitiesAbstract" xlink:to="ifrs-full_DisclosureOfOtherLiabilitiesExplanatory_638043208768989499" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.curevac.com/role/DisclosureLoans" xlink:type="extended" xlink:title="11301 - Disclosure - Loans" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsAbstract" xlink:label="DisclosureOfDetailedInformationAboutBorrowingsAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsExplanatory" xlink:label="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsExplanatory_638043208768999500" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfDetailedInformationAboutBorrowingsAbstract" xlink:to="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsExplanatory_638043208768999500" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.curevac.com/role/DisclosureIncomeTax" xlink:type="extended" xlink:title="11401 - Disclosure - Income tax" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract" xlink:label="MajorComponentsOfTaxExpenseIncomeAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfIncomeTaxExplanatory" xlink:label="ifrs-full_DisclosureOfIncomeTaxExplanatory_638043208768999500" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="MajorComponentsOfTaxExpenseIncomeAbstract" xlink:to="ifrs-full_DisclosureOfIncomeTaxExplanatory_638043208768999500" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.curevac.com/role/DisclosureDisclosureOfFinancialInstrumentsAndRiskManagement" xlink:type="extended" xlink:title="11501 - Disclosure - Disclosure of financial instruments and risk management" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_FinancialInstrumentsAndRiskManagementAbstract" xlink:label="FinancialInstrumentsAndRiskManagementAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfFinancialRiskManagementExplanatory" xlink:label="ifrs-full_DisclosureOfFinancialRiskManagementExplanatory_638043208768999500" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancialInstrumentsAndRiskManagementAbstract" xlink:to="ifrs-full_DisclosureOfFinancialRiskManagementExplanatory_638043208768999500" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.curevac.com/role/DisclosureEarningsPerShare" xlink:type="extended" xlink:title="11601 - Disclosure - Earnings per share" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_EarningsPerShareAbstract" xlink:label="EarningsPerShareAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_EarningsPerShareExplanatory" xlink:label="ifrs-full_EarningsPerShareExplanatory_638043208768999500" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EarningsPerShareAbstract" xlink:to="ifrs-full_EarningsPerShareExplanatory_638043208768999500" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.curevac.com/role/DisclosureRelatedPartyDisclosures" xlink:type="extended" xlink:title="11701 - Disclosure - Related party disclosures" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract" xlink:label="DisclosureOfTransactionsBetweenRelatedPartiesAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfRelatedPartyExplanatory" xlink:label="ifrs-full_DisclosureOfRelatedPartyExplanatory_638043208769009497" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfTransactionsBetweenRelatedPartiesAbstract" xlink:to="ifrs-full_DisclosureOfRelatedPartyExplanatory_638043208769009497" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.curevac.com/role/DisclosureSignificantTransactionsAndEvents" xlink:type="extended" xlink:title="11801 - Disclosure - Significant transactions and events" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfBusinessCombinationsAbstract" xlink:label="ifrs-full_DisclosureOfBusinessCombinationsAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfBusinessCombinationsExplanatory" xlink:label="ifrs-full_DisclosureOfBusinessCombinationsExplanatory_638043208769009497" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsAbstract" xlink:to="ifrs-full_DisclosureOfBusinessCombinationsExplanatory_638043208769009497" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.curevac.com/role/DisclosureSubsequentEvents" xlink:type="extended" xlink:title="11901 - Disclosure - Subsequent events" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract" xlink:label="DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory" xlink:label="ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory_638043208769009497" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract" xlink:to="ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory_638043208769009497" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.curevac.com/role/DisclosureBasisOfPreparationPolicies" xlink:type="extended" xlink:title="20202 - Disclosure - Basis of preparation (Policies)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_DisclosureOfBasisOfPreparationAbstract" xlink:label="DisclosureOfBasisOfPreparationAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory" xlink:label="ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory_638043208769009497" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfBasisOfPreparationAbstract" xlink:to="ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory_638043208769009497" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_DescriptionOfAccountingPolicyOfNewStandardsInterpretationsAndAmendmentsAdoptedTextBlock" xlink:label="cvac_DescriptionOfAccountingPolicyOfNewStandardsInterpretationsAndAmendmentsAdoptedTextBlock_638043208769009497" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfBasisOfPreparationAbstract" xlink:to="cvac_DescriptionOfAccountingPolicyOfNewStandardsInterpretationsAndAmendmentsAdoptedTextBlock_638043208769009497" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory_638043208769019498" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfBasisOfPreparationAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory_638043208769019498" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_DescriptionOfAccountingPolicyForPreLaunchProductsExplanatory" xlink:label="cvac_DescriptionOfAccountingPolicyForPreLaunchProductsExplanatory_638043208769019498" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfBasisOfPreparationAbstract" xlink:to="cvac_DescriptionOfAccountingPolicyForPreLaunchProductsExplanatory_638043208769019498" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_DescriptionOfAccountingPolicyForCovid19ImpactExplanatory" xlink:label="cvac_DescriptionOfAccountingPolicyForCovid19ImpactExplanatory_638043208769019498" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfBasisOfPreparationAbstract" xlink:to="cvac_DescriptionOfAccountingPolicyForCovid19ImpactExplanatory_638043208769019498" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsTables" xlink:type="extended" xlink:title="30303 - Disclosure - Notes to the consolidated financial statements (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_DisclosureOfNotesToConsolidatedFinancialStatementsAbstract" xlink:label="DisclosureOfNotesToConsolidatedFinancialStatementsAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory" xlink:label="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory_638043208769019498" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfNotesToConsolidatedFinancialStatementsAbstract" xlink:to="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory_638043208769019498" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_DisclosureOfUpfrontPaymentsAndRelatedRevenuesRecognizedExplanatory" xlink:label="cvac_DisclosureOfUpfrontPaymentsAndRelatedRevenuesRecognizedExplanatory_638043208769019498" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfNotesToConsolidatedFinancialStatementsAbstract" xlink:to="cvac_DisclosureOfUpfrontPaymentsAndRelatedRevenuesRecognizedExplanatory_638043208769019498" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory" xlink:label="ifrs-full_ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory_638043208769019498" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfNotesToConsolidatedFinancialStatementsAbstract" xlink:to="ifrs-full_ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory_638043208769019498" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfTransactionPriceAllocatedToRemainingPerformanceObligationsExplanatory" xlink:label="ifrs-full_DisclosureOfTransactionPriceAllocatedToRemainingPerformanceObligationsExplanatory_638043208769019498" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfNotesToConsolidatedFinancialStatementsAbstract" xlink:to="ifrs-full_DisclosureOfTransactionPriceAllocatedToRemainingPerformanceObligationsExplanatory_638043208769019498" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfExpensesByNatureExplanatory" xlink:label="ifrs-full_DisclosureOfExpensesByNatureExplanatory_638043208769019498" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfNotesToConsolidatedFinancialStatementsAbstract" xlink:to="ifrs-full_DisclosureOfExpensesByNatureExplanatory_638043208769019498" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfOtherOperatingIncomeExplanatory" xlink:label="ifrs-full_DisclosureOfOtherOperatingIncomeExplanatory_638043208769019498" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfNotesToConsolidatedFinancialStatementsAbstract" xlink:to="ifrs-full_DisclosureOfOtherOperatingIncomeExplanatory_638043208769019498" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfOtherOperatingExpenseExplanatory" xlink:label="ifrs-full_DisclosureOfOtherOperatingExpenseExplanatory_638043208769019498" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfNotesToConsolidatedFinancialStatementsAbstract" xlink:to="ifrs-full_DisclosureOfOtherOperatingExpenseExplanatory_638043208769019498" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.curevac.com/role/DisclosureIssuedCapitalAndReservesTables" xlink:type="extended" xlink:title="30403 - Disclosure - Issued Capital and Reserves (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalAbstract" xlink:label="DisclosureOfClassesOfShareCapitalAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory" xlink:label="ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory_638043208769029501" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfClassesOfShareCapitalAbstract" xlink:to="ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory_638043208769029501" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.curevac.com/role/DisclosureShareBasedPaymentsTables" xlink:type="extended" xlink:title="30503 - Disclosure - Share-based payments (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:label="DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_638043208769029501" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:to="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_638043208769029501" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:label="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_638043208769029501" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_638043208769029501" xlink:to="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_638043208769029501" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_SharebasedPaymentArrangementsMember" xlink:label="ifrs-full_SharebasedPaymentArrangementsMember_638043208769029501" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_638043208769029501" xlink:to="ifrs-full_SharebasedPaymentArrangementsMember_638043208769029501" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_VirtualSharesProgramIMember" xlink:label="cvac_VirtualSharesProgramIMember_638043208769029501" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_SharebasedPaymentArrangementsMember_638043208769029501" xlink:to="cvac_VirtualSharesProgramIMember_638043208769029501" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_VirtualSharesProgramIiMember" xlink:label="cvac_VirtualSharesProgramIiMember_638043208769029501" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_SharebasedPaymentArrangementsMember_638043208769029501" xlink:to="cvac_VirtualSharesProgramIiMember_638043208769029501" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_OptionsGrantedToThenChiefExecutiveOfficerMember" xlink:label="cvac_OptionsGrantedToThenChiefExecutiveOfficerMember_638043208769029501" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_SharebasedPaymentArrangementsMember_638043208769029501" xlink:to="cvac_OptionsGrantedToThenChiefExecutiveOfficerMember_638043208769029501" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_RestrictedStockUnitsMember" xlink:label="cvac_RestrictedStockUnitsMember_638043208769029501" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_SharebasedPaymentArrangementsMember_638043208769029501" xlink:to="cvac_RestrictedStockUnitsMember_638043208769029501" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_638043208769029501" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_638043208769029501" xlink:to="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_638043208769029501" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory" xlink:label="ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory_638043208769029501" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_638043208769029501" xlink:to="ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory_638043208769029501" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory" xlink:label="ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory_638043208769039500" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_638043208769029501" xlink:to="ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory_638043208769039500" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_DisclosureOfExpenseRecognizedForEmployeeServicesExplanatory" xlink:label="cvac_DisclosureOfExpenseRecognizedForEmployeeServicesExplanatory_638043208769039500" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_638043208769029501" xlink:to="cvac_DisclosureOfExpenseRecognizedForEmployeeServicesExplanatory_638043208769039500" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_ScheduleOfExpenseRecognizedForProgramsTableTextBlock" xlink:label="cvac_ScheduleOfExpenseRecognizedForProgramsTableTextBlock_638043208769039500" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_638043208769029501" xlink:to="cvac_ScheduleOfExpenseRecognizedForProgramsTableTextBlock_638043208769039500" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.curevac.com/role/DisclosureSignificantTransactionsAndEventsTables" xlink:type="extended" xlink:title="31803 - Disclosure - Significant transactions and events (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfBusinessCombinationsAbstract" xlink:label="ifrs-full_DisclosureOfBusinessCombinationsAbstract_1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBusinessCombinationsExplanatory" xlink:label="ifrs-full_DisclosureOfDetailedInformationAboutBusinessCombinationsExplanatory_638043208769039500" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsAbstract_1" xlink:to="ifrs-full_DisclosureOfDetailedInformationAboutBusinessCombinationsExplanatory_638043208769039500" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_DisclosureOfGoodwillRecognizedAsResultOfAcquisitionExplanatoryTableTextBlock" xlink:label="cvac_DisclosureOfGoodwillRecognizedAsResultOfAcquisitionExplanatoryTableTextBlock_638043208769039500" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsAbstract_1" xlink:to="cvac_DisclosureOfGoodwillRecognizedAsResultOfAcquisitionExplanatoryTableTextBlock_638043208769039500" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_DisclosureOfAnalysisOfCashFlowsOnAcquisitionExplanatoryTableTextBlock" xlink:label="cvac_DisclosureOfAnalysisOfCashFlowsOnAcquisitionExplanatoryTableTextBlock_638043208769039500" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsAbstract_1" xlink:to="cvac_DisclosureOfAnalysisOfCashFlowsOnAcquisitionExplanatoryTableTextBlock_638043208769039500" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.curevac.com/role/DisclosureCorporateInformationDetails" xlink:type="extended" xlink:title="40101 - Disclosure - Corporate Information (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_CorporateInformationAbstract" xlink:label="CorporateInformationAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfBusinessCombinationsTable" xlink:label="ifrs-full_DisclosureOfBusinessCombinationsTable_638043208769039500" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CorporateInformationAbstract" xlink:to="ifrs-full_DisclosureOfBusinessCombinationsTable_638043208769039500" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_BusinessCombinationsAxis" xlink:label="ifrs-full_BusinessCombinationsAxis_638043208769039500" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsTable_638043208769039500" xlink:to="ifrs-full_BusinessCombinationsAxis_638043208769039500" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_EntitysTotalForBusinessCombinationsMember" xlink:label="ifrs-full_EntitysTotalForBusinessCombinationsMember_638043208769049500" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_BusinessCombinationsAxis_638043208769039500" xlink:to="ifrs-full_EntitysTotalForBusinessCombinationsMember_638043208769049500" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_CurevacN.v.Member" xlink:label="cvac_CurevacN.v.Member_638043208769049500" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EntitysTotalForBusinessCombinationsMember_638043208769049500" xlink:to="cvac_CurevacN.v.Member_638043208769049500" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="srt_ConsolidatedEntitiesAxis_638043208769049500" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsTable_638043208769039500" xlink:to="srt_ConsolidatedEntitiesAxis_638043208769049500" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="srt_ConsolidatedEntitiesDomain_638043208769049500" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ConsolidatedEntitiesAxis_638043208769049500" xlink:to="srt_ConsolidatedEntitiesDomain_638043208769049500" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ParentCompanyMember" xlink:label="srt_ParentCompanyMember_638043208769049500" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ConsolidatedEntitiesDomain_638043208769049500" xlink:to="srt_ParentCompanyMember_638043208769049500" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:label="ifrs-full_DisclosureOfBusinessCombinationsLineItems_638043208769049500" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsTable_638043208769039500" xlink:to="ifrs-full_DisclosureOfBusinessCombinationsLineItems_638043208769049500" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_PercentageOfVotingEquityInterestsAcquired" xlink:label="ifrs-full_PercentageOfVotingEquityInterestsAcquired_638043208769049500" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems_638043208769049500" xlink:to="ifrs-full_PercentageOfVotingEquityInterestsAcquired_638043208769049500" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_CorporateReorganizationStockSplitRatio" xlink:label="cvac_CorporateReorganizationStockSplitRatio_638043208769049500" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems_638043208769049500" xlink:to="cvac_CorporateReorganizationStockSplitRatio_638043208769049500" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProportionOfOwnershipInterestInSubsidiary" xlink:label="ifrs-full_ProportionOfOwnershipInterestInSubsidiary_638043208769049500" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems_638043208769049500" xlink:to="ifrs-full_ProportionOfOwnershipInterestInSubsidiary_638043208769049500" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsRevenueFromContractWithCustomersDetails" xlink:type="extended" xlink:title="40301 - Disclosure - Notes to the consolidated financial statements - Revenue from contract with customers (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_DisclosureOfNotesToConsolidatedFinancialStatementsAbstract" xlink:label="DisclosureOfNotesToConsolidatedFinancialStatementsAbstract" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_DisclosureOfNotesToConsolidatedFinancialStatementsTable" xlink:label="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsTable_638043208769049500" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfNotesToConsolidatedFinancialStatementsAbstract" xlink:to="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsTable_638043208769049500" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_GeographicalAreasAxis" xlink:label="ifrs-full_GeographicalAreasAxis_638043208769049500" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsTable_638043208769049500" xlink:to="ifrs-full_GeographicalAreasAxis_638043208769049500" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_GeographicalAreasMember" xlink:label="ifrs-full_GeographicalAreasMember_638043208769059503" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_GeographicalAreasAxis_638043208769049500" xlink:to="ifrs-full_GeographicalAreasMember_638043208769059503" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_BE" xlink:label="country_BE_638043208769059503" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_GeographicalAreasMember_638043208769059503" xlink:to="country_BE_638043208769059503" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_DE" xlink:label="country_DE_638043208769059503" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_GeographicalAreasMember_638043208769059503" xlink:to="country_DE_638043208769059503" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_NL" xlink:label="country_NL_638043208769059503" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_GeographicalAreasMember_638043208769059503" xlink:to="country_NL_638043208769059503" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_CH" xlink:label="country_CH_638043208769059503" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_GeographicalAreasMember_638043208769059503" xlink:to="country_CH_638043208769059503" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US" xlink:label="country_US_638043208769059503" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_GeographicalAreasMember_638043208769059503" xlink:to="country_US_638043208769059503" order="5" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_MajorCustomersAxis" xlink:label="ifrs-full_MajorCustomersAxis_638043208769059503" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsTable_638043208769049500" xlink:to="ifrs-full_MajorCustomersAxis_638043208769059503" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_MajorCustomersMember" xlink:label="ifrs-full_MajorCustomersMember_638043208769059503" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_MajorCustomersAxis_638043208769059503" xlink:to="ifrs-full_MajorCustomersMember_638043208769059503" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_GlaxosmithklineMember" xlink:label="cvac_GlaxosmithklineMember_638043208769059503" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_MajorCustomersMember_638043208769059503" xlink:to="cvac_GlaxosmithklineMember_638043208769059503" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_BoehringerIngelheimMember" xlink:label="cvac_BoehringerIngelheimMember_638043208769059503" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_MajorCustomersMember_638043208769059503" xlink:to="cvac_BoehringerIngelheimMember_638043208769059503" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_OtherCustomersMember" xlink:label="cvac_OtherCustomersMember_638043208769059503" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_MajorCustomersMember_638043208769059503" xlink:to="cvac_OtherCustomersMember_638043208769059503" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_GenmabMember" xlink:label="cvac_GenmabMember_638043208769059503" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_MajorCustomersMember_638043208769059503" xlink:to="cvac_GenmabMember_638043208769059503" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_CrisprMember" xlink:label="cvac_CrisprMember_638043208769059503" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_MajorCustomersMember_638043208769059503" xlink:to="cvac_CrisprMember_638043208769059503" order="5" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_EliLillyAndCompanyMember" xlink:label="cvac_EliLillyAndCompanyMember_638043208769069501" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_MajorCustomersMember_638043208769059503" xlink:to="cvac_EliLillyAndCompanyMember_638043208769069501" order="6" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProductsAndServicesAxis" xlink:label="ifrs-full_ProductsAndServicesAxis_638043208769069501" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsTable_638043208769049500" xlink:to="ifrs-full_ProductsAndServicesAxis_638043208769069501" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProductsAndServicesMember" xlink:label="ifrs-full_ProductsAndServicesMember_638043208769069501" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ProductsAndServicesAxis_638043208769069501" xlink:to="ifrs-full_ProductsAndServicesMember_638043208769069501" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_ResearchServicesCombinedWithIpLicenseMember" xlink:label="cvac_ResearchServicesCombinedWithIpLicenseMember_638043208769069501" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ProductsAndServicesMember_638043208769069501" xlink:to="cvac_ResearchServicesCombinedWithIpLicenseMember_638043208769069501" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_IfrsProductMember" xlink:label="cvac_IfrsProductMember_638043208769069501" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ProductsAndServicesMember_638043208769069501" xlink:to="cvac_IfrsProductMember_638043208769069501" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_MilestoneRevenuesMember" xlink:label="cvac_MilestoneRevenuesMember_638043208769069501" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ProductsAndServicesMember_638043208769069501" xlink:to="cvac_MilestoneRevenuesMember_638043208769069501" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_ResearchAndDevelopmentServicesMember" xlink:label="cvac_ResearchAndDevelopmentServicesMember_638043208769069501" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ProductsAndServicesMember_638043208769069501" xlink:to="cvac_ResearchAndDevelopmentServicesMember_638043208769069501" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems" xlink:label="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems_638043208769069501" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsTable_638043208769049500" xlink:to="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems_638043208769069501" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RevenueFromContractsWithCustomers" xlink:label="ifrs-full_RevenueFromContractsWithCustomers_638043208769069501" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems_638043208769069501" xlink:to="ifrs-full_RevenueFromContractsWithCustomers_638043208769069501" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_AdditionalDevelopmentMilestonePaymentsReceived" xlink:label="cvac_AdditionalDevelopmentMilestonePaymentsReceived_638043208769069501" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems_638043208769069501" xlink:to="cvac_AdditionalDevelopmentMilestonePaymentsReceived_638043208769069501" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_IfrsDevelopmentMilestonePaymentIncludedInContractLiabilities" xlink:label="cvac_IfrsDevelopmentMilestonePaymentIncludedInContractLiabilities_638043208769079500" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems_638043208769069501" xlink:to="cvac_IfrsDevelopmentMilestonePaymentIncludedInContractLiabilities_638043208769079500" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsSummaryOfUpfrontPaymentsAndRelatedRevenuesRecognizedDetails" xlink:type="extended" xlink:title="40302 - Disclosure - Notes to the consolidated financial statements - Summary of upfront payments and related revenues recognized (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_DisclosureOfNotesToConsolidatedFinancialStatementsAbstract" xlink:label="DisclosureOfNotesToConsolidatedFinancialStatementsAbstract" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_DisclosureOfNotesToConsolidatedFinancialStatementsTable" xlink:label="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsTable_638043208769079500" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfNotesToConsolidatedFinancialStatementsAbstract" xlink:to="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsTable_638043208769079500" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProductsAndServicesAxis" xlink:label="ifrs-full_ProductsAndServicesAxis_638043208769079500" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsTable_638043208769079500" xlink:to="ifrs-full_ProductsAndServicesAxis_638043208769079500" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProductsAndServicesMember" xlink:label="ifrs-full_ProductsAndServicesMember_638043208769079500" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ProductsAndServicesAxis_638043208769079500" xlink:to="ifrs-full_ProductsAndServicesMember_638043208769079500" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_ResearchServicesCombinedWithIpLicenseMember" xlink:label="cvac_ResearchServicesCombinedWithIpLicenseMember_638043208769079500" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ProductsAndServicesMember_638043208769079500" xlink:to="cvac_ResearchServicesCombinedWithIpLicenseMember_638043208769079500" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RangeAxis" xlink:label="ifrs-full_RangeAxis_638043208769079500" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsTable_638043208769079500" xlink:to="ifrs-full_RangeAxis_638043208769079500" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RangesMember" xlink:label="ifrs-full_RangesMember_638043208769079500" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangeAxis_638043208769079500" xlink:to="ifrs-full_RangesMember_638043208769079500" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_BottomOfRangeMember" xlink:label="ifrs-full_BottomOfRangeMember_638043208769079500" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangesMember_638043208769079500" xlink:to="ifrs-full_BottomOfRangeMember_638043208769079500" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_MajorCustomersAxis" xlink:label="ifrs-full_MajorCustomersAxis_638043208769079500" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsTable_638043208769079500" xlink:to="ifrs-full_MajorCustomersAxis_638043208769079500" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_MajorCustomersMember" xlink:label="ifrs-full_MajorCustomersMember_638043208769079500" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_MajorCustomersAxis_638043208769079500" xlink:to="ifrs-full_MajorCustomersMember_638043208769079500" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_EliLillyAndCompanyMember" xlink:label="cvac_EliLillyAndCompanyMember_638043208769079500" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_MajorCustomersMember_638043208769079500" xlink:to="cvac_EliLillyAndCompanyMember_638043208769079500" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_CrisprMember" xlink:label="cvac_CrisprMember_638043208769089501" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_MajorCustomersMember_638043208769079500" xlink:to="cvac_CrisprMember_638043208769089501" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_BoehringerIngelheimMember" xlink:label="cvac_BoehringerIngelheimMember_638043208769089501" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_MajorCustomersMember_638043208769079500" xlink:to="cvac_BoehringerIngelheimMember_638043208769089501" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_GenmabMember" xlink:label="cvac_GenmabMember_638043208769089501" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_MajorCustomersMember_638043208769079500" xlink:to="cvac_GenmabMember_638043208769089501" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_GlaxosmithklineMember" xlink:label="cvac_GlaxosmithklineMember_638043208769089501" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_MajorCustomersMember_638043208769079500" xlink:to="cvac_GlaxosmithklineMember_638043208769089501" order="5" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_Gsk2ndGenMember" xlink:label="cvac_Gsk2ndGenMember_638043208769089501" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_MajorCustomersMember_638043208769079500" xlink:to="cvac_Gsk2ndGenMember_638043208769089501" order="6" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_BmbfMember" xlink:label="cvac_BmbfMember_638043208769089501" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_MajorCustomersMember_638043208769079500" xlink:to="cvac_BmbfMember_638043208769089501" order="7" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_GermanFederalMinistryOfEducationAndResearchMember" xlink:label="cvac_GermanFederalMinistryOfEducationAndResearchMember_638043208769089501" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_MajorCustomersMember_638043208769079500" xlink:to="cvac_GermanFederalMinistryOfEducationAndResearchMember_638043208769089501" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_EuropeanUnionAdvancePurchaseAgreementMember" xlink:label="cvac_EuropeanUnionAdvancePurchaseAgreementMember_638043208769089501" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_MajorCustomersMember_638043208769079500" xlink:to="cvac_EuropeanUnionAdvancePurchaseAgreementMember_638043208769089501" order="9" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_EuropeanCommissionMember" xlink:label="cvac_EuropeanCommissionMember_638043208769089501" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_MajorCustomersMember_638043208769079500" xlink:to="cvac_EuropeanCommissionMember_638043208769089501" order="10" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems" xlink:label="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems_638043208769089501" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsTable_638043208769079500" xlink:to="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems_638043208769089501" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_UpfrontPaymentsReceivedOrReceivable" xlink:label="cvac_UpfrontPaymentsReceivedOrReceivable_638043208769089501" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems_638043208769089501" xlink:to="cvac_UpfrontPaymentsReceivedOrReceivable_638043208769089501" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_UpfrontPaymentsIncludedInContractLiabilities" xlink:label="cvac_UpfrontPaymentsIncludedInContractLiabilities_638043208769099502" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems_638043208769089501" xlink:to="cvac_UpfrontPaymentsIncludedInContractLiabilities_638043208769099502" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod" xlink:label="ifrs-full_RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod_638043208769099502" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems_638043208769089501" xlink:to="ifrs-full_RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod_638043208769099502" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsContractLiabilitiesAllocatedToRemainingPerformanceObligationsDetails" xlink:type="extended" xlink:title="40303 - Disclosure - Notes to the consolidated financial statements - Contract liabilities allocated to the remaining performance obligations (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_DisclosureOfNotesToConsolidatedFinancialStatementsAbstract" xlink:label="DisclosureOfNotesToConsolidatedFinancialStatementsAbstract" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_DisclosureOfNotesToConsolidatedFinancialStatementsTable" xlink:label="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsTable_638043208769099502" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfNotesToConsolidatedFinancialStatementsAbstract" xlink:to="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsTable_638043208769099502" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis_638043208769099502" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsTable_638043208769099502" xlink:to="srt_StatementScenarioAxis_638043208769099502" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain_638043208769099502" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis_638043208769099502" xlink:to="srt_ScenarioUnspecifiedDomain_638043208769099502" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems" xlink:label="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems_638043208769099502" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsTable_638043208769099502" xlink:to="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems_638043208769099502" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CurrentTradeReceivables" xlink:label="ifrs-full_CurrentTradeReceivables_638043208769099502" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems_638043208769099502" xlink:to="ifrs-full_CurrentTradeReceivables_638043208769099502" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CurrentContractAssets" xlink:label="ifrs-full_CurrentContractAssets_638043208769099502" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems_638043208769099502" xlink:to="ifrs-full_CurrentContractAssets_638043208769099502" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ContractLiabilities" xlink:label="ifrs-full_ContractLiabilities_638043208769099502" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems_638043208769099502" xlink:to="ifrs-full_ContractLiabilities_638043208769099502" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsCostOfSalesDetails" xlink:type="extended" xlink:title="40304 - Disclosure - Notes to the consolidated financial statements - Cost of sales (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_DisclosureOfNotesToConsolidatedFinancialStatementsAbstract" xlink:label="DisclosureOfNotesToConsolidatedFinancialStatementsAbstract" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_DisclosureOfNotesToConsolidatedFinancialStatementsTable" xlink:label="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsTable_638043208769109499" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfNotesToConsolidatedFinancialStatementsAbstract" xlink:to="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsTable_638043208769109499" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_IfrsIncomeStatementLocationAxis" xlink:label="cvac_IfrsIncomeStatementLocationAxis_638043208769109499" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsTable_638043208769109499" xlink:to="cvac_IfrsIncomeStatementLocationAxis_638043208769109499" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_IfrsIncomeStatementLocationDomain" xlink:label="cvac_IfrsIncomeStatementLocationDomain_638043208769109499" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_IfrsIncomeStatementLocationAxis_638043208769109499" xlink:to="cvac_IfrsIncomeStatementLocationDomain_638043208769109499" order="1" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_IfrsCostOfSalesMember" xlink:label="cvac_IfrsCostOfSalesMember_638043208769109499" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_IfrsIncomeStatementLocationDomain_638043208769109499" xlink:to="cvac_IfrsCostOfSalesMember_638043208769109499" order="1" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems" xlink:label="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems_638043208769109499" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsTable_638043208769109499" xlink:to="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems_638043208769109499" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_PersonnelExpenses" xlink:label="cvac_PersonnelExpenses_638043208769109499" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems_638043208769109499" xlink:to="cvac_PersonnelExpenses_638043208769109499" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RawMaterialsAndConsumablesUsed" xlink:label="ifrs-full_RawMaterialsAndConsumablesUsed_638043208769109499" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems_638043208769109499" xlink:to="ifrs-full_RawMaterialsAndConsumablesUsed_638043208769109499" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_ThirdPartyServiceExpenses" xlink:label="cvac_ThirdPartyServiceExpenses_638043208769109499" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems_638043208769109499" xlink:to="cvac_ThirdPartyServiceExpenses_638043208769109499" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_MaintenanceAndLeaseExpenses" xlink:label="cvac_MaintenanceAndLeaseExpenses_638043208769109499" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems_638043208769109499" xlink:to="cvac_MaintenanceAndLeaseExpenses_638043208769109499" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DepreciationAndAmortisationExpense" xlink:label="ifrs-full_DepreciationAndAmortisationExpense_638043208769109499" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems_638043208769109499" xlink:to="ifrs-full_DepreciationAndAmortisationExpense_638043208769109499" order="5" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="9" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_OtherExpense" xlink:label="cvac_OtherExpense_638043208769109499" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems_638043208769109499" xlink:to="cvac_OtherExpense_638043208769109499" order="6" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ExpenseByNature" xlink:label="ifrs-full_ExpenseByNature_638043208769109499" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems_638043208769109499" xlink:to="ifrs-full_ExpenseByNature_638043208769109499" order="7" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" priority="8" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DecreaseThroughDerecognitionFinancialAssets" xlink:label="ifrs-full_DecreaseThroughDerecognitionFinancialAssets_638043208769109499" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems_638043208769109499" xlink:to="ifrs-full_DecreaseThroughDerecognitionFinancialAssets_638043208769109499" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_ChangeInExpenseByNature" xlink:label="cvac_ChangeInExpenseByNature_638043208769119501" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems_638043208769109499" xlink:to="cvac_ChangeInExpenseByNature_638043208769119501" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_WriteOffOfRawMaterials" xlink:label="cvac_WriteOffOfRawMaterials_638043208769119501" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems_638043208769109499" xlink:to="cvac_WriteOffOfRawMaterials_638043208769119501" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsSellingAndDistributionExpensesDetails" xlink:type="extended" xlink:title="40305 - Disclosure - Notes to the consolidated financial statements - Selling and distribution expenses (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_DisclosureOfNotesToConsolidatedFinancialStatementsAbstract" xlink:label="DisclosureOfNotesToConsolidatedFinancialStatementsAbstract" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_DisclosureOfNotesToConsolidatedFinancialStatementsTable" xlink:label="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsTable_638043208769119501" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfNotesToConsolidatedFinancialStatementsAbstract" xlink:to="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsTable_638043208769119501" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_IfrsIncomeStatementLocationAxis" xlink:label="cvac_IfrsIncomeStatementLocationAxis_638043208769119501" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsTable_638043208769119501" xlink:to="cvac_IfrsIncomeStatementLocationAxis_638043208769119501" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_IfrsIncomeStatementLocationDomain" xlink:label="cvac_IfrsIncomeStatementLocationDomain_638043208769119501" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_IfrsIncomeStatementLocationAxis_638043208769119501" xlink:to="cvac_IfrsIncomeStatementLocationDomain_638043208769119501" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_SellingAndDistributionExpensesMember" xlink:label="cvac_SellingAndDistributionExpensesMember_638043208769119501" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_IfrsIncomeStatementLocationDomain_638043208769119501" xlink:to="cvac_SellingAndDistributionExpensesMember_638043208769119501" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems" xlink:label="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems_638043208769119501" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsTable_638043208769119501" xlink:to="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems_638043208769119501" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_PersonnelExpenses" xlink:label="cvac_PersonnelExpenses_638043208769119501" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems_638043208769119501" xlink:to="cvac_PersonnelExpenses_638043208769119501" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DepreciationAndAmortisationExpense" xlink:label="ifrs-full_DepreciationAndAmortisationExpense_638043208769119501" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems_638043208769119501" xlink:to="ifrs-full_DepreciationAndAmortisationExpense_638043208769119501" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_OtherExpense" xlink:label="cvac_OtherExpense_638043208769119501" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems_638043208769119501" xlink:to="cvac_OtherExpense_638043208769119501" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ExpenseByNature" xlink:label="ifrs-full_ExpenseByNature_638043208769119501" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems_638043208769119501" xlink:to="ifrs-full_ExpenseByNature_638043208769119501" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ShorttermEmployeeBenefitsExpense" xlink:label="ifrs-full_ShorttermEmployeeBenefitsExpense_638043208769119501" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems_638043208769119501" xlink:to="ifrs-full_ShorttermEmployeeBenefitsExpense_638043208769119501" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" xlink:label="ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets_638043208769129500" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems_638043208769119501" xlink:to="ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets_638043208769129500" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsResearchAndDevelopmentExpensesDetails" xlink:type="extended" xlink:title="40306 - Disclosure - Notes to the consolidated financial statements - Research and development expenses (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_DisclosureOfNotesToConsolidatedFinancialStatementsAbstract" xlink:label="DisclosureOfNotesToConsolidatedFinancialStatementsAbstract" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_DisclosureOfNotesToConsolidatedFinancialStatementsTable" xlink:label="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsTable_638043208769129500" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfNotesToConsolidatedFinancialStatementsAbstract" xlink:to="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsTable_638043208769129500" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_IfrsIncomeStatementLocationAxis" xlink:label="cvac_IfrsIncomeStatementLocationAxis_638043208769129500" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsTable_638043208769129500" xlink:to="cvac_IfrsIncomeStatementLocationAxis_638043208769129500" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_IfrsIncomeStatementLocationDomain" xlink:label="cvac_IfrsIncomeStatementLocationDomain_638043208769129500" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_IfrsIncomeStatementLocationAxis_638043208769129500" xlink:to="cvac_IfrsIncomeStatementLocationDomain_638043208769129500" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_IfrsResearchAndDevelopmentExpenseMember" xlink:label="cvac_IfrsResearchAndDevelopmentExpenseMember_638043208769129500" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_IfrsIncomeStatementLocationDomain_638043208769129500" xlink:to="cvac_IfrsResearchAndDevelopmentExpenseMember_638043208769129500" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems" xlink:label="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems_638043208769129500" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsTable_638043208769129500" xlink:to="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems_638043208769129500" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RawMaterialsAndConsumablesUsed" xlink:label="ifrs-full_RawMaterialsAndConsumablesUsed_638043208769129500" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems_638043208769129500" xlink:to="ifrs-full_RawMaterialsAndConsumablesUsed_638043208769129500" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_PersonnelExpenses" xlink:label="cvac_PersonnelExpenses_638043208769129500" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems_638043208769129500" xlink:to="cvac_PersonnelExpenses_638043208769129500" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DepreciationAndAmortisationExpense" xlink:label="ifrs-full_DepreciationAndAmortisationExpense_638043208769129500" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems_638043208769129500" xlink:to="ifrs-full_DepreciationAndAmortisationExpense_638043208769129500" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_PatentsAndFeesToRegisterLegalRight" xlink:label="cvac_PatentsAndFeesToRegisterLegalRight_638043208769129500" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems_638043208769129500" xlink:to="cvac_PatentsAndFeesToRegisterLegalRight_638043208769129500" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_ThirdPartyServiceExpenses" xlink:label="cvac_ThirdPartyServiceExpenses_638043208769129500" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems_638043208769129500" xlink:to="cvac_ThirdPartyServiceExpenses_638043208769129500" order="5" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_MaintenanceAndLeaseExpenses" xlink:label="cvac_MaintenanceAndLeaseExpenses_638043208769139501" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems_638043208769129500" xlink:to="cvac_MaintenanceAndLeaseExpenses_638043208769139501" order="6" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_OtherExpense" xlink:label="cvac_OtherExpense_638043208769139501" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems_638043208769129500" xlink:to="cvac_OtherExpense_638043208769139501" order="7" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ExpenseByNature" xlink:label="ifrs-full_ExpenseByNature_638043208769139501" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems_638043208769129500" xlink:to="ifrs-full_ExpenseByNature_638043208769139501" order="8" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ShorttermEmployeeBenefitsExpense" xlink:label="ifrs-full_ShorttermEmployeeBenefitsExpense_638043208769139501" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems_638043208769129500" xlink:to="ifrs-full_ShorttermEmployeeBenefitsExpense_638043208769139501" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" xlink:label="ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets_638043208769139501" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems_638043208769129500" xlink:to="ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets_638043208769139501" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_ReversalOfProvisionForOnerousContracts" xlink:label="cvac_ReversalOfProvisionForOnerousContracts_638043208769139501" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems_638043208769129500" xlink:to="cvac_ReversalOfProvisionForOnerousContracts_638043208769139501" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_IfrsIncreaseInExpenseRelatedToIneffectiveSetUpActivitiesAndSettlementCosts" xlink:label="cvac_IfrsIncreaseInExpenseRelatedToIneffectiveSetUpActivitiesAndSettlementCosts_638043208769139501" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems_638043208769129500" xlink:to="cvac_IfrsIncreaseInExpenseRelatedToIneffectiveSetUpActivitiesAndSettlementCosts_638043208769139501" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsGeneralAndAdministrativeExpensesDetails" xlink:type="extended" xlink:title="40307 - Disclosure - Notes to the consolidated financial statements - General and administrative expenses (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_DisclosureOfNotesToConsolidatedFinancialStatementsAbstract" xlink:label="DisclosureOfNotesToConsolidatedFinancialStatementsAbstract" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_DisclosureOfNotesToConsolidatedFinancialStatementsTable" xlink:label="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsTable_638043208769139501" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfNotesToConsolidatedFinancialStatementsAbstract" xlink:to="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsTable_638043208769139501" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_IfrsIncomeStatementLocationAxis" xlink:label="cvac_IfrsIncomeStatementLocationAxis_638043208769139501" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsTable_638043208769139501" xlink:to="cvac_IfrsIncomeStatementLocationAxis_638043208769139501" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_IfrsIncomeStatementLocationDomain" xlink:label="cvac_IfrsIncomeStatementLocationDomain_638043208769139501" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_IfrsIncomeStatementLocationAxis_638043208769139501" xlink:to="cvac_IfrsIncomeStatementLocationDomain_638043208769139501" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_IfrsGeneralAndAdministrativeExpenseMember" xlink:label="cvac_IfrsGeneralAndAdministrativeExpenseMember_638043208769149501" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_IfrsIncomeStatementLocationDomain_638043208769139501" xlink:to="cvac_IfrsGeneralAndAdministrativeExpenseMember_638043208769149501" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems" xlink:label="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems_638043208769149501" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsTable_638043208769139501" xlink:to="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems_638043208769149501" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_PersonnelExpenses" xlink:label="cvac_PersonnelExpenses_638043208769149501" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems_638043208769149501" xlink:to="cvac_PersonnelExpenses_638043208769149501" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_MaintenanceAndLeaseExpenses" xlink:label="cvac_MaintenanceAndLeaseExpenses_638043208769149501" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems_638043208769149501" xlink:to="cvac_MaintenanceAndLeaseExpenses_638043208769149501" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="9" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_ThirdPartyServiceExpenses" xlink:label="cvac_ThirdPartyServiceExpenses_638043208769149501" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems_638043208769149501" xlink:to="cvac_ThirdPartyServiceExpenses_638043208769149501" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProfessionalFeesExpense" xlink:label="ifrs-full_ProfessionalFeesExpense_638043208769149501" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems_638043208769149501" xlink:to="ifrs-full_ProfessionalFeesExpense_638043208769149501" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DepreciationAndAmortisationExpense" xlink:label="ifrs-full_DepreciationAndAmortisationExpense_638043208769149501" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems_638043208769149501" xlink:to="ifrs-full_DepreciationAndAmortisationExpense_638043208769149501" order="5" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_OtherExpense" xlink:label="cvac_OtherExpense_638043208769149501" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems_638043208769149501" xlink:to="cvac_OtherExpense_638043208769149501" order="6" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="8" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ExpenseByNature" xlink:label="ifrs-full_ExpenseByNature_638043208769149501" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems_638043208769149501" xlink:to="ifrs-full_ExpenseByNature_638043208769149501" order="7" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ShorttermEmployeeBenefitsExpense" xlink:label="ifrs-full_ShorttermEmployeeBenefitsExpense_638043208769149501" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems_638043208769149501" xlink:to="ifrs-full_ShorttermEmployeeBenefitsExpense_638043208769149501" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" xlink:label="ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets_638043208769149501" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems_638043208769149501" xlink:to="ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets_638043208769149501" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TravelExpense" xlink:label="ifrs-full_TravelExpense_638043208769149501" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems_638043208769149501" xlink:to="ifrs-full_TravelExpense_638043208769149501" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_InsuranceExpense" xlink:label="ifrs-full_InsuranceExpense_638043208769149501" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems_638043208769149501" xlink:to="ifrs-full_InsuranceExpense_638043208769149501" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_RealEstateTransferTaxes" xlink:label="cvac_RealEstateTransferTaxes_638043208769159501" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems_638043208769149501" xlink:to="cvac_RealEstateTransferTaxes_638043208769159501" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsOtherOperatingIncomeDetails" xlink:type="extended" xlink:title="40308 - Disclosure - Notes to the consolidated financial statements - Other operating income (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_DisclosureOfNotesToConsolidatedFinancialStatementsAbstract" xlink:label="DisclosureOfNotesToConsolidatedFinancialStatementsAbstract" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_CompensationForContractManufacturingOrganizationsTransfer" xlink:label="cvac_CompensationForContractManufacturingOrganizationsTransfer_638043208769159501" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfNotesToConsolidatedFinancialStatementsAbstract" xlink:to="cvac_CompensationForContractManufacturingOrganizationsTransfer_638043208769159501" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_CostOfReimbursementClaim" xlink:label="cvac_CostOfReimbursementClaim_638043208769159501" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfNotesToConsolidatedFinancialStatementsAbstract" xlink:to="cvac_CostOfReimbursementClaim_638043208769159501" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_SaleOfEquipment" xlink:label="cvac_SaleOfEquipment_638043208769159501" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfNotesToConsolidatedFinancialStatementsAbstract" xlink:to="cvac_SaleOfEquipment_638043208769159501" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_OtherOperatingIncomeGovernmentGrants" xlink:label="cvac_OtherOperatingIncomeGovernmentGrants_638043208769159501" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfNotesToConsolidatedFinancialStatementsAbstract" xlink:to="cvac_OtherOperatingIncomeGovernmentGrants_638043208769159501" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_ReversalOfProvisionsForPersonnelExpenses" xlink:label="cvac_ReversalOfProvisionsForPersonnelExpenses_638043208769159501" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfNotesToConsolidatedFinancialStatementsAbstract" xlink:to="cvac_ReversalOfProvisionsForPersonnelExpenses_638043208769159501" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_MiscellaneousOtherOperatingIncomeOther" xlink:label="cvac_MiscellaneousOtherOperatingIncomeOther_638043208769159501" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfNotesToConsolidatedFinancialStatementsAbstract" xlink:to="cvac_MiscellaneousOtherOperatingIncomeOther_638043208769159501" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_MiscellaneousOtherOperatingIncome" xlink:label="ifrs-full_MiscellaneousOtherOperatingIncome_638043208769159501" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfNotesToConsolidatedFinancialStatementsAbstract" xlink:to="ifrs-full_MiscellaneousOtherOperatingIncome_638043208769159501" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsGrantsWithGovernmentAgenciesAndSimilarBodiesDetails" xlink:type="extended" xlink:title="40309 - Disclosure - Notes to the consolidated financial statements - Grants with government agencies and similar bodies (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_DisclosureOfNotesToConsolidatedFinancialStatementsAbstract" xlink:label="DisclosureOfNotesToConsolidatedFinancialStatementsAbstract" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_DisclosureOfGovernmentGrantsTable" xlink:label="cvac_DisclosureOfGovernmentGrantsTable_638043208769159501" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfNotesToConsolidatedFinancialStatementsAbstract" xlink:to="cvac_DisclosureOfGovernmentGrantsTable_638043208769159501" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis_638043208769169500" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfGovernmentGrantsTable_638043208769159501" xlink:to="srt_StatementScenarioAxis_638043208769169500" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain_638043208769169500" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis_638043208769169500" xlink:to="srt_ScenarioUnspecifiedDomain_638043208769169500" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_GovernmentGrantsAxis" xlink:label="cvac_GovernmentGrantsAxis_638043208769169500" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfGovernmentGrantsTable_638043208769159501" xlink:to="cvac_GovernmentGrantsAxis_638043208769169500" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_GovernmentGrantsDomain" xlink:label="cvac_GovernmentGrantsDomain_638043208769169500" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_GovernmentGrantsAxis_638043208769169500" xlink:to="cvac_GovernmentGrantsDomain_638043208769169500" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_GermanFederalMinistryOfEducationAndResearchMember" xlink:label="cvac_GermanFederalMinistryOfEducationAndResearchMember_638043208769169500" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_GovernmentGrantsDomain_638043208769169500" xlink:to="cvac_GermanFederalMinistryOfEducationAndResearchMember_638043208769169500" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_CoalitionForEpidemicPreparednessInnovationsMember" xlink:label="cvac_CoalitionForEpidemicPreparednessInnovationsMember_638043208769169500" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_GovernmentGrantsDomain_638043208769169500" xlink:to="cvac_CoalitionForEpidemicPreparednessInnovationsMember_638043208769169500" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_BillAndMelindaGatesFoundationBmgfMember" xlink:label="cvac_BillAndMelindaGatesFoundationBmgfMember_638043208769169500" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_GovernmentGrantsDomain_638043208769169500" xlink:to="cvac_BillAndMelindaGatesFoundationBmgfMember_638043208769169500" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_BillMelindaGatesFoundationBmgfGrantForDevelopmentOfUniversalInfluenzaVaccineMember" xlink:label="cvac_BillMelindaGatesFoundationBmgfGrantForDevelopmentOfUniversalInfluenzaVaccineMember_638043208769169500" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_BillAndMelindaGatesFoundationBmgfMember_638043208769169500" xlink:to="cvac_BillMelindaGatesFoundationBmgfGrantForDevelopmentOfUniversalInfluenzaVaccineMember_638043208769169500" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_BillMelindaGatesFoundationBmgfGrantForMalariaVaccineMember" xlink:label="cvac_BillMelindaGatesFoundationBmgfGrantForMalariaVaccineMember_638043208769169500" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_BillAndMelindaGatesFoundationBmgfMember_638043208769169500" xlink:to="cvac_BillMelindaGatesFoundationBmgfGrantForMalariaVaccineMember_638043208769169500" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_638043208769169500" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfGovernmentGrantsTable_638043208769159501" xlink:to="srt_CounterpartyNameAxis_638043208769169500" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_638043208769169500" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis_638043208769169500" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_638043208769169500" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_GlaxosmithklineMember" xlink:label="cvac_GlaxosmithklineMember_638043208769169500" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_638043208769169500" xlink:to="cvac_GlaxosmithklineMember_638043208769169500" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_GskAgreement2020Member" xlink:label="cvac_GskAgreement2020Member_638043208769169500" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_638043208769169500" xlink:to="cvac_GskAgreement2020Member_638043208769169500" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_BoehringerIngelheimMember" xlink:label="cvac_BoehringerIngelheimMember_638043208769169500" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_638043208769169500" xlink:to="cvac_BoehringerIngelheimMember_638043208769169500" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_CrisprTherapeuticsMember" xlink:label="cvac_CrisprTherapeuticsMember_638043208769179500" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_638043208769169500" xlink:to="cvac_CrisprTherapeuticsMember_638043208769179500" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_GenmabMember" xlink:label="cvac_GenmabMember_638043208769179500" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_638043208769169500" xlink:to="cvac_GenmabMember_638043208769179500" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_EliLillyMember" xlink:label="cvac_EliLillyMember_638043208769179500" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_638043208769169500" xlink:to="cvac_EliLillyMember_638043208769179500" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_TypeOfArrangementAxis" xlink:label="cvac_TypeOfArrangementAxis_638043208769179500" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfGovernmentGrantsTable_638043208769159501" xlink:to="cvac_TypeOfArrangementAxis_638043208769179500" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_ArrangementsAndNonArrangementTransactionsMember" xlink:label="cvac_ArrangementsAndNonArrangementTransactionsMember_638043208769179500" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_TypeOfArrangementAxis_638043208769179500" xlink:to="cvac_ArrangementsAndNonArrangementTransactionsMember_638043208769179500" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_AdvancedPurchaseAgreementWithEuropeanCommissionMember" xlink:label="cvac_AdvancedPurchaseAgreementWithEuropeanCommissionMember_638043208769179500" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_ArrangementsAndNonArrangementTransactionsMember_638043208769179500" xlink:to="cvac_AdvancedPurchaseAgreementWithEuropeanCommissionMember_638043208769179500" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_DisclosureOfGovernmentGrantsLineItems" xlink:label="cvac_DisclosureOfGovernmentGrantsLineItems_638043208769179500" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfGovernmentGrantsTable_638043208769159501" xlink:to="cvac_DisclosureOfGovernmentGrantsLineItems_638043208769179500" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_NumberOfDosesOfSarsCov2CanBePurchasedByMemberStatesUnderAdvancePurchaseAgreement" xlink:label="cvac_NumberOfDosesOfSarsCov2CanBePurchasedByMemberStatesUnderAdvancePurchaseAgreement_638043208769179500" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfGovernmentGrantsLineItems_638043208769179500" xlink:to="cvac_NumberOfDosesOfSarsCov2CanBePurchasedByMemberStatesUnderAdvancePurchaseAgreement_638043208769179500" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_MaximumGrantToBeReceived" xlink:label="cvac_MaximumGrantToBeReceived_638043208769179500" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfGovernmentGrantsLineItems_638043208769179500" xlink:to="cvac_MaximumGrantToBeReceived_638043208769179500" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_UpfrontPaymentReceived" xlink:label="cvac_UpfrontPaymentReceived_638043208769179500" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfGovernmentGrantsLineItems_638043208769179500" xlink:to="cvac_UpfrontPaymentReceived_638043208769179500" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RevenueFromGovernmentGrants" xlink:label="ifrs-full_RevenueFromGovernmentGrants_638043208769189503" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfGovernmentGrantsLineItems_638043208769179500" xlink:to="ifrs-full_RevenueFromGovernmentGrants_638043208769189503" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_IfrsMilestonePaymentReceived" xlink:label="cvac_IfrsMilestonePaymentReceived_638043208769189503" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfGovernmentGrantsLineItems_638043208769179500" xlink:to="cvac_IfrsMilestonePaymentReceived_638043208769189503" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_IfrsRemainingGrantIncome" xlink:label="cvac_IfrsRemainingGrantIncome_638043208769189503" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfGovernmentGrantsLineItems_638043208769179500" xlink:to="cvac_IfrsRemainingGrantIncome_638043208769189503" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_GovernmentGrants" xlink:label="ifrs-full_GovernmentGrants_638043208769189503" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfGovernmentGrantsLineItems_638043208769179500" xlink:to="ifrs-full_GovernmentGrants_638043208769189503" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_PartnershipAgreementMaximumAmount" xlink:label="cvac_PartnershipAgreementMaximumAmount_638043208769189503" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfGovernmentGrantsLineItems_638043208769179500" xlink:to="cvac_PartnershipAgreementMaximumAmount_638043208769189503" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_PartnershipAgreementTerm" xlink:label="cvac_PartnershipAgreementTerm_638043208769189503" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfGovernmentGrantsLineItems_638043208769179500" xlink:to="cvac_PartnershipAgreementTerm_638043208769189503" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_PartnershipAgreementPeriodOfCostsToBeCovered" xlink:label="cvac_PartnershipAgreementPeriodOfCostsToBeCovered_638043208769189503" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfGovernmentGrantsLineItems_638043208769179500" xlink:to="cvac_PartnershipAgreementPeriodOfCostsToBeCovered_638043208769189503" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProceedsFromGovernmentGrantsClassifiedAsFinancingActivities" xlink:label="ifrs-full_ProceedsFromGovernmentGrantsClassifiedAsFinancingActivities_638043208769189503" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfGovernmentGrantsLineItems_638043208769179500" xlink:to="ifrs-full_ProceedsFromGovernmentGrantsClassifiedAsFinancingActivities_638043208769189503" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_AmountDeductedFromCarryingAmountOfQualifyingAssets" xlink:label="cvac_AmountDeductedFromCarryingAmountOfQualifyingAssets_638043208769189503" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfGovernmentGrantsLineItems_638043208769179500" xlink:to="cvac_AmountDeductedFromCarryingAmountOfQualifyingAssets_638043208769189503" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_NumberOfAdditionalGrantsReceived" xlink:label="cvac_NumberOfAdditionalGrantsReceived_638043208769199503" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfGovernmentGrantsLineItems_638043208769179500" xlink:to="cvac_NumberOfAdditionalGrantsReceived_638043208769199503" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_ReceiptsFromGovernmentGrantsClassifiedAsOperatingActivities" xlink:label="cvac_ReceiptsFromGovernmentGrantsClassifiedAsOperatingActivities_638043208769199503" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfGovernmentGrantsLineItems_638043208769179500" xlink:to="cvac_ReceiptsFromGovernmentGrantsClassifiedAsOperatingActivities_638043208769199503" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_CompensationForContractManufacturingOrganizationsTransferConsiderationForSetUpActivities" xlink:label="cvac_CompensationForContractManufacturingOrganizationsTransferConsiderationForSetUpActivities_638043208769199503" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfGovernmentGrantsLineItems_638043208769179500" xlink:to="cvac_CompensationForContractManufacturingOrganizationsTransferConsiderationForSetUpActivities_638043208769199503" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_CompensationForContractManufacturingOrganizationsTransferManufacturingInterimPeriodReimbursableExpenses" xlink:label="cvac_CompensationForContractManufacturingOrganizationsTransferManufacturingInterimPeriodReimbursableExpenses_638043208769199503" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfGovernmentGrantsLineItems_638043208769179500" xlink:to="cvac_CompensationForContractManufacturingOrganizationsTransferManufacturingInterimPeriodReimbursableExpenses_638043208769199503" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_ReversalOfProvisionRecognizedDueToCertainReservedCapacityTakenOver" xlink:label="cvac_ReversalOfProvisionRecognizedDueToCertainReservedCapacityTakenOver_638043208769199503" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfGovernmentGrantsLineItems_638043208769179500" xlink:to="cvac_ReversalOfProvisionRecognizedDueToCertainReservedCapacityTakenOver_638043208769199503" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.curevac.com/role/DisclosureIssuedCapitalAndReservesOverviewAndGeneralRemarksDetails" xlink:type="extended" xlink:title="40401 - Disclosure - Issued Capital and Reserves - Overview and General Remarks (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalAbstract" xlink:label="DisclosureOfClassesOfShareCapitalAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalTable" xlink:label="ifrs-full_DisclosureOfClassesOfShareCapitalTable_638043208769209502" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfClassesOfShareCapitalAbstract" xlink:to="ifrs-full_DisclosureOfClassesOfShareCapitalTable_638043208769209502" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:label="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_638043208769209502" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalTable_638043208769209502" xlink:to="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_638043208769209502" order="1" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_SharebasedPaymentArrangementsMember" xlink:label="ifrs-full_SharebasedPaymentArrangementsMember_638043208769209502" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_638043208769209502" xlink:to="ifrs-full_SharebasedPaymentArrangementsMember_638043208769209502" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_VirtualSharesProgramIMember" xlink:label="cvac_VirtualSharesProgramIMember_638043208769209502" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_SharebasedPaymentArrangementsMember_638043208769209502" xlink:to="cvac_VirtualSharesProgramIMember_638043208769209502" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ClassesOfShareCapitalAxis" xlink:label="ifrs-full_ClassesOfShareCapitalAxis_638043208769209502" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalTable_638043208769209502" xlink:to="ifrs-full_ClassesOfShareCapitalAxis_638043208769209502" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ClassesOfShareCapitalMember" xlink:label="ifrs-full_ClassesOfShareCapitalMember_638043208769209502" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfShareCapitalAxis_638043208769209502" xlink:to="ifrs-full_ClassesOfShareCapitalMember_638043208769209502" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OrdinarySharesMember" xlink:label="ifrs-full_OrdinarySharesMember_638043208769209502" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfShareCapitalMember_638043208769209502" xlink:to="ifrs-full_OrdinarySharesMember_638043208769209502" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_PreferenceSharesMember" xlink:label="ifrs-full_PreferenceSharesMember_638043208769209502" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfShareCapitalMember_638043208769209502" xlink:to="ifrs-full_PreferenceSharesMember_638043208769209502" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_IfrsSaleOfStockAxis" xlink:label="cvac_IfrsSaleOfStockAxis_638043208769209502" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalTable_638043208769209502" xlink:to="cvac_IfrsSaleOfStockAxis_638043208769209502" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_IfrsSaleOfStockDomain" xlink:label="cvac_IfrsSaleOfStockDomain_638043208769209502" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_IfrsSaleOfStockAxis_638043208769209502" xlink:to="cvac_IfrsSaleOfStockDomain_638043208769209502" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_FollowOnPublicOfferingMember" xlink:label="cvac_FollowOnPublicOfferingMember_638043208769209502" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_IfrsSaleOfStockDomain_638043208769209502" xlink:to="cvac_FollowOnPublicOfferingMember_638043208769209502" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_IfrsOverAllotmentOptionMember" xlink:label="cvac_IfrsOverAllotmentOptionMember_638043208769209502" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_IfrsSaleOfStockDomain_638043208769209502" xlink:to="cvac_IfrsOverAllotmentOptionMember_638043208769209502" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ComponentsOfEquityAxis" xlink:label="ifrs-full_ComponentsOfEquityAxis_638043208769209502" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalTable_638043208769209502" xlink:to="ifrs-full_ComponentsOfEquityAxis_638043208769209502" order="4" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_EquityMember" xlink:label="ifrs-full_EquityMember_638043208769219501" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ComponentsOfEquityAxis_638043208769209502" xlink:to="ifrs-full_EquityMember_638043208769219501" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TreasurySharesMember" xlink:label="ifrs-full_TreasurySharesMember_638043208769219501" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EquityMember_638043208769219501" xlink:to="ifrs-full_TreasurySharesMember_638043208769219501" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:label="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_638043208769219501" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalTable_638043208769209502" xlink:to="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_638043208769219501" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NumberOfSharesAuthorised" xlink:label="ifrs-full_NumberOfSharesAuthorised_638043208769219501" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_638043208769219501" xlink:to="ifrs-full_NumberOfSharesAuthorised_638043208769219501" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ParValuePerShare" xlink:label="ifrs-full_ParValuePerShare_638043208769219501" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_638043208769219501" xlink:to="ifrs-full_ParValuePerShare_638043208769219501" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NumberOfSharesIssued" xlink:label="ifrs-full_NumberOfSharesIssued_638043208769219501" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_638043208769219501" xlink:to="ifrs-full_NumberOfSharesIssued_638043208769219501" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ShareIssueRelatedCost" xlink:label="ifrs-full_ShareIssueRelatedCost_638043208769219501" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_638043208769219501" xlink:to="ifrs-full_ShareIssueRelatedCost_638043208769219501" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_RemainingAuthorizedForSaleValue" xlink:label="cvac_RemainingAuthorizedForSaleValue_638043208769219501" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_638043208769219501" xlink:to="cvac_RemainingAuthorizedForSaleValue_638043208769219501" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_IfrsStockholdersEquityNoteStockSplitConversionRatio" xlink:label="cvac_IfrsStockholdersEquityNoteStockSplitConversionRatio_638043208769219501" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_638043208769219501" xlink:to="cvac_IfrsStockholdersEquityNoteStockSplitConversionRatio_638043208769219501" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.curevac.com/role/DisclosureIssuedCapitalAndReservesImpactOfShareSplitDetails" xlink:type="extended" xlink:title="40402 - Disclosure - Issued Capital and Reserves - Impact of share split (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalAbstract" xlink:label="DisclosureOfClassesOfShareCapitalAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalTable" xlink:label="ifrs-full_DisclosureOfClassesOfShareCapitalTable_638043208769229530" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfClassesOfShareCapitalAbstract" xlink:to="ifrs-full_DisclosureOfClassesOfShareCapitalTable_638043208769229530" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_IfrsSaleOfStockAxis" xlink:label="cvac_IfrsSaleOfStockAxis_638043208769229530" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalTable_638043208769229530" xlink:to="cvac_IfrsSaleOfStockAxis_638043208769229530" order="1" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_IfrsSaleOfStockDomain" xlink:label="cvac_IfrsSaleOfStockDomain_638043208769229530" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_IfrsSaleOfStockAxis_638043208769229530" xlink:to="cvac_IfrsSaleOfStockDomain_638043208769229530" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_CapitalIncreaseByGenmabMember" xlink:label="cvac_CapitalIncreaseByGenmabMember_638043208769229530" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_IfrsSaleOfStockDomain_638043208769229530" xlink:to="cvac_CapitalIncreaseByGenmabMember_638043208769229530" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_PrivatePlacementIsa2020Member" xlink:label="cvac_PrivatePlacementIsa2020Member_638043208769229530" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_IfrsSaleOfStockDomain_638043208769229530" xlink:to="cvac_PrivatePlacementIsa2020Member_638043208769229530" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_InitialPublicOfferingAndPrivatePlacementMember" xlink:label="cvac_InitialPublicOfferingAndPrivatePlacementMember_638043208769229530" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_IfrsSaleOfStockDomain_638043208769229530" xlink:to="cvac_InitialPublicOfferingAndPrivatePlacementMember_638043208769229530" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_ExerciseOfGreenshoeMember" xlink:label="cvac_ExerciseOfGreenshoeMember_638043208769229530" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_IfrsSaleOfStockDomain_638043208769229530" xlink:to="cvac_ExerciseOfGreenshoeMember_638043208769229530" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_FollowOnPublicOfferingMember" xlink:label="cvac_FollowOnPublicOfferingMember_638043208769229530" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_IfrsSaleOfStockDomain_638043208769229530" xlink:to="cvac_FollowOnPublicOfferingMember_638043208769229530" order="5" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_AtMarketOfferingProgramMember" xlink:label="cvac_AtMarketOfferingProgramMember_638043208769229530" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_IfrsSaleOfStockDomain_638043208769229530" xlink:to="cvac_AtMarketOfferingProgramMember_638043208769229530" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ClassesOfShareCapitalAxis" xlink:label="ifrs-full_ClassesOfShareCapitalAxis_638043208769229530" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalTable_638043208769229530" xlink:to="ifrs-full_ClassesOfShareCapitalAxis_638043208769229530" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ClassesOfShareCapitalMember" xlink:label="ifrs-full_ClassesOfShareCapitalMember_638043208769229530" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfShareCapitalAxis_638043208769229530" xlink:to="ifrs-full_ClassesOfShareCapitalMember_638043208769229530" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_SeriesSharesMember" xlink:label="cvac_SeriesSharesMember_638043208769229530" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfShareCapitalMember_638043208769229530" xlink:to="cvac_SeriesSharesMember_638043208769229530" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_SeriesCSharesMember" xlink:label="cvac_SeriesCSharesMember_638043208769239504" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfShareCapitalMember_638043208769229530" xlink:to="cvac_SeriesCSharesMember_638043208769239504" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:label="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_638043208769239504" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalTable_638043208769229530" xlink:to="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_638043208769239504" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NonadjustingEventsMember" xlink:label="ifrs-full_NonadjustingEventsMember_638043208769239504" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_638043208769239504" xlink:to="ifrs-full_NonadjustingEventsMember_638043208769239504" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_MajorOrdinaryShareTransactionsMember" xlink:label="ifrs-full_MajorOrdinaryShareTransactionsMember_638043208769239504" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NonadjustingEventsMember_638043208769239504" xlink:to="ifrs-full_MajorOrdinaryShareTransactionsMember_638043208769239504" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:label="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_638043208769239504" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalTable_638043208769229530" xlink:to="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_638043208769239504" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_CommonSharesIssuedAndOutstanding" xlink:label="cvac_CommonSharesIssuedAndOutstanding_638043208769239504" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_638043208769239504" xlink:to="cvac_CommonSharesIssuedAndOutstanding_638043208769239504" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_IncreaseInNumberOfSharesOutstanding" xlink:label="cvac_IncreaseInNumberOfSharesOutstanding_638043208769239504" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_638043208769239504" xlink:to="cvac_IncreaseInNumberOfSharesOutstanding_638043208769239504" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_ShareOptionExercises" xlink:label="cvac_ShareOptionExercises_638043208769239504" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_638043208769239504" xlink:to="cvac_ShareOptionExercises_638043208769239504" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_DecreaseInNumberOfSharesDueToTreasuryOfShares" xlink:label="cvac_DecreaseInNumberOfSharesDueToTreasuryOfShares_638043208769239504" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_638043208769239504" xlink:to="cvac_DecreaseInNumberOfSharesDueToTreasuryOfShares_638043208769239504" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_StockIssuedDuringPeriodForExercises" xlink:label="cvac_StockIssuedDuringPeriodForExercises_638043208769239504" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_638043208769239504" xlink:to="cvac_StockIssuedDuringPeriodForExercises_638043208769239504" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_StockIssuanceDuringPeriodForExistingShareholders" xlink:label="cvac_StockIssuanceDuringPeriodForExistingShareholders_638043208769239504" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_638043208769239504" xlink:to="cvac_StockIssuanceDuringPeriodForExistingShareholders_638043208769239504" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_IfrsStockIssuedDuringPeriodSharesNewIssues" xlink:label="cvac_IfrsStockIssuedDuringPeriodSharesNewIssues_638043208769249504" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_638043208769239504" xlink:to="cvac_IfrsStockIssuedDuringPeriodSharesNewIssues_638043208769249504" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_CommonSharesIssuedAndOutstanding" xlink:label="cvac_CommonSharesIssuedAndOutstanding_638043208769249504" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_638043208769239504" xlink:to="cvac_CommonSharesIssuedAndOutstanding_638043208769249504" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_AggregateGrossProceedsReceivableFromIssuingShares" xlink:label="cvac_AggregateGrossProceedsReceivableFromIssuingShares_638043208769249504" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_638043208769239504" xlink:to="cvac_AggregateGrossProceedsReceivableFromIssuingShares_638043208769249504" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProceedsFromIssuingShares" xlink:label="ifrs-full_ProceedsFromIssuingShares_638043208769249504" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_638043208769239504" xlink:to="ifrs-full_ProceedsFromIssuingShares_638043208769249504" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ShareIssueRelatedCost" xlink:label="ifrs-full_ShareIssueRelatedCost_638043208769249504" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_638043208769239504" xlink:to="ifrs-full_ShareIssueRelatedCost_638043208769249504" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.curevac.com/role/DisclosureShareBasedPaymentsExpensesDetails" xlink:type="extended" xlink:title="40501 - Disclosure - Share-based payments - Expenses (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:label="DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_638043208769249504" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:to="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_638043208769249504" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:label="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_638043208769249504" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_638043208769249504" xlink:to="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_638043208769249504" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_SharebasedPaymentArrangementsMember" xlink:label="ifrs-full_SharebasedPaymentArrangementsMember_638043208769259503" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_638043208769249504" xlink:to="ifrs-full_SharebasedPaymentArrangementsMember_638043208769259503" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_VirtualSharesProgramIMember" xlink:label="cvac_VirtualSharesProgramIMember_638043208769259503" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_SharebasedPaymentArrangementsMember_638043208769259503" xlink:to="cvac_VirtualSharesProgramIMember_638043208769259503" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_638043208769259503" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_638043208769249504" xlink:to="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_638043208769259503" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInResearchAndDevelopmentExpenses" xlink:label="cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInResearchAndDevelopmentExpenses_638043208769259503" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_638043208769259503" xlink:to="cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInResearchAndDevelopmentExpenses_638043208769259503" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInSellingAndDistributionExpenses" xlink:label="cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInSellingAndDistributionExpenses_638043208769259503" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_638043208769259503" xlink:to="cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInSellingAndDistributionExpenses_638043208769259503" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInGeneralAndAdministrativeExpenses" xlink:label="cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInGeneralAndAdministrativeExpenses_638043208769259503" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_638043208769259503" xlink:to="cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInGeneralAndAdministrativeExpenses_638043208769259503" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_BenefitExpenseRecognizedForShareBasedPayment" xlink:label="cvac_BenefitExpenseRecognizedForShareBasedPayment_638043208769259503" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_638043208769259503" xlink:to="cvac_BenefitExpenseRecognizedForShareBasedPayment_638043208769259503" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.curevac.com/role/DisclosureShareBasedPaymentsExpenseRecognizedForProgramDetails" xlink:type="extended" xlink:title="40502 - Disclosure - Share-based payments - Expense recognized for the program (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:label="DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_638043208769259503" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:to="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_638043208769259503" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:label="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_638043208769259503" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_638043208769259503" xlink:to="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_638043208769259503" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_SharebasedPaymentArrangementsMember" xlink:label="ifrs-full_SharebasedPaymentArrangementsMember_638043208769259503" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_638043208769259503" xlink:to="ifrs-full_SharebasedPaymentArrangementsMember_638043208769259503" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_LongTermIncentivePlanMember" xlink:label="cvac_LongTermIncentivePlanMember_638043208769259503" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_SharebasedPaymentArrangementsMember_638043208769259503" xlink:to="cvac_LongTermIncentivePlanMember_638043208769259503" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_IfrsRestrictedStockUnitMember" xlink:label="cvac_IfrsRestrictedStockUnitMember_638043208769269502" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_SharebasedPaymentArrangementsMember_638043208769259503" xlink:to="cvac_IfrsRestrictedStockUnitMember_638043208769269502" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_RestrictedStockUnitForKeyEmployeesMember" xlink:label="cvac_RestrictedStockUnitForKeyEmployeesMember_638043208769269502" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_SharebasedPaymentArrangementsMember_638043208769259503" xlink:to="cvac_RestrictedStockUnitForKeyEmployeesMember_638043208769269502" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_OptionsGrantedToThenChiefExecutiveOfficerMember" xlink:label="cvac_OptionsGrantedToThenChiefExecutiveOfficerMember_638043208769269502" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_SharebasedPaymentArrangementsMember_638043208769259503" xlink:to="cvac_OptionsGrantedToThenChiefExecutiveOfficerMember_638043208769269502" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_VirtualSharesProgramIiMember" xlink:label="cvac_VirtualSharesProgramIiMember_638043208769269502" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_SharebasedPaymentArrangementsMember_638043208769259503" xlink:to="cvac_VirtualSharesProgramIiMember_638043208769269502" order="5" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_VirtualSharesProgramIMember" xlink:label="cvac_VirtualSharesProgramIMember_638043208769269502" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_SharebasedPaymentArrangementsMember_638043208769259503" xlink:to="cvac_VirtualSharesProgramIMember_638043208769269502" order="6" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_638043208769269502" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_638043208769259503" xlink:to="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_638043208769269502" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_ExpenseRecognizedForEmployeeServices" xlink:label="cvac_ExpenseRecognizedForEmployeeServices_638043208769269502" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_638043208769269502" xlink:to="cvac_ExpenseRecognizedForEmployeeServices_638043208769269502" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.curevac.com/role/DisclosureShareBasedPaymentsDetails" xlink:type="extended" xlink:title="40503 - Disclosure - Share-based payments (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:label="DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_638043208769269502" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:to="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_638043208769269502" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_IfrsSaleOfStockAxis" xlink:label="cvac_IfrsSaleOfStockAxis_638043208769269502" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_638043208769269502" xlink:to="cvac_IfrsSaleOfStockAxis_638043208769269502" order="1" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_IfrsSaleOfStockDomain" xlink:label="cvac_IfrsSaleOfStockDomain_638043208769279502" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_IfrsSaleOfStockAxis_638043208769269502" xlink:to="cvac_IfrsSaleOfStockDomain_638043208769279502" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_ExerciseOfOptionsMember" xlink:label="cvac_ExerciseOfOptionsMember_638043208769279502" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_IfrsSaleOfStockDomain_638043208769279502" xlink:to="cvac_ExerciseOfOptionsMember_638043208769279502" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis_638043208769279502" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_638043208769269502" xlink:to="srt_TitleOfIndividualAxis_638043208769279502" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_638043208769279502" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis_638043208769279502" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_638043208769279502" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_ChiefScientificOfficerMember" xlink:label="cvac_ChiefScientificOfficerMember_638043208769279502" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain_638043208769279502" xlink:to="cvac_ChiefScientificOfficerMember_638043208769279502" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_ChiefOperatingOfficerAndChiefDevelopmentOfficerMember" xlink:label="cvac_ChiefOperatingOfficerAndChiefDevelopmentOfficerMember_638043208769279502" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain_638043208769279502" xlink:to="cvac_ChiefOperatingOfficerAndChiefDevelopmentOfficerMember_638043208769279502" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_ChiefBusinessOfficerAndChiefCommercialOfficerMember" xlink:label="cvac_ChiefBusinessOfficerAndChiefCommercialOfficerMember_638043208769279502" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain_638043208769279502" xlink:to="cvac_ChiefBusinessOfficerAndChiefCommercialOfficerMember_638043208769279502" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ChiefOperatingOfficerMember" xlink:label="srt_ChiefOperatingOfficerMember_638043208769279502" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain_638043208769279502" xlink:to="srt_ChiefOperatingOfficerMember_638043208769279502" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_ChiefDevelopmentOfficerMember" xlink:label="cvac_ChiefDevelopmentOfficerMember_638043208769279502" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain_638043208769279502" xlink:to="cvac_ChiefDevelopmentOfficerMember_638043208769279502" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_ThenChiefExecutiveOfficerMember" xlink:label="cvac_ThenChiefExecutiveOfficerMember_638043208769279502" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain_638043208769279502" xlink:to="cvac_ThenChiefExecutiveOfficerMember_638043208769279502" order="6" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_ManagementBoardMember" xlink:label="cvac_ManagementBoardMember_638043208769279502" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain_638043208769279502" xlink:to="cvac_ManagementBoardMember_638043208769279502" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_MembersOfExecutiveBoardAndVariousKeyEmployeesMember" xlink:label="cvac_MembersOfExecutiveBoardAndVariousKeyEmployeesMember_638043208769279502" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain_638043208769279502" xlink:to="cvac_MembersOfExecutiveBoardAndVariousKeyEmployeesMember_638043208769279502" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_KeyEmployeesMember" xlink:label="cvac_KeyEmployeesMember_638043208769289502" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain_638043208769279502" xlink:to="cvac_KeyEmployeesMember_638043208769289502" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_ExecutiveBoardMembersMember" xlink:label="cvac_ExecutiveBoardMembersMember_638043208769289502" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain_638043208769279502" xlink:to="cvac_ExecutiveBoardMembersMember_638043208769289502" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_SupervisoryBoardMembersMember" xlink:label="cvac_SupervisoryBoardMembersMember_638043208769289502" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain_638043208769279502" xlink:to="cvac_SupervisoryBoardMembersMember_638043208769289502" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_ChiefBusinessOfficerMember" xlink:label="cvac_ChiefBusinessOfficerMember_638043208769289502" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain_638043208769279502" xlink:to="cvac_ChiefBusinessOfficerMember_638043208769289502" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_FormerFrameEmployeesMember" xlink:label="cvac_FormerFrameEmployeesMember_638043208769289502" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain_638043208769279502" xlink:to="cvac_FormerFrameEmployeesMember_638043208769289502" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RangeAxis" xlink:label="ifrs-full_RangeAxis_638043208769289502" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_638043208769269502" xlink:to="ifrs-full_RangeAxis_638043208769289502" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RangesMember" xlink:label="ifrs-full_RangesMember_638043208769289502" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangeAxis_638043208769289502" xlink:to="ifrs-full_RangesMember_638043208769289502" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis_638043208769349505" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_638043208769269502" xlink:to="srt_StatementScenarioAxis_638043208769349505" order="4" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain_638043208769349505" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis_638043208769349505" xlink:to="srt_ScenarioUnspecifiedDomain_638043208769349505" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_MaturityAxis" xlink:label="ifrs-full_MaturityAxis_638043208769349505" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_638043208769269502" xlink:to="ifrs-full_MaturityAxis_638043208769349505" order="5" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AggregatedTimeBandsMember" xlink:label="ifrs-full_AggregatedTimeBandsMember_638043208769349505" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_MaturityAxis_638043208769349505" xlink:to="ifrs-full_AggregatedTimeBandsMember_638043208769349505" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NotLaterThanOneYearMember" xlink:label="ifrs-full_NotLaterThanOneYearMember_638043208769359503" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AggregatedTimeBandsMember_638043208769349505" xlink:to="ifrs-full_NotLaterThanOneYearMember_638043208769359503" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember" xlink:label="ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember_638043208769359503" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AggregatedTimeBandsMember_638043208769349505" xlink:to="ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember_638043208769359503" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_IfrsVestingAxis" xlink:label="cvac_IfrsVestingAxis_638043208769359503" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_638043208769269502" xlink:to="cvac_IfrsVestingAxis_638043208769359503" order="6" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_IfrsVestingDomain" xlink:label="cvac_IfrsVestingDomain_638043208769359503" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_IfrsVestingAxis_638043208769359503" xlink:to="cvac_IfrsVestingDomain_638043208769359503" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_IfrsShareBasedPaymentArrangementTrancheOneMember" xlink:label="cvac_IfrsShareBasedPaymentArrangementTrancheOneMember_638043208769359503" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_IfrsVestingDomain_638043208769359503" xlink:to="cvac_IfrsShareBasedPaymentArrangementTrancheOneMember_638043208769359503" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:label="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_638043208769359503" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_638043208769269502" xlink:to="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_638043208769359503" order="7" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_SharebasedPaymentArrangementsMember" xlink:label="ifrs-full_SharebasedPaymentArrangementsMember_638043208769359503" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_638043208769359503" xlink:to="ifrs-full_SharebasedPaymentArrangementsMember_638043208769359503" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_LongTermIncentivePlanMember" xlink:label="cvac_LongTermIncentivePlanMember_638043208769359503" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_SharebasedPaymentArrangementsMember_638043208769359503" xlink:to="cvac_LongTermIncentivePlanMember_638043208769359503" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_OptionsGrantedToThenChiefExecutiveOfficerMember" xlink:label="cvac_OptionsGrantedToThenChiefExecutiveOfficerMember_638043208769359503" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_SharebasedPaymentArrangementsMember_638043208769359503" xlink:to="cvac_OptionsGrantedToThenChiefExecutiveOfficerMember_638043208769359503" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_VirtualSharesProgramIMember" xlink:label="cvac_VirtualSharesProgramIMember_638043208769369507" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_SharebasedPaymentArrangementsMember_638043208769359503" xlink:to="cvac_VirtualSharesProgramIMember_638043208769369507" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_VirtualSharesProgramIiMember" xlink:label="cvac_VirtualSharesProgramIiMember_638043208769369507" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_SharebasedPaymentArrangementsMember_638043208769359503" xlink:to="cvac_VirtualSharesProgramIiMember_638043208769369507" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_638043208769369507" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_638043208769269502" xlink:to="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_638043208769369507" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees" xlink:label="ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees_638043208769369507" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_638043208769369507" xlink:to="ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees_638043208769369507" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" xlink:label="ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_638043208769369507" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_638043208769369507" xlink:to="ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_638043208769369507" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" xlink:label="ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement_638043208769369507" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_638043208769369507" xlink:to="ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement_638043208769369507" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NumberOfInstrumentsGrantedInSharebasedPaymentArrangement" xlink:label="ifrs-full_NumberOfInstrumentsGrantedInSharebasedPaymentArrangement_638043208769369507" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_638043208769369507" xlink:to="ifrs-full_NumberOfInstrumentsGrantedInSharebasedPaymentArrangement_638043208769369507" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInGeneralAndAdministrativeExpenses" xlink:label="cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInGeneralAndAdministrativeExpenses_638043208769379502" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_638043208769369507" xlink:to="cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInGeneralAndAdministrativeExpenses_638043208769379502" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_RightToExercisePercentageOfVestedVirtualShares" xlink:label="cvac_RightToExercisePercentageOfVestedVirtualShares_638043208769379502" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_638043208769369507" xlink:to="cvac_RightToExercisePercentageOfVestedVirtualShares_638043208769379502" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_LockUpPeriodAfterInitialListing" xlink:label="cvac_LockUpPeriodAfterInitialListing_638043208769379502" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_638043208769369507" xlink:to="cvac_LockUpPeriodAfterInitialListing_638043208769379502" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" xlink:label="ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement_638043208769379502" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_638043208769369507" xlink:to="ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement_638043208769379502" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_NumberOfKeyEmployees" xlink:label="cvac_NumberOfKeyEmployees_638043208769379502" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_638043208769369507" xlink:to="cvac_NumberOfKeyEmployees_638043208769379502" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted" xlink:label="ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted_638043208769379502" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_638043208769369507" xlink:to="ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted_638043208769379502" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019_638043208769379502" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_638043208769369507" xlink:to="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019_638043208769379502" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_ProvisionForEmployerTaxes" xlink:label="cvac_ProvisionForEmployerTaxes_638043208769389505" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_638043208769369507" xlink:to="cvac_ProvisionForEmployerTaxes_638043208769389505" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_AmountOfLiabilityCashClaimAwards" xlink:label="cvac_AmountOfLiabilityCashClaimAwards_638043208769389505" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_638043208769369507" xlink:to="cvac_AmountOfLiabilityCashClaimAwards_638043208769389505" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_AmountOfRestrictedStockUnitsReceived" xlink:label="cvac_AmountOfRestrictedStockUnitsReceived_638043208769389505" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_638043208769369507" xlink:to="cvac_AmountOfRestrictedStockUnitsReceived_638043208769389505" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_NumberOfShareOptionsVestedInShareBasedPaymentArrangement" xlink:label="cvac_NumberOfShareOptionsVestedInShareBasedPaymentArrangement_638043208769389505" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_638043208769369507" xlink:to="cvac_NumberOfShareOptionsVestedInShareBasedPaymentArrangement_638043208769389505" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_NumberOfOtherEquityInstrumentsSettledInShareBasedPaymentArrangement" xlink:label="cvac_NumberOfOtherEquityInstrumentsSettledInShareBasedPaymentArrangement_638043208769389505" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_638043208769369507" xlink:to="cvac_NumberOfOtherEquityInstrumentsSettledInShareBasedPaymentArrangement_638043208769389505" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.curevac.com/role/DisclosureFixedAssetsIntangibleAssetsDetails" xlink:type="extended" xlink:title="40601 - Disclosure - Fixed Assets - Intangible assets (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_DisclosureOfFixedAssetsAbstract" xlink:label="DisclosureOfFixedAssetsAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfIntangibleAssetsTable" xlink:label="ifrs-full_DisclosureOfIntangibleAssetsTable_638043208769399503" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfFixedAssetsAbstract" xlink:to="ifrs-full_DisclosureOfIntangibleAssetsTable_638043208769399503" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis" xlink:label="cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_638043208769399503" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfIntangibleAssetsTable_638043208769399503" xlink:to="cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_638043208769399503" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountDomain" xlink:label="cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountDomain_638043208769399503" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_638043208769399503" xlink:to="cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountDomain_638043208769399503" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_GrossCarryingAmountMember" xlink:label="ifrs-full_GrossCarryingAmountMember_638043208769399503" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountDomain_638043208769399503" xlink:to="ifrs-full_GrossCarryingAmountMember_638043208769399503" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis" xlink:label="ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_638043208769399503" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfIntangibleAssetsTable_638043208769399503" xlink:to="ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_638043208769399503" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwillMember" xlink:label="ifrs-full_IntangibleAssetsOtherThanGoodwillMember_638043208769399503" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_638043208769399503" xlink:to="ifrs-full_IntangibleAssetsOtherThanGoodwillMember_638043208769399503" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_LicensesSoftwareAndPrepaymentsMember" xlink:label="cvac_LicensesSoftwareAndPrepaymentsMember_638043208769399503" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IntangibleAssetsOtherThanGoodwillMember_638043208769399503" xlink:to="cvac_LicensesSoftwareAndPrepaymentsMember_638043208769399503" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:label="ifrs-full_DisclosureOfIntangibleAssetsLineItems_638043208769399503" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfIntangibleAssetsTable_638043208769399503" xlink:to="ifrs-full_DisclosureOfIntangibleAssetsLineItems_638043208769399503" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" xlink:label="ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill_638043208769399503" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfIntangibleAssetsLineItems_638043208769399503" xlink:to="ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill_638043208769399503" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.curevac.com/role/DisclosureFixedAssetsPropertyPlantAndEquipmentDetails" xlink:type="extended" xlink:title="40602 - Disclosure - Fixed Assets - Property, plant and equipment (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_DisclosureOfFixedAssetsAbstract" xlink:label="DisclosureOfFixedAssetsAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable" xlink:label="ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_638043208769409503" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfFixedAssetsAbstract" xlink:to="ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_638043208769409503" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis" xlink:label="cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_638043208769409503" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_638043208769409503" xlink:to="cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_638043208769409503" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountDomain" xlink:label="cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountDomain_638043208769409503" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_638043208769409503" xlink:to="cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountDomain_638043208769409503" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_GrossCarryingAmountMember" xlink:label="ifrs-full_GrossCarryingAmountMember_638043208769409503" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountDomain_638043208769409503" xlink:to="ifrs-full_GrossCarryingAmountMember_638043208769409503" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:label="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_638043208769409503" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_638043208769409503" xlink:to="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_638043208769409503" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_PropertyPlantAndEquipmentMember" xlink:label="ifrs-full_PropertyPlantAndEquipmentMember_638043208769409503" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_638043208769409503" xlink:to="ifrs-full_PropertyPlantAndEquipmentMember_638043208769409503" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_TechnicalEquipmentAndMachinesAndOtherEquipmentMember" xlink:label="cvac_TechnicalEquipmentAndMachinesAndOtherEquipmentMember_638043208769409503" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_PropertyPlantAndEquipmentMember_638043208769409503" xlink:to="cvac_TechnicalEquipmentAndMachinesAndOtherEquipmentMember_638043208769409503" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ConstructionInProgressMember" xlink:label="ifrs-full_ConstructionInProgressMember_638043208769409503" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_PropertyPlantAndEquipmentMember_638043208769409503" xlink:to="ifrs-full_ConstructionInProgressMember_638043208769409503" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_CompanyOwnedGmpIvFacilityMember" xlink:label="cvac_CompanyOwnedGmpIvFacilityMember_638043208769409503" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_PropertyPlantAndEquipmentMember_638043208769409503" xlink:to="cvac_CompanyOwnedGmpIvFacilityMember_638043208769409503" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_EquipmentPhysicallyLocatedAtCmoFacilitiesMember" xlink:label="cvac_EquipmentPhysicallyLocatedAtCmoFacilitiesMember_638043208769409503" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_PropertyPlantAndEquipmentMember_638043208769409503" xlink:to="cvac_EquipmentPhysicallyLocatedAtCmoFacilitiesMember_638043208769409503" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:label="ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_638043208769409503" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_638043208769409503" xlink:to="ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_638043208769409503" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" xlink:label="ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment_638043208769409503" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_638043208769409503" xlink:to="ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment_638043208769409503" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_IncreaseInPropertyAndEquipmentOffSetByImpairmentOfEquipment" xlink:label="cvac_IncreaseInPropertyAndEquipmentOffSetByImpairmentOfEquipment_638043208769419506" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_638043208769409503" xlink:to="cvac_IncreaseInPropertyAndEquipmentOffSetByImpairmentOfEquipment_638043208769419506" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.curevac.com/role/DisclosureAssetsHeldForSaleDetails" xlink:type="extended" xlink:title="40701 - Disclosure - Assets held for sale (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwnersAbstract" xlink:label="ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwnersAbstract_2" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_IfrsDisposalGroupIncludingDiscontinuedOperationConsideration" xlink:label="cvac_IfrsDisposalGroupIncludingDiscontinuedOperationConsideration_638043208769419506" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwnersAbstract_2" xlink:to="cvac_IfrsDisposalGroupIncludingDiscontinuedOperationConsideration_638043208769419506" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.curevac.com/role/DisclosureInventoriesDetails" xlink:type="extended" xlink:title="40801 - Disclosure - Inventories (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ClassesOfInventoriesAbstract" xlink:label="ifrs-full_ClassesOfInventoriesAbstract" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_InventoriesTable" xlink:label="cvac_InventoriesTable_638043208769419506" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfInventoriesAbstract" xlink:to="cvac_InventoriesTable_638043208769419506" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_638043208769419506" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_InventoriesTable_638043208769419506" xlink:to="srt_CounterpartyNameAxis_638043208769419506" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_638043208769419506" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis_638043208769419506" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_638043208769419506" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_GlaxosmithklineMember" xlink:label="cvac_GlaxosmithklineMember_638043208769419506" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_638043208769419506" xlink:to="cvac_GlaxosmithklineMember_638043208769419506" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_InventoriesLineItem" xlink:label="cvac_InventoriesLineItem_638043208769419506" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_InventoriesTable_638043208769419506" xlink:to="cvac_InventoriesLineItem_638043208769419506" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_IncreaseDecreaseInInventory" xlink:label="cvac_IncreaseDecreaseInInventory_638043208769419506" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_InventoriesLineItem_638043208769419506" xlink:to="cvac_IncreaseDecreaseInInventory_638043208769419506" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_NetValueOfInventoryTransferred" xlink:label="cvac_NetValueOfInventoryTransferred_638043208769429503" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_InventoriesLineItem_638043208769419506" xlink:to="cvac_NetValueOfInventoryTransferred_638043208769429503" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_InventoryWritedown2011" xlink:label="ifrs-full_InventoryWritedown2011_638043208769429503" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_InventoriesLineItem_638043208769419506" xlink:to="ifrs-full_InventoryWritedown2011_638043208769429503" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.curevac.com/role/DisclosurePrepaidExpensesAndOtherAssetsCurrentDetails" xlink:type="extended" xlink:title="40901 - Disclosure - Prepaid expenses and other assets (current) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_DisclosureOfPrepaidExpensesAndOtherCurrentAssetsAbstract" xlink:label="DisclosureOfPrepaidExpensesAndOtherCurrentAssetsAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CurrentPrepaymentsAndOtherCurrentAssets" xlink:label="ifrs-full_CurrentPrepaymentsAndOtherCurrentAssets_638043208769429503" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfPrepaidExpensesAndOtherCurrentAssetsAbstract" xlink:to="ifrs-full_CurrentPrepaymentsAndOtherCurrentAssets_638043208769429503" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_PrepaidCompensationForContractManufacturingOrganizationsTransfer" xlink:label="cvac_PrepaidCompensationForContractManufacturingOrganizationsTransfer_638043208769429503" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfPrepaidExpensesAndOtherCurrentAssetsAbstract" xlink:to="cvac_PrepaidCompensationForContractManufacturingOrganizationsTransfer_638043208769429503" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CurrentAdvancesToSuppliers" xlink:label="ifrs-full_CurrentAdvancesToSuppliers_638043208769429503" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfPrepaidExpensesAndOtherCurrentAssetsAbstract" xlink:to="ifrs-full_CurrentAdvancesToSuppliers_638043208769429503" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ReceivablesFromTaxesOtherThanIncomeTax" xlink:label="ifrs-full_ReceivablesFromTaxesOtherThanIncomeTax_638043208769429503" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfPrepaidExpensesAndOtherCurrentAssetsAbstract" xlink:to="ifrs-full_ReceivablesFromTaxesOtherThanIncomeTax_638043208769429503" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.curevac.com/role/DisclosureFinancialAssetsAndFinancialLiabilitiesDetails" xlink:type="extended" xlink:title="41001 - Disclosure - Financial assets and financial liabilities (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfFinancialInstrumentsAbstract" xlink:label="DisclosureOfFinancialInstrumentsAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TransfersOutOfLevel1IntoLevel2OfFairValueHierarchyAssets" xlink:label="ifrs-full_TransfersOutOfLevel1IntoLevel2OfFairValueHierarchyAssets_638043208769429503" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfFinancialInstrumentsAbstract" xlink:to="ifrs-full_TransfersOutOfLevel1IntoLevel2OfFairValueHierarchyAssets_638043208769429503" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TransfersOutOfLevel2IntoLevel1OfFairValueHierarchyAssets" xlink:label="ifrs-full_TransfersOutOfLevel2IntoLevel1OfFairValueHierarchyAssets_638043208769439505" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfFinancialInstrumentsAbstract" xlink:to="ifrs-full_TransfersOutOfLevel2IntoLevel1OfFairValueHierarchyAssets_638043208769439505" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TransfersOutOfLevel1IntoLevel2OfFairValueHierarchyLiabilities" xlink:label="ifrs-full_TransfersOutOfLevel1IntoLevel2OfFairValueHierarchyLiabilities_638043208769439505" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfFinancialInstrumentsAbstract" xlink:to="ifrs-full_TransfersOutOfLevel1IntoLevel2OfFairValueHierarchyLiabilities_638043208769439505" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TransfersOutOfLevel2IntoLevel1OfFairValueHierarchyLiabilities" xlink:label="ifrs-full_TransfersOutOfLevel2IntoLevel1OfFairValueHierarchyLiabilities_638043208769439505" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfFinancialInstrumentsAbstract" xlink:to="ifrs-full_TransfersOutOfLevel2IntoLevel1OfFairValueHierarchyLiabilities_638043208769439505" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TransfersIntoLevel3OfFairValueHierarchyAssets" xlink:label="ifrs-full_TransfersIntoLevel3OfFairValueHierarchyAssets_638043208769439505" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfFinancialInstrumentsAbstract" xlink:to="ifrs-full_TransfersIntoLevel3OfFairValueHierarchyAssets_638043208769439505" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TransfersOutOfLevel3OfFairValueHierarchyAssets" xlink:label="ifrs-full_TransfersOutOfLevel3OfFairValueHierarchyAssets_638043208769439505" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfFinancialInstrumentsAbstract" xlink:to="ifrs-full_TransfersOutOfLevel3OfFairValueHierarchyAssets_638043208769439505" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TransfersIntoLevel3OfFairValueHierarchyLiabilities" xlink:label="ifrs-full_TransfersIntoLevel3OfFairValueHierarchyLiabilities_638043208769439505" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfFinancialInstrumentsAbstract" xlink:to="ifrs-full_TransfersIntoLevel3OfFairValueHierarchyLiabilities_638043208769439505" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TransfersOutOfLevel3OfFairValueHierarchyLiabilities" xlink:label="ifrs-full_TransfersOutOfLevel3OfFairValueHierarchyLiabilities_638043208769439505" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfFinancialInstrumentsAbstract" xlink:to="ifrs-full_TransfersOutOfLevel3OfFairValueHierarchyLiabilities_638043208769439505" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.curevac.com/role/DisclosureTradeAndOtherPayablesDetails" xlink:type="extended" xlink:title="41101 - Disclosure - Trade and other payables (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TradeAndOtherCurrentPayablesAbstract" xlink:label="TradeAndOtherCurrentPayablesAbstract" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_ChangeInTradeAndOtherPayables" xlink:label="cvac_ChangeInTradeAndOtherPayables_638043208769439505" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TradeAndOtherCurrentPayablesAbstract" xlink:to="cvac_ChangeInTradeAndOtherPayables_638043208769439505" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.curevac.com/role/DisclosureOtherLiabilitiesDetails" xlink:type="extended" xlink:title="41201 - Disclosure - Other liabilities (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_IfrsOtherLiabilitiesAbstract" xlink:label="IfrsOtherLiabilitiesAbstract" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_DisclosureOfOtherLiabilitiesTable" xlink:label="cvac_DisclosureOfOtherLiabilitiesTable_638043208769449506" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IfrsOtherLiabilitiesAbstract" xlink:to="cvac_DisclosureOfOtherLiabilitiesTable_638043208769449506" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TypesOfContractsAxis" xlink:label="ifrs-full_TypesOfContractsAxis_638043208769449506" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfOtherLiabilitiesTable_638043208769449506" xlink:to="ifrs-full_TypesOfContractsAxis_638043208769449506" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TypesOfContractsMember" xlink:label="ifrs-full_TypesOfContractsMember_638043208769449506" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TypesOfContractsAxis_638043208769449506" xlink:to="ifrs-full_TypesOfContractsMember_638043208769449506" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_ContractResearchOrganizationAgreementMember" xlink:label="cvac_ContractResearchOrganizationAgreementMember_638043208769449506" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TypesOfContractsMember_638043208769449506" xlink:to="cvac_ContractResearchOrganizationAgreementMember_638043208769449506" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_ContractManufacturingOrganizationAgreementMember" xlink:label="cvac_ContractManufacturingOrganizationAgreementMember_638043208769449506" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TypesOfContractsMember_638043208769449506" xlink:to="cvac_ContractManufacturingOrganizationAgreementMember_638043208769449506" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_DisclosureOfOtherLiabilitiesLineItems" xlink:label="cvac_DisclosureOfOtherLiabilitiesLineItems_638043208769449506" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfOtherLiabilitiesTable_638043208769449506" xlink:to="cvac_DisclosureOfOtherLiabilitiesLineItems_638043208769449506" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_ChangeInOtherLiabilities" xlink:label="cvac_ChangeInOtherLiabilities_638043208769449506" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfOtherLiabilitiesLineItems_638043208769449506" xlink:to="cvac_ChangeInOtherLiabilities_638043208769449506" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.curevac.com/role/DisclosureLoansDetails" xlink:type="extended" xlink:title="41301 - Disclosure - Loans (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsAbstract" xlink:label="DisclosureOfDetailedInformationAboutBorrowingsAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable" xlink:label="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_638043208769449506" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfDetailedInformationAboutBorrowingsAbstract" xlink:to="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_638043208769449506" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_BorrowingsByNameAxis" xlink:label="ifrs-full_BorrowingsByNameAxis_638043208769449506" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_638043208769449506" xlink:to="ifrs-full_BorrowingsByNameAxis_638043208769449506" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_BorrowingsByNameMember" xlink:label="ifrs-full_BorrowingsByNameMember_638043208769449506" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_BorrowingsByNameAxis_638043208769449506" xlink:to="ifrs-full_BorrowingsByNameMember_638043208769449506" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_IfrsLineOfCreditMember" xlink:label="cvac_IfrsLineOfCreditMember_638043208769449506" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_BorrowingsByNameMember_638043208769449506" xlink:to="cvac_IfrsLineOfCreditMember_638043208769449506" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:label="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_638043208769449506" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_638043208769449506" xlink:to="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_638043208769449506" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities" xlink:label="ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities_638043208769459505" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_638043208769449506" xlink:to="ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities_638043208769459505" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_LineOfCreditAccruedInterestPayable" xlink:label="cvac_LineOfCreditAccruedInterestPayable_638043208769459505" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_638043208769449506" xlink:to="cvac_LineOfCreditAccruedInterestPayable_638043208769459505" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities" xlink:label="ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities_638043208769459505" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_638043208769449506" xlink:to="ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities_638043208769459505" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_RepaymentsOfPrincipalAmountOfBorrowings" xlink:label="cvac_RepaymentsOfPrincipalAmountOfBorrowings_638043208769459505" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_638043208769449506" xlink:to="cvac_RepaymentsOfPrincipalAmountOfBorrowings_638043208769459505" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_IfrsRepaymentsOfAccruedInterestAndFeesOfBorrowings" xlink:label="cvac_IfrsRepaymentsOfAccruedInterestAndFeesOfBorrowings_638043208769459505" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_638043208769449506" xlink:to="cvac_IfrsRepaymentsOfAccruedInterestAndFeesOfBorrowings_638043208769459505" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.curevac.com/role/DisclosureIncomeTaxDetails" xlink:type="extended" xlink:title="41401 - Disclosure - Income tax (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract" xlink:label="ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_IncomeTaxDisclosureTable" xlink:label="cvac_IncomeTaxDisclosureTable_638043208769459505" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract" xlink:to="cvac_IncomeTaxDisclosureTable_638043208769459505" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_SignificantInvestmentsInSubsidiariesAxis" xlink:label="ifrs-full_SignificantInvestmentsInSubsidiariesAxis_638043208769459505" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_IncomeTaxDisclosureTable_638043208769459505" xlink:to="ifrs-full_SignificantInvestmentsInSubsidiariesAxis_638043208769459505" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_EntitysTotalForSubsidiariesMember" xlink:label="ifrs-full_EntitysTotalForSubsidiariesMember_638043208769459505" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_SignificantInvestmentsInSubsidiariesAxis_638043208769459505" xlink:to="ifrs-full_EntitysTotalForSubsidiariesMember_638043208769459505" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_CurevacCorporateServiceGmbhMember" xlink:label="cvac_CurevacCorporateServiceGmbhMember_638043208769459505" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EntitysTotalForSubsidiariesMember_638043208769459505" xlink:to="cvac_CurevacCorporateServiceGmbhMember_638043208769459505" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_CurevacSwissAgMember" xlink:label="cvac_CurevacSwissAgMember_638043208769459505" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EntitysTotalForSubsidiariesMember_638043208769459505" xlink:to="cvac_CurevacSwissAgMember_638043208769459505" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_IncomeTaxDisclosureLineItems" xlink:label="cvac_IncomeTaxDisclosureLineItems_638043208769459505" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_IncomeTaxDisclosureTable_638043208769459505" xlink:to="cvac_IncomeTaxDisclosureLineItems_638043208769459505" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:label="ifrs-full_IncomeTaxExpenseContinuingOperations_638043208769469506" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_IncomeTaxDisclosureLineItems_638043208769459505" xlink:to="ifrs-full_IncomeTaxExpenseContinuingOperations_638043208769469506" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CurrentTaxExpenseIncome" xlink:label="ifrs-full_CurrentTaxExpenseIncome_638043208769469506" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_IncomeTaxDisclosureLineItems_638043208769459505" xlink:to="ifrs-full_CurrentTaxExpenseIncome_638043208769469506" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DeferredTaxExpenseIncome" xlink:label="ifrs-full_DeferredTaxExpenseIncome_638043208769469506" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_IncomeTaxDisclosureLineItems_638043208769459505" xlink:to="ifrs-full_DeferredTaxExpenseIncome_638043208769469506" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.curevac.com/role/DisclosureDisclosureOfFinancialInstrumentsAndRiskManagementDetails" xlink:type="extended" xlink:title="41501 - Disclosure - Disclosure of financial instruments and risk management (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_FinancialInstrumentsAndRiskManagementAbstract" xlink:label="FinancialInstrumentsAndRiskManagementAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable" xlink:label="ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable_638043208769469506" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancialInstrumentsAndRiskManagementAbstract" xlink:to="ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable_638043208769469506" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CurrencyAxis" xlink:label="srt_CurrencyAxis_638043208769469506" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable_638043208769469506" xlink:to="srt_CurrencyAxis_638043208769469506" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2021/currency-2021.xsd#currency_AllCurrenciesDomain" xlink:label="currency_AllCurrenciesDomain_638043208769469506" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CurrencyAxis_638043208769469506" xlink:to="currency_AllCurrenciesDomain_638043208769469506" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2021/currency-2021.xsd#currency_USD" xlink:label="currency_USD_638043208769469506" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="currency_AllCurrenciesDomain_638043208769469506" xlink:to="currency_USD_638043208769469506" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2021/currency-2021.xsd#currency_CHF" xlink:label="currency_CHF_638043208769469506" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="currency_AllCurrenciesDomain_638043208769469506" xlink:to="currency_CHF_638043208769469506" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TypesOfRisksAxis" xlink:label="ifrs-full_TypesOfRisksAxis_638043208769469506" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable_638043208769469506" xlink:to="ifrs-full_TypesOfRisksAxis_638043208769469506" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TypesOfRisksMember" xlink:label="ifrs-full_TypesOfRisksMember_638043208769469506" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TypesOfRisksAxis_638043208769469506" xlink:to="ifrs-full_TypesOfRisksMember_638043208769469506" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CurrencyRiskMember" xlink:label="ifrs-full_CurrencyRiskMember_638043208769469506" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TypesOfRisksMember_638043208769469506" xlink:to="ifrs-full_CurrencyRiskMember_638043208769469506" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:label="ifrs-full_ClassesOfFinancialInstrumentsAxis_638043208769479505" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable_638043208769469506" xlink:to="ifrs-full_ClassesOfFinancialInstrumentsAxis_638043208769479505" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ClassesOfFinancialInstrumentsMember" xlink:label="ifrs-full_ClassesOfFinancialInstrumentsMember_638043208769479505" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsAxis_638043208769479505" xlink:to="ifrs-full_ClassesOfFinancialInstrumentsMember_638043208769479505" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_IfrsCashAndCashEquivalentsMember" xlink:label="cvac_IfrsCashAndCashEquivalentsMember_638043208769479505" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsMember_638043208769479505" xlink:to="cvac_IfrsCashAndCashEquivalentsMember_638043208769479505" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems" xlink:label="ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems_638043208769479505" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable_638043208769469506" xlink:to="ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems_638043208769479505" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RiskExposureAssociatedWithInstrumentsSharingCharacteristic" xlink:label="ifrs-full_RiskExposureAssociatedWithInstrumentsSharingCharacteristic_638043208769479505" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems_638043208769479505" xlink:to="ifrs-full_RiskExposureAssociatedWithInstrumentsSharingCharacteristic_638043208769479505" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.curevac.com/role/DisclosureEarningsPerShareDetails" xlink:type="extended" xlink:title="41601 - Disclosure - Earnings per share (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_EarningsPerShareAbstract" xlink:label="EarningsPerShareAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_WeightedAverageShares" xlink:label="ifrs-full_WeightedAverageShares_638043208769479505" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EarningsPerShareAbstract" xlink:to="ifrs-full_WeightedAverageShares_638043208769479505" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_BasicEarningsLossPerShare" xlink:label="ifrs-full_BasicEarningsLossPerShare_638043208769479505" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EarningsPerShareAbstract" xlink:to="ifrs-full_BasicEarningsLossPerShare_638043208769479505" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.curevac.com/role/DisclosureRelatedPartyDisclosuresDetails" xlink:type="extended" xlink:title="41701 - Disclosure - Related party disclosures (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract" xlink:label="DisclosureOfTransactionsBetweenRelatedPartiesAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:label="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_638043208769489505" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfTransactionsBetweenRelatedPartiesAbstract" xlink:to="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_638043208769489505" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RangeAxis" xlink:label="ifrs-full_RangeAxis_638043208769489505" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_638043208769489505" xlink:to="ifrs-full_RangeAxis_638043208769489505" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RangesMember" xlink:label="ifrs-full_RangesMember_638043208769489505" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangeAxis_638043208769489505" xlink:to="ifrs-full_RangesMember_638043208769489505" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_BottomOfRangeMember" xlink:label="ifrs-full_BottomOfRangeMember_638043208769489505" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangesMember_638043208769489505" xlink:to="ifrs-full_BottomOfRangeMember_638043208769489505" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TopOfRangeMember" xlink:label="ifrs-full_TopOfRangeMember_638043208769489505" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangesMember_638043208769489505" xlink:to="ifrs-full_TopOfRangeMember_638043208769489505" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis_638043208769489505" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_638043208769489505" xlink:to="srt_TitleOfIndividualAxis_638043208769489505" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_638043208769489505" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis_638043208769489505" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_638043208769489505" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_BaronJeanStephenneMember" xlink:label="cvac_BaronJeanStephenneMember_638043208769489505" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain_638043208769489505" xlink:to="cvac_BaronJeanStephenneMember_638043208769489505" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_VincentStphenneMember" xlink:label="cvac_VincentStphenneMember_638043208769489505" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain_638043208769489505" xlink:to="cvac_VincentStphenneMember_638043208769489505" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_AntonyBlancMember" xlink:label="cvac_AntonyBlancMember_638043208769489505" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain_638043208769489505" xlink:to="cvac_AntonyBlancMember_638043208769489505" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis_638043208769489505" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_638043208769489505" xlink:to="ifrs-full_CategoriesOfRelatedPartiesAxis_638043208769489505" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="ifrs-full_EntitysTotalForRelatedPartiesMember_638043208769489505" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis_638043208769489505" xlink:to="ifrs-full_EntitysTotalForRelatedPartiesMember_638043208769489505" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_DietmarHoppMember" xlink:label="cvac_DietmarHoppMember_638043208769489505" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember_638043208769489505" xlink:to="cvac_DietmarHoppMember_638043208769489505" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_ClarentisSrlMember" xlink:label="cvac_ClarentisSrlMember_638043208769499506" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember_638043208769489505" xlink:to="cvac_ClarentisSrlMember_638043208769499506" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_BepharbelManufacturingS.aMember" xlink:label="cvac_BepharbelManufacturingS.aMember_638043208769499506" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember_638043208769489505" xlink:to="cvac_BepharbelManufacturingS.aMember_638043208769499506" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_Dr.IngmarHoerrMember" xlink:label="cvac_Dr.IngmarHoerrMember_638043208769499506" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember_638043208769489505" xlink:to="cvac_Dr.IngmarHoerrMember_638043208769499506" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_RittershausRechtsanwaelteMember" xlink:label="cvac_RittershausRechtsanwaelteMember_638043208769499506" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember_638043208769489505" xlink:to="cvac_RittershausRechtsanwaelteMember_638043208769499506" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:label="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_638043208769499506" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_638043208769489505" xlink:to="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_638043208769499506" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_SharebasedPaymentArrangementsMember" xlink:label="ifrs-full_SharebasedPaymentArrangementsMember_638043208769499506" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_638043208769499506" xlink:to="ifrs-full_SharebasedPaymentArrangementsMember_638043208769499506" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_VirtualSharesProgramIMember" xlink:label="cvac_VirtualSharesProgramIMember_638043208769499506" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_SharebasedPaymentArrangementsMember_638043208769499506" xlink:to="cvac_VirtualSharesProgramIMember_638043208769499506" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:label="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_638043208769499506" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_638043208769489505" xlink:to="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_638043208769499506" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_RelatedPartyTransactionNumberOfLoansReceived" xlink:label="cvac_RelatedPartyTransactionNumberOfLoansReceived_638043208769499506" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_638043208769499506" xlink:to="cvac_RelatedPartyTransactionNumberOfLoansReceived_638043208769499506" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_IncreaseInNumberOfSharesOutstanding" xlink:label="cvac_IncreaseInNumberOfSharesOutstanding_638043208769499506" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_638043208769499506" xlink:to="cvac_IncreaseInNumberOfSharesOutstanding_638043208769499506" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_WeightedAverageSharePrice2019" xlink:label="ifrs-full_WeightedAverageSharePrice2019_638043208769509508" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_638043208769499506" xlink:to="ifrs-full_WeightedAverageSharePrice2019_638043208769509508" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_CollaborationAgreementMilestonePayment" xlink:label="cvac_CollaborationAgreementMilestonePayment_638043208769509508" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_638043208769499506" xlink:to="cvac_CollaborationAgreementMilestonePayment_638043208769509508" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_PaymentsToRelatedPartyForServices" xlink:label="cvac_PaymentsToRelatedPartyForServices_638043208769509508" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_638043208769499506" xlink:to="cvac_PaymentsToRelatedPartyForServices_638043208769509508" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CommitmentsMadeByEntityRelatedPartyTransactions" xlink:label="ifrs-full_CommitmentsMadeByEntityRelatedPartyTransactions_638043208769509508" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_638043208769499506" xlink:to="ifrs-full_CommitmentsMadeByEntityRelatedPartyTransactions_638043208769509508" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProportionOfOwnershipInterestInAssociate" xlink:label="ifrs-full_ProportionOfOwnershipInterestInAssociate_638043208769509508" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_638043208769499506" xlink:to="ifrs-full_ProportionOfOwnershipInterestInAssociate_638043208769509508" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TransfersOfResearchAndDevelopmentToEntityRelatedPartyTransactions" xlink:label="ifrs-full_TransfersOfResearchAndDevelopmentToEntityRelatedPartyTransactions_638043208769509508" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_638043208769499506" xlink:to="ifrs-full_TransfersOfResearchAndDevelopmentToEntityRelatedPartyTransactions_638043208769509508" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_RelatedPartyTransactionNoticePeriodForTerminationOfAgreement" xlink:label="cvac_RelatedPartyTransactionNoticePeriodForTerminationOfAgreement_638043208769509508" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_638043208769499506" xlink:to="cvac_RelatedPartyTransactionNoticePeriodForTerminationOfAgreement_638043208769509508" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_RelatedPartyTransactionConsultingFees" xlink:label="cvac_RelatedPartyTransactionConsultingFees_638043208769509508" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_638043208769499506" xlink:to="cvac_RelatedPartyTransactionConsultingFees_638043208769509508" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_RelatedPartyTransactionAdvisoryFees" xlink:label="cvac_RelatedPartyTransactionAdvisoryFees_638043208769509508" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_638043208769499506" xlink:to="cvac_RelatedPartyTransactionAdvisoryFees_638043208769509508" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_AmountPaidAtSigningOfAgreementRelatedPartyTransactions" xlink:label="cvac_AmountPaidAtSigningOfAgreementRelatedPartyTransactions_638043208769519512" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_638043208769499506" xlink:to="cvac_AmountPaidAtSigningOfAgreementRelatedPartyTransactions_638043208769519512" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_PurchasesOfGoodsRelatedPartyTransactions" xlink:label="ifrs-full_PurchasesOfGoodsRelatedPartyTransactions_638043208769519512" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_638043208769499506" xlink:to="ifrs-full_PurchasesOfGoodsRelatedPartyTransactions_638043208769519512" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_TerminationFeeRelatedPartyTransactions" xlink:label="cvac_TerminationFeeRelatedPartyTransactions_638043208769519512" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_638043208769499506" xlink:to="cvac_TerminationFeeRelatedPartyTransactions_638043208769519512" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_IfrsNumberOfSharesOutstandingThroughTransferFromShareholdersToEntity" xlink:label="cvac_IfrsNumberOfSharesOutstandingThroughTransferFromShareholdersToEntity_638043208769519512" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_638043208769499506" xlink:to="cvac_IfrsNumberOfSharesOutstandingThroughTransferFromShareholdersToEntity_638043208769519512" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_IfrsContractualObligation" xlink:label="cvac_IfrsContractualObligation_638043208769519512" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_638043208769499506" xlink:to="cvac_IfrsContractualObligation_638043208769519512" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.curevac.com/role/DisclosureSignificantTransactionsAndEventsDetails" xlink:type="extended" xlink:title="41801 - Disclosure - Significant transactions and events (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfBusinessCombinationsAbstract" xlink:label="ifrs-full_DisclosureOfBusinessCombinationsAbstract_2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfBusinessCombinationsTable" xlink:label="ifrs-full_DisclosureOfBusinessCombinationsTable_638043208769529506" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsAbstract_2" xlink:to="ifrs-full_DisclosureOfBusinessCombinationsTable_638043208769529506" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_BusinessCombinationsAxis" xlink:label="ifrs-full_BusinessCombinationsAxis_638043208769529506" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsTable_638043208769529506" xlink:to="ifrs-full_BusinessCombinationsAxis_638043208769529506" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_EntitysTotalForBusinessCombinationsMember" xlink:label="ifrs-full_EntitysTotalForBusinessCombinationsMember_638043208769529506" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_BusinessCombinationsAxis_638043208769529506" xlink:to="ifrs-full_EntitysTotalForBusinessCombinationsMember_638043208769529506" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_FramePharmaceuticalsB.v.AmsterdamNetherlandsMember" xlink:label="cvac_FramePharmaceuticalsB.v.AmsterdamNetherlandsMember_638043208769529506" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EntitysTotalForBusinessCombinationsMember_638043208769529506" xlink:to="cvac_FramePharmaceuticalsB.v.AmsterdamNetherlandsMember_638043208769529506" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:label="ifrs-full_DisclosureOfBusinessCombinationsLineItems_638043208769529506" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsTable_638043208769529506" xlink:to="ifrs-full_DisclosureOfBusinessCombinationsLineItems_638043208769529506" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RevenueOfAcquiree" xlink:label="ifrs-full_RevenueOfAcquiree_638043208769529506" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems_638043208769529506" xlink:to="ifrs-full_RevenueOfAcquiree_638043208769529506" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProfitLossOfAcquiree" xlink:label="ifrs-full_ProfitLossOfAcquiree_638043208769529506" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems_638043208769529506" xlink:to="ifrs-full_ProfitLossOfAcquiree_638043208769529506" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RevenueOfCombinedEntity" xlink:label="ifrs-full_RevenueOfCombinedEntity_638043208769529506" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems_638043208769529506" xlink:to="ifrs-full_RevenueOfCombinedEntity_638043208769529506" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProfitLossOfCombinedEntity" xlink:label="ifrs-full_ProfitLossOfCombinedEntity_638043208769529506" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems_638043208769529506" xlink:to="ifrs-full_ProfitLossOfCombinedEntity_638043208769529506" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred" xlink:label="ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred_638043208769529506" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems_638043208769529506" xlink:to="ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred_638043208769529506" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_LiabilitiesIncurred" xlink:label="ifrs-full_LiabilitiesIncurred_638043208769529506" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems_638043208769529506" xlink:to="ifrs-full_LiabilitiesIncurred_638043208769529506" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_BusinessAcquisitionSigningSharePriceNumberOfTradingDaysConsidered" xlink:label="cvac_BusinessAcquisitionSigningSharePriceNumberOfTradingDaysConsidered_638043208769529506" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems_638043208769529506" xlink:to="cvac_BusinessAcquisitionSigningSharePriceNumberOfTradingDaysConsidered_638043208769529506" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_BusinessAcquisitionSigningSharePrice" xlink:label="cvac_BusinessAcquisitionSigningSharePrice_638043208769539503" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems_638043208769529506" xlink:to="cvac_BusinessAcquisitionSigningSharePrice_638043208769539503" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_NumberOfPaymentsInWhichTotalConsiderationIsToBePaid" xlink:label="cvac_NumberOfPaymentsInWhichTotalConsiderationIsToBePaid_638043208769539503" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems_638043208769529506" xlink:to="cvac_NumberOfPaymentsInWhichTotalConsiderationIsToBePaid_638043208769539503" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_ContingentConsiderationNumberOfPaymentsConsidered" xlink:label="cvac_ContingentConsiderationNumberOfPaymentsConsidered_638043208769539503" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems_638043208769529506" xlink:to="cvac_ContingentConsiderationNumberOfPaymentsConsidered_638043208769539503" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_FirstPortionOfTotalConsiderationTransferredPercentage" xlink:label="cvac_FirstPortionOfTotalConsiderationTransferredPercentage_638043208769539503" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems_638043208769529506" xlink:to="cvac_FirstPortionOfTotalConsiderationTransferredPercentage_638043208769539503" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_FirstPortionOfTotalConsiderationTransferredAmount" xlink:label="cvac_FirstPortionOfTotalConsiderationTransferredAmount_638043208769539503" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems_638043208769529506" xlink:to="cvac_FirstPortionOfTotalConsiderationTransferredAmount_638043208769539503" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_NumberOfInstrumentsOrInterestsIssuedOrIssuableAsConsiderationToFormerShareholders" xlink:label="cvac_NumberOfInstrumentsOrInterestsIssuedOrIssuableAsConsiderationToFormerShareholders_638043208769539503" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems_638043208769529506" xlink:to="cvac_NumberOfInstrumentsOrInterestsIssuedOrIssuableAsConsiderationToFormerShareholders_638043208769539503" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_ValueOfInstrumentsOrInterestsIssuedOrIssuableAsConsiderationToFormerShareholders" xlink:label="cvac_ValueOfInstrumentsOrInterestsIssuedOrIssuableAsConsiderationToFormerShareholders_638043208769539503" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems_638043208769529506" xlink:to="cvac_ValueOfInstrumentsOrInterestsIssuedOrIssuableAsConsiderationToFormerShareholders_638043208769539503" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_EquityInterestsOfAcquirer" xlink:label="ifrs-full_EquityInterestsOfAcquirer_638043208769539503" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems_638043208769529506" xlink:to="ifrs-full_EquityInterestsOfAcquirer_638043208769539503" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_NumberOfInstrumentsOrInterestIssuedOrIssuable" xlink:label="cvac_NumberOfInstrumentsOrInterestIssuedOrIssuable_638043208769539503" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems_638043208769529506" xlink:to="cvac_NumberOfInstrumentsOrInterestIssuedOrIssuable_638043208769539503" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_IfrsBusinessAcquisitionSharePrice" xlink:label="cvac_IfrsBusinessAcquisitionSharePrice_638043208769539503" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems_638043208769529506" xlink:to="cvac_IfrsBusinessAcquisitionSharePrice_638043208769539503" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_NumberOfInstrumentsOrInterestsIssuedOrIssuableAsConsiderationForDischargingContractualObligations" xlink:label="cvac_NumberOfInstrumentsOrInterestsIssuedOrIssuableAsConsiderationForDischargingContractualObligations_638043208769549503" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems_638043208769529506" xlink:to="cvac_NumberOfInstrumentsOrInterestsIssuedOrIssuableAsConsiderationForDischargingContractualObligations_638043208769549503" order="18" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_ValueOfInstrumentsOrInterestsIssuedOrIssuableAsConsiderationForDischargingContractualObligations" xlink:label="cvac_ValueOfInstrumentsOrInterestsIssuedOrIssuableAsConsiderationForDischargingContractualObligations_638043208769549503" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems_638043208769529506" xlink:to="cvac_ValueOfInstrumentsOrInterestsIssuedOrIssuableAsConsiderationForDischargingContractualObligations_638043208769549503" order="19" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_StrikePriceForExistingShareBasedPayment" xlink:label="cvac_StrikePriceForExistingShareBasedPayment_638043208769549503" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems_638043208769529506" xlink:to="cvac_StrikePriceForExistingShareBasedPayment_638043208769549503" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CashTransferred" xlink:label="ifrs-full_CashTransferred_638043208769549503" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems_638043208769529506" xlink:to="ifrs-full_CashTransferred_638043208769549503" order="21" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_CashTransferredForSettlementOfVestedEmployeeOptions" xlink:label="cvac_CashTransferredForSettlementOfVestedEmployeeOptions_638043208769549503" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems_638043208769529506" xlink:to="cvac_CashTransferredForSettlementOfVestedEmployeeOptions_638043208769549503" order="22" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_AdditionalCashTransferred" xlink:label="cvac_AdditionalCashTransferred_638043208769549503" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems_638043208769529506" xlink:to="cvac_AdditionalCashTransferred_638043208769549503" order="23" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_ContingentConsiderationPercentageOfTotalConsideration" xlink:label="cvac_ContingentConsiderationPercentageOfTotalConsideration_638043208769549503" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems_638043208769529506" xlink:to="cvac_ContingentConsiderationPercentageOfTotalConsideration_638043208769549503" order="24" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_ContingentConsiderationNumberOfMilestones" xlink:label="cvac_ContingentConsiderationNumberOfMilestones_638043208769549503" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems_638043208769529506" xlink:to="cvac_ContingentConsiderationNumberOfMilestones_638043208769549503" order="25" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_NumberOfInstrumentsOrInterestsIssuedOrIssuableUponAchievementOfFirstMilestone" xlink:label="cvac_NumberOfInstrumentsOrInterestsIssuedOrIssuableUponAchievementOfFirstMilestone_638043208769559506" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems_638043208769529506" xlink:to="cvac_NumberOfInstrumentsOrInterestsIssuedOrIssuableUponAchievementOfFirstMilestone_638043208769559506" order="26" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_PercentageOfConsiderationTransferredUponAchievementOfFirstMilestone" xlink:label="cvac_PercentageOfConsiderationTransferredUponAchievementOfFirstMilestone_638043208769559506" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems_638043208769529506" xlink:to="cvac_PercentageOfConsiderationTransferredUponAchievementOfFirstMilestone_638043208769559506" order="27" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_ValueOfInstrumentsOrInterestsIssuedOrIssuableUponAchievementOfFirstMilestone" xlink:label="cvac_ValueOfInstrumentsOrInterestsIssuedOrIssuableUponAchievementOfFirstMilestone_638043208769559506" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems_638043208769529506" xlink:to="cvac_ValueOfInstrumentsOrInterestsIssuedOrIssuableUponAchievementOfFirstMilestone_638043208769559506" order="28" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_NumberOfInstrumentsOrInterestsIssuedOrIssuableUponAchievementOfSecondMilestone" xlink:label="cvac_NumberOfInstrumentsOrInterestsIssuedOrIssuableUponAchievementOfSecondMilestone_638043208769559506" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems_638043208769529506" xlink:to="cvac_NumberOfInstrumentsOrInterestsIssuedOrIssuableUponAchievementOfSecondMilestone_638043208769559506" order="29" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_PercentageOfConsiderationTransferredUponAchievementOfSecondMilestone" xlink:label="cvac_PercentageOfConsiderationTransferredUponAchievementOfSecondMilestone_638043208769559506" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems_638043208769529506" xlink:to="cvac_PercentageOfConsiderationTransferredUponAchievementOfSecondMilestone_638043208769559506" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_ValueOfInstrumentsOrInterestsIssuedOrIssuableUponAchievementOfSecondMilestone" xlink:label="cvac_ValueOfInstrumentsOrInterestsIssuedOrIssuableUponAchievementOfSecondMilestone_638043208769559506" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems_638043208769529506" xlink:to="cvac_ValueOfInstrumentsOrInterestsIssuedOrIssuableUponAchievementOfSecondMilestone_638043208769559506" order="31" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ContingentConsiderationRecognisedAsOfAcquisitionDate" xlink:label="ifrs-full_ContingentConsiderationRecognisedAsOfAcquisitionDate_638043208769559506" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems_638043208769529506" xlink:to="ifrs-full_ContingentConsiderationRecognisedAsOfAcquisitionDate_638043208769559506" order="32" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NumberOfInstrumentsOrInterestsIssuedOrIssuable" xlink:label="ifrs-full_NumberOfInstrumentsOrInterestsIssuedOrIssuable_638043208769569504" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems_638043208769529506" xlink:to="ifrs-full_NumberOfInstrumentsOrInterestsIssuedOrIssuable_638043208769569504" order="33" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_EquityInterestsOfAcquirer" xlink:label="ifrs-full_EquityInterestsOfAcquirer_638043208769569504" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems_638043208769529506" xlink:to="ifrs-full_EquityInterestsOfAcquirer_638043208769569504" order="34" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_ContingentConsiderationMaximumSharesIssuable" xlink:label="cvac_ContingentConsiderationMaximumSharesIssuable_638043208769569504" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems_638043208769529506" xlink:to="cvac_ContingentConsiderationMaximumSharesIssuable_638043208769569504" order="35" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted" xlink:label="ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted_638043208769569504" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems_638043208769529506" xlink:to="ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted_638043208769569504" order="36" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted" xlink:label="ifrs-full_WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted_638043208769569504" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems_638043208769529506" xlink:to="ifrs-full_WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted_638043208769569504" order="37" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_NumberOfTranchesForVestingOfInstrumentsGrantedInShareBasedPaymentArrangement" xlink:label="cvac_NumberOfTranchesForVestingOfInstrumentsGrantedInShareBasedPaymentArrangement_638043208769569504" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems_638043208769529506" xlink:to="cvac_NumberOfTranchesForVestingOfInstrumentsGrantedInShareBasedPaymentArrangement_638043208769569504" order="38" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AcquisitionrelatedCostsForTransactionRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombination" xlink:label="ifrs-full_AcquisitionrelatedCostsForTransactionRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombination_638043208769569504" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems_638043208769529506" xlink:to="ifrs-full_AcquisitionrelatedCostsForTransactionRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombination_638043208769569504" order="39" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_ProvisionalFairValue" xlink:label="cvac_ProvisionalFairValue_638043208769579507" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems_638043208769529506" xlink:to="cvac_ProvisionalFairValue_638043208769579507" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_FairValueOfTotalConsiderationTransferred" xlink:label="cvac_FairValueOfTotalConsiderationTransferred_638043208769579507" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems_638043208769529506" xlink:to="cvac_FairValueOfTotalConsiderationTransferred_638043208769579507" order="41" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_SigningSharePriceRepresenting10" xlink:label="cvac_SigningSharePriceRepresenting10_638043208769579507" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems_638043208769529506" xlink:to="cvac_SigningSharePriceRepresenting10_638043208769579507" order="42" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_SigningSharePriceRepresenting40" xlink:label="cvac_SigningSharePriceRepresenting40_638043208769579507" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems_638043208769529506" xlink:to="cvac_SigningSharePriceRepresenting40_638043208769579507" order="43" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_ClosingSharePriceRepresentingTotalFairValue" xlink:label="cvac_ClosingSharePriceRepresentingTotalFairValue_638043208769579507" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems_638043208769529506" xlink:to="cvac_ClosingSharePriceRepresentingTotalFairValue_638043208769579507" order="44" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.curevac.com/role/DisclosureSignificantTransactionsAndEventsFrameAcquisitionPurchasePriceAllocationDetails" xlink:type="extended" xlink:title="41802 - Disclosure - Significant transactions and events - Frame Acquisition - Purchase Price Allocation (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfBusinessCombinationsAbstract" xlink:label="ifrs-full_DisclosureOfBusinessCombinationsAbstract_3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfBusinessCombinationsTable" xlink:label="ifrs-full_DisclosureOfBusinessCombinationsTable_638043208769589506" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsAbstract_3" xlink:to="ifrs-full_DisclosureOfBusinessCombinationsTable_638043208769589506" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_BusinessCombinationsAxis" xlink:label="ifrs-full_BusinessCombinationsAxis_638043208769589506" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsTable_638043208769589506" xlink:to="ifrs-full_BusinessCombinationsAxis_638043208769589506" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_EntitysTotalForBusinessCombinationsMember" xlink:label="ifrs-full_EntitysTotalForBusinessCombinationsMember_638043208769589506" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_BusinessCombinationsAxis_638043208769589506" xlink:to="ifrs-full_EntitysTotalForBusinessCombinationsMember_638043208769589506" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_FramePharmaceuticalsB.v.AmsterdamNetherlandsMember" xlink:label="cvac_FramePharmaceuticalsB.v.AmsterdamNetherlandsMember_638043208769589506" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EntitysTotalForBusinessCombinationsMember_638043208769589506" xlink:to="cvac_FramePharmaceuticalsB.v.AmsterdamNetherlandsMember_638043208769589506" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:label="ifrs-full_DisclosureOfBusinessCombinationsLineItems_638043208769589506" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsTable_638043208769589506" xlink:to="ifrs-full_DisclosureOfBusinessCombinationsLineItems_638043208769589506" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NoncurrentAssetsRecognisedAsOfAcquisitionDate" xlink:label="ifrs-full_NoncurrentAssetsRecognisedAsOfAcquisitionDate_638043208769589506" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems_638043208769589506" xlink:to="ifrs-full_NoncurrentAssetsRecognisedAsOfAcquisitionDate_638043208769589506" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDate" xlink:label="ifrs-full_PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDate_638043208769589506" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems_638043208769589506" xlink:to="ifrs-full_PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDate_638043208769589506" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_RightOfUseAssetsRecognisedAsOfAcquisitionDate" xlink:label="cvac_RightOfUseAssetsRecognisedAsOfAcquisitionDate_638043208769589506" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems_638043208769589506" xlink:to="cvac_RightOfUseAssetsRecognisedAsOfAcquisitionDate_638043208769589506" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TechnologybasedIntangibleAssetsRecognisedAsOfAcquisitionDate" xlink:label="ifrs-full_TechnologybasedIntangibleAssetsRecognisedAsOfAcquisitionDate_638043208769589506" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems_638043208769589506" xlink:to="ifrs-full_TechnologybasedIntangibleAssetsRecognisedAsOfAcquisitionDate_638043208769589506" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CurrentAssetsRecognisedAsOfAcquisitionDate" xlink:label="ifrs-full_CurrentAssetsRecognisedAsOfAcquisitionDate_638043208769589506" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems_638043208769589506" xlink:to="ifrs-full_CurrentAssetsRecognisedAsOfAcquisitionDate_638043208769589506" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_FairValueOfAcquiredReceivables" xlink:label="ifrs-full_FairValueOfAcquiredReceivables_638043208769599506" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems_638043208769589506" xlink:to="ifrs-full_FairValueOfAcquiredReceivables_638043208769599506" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CashAndCashEquivalentsRecognisedAsOfAcquisitionDate" xlink:label="ifrs-full_CashAndCashEquivalentsRecognisedAsOfAcquisitionDate_638043208769599506" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems_638043208769589506" xlink:to="ifrs-full_CashAndCashEquivalentsRecognisedAsOfAcquisitionDate_638043208769599506" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_TotalAssetsRecognisedAsOfAcquisitionDate" xlink:label="cvac_TotalAssetsRecognisedAsOfAcquisitionDate_638043208769599506" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems_638043208769589506" xlink:to="cvac_TotalAssetsRecognisedAsOfAcquisitionDate_638043208769599506" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NoncurrentLiabilitiesRecognisedAsOfAcquisitionDate" xlink:label="ifrs-full_NoncurrentLiabilitiesRecognisedAsOfAcquisitionDate_638043208769599506" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems_638043208769589506" xlink:to="ifrs-full_NoncurrentLiabilitiesRecognisedAsOfAcquisitionDate_638043208769599506" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_NoncurrentLeaseLiabilitiesRecognisedAsOfAcquisitionDate" xlink:label="cvac_NoncurrentLeaseLiabilitiesRecognisedAsOfAcquisitionDate_638043208769599506" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems_638043208769589506" xlink:to="cvac_NoncurrentLeaseLiabilitiesRecognisedAsOfAcquisitionDate_638043208769599506" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_NetDeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate" xlink:label="cvac_NetDeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate_638043208769599506" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems_638043208769589506" xlink:to="cvac_NetDeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate_638043208769599506" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CurrentLiabilitiesRecognisedAsOfAcquisitionDate" xlink:label="ifrs-full_CurrentLiabilitiesRecognisedAsOfAcquisitionDate_638043208769599506" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems_638043208769589506" xlink:to="ifrs-full_CurrentLiabilitiesRecognisedAsOfAcquisitionDate_638043208769599506" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_CurrentLeaseLiabilitiesRecognisedAsOfAcquisitionDate" xlink:label="cvac_CurrentLeaseLiabilitiesRecognisedAsOfAcquisitionDate_638043208769599506" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems_638043208769589506" xlink:to="cvac_CurrentLeaseLiabilitiesRecognisedAsOfAcquisitionDate_638043208769599506" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TradeAndOtherPayablesRecognisedAsOfAcquisitionDate" xlink:label="ifrs-full_TradeAndOtherPayablesRecognisedAsOfAcquisitionDate_638043208769599506" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems_638043208769589506" xlink:to="ifrs-full_TradeAndOtherPayablesRecognisedAsOfAcquisitionDate_638043208769599506" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_OtherCurrentLiabilitiesRecognisedAsOfAcquisitionDate" xlink:label="cvac_OtherCurrentLiabilitiesRecognisedAsOfAcquisitionDate_638043208769599506" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems_638043208769589506" xlink:to="cvac_OtherCurrentLiabilitiesRecognisedAsOfAcquisitionDate_638043208769599506" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_LiabilitiesRecognisedAsOfAcquisitionDate" xlink:label="cvac_LiabilitiesRecognisedAsOfAcquisitionDate_638043208769609506" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems_638043208769589506" xlink:to="cvac_LiabilitiesRecognisedAsOfAcquisitionDate_638043208769609506" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed" xlink:label="ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed_638043208769609506" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems_638043208769589506" xlink:to="ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed_638043208769609506" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate" xlink:label="ifrs-full_DeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate_638043208769609506" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems_638043208769589506" xlink:to="ifrs-full_DeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate_638043208769609506" order="18" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DeferredTaxAssetsRecognisedAsOfAcquisitionDate" xlink:label="ifrs-full_DeferredTaxAssetsRecognisedAsOfAcquisitionDate_638043208769609506" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems_638043208769589506" xlink:to="ifrs-full_DeferredTaxAssetsRecognisedAsOfAcquisitionDate_638043208769609506" order="19" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised" xlink:label="ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised_638043208769609506" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems_638043208769589506" xlink:to="ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised_638043208769609506" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.curevac.com/role/DisclosureSignificantTransactionsAndEventsGoodwillRecognizedOnFrameAcquisitionDetails" xlink:type="extended" xlink:title="41803 - Disclosure - Significant transactions and events - Goodwill Recognized On Frame Acquisition (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfBusinessCombinationsAbstract" xlink:label="ifrs-full_DisclosureOfBusinessCombinationsAbstract_4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfBusinessCombinationsTable" xlink:label="ifrs-full_DisclosureOfBusinessCombinationsTable_638043208769609506" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsAbstract_4" xlink:to="ifrs-full_DisclosureOfBusinessCombinationsTable_638043208769609506" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_BusinessCombinationsAxis" xlink:label="ifrs-full_BusinessCombinationsAxis_638043208769609506" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsTable_638043208769609506" xlink:to="ifrs-full_BusinessCombinationsAxis_638043208769609506" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_EntitysTotalForBusinessCombinationsMember" xlink:label="ifrs-full_EntitysTotalForBusinessCombinationsMember_638043208769609506" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_BusinessCombinationsAxis_638043208769609506" xlink:to="ifrs-full_EntitysTotalForBusinessCombinationsMember_638043208769609506" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_FramePharmaceuticalsB.v.AmsterdamNetherlandsMember" xlink:label="cvac_FramePharmaceuticalsB.v.AmsterdamNetherlandsMember_638043208769619506" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EntitysTotalForBusinessCombinationsMember_638043208769609506" xlink:to="cvac_FramePharmaceuticalsB.v.AmsterdamNetherlandsMember_638043208769619506" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:label="ifrs-full_DisclosureOfBusinessCombinationsLineItems_638043208769619506" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsTable_638043208769609506" xlink:to="ifrs-full_DisclosureOfBusinessCombinationsLineItems_638043208769619506" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred" xlink:label="ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred_638043208769619506" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems_638043208769619506" xlink:to="ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred_638043208769619506" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed" xlink:label="ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed_638043208769619506" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems_638043208769619506" xlink:to="ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed_638043208769619506" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_GoodwillRecognisedAsOfAcquisitionDate" xlink:label="ifrs-full_GoodwillRecognisedAsOfAcquisitionDate_638043208769619506" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems_638043208769619506" xlink:to="ifrs-full_GoodwillRecognisedAsOfAcquisitionDate_638043208769619506" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.curevac.com/role/DisclosureSignificantTransactionsAndEventsAnalysesOfCashFlowsOnFrameAcquisitionDetails" xlink:type="extended" xlink:title="41804 - Disclosure - Significant transactions and events - Analyses of cash flows on Frame Acquisition (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfBusinessCombinationsAbstract" xlink:label="ifrs-full_DisclosureOfBusinessCombinationsAbstract_5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfBusinessCombinationsTable" xlink:label="ifrs-full_DisclosureOfBusinessCombinationsTable_638043208769619506" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsAbstract_5" xlink:to="ifrs-full_DisclosureOfBusinessCombinationsTable_638043208769619506" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_BusinessCombinationsAxis" xlink:label="ifrs-full_BusinessCombinationsAxis_638043208769619506" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsTable_638043208769619506" xlink:to="ifrs-full_BusinessCombinationsAxis_638043208769619506" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_EntitysTotalForBusinessCombinationsMember" xlink:label="ifrs-full_EntitysTotalForBusinessCombinationsMember_638043208769619506" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_BusinessCombinationsAxis_638043208769619506" xlink:to="ifrs-full_EntitysTotalForBusinessCombinationsMember_638043208769619506" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_FramePharmaceuticalsB.v.AmsterdamNetherlandsMember" xlink:label="cvac_FramePharmaceuticalsB.v.AmsterdamNetherlandsMember_638043208769619506" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EntitysTotalForBusinessCombinationsMember_638043208769619506" xlink:to="cvac_FramePharmaceuticalsB.v.AmsterdamNetherlandsMember_638043208769619506" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:label="ifrs-full_DisclosureOfBusinessCombinationsLineItems_638043208769619506" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsTable_638043208769619506" xlink:to="ifrs-full_DisclosureOfBusinessCombinationsLineItems_638043208769619506" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CashTransferred" xlink:label="ifrs-full_CashTransferred_638043208769619506" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems_638043208769619506" xlink:to="ifrs-full_CashTransferred_638043208769619506" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CashAndCashEquivalentsRecognisedAsOfAcquisitionDate" xlink:label="ifrs-full_CashAndCashEquivalentsRecognisedAsOfAcquisitionDate_638043208769629507" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems_638043208769619506" xlink:to="ifrs-full_CashAndCashEquivalentsRecognisedAsOfAcquisitionDate_638043208769629507" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities" xlink:label="ifrs-full_CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities_638043208769629507" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems_638043208769619506" xlink:to="ifrs-full_CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities_638043208769629507" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20220930.xsd#cvac_IfrsCashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities" xlink:label="cvac_IfrsCashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities_638043208769629507" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems_638043208769619506" xlink:to="cvac_IfrsCashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities_638043208769629507" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AcquisitionrelatedCostsForTransactionRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombination" xlink:label="ifrs-full_AcquisitionrelatedCostsForTransactionRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombination_638043208769629507" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems_638043208769619506" xlink:to="ifrs-full_AcquisitionrelatedCostsForTransactionRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombination_638043208769629507" order="5" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
  </presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140535895555920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document and Entity Information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">6-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">CureVac N.V.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Sep. 30,  2022<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2022<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001809122<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140535897206048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Interim Condensed Consolidated Statements of Operations and Other Comprehensive Income (Loss) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_StatementOfComprehensiveIncomeAbstract', window );"><strong>Interim Condensed Consolidated Statements of Operations and Other Comprehensive Income (Loss)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromContractsWithCustomers', window );">Revenue</a></td>
<td class="nump">&#8364; 55,731<span></span>
</td>
<td class="nump">&#8364; 61,765<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CostOfSales', window );">Cost of sales</a></td>
<td class="num">(103,992)<span></span>
</td>
<td class="num">(168,177)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SalesAndMarketingExpense', window );">Selling and distribution expenses</a></td>
<td class="num">(1,825)<span></span>
</td>
<td class="num">(1,232)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="num">(34,934)<span></span>
</td>
<td class="num">(284,728)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="num">(78,019)<span></span>
</td>
<td class="num">(80,787)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MiscellaneousOtherOperatingIncome', window );">Other operating income</a></td>
<td class="nump">35,901<span></span>
</td>
<td class="nump">66,746<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MiscellaneousOtherOperatingExpense', window );">Other operating expenses</a></td>
<td class="num">(809)<span></span>
</td>
<td class="num">(339)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossFromOperatingActivities', window );">Operating loss</a></td>
<td class="num">(127,947)<span></span>
</td>
<td class="num">(406,752)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinanceIncome', window );">Finance income</a></td>
<td class="nump">10,619<span></span>
</td>
<td class="nump">8,828<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinanceCosts', window );">Finance expenses</a></td>
<td class="num">(3,077)<span></span>
</td>
<td class="num">(10,015)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossBeforeTax', window );">Loss before income tax</a></td>
<td class="num">(120,405)<span></span>
</td>
<td class="num">(407,939)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncomeTaxExpenseContinuingOperations', window );">Income tax benefit/ (expense)</a></td>
<td class="nump">160<span></span>
</td>
<td class="num">(1,841)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Net loss for the period</a></td>
<td class="num">(120,245)<span></span>
</td>
<td class="num">(409,780)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncomeAbstract', window );"><strong>Other comprehensive income (loss):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation', window );">Foreign currency adjustments</a></td>
<td class="num">(364)<span></span>
</td>
<td class="num">(62)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncome', window );">Total comprehensive loss for the period</a></td>
<td class="num">&#8364; (120,609)<span></span>
</td>
<td class="num">&#8364; (409,842)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BasicEarningsLossPerShare', window );">Net loss per share basic</a></td>
<td class="num">&#8364; (0.64)<span></span>
</td>
<td class="num">&#8364; (2.21)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DilutedEarningsLossPerShare', window );">Net loss per share diluted</a></td>
<td class="num">&#8364; (0.64)<span></span>
</td>
<td class="num">&#8364; (2.21)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BasicEarningsLossPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator) divided by the weighted average number of ordinary shares outstanding during the period (the denominator).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2021-01-01<br> -Paragraph 66<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2021-01-01<br> -Paragraph 67<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_67&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BasicEarningsLossPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComprehensiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of change in equity resulting from transactions and other events, other than those changes resulting from transactions with owners in their capacity as owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2021-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause ix<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_B12_b_ix&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2021-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 106<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_106_a&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2021-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2021-03-24<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 81A<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_81A_c&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComprehensiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CostOfSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of all expenses directly or indirectly attributed to the goods or services sold. Attributed expenses include, but are not limited to, costs previously included in the measurement of inventory that has now been sold, such as depreciation and maintenance of factory buildings and equipment used in the production process, unallocated production overheads, and abnormal amounts of production costs of inventories.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 99<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_99&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 103<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CostOfSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DilutedEarningsLossPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator), divided by the weighted average number of ordinary shares outstanding during the period (the denominator), both adjusted for the effects of all dilutive potential ordinary shares. [Refer: Ordinary shares [member]; Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2021-01-01<br> -Paragraph 66<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2021-01-01<br> -Paragraph 67<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_67&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DilutedEarningsLossPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of costs associated with financing activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 82<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_82_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinanceIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income associated with interest and other financing activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 85<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinanceIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense relating to general and administrative activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncomeTaxExpenseContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount included in the determination of profit (loss) for the period in respect of current tax and deferred tax. [Refer: Current tax expense (income); Deferred tax expense (income)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 26<br> -IssueDate 2021-01-01<br> -Paragraph 35<br> -Subparagraph b<br> -Clause viii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=26&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_35_b_viii&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2021-01-01<br> -Paragraph 23<br> -Subparagraph h<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_23_h&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2021-01-01<br> -Paragraph 79<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_79&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2021-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_81_c_i&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 82<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_82_d&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2021-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_81_c_ii&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2021-01-01<br> -Paragraph B13<br> -Subparagraph g<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_B13_g&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncomeTaxExpenseContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MiscellaneousOtherOperatingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of miscellaneous other operating expenses. [Refer: Other operating income (expense)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MiscellaneousOtherOperatingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MiscellaneousOtherOperatingIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of miscellaneous other operating income. [Refer: Other operating income (expense)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MiscellaneousOtherOperatingIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of other comprehensive income, net of tax, after reclassification adjustments, related to exchange differences when financial statements of foreign operations are translated. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 91<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_91_a&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 7<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_7&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 18<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_18_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2021-01-01<br> -Paragraph 28<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Note Effective on first application of IFRS 9<br> -Name IFRS<br> -Number 4<br> -IssueDate 2021-01-01<br> -Paragraph 39L<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=4&amp;code=ifrs-tx-2021-en-b&amp;anchor=para_39L_e&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2021-01-01<br> -Paragraph 23<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Note Effective 2023-01-01<br> -Name IFRS<br> -Number 17<br> -IssueDate 2021-01-01<br> -Paragraph 113<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=17&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_113_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2021-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2021-03-24<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_106_d_i&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 81A<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_81A_a&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The profit (loss) before tax expense or income. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2021-01-01<br> -Paragraph 28<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2021-01-01<br> -Paragraph 23<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 103<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 102<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_102&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 5<br> -IssueDate 2021-01-01<br> -Paragraph 33<br> -Subparagraph b<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=5&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_33_b_i&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossFromOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The profit (loss) from operating activities of the entity. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 32<br> -IssueDate 2021-01-01<br> -Paragraph IE33<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=32&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_IE33&amp;doctype=Illustrative%20Examples<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 85<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossFromOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expenditure directly attributable to research or development activities, recognised in profit or loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2021-01-01<br> -Paragraph 126<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_126&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RevenueFromContractsWithCustomers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of revenue from contracts with customers. A customer is a party that has contracted with an entity to obtain goods or services that are an output of the entity&#8217;s ordinary activities in exchange for consideration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2021-01-01<br> -Paragraph 113<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_113_a&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2021-01-01<br> -Paragraph 114<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_114&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RevenueFromContractsWithCustomers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SalesAndMarketingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense relating to the marketing and selling of goods or services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 85<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SalesAndMarketingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_StatementOfComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_StatementOfComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140535896862608">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Interim Condensed Consolidated Statements of Financial Position - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentAssetsAbstract', window );"><strong>Non-current assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwill', window );">Intangible assets and goodwill</a></td>
<td class="nump">&#8364; 33,775<span></span>
</td>
<td class="nump">&#8364; 13,238<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment</a></td>
<td class="nump">207,660<span></span>
</td>
<td class="nump">168,264<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RightofuseAssets', window );">Right-of-use assets</a></td>
<td class="nump">43,801<span></span>
</td>
<td class="nump">32,129<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherNoncurrentAssets', window );">Other assets</a></td>
<td class="nump">1,688<span></span>
</td>
<td class="nump">1,731<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NetDeferredTaxAssets', window );">Deferred tax assets</a></td>
<td class="nump">1,306<span></span>
</td>
<td class="nump">2,861<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentAssets', window );">Total non-current assets</a></td>
<td class="nump">288,230<span></span>
</td>
<td class="nump">218,223<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentAssetsAbstract', window );"><strong>Current assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners', window );">Assets held for sale</a></td>
<td class="nump">3,828<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Inventories', window );">Inventories</a></td>
<td class="nump">7,868<span></span>
</td>
<td class="nump">56,159<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentTradeReceivables', window );">Trade receivables</a></td>
<td class="nump">6,170<span></span>
</td>
<td class="nump">18,504<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherCurrentFinancialAssets', window );">Other financial assets</a></td>
<td class="nump">2,599<span></span>
</td>
<td class="nump">4,648<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentPrepaymentsAndOtherCurrentAssets', window );">Prepaid expenses and other assets</a></td>
<td class="nump">60,952<span></span>
</td>
<td class="nump">49,244<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="nump">540,865<span></span>
</td>
<td class="nump">811,464<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentAssets', window );">Total current assets</a></td>
<td class="nump">622,282<span></span>
</td>
<td class="nump">940,019<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Assets', window );">Total assets</a></td>
<td class="nump">910,512<span></span>
</td>
<td class="nump">1,158,242<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EquityAbstract', window );"><strong>Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IssuedCapital', window );">Issued capital</a></td>
<td class="nump">22,834<span></span>
</td>
<td class="nump">22,454<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CapitalReserve', window );">Capital reserve</a></td>
<td class="nump">1,781,316<span></span>
</td>
<td class="nump">1,728,658<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TreasuryShares', window );">Treasury Shares</a></td>
<td class="num">(1,734)<span></span>
</td>
<td class="num">(5,817)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RetainedEarnings', window );">Accumulated deficit</a></td>
<td class="num">(1,177,030)<span></span>
</td>
<td class="num">(1,056,785)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AccumulatedOtherComprehensiveIncome', window );">Other comprehensive income</a></td>
<td class="num">(398)<span></span>
</td>
<td class="num">(34)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Total equity</a></td>
<td class="nump">624,988<span></span>
</td>
<td class="nump">688,476<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentLiabilitiesAbstract', window );"><strong>Non-current liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentLeaseLiabilities', window );">Lease liabilities</a></td>
<td class="nump">36,609<span></span>
</td>
<td class="nump">25,423<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentContractLiabilities', window );">Contract liabilities</a></td>
<td class="nump">76,279<span></span>
</td>
<td class="nump">86,345<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherNoncurrentLiabilities', window );">Other liabilities</a></td>
<td class="nump">284<span></span>
</td>
<td class="nump">264<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentLiabilities', window );">Total non-current liabilities</a></td>
<td class="nump">113,172<span></span>
</td>
<td class="nump">112,032<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentLiabilitiesAbstract', window );"><strong>Current liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentLeaseLiabilities', window );">Lease liabilities</a></td>
<td class="nump">4,652<span></span>
</td>
<td class="nump">3,469<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherCurrentPayables', window );">Trade and other payables</a></td>
<td class="nump">52,608<span></span>
</td>
<td class="nump">127,703<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherCurrentLiabilities', window );">Other liabilities</a></td>
<td class="nump">78,967<span></span>
</td>
<td class="nump">170,073<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentTaxLiabilities', window );">Income taxes payable</a></td>
<td class="nump">587<span></span>
</td>
<td class="nump">739<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentContractLiabilities', window );">Contract liabilities</a></td>
<td class="nump">35,538<span></span>
</td>
<td class="nump">55,750<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentLiabilities', window );">Total current liabilities</a></td>
<td class="nump">172,352<span></span>
</td>
<td class="nump">357,734<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Liabilities', window );">Total liabilities</a></td>
<td class="nump">285,524<span></span>
</td>
<td class="nump">469,766<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EquityAndLiabilities', window );">Total equity and liabilities</a></td>
<td class="nump">&#8364; 910,512<span></span>
</td>
<td class="nump">&#8364; 1,158,242<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AccumulatedOtherComprehensiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of accumulated items of income and expense (including reclassification adjustments) that are not recognised in profit or loss as required or permitted by other IFRSs. [Refer: IFRSs [member]; Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 55<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AccumulatedOtherComprehensiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of a present economic resource controlled by the entity as a result of past events. Economic resource is a right that has the potential to produce economic benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2021-01-01<br> -Paragraph 93<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2021-01-01<br> -Paragraph 28<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_28_c&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2021-01-01<br> -Paragraph 93<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2021-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 55<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2021-01-01<br> -Paragraph 23<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CapitalReserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A component of equity representing the capital reserves.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 55<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CapitalReserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 45<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2021-01-01<br> -Paragraph B13<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_B13_a&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2021-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 54<br> -Subparagraph i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_54_i&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of assets that the entity (a) expects to realise or intends to sell or consume in its normal operating cycle; (b) holds primarily for the purpose of trading; (c) expects to realise within twelve months after the reporting period; or (d) classifies as cash or cash equivalents (as defined in IAS 7) unless the asset is restricted from being exchanged or used to settle a liability for at least twelve months after the reporting period. [Refer: Assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2021-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_B12_b_i&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 66<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2021-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentContractLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current contract liabilities. [Refer: Contract liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2021-01-01<br> -Paragraph 105<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_105&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentContractLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current lease liabilities. [Refer: Lease liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2021-01-01<br> -Paragraph 47<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_47_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expiry date 2023-01-01: The amount of liabilities that: (a) the entity expects to settle in its normal operating cycle; (b) the entity holds primarily for the purpose of trading; (c) are due to be settled within twelve months after the reporting period; or (d) the entity does not have an unconditional right to defer settlement for at least twelve months after the reporting period.
Effective 2023-01-01: The amount of liabilities that: (a) the entity expects to settle in its normal operating cycle; (b) the entity holds primarily for the purpose of trading; (c) are due to be settled within twelve months after the reporting period; or (d) the entity does not have the right at the end of the reporting period to defer settlement for at least twelve months after the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2021-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause iii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_B12_b_iii&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 69<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_69&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2021-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentPrepaymentsAndOtherCurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current prepayments and other current assets. [Refer: Other current assets; Current prepayments]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 55<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentPrepaymentsAndOtherCurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current tax for current and prior periods to the extent unpaid. Current tax is the amount of income taxes payable (recoverable) in respect of the taxable profit (tax loss) for a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 54<br> -Subparagraph n<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_54_n&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentTradeReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current trade receivables. [Refer: Trade receivables]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 78<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_78_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 68<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_68&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentTradeReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Equity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of residual interest in the assets of the entity after deducting all its liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 24<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_24_a&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_32_a_i&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2021-01-01<br> -Paragraph 93<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2021-01-01<br> -Paragraph 93<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2021-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 55<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Equity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EquityAndLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the entity's equity and liabilities. [Refer: Equity; Liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 55<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EquityAndLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IntangibleAssetsAndGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of intangible assets and goodwill held by the entity. [Refer: Goodwill; Intangible assets other than goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 55<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IntangibleAssetsAndGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Inventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current inventories. [Refer: Inventories]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 2<br> -IssueDate 2021-01-01<br> -Paragraph 36<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=2&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_36_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 54<br> -Subparagraph g<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_54_g&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 68<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_68&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Inventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IssuedCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The nominal value of capital issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IssuedCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of a present obligation of the entity to transfer an economic resource as a result of past events. Economic resource is a right that has the potential to produce economic benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2021-01-01<br> -Paragraph 93<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2021-01-01<br> -Paragraph 93<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2021-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2021-01-01<br> -Paragraph 28<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_28_d&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2021-01-01<br> -Paragraph 23<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 55<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NetDeferredTaxAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of deferred tax assets net of deferred tax liabilities, when the absolute amount of deferred tax assets is greater than the absolute amount of deferred tax liabilities. [Refer: Deferred tax assets; Deferred tax liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2021-01-01<br> -Paragraph 81<br> -Subparagraph g<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_81_g_i&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NetDeferredTaxAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of assets that do not meet the definition of current assets. [Refer: Current assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 66<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2021-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_B12_b_ii&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2021-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2021-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current assets or disposal groups classified as held for sale or as held for distribution to owners. [Refer: Non-current assets or disposal groups classified as held for distribution to owners; Non-current assets or disposal groups classified as held for sale]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 54<br> -Subparagraph j<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_54_j&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentContractLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current contract liabilities. [Refer: Contract liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2021-01-01<br> -Paragraph 105<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_105&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentContractLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current lease liabilities. [Refer: Lease liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2021-01-01<br> -Paragraph 47<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_47_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of liabilities that do not meet the definition of current liabilities. [Refer: Current liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2021-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause iv<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_B12_b_iv&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 69<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_69&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2021-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherCurrentFinancialAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current financial assets that the entity does not separately disclose in the same statement or note. [Refer: Other financial assets; Current financial assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 54<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_54_d&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherCurrentFinancialAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current liabilities that the entity does not separately disclose in the same statement or note. [Refer: Current liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 55<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current assets that the entity does not separately disclose in the same statement or note. [Refer: Non-current assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 55<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherNoncurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current liabilities that the entity does not separately disclose in the same statement or note. [Refer: Non-current liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 55<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherNoncurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of tangible assets that: (a) are held for use in the production or supply of goods or services, for rental to others, or for administrative purposes; and (b) are expected to be used during more than one period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2021-01-01<br> -Paragraph 73<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_73_e&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 54<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_54_a&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RetainedEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A component of equity representing the entity's cumulative undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph IG6<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_IG6&amp;doctype=Implementation%20Guidance<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RetainedEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RightofuseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of assets that represent a lessee's right to use an underlying asset for the lease term. Underlying asset is an asset that is the subject of a lease, for which the right to use that asset has been provided by a lessor to a lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2021-01-01<br> -Paragraph 53<br> -Subparagraph j<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_53_j&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RightofuseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherCurrentPayables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current trade payables and current other payables. [Refer: Current trade payables; Other current payables]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 54<br> -Subparagraph k<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_54_k&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherCurrentPayables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TreasuryShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>An entity&#8217;s own equity instruments, held by the entity or other members of the consolidated group.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 32<br> -IssueDate 2021-01-01<br> -Paragraph 34<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=32&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_34&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TreasuryShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140535896732432">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Interim Condensed Consolidated Statements of Changes in Shareholders' Equity - EUR (&#8364;)<br></strong></div></th>
<th class="th"><div>Issued capital</div></th>
<th class="th"><div>Capital reserve</div></th>
<th class="th"><div>Treasury Shares</div></th>
<th class="th"><div>Accumulated deficit</div></th>
<th class="th"><div>Currency translation reserve</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Balance at the beginning at Dec. 31, 2020</a></td>
<td class="nump">&#8364; 21,655,000<span></span>
</td>
<td class="nump">&#8364; 1,334,704,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">&#8364; (645,069,000)<span></span>
</td>
<td class="nump">&#8364; 57,000<span></span>
</td>
<td class="nump">&#8364; 711,347,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(409,780,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(409,780,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncome', window );">Other comprehensive income (loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(62,000)<span></span>
</td>
<td class="num">(62,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncome', window );">Total comprehensive income (loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(409,780,000)<span></span>
</td>
<td class="num">(62,000)<span></span>
</td>
<td class="num">(409,842,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_ShareBasedPaymentExpenseIncl.DeferredTaxes', window );">Share-based payments (net of taxes)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,965,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,965,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IssueOfEquity', window );">Issuance of share capital (net of transaction costs)</a></td>
<td class="nump">690,000<span></span>
</td>
<td class="nump">403,372,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">404,062,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions', window );">Exercise of options</a></td>
<td class="nump">101,000<span></span>
</td>
<td class="nump">2,422,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,523,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughTreasuryShareTransactions', window );">Repurchase of common shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(25,550,000)<span></span>
</td>
<td class="num">&#8364; (211,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(25,761,000)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Balance at the end at Sep. 30, 2021</a></td>
<td class="nump">22,446,000<span></span>
</td>
<td class="nump">1,727,913,000<span></span>
</td>
<td class="num">(211,000)<span></span>
</td>
<td class="num">(1,054,849,000)<span></span>
</td>
<td class="num">(5,000)<span></span>
</td>
<td class="nump">695,294,000<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Balance at the beginning at Dec. 31, 2021</a></td>
<td class="nump">22,454,000<span></span>
</td>
<td class="nump">1,728,658,000<span></span>
</td>
<td class="num">(5,817,000)<span></span>
</td>
<td class="num">(1,056,785,000)<span></span>
</td>
<td class="num">(34,000)<span></span>
</td>
<td class="nump">688,476,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(120,245,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(120,245,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncome', window );">Other comprehensive income (loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(364,000)<span></span>
</td>
<td class="num">(364,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncome', window );">Total comprehensive income (loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(120,245,000)<span></span>
</td>
<td class="num">(364,000)<span></span>
</td>
<td class="num">(120,609,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_ShareBasedPaymentExpenseIncl.DeferredTaxes', window );">Share-based payments (net of taxes)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,372,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,372,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IssueOfEquity', window );">Issuance of share capital (net of transaction costs)</a></td>
<td class="nump">378,000<span></span>
</td>
<td class="nump">31,948,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32,326,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions', window );">Exercise of options</a></td>
<td class="nump">2,000<span></span>
</td>
<td class="num">(358,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(356,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_SettlementOfShareBasedPaymentAwardsAmount', window );">Settlement of share-based payment awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,093,000)<span></span>
</td>
<td class="nump">4,083,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">990,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughAcquisitionOfSubsidiary', window );">Capital Increase from Business Combinations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,789,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,789,000<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Balance at the end at Sep. 30, 2022</a></td>
<td class="nump">&#8364; 22,834,000<span></span>
</td>
<td class="nump">&#8364; 1,781,316,000<span></span>
</td>
<td class="num">&#8364; (1,734,000)<span></span>
</td>
<td class="num">&#8364; (1,177,030,000)<span></span>
</td>
<td class="num">&#8364; (398,000)<span></span>
</td>
<td class="nump">&#8364; 624,988,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_SettlementOfShareBasedPaymentAwardsAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of share based payment awards settled in cash.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_SettlementOfShareBasedPaymentAwardsAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_ShareBasedPaymentExpenseIncl.DeferredTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of Share-based payment expense (incl. deferred taxes)</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_ShareBasedPaymentExpenseIncl.DeferredTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComprehensiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of change in equity resulting from transactions and other events, other than those changes resulting from transactions with owners in their capacity as owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2021-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause ix<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_B12_b_ix&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2021-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 106<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_106_a&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2021-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2021-03-24<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 81A<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_81A_c&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComprehensiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Equity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of residual interest in the assets of the entity after deducting all its liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 24<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_24_a&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_32_a_i&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2021-01-01<br> -Paragraph 93<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2021-01-01<br> -Paragraph 93<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2021-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 55<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Equity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughAcquisitionOfSubsidiary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in equity resulting from the acquisition of subsidiaries. [Refer: Subsidiaries [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughAcquisitionOfSubsidiary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in equity resulting from the exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughExerciseOfOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughTreasuryShareTransactions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in equity resulting from treasury share transactions. [Refer: Equity; Treasury shares]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughTreasuryShareTransactions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IssueOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase in equity through the issue of equity instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause iii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_106_d_iii&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IssueOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherComprehensiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income and expense (including reclassification adjustments) that is not recognised in profit or loss as required or permitted by IFRSs. [Refer: IFRSs [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_106_d_ii&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2021-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause viii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_B12_b_viii&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2021-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 81A<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_81A_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 91<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_91_a&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherComprehensiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 18<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_18_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2021-01-01<br> -Paragraph 28<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Note Effective on first application of IFRS 9<br> -Name IFRS<br> -Number 4<br> -IssueDate 2021-01-01<br> -Paragraph 39L<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=4&amp;code=ifrs-tx-2021-en-b&amp;anchor=para_39L_e&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2021-01-01<br> -Paragraph 23<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Note Effective 2023-01-01<br> -Name IFRS<br> -Number 17<br> -IssueDate 2021-01-01<br> -Paragraph 113<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=17&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_113_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2021-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2021-03-24<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_106_d_i&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 81A<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_81A_a&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140535897099504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Interim Condensed Consolidated Statements of Cash Flows<br> &#8364; in Thousands, $ in Millions</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>EUR (&#8364;)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract', window );"><strong>Operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossBeforeTax', window );">Loss before income tax</a></td>
<td class="num">&#8364; (120,405)<span></span>
</td>
<td class="num">&#8364; (407,939)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForReconcileProfitLossAbstract', window );"><strong>Adjustments to reconcile loss before tax to net cash flows</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForFinanceIncome', window );">Finance income</a></td>
<td class="num">(10,619)<span></span>
</td>
<td class="num">(8,828)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForFinanceCosts', window );">Finance expense</a></td>
<td class="nump">3,077<span></span>
</td>
<td class="nump">10,015<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense', window );">Depreciation and impairment of property, plant and equipment and right-of-use assets</a></td>
<td class="nump">23,349<span></span>
</td>
<td class="nump">11,342<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets', window );">Loss on disposal of fixed assets</a></td>
<td class="nump">6,428<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_ImpairmentsOfInventoryAndPrepayments', window );">Impairment of inventory and prepayments</a></td>
<td class="nump">41,295<span></span>
</td>
<td class="nump">39,142<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForSharebasedPayments', window );">Share-based payment expense</a></td>
<td class="nump">6,455<span></span>
</td>
<td class="nump">11,470<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_AdjustmentsForNonCashIncomeFromReleaseOfProvisions', window );">Non-cash income from release of provisions</a></td>
<td class="num">(61,102)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_ChangesInWorkingCapitalAbstract', window );"><strong>Working capital changes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables', window );">Decrease / (increase) in trade receivables and contract assets</a></td>
<td class="nump">12,334<span></span>
</td>
<td class="num">(7,810)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForDecreaseIncreaseInInventories', window );">Decrease / (increase) in inventory</a></td>
<td class="nump">6,996<span></span>
</td>
<td class="num">(143,638)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForDecreaseIncreaseInOtherAssets', window );">Decrease / (increase) in other assets</a></td>
<td class="num">(9,724)<span></span>
</td>
<td class="num">(214,621)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_ReceiptsFromGovernmentGrantsClassifiedAsOperatingActivities', window );">Receipts from grants from government agencies and similar bodies</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38,349<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables', window );">(Decrease) / increase in trade and other payables, other liabilities and contract liabilities</a></td>
<td class="num">(131,746)<span></span>
</td>
<td class="nump">130,022<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_AdjustmentsForIncreaseDecreaseInOtherCurrentFinancialAndOtherLiabilities', window );">(Decrease) / increase in other current financial liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">78<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForDeferredTaxExpense', window );">Decrease / (increase) in deferred taxes</a></td>
<td class="nump">49<span></span>
</td>
<td class="num">(100)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncomeTaxesPaidClassifiedAsOperatingActivities', window );">Income taxes paid</a></td>
<td class="num">(152)<span></span>
</td>
<td class="num">(352)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InterestReceivedClassifiedAsOperatingActivities', window );">Interest received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InterestPaidClassifiedAsOperatingActivities', window );">Interest paid</a></td>
<td class="num">(3,326)<span></span>
</td>
<td class="num">(7,212)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInOperatingActivities', window );">Net cash flow (used in) operating activities</a></td>
<td class="num">(237,091)<span></span>
</td>
<td class="num">(550,057)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract', window );"><strong>Investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities', window );">Purchase of property, plant and equipment</a></td>
<td class="num">(67,124)<span></span>
</td>
<td class="num">(91,032)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities', window );">Purchase of intangible assets</a></td>
<td class="num">(5,435)<span></span>
</td>
<td class="num">(2,273)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInInvestingActivities', window );">Net cash flow (used in) investing activities</a></td>
<td class="num">(72,559)<span></span>
</td>
<td class="num">(93,305)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract', window );"><strong>Financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities', window );">Payments on lease obligations</a></td>
<td class="num">(3,087)<span></span>
</td>
<td class="num">(2,346)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_ProceedFromIssuingOtherEquityInstrument', window );">Payment on / Proceeds from Treasury Shares</a></td>
<td class="nump">991<span></span>
</td>
<td class="num">(23,339)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_IfrsStockIssuedDuringPeriodValueNewIssues', window );">Proceeds from at-the-market offering program (net of transaction costs)</a></td>
<td class="nump">32,325<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_ProceedsOrPaymentsFromExerciseOfOptions', window );">Payments from the exercise of options</a></td>
<td class="num">(356)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromIssuingShares', window );">Proceeds from the issuance of shares (net of transaction costs)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">404,164<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInFinancingActivities', window );">Net cash flow provided by financing activities</a></td>
<td class="nump">29,873<span></span>
</td>
<td class="nump">378,479<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges', window );">Net increase (decrease) in cash and cash equivalents</a></td>
<td class="num">(279,777)<span></span>
</td>
<td class="num">(264,883)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents', window );">Currency translation gains (losses) on cash and cash equivalents</a></td>
<td class="nump">9,178<span></span>
</td>
<td class="nump">3,261<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents, beginning of period</a></td>
<td class="nump">811,464<span></span>
</td>
<td class="nump">1,322,593<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents, end of period</a></td>
<td class="nump">&#8364; 540,865<span></span>
</td>
<td class="nump">&#8364; 1,060,971<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_AdjustmentsForIncreaseDecreaseInOtherCurrentFinancialAndOtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for increase (decrease) in other current financial and other liabilities to reconcile profit(loss) to net cashflow (used in) operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_AdjustmentsForIncreaseDecreaseInOtherCurrentFinancialAndOtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_AdjustmentsForNonCashIncomeFromReleaseOfProvisions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for non cash income from release of provisions to reconcile profit (loss) to net cash flow from (used in) operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_AdjustmentsForNonCashIncomeFromReleaseOfProvisions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_ChangesInWorkingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_ChangesInWorkingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_IfrsStockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from at the market shares issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_IfrsStockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_ImpairmentsOfInventoryAndPrepayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Impairments of inventory and prepayments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_ImpairmentsOfInventoryAndPrepayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_ProceedFromIssuingOtherEquityInstrument">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of Proceed From Issuing Other Equity Instrument</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_ProceedFromIssuingOtherEquityInstrument</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_ProceedsOrPaymentsFromExerciseOfOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow or outflow from the exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_ProceedsOrPaymentsFromExerciseOfOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_ReceiptsFromGovernmentGrantsClassifiedAsOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from government grants and similar bodies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_ReceiptsFromGovernmentGrantsClassifiedAsOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForDecreaseIncreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for decrease (increase) in inventories to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Inventories; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 20<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_20_a&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForDecreaseIncreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForDecreaseIncreaseInOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for decrease (increase) in other assets to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Other assets; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 20<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForDecreaseIncreaseInOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for decrease (increase) in trade and other receivables to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Trade and other receivables; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 20<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForDeferredTaxExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for deferred tax expense to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Deferred tax expense (income); Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 20<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForDeferredTaxExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for depreciation and amortisation expense to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Depreciation and amortisation expense; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 20<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_20_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForFinanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for finance costs to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Finance costs; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 20<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_20_c&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForFinanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForFinanceIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for finance income to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Finance income; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 20<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForFinanceIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for increase (decrease) in trade and other payables to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Trade and other payables; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 20<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for losses (gains) on disposal of non-current assets to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Non-current assets; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 14<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_14&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForReconcileProfitLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForReconcileProfitLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForSharebasedPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for share-based payments to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 20<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_20_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForSharebasedPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 45<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2021-01-01<br> -Paragraph B13<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_B13_a&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2021-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 54<br> -Subparagraph i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_54_i&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash flows from (used in) financing activities, which are activities that result in changes in the size and composition of the contributed equity and borrowings of the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 10<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_10&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 50<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_50_d&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash flows from (used in) investing activities, which are the acquisition and disposal of long-term assets and other investments not included in cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 10<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_10&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 50<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_50_d&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash flows from (used in) operating activities, which are the principal revenue-producing activities of the entity and other activities that are not investing or financing activities. [Refer: Revenue]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 10<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_10&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 50<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_50_d&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The effect of exchange rate changes on cash and cash equivalents held or due in a foreign currency. [Refer: Cash and cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 25<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_25&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 28<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_28&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncomeTaxesPaidClassifiedAsOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for income taxes paid, classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 35<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_35&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncomeTaxesPaidClassifiedAsOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in cash and cash equivalents before the effect of exchange rate changes on cash and cash equivalents held in foreign currencies. [Refer: Cash and cash equivalents; Effect of exchange rate changes on cash and cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 45<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InterestPaidClassifiedAsOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for interest paid, classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 31<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_31&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InterestPaidClassifiedAsOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InterestReceivedClassifiedAsOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from interest received, classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 31<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_31&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InterestReceivedClassifiedAsOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for payment of lease liabilities, classified as financing activities. [Refer: Lease liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 17<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_17_e&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProceedsFromIssuingShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuing shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 17<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_17_a&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProceedsFromIssuingShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The profit (loss) before tax expense or income. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2021-01-01<br> -Paragraph 28<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2021-01-01<br> -Paragraph 23<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 103<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 102<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_102&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 5<br> -IssueDate 2021-01-01<br> -Paragraph 33<br> -Subparagraph b<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=5&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_33_b_i&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for the purchases of intangible assets, classified as investing activities. [Refer: Intangible assets other than goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 16<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_16_a&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for the purchases of property, plant and equipment, classified as investing activities. [Refer: Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 16<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_16_a&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140535896370832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Corporate Information<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_CorporateInformationAbstract', window );"><strong>Corporate Information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_CorporateInformationTextBlock', window );">Corporate Information</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">1. Corporate Information</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">CureVac N.V. (&#8220;CureVac&#8221; or &#8220;CV&#8221; or the &#8220;Company&#8221;) is the parent company of CureVac Group (&#8220;Group&#8221;) and, along with its subsidiaries, is a global biopharmaceutical company developing a new class of transformative medicines based on the messenger ribonucleic acid (mRNA) that has the potential to improve the lives of people.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">The Company is incorporated in the Netherlands and is registered in the commercial register at the Netherlands Chamber of Commerce under 77798031. The Company&#8217;s registered headquarters is Friedrich-Miescher-Strasse 15, 72076 Tuebingen, Germany. During 2021 until now, Dievini Hopp BioTech holding GmbH &amp; Co. KG (dievini), which is an investment company dedicated to the support of companies in health and life sciences, is the largest shareholder of CureVac. Together with its related parties, dievini has held shares and voting rights in CureVac between appr. 45 &#8211; 49 % during that period. dievini is thus considered to be the de facto parent of the Group. Dietmar Hopp, Daniel Hopp and Oliver Hopp are the ultimate controlling persons (of the main shareholders) of dievini, and, therefore, control the voting and investment decisions of dievini.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_CorporateInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_CorporateInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_CorporateInformationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure on corporate information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_CorporateInformationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140535894209968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of preparation<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_DisclosureOfBasisOfPreparationAbstract', window );"><strong>Basis of preparation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_DisclosureOfBasisOfPreparationExplanatoryTextBlock', window );">Basis of preparation</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">2. Basis of preparation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The interim condensed consolidated financial statements for the nine months ended September 30, 2022, have been prepared in accordance with IAS 34 Interim Financial Reporting.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The interim condensed consolidated financial statements do not include all the information and disclosures required in the annual consolidated financial statements and should be read in conjunction with the Group&#8217;s annual consolidated financial statements as of December 31, 2021 and 2020 and for the three years in the period ended December 31, 2021. The interim condensed consolidated financial statements were authorized by the Management Board for presentation to the Supervisory Board on November 16, 2022. The Group&#8217;s interim condensed consolidated financial statements are presented in Euros (&#8220;EUR&#8221;). Unless otherwise stated, amounts are rounded to thousands of Euros, except per share amounts.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">New standards, interpretations and amendments adopted by the Group</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The accounting policies adopted in the preparation of the interim condensed consolidated financial statements are consistent with those followed in the preparation of the Group&#8217;s annual consolidated financial statements for the year ended December 31, 2021. The new and amended standards and interpretations applied for the first time as of January 1, 2022, as disclosed in the notes to the consolidated financial statements as of December 31, 2021, had no impact on the interim condensed consolidated financial statements of the Group as of and for the nine months ended September 30, 2022. The Group has not early adopted any standard, interpretation or amendment that has been issued but is not yet effective.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">Impact of COVID-19 and the Russia-Ukraine Conflict</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As the Group is currently devoting significant resources to the development of COVID vaccines, such development may impair the ability to timely progress other product candidates in clinical trials or into clinical trials from their current preclinical stage. In addition, enrollment in other programs may be delayed as a result of the COVID-19 pandemic and our focus on developing a COVID vaccine could have a negative impact on our progress on and associated revenue recognition from our non-COVID-19 collaborations. The partial disruption, even temporary, may negatively impact the Company&#8217;s operations and overall business by delaying the progress of its clinical trials and preclinical studies. The Group&#8217;s operations, including research and manufacturing, could also be disrupted due to the potential of the impact of staff absences as a result of self-isolation procedures or extended illness. However, the Group has taken a series of actions aimed at safeguarding its employees and business associates, including implementing a work-from-home policy for employees except for those related to its laboratory and production operations. The Group is running COVID antigen tests on a weekly basis for employees on the premises.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The ongoing military conflict between Russia and Ukraine has not and is not expected to have a material direct or indirect effect on the Group&#8217;s operations or financial condition: however, the Group is currently operating in a period of economic uncertainty and capital markets disruption, which has been significantly impacted by geopolitical instability due to the ongoing military conflict between Russia and Ukraine. As a result of this instability and responding actions taken by the United States, Russia, EU, and other Foreign Governments, this may limit or prevent filing, prosecuting, and maintaining of patient applications in Russia. Government actions may also prevent maintenance of issued patents in Russia. These actions could result in abandonment or lapse of our patents or patent applications in Russia, resulting in partial or complete loss of patent rights in Russia. In addition, a decree was adopted by the Russian government in March 2022, allowing Russian companies and individuals to exploit, without consent or compensation, inventions owned by patentees that have citizenship or nationality in, are registered in, or have predominately primary place of business or profit-making activities in countries that Russia has deemed unfriendly. Consequently, we would not be able to prevent third parties from using our inventions in Russia or from selling or importing products made using our inventions in and into Russia. Accordingly, our competitive position may be impaired, and our business, financial condition, results of operations and prospects may be materially adversely affected.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_DisclosureOfBasisOfPreparationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of the basis used for the preparation of the financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_DisclosureOfBasisOfPreparationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_DisclosureOfBasisOfPreparationExplanatoryTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of the basis used for the preparation of the financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_DisclosureOfBasisOfPreparationExplanatoryTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140535899519168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Notes to the consolidated financial statements<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_DisclosureOfNotesToConsolidatedFinancialStatementsAbstract', window );"><strong>Notes to the consolidated financial statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNotesAndOtherExplanatoryInformationExplanatory', window );">Notes to the consolidated financial statements</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">3. Notes to the consolidated financial statements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">3.1 Revenue from contract with customers</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Group recognized the following revenues:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:71.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:26.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Nine months ended September 30</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR k</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR k</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Belgium</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">GSK</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 49,621</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 52,746</p></td></tr><tr><td style="vertical-align:bottom;width:71.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Germany</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Boehringer Ingelheim</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9,990</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:71.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Switzerland</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">CRISPR</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 831</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,646</p></td></tr><tr><td style="vertical-align:bottom;width:71.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Netherlands</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Genmab</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,323</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,339</p></td></tr><tr><td style="vertical-align:bottom;width:71.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 61,765</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 55,731</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Of these revenues, all of which were recognized over time as part of collaboration agreements, during the nine months ended September 30, 2022 EUR 40,278k (September 30, 2021: EUR 49,878k) related to (i) delivery of research services combined with an IP license (recognized from the upfront payments as further illustrated in the table below) and the reaching of a milestone, (ii) EUR 1,413k (September 30, 2021: EUR 1,400k) related to delivery of products and (iii) EUR 14,040k (September 30, 2021: EUR 10,489k) were recognized from those research and development services considered distinct within the agreements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Of the total revenues recognized, in the nine months ended September 30, 2022, EUR 52,746k in revenue was recognized under the collaboration agreements with GSK, entered into in July 2020, for the research, development, manufacturing and commercialization of mRNA-based vaccines and monoclonal antibodies targeting infectious disease pathogens (&#8220;GSK I&#8221;) and in April 2021 for research, development and manufacturing of next-generation mRNA vaccines targeting the original SARS-CoV-2 strain as well as emerging variants, including multivalent and monovalent approaches, such as CureVac&#8217;s second-generation COVID-19 vaccine candidate, CV2CoV (&#8220;GSK II&#8221;). In the first quarter of 2022, the Company reached a development milestone of EUR 10,000k under the GSK I collaboration. Therefore, revenue for the nine months ending September 30, 2022, also includes recognition of EUR 5,789k of the milestone amount. The remaining EUR 4,211k of the milestone amount is deferred as contract liability and will be recognized into revenue through the estimated completion date of Phase 1 clinical trials, which represents the period of time during which CureVac is responsible for development as, subsequent to this period, GSK will be responsible for further development and commercialization. In the nine months ended September 30, 2021, revenue from the collaborations with GSK consisted of EUR 49,621k primarily recognized from the amortization of upfront and milestone payments.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">The Group has received upfront payments which were initially deferred and are subsequently recognized as revenue as the Group renders services over the performance period. Below is a summary of such payments and the related revenues recognized:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:16.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:18.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:18.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:18.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:16.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Upfront and</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Upfront and</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Revenue&#160;recognized from</b></p></td></tr><tr><td style="vertical-align:bottom;width:16.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">milestones payments included</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">milestones payments included</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;upfront and milestones payments </b></p></td></tr><tr><td style="vertical-align:bottom;width:16.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Upfront and milestone&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">in contract</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">in contract</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">for nine months ended</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:16.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">payments</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;liabilities&#160;at</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;liabilities&#160;at</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September 30,</b></p></td></tr><tr><td style="vertical-align:bottom;width:16.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Customer</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September 30, 2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, 2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September 30, 2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="11" style="padding:0pt;"/></tr><tr><td style="vertical-align:bottom;width:16.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(EUR k)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(EUR k)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(EUR k)</b></p></td></tr><tr><td style="vertical-align:bottom;width:16.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">GSK  </span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:18.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">EUR 205,000k (EUR 10,000k milestone payment included)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 135,494</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 106,788</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 38,315</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 38,705</p></td></tr><tr><td style="vertical-align:bottom;width:16.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">CRISPR  </span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:18.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">USD 3,000k (EUR 2,524k)*</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,239</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,007</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 232</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 232</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:16.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Boehringer Ingelheim</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:18.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">EUR 30,000k</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9,990</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:16.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">Genmab  </span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:18.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">USD 10,000k (EUR 8,937k)*</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,362</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,341</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,341</p></td></tr><tr><td style="vertical-align:bottom;width:16.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.86%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 142,095</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.86%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 111,817</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 49,878</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 40,278</b></p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:5.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1px;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"/></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">* Translated at the currency exchange rate prevailing on the transaction date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">Contract balances:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:74.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September 30, </b></p></td></tr><tr><td style="vertical-align:bottom;width:74.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR k</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR k</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Trade receivables</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 18,504</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,170</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:74.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Contract liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 142,095</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 111,817</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Trade receivables are non-interest bearing and are generally settled within 30 to 45 days. The contract liabilities contain upfront payments and milestone payments from Collaboration agreements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">3.2 Cost of sales</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">The cost of sales consists of the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:71.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:27.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Nine months ended September 30,</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR&#160;k</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR k</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Personnel</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (14,897)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (19,076)</p></td></tr><tr><td style="vertical-align:bottom;width:71.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Materials</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (13,945)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (48,962)</p></td></tr><tr><td style="vertical-align:bottom;width:71.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Third-party services</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (130,795)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (24,030)</p></td></tr><tr><td style="vertical-align:bottom;width:71.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Maintenance and lease</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (3,227)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,479)</p></td></tr><tr><td style="vertical-align:bottom;width:71.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Amortization and depreciation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2,944)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (9,757)</p></td></tr><tr><td style="vertical-align:bottom;width:71.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2,369)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (688)</p></td></tr><tr><td style="vertical-align:bottom;width:71.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.66%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (168,177)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.66%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (103,992)</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">During the nine months ended September 30, 2022, cost of sales mainly decreased compared to the same period of 2021 due to Third-Party Services having been higher last year for set-up activities for the CVnCoV production process. This decrease was partially offset by increased write-offs for raw materials amounting to EUR 41,295k, which were procured for manufacturing of products to sell to GSK that are now no longer expected to be purchased.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">3.3 Selling and distribution expenses</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:16.75pt;margin:0pt;">Selling and distribution expenses consist of the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:71.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:27.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Nine months ended September 30,</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR&#160;k</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR k</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Personnel</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (943)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,467)</p></td></tr><tr><td style="vertical-align:bottom;width:71.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Amortization and depreciation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (65)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (38)</p></td></tr><tr><td style="vertical-align:bottom;width:71.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (224)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (320)</p></td></tr><tr><td style="vertical-align:bottom;width:71.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (1,232)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (1,825)</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Personnel expenses mainly include salary and salary-related expenses, during the nine months ended September 30, 2022 of EUR 1,315k (September 30, 2021: 777k) and share-based payment expense of EUR 152k (September 30, 2021: 166k).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">3.4 Research and development expenses</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">R&amp;D expenses consists of the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:71.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:27.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Nine months ended September 30,</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR&#160;k</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR k</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Materials</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (5,893)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (29,618)</p></td></tr><tr><td style="vertical-align:bottom;width:71.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Personnel</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (25,209)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (24,326)</p></td></tr><tr><td style="vertical-align:bottom;width:71.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Amortization and depreciation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (3,051)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (3,866)</p></td></tr><tr><td style="vertical-align:bottom;width:71.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Patents and fees to register a legal right</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2,372)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2,536)</p></td></tr><tr><td style="vertical-align:bottom;width:71.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Third-party services</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (246,185)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 28,525</p></td></tr><tr><td style="vertical-align:bottom;width:71.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Maintenance and lease </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (291)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (789)</p></td></tr><tr><td style="vertical-align:bottom;width:71.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,727)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2,324)</p></td></tr><tr><td style="vertical-align:bottom;width:71.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (284,728)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (34,934)</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">During the nine months ended September 30, 2022, research and development expenses decreased significantly in comparison to the same period of 2021, as the prior period was largely impacted by the Group&#180;s CVnCoV program in 2021. In the prior year, these expenses consist primarily of cost incurred to CROs involved in the CVnCoV development as well as materials used in the administration of clinical trials. As a result of more participants leaving the clinical trials, prior to completion, than originally estimated and of renegotiations of contracts with CROs, in the nine months ended September 30, 2022, the estimated outstanding costs for the CVnCoV studies decreased, due primarily to re-negotiations of contracts, and resulted in the reversal of provision for onerous contracts in the amount of EUR 36,769k. Additionally, a net gain for a change of estimate in the contract termination provisions resulted primarily from GSK taking over, from the Group, committed capacity at Novartis (see Note 3.6 for additional information). The net effect of these two events resulted in an overall gain within the Third-party services category.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Further, in the nine months ended on September 30, 2022, the balance was impacted by an increase in material consumed in research and development. As of September 30, 2022, the Group had no development expenditures which met the requirements for capitalization and thus none have been capitalized. In 2021, according to the terms and conditions of the grant from BMBF, the Group earned income (recognized in other operating income) for certain eligible expenses incurred for the COVID-19 vaccine development; refer to Note 3.6 for more information on amounts recognized from this grant in the nine months ended September 30, 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Personnel expenses mainly include salary and salary-related expenses, during the nine months ended September 30, 2022 of EUR 23,846k (September 30, 2021: EUR 24,637k) and share-based payment expense of EUR 480k (September 30, 2021: 572k).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">3.5 General and administrative expenses</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">General and administrative expenses consist of the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:71.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:27.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Nine months ended September 30,</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR&#160;k</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR k</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Personnel</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (30,039)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (27,971)</p></td></tr><tr><td style="vertical-align:bottom;width:71.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Maintenance and lease </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2,106)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (4,614)</p></td></tr><tr><td style="vertical-align:bottom;width:71.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Third-party services</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (28,699)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (19,607)</p></td></tr><tr><td style="vertical-align:bottom;width:71.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Legal and other professional services</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (6,394)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (7,215)</p></td></tr><tr><td style="vertical-align:bottom;width:71.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Amortization and depreciation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (5,575)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (9,444)</p></td></tr><tr><td style="vertical-align:bottom;width:71.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (7,974)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (9,168)</p></td></tr><tr><td style="vertical-align:bottom;width:71.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.1%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (80,787)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.14%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (78,019)</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Personnel expenses mainly include salary and salary-related expenses, during the nine months ended September 30, 2022, of EUR 21,621k (September 30, 2021: EUR 19,492k) and share-based payment expense of EUR 5,823k (September 30, 2021: EUR 10,547k). During the nine months ended September 30, 2022, third-party services expenses decreased, compared to the same period of 2021, mainly due to less consulting services. The &#8220;Other&#8221; mainly results from insurance costs related to the D&amp;O insurance EUR 4,150k, (September 30, 2021: EUR 4,073k).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">3.6 Other operating income</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:71.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:27.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Nine months ended September 30,</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR&#160;k</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR k</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Compensation for CMO/Material transfer</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 34,379</p></td></tr><tr><td style="vertical-align:bottom;width:71.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Reimbursement claim</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 610</p></td></tr><tr><td style="vertical-align:bottom;width:71.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Sale of equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 310</p></td></tr><tr><td style="vertical-align:bottom;width:71.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Grants and other cost reimbursements from government agencies and similar bodies</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 64,307</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 377</p></td></tr><tr><td style="vertical-align:bottom;width:71.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,439</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 225</p></td></tr><tr><td style="vertical-align:bottom;width:71.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 66,746</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 35,901</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In March 2022, CureVac AG and GlaxoSmithKline Biologicals SA amended and restated the 2020 GSK agreement and the GSK COVID Agreement in connection with GSK entering into a direct agreement with Novartis for use of Novartis as a CMO at the same time as CureVac exited its CMO agreement with Novartis. Additionally, under the restated agreement, CureVac is entitled to further compensation by GSK. The compensations mainly consist of a consideration for set-up activities undertaken by CureVac (EUR 20,500k) and for reimbursement of prepayments (EUR 12,000k), which were recognized in other operating income in the nine months ended September 30, 2022. As an additional result of this agreement, certain reserved capacity at Novartis was also taken over from the Group by GSK, which resulted in the reversal of provisions of EUR 25,059k which had been recognized as of December 31, 2021, and the recognition of a corresponding gain in research and development expenses in the nine months ended September 30, 2022 (see Note 3.4).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">During the nine months ended September 30, 2022 and 2021, income from grants with government agencies and similar bodies resulted from the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">German Federal Ministry of Education and Research (BMBF)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In 2020, the Company received a grant from BMBF to support the development of its COVID-19 vaccine candidate for which it was determined that the arrangement contained two components: a grant component (in the scope of IAS 20) and a supply component (in the scope of IFRS 15). The grant was terminated in 2021. With regard to the grant component, during the nine months ended September 30, 2021, the Group has recognized grant income in the amount of EUR 64,031k (September 30, 2022: EUR 0).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Coalition for Epidemic Preparedness Innovations (CEPI)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In January 2020, CureVac and CEPI entered into a collaboration to develop a vaccine against the new coronavirus SARS-CoV-2. The aim of the cooperation is to safely advance vaccine candidates into clinical testing as quickly as possible. The agreement builds upon the existing partnership between CureVac and CEPI to develop a rapid-response vaccine platform and included additional initial funding of up to USD 8,300k. In May 2020, CEPI increased its grant award to the Group for SARS-CoV-2 vaccine development to up to USD 15,300k.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">For the nine months ended September 30, 2022, CureVac recognized the reimbursement by CEPI of approved expenses of EUR 26k (September 30, 2021: EUR 30k) as &#8220;other operating income&#8221;. As of September 30, 2022, EUR 1,263k in grant funds received have been deferred and are presented within other liabilities (December 31, 2021: EUR 1,288k). </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Bill &amp; Melinda Gates Foundation (BMGF)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">For the nine months ended September 30, 2022, CureVac recognized EUR 132k (September 30, 2021: EUR 246k) from the amortization of the grants on a straight-line basis into other operating income. As of September 30, 2022, EUR 1,747k in grant funds received have been deferred and presented within other liabilities (December 31, 2021: EUR 1,879k). </p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_DisclosureOfNotesToConsolidatedFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_DisclosureOfNotesToConsolidatedFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfNotesAndOtherExplanatoryInformationExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of notes and other explanatory information as part of a complete set of financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfNotesAndOtherExplanatoryInformationExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140535895540800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Issued Capital and Reserves<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalAbstract', window );"><strong>Issued Capital and Reserves</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory', window );">Issued Capital and Reserves</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">4. Issued Capital and Reserves</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">According to the Company&#8217;s articles of association, the Company&#8217;s authorized shares are divided into 386,250,000 common shares and 386,250,000 preferred shares, each having a <span style="-sec-ix-hidden:Hidden_Pn4RGe75pUmEplb8tLMDGA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">nominal</span></span> value of EUR 0.12. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of September 30, 2022, no preferred shares had been issued and all issued common shares issued and outstanding were fully paid.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">All payments received from shareholders in excess of the nominal value of the shares issued and net of transaction costs are recognized in capital reserves. Capital reserves also consists of recognition of share-based payments and the equity components of convertible loans. The Company may only make distributions, whether a distribution of profits or of freely distributable reserves, to shareholders to the extent shareholders&#8217; equity exceeds the sum of the paid-in and called-up share capital plus any reserves required by Dutch law or by the Company&#8217;s articles of association.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In September 2021, the Company entered into a sales agreement, the Open Sale Agreement, with Jefferies LLC and SVB Leerink LLC, as sales agents, to establish an at-the-market (ATM) offering program, pursuant to which it may sell, from time to time, ordinary shares for aggregate gross proceeds of up to $600.0 million. As of September 30, 2022, 2,288,055 shares were issued under the ATM program, raising <span style="-sec-ix-hidden:Hidden_k6p5zM0iFEqRi29XSeuCWQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$31.7</span></span> million in net proceeds, after deducting $1.0 million in transaction costs; related offering expenses were recorded against the proceeds in equity. Following these issuances, the remaining value authorized for sale under the at-the-market program as of September 30, 2022 amounts to $567.3 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">The number of shares issued and outstanding developed as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:79.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:79.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Common shares issued and outstanding at December 31, 2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 187,120,728</b></p></td></tr><tr><td style="vertical-align:bottom;width:79.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Share option exercises between Jan and March 2022</p></td><td style="vertical-align:bottom;width:3.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 78,732</p></td></tr><tr><td style="vertical-align:bottom;width:79.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Treasury shares</p></td><td style="vertical-align:bottom;width:3.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (78,732)</p></td></tr><tr><td style="vertical-align:bottom;width:79.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Common shares issued and outstanding at March 31, 2022</b></p></td><td style="vertical-align:bottom;width:3.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 187,120,728</b></p></td></tr><tr><td style="vertical-align:bottom;width:79.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">At-the-market offering program issuances</p></td><td style="vertical-align:bottom;width:3.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 340,015</p></td></tr><tr><td style="vertical-align:bottom;width:79.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Share issuances for exercises between Apr to June 2022</p></td><td style="vertical-align:bottom;width:3.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,211</p></td></tr><tr><td style="vertical-align:bottom;width:79.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Share option exercises between Apr and June 2022</p></td><td style="vertical-align:bottom;width:3.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 39,418</p></td></tr><tr><td style="vertical-align:bottom;width:79.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Treasury shares</p></td><td style="vertical-align:bottom;width:3.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (39,418)</p></td></tr><tr><td style="vertical-align:bottom;width:79.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Common shares issued and outstanding at June 30, 2022</b></p></td><td style="vertical-align:bottom;width:3.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 187,466,954</b></p></td></tr><tr><td style="vertical-align:bottom;width:79.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">At-the-market offering program issuances</p></td><td style="vertical-align:bottom;width:3.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,948,040</p></td></tr><tr><td style="vertical-align:bottom;width:79.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Share issuances for exercises between July to Sept 2022</p></td><td style="vertical-align:bottom;width:3.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9,746</p></td></tr><tr><td style="vertical-align:bottom;width:79.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Share issuances to former shareholders of Frame Pharmaceuticals</p></td><td style="vertical-align:bottom;width:3.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 858,496</p></td></tr><tr><td style="vertical-align:bottom;width:79.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Common shares issued and outstanding at September 30, 2022</b></p></td><td style="vertical-align:bottom;width:3.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 190,283,236</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfClassesOfShareCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfClassesOfShareCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share capital, reserves and other equity interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 79<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_79&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140535942218144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-based payments<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract', window );"><strong>Share-based payments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory', window );">Share-based payments</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">5. Share-based payments</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">During the nine months ended September 30, 2022 and 2021, the Group recognized share-based based payments expenses of EUR 6,455k and EUR 11,285k, respectively, as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">Nine months ended September 30,</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:77.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:77.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:77.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR&#160;k</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR&#160;k</b></p></td></tr><tr><td style="vertical-align:bottom;width:77.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Research and development expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 572</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 480</p></td></tr><tr><td style="vertical-align:bottom;width:77.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Sales and marketing expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 166</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 152</p></td></tr><tr><td style="vertical-align:bottom;width:77.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">General and administrative expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,547</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,823</p></td></tr><tr><td style="vertical-align:bottom;width:77.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 11,285</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 6,455</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Expense recognized for the equity-settled programs was as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">Nine months ended September 30:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:77.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:77.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Program</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:77.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">EUR&#160;k</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">EUR k</b></p></td></tr><tr><td style="vertical-align:bottom;width:77.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">LTIP</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 10,075</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,430</p></td></tr><tr><td style="vertical-align:bottom;width:77.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">RSU</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 250</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 275</p></td></tr><tr><td style="vertical-align:bottom;width:77.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">New VSOP</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 441</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (96)</p></td></tr><tr><td style="vertical-align:bottom;width:77.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Prior VSOP</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 519</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 99</p></td></tr><tr><td style="vertical-align:bottom;width:77.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">RSU for key employees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,746</p></td></tr><tr><td style="vertical-align:bottom;width:77.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> 11,825</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> 6,455</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">On November 16, 2020, CureVac granted 266,155 options to the Chief Scientific Officer (CSO). Furthermore, on December 1, 2020, CureVac granted 266,156 options (in 3 tranches) to the company`s Chief Business Officer (CBO) and Chief Commercial Officer (CCO). All grants were made at no cost under the terms of a new long-term incentive plan (LTIP) put in place by CureVac N.V. Options </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">will be settled in shares of CureVac N.V. On September 30, 2022, none of the options granted to the CBO/CCO under the LTIP were exercised at that date. The CSO exercised 6,303 of his options in May 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On July 1, 2021, CureVac granted 20,000 options to the Chief Operations Officer (COO). Furthermore, on August 1, 2021, CureVac granted 30,000 options to the Chief Development Officer (CDO). All grants were made at no cost under the terms of the new long-term incentive plan (LTIP) put in place by CureVac N.V. Options will be settled in shares of CureVac N.V. As of September 30, 2022, none of the options granted to the COO under the LTIP were vested and hence, were not exercisable at that date. On September 30, 2022, none of the options granted to the CDO under the LTIP were vested and hence, were not exercisable at the date. As the CDO left CureVac in June 2022, all of his options were forfeited. All expenses recognized up to him leaving were reversed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On March 1, 2022, CureVac granted 11,500 options to two key employees. All grants were made at no cost under the terms of the new long-term incentive plan (LTIP) put in place by CureVac N.V. Options will be settled in shares of CureVac N.V.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On June 22, 2022, CureVac granted 130,000 options to the executive board. All grants were made at no cost under the terms of the new long-term incentive plan (LTIP) put in place by CureVac N.V. Options will be settled in shares of CureVac N.V. As of September 30, 2022, none of the options granted to the executive board under the LTIP were vested and hence, were not exercisable at that date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The expenses recognized for employee services received under the LTIP during the nine months ended September 30, 2022, is in an amount of EUR 4,430k (2021; EUR 10,075k) and is included in general and administrative expenses and sales and marketing expenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In 2021, as part of the LTIP program, CureVac awarded RSUs (restricted stock units) to senior executives as well as supervisory board members. On June 24, 2021, CureVac awarded 10,956 RSUs to supervisory board members and on December 23, 2021, CureVac awarded 63,095 RSUs to the executive board and various key employees. Up to September 30, 2022, 17,887 RSU&#8217;s were settled. The related RSU expense is recorded in the functional cost category to which the award recipient&#8217;s costs are classified.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On February 10, 2022, CureVac awarded 5,000 options to the Chief Operations Officer (COO). The related RSU expense is included in general and administrative expenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On June 22, 2022, CureVac awarded 37,868 RSUs to supervisory board members and 193,340 RSUs to the executive board and various key employees. The related RSU expense is recorded in the functional cost category to which the award recipient&#8217;s costs are classified.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On June 22, 2022, CureVac awarded 36,000 RSUs to the Chief Executive Officer (CEO). The related RSU expense is included in general and administrative expenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On September 22, 2022, CureVac awarded 30,000 RSUs to the Chief Business Officer (CBO). The related RSU expense is included in general and administrative expenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On July 1, 2022, CureVac awarded 89,655 RSUs to the former Frame employees, now CureVac Netherlands. The related RSU expense is recorded in the functional cost category to which the award recipients&#8217; costs are classified.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The remaining expense results from additional grants under the New VSOP and continued vesting of grants under the Prior VSOP. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Exercise of share-based payments</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">For the New VSOP plan, the IPO was a triggering event, by which all vested options, under the plan, became exercisable; 109,917 options were exercised within the first nine months of 2022 at a weighted average share price of USD 18.75.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2021-01-01<br> -Paragraph 44<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_44&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140535897146640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fixed Assets<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_DisclosureOfFixedAssetsAbstract', window );"><strong>Fixed Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_DisclosureOfFixedAssetsExplanatory', window );">Fixed Assets</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">6. Fixed Assets</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">6.1 Intangible assets</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">During the nine months ended September 30, 2022, the Group acquired intangible assets of EUR 24,224k (Nine months ended September 30, 2021: EUR 2,273k). Acquired intangibles mainly related to licenses, software and prepayments made to acquire those and, for the nine months ended September 30, 2022, include technology and goodwill acquired in the Frame acquisition. For more details, refer to Note 18.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">6.2 Property, plant and equipment</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">During the nine months ended September 30, 2022, the increase in property, plant and equipment was due primarily to the purchase of technical equipment and machines and other equipment of EUR 8,661k (September 30, 2021: EUR 8,907k) as well as additional amounts recognized as construction in progress of EUR 56,746k for Company-owned GMP IV facility (EUR 49,366k) and equipment physically located at the CMO facilities (EUR 3,616k) and the remaining amount mainly for Company&#8217;s GMP facilities. The increase was partially offset by EUR 5,854k impairment of equipment located at a CMO facility, which was recognized in cost of sales.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_DisclosureOfFixedAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_DisclosureOfFixedAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_DisclosureOfFixedAssetsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for fixed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_DisclosureOfFixedAssetsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140535896334960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Assets held for sale<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwnersAbstract', window );"><strong>Assets held for sale</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNoncurrentAssetsHeldForSaleAndDiscontinuedOperationsExplanatory', window );">Assets held for sale</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">7. Assets held for sale</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In the second quarter 2022, CureVac signed a sales agreement with a global pharmaceutical contract development and manufacturing organization for the sale of Ultra-Low Temperature freezers for a total price of EUR 865k. The sale of the assets occurred in July 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In the third quarter 2022, CureVac listed lab equipment for sale on the internet portal of a service provider. Additionally, in fourth quarter 2022, CureVac sold equipment to a CMO.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Group classifies non-current assets as held for sale if their carrying amounts will be recovered principally through a sale transaction rather than through continuing use. Non-current assets classified as held for sale are measured at the lower of their carrying amount and fair value less costs to sell. Costs to sell are the incremental costs directly attributable to the disposal of an asset, excluding finance costs and income tax expense.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The criteria for held for sale classification is regarded as met only when the sale is highly probable, and the asset is available for immediate sale in its present condition. Actions required to complete the sale should indicate that it is unlikely that significant changes to the sale will be made or that the decision to sell will be withdrawn. Management must be committed to the plan to sell the asset and the sale expected to be completed within one year from the date of the classification.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Property, plant and equipment and intangible assets are not depreciated or amortized once classified as held for sale.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Assets and liabilities classified as held for sale are presented separately as current items in the statement of financial position.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfNoncurrentAssetsHeldForSaleAndDiscontinuedOperationsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for non-current assets held for sale and discontinued operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 5<br> -IssueDate 2021-01-01<br> -Section Presentation and disclosure<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=5&amp;code=ifrs-tx-2021-en-r&amp;doctype=Standard&amp;dita_xref=IFRS05_g30-42_TI<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfNoncurrentAssetsHeldForSaleAndDiscontinuedOperationsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwnersAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwnersAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140535896394416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventories<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfInventoriesAbstract', window );"><strong>Inventories.</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInventoriesExplanatory', window );">Inventories</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">8. Inventories</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The inventories include only raw materials. During the nine months ended September 30, 2022, the decrease in inventory of EUR 48,291k is due primarily to transfer of inventory EUR <span style="-sec-ix-hidden:Hidden_N17kRFMeX0inGpkHufA1CQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">9,800</span></span>k (net value) to GSK in connection with an agreement into which it entered with Novartis (see Note 3.6 for additional information) and due to further write-offs of EUR 41,295k as certain raw materials, which had been procured for manufacture into products to sell to GSK, but which are now no longer expected to be purchased.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfInventoriesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfInventoriesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfInventoriesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventories.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 2<br> -IssueDate 2021-01-01<br> -Section Disclosure<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=2&amp;code=ifrs-tx-2021-en-r&amp;doctype=Standard&amp;dita_xref=IAS02_g36-39__IAS02_g36-39_TI<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfInventoriesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140535896361952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Prepaid expenses and other assets (current)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_DisclosureOfPrepaidExpensesAndOtherCurrentAssetsAbstract', window );"><strong>Prepaid expenses and other assets (current)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_DisclosureOfPrepaidExpensesAndOtherCurrentAssetsExplanatory', window );">Prepaid expenses and other assets (current)</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">9. Prepaid expenses and other assets (current)</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">Prepaid expenses and other current assets as of September 30, 2022 amounted to EUR 60,952k (December 31, 2021: 49,244k) and mainly include receivables for the GSK compensation of EUR 12,678k (December 31, 2021: EUR 0k). For more details, refer to Note&#160;3.6. In addition, other assets include further prepayments for material and CRO costs in the amount of EUR 21,999k (December 31, 2021: EUR 5,724k) and tax claims against the tax authorities of EUR 18,009k (December 31, 2021: EUR 35,234k). These net amounts of VAT refund claims and VAT payables do not bear interest and are reported to the tax authorities on a monthly basis.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_DisclosureOfPrepaidExpensesAndOtherCurrentAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_DisclosureOfPrepaidExpensesAndOtherCurrentAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_DisclosureOfPrepaidExpensesAndOtherCurrentAssetsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for prepaid expenses and other current assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_DisclosureOfPrepaidExpensesAndOtherCurrentAssetsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140535896368112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial assets and financial liabilities<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsAbstract', window );"><strong>Financial assets and financial liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsExplanatory', window );">Financial assets and financial liabilities</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">10. Financial assets and financial liabilities</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Fair values of cash and cash equivalents, trade receivables, trade payables, and other current liabilities approximate their carrying amounts largely due to the short-term maturities of these instruments. Cash and cash equivalents compromise cash at banks and term deposits.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">Cash and cash equivalents compromise cash at banks and term deposits. There were no transfers between Level 1 and Level 2 fair value measurements and no transfers into or out of Level 3 fair value measurements during the nine months ended September 30, 2022 and 2021.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinancialInstrumentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinancialInstrumentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinancialInstrumentsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for financial instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Section Scope<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;doctype=Standard&amp;dita_xref=IFRS07_g3-5A_TI<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinancialInstrumentsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140535896389936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Trade and other payables<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherCurrentPayablesAbstract', window );"><strong>Trade and other payables.</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory', window );">Trade and other payables</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">11. Trade and other payables</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">During the nine months ended September 30, 2022, the decrease of EUR 75,095k in trade and other payables was primarily due to less payables to suppliers following the withdrawal of the EMA approval application for CVnCoV in Q4 2021.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of trade and other payables. [Refer: Trade and other payables]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherCurrentPayablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherCurrentPayablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140535896361952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other liabilities<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_IfrsOtherLiabilitiesAbstract', window );"><strong>Other liabilities.</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOtherLiabilitiesExplanatory', window );">Other liabilities</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">12. Other liabilities</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">During the nine months ended September 30, 2022, the decrease of EUR 91,106k in other liabilities was primarily due to a net decrease of contract termination provisions (see Note 3.6), due to a reversal of a portion of the provision for onerous contracts relating to CRO arrangements due to a change in estimate (see Note 3.4), due to a consumption of the CRO provision for onerous losses and due to lower accruals for outstanding invoices. </p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_IfrsOtherLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_IfrsOtherLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfOtherLiabilitiesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of other liabilities. [Refer: Other liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfOtherLiabilitiesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140535896530064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loans<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsAbstract', window );"><strong>Loans</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsExplanatory', window );">Loans</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">13. Loans</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of September 30, 2021, CureVac had drawn the first of the three tranches of the EIB loan received in December 2020 and, thus, EUR 25 million (plus accrued interest of EUR 2,543k) was outstanding on the loan as of that date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">During the year ended December 31, 2021, CureVac decided to early terminate the EIB loan for a total cash consideration of EUR 26,633k, which comprises of EUR 25,000k repayment of the loan and 1,633k interest and fees. As of December 31, 2021, the EIB loan was fully repaid.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of detailed information about borrowings. [Refer: Borrowings]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 7<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_7&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140535896407824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income tax<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract', window );"><strong>Income tax</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIncomeTaxExplanatory', window );">Income tax</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">14. Income tax</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Group booked the expected tax benefits or expenses based on a best estimate for a period of nine months ended September 30, 2022. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">For the nine months ended September 30, 2022 and 2021, the Group recorded a consolidated income tax benefit of EUR 160k (September 30, 2021: income tax expense of EUR -1,841k), respectively. The consolidated income tax benefit (September 30, 2021: income tax expense) for the nine months ended September 30, 2022, resulted from income tax benefit from CureVac Inc of EUR 235k for current tax and tax expenses from CureVac Corporate Service and CureVac Swiss AG of EUR 94k. CureVac Corporate Service has a deferred tax benefit of EUR 21k for the nine months ended September 30, 2022.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfIncomeTaxExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2021-01-01<br> -Section Disclosure<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2021-en-r&amp;doctype=Standard&amp;dita_xref=IAS12_g79-88_TI<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfIncomeTaxExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140535896267536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Disclosure of financial instruments and risk management<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_FinancialInstrumentsAndRiskManagementAbstract', window );"><strong>Disclosure of financial instruments and risk management</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialRiskManagementExplanatory', window );">Disclosure of financial instruments and risk management</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">15. Disclosure of financial instruments and risk management</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As the Group requires significant liquid funds available for the financing of its COVID-19 and influenza research and development activities, during the nine months ended September 30, 2022, it has maintained funds as cash and cash equivalents and not in less liquid financial instruments. The Group has distributed the cash amongst several banks and amongst the legal entities in the Group in order to reduce negative interest penalties.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">Refer to Note 15 to the consolidated financial statements as of December&#160;31, 2021 for additional information on the Group&#8217;s risk management activities. As of September 30, 2022, the Group held cash and cash equivalents of USD 82,577k and CHF 117k, which are exposed to foreign currency exchange risk. The Group intends to settle expenses arising in US dollars using these US dollar funds. </p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_FinancialInstrumentsAndRiskManagementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_FinancialInstrumentsAndRiskManagementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinancialRiskManagementExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of the entity's financial risk management practices and policies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinancialRiskManagementExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140535896394416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings per share<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EarningsPerShareAbstract', window );"><strong>Earnings per share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EarningsPerShareExplanatory', window );">Earnings per share</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">16. Earnings per share</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18.2pt;margin:0pt 0pt 12pt 0pt;">Earnings per share is calculated pursuant to <i style="font-style:italic;">IAS 33 Earnings per Share</i> by dividing the consolidated net loss in CureVac N.V. by the average weighted number of shares outstanding in the fiscal period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18.2pt;margin:0pt;">The weighted number of shares outstanding for the nine months ended September 30, 2022 was 188,020,542 (September 30, 2021: 185,702,736). This has led to a basic loss per share for the nine months ended September 30, 2022 and 2021 of EUR 0.64 and EUR 2.21, respectively. Since the conversion of options to ordinary shares would decrease loss per share, they are considered antidilutive. Therefore, the diluted earnings per share equals basic earnings per share for the nine months ended September 30, 2022 and 2021. </p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EarningsPerShareExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2021-01-01<br> -Paragraph 66<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EarningsPerShareExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140535897175024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related party disclosures<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract', window );"><strong>Related party disclosures</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfRelatedPartyExplanatory', window );">Related party disclosures</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">17. Related party disclosures</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Dietmar Hopp</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18.2pt;margin:0pt 0pt 10pt 0pt;">During fiscal 2019, Dietmar Hopp, principal of dievini Hopp BioTech holding GmbH &amp; Co. KG (dievini), the largest shareholder of the Group, granted two convertible loans to the Group, which were repaid in 2020. Additionally, in August 2020, DH-LT Investments GmbH, a company beneficially owned by Dietmar Hopp, managing director of dievini, the Group<span style="font-family:'Arial','Helvetica','sans-serif';">&#8217;</span>s largest shareholder, purchased EUR 100,000k of the Group<span style="font-family:'Arial','Helvetica','sans-serif';">&#8217;</span>s common shares at a price of USD 16.00 per share.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Antony Blanc</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18.2pt;margin:0pt 0pt 11pt 0pt;">In 2020, a consulting agreement between CureVac AG and Clarentis SRL was made. Clarentis SRL is a wholly owned consulting company of Antony Blanc, PhD, the CBO of CureVac. After the transition of Antony Blanc to the Management Board in February 2021, the contract was no longer active, and no new orders were placed. In Q3 2021, a milestone payment, which related to the submission of the EMA dossier for CVnCoV and which amounted to EUR 100k was made to fulfil a contractual obligation from the consulting agreement in place before Antony Blanc joined the Management Board. In addition to his Management Board position at CureVac NV, Antony also took over the role as Management Director at CureVac Belgium SA. He executes this function by using Clarentis SRL. As it relates to these services, CureVac paid until September 2022 an amount of EUR 48k. The amounts invoiced for this function/services will be offset/deducted from his base compensation for his function on the Board of Management of CureVac N.V.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 11pt 0pt;"><span style="font-style:italic;font-weight:bold;">BePharBel Manufacturing S.A.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">In December 2020, CureVac Real Estate GmbH and BePharBel Manufacturing S.A., entered into a commercial supply agreement to develop and manufacture the diluent that was expected to be used to dilute the Group&#8217;s first concentrated COVID-19 vaccine candidate, CVnCoV, to the amount specified by each dose level. Pursuant to the terms of the agreement, it was intended that BePharBel Manufacturing would manufacture and deliver to CureVac Real Estate GmbH a low seven figure amount of commercial batches of diluent per year, in 2021 and 2022. Following the withdrawal of the CVnCoV in October 2021 due to COVID-19 virus drift, WHO COVID vaccine efficiency recommendation and market expectations, CureVac Real Estate GmbH terminated the commercial and supply agreement with BePahrBel and entered into negotiations on a structured and rapid wind-down of the ordered production. The Parties agreed on a settlement in May 2022 of all claims resulting from the commercial and supply agreement for an amount of EUR 3,900k, which had been already recognized in provisions, based on an estimate, as of December 31, 2021. Baron Jean St&#233;phenne, our supervisory board member, holds directly and indirectly 15.61% of BePharBel Manufacturing&#8217;s equity and is a director of BePharBel Manufacturing, and Baron Jean St&#233;phenne&#8217;s son, Vincent St&#233;phenne, holds 1.43% of BePharBel Manufacturing&#8217;s equity and is a managing director of BePharBel Manufacturing.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfRelatedPartyExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related parties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2021-01-01<br> -Section Disclosures<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=24&amp;code=ifrs-tx-2021-en-r&amp;doctype=Standard&amp;dita_xref=IAS24_g13-24_TI<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfRelatedPartyExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140535896455120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant transactions and events<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfBusinessCombinationsAbstract', window );"><strong>Significant transactions and events</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfBusinessCombinationsExplanatory', window );">Significant transactions and events</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">18. Significant transactions and events</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Business Combination and Goodwill &#8211; Frame Acquisition</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18.2pt;margin:0pt 0pt 12pt 0pt;">Effective July 1, 2022 (&#8216;closing date&#8217;), CureVac N.V. acquired all shares of Frame Pharmaceuticals B.V., Amsterdam, Netherlands (&#8216;Frame Pharmaceuticals&#8217;). Frame Pharmaceuticals focuses on the development of a proprietary platform enabling the identification of structural changes within the cancer genome and has strong competencies in antigen discovery as well as validation for personalized cancer vaccines. CureVac&#8217;s management and supervisory board expect that the acquisition will contribute several key elements for the required end-to-end building blocks for CureVac&#8217;s broader oncology strategy.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18.2pt;margin:0pt 0pt 12pt 0pt;">Frame Pharmaceuticals contributed no revenues and a loss of EUR 0.6 million to the consolidated result for the current reporting period. Assuming an initial consolidation of Frame Pharmaceuticals on January 1, 2022, the Group's revenue would be unchanged and the loss would have been EUR 3.0 million higher, respectively, than reported (estimate based on the purchase price allocation). In determining these amounts, management has assumed that the fair value adjustments made at the acquisition date would also have applied on January 1, 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18.2pt;margin:0pt 0pt 12pt 0pt;">In the purchase price agreement (&#8216;SPA&#8217;) dated June 8, 2022, a total consideration of up to EUR 32.0 million, subject to certain adjustments for vested and non-vested employee options of the acquiree plus an amount of EUR 1.56 million for the assumption of an outstanding obligation resulting from advisory services was agreed. The consideration consisted of minor cash payments and the transfer of shares in CureVac N.V. (&#8216;CureVac Shares&#8217;). The number of CureVac Shares to be issued as part of the different consideration payments were agreed in the SPA and based on the 60-trading day volume weighted average price until June 3, 2022, based on a Signing Share Price (&#8216;Signing Share Price&#8217;) at EUR 16.44.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18.2pt;margin:0pt 0pt 12pt 0pt;">The total consideration is split into three payments, two of which are contingent upon the achievement of defined milestones (contingent consideration). At the closing date, CureVac had to pay 50 % of the total consideration, i. e. EUR 16.0 million plus the consideration for the outstanding obligation of EUR 1.56 million as follows:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Issuance and transfer of </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">810,242</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> shares (worth EUR </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">11,040</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">k) to former Frame shareholders. The respective share price of one CureVac Share was EUR </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">13.63</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> (&#8216;Closing Share Price&#8217;).</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Issuance and transfer of further </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">48,254</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> shares (worth EUR </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">657</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">k, valued at the Closing Share Price) as consideration for discharging the contractual obligations for the outstanding advisory agreements of EUR </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1,560</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">k (adjusted by the strike price of EUR </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">767</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">k for the existing share-based payment). </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Payment of EUR </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">585</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">k in cash, consisting of EUR </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">335</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">k being the consideration for the settlement of the vested employee options, and an additional EUR </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">250</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">k.</span></td></tr></table><div style="margin-top:12pt;"/><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Payment of the remaining 50% of the total consideration is contingent upon the achievement of two milestones. A further 194,647 shares (representing 10% of EUR 32.0 million divided by the Signing Share Price, i. e. EUR 1,831k) are issuable upon the achievement of the successful investigational new drug application filing and a further 778,589 shares (representing 40% of EUR 32.0 million divided by the Signing Share Price, i. e. EUR 5,367k) are issuable upon successful proof of mechanism in humans. The fair value of these contingent payments was determined by considering the likelihood of the events occurring and totaled, based on the Closing Share Price, to a total fair value of EUR 7,198k.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Consequently, the total consideration transferred for the business combination was determined to be EUR 19,481k, consisting of:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Issuance and transfer of </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">858,496</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> CureVac shares with a fair value of EUR </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">11,697</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">k,</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Payment of EUR </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">585</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">k in cash, and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Contingent consideration, classified as equity, with a fair value of EUR </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">7,198</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">k. The contingent consideration will be settled by the issuance of a maximum of further </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">973,236</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> CureVac shares.</span></td></tr></table><div style="margin-top:12pt;"/><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition, 89,655 restricted stock units (RSUs) were issued to certain employees to replace existing share-based payment awards of the target. This element will be accounted for as a separate transaction from the business combination and accounted for as an equity-settled share-based transaction according to IFRS 2. The total fair value of the grant was determined to be EUR 1,218k and will be expensed in the functional cost category to which the award recipient&#8217;s costs are classified (general and administrative expenses and research and development expenses) over the individual vesting periods for the 3 tranches, which run through June 30, 2023, June 30, 2024, and June 30, 2025.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Transactions costs in relation to the business combination amounting to total EUR 500k were expensed and recognized within general and administrative expenses. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">The purchase price allocation for the assets acquired and liabilities assumed has not been completed as of the date of issuance of these interim financial statements. This is especially due to ongoing identification and measurement of Intangible Assets acquired. The provisional amounts at the acquisition date were determined as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:57.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:38.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:57.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">in EUR thousands</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:38.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;">Provisional&#160;amounts&#160;at&#160;acquisition&#160;date</b></p></td></tr><tr><td style="vertical-align:bottom;width:57.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Non-current assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:38.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 6,592</b></p></td></tr><tr><td style="vertical-align:bottom;width:57.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Property, plant and equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:38.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 206</p></td></tr><tr><td style="vertical-align:bottom;width:57.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Right-of-use assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:38.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 170</p></td></tr><tr><td style="vertical-align:bottom;width:57.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Intangible assets (Technology)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:38.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,216</p></td></tr><tr><td style="vertical-align:bottom;width:57.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Current assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:38.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 966</b></p></td></tr><tr><td style="vertical-align:bottom;width:57.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Trade and other receivables</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:38.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 658</p></td></tr><tr><td style="vertical-align:bottom;width:57.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:38.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 308</p></td></tr><tr><td style="vertical-align:bottom;width:57.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:38.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 7,558</b></p></td></tr><tr><td style="vertical-align:bottom;width:57.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Non-current liabilities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:38.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 134</b></p></td></tr><tr><td style="vertical-align:bottom;width:57.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:38.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 114</p></td></tr><tr><td style="vertical-align:bottom;width:57.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Deferred tax liabilities (net of deferred tax assets)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:38.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 20</p></td></tr><tr><td style="vertical-align:bottom;width:57.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Current liabilities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:38.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 406</b></p></td></tr><tr><td style="vertical-align:bottom;width:57.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:38.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 55</p></td></tr><tr><td style="vertical-align:bottom;width:57.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accounts Payables</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:38.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 346</p></td></tr><tr><td style="vertical-align:bottom;width:57.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other current liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:38.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5</p></td></tr><tr><td style="vertical-align:bottom;width:57.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total liabilities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:38.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 540</b></p></td></tr><tr><td style="vertical-align:bottom;width:57.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Net assets acquired</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:38.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 7,018</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The acquired receivables are expected to be collected in full.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The (provisional) fair value of the technology of EUR 6,216k was determined by applying the replacement cost approach. The replacement cost was derived from historical costs incurred from 2019 to June 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As per July 1, 2022, a net deferred tax liability of EUR 20k has been recognized for the excess of deferred tax liabilities of EUR 1,550k on taxable temporary differences over deferred tax assets of EUR 1,530k arising mainly from tax loss carry forwards (of approximately EUR 5,800k). </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If, within one year of the acquisition date, new information becomes known about facts and circumstances that existed at the acquisition date and that would have resulted in adjustments to the amounts above, the allocation of the purchase price shall be adjusted. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">Goodwill was provisionally recognized as a result of the acquisition as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 2pt 0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:86.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:86.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">in EURk</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:86.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Consideration transferred</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 19,481</p></td></tr><tr><td style="vertical-align:bottom;width:86.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net Assets acquired</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (7,018)</p></td></tr><tr><td style="vertical-align:bottom;width:86.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Preliminary Goodwill</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> 12,463</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">The preliminary goodwill is mainly attributable to the synergies and an assembled workforce as well as the strategic benefits to the Group. The preliminary goodwill is not deductible for tax purposes.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:86.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:86.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Analyses of cash flows on acquisition:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">EURk</b></p></td></tr><tr><td style="vertical-align:bottom;width:86.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Payment of consideration in cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (585)</p></td></tr><tr><td style="vertical-align:bottom;width:86.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"><span style="font-size:1pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfBusinessCombinationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfBusinessCombinationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfBusinessCombinationsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for business combinations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2021-01-01<br> -Section Disclosures<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2021-en-r&amp;doctype=Standard&amp;dita_xref=IFRS03_g59-63__IFRS03_g59-63_TI<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfBusinessCombinationsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140535895477472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of preparation (Policies)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_DisclosureOfBasisOfPreparationAbstract', window );"><strong>Basis of preparation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory', window );">Basis of preparation</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The interim condensed consolidated financial statements for the nine months ended September 30, 2022, have been prepared in accordance with IAS 34 Interim Financial Reporting.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The interim condensed consolidated financial statements do not include all the information and disclosures required in the annual consolidated financial statements and should be read in conjunction with the Group&#8217;s annual consolidated financial statements as of December 31, 2021 and 2020 and for the three years in the period ended December 31, 2021. The interim condensed consolidated financial statements were authorized by the Management Board for presentation to the Supervisory Board on November 16, 2022. The Group&#8217;s interim condensed consolidated financial statements are presented in Euros (&#8220;EUR&#8221;). Unless otherwise stated, amounts are rounded to thousands of Euros, except per share amounts.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_DescriptionOfAccountingPolicyOfNewStandardsInterpretationsAndAmendmentsAdoptedTextBlock', window );">New standards, interpretations and amendments adopted by the Group</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">New standards, interpretations and amendments adopted by the Group</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The accounting policies adopted in the preparation of the interim condensed consolidated financial statements are consistent with those followed in the preparation of the Group&#8217;s annual consolidated financial statements for the year ended December 31, 2021. The new and amended standards and interpretations applied for the first time as of January 1, 2022, as disclosed in the notes to the consolidated financial statements as of December 31, 2021, had no impact on the interim condensed consolidated financial statements of the Group as of and for the nine months ended September 30, 2022. The Group has not early adopted any standard, interpretation or amendment that has been issued but is not yet effective.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_DescriptionOfAccountingPolicyForCovid19ImpactExplanatory', window );">Impact of COVID-19 and the Russia-Ukraine Conflict</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">Impact of COVID-19 and the Russia-Ukraine Conflict</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As the Group is currently devoting significant resources to the development of COVID vaccines, such development may impair the ability to timely progress other product candidates in clinical trials or into clinical trials from their current preclinical stage. In addition, enrollment in other programs may be delayed as a result of the COVID-19 pandemic and our focus on developing a COVID vaccine could have a negative impact on our progress on and associated revenue recognition from our non-COVID-19 collaborations. The partial disruption, even temporary, may negatively impact the Company&#8217;s operations and overall business by delaying the progress of its clinical trials and preclinical studies. The Group&#8217;s operations, including research and manufacturing, could also be disrupted due to the potential of the impact of staff absences as a result of self-isolation procedures or extended illness. However, the Group has taken a series of actions aimed at safeguarding its employees and business associates, including implementing a work-from-home policy for employees except for those related to its laboratory and production operations. The Group is running COVID antigen tests on a weekly basis for employees on the premises.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The ongoing military conflict between Russia and Ukraine has not and is not expected to have a material direct or indirect effect on the Group&#8217;s operations or financial condition: however, the Group is currently operating in a period of economic uncertainty and capital markets disruption, which has been significantly impacted by geopolitical instability due to the ongoing military conflict between Russia and Ukraine. As a result of this instability and responding actions taken by the United States, Russia, EU, and other Foreign Governments, this may limit or prevent filing, prosecuting, and maintaining of patient applications in Russia. Government actions may also prevent maintenance of issued patents in Russia. These actions could result in abandonment or lapse of our patents or patent applications in Russia, resulting in partial or complete loss of patent rights in Russia. In addition, a decree was adopted by the Russian government in March 2022, allowing Russian companies and individuals to exploit, without consent or compensation, inventions owned by patentees that have citizenship or nationality in, are registered in, or have predominately primary place of business or profit-making activities in countries that Russia has deemed unfriendly. Consequently, we would not be able to prevent third parties from using our inventions in Russia or from selling or importing products made using our inventions in and into Russia. Accordingly, our competitive position may be impaired, and our business, financial condition, results of operations and prospects may be materially adversely affected.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_DescriptionOfAccountingPolicyForCovid19ImpactExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of accounting policy for Covid-19 impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_DescriptionOfAccountingPolicyForCovid19ImpactExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_DescriptionOfAccountingPolicyOfNewStandardsInterpretationsAndAmendmentsAdoptedTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's accounting policy for New standards, interpretations and amendments adopted by the Group.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_DescriptionOfAccountingPolicyOfNewStandardsInterpretationsAndAmendmentsAdoptedTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_DisclosureOfBasisOfPreparationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of the basis used for the preparation of the financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_DisclosureOfBasisOfPreparationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of the basis used for the preparation of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140535897251680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Notes to the consolidated financial statements (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_DisclosureOfNotesToConsolidatedFinancialStatementsAbstract', window );"><strong>Notes to the consolidated financial statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory', window );">Schedule of revenue from contract with customers recognized</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:71.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:26.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Nine months ended September 30</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR k</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR k</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Belgium</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">GSK</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 49,621</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 52,746</p></td></tr><tr><td style="vertical-align:bottom;width:71.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Germany</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Boehringer Ingelheim</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9,990</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:71.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Switzerland</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">CRISPR</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 831</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,646</p></td></tr><tr><td style="vertical-align:bottom;width:71.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Netherlands</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Genmab</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,323</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,339</p></td></tr><tr><td style="vertical-align:bottom;width:71.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 61,765</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 55,731</b></p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_DisclosureOfUpfrontPaymentsAndRelatedRevenuesRecognizedExplanatory', window );">Summary of upfront payments and related revenues recognized</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:16.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:18.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:18.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:18.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:16.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Upfront and</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Upfront and</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Revenue&#160;recognized from</b></p></td></tr><tr><td style="vertical-align:bottom;width:16.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">milestones payments included</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">milestones payments included</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;upfront and milestones payments </b></p></td></tr><tr><td style="vertical-align:bottom;width:16.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Upfront and milestone&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">in contract</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">in contract</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">for nine months ended</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:16.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">payments</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;liabilities&#160;at</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;liabilities&#160;at</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September 30,</b></p></td></tr><tr><td style="vertical-align:bottom;width:16.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Customer</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September 30, 2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, 2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September 30, 2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="11" style="padding:0pt;"/></tr><tr><td style="vertical-align:bottom;width:16.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(EUR k)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(EUR k)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(EUR k)</b></p></td></tr><tr><td style="vertical-align:bottom;width:16.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">GSK  </span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:18.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">EUR 205,000k (EUR 10,000k milestone payment included)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 135,494</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 106,788</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 38,315</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 38,705</p></td></tr><tr><td style="vertical-align:bottom;width:16.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">CRISPR  </span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:18.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">USD 3,000k (EUR 2,524k)*</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,239</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,007</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 232</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 232</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:16.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Boehringer Ingelheim</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:18.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">EUR 30,000k</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9,990</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:16.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">Genmab  </span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:18.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">USD 10,000k (EUR 8,937k)*</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,362</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,341</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,341</p></td></tr><tr><td style="vertical-align:bottom;width:16.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.86%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 142,095</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.86%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 111,817</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 49,878</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 40,278</b></p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:5.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1px;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"/></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">* Translated at the currency exchange rate prevailing on the transaction date.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory', window );">Schedule of contract balances</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:74.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September 30, </b></p></td></tr><tr><td style="vertical-align:bottom;width:74.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR k</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR k</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Trade receivables</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 18,504</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,170</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:74.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Contract liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 142,095</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 111,817</p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfExpensesByNatureExplanatory', window );">Schedule of cost of sales, selling and distribution expenses, research and development expenses and general and administrative expenses</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">The cost of sales consists of the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:71.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:27.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Nine months ended September 30,</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR&#160;k</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR k</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Personnel</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (14,897)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (19,076)</p></td></tr><tr><td style="vertical-align:bottom;width:71.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Materials</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (13,945)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (48,962)</p></td></tr><tr><td style="vertical-align:bottom;width:71.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Third-party services</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (130,795)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (24,030)</p></td></tr><tr><td style="vertical-align:bottom;width:71.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Maintenance and lease</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (3,227)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,479)</p></td></tr><tr><td style="vertical-align:bottom;width:71.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Amortization and depreciation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2,944)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (9,757)</p></td></tr><tr><td style="vertical-align:bottom;width:71.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2,369)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (688)</p></td></tr><tr><td style="vertical-align:bottom;width:71.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.66%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (168,177)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.66%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (103,992)</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:16.75pt;margin:0pt;">Selling and distribution expenses consist of the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:71.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:27.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Nine months ended September 30,</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR&#160;k</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR k</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Personnel</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (943)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,467)</p></td></tr><tr><td style="vertical-align:bottom;width:71.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Amortization and depreciation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (65)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (38)</p></td></tr><tr><td style="vertical-align:bottom;width:71.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (224)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (320)</p></td></tr><tr><td style="vertical-align:bottom;width:71.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (1,232)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (1,825)</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">R&amp;D expenses consists of the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:71.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:27.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Nine months ended September 30,</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR&#160;k</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR k</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Materials</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (5,893)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (29,618)</p></td></tr><tr><td style="vertical-align:bottom;width:71.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Personnel</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (25,209)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (24,326)</p></td></tr><tr><td style="vertical-align:bottom;width:71.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Amortization and depreciation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (3,051)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (3,866)</p></td></tr><tr><td style="vertical-align:bottom;width:71.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Patents and fees to register a legal right</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2,372)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2,536)</p></td></tr><tr><td style="vertical-align:bottom;width:71.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Third-party services</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (246,185)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 28,525</p></td></tr><tr><td style="vertical-align:bottom;width:71.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Maintenance and lease </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (291)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (789)</p></td></tr><tr><td style="vertical-align:bottom;width:71.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,727)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2,324)</p></td></tr><tr><td style="vertical-align:bottom;width:71.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (284,728)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (34,934)</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">General and administrative expenses consist of the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:71.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:27.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Nine months ended September 30,</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR&#160;k</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR k</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Personnel</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (30,039)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (27,971)</p></td></tr><tr><td style="vertical-align:bottom;width:71.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Maintenance and lease </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2,106)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (4,614)</p></td></tr><tr><td style="vertical-align:bottom;width:71.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Third-party services</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (28,699)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (19,607)</p></td></tr><tr><td style="vertical-align:bottom;width:71.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Legal and other professional services</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (6,394)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (7,215)</p></td></tr><tr><td style="vertical-align:bottom;width:71.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Amortization and depreciation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (5,575)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (9,444)</p></td></tr><tr><td style="vertical-align:bottom;width:71.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (7,974)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (9,168)</p></td></tr><tr><td style="vertical-align:bottom;width:71.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.1%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (80,787)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.14%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (78,019)</b></p></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOtherOperatingIncomeExplanatory', window );">Schedule of other operating income</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:71.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:27.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Nine months ended September 30,</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR&#160;k</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR k</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Compensation for CMO/Material transfer</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 34,379</p></td></tr><tr><td style="vertical-align:bottom;width:71.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Reimbursement claim</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 610</p></td></tr><tr><td style="vertical-align:bottom;width:71.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Sale of equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 310</p></td></tr><tr><td style="vertical-align:bottom;width:71.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Grants and other cost reimbursements from government agencies and similar bodies</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 64,307</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 377</p></td></tr><tr><td style="vertical-align:bottom;width:71.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,439</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 225</p></td></tr><tr><td style="vertical-align:bottom;width:71.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 66,746</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 35,901</b></p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_DisclosureOfNotesToConsolidatedFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_DisclosureOfNotesToConsolidatedFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_DisclosureOfUpfrontPaymentsAndRelatedRevenuesRecognizedExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of detailed information about upfront payments and related revenues recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_DisclosureOfUpfrontPaymentsAndRelatedRevenuesRecognizedExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of the disaggregation of revenue from contracts with customers. [Refer: Revenue from contracts with customers]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2021-01-01<br> -Paragraph 114<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_114&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfExpensesByNatureExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of expenses by nature. [Refer: Expenses, by nature]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfExpensesByNatureExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfOtherOperatingIncomeExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of other operating income. [Refer: Other operating income (expense)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfOtherOperatingIncomeExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The explanation of the significant changes in the contract assets and the contract liabilities. [Refer: Contract assets; Contract liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2021-01-01<br> -Paragraph 118<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_118&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140535896449520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Issued Capital and Reserves (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalAbstract', window );"><strong>Issued Capital and Reserves</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory', window );">Schedule of number of shares issued and outstanding</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:79.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:79.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Common shares issued and outstanding at December 31, 2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 187,120,728</b></p></td></tr><tr><td style="vertical-align:bottom;width:79.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Share option exercises between Jan and March 2022</p></td><td style="vertical-align:bottom;width:3.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 78,732</p></td></tr><tr><td style="vertical-align:bottom;width:79.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Treasury shares</p></td><td style="vertical-align:bottom;width:3.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (78,732)</p></td></tr><tr><td style="vertical-align:bottom;width:79.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Common shares issued and outstanding at March 31, 2022</b></p></td><td style="vertical-align:bottom;width:3.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 187,120,728</b></p></td></tr><tr><td style="vertical-align:bottom;width:79.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">At-the-market offering program issuances</p></td><td style="vertical-align:bottom;width:3.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 340,015</p></td></tr><tr><td style="vertical-align:bottom;width:79.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Share issuances for exercises between Apr to June 2022</p></td><td style="vertical-align:bottom;width:3.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,211</p></td></tr><tr><td style="vertical-align:bottom;width:79.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Share option exercises between Apr and June 2022</p></td><td style="vertical-align:bottom;width:3.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 39,418</p></td></tr><tr><td style="vertical-align:bottom;width:79.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Treasury shares</p></td><td style="vertical-align:bottom;width:3.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (39,418)</p></td></tr><tr><td style="vertical-align:bottom;width:79.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Common shares issued and outstanding at June 30, 2022</b></p></td><td style="vertical-align:bottom;width:3.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 187,466,954</b></p></td></tr><tr><td style="vertical-align:bottom;width:79.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">At-the-market offering program issuances</p></td><td style="vertical-align:bottom;width:3.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,948,040</p></td></tr><tr><td style="vertical-align:bottom;width:79.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Share issuances for exercises between July to Sept 2022</p></td><td style="vertical-align:bottom;width:3.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9,746</p></td></tr><tr><td style="vertical-align:bottom;width:79.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Share issuances to former shareholders of Frame Pharmaceuticals</p></td><td style="vertical-align:bottom;width:3.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 858,496</p></td></tr><tr><td style="vertical-align:bottom;width:79.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Common shares issued and outstanding at September 30, 2022</b></p></td><td style="vertical-align:bottom;width:3.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 190,283,236</b></p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfClassesOfShareCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfClassesOfShareCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of classes of share capital. [Refer: Share capital [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 79<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_79_a&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140535896387296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-based payments (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Share-based payments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_DisclosureOfExpenseRecognizedForEmployeeServicesExplanatory', window );">Schedule of expense recognized for employee services received</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">Nine months ended September 30,</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:77.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:77.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:77.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR&#160;k</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR&#160;k</b></p></td></tr><tr><td style="vertical-align:bottom;width:77.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Research and development expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 572</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 480</p></td></tr><tr><td style="vertical-align:bottom;width:77.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Sales and marketing expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 166</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 152</p></td></tr><tr><td style="vertical-align:bottom;width:77.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">General and administrative expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,547</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,823</p></td></tr><tr><td style="vertical-align:bottom;width:77.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 11,285</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 6,455</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_ScheduleOfExpenseRecognizedForProgramsTableTextBlock', window );">Schedule for expense recognized for the programs</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">Nine months ended September 30:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:77.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:77.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Program</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:77.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">EUR&#160;k</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">EUR k</b></p></td></tr><tr><td style="vertical-align:bottom;width:77.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">LTIP</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 10,075</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,430</p></td></tr><tr><td style="vertical-align:bottom;width:77.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">RSU</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 250</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 275</p></td></tr><tr><td style="vertical-align:bottom;width:77.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">New VSOP</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 441</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (96)</p></td></tr><tr><td style="vertical-align:bottom;width:77.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Prior VSOP</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 519</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 99</p></td></tr><tr><td style="vertical-align:bottom;width:77.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">RSU for key employees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,746</p></td></tr><tr><td style="vertical-align:bottom;width:77.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> 11,825</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> 6,455</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_DisclosureOfExpenseRecognizedForEmployeeServicesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of expense recognized for employee services explanatory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_DisclosureOfExpenseRecognizedForEmployeeServicesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_ScheduleOfExpenseRecognizedForProgramsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The tabular disclosure of expense recognized for the programs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_ScheduleOfExpenseRecognizedForProgramsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140535895639920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant transactions and events (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfBusinessCombinationsAbstract', window );"><strong>Significant transactions and events</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBusinessCombinationsExplanatory', window );">Schedule of purchase price allocation</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">The purchase price allocation for the assets acquired and liabilities assumed has not been completed as of the date of issuance of these interim financial statements. This is especially due to ongoing identification and measurement of Intangible Assets acquired. The provisional amounts at the acquisition date were determined as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:57.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:38.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:57.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">in EUR thousands</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:38.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;">Provisional&#160;amounts&#160;at&#160;acquisition&#160;date</b></p></td></tr><tr><td style="vertical-align:bottom;width:57.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Non-current assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:38.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 6,592</b></p></td></tr><tr><td style="vertical-align:bottom;width:57.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Property, plant and equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:38.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 206</p></td></tr><tr><td style="vertical-align:bottom;width:57.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Right-of-use assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:38.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 170</p></td></tr><tr><td style="vertical-align:bottom;width:57.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Intangible assets (Technology)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:38.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,216</p></td></tr><tr><td style="vertical-align:bottom;width:57.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Current assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:38.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 966</b></p></td></tr><tr><td style="vertical-align:bottom;width:57.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Trade and other receivables</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:38.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 658</p></td></tr><tr><td style="vertical-align:bottom;width:57.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:38.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 308</p></td></tr><tr><td style="vertical-align:bottom;width:57.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:38.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 7,558</b></p></td></tr><tr><td style="vertical-align:bottom;width:57.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Non-current liabilities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:38.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 134</b></p></td></tr><tr><td style="vertical-align:bottom;width:57.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:38.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 114</p></td></tr><tr><td style="vertical-align:bottom;width:57.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Deferred tax liabilities (net of deferred tax assets)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:38.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 20</p></td></tr><tr><td style="vertical-align:bottom;width:57.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Current liabilities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:38.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 406</b></p></td></tr><tr><td style="vertical-align:bottom;width:57.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:38.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 55</p></td></tr><tr><td style="vertical-align:bottom;width:57.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accounts Payables</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:38.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 346</p></td></tr><tr><td style="vertical-align:bottom;width:57.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other current liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:38.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5</p></td></tr><tr><td style="vertical-align:bottom;width:57.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total liabilities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:38.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 540</b></p></td></tr><tr><td style="vertical-align:bottom;width:57.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Net assets acquired</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:38.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 7,018</b></p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_DisclosureOfGoodwillRecognizedAsResultOfAcquisitionExplanatoryTableTextBlock', window );">Schedule of goodwill recognized as a result of the acquisition</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 2pt 0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:86.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:86.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">in EURk</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:86.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Consideration transferred</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 19,481</p></td></tr><tr><td style="vertical-align:bottom;width:86.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net Assets acquired</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (7,018)</p></td></tr><tr><td style="vertical-align:bottom;width:86.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Preliminary Goodwill</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> 12,463</b></p></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_DisclosureOfAnalysisOfCashFlowsOnAcquisitionExplanatoryTableTextBlock', window );">Schedule of analyses of cash flows on acquisition</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:86.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:86.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Analyses of cash flows on acquisition:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">EURk</b></p></td></tr><tr><td style="vertical-align:bottom;width:86.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Payment of consideration in cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (585)</p></td></tr><tr><td style="vertical-align:bottom;width:86.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_DisclosureOfAnalysisOfCashFlowsOnAcquisitionExplanatoryTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of detailed information pertaining to analysis of cash flows on acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_DisclosureOfAnalysisOfCashFlowsOnAcquisitionExplanatoryTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_DisclosureOfGoodwillRecognizedAsResultOfAcquisitionExplanatoryTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of detailed information pertaining to goodwill recognized as a result of the acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_DisclosureOfGoodwillRecognizedAsResultOfAcquisitionExplanatoryTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfBusinessCombinationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfBusinessCombinationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDetailedInformationAboutBusinessCombinationsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of detailed information about business combinations. [Refer: Business combinations [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2021-01-01<br> -Section Disclosures application of paragraphs 59 and 61<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2021-en-r&amp;doctype=Appendix&amp;subtype=B&amp;dita_xref=IFRS03_gB64-B67_TI<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDetailedInformationAboutBusinessCombinationsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140535896974016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Notes to the consolidated financial statements - Revenue from contract with customers (Details) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems', window );"><strong>Notes to the consolidated financial statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromContractsWithCustomers', window );">Revenue recognized</a></td>
<td class="nump">&#8364; 55,731<span></span>
</td>
<td class="nump">&#8364; 61,765<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProductsAndServicesAxis=cvac_ResearchServicesCombinedWithIpLicenseMember', window );">Research services combined with an IP license</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems', window );"><strong>Notes to the consolidated financial statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromContractsWithCustomers', window );">Revenue recognized</a></td>
<td class="nump">40,278<span></span>
</td>
<td class="nump">49,878<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProductsAndServicesAxis=cvac_IfrsProductMember', window );">Product</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems', window );"><strong>Notes to the consolidated financial statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromContractsWithCustomers', window );">Revenue recognized</a></td>
<td class="nump">1,413<span></span>
</td>
<td class="nump">1,400<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProductsAndServicesAxis=cvac_MilestoneRevenuesMember', window );">Milestone revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems', window );"><strong>Notes to the consolidated financial statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromContractsWithCustomers', window );">Revenue recognized</a></td>
<td class="nump">5,789<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_AdditionalDevelopmentMilestonePaymentsReceived', window );">Additional development milestone payments</a></td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_IfrsDevelopmentMilestonePaymentIncludedInContractLiabilities', window );">Development milestone payment included in contract liabilities</a></td>
<td class="nump">4,211<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProductsAndServicesAxis=cvac_ResearchAndDevelopmentServicesMember', window );">Research and development services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems', window );"><strong>Notes to the consolidated financial statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromContractsWithCustomers', window );">Revenue recognized</a></td>
<td class="nump">14,040<span></span>
</td>
<td class="nump">10,489<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_BE', window );">Belgium | GSK</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems', window );"><strong>Notes to the consolidated financial statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromContractsWithCustomers', window );">Revenue recognized</a></td>
<td class="nump">52,746<span></span>
</td>
<td class="nump">49,621<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_DE', window );">Germany | Boehringer Ingelheim</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems', window );"><strong>Notes to the consolidated financial statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromContractsWithCustomers', window );">Revenue recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,990<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_NL', window );">Netherlands | Genmab</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems', window );"><strong>Notes to the consolidated financial statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromContractsWithCustomers', window );">Revenue recognized</a></td>
<td class="nump">1,339<span></span>
</td>
<td class="nump">1,323<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_CH', window );">Switzerland | CRISPR</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems', window );"><strong>Notes to the consolidated financial statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromContractsWithCustomers', window );">Revenue recognized</a></td>
<td class="nump">&#8364; 1,646<span></span>
</td>
<td class="nump">&#8364; 831<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_AdditionalDevelopmentMilestonePaymentsReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of additional development milestone payment received.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_AdditionalDevelopmentMilestonePaymentsReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents of disclosure of notes to the consolidated financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_IfrsDevelopmentMilestonePaymentIncludedInContractLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of development milestone payment included in contract liabilities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_IfrsDevelopmentMilestonePaymentIncludedInContractLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RevenueFromContractsWithCustomers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of revenue from contracts with customers. A customer is a party that has contracted with an entity to obtain goods or services that are an output of the entity&#8217;s ordinary activities in exchange for consideration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2021-01-01<br> -Paragraph 113<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_113_a&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2021-01-01<br> -Paragraph 114<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_114&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RevenueFromContractsWithCustomers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=cvac_ResearchServicesCombinedWithIpLicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=cvac_ResearchServicesCombinedWithIpLicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=cvac_IfrsProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=cvac_IfrsProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=cvac_MilestoneRevenuesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=cvac_MilestoneRevenuesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=cvac_ResearchAndDevelopmentServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=cvac_ResearchAndDevelopmentServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=country_BE">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=country_BE</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MajorCustomersAxis=cvac_GlaxosmithklineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MajorCustomersAxis=cvac_GlaxosmithklineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=country_DE">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=country_DE</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MajorCustomersAxis=cvac_BoehringerIngelheimMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MajorCustomersAxis=cvac_BoehringerIngelheimMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=country_NL">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=country_NL</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MajorCustomersAxis=cvac_GenmabMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MajorCustomersAxis=cvac_GenmabMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=country_CH">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=country_CH</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MajorCustomersAxis=cvac_CrisprMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MajorCustomersAxis=cvac_CrisprMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140535874772016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Notes to the consolidated financial statements - Summary of upfront payments and related revenues recognized (Details) - Research services combined with an IP license<br> &#8364; in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>EUR (&#8364;)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems', window );"><strong>Notes to the consolidated financial statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_UpfrontPaymentsIncludedInContractLiabilities', window );">Upfront and milestones payments included in contract liabilities</a></td>
<td class="nump">&#8364; 111,817<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 142,095<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod', window );">Revenue recognized from upfront and milestones payments</a></td>
<td class="nump">40,278<span></span>
</td>
<td class="nump">&#8364; 49,878<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProductsAndServicesAxis=cvac_ResearchServicesCombinedWithIpLicenseMember', window );">CRISPR</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems', window );"><strong>Notes to the consolidated financial statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_UpfrontPaymentsReceivedOrReceivable', window );">Upfront and milestone payments received or receivable</a></td>
<td class="nump">2,524<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_UpfrontPaymentsIncludedInContractLiabilities', window );">Upfront and milestones payments included in contract liabilities</a></td>
<td class="nump">1,007<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,239<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod', window );">Revenue recognized from upfront and milestones payments</a></td>
<td class="nump">232<span></span>
</td>
<td class="nump">232<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProductsAndServicesAxis=cvac_ResearchServicesCombinedWithIpLicenseMember', window );">Boehringer Ingelheim</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems', window );"><strong>Notes to the consolidated financial statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_UpfrontPaymentsReceivedOrReceivable', window );">Upfront and milestone payments received or receivable</a></td>
<td class="nump">30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod', window );">Revenue recognized from upfront and milestones payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,990<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProductsAndServicesAxis=cvac_ResearchServicesCombinedWithIpLicenseMember', window );">Genmab</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems', window );"><strong>Notes to the consolidated financial statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_UpfrontPaymentsReceivedOrReceivable', window );">Upfront and milestone payments received or receivable</a></td>
<td class="nump">8,937<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_UpfrontPaymentsIncludedInContractLiabilities', window );">Upfront and milestones payments included in contract liabilities</a></td>
<td class="nump">4,022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,362<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod', window );">Revenue recognized from upfront and milestones payments</a></td>
<td class="nump">1,341<span></span>
</td>
<td class="nump">1,341<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProductsAndServicesAxis=cvac_ResearchServicesCombinedWithIpLicenseMember', window );">GSK</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems', window );"><strong>Notes to the consolidated financial statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_UpfrontPaymentsReceivedOrReceivable', window );">Upfront and milestone payments received or receivable</a></td>
<td class="nump">205,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_UpfrontPaymentsIncludedInContractLiabilities', window );">Upfront and milestones payments included in contract liabilities</a></td>
<td class="nump">106,788<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 135,494<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod', window );">Revenue recognized from upfront and milestones payments</a></td>
<td class="nump">38,705<span></span>
</td>
<td class="nump">&#8364; 38,315<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProductsAndServicesAxis=cvac_ResearchServicesCombinedWithIpLicenseMember', window );">Minimum | GSK</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems', window );"><strong>Notes to the consolidated financial statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_UpfrontPaymentsReceivedOrReceivable', window );">Upfront and milestone payments received or receivable</a></td>
<td class="nump">&#8364; 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents of disclosure of notes to the consolidated financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_UpfrontPaymentsIncludedInContractLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of upfront payments of the company included in contract liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_UpfrontPaymentsIncludedInContractLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_UpfrontPaymentsReceivedOrReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of upfront payments received or receivable by the company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_UpfrontPaymentsReceivedOrReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of revenue that was included in the contract liability balance at the beginning of the period. [Refer: Contract liabilities; Revenue from contracts with customers]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2021-01-01<br> -Paragraph 116<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_116_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=cvac_ResearchServicesCombinedWithIpLicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=cvac_ResearchServicesCombinedWithIpLicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MajorCustomersAxis=cvac_CrisprMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MajorCustomersAxis=cvac_CrisprMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MajorCustomersAxis=cvac_BoehringerIngelheimMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MajorCustomersAxis=cvac_BoehringerIngelheimMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MajorCustomersAxis=cvac_GenmabMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MajorCustomersAxis=cvac_GenmabMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MajorCustomersAxis=cvac_GlaxosmithklineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MajorCustomersAxis=cvac_GlaxosmithklineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140535895406048">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Notes to the consolidated financial statements - Contract liabilities allocated to the remaining performance obligations (Details) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems', window );"><strong>Notes to the consolidated financial statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentTradeReceivables', window );">Trade receivables</a></td>
<td class="nump">&#8364; 6,170<span></span>
</td>
<td class="nump">&#8364; 18,504<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ContractLiabilities', window );">Contract liabilities</a></td>
<td class="nump">&#8364; 111,817<span></span>
</td>
<td class="nump">&#8364; 142,095<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents of disclosure of notes to the consolidated financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ContractLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of an entity&#8217;s obligation to transfer goods or services to a customer for which the entity has received consideration (or the amount is due) from the customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2021-01-01<br> -Paragraph 105<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_105&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2021-01-01<br> -Paragraph 116<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_116_a&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ContractLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentTradeReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current trade receivables. [Refer: Trade receivables]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 78<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_78_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 68<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_68&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentTradeReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140535896957392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Notes to the consolidated financial statements - Cost of sales (Details) - Cost of sales - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems', window );"><strong>Notes to the consolidated financial statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_PersonnelExpenses', window );">Personnel</a></td>
<td class="num">&#8364; (19,076)<span></span>
</td>
<td class="num">&#8364; (14,897)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RawMaterialsAndConsumablesUsed', window );">Materials</a></td>
<td class="num">(48,962)<span></span>
</td>
<td class="num">(13,945)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_ThirdPartyServiceExpenses', window );">Third-party services</a></td>
<td class="num">(24,030)<span></span>
</td>
<td class="num">(130,795)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_MaintenanceAndLeaseExpenses', window );">Maintenance and lease</a></td>
<td class="num">(1,479)<span></span>
</td>
<td class="num">(3,227)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DepreciationAndAmortisationExpense', window );">Amortization and depreciation</a></td>
<td class="num">(9,757)<span></span>
</td>
<td class="num">(2,944)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_OtherExpense', window );">Other</a></td>
<td class="num">(688)<span></span>
</td>
<td class="num">(2,369)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpenseByNature', window );">Total</a></td>
<td class="num">(103,992)<span></span>
</td>
<td class="num">&#8364; (168,177)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_WriteOffOfRawMaterials', window );">Write off of raw materials</a></td>
<td class="nump">&#8364; 41,295<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents of disclosure of notes to the consolidated financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_MaintenanceAndLeaseExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of maintenance and lease expenses incurred by the company during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_MaintenanceAndLeaseExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_OtherExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of other expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_OtherExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_PersonnelExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of personnel expenses incurred by the company during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_PersonnelExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_ThirdPartyServiceExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred by the company for third party services during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_ThirdPartyServiceExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_WriteOffOfRawMaterials">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of raw materials written off during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_WriteOffOfRawMaterials</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DepreciationAndAmortisationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of depreciation and amortisation expense. Depreciation and amortisation are the systematic allocations of depreciable amounts of assets over their useful lives.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2021-01-01<br> -Paragraph 23<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_23_e&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2021-01-01<br> -Paragraph 28<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_28_e&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2021-01-01<br> -Paragraph B13<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_B13_d&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2021-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 102<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_102&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 99<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_99&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 104<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_104&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DepreciationAndAmortisationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExpenseByNature">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expenses aggregated according to their nature (for example, depreciation, purchases of materials, transport costs, employee benefits and advertising costs), and not reallocated among functions within the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 99<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_99&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExpenseByNature</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RawMaterialsAndConsumablesUsed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of raw materials and consumables used in the production process or in the rendering of services. [Refer: Current raw materials]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 102<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_102&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 99<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_99&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RawMaterialsAndConsumablesUsed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_IfrsIncomeStatementLocationAxis=cvac_IfrsCostOfSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_IfrsIncomeStatementLocationAxis=cvac_IfrsCostOfSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140535874777392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Notes to the consolidated financial statements - Selling and distribution expenses (Details) - Selling and distribution expenses - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems', window );"><strong>Notes to the consolidated financial statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_PersonnelExpenses', window );">Personnel</a></td>
<td class="num">&#8364; (1,467)<span></span>
</td>
<td class="num">&#8364; (943)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DepreciationAndAmortisationExpense', window );">Amortization and depreciation</a></td>
<td class="num">(38)<span></span>
</td>
<td class="num">(65)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_OtherExpense', window );">Other</a></td>
<td class="num">(320)<span></span>
</td>
<td class="num">(224)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpenseByNature', window );">Total</a></td>
<td class="num">(1,825)<span></span>
</td>
<td class="num">(1,232)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ShorttermEmployeeBenefitsExpense', window );">Salary and salary-related expenses</a></td>
<td class="nump">1,315<span></span>
</td>
<td class="nump">777<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets', window );">Expenses from share-based payments</a></td>
<td class="nump">&#8364; 152<span></span>
</td>
<td class="nump">&#8364; 166<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents of disclosure of notes to the consolidated financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_OtherExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of other expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_OtherExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_PersonnelExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of personnel expenses incurred by the company during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_PersonnelExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DepreciationAndAmortisationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of depreciation and amortisation expense. Depreciation and amortisation are the systematic allocations of depreciable amounts of assets over their useful lives.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2021-01-01<br> -Paragraph 23<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_23_e&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2021-01-01<br> -Paragraph 28<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_28_e&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2021-01-01<br> -Paragraph B13<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_B13_d&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2021-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 102<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_102&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 99<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_99&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 104<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_104&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DepreciationAndAmortisationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExpenseByNature">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expenses aggregated according to their nature (for example, depreciation, purchases of materials, transport costs, employee benefits and advertising costs), and not reallocated among functions within the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 99<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_99&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExpenseByNature</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense arising from share-based payment transactions in which the goods or services received did not qualify for recognition as assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2021-01-01<br> -Paragraph 51<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_51_a&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ShorttermEmployeeBenefitsExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense from employee benefits (other than termination benefits) that are expected to be settled wholly within twelve months after the end of the annual reporting period in which the employees render the related services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ShorttermEmployeeBenefitsExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_IfrsIncomeStatementLocationAxis=cvac_SellingAndDistributionExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_IfrsIncomeStatementLocationAxis=cvac_SellingAndDistributionExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140535894228352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Notes to the consolidated financial statements - Research and development expenses (Details) - Research and development expenses - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems', window );"><strong>Notes to the consolidated financial statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RawMaterialsAndConsumablesUsed', window );">Materials</a></td>
<td class="num">&#8364; (29,618)<span></span>
</td>
<td class="num">&#8364; (5,893)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_PersonnelExpenses', window );">Personnel</a></td>
<td class="num">(24,326)<span></span>
</td>
<td class="num">(25,209)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DepreciationAndAmortisationExpense', window );">Amortization and depreciation</a></td>
<td class="num">(3,866)<span></span>
</td>
<td class="num">(3,051)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_PatentsAndFeesToRegisterLegalRight', window );">Patents and fees to register a legal right</a></td>
<td class="num">(2,536)<span></span>
</td>
<td class="num">(2,372)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_ThirdPartyServiceExpenses', window );">Third-party services</a></td>
<td class="nump">28,525<span></span>
</td>
<td class="num">(246,185)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_MaintenanceAndLeaseExpenses', window );">Maintenance and lease</a></td>
<td class="num">(789)<span></span>
</td>
<td class="num">(291)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_OtherExpense', window );">Other</a></td>
<td class="num">(2,324)<span></span>
</td>
<td class="num">(1,727)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpenseByNature', window );">Total</a></td>
<td class="num">(34,934)<span></span>
</td>
<td class="num">(284,728)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ShorttermEmployeeBenefitsExpense', window );">Salary and salary-related expenses</a></td>
<td class="nump">23,846<span></span>
</td>
<td class="nump">24,637<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets', window );">Expenses from share-based payments</a></td>
<td class="nump">480<span></span>
</td>
<td class="nump">&#8364; 572<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_ReversalOfProvisionForOnerousContracts', window );">Reversal of provision of onerous contracts</a></td>
<td class="nump">&#8364; 36,769<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents of disclosure of notes to the consolidated financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_MaintenanceAndLeaseExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of maintenance and lease expenses incurred by the company during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_MaintenanceAndLeaseExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_OtherExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of other expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_OtherExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_PatentsAndFeesToRegisterLegalRight">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred by the company for registering a legal right.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_PatentsAndFeesToRegisterLegalRight</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_PersonnelExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of personnel expenses incurred by the company during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_PersonnelExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_ReversalOfProvisionForOnerousContracts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of reversal of provision for onerous contracts which will decrease in research and development expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_ReversalOfProvisionForOnerousContracts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_ThirdPartyServiceExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred by the company for third party services during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_ThirdPartyServiceExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DepreciationAndAmortisationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of depreciation and amortisation expense. Depreciation and amortisation are the systematic allocations of depreciable amounts of assets over their useful lives.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2021-01-01<br> -Paragraph 23<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_23_e&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2021-01-01<br> -Paragraph 28<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_28_e&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2021-01-01<br> -Paragraph B13<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_B13_d&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2021-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 102<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_102&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 99<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_99&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 104<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_104&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DepreciationAndAmortisationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExpenseByNature">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expenses aggregated according to their nature (for example, depreciation, purchases of materials, transport costs, employee benefits and advertising costs), and not reallocated among functions within the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 99<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_99&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExpenseByNature</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense arising from share-based payment transactions in which the goods or services received did not qualify for recognition as assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2021-01-01<br> -Paragraph 51<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_51_a&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RawMaterialsAndConsumablesUsed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of raw materials and consumables used in the production process or in the rendering of services. [Refer: Current raw materials]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 102<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_102&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 99<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_99&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RawMaterialsAndConsumablesUsed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ShorttermEmployeeBenefitsExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense from employee benefits (other than termination benefits) that are expected to be settled wholly within twelve months after the end of the annual reporting period in which the employees render the related services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ShorttermEmployeeBenefitsExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_IfrsIncomeStatementLocationAxis=cvac_IfrsResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_IfrsIncomeStatementLocationAxis=cvac_IfrsResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140535897231360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Notes to the consolidated financial statements - General and administrative expenses (Details) - General and administrative expenses - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems', window );"><strong>Notes to the consolidated financial statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_PersonnelExpenses', window );">Personnel</a></td>
<td class="num">&#8364; (27,971)<span></span>
</td>
<td class="num">&#8364; (30,039)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_MaintenanceAndLeaseExpenses', window );">Maintenance and lease</a></td>
<td class="num">(4,614)<span></span>
</td>
<td class="num">(2,106)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_ThirdPartyServiceExpenses', window );">Third-party services</a></td>
<td class="num">(19,607)<span></span>
</td>
<td class="num">(28,699)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfessionalFeesExpense', window );">Legal and other professional services</a></td>
<td class="num">(7,215)<span></span>
</td>
<td class="num">(6,394)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DepreciationAndAmortisationExpense', window );">Amortization and depreciation</a></td>
<td class="num">(9,444)<span></span>
</td>
<td class="num">(5,575)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_OtherExpense', window );">Other</a></td>
<td class="num">(9,168)<span></span>
</td>
<td class="num">(7,974)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpenseByNature', window );">Total</a></td>
<td class="num">(78,019)<span></span>
</td>
<td class="num">(80,787)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ShorttermEmployeeBenefitsExpense', window );">Salary and salary-related expenses</a></td>
<td class="nump">21,621<span></span>
</td>
<td class="nump">19,492<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets', window );">Expenses from share-based payments</a></td>
<td class="nump">5,823<span></span>
</td>
<td class="nump">10,547<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InsuranceExpense', window );">Insurance expense</a></td>
<td class="nump">&#8364; 4,150<span></span>
</td>
<td class="nump">&#8364; 4,073<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents of disclosure of notes to the consolidated financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_MaintenanceAndLeaseExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of maintenance and lease expenses incurred by the company during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_MaintenanceAndLeaseExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_OtherExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of other expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_OtherExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_PersonnelExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of personnel expenses incurred by the company during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_PersonnelExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_ThirdPartyServiceExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred by the company for third party services during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_ThirdPartyServiceExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DepreciationAndAmortisationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of depreciation and amortisation expense. Depreciation and amortisation are the systematic allocations of depreciable amounts of assets over their useful lives.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2021-01-01<br> -Paragraph 23<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_23_e&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2021-01-01<br> -Paragraph 28<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_28_e&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2021-01-01<br> -Paragraph B13<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_B13_d&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2021-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 102<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_102&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 99<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_99&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 104<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_104&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DepreciationAndAmortisationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExpenseByNature">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expenses aggregated according to their nature (for example, depreciation, purchases of materials, transport costs, employee benefits and advertising costs), and not reallocated among functions within the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 99<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_99&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExpenseByNature</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense arising from share-based payment transactions in which the goods or services received did not qualify for recognition as assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2021-01-01<br> -Paragraph 51<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_51_a&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InsuranceExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense arising from purchased insurance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InsuranceExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfessionalFeesExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of fees paid or payable for professional services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfessionalFeesExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ShorttermEmployeeBenefitsExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense from employee benefits (other than termination benefits) that are expected to be settled wholly within twelve months after the end of the annual reporting period in which the employees render the related services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ShorttermEmployeeBenefitsExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_IfrsIncomeStatementLocationAxis=cvac_IfrsGeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_IfrsIncomeStatementLocationAxis=cvac_IfrsGeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140535896774432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Notes to the consolidated financial statements - Other operating income (Details) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_DisclosureOfNotesToConsolidatedFinancialStatementsAbstract', window );"><strong>Notes to the consolidated financial statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_CompensationForContractManufacturingOrganizationsTransfer', window );">Compensation for CMO/Material transfer</a></td>
<td class="nump">&#8364; 34,379<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_CostOfReimbursementClaim', window );">Reimbursement claim</a></td>
<td class="nump">610<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_SaleOfEquipment', window );">Sale of equipment</a></td>
<td class="nump">310<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_OtherOperatingIncomeGovernmentGrants', window );">Grants and other cost reimbursements from government agencies and similar bodies</a></td>
<td class="nump">377<span></span>
</td>
<td class="nump">&#8364; 64,307<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_MiscellaneousOtherOperatingIncomeOther', window );">Other</a></td>
<td class="nump">225<span></span>
</td>
<td class="nump">2,439<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MiscellaneousOtherOperatingIncome', window );">Total</a></td>
<td class="nump">&#8364; 35,901<span></span>
</td>
<td class="nump">&#8364; 66,746<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_CompensationForContractManufacturingOrganizationsTransfer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of income recognised on compensation for contract manufacturing organizations transfer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_CompensationForContractManufacturingOrganizationsTransfer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_CostOfReimbursementClaim">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cost of reimbursement claim.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_CostOfReimbursementClaim</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_DisclosureOfNotesToConsolidatedFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_DisclosureOfNotesToConsolidatedFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_MiscellaneousOtherOperatingIncomeOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of miscellaneous other operating income, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_MiscellaneousOtherOperatingIncomeOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_OtherOperatingIncomeGovernmentGrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of other operating income recognized in relation to government agencies and similar bodies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_OtherOperatingIncomeGovernmentGrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_SaleOfEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of sale of equipment in operating income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_SaleOfEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MiscellaneousOtherOperatingIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of miscellaneous other operating income. [Refer: Other operating income (expense)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MiscellaneousOtherOperatingIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140535897015200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Notes to the consolidated financial statements - Grants with government agencies and similar bodies (Details)<br> &#8364; in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="3">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>May 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_DisclosureOfGovernmentGrantsLineItems', window );"><strong>Disclosure Of Government Grants</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_ReceiptsFromGovernmentGrantsClassifiedAsOperatingActivities', window );">Grant amount received/eligible to receive</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 38,349<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_ReversalOfProvisionRecognizedDueToCertainReservedCapacityTakenOver', window );">Reversal of provision recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 25,059<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=cvac_GlaxosmithklineMember', window );">GSK</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_DisclosureOfGovernmentGrantsLineItems', window );"><strong>Disclosure Of Government Grants</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_CompensationForContractManufacturingOrganizationsTransferConsiderationForSetUpActivities', window );">Compensation consist for set-up activities</a></td>
<td class="nump">&#8364; 20,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_CompensationForContractManufacturingOrganizationsTransferManufacturingInterimPeriodReimbursableExpenses', window );">Compensation consist of Manufacturing Interim Period Reimbursable Expenses</a></td>
<td class="nump">12,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_GovernmentGrantsAxis=cvac_GermanFederalMinistryOfEducationAndResearchMember', window );">German Federal Ministry of Education and Research</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_DisclosureOfGovernmentGrantsLineItems', window );"><strong>Disclosure Of Government Grants</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GovernmentGrants', window );">Grants received and deferred</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">64,031<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_GovernmentGrantsAxis=cvac_CoalitionForEpidemicPreparednessInnovationsMember', window );">Coalition for Epidemic Preparedness Innovations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_DisclosureOfGovernmentGrantsLineItems', window );"><strong>Disclosure Of Government Grants</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_MaximumGrantToBeReceived', window );">Maximum grant | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,300<span></span>
</td>
<td class="nump">$ 8,300<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromGovernmentGrants', window );">Income from release of governmental contract liabilities</a></td>
<td class="nump">26<span></span>
</td>
<td class="nump">&#8364; 30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GovernmentGrants', window );">Grants received and deferred</a></td>
<td class="nump">1,263<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,288<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_GovernmentGrantsAxis=cvac_BillAndMelindaGatesFoundationBmgfMember', window );">Bill &amp; Melinda Gates Foundation (BMGF)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_DisclosureOfGovernmentGrantsLineItems', window );"><strong>Disclosure Of Government Grants</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromGovernmentGrants', window );">Income from release of governmental contract liabilities</a></td>
<td class="nump">132<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 246<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GovernmentGrants', window );">Grants received and deferred</a></td>
<td class="nump">&#8364; 1,747<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 1,879<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_CompensationForContractManufacturingOrganizationsTransferConsiderationForSetUpActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of income recognized on compensation for contract manufacturing organizations transfer which is mainly for consideration for set-up activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_CompensationForContractManufacturingOrganizationsTransferConsiderationForSetUpActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_CompensationForContractManufacturingOrganizationsTransferManufacturingInterimPeriodReimbursableExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of income recognized on compensation for contract manufacturing organizations transfer which is mainly for Manufacturing Interim Period Reimbursable Expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_CompensationForContractManufacturingOrganizationsTransferManufacturingInterimPeriodReimbursableExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_DisclosureOfGovernmentGrantsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_DisclosureOfGovernmentGrantsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_MaximumGrantToBeReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of maximum grant receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_MaximumGrantToBeReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_ReceiptsFromGovernmentGrantsClassifiedAsOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from government grants and similar bodies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_ReceiptsFromGovernmentGrantsClassifiedAsOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_ReversalOfProvisionRecognizedDueToCertainReservedCapacityTakenOver">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of provisions reversed due to certain reserved capacity taken over from the group.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_ReversalOfProvisionRecognizedDueToCertainReservedCapacityTakenOver</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GovernmentGrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of assistance by government in the form of transfers of resources to an entity in return for past or future compliance with certain conditions relating to the operating activities of the entity, recognised as deferred income. They exclude those forms of government assistance that cannot reasonably have a value placed upon them and transactions with government that cannot be distinguished from the normal trading transactions of the entity. [Refer: Deferred income other than contract liabilities; Government [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 55<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GovernmentGrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RevenueFromGovernmentGrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income recognised in relation to government grants. [Refer: Government grants]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 20<br> -IssueDate 2021-01-01<br> -Paragraph 39<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=20&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_39_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RevenueFromGovernmentGrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=cvac_GlaxosmithklineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=cvac_GlaxosmithklineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_GovernmentGrantsAxis=cvac_GermanFederalMinistryOfEducationAndResearchMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_GovernmentGrantsAxis=cvac_GermanFederalMinistryOfEducationAndResearchMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_GovernmentGrantsAxis=cvac_CoalitionForEpidemicPreparednessInnovationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_GovernmentGrantsAxis=cvac_CoalitionForEpidemicPreparednessInnovationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_GovernmentGrantsAxis=cvac_BillAndMelindaGatesFoundationBmgfMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_GovernmentGrantsAxis=cvac_BillAndMelindaGatesFoundationBmgfMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140535894231152">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Issued Capital and Reserves - Overview and General Remarks (Details) - 9 months ended Sep. 30, 2022<br> $ in Millions</strong></div></th>
<th class="th"><div>USD ($)</div></th>
<th class="th"><div>&#8364; / shares</div></th>
<th class="th">
<div>USD ($) </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Issued Capital and Reserves</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ShareIssueRelatedCost', window );">Offering costs for legal, accounting, printing and registration fees | $</a></td>
<td class="nump">$ 1.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_RemainingAuthorizedForSaleValue', window );">Remaining authorized for sale value | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 567.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_OrdinarySharesMember', window );">Common shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Issued Capital and Reserves</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesAuthorised', window );">Number of shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">386,250,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ParValuePerShare', window );">Notional value per share | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 0.12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_PreferenceSharesMember', window );">Preferred shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Issued Capital and Reserves</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesAuthorised', window );">Number of shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">386,250,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ParValuePerShare', window );">Notional value per share | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 0.12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssued', window );">Number of shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_RemainingAuthorizedForSaleValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of remaining authorized for sale value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_RemainingAuthorizedForSaleValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfClassesOfShareCapitalLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfSharesAuthorised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares authorised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 79<br> -Subparagraph a<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_79_a_i&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfSharesAuthorised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued by the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ParValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The nominal value per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 79<br> -Subparagraph a<br> -Clause iii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_79_a_iii&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ParValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ShareIssueRelatedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cost related to the issuance of shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ShareIssueRelatedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_OrdinarySharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_OrdinarySharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_PreferenceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_PreferenceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140535874656784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Issued Capital and Reserves - Impact of share split (Details)<br> &#8364; in Thousands, $ in Millions</strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>EUR (&#8364;)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Issued Capital and Reserves</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_CommonSharesIssuedAndOutstanding', window );">Common shares issued and outstanding beginning</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">187,466,954<span></span>
</td>
<td class="nump">187,120,728<span></span>
</td>
<td class="nump">187,120,728<span></span>
</td>
<td class="nump">187,120,728<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_ShareOptionExercises', window );">Share option exercises</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39,418<span></span>
</td>
<td class="nump">78,732<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_DecreaseInNumberOfSharesDueToTreasuryOfShares', window );">Treasury shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(39,418)<span></span>
</td>
<td class="num">(78,732)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_StockIssuedDuringPeriodForExercises', window );">Share issuances for exercises</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,746<span></span>
</td>
<td class="nump">6,211<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_StockIssuanceDuringPeriodForExistingShareholders', window );">Share issuances to former shareholders of Frame Pharmaceuticals</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">858,496<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_IfrsStockIssuedDuringPeriodSharesNewIssues', window );">At-the-market offering program issuances</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,948,040<span></span>
</td>
<td class="nump">340,015<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_CommonSharesIssuedAndOutstanding', window );">Common shares issued and outstanding ending</a></td>
<td class="nump">190,283,236<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">190,283,236<span></span>
</td>
<td class="nump">187,466,954<span></span>
</td>
<td class="nump">187,120,728<span></span>
</td>
<td class="nump">190,283,236<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromIssuingShares', window );">Cash received from issuance of shares</a></td>
<td class="nump">$ 32.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 404,164<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ShareIssueRelatedCost', window );">Shares issue of transaction costs | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_IfrsSaleOfStockAxis=cvac_AtMarketOfferingProgramMember', window );">ATM Offering Program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Issued Capital and Reserves</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_IfrsStockIssuedDuringPeriodSharesNewIssues', window );">At-the-market offering program issuances</a></td>
<td class="nump">2,288,055<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_AggregateGrossProceedsReceivableFromIssuingShares', window );">Aggregate gross proceeds | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_AggregateGrossProceedsReceivableFromIssuingShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum amount of aggregate gross proceeds receivable from issuance of shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_AggregateGrossProceedsReceivableFromIssuingShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_CommonSharesIssuedAndOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued and outstanding for during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_CommonSharesIssuedAndOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_DecreaseInNumberOfSharesDueToTreasuryOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This element represents for decrease in number of shares due to treasury of shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_DecreaseInNumberOfSharesDueToTreasuryOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_IfrsStockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_IfrsStockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_ShareOptionExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of share option exercises.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_ShareOptionExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_StockIssuanceDuringPeriodForExistingShareholders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period for existing shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_StockIssuanceDuringPeriodForExistingShareholders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_StockIssuedDuringPeriodForExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period, upon exercises.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_StockIssuedDuringPeriodForExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfClassesOfShareCapitalLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProceedsFromIssuingShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuing shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 17<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_17_a&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProceedsFromIssuingShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ShareIssueRelatedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cost related to the issuance of shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ShareIssueRelatedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_IfrsSaleOfStockAxis=cvac_AtMarketOfferingProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_IfrsSaleOfStockAxis=cvac_AtMarketOfferingProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140535874616304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-based payments - Expenses (Details) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Share-based payments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInResearchAndDevelopmentExpenses', window );">Research and development expenses</a></td>
<td class="nump">&#8364; 480<span></span>
</td>
<td class="nump">&#8364; 572<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInSellingAndDistributionExpenses', window );">Sales and marketing expenses</a></td>
<td class="nump">152<span></span>
</td>
<td class="nump">166<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInGeneralAndAdministrativeExpenses', window );">General and administrative expenses</a></td>
<td class="nump">5,823<span></span>
</td>
<td class="nump">10,547<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_BenefitExpenseRecognizedForShareBasedPayment', window );">Total</a></td>
<td class="nump">&#8364; 6,455<span></span>
</td>
<td class="nump">&#8364; 11,285<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_BenefitExpenseRecognizedForShareBasedPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of benefit expense benefit recognized for share-based payment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_BenefitExpenseRecognizedForShareBasedPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInGeneralAndAdministrativeExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense arising from share-based payment transactions in which the goods or services received did not qualify for recognition as assets in general and administrative expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInGeneralAndAdministrativeExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInResearchAndDevelopmentExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense arising from share-based payment transactions in which the goods or services received did not qualify for recognition as assets in research and development expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInResearchAndDevelopmentExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInSellingAndDistributionExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense arising from share-based payment transactions in which the goods or services received did not qualify for recognition as assets in selling and distribution expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInSellingAndDistributionExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140535874653520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-based payments - Expense recognized for the program (Details) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Share-based payments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_ExpenseRecognizedForEmployeeServices', window );">Expense Recognized For Employee Services</a></td>
<td class="nump">&#8364; 6,455<span></span>
</td>
<td class="nump">&#8364; 11,825<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=cvac_LongTermIncentivePlanMember', window );">LTIP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Share-based payments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_ExpenseRecognizedForEmployeeServices', window );">Expense Recognized For Employee Services</a></td>
<td class="nump">4,430<span></span>
</td>
<td class="nump">10,075<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=cvac_IfrsRestrictedStockUnitMember', window );">RSU</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Share-based payments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_ExpenseRecognizedForEmployeeServices', window );">Expense Recognized For Employee Services</a></td>
<td class="nump">275<span></span>
</td>
<td class="nump">250<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=cvac_RestrictedStockUnitForKeyEmployeesMember', window );">RSU for key employees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Share-based payments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_ExpenseRecognizedForEmployeeServices', window );">Expense Recognized For Employee Services</a></td>
<td class="nump">1,746<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=cvac_VirtualSharesProgramIiMember', window );">New VSOP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Share-based payments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_ExpenseRecognizedForEmployeeServices', window );">Expense Recognized For Employee Services</a></td>
<td class="num">(96)<span></span>
</td>
<td class="nump">441<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=cvac_VirtualSharesProgramIMember', window );">Prior VSOP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Share-based payments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_ExpenseRecognizedForEmployeeServices', window );">Expense Recognized For Employee Services</a></td>
<td class="nump">&#8364; 99<span></span>
</td>
<td class="nump">&#8364; 519<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_ExpenseRecognizedForEmployeeServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense recognized for employee services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_ExpenseRecognizedForEmployeeServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=cvac_LongTermIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=cvac_LongTermIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=cvac_IfrsRestrictedStockUnitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=cvac_IfrsRestrictedStockUnitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=cvac_RestrictedStockUnitForKeyEmployeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=cvac_RestrictedStockUnitForKeyEmployeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=cvac_VirtualSharesProgramIiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=cvac_VirtualSharesProgramIiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=cvac_VirtualSharesProgramIMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=cvac_VirtualSharesProgramIMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140535870800080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-based payments (Details)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Sep. 22, 2022 </div>
<div>Option</div>
</th>
<th class="th">
<div>Jul. 01, 2022 </div>
<div>Option</div>
</th>
<th class="th">
<div>Jun. 22, 2022 </div>
<div>Option</div>
</th>
<th class="th">
<div>Mar. 01, 2022 </div>
<div>Option </div>
<div>employee</div>
</th>
<th class="th">
<div>Feb. 10, 2022 </div>
<div>Option</div>
</th>
<th class="th">
<div>Dec. 23, 2021 </div>
<div>Option</div>
</th>
<th class="th">
<div>Aug. 01, 2021 </div>
<div>Option</div>
</th>
<th class="th">
<div>Jul. 01, 2021 </div>
<div>Option</div>
</th>
<th class="th">
<div>Jun. 24, 2021 </div>
<div>Option</div>
</th>
<th class="th">
<div>Dec. 01, 2020 </div>
<div>Option</div>
</th>
<th class="th">
<div>Nov. 16, 2020 </div>
<div>Option</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>Option</div>
</th>
<th class="th">
<div>May 31, 2022 </div>
<div>Option</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>EUR (&#8364;) </div>
<div>Option </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>EUR (&#8364;)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Share-based payments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees', window );">Share-based based payments expenses | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 6,455<span></span>
</td>
<td class="nump">&#8364; 11,285<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInGeneralAndAdministrativeExpenses', window );">General and administrative expenses | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 5,823<span></span>
</td>
<td class="nump">10,547<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Number of RSU's awarded</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">89,655<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=cvac_LongTermIncentivePlanMember', window );">LTIP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Share-based payments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_NumberOfOtherEquityInstrumentsSettledInShareBasedPaymentArrangement', window );">Number of RSUs settled | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,887<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=cvac_VirtualSharesProgramIiMember', window );">New VSOP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Share-based payments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement', window );">Thereof exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">109,917<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">109,917<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019', window );">Average share price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=cvac_ChiefScientificOfficerMember', window );">Chief Scientific Officer | LTIP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Share-based payments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement', window );">Number of share options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">266,155<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInGeneralAndAdministrativeExpenses', window );">General and administrative expenses | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 4,430<span></span>
</td>
<td class="nump">&#8364; 10,075<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement', window );">Number of options exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,303<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=cvac_ChiefBusinessOfficerAndChiefCommercialOfficerMember', window );">Chief Business Officer and Chief Commercial Officer | LTIP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Share-based payments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement', window );">Number of share options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">266,156<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_ChiefOperatingOfficerMember', window );">Chief Operating Officer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Share-based payments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Number of RSU's awarded</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_ChiefOperatingOfficerMember', window );">Chief Operating Officer | LTIP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Share-based payments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement', window );">Number of share options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_NumberOfShareOptionsVestedInShareBasedPaymentArrangement', window );">Number of options vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=cvac_ChiefDevelopmentOfficerMember', window );">Chief Development Officer | LTIP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Share-based payments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement', window );">Number of share options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_NumberOfShareOptionsVestedInShareBasedPaymentArrangement', window );">Number of options vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=cvac_ThenChiefExecutiveOfficerMember', window );">Dan Menichella, then Chief Executive Officer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Share-based payments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Number of RSU's awarded</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=cvac_MembersOfExecutiveBoardAndVariousKeyEmployeesMember', window );">Members of executive board and various key employees | LTIP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Share-based payments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Number of RSU's awarded</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">63,095<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=cvac_KeyEmployeesMember', window );">Key employees | LTIP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Share-based payments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement', window );">Number of share options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_NumberOfKeyEmployees', window );">Number of key employees | employee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=cvac_ExecutiveBoardMembersMember', window );">Executive board members</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Share-based payments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Number of RSU's awarded</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">193,340<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=cvac_ExecutiveBoardMembersMember', window );">Executive board members | LTIP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Share-based payments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement', window );">Number of share options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">130,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_NumberOfShareOptionsVestedInShareBasedPaymentArrangement', window );">Number of options vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=cvac_SupervisoryBoardMembersMember', window );">Supervisory board members</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Share-based payments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Number of RSU's awarded</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,868<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=cvac_SupervisoryBoardMembersMember', window );">Supervisory board members | LTIP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Share-based payments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Number of RSU's awarded</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,956<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=cvac_ChiefBusinessOfficerMember', window );">Chief Business Officer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Share-based payments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Number of RSU's awarded</a></td>
<td class="nump">30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=cvac_FormerFrameEmployeesMember', window );">Former Frame employee's</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Share-based payments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Number of RSU's awarded</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">89,655<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInGeneralAndAdministrativeExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense arising from share-based payment transactions in which the goods or services received did not qualify for recognition as assets in general and administrative expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInGeneralAndAdministrativeExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_NumberOfKeyEmployees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the number of key employees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_NumberOfKeyEmployees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_NumberOfOtherEquityInstrumentsSettledInShareBasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of other equity instruments settled in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_NumberOfOtherEquityInstrumentsSettledInShareBasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_NumberOfShareOptionsVestedInShareBasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of share options vested in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_NumberOfShareOptionsVestedInShareBasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense from share-based payment transactions with employees. [Refer: Expense from share-based payment transactions]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of other equity instruments (ie other than share options) granted in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2021-01-01<br> -Paragraph 47<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_47_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2021-01-01<br> -Paragraph 45<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of share options exercisable in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2021-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause vii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_45_b_vii&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of share options exercised in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2021-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause iv<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_45_b_iv&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of share options granted in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2021-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_45_b_ii&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average exercise price of share options exercised in a share-based payment arrangement. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2021-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause iv<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_45_b_iv&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=cvac_LongTermIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=cvac_LongTermIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=cvac_VirtualSharesProgramIiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=cvac_VirtualSharesProgramIiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=cvac_ChiefScientificOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=cvac_ChiefScientificOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=cvac_ChiefBusinessOfficerAndChiefCommercialOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=cvac_ChiefBusinessOfficerAndChiefCommercialOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_ChiefOperatingOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_ChiefOperatingOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=cvac_ChiefDevelopmentOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=cvac_ChiefDevelopmentOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=cvac_ThenChiefExecutiveOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=cvac_ThenChiefExecutiveOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=cvac_MembersOfExecutiveBoardAndVariousKeyEmployeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=cvac_MembersOfExecutiveBoardAndVariousKeyEmployeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=cvac_KeyEmployeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=cvac_KeyEmployeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=cvac_ExecutiveBoardMembersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=cvac_ExecutiveBoardMembersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=cvac_SupervisoryBoardMembersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=cvac_SupervisoryBoardMembersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=cvac_ChiefBusinessOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=cvac_ChiefBusinessOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=cvac_FormerFrameEmployeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=cvac_FormerFrameEmployeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140535897149904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fixed Assets - Intangible assets (Details) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember', window );">Acquisition costs | licenses, software and prepayments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill', window );">Additions</a></td>
<td class="nump">&#8364; 24,224<span></span>
</td>
<td class="nump">&#8364; 2,273<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of additions to intangible assets other than goodwill, other than those acquired through business combinations. [Refer: Business combinations [member]; Intangible assets other than goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2021-01-01<br> -Paragraph 118<br> -Subparagraph e<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_118_e_i&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=cvac_LicensesSoftwareAndPrepaymentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=cvac_LicensesSoftwareAndPrepaymentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140535870650336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fixed Assets - Property, plant and equipment (Details) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Disclosure of detailed information about property, plant and equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_IncreaseInPropertyAndEquipmentOffSetByImpairmentOfEquipment', window );">Partial offset of increase in property, plant and equipment</a></td>
<td class="nump">&#8364; 5,854<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_ConstructionInProgressMember', window );">Assets under construction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Disclosure of detailed information about property, plant and equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Additions</a></td>
<td class="nump">56,746<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=cvac_CompanyOwnedGmpIvFacilityMember', window );">Company-owned GMP IV facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Disclosure of detailed information about property, plant and equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Additions</a></td>
<td class="nump">49,366<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=cvac_EquipmentPhysicallyLocatedAtCmoFacilitiesMember', window );">Equipment physically located at the CMO facilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Disclosure of detailed information about property, plant and equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Additions</a></td>
<td class="nump">3,616<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember', window );">Acquisition costs | Technical equipment and machines</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Disclosure of detailed information about property, plant and equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Additions</a></td>
<td class="nump">&#8364; 8,661<span></span>
</td>
<td class="nump">&#8364; 8,907<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_IncreaseInPropertyAndEquipmentOffSetByImpairmentOfEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in PPE off set by impairment in equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_IncreaseInPropertyAndEquipmentOffSetByImpairmentOfEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of additions to property, plant and equipment other than those acquired through business combinations. [Refer: Business combinations [member]; Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2021-01-01<br> -Paragraph 73<br> -Subparagraph e<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_73_e_i&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_ConstructionInProgressMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_ConstructionInProgressMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=cvac_CompanyOwnedGmpIvFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=cvac_CompanyOwnedGmpIvFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=cvac_EquipmentPhysicallyLocatedAtCmoFacilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=cvac_EquipmentPhysicallyLocatedAtCmoFacilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=cvac_TechnicalEquipmentAndMachinesAndOtherEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=cvac_TechnicalEquipmentAndMachinesAndOtherEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140535898365616">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Assets held for sale (Details)<br> &#8364; in Thousands</strong></div></th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>EUR (&#8364;)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwnersAbstract', window );"><strong>Assets held for sale</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_IfrsDisposalGroupIncludingDiscontinuedOperationConsideration', window );">Total consideration</a></td>
<td class="nump">&#8364; 865<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_IfrsDisposalGroupIncludingDiscontinuedOperationConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>"
Amount of consideration received or receivable for the disposal of assets and liabilities, including discontinued operation."</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_IfrsDisposalGroupIncludingDiscontinuedOperationConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwnersAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwnersAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140535899813104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventories (Details) - GSK<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2022 </div>
<div>EUR (&#8364;)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_InventoriesLineItem', window );"><strong>Inventories</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_IncreaseDecreaseInInventory', window );">Decrease in inventory</a></td>
<td class="nump">&#8364; 48,291<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_NetValueOfInventoryTransferred', window );">Net inventory transferred</a></td>
<td class="nump">98<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InventoryWritedown2011', window );">Inventory write-offs</a></td>
<td class="nump">&#8364; 41,295<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_IncreaseDecreaseInInventory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in inventory during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_IncreaseDecreaseInInventory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_InventoriesLineItem">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>N/A</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_InventoriesLineItem</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_NetValueOfInventoryTransferred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net value of inventory transferred during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_NetValueOfInventoryTransferred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InventoryWritedown2011">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognised related to the write-down of inventories to net realisable value. [Refer: Inventories]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 2<br> -IssueDate 2021-01-01<br> -Paragraph 36<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=2&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_36_e&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 98<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_98_a&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InventoryWritedown2011</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=cvac_GlaxosmithklineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=cvac_GlaxosmithklineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140535896771696">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Prepaid expenses and other assets (current) (Details) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_DisclosureOfPrepaidExpensesAndOtherCurrentAssetsAbstract', window );"><strong>Prepaid expenses and other assets (current)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentPrepaymentsAndOtherCurrentAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">&#8364; 60,952<span></span>
</td>
<td class="nump">&#8364; 49,244<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_PrepaidCompensationForContractManufacturingOrganizationsTransfer', window );">Prepayments for compensation</a></td>
<td class="nump">12,678<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentAdvancesToSuppliers', window );">Prepayments for material</a></td>
<td class="nump">21,999<span></span>
</td>
<td class="nump">5,724<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReceivablesFromTaxesOtherThanIncomeTax', window );">Tax claims against the tax authorities</a></td>
<td class="nump">&#8364; 18,009<span></span>
</td>
<td class="nump">&#8364; 35,234<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_DisclosureOfPrepaidExpensesAndOtherCurrentAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_DisclosureOfPrepaidExpensesAndOtherCurrentAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_PrepaidCompensationForContractManufacturingOrganizationsTransfer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of prepaid compensation for contract manufacturing organizations transfer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_PrepaidCompensationForContractManufacturingOrganizationsTransfer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentAdvancesToSuppliers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current advances made to suppliers before goods or services are received.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentAdvancesToSuppliers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentPrepaymentsAndOtherCurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current prepayments and other current assets. [Refer: Other current assets; Current prepayments]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 55<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentPrepaymentsAndOtherCurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ReceivablesFromTaxesOtherThanIncomeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of receivables from taxes other than income tax. Income taxes include all domestic and foreign taxes that are based on taxable profits. Income taxes also include taxes, such as withholding taxes, that are payable by a subsidiary, associate or joint arrangement on distributions to the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 78<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_78_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ReceivablesFromTaxesOtherThanIncomeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140535896690080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial assets and financial liabilities (Details) - EUR (&#8364;)<br></strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsAbstract', window );"><strong>Financial assets and financial liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TransfersOutOfLevel1IntoLevel2OfFairValueHierarchyAssets', window );">Transfer from Level 1 to Level 2, Assets</a></td>
<td class="nump">&#8364; 0<span></span>
</td>
<td class="nump">&#8364; 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TransfersOutOfLevel2IntoLevel1OfFairValueHierarchyAssets', window );">Transfer from Level 2 to Level 1, Assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TransfersOutOfLevel1IntoLevel2OfFairValueHierarchyLiabilities', window );">Transfer from Level 1 to Level 2, Liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TransfersOutOfLevel2IntoLevel1OfFairValueHierarchyLiabilities', window );">Transfer from Level 2 to Level 1, Liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TransfersIntoLevel3OfFairValueHierarchyAssets', window );">Transfers into Level 3, Assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TransfersOutOfLevel3OfFairValueHierarchyAssets', window );">Transfers out of Level 3, Assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TransfersIntoLevel3OfFairValueHierarchyLiabilities', window );">Transfers into Level 3, Liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TransfersOutOfLevel3OfFairValueHierarchyLiabilities', window );">Transfers out of Level 3, Liabilities</a></td>
<td class="nump">&#8364; 0<span></span>
</td>
<td class="nump">&#8364; 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinancialInstrumentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinancialInstrumentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TransfersIntoLevel3OfFairValueHierarchyAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of transfers of assets into Level 3 of the fair value hierarchy. [Refer: Level 3 of fair value hierarchy [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2021-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -Clause iv<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_93_e_iv&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TransfersIntoLevel3OfFairValueHierarchyAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TransfersIntoLevel3OfFairValueHierarchyLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of transfers of liabilities into Level 3 of the fair value hierarchy. [Refer: Level 3 of fair value hierarchy [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2021-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -Clause iv<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_93_e_iv&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TransfersIntoLevel3OfFairValueHierarchyLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TransfersOutOfLevel1IntoLevel2OfFairValueHierarchyAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of transfers out of Level 1 and into Level 2 of the fair value hierarchy of assets held at the end of the reporting period. [Refer: Level 1 of fair value hierarchy [member]; Level 2 of fair value hierarchy [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2021-01-01<br> -Paragraph 93<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_93_c&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TransfersOutOfLevel1IntoLevel2OfFairValueHierarchyAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TransfersOutOfLevel1IntoLevel2OfFairValueHierarchyLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of transfers out of Level 1 and into Level 2 of the fair value hierarchy of liabilities held at the end of the reporting period. [Refer: Level 1 of fair value hierarchy [member]; Level 2 of fair value hierarchy [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2021-01-01<br> -Paragraph 93<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_93_c&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TransfersOutOfLevel1IntoLevel2OfFairValueHierarchyLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TransfersOutOfLevel2IntoLevel1OfFairValueHierarchyAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of transfers out of Level 2 and into Level 1 of the fair value hierarchy of assets held at the end of the reporting period. [Refer: Level 1 of fair value hierarchy [member]; Level 2 of fair value hierarchy [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2021-01-01<br> -Paragraph 93<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_93_c&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TransfersOutOfLevel2IntoLevel1OfFairValueHierarchyAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TransfersOutOfLevel2IntoLevel1OfFairValueHierarchyLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of transfers out of Level 2 and into Level 1 of the fair value hierarchy of liabilities held at the end of the reporting period. [Refer: Level 1 of fair value hierarchy [member]; Level 2 of fair value hierarchy [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2021-01-01<br> -Paragraph 93<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_93_c&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TransfersOutOfLevel2IntoLevel1OfFairValueHierarchyLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TransfersOutOfLevel3OfFairValueHierarchyAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of transfers of assets out of Level 3 of the fair value hierarchy. [Refer: Level 3 of fair value hierarchy [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2021-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -Clause iv<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_93_e_iv&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TransfersOutOfLevel3OfFairValueHierarchyAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TransfersOutOfLevel3OfFairValueHierarchyLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of transfers of liabilities out of Level 3 of the fair value hierarchy. [Refer: Level 3 of fair value hierarchy [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2021-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -Clause iv<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_93_e_iv&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TransfersOutOfLevel3OfFairValueHierarchyLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140535896497696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Trade and other payables (Details)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2022 </div>
<div>EUR (&#8364;)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherCurrentPayablesAbstract', window );"><strong>Trade and other payables.</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_ChangeInTradeAndOtherPayables', window );">Amount of decrease in trade and other payables</a></td>
<td class="nump">&#8364; 75,095<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_ChangeInTradeAndOtherPayables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of change in trade and other payables.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_ChangeInTradeAndOtherPayables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherCurrentPayablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherCurrentPayablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140535896471008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other liabilities (Details)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2022 </div>
<div>EUR (&#8364;)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_DisclosureOfOtherLiabilitiesLineItems', window );"><strong>Disclosure of Other liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_ChangeInOtherLiabilities', window );">Decrease in other liabilities</a></td>
<td class="nump">&#8364; 91,106<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_ChangeInOtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of increase (decrease) in other liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_ChangeInOtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_DisclosureOfOtherLiabilitiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>NA</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_DisclosureOfOtherLiabilitiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140535896795840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loans (Details) - Line of credit - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities', window );">Amount drawn</a></td>
<td class="nump">&#8364; 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_LineOfCreditAccruedInterestPayable', window );">Accrued interest</a></td>
<td class="nump">&#8364; 2,543<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities', window );">Cash consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 26,633<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_RepaymentsOfPrincipalAmountOfBorrowings', window );">Repayment of principal amount of loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_IfrsRepaymentsOfAccruedInterestAndFeesOfBorrowings', window );">Repayment of accrued interest and fees of loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 1,633<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_IfrsRepaymentsOfAccruedInterestAndFeesOfBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to settle accrued interest and fees of borrowings, classified as financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_IfrsRepaymentsOfAccruedInterestAndFeesOfBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_LineOfCreditAccruedInterestPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lin of credit accrued interest payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_LineOfCreditAccruedInterestPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_RepaymentsOfPrincipalAmountOfBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to settle principal amount of borrowings, classified as financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_RepaymentsOfPrincipalAmountOfBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from borrowings obtained. [Refer: Borrowings]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 17<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_17_c&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to settle borrowings, classified as financing activities. [Refer: Borrowings]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 17<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_17_d&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=cvac_IfrsLineOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=cvac_IfrsLineOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140535874659248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income tax (Details) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncomeTaxExpenseContinuingOperations', window );">Income tax benefit/ (expense)</a></td>
<td class="nump">&#8364; 160<span></span>
</td>
<td class="num">&#8364; (1,841)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=cvac_CurevacCorporateServiceGmbhMember', window );">CureVac Corporate Service GmbH</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentTaxExpenseIncome', window );">Current tax expense</a></td>
<td class="nump">235<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxExpenseIncome', window );">Deferred tax expense (benefit)</a></td>
<td class="nump">21<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=cvac_CurevacSwissAgMember', window );">CureVac Swiss AG</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentTaxExpenseIncome', window );">Current tax expense</a></td>
<td class="nump">&#8364; 94<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_IncomeTaxDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_IncomeTaxDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentTaxExpenseIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income taxes payable (recoverable) in respect of the taxable profit (tax loss) for a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2021-01-01<br> -Paragraph 80<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_80_a&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentTaxExpenseIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DeferredTaxExpenseIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of tax expense (income) relating to changes in deferred tax liabilities and deferred tax assets. [Refer: Deferred tax assets; Deferred tax liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2021-01-01<br> -Paragraph 81<br> -Subparagraph g<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_81_g_ii&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DeferredTaxExpenseIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncomeTaxExpenseContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount included in the determination of profit (loss) for the period in respect of current tax and deferred tax. [Refer: Current tax expense (income); Deferred tax expense (income)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 26<br> -IssueDate 2021-01-01<br> -Paragraph 35<br> -Subparagraph b<br> -Clause viii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=26&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_35_b_viii&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2021-01-01<br> -Paragraph 23<br> -Subparagraph h<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_23_h&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2021-01-01<br> -Paragraph 79<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_79&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2021-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_81_c_i&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 82<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_82_d&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2021-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_81_c_ii&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2021-01-01<br> -Paragraph B13<br> -Subparagraph g<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_B13_g&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncomeTaxExpenseContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=cvac_CurevacCorporateServiceGmbhMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=cvac_CurevacCorporateServiceGmbhMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=cvac_CurevacSwissAgMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=cvac_CurevacSwissAgMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140535897276320">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Disclosure of financial instruments and risk management (Details) - Sep. 30, 2022 - Foreign currency risk - Cash and cash equivalents<br> SFr in Thousands, $ in Thousands</strong></div></th>
<th class="th"><div>USD ($)</div></th>
<th class="th"><div>CHF (SFr)</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CurrencyAxis=currency_USD', window );">USD</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems', window );"><strong>Disclosure of nature and extent of risks arising from financial instruments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RiskExposureAssociatedWithInstrumentsSharingCharacteristic', window );">Exposure in (foreign) currency | $</a></td>
<td class="nump">$ 82,577<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CurrencyAxis=currency_CHF', window );">CHF</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems', window );"><strong>Disclosure of nature and extent of risks arising from financial instruments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RiskExposureAssociatedWithInstrumentsSharingCharacteristic', window );">Exposure in (foreign) currency | SFr</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">SFr 117<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RiskExposureAssociatedWithInstrumentsSharingCharacteristic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of risk exposure associated with financial instruments with a shared characteristic that identifies a concentration of risks. [Refer: Financial instruments, class [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph B8<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_B8_c&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RiskExposureAssociatedWithInstrumentsSharingCharacteristic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_USD">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_USD</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfRisksAxis=ifrs-full_CurrencyRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfRisksAxis=ifrs-full_CurrencyRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=cvac_IfrsCashAndCashEquivalentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialInstrumentsAxis=cvac_IfrsCashAndCashEquivalentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_CHF">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_CHF</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140535897371616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings per share (Details) - &#8364; / shares<br></strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EarningsPerShareAbstract', window );"><strong>Earnings per share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageShares', window );">Weighted number of shares outstanding</a></td>
<td class="nump">188,020,542<span></span>
</td>
<td class="nump">185,702,736<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BasicEarningsLossPerShare', window );">Net loss per share basic</a></td>
<td class="num">&#8364; (0.64)<span></span>
</td>
<td class="num">&#8364; (2.21)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BasicEarningsLossPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator) divided by the weighted average number of ordinary shares outstanding during the period (the denominator).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2021-01-01<br> -Paragraph 66<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2021-01-01<br> -Paragraph 67<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_67&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BasicEarningsLossPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of ordinary shares outstanding at the beginning of the period, adjusted by the number of ordinary shares bought back or issued during the period multiplied by a time-weighting factor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2021-01-01<br> -Paragraph 70<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_70_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140535896878368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related party disclosures (Details)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>May 31, 2022 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Aug. 31, 2020 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>loan</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>EUR (&#8364;)</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=cvac_DietmarHoppMember', window );">Dietmar Hopp</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems', window );"><strong>Related party disclosures</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_RelatedPartyTransactionNumberOfLoansReceived', window );">Number of convertible loans | loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_IncreaseInNumberOfSharesOutstanding', window );">Capital increase (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageSharePrice2019', window );">Price per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=cvac_ClarentisSrlMember', window );">Clarentis SRL</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems', window );"><strong>Related party disclosures</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_CollaborationAgreementMilestonePayment', window );">Milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 100<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=cvac_BepharbelManufacturingS.aMember', window );">BePharBel Manufacturing S.A</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems', window );"><strong>Related party disclosures</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CommitmentsMadeByEntityRelatedPartyTransactions', window );">Maximum settlement amount</a></td>
<td class="nump">&#8364; 3,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=cvac_BaronJeanStephenneMember', window );">Baron Jean Stephenne</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems', window );"><strong>Related party disclosures</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInAssociate', window );">Equity interest held</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.61%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=cvac_VincentStphenneMember', window );">Vincent Stphenne</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems', window );"><strong>Related party disclosures</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInAssociate', window );">Equity interest held</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.43%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=cvac_AntonyBlancMember', window );">Antony Blanc | Clarentis SRL</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems', window );"><strong>Related party disclosures</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_PaymentsToRelatedPartyForServices', window );">Payments to related party for services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 48<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_CollaborationAgreementMilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of milestone payment receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_CollaborationAgreementMilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_IncreaseInNumberOfSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase in the number of shares outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_IncreaseInNumberOfSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_PaymentsToRelatedPartyForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments made to related party by the company for services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_PaymentsToRelatedPartyForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_RelatedPartyTransactionNumberOfLoansReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of loans received from a related party.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_RelatedPartyTransactionNumberOfLoansReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CommitmentsMadeByEntityRelatedPartyTransactions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of related-party commitments made by the entity to do something if a particular event occurs or does not occur in the future, including executory contracts (recognised and unrecognised). [Refer: Related parties [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2021-01-01<br> -Paragraph 21<br> -Subparagraph i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=24&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_21_i&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CommitmentsMadeByEntityRelatedPartyTransactions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProportionOfOwnershipInterestInAssociate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The proportion of ownership interest in an associate attributable to the entity. [Refer: Associates [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 27<br> -IssueDate 2021-01-01<br> -Paragraph 17<br> -Subparagraph b<br> -Clause iii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=27&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_17_b_iii&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 27<br> -IssueDate 2021-01-01<br> -Paragraph 16<br> -Subparagraph b<br> -Clause iii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=27&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_16_b_iii&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2021-01-01<br> -Paragraph 21<br> -Subparagraph a<br> -Clause iv<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_21_a_iv&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProportionOfOwnershipInterestInAssociate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageSharePrice2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average share price. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2021-01-01<br> -Paragraph 45<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_45_c&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageSharePrice2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=cvac_DietmarHoppMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=cvac_DietmarHoppMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=cvac_ClarentisSrlMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=cvac_ClarentisSrlMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=cvac_BepharbelManufacturingS.aMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=cvac_BepharbelManufacturingS.aMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=cvac_BaronJeanStephenneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=cvac_BaronJeanStephenneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=cvac_VincentStphenneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=cvac_VincentStphenneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=cvac_AntonyBlancMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=cvac_AntonyBlancMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140535870483744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant transactions and events (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jun. 08, 2022 </div>
<div>EUR (&#8364;) </div>
<div>D </div>
<div>&#8364; / shares</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>EUR (&#8364;) </div>
<div>Option </div>
<div>payment </div>
<div>Milestone </div>
<div>tranche </div>
<div>&#8364; / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jul. 01, 2022 </div>
<div>EUR (&#8364;)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfBusinessCombinationsLineItems', window );"><strong>Significant transactions and events</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_FirstPortionOfTotalConsiderationTransferredAmount', window );">First portion of total consideration transferred, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 1,560,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_NumberOfInstrumentsOrInterestsIssuedOrIssuableAsConsiderationToFormerShareholders', window );">Issuance and transfer of shares to former Frame shareholders | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">810,242<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_ValueOfInstrumentsOrInterestsIssuedOrIssuableAsConsiderationToFormerShareholders', window );">Value of shares issued to former Frame shareholders</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 11,040,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EquityInterestsOfAcquirer', window );">Value of shares issued to former Frame shareholders</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 7,198,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_NumberOfInstrumentsOrInterestIssuedOrIssuable', window );">Shares transferred | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">858,496<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_IfrsBusinessAcquisitionSharePrice', window );">Closing Share Price | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 13.63<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_NumberOfInstrumentsOrInterestsIssuedOrIssuableAsConsiderationForDischargingContractualObligations', window );">Issuance and transfer of shares as consideration for discharging the contractual obligations for the outstanding advisory agreements | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48,254<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_ValueOfInstrumentsOrInterestsIssuedOrIssuableAsConsiderationForDischargingContractualObligations', window );">Value of shares issued as consideration for discharging the contractual obligations for the outstanding advisory agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 657,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_StrikePriceForExistingShareBasedPayment', window );">Strike price for existing share-based payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">767,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashTransferred', window );">Cash payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">585,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_CashTransferredForSettlementOfVestedEmployeeOptions', window );">Consideration paid in cash for the settlement of the vested employee options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">335,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_AdditionalCashTransferred', window );">Additional cash consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_ContingentConsiderationPercentageOfTotalConsideration', window );">Contingent consideration, Percentage of total consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_ContingentConsiderationNumberOfMilestones', window );">Contingent consideration, Number of milestones | Milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_NumberOfInstrumentsOrInterestsIssuedOrIssuableUponAchievementOfFirstMilestone', window );">Number of shares issued upon the achievement of the successful investigational new drug application filing | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">194,647<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_PercentageOfConsiderationTransferredUponAchievementOfFirstMilestone', window );">Percentage of consideration transferred upon the achievement of the successful investigational new drug application filing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_ValueOfInstrumentsOrInterestsIssuedOrIssuableUponAchievementOfFirstMilestone', window );">Value of shares issued upon the achievement of the successful investigational new drug application filing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 32,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_NumberOfInstrumentsOrInterestsIssuedOrIssuableUponAchievementOfSecondMilestone', window );">Number of shares issued upon successful proof of mechanism in humans | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">778,589<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_PercentageOfConsiderationTransferredUponAchievementOfSecondMilestone', window );">Percentage of consideration transferred upon successful proof of mechanism in humans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_ValueOfInstrumentsOrInterestsIssuedOrIssuableUponAchievementOfSecondMilestone', window );">Value of shares issued upon successful proof of mechanism in humans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 32,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ContingentConsiderationRecognisedAsOfAcquisitionDate', window );">Contingent consideration, fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,481,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EquityInterestsOfAcquirer', window );">Value of aggregate consideration in shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 7,198,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_ContingentConsiderationMaximumSharesIssuable', window );">Contingent Consideration, Maximum shares issuable | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">973,236<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">RSUs issued to certain former employees | Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">89,655<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted', window );">Total fair value of the RSU grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 1,218,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_NumberOfTranchesForVestingOfInstrumentsGrantedInShareBasedPaymentArrangement', window );">Number of tranches for vesting of RSUs granted | tranche</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AcquisitionrelatedCostsForTransactionRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombination', window );">Transactions costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_ProvisionalFairValue', window );">Provisional fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,216,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_FairValueOfTotalConsiderationTransferred', window );">Amount of fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,697,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_SigningSharePriceRepresenting10', window );">Signing share price representing 10%</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,831,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_SigningSharePriceRepresenting40', window );">Signing share price representing 40%</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,367,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_ClosingSharePriceRepresentingTotalFairValue', window );">Closing share price representing total fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,198,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BusinessCombinationsAxis=cvac_FramePharmaceuticalsB.v.AmsterdamNetherlandsMember', window );">Frame Pharmaceuticals B.v.Amsterdam Netherlands</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfBusinessCombinationsLineItems', window );"><strong>Significant transactions and events</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueOfAcquiree', window );">Revenues contributed to the consolidated result</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossOfAcquiree', window );">Loss contributed to the consolidated result</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossOfCombinedEntity', window );">Loss of combined entity as if combination occurred at beginning of period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred', window );">Total purchase price</a></td>
<td class="nump">&#8364; 32,000,000.0<span></span>
</td>
<td class="nump">&#8364; 19,481,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LiabilitiesIncurred', window );">Net amount of discharging contractual obligations</a></td>
<td class="nump">&#8364; 1,560,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_BusinessAcquisitionSigningSharePriceNumberOfTradingDaysConsidered', window );">Signing Share Price, Number of trading days considered | D</a></td>
<td class="nump">60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_BusinessAcquisitionSigningSharePrice', window );">Signing Share Price | &#8364; / shares</a></td>
<td class="nump">&#8364; 16.44<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_NumberOfPaymentsInWhichTotalConsiderationIsToBePaid', window );">Number of payments in which the total consideration is to be paid | payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_ContingentConsiderationNumberOfPaymentsConsidered', window );">Contingent consideration, Number of payments considered | payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_FirstPortionOfTotalConsiderationTransferredPercentage', window );">First portion of total consideration transferred, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_FirstPortionOfTotalConsiderationTransferredAmount', window );">First portion of total consideration transferred, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 16,000,000.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_ValueOfInstrumentsOrInterestsIssuedOrIssuableAsConsiderationForDischargingContractualObligations', window );">Value of shares issued as consideration for discharging the contractual obligations for the outstanding advisory agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 1,560,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashTransferred', window );">Cash payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 585,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_AdditionalCashTransferred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fair value, at acquisition date, of additional cash transferred as consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_AdditionalCashTransferred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_BusinessAcquisitionSigningSharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The price at which the equity interests are to be issued under the business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_BusinessAcquisitionSigningSharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_BusinessAcquisitionSigningSharePriceNumberOfTradingDaysConsidered">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of trading days over which the volume weighted average price is considered for determination of Signing Share Price under the business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_BusinessAcquisitionSigningSharePriceNumberOfTradingDaysConsidered</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_CashTransferredForSettlementOfVestedEmployeeOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash transferred in a business combination for the settlement of the vested employee options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_CashTransferredForSettlementOfVestedEmployeeOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_ClosingSharePriceRepresentingTotalFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount represents of closing share price representing total fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_ClosingSharePriceRepresentingTotalFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_ContingentConsiderationMaximumSharesIssuable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum number of shares issuable as contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_ContingentConsiderationMaximumSharesIssuable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_ContingentConsiderationNumberOfMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of milestones to be achieved under the contingent consideration arrangement under the business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_ContingentConsiderationNumberOfMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_ContingentConsiderationNumberOfPaymentsConsidered">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of payments of total consideration under the business combination arrangement, that are subject to the achievement of defined milestones (contingent considerations).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_ContingentConsiderationNumberOfPaymentsConsidered</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_ContingentConsiderationPercentageOfTotalConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of total consideration transferred under the business combination, that are subject to the achievement of defined milestones (contingent considerations).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_ContingentConsiderationPercentageOfTotalConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_FairValueOfTotalConsiderationTransferred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of fair value of total consideration transferred.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_FairValueOfTotalConsiderationTransferred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_FirstPortionOfTotalConsiderationTransferredAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of first portion of total consideration transferred under the business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_FirstPortionOfTotalConsiderationTransferredAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_FirstPortionOfTotalConsiderationTransferredPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of first portion of total consideration transferred under the business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_FirstPortionOfTotalConsiderationTransferredPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_IfrsBusinessAcquisitionSharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks paid or offered to be paid in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_IfrsBusinessAcquisitionSharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_NumberOfInstrumentsOrInterestIssuedOrIssuable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of instruments or interests issued or issuable at acquisition date for equity interests of the acquirer transferred as consideration to former shareholders in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_NumberOfInstrumentsOrInterestIssuedOrIssuable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_NumberOfInstrumentsOrInterestsIssuedOrIssuableAsConsiderationForDischargingContractualObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of instruments or interests issued or issuable at acquisition date for equity interests of the acquirer transferred as consideration for discharging the contractual obligations for the outstanding advisory agreements in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_NumberOfInstrumentsOrInterestsIssuedOrIssuableAsConsiderationForDischargingContractualObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_NumberOfInstrumentsOrInterestsIssuedOrIssuableAsConsiderationToFormerShareholders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of instruments or interests issued or issuable at acquisition date for equity interests of the acquirer transferred as consideration to former shareholders in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_NumberOfInstrumentsOrInterestsIssuedOrIssuableAsConsiderationToFormerShareholders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_NumberOfInstrumentsOrInterestsIssuedOrIssuableUponAchievementOfFirstMilestone">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of instruments or interests issued or issuable at acquisition date for equity interests of the acquirer transferred as consideration upon the achievement of first milestone in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_NumberOfInstrumentsOrInterestsIssuedOrIssuableUponAchievementOfFirstMilestone</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_NumberOfInstrumentsOrInterestsIssuedOrIssuableUponAchievementOfSecondMilestone">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of instruments or interests issued or issuable at acquisition date for equity interests of the acquirer transferred as consideration upon the achievement of second milestone in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_NumberOfInstrumentsOrInterestsIssuedOrIssuableUponAchievementOfSecondMilestone</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_NumberOfPaymentsInWhichTotalConsiderationIsToBePaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of payments in which the total consideration is to be paid under the business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_NumberOfPaymentsInWhichTotalConsiderationIsToBePaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_NumberOfTranchesForVestingOfInstrumentsGrantedInShareBasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of tranches for vesting of instruments granted in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_NumberOfTranchesForVestingOfInstrumentsGrantedInShareBasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_PercentageOfConsiderationTransferredUponAchievementOfFirstMilestone">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of total consideration transferred under the business combination, upon the achievement of first milestone.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_PercentageOfConsiderationTransferredUponAchievementOfFirstMilestone</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_PercentageOfConsiderationTransferredUponAchievementOfSecondMilestone">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of total consideration transferred under the business combination, upon the achievement of second milestone.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_PercentageOfConsiderationTransferredUponAchievementOfSecondMilestone</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_ProvisionalFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of provisional fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_ProvisionalFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_SigningSharePriceRepresenting10">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount represents of signing share price representing 10%.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_SigningSharePriceRepresenting10</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_SigningSharePriceRepresenting40">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount represents of signing share price representing 40%.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_SigningSharePriceRepresenting40</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_StrikePriceForExistingShareBasedPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Strike price for existing share-based payment considered for payment of consideration under the business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_StrikePriceForExistingShareBasedPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_ValueOfInstrumentsOrInterestsIssuedOrIssuableAsConsiderationForDischargingContractualObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of instruments or interests issued or issuable at acquisition date for equity interests of the acquirer transferred as consideration for discharging the contractual obligations for the outstanding advisory agreements in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_ValueOfInstrumentsOrInterestsIssuedOrIssuableAsConsiderationForDischargingContractualObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_ValueOfInstrumentsOrInterestsIssuedOrIssuableAsConsiderationToFormerShareholders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of instruments or interests issued or issuable at acquisition date for equity interests of the acquirer transferred as consideration to former shareholders in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_ValueOfInstrumentsOrInterestsIssuedOrIssuableAsConsiderationToFormerShareholders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_ValueOfInstrumentsOrInterestsIssuedOrIssuableUponAchievementOfFirstMilestone">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of instruments or interests issued or issuable at acquisition date for equity interests of the acquirer transferred as consideration upon the achievement of first milestone in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_ValueOfInstrumentsOrInterestsIssuedOrIssuableUponAchievementOfFirstMilestone</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_ValueOfInstrumentsOrInterestsIssuedOrIssuableUponAchievementOfSecondMilestone">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of instruments or interests issued or issuable at acquisition date for equity interests of the acquirer transferred as consideration upon the achievement of second milestone in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_ValueOfInstrumentsOrInterestsIssuedOrIssuableUponAchievementOfSecondMilestone</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fair value, at acquisition date, of the consideration transferred in a business combination. [Refer: Business combinations [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2021-01-01<br> -Paragraph B64<br> -Subparagraph f<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_B64_f&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AcquisitionrelatedCostsForTransactionRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of acquisition-related costs for transactions recognised separately from the acquisition of assets and the assumption of liabilities in business combinations. [Refer: Business combinations [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2021-01-01<br> -Paragraph B64<br> -Subparagraph m<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_B64_m&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AcquisitionrelatedCostsForTransactionRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashTransferred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fair value, at acquisition date, of cash transferred as consideration in a business combination. [Refer: Business combinations [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2021-01-01<br> -Paragraph B64<br> -Subparagraph f<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_B64_f_i&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashTransferred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ContingentConsiderationRecognisedAsOfAcquisitionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount, at acquisition date, of contingent consideration arrangements recognised as consideration transferred in a business combination. [Refer: Business combinations [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2021-01-01<br> -Paragraph B64<br> -Subparagraph g<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_B64_g_i&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ContingentConsiderationRecognisedAsOfAcquisitionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfBusinessCombinationsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfBusinessCombinationsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EquityInterestsOfAcquirer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fair value, at the acquisition date, of equity interests of the acquirer transferred as consideration in a business combination. [Refer: Business combinations [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2021-01-01<br> -Paragraph B64<br> -Subparagraph f<br> -Clause iv<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_B64_f_iv&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EquityInterestsOfAcquirer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LiabilitiesIncurred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fair value, at acquisition date, of liabilities incurred (for example, a liability for contingent consideration) as consideration transferred in a business combination. [Refer: Business combinations [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2021-01-01<br> -Paragraph B64<br> -Subparagraph f<br> -Clause iii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_B64_f_iii&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LiabilitiesIncurred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of other equity instruments (ie other than share options) granted in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2021-01-01<br> -Paragraph 47<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_47_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2021-01-01<br> -Paragraph 45<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossOfAcquiree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The profit (loss) of the acquiree, since the acquisition date, included in the consolidated statement of comprehensive income. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2021-01-01<br> -Paragraph B64<br> -Subparagraph q<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_B64_q_i&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossOfAcquiree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossOfCombinedEntity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The profit (loss) of the combined entity as though the acquisition date for all business combinations that occurred during the year had been as of the beginning of the annual reporting period. [Refer: Business combinations [member]; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2021-01-01<br> -Paragraph B64<br> -Subparagraph q<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_B64_q_ii&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossOfCombinedEntity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RevenueOfAcquiree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of revenue of the acquiree since the acquisition date included in the consolidated statement of comprehensive income. [Refer: Revenue]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2021-01-01<br> -Paragraph B64<br> -Subparagraph q<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_B64_q_i&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RevenueOfAcquiree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at the measurement date of granted equity instruments other than share options. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2021-01-01<br> -Paragraph 47<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_47_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BusinessCombinationsAxis=cvac_FramePharmaceuticalsB.v.AmsterdamNetherlandsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BusinessCombinationsAxis=cvac_FramePharmaceuticalsB.v.AmsterdamNetherlandsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140535896745232">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Significant transactions and events - Frame Acquisition - Purchase Price Allocation (Details)<br> &#8364; in Thousands</strong></div></th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>EUR (&#8364;)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfBusinessCombinationsLineItems', window );"><strong>Significant transactions and events</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate', window );">Deferred tax liabilities arising on taxable temporary differences</a></td>
<td class="nump">&#8364; 20<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxAssetsRecognisedAsOfAcquisitionDate', window );">Deferred tax assets arising mainly from tax loss carry forwards</a></td>
<td class="nump">1,550<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised', window );">Tax loss carry forwards</a></td>
<td class="nump">1,530<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BusinessCombinationsAxis=cvac_FramePharmaceuticalsB.v.AmsterdamNetherlandsMember', window );">Frame Pharmaceuticals B.V., Amsterdam, Netherlands</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfBusinessCombinationsLineItems', window );"><strong>Significant transactions and events</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentAssetsRecognisedAsOfAcquisitionDate', window );">Non-current assets</a></td>
<td class="nump">6,592<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDate', window );">Property, plant and equipment</a></td>
<td class="nump">206<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_RightOfUseAssetsRecognisedAsOfAcquisitionDate', window );">Right-of-use assets</a></td>
<td class="nump">170<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TechnologybasedIntangibleAssetsRecognisedAsOfAcquisitionDate', window );">Intangible assets (Technology)</a></td>
<td class="nump">6,216<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentAssetsRecognisedAsOfAcquisitionDate', window );">Current assets</a></td>
<td class="nump">966<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FairValueOfAcquiredReceivables', window );">Trade and other receivables</a></td>
<td class="nump">658<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalentsRecognisedAsOfAcquisitionDate', window );">Cash and cash equivalents</a></td>
<td class="nump">308<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_TotalAssetsRecognisedAsOfAcquisitionDate', window );">Total assets</a></td>
<td class="nump">7,558<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentLiabilitiesRecognisedAsOfAcquisitionDate', window );">Non-current liabilities</a></td>
<td class="nump">134<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_NoncurrentLeaseLiabilitiesRecognisedAsOfAcquisitionDate', window );">Lease liabilities</a></td>
<td class="nump">114<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_NetDeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate', window );">Deferred tax liabilities (net of deferred tax assets)</a></td>
<td class="nump">20<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentLiabilitiesRecognisedAsOfAcquisitionDate', window );">Current liabilities</a></td>
<td class="nump">406<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_CurrentLeaseLiabilitiesRecognisedAsOfAcquisitionDate', window );">Lease liabilities</a></td>
<td class="nump">55<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherPayablesRecognisedAsOfAcquisitionDate', window );">Accounts Payables</a></td>
<td class="nump">346<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_OtherCurrentLiabilitiesRecognisedAsOfAcquisitionDate', window );">Other current liabilities</a></td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_LiabilitiesRecognisedAsOfAcquisitionDate', window );">Total liabilities</a></td>
<td class="nump">540<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed', window );">Net assets acquired</a></td>
<td class="nump">7,018<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised', window );">Tax loss carry forwards</a></td>
<td class="nump">&#8364; 5,800<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_CurrentLeaseLiabilitiesRecognisedAsOfAcquisitionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount recognised as of the acquisition date for current lease liabilities assumed in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_CurrentLeaseLiabilitiesRecognisedAsOfAcquisitionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_LiabilitiesRecognisedAsOfAcquisitionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount recognised as of the acquisition date for total liabilities assumed in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_LiabilitiesRecognisedAsOfAcquisitionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_NetDeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount recognised as of the acquisition date for deferred tax liabilities net of deferred tax assets assumed in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_NetDeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_NoncurrentLeaseLiabilitiesRecognisedAsOfAcquisitionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount recognised as of the acquisition date for non-current lease liabilities assumed in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_NoncurrentLeaseLiabilitiesRecognisedAsOfAcquisitionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_OtherCurrentLiabilitiesRecognisedAsOfAcquisitionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount recognised as of the acquisition date for other liabilities assumed in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_OtherCurrentLiabilitiesRecognisedAsOfAcquisitionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_RightOfUseAssetsRecognisedAsOfAcquisitionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount recognised as of the acquisition date for right-of-use assets assumed in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_RightOfUseAssetsRecognisedAsOfAcquisitionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_TotalAssetsRecognisedAsOfAcquisitionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount recognised as of the acquisition date for total assets assumed in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_TotalAssetsRecognisedAsOfAcquisitionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAndCashEquivalentsRecognisedAsOfAcquisitionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount recognised as of the acquisition date for cash and cash equivalents acquired in a business combination. [Refer: Cash and cash equivalents; Business combinations [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2021-01-01<br> -Paragraph B64<br> -Subparagraph i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_B64_i&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAndCashEquivalentsRecognisedAsOfAcquisitionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentAssetsRecognisedAsOfAcquisitionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expiry date 2022-01-01: The amount recognised as of the acquisition date for current assets acquired in a business combination. [Refer: Business combinations [member]]
Effective 2022-01-01: The amount recognised as of the acquisition date for current assets acquired in a business combination. [Refer: Current assets; Business combinations [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2021-01-01<br> -Paragraph B64<br> -Subparagraph i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_B64_i&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentAssetsRecognisedAsOfAcquisitionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentLiabilitiesRecognisedAsOfAcquisitionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expiry date 2022-01-01: The amount recognised as of the acquisition date for current liabilities assumed in a business combination. [Refer: Business combinations [member]]
Effective 2022-01-01: The amount recognised as of the acquisition date for current liabilities assumed in a business combination. [Refer: Current liabilities; Business combinations [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2021-01-01<br> -Paragraph B64<br> -Subparagraph i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_B64_i&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentLiabilitiesRecognisedAsOfAcquisitionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DeferredTaxAssetsRecognisedAsOfAcquisitionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount recognised as of the acquisition date for deferred tax assets acquired in a business combination. [Refer: Deferred tax assets; Business combinations [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2021-01-01<br> -Paragraph B64<br> -Subparagraph i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_B64_i&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DeferredTaxAssetsRecognisedAsOfAcquisitionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount recognised as of the acquisition date for deferred tax liabilities assumed in a business combination. [Refer: Deferred tax liabilities; Business combinations [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2021-01-01<br> -Paragraph B64<br> -Subparagraph i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_B64_i&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfBusinessCombinationsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfBusinessCombinationsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FairValueOfAcquiredReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fair value of receivables acquired in a business combination. [Refer: Business combinations [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2021-01-01<br> -Paragraph B64<br> -Subparagraph h<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_B64_h_i&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FairValueOfAcquiredReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount recognised as of the acquisition date for net identifiable assets acquired or liabilities assumed in a business combination. [Refer: Business combinations [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2021-01-01<br> -Paragraph B64<br> -Subparagraph i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_B64_i&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2021-01-01<br> -Paragraph IE72<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_IE72&amp;doctype=Illustrative%20Examples<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentAssetsRecognisedAsOfAcquisitionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expiry date 2022-01-01: The amount recognised as of the acquisition date for non-current assets acquired in a business combination. [Refer: Business combinations [member]]
Effective 2022-01-01: The amount recognised as of the acquisition date for non-current assets acquired in a business combination. [Refer: Non-current assets; Business combinations [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2021-01-01<br> -Paragraph B64<br> -Subparagraph i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_B64_i&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentAssetsRecognisedAsOfAcquisitionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentLiabilitiesRecognisedAsOfAcquisitionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expiry date 2022-01-01: The amount recognised as of the acquisition date for non-current liabilities assumed in a business combination. [Refer: Business combinations [member]]
Effective 2022-01-01: The amount recognised as of the acquisition date for non-current liabilities assumed in a business combination. [Refer: Non-current liabilities; Business combinations [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2021-01-01<br> -Paragraph B64<br> -Subparagraph i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_B64_i&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentLiabilitiesRecognisedAsOfAcquisitionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount recognised as of the acquisition date for plant, property and equipment acquired in a business combination. [Refer: Property, plant and equipment; Business combinations [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2021-01-01<br> -Paragraph B64<br> -Subparagraph i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_B64_i&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2021-01-01<br> -Paragraph IE72<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_IE72&amp;doctype=Illustrative%20Examples<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TechnologybasedIntangibleAssetsRecognisedAsOfAcquisitionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount recognised as of the acquisition date for technology-based intangible assets acquired in a business combination. [Refer: Technology-based intangible assets [member]; Business combinations [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2021-01-01<br> -Paragraph B64<br> -Subparagraph i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_B64_i&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TechnologybasedIntangibleAssetsRecognisedAsOfAcquisitionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherPayablesRecognisedAsOfAcquisitionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount recognised as of the acquisition date for trade and other payables assumed in a business combination. [Refer: Trade and other payables; Business combinations [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2021-01-01<br> -Paragraph B64<br> -Subparagraph i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_B64_i&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherPayablesRecognisedAsOfAcquisitionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of unused tax losses for which no deferred tax asset is recognised in the statement of financial position. [Refer: Unused tax losses [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2021-01-01<br> -Paragraph 81<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_81_e&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BusinessCombinationsAxis=cvac_FramePharmaceuticalsB.v.AmsterdamNetherlandsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BusinessCombinationsAxis=cvac_FramePharmaceuticalsB.v.AmsterdamNetherlandsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140535895664032">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Significant transactions and events - Goodwill Recognized On Frame Acquisition (Details) - Frame Pharmaceuticals B.V., Amsterdam, Netherlands - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Jun. 08, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfBusinessCombinationsLineItems', window );"><strong>Significant transactions and events</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred', window );">Consideration transferred</a></td>
<td class="nump">&#8364; 19,481<span></span>
</td>
<td class="nump">&#8364; 32,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed', window );">Net Assets acquired</a></td>
<td class="num">(7,018)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GoodwillRecognisedAsOfAcquisitionDate', window );">Preliminary Goodwill</a></td>
<td class="nump">&#8364; 12,463<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fair value, at acquisition date, of the consideration transferred in a business combination. [Refer: Business combinations [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2021-01-01<br> -Paragraph B64<br> -Subparagraph f<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_B64_f&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfBusinessCombinationsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfBusinessCombinationsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GoodwillRecognisedAsOfAcquisitionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount recognised as of the business combination's acquisition date for goodwill. [Refer: Goodwill; Business combinations [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2021-01-01<br> -Paragraph B64<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_B64&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2021-01-01<br> -Paragraph IE72<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_IE72&amp;doctype=Illustrative%20Examples<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GoodwillRecognisedAsOfAcquisitionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount recognised as of the acquisition date for net identifiable assets acquired or liabilities assumed in a business combination. [Refer: Business combinations [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2021-01-01<br> -Paragraph B64<br> -Subparagraph i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_B64_i&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2021-01-01<br> -Paragraph IE72<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_IE72&amp;doctype=Illustrative%20Examples<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BusinessCombinationsAxis=cvac_FramePharmaceuticalsB.v.AmsterdamNetherlandsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BusinessCombinationsAxis=cvac_FramePharmaceuticalsB.v.AmsterdamNetherlandsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140535874761968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant transactions and events - Analyses of cash flows on Frame Acquisition (Details)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2022 </div>
<div>EUR (&#8364;)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfBusinessCombinationsLineItems', window );"><strong>Significant transactions and events</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashTransferred', window );">Payment of consideration in cash and cash equivalents</a></td>
<td class="num">&#8364; (585)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AcquisitionrelatedCostsForTransactionRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombination', window );">Transaction costs of the acquisition (included in cash flows from operating activities)</a></td>
<td class="num">(500)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BusinessCombinationsAxis=cvac_FramePharmaceuticalsB.v.AmsterdamNetherlandsMember', window );">Frame Pharmaceuticals B.V., Amsterdam, Netherlands</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfBusinessCombinationsLineItems', window );"><strong>Significant transactions and events</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashTransferred', window );">Payment of consideration in cash and cash equivalents</a></td>
<td class="num">(585)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalentsRecognisedAsOfAcquisitionDate', window );">Cash acquired with the subsidiary (included in cash flows from investing activities)</a></td>
<td class="nump">&#8364; 308<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AcquisitionrelatedCostsForTransactionRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of acquisition-related costs for transactions recognised separately from the acquisition of assets and the assumption of liabilities in business combinations. [Refer: Business combinations [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2021-01-01<br> -Paragraph B64<br> -Subparagraph m<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_B64_m&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AcquisitionrelatedCostsForTransactionRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAndCashEquivalentsRecognisedAsOfAcquisitionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount recognised as of the acquisition date for cash and cash equivalents acquired in a business combination. [Refer: Cash and cash equivalents; Business combinations [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2021-01-01<br> -Paragraph B64<br> -Subparagraph i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_B64_i&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAndCashEquivalentsRecognisedAsOfAcquisitionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashTransferred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fair value, at acquisition date, of cash transferred as consideration in a business combination. [Refer: Business combinations [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2021-01-01<br> -Paragraph B64<br> -Subparagraph f<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_B64_f_i&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashTransferred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfBusinessCombinationsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfBusinessCombinationsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BusinessCombinationsAxis=cvac_FramePharmaceuticalsB.v.AmsterdamNetherlandsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BusinessCombinationsAxis=cvac_FramePharmaceuticalsB.v.AmsterdamNetherlandsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>cvac-20220930x6k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:country="http://xbrl.sec.gov/country/2021"
  xmlns:currency="http://xbrl.sec.gov/currency/2021"
  xmlns:cvac="http://www.curevac.com/20220930"
  xmlns:dei="http://xbrl.sec.gov/dei/2021q4"
  xmlns:ifrs-full="http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2021-01-31"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="cvac-20220930.xsd" xlink:type="simple"/>
    <context id="Duration_1_1_2022_To_9_30_2022_GrYkE3mhHEiRA4fxgfABRg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2021_To_9_30_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_VirtualSharesProgramIiMember_H9asqvfrLUqv97coIp3GBQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:VirtualSharesProgramIiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="As_Of_9_30_2022_ifrs-full_ClassesOfFinancialInstrumentsAxis_cvac_IfrsCashAndCashEquivalentsMember_ifrs-full_TypesOfRisksAxis_ifrs-full_CurrencyRiskMember_srt_CurrencyAxis_currency_USD_GbIyOSI9fU6k0lhzbRaN6Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">cvac:IfrsCashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CurrencyRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2022_ifrs-full_ClassesOfFinancialInstrumentsAxis_cvac_IfrsCashAndCashEquivalentsMember_ifrs-full_TypesOfRisksAxis_ifrs-full_CurrencyRiskMember_srt_CurrencyAxis_currency_CHF_GzG5BBakVUCREUh5rLOPgw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CHF</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">cvac:IfrsCashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CurrencyRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_9_30_2022_ifrs-full_MajorCustomersAxis_cvac_GlaxosmithklineMember_ifrs-full_ProductsAndServicesAxis_cvac_ResearchServicesCombinedWithIpLicenseMember_CAXgAqyHKkO0WaEKjGrFrA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">cvac:GlaxosmithklineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">cvac:ResearchServicesCombinedWithIpLicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_9_30_2022_ifrs-full_MajorCustomersAxis_cvac_GenmabMember_ifrs-full_ProductsAndServicesAxis_cvac_ResearchServicesCombinedWithIpLicenseMember_72wIU7VnlkKKba3jsZpOBg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">cvac:GenmabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">cvac:ResearchServicesCombinedWithIpLicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_9_30_2022_ifrs-full_MajorCustomersAxis_cvac_CrisprMember_ifrs-full_ProductsAndServicesAxis_cvac_ResearchServicesCombinedWithIpLicenseMember_khvMaOJtOkK4x-wZSKmcOQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">cvac:CrisprMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">cvac:ResearchServicesCombinedWithIpLicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_9_30_2021_ifrs-full_MajorCustomersAxis_cvac_GlaxosmithklineMember_ifrs-full_ProductsAndServicesAxis_cvac_ResearchServicesCombinedWithIpLicenseMember_xJi4YZnmz0Wq6SdDwRVxBA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">cvac:GlaxosmithklineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">cvac:ResearchServicesCombinedWithIpLicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_9_30_2021_ifrs-full_MajorCustomersAxis_cvac_GenmabMember_ifrs-full_ProductsAndServicesAxis_cvac_ResearchServicesCombinedWithIpLicenseMember_awc6N7gG0USv7ZRK4TKDjw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">cvac:GenmabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">cvac:ResearchServicesCombinedWithIpLicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_9_30_2021_ifrs-full_MajorCustomersAxis_cvac_CrisprMember_ifrs-full_ProductsAndServicesAxis_cvac_ResearchServicesCombinedWithIpLicenseMember_PH-MVv0gkEKmWXldRQgZBA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">cvac:CrisprMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">cvac:ResearchServicesCombinedWithIpLicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_9_30_2021_ifrs-full_MajorCustomersAxis_cvac_BoehringerIngelheimMember_ifrs-full_ProductsAndServicesAxis_cvac_ResearchServicesCombinedWithIpLicenseMember_2uKPlzeQMkesCPFChkjwGg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">cvac:BoehringerIngelheimMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">cvac:ResearchServicesCombinedWithIpLicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_9_30_2022_cvac_GovernmentGrantsAxis_cvac_CoalitionForEpidemicPreparednessInnovationsMember_QaC72j_xJU248NAuCm-NTA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cvac:GovernmentGrantsAxis">cvac:CoalitionForEpidemicPreparednessInnovationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_9_30_2022_cvac_GovernmentGrantsAxis_cvac_BillAndMelindaGatesFoundationBmgfMember_fYCkAgnPgkW1HP0kse2SZQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cvac:GovernmentGrantsAxis">cvac:BillAndMelindaGatesFoundationBmgfMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_9_30_2021_cvac_GovernmentGrantsAxis_cvac_CoalitionForEpidemicPreparednessInnovationsMember_-JHShxg3uU65FRp662VaIA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cvac:GovernmentGrantsAxis">cvac:CoalitionForEpidemicPreparednessInnovationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_9_30_2021_cvac_GovernmentGrantsAxis_cvac_BillAndMelindaGatesFoundationBmgfMember_Mbzwa-uYGkGbrTexrLia1w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cvac:GovernmentGrantsAxis">cvac:BillAndMelindaGatesFoundationBmgfMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_9_30_2022_ifrs-full_GeographicalAreasAxis_country_NL_ifrs-full_MajorCustomersAxis_cvac_GenmabMember_7itxWD0v3UC7-_TEXbaZxQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:NL</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">cvac:GenmabMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_9_30_2022_ifrs-full_GeographicalAreasAxis_country_CH_ifrs-full_MajorCustomersAxis_cvac_CrisprMember_HR3g4DsNXU-KQMdhdtvSTQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:CH</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">cvac:CrisprMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_9_30_2022_ifrs-full_GeographicalAreasAxis_country_BE_ifrs-full_MajorCustomersAxis_cvac_GlaxosmithklineMember_shjcQ9gwY0mzJMJm_89JCQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:BE</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">cvac:GlaxosmithklineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_9_30_2022_ifrs-full_ProductsAndServicesAxis_cvac_ResearchServicesCombinedWithIpLicenseMember_JmxbMa7EOkGM2UmzZvcaYA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">cvac:ResearchServicesCombinedWithIpLicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_9_30_2022_ifrs-full_ProductsAndServicesAxis_cvac_ResearchAndDevelopmentServicesMember_xgWEhIWVP0aG8Oi39YdQdg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">cvac:ResearchAndDevelopmentServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_9_30_2022_ifrs-full_ProductsAndServicesAxis_cvac_IfrsProductMember_ykNdeTyQ_U6ifIHGuP-a8Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">cvac:IfrsProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_9_30_2021_ifrs-full_GeographicalAreasAxis_country_NL_ifrs-full_MajorCustomersAxis_cvac_GenmabMember_SSbVK8fnGE6ChnWCps9ySQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:NL</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">cvac:GenmabMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_9_30_2021_ifrs-full_GeographicalAreasAxis_country_DE_ifrs-full_MajorCustomersAxis_cvac_BoehringerIngelheimMember_GLkAvVsjY0iIfdOVguCCiQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:DE</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">cvac:BoehringerIngelheimMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_9_30_2021_ifrs-full_GeographicalAreasAxis_country_CH_ifrs-full_MajorCustomersAxis_cvac_CrisprMember_H5jO5eGbWE6vAapf30CSfw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:CH</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">cvac:CrisprMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_9_30_2021_ifrs-full_GeographicalAreasAxis_country_BE_ifrs-full_MajorCustomersAxis_cvac_GlaxosmithklineMember_eVwoaEVfAUKlb5HYdjxaQw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:BE</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">cvac:GlaxosmithklineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_9_30_2021_ifrs-full_ProductsAndServicesAxis_cvac_ResearchServicesCombinedWithIpLicenseMember_w9Lhj-1fbUylhw2h1TnuCA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">cvac:ResearchServicesCombinedWithIpLicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_9_30_2021_ifrs-full_ProductsAndServicesAxis_cvac_ResearchAndDevelopmentServicesMember_FqOeAMlR502ph1Wxt4STrA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">cvac:ResearchAndDevelopmentServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_9_30_2021_ifrs-full_ProductsAndServicesAxis_cvac_IfrsProductMember_WafA2PzZ0kOs4a0LCkTNpg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">cvac:IfrsProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_9_30_2022_srt_TitleOfIndividualAxis_cvac_VincentStphenneMember_PA_nLHYdokKpQK-0_a7lSg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cvac:VincentStphenneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_9_30_2022_srt_TitleOfIndividualAxis_cvac_BaronJeanStephenneMember_xZT627rXM0CHsP6C5sklyg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cvac:BaronJeanStephenneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_9_30_2022_ifrs-full_BusinessCombinationsAxis_cvac_FramePharmaceuticalsB.v.AmsterdamNetherlandsMember_APxhOynMm0ePvj-djFEXLQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">cvac:FramePharmaceuticalsB.v.AmsterdamNetherlandsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="Duration_9_1_2022_To_9_30_2022_UpNYd37lHEq8lbtMmcgfVg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
        </entity>
        <period>
            <startDate>2022-09-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_9_30_2021_ifrs-full_BorrowingsByNameAxis_cvac_IfrsLineOfCreditMember_w0otbseHCk-9ZLH1m6FDbA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">cvac:IfrsLineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="As_Of_9_30_2022_ifrs-full_ClassesOfShareCapitalAxis_ifrs-full_PreferenceSharesMember_hPye6EgKFUuclVhFCyaxog">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:PreferenceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2022_ifrs-full_ClassesOfShareCapitalAxis_ifrs-full_OrdinarySharesMember_QerVWaOy8UeUozR8lPK5KA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="Duration_6_22_2022_To_6_22_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ExecutiveBoardMembersMember_HGJGQ29fb0mCC_uf2baYzw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cvac:ExecutiveBoardMembersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:LongTermIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-22</startDate>
            <endDate>2022-06-22</endDate>
        </period>
    </context>
    <context id="Duration_8_1_2021_To_8_1_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ChiefDevelopmentOfficerMember_Sovw0LhIOky6A14jJLrI2g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cvac:ChiefDevelopmentOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:LongTermIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-08-01</startDate>
            <endDate>2021-08-01</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2021_To_7_1_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_srt_ChiefOperatingOfficerMember_lTsgjULrh0unxpPIyz1Ojw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefOperatingOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:LongTermIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-07-01</endDate>
        </period>
    </context>
    <context id="Duration_12_1_2020_To_12_1_2020_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ChiefBusinessOfficerAndChiefCommercialOfficerMember_T3JjiYhNB0mcje4uQOSblw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cvac:ChiefBusinessOfficerAndChiefCommercialOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:LongTermIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-01</startDate>
            <endDate>2020-12-01</endDate>
        </period>
    </context>
    <context id="Duration_11_16_2020_To_11_16_2020_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ChiefScientificOfficerMember_YqQecowO2kuyd-MSikFagg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cvac:ChiefScientificOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:LongTermIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-11-16</startDate>
            <endDate>2020-11-16</endDate>
        </period>
    </context>
    <context id="Duration_5_1_2022_To_5_31_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ChiefScientificOfficerMember_v1kWVxI7sE-mtWe59zilhg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cvac:ChiefScientificOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:LongTermIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-01</startDate>
            <endDate>2022-05-31</endDate>
        </period>
    </context>
    <context id="As_Of_9_30_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_VirtualSharesProgramIiMember_-aEvT6TgvU2aaNALbBrVfw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:VirtualSharesProgramIiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="Duration_9_22_2022_To_9_22_2022_srt_TitleOfIndividualAxis_cvac_ChiefBusinessOfficerMember_GRzsO5WyQEanIaFIpuw0tg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cvac:ChiefBusinessOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-09-22</startDate>
            <endDate>2022-09-22</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2022_To_7_1_2022_srt_TitleOfIndividualAxis_cvac_FormerFrameEmployeesMember_sBysEqLlSUqSMftPMXcxQQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cvac:FormerFrameEmployeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-07-01</endDate>
        </period>
    </context>
    <context id="Duration_6_22_2022_To_6_22_2022_srt_TitleOfIndividualAxis_cvac_ThenChiefExecutiveOfficerMember_MEmTtrB-PEWG-6nmSb4NZw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cvac:ThenChiefExecutiveOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-22</startDate>
            <endDate>2022-06-22</endDate>
        </period>
    </context>
    <context id="Duration_6_22_2022_To_6_22_2022_srt_TitleOfIndividualAxis_cvac_SupervisoryBoardMembersMember_8ClvViKS_0mYv0ZZa7FsSA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cvac:SupervisoryBoardMembersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-22</startDate>
            <endDate>2022-06-22</endDate>
        </period>
    </context>
    <context id="Duration_6_22_2022_To_6_22_2022_srt_TitleOfIndividualAxis_cvac_ExecutiveBoardMembersMember_hf65wxXOEECOwq5tEDpNWQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cvac:ExecutiveBoardMembersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-22</startDate>
            <endDate>2022-06-22</endDate>
        </period>
    </context>
    <context id="Duration_2_10_2022_To_2_10_2022_srt_TitleOfIndividualAxis_srt_ChiefOperatingOfficerMember_iNHQybO4Pk2sc9tkHPztxA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefOperatingOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-02-10</startDate>
            <endDate>2022-02-10</endDate>
        </period>
    </context>
    <context id="Duration_12_23_2021_To_12_23_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_MembersOfExecutiveBoardAndVariousKeyEmployeesMember_sPT0TmgA5UyfJUOLzYAeKg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cvac:MembersOfExecutiveBoardAndVariousKeyEmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:LongTermIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-23</startDate>
            <endDate>2021-12-23</endDate>
        </period>
    </context>
    <context id="Duration_6_24_2021_To_6_24_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_SupervisoryBoardMembersMember_WzScVvwhuUOXBAORYNGw1A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cvac:SupervisoryBoardMembersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:LongTermIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-24</startDate>
            <endDate>2021-06-24</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_9_30_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_TreasurySharesMember_kiA0yBP5YEWvkTpVKfGscg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_9_30_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_jUcA_4Uo70GmthvPRsVfbA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_9_30_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_H-Nfcg0EfkKBQso-1E13qw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="As_Of_9_30_2022_cvac_GovernmentGrantsAxis_cvac_GermanFederalMinistryOfEducationAndResearchMember_fN4famsHHEKl4JoAfEVlag">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cvac:GovernmentGrantsAxis">cvac:GermanFederalMinistryOfEducationAndResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2022_cvac_GovernmentGrantsAxis_cvac_CoalitionForEpidemicPreparednessInnovationsMember_62kXYP2DG0q3hObonbIX3w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cvac:GovernmentGrantsAxis">cvac:CoalitionForEpidemicPreparednessInnovationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2022_cvac_GovernmentGrantsAxis_cvac_BillAndMelindaGatesFoundationBmgfMember_Ws8aHSUk1UC3pLQKXdVR0g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cvac:GovernmentGrantsAxis">cvac:BillAndMelindaGatesFoundationBmgfMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_cvac_GovernmentGrantsAxis_cvac_CoalitionForEpidemicPreparednessInnovationsMember_Vs0aCSCnvE2bQnX-4agCZg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cvac:GovernmentGrantsAxis">cvac:CoalitionForEpidemicPreparednessInnovationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_cvac_GovernmentGrantsAxis_cvac_BillAndMelindaGatesFoundationBmgfMember_nd5DnUyNxE69QH5CpJLGZw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cvac:GovernmentGrantsAxis">cvac:BillAndMelindaGatesFoundationBmgfMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2021_cvac_GovernmentGrantsAxis_cvac_GermanFederalMinistryOfEducationAndResearchMember_f9iNDb6krUGTFEUGF-sh0Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cvac:GovernmentGrantsAxis">cvac:GermanFederalMinistryOfEducationAndResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_TreasurySharesMember_QUC-XwhKoEK4nQE0wgA-OA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember_hG_33slvv0iz_A0sabMEBA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_pOxIHb_0lkKnDUS8JXZwmg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_6KA0EJhWSE603b7Uov1rMg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_CapitalReserveMember_DnDn5AHz-0-rleJrp9WdNg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:CapitalReserveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_TreasurySharesMember_LnSXiw4SC0GJbguDola8gw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember_obI4hBRbIk6bCNEX25ONyQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_0fN-yvhfRke2bER127GqTw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_spYNfmXLlkKn0qRrA7DHrQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_CapitalReserveMember_hKeYNzP2pkyRPXTqS3GOeg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:CapitalReserveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_TreasurySharesMember_1xV3xniJzEa6h2UaD4ZV8A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember_S8HeFlbOnEmNPym3RRCQYQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_A7iYghLG40G30BtbFyy3Fw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_25XvQwjzSUOoEVBaH6bxAA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_CapitalReserveMember_uETolOLN8EO7z8AXUFUrdg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:CapitalReserveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember_ZhVYR0CYCU-n8fXSTddhVA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_ifrs-full_ComponentsOfEquityAxis_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_4SMzjwIAMEaHB7TnvYKL-g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_ZWlHBf5sd0u18E_i-Im1zQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_ifrs-full_ComponentsOfEquityAxis_ifrs-full_CapitalReserveMember_VibTw9zPlkmYxEg1Vcd6Nw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:CapitalReserveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_9_30_2022_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_cvac_CurevacSwissAgMember_uQhhLoLXmEqQ0Uh4SUqsVA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">cvac:CurevacSwissAgMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_9_30_2022_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_cvac_CurevacCorporateServiceGmbhMember_w8u7qadVykiL43suHZX4cQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">cvac:CurevacCorporateServiceGmbhMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_9_30_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember_LBd2SxQlf0unc-mzWThKow">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_9_30_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_pqJl73EEck6icL9CscAZ9w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_9_30_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember_dCKGn2XnRk6SRLx6s50FAw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_9_30_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_N1rU63L0z0CKfWKFMPE8ug">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="Duration_5_1_2022_To_5_31_2022_ifrs-full_CategoriesOfRelatedPartiesAxis_cvac_BepharbelManufacturingS.aMember_OIxhC3wEcEmjhA5CfZ3lqQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">cvac:BepharbelManufacturingS.aMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-01</startDate>
            <endDate>2022-05-31</endDate>
        </period>
    </context>
    <context id="As_Of_9_30_2021_wVcf5oroJEG4KeEdh1LnEw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_gDhEGYRPKEaVXa-xMDWqsw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_9_30_2022_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_ifrs-full_GrossCarryingAmountMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_cvac_TechnicalEquipmentAndMachinesAndOtherEquipmentMember_fDP_vLfur0CDvezFllAP3w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cvac:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">cvac:TechnicalEquipmentAndMachinesAndOtherEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_9_30_2022_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_ConstructionInProgressMember_BqU3Y93BzU-k13235fXn4g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_9_30_2022_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_cvac_EquipmentPhysicallyLocatedAtCmoFacilitiesMember_7vsnG93SaE-EN8D8ClkcNA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">cvac:EquipmentPhysicallyLocatedAtCmoFacilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_9_30_2022_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_cvac_CompanyOwnedGmpIvFacilityMember_ZPOcXZnMYk-Um0cwVb1ZHw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">cvac:CompanyOwnedGmpIvFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_9_30_2021_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_ifrs-full_GrossCarryingAmountMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_cvac_TechnicalEquipmentAndMachinesAndOtherEquipmentMember_4EQ5xotfIUujKtdlrzbPVQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cvac:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">cvac:TechnicalEquipmentAndMachinesAndOtherEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_9_30_2022_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_ifrs-full_GrossCarryingAmountMember_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_cvac_LicensesSoftwareAndPrepaymentsMember_zeXSak6OQ0iEmjYXe9qo9w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cvac:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">cvac:LicensesSoftwareAndPrepaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_9_30_2021_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_ifrs-full_GrossCarryingAmountMember_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_cvac_LicensesSoftwareAndPrepaymentsMember_CzUp1LGslUSZTIy-JKWdLw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cvac:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">cvac:LicensesSoftwareAndPrepaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="As_Of_6_8_2022_ifrs-full_BusinessCombinationsAxis_cvac_FramePharmaceuticalsB.v.AmsterdamNetherlandsMember_VaKO9irU5EuHdCnXXdyNiw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">cvac:FramePharmaceuticalsB.v.AmsterdamNetherlandsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-08</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2022_ifrs-full_MajorCustomersAxis_cvac_GlaxosmithklineMember_ifrs-full_ProductsAndServicesAxis_cvac_ResearchServicesCombinedWithIpLicenseMember_ifrs-full_RangeAxis_ifrs-full_BottomOfRangeMember_7jTi8_0PcEeLFJbzx_wjrQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">cvac:GlaxosmithklineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">cvac:ResearchServicesCombinedWithIpLicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2022_ifrs-full_MajorCustomersAxis_cvac_BoehringerIngelheimMember_ifrs-full_ProductsAndServicesAxis_cvac_ResearchServicesCombinedWithIpLicenseMember_k3sZmRwsjkSNWebj2XPVlg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">cvac:BoehringerIngelheimMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">cvac:ResearchServicesCombinedWithIpLicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2022_ifrs-full_MajorCustomersAxis_cvac_GlaxosmithklineMember_ifrs-full_ProductsAndServicesAxis_cvac_ResearchServicesCombinedWithIpLicenseMember_0AbiwODFUEmyJLdIgNcTfg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">cvac:GlaxosmithklineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">cvac:ResearchServicesCombinedWithIpLicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2022_ifrs-full_MajorCustomersAxis_cvac_GenmabMember_ifrs-full_ProductsAndServicesAxis_cvac_ResearchServicesCombinedWithIpLicenseMember_yfdi7QFOIken6nwnl1VeyA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">cvac:GenmabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">cvac:ResearchServicesCombinedWithIpLicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2022_ifrs-full_MajorCustomersAxis_cvac_CrisprMember_ifrs-full_ProductsAndServicesAxis_cvac_ResearchServicesCombinedWithIpLicenseMember_N0CWO_7EbUeynG_1C6XLwA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">cvac:CrisprMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">cvac:ResearchServicesCombinedWithIpLicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2022_ifrs-full_ProductsAndServicesAxis_cvac_ResearchServicesCombinedWithIpLicenseMember_LDTxHzpQykydqGAuWhIjZQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">cvac:ResearchServicesCombinedWithIpLicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_ifrs-full_MajorCustomersAxis_cvac_GlaxosmithklineMember_ifrs-full_ProductsAndServicesAxis_cvac_ResearchServicesCombinedWithIpLicenseMember_PJOVtNdDh0SBq-RS-4qaSw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">cvac:GlaxosmithklineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">cvac:ResearchServicesCombinedWithIpLicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_ifrs-full_MajorCustomersAxis_cvac_GenmabMember_ifrs-full_ProductsAndServicesAxis_cvac_ResearchServicesCombinedWithIpLicenseMember_g3gSYGvJiUWtJe5m702osQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">cvac:GenmabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">cvac:ResearchServicesCombinedWithIpLicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_ifrs-full_MajorCustomersAxis_cvac_CrisprMember_ifrs-full_ProductsAndServicesAxis_cvac_ResearchServicesCombinedWithIpLicenseMember_lhcV_FVDUEqAgO5rXoI-qw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">cvac:CrisprMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">cvac:ResearchServicesCombinedWithIpLicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_ifrs-full_ProductsAndServicesAxis_cvac_ResearchServicesCombinedWithIpLicenseMember_SuxVutvjF02TZJEYT5xAUg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">cvac:ResearchServicesCombinedWithIpLicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_9_30_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_CapitalReserveMember_cVl-lTMdZ0SyIz4MzbLhUA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:CapitalReserveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_9_30_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_TreasurySharesMember_hUbz0huuf0-lvXUrSj2p7w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_9_30_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_CapitalReserveMember_g_0bQScme0WTxJwAia-iSA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:CapitalReserveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_jm3ww8f3H0egT8wSnNVZZw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_9_30_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsResearchAndDevelopmentExpenseMember_GiIhuFW_ukOtSf0Bvkce7w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cvac:IfrsIncomeStatementLocationAxis">cvac:IfrsResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_12_31_2019_ifrs-full_CategoriesOfRelatedPartiesAxis_cvac_DietmarHoppMember_vhtIRbibYkK_L7RHLy0f_A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">cvac:DietmarHoppMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_9_30_2022_ifrs-full_CategoriesOfRelatedPartiesAxis_cvac_ClarentisSrlMember_srt_TitleOfIndividualAxis_cvac_AntonyBlancMember_GiBB1NZHtU6MtEphFx2MUw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cvac:AntonyBlancMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">cvac:ClarentisSrlMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_9_30_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_SellingAndDistributionExpensesMember_nx7DDIuvEEyD8XuyuNsS6Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cvac:IfrsIncomeStatementLocationAxis">cvac:SellingAndDistributionExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_9_30_2021_cvac_IfrsIncomeStatementLocationAxis_cvac_SellingAndDistributionExpensesMember_-Uy3t4myckOOiYqfNnLrvA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cvac:IfrsIncomeStatementLocationAxis">cvac:SellingAndDistributionExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="Duration_9_1_2022_To_9_30_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_srt_ChiefOperatingOfficerMember_fTDjhW41wkulF-dl-PGYYg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefOperatingOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:LongTermIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-09-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="Duration_9_1_2022_To_9_30_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ExecutiveBoardMembersMember_hjnyCWqWaUG4U5M-ifsvcQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cvac:ExecutiveBoardMembersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:LongTermIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-09-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="Duration_9_1_2022_To_9_30_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ChiefDevelopmentOfficerMember_KVJTFke5SEudjsaztY_vxw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cvac:ChiefDevelopmentOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:LongTermIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-09-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="Duration_3_1_2022_To_3_1_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_KeyEmployeesMember_4k0biTJ1L0OjkLnTREDR-w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cvac:KeyEmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:LongTermIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-01</startDate>
            <endDate>2022-03-01</endDate>
        </period>
    </context>
    <context id="As_Of_5_31_2020_cvac_GovernmentGrantsAxis_cvac_CoalitionForEpidemicPreparednessInnovationsMember_V-hWugM7KEemNT5UugQPwQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cvac:GovernmentGrantsAxis">cvac:CoalitionForEpidemicPreparednessInnovationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-05-31</instant>
        </period>
    </context>
    <context id="As_Of_1_31_2020_cvac_GovernmentGrantsAxis_cvac_CoalitionForEpidemicPreparednessInnovationsMember_3sgz0BFjM0OjLj8LLFk2Lg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cvac:GovernmentGrantsAxis">cvac:CoalitionForEpidemicPreparednessInnovationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_9_30_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsResearchAndDevelopmentExpenseMember_u-Q9gJOBkUqQxOVDUX24Hw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cvac:IfrsIncomeStatementLocationAxis">cvac:IfrsResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_9_30_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsGeneralAndAdministrativeExpenseMember_KMYenp1F1EOV1PWLAQFrFw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cvac:IfrsIncomeStatementLocationAxis">cvac:IfrsGeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_9_30_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsCostOfSalesMember_em7QzpMx20e5-T4Zm2ygyA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cvac:IfrsIncomeStatementLocationAxis">cvac:IfrsCostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_9_30_2021_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsResearchAndDevelopmentExpenseMember_0xeLKyJYAEWBhUtu43GF8g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cvac:IfrsIncomeStatementLocationAxis">cvac:IfrsResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_9_30_2021_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsGeneralAndAdministrativeExpenseMember_pxlCrV2ySESTCd1lVbTlfg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cvac:IfrsIncomeStatementLocationAxis">cvac:IfrsGeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_9_30_2021_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsCostOfSalesMember__hz63wg8m0S72b0NYjaYHQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cvac:IfrsIncomeStatementLocationAxis">cvac:IfrsCostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="As_Of_9_30_2021_ifrs-full_BorrowingsByNameAxis_cvac_IfrsLineOfCreditMember_lKYOAuZEL0axHg8yeQcJvA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">cvac:IfrsLineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="Duration_8_1_2020_To_8_31_2020_ifrs-full_CategoriesOfRelatedPartiesAxis_cvac_DietmarHoppMember_4pr7l6FBv0Cr0BMx5sP5QQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">cvac:DietmarHoppMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-01</startDate>
            <endDate>2020-08-31</endDate>
        </period>
    </context>
    <context id="Duration_9_1_2022_To_9_30_2022_cvac_IfrsSaleOfStockAxis_cvac_AtMarketOfferingProgramMember_aEeSD8tWhUqDkvbkYwvYZA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cvac:IfrsSaleOfStockAxis">cvac:AtMarketOfferingProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-09-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2022_To_9_30_2022_pgUlLsnMwE6GuzWOXk2lcg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_ifrs-full_BorrowingsByNameAxis_cvac_IfrsLineOfCreditMember_Zjc-vTBONUWK_U5c-7CI3w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">cvac:IfrsLineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_9_30_2022_ifrs-full_ProductsAndServicesAxis_cvac_MilestoneRevenuesMember_f7JkTbic-Uq7GDa0pAVbjA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">cvac:MilestoneRevenuesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="As_Of_7_1_2022_ifrs-full_BusinessCombinationsAxis_cvac_FramePharmaceuticalsB.v.AmsterdamNetherlandsMember_TNMnxy-chEOEtWGU9Rxf9g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">cvac:FramePharmaceuticalsB.v.AmsterdamNetherlandsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-01</instant>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_9_30_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_VirtualSharesProgramIMember_8-6ss668qkGhxxIvnx3JTQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:VirtualSharesProgramIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_9_30_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_VirtualSharesProgramIiMember_94K0C2dKwEe87RAK5o3yHg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:VirtualSharesProgramIiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_9_30_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_RestrictedStockUnitForKeyEmployeesMember_dZiMEF-WIUaYDoS6prDgKg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:RestrictedStockUnitForKeyEmployeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_9_30_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_6VLzYOVR1k24GIHsNaoB2A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:LongTermIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_9_30_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_IfrsRestrictedStockUnitMember_XRKL4qJ810SYjrkXptDpGw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:IfrsRestrictedStockUnitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_9_30_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_VirtualSharesProgramIMember_G8wLGie1fkurrNt_KXss3A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:VirtualSharesProgramIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_9_30_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_VirtualSharesProgramIiMember_5phdNMZ4UUa7p62ZO4ZmiQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:VirtualSharesProgramIiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_9_30_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_-7vn4v2-bEuMIEE_cJjuug">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:LongTermIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_9_30_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_IfrsRestrictedStockUnitMember_QgoBjuQOZEO99XfLIWVoQA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:IfrsRestrictedStockUnitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_9_30_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ChiefScientificOfficerMember_UtQLqJhh8UiH4zCtHpD4cQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cvac:ChiefScientificOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:LongTermIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_9_30_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ChiefScientificOfficerMember_Zo3CrV1xc0-l6T3OrHnAhQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cvac:ChiefScientificOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:LongTermIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2022_To_6_30_2022_-gYjaV8XPUKBPSbaN9Qziw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_3_31_2022_LiqLyh4w5EGnOWf_FZQF7Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="As_Of_9_30_2022_ifrs-full_BusinessCombinationsAxis_cvac_FramePharmaceuticalsB.v.AmsterdamNetherlandsMember_vR0Bi5R7KE6kPw8J5q5NTA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">cvac:FramePharmaceuticalsB.v.AmsterdamNetherlandsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_9_30_2022_srt_CounterpartyNameAxis_cvac_GlaxosmithklineMember_3G2M3SARj0GkTuTa4M37uw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cvac:GlaxosmithklineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="As_Of_6_30_2022_kOEc9a1C10m7Rg-HheHYxg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2022_mqhJpd3F8U63gbp_M5KLaw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_kQVJTWPgRUeESxCd99xt9A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2021_ifrs-full_CategoriesOfRelatedPartiesAxis_cvac_ClarentisSrlMember_Dh91pVmxqEWDD100jMo2Fw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">cvac:ClarentisSrlMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="Duration_6_8_2022_To_6_8_2022_ifrs-full_BusinessCombinationsAxis_cvac_FramePharmaceuticalsB.v.AmsterdamNetherlandsMember_1GTamgfVRUOww3XIvpKP3Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">cvac:FramePharmaceuticalsB.v.AmsterdamNetherlandsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-08</startDate>
            <endDate>2022-06-08</endDate>
        </period>
    </context>
    <context id="Duration_9_1_2021_To_9_30_2021_cvac_IfrsSaleOfStockAxis_cvac_AtMarketOfferingProgramMember_UsrXsTjj5kOO1bTEgPYDaA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cvac:IfrsSaleOfStockAxis">cvac:AtMarketOfferingProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-09-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_9_30_2021_5RS16WkLc0uS2ug_bqUm-g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_9_30_2022_ifrs-full_ProductsAndServicesAxis_cvac_MilestoneRevenuesMember_H4PqpAjQEkuxcZ00nka3Eg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">cvac:MilestoneRevenuesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="As_Of_9_30_2022_zuGVrjesE0WhwXSGmTqsgA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <unit id="Unit_Standard_Option_puBmss6yUE6NakwAOqqzng">
        <measure>cvac:Option</measure>
    </unit>
    <unit id="Unit_Standard_tranche__TryzuW6jEmkCnTfvtVlrg">
        <measure>cvac:tranche</measure>
    </unit>
    <unit id="Unit_Standard_loan_2Ze7UTdQEkiZKAdZ7o4zlw">
        <measure>cvac:loan</measure>
    </unit>
    <unit id="Unit_Standard_CHF_BBNACBTv9k-Ei0YBwsfYBA">
        <measure>iso4217:CHF</measure>
    </unit>
    <unit id="Unit_Divide_USD_shares_B3tHpJm3a0ytZJRcE10tTA">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">
        <measure>iso4217:EUR</measure>
    </unit>
    <unit id="Unit_Standard_USD_q8NNp4TBfUC9XydcVDSrpA">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Unit_Divide_EUR_shares_6PEZCHC_WE2a7AmZW169oA">
        <divide>
            <unitNumerator>
                <measure>iso4217:EUR</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Unit_Standard_D_Pu_YZcQO3kKxgZxGvGVflA">
        <measure>cvac:D</measure>
    </unit>
    <unit id="Unit_Standard_shares_FapG5E6UqkK42IfNNOS6tA">
        <measure>shares</measure>
    </unit>
    <unit id="Unit_Standard_Milestone_1ZnSc2qU1UaZ09p9Mr6TGw">
        <measure>cvac:Milestone</measure>
    </unit>
    <unit id="Unit_Standard_payment_4W6g8HbU0USZCbuxzWFKng">
        <measure>cvac:payment</measure>
    </unit>
    <unit id="Unit_Standard_pure_NsGb2Z3yYka4EicmhvoaQQ">
        <measure>pure</measure>
    </unit>
    <unit id="Unit_Standard_employee_-Jetz9Th0ka1WnOToYuqxw">
        <measure>cvac:employee</measure>
    </unit>
    <dei:DocumentType
      contextRef="Duration_1_1_2022_To_9_30_2022_GrYkE3mhHEiRA4fxgfABRg"
      id="Narr_aPaBNMg0nkuUx6vXQB9aZw">6-K</dei:DocumentType>
    <dei:EntityRegistrantName
      contextRef="Duration_1_1_2022_To_9_30_2022_GrYkE3mhHEiRA4fxgfABRg"
      id="Narr_KL7Q8vqBskCIUumvXQ6fRg">CureVac N.V.</dei:EntityRegistrantName>
    <ifrs-full:DilutedEarningsLossPerShare
      contextRef="Duration_1_1_2021_To_9_30_2021_5RS16WkLc0uS2ug_bqUm-g"
      decimals="2"
      id="Hidden_kWSP08hTDU6JsTVRt-1jzQ"
      unitRef="Unit_Divide_EUR_shares_6PEZCHC_WE2a7AmZW169oA">-2.21</ifrs-full:DilutedEarningsLossPerShare>
    <ifrs-full:DilutedEarningsLossPerShare
      contextRef="Duration_1_1_2022_To_9_30_2022_GrYkE3mhHEiRA4fxgfABRg"
      decimals="2"
      id="Hidden_twu7NAo320CgqR-UyIa6xg"
      unitRef="Unit_Divide_EUR_shares_6PEZCHC_WE2a7AmZW169oA">-0.64</ifrs-full:DilutedEarningsLossPerShare>
    <dei:DocumentPeriodEndDate
      contextRef="Duration_1_1_2022_To_9_30_2022_GrYkE3mhHEiRA4fxgfABRg"
      id="Tc_o1T0bdebT0eweikTxfjkHg_7_1">2022-09-30</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate
      contextRef="Duration_1_1_2022_To_9_30_2022_GrYkE3mhHEiRA4fxgfABRg"
      id="Tc_cScBRFFN_kGvmTzC9HmmgA_15_1">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="Duration_1_1_2022_To_9_30_2022_GrYkE3mhHEiRA4fxgfABRg"
      id="Tc_UQeczTIQNUqcmShkx51M5Q_16_1">2022</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="Duration_1_1_2022_To_9_30_2022_GrYkE3mhHEiRA4fxgfABRg"
      id="Tc_W8aHH_3JSkq5TLzjZb8SRA_17_1">Q3</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey
      contextRef="Duration_1_1_2022_To_9_30_2022_GrYkE3mhHEiRA4fxgfABRg"
      id="Tc_LCuFsyuofEyzuIqi0Sbx0g_18_1">0001809122</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="Duration_1_1_2022_To_9_30_2022_GrYkE3mhHEiRA4fxgfABRg"
      id="Tc_48Ap74TDHEahBvHT-qiKKA_19_1">false</dei:AmendmentFlag>
    <ifrs-full:TransfersOutOfLevel2IntoLevel1OfFairValueHierarchyAssets
      contextRef="Duration_1_1_2021_To_9_30_2021_5RS16WkLc0uS2ug_bqUm-g"
      decimals="0"
      id="Hidden_PirsTzfz8ESBJFS11fCP4Q"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">0</ifrs-full:TransfersOutOfLevel2IntoLevel1OfFairValueHierarchyAssets>
    <ifrs-full:TransfersOutOfLevel2IntoLevel1OfFairValueHierarchyAssets
      contextRef="Duration_1_1_2022_To_9_30_2022_GrYkE3mhHEiRA4fxgfABRg"
      decimals="0"
      id="Hidden_Y0MxeO6rLke55_aaQkLudQ"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">0</ifrs-full:TransfersOutOfLevel2IntoLevel1OfFairValueHierarchyAssets>
    <ifrs-full:TransfersOutOfLevel1IntoLevel2OfFairValueHierarchyLiabilities
      contextRef="Duration_1_1_2021_To_9_30_2021_5RS16WkLc0uS2ug_bqUm-g"
      decimals="0"
      id="Hidden_NB6QjTXovEek5POe2TcmUw"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">0</ifrs-full:TransfersOutOfLevel1IntoLevel2OfFairValueHierarchyLiabilities>
    <ifrs-full:TransfersOutOfLevel1IntoLevel2OfFairValueHierarchyLiabilities
      contextRef="Duration_1_1_2022_To_9_30_2022_GrYkE3mhHEiRA4fxgfABRg"
      decimals="0"
      id="Hidden__9uyZNS6lUy8EqQIX9CSkA"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">0</ifrs-full:TransfersOutOfLevel1IntoLevel2OfFairValueHierarchyLiabilities>
    <ifrs-full:TransfersOutOfLevel2IntoLevel1OfFairValueHierarchyLiabilities
      contextRef="Duration_1_1_2021_To_9_30_2021_5RS16WkLc0uS2ug_bqUm-g"
      decimals="0"
      id="Hidden_L0hHurAojU2_aeVDDXvPGA"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">0</ifrs-full:TransfersOutOfLevel2IntoLevel1OfFairValueHierarchyLiabilities>
    <ifrs-full:TransfersOutOfLevel2IntoLevel1OfFairValueHierarchyLiabilities
      contextRef="Duration_1_1_2022_To_9_30_2022_GrYkE3mhHEiRA4fxgfABRg"
      decimals="0"
      id="Hidden_ZpZFbXExjEaiJpkfcLHZQA"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">0</ifrs-full:TransfersOutOfLevel2IntoLevel1OfFairValueHierarchyLiabilities>
    <ifrs-full:TransfersOutOfLevel3OfFairValueHierarchyAssets
      contextRef="Duration_1_1_2021_To_9_30_2021_5RS16WkLc0uS2ug_bqUm-g"
      decimals="0"
      id="Hidden_EyLKUnCsjkqE1Y0Lnu6uXA"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">0</ifrs-full:TransfersOutOfLevel3OfFairValueHierarchyAssets>
    <ifrs-full:TransfersOutOfLevel3OfFairValueHierarchyAssets
      contextRef="Duration_1_1_2022_To_9_30_2022_GrYkE3mhHEiRA4fxgfABRg"
      decimals="0"
      id="Hidden_K-OSXKDmPk6iT1KXoy-UMg"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">0</ifrs-full:TransfersOutOfLevel3OfFairValueHierarchyAssets>
    <ifrs-full:TransfersIntoLevel3OfFairValueHierarchyLiabilities
      contextRef="Duration_1_1_2021_To_9_30_2021_5RS16WkLc0uS2ug_bqUm-g"
      decimals="0"
      id="Hidden_ewhtEuFyckyIHby4z9-g5w"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">0</ifrs-full:TransfersIntoLevel3OfFairValueHierarchyLiabilities>
    <ifrs-full:TransfersIntoLevel3OfFairValueHierarchyLiabilities
      contextRef="Duration_1_1_2022_To_9_30_2022_GrYkE3mhHEiRA4fxgfABRg"
      decimals="0"
      id="Hidden_VR0Qmn3c5Ua04jYeohzSDQ"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">0</ifrs-full:TransfersIntoLevel3OfFairValueHierarchyLiabilities>
    <ifrs-full:TransfersOutOfLevel3OfFairValueHierarchyLiabilities
      contextRef="Duration_1_1_2021_To_9_30_2021_5RS16WkLc0uS2ug_bqUm-g"
      decimals="0"
      id="Hidden_q-UzAK_rjEmLkZUqgaZtvg"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">0</ifrs-full:TransfersOutOfLevel3OfFairValueHierarchyLiabilities>
    <ifrs-full:TransfersOutOfLevel3OfFairValueHierarchyLiabilities
      contextRef="Duration_1_1_2022_To_9_30_2022_GrYkE3mhHEiRA4fxgfABRg"
      decimals="0"
      id="Hidden_mvSP4UQRrUi-6cT-ed3wjA"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">0</ifrs-full:TransfersOutOfLevel3OfFairValueHierarchyLiabilities>
    <ifrs-full:ParValuePerShare
      contextRef="As_Of_9_30_2022_ifrs-full_ClassesOfShareCapitalAxis_ifrs-full_OrdinarySharesMember_QerVWaOy8UeUozR8lPK5KA"
      decimals="2"
      id="Hidden_Pn4RGe75pUmEplb8tLMDGA"
      unitRef="Unit_Divide_EUR_shares_6PEZCHC_WE2a7AmZW169oA">0.12</ifrs-full:ParValuePerShare>
    <ifrs-full:ProceedsFromIssuingShares
      contextRef="Duration_9_1_2022_To_9_30_2022_UpNYd37lHEq8lbtMmcgfVg"
      decimals="-5"
      id="Hidden_k6p5zM0iFEqRi29XSeuCWQ"
      unitRef="Unit_Standard_USD_q8NNp4TBfUC9XydcVDSrpA">32700000</ifrs-full:ProceedsFromIssuingShares>
    <cvac:NetValueOfInventoryTransferred
      contextRef="Duration_1_1_2022_To_9_30_2022_srt_CounterpartyNameAxis_cvac_GlaxosmithklineMember_3G2M3SARj0GkTuTa4M37uw"
      decimals="-3"
      id="Hidden_N17kRFMeX0inGpkHufA1CQ"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">98000</cvac:NetValueOfInventoryTransferred>
    <ifrs-full:RevenueFromContractsWithCustomers
      contextRef="Duration_1_1_2021_To_9_30_2021_5RS16WkLc0uS2ug_bqUm-g"
      decimals="-3"
      id="Tc_zEucKwwuTkeaoX2hZL_fyg_4_4"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">61765000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers
      contextRef="Duration_1_1_2022_To_9_30_2022_GrYkE3mhHEiRA4fxgfABRg"
      decimals="-3"
      id="Tc_lirxWGJcA0WQkRaIH2ZHDw_4_6"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">55731000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:CostOfSales
      contextRef="Duration_1_1_2021_To_9_30_2021_5RS16WkLc0uS2ug_bqUm-g"
      decimals="-3"
      id="Tc_lbi_AEVjhU-kQfUqAvaG9w_5_4"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">168177000</ifrs-full:CostOfSales>
    <ifrs-full:CostOfSales
      contextRef="Duration_1_1_2022_To_9_30_2022_GrYkE3mhHEiRA4fxgfABRg"
      decimals="-3"
      id="Tc_w69vXYpafEeKRfIvohcDag_5_6"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">103992000</ifrs-full:CostOfSales>
    <ifrs-full:SalesAndMarketingExpense
      contextRef="Duration_1_1_2021_To_9_30_2021_5RS16WkLc0uS2ug_bqUm-g"
      decimals="-3"
      id="Tc_1gHjva0ySEqfHUx2ESiTDQ_6_4"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">1232000</ifrs-full:SalesAndMarketingExpense>
    <ifrs-full:SalesAndMarketingExpense
      contextRef="Duration_1_1_2022_To_9_30_2022_GrYkE3mhHEiRA4fxgfABRg"
      decimals="-3"
      id="Tc_cngfnt35AUmlSXSGthgpPQ_6_6"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">1825000</ifrs-full:SalesAndMarketingExpense>
    <ifrs-full:ResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2021_To_9_30_2021_5RS16WkLc0uS2ug_bqUm-g"
      decimals="-3"
      id="Tc_8EDBJ5uJc0mYdR6OJe47RA_7_4"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">284728000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2022_To_9_30_2022_GrYkE3mhHEiRA4fxgfABRg"
      decimals="-3"
      id="Tc_tbNRuXkVi02QCplsMbeHjQ_7_6"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">34934000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:GeneralAndAdministrativeExpense
      contextRef="Duration_1_1_2021_To_9_30_2021_5RS16WkLc0uS2ug_bqUm-g"
      decimals="-3"
      id="Tc_z5MD4GWdUkCGi1iAbPY-Sw_8_4"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">80787000</ifrs-full:GeneralAndAdministrativeExpense>
    <ifrs-full:GeneralAndAdministrativeExpense
      contextRef="Duration_1_1_2022_To_9_30_2022_GrYkE3mhHEiRA4fxgfABRg"
      decimals="-3"
      id="Tc_P7VuikDyn0mI0ZRT652k2Q_8_6"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">78019000</ifrs-full:GeneralAndAdministrativeExpense>
    <ifrs-full:MiscellaneousOtherOperatingIncome
      contextRef="Duration_1_1_2021_To_9_30_2021_5RS16WkLc0uS2ug_bqUm-g"
      decimals="-3"
      id="Tc_VMK2QGOb5EudnmdDwGs99Q_9_4"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">66746000</ifrs-full:MiscellaneousOtherOperatingIncome>
    <ifrs-full:MiscellaneousOtherOperatingIncome
      contextRef="Duration_1_1_2022_To_9_30_2022_GrYkE3mhHEiRA4fxgfABRg"
      decimals="-3"
      id="Tc_ySiD8AYzBU6zf8o0DzRWCw_9_6"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">35901000</ifrs-full:MiscellaneousOtherOperatingIncome>
    <ifrs-full:MiscellaneousOtherOperatingExpense
      contextRef="Duration_1_1_2021_To_9_30_2021_5RS16WkLc0uS2ug_bqUm-g"
      decimals="-3"
      id="Tc_Bz5E8XFj1EGe8LvULFlOlQ_10_4"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">339000</ifrs-full:MiscellaneousOtherOperatingExpense>
    <ifrs-full:MiscellaneousOtherOperatingExpense
      contextRef="Duration_1_1_2022_To_9_30_2022_GrYkE3mhHEiRA4fxgfABRg"
      decimals="-3"
      id="Tc_XOIon8PBq0i8NTbo5BJuzw_10_6"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">809000</ifrs-full:MiscellaneousOtherOperatingExpense>
    <ifrs-full:ProfitLossFromOperatingActivities
      contextRef="Duration_1_1_2021_To_9_30_2021_5RS16WkLc0uS2ug_bqUm-g"
      decimals="-3"
      id="Tc_wFFBe3qptUm_7DDrEZWMew_11_4"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">-406752000</ifrs-full:ProfitLossFromOperatingActivities>
    <ifrs-full:ProfitLossFromOperatingActivities
      contextRef="Duration_1_1_2022_To_9_30_2022_GrYkE3mhHEiRA4fxgfABRg"
      decimals="-3"
      id="Tc_N81gR9dvAU6VAUOLLhjf6g_11_6"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">-127947000</ifrs-full:ProfitLossFromOperatingActivities>
    <ifrs-full:FinanceIncome
      contextRef="Duration_1_1_2021_To_9_30_2021_5RS16WkLc0uS2ug_bqUm-g"
      decimals="-3"
      id="Tc_NlnHcSvWT0iJf4C0Bxqonw_12_4"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">8828000</ifrs-full:FinanceIncome>
    <ifrs-full:FinanceIncome
      contextRef="Duration_1_1_2022_To_9_30_2022_GrYkE3mhHEiRA4fxgfABRg"
      decimals="-3"
      id="Tc_RlYIqtPn_k-AtEDmWaVoxA_12_6"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">10619000</ifrs-full:FinanceIncome>
    <ifrs-full:FinanceCosts
      contextRef="Duration_1_1_2021_To_9_30_2021_5RS16WkLc0uS2ug_bqUm-g"
      decimals="-3"
      id="Tc_d6eJzyS6T0G28RbaN70A9w_13_4"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">10015000</ifrs-full:FinanceCosts>
    <ifrs-full:FinanceCosts
      contextRef="Duration_1_1_2022_To_9_30_2022_GrYkE3mhHEiRA4fxgfABRg"
      decimals="-3"
      id="Tc_8pro4nvUYUu5BHHOKLTrEQ_13_6"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">3077000</ifrs-full:FinanceCosts>
    <ifrs-full:ProfitLossBeforeTax
      contextRef="Duration_1_1_2021_To_9_30_2021_5RS16WkLc0uS2ug_bqUm-g"
      decimals="-3"
      id="Tc_fkYjIjHNzk2LPkCdr7uWWA_14_4"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">-407939000</ifrs-full:ProfitLossBeforeTax>
    <ifrs-full:ProfitLossBeforeTax
      contextRef="Duration_1_1_2022_To_9_30_2022_GrYkE3mhHEiRA4fxgfABRg"
      decimals="-3"
      id="Tc_zWeAI9CBF0-21blUqnUsZA_14_6"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">-120405000</ifrs-full:ProfitLossBeforeTax>
    <ifrs-full:IncomeTaxExpenseContinuingOperations
      contextRef="Duration_1_1_2021_To_9_30_2021_5RS16WkLc0uS2ug_bqUm-g"
      decimals="-3"
      id="Tc_6NSyBwj550afS1cYQ2M50Q_15_4"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">1841000</ifrs-full:IncomeTaxExpenseContinuingOperations>
    <ifrs-full:IncomeTaxExpenseContinuingOperations
      contextRef="Duration_1_1_2022_To_9_30_2022_GrYkE3mhHEiRA4fxgfABRg"
      decimals="-3"
      id="Tc_jiP94FJDzUyy_h8BDKRmLQ_15_6"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">-160000</ifrs-full:IncomeTaxExpenseContinuingOperations>
    <ifrs-full:ProfitLoss
      contextRef="Duration_1_1_2021_To_9_30_2021_5RS16WkLc0uS2ug_bqUm-g"
      decimals="-3"
      id="Tc_N4Eq-J2yH02U_EmR75Ubog_16_4"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">-409780000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="Duration_1_1_2022_To_9_30_2022_GrYkE3mhHEiRA4fxgfABRg"
      decimals="-3"
      id="Tc_lU8AuZcKX0O9EMjHZ5Brog_16_6"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">-120245000</ifrs-full:ProfitLoss>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation
      contextRef="Duration_1_1_2021_To_9_30_2021_5RS16WkLc0uS2ug_bqUm-g"
      decimals="-3"
      id="Tc_eA2QhpDb-k6r0lhKA2V6mg_18_4"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">-62000</ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation
      contextRef="Duration_1_1_2022_To_9_30_2022_GrYkE3mhHEiRA4fxgfABRg"
      decimals="-3"
      id="Tc_-vKk2GvvvEqxDCxu31v6DA_18_6"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">-364000</ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation>
    <ifrs-full:ComprehensiveIncome
      contextRef="Duration_1_1_2021_To_9_30_2021_5RS16WkLc0uS2ug_bqUm-g"
      decimals="-3"
      id="Tc_l5CLrlYJCUC5LU3SLO3ROg_19_4"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">-409842000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="Duration_1_1_2022_To_9_30_2022_GrYkE3mhHEiRA4fxgfABRg"
      decimals="-3"
      id="Tc_ulFJczOVXEmAfaIj9rlc_g_19_6"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">-120609000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:BasicEarningsLossPerShare
      contextRef="Duration_1_1_2021_To_9_30_2021_5RS16WkLc0uS2ug_bqUm-g"
      decimals="2"
      id="Tc_LgUmce25pEyXmxciNFKT_g_20_4"
      unitRef="Unit_Divide_EUR_shares_6PEZCHC_WE2a7AmZW169oA">-2.21</ifrs-full:BasicEarningsLossPerShare>
    <ifrs-full:BasicEarningsLossPerShare
      contextRef="Duration_1_1_2022_To_9_30_2022_GrYkE3mhHEiRA4fxgfABRg"
      decimals="2"
      id="Tc_cEvCl_LFkkCHeeSHcPjdiA_20_6"
      unitRef="Unit_Divide_EUR_shares_6PEZCHC_WE2a7AmZW169oA">-0.64</ifrs-full:BasicEarningsLossPerShare>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="As_Of_12_31_2021_kQVJTWPgRUeESxCd99xt9A"
      decimals="-3"
      id="Tc_DNBEX5giv0y97C9_B6pQbA_6_4"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">13238000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="As_Of_9_30_2022_zuGVrjesE0WhwXSGmTqsgA"
      decimals="-3"
      id="Tc_iRcTv7ooRUuVao76JMzG8A_6_6"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">33775000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="As_Of_12_31_2021_kQVJTWPgRUeESxCd99xt9A"
      decimals="-3"
      id="Tc_LuAXDuP8Rk20tLFanKGdXg_7_4"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">168264000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="As_Of_9_30_2022_zuGVrjesE0WhwXSGmTqsgA"
      decimals="-3"
      id="Tc_Esz_mKCwhkG-pNcsnsNKsg_7_6"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">207660000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:RightofuseAssets
      contextRef="As_Of_12_31_2021_kQVJTWPgRUeESxCd99xt9A"
      decimals="-3"
      id="Tc_P6fz3A2kKUCeRddMjQC6vQ_8_4"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">32129000</ifrs-full:RightofuseAssets>
    <ifrs-full:RightofuseAssets
      contextRef="As_Of_9_30_2022_zuGVrjesE0WhwXSGmTqsgA"
      decimals="-3"
      id="Tc_3E9az2w910O0mksSFbl-cg_8_6"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">43801000</ifrs-full:RightofuseAssets>
    <ifrs-full:OtherNoncurrentAssets
      contextRef="As_Of_12_31_2021_kQVJTWPgRUeESxCd99xt9A"
      decimals="-3"
      id="Tc_RyVHNud7zES9EprS23XFhA_9_4"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">1731000</ifrs-full:OtherNoncurrentAssets>
    <ifrs-full:OtherNoncurrentAssets
      contextRef="As_Of_9_30_2022_zuGVrjesE0WhwXSGmTqsgA"
      decimals="-3"
      id="Tc_Fqy3SPG3jU2y1miZKRyoAg_9_6"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">1688000</ifrs-full:OtherNoncurrentAssets>
    <ifrs-full:NetDeferredTaxAssets
      contextRef="As_Of_12_31_2021_kQVJTWPgRUeESxCd99xt9A"
      decimals="-3"
      id="Tc_CxMCXJVP4kiULx_VsjiOCg_10_4"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">2861000</ifrs-full:NetDeferredTaxAssets>
    <ifrs-full:NetDeferredTaxAssets
      contextRef="As_Of_9_30_2022_zuGVrjesE0WhwXSGmTqsgA"
      decimals="-3"
      id="Tc_mgV65iXqm02k5Kx03eyVAQ_10_6"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">1306000</ifrs-full:NetDeferredTaxAssets>
    <ifrs-full:NoncurrentAssets
      contextRef="As_Of_12_31_2021_kQVJTWPgRUeESxCd99xt9A"
      decimals="-3"
      id="Tc_fKXBMsnQp0Gois5AnH-9ug_11_4"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">218223000</ifrs-full:NoncurrentAssets>
    <ifrs-full:NoncurrentAssets
      contextRef="As_Of_9_30_2022_zuGVrjesE0WhwXSGmTqsgA"
      decimals="-3"
      id="Tc_7Jf1lnexw0-QdXsvOgLztA_11_6"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">288230000</ifrs-full:NoncurrentAssets>
    <ifrs-full:NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners
      contextRef="As_Of_9_30_2022_zuGVrjesE0WhwXSGmTqsgA"
      decimals="-3"
      id="Tc_VBxpl3RS_kqpcyebnSgN_A_13_6"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">3828000</ifrs-full:NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners>
    <ifrs-full:Inventories
      contextRef="As_Of_12_31_2021_kQVJTWPgRUeESxCd99xt9A"
      decimals="-3"
      id="Tc_l4twpXISc06qEw3I4F9VPQ_14_4"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">56159000</ifrs-full:Inventories>
    <ifrs-full:Inventories
      contextRef="As_Of_9_30_2022_zuGVrjesE0WhwXSGmTqsgA"
      decimals="-3"
      id="Tc_6ka9Tltje0yY_VT_gLKETQ_14_6"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">7868000</ifrs-full:Inventories>
    <ifrs-full:CurrentTradeReceivables
      contextRef="As_Of_12_31_2021_kQVJTWPgRUeESxCd99xt9A"
      decimals="-3"
      id="Tc_w6R-sfgDgkKUM7V84F5wGw_15_4"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">18504000</ifrs-full:CurrentTradeReceivables>
    <ifrs-full:CurrentTradeReceivables
      contextRef="As_Of_9_30_2022_zuGVrjesE0WhwXSGmTqsgA"
      decimals="-3"
      id="Tc_IwXbelnYFEmF0q0iTbrt6g_15_6"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">6170000</ifrs-full:CurrentTradeReceivables>
    <ifrs-full:OtherCurrentFinancialAssets
      contextRef="As_Of_12_31_2021_kQVJTWPgRUeESxCd99xt9A"
      decimals="-3"
      id="Tc_4WmOt9OVD0Ct_FklS647Rw_16_4"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">4648000</ifrs-full:OtherCurrentFinancialAssets>
    <ifrs-full:OtherCurrentFinancialAssets
      contextRef="As_Of_9_30_2022_zuGVrjesE0WhwXSGmTqsgA"
      decimals="-3"
      id="Tc_Yo5ZvW9RsUuFWPPmd7DaoQ_16_6"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">2599000</ifrs-full:OtherCurrentFinancialAssets>
    <ifrs-full:CurrentPrepaymentsAndOtherCurrentAssets
      contextRef="As_Of_12_31_2021_kQVJTWPgRUeESxCd99xt9A"
      decimals="-3"
      id="Tc_O7sc30e0_kuC1uXPJu8Nnw_17_4"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">49244000</ifrs-full:CurrentPrepaymentsAndOtherCurrentAssets>
    <ifrs-full:CurrentPrepaymentsAndOtherCurrentAssets
      contextRef="As_Of_9_30_2022_zuGVrjesE0WhwXSGmTqsgA"
      decimals="-3"
      id="Tc_amyaa4AvkE6kSJWwUhaBrQ_17_6"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">60952000</ifrs-full:CurrentPrepaymentsAndOtherCurrentAssets>
    <ifrs-full:CashAndCashEquivalents
      contextRef="As_Of_12_31_2021_kQVJTWPgRUeESxCd99xt9A"
      decimals="-3"
      id="Tc_VfzBnGLZikCZKTmRrwrH-w_18_4"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">811464000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents
      contextRef="As_Of_9_30_2022_zuGVrjesE0WhwXSGmTqsgA"
      decimals="-3"
      id="Tc_kS5alvNdrUugoB4z7sD_EA_18_6"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">540865000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CurrentAssets
      contextRef="As_Of_12_31_2021_kQVJTWPgRUeESxCd99xt9A"
      decimals="-3"
      id="Tc_hD9tUh_zQUmHpNCK5vCUnQ_19_4"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">940019000</ifrs-full:CurrentAssets>
    <ifrs-full:CurrentAssets
      contextRef="As_Of_9_30_2022_zuGVrjesE0WhwXSGmTqsgA"
      decimals="-3"
      id="Tc_k9n_0YMW1EW358CkE4z6wg_19_6"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">622282000</ifrs-full:CurrentAssets>
    <ifrs-full:Assets
      contextRef="As_Of_12_31_2021_kQVJTWPgRUeESxCd99xt9A"
      decimals="-3"
      id="Tc_L2qWrASfNk2c_ekiHF1X3w_20_4"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">1158242000</ifrs-full:Assets>
    <ifrs-full:Assets
      contextRef="As_Of_9_30_2022_zuGVrjesE0WhwXSGmTqsgA"
      decimals="-3"
      id="Tc_TZcny92APEWk57FRKY0rrA_20_6"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">910512000</ifrs-full:Assets>
    <ifrs-full:IssuedCapital
      contextRef="As_Of_12_31_2021_kQVJTWPgRUeESxCd99xt9A"
      decimals="-3"
      id="Tc_UkDDuIayF0q_lXBpzGXVAQ_23_4"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">22454000</ifrs-full:IssuedCapital>
    <ifrs-full:IssuedCapital
      contextRef="As_Of_9_30_2022_zuGVrjesE0WhwXSGmTqsgA"
      decimals="-3"
      id="Tc_JL3uLD9YXUWaxfbxFrF1pA_23_6"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">22834000</ifrs-full:IssuedCapital>
    <ifrs-full:CapitalReserve
      contextRef="As_Of_12_31_2021_kQVJTWPgRUeESxCd99xt9A"
      decimals="-3"
      id="Tc_A_8nIeHw0EihqGB4hmIVLw_24_4"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">1728658000</ifrs-full:CapitalReserve>
    <ifrs-full:CapitalReserve
      contextRef="As_Of_9_30_2022_zuGVrjesE0WhwXSGmTqsgA"
      decimals="-3"
      id="Tc_EQLj9_T9W0ut_QHMRoRBoQ_24_6"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">1781316000</ifrs-full:CapitalReserve>
    <ifrs-full:TreasuryShares
      contextRef="As_Of_12_31_2021_kQVJTWPgRUeESxCd99xt9A"
      decimals="-3"
      id="Tc_pWITyAyvykOT1D27946-0Q_25_4"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">5817000</ifrs-full:TreasuryShares>
    <ifrs-full:TreasuryShares
      contextRef="As_Of_9_30_2022_zuGVrjesE0WhwXSGmTqsgA"
      decimals="-3"
      id="Tc_iPO8J_uqpke0PaOWNbxttQ_25_6"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">1734000</ifrs-full:TreasuryShares>
    <ifrs-full:RetainedEarnings
      contextRef="As_Of_12_31_2021_kQVJTWPgRUeESxCd99xt9A"
      decimals="-3"
      id="Tc_1C_-OsvD7kStAfFuZj2E6Q_26_4"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">-1056785000</ifrs-full:RetainedEarnings>
    <ifrs-full:RetainedEarnings
      contextRef="As_Of_9_30_2022_zuGVrjesE0WhwXSGmTqsgA"
      decimals="-3"
      id="Tc_nePppeejgkCR38f4UM2Bpg_26_6"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">-1177030000</ifrs-full:RetainedEarnings>
    <ifrs-full:AccumulatedOtherComprehensiveIncome
      contextRef="As_Of_12_31_2021_kQVJTWPgRUeESxCd99xt9A"
      decimals="-3"
      id="Tc_WE9CK-jZa0mCyIUDyJs_cQ_27_4"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">-34000</ifrs-full:AccumulatedOtherComprehensiveIncome>
    <ifrs-full:AccumulatedOtherComprehensiveIncome
      contextRef="As_Of_9_30_2022_zuGVrjesE0WhwXSGmTqsgA"
      decimals="-3"
      id="Tc_SYMi5bAhE0ujZxuXArOgYA_27_6"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">-398000</ifrs-full:AccumulatedOtherComprehensiveIncome>
    <ifrs-full:Equity
      contextRef="As_Of_12_31_2021_kQVJTWPgRUeESxCd99xt9A"
      decimals="-3"
      id="Tc_fchTP3crrUaM5oMdHPn8Jg_28_4"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">688476000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="As_Of_9_30_2022_zuGVrjesE0WhwXSGmTqsgA"
      decimals="-3"
      id="Tc_xqsQxGCsC0uGl0jpHzIpBQ_28_6"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">624988000</ifrs-full:Equity>
    <ifrs-full:NoncurrentLeaseLiabilities
      contextRef="As_Of_12_31_2021_kQVJTWPgRUeESxCd99xt9A"
      decimals="-3"
      id="Tc_yGIgEZym9kCYDQPaiCiu2A_30_4"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">25423000</ifrs-full:NoncurrentLeaseLiabilities>
    <ifrs-full:NoncurrentLeaseLiabilities
      contextRef="As_Of_9_30_2022_zuGVrjesE0WhwXSGmTqsgA"
      decimals="-3"
      id="Tc__UM_2tMBXEOBBb0cJ_OunQ_30_6"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">36609000</ifrs-full:NoncurrentLeaseLiabilities>
    <ifrs-full:NoncurrentContractLiabilities
      contextRef="As_Of_12_31_2021_kQVJTWPgRUeESxCd99xt9A"
      decimals="-3"
      id="Tc_a6HwNXFwcUuGR-fQf60E_A_31_4"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">86345000</ifrs-full:NoncurrentContractLiabilities>
    <ifrs-full:NoncurrentContractLiabilities
      contextRef="As_Of_9_30_2022_zuGVrjesE0WhwXSGmTqsgA"
      decimals="-3"
      id="Tc_pj4tWOfockWszn0UCpc6OA_31_6"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">76279000</ifrs-full:NoncurrentContractLiabilities>
    <ifrs-full:OtherNoncurrentLiabilities
      contextRef="As_Of_12_31_2021_kQVJTWPgRUeESxCd99xt9A"
      decimals="-3"
      id="Tc_pHVRBbqZcEe_2aK8T7_Pqg_32_4"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">264000</ifrs-full:OtherNoncurrentLiabilities>
    <ifrs-full:OtherNoncurrentLiabilities
      contextRef="As_Of_9_30_2022_zuGVrjesE0WhwXSGmTqsgA"
      decimals="-3"
      id="Tc_2j5VScEcOUS60pD73SUusQ_32_6"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">284000</ifrs-full:OtherNoncurrentLiabilities>
    <ifrs-full:NoncurrentLiabilities
      contextRef="As_Of_12_31_2021_kQVJTWPgRUeESxCd99xt9A"
      decimals="-3"
      id="Tc_7SeJQVyZBUmHyA19cPqVlQ_33_4"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">112032000</ifrs-full:NoncurrentLiabilities>
    <ifrs-full:NoncurrentLiabilities
      contextRef="As_Of_9_30_2022_zuGVrjesE0WhwXSGmTqsgA"
      decimals="-3"
      id="Tc_ROxKG3X0FEaC3L5hyD-hLQ_33_6"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">113172000</ifrs-full:NoncurrentLiabilities>
    <ifrs-full:CurrentLeaseLiabilities
      contextRef="As_Of_12_31_2021_kQVJTWPgRUeESxCd99xt9A"
      decimals="-3"
      id="Tc_0Xv_P0kmmEm5967L41ITLg_35_4"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">3469000</ifrs-full:CurrentLeaseLiabilities>
    <ifrs-full:CurrentLeaseLiabilities
      contextRef="As_Of_9_30_2022_zuGVrjesE0WhwXSGmTqsgA"
      decimals="-3"
      id="Tc_wD99Opfxukiege2di5Od8A_35_6"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">4652000</ifrs-full:CurrentLeaseLiabilities>
    <ifrs-full:TradeAndOtherCurrentPayables
      contextRef="As_Of_12_31_2021_kQVJTWPgRUeESxCd99xt9A"
      decimals="-3"
      id="Tc_s6EZjOd_B02QHovJ1w7AtQ_36_4"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">127703000</ifrs-full:TradeAndOtherCurrentPayables>
    <ifrs-full:TradeAndOtherCurrentPayables
      contextRef="As_Of_9_30_2022_zuGVrjesE0WhwXSGmTqsgA"
      decimals="-3"
      id="Tc_XZfGo9lfBUWm3hAL1hXCMg_36_6"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">52608000</ifrs-full:TradeAndOtherCurrentPayables>
    <ifrs-full:OtherCurrentLiabilities
      contextRef="As_Of_12_31_2021_kQVJTWPgRUeESxCd99xt9A"
      decimals="-3"
      id="Tc_dwvtAfXy4kunnlz3yDzOqA_37_4"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">170073000</ifrs-full:OtherCurrentLiabilities>
    <ifrs-full:OtherCurrentLiabilities
      contextRef="As_Of_9_30_2022_zuGVrjesE0WhwXSGmTqsgA"
      decimals="-3"
      id="Tc_QBfczfDQMkiMVEz0MXSXJA_37_6"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">78967000</ifrs-full:OtherCurrentLiabilities>
    <ifrs-full:CurrentTaxLiabilities
      contextRef="As_Of_12_31_2021_kQVJTWPgRUeESxCd99xt9A"
      decimals="-3"
      id="Tc_AsuGALuNIUaIQhoGA65Q7A_38_4"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">739000</ifrs-full:CurrentTaxLiabilities>
    <ifrs-full:CurrentTaxLiabilities
      contextRef="As_Of_9_30_2022_zuGVrjesE0WhwXSGmTqsgA"
      decimals="-3"
      id="Tc_Wph6xEbkIkOQnpeWgkK-cA_38_6"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">587000</ifrs-full:CurrentTaxLiabilities>
    <ifrs-full:CurrentContractLiabilities
      contextRef="As_Of_12_31_2021_kQVJTWPgRUeESxCd99xt9A"
      decimals="-3"
      id="Tc_k8Dcg1aQZkGbymrbr1aQIA_39_4"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">55750000</ifrs-full:CurrentContractLiabilities>
    <ifrs-full:CurrentContractLiabilities
      contextRef="As_Of_9_30_2022_zuGVrjesE0WhwXSGmTqsgA"
      decimals="-3"
      id="Tc_uxA-bgfwUU2gVKILzMl5DQ_39_6"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">35538000</ifrs-full:CurrentContractLiabilities>
    <ifrs-full:CurrentLiabilities
      contextRef="As_Of_12_31_2021_kQVJTWPgRUeESxCd99xt9A"
      decimals="-3"
      id="Tc_Mqm9sF9V2k2YVeAasvGQeQ_40_4"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">357734000</ifrs-full:CurrentLiabilities>
    <ifrs-full:CurrentLiabilities
      contextRef="As_Of_9_30_2022_zuGVrjesE0WhwXSGmTqsgA"
      decimals="-3"
      id="Tc_5BItdrDRIkuYDYgORZJp_A_40_6"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">172352000</ifrs-full:CurrentLiabilities>
    <ifrs-full:Liabilities
      contextRef="As_Of_12_31_2021_kQVJTWPgRUeESxCd99xt9A"
      decimals="-3"
      id="Tc_5pS90K-OV0qvh03gjMRjkg_41_4"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">469766000</ifrs-full:Liabilities>
    <ifrs-full:Liabilities
      contextRef="As_Of_9_30_2022_zuGVrjesE0WhwXSGmTqsgA"
      decimals="-3"
      id="Tc_r6hNMsx9B0SBj87ZLWhPNg_41_6"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">285524000</ifrs-full:Liabilities>
    <ifrs-full:EquityAndLiabilities
      contextRef="As_Of_12_31_2021_kQVJTWPgRUeESxCd99xt9A"
      decimals="-3"
      id="Tc_T9A-nA1AbEi62f7NFalQIQ_42_4"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">1158242000</ifrs-full:EquityAndLiabilities>
    <ifrs-full:EquityAndLiabilities
      contextRef="As_Of_9_30_2022_zuGVrjesE0WhwXSGmTqsgA"
      decimals="-3"
      id="Tc_lX-ZMBAxeEuJKqanicf3RA_42_6"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">910512000</ifrs-full:EquityAndLiabilities>
    <ifrs-full:Equity
      contextRef="As_Of_12_31_2020_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_ZWlHBf5sd0u18E_i-Im1zQ"
      decimals="-3"
      id="Tc_I-Hjzpm6nkO5qRtZa3-3fQ_4_2"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">21655000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="As_Of_12_31_2020_ifrs-full_ComponentsOfEquityAxis_ifrs-full_CapitalReserveMember_VibTw9zPlkmYxEg1Vcd6Nw"
      decimals="-3"
      id="Tc_YqkhWmm9K0W-m9ua453ETQ_4_4"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">1334704000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="As_Of_12_31_2020_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember_ZhVYR0CYCU-n8fXSTddhVA"
      decimals="-3"
      id="Tc_G3nf4innJkiS4ITV-Zh-3A_4_8"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">-645069000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="As_Of_12_31_2020_ifrs-full_ComponentsOfEquityAxis_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_4SMzjwIAMEaHB7TnvYKL-g"
      decimals="-3"
      id="Tc_mn4dicwwZk-fHMHWWeqN6w_4_10"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">57000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="As_Of_12_31_2020_gDhEGYRPKEaVXa-xMDWqsw"
      decimals="-3"
      id="Tc_V1YzF3qFO0Wn1RUa_alIcg_4_12"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">711347000</ifrs-full:Equity>
    <ifrs-full:ProfitLoss
      contextRef="Duration_1_1_2021_To_9_30_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember_dCKGn2XnRk6SRLx6s50FAw"
      decimals="-3"
      id="Tc_AWh8TyTevE-QCCZ9gyKLQg_5_8"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">-409780000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="Duration_1_1_2021_To_9_30_2021_5RS16WkLc0uS2ug_bqUm-g"
      decimals="-3"
      id="Tc_FMymM68EkkaJzdy_Xboohg_5_12"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">-409780000</ifrs-full:ProfitLoss>
    <ifrs-full:OtherComprehensiveIncome
      contextRef="Duration_1_1_2021_To_9_30_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_N1rU63L0z0CKfWKFMPE8ug"
      decimals="-3"
      id="Tc_5O42z2Yzd0iZ6Yp-meUp9w_6_10"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">-62000</ifrs-full:OtherComprehensiveIncome>
    <ifrs-full:OtherComprehensiveIncome
      contextRef="Duration_1_1_2021_To_9_30_2021_5RS16WkLc0uS2ug_bqUm-g"
      decimals="-3"
      id="Tc_7gJ_xY80nU685EUoQxxjUw_6_12"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">-62000</ifrs-full:OtherComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="Duration_1_1_2021_To_9_30_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember_dCKGn2XnRk6SRLx6s50FAw"
      decimals="-3"
      id="Tc_FoNTPkmX7EipxdPsvy56LQ_7_8"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">-409780000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="Duration_1_1_2021_To_9_30_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_N1rU63L0z0CKfWKFMPE8ug"
      decimals="-3"
      id="Tc_YrEIjXGv2EKZW3x2ieF34w_7_10"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">-62000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="Duration_1_1_2021_To_9_30_2021_5RS16WkLc0uS2ug_bqUm-g"
      decimals="-3"
      id="Tc_-7IzO7p2dU-w8R9QQcsjtQ_7_12"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">-409842000</ifrs-full:ComprehensiveIncome>
    <cvac:ShareBasedPaymentExpenseIncl.DeferredTaxes
      contextRef="Duration_1_1_2021_To_9_30_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_CapitalReserveMember_cVl-lTMdZ0SyIz4MzbLhUA"
      decimals="3"
      id="Tc_qAEaYzp7xUypMUr2jlxjFA_8_4"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">12965000</cvac:ShareBasedPaymentExpenseIncl.DeferredTaxes>
    <cvac:ShareBasedPaymentExpenseIncl.DeferredTaxes
      contextRef="Duration_1_1_2021_To_9_30_2021_5RS16WkLc0uS2ug_bqUm-g"
      decimals="-3"
      id="Tc_b_APNKUWk0etC5j7wyuUlA_8_12"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">12965000</cvac:ShareBasedPaymentExpenseIncl.DeferredTaxes>
    <ifrs-full:IssueOfEquity
      contextRef="Duration_1_1_2021_To_9_30_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_H-Nfcg0EfkKBQso-1E13qw"
      decimals="-3"
      id="Tc_GoovFcUcaE6WMfaSl_FGkA_9_2"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">690000</ifrs-full:IssueOfEquity>
    <ifrs-full:IssueOfEquity
      contextRef="Duration_1_1_2021_To_9_30_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_CapitalReserveMember_cVl-lTMdZ0SyIz4MzbLhUA"
      decimals="-3"
      id="Tc_a8mTJiu6Y0K8RdqiL37QQw_9_4"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">403372000</ifrs-full:IssueOfEquity>
    <ifrs-full:IssueOfEquity
      contextRef="Duration_1_1_2021_To_9_30_2021_5RS16WkLc0uS2ug_bqUm-g"
      decimals="-3"
      id="Tc_1QlJEouhHUa8Laj2qLRwVA_9_12"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">404062000</ifrs-full:IssueOfEquity>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions
      contextRef="Duration_1_1_2021_To_9_30_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_H-Nfcg0EfkKBQso-1E13qw"
      decimals="-3"
      id="Tc_yN7CNqsDc0S2BtBNjyrG9A_10_2"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">101000</ifrs-full:IncreaseDecreaseThroughExerciseOfOptions>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions
      contextRef="Duration_1_1_2021_To_9_30_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_CapitalReserveMember_cVl-lTMdZ0SyIz4MzbLhUA"
      decimals="-3"
      id="Tc_aL-qvJpKfU-EP0cx3kujFg_10_4"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">2422000</ifrs-full:IncreaseDecreaseThroughExerciseOfOptions>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions
      contextRef="Duration_1_1_2021_To_9_30_2021_5RS16WkLc0uS2ug_bqUm-g"
      decimals="-3"
      id="Tc_fAkHbh1Ta0ePhjT8PFvOVA_10_12"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">2523000</ifrs-full:IncreaseDecreaseThroughExerciseOfOptions>
    <ifrs-full:IncreaseDecreaseThroughTreasuryShareTransactions
      contextRef="Duration_1_1_2021_To_9_30_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_CapitalReserveMember_cVl-lTMdZ0SyIz4MzbLhUA"
      decimals="-3"
      id="Tc_GpCt6S8dFkCttoUiyUifCA_11_4"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">-25550000</ifrs-full:IncreaseDecreaseThroughTreasuryShareTransactions>
    <ifrs-full:IncreaseDecreaseThroughTreasuryShareTransactions
      contextRef="Duration_1_1_2021_To_9_30_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_TreasurySharesMember_kiA0yBP5YEWvkTpVKfGscg"
      decimals="-3"
      id="Tc_VU0GXhwIrUapt2Tqt9LiYg_11_6"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">-211000</ifrs-full:IncreaseDecreaseThroughTreasuryShareTransactions>
    <ifrs-full:IncreaseDecreaseThroughTreasuryShareTransactions
      contextRef="Duration_1_1_2021_To_9_30_2021_5RS16WkLc0uS2ug_bqUm-g"
      decimals="-3"
      id="Tc_V0jVWNpIc0KtH3o_VPsSaQ_11_12"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">-25761000</ifrs-full:IncreaseDecreaseThroughTreasuryShareTransactions>
    <ifrs-full:Equity
      contextRef="As_Of_9_30_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_25XvQwjzSUOoEVBaH6bxAA"
      decimals="3"
      id="Tc_luszhGJq6UaQhrzW5d6ZdQ_12_2"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">22446000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="As_Of_9_30_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_CapitalReserveMember_uETolOLN8EO7z8AXUFUrdg"
      decimals="-3"
      id="Tc_uP_nfr9yxEeYnoDQIXYKmw_12_4"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">1727913000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="As_Of_9_30_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_TreasurySharesMember_1xV3xniJzEa6h2UaD4ZV8A"
      decimals="-3"
      id="Tc_-qGlGog0B0SquzOXFzEkSw_12_6"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">-211000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="As_Of_9_30_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember_S8HeFlbOnEmNPym3RRCQYQ"
      decimals="-3"
      id="Tc_SE9QIG3pkUagD2w21XHwRw_12_8"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">-1054849000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="As_Of_9_30_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_A7iYghLG40G30BtbFyy3Fw"
      decimals="-3"
      id="Tc_rOsuE9zt_0SRo4gf5Q1-Ow_12_10"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">-5000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="As_Of_9_30_2021_wVcf5oroJEG4KeEdh1LnEw"
      decimals="-3"
      id="Tc_RTuiTatZ90GUOBBhxiLlEQ_12_12"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">695294000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="As_Of_12_31_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_spYNfmXLlkKn0qRrA7DHrQ"
      decimals="-3"
      id="Tc_Nv_exT6awEeYItzkz8Sw7Q_4_2"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">22454000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="As_Of_12_31_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_CapitalReserveMember_hKeYNzP2pkyRPXTqS3GOeg"
      decimals="-3"
      id="Tc_ulE_scn0FE2c1-qDH8A2wA_4_4"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">1728658000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="As_Of_12_31_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_TreasurySharesMember_LnSXiw4SC0GJbguDola8gw"
      decimals="-3"
      id="Tc_ge7wi2owX0qWjMwOjMUAgA_4_6"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">-5817000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="As_Of_12_31_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember_obI4hBRbIk6bCNEX25ONyQ"
      decimals="-3"
      id="Tc_tiMYDjfacEqYtEbEP_wfNg_4_8"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">-1056785000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="As_Of_12_31_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_0fN-yvhfRke2bER127GqTw"
      decimals="-3"
      id="Tc_-FbwxWp2SUWI2eySPAySmQ_4_10"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">-34000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="As_Of_12_31_2021_kQVJTWPgRUeESxCd99xt9A"
      decimals="-3"
      id="Tc_HmS22zenmEWjtY1hSlUjpw_4_12"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">688476000</ifrs-full:Equity>
    <ifrs-full:ProfitLoss
      contextRef="Duration_1_1_2022_To_9_30_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember_LBd2SxQlf0unc-mzWThKow"
      decimals="-3"
      id="Tc_6bcm7RdWzE2uvXTnRW_2mA_5_8"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">-120245000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="Duration_1_1_2022_To_9_30_2022_GrYkE3mhHEiRA4fxgfABRg"
      decimals="-3"
      id="Tc_3mcy3rhEi0Ka5_Rx5DdGnw_5_12"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">-120245000</ifrs-full:ProfitLoss>
    <ifrs-full:OtherComprehensiveIncome
      contextRef="Duration_1_1_2022_To_9_30_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_pqJl73EEck6icL9CscAZ9w"
      decimals="-3"
      id="Tc_B9h4zoGrq0CgJItWKL9exg_6_10"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">-364000</ifrs-full:OtherComprehensiveIncome>
    <ifrs-full:OtherComprehensiveIncome
      contextRef="Duration_1_1_2022_To_9_30_2022_GrYkE3mhHEiRA4fxgfABRg"
      decimals="-3"
      id="Tc_28PpIX_Pf0-48Tz6klqz1A_6_12"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">-364000</ifrs-full:OtherComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="Duration_1_1_2022_To_9_30_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember_LBd2SxQlf0unc-mzWThKow"
      decimals="-3"
      id="Tc_YqTZJ2QfOUmSQu6UeOzA3A_7_8"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">-120245000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="Duration_1_1_2022_To_9_30_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_pqJl73EEck6icL9CscAZ9w"
      decimals="-3"
      id="Tc_JWS_PhearUqv9sRqv0e9Zw_7_10"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">-364000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="Duration_1_1_2022_To_9_30_2022_GrYkE3mhHEiRA4fxgfABRg"
      decimals="-3"
      id="Tc_3HhFk_ed00OV6VWTboheZw_7_12"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">-120609000</ifrs-full:ComprehensiveIncome>
    <cvac:ShareBasedPaymentExpenseIncl.DeferredTaxes
      contextRef="Duration_1_1_2022_To_9_30_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_CapitalReserveMember_g_0bQScme0WTxJwAia-iSA"
      decimals="-3"
      id="Tc_r4al29UrIU6jB5RcT__-pg_8_4"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">5372000</cvac:ShareBasedPaymentExpenseIncl.DeferredTaxes>
    <cvac:ShareBasedPaymentExpenseIncl.DeferredTaxes
      contextRef="Duration_1_1_2022_To_9_30_2022_GrYkE3mhHEiRA4fxgfABRg"
      decimals="-3"
      id="Tc_x-zXvNdChUW8kKBl5IeFTg_8_12"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">5372000</cvac:ShareBasedPaymentExpenseIncl.DeferredTaxes>
    <ifrs-full:IssueOfEquity
      contextRef="Duration_1_1_2022_To_9_30_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_jUcA_4Uo70GmthvPRsVfbA"
      decimals="-3"
      id="Tc_4rARNl1ZHkCZ_CTozndVzg_9_2"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">378000</ifrs-full:IssueOfEquity>
    <ifrs-full:IssueOfEquity
      contextRef="Duration_1_1_2022_To_9_30_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_CapitalReserveMember_g_0bQScme0WTxJwAia-iSA"
      decimals="-3"
      id="Tc_sg__P3Tk70663ygrdv0LmA_9_4"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">31948000</ifrs-full:IssueOfEquity>
    <ifrs-full:IssueOfEquity
      contextRef="Duration_1_1_2022_To_9_30_2022_GrYkE3mhHEiRA4fxgfABRg"
      decimals="-3"
      id="Tc_lsXtPqDS50acQrIyG6FQmw_9_12"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">32326000</ifrs-full:IssueOfEquity>
    <ifrs-full:IncreaseDecreaseThroughAcquisitionOfSubsidiary
      contextRef="Duration_1_1_2022_To_9_30_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_CapitalReserveMember_g_0bQScme0WTxJwAia-iSA"
      decimals="-3"
      id="Tc_ogm0HiYWEk-gr3G6FaJHCQ_10_4"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">18789000</ifrs-full:IncreaseDecreaseThroughAcquisitionOfSubsidiary>
    <ifrs-full:IncreaseDecreaseThroughAcquisitionOfSubsidiary
      contextRef="Duration_1_1_2022_To_9_30_2022_GrYkE3mhHEiRA4fxgfABRg"
      decimals="-3"
      id="Tc_oWS6MDw-BUuuENtPKn57wA_10_12"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">18789000</ifrs-full:IncreaseDecreaseThroughAcquisitionOfSubsidiary>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions
      contextRef="Duration_1_1_2022_To_9_30_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_jUcA_4Uo70GmthvPRsVfbA"
      decimals="-3"
      id="Tc_aLqXj2sd2kmpGdZI1nR5FA_11_2"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">2000</ifrs-full:IncreaseDecreaseThroughExerciseOfOptions>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions
      contextRef="Duration_1_1_2022_To_9_30_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_CapitalReserveMember_g_0bQScme0WTxJwAia-iSA"
      decimals="-3"
      id="Tc_PzqnNmbczkqF364CX8lADQ_11_4"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">-358000</ifrs-full:IncreaseDecreaseThroughExerciseOfOptions>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions
      contextRef="Duration_1_1_2022_To_9_30_2022_GrYkE3mhHEiRA4fxgfABRg"
      decimals="-3"
      id="Tc_QhaJaVcwO0iagnU2MnQikw_11_12"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">-356000</ifrs-full:IncreaseDecreaseThroughExerciseOfOptions>
    <cvac:SettlementOfShareBasedPaymentAwardsAmount
      contextRef="Duration_1_1_2022_To_9_30_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_CapitalReserveMember_g_0bQScme0WTxJwAia-iSA"
      decimals="-3"
      id="Tc_rkop_K6BqUWnuDY-merR4g_12_4"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">-3093000</cvac:SettlementOfShareBasedPaymentAwardsAmount>
    <cvac:SettlementOfShareBasedPaymentAwardsAmount
      contextRef="Duration_1_1_2022_To_9_30_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_TreasurySharesMember_hUbz0huuf0-lvXUrSj2p7w"
      decimals="-3"
      id="Tc_1bAki70g30SGyh-wPtjkzA_12_6"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">4083000</cvac:SettlementOfShareBasedPaymentAwardsAmount>
    <cvac:SettlementOfShareBasedPaymentAwardsAmount
      contextRef="Duration_1_1_2022_To_9_30_2022_GrYkE3mhHEiRA4fxgfABRg"
      decimals="-3"
      id="Tc_-pUG72WJhUOwMu3BubrE1g_12_12"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">990000</cvac:SettlementOfShareBasedPaymentAwardsAmount>
    <ifrs-full:Equity
      contextRef="As_Of_9_30_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_6KA0EJhWSE603b7Uov1rMg"
      decimals="-3"
      id="Tc_olDy6br2dEO5puNXtj-hvg_13_2"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">22834000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="As_Of_9_30_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_CapitalReserveMember_DnDn5AHz-0-rleJrp9WdNg"
      decimals="-3"
      id="Tc_RstJN_y07ESe0MbqIC2p8A_13_4"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">1781316000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="As_Of_9_30_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_TreasurySharesMember_QUC-XwhKoEK4nQE0wgA-OA"
      decimals="-3"
      id="Tc_UWFngXgLGUaUYRapbOuYxQ_13_6"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">-1734000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="As_Of_9_30_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember_hG_33slvv0iz_A0sabMEBA"
      decimals="-3"
      id="Tc_KEuAs4WVlEyw3VkpJGBHtg_13_8"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">-1177030000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="As_Of_9_30_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_pOxIHb_0lkKnDUS8JXZwmg"
      decimals="-3"
      id="Tc_1JofZsH1vkiw6ZWnypGw9Q_13_10"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">-398000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="As_Of_9_30_2022_zuGVrjesE0WhwXSGmTqsgA"
      decimals="-3"
      id="Tc_jWvnpH_jYkCFaGavX4lAfA_13_12"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">624988000</ifrs-full:Equity>
    <ifrs-full:ProfitLossBeforeTax
      contextRef="Duration_1_1_2021_To_9_30_2021_5RS16WkLc0uS2ug_bqUm-g"
      decimals="-3"
      id="Tc_Z_GszAbqSE2i4jnyrBW1gg_5_2"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">-407939000</ifrs-full:ProfitLossBeforeTax>
    <ifrs-full:ProfitLossBeforeTax
      contextRef="Duration_1_1_2022_To_9_30_2022_GrYkE3mhHEiRA4fxgfABRg"
      decimals="-3"
      id="Tc_JxbFS3xejk2iLjyLytsaug_5_4"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">-120405000</ifrs-full:ProfitLossBeforeTax>
    <ifrs-full:AdjustmentsForFinanceIncome
      contextRef="Duration_1_1_2021_To_9_30_2021_5RS16WkLc0uS2ug_bqUm-g"
      decimals="-3"
      id="Tc_fK9brRGD5EaK0Rc6Xi57wg_7_2"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">8828000</ifrs-full:AdjustmentsForFinanceIncome>
    <ifrs-full:AdjustmentsForFinanceIncome
      contextRef="Duration_1_1_2022_To_9_30_2022_GrYkE3mhHEiRA4fxgfABRg"
      decimals="-3"
      id="Tc_oE0h213itUKepZTJKC_peQ_7_4"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">10619000</ifrs-full:AdjustmentsForFinanceIncome>
    <ifrs-full:AdjustmentsForFinanceCosts
      contextRef="Duration_1_1_2021_To_9_30_2021_5RS16WkLc0uS2ug_bqUm-g"
      decimals="-3"
      id="Tc_J3uX8YvDsEWI1kvjawEh1A_8_2"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">10015000</ifrs-full:AdjustmentsForFinanceCosts>
    <ifrs-full:AdjustmentsForFinanceCosts
      contextRef="Duration_1_1_2022_To_9_30_2022_GrYkE3mhHEiRA4fxgfABRg"
      decimals="-3"
      id="Tc_PmP0LZKiqEWJKMAWDcdVPg_8_4"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">3077000</ifrs-full:AdjustmentsForFinanceCosts>
    <ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense
      contextRef="Duration_1_1_2021_To_9_30_2021_5RS16WkLc0uS2ug_bqUm-g"
      decimals="-3"
      id="Tc_m06kDl6pt0Cb2pY33lKF1A_9_2"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">11342000</ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense>
    <ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense
      contextRef="Duration_1_1_2022_To_9_30_2022_GrYkE3mhHEiRA4fxgfABRg"
      decimals="-3"
      id="Tc_c2wlyTa3k0uoMB3dBVQd_Q_9_4"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">23349000</ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense>
    <ifrs-full:AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets
      contextRef="Duration_1_1_2022_To_9_30_2022_GrYkE3mhHEiRA4fxgfABRg"
      decimals="-3"
      id="Tc_J4FwOHlCPk2nBPqI-EELMw_10_4"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">6428000</ifrs-full:AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets>
    <cvac:ImpairmentsOfInventoryAndPrepayments
      contextRef="Duration_1_1_2021_To_9_30_2021_5RS16WkLc0uS2ug_bqUm-g"
      decimals="-3"
      id="Tc_SlgQ7eWlGEq4EddwzdoScw_11_2"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">39142000</cvac:ImpairmentsOfInventoryAndPrepayments>
    <cvac:ImpairmentsOfInventoryAndPrepayments
      contextRef="Duration_1_1_2022_To_9_30_2022_GrYkE3mhHEiRA4fxgfABRg"
      decimals="-3"
      id="Tc_92k9qitDiEiFmzOt83Elrg_11_4"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">41295000</cvac:ImpairmentsOfInventoryAndPrepayments>
    <ifrs-full:AdjustmentsForSharebasedPayments
      contextRef="Duration_1_1_2021_To_9_30_2021_5RS16WkLc0uS2ug_bqUm-g"
      decimals="-3"
      id="Tc_ZxIVM1kuwkGekL6F5Zzr5A_12_2"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">11470000</ifrs-full:AdjustmentsForSharebasedPayments>
    <ifrs-full:AdjustmentsForSharebasedPayments
      contextRef="Duration_1_1_2022_To_9_30_2022_GrYkE3mhHEiRA4fxgfABRg"
      decimals="-3"
      id="Tc_DgUw-rBDY066ZMFkxK5LIQ_12_4"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">6455000</ifrs-full:AdjustmentsForSharebasedPayments>
    <cvac:AdjustmentsForNonCashIncomeFromReleaseOfProvisions
      contextRef="Duration_1_1_2022_To_9_30_2022_GrYkE3mhHEiRA4fxgfABRg"
      decimals="-3"
      id="Tc_8hqMQCKrf0Kak-XaUCZ_6Q_13_4"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">61102000</cvac:AdjustmentsForNonCashIncomeFromReleaseOfProvisions>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables
      contextRef="Duration_1_1_2021_To_9_30_2021_5RS16WkLc0uS2ug_bqUm-g"
      decimals="-3"
      id="Tc_ox7-zNcuUkK7hE1ttogxCQ_16_2"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">-7810000</ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables
      contextRef="Duration_1_1_2022_To_9_30_2022_GrYkE3mhHEiRA4fxgfABRg"
      decimals="-3"
      id="Tc_pGWMlrE3MUm_sRE83hw-Iw_16_4"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">12334000</ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInInventories
      contextRef="Duration_1_1_2021_To_9_30_2021_5RS16WkLc0uS2ug_bqUm-g"
      decimals="-3"
      id="Tc_tT7FWJO6cEiNOy7xpeLqWA_17_2"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">-143638000</ifrs-full:AdjustmentsForDecreaseIncreaseInInventories>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInInventories
      contextRef="Duration_1_1_2022_To_9_30_2022_GrYkE3mhHEiRA4fxgfABRg"
      decimals="-3"
      id="Tc_YjkpuBINkUexxaLiGrv6Pw_17_4"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">6996000</ifrs-full:AdjustmentsForDecreaseIncreaseInInventories>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInOtherAssets
      contextRef="Duration_1_1_2021_To_9_30_2021_5RS16WkLc0uS2ug_bqUm-g"
      decimals="-3"
      id="Tc_KXNreD45NU--xECiW7HI-Q_18_2"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">-214621000</ifrs-full:AdjustmentsForDecreaseIncreaseInOtherAssets>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInOtherAssets
      contextRef="Duration_1_1_2022_To_9_30_2022_GrYkE3mhHEiRA4fxgfABRg"
      decimals="-3"
      id="Tc_fH3VOhARtEyjFcYYzFJJ8g_18_4"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">-9724000</ifrs-full:AdjustmentsForDecreaseIncreaseInOtherAssets>
    <cvac:ReceiptsFromGovernmentGrantsClassifiedAsOperatingActivities
      contextRef="Duration_1_1_2021_To_9_30_2021_5RS16WkLc0uS2ug_bqUm-g"
      decimals="-3"
      id="Tc_bOAt-AZ2T0C84t4gMirYLA_19_2"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">38349000</cvac:ReceiptsFromGovernmentGrantsClassifiedAsOperatingActivities>
    <ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables
      contextRef="Duration_1_1_2021_To_9_30_2021_5RS16WkLc0uS2ug_bqUm-g"
      decimals="-3"
      id="Tc_DZ3cL22zMEW-KSv6Uhd3Qw_20_2"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">130022000</ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables>
    <ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables
      contextRef="Duration_1_1_2022_To_9_30_2022_GrYkE3mhHEiRA4fxgfABRg"
      decimals="-3"
      id="Tc_MpCM0RIcdkiJZqsfE_taZg_20_4"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">-131746000</ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables>
    <cvac:AdjustmentsForIncreaseDecreaseInOtherCurrentFinancialAndOtherLiabilities
      contextRef="Duration_1_1_2021_To_9_30_2021_5RS16WkLc0uS2ug_bqUm-g"
      decimals="-3"
      id="Tc_OGRU1X_WS0SZ-XiJi1lweQ_21_2"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">78000</cvac:AdjustmentsForIncreaseDecreaseInOtherCurrentFinancialAndOtherLiabilities>
    <ifrs-full:AdjustmentsForDeferredTaxExpense
      contextRef="Duration_1_1_2021_To_9_30_2021_5RS16WkLc0uS2ug_bqUm-g"
      decimals="-3"
      id="Tc_FpixhTlnWEqtzbT1zCQIew_22_2"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">-100000</ifrs-full:AdjustmentsForDeferredTaxExpense>
    <ifrs-full:AdjustmentsForDeferredTaxExpense
      contextRef="Duration_1_1_2022_To_9_30_2022_GrYkE3mhHEiRA4fxgfABRg"
      decimals="-3"
      id="Tc_R9OdQqHUtkCTzkqsiesb-w_22_4"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">49000</ifrs-full:AdjustmentsForDeferredTaxExpense>
    <ifrs-full:IncomeTaxesPaidClassifiedAsOperatingActivities
      contextRef="Duration_1_1_2021_To_9_30_2021_5RS16WkLc0uS2ug_bqUm-g"
      decimals="-3"
      id="Tc_Mt14MZbkZk29nIiGKCcxmQ_23_2"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">352000</ifrs-full:IncomeTaxesPaidClassifiedAsOperatingActivities>
    <ifrs-full:IncomeTaxesPaidClassifiedAsOperatingActivities
      contextRef="Duration_1_1_2022_To_9_30_2022_GrYkE3mhHEiRA4fxgfABRg"
      decimals="-3"
      id="Tc_EpnVRdDTskONrIT5tgAZFQ_23_4"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">152000</ifrs-full:IncomeTaxesPaidClassifiedAsOperatingActivities>
    <ifrs-full:InterestReceivedClassifiedAsOperatingActivities
      contextRef="Duration_1_1_2021_To_9_30_2021_5RS16WkLc0uS2ug_bqUm-g"
      decimals="-3"
      id="Tc_qBiN3ESb1UuByzMmRIsriA_24_2"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">25000</ifrs-full:InterestReceivedClassifiedAsOperatingActivities>
    <ifrs-full:InterestPaidClassifiedAsOperatingActivities
      contextRef="Duration_1_1_2021_To_9_30_2021_5RS16WkLc0uS2ug_bqUm-g"
      decimals="-3"
      id="Tc_9BdgEe5oO0S9_HoJhI1NlQ_25_2"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">7212000</ifrs-full:InterestPaidClassifiedAsOperatingActivities>
    <ifrs-full:InterestPaidClassifiedAsOperatingActivities
      contextRef="Duration_1_1_2022_To_9_30_2022_GrYkE3mhHEiRA4fxgfABRg"
      decimals="-3"
      id="Tc_UiWulRuAaUuvEq2uUZMmvw_25_4"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">3326000</ifrs-full:InterestPaidClassifiedAsOperatingActivities>
    <ifrs-full:CashFlowsFromUsedInOperatingActivities
      contextRef="Duration_1_1_2021_To_9_30_2021_5RS16WkLc0uS2ug_bqUm-g"
      decimals="-3"
      id="Tc_stgfy11zg0GOSRw6LIXt7A_26_2"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">-550057000</ifrs-full:CashFlowsFromUsedInOperatingActivities>
    <ifrs-full:CashFlowsFromUsedInOperatingActivities
      contextRef="Duration_1_1_2022_To_9_30_2022_GrYkE3mhHEiRA4fxgfABRg"
      decimals="-3"
      id="Tc_LypwqQUStUCh-RsqV46l6w_26_4"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">-237091000</ifrs-full:CashFlowsFromUsedInOperatingActivities>
    <ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities
      contextRef="Duration_1_1_2021_To_9_30_2021_5RS16WkLc0uS2ug_bqUm-g"
      decimals="-3"
      id="Tc_HkhjX2o-vUeFpaj_-i4JRw_29_2"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">91032000</ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities>
    <ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities
      contextRef="Duration_1_1_2022_To_9_30_2022_GrYkE3mhHEiRA4fxgfABRg"
      decimals="-3"
      id="Tc_o6wEzyccgkSUkB6fHPxbMw_29_4"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">67124000</ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities>
    <ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities
      contextRef="Duration_1_1_2021_To_9_30_2021_5RS16WkLc0uS2ug_bqUm-g"
      decimals="-3"
      id="Tc_or7YbEv2-UqMoBTMiaa_JQ_30_2"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">2273000</ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities>
    <ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities
      contextRef="Duration_1_1_2022_To_9_30_2022_GrYkE3mhHEiRA4fxgfABRg"
      decimals="-3"
      id="Tc_jpZq5_zyQU6DW_pKN8Vi4g_30_4"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">5435000</ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities>
    <ifrs-full:CashFlowsFromUsedInInvestingActivities
      contextRef="Duration_1_1_2021_To_9_30_2021_5RS16WkLc0uS2ug_bqUm-g"
      decimals="-3"
      id="Tc_qtBoZPn1cUWYdSqwtnZeGg_31_2"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">-93305000</ifrs-full:CashFlowsFromUsedInInvestingActivities>
    <ifrs-full:CashFlowsFromUsedInInvestingActivities
      contextRef="Duration_1_1_2022_To_9_30_2022_GrYkE3mhHEiRA4fxgfABRg"
      decimals="-3"
      id="Tc_I9klsE7wKkCy6mmq8eMXkg_31_4"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">-72559000</ifrs-full:CashFlowsFromUsedInInvestingActivities>
    <ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities
      contextRef="Duration_1_1_2021_To_9_30_2021_5RS16WkLc0uS2ug_bqUm-g"
      decimals="-3"
      id="Tc_fV_pmxBU7kOQGz5tUQvtZQ_34_2"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">2346000</ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities>
    <ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities
      contextRef="Duration_1_1_2022_To_9_30_2022_GrYkE3mhHEiRA4fxgfABRg"
      decimals="-3"
      id="Tc_xjrn4TSmUkuespb-OzGwDw_34_4"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">3087000</ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities>
    <cvac:ProceedFromIssuingOtherEquityInstrument
      contextRef="Duration_1_1_2021_To_9_30_2021_5RS16WkLc0uS2ug_bqUm-g"
      decimals="-3"
      id="Tc_BpcZbfO4WUCtqrhmRzyLyA_35_2"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">-23339000</cvac:ProceedFromIssuingOtherEquityInstrument>
    <cvac:ProceedFromIssuingOtherEquityInstrument
      contextRef="Duration_1_1_2022_To_9_30_2022_GrYkE3mhHEiRA4fxgfABRg"
      decimals="-3"
      id="Tc_Cfmnplm42EuGgpleobcTwA_35_4"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">991000</cvac:ProceedFromIssuingOtherEquityInstrument>
    <cvac:IfrsStockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2022_To_9_30_2022_GrYkE3mhHEiRA4fxgfABRg"
      decimals="-3"
      id="Tc_eFjwvf5dXUuGJ2Pu0sLUoA_36_4"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">-32325000</cvac:IfrsStockIssuedDuringPeriodValueNewIssues>
    <cvac:ProceedsOrPaymentsFromExerciseOfOptions
      contextRef="Duration_1_1_2022_To_9_30_2022_GrYkE3mhHEiRA4fxgfABRg"
      decimals="-3"
      id="Tc_6UnRoccNLU2gHyp1NGgbVQ_37_4"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">356000</cvac:ProceedsOrPaymentsFromExerciseOfOptions>
    <ifrs-full:ProceedsFromIssuingShares
      contextRef="Duration_1_1_2021_To_9_30_2021_5RS16WkLc0uS2ug_bqUm-g"
      decimals="-3"
      id="Tc_r2dchFuoeUmSP5j-wYMKcw_38_2"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">404164000</ifrs-full:ProceedsFromIssuingShares>
    <ifrs-full:CashFlowsFromUsedInFinancingActivities
      contextRef="Duration_1_1_2021_To_9_30_2021_5RS16WkLc0uS2ug_bqUm-g"
      decimals="-3"
      id="Tc_2B8x45D5q06kUr2zr5W34w_39_2"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">378479000</ifrs-full:CashFlowsFromUsedInFinancingActivities>
    <ifrs-full:CashFlowsFromUsedInFinancingActivities
      contextRef="Duration_1_1_2022_To_9_30_2022_GrYkE3mhHEiRA4fxgfABRg"
      decimals="-3"
      id="Tc_qKR_Hk-sREanL7cfjaTjDg_39_4"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">29873000</ifrs-full:CashFlowsFromUsedInFinancingActivities>
    <ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges
      contextRef="Duration_1_1_2021_To_9_30_2021_5RS16WkLc0uS2ug_bqUm-g"
      decimals="-3"
      id="Tc_h3wG5VEtL0qTZaWqOI9FhA_40_2"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">-264883000</ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges>
    <ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges
      contextRef="Duration_1_1_2022_To_9_30_2022_GrYkE3mhHEiRA4fxgfABRg"
      decimals="-3"
      id="Tc_-cMqb6yaS0e1qsGS17EEmg_40_4"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">-279777000</ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges>
    <ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents
      contextRef="Duration_1_1_2021_To_9_30_2021_5RS16WkLc0uS2ug_bqUm-g"
      decimals="-3"
      id="Tc_t88ahNfsbEuZ16KAjK8qEQ_41_2"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">3261000</ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents>
    <ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents
      contextRef="Duration_1_1_2022_To_9_30_2022_GrYkE3mhHEiRA4fxgfABRg"
      decimals="-3"
      id="Tc_vzgMkBuVYEGHlvOVYIYQ2A_41_4"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">9178000</ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents
      contextRef="As_Of_12_31_2020_gDhEGYRPKEaVXa-xMDWqsw"
      decimals="-3"
      id="Tc_QvGJymfzS0-o_U6_V8Bx2Q_42_2"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">1322593000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents
      contextRef="As_Of_12_31_2021_kQVJTWPgRUeESxCd99xt9A"
      decimals="-3"
      id="Tc_Hp_w-_Avmkqd1DOK0yy5XQ_42_4"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">811464000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents
      contextRef="As_Of_9_30_2021_wVcf5oroJEG4KeEdh1LnEw"
      decimals="-3"
      id="Tc_JXccl3zAGkGgyfSrvn2rng_43_2"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">1060971000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents
      contextRef="As_Of_9_30_2022_zuGVrjesE0WhwXSGmTqsgA"
      decimals="-3"
      id="Tc_RU2xFtiiEkmoQRDtpda2lA_43_4"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">540865000</ifrs-full:CashAndCashEquivalents>
    <cvac:CorporateInformationTextBlock
      contextRef="Duration_1_1_2022_To_9_30_2022_GrYkE3mhHEiRA4fxgfABRg"
      id="Tb_kkrBNcAzkUGEMZhWqPqL2w">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;1. Corporate Information&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;CureVac N.V. (&#x201c;CureVac&#x201d; or &#x201c;CV&#x201d; or the &#x201c;Company&#x201d;) is the parent company of CureVac Group (&#x201c;Group&#x201d;) and, along with its subsidiaries, is a global biopharmaceutical company developing a new class of transformative medicines based on the messenger ribonucleic acid (mRNA) that has the potential to improve the lives of people.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"&gt;The Company is incorporated in the Netherlands and is registered in the commercial register at the Netherlands Chamber of Commerce under 77798031. The Company&#x2019;s registered headquarters is Friedrich-Miescher-Strasse 15, 72076 Tuebingen, Germany. During 2021 until now, Dievini Hopp BioTech holding GmbH &amp;amp; Co. KG (dievini), which is an investment company dedicated to the support of companies in health and life sciences, is the largest shareholder of CureVac. Together with its related parties, dievini has held shares and voting rights in CureVac between appr. 45 &#x2013; 49 % during that period. dievini is thus considered to be the de facto parent of the Group. Dietmar Hopp, Daniel Hopp and Oliver Hopp are the ultimate controlling persons (of the main shareholders) of dievini, and, therefore, control the voting and investment decisions of dievini.&lt;/p&gt;</cvac:CorporateInformationTextBlock>
    <cvac:DisclosureOfBasisOfPreparationExplanatoryTextBlock
      contextRef="Duration_1_1_2022_To_9_30_2022_GrYkE3mhHEiRA4fxgfABRg"
      id="Tb_ilauMsZcMUmLn_tWPxvlmA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;2. Basis of preparation&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The interim condensed consolidated financial statements for the nine months ended September 30, 2022, have been prepared in accordance with IAS 34 Interim Financial Reporting.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The interim condensed consolidated financial statements do not include all the information and disclosures required in the annual consolidated financial statements and should be read in conjunction with the Group&#x2019;s annual consolidated financial statements as of December 31, 2021 and 2020 and for the three years in the period ended December 31, 2021. The interim condensed consolidated financial statements were authorized by the Management Board for presentation to the Supervisory Board on November 16, 2022. The Group&#x2019;s interim condensed consolidated financial statements are presented in Euros (&#x201c;EUR&#x201d;). Unless otherwise stated, amounts are rounded to thousands of Euros, except per share amounts.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;New standards, interpretations and amendments adopted by the Group&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The accounting policies adopted in the preparation of the interim condensed consolidated financial statements are consistent with those followed in the preparation of the Group&#x2019;s annual consolidated financial statements for the year ended December 31, 2021. The new and amended standards and interpretations applied for the first time as of January 1, 2022, as disclosed in the notes to the consolidated financial statements as of December 31, 2021, had no impact on the interim condensed consolidated financial statements of the Group as of and for the nine months ended September 30, 2022. The Group has not early adopted any standard, interpretation or amendment that has been issued but is not yet effective.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;"&gt;Impact of COVID-19 and the Russia-Ukraine Conflict&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;As the Group is currently devoting significant resources to the development of COVID vaccines, such development may impair the ability to timely progress other product candidates in clinical trials or into clinical trials from their current preclinical stage. In addition, enrollment in other programs may be delayed as a result of the COVID-19 pandemic and our focus on developing a COVID vaccine could have a negative impact on our progress on and associated revenue recognition from our non-COVID-19 collaborations. The partial disruption, even temporary, may negatively impact the Company&#x2019;s operations and overall business by delaying the progress of its clinical trials and preclinical studies. The Group&#x2019;s operations, including research and manufacturing, could also be disrupted due to the potential of the impact of staff absences as a result of self-isolation procedures or extended illness. However, the Group has taken a series of actions aimed at safeguarding its employees and business associates, including implementing a work-from-home policy for employees except for those related to its laboratory and production operations. The Group is running COVID antigen tests on a weekly basis for employees on the premises.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The ongoing military conflict between Russia and Ukraine has not and is not expected to have a material direct or indirect effect on the Group&#x2019;s operations or financial condition: however, the Group is currently operating in a period of economic uncertainty and capital markets disruption, which has been significantly impacted by geopolitical instability due to the ongoing military conflict between Russia and Ukraine. As a result of this instability and responding actions taken by the United States, Russia, EU, and other Foreign Governments, this may limit or prevent filing, prosecuting, and maintaining of patient applications in Russia. Government actions may also prevent maintenance of issued patents in Russia. These actions could result in abandonment or lapse of our patents or patent applications in Russia, resulting in partial or complete loss of patent rights in Russia. In addition, a decree was adopted by the Russian government in March 2022, allowing Russian companies and individuals to exploit, without consent or compensation, inventions owned by patentees that have citizenship or nationality in, are registered in, or have predominately primary place of business or profit-making activities in countries that Russia has deemed unfriendly. Consequently, we would not be able to prevent third parties from using our inventions in Russia or from selling or importing products made using our inventions in and into Russia. Accordingly, our competitive position may be impaired, and our business, financial condition, results of operations and prospects may be materially adversely affected.&lt;/p&gt;</cvac:DisclosureOfBasisOfPreparationExplanatoryTextBlock>
    <ifrs-full:DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory
      contextRef="Duration_1_1_2022_To_9_30_2022_GrYkE3mhHEiRA4fxgfABRg"
      id="Tb_Kd6tlYvOvUmVfRtzdfqmhQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The interim condensed consolidated financial statements for the nine months ended September 30, 2022, have been prepared in accordance with IAS 34 Interim Financial Reporting.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The interim condensed consolidated financial statements do not include all the information and disclosures required in the annual consolidated financial statements and should be read in conjunction with the Group&#x2019;s annual consolidated financial statements as of December 31, 2021 and 2020 and for the three years in the period ended December 31, 2021. The interim condensed consolidated financial statements were authorized by the Management Board for presentation to the Supervisory Board on November 16, 2022. The Group&#x2019;s interim condensed consolidated financial statements are presented in Euros (&#x201c;EUR&#x201d;). Unless otherwise stated, amounts are rounded to thousands of Euros, except per share amounts.&lt;/p&gt;</ifrs-full:DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory>
    <cvac:DescriptionOfAccountingPolicyOfNewStandardsInterpretationsAndAmendmentsAdoptedTextBlock
      contextRef="Duration_1_1_2022_To_9_30_2022_GrYkE3mhHEiRA4fxgfABRg"
      id="Tb_3SkoRjI0REuhB3iNkLToEQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;New standards, interpretations and amendments adopted by the Group&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The accounting policies adopted in the preparation of the interim condensed consolidated financial statements are consistent with those followed in the preparation of the Group&#x2019;s annual consolidated financial statements for the year ended December 31, 2021. The new and amended standards and interpretations applied for the first time as of January 1, 2022, as disclosed in the notes to the consolidated financial statements as of December 31, 2021, had no impact on the interim condensed consolidated financial statements of the Group as of and for the nine months ended September 30, 2022. The Group has not early adopted any standard, interpretation or amendment that has been issued but is not yet effective.&lt;/p&gt;</cvac:DescriptionOfAccountingPolicyOfNewStandardsInterpretationsAndAmendmentsAdoptedTextBlock>
    <cvac:DescriptionOfAccountingPolicyForCovid19ImpactExplanatory
      contextRef="Duration_1_1_2022_To_9_30_2022_GrYkE3mhHEiRA4fxgfABRg"
      id="Tb_42roIoWD5EKsZipFoBYKsg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;"&gt;Impact of COVID-19 and the Russia-Ukraine Conflict&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;As the Group is currently devoting significant resources to the development of COVID vaccines, such development may impair the ability to timely progress other product candidates in clinical trials or into clinical trials from their current preclinical stage. In addition, enrollment in other programs may be delayed as a result of the COVID-19 pandemic and our focus on developing a COVID vaccine could have a negative impact on our progress on and associated revenue recognition from our non-COVID-19 collaborations. The partial disruption, even temporary, may negatively impact the Company&#x2019;s operations and overall business by delaying the progress of its clinical trials and preclinical studies. The Group&#x2019;s operations, including research and manufacturing, could also be disrupted due to the potential of the impact of staff absences as a result of self-isolation procedures or extended illness. However, the Group has taken a series of actions aimed at safeguarding its employees and business associates, including implementing a work-from-home policy for employees except for those related to its laboratory and production operations. The Group is running COVID antigen tests on a weekly basis for employees on the premises.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The ongoing military conflict between Russia and Ukraine has not and is not expected to have a material direct or indirect effect on the Group&#x2019;s operations or financial condition: however, the Group is currently operating in a period of economic uncertainty and capital markets disruption, which has been significantly impacted by geopolitical instability due to the ongoing military conflict between Russia and Ukraine. As a result of this instability and responding actions taken by the United States, Russia, EU, and other Foreign Governments, this may limit or prevent filing, prosecuting, and maintaining of patient applications in Russia. Government actions may also prevent maintenance of issued patents in Russia. These actions could result in abandonment or lapse of our patents or patent applications in Russia, resulting in partial or complete loss of patent rights in Russia. In addition, a decree was adopted by the Russian government in March 2022, allowing Russian companies and individuals to exploit, without consent or compensation, inventions owned by patentees that have citizenship or nationality in, are registered in, or have predominately primary place of business or profit-making activities in countries that Russia has deemed unfriendly. Consequently, we would not be able to prevent third parties from using our inventions in Russia or from selling or importing products made using our inventions in and into Russia. Accordingly, our competitive position may be impaired, and our business, financial condition, results of operations and prospects may be materially adversely affected.&lt;/p&gt;</cvac:DescriptionOfAccountingPolicyForCovid19ImpactExplanatory>
    <ifrs-full:DisclosureOfNotesAndOtherExplanatoryInformationExplanatory
      contextRef="Duration_1_1_2022_To_9_30_2022_GrYkE3mhHEiRA4fxgfABRg"
      id="Tb_bjSJ6MGdEU6Hl25QLMb2og">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;3. Notes to the consolidated financial statements&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;3.1 Revenue from contract with customers&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Group recognized the following revenues:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:71.57%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:26.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Nine months ended September 30&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EUR k&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EUR k&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Belgium&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;GSK&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 49,621&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 52,746&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Germany&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Boehringer Ingelheim&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 9,990&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Switzerland&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;CRISPR&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 831&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,646&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Netherlands&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Genmab&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,323&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,339&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 61,765&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 55,731&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Of these revenues, all of which were recognized over time as part of collaboration agreements, during the nine months ended September 30, 2022 EUR 40,278k (September 30, 2021: EUR 49,878k) related to (i) delivery of research services combined with an IP license (recognized from the upfront payments as further illustrated in the table below) and the reaching of a milestone, (ii) EUR 1,413k (September 30, 2021: EUR 1,400k) related to delivery of products and (iii) EUR 14,040k (September 30, 2021: EUR 10,489k) were recognized from those research and development services considered distinct within the agreements.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Of the total revenues recognized, in the nine months ended September 30, 2022, EUR 52,746k in revenue was recognized under the collaboration agreements with GSK, entered into in July 2020, for the research, development, manufacturing and commercialization of mRNA-based vaccines and monoclonal antibodies targeting infectious disease pathogens (&#x201c;GSK I&#x201d;) and in April 2021 for research, development and manufacturing of next-generation mRNA vaccines targeting the original SARS-CoV-2 strain as well as emerging variants, including multivalent and monovalent approaches, such as CureVac&#x2019;s second-generation COVID-19 vaccine candidate, CV2CoV (&#x201c;GSK II&#x201d;). In the first quarter of 2022, the Company reached a development milestone of EUR 10,000k under the GSK I collaboration. Therefore, revenue for the nine months ending September 30, 2022, also includes recognition of EUR 5,789k of the milestone amount. The remaining EUR 4,211k of the milestone amount is deferred as contract liability and will be recognized into revenue through the estimated completion date of Phase 1 clinical trials, which represents the period of time during which CureVac is responsible for development as, subsequent to this period, GSK will be responsible for further development and commercialization. In the nine months ended September 30, 2021, revenue from the collaborations with GSK consisted of EUR 49,621k primarily recognized from the amortization of upfront and milestone payments.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"&gt;The Group has received upfront payments which were initially deferred and are subsequently recognized as revenue as the Group renders services over the performance period. Below is a summary of such payments and the related revenues recognized:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:16.3%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.63%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:16.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Upfront and&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Upfront and&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Revenue&#160;recognized from&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:16.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;milestones payments included&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;milestones payments included&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;upfront and milestones payments &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:16.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Upfront and milestone&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;in contract&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;in contract&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;for nine months ended&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;payments&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;liabilities&#160;at&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;liabilities&#160;at&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September 30,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:16.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Customer&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September 30, 2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December 31, 2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September 30, 2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:0pt;visibility:hidden;"&gt;&lt;td colspan="11" style="padding:0pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:16.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(EUR k)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(EUR k)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(EUR k)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:16.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;GSK  &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:18.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;EUR 205,000k (EUR 10,000k milestone payment included)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 135,494&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 106,788&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 38,315&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 38,705&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:16.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;CRISPR  &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:18.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;USD 3,000k (EUR 2,524k)*&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,239&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,007&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 232&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 232&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Boehringer Ingelheim&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:18.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;EUR 30,000k&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 9,990&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:16.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;Genmab  &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:18.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;USD 10,000k (EUR 8,937k)*&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,362&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,341&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,341&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:16.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.86%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 142,095&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.86%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 111,817&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 49,878&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 40,278&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-family:'Times New Roman','Times','serif';font-size:5.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"&gt;&lt;div style="background-color:#000000;height:1px;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"/&gt;&lt;/div&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;* Translated at the currency exchange rate prevailing on the transaction date.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"&gt;Contract balances:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:74.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December 31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September 30, &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EUR k&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EUR k&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Trade receivables&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 18,504&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,170&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:74.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Contract liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 142,095&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 111,817&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Trade receivables are non-interest bearing and are generally settled within 30 to 45 days. The contract liabilities contain upfront payments and milestone payments from Collaboration agreements.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;3.2 Cost of sales&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"&gt;The cost of sales consists of the following:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:71.11%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.66%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.66%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:27.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Nine months ended September 30,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EUR&#160;k&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EUR k&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Personnel&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (14,897)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (19,076)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Materials&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (13,945)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (48,962)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Third-party services&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (130,795)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (24,030)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Maintenance and lease&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (3,227)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1,479)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Amortization and depreciation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (2,944)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (9,757)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Other&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (2,369)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (688)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.66%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; (168,177)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.66%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; (103,992)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;During the nine months ended September 30, 2022, cost of sales mainly decreased compared to the same period of 2021 due to Third-Party Services having been higher last year for set-up activities for the CVnCoV production process. This decrease was partially offset by increased write-offs for raw materials amounting to EUR 41,295k, which were procured for manufacturing of products to sell to GSK that are now no longer expected to be purchased.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;3.3 Selling and distribution expenses&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:16.75pt;margin:0pt;"&gt;Selling and distribution expenses consist of the following:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:71.11%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:27.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Nine months ended September 30,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EUR&#160;k&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EUR k&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Personnel&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (943)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1,467)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Amortization and depreciation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (65)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (38)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Other&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.19%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (224)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (320)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.19%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; (1,232)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; (1,825)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Personnel expenses mainly include salary and salary-related expenses, during the nine months ended September 30, 2022 of EUR 1,315k (September 30, 2021: 777k) and share-based payment expense of EUR 152k (September 30, 2021: 166k).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;3.4 Research and development expenses&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"&gt;R&amp;amp;D expenses consists of the following:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:71.11%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:27.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Nine months ended September 30,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EUR&#160;k&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EUR k&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Materials&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (5,893)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (29,618)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Personnel&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (25,209)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (24,326)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Amortization and depreciation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (3,051)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (3,866)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Patents and fees to register a legal right&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (2,372)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (2,536)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Third-party services&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (246,185)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 28,525&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Maintenance and lease &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (291)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (789)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Other&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.19%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1,727)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (2,324)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.19%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; (284,728)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; (34,934)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;During the nine months ended September 30, 2022, research and development expenses decreased significantly in comparison to the same period of 2021, as the prior period was largely impacted by the Group&#xb4;s CVnCoV program in 2021. In the prior year, these expenses consist primarily of cost incurred to CROs involved in the CVnCoV development as well as materials used in the administration of clinical trials. As a result of more participants leaving the clinical trials, prior to completion, than originally estimated and of renegotiations of contracts with CROs, in the nine months ended September 30, 2022, the estimated outstanding costs for the CVnCoV studies decreased, due primarily to re-negotiations of contracts, and resulted in the reversal of provision for onerous contracts in the amount of EUR 36,769k. Additionally, a net gain for a change of estimate in the contract termination provisions resulted primarily from GSK taking over, from the Group, committed capacity at Novartis (see Note 3.6 for additional information). The net effect of these two events resulted in an overall gain within the Third-party services category.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Further, in the nine months ended on September 30, 2022, the balance was impacted by an increase in material consumed in research and development. As of September 30, 2022, the Group had no development expenditures which met the requirements for capitalization and thus none have been capitalized. In 2021, according to the terms and conditions of the grant from BMBF, the Group earned income (recognized in other operating income) for certain eligible expenses incurred for the COVID-19 vaccine development; refer to Note 3.6 for more information on amounts recognized from this grant in the nine months ended September 30, 2021.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Personnel expenses mainly include salary and salary-related expenses, during the nine months ended September 30, 2022 of EUR 23,846k (September 30, 2021: EUR 24,637k) and share-based payment expense of EUR 480k (September 30, 2021: 572k).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;3.5 General and administrative expenses&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"&gt;General and administrative expenses consist of the following:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:71.11%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.1%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.14%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:27.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Nine months ended September 30,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EUR&#160;k&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EUR k&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Personnel&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (30,039)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (27,971)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Maintenance and lease &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (2,106)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (4,614)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Third-party services&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (28,699)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (19,607)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Legal and other professional services&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (6,394)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (7,215)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Amortization and depreciation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (5,575)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (9,444)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Other&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (7,974)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (9,168)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.1%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; (80,787)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.14%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; (78,019)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Personnel expenses mainly include salary and salary-related expenses, during the nine months ended September 30, 2022, of EUR 21,621k (September 30, 2021: EUR 19,492k) and share-based payment expense of EUR 5,823k (September 30, 2021: EUR 10,547k). During the nine months ended September 30, 2022, third-party services expenses decreased, compared to the same period of 2021, mainly due to less consulting services. The &#x201c;Other&#x201d; mainly results from insurance costs related to the D&amp;amp;O insurance EUR 4,150k, (September 30, 2021: EUR 4,073k).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;3.6 Other operating income&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:71.11%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:27.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Nine months ended September 30,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EUR&#160;k&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EUR k&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Compensation for CMO/Material transfer&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 34,379&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Reimbursement claim&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 610&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Sale of equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 310&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Grants and other cost reimbursements from government agencies and similar bodies&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 64,307&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 377&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Other&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.19%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,439&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 225&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.19%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 66,746&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 35,901&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;In March 2022, CureVac AG and GlaxoSmithKline Biologicals SA amended and restated the 2020 GSK agreement and the GSK COVID Agreement in connection with GSK entering into a direct agreement with Novartis for use of Novartis as a CMO at the same time as CureVac exited its CMO agreement with Novartis. Additionally, under the restated agreement, CureVac is entitled to further compensation by GSK. The compensations mainly consist of a consideration for set-up activities undertaken by CureVac (EUR 20,500k) and for reimbursement of prepayments (EUR 12,000k), which were recognized in other operating income in the nine months ended September 30, 2022. As an additional result of this agreement, certain reserved capacity at Novartis was also taken over from the Group by GSK, which resulted in the reversal of provisions of EUR 25,059k which had been recognized as of December 31, 2021, and the recognition of a corresponding gain in research and development expenses in the nine months ended September 30, 2022 (see Note 3.4).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;During the nine months ended September 30, 2022 and 2021, income from grants with government agencies and similar bodies resulted from the following:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;German Federal Ministry of Education and Research (BMBF)&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;In 2020, the Company received a grant from BMBF to support the development of its COVID-19 vaccine candidate for which it was determined that the arrangement contained two components: a grant component (in the scope of IAS 20) and a supply component (in the scope of IFRS 15). The grant was terminated in 2021. With regard to the grant component, during the nine months ended September 30, 2021, the Group has recognized grant income in the amount of EUR 64,031k (September 30, 2022: EUR 0).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Coalition for Epidemic Preparedness Innovations (CEPI)&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;In January 2020, CureVac and CEPI entered into a collaboration to develop a vaccine against the new coronavirus SARS-CoV-2. The aim of the cooperation is to safely advance vaccine candidates into clinical testing as quickly as possible. The agreement builds upon the existing partnership between CureVac and CEPI to develop a rapid-response vaccine platform and included additional initial funding of up to USD 8,300k. In May 2020, CEPI increased its grant award to the Group for SARS-CoV-2 vaccine development to up to USD 15,300k.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;For the nine months ended September 30, 2022, CureVac recognized the reimbursement by CEPI of approved expenses of EUR 26k (September 30, 2021: EUR 30k) as &#x201c;other operating income&#x201d;. As of September 30, 2022, EUR 1,263k in grant funds received have been deferred and are presented within other liabilities (December 31, 2021: EUR 1,288k). &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Bill &amp;amp; Melinda Gates Foundation (BMGF)&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"&gt;For the nine months ended September 30, 2022, CureVac recognized EUR 132k (September 30, 2021: EUR 246k) from the amortization of the grants on a straight-line basis into other operating income. As of September 30, 2022, EUR 1,747k in grant funds received have been deferred and presented within other liabilities (December 31, 2021: EUR 1,879k). &lt;/p&gt;</ifrs-full:DisclosureOfNotesAndOtherExplanatoryInformationExplanatory>
    <ifrs-full:DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory
      contextRef="Duration_1_1_2022_To_9_30_2022_GrYkE3mhHEiRA4fxgfABRg"
      id="Tb_ElnYnKEQQUeTq9cHvgBPRQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:71.57%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:26.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Nine months ended September 30&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EUR k&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EUR k&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Belgium&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;GSK&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 49,621&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 52,746&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Germany&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Boehringer Ingelheim&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 9,990&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Switzerland&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;CRISPR&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 831&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,646&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Netherlands&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Genmab&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,323&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,339&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 61,765&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 55,731&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</ifrs-full:DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory>
    <ifrs-full:RevenueFromContractsWithCustomers
      contextRef="Duration_1_1_2021_To_9_30_2021_ifrs-full_GeographicalAreasAxis_country_BE_ifrs-full_MajorCustomersAxis_cvac_GlaxosmithklineMember_eVwoaEVfAUKlb5HYdjxaQw"
      decimals="-3"
      id="Tc_1Sv9apT_I0mNENmMI8rVQw_5_2"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">49621000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers
      contextRef="Duration_1_1_2022_To_9_30_2022_ifrs-full_GeographicalAreasAxis_country_BE_ifrs-full_MajorCustomersAxis_cvac_GlaxosmithklineMember_shjcQ9gwY0mzJMJm_89JCQ"
      decimals="-3"
      id="Tc_-F5nKDg8MEyeheFjLeSi1g_5_4"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">52746000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers
      contextRef="Duration_1_1_2021_To_9_30_2021_ifrs-full_GeographicalAreasAxis_country_DE_ifrs-full_MajorCustomersAxis_cvac_BoehringerIngelheimMember_GLkAvVsjY0iIfdOVguCCiQ"
      decimals="-3"
      id="Tc_8LlaAZ_ZbEy9v8pfTZ3NHA_7_2"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">9990000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers
      contextRef="Duration_1_1_2021_To_9_30_2021_ifrs-full_GeographicalAreasAxis_country_CH_ifrs-full_MajorCustomersAxis_cvac_CrisprMember_H5jO5eGbWE6vAapf30CSfw"
      decimals="-3"
      id="Tc_7XVtUGEh_ESHmVtV57u2hg_9_2"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">831000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers
      contextRef="Duration_1_1_2022_To_9_30_2022_ifrs-full_GeographicalAreasAxis_country_CH_ifrs-full_MajorCustomersAxis_cvac_CrisprMember_HR3g4DsNXU-KQMdhdtvSTQ"
      decimals="-3"
      id="Tc_LWQy97oUE0G8h-5ZuN9oJA_9_4"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">1646000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers
      contextRef="Duration_1_1_2021_To_9_30_2021_ifrs-full_GeographicalAreasAxis_country_NL_ifrs-full_MajorCustomersAxis_cvac_GenmabMember_SSbVK8fnGE6ChnWCps9ySQ"
      decimals="-3"
      id="Tc_yBWmyTjzo02-nmoeygNF8A_11_2"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">1323000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers
      contextRef="Duration_1_1_2022_To_9_30_2022_ifrs-full_GeographicalAreasAxis_country_NL_ifrs-full_MajorCustomersAxis_cvac_GenmabMember_7itxWD0v3UC7-_TEXbaZxQ"
      decimals="-3"
      id="Tc_QpRWgC65H0uD41OYdLKizg_11_4"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">1339000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers
      contextRef="Duration_1_1_2021_To_9_30_2021_5RS16WkLc0uS2ug_bqUm-g"
      decimals="-3"
      id="Tc_bPOmPYl4_E6KHw234sz15g_12_2"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">61765000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers
      contextRef="Duration_1_1_2022_To_9_30_2022_GrYkE3mhHEiRA4fxgfABRg"
      decimals="-3"
      id="Tc_pXuvneSZoUa4H-bJb4v_eA_12_4"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">55731000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers
      contextRef="Duration_1_1_2022_To_9_30_2022_ifrs-full_ProductsAndServicesAxis_cvac_ResearchServicesCombinedWithIpLicenseMember_JmxbMa7EOkGM2UmzZvcaYA"
      decimals="-3"
      id="Narr_mvA1F8EEtk-DLVqhePwwbQ"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">40278000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers
      contextRef="Duration_1_1_2021_To_9_30_2021_ifrs-full_ProductsAndServicesAxis_cvac_ResearchServicesCombinedWithIpLicenseMember_w9Lhj-1fbUylhw2h1TnuCA"
      decimals="-3"
      id="Narr_Nblu8ZU1rEyznyBAn43pgg"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">49878000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers
      contextRef="Duration_1_1_2022_To_9_30_2022_ifrs-full_ProductsAndServicesAxis_cvac_IfrsProductMember_ykNdeTyQ_U6ifIHGuP-a8Q"
      decimals="-3"
      id="Narr_OEt_7C2_jkiq08NYdAl2rw"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">1413000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers
      contextRef="Duration_1_1_2021_To_9_30_2021_ifrs-full_ProductsAndServicesAxis_cvac_IfrsProductMember_WafA2PzZ0kOs4a0LCkTNpg"
      decimals="-3"
      id="Narr_KsHoDduexUOH7ZmyyVNhqQ"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">1400000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers
      contextRef="Duration_1_1_2022_To_9_30_2022_ifrs-full_ProductsAndServicesAxis_cvac_ResearchAndDevelopmentServicesMember_xgWEhIWVP0aG8Oi39YdQdg"
      decimals="-3"
      id="Narr_cR74iiZIl0K09OreMQyIXw"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">14040000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers
      contextRef="Duration_1_1_2021_To_9_30_2021_ifrs-full_ProductsAndServicesAxis_cvac_ResearchAndDevelopmentServicesMember_FqOeAMlR502ph1Wxt4STrA"
      decimals="-3"
      id="Narr_tPJZEdI9wkuR7khqgDA2Ag"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">10489000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers
      contextRef="Duration_1_1_2022_To_9_30_2022_ifrs-full_GeographicalAreasAxis_country_BE_ifrs-full_MajorCustomersAxis_cvac_GlaxosmithklineMember_shjcQ9gwY0mzJMJm_89JCQ"
      decimals="-3"
      id="Narr_hcHmR0pVEE2qD1vriiDFKA"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">52746000</ifrs-full:RevenueFromContractsWithCustomers>
    <cvac:AdditionalDevelopmentMilestonePaymentsReceived
      contextRef="Duration_1_1_2022_To_9_30_2022_ifrs-full_ProductsAndServicesAxis_cvac_MilestoneRevenuesMember_H4PqpAjQEkuxcZ00nka3Eg"
      decimals="-3"
      id="Narr_CLTjMLqZrUaRYUa5e_mS2w"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">10000000</cvac:AdditionalDevelopmentMilestonePaymentsReceived>
    <ifrs-full:RevenueFromContractsWithCustomers
      contextRef="Duration_1_1_2022_To_9_30_2022_ifrs-full_ProductsAndServicesAxis_cvac_MilestoneRevenuesMember_H4PqpAjQEkuxcZ00nka3Eg"
      decimals="-3"
      id="Narr_9ZlXWG4KnUK5hmCqiCdbRQ"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">5789000</ifrs-full:RevenueFromContractsWithCustomers>
    <cvac:IfrsDevelopmentMilestonePaymentIncludedInContractLiabilities
      contextRef="As_Of_9_30_2022_ifrs-full_ProductsAndServicesAxis_cvac_MilestoneRevenuesMember_f7JkTbic-Uq7GDa0pAVbjA"
      decimals="-3"
      id="Narr_YHe4uvtJw06PHukRIx-1EA"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">4211000</cvac:IfrsDevelopmentMilestonePaymentIncludedInContractLiabilities>
    <ifrs-full:RevenueFromContractsWithCustomers
      contextRef="Duration_1_1_2021_To_9_30_2021_ifrs-full_GeographicalAreasAxis_country_BE_ifrs-full_MajorCustomersAxis_cvac_GlaxosmithklineMember_eVwoaEVfAUKlb5HYdjxaQw"
      decimals="-3"
      id="Narr_QYIri_3M_0Cw3DBguGMhkQ"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">49621000</ifrs-full:RevenueFromContractsWithCustomers>
    <cvac:DisclosureOfUpfrontPaymentsAndRelatedRevenuesRecognizedExplanatory
      contextRef="Duration_1_1_2022_To_9_30_2022_GrYkE3mhHEiRA4fxgfABRg"
      id="Tb_RTF5Lo-bHEmm3DT1JOJvJQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:16.3%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.63%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:16.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Upfront and&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Upfront and&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Revenue&#160;recognized from&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:16.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;milestones payments included&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;milestones payments included&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;upfront and milestones payments &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:16.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Upfront and milestone&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;in contract&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;in contract&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;for nine months ended&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;payments&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;liabilities&#160;at&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;liabilities&#160;at&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September 30,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:16.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Customer&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September 30, 2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December 31, 2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September 30, 2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:0pt;visibility:hidden;"&gt;&lt;td colspan="11" style="padding:0pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:16.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(EUR k)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(EUR k)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(EUR k)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:16.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;GSK  &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:18.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;EUR 205,000k (EUR 10,000k milestone payment included)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 135,494&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 106,788&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 38,315&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 38,705&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:16.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;CRISPR  &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:18.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;USD 3,000k (EUR 2,524k)*&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,239&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,007&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 232&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 232&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Boehringer Ingelheim&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:18.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;EUR 30,000k&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 9,990&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:16.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;Genmab  &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:18.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;USD 10,000k (EUR 8,937k)*&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,362&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,341&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,341&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:16.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.86%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 142,095&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.86%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 111,817&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 49,878&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 40,278&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-family:'Times New Roman','Times','serif';font-size:5.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"&gt;&lt;div style="background-color:#000000;height:1px;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"/&gt;&lt;/div&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;* Translated at the currency exchange rate prevailing on the transaction date.&lt;/p&gt;</cvac:DisclosureOfUpfrontPaymentsAndRelatedRevenuesRecognizedExplanatory>
    <cvac:UpfrontPaymentsReceivedOrReceivable
      contextRef="As_Of_9_30_2022_ifrs-full_MajorCustomersAxis_cvac_GlaxosmithklineMember_ifrs-full_ProductsAndServicesAxis_cvac_ResearchServicesCombinedWithIpLicenseMember_0AbiwODFUEmyJLdIgNcTfg"
      decimals="-3"
      id="Narr_eB90QURYOESOAwdocVxhBg"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">205000000</cvac:UpfrontPaymentsReceivedOrReceivable>
    <cvac:UpfrontPaymentsReceivedOrReceivable
      contextRef="As_Of_9_30_2022_ifrs-full_MajorCustomersAxis_cvac_GlaxosmithklineMember_ifrs-full_ProductsAndServicesAxis_cvac_ResearchServicesCombinedWithIpLicenseMember_ifrs-full_RangeAxis_ifrs-full_BottomOfRangeMember_7jTi8_0PcEeLFJbzx_wjrQ"
      decimals="-3"
      id="Narr_rsY1v8iI0Uu5-xh_m4VQdQ"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">10000000</cvac:UpfrontPaymentsReceivedOrReceivable>
    <cvac:UpfrontPaymentsIncludedInContractLiabilities
      contextRef="As_Of_12_31_2021_ifrs-full_MajorCustomersAxis_cvac_GlaxosmithklineMember_ifrs-full_ProductsAndServicesAxis_cvac_ResearchServicesCombinedWithIpLicenseMember_PJOVtNdDh0SBq-RS-4qaSw"
      decimals="-3"
      id="Tc_cMQO7DIYi0WNxVh2iuVr8Q_7_4"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">135494000</cvac:UpfrontPaymentsIncludedInContractLiabilities>
    <cvac:UpfrontPaymentsIncludedInContractLiabilities
      contextRef="As_Of_9_30_2022_ifrs-full_MajorCustomersAxis_cvac_GlaxosmithklineMember_ifrs-full_ProductsAndServicesAxis_cvac_ResearchServicesCombinedWithIpLicenseMember_0AbiwODFUEmyJLdIgNcTfg"
      decimals="-3"
      id="Tc_EVAYlKDkoE63TlHH8Y1svg_7_6"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">106788000</cvac:UpfrontPaymentsIncludedInContractLiabilities>
    <ifrs-full:RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod
      contextRef="Duration_1_1_2021_To_9_30_2021_ifrs-full_MajorCustomersAxis_cvac_GlaxosmithklineMember_ifrs-full_ProductsAndServicesAxis_cvac_ResearchServicesCombinedWithIpLicenseMember_xJi4YZnmz0Wq6SdDwRVxBA"
      decimals="-3"
      id="Tc_j1OjYsef9kCuJ8EdYJY6MQ_7_8"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">38315000</ifrs-full:RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod>
    <ifrs-full:RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod
      contextRef="Duration_1_1_2022_To_9_30_2022_ifrs-full_MajorCustomersAxis_cvac_GlaxosmithklineMember_ifrs-full_ProductsAndServicesAxis_cvac_ResearchServicesCombinedWithIpLicenseMember_CAXgAqyHKkO0WaEKjGrFrA"
      decimals="-3"
      id="Tc_S-BE3KbvxEGu67CsoWn69w_7_10"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">38705000</ifrs-full:RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod>
    <cvac:UpfrontPaymentsReceivedOrReceivable
      contextRef="As_Of_9_30_2022_ifrs-full_MajorCustomersAxis_cvac_CrisprMember_ifrs-full_ProductsAndServicesAxis_cvac_ResearchServicesCombinedWithIpLicenseMember_N0CWO_7EbUeynG_1C6XLwA"
      decimals="-3"
      id="Narr_LQ7WKbf_FECawBGoTwwCvg"
      unitRef="Unit_Standard_USD_q8NNp4TBfUC9XydcVDSrpA">3000000</cvac:UpfrontPaymentsReceivedOrReceivable>
    <cvac:UpfrontPaymentsReceivedOrReceivable
      contextRef="As_Of_9_30_2022_ifrs-full_MajorCustomersAxis_cvac_CrisprMember_ifrs-full_ProductsAndServicesAxis_cvac_ResearchServicesCombinedWithIpLicenseMember_N0CWO_7EbUeynG_1C6XLwA"
      decimals="-3"
      id="Narr_XmVBfDeLNE6NoRjaKw2RTQ"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">2524000</cvac:UpfrontPaymentsReceivedOrReceivable>
    <cvac:UpfrontPaymentsIncludedInContractLiabilities
      contextRef="As_Of_12_31_2021_ifrs-full_MajorCustomersAxis_cvac_CrisprMember_ifrs-full_ProductsAndServicesAxis_cvac_ResearchServicesCombinedWithIpLicenseMember_lhcV_FVDUEqAgO5rXoI-qw"
      decimals="-3"
      id="Tc_hVg6pXSd00KJuhCI_VHhKA_8_4"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">1239000</cvac:UpfrontPaymentsIncludedInContractLiabilities>
    <cvac:UpfrontPaymentsIncludedInContractLiabilities
      contextRef="As_Of_9_30_2022_ifrs-full_MajorCustomersAxis_cvac_CrisprMember_ifrs-full_ProductsAndServicesAxis_cvac_ResearchServicesCombinedWithIpLicenseMember_N0CWO_7EbUeynG_1C6XLwA"
      decimals="-3"
      id="Tc_6GlJJREVkE6UJlyVzamPUw_8_6"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">1007000</cvac:UpfrontPaymentsIncludedInContractLiabilities>
    <ifrs-full:RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod
      contextRef="Duration_1_1_2021_To_9_30_2021_ifrs-full_MajorCustomersAxis_cvac_CrisprMember_ifrs-full_ProductsAndServicesAxis_cvac_ResearchServicesCombinedWithIpLicenseMember_PH-MVv0gkEKmWXldRQgZBA"
      decimals="-3"
      id="Tc_SVrvU0Aia0-3JuWayn09BA_8_8"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">232000</ifrs-full:RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod>
    <ifrs-full:RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod
      contextRef="Duration_1_1_2022_To_9_30_2022_ifrs-full_MajorCustomersAxis_cvac_CrisprMember_ifrs-full_ProductsAndServicesAxis_cvac_ResearchServicesCombinedWithIpLicenseMember_khvMaOJtOkK4x-wZSKmcOQ"
      decimals="-3"
      id="Tc_g_nI_pJ74EOEJPqXgFgLGw_8_10"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">232000</ifrs-full:RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod>
    <cvac:UpfrontPaymentsReceivedOrReceivable
      contextRef="As_Of_9_30_2022_ifrs-full_MajorCustomersAxis_cvac_BoehringerIngelheimMember_ifrs-full_ProductsAndServicesAxis_cvac_ResearchServicesCombinedWithIpLicenseMember_k3sZmRwsjkSNWebj2XPVlg"
      decimals="-3"
      id="Narr_VRen4LrdqUO2yXzAkjlEVA"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">30000000</cvac:UpfrontPaymentsReceivedOrReceivable>
    <ifrs-full:RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod
      contextRef="Duration_1_1_2021_To_9_30_2021_ifrs-full_MajorCustomersAxis_cvac_BoehringerIngelheimMember_ifrs-full_ProductsAndServicesAxis_cvac_ResearchServicesCombinedWithIpLicenseMember_2uKPlzeQMkesCPFChkjwGg"
      decimals="-3"
      id="Tc_D4vXE1YdakWAfJh79NNmkQ_9_8"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">9990000</ifrs-full:RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod>
    <cvac:UpfrontPaymentsReceivedOrReceivable
      contextRef="As_Of_9_30_2022_ifrs-full_MajorCustomersAxis_cvac_GenmabMember_ifrs-full_ProductsAndServicesAxis_cvac_ResearchServicesCombinedWithIpLicenseMember_yfdi7QFOIken6nwnl1VeyA"
      decimals="-3"
      id="Narr_DOyymkFjjEmdEvaYrE0-VQ"
      unitRef="Unit_Standard_USD_q8NNp4TBfUC9XydcVDSrpA">10000000</cvac:UpfrontPaymentsReceivedOrReceivable>
    <cvac:UpfrontPaymentsReceivedOrReceivable
      contextRef="As_Of_9_30_2022_ifrs-full_MajorCustomersAxis_cvac_GenmabMember_ifrs-full_ProductsAndServicesAxis_cvac_ResearchServicesCombinedWithIpLicenseMember_yfdi7QFOIken6nwnl1VeyA"
      decimals="-3"
      id="Narr_H9IZE8nyakyx1GI-UOMKZA"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">8937000</cvac:UpfrontPaymentsReceivedOrReceivable>
    <cvac:UpfrontPaymentsIncludedInContractLiabilities
      contextRef="As_Of_12_31_2021_ifrs-full_MajorCustomersAxis_cvac_GenmabMember_ifrs-full_ProductsAndServicesAxis_cvac_ResearchServicesCombinedWithIpLicenseMember_g3gSYGvJiUWtJe5m702osQ"
      decimals="-3"
      id="Tc_5kd5IemQvECXpYRJMrdUAw_10_4"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">5362000</cvac:UpfrontPaymentsIncludedInContractLiabilities>
    <cvac:UpfrontPaymentsIncludedInContractLiabilities
      contextRef="As_Of_9_30_2022_ifrs-full_MajorCustomersAxis_cvac_GenmabMember_ifrs-full_ProductsAndServicesAxis_cvac_ResearchServicesCombinedWithIpLicenseMember_yfdi7QFOIken6nwnl1VeyA"
      decimals="-3"
      id="Tc_7DErYQzrRki-7j3gb5KDSQ_10_6"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">4022000</cvac:UpfrontPaymentsIncludedInContractLiabilities>
    <ifrs-full:RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod
      contextRef="Duration_1_1_2021_To_9_30_2021_ifrs-full_MajorCustomersAxis_cvac_GenmabMember_ifrs-full_ProductsAndServicesAxis_cvac_ResearchServicesCombinedWithIpLicenseMember_awc6N7gG0USv7ZRK4TKDjw"
      decimals="-3"
      id="Tc_TtoNlvpcsUiv01uaCs6wEg_10_8"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">1341000</ifrs-full:RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod>
    <ifrs-full:RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod
      contextRef="Duration_1_1_2022_To_9_30_2022_ifrs-full_MajorCustomersAxis_cvac_GenmabMember_ifrs-full_ProductsAndServicesAxis_cvac_ResearchServicesCombinedWithIpLicenseMember_72wIU7VnlkKKba3jsZpOBg"
      decimals="-3"
      id="Tc_twhOFT6kNk6oWGn87kdwmQ_10_10"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">1341000</ifrs-full:RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod>
    <cvac:UpfrontPaymentsIncludedInContractLiabilities
      contextRef="As_Of_12_31_2021_ifrs-full_ProductsAndServicesAxis_cvac_ResearchServicesCombinedWithIpLicenseMember_SuxVutvjF02TZJEYT5xAUg"
      decimals="-3"
      id="Tc__-f4KpHHMk-c2XMPaDSThA_11_4"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">142095000</cvac:UpfrontPaymentsIncludedInContractLiabilities>
    <cvac:UpfrontPaymentsIncludedInContractLiabilities
      contextRef="As_Of_9_30_2022_ifrs-full_ProductsAndServicesAxis_cvac_ResearchServicesCombinedWithIpLicenseMember_LDTxHzpQykydqGAuWhIjZQ"
      decimals="-3"
      id="Tc_1OSDc_2lFkOGJP7H568UXg_11_6"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">111817000</cvac:UpfrontPaymentsIncludedInContractLiabilities>
    <ifrs-full:RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod
      contextRef="Duration_1_1_2021_To_9_30_2021_ifrs-full_ProductsAndServicesAxis_cvac_ResearchServicesCombinedWithIpLicenseMember_w9Lhj-1fbUylhw2h1TnuCA"
      decimals="-3"
      id="Tc_i4yy5FLZDESpa8g3v2qPHg_11_8"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">49878000</ifrs-full:RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod>
    <ifrs-full:RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod
      contextRef="Duration_1_1_2022_To_9_30_2022_ifrs-full_ProductsAndServicesAxis_cvac_ResearchServicesCombinedWithIpLicenseMember_JmxbMa7EOkGM2UmzZvcaYA"
      decimals="-3"
      id="Tc_ECM65wz65kGpWNYhaE_LAQ_11_10"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">40278000</ifrs-full:RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod>
    <ifrs-full:ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory
      contextRef="Duration_1_1_2022_To_9_30_2022_GrYkE3mhHEiRA4fxgfABRg"
      id="Tb_bMLmEhD9vkKSLANGOYHYdg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:74.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December 31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September 30, &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EUR k&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EUR k&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Trade receivables&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 18,504&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,170&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:74.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Contract liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 142,095&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 111,817&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</ifrs-full:ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory>
    <ifrs-full:CurrentTradeReceivables
      contextRef="As_Of_12_31_2021_kQVJTWPgRUeESxCd99xt9A"
      decimals="-3"
      id="Tc_h-NnX8qxLU-Ygk4nDTKw1w_4_2"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">18504000</ifrs-full:CurrentTradeReceivables>
    <ifrs-full:CurrentTradeReceivables
      contextRef="As_Of_9_30_2022_zuGVrjesE0WhwXSGmTqsgA"
      decimals="-3"
      id="Tc_0GAKBR1hlUOSikyktRAjkA_4_4"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">6170000</ifrs-full:CurrentTradeReceivables>
    <ifrs-full:ContractLiabilities
      contextRef="As_Of_12_31_2021_kQVJTWPgRUeESxCd99xt9A"
      decimals="-3"
      id="Tc_OON6KzFoiEe9sFglNj2I7g_5_2"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">142095000</ifrs-full:ContractLiabilities>
    <ifrs-full:ContractLiabilities
      contextRef="As_Of_9_30_2022_zuGVrjesE0WhwXSGmTqsgA"
      decimals="-3"
      id="Tc_SBhnVCZOOUOlDTvd2ZIlJQ_5_4"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">111817000</ifrs-full:ContractLiabilities>
    <ifrs-full:DisclosureOfExpensesByNatureExplanatory
      contextRef="Duration_1_1_2022_To_9_30_2022_GrYkE3mhHEiRA4fxgfABRg"
      id="Group_GxE3bduSwEWI74TGKMZFrw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"&gt;The cost of sales consists of the following:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:71.11%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.66%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.66%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:27.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Nine months ended September 30,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EUR&#160;k&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EUR k&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Personnel&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (14,897)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (19,076)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Materials&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (13,945)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (48,962)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Third-party services&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (130,795)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (24,030)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Maintenance and lease&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (3,227)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1,479)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Amortization and depreciation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (2,944)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (9,757)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Other&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (2,369)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (688)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.66%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; (168,177)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.66%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; (103,992)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:16.75pt;margin:0pt;"&gt;Selling and distribution expenses consist of the following:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:71.11%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:27.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Nine months ended September 30,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EUR&#160;k&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EUR k&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Personnel&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (943)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1,467)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Amortization and depreciation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (65)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (38)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Other&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.19%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (224)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (320)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.19%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; (1,232)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; (1,825)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"&gt;R&amp;amp;D expenses consists of the following:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:71.11%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:27.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Nine months ended September 30,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EUR&#160;k&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EUR k&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Materials&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (5,893)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (29,618)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Personnel&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (25,209)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (24,326)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Amortization and depreciation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (3,051)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (3,866)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Patents and fees to register a legal right&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (2,372)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (2,536)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Third-party services&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (246,185)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 28,525&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Maintenance and lease &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (291)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (789)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Other&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.19%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1,727)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (2,324)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.19%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; (284,728)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; (34,934)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"&gt;General and administrative expenses consist of the following:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:71.11%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.1%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.14%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:27.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Nine months ended September 30,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EUR&#160;k&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EUR k&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Personnel&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (30,039)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (27,971)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Maintenance and lease &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (2,106)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (4,614)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Third-party services&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (28,699)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (19,607)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Legal and other professional services&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (6,394)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (7,215)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Amortization and depreciation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (5,575)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (9,444)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Other&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (7,974)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (9,168)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.1%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; (80,787)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.14%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; (78,019)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</ifrs-full:DisclosureOfExpensesByNatureExplanatory>
    <cvac:PersonnelExpenses
      contextRef="Duration_1_1_2021_To_9_30_2021_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsCostOfSalesMember__hz63wg8m0S72b0NYjaYHQ"
      decimals="-3"
      id="Tc_ySrE3ba2xEumGtIBvdolMA_4_2"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">14897000</cvac:PersonnelExpenses>
    <cvac:PersonnelExpenses
      contextRef="Duration_1_1_2022_To_9_30_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsCostOfSalesMember_em7QzpMx20e5-T4Zm2ygyA"
      decimals="-3"
      id="Tc_VS7pPFQXHEaaocbBSV6Svw_4_4"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">19076000</cvac:PersonnelExpenses>
    <ifrs-full:RawMaterialsAndConsumablesUsed
      contextRef="Duration_1_1_2021_To_9_30_2021_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsCostOfSalesMember__hz63wg8m0S72b0NYjaYHQ"
      decimals="-3"
      id="Tc_zJPppj0Bg06RlXc2jHIiUw_5_2"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">13945000</ifrs-full:RawMaterialsAndConsumablesUsed>
    <ifrs-full:RawMaterialsAndConsumablesUsed
      contextRef="Duration_1_1_2022_To_9_30_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsCostOfSalesMember_em7QzpMx20e5-T4Zm2ygyA"
      decimals="-3"
      id="Tc_ydWbSDbz3Uq1zZK5CdcBsQ_5_4"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">48962000</ifrs-full:RawMaterialsAndConsumablesUsed>
    <cvac:ThirdPartyServiceExpenses
      contextRef="Duration_1_1_2021_To_9_30_2021_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsCostOfSalesMember__hz63wg8m0S72b0NYjaYHQ"
      decimals="-3"
      id="Tc_idWlHa2g5Ue-QqexuDzikw_6_2"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">130795000</cvac:ThirdPartyServiceExpenses>
    <cvac:ThirdPartyServiceExpenses
      contextRef="Duration_1_1_2022_To_9_30_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsCostOfSalesMember_em7QzpMx20e5-T4Zm2ygyA"
      decimals="-3"
      id="Tc_fho0Ij1drUiWSn4BJ5trLg_6_4"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">24030000</cvac:ThirdPartyServiceExpenses>
    <cvac:MaintenanceAndLeaseExpenses
      contextRef="Duration_1_1_2021_To_9_30_2021_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsCostOfSalesMember__hz63wg8m0S72b0NYjaYHQ"
      decimals="-3"
      id="Tc_7h7QM2ejxUCFdxQIligl7A_7_2"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">3227000</cvac:MaintenanceAndLeaseExpenses>
    <cvac:MaintenanceAndLeaseExpenses
      contextRef="Duration_1_1_2022_To_9_30_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsCostOfSalesMember_em7QzpMx20e5-T4Zm2ygyA"
      decimals="-3"
      id="Tc_MFBSeYa-3UaOvCUQ1J0wMw_7_4"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">1479000</cvac:MaintenanceAndLeaseExpenses>
    <ifrs-full:DepreciationAndAmortisationExpense
      contextRef="Duration_1_1_2021_To_9_30_2021_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsCostOfSalesMember__hz63wg8m0S72b0NYjaYHQ"
      decimals="-3"
      id="Tc_HZmu1pNorkmRA1W41R8yyA_8_2"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">2944000</ifrs-full:DepreciationAndAmortisationExpense>
    <ifrs-full:DepreciationAndAmortisationExpense
      contextRef="Duration_1_1_2022_To_9_30_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsCostOfSalesMember_em7QzpMx20e5-T4Zm2ygyA"
      decimals="-3"
      id="Tc_uLTT3Uc5bken7O24YwHOYw_8_4"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">9757000</ifrs-full:DepreciationAndAmortisationExpense>
    <cvac:OtherExpense
      contextRef="Duration_1_1_2021_To_9_30_2021_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsCostOfSalesMember__hz63wg8m0S72b0NYjaYHQ"
      decimals="-3"
      id="Tc_ZtLd2gVNG0aTugHrmtzlWg_9_2"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">2369000</cvac:OtherExpense>
    <cvac:OtherExpense
      contextRef="Duration_1_1_2022_To_9_30_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsCostOfSalesMember_em7QzpMx20e5-T4Zm2ygyA"
      decimals="-3"
      id="Tc_GhFVGaadkUi0H3ngwNEgOA_9_4"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">688000</cvac:OtherExpense>
    <ifrs-full:ExpenseByNature
      contextRef="Duration_1_1_2021_To_9_30_2021_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsCostOfSalesMember__hz63wg8m0S72b0NYjaYHQ"
      decimals="-3"
      id="Tc_atgHK84fakCsyz0YpI3l1Q_10_2"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">168177000</ifrs-full:ExpenseByNature>
    <ifrs-full:ExpenseByNature
      contextRef="Duration_1_1_2022_To_9_30_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsCostOfSalesMember_em7QzpMx20e5-T4Zm2ygyA"
      decimals="-3"
      id="Tc_pz02VFLU5kGBvb2a4y3LXg_10_4"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">103992000</ifrs-full:ExpenseByNature>
    <cvac:WriteOffOfRawMaterials
      contextRef="Duration_1_1_2022_To_9_30_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsCostOfSalesMember_em7QzpMx20e5-T4Zm2ygyA"
      decimals="-3"
      id="Narr_gHjndlsm3kWTve4HDRZLPA"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">41295000</cvac:WriteOffOfRawMaterials>
    <cvac:PersonnelExpenses
      contextRef="Duration_1_1_2021_To_9_30_2021_cvac_IfrsIncomeStatementLocationAxis_cvac_SellingAndDistributionExpensesMember_-Uy3t4myckOOiYqfNnLrvA"
      decimals="-3"
      id="Tc_EH9RoSSrREC-FT4GmVJGsw_4_2"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">943000</cvac:PersonnelExpenses>
    <cvac:PersonnelExpenses
      contextRef="Duration_1_1_2022_To_9_30_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_SellingAndDistributionExpensesMember_nx7DDIuvEEyD8XuyuNsS6Q"
      decimals="-3"
      id="Tc_aN6fkIxqCUaAemELS2ZmkQ_4_4"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">1467000</cvac:PersonnelExpenses>
    <ifrs-full:DepreciationAndAmortisationExpense
      contextRef="Duration_1_1_2021_To_9_30_2021_cvac_IfrsIncomeStatementLocationAxis_cvac_SellingAndDistributionExpensesMember_-Uy3t4myckOOiYqfNnLrvA"
      decimals="-3"
      id="Tc_RGsA7SCRjk2s1MTyLSjyTA_5_2"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">65000</ifrs-full:DepreciationAndAmortisationExpense>
    <ifrs-full:DepreciationAndAmortisationExpense
      contextRef="Duration_1_1_2022_To_9_30_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_SellingAndDistributionExpensesMember_nx7DDIuvEEyD8XuyuNsS6Q"
      decimals="-3"
      id="Tc__aEDp2VCkUKS02W_4NPc2Q_5_4"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">38000</ifrs-full:DepreciationAndAmortisationExpense>
    <cvac:OtherExpense
      contextRef="Duration_1_1_2021_To_9_30_2021_cvac_IfrsIncomeStatementLocationAxis_cvac_SellingAndDistributionExpensesMember_-Uy3t4myckOOiYqfNnLrvA"
      decimals="-3"
      id="Tc_DHxXJapsGkGcOgNevu-i3A_6_2"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">224000</cvac:OtherExpense>
    <cvac:OtherExpense
      contextRef="Duration_1_1_2022_To_9_30_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_SellingAndDistributionExpensesMember_nx7DDIuvEEyD8XuyuNsS6Q"
      decimals="-3"
      id="Tc_QNplw96MWUSNMIC6rrJS3A_6_4"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">320000</cvac:OtherExpense>
    <ifrs-full:ExpenseByNature
      contextRef="Duration_1_1_2021_To_9_30_2021_cvac_IfrsIncomeStatementLocationAxis_cvac_SellingAndDistributionExpensesMember_-Uy3t4myckOOiYqfNnLrvA"
      decimals="-3"
      id="Tc_pAs3_m7fU0uybArsYJSjFg_7_2"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">1232000</ifrs-full:ExpenseByNature>
    <ifrs-full:ExpenseByNature
      contextRef="Duration_1_1_2022_To_9_30_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_SellingAndDistributionExpensesMember_nx7DDIuvEEyD8XuyuNsS6Q"
      decimals="-3"
      id="Tc_YhHSZxNuNEqdD-SRg-eauQ_7_4"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">1825000</ifrs-full:ExpenseByNature>
    <ifrs-full:ShorttermEmployeeBenefitsExpense
      contextRef="Duration_1_1_2022_To_9_30_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_SellingAndDistributionExpensesMember_nx7DDIuvEEyD8XuyuNsS6Q"
      decimals="-3"
      id="Narr_Fo9WJrim9U6QzmcQ60WIaQ"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">1315000</ifrs-full:ShorttermEmployeeBenefitsExpense>
    <ifrs-full:ShorttermEmployeeBenefitsExpense
      contextRef="Duration_1_1_2021_To_9_30_2021_cvac_IfrsIncomeStatementLocationAxis_cvac_SellingAndDistributionExpensesMember_-Uy3t4myckOOiYqfNnLrvA"
      decimals="-3"
      id="Narr_metJN2F5Zk-94A4ZbxPIOA"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">777000</ifrs-full:ShorttermEmployeeBenefitsExpense>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets
      contextRef="Duration_1_1_2022_To_9_30_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_SellingAndDistributionExpensesMember_nx7DDIuvEEyD8XuyuNsS6Q"
      decimals="-3"
      id="Narr_VpSrMVL8EUCfwINCFWvV_A"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">152000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets
      contextRef="Duration_1_1_2021_To_9_30_2021_cvac_IfrsIncomeStatementLocationAxis_cvac_SellingAndDistributionExpensesMember_-Uy3t4myckOOiYqfNnLrvA"
      decimals="-3"
      id="Narr_ptk85Gecc02mE9Fuf1TCRA"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">166000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <ifrs-full:RawMaterialsAndConsumablesUsed
      contextRef="Duration_1_1_2021_To_9_30_2021_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsResearchAndDevelopmentExpenseMember_0xeLKyJYAEWBhUtu43GF8g"
      decimals="-3"
      id="Tc__EEOUFAdz0KOiJe6K5GumQ_4_2"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">5893000</ifrs-full:RawMaterialsAndConsumablesUsed>
    <ifrs-full:RawMaterialsAndConsumablesUsed
      contextRef="Duration_1_1_2022_To_9_30_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsResearchAndDevelopmentExpenseMember_u-Q9gJOBkUqQxOVDUX24Hw"
      decimals="-3"
      id="Tc_I7wGEB9VX0GX-WXoJTEwFg_4_4"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">29618000</ifrs-full:RawMaterialsAndConsumablesUsed>
    <cvac:PersonnelExpenses
      contextRef="Duration_1_1_2021_To_9_30_2021_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsResearchAndDevelopmentExpenseMember_0xeLKyJYAEWBhUtu43GF8g"
      decimals="-3"
      id="Tc_OT_T_K5yJU2uTIOhy8CSFg_5_2"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">25209000</cvac:PersonnelExpenses>
    <cvac:PersonnelExpenses
      contextRef="Duration_1_1_2022_To_9_30_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsResearchAndDevelopmentExpenseMember_u-Q9gJOBkUqQxOVDUX24Hw"
      decimals="-3"
      id="Tc_sCx4rIWlP0mNch_ErPpoew_5_4"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">24326000</cvac:PersonnelExpenses>
    <ifrs-full:DepreciationAndAmortisationExpense
      contextRef="Duration_1_1_2021_To_9_30_2021_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsResearchAndDevelopmentExpenseMember_0xeLKyJYAEWBhUtu43GF8g"
      decimals="-3"
      id="Tc_PJuEcGfPHUm-rj7V1Mtnig_6_2"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">3051000</ifrs-full:DepreciationAndAmortisationExpense>
    <ifrs-full:DepreciationAndAmortisationExpense
      contextRef="Duration_1_1_2022_To_9_30_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsResearchAndDevelopmentExpenseMember_u-Q9gJOBkUqQxOVDUX24Hw"
      decimals="-3"
      id="Tc_RMKNkRgB2UGsnbkxOMzzqA_6_4"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">3866000</ifrs-full:DepreciationAndAmortisationExpense>
    <cvac:PatentsAndFeesToRegisterLegalRight
      contextRef="Duration_1_1_2021_To_9_30_2021_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsResearchAndDevelopmentExpenseMember_0xeLKyJYAEWBhUtu43GF8g"
      decimals="-3"
      id="Tc_Z3lw779MZkSTvpJwhTrXNg_7_2"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">2372000</cvac:PatentsAndFeesToRegisterLegalRight>
    <cvac:PatentsAndFeesToRegisterLegalRight
      contextRef="Duration_1_1_2022_To_9_30_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsResearchAndDevelopmentExpenseMember_u-Q9gJOBkUqQxOVDUX24Hw"
      decimals="-3"
      id="Tc_pr2KSBLdbk-n4zztmtxyRg_7_4"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">2536000</cvac:PatentsAndFeesToRegisterLegalRight>
    <cvac:ThirdPartyServiceExpenses
      contextRef="Duration_1_1_2021_To_9_30_2021_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsResearchAndDevelopmentExpenseMember_0xeLKyJYAEWBhUtu43GF8g"
      decimals="-3"
      id="Tc_rY1FtAzcV0Wlb_m6bayesQ_8_2"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">246185000</cvac:ThirdPartyServiceExpenses>
    <cvac:ThirdPartyServiceExpenses
      contextRef="Duration_1_1_2022_To_9_30_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsResearchAndDevelopmentExpenseMember_u-Q9gJOBkUqQxOVDUX24Hw"
      decimals="-3"
      id="Tc_2IHYOTdbJk6E9-Iqx8hMbA_8_4"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">-28525000</cvac:ThirdPartyServiceExpenses>
    <cvac:MaintenanceAndLeaseExpenses
      contextRef="Duration_1_1_2021_To_9_30_2021_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsResearchAndDevelopmentExpenseMember_0xeLKyJYAEWBhUtu43GF8g"
      decimals="-3"
      id="Tc_Nci8AzWL8EGYmwDs2oA5Gw_9_2"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">291000</cvac:MaintenanceAndLeaseExpenses>
    <cvac:MaintenanceAndLeaseExpenses
      contextRef="Duration_1_1_2022_To_9_30_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsResearchAndDevelopmentExpenseMember_u-Q9gJOBkUqQxOVDUX24Hw"
      decimals="-3"
      id="Tc_yq31NmGyxE6VZyQ5gg-w-w_9_4"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">789000</cvac:MaintenanceAndLeaseExpenses>
    <cvac:OtherExpense
      contextRef="Duration_1_1_2021_To_9_30_2021_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsResearchAndDevelopmentExpenseMember_0xeLKyJYAEWBhUtu43GF8g"
      decimals="-3"
      id="Tc_Dfx0C22ye0OxR_oN0ciR4w_10_2"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">1727000</cvac:OtherExpense>
    <cvac:OtherExpense
      contextRef="Duration_1_1_2022_To_9_30_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsResearchAndDevelopmentExpenseMember_u-Q9gJOBkUqQxOVDUX24Hw"
      decimals="-3"
      id="Tc_CFe0Hu1vSkCAV2h_WRqJKw_10_4"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">2324000</cvac:OtherExpense>
    <ifrs-full:ExpenseByNature
      contextRef="Duration_1_1_2021_To_9_30_2021_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsResearchAndDevelopmentExpenseMember_0xeLKyJYAEWBhUtu43GF8g"
      decimals="-3"
      id="Tc_rsx_serQ0EKe6fpWUAy1Tw_11_2"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">284728000</ifrs-full:ExpenseByNature>
    <ifrs-full:ExpenseByNature
      contextRef="Duration_1_1_2022_To_9_30_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsResearchAndDevelopmentExpenseMember_u-Q9gJOBkUqQxOVDUX24Hw"
      decimals="-3"
      id="Tc_sgiLdFDcLUKb3d1-xkqtHA_11_4"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">34934000</ifrs-full:ExpenseByNature>
    <cvac:ReversalOfProvisionForOnerousContracts
      contextRef="As_Of_9_30_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsResearchAndDevelopmentExpenseMember_GiIhuFW_ukOtSf0Bvkce7w"
      decimals="-3"
      id="Narr_H572OwJbbUu7BCIaCkGJbw"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">36769000</cvac:ReversalOfProvisionForOnerousContracts>
    <ifrs-full:ShorttermEmployeeBenefitsExpense
      contextRef="Duration_1_1_2022_To_9_30_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsResearchAndDevelopmentExpenseMember_u-Q9gJOBkUqQxOVDUX24Hw"
      decimals="-3"
      id="Narr_TkhXmc2ZtUKhMjPdOPAuFw"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">23846000</ifrs-full:ShorttermEmployeeBenefitsExpense>
    <ifrs-full:ShorttermEmployeeBenefitsExpense
      contextRef="Duration_1_1_2021_To_9_30_2021_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsResearchAndDevelopmentExpenseMember_0xeLKyJYAEWBhUtu43GF8g"
      decimals="-3"
      id="Narr_IcEIIh9y3Em64IASZUfXrw"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">24637000</ifrs-full:ShorttermEmployeeBenefitsExpense>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets
      contextRef="Duration_1_1_2022_To_9_30_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsResearchAndDevelopmentExpenseMember_u-Q9gJOBkUqQxOVDUX24Hw"
      decimals="-3"
      id="Narr_ZFbfv6WjnEuoxa_JcSQ2_A"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">480000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets
      contextRef="Duration_1_1_2021_To_9_30_2021_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsResearchAndDevelopmentExpenseMember_0xeLKyJYAEWBhUtu43GF8g"
      decimals="-3"
      id="Narr_huMSulLDRUWS96fINzbdgQ"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">572000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <cvac:PersonnelExpenses
      contextRef="Duration_1_1_2021_To_9_30_2021_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsGeneralAndAdministrativeExpenseMember_pxlCrV2ySESTCd1lVbTlfg"
      decimals="-3"
      id="Tc_WRRNwgkY6EaCtVtOT9ZNvQ_4_2"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">30039000</cvac:PersonnelExpenses>
    <cvac:PersonnelExpenses
      contextRef="Duration_1_1_2022_To_9_30_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsGeneralAndAdministrativeExpenseMember_KMYenp1F1EOV1PWLAQFrFw"
      decimals="-3"
      id="Tc_wS5HHqfygk-kYA-t9eJ8bw_4_4"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">27971000</cvac:PersonnelExpenses>
    <cvac:MaintenanceAndLeaseExpenses
      contextRef="Duration_1_1_2021_To_9_30_2021_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsGeneralAndAdministrativeExpenseMember_pxlCrV2ySESTCd1lVbTlfg"
      decimals="-3"
      id="Tc_7CEGF7EAQUCBf3yEdCJWqg_5_2"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">2106000</cvac:MaintenanceAndLeaseExpenses>
    <cvac:MaintenanceAndLeaseExpenses
      contextRef="Duration_1_1_2022_To_9_30_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsGeneralAndAdministrativeExpenseMember_KMYenp1F1EOV1PWLAQFrFw"
      decimals="-3"
      id="Tc_ciVyAOHyXEykjbN2qoioow_5_4"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">4614000</cvac:MaintenanceAndLeaseExpenses>
    <cvac:ThirdPartyServiceExpenses
      contextRef="Duration_1_1_2021_To_9_30_2021_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsGeneralAndAdministrativeExpenseMember_pxlCrV2ySESTCd1lVbTlfg"
      decimals="-3"
      id="Tc_xKVliXbwvUqdh2RS2UH7Gw_6_2"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">28699000</cvac:ThirdPartyServiceExpenses>
    <cvac:ThirdPartyServiceExpenses
      contextRef="Duration_1_1_2022_To_9_30_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsGeneralAndAdministrativeExpenseMember_KMYenp1F1EOV1PWLAQFrFw"
      decimals="-3"
      id="Tc_vbUA99jxu0q7E_gADCqy5g_6_4"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">19607000</cvac:ThirdPartyServiceExpenses>
    <ifrs-full:ProfessionalFeesExpense
      contextRef="Duration_1_1_2021_To_9_30_2021_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsGeneralAndAdministrativeExpenseMember_pxlCrV2ySESTCd1lVbTlfg"
      decimals="-3"
      id="Tc_2az495MY20WSnokNkXhZZQ_7_2"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">6394000</ifrs-full:ProfessionalFeesExpense>
    <ifrs-full:ProfessionalFeesExpense
      contextRef="Duration_1_1_2022_To_9_30_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsGeneralAndAdministrativeExpenseMember_KMYenp1F1EOV1PWLAQFrFw"
      decimals="-3"
      id="Tc_q6K1PlGC8UaoEIFr1Qn8Fw_7_4"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">7215000</ifrs-full:ProfessionalFeesExpense>
    <ifrs-full:DepreciationAndAmortisationExpense
      contextRef="Duration_1_1_2021_To_9_30_2021_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsGeneralAndAdministrativeExpenseMember_pxlCrV2ySESTCd1lVbTlfg"
      decimals="-3"
      id="Tc_WJ0jA7_vsUKD1ZjY3OxGgw_8_2"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">5575000</ifrs-full:DepreciationAndAmortisationExpense>
    <ifrs-full:DepreciationAndAmortisationExpense
      contextRef="Duration_1_1_2022_To_9_30_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsGeneralAndAdministrativeExpenseMember_KMYenp1F1EOV1PWLAQFrFw"
      decimals="-3"
      id="Tc_K9gg6daWn02EjLDziHDjCw_8_4"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">9444000</ifrs-full:DepreciationAndAmortisationExpense>
    <cvac:OtherExpense
      contextRef="Duration_1_1_2021_To_9_30_2021_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsGeneralAndAdministrativeExpenseMember_pxlCrV2ySESTCd1lVbTlfg"
      decimals="-3"
      id="Tc_5konuDMRe0iaTBm4TuPPfg_9_2"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">7974000</cvac:OtherExpense>
    <cvac:OtherExpense
      contextRef="Duration_1_1_2022_To_9_30_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsGeneralAndAdministrativeExpenseMember_KMYenp1F1EOV1PWLAQFrFw"
      decimals="-3"
      id="Tc_hzEz8S69JUq4xfIJEQifiw_9_4"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">9168000</cvac:OtherExpense>
    <ifrs-full:ExpenseByNature
      contextRef="Duration_1_1_2021_To_9_30_2021_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsGeneralAndAdministrativeExpenseMember_pxlCrV2ySESTCd1lVbTlfg"
      decimals="-3"
      id="Tc_JTJ4uxW6bkKFF7QuYwNaBQ_10_2"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">80787000</ifrs-full:ExpenseByNature>
    <ifrs-full:ExpenseByNature
      contextRef="Duration_1_1_2022_To_9_30_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsGeneralAndAdministrativeExpenseMember_KMYenp1F1EOV1PWLAQFrFw"
      decimals="-3"
      id="Tc_va30oP7GAUiXOUSfAlHUFw_10_4"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">78019000</ifrs-full:ExpenseByNature>
    <ifrs-full:ShorttermEmployeeBenefitsExpense
      contextRef="Duration_1_1_2022_To_9_30_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsGeneralAndAdministrativeExpenseMember_KMYenp1F1EOV1PWLAQFrFw"
      decimals="-3"
      id="Narr_iVkyR7jUrkS9kXPu01ziAg"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">21621000</ifrs-full:ShorttermEmployeeBenefitsExpense>
    <ifrs-full:ShorttermEmployeeBenefitsExpense
      contextRef="Duration_1_1_2021_To_9_30_2021_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsGeneralAndAdministrativeExpenseMember_pxlCrV2ySESTCd1lVbTlfg"
      decimals="-3"
      id="Narr_e2MFnCtBwE2gTpTbt69raA"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">19492000</ifrs-full:ShorttermEmployeeBenefitsExpense>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets
      contextRef="Duration_1_1_2022_To_9_30_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsGeneralAndAdministrativeExpenseMember_KMYenp1F1EOV1PWLAQFrFw"
      decimals="-3"
      id="Narr_uA9qKpN1RkqTqTTJpVd7FQ"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">5823000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets
      contextRef="Duration_1_1_2021_To_9_30_2021_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsGeneralAndAdministrativeExpenseMember_pxlCrV2ySESTCd1lVbTlfg"
      decimals="-3"
      id="Narr_MKI3vV8QrUmMbNiXEfqaFg"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">10547000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <ifrs-full:InsuranceExpense
      contextRef="Duration_1_1_2022_To_9_30_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsGeneralAndAdministrativeExpenseMember_KMYenp1F1EOV1PWLAQFrFw"
      decimals="-3"
      id="Narr_WbSeF3r2m0e6hwB7c9Bg9g"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">4150000</ifrs-full:InsuranceExpense>
    <ifrs-full:InsuranceExpense
      contextRef="Duration_1_1_2021_To_9_30_2021_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsGeneralAndAdministrativeExpenseMember_pxlCrV2ySESTCd1lVbTlfg"
      decimals="-3"
      id="Narr_2Dgjdayl9E6RSDDffGnLiw"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">4073000</ifrs-full:InsuranceExpense>
    <ifrs-full:DisclosureOfOtherOperatingIncomeExplanatory
      contextRef="Duration_1_1_2022_To_9_30_2022_GrYkE3mhHEiRA4fxgfABRg"
      id="Tb_fg8RAfbD2k2mRwTNYmZ7Gw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:71.11%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:27.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Nine months ended September 30,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EUR&#160;k&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EUR k&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Compensation for CMO/Material transfer&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 34,379&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Reimbursement claim&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 610&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Sale of equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 310&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Grants and other cost reimbursements from government agencies and similar bodies&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 64,307&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 377&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Other&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.19%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,439&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 225&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.19%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 66,746&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 35,901&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</ifrs-full:DisclosureOfOtherOperatingIncomeExplanatory>
    <cvac:CompensationForContractManufacturingOrganizationsTransfer
      contextRef="Duration_1_1_2022_To_9_30_2022_GrYkE3mhHEiRA4fxgfABRg"
      decimals="-3"
      id="Tc_KxtqA1q93EG3rw6VFdnUyw_4_4"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">34379000</cvac:CompensationForContractManufacturingOrganizationsTransfer>
    <cvac:CostOfReimbursementClaim
      contextRef="Duration_1_1_2022_To_9_30_2022_GrYkE3mhHEiRA4fxgfABRg"
      decimals="-3"
      id="Tc_pIrCWRk4b0mE77cI_TZBmA_5_4"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">610000</cvac:CostOfReimbursementClaim>
    <cvac:SaleOfEquipment
      contextRef="Duration_1_1_2022_To_9_30_2022_GrYkE3mhHEiRA4fxgfABRg"
      decimals="-3"
      id="Tc_F0uQtZIFoEWtaIavuwqS8A_6_4"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">310000</cvac:SaleOfEquipment>
    <cvac:OtherOperatingIncomeGovernmentGrants
      contextRef="Duration_1_1_2021_To_9_30_2021_5RS16WkLc0uS2ug_bqUm-g"
      decimals="-3"
      id="Tc_sEeppZoF6kGgzhkRSo5XHA_7_2"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">64307000</cvac:OtherOperatingIncomeGovernmentGrants>
    <cvac:OtherOperatingIncomeGovernmentGrants
      contextRef="Duration_1_1_2022_To_9_30_2022_GrYkE3mhHEiRA4fxgfABRg"
      decimals="-3"
      id="Tc_K_0G_946JUasP0rLmbketA_7_4"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">377000</cvac:OtherOperatingIncomeGovernmentGrants>
    <cvac:MiscellaneousOtherOperatingIncomeOther
      contextRef="Duration_1_1_2021_To_9_30_2021_5RS16WkLc0uS2ug_bqUm-g"
      decimals="-3"
      id="Tc_6kx-vx3JVUqaB1Aw-Xp5dA_8_2"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">2439000</cvac:MiscellaneousOtherOperatingIncomeOther>
    <cvac:MiscellaneousOtherOperatingIncomeOther
      contextRef="Duration_1_1_2022_To_9_30_2022_GrYkE3mhHEiRA4fxgfABRg"
      decimals="-3"
      id="Tc_4HHifBwiHkuAyt2LOs7NCA_8_4"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">225000</cvac:MiscellaneousOtherOperatingIncomeOther>
    <ifrs-full:MiscellaneousOtherOperatingIncome
      contextRef="Duration_1_1_2021_To_9_30_2021_5RS16WkLc0uS2ug_bqUm-g"
      decimals="-3"
      id="Tc_0DMSoCK0a0WUjfgeQl7Ghg_9_2"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">66746000</ifrs-full:MiscellaneousOtherOperatingIncome>
    <ifrs-full:MiscellaneousOtherOperatingIncome
      contextRef="Duration_1_1_2022_To_9_30_2022_GrYkE3mhHEiRA4fxgfABRg"
      decimals="-3"
      id="Tc_t_xgKQB3C0GdpIcrREIbOg_9_4"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">35901000</ifrs-full:MiscellaneousOtherOperatingIncome>
    <cvac:CompensationForContractManufacturingOrganizationsTransferConsiderationForSetUpActivities
      contextRef="Duration_1_1_2022_To_9_30_2022_srt_CounterpartyNameAxis_cvac_GlaxosmithklineMember_3G2M3SARj0GkTuTa4M37uw"
      decimals="-3"
      id="Narr_KE8v_hwqEUWyQnaljktb0Q"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">20500000</cvac:CompensationForContractManufacturingOrganizationsTransferConsiderationForSetUpActivities>
    <cvac:CompensationForContractManufacturingOrganizationsTransferManufacturingInterimPeriodReimbursableExpenses
      contextRef="Duration_1_1_2022_To_9_30_2022_srt_CounterpartyNameAxis_cvac_GlaxosmithklineMember_3G2M3SARj0GkTuTa4M37uw"
      decimals="-3"
      id="Narr_IMSIeF61TU6n8eQ-_Zgv6w"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">12000000</cvac:CompensationForContractManufacturingOrganizationsTransferManufacturingInterimPeriodReimbursableExpenses>
    <cvac:ReversalOfProvisionRecognizedDueToCertainReservedCapacityTakenOver
      contextRef="Duration_1_1_2021_To_12_31_2021_jm3ww8f3H0egT8wSnNVZZw"
      decimals="-3"
      id="Narr_hJbdW8Vhmk-UxKkuFNTmdA"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">25059000</cvac:ReversalOfProvisionRecognizedDueToCertainReservedCapacityTakenOver>
    <ifrs-full:GovernmentGrants
      contextRef="As_Of_9_30_2021_cvac_GovernmentGrantsAxis_cvac_GermanFederalMinistryOfEducationAndResearchMember_f9iNDb6krUGTFEUGF-sh0Q"
      decimals="-3"
      id="Narr_qxgFZ81mWE-OF9Uh77QYwg"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">64031000</ifrs-full:GovernmentGrants>
    <ifrs-full:GovernmentGrants
      contextRef="As_Of_9_30_2022_cvac_GovernmentGrantsAxis_cvac_GermanFederalMinistryOfEducationAndResearchMember_fN4famsHHEKl4JoAfEVlag"
      decimals="-3"
      id="Narr_axf0eD3R_k-3Lkc0eaK2fA"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">0</ifrs-full:GovernmentGrants>
    <cvac:MaximumGrantToBeReceived
      contextRef="As_Of_1_31_2020_cvac_GovernmentGrantsAxis_cvac_CoalitionForEpidemicPreparednessInnovationsMember_3sgz0BFjM0OjLj8LLFk2Lg"
      decimals="-3"
      id="Narr_icdWzYJ2CEKXumpSOTZ6OA"
      unitRef="Unit_Standard_USD_q8NNp4TBfUC9XydcVDSrpA">8300000</cvac:MaximumGrantToBeReceived>
    <cvac:MaximumGrantToBeReceived
      contextRef="As_Of_5_31_2020_cvac_GovernmentGrantsAxis_cvac_CoalitionForEpidemicPreparednessInnovationsMember_V-hWugM7KEemNT5UugQPwQ"
      decimals="-3"
      id="Narr_j63tohHr3U-35Y1diptlEQ"
      unitRef="Unit_Standard_USD_q8NNp4TBfUC9XydcVDSrpA">15300000</cvac:MaximumGrantToBeReceived>
    <ifrs-full:RevenueFromGovernmentGrants
      contextRef="Duration_1_1_2022_To_9_30_2022_cvac_GovernmentGrantsAxis_cvac_CoalitionForEpidemicPreparednessInnovationsMember_QaC72j_xJU248NAuCm-NTA"
      decimals="-3"
      id="Narr_weSQ-HXwQEimYAVhynKr4g"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">26000</ifrs-full:RevenueFromGovernmentGrants>
    <ifrs-full:RevenueFromGovernmentGrants
      contextRef="Duration_1_1_2021_To_9_30_2021_cvac_GovernmentGrantsAxis_cvac_CoalitionForEpidemicPreparednessInnovationsMember_-JHShxg3uU65FRp662VaIA"
      decimals="-3"
      id="Narr_QHCvOg9CMUeVu3ADneIb-g"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">30000</ifrs-full:RevenueFromGovernmentGrants>
    <ifrs-full:GovernmentGrants
      contextRef="As_Of_9_30_2022_cvac_GovernmentGrantsAxis_cvac_CoalitionForEpidemicPreparednessInnovationsMember_62kXYP2DG0q3hObonbIX3w"
      decimals="-3"
      id="Narr_vdXrnuH9XEGGbJ67vp5t9Q"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">1263000</ifrs-full:GovernmentGrants>
    <ifrs-full:GovernmentGrants
      contextRef="As_Of_12_31_2021_cvac_GovernmentGrantsAxis_cvac_CoalitionForEpidemicPreparednessInnovationsMember_Vs0aCSCnvE2bQnX-4agCZg"
      decimals="-3"
      id="Narr_Q1gGgUQaS0SIxrtWKVZZ7A"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">1288000</ifrs-full:GovernmentGrants>
    <ifrs-full:RevenueFromGovernmentGrants
      contextRef="Duration_1_1_2022_To_9_30_2022_cvac_GovernmentGrantsAxis_cvac_BillAndMelindaGatesFoundationBmgfMember_fYCkAgnPgkW1HP0kse2SZQ"
      decimals="-3"
      id="Narr_qi5Wbs4kSEiUb6bzcnrICg"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">132000</ifrs-full:RevenueFromGovernmentGrants>
    <ifrs-full:RevenueFromGovernmentGrants
      contextRef="Duration_1_1_2021_To_9_30_2021_cvac_GovernmentGrantsAxis_cvac_BillAndMelindaGatesFoundationBmgfMember_Mbzwa-uYGkGbrTexrLia1w"
      decimals="-3"
      id="Narr_o1U-MPsJ60OTajI1z4Fyzw"
      unitRef="Unit_Standard_USD_q8NNp4TBfUC9XydcVDSrpA">246000</ifrs-full:RevenueFromGovernmentGrants>
    <ifrs-full:GovernmentGrants
      contextRef="As_Of_9_30_2022_cvac_GovernmentGrantsAxis_cvac_BillAndMelindaGatesFoundationBmgfMember_Ws8aHSUk1UC3pLQKXdVR0g"
      decimals="-3"
      id="Narr_hi1jcc9qKEG120wbaR3Wjg"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">1747000</ifrs-full:GovernmentGrants>
    <ifrs-full:GovernmentGrants
      contextRef="As_Of_12_31_2021_cvac_GovernmentGrantsAxis_cvac_BillAndMelindaGatesFoundationBmgfMember_nd5DnUyNxE69QH5CpJLGZw"
      decimals="-3"
      id="Narr_KCe5JyEvJ0W6ArYlwcB7LA"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">1879000</ifrs-full:GovernmentGrants>
    <ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory
      contextRef="Duration_1_1_2022_To_9_30_2022_GrYkE3mhHEiRA4fxgfABRg"
      id="Tb_WdaEjK7fiEeQn5nKd2BgUg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;4. Issued Capital and Reserves&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;According to the Company&#x2019;s articles of association, the Company&#x2019;s authorized shares are divided into 386,250,000 common shares and 386,250,000 preferred shares, each having a &lt;span style="-sec-ix-hidden:Hidden_Pn4RGe75pUmEplb8tLMDGA;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;nominal&lt;/span&gt;&lt;/span&gt; value of EUR 0.12. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;As of September 30, 2022, no preferred shares had been issued and all issued common shares issued and outstanding were fully paid.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;All payments received from shareholders in excess of the nominal value of the shares issued and net of transaction costs are recognized in capital reserves. Capital reserves also consists of recognition of share-based payments and the equity components of convertible loans. The Company may only make distributions, whether a distribution of profits or of freely distributable reserves, to shareholders to the extent shareholders&#x2019; equity exceeds the sum of the paid-in and called-up share capital plus any reserves required by Dutch law or by the Company&#x2019;s articles of association.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;In September 2021, the Company entered into a sales agreement, the Open Sale Agreement, with Jefferies LLC and SVB Leerink LLC, as sales agents, to establish an at-the-market (ATM) offering program, pursuant to which it may sell, from time to time, ordinary shares for aggregate gross proceeds of up to $600.0 million. As of September 30, 2022, 2,288,055 shares were issued under the ATM program, raising &lt;span style="-sec-ix-hidden:Hidden_k6p5zM0iFEqRi29XSeuCWQ;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;$31.7&lt;/span&gt;&lt;/span&gt; million in net proceeds, after deducting $1.0 million in transaction costs; related offering expenses were recorded against the proceeds in equity. Following these issuances, the remaining value authorized for sale under the at-the-market program as of September 30, 2022 amounts to $567.3 million.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"&gt;The number of shares issued and outstanding developed as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:79.74%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.55%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.7%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:79.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Common shares issued and outstanding at December 31, 2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 187,120,728&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:79.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Share option exercises between Jan and March 2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 78,732&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:79.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Treasury shares&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (78,732)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:79.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Common shares issued and outstanding at March 31, 2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 187,120,728&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:79.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;At-the-market offering program issuances&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 340,015&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:79.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Share issuances for exercises between Apr to June 2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,211&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:79.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Share option exercises between Apr and June 2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 39,418&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:79.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Treasury shares&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (39,418)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:79.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Common shares issued and outstanding at June 30, 2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 187,466,954&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:79.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;At-the-market offering program issuances&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,948,040&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:79.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Share issuances for exercises between July to Sept 2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 9,746&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:79.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Share issuances to former shareholders of Frame Pharmaceuticals&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 858,496&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:79.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Common shares issued and outstanding at September 30, 2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 190,283,236&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory>
    <ifrs-full:NumberOfSharesAuthorised
      contextRef="As_Of_9_30_2022_ifrs-full_ClassesOfShareCapitalAxis_ifrs-full_OrdinarySharesMember_QerVWaOy8UeUozR8lPK5KA"
      decimals="INF"
      id="Narr_8NuGPpOlhEaKiXymKDYMDw"
      unitRef="Unit_Standard_shares_FapG5E6UqkK42IfNNOS6tA">386250000</ifrs-full:NumberOfSharesAuthorised>
    <ifrs-full:NumberOfSharesAuthorised
      contextRef="As_Of_9_30_2022_ifrs-full_ClassesOfShareCapitalAxis_ifrs-full_PreferenceSharesMember_hPye6EgKFUuclVhFCyaxog"
      decimals="INF"
      id="Narr_bUrAZmlCf0KYt9NNaweWoQ"
      unitRef="Unit_Standard_shares_FapG5E6UqkK42IfNNOS6tA">386250000</ifrs-full:NumberOfSharesAuthorised>
    <ifrs-full:ParValuePerShare
      contextRef="As_Of_9_30_2022_ifrs-full_ClassesOfShareCapitalAxis_ifrs-full_PreferenceSharesMember_hPye6EgKFUuclVhFCyaxog"
      decimals="2"
      id="Narr_yHEhLLJfdkyle4kRoy_y7g"
      unitRef="Unit_Divide_EUR_shares_6PEZCHC_WE2a7AmZW169oA">0.12</ifrs-full:ParValuePerShare>
    <ifrs-full:NumberOfSharesIssued
      contextRef="As_Of_9_30_2022_ifrs-full_ClassesOfShareCapitalAxis_ifrs-full_PreferenceSharesMember_hPye6EgKFUuclVhFCyaxog"
      decimals="0"
      id="Narr_y4os6g_7K0ubYcewFZlT4g"
      unitRef="Unit_Standard_shares_FapG5E6UqkK42IfNNOS6tA">0</ifrs-full:NumberOfSharesIssued>
    <cvac:AggregateGrossProceedsReceivableFromIssuingShares
      contextRef="Duration_9_1_2021_To_9_30_2021_cvac_IfrsSaleOfStockAxis_cvac_AtMarketOfferingProgramMember_UsrXsTjj5kOO1bTEgPYDaA"
      decimals="-5"
      id="Narr_5NiOBIrMjkWERvMyUg8vCA"
      unitRef="Unit_Standard_USD_q8NNp4TBfUC9XydcVDSrpA">600000000.0</cvac:AggregateGrossProceedsReceivableFromIssuingShares>
    <cvac:IfrsStockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_9_1_2022_To_9_30_2022_cvac_IfrsSaleOfStockAxis_cvac_AtMarketOfferingProgramMember_aEeSD8tWhUqDkvbkYwvYZA"
      decimals="INF"
      id="Narr_NwckqOvMgEWlsHo0gUrpzQ"
      unitRef="Unit_Standard_shares_FapG5E6UqkK42IfNNOS6tA">2288055</cvac:IfrsStockIssuedDuringPeriodSharesNewIssues>
    <ifrs-full:ShareIssueRelatedCost
      contextRef="Duration_1_1_2022_To_9_30_2022_GrYkE3mhHEiRA4fxgfABRg"
      decimals="-5"
      id="Narr_zp0HQRLAJEmT0fhGo__fKg"
      unitRef="Unit_Standard_USD_q8NNp4TBfUC9XydcVDSrpA">1000000.0</ifrs-full:ShareIssueRelatedCost>
    <cvac:RemainingAuthorizedForSaleValue
      contextRef="As_Of_9_30_2022_zuGVrjesE0WhwXSGmTqsgA"
      decimals="-5"
      id="Narr__lzBgzUdvkekPnVwpMBTIQ"
      unitRef="Unit_Standard_USD_q8NNp4TBfUC9XydcVDSrpA">567300000</cvac:RemainingAuthorizedForSaleValue>
    <ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory
      contextRef="Duration_1_1_2022_To_9_30_2022_GrYkE3mhHEiRA4fxgfABRg"
      id="Tb_blfjgBRTqUe1_m9upx1ypw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:79.74%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.55%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.7%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:79.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Common shares issued and outstanding at December 31, 2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 187,120,728&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:79.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Share option exercises between Jan and March 2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 78,732&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:79.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Treasury shares&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (78,732)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:79.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Common shares issued and outstanding at March 31, 2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 187,120,728&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:79.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;At-the-market offering program issuances&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 340,015&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:79.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Share issuances for exercises between Apr to June 2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,211&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:79.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Share option exercises between Apr and June 2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 39,418&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:79.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Treasury shares&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (39,418)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:79.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Common shares issued and outstanding at June 30, 2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 187,466,954&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:79.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;At-the-market offering program issuances&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,948,040&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:79.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Share issuances for exercises between July to Sept 2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 9,746&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:79.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Share issuances to former shareholders of Frame Pharmaceuticals&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 858,496&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:79.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Common shares issued and outstanding at September 30, 2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 190,283,236&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory>
    <cvac:CommonSharesIssuedAndOutstanding
      contextRef="As_Of_12_31_2021_kQVJTWPgRUeESxCd99xt9A"
      decimals="INF"
      id="Tc_8f9Pj4mkVEGPgtL5rTYXcA_1_2"
      unitRef="Unit_Standard_shares_FapG5E6UqkK42IfNNOS6tA">187120728</cvac:CommonSharesIssuedAndOutstanding>
    <cvac:ShareOptionExercises
      contextRef="Duration_1_1_2022_To_3_31_2022_LiqLyh4w5EGnOWf_FZQF7Q"
      decimals="INF"
      id="Tc_Ns7tNpNvD02P4OF62zoEzA_2_2"
      unitRef="Unit_Standard_shares_FapG5E6UqkK42IfNNOS6tA">78732</cvac:ShareOptionExercises>
    <cvac:DecreaseInNumberOfSharesDueToTreasuryOfShares
      contextRef="Duration_1_1_2022_To_3_31_2022_LiqLyh4w5EGnOWf_FZQF7Q"
      decimals="INF"
      id="Tc_rKHAoG5bMk6N5GzaTbGfmQ_3_2"
      unitRef="Unit_Standard_shares_FapG5E6UqkK42IfNNOS6tA">-78732</cvac:DecreaseInNumberOfSharesDueToTreasuryOfShares>
    <cvac:CommonSharesIssuedAndOutstanding
      contextRef="As_Of_3_31_2022_mqhJpd3F8U63gbp_M5KLaw"
      decimals="INF"
      id="Tc_-fV9hqsBTkOQsCRNhLohqA_4_2"
      unitRef="Unit_Standard_shares_FapG5E6UqkK42IfNNOS6tA">187120728</cvac:CommonSharesIssuedAndOutstanding>
    <cvac:IfrsStockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_4_1_2022_To_6_30_2022_-gYjaV8XPUKBPSbaN9Qziw"
      decimals="INF"
      id="Tc_WP62pLqBzEavPv6xteAx1A_5_2"
      unitRef="Unit_Standard_shares_FapG5E6UqkK42IfNNOS6tA">340015</cvac:IfrsStockIssuedDuringPeriodSharesNewIssues>
    <cvac:StockIssuedDuringPeriodForExercises
      contextRef="Duration_4_1_2022_To_6_30_2022_-gYjaV8XPUKBPSbaN9Qziw"
      decimals="INF"
      id="Tc_pFy-A8bBYUWmjBFJ33f-nA_6_2"
      unitRef="Unit_Standard_shares_FapG5E6UqkK42IfNNOS6tA">6211</cvac:StockIssuedDuringPeriodForExercises>
    <cvac:ShareOptionExercises
      contextRef="Duration_4_1_2022_To_6_30_2022_-gYjaV8XPUKBPSbaN9Qziw"
      decimals="INF"
      id="Tc_Lrffp3iKdEWui9wRMO-o6A_7_2"
      unitRef="Unit_Standard_shares_FapG5E6UqkK42IfNNOS6tA">39418</cvac:ShareOptionExercises>
    <cvac:DecreaseInNumberOfSharesDueToTreasuryOfShares
      contextRef="Duration_4_1_2022_To_6_30_2022_-gYjaV8XPUKBPSbaN9Qziw"
      decimals="INF"
      id="Tc_A1DKIsBsKk6Meu414iHX0g_8_2"
      unitRef="Unit_Standard_shares_FapG5E6UqkK42IfNNOS6tA">-39418</cvac:DecreaseInNumberOfSharesDueToTreasuryOfShares>
    <cvac:CommonSharesIssuedAndOutstanding
      contextRef="As_Of_6_30_2022_kOEc9a1C10m7Rg-HheHYxg"
      decimals="INF"
      id="Tc_eFk5DOLE0UCcBK5eHGgpfw_9_2"
      unitRef="Unit_Standard_shares_FapG5E6UqkK42IfNNOS6tA">187466954</cvac:CommonSharesIssuedAndOutstanding>
    <cvac:IfrsStockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_7_1_2022_To_9_30_2022_pgUlLsnMwE6GuzWOXk2lcg"
      decimals="INF"
      id="Tc_0O50GDCjq0iiW1StftWtMA_10_2"
      unitRef="Unit_Standard_shares_FapG5E6UqkK42IfNNOS6tA">1948040</cvac:IfrsStockIssuedDuringPeriodSharesNewIssues>
    <cvac:StockIssuedDuringPeriodForExercises
      contextRef="Duration_7_1_2022_To_9_30_2022_pgUlLsnMwE6GuzWOXk2lcg"
      decimals="INF"
      id="Tc_vYggyswBjU2_O98a8QXVjA_11_2"
      unitRef="Unit_Standard_shares_FapG5E6UqkK42IfNNOS6tA">9746</cvac:StockIssuedDuringPeriodForExercises>
    <cvac:StockIssuanceDuringPeriodForExistingShareholders
      contextRef="Duration_7_1_2022_To_9_30_2022_pgUlLsnMwE6GuzWOXk2lcg"
      decimals="INF"
      id="Tc_F68tJCEiHEqruQdj-R5a0w_12_2"
      unitRef="Unit_Standard_shares_FapG5E6UqkK42IfNNOS6tA">858496</cvac:StockIssuanceDuringPeriodForExistingShareholders>
    <cvac:CommonSharesIssuedAndOutstanding
      contextRef="As_Of_9_30_2022_zuGVrjesE0WhwXSGmTqsgA"
      decimals="INF"
      id="Tc_GlvNpnyiH0qC75DXz4q68A_13_2"
      unitRef="Unit_Standard_shares_FapG5E6UqkK42IfNNOS6tA">190283236</cvac:CommonSharesIssuedAndOutstanding>
    <ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory
      contextRef="Duration_1_1_2022_To_9_30_2022_GrYkE3mhHEiRA4fxgfABRg"
      id="Tb_kcScwj880063aYxVhtrhXg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;5. Share-based payments&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;During the nine months ended September 30, 2022 and 2021, the Group recognized share-based based payments expenses of EUR 6,455k and EUR 11,285k, respectively, as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"&gt;Nine months ended September 30,&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:77.21%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.66%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:77.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:77.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EUR&#160;k&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EUR&#160;k&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:77.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Research and development expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 572&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 480&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:77.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Sales and marketing expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 166&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 152&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:77.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;General and administrative expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.66%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 10,547&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,823&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:77.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.66%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 11,285&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 6,455&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Expense recognized for the equity-settled programs was as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"&gt;Nine months ended September 30:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:77.21%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.66%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:77.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Program&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:77.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EUR&#160;k&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EUR k&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:77.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;LTIP&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 10,075&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,430&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:77.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;RSU&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 250&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 275&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:77.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;New VSOP&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 441&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (96)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:77.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Prior VSOP&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 519&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 99&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:77.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;RSU for key employees&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.66%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,746&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:77.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.66%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 11,825&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 6,455&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"&gt;On November 16, 2020, CureVac granted 266,155 options to the Chief Scientific Officer (CSO). Furthermore, on December 1, 2020, CureVac granted 266,156 options (in 3 tranches) to the company`s Chief Business Officer (CBO) and Chief Commercial Officer (CCO). All grants were made at no cost under the terms of a new long-term incentive plan (LTIP) put in place by CureVac N.V. Options &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;will be settled in shares of CureVac N.V. On September 30, 2022, none of the options granted to the CBO/CCO under the LTIP were exercised at that date. The CSO exercised 6,303 of his options in May 2022.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;On July 1, 2021, CureVac granted 20,000 options to the Chief Operations Officer (COO). Furthermore, on August 1, 2021, CureVac granted 30,000 options to the Chief Development Officer (CDO). All grants were made at no cost under the terms of the new long-term incentive plan (LTIP) put in place by CureVac N.V. Options will be settled in shares of CureVac N.V. As of September 30, 2022, none of the options granted to the COO under the LTIP were vested and hence, were not exercisable at that date. On September 30, 2022, none of the options granted to the CDO under the LTIP were vested and hence, were not exercisable at the date. As the CDO left CureVac in June 2022, all of his options were forfeited. All expenses recognized up to him leaving were reversed.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;On March 1, 2022, CureVac granted 11,500 options to two key employees. All grants were made at no cost under the terms of the new long-term incentive plan (LTIP) put in place by CureVac N.V. Options will be settled in shares of CureVac N.V.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;On June 22, 2022, CureVac granted 130,000 options to the executive board. All grants were made at no cost under the terms of the new long-term incentive plan (LTIP) put in place by CureVac N.V. Options will be settled in shares of CureVac N.V. As of September 30, 2022, none of the options granted to the executive board under the LTIP were vested and hence, were not exercisable at that date.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The expenses recognized for employee services received under the LTIP during the nine months ended September 30, 2022, is in an amount of EUR 4,430k (2021; EUR 10,075k) and is included in general and administrative expenses and sales and marketing expenses.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;In 2021, as part of the LTIP program, CureVac awarded RSUs (restricted stock units) to senior executives as well as supervisory board members. On June 24, 2021, CureVac awarded 10,956 RSUs to supervisory board members and on December 23, 2021, CureVac awarded 63,095 RSUs to the executive board and various key employees. Up to September 30, 2022, 17,887 RSU&#x2019;s were settled. The related RSU expense is recorded in the functional cost category to which the award recipient&#x2019;s costs are classified.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;On February 10, 2022, CureVac awarded 5,000 options to the Chief Operations Officer (COO). The related RSU expense is included in general and administrative expenses.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;On June 22, 2022, CureVac awarded 37,868 RSUs to supervisory board members and 193,340 RSUs to the executive board and various key employees. The related RSU expense is recorded in the functional cost category to which the award recipient&#x2019;s costs are classified.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;On June 22, 2022, CureVac awarded 36,000 RSUs to the Chief Executive Officer (CEO). The related RSU expense is included in general and administrative expenses.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;On September 22, 2022, CureVac awarded 30,000 RSUs to the Chief Business Officer (CBO). The related RSU expense is included in general and administrative expenses.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;On July 1, 2022, CureVac awarded 89,655 RSUs to the former Frame employees, now CureVac Netherlands. The related RSU expense is recorded in the functional cost category to which the award recipients&#x2019; costs are classified.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The remaining expense results from additional grants under the New VSOP and continued vesting of grants under the Prior VSOP. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Exercise of share-based payments&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"&gt;For the New VSOP plan, the IPO was a triggering event, by which all vested options, under the plan, became exercisable; 109,917 options were exercised within the first nine months of 2022 at a weighted average share price of USD 18.75.&lt;/p&gt;</ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees
      contextRef="Duration_1_1_2022_To_9_30_2022_GrYkE3mhHEiRA4fxgfABRg"
      decimals="-3"
      id="Narr_q_0mq82ioEew77nao29g5g"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">6455000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees
      contextRef="Duration_1_1_2021_To_9_30_2021_5RS16WkLc0uS2ug_bqUm-g"
      decimals="-3"
      id="Narr_kRXF54_DyESVNISqejftRQ"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">11285000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
    <cvac:DisclosureOfExpenseRecognizedForEmployeeServicesExplanatory
      contextRef="Duration_1_1_2022_To_9_30_2022_GrYkE3mhHEiRA4fxgfABRg"
      id="Tb_V2vjtKM59ESorVeIpLaMpg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"&gt;Nine months ended September 30,&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:77.21%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.66%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:77.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:77.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EUR&#160;k&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EUR&#160;k&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:77.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Research and development expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 572&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 480&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:77.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Sales and marketing expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 166&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 152&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:77.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;General and administrative expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.66%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 10,547&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,823&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:77.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.66%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 11,285&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 6,455&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</cvac:DisclosureOfExpenseRecognizedForEmployeeServicesExplanatory>
    <cvac:ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInResearchAndDevelopmentExpenses
      contextRef="Duration_1_1_2021_To_9_30_2021_5RS16WkLc0uS2ug_bqUm-g"
      decimals="-3"
      id="Tc_4t-GpgkoHEuJzQwoF0A_XQ_3_2"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">572000</cvac:ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInResearchAndDevelopmentExpenses>
    <cvac:ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInResearchAndDevelopmentExpenses
      contextRef="Duration_1_1_2022_To_9_30_2022_GrYkE3mhHEiRA4fxgfABRg"
      decimals="-3"
      id="Tc_icOww8P4D0C42JhKNpuWjg_3_4"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">480000</cvac:ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInResearchAndDevelopmentExpenses>
    <cvac:ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInSellingAndDistributionExpenses
      contextRef="Duration_1_1_2021_To_9_30_2021_5RS16WkLc0uS2ug_bqUm-g"
      decimals="-3"
      id="Tc_Vks5nIeCDEiczQbXxZ1lRw_4_2"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">166000</cvac:ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInSellingAndDistributionExpenses>
    <cvac:ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInSellingAndDistributionExpenses
      contextRef="Duration_1_1_2022_To_9_30_2022_GrYkE3mhHEiRA4fxgfABRg"
      decimals="-3"
      id="Tc_OyqepjNZkEG3ljtXNlKrqg_4_4"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">152000</cvac:ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInSellingAndDistributionExpenses>
    <cvac:ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInGeneralAndAdministrativeExpenses
      contextRef="Duration_1_1_2021_To_9_30_2021_5RS16WkLc0uS2ug_bqUm-g"
      decimals="-3"
      id="Tc_dipF1ABjAU2PRpadcKpsKw_5_2"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">10547000</cvac:ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInGeneralAndAdministrativeExpenses>
    <cvac:ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInGeneralAndAdministrativeExpenses
      contextRef="Duration_1_1_2022_To_9_30_2022_GrYkE3mhHEiRA4fxgfABRg"
      decimals="-3"
      id="Tc_zmELOFYMrEC4fsWuebdljg_5_4"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">5823000</cvac:ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInGeneralAndAdministrativeExpenses>
    <cvac:BenefitExpenseRecognizedForShareBasedPayment
      contextRef="Duration_1_1_2021_To_9_30_2021_5RS16WkLc0uS2ug_bqUm-g"
      decimals="-3"
      id="Tc_O4msm3ivNUKzxvAaDKQpww_6_2"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">11285000</cvac:BenefitExpenseRecognizedForShareBasedPayment>
    <cvac:BenefitExpenseRecognizedForShareBasedPayment
      contextRef="Duration_1_1_2022_To_9_30_2022_GrYkE3mhHEiRA4fxgfABRg"
      decimals="-3"
      id="Tc_pgRekpCwvkaKgloy00bzxw_6_4"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">6455000</cvac:BenefitExpenseRecognizedForShareBasedPayment>
    <cvac:ScheduleOfExpenseRecognizedForProgramsTableTextBlock
      contextRef="Duration_1_1_2022_To_9_30_2022_GrYkE3mhHEiRA4fxgfABRg"
      id="Tb_0rkc7Mi14EOU4Z-7BCcu2Q">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"&gt;Nine months ended September 30:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:77.21%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.66%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:77.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Program&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:77.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EUR&#160;k&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EUR k&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:77.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;LTIP&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 10,075&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,430&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:77.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;RSU&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 250&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 275&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:77.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;New VSOP&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 441&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (96)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:77.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Prior VSOP&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 519&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 99&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:77.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;RSU for key employees&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.66%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,746&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:77.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.66%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 11,825&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 6,455&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</cvac:ScheduleOfExpenseRecognizedForProgramsTableTextBlock>
    <cvac:ExpenseRecognizedForEmployeeServices
      contextRef="Duration_1_1_2021_To_9_30_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_-7vn4v2-bEuMIEE_cJjuug"
      decimals="-3"
      id="Tc_DXAcXqustUuqpxxXBLxE6A_3_2"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">10075000</cvac:ExpenseRecognizedForEmployeeServices>
    <cvac:ExpenseRecognizedForEmployeeServices
      contextRef="Duration_1_1_2022_To_9_30_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_6VLzYOVR1k24GIHsNaoB2A"
      decimals="-3"
      id="Tc_FFf8zFVGjEykehqdGT3Nog_3_4"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">4430000</cvac:ExpenseRecognizedForEmployeeServices>
    <cvac:ExpenseRecognizedForEmployeeServices
      contextRef="Duration_1_1_2021_To_9_30_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_IfrsRestrictedStockUnitMember_QgoBjuQOZEO99XfLIWVoQA"
      decimals="-3"
      id="Tc_htbki9qpBEm7YXRw6cSyyQ_4_2"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">250000</cvac:ExpenseRecognizedForEmployeeServices>
    <cvac:ExpenseRecognizedForEmployeeServices
      contextRef="Duration_1_1_2022_To_9_30_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_IfrsRestrictedStockUnitMember_XRKL4qJ810SYjrkXptDpGw"
      decimals="-3"
      id="Tc_AS8Ace9S2E-OvtCFvQdUFA_4_4"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">275000</cvac:ExpenseRecognizedForEmployeeServices>
    <cvac:ExpenseRecognizedForEmployeeServices
      contextRef="Duration_1_1_2021_To_9_30_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_VirtualSharesProgramIiMember_5phdNMZ4UUa7p62ZO4ZmiQ"
      decimals="-3"
      id="Tc_t2lHMRQNWU25TGVZHQevow_5_2"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">441000</cvac:ExpenseRecognizedForEmployeeServices>
    <cvac:ExpenseRecognizedForEmployeeServices
      contextRef="Duration_1_1_2022_To_9_30_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_VirtualSharesProgramIiMember_94K0C2dKwEe87RAK5o3yHg"
      decimals="-3"
      id="Tc_d1J0JtE6RUGlDDq-xwLUlg_5_4"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">-96000</cvac:ExpenseRecognizedForEmployeeServices>
    <cvac:ExpenseRecognizedForEmployeeServices
      contextRef="Duration_1_1_2021_To_9_30_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_VirtualSharesProgramIMember_G8wLGie1fkurrNt_KXss3A"
      decimals="-3"
      id="Tc_Vw_1XbcwkUG0Go_TX9PyIg_6_2"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">519000</cvac:ExpenseRecognizedForEmployeeServices>
    <cvac:ExpenseRecognizedForEmployeeServices
      contextRef="Duration_1_1_2022_To_9_30_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_VirtualSharesProgramIMember_8-6ss668qkGhxxIvnx3JTQ"
      decimals="-3"
      id="Tc_werTFo5zjk-XbC3OMrd3Gw_6_4"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">99000</cvac:ExpenseRecognizedForEmployeeServices>
    <cvac:ExpenseRecognizedForEmployeeServices
      contextRef="Duration_1_1_2022_To_9_30_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_RestrictedStockUnitForKeyEmployeesMember_dZiMEF-WIUaYDoS6prDgKg"
      decimals="-3"
      id="Tc_tfn8tqQUN0qo9ReH51kVZg_7_4"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">1746000</cvac:ExpenseRecognizedForEmployeeServices>
    <cvac:ExpenseRecognizedForEmployeeServices
      contextRef="Duration_1_1_2021_To_9_30_2021_5RS16WkLc0uS2ug_bqUm-g"
      decimals="-3"
      id="Tc_AZfBebEZ3kCZthTtcNt2yw_8_2"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">11825000</cvac:ExpenseRecognizedForEmployeeServices>
    <cvac:ExpenseRecognizedForEmployeeServices
      contextRef="Duration_1_1_2022_To_9_30_2022_GrYkE3mhHEiRA4fxgfABRg"
      decimals="-3"
      id="Tc_Dsb_N3ipS02lufHltU339A_8_4"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">6455000</cvac:ExpenseRecognizedForEmployeeServices>
    <ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement
      contextRef="Duration_11_16_2020_To_11_16_2020_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ChiefScientificOfficerMember_YqQecowO2kuyd-MSikFagg"
      decimals="INF"
      id="Narr_VeoqoyI810KbxHgF5KBP1g"
      unitRef="Unit_Standard_Option_puBmss6yUE6NakwAOqqzng">266155</ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement
      contextRef="Duration_12_1_2020_To_12_1_2020_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ChiefBusinessOfficerAndChiefCommercialOfficerMember_T3JjiYhNB0mcje4uQOSblw"
      decimals="INF"
      id="Narr_4zrojxpjCkmtFWswVrXAaQ"
      unitRef="Unit_Standard_Option_puBmss6yUE6NakwAOqqzng">266156</ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement
      contextRef="Duration_5_1_2022_To_5_31_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ChiefScientificOfficerMember_v1kWVxI7sE-mtWe59zilhg"
      decimals="INF"
      id="Narr_QMUyydDpFUifiSeZpdU-SA"
      unitRef="Unit_Standard_Option_puBmss6yUE6NakwAOqqzng">6303</ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement
      contextRef="Duration_7_1_2021_To_7_1_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_srt_ChiefOperatingOfficerMember_lTsgjULrh0unxpPIyz1Ojw"
      decimals="INF"
      id="Narr_4mlwvlcnYk2G6a1TymHCrA"
      unitRef="Unit_Standard_Option_puBmss6yUE6NakwAOqqzng">20000</ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement
      contextRef="Duration_8_1_2021_To_8_1_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ChiefDevelopmentOfficerMember_Sovw0LhIOky6A14jJLrI2g"
      decimals="INF"
      id="Narr_56mqKOX_gUqDqgMGIyWUVA"
      unitRef="Unit_Standard_Option_puBmss6yUE6NakwAOqqzng">30000</ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement>
    <cvac:NumberOfShareOptionsVestedInShareBasedPaymentArrangement
      contextRef="Duration_9_1_2022_To_9_30_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_srt_ChiefOperatingOfficerMember_fTDjhW41wkulF-dl-PGYYg"
      decimals="INF"
      id="Narr_aFjOGZrR6UKtR-o7tB8XLg"
      unitRef="Unit_Standard_Option_puBmss6yUE6NakwAOqqzng">0</cvac:NumberOfShareOptionsVestedInShareBasedPaymentArrangement>
    <cvac:NumberOfShareOptionsVestedInShareBasedPaymentArrangement
      contextRef="Duration_9_1_2022_To_9_30_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ChiefDevelopmentOfficerMember_KVJTFke5SEudjsaztY_vxw"
      decimals="INF"
      id="Narr_M1PD1MAJNkCJ8cLz2W2rnA"
      unitRef="Unit_Standard_Option_puBmss6yUE6NakwAOqqzng">0</cvac:NumberOfShareOptionsVestedInShareBasedPaymentArrangement>
    <ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement
      contextRef="Duration_3_1_2022_To_3_1_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_KeyEmployeesMember_4k0biTJ1L0OjkLnTREDR-w"
      decimals="INF"
      id="Narr_nzXq85jng0ahNaGxKArxNg"
      unitRef="Unit_Standard_Option_puBmss6yUE6NakwAOqqzng">11500</ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement>
    <cvac:NumberOfKeyEmployees
      contextRef="Duration_3_1_2022_To_3_1_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_KeyEmployeesMember_4k0biTJ1L0OjkLnTREDR-w"
      decimals="INF"
      id="Narr_d9wN0tFWv0OCFq4-YA2ETA"
      unitRef="Unit_Standard_employee_-Jetz9Th0ka1WnOToYuqxw">2</cvac:NumberOfKeyEmployees>
    <ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement
      contextRef="Duration_6_22_2022_To_6_22_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ExecutiveBoardMembersMember_HGJGQ29fb0mCC_uf2baYzw"
      decimals="INF"
      id="Narr_TOQddotQvki89BlaWBYQKw"
      unitRef="Unit_Standard_Option_puBmss6yUE6NakwAOqqzng">130000</ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement>
    <cvac:NumberOfShareOptionsVestedInShareBasedPaymentArrangement
      contextRef="Duration_9_1_2022_To_9_30_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ExecutiveBoardMembersMember_hjnyCWqWaUG4U5M-ifsvcQ"
      decimals="INF"
      id="Narr_i5KCBMlrdkOW9qFWOhhLvw"
      unitRef="Unit_Standard_Option_puBmss6yUE6NakwAOqqzng">0</cvac:NumberOfShareOptionsVestedInShareBasedPaymentArrangement>
    <cvac:ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInGeneralAndAdministrativeExpenses
      contextRef="Duration_1_1_2022_To_9_30_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ChiefScientificOfficerMember_UtQLqJhh8UiH4zCtHpD4cQ"
      decimals="-3"
      id="Narr_h_6bcD2AoUOHCnuzofXPdg"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">4430000</cvac:ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInGeneralAndAdministrativeExpenses>
    <cvac:ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInGeneralAndAdministrativeExpenses
      contextRef="Duration_1_1_2021_To_9_30_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ChiefScientificOfficerMember_Zo3CrV1xc0-l6T3OrHnAhQ"
      decimals="-3"
      id="Narr_K_PUV4qSlkesDx1_DN7RXA"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">10075000</cvac:ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInGeneralAndAdministrativeExpenses>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="Duration_6_24_2021_To_6_24_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_SupervisoryBoardMembersMember_WzScVvwhuUOXBAORYNGw1A"
      decimals="INF"
      id="Narr_7phhPaJMjUeC4fFgOw2jIg"
      unitRef="Unit_Standard_Option_puBmss6yUE6NakwAOqqzng">10956</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="Duration_12_23_2021_To_12_23_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_MembersOfExecutiveBoardAndVariousKeyEmployeesMember_sPT0TmgA5UyfJUOLzYAeKg"
      decimals="INF"
      id="Narr_2mUE_8EuakmaqCpYAaKikA"
      unitRef="Unit_Standard_Option_puBmss6yUE6NakwAOqqzng">63095</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <cvac:NumberOfOtherEquityInstrumentsSettledInShareBasedPaymentArrangement
      contextRef="Duration_1_1_2022_To_9_30_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_6VLzYOVR1k24GIHsNaoB2A"
      decimals="INF"
      id="Narr_6OLpXAUg_U60kRfA5xb73g"
      unitRef="Unit_Standard_shares_FapG5E6UqkK42IfNNOS6tA">17887</cvac:NumberOfOtherEquityInstrumentsSettledInShareBasedPaymentArrangement>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="Duration_2_10_2022_To_2_10_2022_srt_TitleOfIndividualAxis_srt_ChiefOperatingOfficerMember_iNHQybO4Pk2sc9tkHPztxA"
      decimals="INF"
      id="Narr_UXvLGapbEku3tcT1kUQ0Dg"
      unitRef="Unit_Standard_Option_puBmss6yUE6NakwAOqqzng">5000</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="Duration_6_22_2022_To_6_22_2022_srt_TitleOfIndividualAxis_cvac_SupervisoryBoardMembersMember_8ClvViKS_0mYv0ZZa7FsSA"
      decimals="INF"
      id="Narr_1tN673pQbky8CmfGhFDbtw"
      unitRef="Unit_Standard_Option_puBmss6yUE6NakwAOqqzng">37868</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="Duration_6_22_2022_To_6_22_2022_srt_TitleOfIndividualAxis_cvac_ExecutiveBoardMembersMember_hf65wxXOEECOwq5tEDpNWQ"
      decimals="INF"
      id="Narr_h2o5pGQRREy5cHUAhTwWag"
      unitRef="Unit_Standard_Option_puBmss6yUE6NakwAOqqzng">193340</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="Duration_6_22_2022_To_6_22_2022_srt_TitleOfIndividualAxis_cvac_ThenChiefExecutiveOfficerMember_MEmTtrB-PEWG-6nmSb4NZw"
      decimals="INF"
      id="Narr_es4Q5jYZDEaGFdTWcZsGyQ"
      unitRef="Unit_Standard_Option_puBmss6yUE6NakwAOqqzng">36000</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="Duration_9_22_2022_To_9_22_2022_srt_TitleOfIndividualAxis_cvac_ChiefBusinessOfficerMember_GRzsO5WyQEanIaFIpuw0tg"
      decimals="INF"
      id="Narr_bufsV0qB002Du8VulfSkfA"
      unitRef="Unit_Standard_Option_puBmss6yUE6NakwAOqqzng">30000</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="Duration_7_1_2022_To_7_1_2022_srt_TitleOfIndividualAxis_cvac_FormerFrameEmployeesMember_sBysEqLlSUqSMftPMXcxQQ"
      decimals="INF"
      id="Narr_75v354gjSkWU_7A_db9gFQ"
      unitRef="Unit_Standard_Option_puBmss6yUE6NakwAOqqzng">89655</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement
      contextRef="As_Of_9_30_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_VirtualSharesProgramIiMember_-aEvT6TgvU2aaNALbBrVfw"
      decimals="INF"
      id="Narr_21wUJZN9GkG3FhUXL7YGeA"
      unitRef="Unit_Standard_Option_puBmss6yUE6NakwAOqqzng">109917</ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019
      contextRef="Duration_4_1_2021_To_9_30_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_VirtualSharesProgramIiMember_H9asqvfrLUqv97coIp3GBQ"
      decimals="2"
      id="Narr_-DyjcK5gzkKD306y22O55w"
      unitRef="Unit_Divide_USD_shares_B3tHpJm3a0ytZJRcE10tTA">18750000</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019>
    <cvac:DisclosureOfFixedAssetsExplanatory
      contextRef="Duration_1_1_2022_To_9_30_2022_GrYkE3mhHEiRA4fxgfABRg"
      id="Tb_sBUouVkIKUae2H-q1QoNhQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;6. Fixed Assets&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;6.1 Intangible assets&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;During the nine months ended September 30, 2022, the Group acquired intangible assets of EUR 24,224k (Nine months ended September 30, 2021: EUR 2,273k). Acquired intangibles mainly related to licenses, software and prepayments made to acquire those and, for the nine months ended September 30, 2022, include technology and goodwill acquired in the Frame acquisition. For more details, refer to Note 18.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;6.2 Property, plant and equipment&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;During the nine months ended September 30, 2022, the increase in property, plant and equipment was due primarily to the purchase of technical equipment and machines and other equipment of EUR 8,661k (September 30, 2021: EUR 8,907k) as well as additional amounts recognized as construction in progress of EUR 56,746k for Company-owned GMP IV facility (EUR 49,366k) and equipment physically located at the CMO facilities (EUR 3,616k) and the remaining amount mainly for Company&#x2019;s GMP facilities. The increase was partially offset by EUR 5,854k impairment of equipment located at a CMO facility, which was recognized in cost of sales.&lt;/p&gt;</cvac:DisclosureOfFixedAssetsExplanatory>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill
      contextRef="Duration_1_1_2022_To_9_30_2022_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_ifrs-full_GrossCarryingAmountMember_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_cvac_LicensesSoftwareAndPrepaymentsMember_zeXSak6OQ0iEmjYXe9qo9w"
      decimals="-3"
      id="Narr_pl1wyBC_3ke4uc19KesI7A"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">24224000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill
      contextRef="Duration_1_1_2021_To_9_30_2021_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_ifrs-full_GrossCarryingAmountMember_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_cvac_LicensesSoftwareAndPrepaymentsMember_CzUp1LGslUSZTIy-JKWdLw"
      decimals="-3"
      id="Narr_jYxNM6ESak-GKscOZYC_UA"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">2273000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment
      contextRef="Duration_1_1_2022_To_9_30_2022_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_ifrs-full_GrossCarryingAmountMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_cvac_TechnicalEquipmentAndMachinesAndOtherEquipmentMember_fDP_vLfur0CDvezFllAP3w"
      decimals="-3"
      id="Narr_aoE5R-cfIkCCgxbTt0jjVw"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">8661000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment
      contextRef="Duration_1_1_2021_To_9_30_2021_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_ifrs-full_GrossCarryingAmountMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_cvac_TechnicalEquipmentAndMachinesAndOtherEquipmentMember_4EQ5xotfIUujKtdlrzbPVQ"
      decimals="-3"
      id="Narr_igqIY1cu40Gxqgt4-qe5Sw"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">8907000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment
      contextRef="Duration_1_1_2022_To_9_30_2022_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_ConstructionInProgressMember_BqU3Y93BzU-k13235fXn4g"
      decimals="-3"
      id="Narr_AhHJJsr0BEmN7dn6r_pF1g"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">56746000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment
      contextRef="Duration_1_1_2022_To_9_30_2022_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_cvac_CompanyOwnedGmpIvFacilityMember_ZPOcXZnMYk-Um0cwVb1ZHw"
      decimals="-3"
      id="Narr_KtoCH9YZZ0qa_HDaXdhDnA"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">49366000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment
      contextRef="Duration_1_1_2022_To_9_30_2022_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_cvac_EquipmentPhysicallyLocatedAtCmoFacilitiesMember_7vsnG93SaE-EN8D8ClkcNA"
      decimals="-3"
      id="Narr_cVInoADr2UWpRA1ZhcYFEw"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">3616000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <cvac:IncreaseInPropertyAndEquipmentOffSetByImpairmentOfEquipment
      contextRef="Duration_1_1_2022_To_9_30_2022_GrYkE3mhHEiRA4fxgfABRg"
      decimals="-3"
      id="Narr_V5EelMGCo0SxghuJsD1mvA"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">5854000</cvac:IncreaseInPropertyAndEquipmentOffSetByImpairmentOfEquipment>
    <ifrs-full:DisclosureOfNoncurrentAssetsHeldForSaleAndDiscontinuedOperationsExplanatory
      contextRef="Duration_1_1_2022_To_9_30_2022_GrYkE3mhHEiRA4fxgfABRg"
      id="Tb_tj_fwEAcFUShSTkfxVXV4A">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;7. Assets held for sale&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;In the second quarter 2022, CureVac signed a sales agreement with a global pharmaceutical contract development and manufacturing organization for the sale of Ultra-Low Temperature freezers for a total price of EUR 865k. The sale of the assets occurred in July 2022.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;In the third quarter 2022, CureVac listed lab equipment for sale on the internet portal of a service provider. Additionally, in fourth quarter 2022, CureVac sold equipment to a CMO.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Group classifies non-current assets as held for sale if their carrying amounts will be recovered principally through a sale transaction rather than through continuing use. Non-current assets classified as held for sale are measured at the lower of their carrying amount and fair value less costs to sell. Costs to sell are the incremental costs directly attributable to the disposal of an asset, excluding finance costs and income tax expense.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The criteria for held for sale classification is regarded as met only when the sale is highly probable, and the asset is available for immediate sale in its present condition. Actions required to complete the sale should indicate that it is unlikely that significant changes to the sale will be made or that the decision to sell will be withdrawn. Management must be committed to the plan to sell the asset and the sale expected to be completed within one year from the date of the classification.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Property, plant and equipment and intangible assets are not depreciated or amortized once classified as held for sale.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Assets and liabilities classified as held for sale are presented separately as current items in the statement of financial position.&lt;/p&gt;</ifrs-full:DisclosureOfNoncurrentAssetsHeldForSaleAndDiscontinuedOperationsExplanatory>
    <cvac:IfrsDisposalGroupIncludingDiscontinuedOperationConsideration
      contextRef="As_Of_6_30_2022_kOEc9a1C10m7Rg-HheHYxg"
      decimals="-3"
      id="Narr_k5emFVGq-U2C1ymm1biOmA"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">865000</cvac:IfrsDisposalGroupIncludingDiscontinuedOperationConsideration>
    <ifrs-full:DisclosureOfInventoriesExplanatory
      contextRef="Duration_1_1_2022_To_9_30_2022_GrYkE3mhHEiRA4fxgfABRg"
      id="Tb_RcZcN9nn_EGkV9EQzNfk5A">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;8. Inventories&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The inventories include only raw materials. During the nine months ended September 30, 2022, the decrease in inventory of EUR 48,291k is due primarily to transfer of inventory EUR &lt;span style="-sec-ix-hidden:Hidden_N17kRFMeX0inGpkHufA1CQ;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;9,800&lt;/span&gt;&lt;/span&gt;k (net value) to GSK in connection with an agreement into which it entered with Novartis (see Note 3.6 for additional information) and due to further write-offs of EUR 41,295k as certain raw materials, which had been procured for manufacture into products to sell to GSK, but which are now no longer expected to be purchased.&lt;/p&gt;</ifrs-full:DisclosureOfInventoriesExplanatory>
    <cvac:IncreaseDecreaseInInventory
      contextRef="Duration_1_1_2022_To_9_30_2022_srt_CounterpartyNameAxis_cvac_GlaxosmithklineMember_3G2M3SARj0GkTuTa4M37uw"
      decimals="-3"
      id="Narr_UXOmGurfDEOZA5bv46jEEQ"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">48291000</cvac:IncreaseDecreaseInInventory>
    <ifrs-full:InventoryWritedown2011
      contextRef="Duration_1_1_2022_To_9_30_2022_srt_CounterpartyNameAxis_cvac_GlaxosmithklineMember_3G2M3SARj0GkTuTa4M37uw"
      decimals="-3"
      id="Narr_Md3EXrt-UkOxv6Eb2nXmwQ"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">41295000</ifrs-full:InventoryWritedown2011>
    <cvac:DisclosureOfPrepaidExpensesAndOtherCurrentAssetsExplanatory
      contextRef="Duration_1_1_2022_To_9_30_2022_GrYkE3mhHEiRA4fxgfABRg"
      id="Tb_cUA_pTJKE0SrCQjD9ahsdw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;9. Prepaid expenses and other assets (current)&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"&gt;Prepaid expenses and other current assets as of September 30, 2022 amounted to EUR 60,952k (December 31, 2021: 49,244k) and mainly include receivables for the GSK compensation of EUR 12,678k (December 31, 2021: EUR 0k). For more details, refer to Note&#160;3.6. In addition, other assets include further prepayments for material and CRO costs in the amount of EUR 21,999k (December 31, 2021: EUR 5,724k) and tax claims against the tax authorities of EUR 18,009k (December 31, 2021: EUR 35,234k). These net amounts of VAT refund claims and VAT payables do not bear interest and are reported to the tax authorities on a monthly basis.&lt;/p&gt;</cvac:DisclosureOfPrepaidExpensesAndOtherCurrentAssetsExplanatory>
    <ifrs-full:CurrentPrepaymentsAndOtherCurrentAssets
      contextRef="As_Of_9_30_2022_zuGVrjesE0WhwXSGmTqsgA"
      decimals="-3"
      id="Narr_l81-a4_C2ESMDnq_YsJVkw"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">60952000</ifrs-full:CurrentPrepaymentsAndOtherCurrentAssets>
    <ifrs-full:CurrentPrepaymentsAndOtherCurrentAssets
      contextRef="As_Of_12_31_2021_kQVJTWPgRUeESxCd99xt9A"
      decimals="-3"
      id="Narr_aWSrTY9Z9EG6lJOc20CUdQ"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">49244000</ifrs-full:CurrentPrepaymentsAndOtherCurrentAssets>
    <cvac:PrepaidCompensationForContractManufacturingOrganizationsTransfer
      contextRef="As_Of_9_30_2022_zuGVrjesE0WhwXSGmTqsgA"
      decimals="-3"
      id="Narr_igwnn0TeUUWJ0iF7iPU2LQ"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">12678000</cvac:PrepaidCompensationForContractManufacturingOrganizationsTransfer>
    <cvac:PrepaidCompensationForContractManufacturingOrganizationsTransfer
      contextRef="As_Of_12_31_2021_kQVJTWPgRUeESxCd99xt9A"
      decimals="-3"
      id="Narr_vkeZUdNzNk6yfpHdWR1LNw"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">0</cvac:PrepaidCompensationForContractManufacturingOrganizationsTransfer>
    <ifrs-full:CurrentAdvancesToSuppliers
      contextRef="As_Of_9_30_2022_zuGVrjesE0WhwXSGmTqsgA"
      decimals="-3"
      id="Narr_QtGjI0sHgkayypCno3tbaw"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">21999000</ifrs-full:CurrentAdvancesToSuppliers>
    <ifrs-full:CurrentAdvancesToSuppliers
      contextRef="As_Of_12_31_2021_kQVJTWPgRUeESxCd99xt9A"
      decimals="-3"
      id="Narr_m7k0W4xQbEyQiogsIjjqKg"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">5724000</ifrs-full:CurrentAdvancesToSuppliers>
    <ifrs-full:ReceivablesFromTaxesOtherThanIncomeTax
      contextRef="As_Of_9_30_2022_zuGVrjesE0WhwXSGmTqsgA"
      decimals="-3"
      id="Narr_pB2b29kOUkOr2ol53WrmtA"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">18009000</ifrs-full:ReceivablesFromTaxesOtherThanIncomeTax>
    <ifrs-full:ReceivablesFromTaxesOtherThanIncomeTax
      contextRef="As_Of_12_31_2021_kQVJTWPgRUeESxCd99xt9A"
      decimals="-3"
      id="Narr_bb_g3Wgjb0uvHIrcIG7aKA"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">35234000</ifrs-full:ReceivablesFromTaxesOtherThanIncomeTax>
    <ifrs-full:DisclosureOfFinancialInstrumentsExplanatory
      contextRef="Duration_1_1_2022_To_9_30_2022_GrYkE3mhHEiRA4fxgfABRg"
      id="Tb_7iZBc8YDRECNSfusUlgbTg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;10. Financial assets and financial liabilities&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Fair values of cash and cash equivalents, trade receivables, trade payables, and other current liabilities approximate their carrying amounts largely due to the short-term maturities of these instruments. Cash and cash equivalents compromise cash at banks and term deposits.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"&gt;Cash and cash equivalents compromise cash at banks and term deposits. There were no transfers between Level 1 and Level 2 fair value measurements and no transfers into or out of Level 3 fair value measurements during the nine months ended September 30, 2022 and 2021.&lt;/p&gt;</ifrs-full:DisclosureOfFinancialInstrumentsExplanatory>
    <ifrs-full:TransfersOutOfLevel1IntoLevel2OfFairValueHierarchyAssets
      contextRef="Duration_1_1_2021_To_9_30_2021_5RS16WkLc0uS2ug_bqUm-g"
      decimals="0"
      id="Narr_MbZpJQeIOEuHTPXuUdNaPQ"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">0</ifrs-full:TransfersOutOfLevel1IntoLevel2OfFairValueHierarchyAssets>
    <ifrs-full:TransfersOutOfLevel1IntoLevel2OfFairValueHierarchyAssets
      contextRef="Duration_1_1_2022_To_9_30_2022_GrYkE3mhHEiRA4fxgfABRg"
      decimals="0"
      id="Narr_PqH7lVike0O0VecC-vkDjA"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">0</ifrs-full:TransfersOutOfLevel1IntoLevel2OfFairValueHierarchyAssets>
    <ifrs-full:TransfersIntoLevel3OfFairValueHierarchyAssets
      contextRef="Duration_1_1_2021_To_9_30_2021_5RS16WkLc0uS2ug_bqUm-g"
      decimals="0"
      id="Narr_JDvbOTqxYEKe68grU_mk9w"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">0</ifrs-full:TransfersIntoLevel3OfFairValueHierarchyAssets>
    <ifrs-full:TransfersIntoLevel3OfFairValueHierarchyAssets
      contextRef="Duration_1_1_2022_To_9_30_2022_GrYkE3mhHEiRA4fxgfABRg"
      decimals="0"
      id="Narr_aXr3ekyUPEWzPCHGtBPZJg"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">0</ifrs-full:TransfersIntoLevel3OfFairValueHierarchyAssets>
    <ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory
      contextRef="Duration_1_1_2022_To_9_30_2022_GrYkE3mhHEiRA4fxgfABRg"
      id="Tb_1dxviq-c0kmFX9pc_huKhg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;11. Trade and other payables&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"&gt;During the nine months ended September 30, 2022, the decrease of EUR 75,095k in trade and other payables was primarily due to less payables to suppliers following the withdrawal of the EMA approval application for CVnCoV in Q4 2021.&lt;/p&gt;</ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory>
    <cvac:ChangeInTradeAndOtherPayables
      contextRef="Duration_1_1_2022_To_9_30_2022_GrYkE3mhHEiRA4fxgfABRg"
      decimals="-3"
      id="Narr_LwkuFXQamE6IafehDf5UZA"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">75095000</cvac:ChangeInTradeAndOtherPayables>
    <ifrs-full:DisclosureOfOtherLiabilitiesExplanatory
      contextRef="Duration_1_1_2022_To_9_30_2022_GrYkE3mhHEiRA4fxgfABRg"
      id="Tb_Z5CVGaQLf0ioJpZyv8uIfg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;12. Other liabilities&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"&gt;During the nine months ended September 30, 2022, the decrease of EUR 91,106k in other liabilities was primarily due to a net decrease of contract termination provisions (see Note 3.6), due to a reversal of a portion of the provision for onerous contracts relating to CRO arrangements due to a change in estimate (see Note 3.4), due to a consumption of the CRO provision for onerous losses and due to lower accruals for outstanding invoices. &lt;/p&gt;</ifrs-full:DisclosureOfOtherLiabilitiesExplanatory>
    <cvac:ChangeInOtherLiabilities
      contextRef="Duration_1_1_2022_To_9_30_2022_GrYkE3mhHEiRA4fxgfABRg"
      decimals="-3"
      id="Narr_Phn6icGUn02zPB3Km2xUQw"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">91106000</cvac:ChangeInOtherLiabilities>
    <ifrs-full:DisclosureOfDetailedInformationAboutBorrowingsExplanatory
      contextRef="Duration_1_1_2022_To_9_30_2022_GrYkE3mhHEiRA4fxgfABRg"
      id="Tb_2FFsVI_txU6ALpL9cQbJCw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;13. Loans&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;As of September 30, 2021, CureVac had drawn the first of the three tranches of the EIB loan received in December 2020 and, thus, EUR 25 million (plus accrued interest of EUR 2,543k) was outstanding on the loan as of that date.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"&gt;During the year ended December 31, 2021, CureVac decided to early terminate the EIB loan for a total cash consideration of EUR 26,633k, which comprises of EUR 25,000k repayment of the loan and 1,633k interest and fees. As of December 31, 2021, the EIB loan was fully repaid.&lt;/p&gt;</ifrs-full:DisclosureOfDetailedInformationAboutBorrowingsExplanatory>
    <ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities
      contextRef="Duration_1_1_2021_To_9_30_2021_ifrs-full_BorrowingsByNameAxis_cvac_IfrsLineOfCreditMember_w0otbseHCk-9ZLH1m6FDbA"
      decimals="-6"
      id="Narr_bHcJV6fChUuTbJNUJ64Ckg"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">25000000</ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities>
    <cvac:LineOfCreditAccruedInterestPayable
      contextRef="As_Of_9_30_2021_ifrs-full_BorrowingsByNameAxis_cvac_IfrsLineOfCreditMember_lKYOAuZEL0axHg8yeQcJvA"
      decimals="-3"
      id="Narr_6sOO03p0K06XA5bLbpnS-w"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">2543000</cvac:LineOfCreditAccruedInterestPayable>
    <ifrs-full:RepaymentsOfBorrowingsClassifiedAsFinancingActivities
      contextRef="Duration_1_1_2021_To_12_31_2021_ifrs-full_BorrowingsByNameAxis_cvac_IfrsLineOfCreditMember_Zjc-vTBONUWK_U5c-7CI3w"
      decimals="-3"
      id="Narr_RmJmyHZfg0mdk7AIfspCIw"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">26633000</ifrs-full:RepaymentsOfBorrowingsClassifiedAsFinancingActivities>
    <cvac:RepaymentsOfPrincipalAmountOfBorrowings
      contextRef="Duration_1_1_2021_To_12_31_2021_ifrs-full_BorrowingsByNameAxis_cvac_IfrsLineOfCreditMember_Zjc-vTBONUWK_U5c-7CI3w"
      decimals="-3"
      id="Narr_ixPPqNIKjEqj9xqmXGkW_w"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">25000000</cvac:RepaymentsOfPrincipalAmountOfBorrowings>
    <cvac:IfrsRepaymentsOfAccruedInterestAndFeesOfBorrowings
      contextRef="Duration_1_1_2021_To_12_31_2021_ifrs-full_BorrowingsByNameAxis_cvac_IfrsLineOfCreditMember_Zjc-vTBONUWK_U5c-7CI3w"
      decimals="-3"
      id="Narr_q2zSwRHrHUa8xGXTMvzOmA"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">1633000</cvac:IfrsRepaymentsOfAccruedInterestAndFeesOfBorrowings>
    <ifrs-full:DisclosureOfIncomeTaxExplanatory
      contextRef="Duration_1_1_2022_To_9_30_2022_GrYkE3mhHEiRA4fxgfABRg"
      id="Tb_9qn5VpEfrkOKmziJW-Nhvg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;14. Income tax&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Group booked the expected tax benefits or expenses based on a best estimate for a period of nine months ended September 30, 2022. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"&gt;For the nine months ended September 30, 2022 and 2021, the Group recorded a consolidated income tax benefit of EUR 160k (September 30, 2021: income tax expense of EUR -1,841k), respectively. The consolidated income tax benefit (September 30, 2021: income tax expense) for the nine months ended September 30, 2022, resulted from income tax benefit from CureVac Inc of EUR 235k for current tax and tax expenses from CureVac Corporate Service and CureVac Swiss AG of EUR 94k. CureVac Corporate Service has a deferred tax benefit of EUR 21k for the nine months ended September 30, 2022.&lt;/p&gt;</ifrs-full:DisclosureOfIncomeTaxExplanatory>
    <ifrs-full:IncomeTaxExpenseContinuingOperations
      contextRef="Duration_1_1_2022_To_9_30_2022_GrYkE3mhHEiRA4fxgfABRg"
      decimals="-3"
      id="Narr_7jRVj4aimkGuuCw1LATJxw"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">-160000</ifrs-full:IncomeTaxExpenseContinuingOperations>
    <ifrs-full:IncomeTaxExpenseContinuingOperations
      contextRef="Duration_1_1_2021_To_9_30_2021_5RS16WkLc0uS2ug_bqUm-g"
      decimals="-3"
      id="Narr_-b9u8TIhGkW4DpmGohG8-Q"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">1841000</ifrs-full:IncomeTaxExpenseContinuingOperations>
    <ifrs-full:CurrentTaxExpenseIncome
      contextRef="Duration_1_1_2022_To_9_30_2022_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_cvac_CurevacCorporateServiceGmbhMember_w8u7qadVykiL43suHZX4cQ"
      decimals="-3"
      id="Narr_IkoWRR8bhUGqj6GagqmmLw"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">235000</ifrs-full:CurrentTaxExpenseIncome>
    <ifrs-full:CurrentTaxExpenseIncome
      contextRef="Duration_1_1_2022_To_9_30_2022_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_cvac_CurevacSwissAgMember_uQhhLoLXmEqQ0Uh4SUqsVA"
      decimals="-3"
      id="Narr_pUKP_FrJHEW54LclzqeP-Q"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">94000</ifrs-full:CurrentTaxExpenseIncome>
    <ifrs-full:DeferredTaxExpenseIncome
      contextRef="Duration_1_1_2022_To_9_30_2022_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_cvac_CurevacCorporateServiceGmbhMember_w8u7qadVykiL43suHZX4cQ"
      decimals="-3"
      id="Narr_7-PEJ4824k-x7hL_o33Zog"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">21000</ifrs-full:DeferredTaxExpenseIncome>
    <ifrs-full:DisclosureOfFinancialRiskManagementExplanatory
      contextRef="Duration_1_1_2022_To_9_30_2022_GrYkE3mhHEiRA4fxgfABRg"
      id="Tb_4zYgedxufk-z7YSdSqrBIA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;15. Disclosure of financial instruments and risk management&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;As the Group requires significant liquid funds available for the financing of its COVID-19 and influenza research and development activities, during the nine months ended September 30, 2022, it has maintained funds as cash and cash equivalents and not in less liquid financial instruments. The Group has distributed the cash amongst several banks and amongst the legal entities in the Group in order to reduce negative interest penalties.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"&gt;Refer to Note 15 to the consolidated financial statements as of December&#160;31, 2021 for additional information on the Group&#x2019;s risk management activities. As of September 30, 2022, the Group held cash and cash equivalents of USD 82,577k and CHF 117k, which are exposed to foreign currency exchange risk. The Group intends to settle expenses arising in US dollars using these US dollar funds. &lt;/p&gt;</ifrs-full:DisclosureOfFinancialRiskManagementExplanatory>
    <ifrs-full:RiskExposureAssociatedWithInstrumentsSharingCharacteristic
      contextRef="As_Of_9_30_2022_ifrs-full_ClassesOfFinancialInstrumentsAxis_cvac_IfrsCashAndCashEquivalentsMember_ifrs-full_TypesOfRisksAxis_ifrs-full_CurrencyRiskMember_srt_CurrencyAxis_currency_USD_GbIyOSI9fU6k0lhzbRaN6Q"
      decimals="-3"
      id="Narr_8FegT2ZRn0K4KkONCNEicg"
      unitRef="Unit_Standard_USD_q8NNp4TBfUC9XydcVDSrpA">82577000</ifrs-full:RiskExposureAssociatedWithInstrumentsSharingCharacteristic>
    <ifrs-full:RiskExposureAssociatedWithInstrumentsSharingCharacteristic
      contextRef="As_Of_9_30_2022_ifrs-full_ClassesOfFinancialInstrumentsAxis_cvac_IfrsCashAndCashEquivalentsMember_ifrs-full_TypesOfRisksAxis_ifrs-full_CurrencyRiskMember_srt_CurrencyAxis_currency_CHF_GzG5BBakVUCREUh5rLOPgw"
      decimals="-3"
      id="Narr_SGEr6-QtfEO7-Z21DwQqPA"
      unitRef="Unit_Standard_CHF_BBNACBTv9k-Ei0YBwsfYBA">117000</ifrs-full:RiskExposureAssociatedWithInstrumentsSharingCharacteristic>
    <ifrs-full:EarningsPerShareExplanatory
      contextRef="Duration_1_1_2022_To_9_30_2022_GrYkE3mhHEiRA4fxgfABRg"
      id="Tb_fb4X7p3CCEqXzFJpp8nbEA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;16. Earnings per share&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18.2pt;margin:0pt 0pt 12pt 0pt;"&gt;Earnings per share is calculated pursuant to &lt;i style="font-style:italic;"&gt;IAS 33 Earnings per Share&lt;/i&gt; by dividing the consolidated net loss in CureVac N.V. by the average weighted number of shares outstanding in the fiscal period.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18.2pt;margin:0pt;"&gt;The weighted number of shares outstanding for the nine months ended September 30, 2022 was 188,020,542 (September 30, 2021: 185,702,736). This has led to a basic loss per share for the nine months ended September 30, 2022 and 2021 of EUR 0.64 and EUR 2.21, respectively. Since the conversion of options to ordinary shares would decrease loss per share, they are considered antidilutive. Therefore, the diluted earnings per share equals basic earnings per share for the nine months ended September 30, 2022 and 2021. &lt;/p&gt;</ifrs-full:EarningsPerShareExplanatory>
    <ifrs-full:WeightedAverageShares
      contextRef="Duration_1_1_2022_To_9_30_2022_GrYkE3mhHEiRA4fxgfABRg"
      decimals="INF"
      id="Narr_oY9fEKQrUUG2-ME6SC4iJw"
      unitRef="Unit_Standard_shares_FapG5E6UqkK42IfNNOS6tA">188020542</ifrs-full:WeightedAverageShares>
    <ifrs-full:WeightedAverageShares
      contextRef="Duration_1_1_2021_To_9_30_2021_5RS16WkLc0uS2ug_bqUm-g"
      decimals="INF"
      id="Narr_SfKxzmH040qS50d50Qj1Hg"
      unitRef="Unit_Standard_shares_FapG5E6UqkK42IfNNOS6tA">185702736</ifrs-full:WeightedAverageShares>
    <ifrs-full:BasicEarningsLossPerShare
      contextRef="Duration_1_1_2022_To_9_30_2022_GrYkE3mhHEiRA4fxgfABRg"
      decimals="2"
      id="Narr_QOtD-UE1jk2lIvQrWn87mQ"
      unitRef="Unit_Divide_EUR_shares_6PEZCHC_WE2a7AmZW169oA">-0.64</ifrs-full:BasicEarningsLossPerShare>
    <ifrs-full:BasicEarningsLossPerShare
      contextRef="Duration_1_1_2021_To_9_30_2021_5RS16WkLc0uS2ug_bqUm-g"
      decimals="2"
      id="Narr_hdI2-f74x0O9IdSa6ChOdQ"
      unitRef="Unit_Divide_EUR_shares_6PEZCHC_WE2a7AmZW169oA">-2.21</ifrs-full:BasicEarningsLossPerShare>
    <ifrs-full:DisclosureOfRelatedPartyExplanatory
      contextRef="Duration_1_1_2022_To_9_30_2022_GrYkE3mhHEiRA4fxgfABRg"
      id="Tb_WyUIOHu1YEGdqByE06Xb-w">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;17. Related party disclosures&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Dietmar Hopp&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18.2pt;margin:0pt 0pt 10pt 0pt;"&gt;During fiscal 2019, Dietmar Hopp, principal of dievini Hopp BioTech holding GmbH &amp;amp; Co. KG (dievini), the largest shareholder of the Group, granted two convertible loans to the Group, which were repaid in 2020. Additionally, in August 2020, DH-LT Investments GmbH, a company beneficially owned by Dietmar Hopp, managing director of dievini, the Group&lt;span style="font-family:'Arial','Helvetica','sans-serif';"&gt;&#x2019;&lt;/span&gt;s largest shareholder, purchased EUR 100,000k of the Group&lt;span style="font-family:'Arial','Helvetica','sans-serif';"&gt;&#x2019;&lt;/span&gt;s common shares at a price of USD 16.00 per share.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Antony Blanc&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18.2pt;margin:0pt 0pt 11pt 0pt;"&gt;In 2020, a consulting agreement between CureVac AG and Clarentis SRL was made. Clarentis SRL is a wholly owned consulting company of Antony Blanc, PhD, the CBO of CureVac. After the transition of Antony Blanc to the Management Board in February 2021, the contract was no longer active, and no new orders were placed. In Q3 2021, a milestone payment, which related to the submission of the EMA dossier for CVnCoV and which amounted to EUR 100k was made to fulfil a contractual obligation from the consulting agreement in place before Antony Blanc joined the Management Board. In addition to his Management Board position at CureVac NV, Antony also took over the role as Management Director at CureVac Belgium SA. He executes this function by using Clarentis SRL. As it relates to these services, CureVac paid until September 2022 an amount of EUR 48k. The amounts invoiced for this function/services will be offset/deducted from his base compensation for his function on the Board of Management of CureVac N.V.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 11pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;BePharBel Manufacturing S.A.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"&gt;In December 2020, CureVac Real Estate GmbH and BePharBel Manufacturing S.A., entered into a commercial supply agreement to develop and manufacture the diluent that was expected to be used to dilute the Group&#x2019;s first concentrated COVID-19 vaccine candidate, CVnCoV, to the amount specified by each dose level. Pursuant to the terms of the agreement, it was intended that BePharBel Manufacturing would manufacture and deliver to CureVac Real Estate GmbH a low seven figure amount of commercial batches of diluent per year, in 2021 and 2022. Following the withdrawal of the CVnCoV in October 2021 due to COVID-19 virus drift, WHO COVID vaccine efficiency recommendation and market expectations, CureVac Real Estate GmbH terminated the commercial and supply agreement with BePahrBel and entered into negotiations on a structured and rapid wind-down of the ordered production. The Parties agreed on a settlement in May 2022 of all claims resulting from the commercial and supply agreement for an amount of EUR 3,900k, which had been already recognized in provisions, based on an estimate, as of December 31, 2021. Baron Jean St&#xe9;phenne, our supervisory board member, holds directly and indirectly 15.61% of BePharBel Manufacturing&#x2019;s equity and is a director of BePharBel Manufacturing, and Baron Jean St&#xe9;phenne&#x2019;s son, Vincent St&#xe9;phenne, holds 1.43% of BePharBel Manufacturing&#x2019;s equity and is a managing director of BePharBel Manufacturing.&lt;/p&gt;</ifrs-full:DisclosureOfRelatedPartyExplanatory>
    <cvac:RelatedPartyTransactionNumberOfLoansReceived
      contextRef="Duration_1_1_2019_To_12_31_2019_ifrs-full_CategoriesOfRelatedPartiesAxis_cvac_DietmarHoppMember_vhtIRbibYkK_L7RHLy0f_A"
      decimals="INF"
      id="Narr_sVFHaEk71kCG5mK5v4wUlw"
      unitRef="Unit_Standard_loan_2Ze7UTdQEkiZKAdZ7o4zlw">2</cvac:RelatedPartyTransactionNumberOfLoansReceived>
    <cvac:IncreaseInNumberOfSharesOutstanding
      contextRef="Duration_8_1_2020_To_8_31_2020_ifrs-full_CategoriesOfRelatedPartiesAxis_cvac_DietmarHoppMember_4pr7l6FBv0Cr0BMx5sP5QQ"
      decimals="INF"
      id="Narr__5smC5F-vk-RcdePLpm_VA"
      unitRef="Unit_Standard_shares_FapG5E6UqkK42IfNNOS6tA">100000</cvac:IncreaseInNumberOfSharesOutstanding>
    <ifrs-full:WeightedAverageSharePrice2019
      contextRef="Duration_8_1_2020_To_8_31_2020_ifrs-full_CategoriesOfRelatedPartiesAxis_cvac_DietmarHoppMember_4pr7l6FBv0Cr0BMx5sP5QQ"
      decimals="2"
      id="Narr_EcV4HnwmX026XZhVXlZcQQ"
      unitRef="Unit_Divide_USD_shares_B3tHpJm3a0ytZJRcE10tTA">16.00</ifrs-full:WeightedAverageSharePrice2019>
    <cvac:CollaborationAgreementMilestonePayment
      contextRef="As_Of_9_30_2021_ifrs-full_CategoriesOfRelatedPartiesAxis_cvac_ClarentisSrlMember_Dh91pVmxqEWDD100jMo2Fw"
      decimals="-3"
      id="Narr_nyURrB63rUWgDnF91vLHog"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">100000</cvac:CollaborationAgreementMilestonePayment>
    <cvac:PaymentsToRelatedPartyForServices
      contextRef="Duration_1_1_2022_To_9_30_2022_ifrs-full_CategoriesOfRelatedPartiesAxis_cvac_ClarentisSrlMember_srt_TitleOfIndividualAxis_cvac_AntonyBlancMember_GiBB1NZHtU6MtEphFx2MUw"
      decimals="-3"
      id="Narr_yGjjClstHUS8XaFC1W3MDA"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">48000</cvac:PaymentsToRelatedPartyForServices>
    <ifrs-full:CommitmentsMadeByEntityRelatedPartyTransactions
      contextRef="Duration_5_1_2022_To_5_31_2022_ifrs-full_CategoriesOfRelatedPartiesAxis_cvac_BepharbelManufacturingS.aMember_OIxhC3wEcEmjhA5CfZ3lqQ"
      decimals="-5"
      id="Narr_xgBx6IuwYkmcNb96VZZdaQ"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">3900000000</ifrs-full:CommitmentsMadeByEntityRelatedPartyTransactions>
    <ifrs-full:ProportionOfOwnershipInterestInAssociate
      contextRef="Duration_1_1_2022_To_9_30_2022_srt_TitleOfIndividualAxis_cvac_BaronJeanStephenneMember_xZT627rXM0CHsP6C5sklyg"
      decimals="4"
      id="Narr_KEmy-Zasn0Wi4ApuaxKQlA"
      unitRef="Unit_Standard_pure_NsGb2Z3yYka4EicmhvoaQQ">0.1561</ifrs-full:ProportionOfOwnershipInterestInAssociate>
    <ifrs-full:ProportionOfOwnershipInterestInAssociate
      contextRef="Duration_1_1_2022_To_9_30_2022_srt_TitleOfIndividualAxis_cvac_VincentStphenneMember_PA_nLHYdokKpQK-0_a7lSg"
      decimals="4"
      id="Narr_j5yTNAV6lECjrBDZtMwP0g"
      unitRef="Unit_Standard_pure_NsGb2Z3yYka4EicmhvoaQQ">0.0143</ifrs-full:ProportionOfOwnershipInterestInAssociate>
    <ifrs-full:DisclosureOfBusinessCombinationsExplanatory
      contextRef="Duration_1_1_2022_To_9_30_2022_GrYkE3mhHEiRA4fxgfABRg"
      id="Tb__PlzDS7D-0m3TofHmnuL5Q">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;18. Significant transactions and events&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Business Combination and Goodwill &#x2013; Frame Acquisition&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18.2pt;margin:0pt 0pt 12pt 0pt;"&gt;Effective July 1, 2022 (&#x2018;closing date&#x2019;), CureVac N.V. acquired all shares of Frame Pharmaceuticals B.V., Amsterdam, Netherlands (&#x2018;Frame Pharmaceuticals&#x2019;). Frame Pharmaceuticals focuses on the development of a proprietary platform enabling the identification of structural changes within the cancer genome and has strong competencies in antigen discovery as well as validation for personalized cancer vaccines. CureVac&#x2019;s management and supervisory board expect that the acquisition will contribute several key elements for the required end-to-end building blocks for CureVac&#x2019;s broader oncology strategy.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18.2pt;margin:0pt 0pt 12pt 0pt;"&gt;Frame Pharmaceuticals contributed no revenues and a loss of EUR 0.6 million to the consolidated result for the current reporting period. Assuming an initial consolidation of Frame Pharmaceuticals on January 1, 2022, the Group's revenue would be unchanged and the loss would have been EUR 3.0 million higher, respectively, than reported (estimate based on the purchase price allocation). In determining these amounts, management has assumed that the fair value adjustments made at the acquisition date would also have applied on January 1, 2022.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18.2pt;margin:0pt 0pt 12pt 0pt;"&gt;In the purchase price agreement (&#x2018;SPA&#x2019;) dated June 8, 2022, a total consideration of up to EUR 32.0 million, subject to certain adjustments for vested and non-vested employee options of the acquiree plus an amount of EUR 1.56 million for the assumption of an outstanding obligation resulting from advisory services was agreed. The consideration consisted of minor cash payments and the transfer of shares in CureVac N.V. (&#x2018;CureVac Shares&#x2019;). The number of CureVac Shares to be issued as part of the different consideration payments were agreed in the SPA and based on the 60-trading day volume weighted average price until June 3, 2022, based on a Signing Share Price (&#x2018;Signing Share Price&#x2019;) at EUR 16.44.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18.2pt;margin:0pt 0pt 12pt 0pt;"&gt;The total consideration is split into three payments, two of which are contingent upon the achievement of defined milestones (contingent consideration). At the closing date, CureVac had to pay 50 % of the total consideration, i. e. EUR 16.0 million plus the consideration for the outstanding obligation of EUR 1.56 million as follows:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"/&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Issuance and transfer of &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;810,242&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; shares (worth EUR &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;11,040&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;k) to former Frame shareholders. The respective share price of one CureVac Share was EUR &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;13.63&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; (&#x2018;Closing Share Price&#x2019;).&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"/&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Issuance and transfer of further &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;48,254&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; shares (worth EUR &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;657&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;k, valued at the Closing Share Price) as consideration for discharging the contractual obligations for the outstanding advisory agreements of EUR &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;1,560&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;k (adjusted by the strike price of EUR &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;767&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;k for the existing share-based payment). &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"/&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Payment of EUR &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;585&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;k in cash, consisting of EUR &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;335&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;k being the consideration for the settlement of the vested employee options, and an additional EUR &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;250&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;k.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt;"/&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Payment of the remaining 50% of the total consideration is contingent upon the achievement of two milestones. A further 194,647 shares (representing 10% of EUR 32.0 million divided by the Signing Share Price, i. e. EUR 1,831k) are issuable upon the achievement of the successful investigational new drug application filing and a further 778,589 shares (representing 40% of EUR 32.0 million divided by the Signing Share Price, i. e. EUR 5,367k) are issuable upon successful proof of mechanism in humans. The fair value of these contingent payments was determined by considering the likelihood of the events occurring and totaled, based on the Closing Share Price, to a total fair value of EUR 7,198k.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Consequently, the total consideration transferred for the business combination was determined to be EUR 19,481k, consisting of:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"/&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Issuance and transfer of &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;858,496&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; CureVac shares with a fair value of EUR &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;11,697&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;k,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"/&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Payment of EUR &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;585&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;k in cash, and&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"/&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Contingent consideration, classified as equity, with a fair value of EUR &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;7,198&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;k. The contingent consideration will be settled by the issuance of a maximum of further &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;973,236&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; CureVac shares.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt;"/&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;In addition, 89,655 restricted stock units (RSUs) were issued to certain employees to replace existing share-based payment awards of the target. This element will be accounted for as a separate transaction from the business combination and accounted for as an equity-settled share-based transaction according to IFRS 2. The total fair value of the grant was determined to be EUR 1,218k and will be expensed in the functional cost category to which the award recipient&#x2019;s costs are classified (general and administrative expenses and research and development expenses) over the individual vesting periods for the 3 tranches, which run through June 30, 2023, June 30, 2024, and June 30, 2025.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Transactions costs in relation to the business combination amounting to total EUR 500k were expensed and recognized within general and administrative expenses. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"&gt;The purchase price allocation for the assets acquired and liabilities assumed has not been completed as of the date of issuance of these interim financial statements. This is especially due to ongoing identification and measurement of Intangible Assets acquired. The provisional amounts at the acquisition date were determined as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:57.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:38.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;in EUR thousands&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:38.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Provisional&#160;amounts&#160;at&#160;acquisition&#160;date&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Non-current assets&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:38.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 6,592&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Property, plant and equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:38.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 206&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Right-of-use assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:38.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 170&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Intangible assets (Technology)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:38.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,216&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Current assets&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:38.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 966&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Trade and other receivables&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:38.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 658&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Cash and cash equivalents&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:38.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 308&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total assets&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:38.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 7,558&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Non-current liabilities&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:38.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 134&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Lease liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:38.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 114&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Deferred tax liabilities (net of deferred tax assets)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:38.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 20&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Current liabilities&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:38.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 406&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Lease liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:38.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 55&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Accounts Payables&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:38.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 346&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Other current liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:38.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total liabilities&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:38.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 540&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Net assets acquired&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:38.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 7,018&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The acquired receivables are expected to be collected in full.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The (provisional) fair value of the technology of EUR 6,216k was determined by applying the replacement cost approach. The replacement cost was derived from historical costs incurred from 2019 to June 2022.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;As per July 1, 2022, a net deferred tax liability of EUR 20k has been recognized for the excess of deferred tax liabilities of EUR 1,550k on taxable temporary differences over deferred tax assets of EUR 1,530k arising mainly from tax loss carry forwards (of approximately EUR 5,800k). &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;If, within one year of the acquisition date, new information becomes known about facts and circumstances that existed at the acquisition date and that would have resulted in adjustments to the amounts above, the allocation of the purchase price shall be adjusted. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"&gt;Goodwill was provisionally recognized as a result of the acquisition as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 2pt 0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:86.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:86.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;in EURk&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:86.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Consideration transferred&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 19,481&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:86.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Net Assets acquired&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (7,018)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:86.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Preliminary Goodwill&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 12,463&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"&gt;The preliminary goodwill is mainly attributable to the synergies and an assembled workforce as well as the strategic benefits to the Group. The preliminary goodwill is not deductible for tax purposes.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:86.45%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:86.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Analyses of cash flows on acquisition:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EURk&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:86.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Payment of consideration in cash and cash equivalents&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (585)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:86.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</ifrs-full:DisclosureOfBusinessCombinationsExplanatory>
    <ifrs-full:RevenueOfAcquiree
      contextRef="Duration_1_1_2022_To_9_30_2022_ifrs-full_BusinessCombinationsAxis_cvac_FramePharmaceuticalsB.v.AmsterdamNetherlandsMember_APxhOynMm0ePvj-djFEXLQ"
      decimals="0"
      id="Narr_vTUrBh-rakShkE-WqTNL4g"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">0</ifrs-full:RevenueOfAcquiree>
    <ifrs-full:ProfitLossOfAcquiree
      contextRef="Duration_1_1_2022_To_9_30_2022_ifrs-full_BusinessCombinationsAxis_cvac_FramePharmaceuticalsB.v.AmsterdamNetherlandsMember_APxhOynMm0ePvj-djFEXLQ"
      decimals="-5"
      id="Narr_Cjqc6NKHQUSgVrplz-zx7A"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">600000</ifrs-full:ProfitLossOfAcquiree>
    <ifrs-full:ProfitLossOfCombinedEntity
      contextRef="Duration_1_1_2022_To_9_30_2022_ifrs-full_BusinessCombinationsAxis_cvac_FramePharmaceuticalsB.v.AmsterdamNetherlandsMember_APxhOynMm0ePvj-djFEXLQ"
      decimals="-5"
      id="Narr_EVCEYHbbTkqXKLs63VAEBw"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">3000000.0</ifrs-full:ProfitLossOfCombinedEntity>
    <ifrs-full:AcquisitiondateFairValueOfTotalConsiderationTransferred
      contextRef="As_Of_6_8_2022_ifrs-full_BusinessCombinationsAxis_cvac_FramePharmaceuticalsB.v.AmsterdamNetherlandsMember_VaKO9irU5EuHdCnXXdyNiw"
      decimals="-5"
      id="Narr_dasTdkCe4kiZF9LNOxYe4w"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">32000000.0</ifrs-full:AcquisitiondateFairValueOfTotalConsiderationTransferred>
    <ifrs-full:LiabilitiesIncurred
      contextRef="As_Of_6_8_2022_ifrs-full_BusinessCombinationsAxis_cvac_FramePharmaceuticalsB.v.AmsterdamNetherlandsMember_VaKO9irU5EuHdCnXXdyNiw"
      decimals="-4"
      id="Narr_TUY6RfeEo0aOf5UwdZNLmQ"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">1560000</ifrs-full:LiabilitiesIncurred>
    <cvac:BusinessAcquisitionSigningSharePriceNumberOfTradingDaysConsidered
      contextRef="Duration_6_8_2022_To_6_8_2022_ifrs-full_BusinessCombinationsAxis_cvac_FramePharmaceuticalsB.v.AmsterdamNetherlandsMember_1GTamgfVRUOww3XIvpKP3Q"
      decimals="INF"
      id="Narr_eGOlbzfRmUKNn-MDPK1zag"
      unitRef="Unit_Standard_D_Pu_YZcQO3kKxgZxGvGVflA">60</cvac:BusinessAcquisitionSigningSharePriceNumberOfTradingDaysConsidered>
    <cvac:BusinessAcquisitionSigningSharePrice
      contextRef="Duration_6_8_2022_To_6_8_2022_ifrs-full_BusinessCombinationsAxis_cvac_FramePharmaceuticalsB.v.AmsterdamNetherlandsMember_1GTamgfVRUOww3XIvpKP3Q"
      decimals="2"
      id="Narr_xD_pOjJ74km_i9_5Gv4RUw"
      unitRef="Unit_Divide_EUR_shares_6PEZCHC_WE2a7AmZW169oA">16.44</cvac:BusinessAcquisitionSigningSharePrice>
    <cvac:NumberOfPaymentsInWhichTotalConsiderationIsToBePaid
      contextRef="As_Of_9_30_2022_ifrs-full_BusinessCombinationsAxis_cvac_FramePharmaceuticalsB.v.AmsterdamNetherlandsMember_vR0Bi5R7KE6kPw8J5q5NTA"
      decimals="INF"
      id="Narr_fsKiXg0wqkuPPeWrCLbWzQ"
      unitRef="Unit_Standard_payment_4W6g8HbU0USZCbuxzWFKng">3</cvac:NumberOfPaymentsInWhichTotalConsiderationIsToBePaid>
    <cvac:ContingentConsiderationNumberOfPaymentsConsidered
      contextRef="As_Of_9_30_2022_ifrs-full_BusinessCombinationsAxis_cvac_FramePharmaceuticalsB.v.AmsterdamNetherlandsMember_vR0Bi5R7KE6kPw8J5q5NTA"
      decimals="INF"
      id="Narr_jZQAvqVnhEu7An1MmwVaGA"
      unitRef="Unit_Standard_payment_4W6g8HbU0USZCbuxzWFKng">2</cvac:ContingentConsiderationNumberOfPaymentsConsidered>
    <cvac:FirstPortionOfTotalConsiderationTransferredPercentage
      contextRef="As_Of_7_1_2022_ifrs-full_BusinessCombinationsAxis_cvac_FramePharmaceuticalsB.v.AmsterdamNetherlandsMember_TNMnxy-chEOEtWGU9Rxf9g"
      decimals="2"
      id="Narr_xUJ44-54w0qlBAH_ZaCz1Q"
      unitRef="Unit_Standard_pure_NsGb2Z3yYka4EicmhvoaQQ">0.50</cvac:FirstPortionOfTotalConsiderationTransferredPercentage>
    <cvac:FirstPortionOfTotalConsiderationTransferredAmount
      contextRef="As_Of_7_1_2022_ifrs-full_BusinessCombinationsAxis_cvac_FramePharmaceuticalsB.v.AmsterdamNetherlandsMember_TNMnxy-chEOEtWGU9Rxf9g"
      decimals="-5"
      id="Narr_YgCHI378vEqB3KJPLxiyeg"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">16000000.0</cvac:FirstPortionOfTotalConsiderationTransferredAmount>
    <cvac:FirstPortionOfTotalConsiderationTransferredAmount
      contextRef="As_Of_9_30_2022_zuGVrjesE0WhwXSGmTqsgA"
      decimals="-4"
      id="Narr_vOHtj26vbk-XQ1FapUdY2Q"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">1560000</cvac:FirstPortionOfTotalConsiderationTransferredAmount>
    <cvac:NumberOfInstrumentsOrInterestsIssuedOrIssuableAsConsiderationToFormerShareholders
      contextRef="As_Of_9_30_2022_zuGVrjesE0WhwXSGmTqsgA"
      decimals="INF"
      id="Narr_YaegueP0UkqpmxgyXAaYDg"
      unitRef="Unit_Standard_shares_FapG5E6UqkK42IfNNOS6tA">810242</cvac:NumberOfInstrumentsOrInterestsIssuedOrIssuableAsConsiderationToFormerShareholders>
    <cvac:ValueOfInstrumentsOrInterestsIssuedOrIssuableAsConsiderationToFormerShareholders
      contextRef="As_Of_9_30_2022_zuGVrjesE0WhwXSGmTqsgA"
      decimals="-3"
      id="Narr_JAxXyeIFkUW8RdPQ8QvS_Q"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">11040000</cvac:ValueOfInstrumentsOrInterestsIssuedOrIssuableAsConsiderationToFormerShareholders>
    <cvac:IfrsBusinessAcquisitionSharePrice
      contextRef="As_Of_9_30_2022_zuGVrjesE0WhwXSGmTqsgA"
      decimals="2"
      id="Narr_Ev3fwGsTOky2uSXRASMhhA"
      unitRef="Unit_Divide_EUR_shares_6PEZCHC_WE2a7AmZW169oA">13.63</cvac:IfrsBusinessAcquisitionSharePrice>
    <cvac:NumberOfInstrumentsOrInterestsIssuedOrIssuableAsConsiderationForDischargingContractualObligations
      contextRef="As_Of_9_30_2022_zuGVrjesE0WhwXSGmTqsgA"
      decimals="INF"
      id="Narr_7A4zUZEc3EColsqg0_z1qg"
      unitRef="Unit_Standard_shares_FapG5E6UqkK42IfNNOS6tA">48254</cvac:NumberOfInstrumentsOrInterestsIssuedOrIssuableAsConsiderationForDischargingContractualObligations>
    <cvac:ValueOfInstrumentsOrInterestsIssuedOrIssuableAsConsiderationForDischargingContractualObligations
      contextRef="As_Of_9_30_2022_zuGVrjesE0WhwXSGmTqsgA"
      decimals="-3"
      id="Narr_u8BOlrFyvUevCy5QbzIj4g"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">657000</cvac:ValueOfInstrumentsOrInterestsIssuedOrIssuableAsConsiderationForDischargingContractualObligations>
    <cvac:ValueOfInstrumentsOrInterestsIssuedOrIssuableAsConsiderationForDischargingContractualObligations
      contextRef="As_Of_9_30_2022_ifrs-full_BusinessCombinationsAxis_cvac_FramePharmaceuticalsB.v.AmsterdamNetherlandsMember_vR0Bi5R7KE6kPw8J5q5NTA"
      decimals="-3"
      id="Narr_5oUP12Ov90Wy-TRuvIqc7A"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">1560000</cvac:ValueOfInstrumentsOrInterestsIssuedOrIssuableAsConsiderationForDischargingContractualObligations>
    <cvac:StrikePriceForExistingShareBasedPayment
      contextRef="As_Of_9_30_2022_zuGVrjesE0WhwXSGmTqsgA"
      decimals="-3"
      id="Narr_bF8fvBGO2E-i1DaANUAsRg"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">767000</cvac:StrikePriceForExistingShareBasedPayment>
    <ifrs-full:CashTransferred
      contextRef="As_Of_9_30_2022_zuGVrjesE0WhwXSGmTqsgA"
      decimals="-3"
      id="Narr_A9kRjS9EdEaiLuch7e3s_w"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">585000</ifrs-full:CashTransferred>
    <cvac:CashTransferredForSettlementOfVestedEmployeeOptions
      contextRef="As_Of_9_30_2022_zuGVrjesE0WhwXSGmTqsgA"
      decimals="-3"
      id="Narr_Grou3YawokepRPzjjIkNmg"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">335000</cvac:CashTransferredForSettlementOfVestedEmployeeOptions>
    <cvac:AdditionalCashTransferred
      contextRef="As_Of_9_30_2022_zuGVrjesE0WhwXSGmTqsgA"
      decimals="-3"
      id="Narr_LTY7nswcsE6PNLEzLo6Hvg"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">250000</cvac:AdditionalCashTransferred>
    <cvac:ContingentConsiderationPercentageOfTotalConsideration
      contextRef="As_Of_9_30_2022_zuGVrjesE0WhwXSGmTqsgA"
      decimals="2"
      id="Narr_6NBRyHAqJUWyIGeReB8WsA"
      unitRef="Unit_Standard_pure_NsGb2Z3yYka4EicmhvoaQQ">0.50</cvac:ContingentConsiderationPercentageOfTotalConsideration>
    <cvac:ContingentConsiderationNumberOfMilestones
      contextRef="As_Of_9_30_2022_zuGVrjesE0WhwXSGmTqsgA"
      decimals="INF"
      id="Narr_r1AbDnx2ykGHnNH7dvB9HA"
      unitRef="Unit_Standard_Milestone_1ZnSc2qU1UaZ09p9Mr6TGw">2</cvac:ContingentConsiderationNumberOfMilestones>
    <cvac:NumberOfInstrumentsOrInterestsIssuedOrIssuableUponAchievementOfFirstMilestone
      contextRef="As_Of_9_30_2022_zuGVrjesE0WhwXSGmTqsgA"
      decimals="INF"
      id="Narr_Bw9h_TSpmEa9ZFDXTnwTnw"
      unitRef="Unit_Standard_shares_FapG5E6UqkK42IfNNOS6tA">194647</cvac:NumberOfInstrumentsOrInterestsIssuedOrIssuableUponAchievementOfFirstMilestone>
    <cvac:PercentageOfConsiderationTransferredUponAchievementOfFirstMilestone
      contextRef="As_Of_9_30_2022_zuGVrjesE0WhwXSGmTqsgA"
      decimals="2"
      id="Narr_DdeV3NiT4ECo2aLBuVtkjg"
      unitRef="Unit_Standard_pure_NsGb2Z3yYka4EicmhvoaQQ">0.10</cvac:PercentageOfConsiderationTransferredUponAchievementOfFirstMilestone>
    <cvac:ValueOfInstrumentsOrInterestsIssuedOrIssuableUponAchievementOfFirstMilestone
      contextRef="As_Of_9_30_2022_zuGVrjesE0WhwXSGmTqsgA"
      decimals="-5"
      id="Narr__Jn5jg-xZ0mXdt1nu4UwmQ"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">32000000.0</cvac:ValueOfInstrumentsOrInterestsIssuedOrIssuableUponAchievementOfFirstMilestone>
    <cvac:SigningSharePriceRepresenting10
      contextRef="As_Of_9_30_2022_zuGVrjesE0WhwXSGmTqsgA"
      decimals="-3"
      id="Narr_HD8VsOoX4kejijxlmaYR8Q"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">1831000</cvac:SigningSharePriceRepresenting10>
    <cvac:NumberOfInstrumentsOrInterestsIssuedOrIssuableUponAchievementOfSecondMilestone
      contextRef="As_Of_9_30_2022_zuGVrjesE0WhwXSGmTqsgA"
      decimals="INF"
      id="Narr_9sjaNog3e02SRiFdgfBlwg"
      unitRef="Unit_Standard_shares_FapG5E6UqkK42IfNNOS6tA">778589</cvac:NumberOfInstrumentsOrInterestsIssuedOrIssuableUponAchievementOfSecondMilestone>
    <cvac:PercentageOfConsiderationTransferredUponAchievementOfSecondMilestone
      contextRef="As_Of_9_30_2022_zuGVrjesE0WhwXSGmTqsgA"
      decimals="2"
      id="Narr_cTr_vf7n7E6Q1UVHjMbLTw"
      unitRef="Unit_Standard_pure_NsGb2Z3yYka4EicmhvoaQQ">0.40</cvac:PercentageOfConsiderationTransferredUponAchievementOfSecondMilestone>
    <cvac:ValueOfInstrumentsOrInterestsIssuedOrIssuableUponAchievementOfSecondMilestone
      contextRef="As_Of_9_30_2022_zuGVrjesE0WhwXSGmTqsgA"
      decimals="-5"
      id="Narr_-Pj1WbWBSk6jaWc6pU_s9A"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">32000000.0</cvac:ValueOfInstrumentsOrInterestsIssuedOrIssuableUponAchievementOfSecondMilestone>
    <cvac:SigningSharePriceRepresenting40
      contextRef="As_Of_9_30_2022_zuGVrjesE0WhwXSGmTqsgA"
      decimals="-3"
      id="Narr_FlG3lKxUQEqVwle62VMdeg"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">5367000</cvac:SigningSharePriceRepresenting40>
    <cvac:ClosingSharePriceRepresentingTotalFairValue
      contextRef="As_Of_9_30_2022_zuGVrjesE0WhwXSGmTqsgA"
      decimals="-3"
      id="Narr_jcL7m3oEqECImxm4VlH4nQ"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">7198000</cvac:ClosingSharePriceRepresentingTotalFairValue>
    <ifrs-full:ContingentConsiderationRecognisedAsOfAcquisitionDate
      contextRef="As_Of_9_30_2022_zuGVrjesE0WhwXSGmTqsgA"
      decimals="-3"
      id="Narr_PMH1ym4a-ECCv6B66d-Vyw"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">19481000</ifrs-full:ContingentConsiderationRecognisedAsOfAcquisitionDate>
    <cvac:NumberOfInstrumentsOrInterestIssuedOrIssuable
      contextRef="As_Of_9_30_2022_zuGVrjesE0WhwXSGmTqsgA"
      decimals="INF"
      id="Narr_u0EsbzsENUSUO5iey-qGjQ"
      unitRef="Unit_Standard_shares_FapG5E6UqkK42IfNNOS6tA">858496</cvac:NumberOfInstrumentsOrInterestIssuedOrIssuable>
    <cvac:FairValueOfTotalConsiderationTransferred
      contextRef="Duration_1_1_2022_To_9_30_2022_GrYkE3mhHEiRA4fxgfABRg"
      decimals="-3"
      id="Narr_Zik1HKz84UKiY4tirr8PRQ"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">11697000</cvac:FairValueOfTotalConsiderationTransferred>
    <ifrs-full:CashTransferred
      contextRef="As_Of_9_30_2022_zuGVrjesE0WhwXSGmTqsgA"
      decimals="-3"
      id="Narr_YSY59N7SS02kLAMeiNiZ2Q"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">585000</ifrs-full:CashTransferred>
    <ifrs-full:EquityInterestsOfAcquirer
      contextRef="As_Of_9_30_2022_zuGVrjesE0WhwXSGmTqsgA"
      decimals="-3"
      id="Narr_yTg2aRUHME6seW_G7rfT7Q"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">7198000</ifrs-full:EquityInterestsOfAcquirer>
    <cvac:ContingentConsiderationMaximumSharesIssuable
      contextRef="As_Of_9_30_2022_zuGVrjesE0WhwXSGmTqsgA"
      decimals="INF"
      id="Narr_kJ9X3Mk3TEm1a9z2pCD4nw"
      unitRef="Unit_Standard_shares_FapG5E6UqkK42IfNNOS6tA">973236</cvac:ContingentConsiderationMaximumSharesIssuable>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="Duration_1_1_2022_To_9_30_2022_GrYkE3mhHEiRA4fxgfABRg"
      decimals="INF"
      id="Narr_f3cw95tRGEC8kG3zFy4gWw"
      unitRef="Unit_Standard_Option_puBmss6yUE6NakwAOqqzng">89655</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <ifrs-full:WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted
      contextRef="As_Of_9_30_2022_zuGVrjesE0WhwXSGmTqsgA"
      decimals="-3"
      id="Narr_n_Sg7yImrUaYgcyHnYxKMg"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">1218000</ifrs-full:WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted>
    <cvac:NumberOfTranchesForVestingOfInstrumentsGrantedInShareBasedPaymentArrangement
      contextRef="Duration_1_1_2022_To_9_30_2022_GrYkE3mhHEiRA4fxgfABRg"
      decimals="INF"
      id="Narr_nBhXtXm6xEy2SGHwfHpecg"
      unitRef="Unit_Standard_tranche__TryzuW6jEmkCnTfvtVlrg">3</cvac:NumberOfTranchesForVestingOfInstrumentsGrantedInShareBasedPaymentArrangement>
    <ifrs-full:AcquisitionrelatedCostsForTransactionRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombination
      contextRef="Duration_1_1_2022_To_9_30_2022_GrYkE3mhHEiRA4fxgfABRg"
      decimals="-3"
      id="Narr__1QTI7Fm-Em7FhyQFDEbng"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">500000</ifrs-full:AcquisitionrelatedCostsForTransactionRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombination>
    <ifrs-full:DisclosureOfDetailedInformationAboutBusinessCombinationsExplanatory
      contextRef="Duration_1_1_2022_To_9_30_2022_GrYkE3mhHEiRA4fxgfABRg"
      id="Tb_6c_hikYie0CPkupXoED9hA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"&gt;The purchase price allocation for the assets acquired and liabilities assumed has not been completed as of the date of issuance of these interim financial statements. This is especially due to ongoing identification and measurement of Intangible Assets acquired. The provisional amounts at the acquisition date were determined as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:57.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:38.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;in EUR thousands&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:38.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Provisional&#160;amounts&#160;at&#160;acquisition&#160;date&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Non-current assets&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:38.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 6,592&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Property, plant and equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:38.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 206&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Right-of-use assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:38.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 170&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Intangible assets (Technology)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:38.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,216&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Current assets&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:38.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 966&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Trade and other receivables&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:38.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 658&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Cash and cash equivalents&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:38.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 308&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total assets&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:38.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 7,558&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Non-current liabilities&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:38.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 134&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Lease liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:38.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 114&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Deferred tax liabilities (net of deferred tax assets)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:38.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 20&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Current liabilities&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:38.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 406&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Lease liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:38.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 55&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Accounts Payables&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:38.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 346&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Other current liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:38.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total liabilities&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:38.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 540&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Net assets acquired&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:38.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 7,018&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</ifrs-full:DisclosureOfDetailedInformationAboutBusinessCombinationsExplanatory>
    <ifrs-full:NoncurrentAssetsRecognisedAsOfAcquisitionDate
      contextRef="As_Of_9_30_2022_ifrs-full_BusinessCombinationsAxis_cvac_FramePharmaceuticalsB.v.AmsterdamNetherlandsMember_vR0Bi5R7KE6kPw8J5q5NTA"
      decimals="-3"
      id="Tc_yfcrMPIm10u6APgoS2NB1w_2_2"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">6592000</ifrs-full:NoncurrentAssetsRecognisedAsOfAcquisitionDate>
    <ifrs-full:PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDate
      contextRef="As_Of_9_30_2022_ifrs-full_BusinessCombinationsAxis_cvac_FramePharmaceuticalsB.v.AmsterdamNetherlandsMember_vR0Bi5R7KE6kPw8J5q5NTA"
      decimals="-3"
      id="Tc_YWOvHbKk606J9l5v9Dv_Bg_3_2"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">206000</ifrs-full:PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDate>
    <cvac:RightOfUseAssetsRecognisedAsOfAcquisitionDate
      contextRef="As_Of_9_30_2022_ifrs-full_BusinessCombinationsAxis_cvac_FramePharmaceuticalsB.v.AmsterdamNetherlandsMember_vR0Bi5R7KE6kPw8J5q5NTA"
      decimals="-3"
      id="Tc_jOQ7I2Ew0kKFrzLU6JpLOA_4_2"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">170000</cvac:RightOfUseAssetsRecognisedAsOfAcquisitionDate>
    <ifrs-full:TechnologybasedIntangibleAssetsRecognisedAsOfAcquisitionDate
      contextRef="As_Of_9_30_2022_ifrs-full_BusinessCombinationsAxis_cvac_FramePharmaceuticalsB.v.AmsterdamNetherlandsMember_vR0Bi5R7KE6kPw8J5q5NTA"
      decimals="-3"
      id="Tc_Xqf546yZw0eMusaqpJ185Q_5_2"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">6216000</ifrs-full:TechnologybasedIntangibleAssetsRecognisedAsOfAcquisitionDate>
    <ifrs-full:CurrentAssetsRecognisedAsOfAcquisitionDate
      contextRef="As_Of_9_30_2022_ifrs-full_BusinessCombinationsAxis_cvac_FramePharmaceuticalsB.v.AmsterdamNetherlandsMember_vR0Bi5R7KE6kPw8J5q5NTA"
      decimals="-3"
      id="Tc__r3elxF5GU-g9pE_SPrTZQ_6_2"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">966000</ifrs-full:CurrentAssetsRecognisedAsOfAcquisitionDate>
    <ifrs-full:FairValueOfAcquiredReceivables
      contextRef="As_Of_9_30_2022_ifrs-full_BusinessCombinationsAxis_cvac_FramePharmaceuticalsB.v.AmsterdamNetherlandsMember_vR0Bi5R7KE6kPw8J5q5NTA"
      decimals="-3"
      id="Tc_vp_-mrA1Qk6qogYjb8M4MA_7_2"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">658000</ifrs-full:FairValueOfAcquiredReceivables>
    <ifrs-full:CashAndCashEquivalentsRecognisedAsOfAcquisitionDate
      contextRef="As_Of_9_30_2022_ifrs-full_BusinessCombinationsAxis_cvac_FramePharmaceuticalsB.v.AmsterdamNetherlandsMember_vR0Bi5R7KE6kPw8J5q5NTA"
      decimals="-3"
      id="Tc_DpJiEJtmokeC_nRNP5Ds8A_8_2"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">308000</ifrs-full:CashAndCashEquivalentsRecognisedAsOfAcquisitionDate>
    <cvac:TotalAssetsRecognisedAsOfAcquisitionDate
      contextRef="As_Of_9_30_2022_ifrs-full_BusinessCombinationsAxis_cvac_FramePharmaceuticalsB.v.AmsterdamNetherlandsMember_vR0Bi5R7KE6kPw8J5q5NTA"
      decimals="-3"
      id="Tc_05GoYEPyrEaFehRsBhP1WA_9_2"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">7558000</cvac:TotalAssetsRecognisedAsOfAcquisitionDate>
    <ifrs-full:NoncurrentLiabilitiesRecognisedAsOfAcquisitionDate
      contextRef="As_Of_9_30_2022_ifrs-full_BusinessCombinationsAxis_cvac_FramePharmaceuticalsB.v.AmsterdamNetherlandsMember_vR0Bi5R7KE6kPw8J5q5NTA"
      decimals="-3"
      id="Tc_d5NBXsR_zkiIYphbxpo1UQ_10_2"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">134000</ifrs-full:NoncurrentLiabilitiesRecognisedAsOfAcquisitionDate>
    <cvac:NoncurrentLeaseLiabilitiesRecognisedAsOfAcquisitionDate
      contextRef="As_Of_9_30_2022_ifrs-full_BusinessCombinationsAxis_cvac_FramePharmaceuticalsB.v.AmsterdamNetherlandsMember_vR0Bi5R7KE6kPw8J5q5NTA"
      decimals="-3"
      id="Tc_k8dlaB_OuUuvRARjIg4vwQ_11_2"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">114000</cvac:NoncurrentLeaseLiabilitiesRecognisedAsOfAcquisitionDate>
    <cvac:NetDeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate
      contextRef="As_Of_9_30_2022_ifrs-full_BusinessCombinationsAxis_cvac_FramePharmaceuticalsB.v.AmsterdamNetherlandsMember_vR0Bi5R7KE6kPw8J5q5NTA"
      decimals="-3"
      id="Tc_6s6rmNFjpUegxH4Hvrngtw_12_2"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">20000</cvac:NetDeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate>
    <ifrs-full:CurrentLiabilitiesRecognisedAsOfAcquisitionDate
      contextRef="As_Of_9_30_2022_ifrs-full_BusinessCombinationsAxis_cvac_FramePharmaceuticalsB.v.AmsterdamNetherlandsMember_vR0Bi5R7KE6kPw8J5q5NTA"
      decimals="-3"
      id="Tc_hlYrGExAoEuJRB2BsQYRhw_13_2"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">406000</ifrs-full:CurrentLiabilitiesRecognisedAsOfAcquisitionDate>
    <cvac:CurrentLeaseLiabilitiesRecognisedAsOfAcquisitionDate
      contextRef="As_Of_9_30_2022_ifrs-full_BusinessCombinationsAxis_cvac_FramePharmaceuticalsB.v.AmsterdamNetherlandsMember_vR0Bi5R7KE6kPw8J5q5NTA"
      decimals="-3"
      id="Tc_Zw9wAwoGJEe0S0qSBdEp9A_14_2"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">55000</cvac:CurrentLeaseLiabilitiesRecognisedAsOfAcquisitionDate>
    <ifrs-full:TradeAndOtherPayablesRecognisedAsOfAcquisitionDate
      contextRef="As_Of_9_30_2022_ifrs-full_BusinessCombinationsAxis_cvac_FramePharmaceuticalsB.v.AmsterdamNetherlandsMember_vR0Bi5R7KE6kPw8J5q5NTA"
      decimals="-3"
      id="Tc_YenaO_jXjUSRD09pzbyWIw_15_2"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">346000</ifrs-full:TradeAndOtherPayablesRecognisedAsOfAcquisitionDate>
    <cvac:OtherCurrentLiabilitiesRecognisedAsOfAcquisitionDate
      contextRef="As_Of_9_30_2022_ifrs-full_BusinessCombinationsAxis_cvac_FramePharmaceuticalsB.v.AmsterdamNetherlandsMember_vR0Bi5R7KE6kPw8J5q5NTA"
      decimals="-3"
      id="Tc_mQcoIiJFrku_Qet7xekc1Q_16_2"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">5000</cvac:OtherCurrentLiabilitiesRecognisedAsOfAcquisitionDate>
    <cvac:LiabilitiesRecognisedAsOfAcquisitionDate
      contextRef="As_Of_9_30_2022_ifrs-full_BusinessCombinationsAxis_cvac_FramePharmaceuticalsB.v.AmsterdamNetherlandsMember_vR0Bi5R7KE6kPw8J5q5NTA"
      decimals="-3"
      id="Tc_t2n_25_Yf0GffV962eN-5Q_17_2"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">540000</cvac:LiabilitiesRecognisedAsOfAcquisitionDate>
    <ifrs-full:IdentifiableAssetsAcquiredLiabilitiesAssumed
      contextRef="As_Of_9_30_2022_ifrs-full_BusinessCombinationsAxis_cvac_FramePharmaceuticalsB.v.AmsterdamNetherlandsMember_vR0Bi5R7KE6kPw8J5q5NTA"
      decimals="-3"
      id="Tc_rUH_l6g9Dk28q1NJH6FZhw_18_2"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">7018000</ifrs-full:IdentifiableAssetsAcquiredLiabilitiesAssumed>
    <cvac:ProvisionalFairValue
      contextRef="Duration_1_1_2022_To_9_30_2022_GrYkE3mhHEiRA4fxgfABRg"
      decimals="-3"
      id="Narr_8YOMUTBnFkyqw2btjNEYEg"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">6216000</cvac:ProvisionalFairValue>
    <ifrs-full:DeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate
      contextRef="As_Of_9_30_2022_zuGVrjesE0WhwXSGmTqsgA"
      decimals="-3"
      id="Narr_0aAInHCsXEugzUCrpHhPvg"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">20000</ifrs-full:DeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate>
    <ifrs-full:DeferredTaxAssetsRecognisedAsOfAcquisitionDate
      contextRef="As_Of_9_30_2022_zuGVrjesE0WhwXSGmTqsgA"
      decimals="-3"
      id="Narr_ycXnqFEIn0KqUI84DHpt-g"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">1550000</ifrs-full:DeferredTaxAssetsRecognisedAsOfAcquisitionDate>
    <ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised
      contextRef="As_Of_9_30_2022_zuGVrjesE0WhwXSGmTqsgA"
      decimals="-3"
      id="Narr_zOcrCWaVbUi2v80Dd_F0kg"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">1530000</ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised>
    <ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised
      contextRef="As_Of_9_30_2022_ifrs-full_BusinessCombinationsAxis_cvac_FramePharmaceuticalsB.v.AmsterdamNetherlandsMember_vR0Bi5R7KE6kPw8J5q5NTA"
      decimals="-3"
      id="Narr_xOCOqtiKd0Wwt2LJYkdArg"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">5800000</ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised>
    <cvac:DisclosureOfGoodwillRecognizedAsResultOfAcquisitionExplanatoryTableTextBlock
      contextRef="Duration_1_1_2022_To_9_30_2022_GrYkE3mhHEiRA4fxgfABRg"
      id="Tb_hkkKaFfacEiHKDQMda426g">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 2pt 0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:86.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:86.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;in EURk&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:86.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Consideration transferred&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 19,481&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:86.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Net Assets acquired&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (7,018)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:86.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Preliminary Goodwill&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 12,463&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</cvac:DisclosureOfGoodwillRecognizedAsResultOfAcquisitionExplanatoryTableTextBlock>
    <ifrs-full:AcquisitiondateFairValueOfTotalConsiderationTransferred
      contextRef="As_Of_9_30_2022_ifrs-full_BusinessCombinationsAxis_cvac_FramePharmaceuticalsB.v.AmsterdamNetherlandsMember_vR0Bi5R7KE6kPw8J5q5NTA"
      decimals="-3"
      id="Tc_7dhGA7n3C0mG7f5D-r0DjA_2_2"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">19481000</ifrs-full:AcquisitiondateFairValueOfTotalConsiderationTransferred>
    <ifrs-full:IdentifiableAssetsAcquiredLiabilitiesAssumed
      contextRef="As_Of_9_30_2022_ifrs-full_BusinessCombinationsAxis_cvac_FramePharmaceuticalsB.v.AmsterdamNetherlandsMember_vR0Bi5R7KE6kPw8J5q5NTA"
      decimals="-3"
      id="Tc_5TNjR6Uz2kmlpq2WmjrcmQ_3_2"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">7018000</ifrs-full:IdentifiableAssetsAcquiredLiabilitiesAssumed>
    <ifrs-full:GoodwillRecognisedAsOfAcquisitionDate
      contextRef="As_Of_9_30_2022_ifrs-full_BusinessCombinationsAxis_cvac_FramePharmaceuticalsB.v.AmsterdamNetherlandsMember_vR0Bi5R7KE6kPw8J5q5NTA"
      decimals="-3"
      id="Tc_AcVGvQJW60aAF3mtSoAX7g_4_2"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">-12463000</ifrs-full:GoodwillRecognisedAsOfAcquisitionDate>
    <cvac:DisclosureOfAnalysisOfCashFlowsOnAcquisitionExplanatoryTableTextBlock
      contextRef="Duration_1_1_2022_To_9_30_2022_GrYkE3mhHEiRA4fxgfABRg"
      id="Tb_R2pZvURcGESbgEQt0q5GVw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:86.45%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:86.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Analyses of cash flows on acquisition:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EURk&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:86.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Payment of consideration in cash and cash equivalents&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (585)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:86.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</cvac:DisclosureOfAnalysisOfCashFlowsOnAcquisitionExplanatoryTableTextBlock>
    <ifrs-full:CashTransferred
      contextRef="As_Of_9_30_2022_ifrs-full_BusinessCombinationsAxis_cvac_FramePharmaceuticalsB.v.AmsterdamNetherlandsMember_vR0Bi5R7KE6kPw8J5q5NTA"
      decimals="-3"
      id="Tc_rzVNnQKLfEayuzucjw8uNg_2_2"
      unitRef="Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg">585000</ifrs-full:CashTransferred>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>71
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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MY2SATAC _QLA]/.%>4#[46?U+U!+ P04    " # BW%53=WOGD8&   _'0
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M J$]D:PQ+_'73$I6F<,=P07AVD#]OF%,OI[H!_3?@:S^#U!+ P04    " #
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MUU$Z/4K:LFT7P=;Q<LUMH*LZ/O+\H&,#.E]:>E-T"P[0?VTM_@%02P,$%
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MZ%HCUWFC<>=4H>MP4>AW+@6 $/;6&8?#77?J^&I5:UW$(A;R&P+SQ)/Y>-K
M]V;&ZWN13?5.R.= )RV.@3',JDL8F&WN-'#*+MT2&H8'R 2CT<,)F=T @/U
MSZV5_.YGN5I??-BQLO^>/.+DB"'2B&MH(4K4 );C6&(X]$)_TD\+43CZH34"
MD0X#U^Z\\0BS;K%XD]_GRARI%&I!A7*!LC!5"^I/TLDB9X/8-4\ VVAT*'^%
M T"?L6.](0!1.#R4O<*)RUP\GK3N$GAQ+Z^!"W(@ZS+A>(#W8U>P ;"NXV&O
M3CX'^[RMB769J-0H(^<ZD5R@<^E%J4F7A&X/)B>O*=K7^+9H7E+&2*F32)1
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M,,TKH!DX7?F;]T([W./]9X:'$QG>@/6EUJX=L(+N*7;Y#U!+ P04    " #
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M?ML[STO.5CROBE?DEQJU:7@!U?'PX]% ^;Q^Y4-T35IYYBYB@4J/%396]B*
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M0/>SK-]8U?CYL5&6II%?5C3^43L ?2^5LH>-"S#^H:S^ E!+ P04    " #
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MPBE3ZA;-WP*8K7!%%8\E/M/+U$0&\8E00:$?@6P=1^*XAI1#W74O<O<"]5[
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MVM4U6/CIQR\/;-1NVEZD-=MHNJ\Y#^]D-%SLG%;13AK22W/L7-<8$@,3ILH
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M2P'R?RM;3AOZQ6@P?GOV7^DO2^Q6U<;=)-YW'_SBT,\8V^.=4(C(+)DN1R0
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M%0%HSPOP>^4PI>0/?,#P>O_TOU!+ P04    " # BW%5'_YS+B('  #3%P
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M#<H:X/U*2K/=6 ?]_X'9/U!+ P04    " #!BW%5<18D[QD#  #_!P  &0
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M:W-H965T<R]S:&5E=#(X+GAM;)U6;6_;. S^*X0'#"V0-K:3N&F7!&B[W6[
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MQJQGP$F!R10WYV2;2XN:5Y!S21><"3"6A"OW%I<P+[DA)4!3H[L4:\@:!*M
MR4)Q60#/2-*_:5OVY&&%S#3:0S@[7Z1ELN"4TW"[S\?A._9JR5W7(=NL4HVK
M 69;_D[0<(_L*:Q0$QDBIZDX6X:YHKBMS V\?S>.P\&'HU\NX=./1\)5C2$W
M#3P<-OS*Z#<E+])&:\=G\R));W0=.X :M5WWH!8NI7T6DW+MJ<=A K[K7JC\
MHC'=:T97X6Y,-J=G<TQ+J80JUN<$'T<)W._;O$X2F&N6H;>C*#Z:^G2*?.G[
M!22C,=PS4_KKU"V<+TLF?%<9A&.8*^NHMG!7O1$I['+;S:QH,(0_T"7GWFDT
MA(^8HW;):-G+WN691/_>V:Y :^R<@M'1V=494HQ>FQF-X#9-VP=Y8.N6WF"8
MP'=/^I"_HPVYO;-A"-_0OJJBJUX8C4^TAE'7&D9O;@V%4MF*"^%>1%&3^[M-
M3D9[0_]8VSK<R:U#/>.TO;<E^#/<4T>ELM1M1?H^NWF1Z+HW'$<^*/\J13CS
M43FGG$;!J;AH9(#/6U)1W!LF@Q,A2[J0)6\.&:.Z6QOT/<JG:^[J&/SL<#)*
MITW\5Y1NWV+VIHTD)=^VBZ5[0:50IT=+[6PT'IT?LW\HB/V=@:)"7?BQR8"O
M@':VZ$Z[R>RV'4A^B;=CW5>F"TY_J )S4@TOKRBE=#LJM1NK:C^>+)2E8<<O
M2YHN43L!NL^5LMN-,]#-J[-_ %!+ P04    " #!BW%5V09Z\ 8%  !O'0
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MNT@P0ME7/7U'B[8K'!Z$QC*D:U98*8(T!CB_$9BMAHY98*P]\Y]02P,$%
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M#Y%(-0V[F1A9NYZWD 8[J!N6>,8!90WP^4IB 6TG]@7=J2G_ U!+ P04
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MN[7# C] 0!H!?+X6V-QT$_."_I-F^2]02P,$%     @ P8MQ5=\J4%_$ P
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M)]W-"MW&JM:WVWMEL7G[98/C%6AG@,]KA:6^W[@+AH&M^ E02P,$%     @
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MD7>R5>K5)S_+#$=>$ @HK&=@[G6 .Q#"$SD9?P9./+;TP-/XR/X]>'=>MLS
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MKQT\ .>>R-GXTW'B7M(##]=[]N^A=E?+AAIX4/PWRVTYQ[<8Y5#0FMNU:GY
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M>!_PG4&GC_;(5;*5\M497XH4!TX0<,B-8Z!VV<,C<.Z(K(R? R<>4SK@\?[
M_LG7;FO94@V/DO]@A:E2?(M1 25MN5G+[C,,]=PXOEQR[;^HZV/C"*.\U4;6
M ]@JJ)GH5_HVW,,1( Q/ ,(!$'K=?2*O<DD-S1(E.Z1<M&5S&U^J1UMQ3+B?
MLC'*GC*+,]E74X%"G-$MX\PPT.AJ"88RKJ_1Y<5M-(OO$1/H6R5;346A$V)L
M5H<E^9!AT6<(3V2X0\]2F$JC)U% \3>>6+6CY/ @>1&>)=Q ,T%1\ &%01BB
MIY<UNAJ47I]AC\8+B3Q[=()]R73.I6X5(%FB?Z[GO?I[POA]0C=5<]W0'%)L
MQT:#V@/.+B^FL^#^C-QXE!N?8\^6D-M9U.!^DOP?L3W=C:=S$[O/[J;38):0
M_;$*<M11-:B=GQN-<MD*TS?7Z!U'\Z'OR#_A_5P_4[5C0B,.I84&DX\VM^IG
MI3>,;'Q_;J6QW>ZWE7U>0+D >UY*:0Z&2S ^6-EO4$L#!!0    ( ,&+<57;
MO)J6\0(  %P)   9    >&PO=V]R:W-H965T<R]S:&5E=#4Q+GAM;*U684_;
M,!#]*U8F(9 VDB9MZ*"-!(5IDT!"96R?W>3:6#AV9CLM_/N=G1!:2*.!]J6U
MG7OO[MW9/D\V4CWH',"0QX(+/?5R8\I3W]=I#@75Q[($@5^64A74X%2M?%TJ
MH)D#%=P/@R#V"\J$ETS<VJU*)K(RG FX541714'5TP5PN9EZ ^]Y8<Y6N;$+
M?C(IZ0KNP-R7MPIG?LN2L0*$9E(0!<NI=SXXG8VMO3/XQ6"CM\;$*EE(^6 G
M/[*I%]B @$-J+ /%OS7,@'-+A&'\:3B]UJ4%;H^?V;\Y[:AE037,)/_-,I-/
MO;%',EC2BINYW'R'1L_(\J62:_=+-K7M"(W32AM9-&",H&"B_J>/31ZV ,C3
M#0@;0/@:$.\!1 T@<D+KR)RL2VIH,E%R0Y2U1C8[<+EQ:%3#A*WBG5'XE2'.
M)->2"DT.+\%0QO41^4*NT8+()4D59,S@PM7]G!P>?!I'\?#LB#0#P@3YF<M*
M4Y'IB6\P%$OHIXW;B]IMN,?M5W(CA<DUN1(99!WX63]^$/80^)B#-A'A<R(N
MPE[&.RB/211\)F$0#KH"ZH=?0HKP01=\)YRHK4OD^*)]?$RG7.I*N5IDKCR0
M8=;K@^M.P )/)5E(A=1,K#JK4#L9=CNQ-\2I+FD*4P^O  UJ#5YR\&D0!V==
M&?A/9#OY&+;Y&/:Q)^>%K(0AF:(;T26T1H\<VMY<ZR0<!4$P\=?;"GI]?%#!
MJ%4PZE>0IJIR)32 [*9+Q:A#Q3!Z):+7S0=%Q*V(N%?$C.J<I!(O\0R4VX9=
M,GHYWKOKXK<YB>/H)2D[.DY:'2>].N90TB=L1L:>KE(QD;*2<D+K789K'._%
M+FF]M.^55I/%>S?MCK1Q*VW\[]+HJTU'\+HF2P#=I[&7_[T:QV_*-WA;/7^K
M@16@5JZO:]QH6(VZE[6K[=/AW'5,_\6\?G?<4+5BV-(X+!$:')^@:U7W\GIB
M9.G:X4(:;*YNF./S!Y0UP.]+*<WSQ#IH'U3)7U!+ P04    " #!BW%5A!$=
MQ <#  #9"P  &0   'AL+W=O<FMS:&5E=',O<VAE970U,BYX;6RMEMM.XS 0
MAE_%RDJH2 LYMA1H(]&6!2Z0$ 7VVDVFK45B9VWWL&^_MI.&M(0LH-PTMN/Y
M9SY[)IW!AO%7L020:)LF5 RMI939A6V+: DI%J<L ZK>S!E/L513OK!%Q@''
MQBA-;,]Q>G:*";7"@5E[X.& K61"*#QP)%9IBOG?$21L,[1<:[?P2!9+J1?L
M<)#A!4Q!/F</7,WL4B4F*5!!&$4<YD/KRKT8N\; ['@AL!&5,=(H,\9>]>0N
M'EJ.C@@2B*26P.JQAC$DB592<?PI1*W2IS:LCG?JOPR\@IEA 6.6_":Q7 ZM
MOH5BF.-5(A_9YA8*H*[6BU@BS"_:Y'N#GH6BE9 L+8Q5!"FA^1-OBX.H&"B=
M>@.O,/ .#8(/#/S"P#>@>60&:X(E#@><;1#7NY6:'IBS,=:*AE!]C5/)U5NB
M[&1X1R.6 I)XBSH3D)@DXAB=H.OG1]0Y^M'W>\'E,2H&B%#TM&0K@6DL!K94
M[K6('16N1KDK[P-7Y^B>4;D4Z)K&$._;VRKL,G9O%_O(:Q2<0G:*?.<G\AS/
MJXEG_'ESMR$<OSQ*W^CYS4?YI(YR0D24,+'B4'=,N4Q0+Z/K]D)D.(*AI0I3
M %^#%1[]<'O.91UC2V)[Q$%)'#2I5Y-G!A3F1-JH UOUB1%P7$>>RW6-G/[
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MGO1B?:"-'U!:"$5KZVMZ/]C:?9@OB!0<_44)1VM-TSWEG':: VW\@-)\4%H
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M;\Q@R7)R8[FB15I,QGL46HND6-Q3LJ$RW\%\OQ5"'U;R!/44T_G_4$L#!!0
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M7,J"TZ0U?]N8AR?,K\"'LN [!GXK4IR:Y:>BJL?ZPD-];Z#3X+_JX@+,EF\
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M:$R63JF1>LK+=JV?@.I/[]68B;0'LSX&&K%1#;0SZX27\?(O;)0T4G9K[.
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M*^JM!'H;ZFT$>AOJ;01Z&^IM!'K;9+.$0&]#O8U ;T.]C4!O0[V-0&]#O8U
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MD7EJ0C:YWD_LLQ:9<:ZI"Q/3.-MVY9>4Z5M"GE8.<T)5NW"2)F3LVX1^Y.>
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M4')O<',O87!P+GAM;%!+ 0(4 Q0    ( ,"+<555#+K8[P   "L"   1
M          "  :\   !D;V-0<F]P<R]C;W)E+GAM;%!+ 0(4 Q0    ( ,"+
M<5697)PC$ 8  )PG   3              "  <T!  !X;"]T:&5M92]T:&5M
M93$N>&UL4$L! A0#%     @ P(MQ53\U_V.O @  L@@  !@
M ("!#@@  'AL+W=O<FMS:&5E=',O<VAE970Q+GAM;%!+ 0(4 Q0    ( ,"+
M<56/79)3O 0  . 1   8              " @?,*  !X;"]W;W)K<VAE971S
M+W-H965T,BYX;6Q02P$"% ,4    " # BW%53=WOGD8&   _'0  &
M        @('E#P  >&PO=V]R:W-H965T<R]S:&5E=#,N>&UL4$L! A0#%
M  @ P(MQ5<]F&_$\!@  U28  !@              ("!818  'AL+W=O<FMS
M:&5E=',O<VAE970T+GAM;%!+ 0(4 Q0    ( ,"+<56 N<&$U@<  !,B   8
M              " @=,<  !X;"]W;W)K<VAE971S+W-H965T-2YX;6Q02P$"
M% ,4    " # BW%5C*UPZV $  !Y"0  &               @('?)   >&PO
M=V]R:W-H965T<R]S:&5E=#8N>&UL4$L! A0#%     @ P(MQ59/PC\3&"
MFQ8  !@              ("!=2D  'AL+W=O<FMS:&5E=',O<VAE970W+GAM
M;%!+ 0(4 Q0    ( ,"+<54%9@R*.!(  #\Y   8              " @7$R
M  !X;"]W;W)K<VAE971S+W-H965T."YX;6Q02P$"% ,4    " # BW%5!) 1
M+V@%  "6#0  &               @('?1   >&PO=V]R:W-H965T<R]S:&5E
M=#DN>&UL4$L! A0#%     @ P(MQ5;\8$;-3!P  51@  !D
M ("!?4H  'AL+W=O<FMS:&5E=',O<VAE970Q,"YX;6Q02P$"% ,4    " #
MBW%5$+O#],T#  #*"   &0              @($'4@  >&PO=V]R:W-H965T
M<R]S:&5E=#$Q+GAM;%!+ 0(4 Q0    ( ,"+<56@W^U5V 0   \+   9
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M970Q-BYX;6Q02P$"% ,4    " # BW%5 ]LS6,0"  !F!@  &0
M    @(&U9@  >&PO=V]R:W-H965T<R]S:&5E=#$W+GAM;%!+ 0(4 Q0    (
M ,"+<56[WCE@W0(  %P&   9              " @;!I  !X;"]W;W)K<VAE
M971S+W-H965T,3@N>&UL4$L! A0#%     @ P(MQ50[G1YS? @  1P<  !D
M             ("!Q&P  'AL+W=O<FMS:&5E=',O<VAE970Q.2YX;6Q02P$"
M% ,4    " # BW%5G]^8LYH#  "&"   &0              @(':;P  >&PO
M=V]R:W-H965T<R]S:&5E=#(P+GAM;%!+ 0(4 Q0    ( ,"+<57@W^=@WP(
M /L&   9              " @:MS  !X;"]W;W)K<VAE971S+W-H965T,C$N
M>&UL4$L! A0#%     @ P(MQ5:X2DKK?!@  $A   !D              ("!
MP78  'AL+W=O<FMS:&5E=',O<VAE970R,BYX;6Q02P$"% ,4    " # BW%5
MW2IG;; ,  !T(0  &0              @('7?0  >&PO=V]R:W-H965T<R]S
M:&5E=#(S+GAM;%!+ 0(4 Q0    ( ,"+<54.JWJL\P@  .H7   9
M      " @;Z*  !X;"]W;W)K<VAE971S+W-H965T,C0N>&UL4$L! A0#%
M  @ P(MQ51_^<RXB!P  TQ<  !D              ("!Z),  'AL+W=O<FMS
M:&5E=',O<VAE970R-2YX;6Q02P$"% ,4    " # BW%5C7HJ9B8#   ;"
M&0              @(%!FP  >&PO=V]R:W-H965T<R]S:&5E=#(V+GAM;%!+
M 0(4 Q0    ( ,&+<55Q%B3O&0,  /\'   9              " @9Z>  !X
M;"]W;W)K<VAE971S+W-H965T,C<N>&UL4$L! A0#%     @ P8MQ5>QPZH@X
M!   NPH  !D              ("![J$  'AL+W=O<FMS:&5E=',O<VAE970R
M."YX;6Q02P$"% ,4    " #!BW%5V09Z\ 8%  !O'0  &0
M@(%=I@  >&PO=V]R:W-H965T<R]S:&5E=#(Y+GAM;%!+ 0(4 Q0    ( ,&+
M<55BK?:FP 4  &DK   9              " @9JK  !X;"]W;W)K<VAE971S
M+W-H965T,S N>&UL4$L! A0#%     @ P8MQ5=8E*)MW @  (P8  !D
M         ("!D;$  'AL+W=O<FMS:&5E=',O<VAE970S,2YX;6Q02P$"% ,4
M    " #!BW%5=Y6B66$#  "'"@  &0              @($_M   >&PO=V]R
M:W-H965T<R]S:&5E=#,R+GAM;%!+ 0(4 Q0    ( ,&+<560>=3E'P,  $$)
M   9              " @=>W  !X;"]W;W)K<VAE971S+W-H965T,S,N>&UL
M4$L! A0#%     @ P8MQ54PH8!;S P  W@P  !D              ("!+;L
M 'AL+W=O<FMS:&5E=',O<VAE970S-"YX;6Q02P$"% ,4    " #!BW%5WRI0
M7\0#   "#   &0              @(%7OP  >&PO=V]R:W-H965T<R]S:&5E
M=#,U+GAM;%!+ 0(4 Q0    ( ,&+<55VYFLF/ ,  +P)   9
M  " @5+#  !X;"]W;W)K<VAE971S+W-H965T,S8N>&UL4$L! A0#%     @
MP8MQ5:\:2J Q!@  @"X  !D              ("!Q<8  'AL+W=O<FMS:&5E
M=',O<VAE970S-RYX;6Q02P$"% ,4    " #!BW%58.]85J<#  "&$@  &0
M            @($MS0  >&PO=V]R:W-H965T<R]S:&5E=#,X+GAM;%!+ 0(4
M Q0    ( ,&+<54!'2O\EP4  #PG   9              " @0O1  !X;"]W
M;W)K<VAE971S+W-H965T,SDN>&UL4$L! A0#%     @ P8MQ5>-,ZRG$ @
MIP<  !D              ("!V=8  'AL+W=O<FMS:&5E=',O<VAE970T,"YX
M;6Q02P$"% ,4    " #!BW%57']-UJ@#  #H$@  &0              @('4
MV0  >&PO=V]R:W-H965T<R]S:&5E=#0Q+GAM;%!+ 0(4 Q0    ( ,&+<57;
MX AIRQ   -L[ 0 9              " @;/=  !X;"]W;W)K<VAE971S+W-H
M965T-#(N>&UL4$L! A0#%     @ P8MQ57E"3(2< @  X08  !D
M     ("!M>X  'AL+W=O<FMS:&5E=',O<VAE970T,RYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( ,&+<55XB;Z^U@(  (T*   9              "
M@2G]  !X;"]W;W)K<VAE971S+W-H965T-#@N>&UL4$L! A0#%     @ P8MQ
M59$X$K L @  S@0  !D              ("!-@ ! 'AL+W=O<FMS:&5E=',O
M<VAE970T.2YX;6Q02P$"% ,4    " #!BW%5"W;NOBH"  "\!   &0
M        @(&9 @$ >&PO=V]R:W-H965T<R]S:&5E=#4P+GAM;%!+ 0(4 Q0
M   ( ,&+<57;O)J6\0(  %P)   9              " @?H$ 0!X;"]W;W)K
M<VAE971S+W-H965T-3$N>&UL4$L! A0#%     @ P8MQ5801'<0' P  V0L
M !D              ("!(@@! 'AL+W=O<FMS:&5E=',O<VAE970U,BYX;6Q0
M2P$"% ,4    " #!BW%5YHY]M,("  "*"0  &0              @(%@"P$
M>&PO=V]R:W-H965T<R]S:&5E=#4S+GAM;%!+ 0(4 Q0    ( ,&+<57$:,3<
M=@(  %(&   9              " @5D. 0!X;"]W;W)K<VAE971S+W-H965T
M-30N>&UL4$L! A0#%     @ P8MQ52" PIE:!0  ;BH  !D
M ("!!A$! 'AL+W=O<FMS:&5E=',O<VAE970U-2YX;6Q02P$"% ,4    " #!
MBW%5$<P?MYL)   A00  &0              @(&7%@$ >&PO=V]R:W-H965T
M<R]S:&5E=#4V+GAM;%!+ 0(4 Q0    ( ,&+<55WU3X@7 0  #80   9
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M 0!X;"]S='EL97,N>&UL4$L! A0#%     @ P8MQ59>*NQS     $P(   L
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64$L%!@    !# $, 3!(  (8X 0    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.2.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>157</ContextCount>
  <ElementCount>279</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>65</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>14</UnitCount>
  <MyReports>
    <Report instance="cvac-20220930x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00090 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.curevac.com/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="cvac-20220930x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>00100 - Statement - Interim Condensed Consolidated Statements of Operations and Other Comprehensive Income (Loss)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfOperationsAndOtherComprehensiveIncomeLoss</Role>
      <ShortName>Interim Condensed Consolidated Statements of Operations and Other Comprehensive Income (Loss)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="cvac-20220930x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>00200 - Statement - Interim Condensed Consolidated Statements of Financial Position</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition</Role>
      <ShortName>Interim Condensed Consolidated Statements of Financial Position</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="cvac-20220930x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>00300 - Statement - Interim Condensed Consolidated Statements of Changes in Shareholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfChangesInShareholdersEquity</Role>
      <ShortName>Interim Condensed Consolidated Statements of Changes in Shareholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="cvac-20220930x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>00400 - Statement - Interim Condensed Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows</Role>
      <ShortName>Interim Condensed Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="cvac-20220930x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>10101 - Disclosure - Corporate Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.curevac.com/role/DisclosureCorporateInformation</Role>
      <ShortName>Corporate Information</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="cvac-20220930x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>10201 - Disclosure - Basis of preparation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.curevac.com/role/DisclosureBasisOfPreparation</Role>
      <ShortName>Basis of preparation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="cvac-20220930x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>10301 - Disclosure - Notes to the consolidated financial statements</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatements</Role>
      <ShortName>Notes to the consolidated financial statements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="cvac-20220930x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>10401 - Disclosure - Issued Capital and Reserves</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.curevac.com/role/DisclosureIssuedCapitalAndReserves</Role>
      <ShortName>Issued Capital and Reserves</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="cvac-20220930x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>10501 - Disclosure - Share-based payments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.curevac.com/role/DisclosureShareBasedPayments</Role>
      <ShortName>Share-based payments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="cvac-20220930x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>10601 - Disclosure - Fixed Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.curevac.com/role/DisclosureFixedAssets</Role>
      <ShortName>Fixed Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="cvac-20220930x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>10701 - Disclosure - Assets held for sale</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.curevac.com/role/DisclosureAssetsHeldForSale</Role>
      <ShortName>Assets held for sale</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="cvac-20220930x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>10801 - Disclosure - Inventories</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.curevac.com/role/DisclosureInventories</Role>
      <ShortName>Inventories</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="cvac-20220930x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>10901 - Disclosure - Prepaid expenses and other assets (current)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.curevac.com/role/DisclosurePrepaidExpensesAndOtherAssetsCurrent</Role>
      <ShortName>Prepaid expenses and other assets (current)</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="cvac-20220930x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>11001 - Disclosure - Financial assets and financial liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.curevac.com/role/DisclosureFinancialAssetsAndFinancialLiabilities</Role>
      <ShortName>Financial assets and financial liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="cvac-20220930x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>11101 - Disclosure - Trade and other payables</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.curevac.com/role/DisclosureTradeAndOtherPayables</Role>
      <ShortName>Trade and other payables</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="cvac-20220930x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>11201 - Disclosure - Other liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.curevac.com/role/DisclosureOtherLiabilities</Role>
      <ShortName>Other liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="cvac-20220930x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>11301 - Disclosure - Loans</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.curevac.com/role/DisclosureLoans</Role>
      <ShortName>Loans</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="cvac-20220930x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>11401 - Disclosure - Income tax</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.curevac.com/role/DisclosureIncomeTax</Role>
      <ShortName>Income tax</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="cvac-20220930x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>11501 - Disclosure - Disclosure of financial instruments and risk management</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.curevac.com/role/DisclosureDisclosureOfFinancialInstrumentsAndRiskManagement</Role>
      <ShortName>Disclosure of financial instruments and risk management</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="cvac-20220930x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>11601 - Disclosure - Earnings per share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.curevac.com/role/DisclosureEarningsPerShare</Role>
      <ShortName>Earnings per share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="cvac-20220930x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>11701 - Disclosure - Related party disclosures</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.curevac.com/role/DisclosureRelatedPartyDisclosures</Role>
      <ShortName>Related party disclosures</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="cvac-20220930x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>11801 - Disclosure - Significant transactions and events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.curevac.com/role/DisclosureSignificantTransactionsAndEvents</Role>
      <ShortName>Significant transactions and events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="cvac-20220930x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>20202 - Disclosure - Basis of preparation (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.curevac.com/role/DisclosureBasisOfPreparationPolicies</Role>
      <ShortName>Basis of preparation (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="cvac-20220930x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>30303 - Disclosure - Notes to the consolidated financial statements (Tables)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsTables</Role>
      <ShortName>Notes to the consolidated financial statements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatements</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="cvac-20220930x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>30403 - Disclosure - Issued Capital and Reserves (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.curevac.com/role/DisclosureIssuedCapitalAndReservesTables</Role>
      <ShortName>Issued Capital and Reserves (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.curevac.com/role/DisclosureIssuedCapitalAndReserves</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="cvac-20220930x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>30503 - Disclosure - Share-based payments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.curevac.com/role/DisclosureShareBasedPaymentsTables</Role>
      <ShortName>Share-based payments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.curevac.com/role/DisclosureShareBasedPayments</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="cvac-20220930x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>31803 - Disclosure - Significant transactions and events (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.curevac.com/role/DisclosureSignificantTransactionsAndEventsTables</Role>
      <ShortName>Significant transactions and events (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.curevac.com/role/DisclosureSignificantTransactionsAndEvents</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="cvac-20220930x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>40301 - Disclosure - Notes to the consolidated financial statements - Revenue from contract with customers (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsRevenueFromContractWithCustomersDetails</Role>
      <ShortName>Notes to the consolidated financial statements - Revenue from contract with customers (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="cvac-20220930x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>40302 - Disclosure - Notes to the consolidated financial statements - Summary of upfront payments and related revenues recognized (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsSummaryOfUpfrontPaymentsAndRelatedRevenuesRecognizedDetails</Role>
      <ShortName>Notes to the consolidated financial statements - Summary of upfront payments and related revenues recognized (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="cvac-20220930x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>40303 - Disclosure - Notes to the consolidated financial statements - Contract liabilities allocated to the remaining performance obligations (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsContractLiabilitiesAllocatedToRemainingPerformanceObligationsDetails</Role>
      <ShortName>Notes to the consolidated financial statements - Contract liabilities allocated to the remaining performance obligations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="cvac-20220930x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>40304 - Disclosure - Notes to the consolidated financial statements - Cost of sales (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsCostOfSalesDetails</Role>
      <ShortName>Notes to the consolidated financial statements - Cost of sales (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="cvac-20220930x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>40305 - Disclosure - Notes to the consolidated financial statements - Selling and distribution expenses (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsSellingAndDistributionExpensesDetails</Role>
      <ShortName>Notes to the consolidated financial statements - Selling and distribution expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="cvac-20220930x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>40306 - Disclosure - Notes to the consolidated financial statements - Research and development expenses (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsResearchAndDevelopmentExpensesDetails</Role>
      <ShortName>Notes to the consolidated financial statements - Research and development expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="cvac-20220930x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>40307 - Disclosure - Notes to the consolidated financial statements - General and administrative expenses (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsGeneralAndAdministrativeExpensesDetails</Role>
      <ShortName>Notes to the consolidated financial statements - General and administrative expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="cvac-20220930x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>40308 - Disclosure - Notes to the consolidated financial statements - Other operating income (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsOtherOperatingIncomeDetails</Role>
      <ShortName>Notes to the consolidated financial statements - Other operating income (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="cvac-20220930x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>40309 - Disclosure - Notes to the consolidated financial statements - Grants with government agencies and similar bodies (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsGrantsWithGovernmentAgenciesAndSimilarBodiesDetails</Role>
      <ShortName>Notes to the consolidated financial statements - Grants with government agencies and similar bodies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="cvac-20220930x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>40401 - Disclosure - Issued Capital and Reserves - Overview and General Remarks (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.curevac.com/role/DisclosureIssuedCapitalAndReservesOverviewAndGeneralRemarksDetails</Role>
      <ShortName>Issued Capital and Reserves - Overview and General Remarks (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="cvac-20220930x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>40402 - Disclosure - Issued Capital and Reserves - Impact of share split (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.curevac.com/role/DisclosureIssuedCapitalAndReservesImpactOfShareSplitDetails</Role>
      <ShortName>Issued Capital and Reserves - Impact of share split (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="cvac-20220930x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>40501 - Disclosure - Share-based payments - Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.curevac.com/role/DisclosureShareBasedPaymentsExpensesDetails</Role>
      <ShortName>Share-based payments - Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="cvac-20220930x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>40502 - Disclosure - Share-based payments - Expense recognized for the program (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.curevac.com/role/DisclosureShareBasedPaymentsExpenseRecognizedForProgramDetails</Role>
      <ShortName>Share-based payments - Expense recognized for the program (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="cvac-20220930x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>40503 - Disclosure - Share-based payments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.curevac.com/role/DisclosureShareBasedPaymentsDetails</Role>
      <ShortName>Share-based payments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.curevac.com/role/DisclosureShareBasedPaymentsTables</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="cvac-20220930x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>40601 - Disclosure - Fixed Assets - Intangible assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.curevac.com/role/DisclosureFixedAssetsIntangibleAssetsDetails</Role>
      <ShortName>Fixed Assets - Intangible assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="cvac-20220930x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>40602 - Disclosure - Fixed Assets - Property, plant and equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.curevac.com/role/DisclosureFixedAssetsPropertyPlantAndEquipmentDetails</Role>
      <ShortName>Fixed Assets - Property, plant and equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="cvac-20220930x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>40701 - Disclosure - Assets held for sale (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.curevac.com/role/DisclosureAssetsHeldForSaleDetails</Role>
      <ShortName>Assets held for sale (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.curevac.com/role/DisclosureAssetsHeldForSale</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="cvac-20220930x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>40801 - Disclosure - Inventories (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.curevac.com/role/DisclosureInventoriesDetails</Role>
      <ShortName>Inventories (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.curevac.com/role/DisclosureInventories</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="cvac-20220930x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>40901 - Disclosure - Prepaid expenses and other assets (current) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.curevac.com/role/DisclosurePrepaidExpensesAndOtherAssetsCurrentDetails</Role>
      <ShortName>Prepaid expenses and other assets (current) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.curevac.com/role/DisclosurePrepaidExpensesAndOtherAssetsCurrent</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="cvac-20220930x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>41001 - Disclosure - Financial assets and financial liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.curevac.com/role/DisclosureFinancialAssetsAndFinancialLiabilitiesDetails</Role>
      <ShortName>Financial assets and financial liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.curevac.com/role/DisclosureFinancialAssetsAndFinancialLiabilities</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="cvac-20220930x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>41101 - Disclosure - Trade and other payables (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.curevac.com/role/DisclosureTradeAndOtherPayablesDetails</Role>
      <ShortName>Trade and other payables (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.curevac.com/role/DisclosureTradeAndOtherPayables</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="cvac-20220930x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>41201 - Disclosure - Other liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.curevac.com/role/DisclosureOtherLiabilitiesDetails</Role>
      <ShortName>Other liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.curevac.com/role/DisclosureOtherLiabilities</ParentRole>
      <Position>50</Position>
    </Report>
    <Report instance="cvac-20220930x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>41301 - Disclosure - Loans (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.curevac.com/role/DisclosureLoansDetails</Role>
      <ShortName>Loans (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.curevac.com/role/DisclosureLoans</ParentRole>
      <Position>51</Position>
    </Report>
    <Report instance="cvac-20220930x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>41401 - Disclosure - Income tax (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.curevac.com/role/DisclosureIncomeTaxDetails</Role>
      <ShortName>Income tax (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.curevac.com/role/DisclosureIncomeTax</ParentRole>
      <Position>52</Position>
    </Report>
    <Report instance="cvac-20220930x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>41501 - Disclosure - Disclosure of financial instruments and risk management (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.curevac.com/role/DisclosureDisclosureOfFinancialInstrumentsAndRiskManagementDetails</Role>
      <ShortName>Disclosure of financial instruments and risk management (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.curevac.com/role/DisclosureDisclosureOfFinancialInstrumentsAndRiskManagement</ParentRole>
      <Position>53</Position>
    </Report>
    <Report instance="cvac-20220930x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>41601 - Disclosure - Earnings per share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.curevac.com/role/DisclosureEarningsPerShareDetails</Role>
      <ShortName>Earnings per share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.curevac.com/role/DisclosureEarningsPerShare</ParentRole>
      <Position>54</Position>
    </Report>
    <Report instance="cvac-20220930x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>41701 - Disclosure - Related party disclosures (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.curevac.com/role/DisclosureRelatedPartyDisclosuresDetails</Role>
      <ShortName>Related party disclosures (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.curevac.com/role/DisclosureRelatedPartyDisclosures</ParentRole>
      <Position>55</Position>
    </Report>
    <Report instance="cvac-20220930x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>41801 - Disclosure - Significant transactions and events (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.curevac.com/role/DisclosureSignificantTransactionsAndEventsDetails</Role>
      <ShortName>Significant transactions and events (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.curevac.com/role/DisclosureSignificantTransactionsAndEventsTables</ParentRole>
      <Position>56</Position>
    </Report>
    <Report instance="cvac-20220930x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>41802 - Disclosure - Significant transactions and events - Frame Acquisition - Purchase Price Allocation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.curevac.com/role/DisclosureSignificantTransactionsAndEventsFrameAcquisitionPurchasePriceAllocationDetails</Role>
      <ShortName>Significant transactions and events - Frame Acquisition - Purchase Price Allocation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="cvac-20220930x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>41803 - Disclosure - Significant transactions and events - Goodwill Recognized On Frame Acquisition (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.curevac.com/role/DisclosureSignificantTransactionsAndEventsGoodwillRecognizedOnFrameAcquisitionDetails</Role>
      <ShortName>Significant transactions and events - Goodwill Recognized On Frame Acquisition (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="cvac-20220930x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>41804 - Disclosure - Significant transactions and events - Analyses of cash flows on Frame Acquisition (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.curevac.com/role/DisclosureSignificantTransactionsAndEventsAnalysesOfCashFlowsOnFrameAcquisitionDetails</Role>
      <ShortName>Significant transactions and events - Analyses of cash flows on Frame Acquisition (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Warning">[ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 17 fact(s) appearing in ix:hidden were eligible for transformation: cvac:NetValueOfInventoryTransferred, ifrs-full:DilutedEarningsLossPerShare, ifrs-full:ParValuePerShare, ifrs-full:ProceedsFromIssuingShares, ifrs-full:TransfersIntoLevel3OfFairValueHierarchyLiabilities, ifrs-full:TransfersOutOfLevel1IntoLevel2OfFairValueHierarchyLiabilities, ifrs-full:TransfersOutOfLevel2IntoLevel1OfFairValueHierarchyAssets, ifrs-full:TransfersOutOfLevel2IntoLevel1OfFairValueHierarchyLiabilities, ifrs-full:TransfersOutOfLevel3OfFairValueHierarchyAssets, ifrs-full:TransfersOutOfLevel3OfFairValueHierarchyLiabilities -  cvac-20220930xex99d1.htm 9</Log>
  </Logs>
  <InputFiles>
    <File doctype="6-K" original="cvac-20220930x6k.htm">cvac-20220930x6k.htm</File>
    <File doctype="6-K" original="cvac-20220930xex99d1.htm">cvac-20220930xex99d1.htm</File>
    <File>cvac-20220930.xsd</File>
    <File>cvac-20220930_cal.xml</File>
    <File>cvac-20220930_def.xml</File>
    <File>cvac-20220930_lab.xml</File>
    <File>cvac-20220930_pre.xml</File>
    <File>cvac-20220930xex99d2.htm</File>
    <File>cvac-20220930xex99d3.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>cvac-20220930xex99d1001.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="401">http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full</BaseTaxonomy>
    <BaseTaxonomy items="8">http://xbrl.sec.gov/dei/2021q4</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>77
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "cvac-20220930x6k.htm cvac-20220930xex99d1.htm": {
   "axisCustom": 4,
   "axisStandard": 18,
   "contextCount": 157,
   "dts": {
    "calculationLink": {
     "local": [
      "cvac-20220930_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "cvac-20220930_def.xml"
     ]
    },
    "inline": {
     "local": [
      "cvac-20220930x6k.htm",
      "cvac-20220930xex99d1.htm"
     ]
    },
    "labelLink": {
     "local": [
      "cvac-20220930_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "cvac-20220930_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "cvac-20220930.xsd",
      "reference-2009-12-16.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd",
      "https://xbrl.sec.gov/country/2021/country-2021.xsd",
      "https://xbrl.sec.gov/currency/2021/currency-2021.xsd",
      "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd"
     ]
    }
   },
   "elementCount": 614,
   "entityCount": 1,
   "hidden": {
    "http://www.curevac.com/20220930": 1,
    "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full": 16,
    "http://xbrl.sec.gov/dei/2021q4": 6,
    "total": 23
   },
   "keyCustom": 107,
   "keyStandard": 172,
   "memberCustom": 46,
   "memberStandard": 18,
   "nsprefix": "cvac",
   "nsuri": "http://www.curevac.com/20220930",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20220930x6k.htm",
      "contextRef": "Duration_1_1_2022_To_9_30_2022_GrYkE3mhHEiRA4fxgfABRg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "00090 - Document - Document and Entity Information",
     "role": "http://www.curevac.com/role/DocumentDocumentAndEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20220930x6k.htm",
      "contextRef": "Duration_1_1_2022_To_9_30_2022_GrYkE3mhHEiRA4fxgfABRg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20220930xex99d1.htm",
      "contextRef": "Duration_1_1_2022_To_9_30_2022_GrYkE3mhHEiRA4fxgfABRg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10501 - Disclosure - Share-based payments",
     "role": "http://www.curevac.com/role/DisclosureShareBasedPayments",
     "shortName": "Share-based payments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20220930xex99d1.htm",
      "contextRef": "Duration_1_1_2022_To_9_30_2022_GrYkE3mhHEiRA4fxgfABRg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20220930xex99d1.htm",
      "contextRef": "Duration_1_1_2022_To_9_30_2022_GrYkE3mhHEiRA4fxgfABRg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "cvac:DisclosureOfFixedAssetsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10601 - Disclosure - Fixed Assets",
     "role": "http://www.curevac.com/role/DisclosureFixedAssets",
     "shortName": "Fixed Assets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20220930xex99d1.htm",
      "contextRef": "Duration_1_1_2022_To_9_30_2022_GrYkE3mhHEiRA4fxgfABRg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "cvac:DisclosureOfFixedAssetsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20220930xex99d1.htm",
      "contextRef": "Duration_1_1_2022_To_9_30_2022_GrYkE3mhHEiRA4fxgfABRg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfNoncurrentAssetsHeldForSaleAndDiscontinuedOperationsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10701 - Disclosure - Assets held for sale",
     "role": "http://www.curevac.com/role/DisclosureAssetsHeldForSale",
     "shortName": "Assets held for sale",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20220930xex99d1.htm",
      "contextRef": "Duration_1_1_2022_To_9_30_2022_GrYkE3mhHEiRA4fxgfABRg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfNoncurrentAssetsHeldForSaleAndDiscontinuedOperationsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20220930xex99d1.htm",
      "contextRef": "Duration_1_1_2022_To_9_30_2022_GrYkE3mhHEiRA4fxgfABRg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfInventoriesExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10801 - Disclosure - Inventories",
     "role": "http://www.curevac.com/role/DisclosureInventories",
     "shortName": "Inventories",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20220930xex99d1.htm",
      "contextRef": "Duration_1_1_2022_To_9_30_2022_GrYkE3mhHEiRA4fxgfABRg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfInventoriesExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20220930xex99d1.htm",
      "contextRef": "Duration_1_1_2022_To_9_30_2022_GrYkE3mhHEiRA4fxgfABRg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "cvac:DisclosureOfPrepaidExpensesAndOtherCurrentAssetsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10901 - Disclosure - Prepaid expenses and other assets (current)",
     "role": "http://www.curevac.com/role/DisclosurePrepaidExpensesAndOtherAssetsCurrent",
     "shortName": "Prepaid expenses and other assets (current)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20220930xex99d1.htm",
      "contextRef": "Duration_1_1_2022_To_9_30_2022_GrYkE3mhHEiRA4fxgfABRg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "cvac:DisclosureOfPrepaidExpensesAndOtherCurrentAssetsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20220930xex99d1.htm",
      "contextRef": "Duration_1_1_2022_To_9_30_2022_GrYkE3mhHEiRA4fxgfABRg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "11001 - Disclosure - Financial assets and financial liabilities",
     "role": "http://www.curevac.com/role/DisclosureFinancialAssetsAndFinancialLiabilities",
     "shortName": "Financial assets and financial liabilities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20220930xex99d1.htm",
      "contextRef": "Duration_1_1_2022_To_9_30_2022_GrYkE3mhHEiRA4fxgfABRg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20220930xex99d1.htm",
      "contextRef": "Duration_1_1_2022_To_9_30_2022_GrYkE3mhHEiRA4fxgfABRg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "11101 - Disclosure - Trade and other payables",
     "role": "http://www.curevac.com/role/DisclosureTradeAndOtherPayables",
     "shortName": "Trade and other payables",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20220930xex99d1.htm",
      "contextRef": "Duration_1_1_2022_To_9_30_2022_GrYkE3mhHEiRA4fxgfABRg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20220930xex99d1.htm",
      "contextRef": "Duration_1_1_2022_To_9_30_2022_GrYkE3mhHEiRA4fxgfABRg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfOtherLiabilitiesExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "11201 - Disclosure - Other liabilities",
     "role": "http://www.curevac.com/role/DisclosureOtherLiabilities",
     "shortName": "Other liabilities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20220930xex99d1.htm",
      "contextRef": "Duration_1_1_2022_To_9_30_2022_GrYkE3mhHEiRA4fxgfABRg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfOtherLiabilitiesExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20220930xex99d1.htm",
      "contextRef": "Duration_1_1_2022_To_9_30_2022_GrYkE3mhHEiRA4fxgfABRg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfDetailedInformationAboutBorrowingsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "11301 - Disclosure - Loans",
     "role": "http://www.curevac.com/role/DisclosureLoans",
     "shortName": "Loans",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20220930xex99d1.htm",
      "contextRef": "Duration_1_1_2022_To_9_30_2022_GrYkE3mhHEiRA4fxgfABRg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfDetailedInformationAboutBorrowingsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20220930xex99d1.htm",
      "contextRef": "Duration_1_1_2022_To_9_30_2022_GrYkE3mhHEiRA4fxgfABRg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfIncomeTaxExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "11401 - Disclosure - Income tax",
     "role": "http://www.curevac.com/role/DisclosureIncomeTax",
     "shortName": "Income tax",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20220930xex99d1.htm",
      "contextRef": "Duration_1_1_2022_To_9_30_2022_GrYkE3mhHEiRA4fxgfABRg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfIncomeTaxExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20220930xex99d1.htm",
      "contextRef": "Duration_1_1_2022_To_9_30_2022_GrYkE3mhHEiRA4fxgfABRg",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "ifrs-full:RevenueFromContractsWithCustomers",
      "reportCount": 1,
      "unitRef": "Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00100 - Statement - Interim Condensed Consolidated Statements of Operations and Other Comprehensive Income (Loss)",
     "role": "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfOperationsAndOtherComprehensiveIncomeLoss",
     "shortName": "Interim Condensed Consolidated Statements of Operations and Other Comprehensive Income (Loss)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20220930xex99d1.htm",
      "contextRef": "Duration_1_1_2022_To_9_30_2022_GrYkE3mhHEiRA4fxgfABRg",
      "decimals": "-3",
      "lang": null,
      "name": "ifrs-full:CostOfSales",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20220930xex99d1.htm",
      "contextRef": "Duration_1_1_2022_To_9_30_2022_GrYkE3mhHEiRA4fxgfABRg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfFinancialRiskManagementExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "11501 - Disclosure - Disclosure of financial instruments and risk management",
     "role": "http://www.curevac.com/role/DisclosureDisclosureOfFinancialInstrumentsAndRiskManagement",
     "shortName": "Disclosure of financial instruments and risk management",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20220930xex99d1.htm",
      "contextRef": "Duration_1_1_2022_To_9_30_2022_GrYkE3mhHEiRA4fxgfABRg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfFinancialRiskManagementExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20220930xex99d1.htm",
      "contextRef": "Duration_1_1_2022_To_9_30_2022_GrYkE3mhHEiRA4fxgfABRg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:EarningsPerShareExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "11601 - Disclosure - Earnings per share",
     "role": "http://www.curevac.com/role/DisclosureEarningsPerShare",
     "shortName": "Earnings per share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20220930xex99d1.htm",
      "contextRef": "Duration_1_1_2022_To_9_30_2022_GrYkE3mhHEiRA4fxgfABRg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:EarningsPerShareExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20220930xex99d1.htm",
      "contextRef": "Duration_1_1_2022_To_9_30_2022_GrYkE3mhHEiRA4fxgfABRg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfRelatedPartyExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "11701 - Disclosure - Related party disclosures",
     "role": "http://www.curevac.com/role/DisclosureRelatedPartyDisclosures",
     "shortName": "Related party disclosures",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20220930xex99d1.htm",
      "contextRef": "Duration_1_1_2022_To_9_30_2022_GrYkE3mhHEiRA4fxgfABRg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfRelatedPartyExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20220930xex99d1.htm",
      "contextRef": "Duration_1_1_2022_To_9_30_2022_GrYkE3mhHEiRA4fxgfABRg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfBusinessCombinationsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "11801 - Disclosure - Significant transactions and events",
     "role": "http://www.curevac.com/role/DisclosureSignificantTransactionsAndEvents",
     "shortName": "Significant transactions and events",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20220930xex99d1.htm",
      "contextRef": "Duration_1_1_2022_To_9_30_2022_GrYkE3mhHEiRA4fxgfABRg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfBusinessCombinationsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "cvac:DisclosureOfBasisOfPreparationExplanatoryTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20220930xex99d1.htm",
      "contextRef": "Duration_1_1_2022_To_9_30_2022_GrYkE3mhHEiRA4fxgfABRg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "20202 - Disclosure - Basis of preparation (Policies)",
     "role": "http://www.curevac.com/role/DisclosureBasisOfPreparationPolicies",
     "shortName": "Basis of preparation (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "cvac:DisclosureOfBasisOfPreparationExplanatoryTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20220930xex99d1.htm",
      "contextRef": "Duration_1_1_2022_To_9_30_2022_GrYkE3mhHEiRA4fxgfABRg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "ifrs-full:DisclosureOfNotesAndOtherExplanatoryInformationExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20220930xex99d1.htm",
      "contextRef": "Duration_1_1_2022_To_9_30_2022_GrYkE3mhHEiRA4fxgfABRg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30303 - Disclosure - Notes to the consolidated financial statements (Tables)",
     "role": "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsTables",
     "shortName": "Notes to the consolidated financial statements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ifrs-full:DisclosureOfNotesAndOtherExplanatoryInformationExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20220930xex99d1.htm",
      "contextRef": "Duration_1_1_2022_To_9_30_2022_GrYkE3mhHEiRA4fxgfABRg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20220930xex99d1.htm",
      "contextRef": "Duration_1_1_2022_To_9_30_2022_GrYkE3mhHEiRA4fxgfABRg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30403 - Disclosure - Issued Capital and Reserves (Tables)",
     "role": "http://www.curevac.com/role/DisclosureIssuedCapitalAndReservesTables",
     "shortName": "Issued Capital and Reserves (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20220930xex99d1.htm",
      "contextRef": "Duration_1_1_2022_To_9_30_2022_GrYkE3mhHEiRA4fxgfABRg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20220930xex99d1.htm",
      "contextRef": "Duration_1_1_2022_To_9_30_2022_GrYkE3mhHEiRA4fxgfABRg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "cvac:DisclosureOfExpenseRecognizedForEmployeeServicesExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30503 - Disclosure - Share-based payments (Tables)",
     "role": "http://www.curevac.com/role/DisclosureShareBasedPaymentsTables",
     "shortName": "Share-based payments (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20220930xex99d1.htm",
      "contextRef": "Duration_1_1_2022_To_9_30_2022_GrYkE3mhHEiRA4fxgfABRg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "cvac:DisclosureOfExpenseRecognizedForEmployeeServicesExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20220930xex99d1.htm",
      "contextRef": "Duration_1_1_2022_To_9_30_2022_GrYkE3mhHEiRA4fxgfABRg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfDetailedInformationAboutBusinessCombinationsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "31803 - Disclosure - Significant transactions and events (Tables)",
     "role": "http://www.curevac.com/role/DisclosureSignificantTransactionsAndEventsTables",
     "shortName": "Significant transactions and events (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20220930xex99d1.htm",
      "contextRef": "Duration_1_1_2022_To_9_30_2022_GrYkE3mhHEiRA4fxgfABRg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfDetailedInformationAboutBusinessCombinationsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20220930xex99d1.htm",
      "contextRef": "Duration_1_1_2022_To_9_30_2022_GrYkE3mhHEiRA4fxgfABRg",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "ifrs-full:RevenueFromContractsWithCustomers",
      "reportCount": 1,
      "unitRef": "Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40301 - Disclosure - Notes to the consolidated financial statements - Revenue from contract with customers (Details)",
     "role": "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsRevenueFromContractWithCustomersDetails",
     "shortName": "Notes to the consolidated financial statements - Revenue from contract with customers (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ifrs-full:DisclosureOfNotesAndOtherExplanatoryInformationExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20220930xex99d1.htm",
      "contextRef": "Duration_1_1_2022_To_9_30_2022_ifrs-full_ProductsAndServicesAxis_cvac_ResearchServicesCombinedWithIpLicenseMember_JmxbMa7EOkGM2UmzZvcaYA",
      "decimals": "-3",
      "lang": null,
      "name": "ifrs-full:RevenueFromContractsWithCustomers",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20220930xex99d1.htm",
      "contextRef": "As_Of_9_30_2022_zuGVrjesE0WhwXSGmTqsgA",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "ifrs-full:IntangibleAssetsAndGoodwill",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00200 - Statement - Interim Condensed Consolidated Statements of Financial Position",
     "role": "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition",
     "shortName": "Interim Condensed Consolidated Statements of Financial Position",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20220930xex99d1.htm",
      "contextRef": "As_Of_9_30_2022_zuGVrjesE0WhwXSGmTqsgA",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "ifrs-full:IntangibleAssetsAndGoodwill",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "b",
       "p",
       "td",
       "tr",
       "table",
       "cvac:DisclosureOfUpfrontPaymentsAndRelatedRevenuesRecognizedExplanatory",
       "ifrs-full:DisclosureOfNotesAndOtherExplanatoryInformationExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20220930xex99d1.htm",
      "contextRef": "As_Of_9_30_2022_ifrs-full_ProductsAndServicesAxis_cvac_ResearchServicesCombinedWithIpLicenseMember_LDTxHzpQykydqGAuWhIjZQ",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "cvac:UpfrontPaymentsIncludedInContractLiabilities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40302 - Disclosure - Notes to the consolidated financial statements - Summary of upfront payments and related revenues recognized (Details)",
     "role": "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsSummaryOfUpfrontPaymentsAndRelatedRevenuesRecognizedDetails",
     "shortName": "Notes to the consolidated financial statements - Summary of upfront payments and related revenues recognized (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "b",
       "p",
       "td",
       "tr",
       "table",
       "cvac:DisclosureOfUpfrontPaymentsAndRelatedRevenuesRecognizedExplanatory",
       "ifrs-full:DisclosureOfNotesAndOtherExplanatoryInformationExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20220930xex99d1.htm",
      "contextRef": "As_Of_9_30_2022_ifrs-full_ProductsAndServicesAxis_cvac_ResearchServicesCombinedWithIpLicenseMember_LDTxHzpQykydqGAuWhIjZQ",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "cvac:UpfrontPaymentsIncludedInContractLiabilities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20220930xex99d1.htm",
      "contextRef": "As_Of_9_30_2022_zuGVrjesE0WhwXSGmTqsgA",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "ifrs-full:CurrentTradeReceivables",
      "reportCount": 1,
      "unitRef": "Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40303 - Disclosure - Notes to the consolidated financial statements - Contract liabilities allocated to the remaining performance obligations (Details)",
     "role": "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsContractLiabilitiesAllocatedToRemainingPerformanceObligationsDetails",
     "shortName": "Notes to the consolidated financial statements - Contract liabilities allocated to the remaining performance obligations (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ifrs-full:ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20220930xex99d1.htm",
      "contextRef": "As_Of_9_30_2022_zuGVrjesE0WhwXSGmTqsgA",
      "decimals": "-3",
      "lang": null,
      "name": "ifrs-full:ContractLiabilities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfExpensesByNatureExplanatory",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20220930xex99d1.htm",
      "contextRef": "Duration_1_1_2022_To_9_30_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsCostOfSalesMember_em7QzpMx20e5-T4Zm2ygyA",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "cvac:PersonnelExpenses",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40304 - Disclosure - Notes to the consolidated financial statements - Cost of sales (Details)",
     "role": "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsCostOfSalesDetails",
     "shortName": "Notes to the consolidated financial statements - Cost of sales (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfExpensesByNatureExplanatory",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20220930xex99d1.htm",
      "contextRef": "Duration_1_1_2022_To_9_30_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsCostOfSalesMember_em7QzpMx20e5-T4Zm2ygyA",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "cvac:PersonnelExpenses",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20220930xex99d1.htm",
      "contextRef": "Duration_1_1_2022_To_9_30_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_SellingAndDistributionExpensesMember_nx7DDIuvEEyD8XuyuNsS6Q",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "cvac:PersonnelExpenses",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40305 - Disclosure - Notes to the consolidated financial statements - Selling and distribution expenses (Details)",
     "role": "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsSellingAndDistributionExpensesDetails",
     "shortName": "Notes to the consolidated financial statements - Selling and distribution expenses (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20220930xex99d1.htm",
      "contextRef": "Duration_1_1_2022_To_9_30_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_SellingAndDistributionExpensesMember_nx7DDIuvEEyD8XuyuNsS6Q",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "cvac:PersonnelExpenses",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20220930xex99d1.htm",
      "contextRef": "Duration_1_1_2022_To_9_30_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsResearchAndDevelopmentExpenseMember_u-Q9gJOBkUqQxOVDUX24Hw",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "ifrs-full:RawMaterialsAndConsumablesUsed",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40306 - Disclosure - Notes to the consolidated financial statements - Research and development expenses (Details)",
     "role": "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsResearchAndDevelopmentExpensesDetails",
     "shortName": "Notes to the consolidated financial statements - Research and development expenses (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20220930xex99d1.htm",
      "contextRef": "Duration_1_1_2022_To_9_30_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsResearchAndDevelopmentExpenseMember_u-Q9gJOBkUqQxOVDUX24Hw",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "ifrs-full:RawMaterialsAndConsumablesUsed",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20220930xex99d1.htm",
      "contextRef": "Duration_1_1_2022_To_9_30_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsGeneralAndAdministrativeExpenseMember_KMYenp1F1EOV1PWLAQFrFw",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "cvac:PersonnelExpenses",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40307 - Disclosure - Notes to the consolidated financial statements - General and administrative expenses (Details)",
     "role": "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsGeneralAndAdministrativeExpensesDetails",
     "shortName": "Notes to the consolidated financial statements - General and administrative expenses (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20220930xex99d1.htm",
      "contextRef": "Duration_1_1_2022_To_9_30_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsGeneralAndAdministrativeExpenseMember_KMYenp1F1EOV1PWLAQFrFw",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "cvac:PersonnelExpenses",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfOtherOperatingIncomeExplanatory",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20220930xex99d1.htm",
      "contextRef": "Duration_1_1_2022_To_9_30_2022_GrYkE3mhHEiRA4fxgfABRg",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "cvac:CompensationForContractManufacturingOrganizationsTransfer",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40308 - Disclosure - Notes to the consolidated financial statements - Other operating income (Details)",
     "role": "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsOtherOperatingIncomeDetails",
     "shortName": "Notes to the consolidated financial statements - Other operating income (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfOtherOperatingIncomeExplanatory",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20220930xex99d1.htm",
      "contextRef": "Duration_1_1_2022_To_9_30_2022_GrYkE3mhHEiRA4fxgfABRg",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "cvac:CompensationForContractManufacturingOrganizationsTransfer",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20220930xex99d1.htm",
      "contextRef": "Duration_1_1_2021_To_9_30_2021_5RS16WkLc0uS2ug_bqUm-g",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "cvac:ReceiptsFromGovernmentGrantsClassifiedAsOperatingActivities",
      "reportCount": 1,
      "unitRef": "Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40309 - Disclosure - Notes to the consolidated financial statements - Grants with government agencies and similar bodies (Details)",
     "role": "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsGrantsWithGovernmentAgenciesAndSimilarBodiesDetails",
     "shortName": "Notes to the consolidated financial statements - Grants with government agencies and similar bodies (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20220930xex99d1.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_jm3ww8f3H0egT8wSnNVZZw",
      "decimals": "-3",
      "lang": null,
      "name": "cvac:ReversalOfProvisionRecognizedDueToCertainReservedCapacityTakenOver",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20220930xex99d1.htm",
      "contextRef": "Duration_1_1_2022_To_9_30_2022_GrYkE3mhHEiRA4fxgfABRg",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "ifrs-full:ShareIssueRelatedCost",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_q8NNp4TBfUC9XydcVDSrpA",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40401 - Disclosure - Issued Capital and Reserves - Overview and General Remarks (Details)",
     "role": "http://www.curevac.com/role/DisclosureIssuedCapitalAndReservesOverviewAndGeneralRemarksDetails",
     "shortName": "Issued Capital and Reserves - Overview and General Remarks (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20220930xex99d1.htm",
      "contextRef": "As_Of_9_30_2022_zuGVrjesE0WhwXSGmTqsgA",
      "decimals": "-5",
      "lang": null,
      "name": "cvac:RemainingAuthorizedForSaleValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_q8NNp4TBfUC9XydcVDSrpA",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "b",
       "p",
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20220930xex99d1.htm",
      "contextRef": "As_Of_6_30_2022_kOEc9a1C10m7Rg-HheHYxg",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "cvac:CommonSharesIssuedAndOutstanding",
      "reportCount": 1,
      "unitRef": "Unit_Standard_shares_FapG5E6UqkK42IfNNOS6tA",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40402 - Disclosure - Issued Capital and Reserves - Impact of share split (Details)",
     "role": "http://www.curevac.com/role/DisclosureIssuedCapitalAndReservesImpactOfShareSplitDetails",
     "shortName": "Issued Capital and Reserves - Impact of share split (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20220930xex99d1.htm",
      "contextRef": "Duration_4_1_2022_To_6_30_2022_-gYjaV8XPUKBPSbaN9Qziw",
      "decimals": "INF",
      "lang": null,
      "name": "cvac:ShareOptionExercises",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_FapG5E6UqkK42IfNNOS6tA",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "b",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20220930xex99d1.htm",
      "contextRef": "As_Of_12_31_2020_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_ZWlHBf5sd0u18E_i-Im1zQ",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "ifrs-full:Equity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00300 - Statement - Interim Condensed Consolidated Statements of Changes in Shareholders' Equity",
     "role": "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfChangesInShareholdersEquity",
     "shortName": "Interim Condensed Consolidated Statements of Changes in Shareholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "b",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20220930xex99d1.htm",
      "contextRef": "As_Of_12_31_2020_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_ZWlHBf5sd0u18E_i-Im1zQ",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "ifrs-full:Equity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "cvac:DisclosureOfExpenseRecognizedForEmployeeServicesExplanatory",
       "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20220930xex99d1.htm",
      "contextRef": "Duration_1_1_2022_To_9_30_2022_GrYkE3mhHEiRA4fxgfABRg",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "cvac:ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInResearchAndDevelopmentExpenses",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40501 - Disclosure - Share-based payments - Expenses (Details)",
     "role": "http://www.curevac.com/role/DisclosureShareBasedPaymentsExpensesDetails",
     "shortName": "Share-based payments - Expenses (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "cvac:DisclosureOfExpenseRecognizedForEmployeeServicesExplanatory",
       "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20220930xex99d1.htm",
      "contextRef": "Duration_1_1_2022_To_9_30_2022_GrYkE3mhHEiRA4fxgfABRg",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "cvac:ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInResearchAndDevelopmentExpenses",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "b",
       "p",
       "td",
       "tr",
       "table",
       "cvac:ScheduleOfExpenseRecognizedForProgramsTableTextBlock",
       "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20220930xex99d1.htm",
      "contextRef": "Duration_1_1_2022_To_9_30_2022_GrYkE3mhHEiRA4fxgfABRg",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "cvac:ExpenseRecognizedForEmployeeServices",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40502 - Disclosure - Share-based payments - Expense recognized for the program (Details)",
     "role": "http://www.curevac.com/role/DisclosureShareBasedPaymentsExpenseRecognizedForProgramDetails",
     "shortName": "Share-based payments - Expense recognized for the program (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "b",
       "p",
       "td",
       "tr",
       "table",
       "cvac:ScheduleOfExpenseRecognizedForProgramsTableTextBlock",
       "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20220930xex99d1.htm",
      "contextRef": "Duration_1_1_2022_To_9_30_2022_GrYkE3mhHEiRA4fxgfABRg",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "cvac:ExpenseRecognizedForEmployeeServices",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20220930xex99d1.htm",
      "contextRef": "Duration_1_1_2022_To_9_30_2022_GrYkE3mhHEiRA4fxgfABRg",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40503 - Disclosure - Share-based payments (Details)",
     "role": "http://www.curevac.com/role/DisclosureShareBasedPaymentsDetails",
     "shortName": "Share-based payments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20220930xex99d1.htm",
      "contextRef": "Duration_1_1_2022_To_9_30_2022_GrYkE3mhHEiRA4fxgfABRg",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "cvac:DisclosureOfFixedAssetsExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20220930xex99d1.htm",
      "contextRef": "Duration_1_1_2022_To_9_30_2022_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_ifrs-full_GrossCarryingAmountMember_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_cvac_LicensesSoftwareAndPrepaymentsMember_zeXSak6OQ0iEmjYXe9qo9w",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40601 - Disclosure - Fixed Assets - Intangible assets (Details)",
     "role": "http://www.curevac.com/role/DisclosureFixedAssetsIntangibleAssetsDetails",
     "shortName": "Fixed Assets - Intangible assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "cvac:DisclosureOfFixedAssetsExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20220930xex99d1.htm",
      "contextRef": "Duration_1_1_2022_To_9_30_2022_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_ifrs-full_GrossCarryingAmountMember_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_cvac_LicensesSoftwareAndPrepaymentsMember_zeXSak6OQ0iEmjYXe9qo9w",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20220930xex99d1.htm",
      "contextRef": "Duration_1_1_2022_To_9_30_2022_GrYkE3mhHEiRA4fxgfABRg",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "cvac:IncreaseInPropertyAndEquipmentOffSetByImpairmentOfEquipment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40602 - Disclosure - Fixed Assets - Property, plant and equipment (Details)",
     "role": "http://www.curevac.com/role/DisclosureFixedAssetsPropertyPlantAndEquipmentDetails",
     "shortName": "Fixed Assets - Property, plant and equipment (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20220930xex99d1.htm",
      "contextRef": "Duration_1_1_2022_To_9_30_2022_GrYkE3mhHEiRA4fxgfABRg",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "cvac:IncreaseInPropertyAndEquipmentOffSetByImpairmentOfEquipment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ifrs-full:DisclosureOfNoncurrentAssetsHeldForSaleAndDiscontinuedOperationsExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20220930xex99d1.htm",
      "contextRef": "As_Of_6_30_2022_kOEc9a1C10m7Rg-HheHYxg",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "cvac:IfrsDisposalGroupIncludingDiscontinuedOperationConsideration",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40701 - Disclosure - Assets held for sale (Details)",
     "role": "http://www.curevac.com/role/DisclosureAssetsHeldForSaleDetails",
     "shortName": "Assets held for sale (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ifrs-full:DisclosureOfNoncurrentAssetsHeldForSaleAndDiscontinuedOperationsExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20220930xex99d1.htm",
      "contextRef": "As_Of_6_30_2022_kOEc9a1C10m7Rg-HheHYxg",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "cvac:IfrsDisposalGroupIncludingDiscontinuedOperationConsideration",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ifrs-full:DisclosureOfInventoriesExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20220930xex99d1.htm",
      "contextRef": "Duration_1_1_2022_To_9_30_2022_srt_CounterpartyNameAxis_cvac_GlaxosmithklineMember_3G2M3SARj0GkTuTa4M37uw",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "cvac:IncreaseDecreaseInInventory",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40801 - Disclosure - Inventories (Details)",
     "role": "http://www.curevac.com/role/DisclosureInventoriesDetails",
     "shortName": "Inventories (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ifrs-full:DisclosureOfInventoriesExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20220930xex99d1.htm",
      "contextRef": "Duration_1_1_2022_To_9_30_2022_srt_CounterpartyNameAxis_cvac_GlaxosmithklineMember_3G2M3SARj0GkTuTa4M37uw",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "cvac:IncreaseDecreaseInInventory",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20220930xex99d1.htm",
      "contextRef": "As_Of_9_30_2022_zuGVrjesE0WhwXSGmTqsgA",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "ifrs-full:CurrentPrepaymentsAndOtherCurrentAssets",
      "reportCount": 1,
      "unitRef": "Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40901 - Disclosure - Prepaid expenses and other assets (current) (Details)",
     "role": "http://www.curevac.com/role/DisclosurePrepaidExpensesAndOtherAssetsCurrentDetails",
     "shortName": "Prepaid expenses and other assets (current) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "cvac:DisclosureOfPrepaidExpensesAndOtherCurrentAssetsExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20220930xex99d1.htm",
      "contextRef": "As_Of_9_30_2022_zuGVrjesE0WhwXSGmTqsgA",
      "decimals": "-3",
      "lang": null,
      "name": "cvac:PrepaidCompensationForContractManufacturingOrganizationsTransfer",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "ifrs-full:TransfersOutOfLevel1IntoLevel2OfFairValueHierarchyAssets",
       "p",
       "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20220930xex99d1.htm",
      "contextRef": "Duration_1_1_2022_To_9_30_2022_GrYkE3mhHEiRA4fxgfABRg",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "ifrs-full:TransfersOutOfLevel1IntoLevel2OfFairValueHierarchyAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41001 - Disclosure - Financial assets and financial liabilities (Details)",
     "role": "http://www.curevac.com/role/DisclosureFinancialAssetsAndFinancialLiabilitiesDetails",
     "shortName": "Financial assets and financial liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ifrs-full:TransfersOutOfLevel1IntoLevel2OfFairValueHierarchyAssets",
       "p",
       "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20220930xex99d1.htm",
      "contextRef": "Duration_1_1_2022_To_9_30_2022_GrYkE3mhHEiRA4fxgfABRg",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "ifrs-full:TransfersOutOfLevel1IntoLevel2OfFairValueHierarchyAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20220930xex99d1.htm",
      "contextRef": "Duration_1_1_2022_To_9_30_2022_GrYkE3mhHEiRA4fxgfABRg",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "cvac:ChangeInTradeAndOtherPayables",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41101 - Disclosure - Trade and other payables (Details)",
     "role": "http://www.curevac.com/role/DisclosureTradeAndOtherPayablesDetails",
     "shortName": "Trade and other payables (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20220930xex99d1.htm",
      "contextRef": "Duration_1_1_2022_To_9_30_2022_GrYkE3mhHEiRA4fxgfABRg",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "cvac:ChangeInTradeAndOtherPayables",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "b",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20220930xex99d1.htm",
      "contextRef": "Duration_1_1_2022_To_9_30_2022_GrYkE3mhHEiRA4fxgfABRg",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "ifrs-full:ProfitLossBeforeTax",
      "reportCount": 1,
      "unitRef": "Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00400 - Statement - Interim Condensed Consolidated Statements of Cash Flows",
     "role": "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows",
     "shortName": "Interim Condensed Consolidated Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20220930xex99d1.htm",
      "contextRef": "Duration_1_1_2022_To_9_30_2022_GrYkE3mhHEiRA4fxgfABRg",
      "decimals": "-3",
      "lang": null,
      "name": "ifrs-full:AdjustmentsForFinanceIncome",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ifrs-full:DisclosureOfOtherLiabilitiesExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20220930xex99d1.htm",
      "contextRef": "Duration_1_1_2022_To_9_30_2022_GrYkE3mhHEiRA4fxgfABRg",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "cvac:ChangeInOtherLiabilities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41201 - Disclosure - Other liabilities (Details)",
     "role": "http://www.curevac.com/role/DisclosureOtherLiabilitiesDetails",
     "shortName": "Other liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ifrs-full:DisclosureOfOtherLiabilitiesExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20220930xex99d1.htm",
      "contextRef": "Duration_1_1_2022_To_9_30_2022_GrYkE3mhHEiRA4fxgfABRg",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "cvac:ChangeInOtherLiabilities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ifrs-full:DisclosureOfDetailedInformationAboutBorrowingsExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20220930xex99d1.htm",
      "contextRef": "Duration_1_1_2021_To_9_30_2021_ifrs-full_BorrowingsByNameAxis_cvac_IfrsLineOfCreditMember_w0otbseHCk-9ZLH1m6FDbA",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41301 - Disclosure - Loans (Details)",
     "role": "http://www.curevac.com/role/DisclosureLoansDetails",
     "shortName": "Loans (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ifrs-full:DisclosureOfDetailedInformationAboutBorrowingsExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20220930xex99d1.htm",
      "contextRef": "Duration_1_1_2021_To_9_30_2021_ifrs-full_BorrowingsByNameAxis_cvac_IfrsLineOfCreditMember_w0otbseHCk-9ZLH1m6FDbA",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20220930xex99d1.htm",
      "contextRef": "Duration_1_1_2022_To_9_30_2022_GrYkE3mhHEiRA4fxgfABRg",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "ifrs-full:IncomeTaxExpenseContinuingOperations",
      "reportCount": 1,
      "unitRef": "Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41401 - Disclosure - Income tax (Details)",
     "role": "http://www.curevac.com/role/DisclosureIncomeTaxDetails",
     "shortName": "Income tax (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ifrs-full:DisclosureOfIncomeTaxExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20220930xex99d1.htm",
      "contextRef": "Duration_1_1_2022_To_9_30_2022_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_cvac_CurevacCorporateServiceGmbhMember_w8u7qadVykiL43suHZX4cQ",
      "decimals": "-3",
      "lang": null,
      "name": "ifrs-full:CurrentTaxExpenseIncome",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ifrs-full:DisclosureOfFinancialRiskManagementExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20220930xex99d1.htm",
      "contextRef": "As_Of_9_30_2022_ifrs-full_ClassesOfFinancialInstrumentsAxis_cvac_IfrsCashAndCashEquivalentsMember_ifrs-full_TypesOfRisksAxis_ifrs-full_CurrencyRiskMember_srt_CurrencyAxis_currency_USD_GbIyOSI9fU6k0lhzbRaN6Q",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "ifrs-full:RiskExposureAssociatedWithInstrumentsSharingCharacteristic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_q8NNp4TBfUC9XydcVDSrpA",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41501 - Disclosure - Disclosure of financial instruments and risk management (Details)",
     "role": "http://www.curevac.com/role/DisclosureDisclosureOfFinancialInstrumentsAndRiskManagementDetails",
     "shortName": "Disclosure of financial instruments and risk management (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ifrs-full:DisclosureOfFinancialRiskManagementExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20220930xex99d1.htm",
      "contextRef": "As_Of_9_30_2022_ifrs-full_ClassesOfFinancialInstrumentsAxis_cvac_IfrsCashAndCashEquivalentsMember_ifrs-full_TypesOfRisksAxis_ifrs-full_CurrencyRiskMember_srt_CurrencyAxis_currency_USD_GbIyOSI9fU6k0lhzbRaN6Q",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "ifrs-full:RiskExposureAssociatedWithInstrumentsSharingCharacteristic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_q8NNp4TBfUC9XydcVDSrpA",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ifrs-full:EarningsPerShareExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20220930xex99d1.htm",
      "contextRef": "Duration_1_1_2022_To_9_30_2022_GrYkE3mhHEiRA4fxgfABRg",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "ifrs-full:WeightedAverageShares",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_FapG5E6UqkK42IfNNOS6tA",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41601 - Disclosure - Earnings per share (Details)",
     "role": "http://www.curevac.com/role/DisclosureEarningsPerShareDetails",
     "shortName": "Earnings per share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ifrs-full:EarningsPerShareExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20220930xex99d1.htm",
      "contextRef": "Duration_1_1_2022_To_9_30_2022_GrYkE3mhHEiRA4fxgfABRg",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "ifrs-full:WeightedAverageShares",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_FapG5E6UqkK42IfNNOS6tA",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ifrs-full:DisclosureOfRelatedPartyExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20220930xex99d1.htm",
      "contextRef": "Duration_1_1_2019_To_12_31_2019_ifrs-full_CategoriesOfRelatedPartiesAxis_cvac_DietmarHoppMember_vhtIRbibYkK_L7RHLy0f_A",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "cvac:RelatedPartyTransactionNumberOfLoansReceived",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_loan_2Ze7UTdQEkiZKAdZ7o4zlw",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41701 - Disclosure - Related party disclosures (Details)",
     "role": "http://www.curevac.com/role/DisclosureRelatedPartyDisclosuresDetails",
     "shortName": "Related party disclosures (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ifrs-full:DisclosureOfRelatedPartyExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20220930xex99d1.htm",
      "contextRef": "Duration_1_1_2019_To_12_31_2019_ifrs-full_CategoriesOfRelatedPartiesAxis_cvac_DietmarHoppMember_vhtIRbibYkK_L7RHLy0f_A",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "cvac:RelatedPartyTransactionNumberOfLoansReceived",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_loan_2Ze7UTdQEkiZKAdZ7o4zlw",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ifrs-full:DisclosureOfBusinessCombinationsExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20220930xex99d1.htm",
      "contextRef": "As_Of_9_30_2022_zuGVrjesE0WhwXSGmTqsgA",
      "decimals": "-4",
      "first": true,
      "lang": null,
      "name": "cvac:FirstPortionOfTotalConsiderationTransferredAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41801 - Disclosure - Significant transactions and events (Details)",
     "role": "http://www.curevac.com/role/DisclosureSignificantTransactionsAndEventsDetails",
     "shortName": "Significant transactions and events (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ifrs-full:DisclosureOfBusinessCombinationsExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20220930xex99d1.htm",
      "contextRef": "As_Of_9_30_2022_zuGVrjesE0WhwXSGmTqsgA",
      "decimals": "-4",
      "first": true,
      "lang": null,
      "name": "cvac:FirstPortionOfTotalConsiderationTransferredAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20220930xex99d1.htm",
      "contextRef": "As_Of_9_30_2022_zuGVrjesE0WhwXSGmTqsgA",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "ifrs-full:DeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41802 - Disclosure - Significant transactions and events - Frame Acquisition - Purchase Price Allocation (Details)",
     "role": "http://www.curevac.com/role/DisclosureSignificantTransactionsAndEventsFrameAcquisitionPurchasePriceAllocationDetails",
     "shortName": "Significant transactions and events - Frame Acquisition - Purchase Price Allocation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20220930xex99d1.htm",
      "contextRef": "As_Of_9_30_2022_zuGVrjesE0WhwXSGmTqsgA",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "ifrs-full:DeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "cvac:DisclosureOfGoodwillRecognizedAsResultOfAcquisitionExplanatoryTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20220930xex99d1.htm",
      "contextRef": "As_Of_9_30_2022_ifrs-full_BusinessCombinationsAxis_cvac_FramePharmaceuticalsB.v.AmsterdamNetherlandsMember_vR0Bi5R7KE6kPw8J5q5NTA",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "ifrs-full:AcquisitiondateFairValueOfTotalConsiderationTransferred",
      "reportCount": 1,
      "unitRef": "Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41803 - Disclosure - Significant transactions and events - Goodwill Recognized On Frame Acquisition (Details)",
     "role": "http://www.curevac.com/role/DisclosureSignificantTransactionsAndEventsGoodwillRecognizedOnFrameAcquisitionDetails",
     "shortName": "Significant transactions and events - Goodwill Recognized On Frame Acquisition (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "b",
       "p",
       "td",
       "tr",
       "table",
       "cvac:DisclosureOfGoodwillRecognizedAsResultOfAcquisitionExplanatoryTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20220930xex99d1.htm",
      "contextRef": "As_Of_9_30_2022_ifrs-full_BusinessCombinationsAxis_cvac_FramePharmaceuticalsB.v.AmsterdamNetherlandsMember_vR0Bi5R7KE6kPw8J5q5NTA",
      "decimals": "-3",
      "lang": null,
      "name": "ifrs-full:GoodwillRecognisedAsOfAcquisitionDate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfBusinessCombinationsExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20220930xex99d1.htm",
      "contextRef": "As_Of_9_30_2022_zuGVrjesE0WhwXSGmTqsgA",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "ifrs-full:CashTransferred",
      "reportCount": 1,
      "unitRef": "Unit_Standard_EUR_ApaSWBfrtUq3s1lb_jhxTg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41804 - Disclosure - Significant transactions and events - Analyses of cash flows on Frame Acquisition (Details)",
     "role": "http://www.curevac.com/role/DisclosureSignificantTransactionsAndEventsAnalysesOfCashFlowsOnFrameAcquisitionDetails",
     "shortName": "Significant transactions and events - Analyses of cash flows on Frame Acquisition (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20220930xex99d1.htm",
      "contextRef": "Duration_1_1_2022_To_9_30_2022_GrYkE3mhHEiRA4fxgfABRg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "cvac:CorporateInformationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10101 - Disclosure - Corporate Information",
     "role": "http://www.curevac.com/role/DisclosureCorporateInformation",
     "shortName": "Corporate Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20220930xex99d1.htm",
      "contextRef": "Duration_1_1_2022_To_9_30_2022_GrYkE3mhHEiRA4fxgfABRg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "cvac:CorporateInformationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20220930xex99d1.htm",
      "contextRef": "Duration_1_1_2022_To_9_30_2022_GrYkE3mhHEiRA4fxgfABRg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "cvac:DisclosureOfBasisOfPreparationExplanatoryTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10201 - Disclosure - Basis of preparation",
     "role": "http://www.curevac.com/role/DisclosureBasisOfPreparation",
     "shortName": "Basis of preparation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20220930xex99d1.htm",
      "contextRef": "Duration_1_1_2022_To_9_30_2022_GrYkE3mhHEiRA4fxgfABRg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "cvac:DisclosureOfBasisOfPreparationExplanatoryTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20220930xex99d1.htm",
      "contextRef": "Duration_1_1_2022_To_9_30_2022_GrYkE3mhHEiRA4fxgfABRg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfNotesAndOtherExplanatoryInformationExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10301 - Disclosure - Notes to the consolidated financial statements",
     "role": "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatements",
     "shortName": "Notes to the consolidated financial statements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20220930xex99d1.htm",
      "contextRef": "Duration_1_1_2022_To_9_30_2022_GrYkE3mhHEiRA4fxgfABRg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfNotesAndOtherExplanatoryInformationExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20220930xex99d1.htm",
      "contextRef": "Duration_1_1_2022_To_9_30_2022_GrYkE3mhHEiRA4fxgfABRg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10401 - Disclosure - Issued Capital and Reserves",
     "role": "http://www.curevac.com/role/DisclosureIssuedCapitalAndReserves",
     "shortName": "Issued Capital and Reserves",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20220930xex99d1.htm",
      "contextRef": "Duration_1_1_2022_To_9_30_2022_GrYkE3mhHEiRA4fxgfABRg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 65,
   "tag": {
    "country_BE": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Belgium"
       }
      }
     },
     "localname": "BE",
     "nsuri": "http://xbrl.sec.gov/country/2021",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsRevenueFromContractWithCustomersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_CH": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Switzerland"
       }
      }
     },
     "localname": "CH",
     "nsuri": "http://xbrl.sec.gov/country/2021",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsRevenueFromContractWithCustomersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_DE": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Germany"
       }
      }
     },
     "localname": "DE",
     "nsuri": "http://xbrl.sec.gov/country/2021",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsRevenueFromContractWithCustomersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_NL": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Netherlands"
       }
      }
     },
     "localname": "NL",
     "nsuri": "http://xbrl.sec.gov/country/2021",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsRevenueFromContractWithCustomersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_US": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "United States"
       }
      }
     },
     "localname": "US",
     "nsuri": "http://xbrl.sec.gov/country/2021",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsRevenueFromContractWithCustomersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "currency_AllCurrenciesDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Currencies [Domain]"
       }
      }
     },
     "localname": "AllCurrenciesDomain",
     "nsuri": "http://xbrl.sec.gov/currency/2021",
     "presentation": [
      "http://www.curevac.com/role/DisclosureDisclosureOfFinancialInstrumentsAndRiskManagementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "currency_CHF": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CHF"
       }
      }
     },
     "localname": "CHF",
     "nsuri": "http://xbrl.sec.gov/currency/2021",
     "presentation": [
      "http://www.curevac.com/role/DisclosureDisclosureOfFinancialInstrumentsAndRiskManagementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "currency_USD": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "USD"
       }
      }
     },
     "localname": "USD",
     "nsuri": "http://xbrl.sec.gov/currency/2021",
     "presentation": [
      "http://www.curevac.com/role/DisclosureDisclosureOfFinancialInstrumentsAndRiskManagementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvac_AdditionalCashTransferred": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The fair value, at acquisition date, of additional cash transferred as consideration in a business combination.",
        "label": "Additional Cash Transferred",
        "terseLabel": "Additional cash consideration"
       }
      }
     },
     "localname": "AdditionalCashTransferred",
     "nsuri": "http://www.curevac.com/20220930",
     "presentation": [
      "http://www.curevac.com/role/DisclosureSignificantTransactionsAndEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvac_AdditionalDevelopmentMilestonePaymentsReceived": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of additional development milestone payment received.",
        "label": "Additional Development Milestone Payments Received",
        "terseLabel": "Additional development milestone payments"
       }
      }
     },
     "localname": "AdditionalDevelopmentMilestonePaymentsReceived",
     "nsuri": "http://www.curevac.com/20220930",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsRevenueFromContractWithCustomersDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvac_AdjustmentsForIncreaseDecreaseInOtherCurrentFinancialAndOtherLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows": {
       "order": 14.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Adjustments for increase (decrease) in other current financial and other liabilities to reconcile profit(loss) to net cashflow (used in) operating activities.",
        "label": "Adjustments For Increase Decrease In Other Current Financial And Other Liabilities",
        "terseLabel": "(Decrease) / increase in other current financial liabilities"
       }
      }
     },
     "localname": "AdjustmentsForIncreaseDecreaseInOtherCurrentFinancialAndOtherLiabilities",
     "nsuri": "http://www.curevac.com/20220930",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvac_AdjustmentsForNonCashIncomeFromReleaseOfProvisions": {
     "auth_ref": [],
     "calculation": {
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows": {
       "order": 6.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Adjustments for non cash income from release of provisions to reconcile profit (loss) to net cash flow from (used in) operating activities.",
        "label": "Adjustments For Non Cash Income From Release Of Provisions",
        "negatedLabel": "Non-cash income from release of provisions"
       }
      }
     },
     "localname": "AdjustmentsForNonCashIncomeFromReleaseOfProvisions",
     "nsuri": "http://www.curevac.com/20220930",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvac_AdvancedPurchaseAgreementWithEuropeanCommissionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for Advance Purchase Agreement with European Commission",
        "label": "Advance Purchase Agreement with European Commission"
       }
      }
     },
     "localname": "AdvancedPurchaseAgreementWithEuropeanCommissionMember",
     "nsuri": "http://www.curevac.com/20220930",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsGrantsWithGovernmentAgenciesAndSimilarBodiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvac_AggregateGrossProceedsReceivableFromIssuingShares": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum amount of aggregate gross proceeds receivable from issuance of shares.",
        "label": "Aggregate Gross Proceeds Receivable From Issuing Shares",
        "terseLabel": "Aggregate gross proceeds"
       }
      }
     },
     "localname": "AggregateGrossProceedsReceivableFromIssuingShares",
     "nsuri": "http://www.curevac.com/20220930",
     "presentation": [
      "http://www.curevac.com/role/DisclosureIssuedCapitalAndReservesImpactOfShareSplitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvac_AmountDeductedFromCarryingAmountOfQualifyingAssets": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount pertaining to grants deducted from the carrying amount of qualifying assets.",
        "label": "Amount Deducted From Carrying Amount Of Qualifying Assets",
        "terseLabel": "Amount deducted from the carrying amount of qualifying assets"
       }
      }
     },
     "localname": "AmountDeductedFromCarryingAmountOfQualifyingAssets",
     "nsuri": "http://www.curevac.com/20220930",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsGrantsWithGovernmentAgenciesAndSimilarBodiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvac_AmountOfLiabilityCashClaimAwards": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability recognized in financial statements towards cash claim of Awards.",
        "label": "Amount of Liability, Cash Claim Awards",
        "terseLabel": "Amount of liability, cash claim awards"
       }
      }
     },
     "localname": "AmountOfLiabilityCashClaimAwards",
     "nsuri": "http://www.curevac.com/20220930",
     "presentation": [
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvac_AmountOfRestrictedStockUnitsReceived": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of Restricted Stock Units Received.",
        "label": "Amount of Restricted Stock Units Received",
        "terseLabel": "Amount of restricted stock units received"
       }
      }
     },
     "localname": "AmountOfRestrictedStockUnitsReceived",
     "nsuri": "http://www.curevac.com/20220930",
     "presentation": [
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvac_AmountPaidAtSigningOfAgreementRelatedPartyTransactions": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount paid at signing of the agreement in related party transactions.",
        "label": "Amount Paid at Signing of Agreement, Related Party Transactions",
        "terseLabel": "Amount paid at signing of the agreement"
       }
      }
     },
     "localname": "AmountPaidAtSigningOfAgreementRelatedPartyTransactions",
     "nsuri": "http://www.curevac.com/20220930",
     "presentation": [
      "http://www.curevac.com/role/DisclosureRelatedPartyDisclosuresDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvac_AntonyBlancMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for Antony Blanc.",
        "label": "Antony Blanc",
        "terseLabel": "Antony Blanc"
       }
      }
     },
     "localname": "AntonyBlancMember",
     "nsuri": "http://www.curevac.com/20220930",
     "presentation": [
      "http://www.curevac.com/role/DisclosureRelatedPartyDisclosuresDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvac_ArrangementsAndNonArrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Arrangements And Non-arrangement Transactions [Member]"
       }
      }
     },
     "localname": "ArrangementsAndNonArrangementTransactionsMember",
     "nsuri": "http://www.curevac.com/20220930",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsGrantsWithGovernmentAgenciesAndSimilarBodiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvac_AtMarketOfferingProgramMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to at the market offering program.",
        "label": "ATM Offering Program"
       }
      }
     },
     "localname": "AtMarketOfferingProgramMember",
     "nsuri": "http://www.curevac.com/20220930",
     "presentation": [
      "http://www.curevac.com/role/DisclosureIssuedCapitalAndReservesImpactOfShareSplitDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvac_BaronJeanStephenneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for Baron Jean Stephenne.",
        "label": "Baron Jean Stephenne",
        "terseLabel": "Baron Jean Stephenne"
       }
      }
     },
     "localname": "BaronJeanStephenneMember",
     "nsuri": "http://www.curevac.com/20220930",
     "presentation": [
      "http://www.curevac.com/role/DisclosureRelatedPartyDisclosuresDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvac_BenefitExpenseRecognizedForShareBasedPayment": {
     "auth_ref": [],
     "calculation": {
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsExpensesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of benefit expense benefit recognized for share-based payment.",
        "label": "Benefit Expense Recognized For Share Based Payment",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "BenefitExpenseRecognizedForShareBasedPayment",
     "nsuri": "http://www.curevac.com/20220930",
     "presentation": [
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvac_BepharbelManufacturingS.aMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for BePharBel Manufacturing S.A.",
        "label": "BePharBel Manufacturing S.A",
        "terseLabel": "BePharBel Manufacturing S.A"
       }
      }
     },
     "localname": "BepharbelManufacturingS.aMember",
     "nsuri": "http://www.curevac.com/20220930",
     "presentation": [
      "http://www.curevac.com/role/DisclosureRelatedPartyDisclosuresDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvac_BillAndMelindaGatesFoundationBmgfMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for grants from Bill &amp; Melinda Gates Foundation (BMGF).",
        "label": "Bill &amp; Melinda Gates Foundation (BMGF)"
       }
      }
     },
     "localname": "BillAndMelindaGatesFoundationBmgfMember",
     "nsuri": "http://www.curevac.com/20220930",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsGrantsWithGovernmentAgenciesAndSimilarBodiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvac_BillMelindaGatesFoundationBmgfGrantForDevelopmentOfUniversalInfluenzaVaccineMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for grants from Bill &amp; Melinda Gates Foundation (BMGF) for development of a universal influenza vaccine.",
        "label": "Bill &amp; Melinda Gates Foundation (BMGF), Grant for development of a universal influenza vaccine"
       }
      }
     },
     "localname": "BillMelindaGatesFoundationBmgfGrantForDevelopmentOfUniversalInfluenzaVaccineMember",
     "nsuri": "http://www.curevac.com/20220930",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsGrantsWithGovernmentAgenciesAndSimilarBodiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvac_BillMelindaGatesFoundationBmgfGrantForMalariaVaccineMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for grants from Bill &amp; Melinda Gates Foundation (BMGF) for malaria vaccine.",
        "label": "Bill &amp; Melinda Gates Foundation (BMGF), Grant for malaria vaccine"
       }
      }
     },
     "localname": "BillMelindaGatesFoundationBmgfGrantForMalariaVaccineMember",
     "nsuri": "http://www.curevac.com/20220930",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsGrantsWithGovernmentAgenciesAndSimilarBodiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvac_BmbfMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for BMBF",
        "label": "BMBF"
       }
      }
     },
     "localname": "BmbfMember",
     "nsuri": "http://www.curevac.com/20220930",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsSummaryOfUpfrontPaymentsAndRelatedRevenuesRecognizedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvac_BoehringerIngelheimMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for Boehringer Ingelheim.",
        "label": "Boehringer Ingelheim"
       }
      }
     },
     "localname": "BoehringerIngelheimMember",
     "nsuri": "http://www.curevac.com/20220930",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsGrantsWithGovernmentAgenciesAndSimilarBodiesDetails",
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsRevenueFromContractWithCustomersDetails",
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsSummaryOfUpfrontPaymentsAndRelatedRevenuesRecognizedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvac_BusinessAcquisitionSigningSharePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The price at which the equity interests are to be issued under the business combination.",
        "label": "Business Acquisition, Signing Share Price",
        "terseLabel": "Signing Share Price"
       }
      }
     },
     "localname": "BusinessAcquisitionSigningSharePrice",
     "nsuri": "http://www.curevac.com/20220930",
     "presentation": [
      "http://www.curevac.com/role/DisclosureSignificantTransactionsAndEventsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "cvac_BusinessAcquisitionSigningSharePriceNumberOfTradingDaysConsidered": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of trading days over which the volume weighted average price is considered for determination of Signing Share Price under the business combination.",
        "label": "Business Acquisition, Signing Share Price, Number Of Trading Days Considered",
        "terseLabel": "Signing Share Price, Number of trading days considered"
       }
      }
     },
     "localname": "BusinessAcquisitionSigningSharePriceNumberOfTradingDaysConsidered",
     "nsuri": "http://www.curevac.com/20220930",
     "presentation": [
      "http://www.curevac.com/role/DisclosureSignificantTransactionsAndEventsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "cvac_CapitalIncreaseByGenmabMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for Genmab, capital increase.",
        "label": "Genmab Investment"
       }
      }
     },
     "localname": "CapitalIncreaseByGenmabMember",
     "nsuri": "http://www.curevac.com/20220930",
     "presentation": [
      "http://www.curevac.com/role/DisclosureIssuedCapitalAndReservesImpactOfShareSplitDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "NA.",
        "label": "Carrying Amount Accumulated Depreciation Amortisation And Impairments And Gross Carrying Amount [axis]"
       }
      }
     },
     "localname": "CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis",
     "nsuri": "http://www.curevac.com/20220930",
     "presentation": [
      "http://www.curevac.com/role/DisclosureFixedAssetsIntangibleAssetsDetails",
      "http://www.curevac.com/role/DisclosureFixedAssetsPropertyPlantAndEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "NA",
        "label": "Carrying Amount Accumulated Depreciation Amortisation And Impairments And Gross Carrying Amount [Domain]"
       }
      }
     },
     "localname": "CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountDomain",
     "nsuri": "http://www.curevac.com/20220930",
     "presentation": [
      "http://www.curevac.com/role/DisclosureFixedAssetsIntangibleAssetsDetails",
      "http://www.curevac.com/role/DisclosureFixedAssetsPropertyPlantAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvac_CashTransferredForSettlementOfVestedEmployeeOptions": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash transferred in a business combination for the settlement of the vested employee options.",
        "label": "Cash Transferred For The Settlement Of The Vested Employee Options",
        "terseLabel": "Consideration paid in cash for the settlement of the vested employee options"
       }
      }
     },
     "localname": "CashTransferredForSettlementOfVestedEmployeeOptions",
     "nsuri": "http://www.curevac.com/20220930",
     "presentation": [
      "http://www.curevac.com/role/DisclosureSignificantTransactionsAndEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvac_ChangeInExpenseByNature": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) in expense by nature.",
        "label": "Change in Expense By Nature",
        "terseLabel": "Increase in cost of sales"
       }
      }
     },
     "localname": "ChangeInExpenseByNature",
     "nsuri": "http://www.curevac.com/20220930",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsCostOfSalesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvac_ChangeInOtherLiabilities": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of increase (decrease) in other liabilities.",
        "label": "Change in Other Liabilities",
        "verboseLabel": "Decrease in other liabilities"
       }
      }
     },
     "localname": "ChangeInOtherLiabilities",
     "nsuri": "http://www.curevac.com/20220930",
     "presentation": [
      "http://www.curevac.com/role/DisclosureOtherLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvac_ChangeInTradeAndOtherPayables": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of change in trade and other payables.",
        "label": "Change in Trade and Other Payables",
        "terseLabel": "Amount of decrease in trade and other payables"
       }
      }
     },
     "localname": "ChangeInTradeAndOtherPayables",
     "nsuri": "http://www.curevac.com/20220930",
     "presentation": [
      "http://www.curevac.com/role/DisclosureTradeAndOtherPayablesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvac_ChangesInWorkingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "No definition available.",
        "label": "Changes in Working Capital [Abstract]",
        "terseLabel": "Working capital changes"
       }
      }
     },
     "localname": "ChangesInWorkingCapitalAbstract",
     "nsuri": "http://www.curevac.com/20220930",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "cvac_ChiefBusinessOfficerAndChiefCommercialOfficerMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for Chief Business Officer and Chief Commercial Officer.",
        "label": "Chief Business Officer and Chief Commercial Officer"
       }
      }
     },
     "localname": "ChiefBusinessOfficerAndChiefCommercialOfficerMember",
     "nsuri": "http://www.curevac.com/20220930",
     "presentation": [
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvac_ChiefBusinessOfficerMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for Chief Business Officer.",
        "label": "Chief Business Officer [Member]",
        "terseLabel": "Chief Business Officer"
       }
      }
     },
     "localname": "ChiefBusinessOfficerMember",
     "nsuri": "http://www.curevac.com/20220930",
     "presentation": [
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvac_ChiefDevelopmentOfficerMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for Chief Development Officer",
        "label": "Chief Development Officer"
       }
      }
     },
     "localname": "ChiefDevelopmentOfficerMember",
     "nsuri": "http://www.curevac.com/20220930",
     "presentation": [
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvac_ChiefOperatingOfficerAndChiefDevelopmentOfficerMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Person with designation of Chief operating officer and Chief development officer.",
        "label": "Chief Operating Officer and Chief Development Officer"
       }
      }
     },
     "localname": "ChiefOperatingOfficerAndChiefDevelopmentOfficerMember",
     "nsuri": "http://www.curevac.com/20220930",
     "presentation": [
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvac_ChiefScientificOfficerMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for Chief Scientific Officer.",
        "label": "Chief Scientific Officer"
       }
      }
     },
     "localname": "ChiefScientificOfficerMember",
     "nsuri": "http://www.curevac.com/20220930",
     "presentation": [
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvac_ClarentisSrlMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Member stands for Clarentis SRL, wholly owned consulting company of Antony Blanc, Chief business officer, a related party.",
        "label": "Clarentis SRL",
        "terseLabel": "Clarentis SRL"
       }
      }
     },
     "localname": "ClarentisSrlMember",
     "nsuri": "http://www.curevac.com/20220930",
     "presentation": [
      "http://www.curevac.com/role/DisclosureRelatedPartyDisclosuresDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvac_ClosingSharePriceRepresentingTotalFairValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount represents of closing share price representing total fair value.",
        "label": "Closing Share Price Representing Total Fair Value",
        "terseLabel": "Closing share price representing total fair value"
       }
      }
     },
     "localname": "ClosingSharePriceRepresentingTotalFairValue",
     "nsuri": "http://www.curevac.com/20220930",
     "presentation": [
      "http://www.curevac.com/role/DisclosureSignificantTransactionsAndEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvac_CoalitionForEpidemicPreparednessInnovationsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for grants related to Coalition for Epidemic Preparedness Innovations.",
        "label": "Coalition for Epidemic Preparedness Innovations"
       }
      }
     },
     "localname": "CoalitionForEpidemicPreparednessInnovationsMember",
     "nsuri": "http://www.curevac.com/20220930",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsGrantsWithGovernmentAgenciesAndSimilarBodiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvac_CollaborationAgreementMilestonePayment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the amount of milestone payment receivable.",
        "label": "Collaboration Agreement, Milestone Payment",
        "terseLabel": "Milestone payment"
       }
      }
     },
     "localname": "CollaborationAgreementMilestonePayment",
     "nsuri": "http://www.curevac.com/20220930",
     "presentation": [
      "http://www.curevac.com/role/DisclosureRelatedPartyDisclosuresDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvac_CommonSharesIssuedAndOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares issued and outstanding for during the period.",
        "label": "Common Shares Issued And Outstanding",
        "periodEndLabel": "Common shares issued and outstanding ending",
        "periodStartLabel": "Common shares issued and outstanding beginning"
       }
      }
     },
     "localname": "CommonSharesIssuedAndOutstanding",
     "nsuri": "http://www.curevac.com/20220930",
     "presentation": [
      "http://www.curevac.com/role/DisclosureIssuedCapitalAndReservesImpactOfShareSplitDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "cvac_CompanyOwnedGmpIvFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for company-owned GMP IV facility.",
        "label": "Company-owned GMP IV facility"
       }
      }
     },
     "localname": "CompanyOwnedGmpIvFacilityMember",
     "nsuri": "http://www.curevac.com/20220930",
     "presentation": [
      "http://www.curevac.com/role/DisclosureFixedAssetsPropertyPlantAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvac_CompensationForContractManufacturingOrganizationsTransfer": {
     "auth_ref": [],
     "calculation": {
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsOtherOperatingIncomeDetails": {
       "order": 3.0,
       "parentTag": "ifrs-full_MiscellaneousOtherOperatingIncome",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the amount of income recognised on compensation for contract manufacturing organizations transfer.",
        "label": "Compensation for Contract Manufacturing organizations Transfer",
        "terseLabel": "Compensation for CMO/Material transfer"
       }
      }
     },
     "localname": "CompensationForContractManufacturingOrganizationsTransfer",
     "nsuri": "http://www.curevac.com/20220930",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsOtherOperatingIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvac_CompensationForContractManufacturingOrganizationsTransferConsiderationForSetUpActivities": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the amount of income recognized on compensation for contract manufacturing organizations transfer which is mainly for consideration for set-up activities.",
        "label": "Compensation for Contract Manufacturing organizations Transfer, Consideration for Set-up Activities",
        "terseLabel": "Compensation consist for set-up activities"
       }
      }
     },
     "localname": "CompensationForContractManufacturingOrganizationsTransferConsiderationForSetUpActivities",
     "nsuri": "http://www.curevac.com/20220930",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsGrantsWithGovernmentAgenciesAndSimilarBodiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvac_CompensationForContractManufacturingOrganizationsTransferManufacturingInterimPeriodReimbursableExpenses": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the amount of income recognized on compensation for contract manufacturing organizations transfer which is mainly for Manufacturing Interim Period Reimbursable Expenses.",
        "label": "Compensation for Contract Manufacturing organizations Transfer, Manufacturing Interim Period Reimbursable Expenses",
        "terseLabel": "Compensation consist of Manufacturing Interim Period Reimbursable Expenses"
       }
      }
     },
     "localname": "CompensationForContractManufacturingOrganizationsTransferManufacturingInterimPeriodReimbursableExpenses",
     "nsuri": "http://www.curevac.com/20220930",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsGrantsWithGovernmentAgenciesAndSimilarBodiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvac_ComprehensiveIncomeLoss": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of income (loss) in equity resulting from transactions and other events, other than those income (loss) resulting from transactions with owners in their capacity as owners.",
        "label": "Comprehensive Income (Loss)",
        "totalLabel": "Total comprehensive income (loss)"
       }
      }
     },
     "localname": "ComprehensiveIncomeLoss",
     "nsuri": "http://www.curevac.com/20220930",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfChangesInShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvac_ContingentConsiderationMaximumSharesIssuable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum number of shares issuable as contingent consideration in a business combination.",
        "label": "Contingent Consideration, Maximum Shares Issuable",
        "terseLabel": "Contingent Consideration, Maximum shares issuable"
       }
      }
     },
     "localname": "ContingentConsiderationMaximumSharesIssuable",
     "nsuri": "http://www.curevac.com/20220930",
     "presentation": [
      "http://www.curevac.com/role/DisclosureSignificantTransactionsAndEventsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "cvac_ContingentConsiderationNumberOfMilestones": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of milestones to be achieved under the contingent consideration arrangement under the business combination.",
        "label": "Contingent Consideration, Number Of Milestones",
        "terseLabel": "Contingent consideration, Number of milestones"
       }
      }
     },
     "localname": "ContingentConsiderationNumberOfMilestones",
     "nsuri": "http://www.curevac.com/20220930",
     "presentation": [
      "http://www.curevac.com/role/DisclosureSignificantTransactionsAndEventsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "cvac_ContingentConsiderationNumberOfPaymentsConsidered": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of payments of total consideration under the business combination arrangement, that are subject to the achievement of defined milestones (contingent considerations).",
        "label": "Contingent Consideration, Number Of Payments Considered",
        "terseLabel": "Contingent consideration, Number of payments considered"
       }
      }
     },
     "localname": "ContingentConsiderationNumberOfPaymentsConsidered",
     "nsuri": "http://www.curevac.com/20220930",
     "presentation": [
      "http://www.curevac.com/role/DisclosureSignificantTransactionsAndEventsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "cvac_ContingentConsiderationPercentageOfTotalConsideration": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of total consideration transferred under the business combination, that are subject to the achievement of defined milestones (contingent considerations).",
        "label": "Contingent Consideration, Percentage Of Total Consideration",
        "terseLabel": "Contingent consideration, Percentage of total consideration"
       }
      }
     },
     "localname": "ContingentConsiderationPercentageOfTotalConsideration",
     "nsuri": "http://www.curevac.com/20220930",
     "presentation": [
      "http://www.curevac.com/role/DisclosureSignificantTransactionsAndEventsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "cvac_ContractManufacturingOrganizationAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for contract manufacturing organization Agreement",
        "label": "CMO agreement"
       }
      }
     },
     "localname": "ContractManufacturingOrganizationAgreementMember",
     "nsuri": "http://www.curevac.com/20220930",
     "presentation": [
      "http://www.curevac.com/role/DisclosureOtherLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvac_ContractResearchOrganizationAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for contract research organization Agreement.",
        "label": "CRO agreement"
       }
      }
     },
     "localname": "ContractResearchOrganizationAgreementMember",
     "nsuri": "http://www.curevac.com/20220930",
     "presentation": [
      "http://www.curevac.com/role/DisclosureOtherLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvac_CorporateInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "No definition available.",
        "label": "Corporate Information"
       }
      }
     },
     "localname": "CorporateInformationAbstract",
     "nsuri": "http://www.curevac.com/20220930",
     "xbrltype": "stringItemType"
    },
    "cvac_CorporateInformationTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure on corporate information.",
        "label": "Corporate Information [Text Block]",
        "terseLabel": "Corporate Information"
       }
      }
     },
     "localname": "CorporateInformationTextBlock",
     "nsuri": "http://www.curevac.com/20220930",
     "presentation": [
      "http://www.curevac.com/role/DisclosureCorporateInformation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cvac_CorporateReorganizationStockSplitRatio": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock split ratio upon corporate reorganization for determining the basis for issuance of shares to the holders of the entity.",
        "label": "Corporate Reorganization, Stock Split Ratio",
        "terseLabel": "Share split ratio"
       }
      }
     },
     "localname": "CorporateReorganizationStockSplitRatio",
     "nsuri": "http://www.curevac.com/20220930",
     "presentation": [
      "http://www.curevac.com/role/DisclosureCorporateInformationDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "cvac_CostOfReimbursementClaim": {
     "auth_ref": [],
     "calculation": {
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsOtherOperatingIncomeDetails": {
       "order": 2.0,
       "parentTag": "ifrs-full_MiscellaneousOtherOperatingIncome",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cost of reimbursement claim.",
        "label": "Cost of reimbursement claim",
        "terseLabel": "Reimbursement claim"
       }
      }
     },
     "localname": "CostOfReimbursementClaim",
     "nsuri": "http://www.curevac.com/20220930",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsOtherOperatingIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvac_CrisprMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for CRISPR.",
        "label": "CRISPR"
       }
      }
     },
     "localname": "CrisprMember",
     "nsuri": "http://www.curevac.com/20220930",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsRevenueFromContractWithCustomersDetails",
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsSummaryOfUpfrontPaymentsAndRelatedRevenuesRecognizedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvac_CrisprTherapeuticsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for CRISPR Therapeutics",
        "label": "CRISPR Therapeutics"
       }
      }
     },
     "localname": "CrisprTherapeuticsMember",
     "nsuri": "http://www.curevac.com/20220930",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsGrantsWithGovernmentAgenciesAndSimilarBodiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvac_CurevacCorporateServiceGmbhMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for CureVac Corporate Service GmbH.",
        "label": "CureVac Corporate Service GmbH"
       }
      }
     },
     "localname": "CurevacCorporateServiceGmbhMember",
     "nsuri": "http://www.curevac.com/20220930",
     "presentation": [
      "http://www.curevac.com/role/DisclosureIncomeTaxDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvac_CurevacN.v.Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Member stands for CureVac N.V. , a former holding company to the entity.",
        "label": "CureVac N.V."
       }
      }
     },
     "localname": "CurevacN.v.Member",
     "nsuri": "http://www.curevac.com/20220930",
     "presentation": [
      "http://www.curevac.com/role/DisclosureCorporateInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvac_CurevacSwissAgMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for CureVac Swiss AG.",
        "label": "CureVac Swiss AG"
       }
      }
     },
     "localname": "CurevacSwissAgMember",
     "nsuri": "http://www.curevac.com/20220930",
     "presentation": [
      "http://www.curevac.com/role/DisclosureIncomeTaxDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvac_CurrentLeaseLiabilitiesRecognisedAsOfAcquisitionDate": {
     "auth_ref": [],
     "calculation": {
      "http://www.curevac.com/role/DisclosureSignificantTransactionsAndEventsFrameAcquisitionPurchasePriceAllocationDetails": {
       "order": 1.0,
       "parentTag": "ifrs-full_CurrentLiabilitiesRecognisedAsOfAcquisitionDate",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount recognised as of the acquisition date for current lease liabilities assumed in a business combination.",
        "label": "Current Lease Liabilities Recognised As Of Acquisition Date",
        "terseLabel": "Lease liabilities"
       }
      }
     },
     "localname": "CurrentLeaseLiabilitiesRecognisedAsOfAcquisitionDate",
     "nsuri": "http://www.curevac.com/20220930",
     "presentation": [
      "http://www.curevac.com/role/DisclosureSignificantTransactionsAndEventsFrameAcquisitionPurchasePriceAllocationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvac_DecreaseInNumberOfSharesDueToTreasuryOfShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents for decrease in number of shares due to treasury of shares.",
        "label": "Decrease In Number Of Shares Due To Treasury Of Shares",
        "terseLabel": "Treasury shares"
       }
      }
     },
     "localname": "DecreaseInNumberOfSharesDueToTreasuryOfShares",
     "nsuri": "http://www.curevac.com/20220930",
     "presentation": [
      "http://www.curevac.com/role/DisclosureIssuedCapitalAndReservesImpactOfShareSplitDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "cvac_DescriptionOfAccountingPolicyForCovid19ImpactExplanatory": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of accounting policy for Covid-19 impact.",
        "label": "Description of Accounting Policy for Covid-19 Impact, Explanatory",
        "terseLabel": "Impact of COVID-19 and the Russia-Ukraine Conflict"
       }
      }
     },
     "localname": "DescriptionOfAccountingPolicyForCovid19ImpactExplanatory",
     "nsuri": "http://www.curevac.com/20220930",
     "presentation": [
      "http://www.curevac.com/role/DisclosureBasisOfPreparationPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cvac_DescriptionOfAccountingPolicyForPreLaunchProductsExplanatory": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of accounting policy for Pre-launch products.",
        "label": "Description of Accounting Policy for Pre-Launch Products, Explanatory",
        "terseLabel": "Pre-launch products"
       }
      }
     },
     "localname": "DescriptionOfAccountingPolicyForPreLaunchProductsExplanatory",
     "nsuri": "http://www.curevac.com/20220930",
     "presentation": [
      "http://www.curevac.com/role/DisclosureBasisOfPreparationPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cvac_DescriptionOfAccountingPolicyOfNewStandardsInterpretationsAndAmendmentsAdoptedTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The description of the entity's accounting policy for New standards, interpretations and amendments adopted by the Group.",
        "label": "Description of Accounting Policy of New Standards, Interpretations and Amendments Adopted [Text Block]",
        "terseLabel": "New standards, interpretations and amendments adopted by the Group"
       }
      }
     },
     "localname": "DescriptionOfAccountingPolicyOfNewStandardsInterpretationsAndAmendmentsAdoptedTextBlock",
     "nsuri": "http://www.curevac.com/20220930",
     "presentation": [
      "http://www.curevac.com/role/DisclosureBasisOfPreparationPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cvac_DietmarHoppMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Member stands for Mr. Dietmar Hopp, principal of dievini Hopp BioTech holding GmbH &amp; Co. KG , a majority shareholder of the entity, a related party.",
        "label": "Dietmar Hopp",
        "terseLabel": "Dietmar Hopp"
       }
      }
     },
     "localname": "DietmarHoppMember",
     "nsuri": "http://www.curevac.com/20220930",
     "presentation": [
      "http://www.curevac.com/role/DisclosureRelatedPartyDisclosuresDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvac_DisclosureOfAnalysisOfCashFlowsOnAcquisitionExplanatoryTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The disclosure of detailed information pertaining to analysis of cash flows on acquisition.",
        "label": "Disclosure Of Analysis Of Cash Flows On Acquisition, Explanatory [Table Text Block]",
        "terseLabel": "Schedule of analyses of cash flows on acquisition"
       }
      }
     },
     "localname": "DisclosureOfAnalysisOfCashFlowsOnAcquisitionExplanatoryTableTextBlock",
     "nsuri": "http://www.curevac.com/20220930",
     "presentation": [
      "http://www.curevac.com/role/DisclosureSignificantTransactionsAndEventsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cvac_DisclosureOfBasisOfPreparationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The disclosure of the basis used for the preparation of the financial statement.",
        "label": "Basis of preparation"
       }
      }
     },
     "localname": "DisclosureOfBasisOfPreparationAbstract",
     "nsuri": "http://www.curevac.com/20220930",
     "xbrltype": "stringItemType"
    },
    "cvac_DisclosureOfBasisOfPreparationExplanatoryTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The disclosure of the basis used for the preparation of the financial statement.",
        "label": "Disclosure of Basis of Preparation Explanatory [Text Block]",
        "terseLabel": "Basis of preparation"
       }
      }
     },
     "localname": "DisclosureOfBasisOfPreparationExplanatoryTextBlock",
     "nsuri": "http://www.curevac.com/20220930",
     "presentation": [
      "http://www.curevac.com/role/DisclosureBasisOfPreparation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cvac_DisclosureOfExpenseRecognizedForEmployeeServicesExplanatory": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of expense recognized for employee services explanatory.",
        "label": "Disclosure of Expense Recognized For Employee Services Explanatory",
        "terseLabel": "Schedule of expense recognized for employee services received"
       }
      }
     },
     "localname": "DisclosureOfExpenseRecognizedForEmployeeServicesExplanatory",
     "nsuri": "http://www.curevac.com/20220930",
     "presentation": [
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cvac_DisclosureOfFixedAssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "No definition available.",
        "label": "Fixed Assets"
       }
      }
     },
     "localname": "DisclosureOfFixedAssetsAbstract",
     "nsuri": "http://www.curevac.com/20220930",
     "xbrltype": "stringItemType"
    },
    "cvac_DisclosureOfFixedAssetsExplanatory": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for fixed assets.",
        "label": "Disclosure Of Fixed Assets, Explanatory",
        "terseLabel": "Fixed Assets"
       }
      }
     },
     "localname": "DisclosureOfFixedAssetsExplanatory",
     "nsuri": "http://www.curevac.com/20220930",
     "presentation": [
      "http://www.curevac.com/role/DisclosureFixedAssets"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cvac_DisclosureOfGoodwillRecognizedAsResultOfAcquisitionExplanatoryTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The disclosure of detailed information pertaining to goodwill recognized as a result of the acquisition.",
        "label": "Disclosure Of Goodwill Recognized As A Result Of Acquisition, Explanatory [Table Text Block]",
        "terseLabel": "Schedule of goodwill recognized as a result of the acquisition"
       }
      }
     },
     "localname": "DisclosureOfGoodwillRecognizedAsResultOfAcquisitionExplanatoryTableTextBlock",
     "nsuri": "http://www.curevac.com/20220930",
     "presentation": [
      "http://www.curevac.com/role/DisclosureSignificantTransactionsAndEventsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cvac_DisclosureOfGovernmentGrantsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.",
        "label": "Disclosure Of Government Grants [Line Items]",
        "verboseLabel": "Disclosure Of Government Grants"
       }
      }
     },
     "localname": "DisclosureOfGovernmentGrantsLineItems",
     "nsuri": "http://www.curevac.com/20220930",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsGrantsWithGovernmentAgenciesAndSimilarBodiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cvac_DisclosureOfGovernmentGrantsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of information pertaining to disclosure of government grants.",
        "label": "Disclosure Of Government Grants [Table]"
       }
      }
     },
     "localname": "DisclosureOfGovernmentGrantsTable",
     "nsuri": "http://www.curevac.com/20220930",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsGrantsWithGovernmentAgenciesAndSimilarBodiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cvac_DisclosureOfNotesToConsolidatedFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "No definition available.",
        "label": "Notes to the consolidated financial statements"
       }
      }
     },
     "localname": "DisclosureOfNotesToConsolidatedFinancialStatementsAbstract",
     "nsuri": "http://www.curevac.com/20220930",
     "xbrltype": "stringItemType"
    },
    "cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents of disclosure of notes to the consolidated financial statements.",
        "label": "Disclosure Of Notes To The Consolidated Financial Statements [Line Items]",
        "terseLabel": "Notes to the consolidated financial statements"
       }
      }
     },
     "localname": "DisclosureOfNotesToConsolidatedFinancialStatementsLineItems",
     "nsuri": "http://www.curevac.com/20220930",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsContractLiabilitiesAllocatedToRemainingPerformanceObligationsDetails",
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsCostOfSalesDetails",
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsGeneralAndAdministrativeExpensesDetails",
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsResearchAndDevelopmentExpensesDetails",
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsRevenueFromContractWithCustomersDetails",
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsSellingAndDistributionExpensesDetails",
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsSummaryOfUpfrontPaymentsAndRelatedRevenuesRecognizedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cvac_DisclosureOfNotesToConsolidatedFinancialStatementsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of information pertaining to disclosure of notes to the consolidated financial statements.",
        "label": "Disclosure Of Notes To The Consolidated Financial Statements [Table]"
       }
      }
     },
     "localname": "DisclosureOfNotesToConsolidatedFinancialStatementsTable",
     "nsuri": "http://www.curevac.com/20220930",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsContractLiabilitiesAllocatedToRemainingPerformanceObligationsDetails",
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsCostOfSalesDetails",
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsGeneralAndAdministrativeExpensesDetails",
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsResearchAndDevelopmentExpensesDetails",
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsRevenueFromContractWithCustomersDetails",
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsSellingAndDistributionExpensesDetails",
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsSummaryOfUpfrontPaymentsAndRelatedRevenuesRecognizedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cvac_DisclosureOfOtherLiabilitiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "NA",
        "label": "Disclosure of Other liabilities [Line Items]",
        "terseLabel": "Disclosure of Other liabilities"
       }
      }
     },
     "localname": "DisclosureOfOtherLiabilitiesLineItems",
     "nsuri": "http://www.curevac.com/20220930",
     "presentation": [
      "http://www.curevac.com/role/DisclosureOtherLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cvac_DisclosureOfOtherLiabilitiesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule disclosing information related to other liabilities.",
        "label": "Disclosure of Other liabilities [table]"
       }
      }
     },
     "localname": "DisclosureOfOtherLiabilitiesTable",
     "nsuri": "http://www.curevac.com/20220930",
     "presentation": [
      "http://www.curevac.com/role/DisclosureOtherLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cvac_DisclosureOfPrepaidExpensesAndOtherCurrentAssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "No definition available.",
        "label": "Prepaid expenses and other assets (current)"
       }
      }
     },
     "localname": "DisclosureOfPrepaidExpensesAndOtherCurrentAssetsAbstract",
     "nsuri": "http://www.curevac.com/20220930",
     "xbrltype": "stringItemType"
    },
    "cvac_DisclosureOfPrepaidExpensesAndOtherCurrentAssetsExplanatory": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for prepaid expenses and other current assets.",
        "label": "Disclosure Of Prepaid Expenses And Other Current Assets, Explanatory",
        "terseLabel": "Prepaid expenses and other assets (current)"
       }
      }
     },
     "localname": "DisclosureOfPrepaidExpensesAndOtherCurrentAssetsExplanatory",
     "nsuri": "http://www.curevac.com/20220930",
     "presentation": [
      "http://www.curevac.com/role/DisclosurePrepaidExpensesAndOtherAssetsCurrent"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cvac_DisclosureOfUpfrontPaymentsAndRelatedRevenuesRecognizedExplanatory": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of detailed information about upfront payments and related revenues recognized.",
        "label": "Disclosure Of Upfront Payments And Related Revenues Recognized, Explanatory",
        "terseLabel": "Summary of upfront payments and related revenues recognized"
       }
      }
     },
     "localname": "DisclosureOfUpfrontPaymentsAndRelatedRevenuesRecognizedExplanatory",
     "nsuri": "http://www.curevac.com/20220930",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cvac_Dr.IngmarHoerrMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Member stands for Dr. Ingmar Hoerr, a related party.",
        "label": "Dr. Ingmar Hoerr",
        "terseLabel": "Dr. Ingmar Hoerr"
       }
      }
     },
     "localname": "Dr.IngmarHoerrMember",
     "nsuri": "http://www.curevac.com/20220930",
     "presentation": [
      "http://www.curevac.com/role/DisclosureRelatedPartyDisclosuresDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvac_EliLillyAndCompanyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for Eli Lilly and Company.",
        "label": "Eli Lilly."
       }
      }
     },
     "localname": "EliLillyAndCompanyMember",
     "nsuri": "http://www.curevac.com/20220930",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsRevenueFromContractWithCustomersDetails",
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsSummaryOfUpfrontPaymentsAndRelatedRevenuesRecognizedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvac_EliLillyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for Eli Lilly",
        "label": "Eli Lilly"
       }
      }
     },
     "localname": "EliLillyMember",
     "nsuri": "http://www.curevac.com/20220930",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsGrantsWithGovernmentAgenciesAndSimilarBodiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvac_EquipmentPhysicallyLocatedAtCmoFacilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for equipment physically located at the CMO facilities.",
        "label": "Equipment physically located at the CMO facilities"
       }
      }
     },
     "localname": "EquipmentPhysicallyLocatedAtCmoFacilitiesMember",
     "nsuri": "http://www.curevac.com/20220930",
     "presentation": [
      "http://www.curevac.com/role/DisclosureFixedAssetsPropertyPlantAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvac_EuropeanCommissionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for European Commission.",
        "label": "European Commission"
       }
      }
     },
     "localname": "EuropeanCommissionMember",
     "nsuri": "http://www.curevac.com/20220930",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsSummaryOfUpfrontPaymentsAndRelatedRevenuesRecognizedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvac_EuropeanUnionAdvancePurchaseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to EU APA.",
        "label": "EU APA"
       }
      }
     },
     "localname": "EuropeanUnionAdvancePurchaseAgreementMember",
     "nsuri": "http://www.curevac.com/20220930",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsSummaryOfUpfrontPaymentsAndRelatedRevenuesRecognizedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvac_ExecutiveBoardMembersMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for executive board members.",
        "label": "Executive board members"
       }
      }
     },
     "localname": "ExecutiveBoardMembersMember",
     "nsuri": "http://www.curevac.com/20220930",
     "presentation": [
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvac_ExerciseOfGreenshoeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for exercise of Greenshoe.",
        "label": "Exercise \"Greenshoe\""
       }
      }
     },
     "localname": "ExerciseOfGreenshoeMember",
     "nsuri": "http://www.curevac.com/20220930",
     "presentation": [
      "http://www.curevac.com/role/DisclosureIssuedCapitalAndReservesImpactOfShareSplitDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvac_ExerciseOfOptionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for exercise of options.",
        "label": "Exercise of options"
       }
      }
     },
     "localname": "ExerciseOfOptionsMember",
     "nsuri": "http://www.curevac.com/20220930",
     "presentation": [
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInGeneralAndAdministrativeExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsExpensesDetails": {
       "order": 1.0,
       "parentTag": "cvac_BenefitExpenseRecognizedForShareBasedPayment",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense arising from share-based payment transactions in which the goods or services received did not qualify for recognition as assets in general and administrative expenses.",
        "label": "Expense From Share-Based Payment Transactions In Which Goods Or Services Received Did Not Qualify For Recognition As Assets In General And Administrative Expenses",
        "verboseLabel": "General and administrative expenses"
       }
      }
     },
     "localname": "ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInGeneralAndAdministrativeExpenses",
     "nsuri": "http://www.curevac.com/20220930",
     "presentation": [
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsDetails",
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInResearchAndDevelopmentExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsExpensesDetails": {
       "order": 2.0,
       "parentTag": "cvac_BenefitExpenseRecognizedForShareBasedPayment",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense arising from share-based payment transactions in which the goods or services received did not qualify for recognition as assets in research and development expenses.",
        "label": "Expense From Share-Based Payment Transactions In Which Goods Or Services Received Did Not Qualify For Recognition As Assets In Research And Development Expenses",
        "verboseLabel": "Research and development expenses"
       }
      }
     },
     "localname": "ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInResearchAndDevelopmentExpenses",
     "nsuri": "http://www.curevac.com/20220930",
     "presentation": [
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInSellingAndDistributionExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsExpensesDetails": {
       "order": 3.0,
       "parentTag": "cvac_BenefitExpenseRecognizedForShareBasedPayment",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense arising from share-based payment transactions in which the goods or services received did not qualify for recognition as assets in selling and distribution expenses.",
        "label": "Expense From Share-Based Payment Transactions In Which Goods Or Services Received Did Not Qualify For Recognition As Assets In Selling And Distribution Expenses",
        "terseLabel": "Sales and marketing expenses"
       }
      }
     },
     "localname": "ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInSellingAndDistributionExpenses",
     "nsuri": "http://www.curevac.com/20220930",
     "presentation": [
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvac_ExpenseRecognizedForEmployeeServices": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense recognized for employee services.",
        "label": "Expense Recognized For Employee Services",
        "verboseLabel": "Expense Recognized For Employee Services"
       }
      }
     },
     "localname": "ExpenseRecognizedForEmployeeServices",
     "nsuri": "http://www.curevac.com/20220930",
     "presentation": [
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsExpenseRecognizedForProgramDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvac_FairValueOfTotalConsiderationTransferred": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of fair value of total consideration transferred.",
        "label": "Fair Value Of Total Consideration Transferred",
        "terseLabel": "Amount of fair value"
       }
      }
     },
     "localname": "FairValueOfTotalConsiderationTransferred",
     "nsuri": "http://www.curevac.com/20220930",
     "presentation": [
      "http://www.curevac.com/role/DisclosureSignificantTransactionsAndEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvac_FinancialInstrumentsAndRiskManagementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "No definition available.",
        "label": "Disclosure of financial instruments and risk management"
       }
      }
     },
     "localname": "FinancialInstrumentsAndRiskManagementAbstract",
     "nsuri": "http://www.curevac.com/20220930",
     "xbrltype": "stringItemType"
    },
    "cvac_FirstPortionOfTotalConsiderationTransferredAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of first portion of total consideration transferred under the business combination.",
        "label": "First Portion Of Total Consideration Transferred, Amount",
        "terseLabel": "First portion of total consideration transferred, amount"
       }
      }
     },
     "localname": "FirstPortionOfTotalConsiderationTransferredAmount",
     "nsuri": "http://www.curevac.com/20220930",
     "presentation": [
      "http://www.curevac.com/role/DisclosureSignificantTransactionsAndEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvac_FirstPortionOfTotalConsiderationTransferredPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of first portion of total consideration transferred under the business combination.",
        "label": "First Portion Of Total Consideration Transferred, Percentage",
        "terseLabel": "First portion of total consideration transferred, percentage"
       }
      }
     },
     "localname": "FirstPortionOfTotalConsiderationTransferredPercentage",
     "nsuri": "http://www.curevac.com/20220930",
     "presentation": [
      "http://www.curevac.com/role/DisclosureSignificantTransactionsAndEventsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "cvac_FollowOnPublicOfferingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to follow on public offering.",
        "label": "Follow-on public offering, incl. Greenshoe"
       }
      }
     },
     "localname": "FollowOnPublicOfferingMember",
     "nsuri": "http://www.curevac.com/20220930",
     "presentation": [
      "http://www.curevac.com/role/DisclosureIssuedCapitalAndReservesImpactOfShareSplitDetails",
      "http://www.curevac.com/role/DisclosureIssuedCapitalAndReservesOverviewAndGeneralRemarksDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvac_FormerFrameEmployeesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Former Frame employee's",
        "label": "Former Frame Employee&amp;rsquo;s [Member]",
        "terseLabel": "Former Frame employee's"
       }
      }
     },
     "localname": "FormerFrameEmployeesMember",
     "nsuri": "http://www.curevac.com/20220930",
     "presentation": [
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvac_FramePharmaceuticalsB.v.AmsterdamNetherlandsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to Frame Pharmaceuticals B.V., Amsterdam, Netherlands.",
        "label": "Frame Pharmaceuticals B.V., Amsterdam, Netherlands",
        "verboseLabel": "Frame Pharmaceuticals B.v.Amsterdam Netherlands"
       }
      }
     },
     "localname": "FramePharmaceuticalsB.v.AmsterdamNetherlandsMember",
     "nsuri": "http://www.curevac.com/20220930",
     "presentation": [
      "http://www.curevac.com/role/DisclosureSignificantTransactionsAndEventsAnalysesOfCashFlowsOnFrameAcquisitionDetails",
      "http://www.curevac.com/role/DisclosureSignificantTransactionsAndEventsDetails",
      "http://www.curevac.com/role/DisclosureSignificantTransactionsAndEventsFrameAcquisitionPurchasePriceAllocationDetails",
      "http://www.curevac.com/role/DisclosureSignificantTransactionsAndEventsGoodwillRecognizedOnFrameAcquisitionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvac_GenmabMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for Genmab.",
        "label": "Genmab"
       }
      }
     },
     "localname": "GenmabMember",
     "nsuri": "http://www.curevac.com/20220930",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsGrantsWithGovernmentAgenciesAndSimilarBodiesDetails",
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsRevenueFromContractWithCustomersDetails",
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsSummaryOfUpfrontPaymentsAndRelatedRevenuesRecognizedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvac_GermanFederalMinistryOfEducationAndResearchMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for German Federal Ministry of Education and Research.",
        "label": "German Federal Ministry of Education and Research"
       }
      }
     },
     "localname": "GermanFederalMinistryOfEducationAndResearchMember",
     "nsuri": "http://www.curevac.com/20220930",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsGrantsWithGovernmentAgenciesAndSimilarBodiesDetails",
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsSummaryOfUpfrontPaymentsAndRelatedRevenuesRecognizedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvac_GlaxosmithklineMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for GlaxoSmithKline.",
        "label": "GSK"
       }
      }
     },
     "localname": "GlaxosmithklineMember",
     "nsuri": "http://www.curevac.com/20220930",
     "presentation": [
      "http://www.curevac.com/role/DisclosureInventoriesDetails",
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsGrantsWithGovernmentAgenciesAndSimilarBodiesDetails",
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsRevenueFromContractWithCustomersDetails",
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsSummaryOfUpfrontPaymentsAndRelatedRevenuesRecognizedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvac_GovernmentGrantsAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of information pertaining to government grants.",
        "label": "Government Grants [Axis]"
       }
      }
     },
     "localname": "GovernmentGrantsAxis",
     "nsuri": "http://www.curevac.com/20220930",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsGrantsWithGovernmentAgenciesAndSimilarBodiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cvac_GovernmentGrantsDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information pertaining to government grants.",
        "label": "Government Grants [Domain]"
       }
      }
     },
     "localname": "GovernmentGrantsDomain",
     "nsuri": "http://www.curevac.com/20220930",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsGrantsWithGovernmentAgenciesAndSimilarBodiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvac_Gsk2ndGenMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for GSK 2nd Gen.",
        "label": "GSK 2nd Gen"
       }
      }
     },
     "localname": "Gsk2ndGenMember",
     "nsuri": "http://www.curevac.com/20220930",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsSummaryOfUpfrontPaymentsAndRelatedRevenuesRecognizedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvac_GskAgreement2020Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for GSK Agreement 2020.",
        "label": "2020 GSK AGREEMENT"
       }
      }
     },
     "localname": "GskAgreement2020Member",
     "nsuri": "http://www.curevac.com/20220930",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsGrantsWithGovernmentAgenciesAndSimilarBodiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvac_IfrsBusinessAcquisitionSharePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Price of a single share of a number of saleable stocks paid or offered to be paid in a business combination.",
        "label": "Ifrs Business Acquisition, Share Price",
        "terseLabel": "Closing Share Price"
       }
      }
     },
     "localname": "IfrsBusinessAcquisitionSharePrice",
     "nsuri": "http://www.curevac.com/20220930",
     "presentation": [
      "http://www.curevac.com/role/DisclosureSignificantTransactionsAndEventsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "cvac_IfrsCashAndCashEquivalentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for cash and cash equivalents.",
        "label": "Cash and cash equivalents"
       }
      }
     },
     "localname": "IfrsCashAndCashEquivalentsMember",
     "nsuri": "http://www.curevac.com/20220930",
     "presentation": [
      "http://www.curevac.com/role/DisclosureDisclosureOfFinancialInstrumentsAndRiskManagementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvac_IfrsCashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities": {
     "auth_ref": [],
     "calculation": {
      "http://www.curevac.com/role/DisclosureSignificantTransactionsAndEventsAnalysesOfCashFlowsOnFrameAcquisitionDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate cash flows used in obtaining control of subsidiaries or other businesses, classified as investing activities. [Refer: Subsidiaries [member]]",
        "label": "IFRS Cash Flows Used In Obtaining Control Of Subsidiaries Or Other Businesses Classified As Investing Activities",
        "negatedTotalLabel": "Included in cash flows from investing activities"
       }
      }
     },
     "localname": "IfrsCashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities",
     "nsuri": "http://www.curevac.com/20220930",
     "presentation": [
      "http://www.curevac.com/role/DisclosureSignificantTransactionsAndEventsAnalysesOfCashFlowsOnFrameAcquisitionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvac_IfrsContractualObligation": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of contractual obligation, including but not limited to, long-term debt, capital lease obligations, operating lease obligations, purchase obligations, and other commitments.",
        "label": "IFRS Contractual Obligation",
        "terseLabel": "Contractual obligation amount"
       }
      }
     },
     "localname": "IfrsContractualObligation",
     "nsuri": "http://www.curevac.com/20220930",
     "presentation": [
      "http://www.curevac.com/role/DisclosureRelatedPartyDisclosuresDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvac_IfrsCostOfSalesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing cost of sales.",
        "label": "Cost of sales"
       }
      }
     },
     "localname": "IfrsCostOfSalesMember",
     "nsuri": "http://www.curevac.com/20220930",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsCostOfSalesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvac_IfrsDevelopmentMilestonePaymentIncludedInContractLiabilities": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of development milestone payment included in contract liabilities",
        "label": "IFRS Development Milestone Payment Included In Contract Liabilities",
        "terseLabel": "Development milestone payment included in contract liabilities"
       }
      }
     },
     "localname": "IfrsDevelopmentMilestonePaymentIncludedInContractLiabilities",
     "nsuri": "http://www.curevac.com/20220930",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsRevenueFromContractWithCustomersDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvac_IfrsDisposalGroupIncludingDiscontinuedOperationConsideration": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "\"\t\nAmount of consideration received or receivable for the disposal of assets and liabilities, including discontinued operation.\"",
        "label": "Ifrs Disposal Group, Including Discontinued Operation, Consideration",
        "terseLabel": "Total consideration"
       }
      }
     },
     "localname": "IfrsDisposalGroupIncludingDiscontinuedOperationConsideration",
     "nsuri": "http://www.curevac.com/20220930",
     "presentation": [
      "http://www.curevac.com/role/DisclosureAssetsHeldForSaleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvac_IfrsGeneralAndAdministrativeExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General and administrative expenses"
       }
      }
     },
     "localname": "IfrsGeneralAndAdministrativeExpenseMember",
     "nsuri": "http://www.curevac.com/20220930",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsGeneralAndAdministrativeExpensesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvac_IfrsIncomeStatementLocationAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Ifrs Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IfrsIncomeStatementLocationAxis",
     "nsuri": "http://www.curevac.com/20220930",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsCostOfSalesDetails",
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsGeneralAndAdministrativeExpensesDetails",
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsResearchAndDevelopmentExpensesDetails",
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsSellingAndDistributionExpensesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cvac_IfrsIncomeStatementLocationDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Ifrs Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IfrsIncomeStatementLocationDomain",
     "nsuri": "http://www.curevac.com/20220930",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsCostOfSalesDetails",
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsGeneralAndAdministrativeExpensesDetails",
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsResearchAndDevelopmentExpensesDetails",
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsSellingAndDistributionExpensesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvac_IfrsIncreaseDecreaseInPrepaidExpenseAndOtherAssets": {
     "auth_ref": [],
     "calculation": {
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows": {
       "order": 21.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Ifrs Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Decrease / (increase) in prepaid expenses and other assets"
       }
      }
     },
     "localname": "IfrsIncreaseDecreaseInPrepaidExpenseAndOtherAssets",
     "nsuri": "http://www.curevac.com/20220930",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvac_IfrsIncreaseInExpenseRelatedToIneffectiveSetUpActivitiesAndSettlementCosts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase in expense related to in-effective set-up activities and settlement costs",
        "label": "IFRS Increase In Expense Related To Ineffective Set-up activities And Settlement Costs",
        "terseLabel": "Recognition of expenses related to ineffective set-up activities and settlement costs"
       }
      }
     },
     "localname": "IfrsIncreaseInExpenseRelatedToIneffectiveSetUpActivitiesAndSettlementCosts",
     "nsuri": "http://www.curevac.com/20220930",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsResearchAndDevelopmentExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvac_IfrsLineOfCreditMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A contractual arrangement with a lender under which borrowings can be made up to a specific amount at any point in time, and under which borrowings outstanding may be either short-term or long-term, depending upon the particulars.",
        "label": "Line of credit"
       }
      }
     },
     "localname": "IfrsLineOfCreditMember",
     "nsuri": "http://www.curevac.com/20220930",
     "presentation": [
      "http://www.curevac.com/role/DisclosureLoansDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvac_IfrsMilestonePaymentReceived": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of milestone payment received.",
        "label": "IFRS Milestone Payment Received",
        "terseLabel": "Milestone payment received"
       }
      }
     },
     "localname": "IfrsMilestonePaymentReceived",
     "nsuri": "http://www.curevac.com/20220930",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsGrantsWithGovernmentAgenciesAndSimilarBodiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvac_IfrsNumberOfSharesOutstandingThroughTransferFromShareholdersToEntity": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares received from the participants.",
        "label": "IFRS Number Of Shares Outstanding Through Transfer From Shareholders To Entity",
        "terseLabel": "Number of shares received"
       }
      }
     },
     "localname": "IfrsNumberOfSharesOutstandingThroughTransferFromShareholdersToEntity",
     "nsuri": "http://www.curevac.com/20220930",
     "presentation": [
      "http://www.curevac.com/role/DisclosureRelatedPartyDisclosuresDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "cvac_IfrsOtherLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "No definition available.",
        "label": "Other liabilities."
       }
      }
     },
     "localname": "IfrsOtherLiabilitiesAbstract",
     "nsuri": "http://www.curevac.com/20220930",
     "xbrltype": "stringItemType"
    },
    "cvac_IfrsOverAllotmentOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right given to the underwriter to sell additional shares over the initial allotment.",
        "label": "Over-Allotment Option"
       }
      }
     },
     "localname": "IfrsOverAllotmentOptionMember",
     "nsuri": "http://www.curevac.com/20220930",
     "presentation": [
      "http://www.curevac.com/role/DisclosureIssuedCapitalAndReservesOverviewAndGeneralRemarksDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvac_IfrsProductMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Article or substance produced by nature, labor or machinery.",
        "label": "Product"
       }
      }
     },
     "localname": "IfrsProductMember",
     "nsuri": "http://www.curevac.com/20220930",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsRevenueFromContractWithCustomersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvac_IfrsRemainingGrantIncome": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of remaining grant income classified as other operating income.",
        "label": "IFRS Remaining Grant Income",
        "terseLabel": "Remaining grant income"
       }
      }
     },
     "localname": "IfrsRemainingGrantIncome",
     "nsuri": "http://www.curevac.com/20220930",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsGrantsWithGovernmentAgenciesAndSimilarBodiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvac_IfrsRepaymentsOfAccruedInterestAndFeesOfBorrowings": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow to settle accrued interest and fees of borrowings, classified as financing activities.",
        "label": "IFRS Repayments Of Accrued Interest And Fees Of Borrowings",
        "terseLabel": "Repayment of accrued interest and fees of loan"
       }
      }
     },
     "localname": "IfrsRepaymentsOfAccruedInterestAndFeesOfBorrowings",
     "nsuri": "http://www.curevac.com/20220930",
     "presentation": [
      "http://www.curevac.com/role/DisclosureLoansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvac_IfrsResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and development expenses"
       }
      }
     },
     "localname": "IfrsResearchAndDevelopmentExpenseMember",
     "nsuri": "http://www.curevac.com/20220930",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsResearchAndDevelopmentExpensesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvac_IfrsRestrictedStockUnitMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member represents for restricted stock unit.",
        "label": "RSU"
       }
      }
     },
     "localname": "IfrsRestrictedStockUnitMember",
     "nsuri": "http://www.curevac.com/20220930",
     "presentation": [
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsExpenseRecognizedForProgramDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvac_IfrsSaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "IFRS Sale of Stock [Axis]"
       }
      }
     },
     "localname": "IfrsSaleOfStockAxis",
     "nsuri": "http://www.curevac.com/20220930",
     "presentation": [
      "http://www.curevac.com/role/DisclosureIssuedCapitalAndReservesImpactOfShareSplitDetails",
      "http://www.curevac.com/role/DisclosureIssuedCapitalAndReservesOverviewAndGeneralRemarksDetails",
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cvac_IfrsSaleOfStockDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "IFRS Sale of Stock [Domain]"
       }
      }
     },
     "localname": "IfrsSaleOfStockDomain",
     "nsuri": "http://www.curevac.com/20220930",
     "presentation": [
      "http://www.curevac.com/role/DisclosureIssuedCapitalAndReservesImpactOfShareSplitDetails",
      "http://www.curevac.com/role/DisclosureIssuedCapitalAndReservesOverviewAndGeneralRemarksDetails",
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvac_IfrsShareBasedPaymentArrangementTrancheOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.",
        "label": "First tranche"
       }
      }
     },
     "localname": "IfrsShareBasedPaymentArrangementTrancheOneMember",
     "nsuri": "http://www.curevac.com/20220930",
     "presentation": [
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvac_IfrsStockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Ifrs Stock Issued During Period, Shares, New Issues",
        "verboseLabel": "At-the-market offering program issuances"
       }
      }
     },
     "localname": "IfrsStockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://www.curevac.com/20220930",
     "presentation": [
      "http://www.curevac.com/role/DisclosureIssuedCapitalAndReservesImpactOfShareSplitDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "cvac_IfrsStockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [],
     "calculation": {
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows": {
       "order": 9.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from at the market shares issued during the period.",
        "label": "Ifrs Stock Issued During Period Value New Issues",
        "negatedLabel": "Proceeds from at-the-market offering program (net of transaction costs)"
       }
      }
     },
     "localname": "IfrsStockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://www.curevac.com/20220930",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvac_IfrsStockholdersEquityNoteStockSplitConversionRatio": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.",
        "label": "IFRS Stockholders' Equity Note, Stock Split, Conversion Ratio",
        "terseLabel": "Share split ratio"
       }
      }
     },
     "localname": "IfrsStockholdersEquityNoteStockSplitConversionRatio",
     "nsuri": "http://www.curevac.com/20220930",
     "presentation": [
      "http://www.curevac.com/role/DisclosureIssuedCapitalAndReservesOverviewAndGeneralRemarksDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "cvac_IfrsVestingAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by vesting schedule of award under share-based payment arrangement.",
        "label": "Ifrs Vesting [Axis]"
       }
      }
     },
     "localname": "IfrsVestingAxis",
     "nsuri": "http://www.curevac.com/20220930",
     "presentation": [
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cvac_IfrsVestingDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vesting schedule of award under share-based payment arrangement.",
        "label": "Ifrs Vesting [Domain]"
       }
      }
     },
     "localname": "IfrsVestingDomain",
     "nsuri": "http://www.curevac.com/20220930",
     "presentation": [
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvac_ImpairmentsOfInventoryAndPrepayments": {
     "auth_ref": [],
     "calculation": {
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows": {
       "order": 8.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Impairments of inventory and prepayments",
        "label": "Impairments of inventory and prepayments",
        "terseLabel": "Impairment of inventory and prepayments"
       }
      }
     },
     "localname": "ImpairmentsOfInventoryAndPrepayments",
     "nsuri": "http://www.curevac.com/20220930",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvac_IncomeTaxDisclosureLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.",
        "label": "Income Tax Disclosure [Line Items]",
        "terseLabel": "Income Tax Disclosure"
       }
      }
     },
     "localname": "IncomeTaxDisclosureLineItems",
     "nsuri": "http://www.curevac.com/20220930",
     "presentation": [
      "http://www.curevac.com/role/DisclosureIncomeTaxDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cvac_IncomeTaxDisclosureTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule disclosing information related to income tax disclosures.",
        "label": "Income Tax Disclosure [Table]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTable",
     "nsuri": "http://www.curevac.com/20220930",
     "presentation": [
      "http://www.curevac.com/role/DisclosureIncomeTaxDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cvac_IncreaseDecreaseInInventory": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in inventory during the period.",
        "label": "Increase (Decrease) In Inventory",
        "terseLabel": "Decrease in inventory"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventory",
     "nsuri": "http://www.curevac.com/20220930",
     "presentation": [
      "http://www.curevac.com/role/DisclosureInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvac_IncreaseInNumberOfSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase in the number of shares outstanding.",
        "label": "Increase In Number Of Shares Outstanding",
        "terseLabel": "Capital Investment",
        "verboseLabel": "Capital increase (in shares)"
       }
      }
     },
     "localname": "IncreaseInNumberOfSharesOutstanding",
     "nsuri": "http://www.curevac.com/20220930",
     "presentation": [
      "http://www.curevac.com/role/DisclosureIssuedCapitalAndReservesImpactOfShareSplitDetails",
      "http://www.curevac.com/role/DisclosureRelatedPartyDisclosuresDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "cvac_IncreaseInPropertyAndEquipmentOffSetByImpairmentOfEquipment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in PPE off set by impairment in equipment.",
        "label": "Increase In Property and Equipment Off Set By Impairment of Equipment",
        "terseLabel": "Partial offset of increase in property, plant and equipment"
       }
      }
     },
     "localname": "IncreaseInPropertyAndEquipmentOffSetByImpairmentOfEquipment",
     "nsuri": "http://www.curevac.com/20220930",
     "presentation": [
      "http://www.curevac.com/role/DisclosureFixedAssetsPropertyPlantAndEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvac_InitialPublicOfferingAndPrivatePlacementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for initial public offering and private placement.",
        "label": "Initial Public Offering and Private Placement"
       }
      }
     },
     "localname": "InitialPublicOfferingAndPrivatePlacementMember",
     "nsuri": "http://www.curevac.com/20220930",
     "presentation": [
      "http://www.curevac.com/role/DisclosureIssuedCapitalAndReservesImpactOfShareSplitDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvac_InventoriesLineItem": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "N/A",
        "label": "Inventories [Line item",
        "terseLabel": "Inventories"
       }
      }
     },
     "localname": "InventoriesLineItem",
     "nsuri": "http://www.curevac.com/20220930",
     "presentation": [
      "http://www.curevac.com/role/DisclosureInventoriesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cvac_InventoriesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "N/A",
        "label": "Inventories [Table]"
       }
      }
     },
     "localname": "InventoriesTable",
     "nsuri": "http://www.curevac.com/20220930",
     "presentation": [
      "http://www.curevac.com/role/DisclosureInventoriesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cvac_KeyEmployeesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for key employees.",
        "label": "Key employees"
       }
      }
     },
     "localname": "KeyEmployeesMember",
     "nsuri": "http://www.curevac.com/20220930",
     "presentation": [
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvac_LiabilitiesRecognisedAsOfAcquisitionDate": {
     "auth_ref": [],
     "calculation": {
      "http://www.curevac.com/role/DisclosureSignificantTransactionsAndEventsFrameAcquisitionPurchasePriceAllocationDetails": {
       "order": 2.0,
       "parentTag": "ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount recognised as of the acquisition date for total liabilities assumed in a business combination.",
        "label": "Liabilities Recognised As Of Acquisition Date",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "LiabilitiesRecognisedAsOfAcquisitionDate",
     "nsuri": "http://www.curevac.com/20220930",
     "presentation": [
      "http://www.curevac.com/role/DisclosureSignificantTransactionsAndEventsFrameAcquisitionPurchasePriceAllocationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvac_LicensesSoftwareAndPrepaymentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "licenses, software and prepayments",
        "label": "licenses, software and prepayments"
       }
      }
     },
     "localname": "LicensesSoftwareAndPrepaymentsMember",
     "nsuri": "http://www.curevac.com/20220930",
     "presentation": [
      "http://www.curevac.com/role/DisclosureFixedAssetsIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvac_LineOfCreditAccruedInterestPayable": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lin of credit accrued interest payable.",
        "label": "Line of Credit Accrued Interest Payable",
        "terseLabel": "Accrued interest"
       }
      }
     },
     "localname": "LineOfCreditAccruedInterestPayable",
     "nsuri": "http://www.curevac.com/20220930",
     "presentation": [
      "http://www.curevac.com/role/DisclosureLoansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvac_LockUpPeriodAfterInitialListing": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the lock-up period, which is days after the initial listing.",
        "label": "lock Up Period, After Initial Listing",
        "terseLabel": "Lock-up period"
       }
      }
     },
     "localname": "LockUpPeriodAfterInitialListing",
     "nsuri": "http://www.curevac.com/20220930",
     "presentation": [
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "cvac_LongTermIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for Long-Term Incentive Plan.",
        "label": "LTIP"
       }
      }
     },
     "localname": "LongTermIncentivePlanMember",
     "nsuri": "http://www.curevac.com/20220930",
     "presentation": [
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsDetails",
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsExpenseRecognizedForProgramDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvac_MaintenanceAndLeaseExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsCostOfSalesDetails": {
       "order": 4.0,
       "parentTag": "ifrs-full_ExpenseByNature",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of maintenance and lease expenses incurred by the company during the period.",
        "label": "Maintenance And Lease Expenses",
        "negatedLabel": "Maintenance and lease"
       }
      }
     },
     "localname": "MaintenanceAndLeaseExpenses",
     "nsuri": "http://www.curevac.com/20220930",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsCostOfSalesDetails",
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsGeneralAndAdministrativeExpensesDetails",
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsResearchAndDevelopmentExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvac_ManagementBoardMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Member stands for management board of the entity's key management personnel.",
        "label": "Management Board"
       }
      }
     },
     "localname": "ManagementBoardMember",
     "nsuri": "http://www.curevac.com/20220930",
     "presentation": [
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvac_MaximumGrantToBeReceived": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of maximum grant receivable.",
        "label": "Maximum Grant To Be Received",
        "terseLabel": "Maximum grant"
       }
      }
     },
     "localname": "MaximumGrantToBeReceived",
     "nsuri": "http://www.curevac.com/20220930",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsGrantsWithGovernmentAgenciesAndSimilarBodiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvac_MembersOfExecutiveBoardAndVariousKeyEmployeesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for person or persons designated as part of Executive board and various key employees.",
        "label": "Members of executive board and various key employees"
       }
      }
     },
     "localname": "MembersOfExecutiveBoardAndVariousKeyEmployeesMember",
     "nsuri": "http://www.curevac.com/20220930",
     "presentation": [
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvac_MilestoneRevenuesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for milestone revenues.",
        "label": "Milestone revenues"
       }
      }
     },
     "localname": "MilestoneRevenuesMember",
     "nsuri": "http://www.curevac.com/20220930",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsRevenueFromContractWithCustomersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvac_MiscellaneousOtherOperatingIncomeOther": {
     "auth_ref": [],
     "calculation": {
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsOtherOperatingIncomeDetails": {
       "order": 6.0,
       "parentTag": "ifrs-full_MiscellaneousOtherOperatingIncome",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of miscellaneous other operating income, classified as other.",
        "label": "Miscellaneous Other Operating Income, Other",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "MiscellaneousOtherOperatingIncomeOther",
     "nsuri": "http://www.curevac.com/20220930",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsOtherOperatingIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvac_NetDeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate": {
     "auth_ref": [],
     "calculation": {
      "http://www.curevac.com/role/DisclosureSignificantTransactionsAndEventsFrameAcquisitionPurchasePriceAllocationDetails": {
       "order": 2.0,
       "parentTag": "ifrs-full_NoncurrentLiabilitiesRecognisedAsOfAcquisitionDate",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount recognised as of the acquisition date for deferred tax liabilities net of deferred tax assets assumed in a business combination.",
        "label": "Net Deferred Tax Liabilities Recognised As Of Acquisition Date",
        "terseLabel": "Deferred tax liabilities (net of deferred tax assets)"
       }
      }
     },
     "localname": "NetDeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate",
     "nsuri": "http://www.curevac.com/20220930",
     "presentation": [
      "http://www.curevac.com/role/DisclosureSignificantTransactionsAndEventsFrameAcquisitionPurchasePriceAllocationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvac_NetLoss": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income.",
        "label": "Net Loss",
        "terseLabel": "Net loss"
       }
      }
     },
     "localname": "NetLoss",
     "nsuri": "http://www.curevac.com/20220930",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfChangesInShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvac_NetValueOfInventoryTransferred": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net value of inventory transferred during the period.",
        "label": "Net Value Of Inventory Transferred",
        "terseLabel": "Net inventory transferred"
       }
      }
     },
     "localname": "NetValueOfInventoryTransferred",
     "nsuri": "http://www.curevac.com/20220930",
     "presentation": [
      "http://www.curevac.com/role/DisclosureInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvac_NoncurrentLeaseLiabilitiesRecognisedAsOfAcquisitionDate": {
     "auth_ref": [],
     "calculation": {
      "http://www.curevac.com/role/DisclosureSignificantTransactionsAndEventsFrameAcquisitionPurchasePriceAllocationDetails": {
       "order": 1.0,
       "parentTag": "ifrs-full_NoncurrentLiabilitiesRecognisedAsOfAcquisitionDate",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount recognised as of the acquisition date for non-current lease liabilities assumed in a business combination.",
        "label": "Noncurrent Lease Liabilities Recognised As Of Acquisition Date",
        "terseLabel": "Lease liabilities"
       }
      }
     },
     "localname": "NoncurrentLeaseLiabilitiesRecognisedAsOfAcquisitionDate",
     "nsuri": "http://www.curevac.com/20220930",
     "presentation": [
      "http://www.curevac.com/role/DisclosureSignificantTransactionsAndEventsFrameAcquisitionPurchasePriceAllocationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvac_NumberOfAdditionalGrantsReceived": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of additional grants received by the company.",
        "label": "Number Of Additional Grants Received",
        "terseLabel": "Number of additional grants received"
       }
      }
     },
     "localname": "NumberOfAdditionalGrantsReceived",
     "nsuri": "http://www.curevac.com/20220930",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsGrantsWithGovernmentAgenciesAndSimilarBodiesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "cvac_NumberOfDosesOfSarsCov2CanBePurchasedByMemberStatesUnderAdvancePurchaseAgreement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of doses of SARS-CoV-2 advance purchase by the Member States under agreement.",
        "label": "Number of Doses of SARS-CoV-2 Can be Purchased By Member States under Advance purchase Agreement",
        "terseLabel": "Number of doses of SARS-CoV-2 advance purchase by the Member States under agreement"
       }
      }
     },
     "localname": "NumberOfDosesOfSarsCov2CanBePurchasedByMemberStatesUnderAdvancePurchaseAgreement",
     "nsuri": "http://www.curevac.com/20220930",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsGrantsWithGovernmentAgenciesAndSimilarBodiesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "cvac_NumberOfInstrumentsOrInterestIssuedOrIssuable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of instruments or interests issued or issuable at acquisition date for equity interests of the acquirer transferred as consideration to former shareholders in a business combination.",
        "label": "Number Of Instruments Or Interest Issued Or Issuable",
        "terseLabel": "Shares transferred"
       }
      }
     },
     "localname": "NumberOfInstrumentsOrInterestIssuedOrIssuable",
     "nsuri": "http://www.curevac.com/20220930",
     "presentation": [
      "http://www.curevac.com/role/DisclosureSignificantTransactionsAndEventsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "cvac_NumberOfInstrumentsOrInterestsIssuedOrIssuableAsConsiderationForDischargingContractualObligations": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of instruments or interests issued or issuable at acquisition date for equity interests of the acquirer transferred as consideration for discharging the contractual obligations for the outstanding advisory agreements in a business combination.",
        "label": "Number Of Instruments Or Interests Issued Or Issuable, As Consideration For Discharging Contractual Obligations",
        "terseLabel": "Issuance and transfer of shares as consideration for discharging the contractual obligations for the outstanding advisory agreements"
       }
      }
     },
     "localname": "NumberOfInstrumentsOrInterestsIssuedOrIssuableAsConsiderationForDischargingContractualObligations",
     "nsuri": "http://www.curevac.com/20220930",
     "presentation": [
      "http://www.curevac.com/role/DisclosureSignificantTransactionsAndEventsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "cvac_NumberOfInstrumentsOrInterestsIssuedOrIssuableAsConsiderationToFormerShareholders": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of instruments or interests issued or issuable at acquisition date for equity interests of the acquirer transferred as consideration to former shareholders in a business combination.",
        "label": "Number Of Instruments Or Interests Issued Or Issuable, As Consideration To Former Shareholders",
        "terseLabel": "Issuance and transfer of shares to former Frame shareholders"
       }
      }
     },
     "localname": "NumberOfInstrumentsOrInterestsIssuedOrIssuableAsConsiderationToFormerShareholders",
     "nsuri": "http://www.curevac.com/20220930",
     "presentation": [
      "http://www.curevac.com/role/DisclosureSignificantTransactionsAndEventsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "cvac_NumberOfInstrumentsOrInterestsIssuedOrIssuableUponAchievementOfFirstMilestone": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of instruments or interests issued or issuable at acquisition date for equity interests of the acquirer transferred as consideration upon the achievement of first milestone in a business combination.",
        "label": "Number Of Instruments Or Interests Issued Or Issuable, Upon Achievement Of First Milestone",
        "terseLabel": "Number of shares issued upon the achievement of the successful investigational new drug application filing"
       }
      }
     },
     "localname": "NumberOfInstrumentsOrInterestsIssuedOrIssuableUponAchievementOfFirstMilestone",
     "nsuri": "http://www.curevac.com/20220930",
     "presentation": [
      "http://www.curevac.com/role/DisclosureSignificantTransactionsAndEventsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "cvac_NumberOfInstrumentsOrInterestsIssuedOrIssuableUponAchievementOfSecondMilestone": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of instruments or interests issued or issuable at acquisition date for equity interests of the acquirer transferred as consideration upon the achievement of second milestone in a business combination.",
        "label": "Number Of Instruments Or Interests Issued Or Issuable, Upon Achievement Of Second Milestone",
        "terseLabel": "Number of shares issued upon successful proof of mechanism in humans"
       }
      }
     },
     "localname": "NumberOfInstrumentsOrInterestsIssuedOrIssuableUponAchievementOfSecondMilestone",
     "nsuri": "http://www.curevac.com/20220930",
     "presentation": [
      "http://www.curevac.com/role/DisclosureSignificantTransactionsAndEventsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "cvac_NumberOfKeyEmployees": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the number of key employees.",
        "label": "Number of Key Employees",
        "terseLabel": "Number of key employees"
       }
      }
     },
     "localname": "NumberOfKeyEmployees",
     "nsuri": "http://www.curevac.com/20220930",
     "presentation": [
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "cvac_NumberOfOtherEquityInstrumentsSettledInShareBasedPaymentArrangement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of other equity instruments settled in a share-based payment arrangement.",
        "label": "Number Of Other Equity Instruments Settled In Share-Based Payment Arrangement",
        "terseLabel": "Number of RSUs settled"
       }
      }
     },
     "localname": "NumberOfOtherEquityInstrumentsSettledInShareBasedPaymentArrangement",
     "nsuri": "http://www.curevac.com/20220930",
     "presentation": [
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "cvac_NumberOfPaymentsInWhichTotalConsiderationIsToBePaid": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of payments in which the total consideration is to be paid under the business combination.",
        "label": "Number Of Payments In Which The Total Consideration Is To Be Paid",
        "terseLabel": "Number of payments in which the total consideration is to be paid"
       }
      }
     },
     "localname": "NumberOfPaymentsInWhichTotalConsiderationIsToBePaid",
     "nsuri": "http://www.curevac.com/20220930",
     "presentation": [
      "http://www.curevac.com/role/DisclosureSignificantTransactionsAndEventsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "cvac_NumberOfShareOptionsVestedInShareBasedPaymentArrangement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of share options vested in a share-based payment arrangement.",
        "label": "Number Of Share Options Vested In Share-Based Payment Arrangement",
        "verboseLabel": "Number of options vested"
       }
      }
     },
     "localname": "NumberOfShareOptionsVestedInShareBasedPaymentArrangement",
     "nsuri": "http://www.curevac.com/20220930",
     "presentation": [
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "cvac_NumberOfTranchesForVestingOfInstrumentsGrantedInShareBasedPaymentArrangement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of tranches for vesting of instruments granted in a share-based payment arrangement.",
        "label": "Number Of Tranches For Vesting Of Instruments Granted In Share-Based Payment Arrangement",
        "terseLabel": "Number of tranches for vesting of RSUs granted"
       }
      }
     },
     "localname": "NumberOfTranchesForVestingOfInstrumentsGrantedInShareBasedPaymentArrangement",
     "nsuri": "http://www.curevac.com/20220930",
     "presentation": [
      "http://www.curevac.com/role/DisclosureSignificantTransactionsAndEventsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "cvac_OptionsGrantedToThenChiefExecutiveOfficerMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for options granted to Dan Menichella, the then Chief Executive Officer (CEO).",
        "label": "Former Chief Executive Officer Grant"
       }
      }
     },
     "localname": "OptionsGrantedToThenChiefExecutiveOfficerMember",
     "nsuri": "http://www.curevac.com/20220930",
     "presentation": [
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsDetails",
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsExpenseRecognizedForProgramDetails",
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsTables"
     ],
     "xbrltype": "domainItemType"
    },
    "cvac_OtherCurrentLiabilitiesRecognisedAsOfAcquisitionDate": {
     "auth_ref": [],
     "calculation": {
      "http://www.curevac.com/role/DisclosureSignificantTransactionsAndEventsFrameAcquisitionPurchasePriceAllocationDetails": {
       "order": 3.0,
       "parentTag": "ifrs-full_CurrentLiabilitiesRecognisedAsOfAcquisitionDate",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount recognised as of the acquisition date for other liabilities assumed in a business combination.",
        "label": "Other Current Liabilities Recognised As Of Acquisition Date",
        "terseLabel": "Other current liabilities"
       }
      }
     },
     "localname": "OtherCurrentLiabilitiesRecognisedAsOfAcquisitionDate",
     "nsuri": "http://www.curevac.com/20220930",
     "presentation": [
      "http://www.curevac.com/role/DisclosureSignificantTransactionsAndEventsFrameAcquisitionPurchasePriceAllocationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvac_OtherCustomersMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for Other customers.",
        "label": "Others"
       }
      }
     },
     "localname": "OtherCustomersMember",
     "nsuri": "http://www.curevac.com/20220930",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsRevenueFromContractWithCustomersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvac_OtherExpense": {
     "auth_ref": [],
     "calculation": {
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsCostOfSalesDetails": {
       "order": 8.0,
       "parentTag": "ifrs-full_ExpenseByNature",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of other expense.",
        "label": "Other Expense",
        "negatedLabel": "Other"
       }
      }
     },
     "localname": "OtherExpense",
     "nsuri": "http://www.curevac.com/20220930",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsCostOfSalesDetails",
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsGeneralAndAdministrativeExpensesDetails",
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsResearchAndDevelopmentExpensesDetails",
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsSellingAndDistributionExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvac_OtherOperatingIncomeGovernmentGrants": {
     "auth_ref": [],
     "calculation": {
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsOtherOperatingIncomeDetails": {
       "order": 5.0,
       "parentTag": "ifrs-full_MiscellaneousOtherOperatingIncome",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of other operating income recognized in relation to government agencies and similar bodies.",
        "label": "Other Operating Income, Government Grants",
        "verboseLabel": "Grants and other cost reimbursements from government agencies and similar bodies"
       }
      }
     },
     "localname": "OtherOperatingIncomeGovernmentGrants",
     "nsuri": "http://www.curevac.com/20220930",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsOtherOperatingIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvac_PartnershipAgreementMaximumAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum amount agreed under the partnership agreement.",
        "label": "Partnership Agreement, Maximum Amount",
        "terseLabel": "Maximum amount under the partnership agreement"
       }
      }
     },
     "localname": "PartnershipAgreementMaximumAmount",
     "nsuri": "http://www.curevac.com/20220930",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsGrantsWithGovernmentAgenciesAndSimilarBodiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvac_PartnershipAgreementPeriodOfCostsToBeCovered": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period for which the costs are to be covered by the funds received under the partnership agreement.",
        "label": "Partnership Agreement, Period Of Costs To Be Covered",
        "terseLabel": "Period for which the costs are to be covered"
       }
      }
     },
     "localname": "PartnershipAgreementPeriodOfCostsToBeCovered",
     "nsuri": "http://www.curevac.com/20220930",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsGrantsWithGovernmentAgenciesAndSimilarBodiesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "cvac_PartnershipAgreementTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of the partnership agreement.",
        "label": "Partnership Agreement, Term",
        "terseLabel": "Term of the partnership agreement"
       }
      }
     },
     "localname": "PartnershipAgreementTerm",
     "nsuri": "http://www.curevac.com/20220930",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsGrantsWithGovernmentAgenciesAndSimilarBodiesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "cvac_PatentsAndFeesToRegisterLegalRight": {
     "auth_ref": [],
     "calculation": {
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsCostOfSalesDetails": {
       "order": 7.0,
       "parentTag": "ifrs-full_ExpenseByNature",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred by the company for registering a legal right.",
        "label": "Patents And Fees To Register Legal Right",
        "negatedLabel": "Patents and fees to register a legal right"
       }
      }
     },
     "localname": "PatentsAndFeesToRegisterLegalRight",
     "nsuri": "http://www.curevac.com/20220930",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsResearchAndDevelopmentExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvac_PaymentsToRelatedPartyForServices": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments made to related party by the company for services.",
        "label": "Payments To Related Party For Services",
        "terseLabel": "Payments to related party for services"
       }
      }
     },
     "localname": "PaymentsToRelatedPartyForServices",
     "nsuri": "http://www.curevac.com/20220930",
     "presentation": [
      "http://www.curevac.com/role/DisclosureRelatedPartyDisclosuresDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvac_PercentageOfConsiderationTransferredUponAchievementOfFirstMilestone": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of total consideration transferred under the business combination, upon the achievement of first milestone.",
        "label": "Percentage Of Consideration Transferred Upon Achievement Of First Milestone",
        "terseLabel": "Percentage of consideration transferred upon the achievement of the successful investigational new drug application filing"
       }
      }
     },
     "localname": "PercentageOfConsiderationTransferredUponAchievementOfFirstMilestone",
     "nsuri": "http://www.curevac.com/20220930",
     "presentation": [
      "http://www.curevac.com/role/DisclosureSignificantTransactionsAndEventsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "cvac_PercentageOfConsiderationTransferredUponAchievementOfSecondMilestone": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of total consideration transferred under the business combination, upon the achievement of second milestone.",
        "label": "Percentage Of Consideration Transferred Upon Achievement Of Second Milestone",
        "terseLabel": "Percentage of consideration transferred upon successful proof of mechanism in humans"
       }
      }
     },
     "localname": "PercentageOfConsiderationTransferredUponAchievementOfSecondMilestone",
     "nsuri": "http://www.curevac.com/20220930",
     "presentation": [
      "http://www.curevac.com/role/DisclosureSignificantTransactionsAndEventsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "cvac_PersonnelExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsCostOfSalesDetails": {
       "order": 1.0,
       "parentTag": "ifrs-full_ExpenseByNature",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of personnel expenses incurred by the company during the period.",
        "label": "Personnel Expenses",
        "negatedLabel": "Personnel"
       }
      }
     },
     "localname": "PersonnelExpenses",
     "nsuri": "http://www.curevac.com/20220930",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsCostOfSalesDetails",
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsGeneralAndAdministrativeExpensesDetails",
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsResearchAndDevelopmentExpensesDetails",
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsSellingAndDistributionExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvac_PrepaidCompensationForContractManufacturingOrganizationsTransfer": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the amount of prepaid compensation for contract manufacturing organizations transfer.",
        "label": "Prepaid Compensation for Contract Manufacturing organizations Transfer",
        "terseLabel": "Prepayments for compensation"
       }
      }
     },
     "localname": "PrepaidCompensationForContractManufacturingOrganizationsTransfer",
     "nsuri": "http://www.curevac.com/20220930",
     "presentation": [
      "http://www.curevac.com/role/DisclosurePrepaidExpensesAndOtherAssetsCurrentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvac_PrivatePlacementIsa2020Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for private Placement \"ISA 2020\".",
        "label": "2020 Private Investment"
       }
      }
     },
     "localname": "PrivatePlacementIsa2020Member",
     "nsuri": "http://www.curevac.com/20220930",
     "presentation": [
      "http://www.curevac.com/role/DisclosureIssuedCapitalAndReservesImpactOfShareSplitDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvac_ProceedFromIssuingOtherEquityInstrument": {
     "auth_ref": [],
     "calculation": {
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows": {
       "order": 11.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of Proceed From Issuing Other Equity Instrument",
        "label": "Proceed From Issuing Other Equity Instrument",
        "terseLabel": "Payment on / Proceeds from Treasury Shares"
       }
      }
     },
     "localname": "ProceedFromIssuingOtherEquityInstrument",
     "nsuri": "http://www.curevac.com/20220930",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvac_ProceedsFromRepaymentsOfBorrowingsClassifiedAsFinancingActivities": {
     "auth_ref": [],
     "calculation": {
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from borrowings obtained. [Refer: Borrowings]",
        "label": "Proceeds from (Repayments of) borrowings, classified as financing activities",
        "terseLabel": "Proceeds from (repayment of) the EIB loan"
       }
      }
     },
     "localname": "ProceedsFromRepaymentsOfBorrowingsClassifiedAsFinancingActivities",
     "nsuri": "http://www.curevac.com/20220930",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvac_ProceedsOnExerciseOfOptions": {
     "auth_ref": [],
     "calculation": {
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows": {
       "order": 8.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds on exercise of options.",
        "label": "Proceeds On Exercise Of Options",
        "negatedLabel": "Proceeds on exercise of options"
       }
      }
     },
     "localname": "ProceedsOnExerciseOfOptions",
     "nsuri": "http://www.curevac.com/20220930",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvac_ProceedsOrPaymentsFromExerciseOfOptions": {
     "auth_ref": [],
     "calculation": {
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows": {
       "order": 7.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow or outflow from the exercise of options.",
        "label": "Proceeds Or Payments From Exercise Of Options",
        "negatedLabel": "Payments from the exercise of options"
       }
      }
     },
     "localname": "ProceedsOrPaymentsFromExerciseOfOptions",
     "nsuri": "http://www.curevac.com/20220930",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvac_ProvisionForEmployerTaxes": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of provision for employer taxes arising according to US regulations for future exercises.",
        "label": "Provision for Employer Taxes",
        "verboseLabel": "Provision for employer taxes"
       }
      }
     },
     "localname": "ProvisionForEmployerTaxes",
     "nsuri": "http://www.curevac.com/20220930",
     "presentation": [
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvac_ProvisionalFairValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of provisional fair value.",
        "label": "Provisional Fair Value",
        "terseLabel": "Provisional fair value"
       }
      }
     },
     "localname": "ProvisionalFairValue",
     "nsuri": "http://www.curevac.com/20220930",
     "presentation": [
      "http://www.curevac.com/role/DisclosureSignificantTransactionsAndEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvac_RealEstateTransferTaxes": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of real estate transfer taxes.",
        "label": "Real Estate Transfer Taxes",
        "terseLabel": "Real estate transfer taxes"
       }
      }
     },
     "localname": "RealEstateTransferTaxes",
     "nsuri": "http://www.curevac.com/20220930",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsGeneralAndAdministrativeExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvac_ReceiptsFromGovernmentGrantsClassifiedAsOperatingActivities": {
     "auth_ref": [],
     "calculation": {
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows": {
       "order": 15.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from government grants and similar bodies.",
        "label": "Receipts from Government Grants Classified as Operating Activities",
        "terseLabel": "Receipts from grants from government agencies and similar bodies",
        "verboseLabel": "Grant amount received/eligible to receive"
       }
      }
     },
     "localname": "ReceiptsFromGovernmentGrantsClassifiedAsOperatingActivities",
     "nsuri": "http://www.curevac.com/20220930",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsGrantsWithGovernmentAgenciesAndSimilarBodiesDetails",
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvac_RelatedPartyTransactionAdvisoryFees": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of advisory fees incurred as a part of related party transaction.",
        "label": "Related Party Transaction, Advisory Fees",
        "terseLabel": "Advisory fees"
       }
      }
     },
     "localname": "RelatedPartyTransactionAdvisoryFees",
     "nsuri": "http://www.curevac.com/20220930",
     "presentation": [
      "http://www.curevac.com/role/DisclosureRelatedPartyDisclosuresDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvac_RelatedPartyTransactionConsultingFees": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of consulting fees incurred as a part of related party transaction.",
        "label": "Related Party Transaction, Consulting Fees",
        "terseLabel": "consulting fees"
       }
      }
     },
     "localname": "RelatedPartyTransactionConsultingFees",
     "nsuri": "http://www.curevac.com/20220930",
     "presentation": [
      "http://www.curevac.com/role/DisclosureRelatedPartyDisclosuresDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvac_RelatedPartyTransactionNoticePeriodForTerminationOfAgreement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period of notice for termination of the agreement at the option of the party.",
        "label": "Related Party Transaction, Notice Period for Termination of Agreement",
        "terseLabel": "Notice period for termination at the option"
       }
      }
     },
     "localname": "RelatedPartyTransactionNoticePeriodForTerminationOfAgreement",
     "nsuri": "http://www.curevac.com/20220930",
     "presentation": [
      "http://www.curevac.com/role/DisclosureRelatedPartyDisclosuresDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "cvac_RelatedPartyTransactionNumberOfLoansReceived": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of loans received from a related party.",
        "label": "Related Party Transaction, Number of Loans Received",
        "terseLabel": "Number of convertible loans"
       }
      }
     },
     "localname": "RelatedPartyTransactionNumberOfLoansReceived",
     "nsuri": "http://www.curevac.com/20220930",
     "presentation": [
      "http://www.curevac.com/role/DisclosureRelatedPartyDisclosuresDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "cvac_RemainingAuthorizedForSaleValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of remaining authorized for sale value.",
        "label": "Remaining Authorized For Sale Value",
        "terseLabel": "Remaining authorized for sale value"
       }
      }
     },
     "localname": "RemainingAuthorizedForSaleValue",
     "nsuri": "http://www.curevac.com/20220930",
     "presentation": [
      "http://www.curevac.com/role/DisclosureIssuedCapitalAndReservesOverviewAndGeneralRemarksDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvac_RepaymentsOfPrincipalAmountOfBorrowings": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow to settle principal amount of borrowings, classified as financing activities.",
        "label": "Repayments of Principal Amount of Borrowings",
        "verboseLabel": "Repayment of principal amount of loan"
       }
      }
     },
     "localname": "RepaymentsOfPrincipalAmountOfBorrowings",
     "nsuri": "http://www.curevac.com/20220930",
     "presentation": [
      "http://www.curevac.com/role/DisclosureLoansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvac_ResearchAndDevelopmentServicesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for research and development services.",
        "label": "Research and development services"
       }
      }
     },
     "localname": "ResearchAndDevelopmentServicesMember",
     "nsuri": "http://www.curevac.com/20220930",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsRevenueFromContractWithCustomersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvac_ResearchServicesCombinedWithIpLicenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for research services combined with an IP license.",
        "label": "Research services combined with an IP license"
       }
      }
     },
     "localname": "ResearchServicesCombinedWithIpLicenseMember",
     "nsuri": "http://www.curevac.com/20220930",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsRevenueFromContractWithCustomersDetails",
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsSummaryOfUpfrontPaymentsAndRelatedRevenuesRecognizedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvac_RestrictedStockUnitForKeyEmployeesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for RSU for key employees.",
        "label": "RSU for key employees"
       }
      }
     },
     "localname": "RestrictedStockUnitForKeyEmployeesMember",
     "nsuri": "http://www.curevac.com/20220930",
     "presentation": [
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsExpenseRecognizedForProgramDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvac_RestrictedStockUnitsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for Restricted stock Units",
        "label": "Restricted Stock Units"
       }
      }
     },
     "localname": "RestrictedStockUnitsMember",
     "nsuri": "http://www.curevac.com/20220930",
     "presentation": [
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsTables"
     ],
     "xbrltype": "domainItemType"
    },
    "cvac_ReversalOfProvisionForOnerousContracts": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the amount of reversal of provision for onerous contracts which will decrease in research and development expenses.",
        "label": "Reversal of Provision for Onerous Contracts",
        "terseLabel": "Reversal of provision of onerous contracts"
       }
      }
     },
     "localname": "ReversalOfProvisionForOnerousContracts",
     "nsuri": "http://www.curevac.com/20220930",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsResearchAndDevelopmentExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvac_ReversalOfProvisionRecognizedDueToCertainReservedCapacityTakenOver": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the amount of provisions reversed due to certain reserved capacity taken over from the group.",
        "label": "Reversal Of Provision Recognized Due to Certain Reserved Capacity Taken Over",
        "terseLabel": "Reversal of provision recognized"
       }
      }
     },
     "localname": "ReversalOfProvisionRecognizedDueToCertainReservedCapacityTakenOver",
     "nsuri": "http://www.curevac.com/20220930",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsGrantsWithGovernmentAgenciesAndSimilarBodiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvac_ReversalOfProvisionsForPersonnelExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsOtherOperatingIncomeDetails": {
       "order": 4.0,
       "parentTag": "ifrs-full_MiscellaneousOtherOperatingIncome",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of personnel expenses reversed during the period.",
        "label": "Reversal Of Provisions For Personnel Expenses",
        "verboseLabel": "Income from reversal of provisions"
       }
      }
     },
     "localname": "ReversalOfProvisionsForPersonnelExpenses",
     "nsuri": "http://www.curevac.com/20220930",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsOtherOperatingIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvac_RightOfUseAssetsRecognisedAsOfAcquisitionDate": {
     "auth_ref": [],
     "calculation": {
      "http://www.curevac.com/role/DisclosureSignificantTransactionsAndEventsFrameAcquisitionPurchasePriceAllocationDetails": {
       "order": 2.0,
       "parentTag": "ifrs-full_NoncurrentAssetsRecognisedAsOfAcquisitionDate",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount recognised as of the acquisition date for right-of-use assets assumed in a business combination.",
        "label": "Right Of Use Assets Recognised As Of Acquisition Date",
        "terseLabel": "Right-of-use assets"
       }
      }
     },
     "localname": "RightOfUseAssetsRecognisedAsOfAcquisitionDate",
     "nsuri": "http://www.curevac.com/20220930",
     "presentation": [
      "http://www.curevac.com/role/DisclosureSignificantTransactionsAndEventsFrameAcquisitionPurchasePriceAllocationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvac_RightToExercisePercentageOfVestedVirtualShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the right to exercise percentage of vested virtual shares.",
        "label": "Right To Exercise Percentage Of Vested Virtual Shares",
        "terseLabel": "Right to exercise percentage of vested virtual shares"
       }
      }
     },
     "localname": "RightToExercisePercentageOfVestedVirtualShares",
     "nsuri": "http://www.curevac.com/20220930",
     "presentation": [
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "cvac_RittershausRechtsanwaelteMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Member stands for Rittershaus Rechtsanwaelte , a related party.",
        "label": "Rittershaus Rechtsanwaelte",
        "terseLabel": "Rittershaus Rechtsanwaelte"
       }
      }
     },
     "localname": "RittershausRechtsanwaelteMember",
     "nsuri": "http://www.curevac.com/20220930",
     "presentation": [
      "http://www.curevac.com/role/DisclosureRelatedPartyDisclosuresDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvac_SaleOfEquipment": {
     "auth_ref": [],
     "calculation": {
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsOtherOperatingIncomeDetails": {
       "order": 1.0,
       "parentTag": "ifrs-full_MiscellaneousOtherOperatingIncome",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of sale of equipment in operating income.",
        "label": "Sale of equipment",
        "terseLabel": "Sale of equipment"
       }
      }
     },
     "localname": "SaleOfEquipment",
     "nsuri": "http://www.curevac.com/20220930",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsOtherOperatingIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvac_ScheduleOfExpenseRecognizedForProgramsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The tabular disclosure of expense recognized for the programs.",
        "label": "Schedule of Expense Recognized for the Programs [Table Text Block]",
        "terseLabel": "Schedule for expense recognized for the programs"
       }
      }
     },
     "localname": "ScheduleOfExpenseRecognizedForProgramsTableTextBlock",
     "nsuri": "http://www.curevac.com/20220930",
     "presentation": [
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cvac_SellingAndDistributionExpensesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for selling and distribution expenses.",
        "label": "Selling and distribution expenses"
       }
      }
     },
     "localname": "SellingAndDistributionExpensesMember",
     "nsuri": "http://www.curevac.com/20220930",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsSellingAndDistributionExpensesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvac_SeriesCSharesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for Series C shares.",
        "label": "Series C"
       }
      }
     },
     "localname": "SeriesCSharesMember",
     "nsuri": "http://www.curevac.com/20220930",
     "presentation": [
      "http://www.curevac.com/role/DisclosureIssuedCapitalAndReservesImpactOfShareSplitDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvac_SeriesSharesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for Series A shares.",
        "label": "Series A"
       }
      }
     },
     "localname": "SeriesSharesMember",
     "nsuri": "http://www.curevac.com/20220930",
     "presentation": [
      "http://www.curevac.com/role/DisclosureIssuedCapitalAndReservesImpactOfShareSplitDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvac_SettlementOfShareBasedPaymentAwardsAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of share based payment awards settled in cash.",
        "label": "Settlement Of Share Based Payment Awards , Amount",
        "terseLabel": "Settlement of share-based payment awards"
       }
      }
     },
     "localname": "SettlementOfShareBasedPaymentAwardsAmount",
     "nsuri": "http://www.curevac.com/20220930",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfChangesInShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvac_ShareBasedPaymentExpenseIncl.DeferredTaxes": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of Share-based payment expense (incl. deferred taxes)",
        "label": "Share-based payment expense (incl. deferred taxes)",
        "terseLabel": "Share-based payments (net of taxes)"
       }
      }
     },
     "localname": "ShareBasedPaymentExpenseIncl.DeferredTaxes",
     "nsuri": "http://www.curevac.com/20220930",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfChangesInShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvac_ShareOptionExercises": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of share option exercises.",
        "label": "Share Option Exercises",
        "terseLabel": "Share option exercises"
       }
      }
     },
     "localname": "ShareOptionExercises",
     "nsuri": "http://www.curevac.com/20220930",
     "presentation": [
      "http://www.curevac.com/role/DisclosureIssuedCapitalAndReservesImpactOfShareSplitDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "cvac_SigningSharePriceRepresenting10": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount represents of signing share price representing 10%.",
        "label": "Signing Share Price Representing 10%",
        "terseLabel": "Signing share price representing 10%"
       }
      }
     },
     "localname": "SigningSharePriceRepresenting10",
     "nsuri": "http://www.curevac.com/20220930",
     "presentation": [
      "http://www.curevac.com/role/DisclosureSignificantTransactionsAndEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvac_SigningSharePriceRepresenting40": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount represents of signing share price representing 40%.",
        "label": "Signing Share Price Representing 40%",
        "terseLabel": "Signing share price representing 40%"
       }
      }
     },
     "localname": "SigningSharePriceRepresenting40",
     "nsuri": "http://www.curevac.com/20220930",
     "presentation": [
      "http://www.curevac.com/role/DisclosureSignificantTransactionsAndEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvac_StockIssuanceDuringPeriodForExistingShareholders": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period for existing shareholders.",
        "label": "Stock Issuance During Period For Existing Shareholders",
        "terseLabel": "Share issuances to former shareholders of Frame Pharmaceuticals"
       }
      }
     },
     "localname": "StockIssuanceDuringPeriodForExistingShareholders",
     "nsuri": "http://www.curevac.com/20220930",
     "presentation": [
      "http://www.curevac.com/role/DisclosureIssuedCapitalAndReservesImpactOfShareSplitDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "cvac_StockIssuedDuringPeriodForExercises": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period, upon exercises.",
        "label": "Stock Issued During Period, For Exercises",
        "terseLabel": "Share issuances for exercises"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodForExercises",
     "nsuri": "http://www.curevac.com/20220930",
     "presentation": [
      "http://www.curevac.com/role/DisclosureIssuedCapitalAndReservesImpactOfShareSplitDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "cvac_StrikePriceForExistingShareBasedPayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Strike price for existing share-based payment considered for payment of consideration under the business combination.",
        "label": "Strike Price For Existing Share-Based Payment",
        "terseLabel": "Strike price for existing share-based payment"
       }
      }
     },
     "localname": "StrikePriceForExistingShareBasedPayment",
     "nsuri": "http://www.curevac.com/20220930",
     "presentation": [
      "http://www.curevac.com/role/DisclosureSignificantTransactionsAndEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvac_SupervisoryBoardMembersMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for supervisory board members.",
        "label": "Supervisory board members"
       }
      }
     },
     "localname": "SupervisoryBoardMembersMember",
     "nsuri": "http://www.curevac.com/20220930",
     "presentation": [
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvac_TechnicalEquipmentAndMachinesAndOtherEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for technical equipment and machines and other equipment.",
        "label": "Technical equipment and machines"
       }
      }
     },
     "localname": "TechnicalEquipmentAndMachinesAndOtherEquipmentMember",
     "nsuri": "http://www.curevac.com/20220930",
     "presentation": [
      "http://www.curevac.com/role/DisclosureFixedAssetsPropertyPlantAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvac_TerminationFeeRelatedPartyTransactions": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of termination fee in related party transactions.",
        "label": "Termination Fee, Related Party Transactions",
        "terseLabel": "Termination fee"
       }
      }
     },
     "localname": "TerminationFeeRelatedPartyTransactions",
     "nsuri": "http://www.curevac.com/20220930",
     "presentation": [
      "http://www.curevac.com/role/DisclosureRelatedPartyDisclosuresDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvac_ThenChiefExecutiveOfficerMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for Dan Menichella, then Chief Executive Officer.",
        "label": "Dan Menichella, then Chief Executive Officer"
       }
      }
     },
     "localname": "ThenChiefExecutiveOfficerMember",
     "nsuri": "http://www.curevac.com/20220930",
     "presentation": [
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvac_ThirdPartyServiceExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsCostOfSalesDetails": {
       "order": 3.0,
       "parentTag": "ifrs-full_ExpenseByNature",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred by the company for third party services during the period.",
        "label": "Third Party Service Expenses",
        "negatedLabel": "Third-party services"
       }
      }
     },
     "localname": "ThirdPartyServiceExpenses",
     "nsuri": "http://www.curevac.com/20220930",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsCostOfSalesDetails",
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsGeneralAndAdministrativeExpensesDetails",
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsResearchAndDevelopmentExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvac_TotalAssetsRecognisedAsOfAcquisitionDate": {
     "auth_ref": [],
     "calculation": {
      "http://www.curevac.com/role/DisclosureSignificantTransactionsAndEventsFrameAcquisitionPurchasePriceAllocationDetails": {
       "order": 1.0,
       "parentTag": "ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount recognised as of the acquisition date for total assets assumed in a business combination.",
        "label": "Total Assets Recognised As Of Acquisition Date",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "TotalAssetsRecognisedAsOfAcquisitionDate",
     "nsuri": "http://www.curevac.com/20220930",
     "presentation": [
      "http://www.curevac.com/role/DisclosureSignificantTransactionsAndEventsFrameAcquisitionPurchasePriceAllocationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvac_TypeOfArrangementAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Type Of Arrangement [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://www.curevac.com/20220930",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsGrantsWithGovernmentAgenciesAndSimilarBodiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cvac_UpfrontPaymentReceived": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of upfront payment received.",
        "label": "Upfront Payment Received"
       }
      }
     },
     "localname": "UpfrontPaymentReceived",
     "nsuri": "http://www.curevac.com/20220930",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsGrantsWithGovernmentAgenciesAndSimilarBodiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvac_UpfrontPaymentsIncludedInContractLiabilities": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of upfront payments of the company included in contract liabilities.",
        "label": "Upfront Payments Included In Contract Liabilities",
        "terseLabel": "Upfront and milestones payments included in contract liabilities"
       }
      }
     },
     "localname": "UpfrontPaymentsIncludedInContractLiabilities",
     "nsuri": "http://www.curevac.com/20220930",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsSummaryOfUpfrontPaymentsAndRelatedRevenuesRecognizedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvac_UpfrontPaymentsReceivedOrReceivable": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of upfront payments received or receivable by the company.",
        "label": "Upfront Payments Received Or Receivable",
        "terseLabel": "Upfront and milestone payments received or receivable"
       }
      }
     },
     "localname": "UpfrontPaymentsReceivedOrReceivable",
     "nsuri": "http://www.curevac.com/20220930",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsSummaryOfUpfrontPaymentsAndRelatedRevenuesRecognizedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvac_ValueOfInstrumentsOrInterestsIssuedOrIssuableAsConsiderationForDischargingContractualObligations": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of instruments or interests issued or issuable at acquisition date for equity interests of the acquirer transferred as consideration for discharging the contractual obligations for the outstanding advisory agreements in a business combination.",
        "label": "Value Of Instruments Or Interests Issued Or Issuable, As Consideration For Discharging Contractual Obligations",
        "terseLabel": "Value of shares issued as consideration for discharging the contractual obligations for the outstanding advisory agreements"
       }
      }
     },
     "localname": "ValueOfInstrumentsOrInterestsIssuedOrIssuableAsConsiderationForDischargingContractualObligations",
     "nsuri": "http://www.curevac.com/20220930",
     "presentation": [
      "http://www.curevac.com/role/DisclosureSignificantTransactionsAndEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvac_ValueOfInstrumentsOrInterestsIssuedOrIssuableAsConsiderationToFormerShareholders": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of instruments or interests issued or issuable at acquisition date for equity interests of the acquirer transferred as consideration to former shareholders in a business combination.",
        "label": "Value Of Instruments Or Interests Issued Or Issuable, As Consideration To Former Shareholders",
        "terseLabel": "Value of shares issued to former Frame shareholders"
       }
      }
     },
     "localname": "ValueOfInstrumentsOrInterestsIssuedOrIssuableAsConsiderationToFormerShareholders",
     "nsuri": "http://www.curevac.com/20220930",
     "presentation": [
      "http://www.curevac.com/role/DisclosureSignificantTransactionsAndEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvac_ValueOfInstrumentsOrInterestsIssuedOrIssuableUponAchievementOfFirstMilestone": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of instruments or interests issued or issuable at acquisition date for equity interests of the acquirer transferred as consideration upon the achievement of first milestone in a business combination.",
        "label": "Value Of Instruments Or Interests Issued Or Issuable, Upon Achievement Of First Milestone",
        "terseLabel": "Value of shares issued upon the achievement of the successful investigational new drug application filing"
       }
      }
     },
     "localname": "ValueOfInstrumentsOrInterestsIssuedOrIssuableUponAchievementOfFirstMilestone",
     "nsuri": "http://www.curevac.com/20220930",
     "presentation": [
      "http://www.curevac.com/role/DisclosureSignificantTransactionsAndEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvac_ValueOfInstrumentsOrInterestsIssuedOrIssuableUponAchievementOfSecondMilestone": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of instruments or interests issued or issuable at acquisition date for equity interests of the acquirer transferred as consideration upon the achievement of second milestone in a business combination.",
        "label": "Value Of Instruments Or Interests Issued Or Issuable, Upon Achievement Of Second Milestone",
        "terseLabel": "Value of shares issued upon successful proof of mechanism in humans"
       }
      }
     },
     "localname": "ValueOfInstrumentsOrInterestsIssuedOrIssuableUponAchievementOfSecondMilestone",
     "nsuri": "http://www.curevac.com/20220930",
     "presentation": [
      "http://www.curevac.com/role/DisclosureSignificantTransactionsAndEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvac_VincentStphenneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for Vincent Stphenne.",
        "label": "Vincent Stphenne",
        "terseLabel": "Vincent Stphenne"
       }
      }
     },
     "localname": "VincentStphenneMember",
     "nsuri": "http://www.curevac.com/20220930",
     "presentation": [
      "http://www.curevac.com/role/DisclosureRelatedPartyDisclosuresDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvac_VirtualSharesProgramIMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for Virtual shares program I.",
        "label": "Prior VSOP",
        "terseLabel": "Prior VSOP"
       }
      }
     },
     "localname": "VirtualSharesProgramIMember",
     "nsuri": "http://www.curevac.com/20220930",
     "presentation": [
      "http://www.curevac.com/role/DisclosureIssuedCapitalAndReservesOverviewAndGeneralRemarksDetails",
      "http://www.curevac.com/role/DisclosureRelatedPartyDisclosuresDetails",
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsDetails",
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsExpenseRecognizedForProgramDetails",
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsExpensesDetails",
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsTables"
     ],
     "xbrltype": "domainItemType"
    },
    "cvac_VirtualSharesProgramIiMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for Virtual shares program II (New VSOP).",
        "label": "New VSOP"
       }
      }
     },
     "localname": "VirtualSharesProgramIiMember",
     "nsuri": "http://www.curevac.com/20220930",
     "presentation": [
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsDetails",
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsExpenseRecognizedForProgramDetails",
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsTables"
     ],
     "xbrltype": "domainItemType"
    },
    "cvac_WriteOffOfRawMaterials": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of raw materials written off during the period.",
        "label": "Write Off Of Raw Materials",
        "terseLabel": "Write off of raw materials"
       }
      }
     },
     "localname": "WriteOffOfRawMaterials",
     "nsuri": "http://www.curevac.com/20220930",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsCostOfSalesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_AddressTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An entity may have several addresses for different purposes and this domain represents all such types.",
        "label": "Address Type [Domain]"
       }
      }
     },
     "localname": "AddressTypeDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.curevac.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of changes contained within amended document.",
        "label": "Amendment Description"
       }
      }
     },
     "localname": "AmendmentDescription",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.curevac.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.curevac.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditorFirmId": {
     "auth_ref": [
      "r242",
      "r243",
      "r244"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "PCAOB issued Audit Firm Identifier",
        "label": "Auditor Firm ID"
       }
      }
     },
     "localname": "AuditorFirmId",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.curevac.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "nonemptySequenceNumberItemType"
    },
    "dei_AuditorLocation": {
     "auth_ref": [
      "r242",
      "r243",
      "r244"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location"
       }
      }
     },
     "localname": "AuditorLocation",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.curevac.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_AuditorName": {
     "auth_ref": [
      "r242",
      "r243",
      "r244"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name"
       }
      }
     },
     "localname": "AuditorName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.curevac.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_BusinessContactMember": {
     "auth_ref": [
      "r243",
      "r244"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business contact for the entity",
        "label": "Business Contact"
       }
      }
     },
     "localname": "BusinessContactMember",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.curevac.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.curevac.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_ContactPersonnelEmailAddress": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Email address of contact personnel.",
        "label": "Contact Personnel Email Address"
       }
      }
     },
     "localname": "ContactPersonnelEmailAddress",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.curevac.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_ContactPersonnelName": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of contact personnel",
        "label": "Contact Personnel Name"
       }
      }
     },
     "localname": "ContactPersonnelName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.curevac.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CountryRegion": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Region code of country",
        "label": "Country Region"
       }
      }
     },
     "localname": "CountryRegion",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.curevac.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Document and Entity Information"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.curevac.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAccountingStandard": {
     "auth_ref": [
      "r243"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.",
        "label": "Document Accounting Standard"
       }
      }
     },
     "localname": "DocumentAccountingStandard",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.curevac.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "accountingStandardItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r242",
      "r243",
      "r244"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.curevac.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.curevac.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.curevac.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Document Information [Line Items]",
        "terseLabel": "Document and Entity Information"
       }
      }
     },
     "localname": "DocumentInformationLineItems",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.curevac.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_DocumentInformationTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package.",
        "label": "Document Information [Table]"
       }
      }
     },
     "localname": "DocumentInformationTable",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.curevac.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.curevac.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentRegistrationStatement": {
     "auth_ref": [
      "r238"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a registration statement.",
        "label": "Document Registration Statement"
       }
      }
     },
     "localname": "DocumentRegistrationStatement",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.curevac.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentShellCompanyReport": {
     "auth_ref": [
      "r243"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.",
        "label": "Document Shell Company Report"
       }
      }
     },
     "localname": "DocumentShellCompanyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.curevac.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r245"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.curevac.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.curevac.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.curevac.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.curevac.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.curevac.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCountry": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ISO 3166-1 alpha-2 country code.",
        "label": "Entity Address, Country"
       }
      }
     },
     "localname": "EntityAddressCountry",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.curevac.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "countryCodeItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.curevac.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.curevac.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityAddressesAddressTypeAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table.",
        "label": "Entity Addresses, Address Type [Axis]"
       }
      }
     },
     "localname": "EntityAddressesAddressTypeAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.curevac.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r240"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.curevac.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.curevac.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.curevac.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r240"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.curevac.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r248"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Entity Ex Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.curevac.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.curevac.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r240"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.curevac.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.curevac.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r246"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.curevac.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.curevac.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r240"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.curevac.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r240"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.curevac.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.curevac.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r247"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.curevac.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_IcfrAuditorAttestationFlag": {
     "auth_ref": [
      "r242",
      "r243",
      "r244"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "localname": "IcfrAuditorAttestationFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.curevac.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.curevac.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r239"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.curevac.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r241"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.curevac.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.curevac.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "ifrs-full_AccumulatedOtherComprehensiveIncome": {
     "auth_ref": [
      "r24"
     ],
     "calculation": {
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition": {
       "order": 5.0,
       "parentTag": "ifrs-full_Equity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of accumulated items of income and expense (including reclassification adjustments) that are not recognised in profit or loss as required or permitted by other IFRSs. [Refer: IFRSs [member]; Other comprehensive income]"
       }
      },
      "en-us": {
       "role": {
        "label": "Accumulated other comprehensive income",
        "terseLabel": "Other comprehensive income"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncome",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred": {
     "auth_ref": [
      "r177"
     ],
     "calculation": {
      "http://www.curevac.com/role/DisclosureSignificantTransactionsAndEventsGoodwillRecognizedOnFrameAcquisitionDetails": {
       "order": 1.0,
       "parentTag": "ifrs-full_GoodwillRecognisedAsOfAcquisitionDate",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The fair value, at acquisition date, of the consideration transferred in a business combination. [Refer: Business combinations [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Consideration transferred, acquisition-date fair value",
        "terseLabel": "Total purchase price",
        "verboseLabel": "Consideration transferred"
       }
      }
     },
     "localname": "AcquisitiondateFairValueOfTotalConsiderationTransferred",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureSignificantTransactionsAndEventsDetails",
      "http://www.curevac.com/role/DisclosureSignificantTransactionsAndEventsGoodwillRecognizedOnFrameAcquisitionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AcquisitionrelatedCostsForTransactionRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombination": {
     "auth_ref": [
      "r181"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of acquisition-related costs for transactions recognised separately from the acquisition of assets and the assumption of liabilities in business combinations. [Refer: Business combinations [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Acquisition-related costs for transaction recognised separately from acquisition of assets and assumption of liabilities in business combination",
        "negatedLabel": "Transaction costs of the acquisition (included in cash flows from operating activities)",
        "verboseLabel": "Transactions costs"
       }
      }
     },
     "localname": "AcquisitionrelatedCostsForTransactionRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombination",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureSignificantTransactionsAndEventsAnalysesOfCashFlowsOnFrameAcquisitionDetails",
      "http://www.curevac.com/role/DisclosureSignificantTransactionsAndEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill": {
     "auth_ref": [
      "r89"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of additions to intangible assets other than goodwill, other than those acquired through business combinations. [Refer: Business combinations [member]; Intangible assets other than goodwill]"
       }
      },
      "en-us": {
       "role": {
        "label": "Additions other than through business combinations, intangible assets other than goodwill",
        "terseLabel": "Additions"
       }
      }
     },
     "localname": "AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureFixedAssetsIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment": {
     "auth_ref": [
      "r61"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of additions to property, plant and equipment other than those acquired through business combinations. [Refer: Business combinations [member]; Property, plant and equipment]"
       }
      },
      "en-us": {
       "role": {
        "label": "Additions other than through business combinations, property, plant and equipment",
        "terseLabel": "Additions"
       }
      }
     },
     "localname": "AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureFixedAssetsPropertyPlantAndEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AdjustmentsForDecreaseIncreaseInInventories": {
     "auth_ref": [
      "r104"
     ],
     "calculation": {
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows": {
       "order": 13.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "Adjustments for decrease (increase) in inventories to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Inventories; Profit (loss)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Adjustments for decrease (increase) in inventories",
        "terseLabel": "Decrease / (increase) in inventory"
       }
      }
     },
     "localname": "AdjustmentsForDecreaseIncreaseInInventories",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AdjustmentsForDecreaseIncreaseInOtherAssets": {
     "auth_ref": [
      "r107"
     ],
     "calculation": {
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows": {
       "order": 10.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "Adjustments for decrease (increase) in other assets to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Other assets; Profit (loss)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Adjustments for decrease (increase) in other assets",
        "terseLabel": "Decrease / (increase) in other assets"
       }
      }
     },
     "localname": "AdjustmentsForDecreaseIncreaseInOtherAssets",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables": {
     "auth_ref": [
      "r107"
     ],
     "calculation": {
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows": {
       "order": 12.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "Adjustments for decrease (increase) in trade and other receivables to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Trade and other receivables; Profit (loss)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Adjustments for decrease (increase) in trade and other receivables",
        "terseLabel": "Decrease / (increase) in trade receivables and contract assets"
       }
      }
     },
     "localname": "AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AdjustmentsForDeferredTaxExpense": {
     "auth_ref": [
      "r107"
     ],
     "calculation": {
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows": {
       "order": 20.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "Adjustments for deferred tax expense to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Deferred tax expense (income); Profit (loss)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Adjustments for deferred tax expense",
        "terseLabel": "Decrease / (increase) in deferred taxes"
       }
      }
     },
     "localname": "AdjustmentsForDeferredTaxExpense",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense": {
     "auth_ref": [
      "r105"
     ],
     "calculation": {
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows": {
       "order": 9.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "Adjustments for depreciation and amortisation expense to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Depreciation and amortisation expense; Profit (loss)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Adjustments for depreciation and amortisation expense",
        "terseLabel": "Depreciation and impairment of property, plant and equipment and right-of-use assets"
       }
      }
     },
     "localname": "AdjustmentsForDepreciationAndAmortisationExpense",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AdjustmentsForFinanceCosts": {
     "auth_ref": [
      "r106"
     ],
     "calculation": {
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows": {
       "order": 5.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "Adjustments for finance costs to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Finance costs; Profit (loss)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Adjustments for finance costs",
        "terseLabel": "Finance expense"
       }
      }
     },
     "localname": "AdjustmentsForFinanceCosts",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AdjustmentsForFinanceIncome": {
     "auth_ref": [
      "r107"
     ],
     "calculation": {
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "Adjustments for finance income to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Finance income; Profit (loss)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Adjustments for finance income",
        "negatedLabel": "Finance income"
       }
      }
     },
     "localname": "AdjustmentsForFinanceIncome",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AdjustmentsForGainLossOnDisposalsPropertyPlantAndEquipment": {
     "auth_ref": [
      "r107"
     ],
     "calculation": {
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "Adjustments for gain (loss) on disposals of property, plant and equipment to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss); Property, plant and equipment; Disposals, property, plant and equipment]"
       }
      },
      "en-us": {
       "role": {
        "label": "Adjustments for gain (loss) on disposals, property, plant and equipment",
        "negatedLabel": "Loss on disposal of fixed assets"
       }
      }
     },
     "localname": "AdjustmentsForGainLossOnDisposalsPropertyPlantAndEquipment",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment": {
     "auth_ref": [
      "r107"
     ],
     "calculation": {
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows": {
       "order": 7.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "Adjustments for impairment loss (reversal of impairment loss) on property, plant and equipment recognised in profit or loss to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Adjustments for impairment loss (reversal of impairment loss) recognised in profit or loss; Property, plant and equipment]"
       }
      },
      "en-us": {
       "role": {
        "label": "Adjustments for impairment loss (reversal of impairment loss) recognised in profit or loss, property, plant and equipment",
        "terseLabel": "Impairment to property, plant and equipment"
       }
      }
     },
     "localname": "AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables": {
     "auth_ref": [
      "r107"
     ],
     "calculation": {
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows": {
       "order": 16.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "Adjustments for increase (decrease) in trade and other payables to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Trade and other payables; Profit (loss)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Adjustments for increase (decrease) in trade and other payables",
        "terseLabel": "(Decrease) / increase in trade and other payables, other liabilities and contract liabilities"
       }
      }
     },
     "localname": "AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets": {
     "auth_ref": [
      "r96"
     ],
     "calculation": {
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "Adjustments for losses (gains) on disposal of non-current assets to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Non-current assets; Profit (loss)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Adjustments for losses (gains) on disposal of non-current assets",
        "terseLabel": "Loss on disposal of fixed assets"
       }
      }
     },
     "localname": "AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AdjustmentsForReconcileProfitLossAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to reconcile profit (loss) [abstract]",
        "terseLabel": "Adjustments to reconcile loss before tax to net cash flows"
       }
      }
     },
     "localname": "AdjustmentsForReconcileProfitLossAbstract",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_AdjustmentsForSharebasedPayments": {
     "auth_ref": [
      "r105"
     ],
     "calculation": {
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows": {
       "order": 11.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "Adjustments for share-based payments to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Adjustments for share-based payments",
        "verboseLabel": "Share-based payment expense"
       }
      }
     },
     "localname": "AdjustmentsForSharebasedPayments",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AggregatedTimeBandsMember": {
     "auth_ref": [
      "r26",
      "r65",
      "r150",
      "r158",
      "r159",
      "r193",
      "r206",
      "r207",
      "r223",
      "r224",
      "r226",
      "r232"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for aggregated time bands. It also represents the standard value for the 'Maturity' axis if no other member is used."
       }
      },
      "en-us": {
       "role": {
        "label": "Aggregated time bands [member]"
       }
      }
     },
     "localname": "AggregatedTimeBandsMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_Assets": {
     "auth_ref": [
      "r24",
      "r136",
      "r137",
      "r140",
      "r215",
      "r217"
     ],
     "calculation": {
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of a present economic resource controlled by the entity as a result of past events. Economic resource is a right that has the potential to produce economic benefits."
       }
      },
      "en-us": {
       "role": {
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "AssetsAbstract",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_BasicEarningsLossPerShare": {
     "auth_ref": [
      "r84",
      "r85"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator) divided by the weighted average number of ordinary shares outstanding during the period (the denominator)."
       }
      },
      "en-us": {
       "role": {
        "label": "Basic earnings (loss) per share",
        "terseLabel": "Net loss per share basic"
       }
      }
     },
     "localname": "BasicEarningsLossPerShare",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureEarningsPerShareDetails",
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfOperationsAndOtherComprehensiveIncomeLoss"
     ],
     "xbrltype": "perShareItemType"
    },
    "ifrs-full_BorrowingsByNameAxis": {
     "auth_ref": [
      "r205"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Borrowings by name [axis]"
       }
      }
     },
     "localname": "BorrowingsByNameAxis",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureLoansDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_BorrowingsByNameMember": {
     "auth_ref": [
      "r205"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for all borrowings when disaggregated by name. It also represents the standard value for the 'Borrowings by name' axis if no other member is used. [Refer: Borrowings]"
       }
      },
      "en-us": {
       "role": {
        "label": "Borrowings by name [member]"
       }
      }
     },
     "localname": "BorrowingsByNameMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureLoansDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_BottomOfRangeMember": {
     "auth_ref": [
      "r141",
      "r142",
      "r143",
      "r167",
      "r205",
      "r226"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for the bottom of a range."
       }
      },
      "en-us": {
       "role": {
        "label": "Minimum",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "BottomOfRangeMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsSummaryOfUpfrontPaymentsAndRelatedRevenuesRecognizedDetails",
      "http://www.curevac.com/role/DisclosureRelatedPartyDisclosuresDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_BusinessCombinationsAxis": {
     "auth_ref": [
      "r184"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Business combinations [axis]"
       }
      }
     },
     "localname": "BusinessCombinationsAxis",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureCorporateInformationDetails",
      "http://www.curevac.com/role/DisclosureSignificantTransactionsAndEventsAnalysesOfCashFlowsOnFrameAcquisitionDetails",
      "http://www.curevac.com/role/DisclosureSignificantTransactionsAndEventsDetails",
      "http://www.curevac.com/role/DisclosureSignificantTransactionsAndEventsFrameAcquisitionPurchasePriceAllocationDetails",
      "http://www.curevac.com/role/DisclosureSignificantTransactionsAndEventsGoodwillRecognizedOnFrameAcquisitionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_CapitalReserve": {
     "auth_ref": [
      "r24"
     ],
     "calculation": {
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition": {
       "order": 3.0,
       "parentTag": "ifrs-full_Equity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "A component of equity representing the capital reserves."
       }
      },
      "en-us": {
       "role": {
        "label": "Capital reserve.",
        "terseLabel": "Capital reserve"
       }
      }
     },
     "localname": "CapitalReserve",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CapitalReserveMember": {
     "auth_ref": [
      "r11"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for a component of equity representing capital reserves."
       }
      },
      "en-us": {
       "role": {
        "label": "Capital reserve"
       }
      }
     },
     "localname": "CapitalReserveMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfChangesInShareholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_CashAndCashEquivalents": {
     "auth_ref": [
      "r19",
      "r113",
      "r131"
     ],
     "calculation": {
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition": {
       "order": 6.0,
       "parentTag": "ifrs-full_CurrentAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]"
       }
      },
      "en-us": {
       "role": {
        "label": "Cash and cash equivalents.",
        "periodEndLabel": "Cash and cash equivalents, end of period",
        "periodStartLabel": "Cash and cash equivalents, beginning of period",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalents",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows",
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CashAndCashEquivalentsRecognisedAsOfAcquisitionDate": {
     "auth_ref": [
      "r180"
     ],
     "calculation": {
      "http://www.curevac.com/role/DisclosureSignificantTransactionsAndEventsAnalysesOfCashFlowsOnFrameAcquisitionDetails": {
       "order": 2.0,
       "parentTag": "cvac_IfrsCashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities",
       "weight": -1.0
      },
      "http://www.curevac.com/role/DisclosureSignificantTransactionsAndEventsFrameAcquisitionPurchasePriceAllocationDetails": {
       "order": 1.0,
       "parentTag": "ifrs-full_CurrentAssetsRecognisedAsOfAcquisitionDate",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount recognised as of the acquisition date for cash and cash equivalents acquired in a business combination. [Refer: Cash and cash equivalents; Business combinations [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Cash and cash equivalents recognised as of acquisition date",
        "terseLabel": "Cash acquired with the subsidiary (included in cash flows from investing activities)",
        "verboseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsRecognisedAsOfAcquisitionDate",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureSignificantTransactionsAndEventsAnalysesOfCashFlowsOnFrameAcquisitionDetails",
      "http://www.curevac.com/role/DisclosureSignificantTransactionsAndEventsFrameAcquisitionPurchasePriceAllocationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CashFlowsFromUsedInFinancingActivities": {
     "auth_ref": [
      "r95",
      "r114"
     ],
     "calculation": {
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash flows from (used in) financing activities, which are activities that result in changes in the size and composition of the contributed equity and borrowings of the entity."
       }
      },
      "en-us": {
       "role": {
        "label": "Cash flows from (used in) financing activities",
        "totalLabel": "Net cash flow provided by financing activities"
       }
      }
     },
     "localname": "CashFlowsFromUsedInFinancingActivities",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from (used in) financing activities [abstract]",
        "terseLabel": "Financing activities"
       }
      }
     },
     "localname": "CashFlowsFromUsedInFinancingActivitiesAbstract",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_CashFlowsFromUsedInInvestingActivities": {
     "auth_ref": [
      "r95",
      "r114"
     ],
     "calculation": {
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash flows from (used in) investing activities, which are the acquisition and disposal of long-term assets and other investments not included in cash equivalents."
       }
      },
      "en-us": {
       "role": {
        "label": "Cash flows from (used in) investing activities",
        "totalLabel": "Net cash flow (used in) investing activities"
       }
      }
     },
     "localname": "CashFlowsFromUsedInInvestingActivities",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from (used in) investing activities [abstract]",
        "terseLabel": "Investing activities"
       }
      }
     },
     "localname": "CashFlowsFromUsedInInvestingActivitiesAbstract",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_CashFlowsFromUsedInOperatingActivities": {
     "auth_ref": [
      "r95",
      "r114"
     ],
     "calculation": {
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges",
       "weight": 1.0
      }
     },
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash flows from (used in) operating activities, which are the principal revenue-producing activities of the entity and other activities that are not investing or financing activities. [Refer: Revenue]"
       }
      },
      "en-us": {
       "role": {
        "label": "Cash flows from (used in) operating activities",
        "totalLabel": "Net cash flow (used in) operating activities"
       }
      }
     },
     "localname": "CashFlowsFromUsedInOperatingActivities",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from (used in) operating activities [abstract]",
        "terseLabel": "Operating activities"
       }
      }
     },
     "localname": "CashFlowsFromUsedInOperatingActivitiesAbstract",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities": {
     "auth_ref": [
      "r112"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The aggregate cash flows used in obtaining control of subsidiaries or other businesses, classified as investing activities. [Refer: Subsidiaries [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Cash flows used in obtaining control of subsidiaries or other businesses, classified as investing activities",
        "totalLabel": "Included in cash flows from investing activities"
       }
      }
     },
     "localname": "CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureSignificantTransactionsAndEventsAnalysesOfCashFlowsOnFrameAcquisitionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CashTransferred": {
     "auth_ref": [
      "r174"
     ],
     "calculation": {
      "http://www.curevac.com/role/DisclosureSignificantTransactionsAndEventsAnalysesOfCashFlowsOnFrameAcquisitionDetails": {
       "order": 1.0,
       "parentTag": "cvac_IfrsCashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The fair value, at acquisition date, of cash transferred as consideration in a business combination. [Refer: Business combinations [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Cash transferred",
        "negatedLabel": "Payment of consideration in cash and cash equivalents",
        "terseLabel": "Cash payments"
       }
      }
     },
     "localname": "CashTransferred",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureSignificantTransactionsAndEventsAnalysesOfCashFlowsOnFrameAcquisitionDetails",
      "http://www.curevac.com/role/DisclosureSignificantTransactionsAndEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CategoriesOfRelatedPartiesAxis": {
     "auth_ref": [
      "r72"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Categories of related parties [axis]"
       }
      }
     },
     "localname": "CategoriesOfRelatedPartiesAxis",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureRelatedPartyDisclosuresDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_ClassesOfFinancialInstrumentsAxis": {
     "auth_ref": [
      "r197",
      "r200",
      "r201",
      "r203"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Classes of financial instruments [axis]"
       }
      }
     },
     "localname": "ClassesOfFinancialInstrumentsAxis",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureDisclosureOfFinancialInstrumentsAndRiskManagementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_ClassesOfFinancialInstrumentsMember": {
     "auth_ref": [
      "r197",
      "r200",
      "r201",
      "r203"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for aggregated classes of financial instruments. Financial instruments are contracts that give rise to a financial asset of one entity and a financial liability or equity instrument of another entity. It also represents the standard value for the 'Classes of financial instruments' axis if no other member is used. [Refer: Financial assets; Financial liabilities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Financial instruments, class [member]"
       }
      }
     },
     "localname": "ClassesOfFinancialInstrumentsMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureDisclosureOfFinancialInstrumentsAndRiskManagementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis": {
     "auth_ref": [
      "r91"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Classes of intangible assets other than goodwill [axis]"
       }
      }
     },
     "localname": "ClassesOfIntangibleAssetsOtherThanGoodwillAxis",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureFixedAssetsIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_ClassesOfInventoriesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventories."
       }
      }
     },
     "localname": "ClassesOfInventoriesAbstract",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis": {
     "auth_ref": [
      "r63"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Classes of property, plant and equipment [axis]"
       }
      }
     },
     "localname": "ClassesOfPropertyPlantAndEquipmentAxis",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureFixedAssetsPropertyPlantAndEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_ClassesOfShareCapitalAxis": {
     "auth_ref": [
      "r36"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Classes of share capital [axis]"
       }
      }
     },
     "localname": "ClassesOfShareCapitalAxis",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureIssuedCapitalAndReservesImpactOfShareSplitDetails",
      "http://www.curevac.com/role/DisclosureIssuedCapitalAndReservesOverviewAndGeneralRemarksDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_ClassesOfShareCapitalMember": {
     "auth_ref": [
      "r36"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for share capital of the entity. It also represents the standard value for the 'Classes of share capital' axis if no other member is used."
       }
      },
      "en-us": {
       "role": {
        "label": "Share capital [member]"
       }
      }
     },
     "localname": "ClassesOfShareCapitalMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureIssuedCapitalAndReservesImpactOfShareSplitDetails",
      "http://www.curevac.com/role/DisclosureIssuedCapitalAndReservesOverviewAndGeneralRemarksDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_CommitmentsMadeByEntityRelatedPartyTransactions": {
     "auth_ref": [
      "r75"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of related-party commitments made by the entity to do something if a particular event occurs or does not occur in the future, including executory contracts (recognised and unrecognised). [Refer: Related parties [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Commitments made by entity, related party transactions",
        "terseLabel": "Maximum settlement amount"
       }
      }
     },
     "localname": "CommitmentsMadeByEntityRelatedPartyTransactions",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureRelatedPartyDisclosuresDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ComponentsOfEquityAxis": {
     "auth_ref": [
      "r10"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Components of equity [axis]"
       }
      }
     },
     "localname": "ComponentsOfEquityAxis",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureIssuedCapitalAndReservesOverviewAndGeneralRemarksDetails",
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfChangesInShareholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_ComprehensiveIncome": {
     "auth_ref": [
      "r4",
      "r40",
      "r119",
      "r121",
      "r124",
      "r129"
     ],
     "calculation": {
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfOperationsAndOtherComprehensiveIncomeLoss": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of change in equity resulting from transactions and other events, other than those changes resulting from transactions with owners in their capacity as owners."
       }
      },
      "en-us": {
       "role": {
        "label": "Comprehensive income",
        "terseLabel": "Total comprehensive income (loss)",
        "totalLabel": "Total comprehensive loss for the period"
       }
      }
     },
     "localname": "ComprehensiveIncome",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfChangesInShareholdersEquity",
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfOperationsAndOtherComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ConstructionInProgressMember": {
     "auth_ref": [
      "r59"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for expenditure capitalised during the construction of items of property, plant and equipment that are not yet available for use (ie not yet in the location and condition necessary for it to be capable of operating in the manner intended by the management). [Refer: Property, plant and equipment]"
       }
      },
      "en-us": {
       "role": {
        "label": "Assets under construction"
       }
      }
     },
     "localname": "ConstructionInProgressMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureFixedAssetsPropertyPlantAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_ContingentConsiderationRecognisedAsOfAcquisitionDate": {
     "auth_ref": [
      "r178"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount, at acquisition date, of contingent consideration arrangements recognised as consideration transferred in a business combination. [Refer: Business combinations [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Contingent consideration recognised as of acquisition date",
        "verboseLabel": "Contingent consideration, fair value"
       }
      }
     },
     "localname": "ContingentConsiderationRecognisedAsOfAcquisitionDate",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureSignificantTransactionsAndEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ContractLiabilities": {
     "auth_ref": [
      "r144",
      "r147"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of an entity\u2019s obligation to transfer goods or services to a customer for which the entity has received consideration (or the amount is due) from the customer."
       }
      },
      "en-us": {
       "role": {
        "label": "Contract liabilities",
        "verboseLabel": "Contract liabilities"
       }
      }
     },
     "localname": "ContractLiabilities",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsContractLiabilitiesAllocatedToRemainingPerformanceObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CostOfSales": {
     "auth_ref": [
      "r2",
      "r46"
     ],
     "calculation": {
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfOperationsAndOtherComprehensiveIncomeLoss": {
       "order": 2.0,
       "parentTag": "ifrs-full_ProfitLossFromOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of all expenses directly or indirectly attributed to the goods or services sold. Attributed expenses include, but are not limited to, costs previously included in the measurement of inventory that has now been sold, such as depreciation and maintenance of factory buildings and equipment used in the production process, unallocated production overheads, and abnormal amounts of production costs of inventories."
       }
      },
      "en-us": {
       "role": {
        "label": "Cost of sales.",
        "negatedLabel": "Cost of sales"
       }
      }
     },
     "localname": "CostOfSales",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfOperationsAndOtherComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CurrencyRiskMember": {
     "auth_ref": [
      "r211",
      "r227",
      "r228",
      "r229",
      "r230"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for a type of market risk representing the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in foreign exchange rates. [Refer: Financial instruments, class [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Foreign currency risk"
       }
      }
     },
     "localname": "CurrencyRiskMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureDisclosureOfFinancialInstrumentsAndRiskManagementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_CurrentAdvancesToSuppliers": {
     "auth_ref": [
      "r12"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of current advances made to suppliers before goods or services are received."
       }
      },
      "en-us": {
       "role": {
        "label": "Current advances to suppliers",
        "terseLabel": "Prepayments for material"
       }
      }
     },
     "localname": "CurrentAdvancesToSuppliers",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosurePrepaidExpensesAndOtherAssetsCurrentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CurrentAssets": {
     "auth_ref": [
      "r27",
      "r124",
      "r125"
     ],
     "calculation": {
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition": {
       "order": 2.0,
       "parentTag": "ifrs-full_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of assets that the entity (a) expects to realise or intends to sell or consume in its normal operating cycle; (b) holds primarily for the purpose of trading; (c) expects to realise within twelve months after the reporting period; or (d) classifies as cash or cash equivalents (as defined in IAS 7) unless the asset is restricted from being exchanged or used to settle a liability for at least twelve months after the reporting period. [Refer: Assets]"
       }
      },
      "en-us": {
       "role": {
        "label": "Current assets",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "CurrentAssets",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CurrentAssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CurrentAssetsAbstract",
        "terseLabel": "Current assets"
       }
      }
     },
     "localname": "CurrentAssetsAbstract",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_CurrentAssetsRecognisedAsOfAcquisitionDate": {
     "auth_ref": [
      "r180"
     ],
     "calculation": {
      "http://www.curevac.com/role/DisclosureSignificantTransactionsAndEventsFrameAcquisitionPurchasePriceAllocationDetails": {
       "order": 2.0,
       "parentTag": "cvac_TotalAssetsRecognisedAsOfAcquisitionDate",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "Expiry date 2022-01-01: The amount recognised as of the acquisition date for current assets acquired in a business combination. [Refer: Business combinations [member]]\nEffective 2022-01-01: The amount recognised as of the acquisition date for current assets acquired in a business combination. [Refer: Current assets; Business combinations [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Current assets recognised as of acquisition date",
        "totalLabel": "Current assets"
       }
      }
     },
     "localname": "CurrentAssetsRecognisedAsOfAcquisitionDate",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureSignificantTransactionsAndEventsFrameAcquisitionPurchasePriceAllocationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CurrentContractAssets": {
     "auth_ref": [
      "r144"
     ],
     "calculation": {
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition": {
       "order": 3.0,
       "parentTag": "ifrs-full_CurrentAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of current contract assets. [Refer: Contract assets]"
       }
      },
      "en-us": {
       "role": {
        "label": "Current contract assets",
        "terseLabel": "Contract assets",
        "verboseLabel": "Contract assets"
       }
      }
     },
     "localname": "CurrentContractAssets",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsContractLiabilitiesAllocatedToRemainingPerformanceObligationsDetails",
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CurrentContractLiabilities": {
     "auth_ref": [
      "r144"
     ],
     "calculation": {
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition": {
       "order": 6.0,
       "parentTag": "ifrs-full_CurrentLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of current contract liabilities. [Refer: Contract liabilities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Current contract liabilities",
        "terseLabel": "Contract liabilities"
       }
      }
     },
     "localname": "CurrentContractLiabilities",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CurrentLeaseLiabilities": {
     "auth_ref": [
      "r155"
     ],
     "calculation": {
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition": {
       "order": 2.0,
       "parentTag": "ifrs-full_CurrentLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of current lease liabilities. [Refer: Lease liabilities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Current lease liabilities",
        "terseLabel": "Lease liabilities"
       }
      }
     },
     "localname": "CurrentLeaseLiabilities",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CurrentLiabilities": {
     "auth_ref": [
      "r29",
      "r124",
      "r127"
     ],
     "calculation": {
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition": {
       "order": 2.0,
       "parentTag": "ifrs-full_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "Expiry date 2023-01-01: The amount of liabilities that: (a) the entity expects to settle in its normal operating cycle; (b) the entity holds primarily for the purpose of trading; (c) are due to be settled within twelve months after the reporting period; or (d) the entity does not have an unconditional right to defer settlement for at least twelve months after the reporting period.\nEffective 2023-01-01: The amount of liabilities that: (a) the entity expects to settle in its normal operating cycle; (b) the entity holds primarily for the purpose of trading; (c) are due to be settled within twelve months after the reporting period; or (d) the entity does not have the right at the end of the reporting period to defer settlement for at least twelve months after the reporting period."
       }
      },
      "en-us": {
       "role": {
        "label": "Current liabilities",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "CurrentLiabilities",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CurrentLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current liabilities [abstract]",
        "terseLabel": "Current liabilities"
       }
      }
     },
     "localname": "CurrentLiabilitiesAbstract",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_CurrentLiabilitiesRecognisedAsOfAcquisitionDate": {
     "auth_ref": [
      "r180"
     ],
     "calculation": {
      "http://www.curevac.com/role/DisclosureSignificantTransactionsAndEventsFrameAcquisitionPurchasePriceAllocationDetails": {
       "order": 1.0,
       "parentTag": "cvac_LiabilitiesRecognisedAsOfAcquisitionDate",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "Expiry date 2022-01-01: The amount recognised as of the acquisition date for current liabilities assumed in a business combination. [Refer: Business combinations [member]]\nEffective 2022-01-01: The amount recognised as of the acquisition date for current liabilities assumed in a business combination. [Refer: Current liabilities; Business combinations [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Current liabilities recognised as of acquisition date",
        "totalLabel": "Current liabilities"
       }
      }
     },
     "localname": "CurrentLiabilitiesRecognisedAsOfAcquisitionDate",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureSignificantTransactionsAndEventsFrameAcquisitionPurchasePriceAllocationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CurrentPrepaymentsAndOtherCurrentAssets": {
     "auth_ref": [
      "r24"
     ],
     "calculation": {
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition": {
       "order": 4.0,
       "parentTag": "ifrs-full_CurrentAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of current prepayments and other current assets. [Refer: Other current assets; Current prepayments]"
       }
      },
      "en-us": {
       "role": {
        "label": "Current prepayments and other current assets",
        "terseLabel": "Prepaid expenses and other assets",
        "verboseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "CurrentPrepaymentsAndOtherCurrentAssets",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosurePrepaidExpensesAndOtherAssetsCurrentDetails",
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CurrentTaxExpenseIncome": {
     "auth_ref": [
      "r52"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of income taxes payable (recoverable) in respect of the taxable profit (tax loss) for a period."
       }
      },
      "en-us": {
       "role": {
        "label": "Current tax expense (income)",
        "terseLabel": "Current tax expense"
       }
      }
     },
     "localname": "CurrentTaxExpenseIncome",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureIncomeTaxDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CurrentTaxLiabilities": {
     "auth_ref": [
      "r23"
     ],
     "calculation": {
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition": {
       "order": 5.0,
       "parentTag": "ifrs-full_CurrentLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of current tax for current and prior periods to the extent unpaid. Current tax is the amount of income taxes payable (recoverable) in respect of the taxable profit (tax loss) for a period."
       }
      },
      "en-us": {
       "role": {
        "label": "Current tax liabilities",
        "verboseLabel": "Income taxes payable"
       }
      }
     },
     "localname": "CurrentTaxLiabilities",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CurrentTradeReceivables": {
     "auth_ref": [
      "r28",
      "r31"
     ],
     "calculation": {
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition": {
       "order": 2.0,
       "parentTag": "ifrs-full_CurrentAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of current trade receivables. [Refer: Trade receivables]"
       }
      },
      "en-us": {
       "role": {
        "label": "Current trade receivables",
        "terseLabel": "Trade receivables"
       }
      }
     },
     "localname": "CurrentTradeReceivables",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsContractLiabilitiesAllocatedToRemainingPerformanceObligationsDetails",
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_DecreaseIncreaseThroughTaxOnSharebasedPaymentTransactions": {
     "auth_ref": [
      "r9"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The decrease (increase) in equity resulting from tax on transactions in which the entity: (a) receives goods or services from the supplier of those goods or services (including an employee) in a share-based payment arrangement; or (b) incurs an obligation to settle the transaction with the supplier in a share-based payment arrangement when another group entity receives those goods or services. [Refer: Share-based payment arrangements [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Decrease (increase) through tax on share-based payment transactions, equity",
        "negatedLabel": "Deferred taxes on convertible loan"
       }
      }
     },
     "localname": "DecreaseIncreaseThroughTaxOnSharebasedPaymentTransactions",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfChangesInShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_DecreaseThroughDerecognitionFinancialAssets": {
     "auth_ref": [
      "r197",
      "r198",
      "r209"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The decrease in financial assets resulting from derecognition. [Refer: Financial assets]"
       }
      },
      "en-us": {
       "role": {
        "label": "Decrease through derecognition, financial assets",
        "terseLabel": "Loss on derecognition of fixed assets"
       }
      }
     },
     "localname": "DecreaseThroughDerecognitionFinancialAssets",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsCostOfSalesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_DeferredTaxAssetsRecognisedAsOfAcquisitionDate": {
     "auth_ref": [
      "r180"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount recognised as of the acquisition date for deferred tax assets acquired in a business combination. [Refer: Deferred tax assets; Business combinations [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Deferred tax assets recognised as of acquisition date",
        "terseLabel": "Deferred tax assets arising mainly from tax loss carry forwards"
       }
      }
     },
     "localname": "DeferredTaxAssetsRecognisedAsOfAcquisitionDate",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureSignificantTransactionsAndEventsFrameAcquisitionPurchasePriceAllocationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_DeferredTaxExpenseIncome": {
     "auth_ref": [
      "r57"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of tax expense (income) relating to changes in deferred tax liabilities and deferred tax assets. [Refer: Deferred tax assets; Deferred tax liabilities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Deferred tax expense (income)",
        "terseLabel": "Deferred tax expense (benefit)"
       }
      }
     },
     "localname": "DeferredTaxExpenseIncome",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureIncomeTaxDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_DeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate": {
     "auth_ref": [
      "r180"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount recognised as of the acquisition date for deferred tax liabilities assumed in a business combination. [Refer: Deferred tax liabilities; Business combinations [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Deferred tax liabilities recognised as of acquisition date",
        "terseLabel": "Deferred tax liabilities arising on taxable temporary differences"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureSignificantTransactionsAndEventsFrameAcquisitionPurchasePriceAllocationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_DepreciationAndAmortisationExpense": {
     "auth_ref": [
      "r1",
      "r3",
      "r46",
      "r133",
      "r213",
      "r219"
     ],
     "calculation": {
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsCostOfSalesDetails": {
       "order": 5.0,
       "parentTag": "ifrs-full_ExpenseByNature",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of depreciation and amortisation expense. Depreciation and amortisation are the systematic allocations of depreciable amounts of assets over their useful lives."
       }
      },
      "en-us": {
       "role": {
        "label": "Depreciation and amortisation expense",
        "negatedLabel": "Amortization and depreciation"
       }
      }
     },
     "localname": "DepreciationAndAmortisationExpense",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsCostOfSalesDetails",
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsGeneralAndAdministrativeExpensesDetails",
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsResearchAndDevelopmentExpensesDetails",
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsSellingAndDistributionExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The description of the entity's accounting policy for research and development expense. [Refer: Research and development expense]"
       }
      },
      "en-us": {
       "role": {
        "label": "Description of accounting policy for research and development expense [text block]",
        "terseLabel": "Research and Development Expenses"
       }
      }
     },
     "localname": "DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureBasisOfPreparationPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DilutedEarningsLossPerShare": {
     "auth_ref": [
      "r84",
      "r85"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator), divided by the weighted average number of ordinary shares outstanding during the period (the denominator), both adjusted for the effects of all dilutive potential ordinary shares. [Refer: Ordinary shares [member]; Weighted average [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Diluted earnings (loss) per share",
        "terseLabel": "Net loss per share diluted"
       }
      }
     },
     "localname": "DilutedEarningsLossPerShare",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfOperationsAndOtherComprehensiveIncomeLoss"
     ],
     "xbrltype": "perShareItemType"
    },
    "ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of the basis used for the preparation of the financial statements."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of basis of preparation of financial statements [text block]",
        "terseLabel": "Basis of preparation"
       }
      }
     },
     "localname": "DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureBasisOfPreparationPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfBusinessCombinationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Significant transactions and events"
       }
      }
     },
     "localname": "DisclosureOfBusinessCombinationsAbstract",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfBusinessCombinationsExplanatory": {
     "auth_ref": [
      "r188"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The entire disclosure for business combinations."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of business combinations [text block]",
        "terseLabel": "Significant transactions and events"
       }
      }
     },
     "localname": "DisclosureOfBusinessCombinationsExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureSignificantTransactionsAndEvents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfBusinessCombinationsLineItems": {
     "auth_ref": [],
     "lang": {
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of detailed information about business combination",
        "terseLabel": "Significant transactions and events",
        "verboseLabel": "Significant transactions and events"
       }
      }
     },
     "localname": "DisclosureOfBusinessCombinationsLineItems",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureCorporateInformationDetails",
      "http://www.curevac.com/role/DisclosureSignificantTransactionsAndEventsAnalysesOfCashFlowsOnFrameAcquisitionDetails",
      "http://www.curevac.com/role/DisclosureSignificantTransactionsAndEventsDetails",
      "http://www.curevac.com/role/DisclosureSignificantTransactionsAndEventsFrameAcquisitionPurchasePriceAllocationDetails",
      "http://www.curevac.com/role/DisclosureSignificantTransactionsAndEventsGoodwillRecognizedOnFrameAcquisitionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfBusinessCombinationsTable": {
     "auth_ref": [
      "r184"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to details of business combinations."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of detailed information about business combination [table]"
       }
      }
     },
     "localname": "DisclosureOfBusinessCombinationsTable",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureCorporateInformationDetails",
      "http://www.curevac.com/role/DisclosureSignificantTransactionsAndEventsAnalysesOfCashFlowsOnFrameAcquisitionDetails",
      "http://www.curevac.com/role/DisclosureSignificantTransactionsAndEventsDetails",
      "http://www.curevac.com/role/DisclosureSignificantTransactionsAndEventsFrameAcquisitionPurchasePriceAllocationDetails",
      "http://www.curevac.com/role/DisclosureSignificantTransactionsAndEventsGoodwillRecognizedOnFrameAcquisitionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfClassesOfShareCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issued Capital and Reserves"
       }
      }
     },
     "localname": "DisclosureOfClassesOfShareCapitalAbstract",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory": {
     "auth_ref": [
      "r36"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of classes of share capital. [Refer: Share capital [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of classes of share capital [text block]",
        "verboseLabel": "Schedule of number of shares issued and outstanding"
       }
      }
     },
     "localname": "DisclosureOfClassesOfShareCapitalExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureIssuedCapitalAndReservesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfClassesOfShareCapitalLineItems": {
     "auth_ref": [],
     "lang": {
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of classes of share capital [line items]",
        "verboseLabel": "Issued Capital and Reserves"
       }
      }
     },
     "localname": "DisclosureOfClassesOfShareCapitalLineItems",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureIssuedCapitalAndReservesImpactOfShareSplitDetails",
      "http://www.curevac.com/role/DisclosureIssuedCapitalAndReservesOverviewAndGeneralRemarksDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfClassesOfShareCapitalTable": {
     "auth_ref": [
      "r36"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to classes of share capital."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of classes of share capital [table]"
       }
      }
     },
     "localname": "DisclosureOfClassesOfShareCapitalTable",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureIssuedCapitalAndReservesImpactOfShareSplitDetails",
      "http://www.curevac.com/role/DisclosureIssuedCapitalAndReservesOverviewAndGeneralRemarksDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loans"
       }
      }
     },
     "localname": "DisclosureOfDetailedInformationAboutBorrowingsAbstract",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsExplanatory": {
     "auth_ref": [
      "r205"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of detailed information about borrowings. [Refer: Borrowings]"
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of detailed information about borrowings [text block]",
        "terseLabel": "Loans"
       }
      }
     },
     "localname": "DisclosureOfDetailedInformationAboutBorrowingsExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureLoans"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems": {
     "auth_ref": [],
     "lang": {
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of detailed information about borrowings [line items]",
        "terseLabel": "Disclosure of detailed information about borrowings"
       }
      }
     },
     "localname": "DisclosureOfDetailedInformationAboutBorrowingsLineItems",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureLoansDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable": {
     "auth_ref": [
      "r205"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to details of borrowings."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of detailed information about borrowings [table]"
       }
      }
     },
     "localname": "DisclosureOfDetailedInformationAboutBorrowingsTable",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureLoansDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfDetailedInformationAboutBusinessCombinationsExplanatory": {
     "auth_ref": [
      "r189"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of detailed information about business combinations. [Refer: Business combinations [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of detailed information about business combination [text block]",
        "terseLabel": "Schedule of purchase price allocation"
       }
      }
     },
     "localname": "DisclosureOfDetailedInformationAboutBusinessCombinationsExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureSignificantTransactionsAndEventsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory": {
     "auth_ref": [
      "r146"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of the disaggregation of revenue from contracts with customers. [Refer: Revenue from contracts with customers]"
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of disaggregation of revenue from contracts with customers [text block]",
        "terseLabel": "Schedule of revenue from contract with customers recognized"
       }
      }
     },
     "localname": "DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory": {
     "auth_ref": [
      "r50"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The entire disclosure for events after the reporting period."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of events after reporting period [text block]",
        "terseLabel": "Subsequent events"
       }
      }
     },
     "localname": "DisclosureOfEventsAfterReportingPeriodExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureSubsequentEvents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfExpensesByNatureExplanatory": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of expenses by nature. [Refer: Expenses, by nature]"
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of expenses by nature [text block]",
        "terseLabel": "Schedule of cost of sales, selling and distribution expenses, research and development expenses and general and administrative expenses"
       }
      }
     },
     "localname": "DisclosureOfExpensesByNatureExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfFinancialInstrumentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial assets and financial liabilities"
       }
      }
     },
     "localname": "DisclosureOfFinancialInstrumentsAbstract",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfFinancialInstrumentsExplanatory": {
     "auth_ref": [
      "r212"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The entire disclosure for financial instruments."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of financial instruments [text block]",
        "terseLabel": "Financial assets and financial liabilities"
       }
      }
     },
     "localname": "DisclosureOfFinancialInstrumentsExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureFinancialAssetsAndFinancialLiabilities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfFinancialRiskManagementExplanatory": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of the entity's financial risk management practices and policies."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of financial risk management [text block]",
        "terseLabel": "Disclosure of financial instruments and risk management"
       }
      }
     },
     "localname": "DisclosureOfFinancialRiskManagementExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureDisclosureOfFinancialInstrumentsAndRiskManagement"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfIncomeTaxExplanatory": {
     "auth_ref": [
      "r58"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The entire disclosure for income taxes."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of income tax [text block]",
        "terseLabel": "Income tax"
       }
      }
     },
     "localname": "DisclosureOfIncomeTaxExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureIncomeTax"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory": {
     "auth_ref": [
      "r169"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of information about indirect, by reference to the fair value of the equity instruments granted, measurement of the fair value of goods or services received as consideration for the entity's share options."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of indirect measurement of fair value of goods or services received, share options granted during period [text block]",
        "terseLabel": "Schedule of inputs used in the measurement of the fair value at grant date"
       }
      }
     },
     "localname": "DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfIntangibleAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of detailed information about intangible assets [line items]",
        "terseLabel": "Disclosure of detailed information about intangible assets"
       }
      }
     },
     "localname": "DisclosureOfIntangibleAssetsLineItems",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureFixedAssetsIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfIntangibleAssetsTable": {
     "auth_ref": [
      "r91"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to details of intangible assets."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of detailed information about intangible assets [table]"
       }
      }
     },
     "localname": "DisclosureOfIntangibleAssetsTable",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureFixedAssetsIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfInventoriesExplanatory": {
     "auth_ref": [
      "r68"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The entire disclosure for inventories."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of inventories [text block]",
        "terseLabel": "Inventories"
       }
      }
     },
     "localname": "DisclosureOfInventoriesExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureInventories"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems": {
     "auth_ref": [],
     "lang": {
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of nature and extent of risks arising from financial instruments [line items]",
        "terseLabel": "Disclosure of nature and extent of risks arising from financial instruments"
       }
      }
     },
     "localname": "DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureDisclosureOfFinancialInstrumentsAndRiskManagementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable": {
     "auth_ref": [
      "r195",
      "r196"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to the nature and extent of risks arising from financial instruments."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of nature and extent of risks arising from financial instruments [table]"
       }
      }
     },
     "localname": "DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureDisclosureOfFinancialInstrumentsAndRiskManagementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent events"
       }
      }
     },
     "localname": "DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfNoncurrentAssetsHeldForSaleAndDiscontinuedOperationsExplanatory": {
     "auth_ref": [
      "r191"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The entire disclosure for non-current assets held for sale and discontinued operations."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of non-current assets held for sale and discontinued operations [text block]",
        "terseLabel": "Assets held for sale"
       }
      }
     },
     "localname": "DisclosureOfNoncurrentAssetsHeldForSaleAndDiscontinuedOperationsExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureAssetsHeldForSale"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfNotesAndOtherExplanatoryInformationExplanatory": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of notes and other explanatory information as part of a complete set of financial statements."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of notes and other explanatory information [text block]",
        "terseLabel": "Notes to the consolidated financial statements"
       }
      }
     },
     "localname": "DisclosureOfNotesAndOtherExplanatoryInformationExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory": {
     "auth_ref": [
      "r165"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of the number and weighted average exercise prices of share options. [Refer: Weighted average [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of number and weighted average exercise prices of share options [text block]",
        "terseLabel": "Schedule of reconciliation of outstanding awards"
       }
      }
     },
     "localname": "DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfOtherLiabilitiesExplanatory": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of other liabilities. [Refer: Other liabilities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of other liabilities [text block]",
        "terseLabel": "Other liabilities"
       }
      }
     },
     "localname": "DisclosureOfOtherLiabilitiesExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureOtherLiabilities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfOtherOperatingExpenseExplanatory": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of other operating expense. [Refer: Other operating income (expense)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of other operating expense [text block]",
        "terseLabel": "Schedule of other operating expenses"
       }
      }
     },
     "localname": "DisclosureOfOtherOperatingExpenseExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfOtherOperatingIncomeExplanatory": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of other operating income. [Refer: Other operating income (expense)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of other operating income [text block]",
        "terseLabel": "Schedule of other operating income"
       }
      }
     },
     "localname": "DisclosureOfOtherOperatingIncomeExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of detailed information about property, plant and equipment [line items]",
        "terseLabel": "Disclosure of detailed information about property, plant and equipment"
       }
      }
     },
     "localname": "DisclosureOfPropertyPlantAndEquipmentLineItems",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureFixedAssetsPropertyPlantAndEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r63"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to details of property, plant and equipment."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of detailed information about property, plant and equipment [table]"
       }
      }
     },
     "localname": "DisclosureOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureFixedAssetsPropertyPlantAndEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfRelatedPartyExplanatory": {
     "auth_ref": [
      "r76"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The entire disclosure for related parties."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of related party [text block]",
        "terseLabel": "Related party disclosures"
       }
      }
     },
     "localname": "DisclosureOfRelatedPartyExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureRelatedPartyDisclosures"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory": {
     "auth_ref": [
      "r37"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The entire disclosure for share capital, reserves and other equity interest."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of share capital, reserves and other equity interest [text block]",
        "verboseLabel": "Issued Capital and Reserves"
       }
      }
     },
     "localname": "DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureIssuedCapitalAndReserves"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory": {
     "auth_ref": [
      "r160"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangements."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of share-based payment arrangements [text block]",
        "terseLabel": "Share-based payments"
       }
      }
     },
     "localname": "DisclosureOfSharebasedPaymentArrangementsExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureShareBasedPayments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based payments"
       }
      }
     },
     "localname": "DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems": {
     "auth_ref": [],
     "lang": {
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of terms and conditions of share-based payment arrangement [line items]",
        "terseLabel": "Share-based payments"
       }
      }
     },
     "localname": "DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsDetails",
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsExpenseRecognizedForProgramDetails",
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsExpensesDetails",
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsTables"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable": {
     "auth_ref": [
      "r168"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to terms and conditions of share-based payment arrangements."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of terms and conditions of share-based payment arrangement [table]"
       }
      }
     },
     "localname": "DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsDetails",
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsExpenseRecognizedForProgramDetails",
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsExpensesDetails",
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsTables"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of trade and other payables. [Refer: Trade and other payables]"
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of trade and other payables [text block]",
        "terseLabel": "Trade and other payables"
       }
      }
     },
     "localname": "DisclosureOfTradeAndOtherPayablesExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureTradeAndOtherPayables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfTransactionPriceAllocatedToRemainingPerformanceObligationsExplanatory": {
     "auth_ref": [
      "r150"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of the transaction price allocated to the remaining performance obligations in contracts with customers."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of transaction price allocated to remaining performance obligations [text block]",
        "terseLabel": "Schedule of Contract liabilities allocated to the remaining performance obligations (unsatisfied or partially unsatisfied) as at year-end"
       }
      }
     },
     "localname": "DisclosureOfTransactionPriceAllocatedToRemainingPerformanceObligationsExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related party disclosures"
       }
      }
     },
     "localname": "DisclosureOfTransactionsBetweenRelatedPartiesAbstract",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of transactions between related parties [line items]",
        "terseLabel": "Related party disclosures"
       }
      }
     },
     "localname": "DisclosureOfTransactionsBetweenRelatedPartiesLineItems",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureRelatedPartyDisclosuresDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable": {
     "auth_ref": [
      "r72"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to transactions between related parties."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of transactions between related parties [table]"
       }
      }
     },
     "localname": "DisclosureOfTransactionsBetweenRelatedPartiesTable",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureRelatedPartyDisclosuresDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings per share"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_EarningsPerShareExplanatory": {
     "auth_ref": [
      "r84"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of earnings per share."
       }
      },
      "en-us": {
       "role": {
        "label": "Earnings per share [text block]",
        "terseLabel": "Earnings per share"
       }
      }
     },
     "localname": "EarningsPerShareExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureEarningsPerShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents": {
     "auth_ref": [
      "r108",
      "r109"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The effect of exchange rate changes on cash and cash equivalents held or due in a foreign currency. [Refer: Cash and cash equivalents]"
       }
      },
      "en-us": {
       "role": {
        "label": "Effect of exchange rate changes on cash and cash equivalents",
        "terseLabel": "Currency translation gains (losses) on cash and cash equivalents"
       }
      }
     },
     "localname": "EffectOfExchangeRateChangesOnCashAndCashEquivalents",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_EntitysTotalForBusinessCombinationsMember": {
     "auth_ref": [
      "r184",
      "r186"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for the standard value for the 'Business combinations' axis if no other member is used."
       }
      },
      "en-us": {
       "role": {
        "label": "Entity's total for business combinations [member]"
       }
      }
     },
     "localname": "EntitysTotalForBusinessCombinationsMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureCorporateInformationDetails",
      "http://www.curevac.com/role/DisclosureSignificantTransactionsAndEventsAnalysesOfCashFlowsOnFrameAcquisitionDetails",
      "http://www.curevac.com/role/DisclosureSignificantTransactionsAndEventsDetails",
      "http://www.curevac.com/role/DisclosureSignificantTransactionsAndEventsFrameAcquisitionPurchasePriceAllocationDetails",
      "http://www.curevac.com/role/DisclosureSignificantTransactionsAndEventsGoodwillRecognizedOnFrameAcquisitionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_EntitysTotalForRelatedPartiesMember": {
     "auth_ref": [
      "r72"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for the standard value for the 'Categories of related parties' axis if no other member is used."
       }
      },
      "en-us": {
       "role": {
        "label": "Entity's total for related parties [member]"
       }
      }
     },
     "localname": "EntitysTotalForRelatedPartiesMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureRelatedPartyDisclosuresDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_EntitysTotalForSubsidiariesMember": {
     "auth_ref": [
      "r79",
      "r81",
      "r135"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for the standard value for the 'Subsidiaries' axis if no other member is used."
       }
      },
      "en-us": {
       "role": {
        "label": "Entity's total for subsidiaries [member]"
       }
      }
     },
     "localname": "EntitysTotalForSubsidiariesMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureIncomeTaxDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_Equity": {
     "auth_ref": [
      "r24",
      "r32",
      "r118",
      "r120",
      "r136",
      "r137",
      "r140"
     ],
     "calculation": {
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition": {
       "order": 1.0,
       "parentTag": "ifrs-full_EquityAndLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of residual interest in the assets of the entity after deducting all its liabilities."
       }
      },
      "en-us": {
       "role": {
        "label": "Equity.",
        "periodEndLabel": "Balance at the end",
        "periodStartLabel": "Balance at the beginning",
        "totalLabel": "Total equity"
       }
      }
     },
     "localname": "Equity",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfChangesInShareholdersEquity",
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [abstract]",
        "terseLabel": "Equity"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_EquityAndLiabilities": {
     "auth_ref": [
      "r24"
     ],
     "calculation": {
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of the entity's equity and liabilities. [Refer: Equity; Liabilities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Equity and liabilities",
        "totalLabel": "Total equity and liabilities"
       }
      }
     },
     "localname": "EquityAndLiabilities",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_EquityAndLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "EquityAndLiabilitiesAbstract",
        "terseLabel": "Equity and liabilities"
       }
      }
     },
     "localname": "EquityAndLiabilitiesAbstract",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_EquityInterestsOfAcquirer": {
     "auth_ref": [
      "r176"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The fair value, at the acquisition date, of equity interests of the acquirer transferred as consideration in a business combination. [Refer: Business combinations [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Equity interests of acquirer",
        "terseLabel": "Value of shares issued to former Frame shareholders",
        "verboseLabel": "Value of aggregate consideration in shares"
       }
      }
     },
     "localname": "EquityInterestsOfAcquirer",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureSignificantTransactionsAndEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_EquityMember": {
     "auth_ref": [
      "r10"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for the residual interest in the assets of the entity after deducting all its liabilities. It also represents the standard value for the 'Components of equity' axis if no other member is used."
       }
      },
      "en-us": {
       "role": {
        "label": "Equity [member]"
       }
      }
     },
     "localname": "EquityMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureIssuedCapitalAndReservesOverviewAndGeneralRemarksDetails",
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfChangesInShareholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_ExpenseByNature": {
     "auth_ref": [
      "r46"
     ],
     "calculation": {
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsCostOfSalesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of expenses aggregated according to their nature (for example, depreciation, purchases of materials, transport costs, employee benefits and advertising costs), and not reallocated among functions within the entity."
       }
      },
      "en-us": {
       "role": {
        "label": "Expenses, by nature",
        "negatedTotalLabel": "Total"
       }
      }
     },
     "localname": "ExpenseByNature",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsCostOfSalesDetails",
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsGeneralAndAdministrativeExpensesDetails",
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsResearchAndDevelopmentExpensesDetails",
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsSellingAndDistributionExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets": {
     "auth_ref": [
      "r171"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of expense arising from share-based payment transactions in which the goods or services received did not qualify for recognition as assets."
       }
      },
      "en-us": {
       "role": {
        "label": "Expense from share-based payment transactions in which goods or services received did not qualify for recognition as assets",
        "terseLabel": "Expenses from share-based payments"
       }
      }
     },
     "localname": "ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsGeneralAndAdministrativeExpensesDetails",
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsResearchAndDevelopmentExpensesDetails",
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsSellingAndDistributionExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees": {
     "auth_ref": [
      "r12"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of expense from share-based payment transactions with employees. [Refer: Expense from share-based payment transactions]"
       }
      },
      "en-us": {
       "role": {
        "label": "Expense from share-based payment transactions with employees",
        "terseLabel": "Share-based based payments expenses"
       }
      }
     },
     "localname": "ExpenseFromSharebasedPaymentTransactionsWithEmployees",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory": {
     "auth_ref": [
      "r149"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The explanation of the significant changes in the contract assets and the contract liabilities. [Refer: Contract assets; Contract liabilities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Explanation of significant changes in contract assets and contract liabilities [text block]",
        "terseLabel": "Schedule of contract balances"
       }
      }
     },
     "localname": "ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_FairValueOfAcquiredReceivables": {
     "auth_ref": [
      "r179"
     ],
     "calculation": {
      "http://www.curevac.com/role/DisclosureSignificantTransactionsAndEventsFrameAcquisitionPurchasePriceAllocationDetails": {
       "order": 2.0,
       "parentTag": "ifrs-full_CurrentAssetsRecognisedAsOfAcquisitionDate",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The fair value of receivables acquired in a business combination. [Refer: Business combinations [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Fair value of acquired receivables",
        "terseLabel": "Trade and other receivables"
       }
      }
     },
     "localname": "FairValueOfAcquiredReceivables",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureSignificantTransactionsAndEventsFrameAcquisitionPurchasePriceAllocationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_FinanceCosts": {
     "auth_ref": [
      "r41"
     ],
     "calculation": {
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfOperationsAndOtherComprehensiveIncomeLoss": {
       "order": 2.0,
       "parentTag": "ifrs-full_ProfitLossBeforeTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of costs associated with financing activities of the entity."
       }
      },
      "en-us": {
       "role": {
        "label": "Finance costs",
        "negatedLabel": "Finance expenses"
       }
      }
     },
     "localname": "FinanceCosts",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfOperationsAndOtherComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_FinanceIncome": {
     "auth_ref": [
      "r43"
     ],
     "calculation": {
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfOperationsAndOtherComprehensiveIncomeLoss": {
       "order": 1.0,
       "parentTag": "ifrs-full_ProfitLossBeforeTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of income associated with interest and other financing activities of the entity."
       }
      },
      "en-us": {
       "role": {
        "label": "Finance income",
        "terseLabel": "Finance income"
       }
      }
     },
     "localname": "FinanceIncome",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfOperationsAndOtherComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r12"
     ],
     "calculation": {
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfOperationsAndOtherComprehensiveIncomeLoss": {
       "order": 5.0,
       "parentTag": "ifrs-full_ProfitLossFromOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of expense relating to general and administrative activities of the entity."
       }
      },
      "en-us": {
       "role": {
        "label": "General and administrative expense",
        "negatedLabel": "General and administrative expenses"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfOperationsAndOtherComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_GeographicalAreasAxis": {
     "auth_ref": [
      "r64",
      "r152",
      "r221",
      "r234"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Geographical areas [axis]"
       }
      }
     },
     "localname": "GeographicalAreasAxis",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsRevenueFromContractWithCustomersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_GeographicalAreasMember": {
     "auth_ref": [
      "r64",
      "r152",
      "r221",
      "r234"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for aggregated geographical areas. It also represents the standard value for the 'Geographical areas' axis if no other member is used."
       }
      },
      "en-us": {
       "role": {
        "label": "Geographical areas [member]"
       }
      }
     },
     "localname": "GeographicalAreasMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsRevenueFromContractWithCustomersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_GoodwillRecognisedAsOfAcquisitionDate": {
     "auth_ref": [
      "r184",
      "r187"
     ],
     "calculation": {
      "http://www.curevac.com/role/DisclosureSignificantTransactionsAndEventsGoodwillRecognizedOnFrameAcquisitionDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount recognised as of the business combination's acquisition date for goodwill. [Refer: Goodwill; Business combinations [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Goodwill recognised as of acquisition date",
        "negatedTotalLabel": "Preliminary Goodwill"
       }
      }
     },
     "localname": "GoodwillRecognisedAsOfAcquisitionDate",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureSignificantTransactionsAndEventsGoodwillRecognizedOnFrameAcquisitionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_GovernmentGrants": {
     "auth_ref": [
      "r24"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of assistance by government in the form of transfers of resources to an entity in return for past or future compliance with certain conditions relating to the operating activities of the entity, recognised as deferred income. They exclude those forms of government assistance that cannot reasonably have a value placed upon them and transactions with government that cannot be distinguished from the normal trading transactions of the entity. [Refer: Deferred income other than contract liabilities; Government [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Government grants",
        "terseLabel": "Grants received and deferred"
       }
      }
     },
     "localname": "GovernmentGrants",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsGrantsWithGovernmentAgenciesAndSimilarBodiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_GrossCarryingAmountMember": {
     "auth_ref": [
      "r60",
      "r88",
      "r93",
      "r94",
      "r185",
      "r199",
      "r201",
      "r202",
      "r236",
      "r237"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for the amount at which an asset is recognised before deducting any accumulated depreciation (amortisation) and accumulated impairment losses thereon. [Refer: Depreciation and amortisation expense; Impairment loss]"
       }
      },
      "en-us": {
       "role": {
        "label": "Acquisition costs"
       }
      }
     },
     "localname": "GrossCarryingAmountMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureFixedAssetsIntangibleAssetsDetails",
      "http://www.curevac.com/role/DisclosureFixedAssetsPropertyPlantAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed": {
     "auth_ref": [
      "r180",
      "r187"
     ],
     "calculation": {
      "http://www.curevac.com/role/DisclosureSignificantTransactionsAndEventsFrameAcquisitionPurchasePriceAllocationDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.curevac.com/role/DisclosureSignificantTransactionsAndEventsGoodwillRecognizedOnFrameAcquisitionDetails": {
       "order": 2.0,
       "parentTag": "ifrs-full_GoodwillRecognisedAsOfAcquisitionDate",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount recognised as of the acquisition date for net identifiable assets acquired or liabilities assumed in a business combination. [Refer: Business combinations [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Identifiable assets acquired (liabilities assumed)",
        "negatedLabel": "Net Assets acquired",
        "totalLabel": "Net assets acquired"
       }
      }
     },
     "localname": "IdentifiableAssetsAcquiredLiabilitiesAssumed",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureSignificantTransactionsAndEventsFrameAcquisitionPurchasePriceAllocationDetails",
      "http://www.curevac.com/role/DisclosureSignificantTransactionsAndEventsGoodwillRecognizedOnFrameAcquisitionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_InAccordanceWithIFRS9Member": {
     "auth_ref": [
      "r235"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for the information reported in accordance with IFRS 9."
       }
      },
      "en-us": {
       "role": {
        "label": "Effects from the first-time adoption of IFRS 9"
       }
      }
     },
     "localname": "InAccordanceWithIFRS9Member",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfChangesInShareholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_IncomeTaxExpenseContinuingOperations": {
     "auth_ref": [
      "r42",
      "r51",
      "r53",
      "r54",
      "r77",
      "r134",
      "r214"
     ],
     "calculation": {
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfOperationsAndOtherComprehensiveIncomeLoss": {
       "order": 2.0,
       "parentTag": "ifrs-full_ProfitLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The aggregate amount included in the determination of profit (loss) for the period in respect of current tax and deferred tax. [Refer: Current tax expense (income); Deferred tax expense (income)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Tax expense (income)",
        "negatedLabel": "Income tax benefit/ (expense)"
       }
      }
     },
     "localname": "IncomeTaxExpenseContinuingOperations",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureIncomeTaxDetails",
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfOperationsAndOtherComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IncomeTaxesPaidClassifiedAsOperatingActivities": {
     "auth_ref": [
      "r111"
     ],
     "calculation": {
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows": {
       "order": 17.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash outflow for income taxes paid, classified as operating activities."
       }
      },
      "en-us": {
       "role": {
        "label": "Income taxes paid, classified as operating activities",
        "negatedLabel": "Income taxes paid"
       }
      }
     },
     "localname": "IncomeTaxesPaidClassifiedAsOperatingActivities",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IncreaseDecreaseDueToApplicationOfIFRS15Member": {
     "auth_ref": [
      "r154"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for IFRS 15 Revenue with Contracts with Customers."
       }
      },
      "en-us": {
       "role": {
        "label": "Effects from the first-time adoption of IFRS 15"
       }
      }
     },
     "localname": "IncreaseDecreaseDueToApplicationOfIFRS15Member",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfChangesInShareholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges": {
     "auth_ref": [
      "r113"
     ],
     "calculation": {
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The increase (decrease) in cash and cash equivalents before the effect of exchange rate changes on cash and cash equivalents held in foreign currencies. [Refer: Cash and cash equivalents; Effect of exchange rate changes on cash and cash equivalents]"
       }
      },
      "en-us": {
       "role": {
        "label": "Increase (decrease) in cash and cash equivalents before effect of exchange rate changes",
        "totalLabel": "Net increase (decrease) in cash and cash equivalents"
       }
      }
     },
     "localname": "IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IncreaseDecreaseThroughAcquisitionOfSubsidiary": {
     "auth_ref": [
      "r9"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The increase (decrease) in equity resulting from the acquisition of subsidiaries. [Refer: Subsidiaries [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Increase (decrease) through acquisition of subsidiary, equity",
        "terseLabel": "Capital Increase from Business Combinations"
       }
      }
     },
     "localname": "IncreaseDecreaseThroughAcquisitionOfSubsidiary",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfChangesInShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IncreaseDecreaseThroughConversionOfConvertibleInstruments": {
     "auth_ref": [
      "r9"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The increase (decrease) in equity resulting from the conversion of convertible instruments."
       }
      },
      "en-us": {
       "role": {
        "label": "Increase (decrease) through conversion of convertible instruments, equity",
        "positiveTerseLabel": "Equity component of convertible loans (net of tax)"
       }
      }
     },
     "localname": "IncreaseDecreaseThroughConversionOfConvertibleInstruments",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfChangesInShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IncreaseDecreaseThroughExerciseOfOptions": {
     "auth_ref": [
      "r9"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The increase (decrease) in equity resulting from the exercise of options."
       }
      },
      "en-us": {
       "role": {
        "label": "Shares issued on exercise of option",
        "terseLabel": "Exercise of options"
       }
      }
     },
     "localname": "IncreaseDecreaseThroughExerciseOfOptions",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfChangesInShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IncreaseDecreaseThroughTreasuryShareTransactions": {
     "auth_ref": [
      "r9"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The increase (decrease) in equity resulting from treasury share transactions. [Refer: Equity; Treasury shares]"
       }
      },
      "en-us": {
       "role": {
        "label": "Increase (decrease) through treasury share transactions, equity",
        "terseLabel": "Repurchase of common shares"
       }
      }
     },
     "localname": "IncreaseDecreaseThroughTreasuryShareTransactions",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfChangesInShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_InsuranceExpense": {
     "auth_ref": [
      "r12"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of expense arising from purchased insurance."
       }
      },
      "en-us": {
       "role": {
        "label": "Insurance expense",
        "terseLabel": "Insurance expense"
       }
      }
     },
     "localname": "InsuranceExpense",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsGeneralAndAdministrativeExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IntangibleAssetsAndGoodwill": {
     "auth_ref": [
      "r24"
     ],
     "calculation": {
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition": {
       "order": 2.0,
       "parentTag": "ifrs-full_NoncurrentAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of intangible assets and goodwill held by the entity. [Refer: Goodwill; Intangible assets other than goodwill]"
       }
      },
      "en-us": {
       "role": {
        "label": "Intangible assets and goodwill",
        "terseLabel": "Intangible assets and goodwill"
       }
      }
     },
     "localname": "IntangibleAssetsAndGoodwill",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IntangibleAssetsOtherThanGoodwill": {
     "auth_ref": [
      "r16",
      "r90"
     ],
     "calculation": {
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition": {
       "order": 1.0,
       "parentTag": "ifrs-full_NoncurrentAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of identifiable non-monetary assets without physical substance. This amount does not include goodwill. [Refer: Goodwill]"
       }
      },
      "en-us": {
       "role": {
        "label": "IntangibleAssetsOtherThanGoodwill",
        "terseLabel": "Intangible assets"
       }
      }
     },
     "localname": "IntangibleAssetsOtherThanGoodwill",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IntangibleAssetsOtherThanGoodwillMember": {
     "auth_ref": [
      "r87",
      "r91",
      "r157"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for intangible assets other than goodwill. It also represents the standard value for the 'Classes of intangible assets other than goodwill' axis if no other member is used. [Refer: Intangible assets other than goodwill]"
       }
      },
      "en-us": {
       "role": {
        "label": "Intangible assets other than goodwill [member]"
       }
      }
     },
     "localname": "IntangibleAssetsOtherThanGoodwillMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureFixedAssetsIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_InterestPaidClassifiedAsOperatingActivities": {
     "auth_ref": [
      "r110"
     ],
     "calculation": {
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows": {
       "order": 19.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash outflow for interest paid, classified as operating activities."
       }
      },
      "en-us": {
       "role": {
        "label": "Interest paid, classified as operating activities",
        "negatedTerseLabel": "Interest paid"
       }
      }
     },
     "localname": "InterestPaidClassifiedAsOperatingActivities",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_InterestReceivedClassifiedAsOperatingActivities": {
     "auth_ref": [
      "r110"
     ],
     "calculation": {
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows": {
       "order": 18.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash inflow from interest received, classified as operating activities."
       }
      },
      "en-us": {
       "role": {
        "label": "Interest received, classified as operating activities",
        "verboseLabel": "Interest received"
       }
      }
     },
     "localname": "InterestReceivedClassifiedAsOperatingActivities",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_Inventories": {
     "auth_ref": [
      "r18",
      "r28",
      "r66"
     ],
     "calculation": {
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition": {
       "order": 1.0,
       "parentTag": "ifrs-full_CurrentAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of current inventories. [Refer: Inventories]"
       }
      },
      "en-us": {
       "role": {
        "label": "Inventories",
        "terseLabel": "Inventories"
       }
      }
     },
     "localname": "Inventories",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_InventoryWritedown2011": {
     "auth_ref": [
      "r45",
      "r67"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of expense recognised related to the write-down of inventories to net realisable value. [Refer: Inventories]"
       }
      },
      "en-us": {
       "role": {
        "label": "Inventory write-down",
        "terseLabel": "Inventory write-offs"
       }
      }
     },
     "localname": "InventoryWritedown2011",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IssueOfEquity": {
     "auth_ref": [
      "r8"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The increase in equity through the issue of equity instruments."
       }
      },
      "en-us": {
       "role": {
        "label": "Issue of equity",
        "verboseLabel": "Issuance of share capital (net of transaction costs)"
       }
      }
     },
     "localname": "IssueOfEquity",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfChangesInShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IssuedCapital": {
     "auth_ref": [
      "r32"
     ],
     "calculation": {
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition": {
       "order": 1.0,
       "parentTag": "ifrs-full_Equity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The nominal value of capital issued."
       }
      },
      "en-us": {
       "role": {
        "label": "Issued capital.",
        "terseLabel": "Issued capital"
       }
      }
     },
     "localname": "IssuedCapital",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IssuedCapitalMember": {
     "auth_ref": [
      "r10"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for a component of equity representing issued capital."
       }
      },
      "en-us": {
       "role": {
        "label": "Issued capital"
       }
      }
     },
     "localname": "IssuedCapitalMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfChangesInShareholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember": {
     "auth_ref": [
      "r12",
      "r158",
      "r159",
      "r206",
      "r210",
      "r232"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for a time band of later than one year and not later than two years."
       }
      },
      "en-us": {
       "role": {
        "label": "2022"
       }
      }
     },
     "localname": "LaterThanOneYearAndNotLaterThanTwoYearsMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_Liabilities": {
     "auth_ref": [
      "r24",
      "r136",
      "r137",
      "r140",
      "r215",
      "r218"
     ],
     "calculation": {
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition": {
       "order": 2.0,
       "parentTag": "ifrs-full_EquityAndLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of a present obligation of the entity to transfer an economic resource as a result of past events. Economic resource is a right that has the potential to produce economic benefits."
       }
      },
      "en-us": {
       "role": {
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_LiabilitiesIncurred": {
     "auth_ref": [
      "r175"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The fair value, at acquisition date, of liabilities incurred (for example, a liability for contingent consideration) as consideration transferred in a business combination. [Refer: Business combinations [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Liabilities incurred",
        "terseLabel": "Net amount of discharging contractual obligations"
       }
      }
     },
     "localname": "LiabilitiesIncurred",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureSignificantTransactionsAndEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income tax"
       }
      }
     },
     "localname": "MajorComponentsOfTaxExpenseIncomeAbstract",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_MajorCustomersAxis": {
     "auth_ref": [
      "r222"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Major customers [axis]"
       }
      }
     },
     "localname": "MajorCustomersAxis",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsRevenueFromContractWithCustomersDetails",
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsSummaryOfUpfrontPaymentsAndRelatedRevenuesRecognizedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_MajorCustomersMember": {
     "auth_ref": [
      "r222"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for customers. It also represents the standard value for the 'Major customers' axis if no other member is used."
       }
      },
      "en-us": {
       "role": {
        "label": "Customers [member]"
       }
      }
     },
     "localname": "MajorCustomersMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsRevenueFromContractWithCustomersDetails",
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsSummaryOfUpfrontPaymentsAndRelatedRevenuesRecognizedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_MajorOrdinaryShareTransactionsMember": {
     "auth_ref": [
      "r49"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for major ordinary share transactions. [Refer: Ordinary shares [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Share transaction"
       }
      }
     },
     "localname": "MajorOrdinaryShareTransactionsMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureIssuedCapitalAndReservesImpactOfShareSplitDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_MaturityAxis": {
     "auth_ref": [
      "r26",
      "r65",
      "r150",
      "r158",
      "r159",
      "r193",
      "r204",
      "r206",
      "r223",
      "r224",
      "r226",
      "r232"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Maturity [axis]"
       }
      }
     },
     "localname": "MaturityAxis",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_MiscellaneousOtherOperatingExpense": {
     "auth_ref": [
      "r12"
     ],
     "calculation": {
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfOperationsAndOtherComprehensiveIncomeLoss": {
       "order": 7.0,
       "parentTag": "ifrs-full_ProfitLossFromOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of miscellaneous other operating expenses. [Refer: Other operating income (expense)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Miscellaneous other operating expense",
        "negatedLabel": "Other operating expenses"
       }
      }
     },
     "localname": "MiscellaneousOtherOperatingExpense",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfOperationsAndOtherComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_MiscellaneousOtherOperatingIncome": {
     "auth_ref": [
      "r12"
     ],
     "calculation": {
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsOtherOperatingIncomeDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfOperationsAndOtherComprehensiveIncomeLoss": {
       "order": 6.0,
       "parentTag": "ifrs-full_ProfitLossFromOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of miscellaneous other operating income. [Refer: Other operating income (expense)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Miscellaneous other operating income",
        "terseLabel": "Other operating income",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "MiscellaneousOtherOperatingIncome",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsOtherOperatingIncomeDetails",
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfOperationsAndOtherComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_NetDeferredTaxAssets": {
     "auth_ref": [
      "r56"
     ],
     "calculation": {
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition": {
       "order": 5.0,
       "parentTag": "ifrs-full_NoncurrentAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of deferred tax assets net of deferred tax liabilities, when the absolute amount of deferred tax assets is greater than the absolute amount of deferred tax liabilities. [Refer: Deferred tax assets; Deferred tax liabilities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Net deferred tax assets",
        "terseLabel": "Deferred tax assets"
       }
      }
     },
     "localname": "NetDeferredTaxAssets",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_NonadjustingEventsAfterReportingPeriodAxis": {
     "auth_ref": [
      "r48"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Non-adjusting events after reporting period [axis]"
       }
      }
     },
     "localname": "NonadjustingEventsAfterReportingPeriodAxis",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureIssuedCapitalAndReservesImpactOfShareSplitDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_NonadjustingEventsMember": {
     "auth_ref": [
      "r48"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for events that occur between the end of the reporting period and the date when the financial statements are authorised for issue and are indicative of conditions that arose after the reporting period. It also represents the standard value for the 'Non-adjusting events after reporting period' axis if no other member is used."
       }
      },
      "en-us": {
       "role": {
        "label": "Non-adjusting events after reporting period [member]"
       }
      }
     },
     "localname": "NonadjustingEventsMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureIssuedCapitalAndReservesImpactOfShareSplitDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_NoncurrentAssets": {
     "auth_ref": [
      "r27",
      "r124",
      "r126"
     ],
     "calculation": {
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition": {
       "order": 1.0,
       "parentTag": "ifrs-full_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of assets that do not meet the definition of current assets. [Refer: Current assets]"
       }
      },
      "en-us": {
       "role": {
        "label": "Total non-current assets",
        "totalLabel": "Total non-current assets"
       }
      }
     },
     "localname": "NoncurrentAssets",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_NoncurrentAssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "NoncurrentAssets",
        "terseLabel": "Non-current assets"
       }
      }
     },
     "localname": "NoncurrentAssetsAbstract",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners": {
     "auth_ref": [
      "r20"
     ],
     "calculation": {
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition": {
       "order": 7.0,
       "parentTag": "ifrs-full_CurrentAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of non-current assets or disposal groups classified as held for sale or as held for distribution to owners. [Refer: Non-current assets or disposal groups classified as held for distribution to owners; Non-current assets or disposal groups classified as held for sale]"
       }
      },
      "en-us": {
       "role": {
        "label": "Non-current assets or disposal groups classified as held for sale or as held for distribution to owners",
        "terseLabel": "Assets held for sale"
       }
      }
     },
     "localname": "NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwnersAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets held for sale"
       }
      }
     },
     "localname": "NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwnersAbstract",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_NoncurrentAssetsRecognisedAsOfAcquisitionDate": {
     "auth_ref": [
      "r180"
     ],
     "calculation": {
      "http://www.curevac.com/role/DisclosureSignificantTransactionsAndEventsFrameAcquisitionPurchasePriceAllocationDetails": {
       "order": 1.0,
       "parentTag": "cvac_TotalAssetsRecognisedAsOfAcquisitionDate",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "Expiry date 2022-01-01: The amount recognised as of the acquisition date for non-current assets acquired in a business combination. [Refer: Business combinations [member]]\nEffective 2022-01-01: The amount recognised as of the acquisition date for non-current assets acquired in a business combination. [Refer: Non-current assets; Business combinations [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Non-current assets recognised as of acquisition date",
        "totalLabel": "Non-current assets"
       }
      }
     },
     "localname": "NoncurrentAssetsRecognisedAsOfAcquisitionDate",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureSignificantTransactionsAndEventsFrameAcquisitionPurchasePriceAllocationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_NoncurrentContractLiabilities": {
     "auth_ref": [
      "r144"
     ],
     "calculation": {
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition": {
       "order": 2.0,
       "parentTag": "ifrs-full_NoncurrentLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of non-current contract liabilities. [Refer: Contract liabilities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Non-current contract liabilities",
        "terseLabel": "Contract liabilities"
       }
      }
     },
     "localname": "NoncurrentContractLiabilities",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_NoncurrentFinancialLiabilities": {
     "auth_ref": [
      "r194"
     ],
     "calculation": {
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition": {
       "order": 3.0,
       "parentTag": "ifrs-full_NoncurrentLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of non-current financial liabilities. [Refer: Financial liabilities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Non-current financial liabilities",
        "terseLabel": "Finance Liabilities"
       }
      }
     },
     "localname": "NoncurrentFinancialLiabilities",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_NoncurrentLeaseLiabilities": {
     "auth_ref": [
      "r155"
     ],
     "calculation": {
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition": {
       "order": 1.0,
       "parentTag": "ifrs-full_NoncurrentLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of non-current lease liabilities. [Refer: Lease liabilities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Non-current lease liabilities",
        "terseLabel": "Lease liabilities"
       }
      }
     },
     "localname": "NoncurrentLeaseLiabilities",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_NoncurrentLiabilities": {
     "auth_ref": [
      "r29",
      "r124",
      "r128"
     ],
     "calculation": {
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition": {
       "order": 1.0,
       "parentTag": "ifrs-full_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of liabilities that do not meet the definition of current liabilities. [Refer: Current liabilities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Non-current liabilities",
        "totalLabel": "Total non-current liabilities"
       }
      }
     },
     "localname": "NoncurrentLiabilities",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_NoncurrentLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "NoncurrentLiabilitiesAbstract",
        "terseLabel": "Non-current liabilities"
       }
      }
     },
     "localname": "NoncurrentLiabilitiesAbstract",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_NoncurrentLiabilitiesRecognisedAsOfAcquisitionDate": {
     "auth_ref": [
      "r180"
     ],
     "calculation": {
      "http://www.curevac.com/role/DisclosureSignificantTransactionsAndEventsFrameAcquisitionPurchasePriceAllocationDetails": {
       "order": 2.0,
       "parentTag": "cvac_LiabilitiesRecognisedAsOfAcquisitionDate",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "Expiry date 2022-01-01: The amount recognised as of the acquisition date for non-current liabilities assumed in a business combination. [Refer: Business combinations [member]]\nEffective 2022-01-01: The amount recognised as of the acquisition date for non-current liabilities assumed in a business combination. [Refer: Non-current liabilities; Business combinations [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Non-current liabilities recognised as of acquisition date",
        "totalLabel": "Non-current liabilities"
       }
      }
     },
     "localname": "NoncurrentLiabilitiesRecognisedAsOfAcquisitionDate",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureSignificantTransactionsAndEventsFrameAcquisitionPurchasePriceAllocationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_NotLaterThanOneYearMember": {
     "auth_ref": [
      "r25",
      "r158",
      "r159",
      "r206",
      "r210",
      "r232"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for a time band of not later than one year."
       }
      },
      "en-us": {
       "role": {
        "label": "Within one year"
       }
      }
     },
     "localname": "NotLaterThanOneYearMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_NumberOfInstrumentsGrantedInSharebasedPaymentArrangement": {
     "auth_ref": [
      "r161",
      "r172"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The number of instruments granted in share-based payment arrangement."
       }
      },
      "en-us": {
       "role": {
        "label": "Number of instruments granted in share-based payment arrangement",
        "terseLabel": "Number of awards granted"
       }
      }
     },
     "localname": "NumberOfInstrumentsGrantedInSharebasedPaymentArrangement",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "ifrs-full_NumberOfInstrumentsOrInterestsIssuedOrIssuable": {
     "auth_ref": [
      "r176"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The number of instruments or interests issued or issuable at acquisition date for equity interests of the acquirer transferred as consideration in a business combination."
       }
      },
      "en-us": {
       "role": {
        "label": "Number of instruments or interests issued or issuable",
        "verboseLabel": "Aggregate consideration in shares"
       }
      }
     },
     "localname": "NumberOfInstrumentsOrInterestsIssuedOrIssuable",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureSignificantTransactionsAndEventsDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted": {
     "auth_ref": [
      "r168",
      "r170"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The number of other equity instruments (ie other than share options) granted in a share-based payment arrangement."
       }
      },
      "en-us": {
       "role": {
        "label": "Number of other equity instruments granted in share-based payment arrangement",
        "terseLabel": "Number of RSU's awarded",
        "verboseLabel": "RSUs issued to certain former employees"
       }
      }
     },
     "localname": "NumberOfInstrumentsOtherEquityInstrumentsGranted",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsDetails",
      "http://www.curevac.com/role/DisclosureSignificantTransactionsAndEventsDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement": {
     "auth_ref": [
      "r164"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The number of share options exercisable in a share-based payment arrangement."
       }
      },
      "en-us": {
       "role": {
        "label": "Options exercisable",
        "terseLabel": "Thereof exercisable"
       }
      }
     },
     "localname": "NumberOfShareOptionsExercisableInSharebasedPaymentArrangement",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement": {
     "auth_ref": [
      "r163"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The number of share options exercised in a share-based payment arrangement."
       }
      },
      "en-us": {
       "role": {
        "label": "Number of share options exercised in share-based payment arrangement",
        "terseLabel": "Number of options exercised"
       }
      }
     },
     "localname": "NumberOfShareOptionsExercisedInSharebasedPaymentArrangement",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement": {
     "auth_ref": [
      "r162"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The number of share options granted in a share-based payment arrangement."
       }
      },
      "en-us": {
       "role": {
        "label": "Number of share options granted",
        "verboseLabel": "Number of share options granted"
       }
      }
     },
     "localname": "NumberOfShareOptionsGrantedInSharebasedPaymentArrangement",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "ifrs-full_NumberOfSharesAuthorised": {
     "auth_ref": [
      "r33"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The number of shares authorised."
       }
      },
      "en-us": {
       "role": {
        "label": "Number of shares authorised",
        "terseLabel": "Number of shares authorized"
       }
      }
     },
     "localname": "NumberOfSharesAuthorised",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureIssuedCapitalAndReservesOverviewAndGeneralRemarksDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "ifrs-full_NumberOfSharesIssued": {
     "auth_ref": [
      "r9"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The number of shares issued by the entity."
       }
      },
      "en-us": {
       "role": {
        "label": "Number of shares issued",
        "verboseLabel": "Number of shares issued"
       }
      }
     },
     "localname": "NumberOfSharesIssued",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureIssuedCapitalAndReservesOverviewAndGeneralRemarksDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "ifrs-full_NumberOfSharesOutstanding": {
     "auth_ref": [
      "r35"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The number of shares that have been authorised and issued, reduced by treasury shares held. [Refer: Treasury shares]"
       }
      },
      "en-us": {
       "role": {
        "label": "Number of shares outstanding",
        "periodEndLabel": "Balance at the end (in shares)"
       }
      }
     },
     "localname": "NumberOfSharesOutstanding",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfChangesInShareholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "ifrs-full_OrdinarySharesMember": {
     "auth_ref": [
      "r36",
      "r84"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for equity instruments that are subordinate to all other classes of equity instruments. It also represents the standard value for the 'Classes of ordinary shares' axis if no other member is used."
       }
      },
      "en-us": {
       "role": {
        "label": "Common shares"
       }
      }
     },
     "localname": "OrdinarySharesMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureIssuedCapitalAndReservesOverviewAndGeneralRemarksDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_OtherComprehensiveIncome": {
     "auth_ref": [
      "r7",
      "r39",
      "r44",
      "r130"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of income and expense (including reclassification adjustments) that is not recognised in profit or loss as required or permitted by IFRSs. [Refer: IFRSs [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Other comprehensive income",
        "terseLabel": "Other comprehensive income (loss)"
       }
      }
     },
     "localname": "OtherComprehensiveIncome",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfChangesInShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_OtherComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other comprehensive income [abstract]",
        "terseLabel": "Other comprehensive income (loss):"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeAbstract",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfOperationsAndOtherComprehensiveIncomeLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation": {
     "auth_ref": [
      "r30",
      "r44"
     ],
     "calculation": {
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfOperationsAndOtherComprehensiveIncomeLoss": {
       "order": 1.0,
       "parentTag": "ifrs-full_ComprehensiveIncome",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of other comprehensive income, net of tax, after reclassification adjustments, related to exchange differences when financial statements of foreign operations are translated. [Refer: Other comprehensive income]"
       }
      },
      "en-us": {
       "role": {
        "label": "Other comprehensive income, net of tax, exchange differences on translation",
        "terseLabel": "Foreign currency adjustments"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfOperationsAndOtherComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_OtherCurrentFinancialAssets": {
     "auth_ref": [
      "r17"
     ],
     "calculation": {
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition": {
       "order": 5.0,
       "parentTag": "ifrs-full_CurrentAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of current financial assets that the entity does not separately disclose in the same statement or note. [Refer: Other financial assets; Current financial assets]"
       }
      },
      "en-us": {
       "role": {
        "label": "Other current financial assets",
        "terseLabel": "Other financial assets"
       }
      }
     },
     "localname": "OtherCurrentFinancialAssets",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_OtherCurrentFinancialLiabilities": {
     "auth_ref": [
      "r22",
      "r132"
     ],
     "calculation": {
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition": {
       "order": 1.0,
       "parentTag": "ifrs-full_CurrentLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of current financial liabilities that the entity does not separately disclose in the same statement or note. [Refer: Other financial liabilities; Current financial liabilities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Other current financial liabilities"
       }
      }
     },
     "localname": "OtherCurrentFinancialLiabilities",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_OtherCurrentLiabilities": {
     "auth_ref": [
      "r24"
     ],
     "calculation": {
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition": {
       "order": 4.0,
       "parentTag": "ifrs-full_CurrentLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of current liabilities that the entity does not separately disclose in the same statement or note. [Refer: Current liabilities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Other current liabilities",
        "terseLabel": "Other liabilities"
       }
      }
     },
     "localname": "OtherCurrentLiabilities",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_OtherNoncurrentAssets": {
     "auth_ref": [
      "r24"
     ],
     "calculation": {
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition": {
       "order": 4.0,
       "parentTag": "ifrs-full_NoncurrentAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of non-current assets that the entity does not separately disclose in the same statement or note. [Refer: Non-current assets]"
       }
      },
      "en-us": {
       "role": {
        "label": "Other assets.",
        "terseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherNoncurrentAssets",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_OtherNoncurrentLiabilities": {
     "auth_ref": [
      "r24"
     ],
     "calculation": {
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition": {
       "order": 4.0,
       "parentTag": "ifrs-full_NoncurrentLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of non-current liabilities that the entity does not separately disclose in the same statement or note. [Refer: Non-current liabilities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Other non-current liabilities.",
        "terseLabel": "Other liabilities"
       }
      }
     },
     "localname": "OtherNoncurrentLiabilities",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ParValuePerShare": {
     "auth_ref": [
      "r34"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The nominal value per share."
       }
      },
      "en-us": {
       "role": {
        "label": "Par value per share",
        "verboseLabel": "Notional value per share"
       }
      }
     },
     "localname": "ParValuePerShare",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureIssuedCapitalAndReservesOverviewAndGeneralRemarksDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities": {
     "auth_ref": [
      "r101"
     ],
     "calculation": {
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash outflow for payment of lease liabilities, classified as financing activities. [Refer: Lease liabilities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Payments of lease liabilities, classified as financing activities",
        "negatedTerseLabel": "Payments on lease obligations"
       }
      }
     },
     "localname": "PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_PercentageOfVotingEquityInterestsAcquired": {
     "auth_ref": [
      "r173"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The percentage of voting equity interests acquired in a business combination. [Refer: Business combinations [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Percentage of voting equity interests acquired",
        "terseLabel": "Voting interests held"
       }
      }
     },
     "localname": "PercentageOfVotingEquityInterestsAcquired",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureCorporateInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ifrs-full_PreferenceSharesMember": {
     "auth_ref": [
      "r36"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for equity instruments that are senior in some aspects to ordinary shares, but subordinate to debt instruments in terms of claim. [Refer: Ordinary shares [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Preferred shares"
       }
      }
     },
     "localname": "PreferenceSharesMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureIssuedCapitalAndReservesOverviewAndGeneralRemarksDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_PreviouslyStatedMember": {
     "auth_ref": [
      "r5",
      "r115",
      "r116",
      "r117"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for the information previously stated in the financial statements (ie before retrospective application or retrospective restatement)."
       }
      },
      "en-us": {
       "role": {
        "label": "Previously stated"
       }
      }
     },
     "localname": "PreviouslyStatedMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfChangesInShareholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities": {
     "auth_ref": [
      "r99"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash inflow from borrowings obtained. [Refer: Borrowings]"
       }
      },
      "en-us": {
       "role": {
        "label": "Proceeds from borrowings, classified as financing activities",
        "terseLabel": "Amount drawn"
       }
      }
     },
     "localname": "ProceedsFromBorrowingsClassifiedAsFinancingActivities",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureLoansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ProceedsFromExerciseOfOptions": {
     "auth_ref": [
      "r102"
     ],
     "calculation": {
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows": {
       "order": 6.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash inflow from the exercise of options."
       }
      },
      "en-us": {
       "role": {
        "label": "Proceeds from exercise of options",
        "terseLabel": "Proceeds from the exercise of options"
       }
      }
     },
     "localname": "ProceedsFromExerciseOfOptions",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ProceedsFromGovernmentGrantsClassifiedAsFinancingActivities": {
     "auth_ref": [
      "r69"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash inflow from government grants, classified as financing activities. [Refer: Government [member]; Government grants]"
       }
      },
      "en-us": {
       "role": {
        "label": "Proceeds from government grants, classified as financing activities",
        "verboseLabel": "Government grants"
       }
      }
     },
     "localname": "ProceedsFromGovernmentGrantsClassifiedAsFinancingActivities",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsGrantsWithGovernmentAgenciesAndSimilarBodiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ProceedsFromIssueOfBondsNotesAndDebentures": {
     "auth_ref": [
      "r102"
     ],
     "calculation": {
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash inflow from the issuing of bonds, notes and debentures."
       }
      },
      "en-us": {
       "role": {
        "label": "Proceeds from issue of bonds, notes and debentures",
        "verboseLabel": "Proceeds from the convertible loan"
       }
      }
     },
     "localname": "ProceedsFromIssueOfBondsNotesAndDebentures",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ProceedsFromIssuingOtherEquityInstruments": {
     "auth_ref": [
      "r98"
     ],
     "calculation": {
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash inflow from issuing equity instruments that the entity does not separately disclose in the same statement or note."
       }
      },
      "en-us": {
       "role": {
        "label": "Proceeds from issuing other equity instruments",
        "terseLabel": "Payment on Treasury Shares"
       }
      }
     },
     "localname": "ProceedsFromIssuingOtherEquityInstruments",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ProceedsFromIssuingShares": {
     "auth_ref": [
      "r98"
     ],
     "calculation": {
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows": {
       "order": 5.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash inflow from issuing shares."
       }
      },
      "en-us": {
       "role": {
        "label": "Proceeds from issuing shares",
        "terseLabel": "Cash received from issuance of shares",
        "verboseLabel": "Proceeds from the issuance of shares (net of transaction costs)"
       }
      }
     },
     "localname": "ProceedsFromIssuingShares",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureIssuedCapitalAndReservesImpactOfShareSplitDetails",
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ProductsAndServicesAxis": {
     "auth_ref": [
      "r151",
      "r220"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Products and services [axis]"
       }
      }
     },
     "localname": "ProductsAndServicesAxis",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsRevenueFromContractWithCustomersDetails",
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsSummaryOfUpfrontPaymentsAndRelatedRevenuesRecognizedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_ProductsAndServicesMember": {
     "auth_ref": [
      "r151",
      "r220"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for the entity's products and services. It also represents the standard value for the 'Products and services' axis if no other member is used."
       }
      },
      "en-us": {
       "role": {
        "label": "Products and services [member]"
       }
      }
     },
     "localname": "ProductsAndServicesMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsRevenueFromContractWithCustomersDetails",
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsSummaryOfUpfrontPaymentsAndRelatedRevenuesRecognizedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_ProfessionalFeesExpense": {
     "auth_ref": [
      "r12"
     ],
     "calculation": {
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsCostOfSalesDetails": {
       "order": 6.0,
       "parentTag": "ifrs-full_ExpenseByNature",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of fees paid or payable for professional services."
       }
      },
      "en-us": {
       "role": {
        "label": "Professional fees expense",
        "negatedLabel": "Legal and other professional services"
       }
      }
     },
     "localname": "ProfessionalFeesExpense",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsGeneralAndAdministrativeExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ProfitLoss": {
     "auth_ref": [
      "r6",
      "r38",
      "r103",
      "r119",
      "r121",
      "r124",
      "r215",
      "r216",
      "r225",
      "r235"
     ],
     "calculation": {
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfOperationsAndOtherComprehensiveIncomeLoss": {
       "order": 2.0,
       "parentTag": "ifrs-full_ComprehensiveIncome",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]"
       }
      },
      "en-us": {
       "role": {
        "label": "Profit (loss)",
        "totalLabel": "Net loss for the period",
        "verboseLabel": "Net loss"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfChangesInShareholdersEquity",
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfOperationsAndOtherComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ProfitLossBeforeTax": {
     "auth_ref": [
      "r1",
      "r2",
      "r190",
      "r215",
      "r216"
     ],
     "calculation": {
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfOperationsAndOtherComprehensiveIncomeLoss": {
       "order": 1.0,
       "parentTag": "ifrs-full_ProfitLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The profit (loss) before tax expense or income. [Refer: Profit (loss)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Profit (loss) before tax",
        "terseLabel": "Loss before income tax",
        "totalLabel": "Loss before income tax"
       }
      }
     },
     "localname": "ProfitLossBeforeTax",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows",
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfOperationsAndOtherComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ProfitLossFromOperatingActivities": {
     "auth_ref": [
      "r43",
      "r83"
     ],
     "calculation": {
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfOperationsAndOtherComprehensiveIncomeLoss": {
       "order": 3.0,
       "parentTag": "ifrs-full_ProfitLossBeforeTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The profit (loss) from operating activities of the entity. [Refer: Profit (loss)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Profit (loss) from operating activities",
        "totalLabel": "Operating loss"
       }
      }
     },
     "localname": "ProfitLossFromOperatingActivities",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfOperationsAndOtherComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ProfitLossOfAcquiree": {
     "auth_ref": [
      "r182"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The profit (loss) of the acquiree, since the acquisition date, included in the consolidated statement of comprehensive income. [Refer: Profit (loss)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Profit (loss) of acquiree since acquisition date",
        "terseLabel": "Loss contributed to the consolidated result"
       }
      }
     },
     "localname": "ProfitLossOfAcquiree",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureSignificantTransactionsAndEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ProfitLossOfCombinedEntity": {
     "auth_ref": [
      "r183"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The profit (loss) of the combined entity as though the acquisition date for all business combinations that occurred during the year had been as of the beginning of the annual reporting period. [Refer: Business combinations [member]; Profit (loss)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Profit (loss) of combined entity as if combination occurred at beginning of period",
        "terseLabel": "Loss of combined entity as if combination occurred at beginning of period"
       }
      }
     },
     "localname": "ProfitLossOfCombinedEntity",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureSignificantTransactionsAndEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_PropertyPlantAndEquipment": {
     "auth_ref": [
      "r15",
      "r62"
     ],
     "calculation": {
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition": {
       "order": 3.0,
       "parentTag": "ifrs-full_NoncurrentAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of tangible assets that: (a) are held for use in the production or supply of goods or services, for rental to others, or for administrative purposes; and (b) are expected to be used during more than one period."
       }
      },
      "en-us": {
       "role": {
        "label": "Property, plant and equipment.",
        "terseLabel": "Property, plant and equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipment",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_PropertyPlantAndEquipmentMember": {
     "auth_ref": [
      "r63",
      "r87",
      "r157"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for property, plant and equipment. It also represents the standard value for the 'Classes of property, plant and equipment' axis if no other member is used. [Refer: Property, plant and equipment]"
       }
      },
      "en-us": {
       "role": {
        "label": "Property, plant and equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureFixedAssetsPropertyPlantAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDate": {
     "auth_ref": [
      "r180",
      "r187"
     ],
     "calculation": {
      "http://www.curevac.com/role/DisclosureSignificantTransactionsAndEventsFrameAcquisitionPurchasePriceAllocationDetails": {
       "order": 3.0,
       "parentTag": "ifrs-full_NoncurrentAssetsRecognisedAsOfAcquisitionDate",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount recognised as of the acquisition date for plant, property and equipment acquired in a business combination. [Refer: Property, plant and equipment; Business combinations [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Property, plant and equipment recognised as of acquisition date",
        "terseLabel": "Property, plant and equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDate",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureSignificantTransactionsAndEventsFrameAcquisitionPurchasePriceAllocationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ProportionOfOwnershipInterestInAssociate": {
     "auth_ref": [
      "r78",
      "r80",
      "r123"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The proportion of ownership interest in an associate attributable to the entity. [Refer: Associates [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Proportion of ownership interest in associate",
        "terseLabel": "Equity interest held"
       }
      }
     },
     "localname": "ProportionOfOwnershipInterestInAssociate",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureRelatedPartyDisclosuresDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ifrs-full_ProportionOfOwnershipInterestInSubsidiary": {
     "auth_ref": [
      "r78",
      "r80",
      "r122"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The proportion of ownership interest in a subsidiary attributable to the entity. [Refer: Subsidiaries [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Proportion of ownership interest in subsidiary",
        "terseLabel": "Ownership percentage"
       }
      }
     },
     "localname": "ProportionOfOwnershipInterestInSubsidiary",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureCorporateInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities": {
     "auth_ref": [
      "r97"
     ],
     "calculation": {
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash outflow for the purchases of intangible assets, classified as investing activities. [Refer: Intangible assets other than goodwill]"
       }
      },
      "en-us": {
       "role": {
        "label": "Purchase of intangible assets, classified as investing activities",
        "negatedTerseLabel": "Purchase of intangible assets"
       }
      }
     },
     "localname": "PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_PurchaseOfOtherLongtermAssetsClassifiedAsInvestingActivities": {
     "auth_ref": [
      "r97"
     ],
     "calculation": {
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash outflow for the purchases of long-term assets that the entity does not separately disclose in the same statement or note, classified as investing activities. [Refer: Assets]"
       }
      },
      "en-us": {
       "role": {
        "label": "Purchase of other long-term assets, classified as investing activities",
        "negatedLabel": "Purchases of financial assets"
       }
      }
     },
     "localname": "PurchaseOfOtherLongtermAssetsClassifiedAsInvestingActivities",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities": {
     "auth_ref": [
      "r97"
     ],
     "calculation": {
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash outflow for the purchases of property, plant and equipment, classified as investing activities. [Refer: Property, plant and equipment]"
       }
      },
      "en-us": {
       "role": {
        "label": "Purchase of property, plant and equipment, classified as investing activities",
        "negatedTerseLabel": "Purchase of property, plant and equipment"
       }
      }
     },
     "localname": "PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_PurchasesOfGoodsRelatedPartyTransactions": {
     "auth_ref": [
      "r73"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of goods purchased by the entity in related party transactions. [Refer: Related parties [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Purchases of goods, related party transactions",
        "terseLabel": "Total payments"
       }
      }
     },
     "localname": "PurchasesOfGoodsRelatedPartyTransactions",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureRelatedPartyDisclosuresDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_RangeAxis": {
     "auth_ref": [
      "r141",
      "r142",
      "r143",
      "r167",
      "r205",
      "r226"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Range [axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsSummaryOfUpfrontPaymentsAndRelatedRevenuesRecognizedDetails",
      "http://www.curevac.com/role/DisclosureRelatedPartyDisclosuresDetails",
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_RangesMember": {
     "auth_ref": [
      "r141",
      "r142",
      "r143",
      "r167",
      "r205",
      "r226"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for aggregate ranges. It also represents the standard value for the 'Range' axis if no other member is used."
       }
      },
      "en-us": {
       "role": {
        "label": "Ranges [member]"
       }
      }
     },
     "localname": "RangesMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsSummaryOfUpfrontPaymentsAndRelatedRevenuesRecognizedDetails",
      "http://www.curevac.com/role/DisclosureRelatedPartyDisclosuresDetails",
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_RawMaterialsAndConsumablesUsed": {
     "auth_ref": [
      "r1",
      "r46"
     ],
     "calculation": {
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsCostOfSalesDetails": {
       "order": 2.0,
       "parentTag": "ifrs-full_ExpenseByNature",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of raw materials and consumables used in the production process or in the rendering of services. [Refer: Current raw materials]"
       }
      },
      "en-us": {
       "role": {
        "label": "Raw materials and consumables used",
        "negatedTerseLabel": "Materials"
       }
      }
     },
     "localname": "RawMaterialsAndConsumablesUsed",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsCostOfSalesDetails",
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsResearchAndDevelopmentExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ReceivablesFromTaxesOtherThanIncomeTax": {
     "auth_ref": [
      "r31"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of receivables from taxes other than income tax. Income taxes include all domestic and foreign taxes that are based on taxable profits. Income taxes also include taxes, such as withholding taxes, that are payable by a subsidiary, associate or joint arrangement on distributions to the reporting entity."
       }
      },
      "en-us": {
       "role": {
        "label": "Receivables from taxes other than income tax",
        "terseLabel": "Tax claims against the tax authorities"
       }
      }
     },
     "localname": "ReceivablesFromTaxesOtherThanIncomeTax",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosurePrepaidExpensesAndOtherAssetsCurrentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_RepaymentsOfBondsNotesAndDebentures": {
     "auth_ref": [
      "r102"
     ],
     "calculation": {
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows": {
       "order": 10.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash outflow for repayments of bonds, notes and debentures."
       }
      },
      "en-us": {
       "role": {
        "label": "Repayments of bonds, notes and debentures",
        "negatedLabel": "Repayments of convertible loan"
       }
      }
     },
     "localname": "RepaymentsOfBondsNotesAndDebentures",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities": {
     "auth_ref": [
      "r100"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash outflow to settle borrowings, classified as financing activities. [Refer: Borrowings]"
       }
      },
      "en-us": {
       "role": {
        "label": "Repayments of borrowings, classified as financing activities",
        "terseLabel": "Cash consideration"
       }
      }
     },
     "localname": "RepaymentsOfBorrowingsClassifiedAsFinancingActivities",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureLoansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r92"
     ],
     "calculation": {
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfOperationsAndOtherComprehensiveIncomeLoss": {
       "order": 4.0,
       "parentTag": "ifrs-full_ProfitLossFromOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of expenditure directly attributable to research or development activities, recognised in profit or loss."
       }
      },
      "en-us": {
       "role": {
        "label": "Research and development expense",
        "negatedLabel": "Research and development expenses"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfOperationsAndOtherComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember": {
     "auth_ref": [
      "r11",
      "r71"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for a component of equity representing accumulated exchange differences on the translation of financial statements recognised in other comprehensive income. [Refer: Other comprehensive income]"
       }
      },
      "en-us": {
       "role": {
        "label": "Currency translation reserve"
       }
      }
     },
     "localname": "ReserveOfExchangeDifferencesOnTranslationMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfChangesInShareholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_RestatedMember": {
     "auth_ref": [
      "r5",
      "r14",
      "r115",
      "r116",
      "r117",
      "r225"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for the information currently stated in the financial statements. It also represents the standard value for the 'Retrospective application and retrospective restatement' and 'Departure from requirement of IFRS' axes if no other member is used."
       }
      },
      "en-us": {
       "role": {
        "label": "Currently stated [member]"
       }
      }
     },
     "localname": "RestatedMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfChangesInShareholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_RetainedEarnings": {
     "auth_ref": [
      "r32",
      "r47"
     ],
     "calculation": {
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition": {
       "order": 4.0,
       "parentTag": "ifrs-full_Equity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "A component of equity representing the entity's cumulative undistributed earnings or deficit."
       }
      },
      "en-us": {
       "role": {
        "label": "Retained earnings",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarnings",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_RetainedEarningsMember": {
     "auth_ref": [
      "r10",
      "r11"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for a component of equity representing an entity's cumulative undistributed earnings or deficit."
       }
      },
      "en-us": {
       "role": {
        "label": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfChangesInShareholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis": {
     "auth_ref": [
      "r5",
      "r115",
      "r116",
      "r117"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Retrospective application and retrospective restatement [axis]"
       }
      }
     },
     "localname": "RetrospectiveApplicationAndRetrospectiveRestatementAxis",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfChangesInShareholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_RevenueFromContractsWithCustomers": {
     "auth_ref": [
      "r145",
      "r146"
     ],
     "calculation": {
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfOperationsAndOtherComprehensiveIncomeLoss": {
       "order": 1.0,
       "parentTag": "ifrs-full_ProfitLossFromOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of revenue from contracts with customers. A customer is a party that has contracted with an entity to obtain goods or services that are an output of the entity\u2019s ordinary activities in exchange for consideration."
       }
      },
      "en-us": {
       "role": {
        "label": "Total revenues",
        "terseLabel": "Revenue",
        "verboseLabel": "Revenue recognized"
       }
      }
     },
     "localname": "RevenueFromContractsWithCustomers",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsRevenueFromContractWithCustomersDetails",
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfOperationsAndOtherComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_RevenueFromGovernmentGrants": {
     "auth_ref": [
      "r70"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of income recognised in relation to government grants. [Refer: Government grants]"
       }
      },
      "en-us": {
       "role": {
        "label": "Income from government grants",
        "verboseLabel": "Income from release of governmental contract liabilities"
       }
      }
     },
     "localname": "RevenueFromGovernmentGrants",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsGrantsWithGovernmentAgenciesAndSimilarBodiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_RevenueOfAcquiree": {
     "auth_ref": [
      "r182"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of revenue of the acquiree since the acquisition date included in the consolidated statement of comprehensive income. [Refer: Revenue]"
       }
      },
      "en-us": {
       "role": {
        "label": "Revenue of acquiree since acquisition date",
        "terseLabel": "Revenues contributed to the consolidated result"
       }
      }
     },
     "localname": "RevenueOfAcquiree",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureSignificantTransactionsAndEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_RevenueOfCombinedEntity": {
     "auth_ref": [
      "r183"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The revenue of the combined entity as though the acquisition date for all business combinations that occurred during the year had been as of the beginning of the annual reporting period. [Refer: Business combinations [member]; Revenue]"
       }
      },
      "en-us": {
       "role": {
        "label": "Revenue of combined entity as if combination occurred at beginning of period",
        "terseLabel": "Revenue of combined entity as if combination occurred at beginning of period"
       }
      }
     },
     "localname": "RevenueOfCombinedEntity",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureSignificantTransactionsAndEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod": {
     "auth_ref": [
      "r148"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of revenue that was included in the contract liability balance at the beginning of the period. [Refer: Contract liabilities; Revenue from contracts with customers]"
       }
      },
      "en-us": {
       "role": {
        "label": "Revenue that was included in contract liability balance at beginning of period",
        "terseLabel": "Revenue recognized from upfront and milestones payments"
       }
      }
     },
     "localname": "RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsSummaryOfUpfrontPaymentsAndRelatedRevenuesRecognizedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_RightofuseAssets": {
     "auth_ref": [
      "r156"
     ],
     "calculation": {
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition": {
       "order": 6.0,
       "parentTag": "ifrs-full_NoncurrentAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of assets that represent a lessee's right to use an underlying asset for the lease term. Underlying asset is an asset that is the subject of a lease, for which the right to use that asset has been provided by a lessor to a lessee."
       }
      },
      "en-us": {
       "role": {
        "label": "RightofuseAssets",
        "terseLabel": "Right-of-use assets"
       }
      }
     },
     "localname": "RightofuseAssets",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_RiskExposureAssociatedWithInstrumentsSharingCharacteristic": {
     "auth_ref": [
      "r208"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of risk exposure associated with financial instruments with a shared characteristic that identifies a concentration of risks. [Refer: Financial instruments, class [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Risk exposure associated with instruments sharing characteristic",
        "terseLabel": "Exposure in (foreign) currency"
       }
      }
     },
     "localname": "RiskExposureAssociatedWithInstrumentsSharingCharacteristic",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureDisclosureOfFinancialInstrumentsAndRiskManagementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_SalesAndMarketingExpense": {
     "auth_ref": [
      "r43"
     ],
     "calculation": {
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfOperationsAndOtherComprehensiveIncomeLoss": {
       "order": 3.0,
       "parentTag": "ifrs-full_ProfitLossFromOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of expense relating to the marketing and selling of goods or services."
       }
      },
      "en-us": {
       "role": {
        "label": "Sales and marketing expense",
        "negatedLabel": "Selling and distribution expenses"
       }
      }
     },
     "localname": "SalesAndMarketingExpense",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfOperationsAndOtherComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ShareIssueRelatedCost": {
     "auth_ref": [
      "r9"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of cost related to the issuance of shares."
       }
      },
      "en-us": {
       "role": {
        "label": "Share issue related cost",
        "terseLabel": "Offering costs for legal, accounting, printing and registration fees",
        "verboseLabel": "Shares issue of transaction costs"
       }
      }
     },
     "localname": "ShareIssueRelatedCost",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureIssuedCapitalAndReservesImpactOfShareSplitDetails",
      "http://www.curevac.com/role/DisclosureIssuedCapitalAndReservesOverviewAndGeneralRemarksDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_SharebasedPaymentArrangementsMember": {
     "auth_ref": [
      "r168"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for an agreement between the entity or another group entity or any shareholder of the group entity and another party (including an employee) that entitles the other party to receive (a) cash or other assets of the entity for amounts that are based on the price (or value) of equity instruments (including shares or share options) of the entity or another group entity; or (b) equity instruments (including shares or share options) of the entity or another group entity, provided that the specified vesting conditions, if any, are met. It also represents the standard value for the 'Types of share-based payment arrangements' axis if no other member is used."
       }
      },
      "en-us": {
       "role": {
        "label": "Share-based payment arrangements [member]"
       }
      }
     },
     "localname": "SharebasedPaymentArrangementsMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureIssuedCapitalAndReservesOverviewAndGeneralRemarksDetails",
      "http://www.curevac.com/role/DisclosureRelatedPartyDisclosuresDetails",
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsDetails",
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsExpenseRecognizedForProgramDetails",
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsExpensesDetails",
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsTables"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_ShorttermEmployeeBenefitsExpense": {
     "auth_ref": [
      "r12"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of expense from employee benefits (other than termination benefits) that are expected to be settled wholly within twelve months after the end of the annual reporting period in which the employees render the related services."
       }
      },
      "en-us": {
       "role": {
        "label": "Short-term employee benefits expense",
        "terseLabel": "Salary and salary-related expenses",
        "verboseLabel": "Salary and salary-related expenses"
       }
      }
     },
     "localname": "ShorttermEmployeeBenefitsExpense",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsGeneralAndAdministrativeExpensesDetails",
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsResearchAndDevelopmentExpensesDetails",
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsSellingAndDistributionExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_SignificantInvestmentsInSubsidiariesAxis": {
     "auth_ref": [
      "r79",
      "r81",
      "r135"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Subsidiaries [axis]"
       }
      }
     },
     "localname": "SignificantInvestmentsInSubsidiariesAxis",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureIncomeTaxDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interim Condensed Consolidated Statements of Cash Flows"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_StatementOfChangesInEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interim Condensed Consolidated Statements of Changes in Shareholders' Equity"
       }
      }
     },
     "localname": "StatementOfChangesInEquityAbstract",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_StatementOfChangesInEquityLineItems": {
     "auth_ref": [],
     "lang": {
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Statement of changes in equity [line items]",
        "terseLabel": "Statement of changes in equity"
       }
      }
     },
     "localname": "StatementOfChangesInEquityLineItems",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfChangesInShareholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_StatementOfChangesInEquityTable": {
     "auth_ref": [
      "r10"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to changes in equity."
       }
      },
      "en-us": {
       "role": {
        "label": "Statement of changes in equity [table]"
       }
      }
     },
     "localname": "StatementOfChangesInEquityTable",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfChangesInShareholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_StatementOfComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interim Condensed Consolidated Statements of Operations and Other Comprehensive Income (Loss)"
       }
      }
     },
     "localname": "StatementOfComprehensiveIncomeAbstract",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interim Condensed Consolidated Statements of Financial Position"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_TechnologybasedIntangibleAssetsRecognisedAsOfAcquisitionDate": {
     "auth_ref": [
      "r180"
     ],
     "calculation": {
      "http://www.curevac.com/role/DisclosureSignificantTransactionsAndEventsFrameAcquisitionPurchasePriceAllocationDetails": {
       "order": 1.0,
       "parentTag": "ifrs-full_NoncurrentAssetsRecognisedAsOfAcquisitionDate",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount recognised as of the acquisition date for technology-based intangible assets acquired in a business combination. [Refer: Technology-based intangible assets [member]; Business combinations [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Technology-based intangible assets recognised as of acquisition date",
        "terseLabel": "Intangible assets (Technology)"
       }
      }
     },
     "localname": "TechnologybasedIntangibleAssetsRecognisedAsOfAcquisitionDate",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureSignificantTransactionsAndEventsFrameAcquisitionPurchasePriceAllocationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_TopOfRangeMember": {
     "auth_ref": [
      "r141",
      "r142",
      "r143",
      "r167",
      "r205",
      "r226"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for top of a range."
       }
      },
      "en-us": {
       "role": {
        "label": "Maximum",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "TopOfRangeMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureRelatedPartyDisclosuresDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_TradeAndOtherCurrentPayables": {
     "auth_ref": [
      "r21"
     ],
     "calculation": {
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition": {
       "order": 3.0,
       "parentTag": "ifrs-full_CurrentLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of current trade payables and current other payables. [Refer: Current trade payables; Other current payables]"
       }
      },
      "en-us": {
       "role": {
        "label": "Trade and other current payables",
        "terseLabel": "Trade and other payables"
       }
      }
     },
     "localname": "TradeAndOtherCurrentPayables",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_TradeAndOtherCurrentPayablesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trade and other payables."
       }
      }
     },
     "localname": "TradeAndOtherCurrentPayablesAbstract",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_TradeAndOtherPayablesRecognisedAsOfAcquisitionDate": {
     "auth_ref": [
      "r180"
     ],
     "calculation": {
      "http://www.curevac.com/role/DisclosureSignificantTransactionsAndEventsFrameAcquisitionPurchasePriceAllocationDetails": {
       "order": 2.0,
       "parentTag": "ifrs-full_CurrentLiabilitiesRecognisedAsOfAcquisitionDate",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount recognised as of the acquisition date for trade and other payables assumed in a business combination. [Refer: Trade and other payables; Business combinations [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Trade and other payables recognised as of acquisition date",
        "terseLabel": "Accounts Payables"
       }
      }
     },
     "localname": "TradeAndOtherPayablesRecognisedAsOfAcquisitionDate",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureSignificantTransactionsAndEventsFrameAcquisitionPurchasePriceAllocationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_TransfersIntoLevel3OfFairValueHierarchyAssets": {
     "auth_ref": [
      "r139"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of transfers of assets into Level 3 of the fair value hierarchy. [Refer: Level 3 of fair value hierarchy [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Transfers into Level 3 of fair value hierarchy, assets",
        "terseLabel": "Transfers into Level 3, Assets"
       }
      }
     },
     "localname": "TransfersIntoLevel3OfFairValueHierarchyAssets",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureFinancialAssetsAndFinancialLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_TransfersIntoLevel3OfFairValueHierarchyLiabilities": {
     "auth_ref": [
      "r139"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of transfers of liabilities into Level 3 of the fair value hierarchy. [Refer: Level 3 of fair value hierarchy [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Transfers into Level 3 of fair value hierarchy, liabilities",
        "terseLabel": "Transfers into Level 3, Liabilities"
       }
      }
     },
     "localname": "TransfersIntoLevel3OfFairValueHierarchyLiabilities",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureFinancialAssetsAndFinancialLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_TransfersOfResearchAndDevelopmentToEntityRelatedPartyTransactions": {
     "auth_ref": [
      "r74"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of transfers of research and development to the entity in related party transactions. [Refer: Related parties [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Research and development expenses.",
        "terseLabel": "Research and development expense"
       }
      }
     },
     "localname": "TransfersOfResearchAndDevelopmentToEntityRelatedPartyTransactions",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureRelatedPartyDisclosuresDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_TransfersOutOfLevel1IntoLevel2OfFairValueHierarchyAssets": {
     "auth_ref": [
      "r138"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of transfers out of Level 1 and into Level 2 of the fair value hierarchy of assets held at the end of the reporting period. [Refer: Level 1 of fair value hierarchy [member]; Level 2 of fair value hierarchy [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Transfers out of Level 1 into Level 2 of fair value hierarchy, assets held at end of reporting period",
        "terseLabel": "Transfer from Level 1 to Level 2, Assets"
       }
      }
     },
     "localname": "TransfersOutOfLevel1IntoLevel2OfFairValueHierarchyAssets",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureFinancialAssetsAndFinancialLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_TransfersOutOfLevel1IntoLevel2OfFairValueHierarchyLiabilities": {
     "auth_ref": [
      "r138"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of transfers out of Level 1 and into Level 2 of the fair value hierarchy of liabilities held at the end of the reporting period. [Refer: Level 1 of fair value hierarchy [member]; Level 2 of fair value hierarchy [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Transfers out of Level 1 into Level 2 of fair value hierarchy, liabilities held at end of reporting period",
        "terseLabel": "Transfer from Level 1 to Level 2, Liabilities"
       }
      }
     },
     "localname": "TransfersOutOfLevel1IntoLevel2OfFairValueHierarchyLiabilities",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureFinancialAssetsAndFinancialLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_TransfersOutOfLevel2IntoLevel1OfFairValueHierarchyAssets": {
     "auth_ref": [
      "r138"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of transfers out of Level 2 and into Level 1 of the fair value hierarchy of assets held at the end of the reporting period. [Refer: Level 1 of fair value hierarchy [member]; Level 2 of fair value hierarchy [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Transfers out of Level 2 into Level 1 of fair value hierarchy, assets held at end of reporting period",
        "terseLabel": "Transfer from Level 2 to Level 1, Assets"
       }
      }
     },
     "localname": "TransfersOutOfLevel2IntoLevel1OfFairValueHierarchyAssets",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureFinancialAssetsAndFinancialLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_TransfersOutOfLevel2IntoLevel1OfFairValueHierarchyLiabilities": {
     "auth_ref": [
      "r138"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of transfers out of Level 2 and into Level 1 of the fair value hierarchy of liabilities held at the end of the reporting period. [Refer: Level 1 of fair value hierarchy [member]; Level 2 of fair value hierarchy [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Transfers out of Level 2 into Level 1 of fair value hierarchy, liabilities held at end of reporting period",
        "terseLabel": "Transfer from Level 2 to Level 1, Liabilities"
       }
      }
     },
     "localname": "TransfersOutOfLevel2IntoLevel1OfFairValueHierarchyLiabilities",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureFinancialAssetsAndFinancialLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_TransfersOutOfLevel3OfFairValueHierarchyAssets": {
     "auth_ref": [
      "r139"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of transfers of assets out of Level 3 of the fair value hierarchy. [Refer: Level 3 of fair value hierarchy [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Transfers out of Level 3 of fair value hierarchy, assets",
        "terseLabel": "Transfers out of Level 3, Assets"
       }
      }
     },
     "localname": "TransfersOutOfLevel3OfFairValueHierarchyAssets",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureFinancialAssetsAndFinancialLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_TransfersOutOfLevel3OfFairValueHierarchyLiabilities": {
     "auth_ref": [
      "r139"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of transfers of liabilities out of Level 3 of the fair value hierarchy. [Refer: Level 3 of fair value hierarchy [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Transfers out of Level 3 of fair value hierarchy, liabilities",
        "terseLabel": "Transfers out of Level 3, Liabilities"
       }
      }
     },
     "localname": "TransfersOutOfLevel3OfFairValueHierarchyLiabilities",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureFinancialAssetsAndFinancialLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_TravelExpense": {
     "auth_ref": [
      "r12"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of expense arising from travel."
       }
      },
      "en-us": {
       "role": {
        "label": "Travel expense",
        "terseLabel": "Travel expenses"
       }
      }
     },
     "localname": "TravelExpense",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsGeneralAndAdministrativeExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_TreasuryShares": {
     "auth_ref": [
      "r32",
      "r82"
     ],
     "calculation": {
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition": {
       "order": 2.0,
       "parentTag": "ifrs-full_Equity",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "An entity\u2019s own equity instruments, held by the entity or other members of the consolidated group."
       }
      },
      "en-us": {
       "role": {
        "label": "Treasury shares.",
        "negatedLabel": "Treasury Shares"
       }
      }
     },
     "localname": "TreasuryShares",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_TreasurySharesMember": {
     "auth_ref": [
      "r10"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for the entity\u2019s own equity instruments, held by the entity or other members of the consolidated group."
       }
      },
      "en-us": {
       "role": {
        "label": "Treasury Shares"
       }
      }
     },
     "localname": "TreasurySharesMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureIssuedCapitalAndReservesOverviewAndGeneralRemarksDetails",
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfChangesInShareholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_TypesOfContractsAxis": {
     "auth_ref": [
      "r153",
      "r233"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Types of contracts [axis]"
       }
      }
     },
     "localname": "TypesOfContractsAxis",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureOtherLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_TypesOfContractsMember": {
     "auth_ref": [
      "r153",
      "r233"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for all types of contracts with customers. It also represents the standard value for the 'Types of contracts' axis if no other member is used."
       }
      },
      "en-us": {
       "role": {
        "label": "Types of contracts [member]"
       }
      }
     },
     "localname": "TypesOfContractsMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureOtherLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_TypesOfRisksAxis": {
     "auth_ref": [
      "r192",
      "r195",
      "r196",
      "r227",
      "r228",
      "r229",
      "r231"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Types of risks [axis]"
       }
      }
     },
     "localname": "TypesOfRisksAxis",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureDisclosureOfFinancialInstrumentsAndRiskManagementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_TypesOfRisksMember": {
     "auth_ref": [
      "r192",
      "r195",
      "r196",
      "r227",
      "r228",
      "r229",
      "r231"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for all types of risks. It also represents the standard value for the 'Types of risks' axis if no other member is used."
       }
      },
      "en-us": {
       "role": {
        "label": "Risks [member]"
       }
      }
     },
     "localname": "TypesOfRisksMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureDisclosureOfFinancialInstrumentsAndRiskManagementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_TypesOfSharebasedPaymentArrangementsAxis": {
     "auth_ref": [
      "r168"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Types of share-based payment arrangements [axis]"
       }
      }
     },
     "localname": "TypesOfSharebasedPaymentArrangementsAxis",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureIssuedCapitalAndReservesOverviewAndGeneralRemarksDetails",
      "http://www.curevac.com/role/DisclosureRelatedPartyDisclosuresDetails",
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsDetails",
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsExpenseRecognizedForProgramDetails",
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsExpensesDetails",
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsTables"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised": {
     "auth_ref": [
      "r55"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of unused tax losses for which no deferred tax asset is recognised in the statement of financial position. [Refer: Unused tax losses [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Unused tax losses for which no deferred tax asset recognised",
        "terseLabel": "Tax loss carry forwards"
       }
      }
     },
     "localname": "UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureSignificantTransactionsAndEventsFrameAcquisitionPurchasePriceAllocationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019": {
     "auth_ref": [
      "r163"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The weighted average exercise price of share options exercised in a share-based payment arrangement. [Refer: Weighted average [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Weighted average exercise price of share options exercised in share-based payment arrangement",
        "terseLabel": "Average share price"
       }
      }
     },
     "localname": "WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "ifrs-full_WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted": {
     "auth_ref": [
      "r170"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The weighted average fair value at the measurement date of granted equity instruments other than share options. [Refer: Weighted average [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Weighted average fair value at measurement date, other equity instruments granted",
        "terseLabel": "Total fair value of the RSU grant"
       }
      }
     },
     "localname": "WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureSignificantTransactionsAndEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_WeightedAverageSharePrice2019": {
     "auth_ref": [
      "r166"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The weighted average share price. [Refer: Weighted average [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Weighted average share price",
        "terseLabel": "Price per share"
       }
      }
     },
     "localname": "WeightedAverageSharePrice2019",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureRelatedPartyDisclosuresDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "ifrs-full_WeightedAverageShares": {
     "auth_ref": [
      "r86"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The number of ordinary shares outstanding at the beginning of the period, adjusted by the number of ordinary shares bought back or issued during the period multiplied by a time-weighting factor."
       }
      },
      "en-us": {
       "role": {
        "label": "Weighted average number of ordinary shares outstanding",
        "terseLabel": "Weighted number of shares outstanding"
       }
      }
     },
     "localname": "WeightedAverageShares",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureEarningsPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "srt_ChiefOperatingOfficerMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Chief Operating Officer"
       }
      }
     },
     "localname": "ChiefOperatingOfficerMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ConsolidatedEntitiesAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Entities [Axis]"
       }
      }
     },
     "localname": "ConsolidatedEntitiesAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.curevac.com/role/DisclosureCorporateInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ConsolidatedEntitiesDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Entities [Domain]"
       }
      }
     },
     "localname": "ConsolidatedEntitiesDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.curevac.com/role/DisclosureCorporateInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.curevac.com/role/DisclosureInventoriesDetails",
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsGrantsWithGovernmentAgenciesAndSimilarBodiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_CurrencyAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Currency [Axis]"
       }
      }
     },
     "localname": "CurrencyAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.curevac.com/role/DisclosureDisclosureOfFinancialInstrumentsAndRiskManagementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ParentCompanyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cure Vac B.V."
       }
      }
     },
     "localname": "ParentCompanyMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.curevac.com/role/DisclosureCorporateInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.curevac.com/role/DisclosureInventoriesDetails",
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsGrantsWithGovernmentAgenciesAndSimilarBodiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioUnspecifiedDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Domain]"
       }
      }
     },
     "localname": "ScenarioUnspecifiedDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsContractLiabilitiesAllocatedToRemainingPerformanceObligationsDetails",
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsGrantsWithGovernmentAgenciesAndSimilarBodiesDetails",
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementScenarioAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Axis]"
       }
      }
     },
     "localname": "StatementScenarioAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsContractLiabilitiesAllocatedToRemainingPerformanceObligationsDetails",
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedFinancialStatementsGrantsWithGovernmentAgenciesAndSimilarBodiesDetails",
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Axis]"
       }
      }
     },
     "localname": "TitleOfIndividualAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.curevac.com/role/DisclosureRelatedPartyDisclosuresDetails",
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Domain]"
       }
      }
     },
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.curevac.com/role/DisclosureRelatedPartyDisclosuresDetails",
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsDetails"
     ],
     "xbrltype": "domainItemType"
    }
   },
   "unitCount": 14
  }
 },
 "std_ref": {
  "r0": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "10",
   "Subparagraph": "e",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_10_e&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r1": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "102",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_102&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r10": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "106",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_106&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r100": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "17",
   "Subparagraph": "d",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_17_d&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r101": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "17",
   "Subparagraph": "e",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_17_e&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r102": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "17",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_17&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r103": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "18",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_18_b&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r104": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "20",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_20_a&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r105": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "20",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_20_b&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r106": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "20",
   "Subparagraph": "c",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_20_c&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r107": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "20",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_20&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r108": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "25",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_25&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r109": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "28",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_28&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r11": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "108",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_108&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r110": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "31",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_31&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r111": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "35",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_35&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r112": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "39",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_39&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r113": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "45",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_45&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r114": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "50",
   "Subparagraph": "d",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_50_d&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r115": {
   "Clause": "i",
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "8",
   "Paragraph": "28",
   "Subparagraph": "f",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=8&code=ifrs-tx-2021-en-r&anchor=para_28_f_i&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r116": {
   "Clause": "i",
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "8",
   "Paragraph": "29",
   "Subparagraph": "c",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=8&code=ifrs-tx-2021-en-r&anchor=para_29_c_i&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r117": {
   "Clause": "i",
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "8",
   "Paragraph": "49",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=8&code=ifrs-tx-2021-en-r&anchor=para_49_b_i&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r118": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "1",
   "Paragraph": "24",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2021-en-r&anchor=para_24_a&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r119": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "1",
   "Paragraph": "24",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2021-en-r&anchor=para_24_b&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r12": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "112",
   "Subparagraph": "c",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_112_c&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r120": {
   "Clause": "i",
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "1",
   "Paragraph": "32",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2021-en-r&anchor=para_32_a_i&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r121": {
   "Clause": "ii",
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "1",
   "Paragraph": "32",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2021-en-r&anchor=para_32_a_ii&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r122": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "12",
   "Paragraph": "19B",
   "Subparagraph": "c",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2021-en-r&anchor=para_19B_c&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r123": {
   "Clause": "iv",
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "12",
   "Paragraph": "21",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2021-en-r&anchor=para_21_a_iv&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r124": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "12",
   "Paragraph": "B10",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2021-en-r&anchor=para_B10_b&doctype=Appendix&subtype=B",
   "URIDate": "2021-03-24"
  },
  "r125": {
   "Clause": "i",
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "12",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2021-en-r&anchor=para_B12_b_i&doctype=Appendix&subtype=B",
   "URIDate": "2021-03-24"
  },
  "r126": {
   "Clause": "ii",
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "12",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2021-en-r&anchor=para_B12_b_ii&doctype=Appendix&subtype=B",
   "URIDate": "2021-03-24"
  },
  "r127": {
   "Clause": "iii",
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "12",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2021-en-r&anchor=para_B12_b_iii&doctype=Appendix&subtype=B",
   "URIDate": "2021-03-24"
  },
  "r128": {
   "Clause": "iv",
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "12",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2021-en-r&anchor=para_B12_b_iv&doctype=Appendix&subtype=B",
   "URIDate": "2021-03-24"
  },
  "r129": {
   "Clause": "ix",
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "12",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2021-en-r&anchor=para_B12_b_ix&doctype=Appendix&subtype=B",
   "URIDate": "2021-03-24"
  },
  "r13": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "117",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_117_b&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r130": {
   "Clause": "viii",
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "12",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2021-en-r&anchor=para_B12_b_viii&doctype=Appendix&subtype=B",
   "URIDate": "2021-03-24"
  },
  "r131": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "12",
   "Paragraph": "B13",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2021-en-r&anchor=para_B13_a&doctype=Appendix&subtype=B",
   "URIDate": "2021-03-24"
  },
  "r132": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "12",
   "Paragraph": "B13",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2021-en-r&anchor=para_B13_b&doctype=Appendix&subtype=B",
   "URIDate": "2021-03-24"
  },
  "r133": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "12",
   "Paragraph": "B13",
   "Subparagraph": "d",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2021-en-r&anchor=para_B13_d&doctype=Appendix&subtype=B",
   "URIDate": "2021-03-24"
  },
  "r134": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "12",
   "Paragraph": "B13",
   "Subparagraph": "g",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2021-en-r&anchor=para_B13_g&doctype=Appendix&subtype=B",
   "URIDate": "2021-03-24"
  },
  "r135": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "12",
   "Paragraph": "B4",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2021-en-r&anchor=para_B4_a&doctype=Appendix&subtype=B",
   "URIDate": "2021-03-24"
  },
  "r136": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "13",
   "Paragraph": "93",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2021-en-r&anchor=para_93_a&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r137": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "13",
   "Paragraph": "93",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2021-en-r&anchor=para_93_b&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r138": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "13",
   "Paragraph": "93",
   "Subparagraph": "c",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2021-en-r&anchor=para_93_c&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r139": {
   "Clause": "iv",
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "13",
   "Paragraph": "93",
   "Subparagraph": "e",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2021-en-r&anchor=para_93_e_iv&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r14": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "20",
   "Subparagraph": "d",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_20_d&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r140": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "13",
   "Paragraph": "93",
   "Subparagraph": "e",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2021-en-r&anchor=para_93_e&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r141": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "13",
   "Paragraph": "B6",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2021-en-r&anchor=para_B6&doctype=Appendix&subtype=B",
   "URIDate": "2021-03-24"
  },
  "r142": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "13",
   "Paragraph": "IE63",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2021-en-r&anchor=para_IE63&doctype=Illustrative%20Examples",
   "URIDate": "2021-03-24"
  },
  "r143": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "14",
   "Paragraph": "33",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=14&code=ifrs-tx-2021-en-r&anchor=para_33_b&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r144": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "15",
   "Paragraph": "105",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2021-en-r&anchor=para_105&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r145": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "15",
   "Paragraph": "113",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2021-en-r&anchor=para_113_a&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r146": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "15",
   "Paragraph": "114",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2021-en-r&anchor=para_114&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r147": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "15",
   "Paragraph": "116",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2021-en-r&anchor=para_116_a&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r148": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "15",
   "Paragraph": "116",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2021-en-r&anchor=para_116_b&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r149": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "15",
   "Paragraph": "118",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2021-en-r&anchor=para_118&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r15": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "54",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_54_a&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r150": {
   "Clause": "i",
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "15",
   "Paragraph": "120",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2021-en-r&anchor=para_120_b_i&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r151": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "15",
   "Paragraph": "B89",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2021-en-r&anchor=para_B89_a&doctype=Appendix&subtype=B",
   "URIDate": "2021-03-24"
  },
  "r152": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "15",
   "Paragraph": "B89",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2021-en-r&anchor=para_B89_b&doctype=Appendix&subtype=B",
   "URIDate": "2021-03-24"
  },
  "r153": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "15",
   "Paragraph": "B89",
   "Subparagraph": "d",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2021-en-r&anchor=para_B89_d&doctype=Appendix&subtype=B",
   "URIDate": "2021-03-24"
  },
  "r154": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "15",
   "Paragraph": "C8",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2021-en-r&anchor=para_C8_a&doctype=Appendix&subtype=C",
   "URIDate": "2021-03-24"
  },
  "r155": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "16",
   "Paragraph": "47",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2021-en-r&anchor=para_47_b&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r156": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "16",
   "Paragraph": "53",
   "Subparagraph": "j",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2021-en-r&anchor=para_53_j&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r157": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "16",
   "Paragraph": "53",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2021-en-r&anchor=para_53&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r158": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "16",
   "Paragraph": "94",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2021-en-r&anchor=para_94&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r159": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "16",
   "Paragraph": "97",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2021-en-r&anchor=para_97&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r16": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "54",
   "Subparagraph": "c",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_54_c&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r160": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "2",
   "Paragraph": "44",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2021-en-r&anchor=para_44&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r161": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "2",
   "Paragraph": "45",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2021-en-r&anchor=para_45_a&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r162": {
   "Clause": "ii",
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "2",
   "Paragraph": "45",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2021-en-r&anchor=para_45_b_ii&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r163": {
   "Clause": "iv",
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "2",
   "Paragraph": "45",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2021-en-r&anchor=para_45_b_iv&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r164": {
   "Clause": "vii",
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "2",
   "Paragraph": "45",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2021-en-r&anchor=para_45_b_vii&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r165": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "2",
   "Paragraph": "45",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2021-en-r&anchor=para_45_b&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r166": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "2",
   "Paragraph": "45",
   "Subparagraph": "c",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2021-en-r&anchor=para_45_c&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r167": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "2",
   "Paragraph": "45",
   "Subparagraph": "d",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2021-en-r&anchor=para_45_d&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r168": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "2",
   "Paragraph": "45",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2021-en-r&anchor=para_45&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r169": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "2",
   "Paragraph": "47",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2021-en-r&anchor=para_47_a&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r17": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "54",
   "Subparagraph": "d",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_54_d&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r170": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "2",
   "Paragraph": "47",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2021-en-r&anchor=para_47_b&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r171": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "2",
   "Paragraph": "51",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2021-en-r&anchor=para_51_a&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r172": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "2",
   "Paragraph": "IG23",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2021-en-r&anchor=para_IG23&doctype=Implementation%20Guidance",
   "URIDate": "2021-03-24"
  },
  "r173": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "3",
   "Paragraph": "B64",
   "Subparagraph": "c",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2021-en-r&anchor=para_B64_c&doctype=Appendix&subtype=B",
   "URIDate": "2021-03-24"
  },
  "r174": {
   "Clause": "i",
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "3",
   "Paragraph": "B64",
   "Subparagraph": "f",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2021-en-r&anchor=para_B64_f_i&doctype=Appendix&subtype=B",
   "URIDate": "2021-03-24"
  },
  "r175": {
   "Clause": "iii",
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "3",
   "Paragraph": "B64",
   "Subparagraph": "f",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2021-en-r&anchor=para_B64_f_iii&doctype=Appendix&subtype=B",
   "URIDate": "2021-03-24"
  },
  "r176": {
   "Clause": "iv",
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "3",
   "Paragraph": "B64",
   "Subparagraph": "f",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2021-en-r&anchor=para_B64_f_iv&doctype=Appendix&subtype=B",
   "URIDate": "2021-03-24"
  },
  "r177": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "3",
   "Paragraph": "B64",
   "Subparagraph": "f",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2021-en-r&anchor=para_B64_f&doctype=Appendix&subtype=B",
   "URIDate": "2021-03-24"
  },
  "r178": {
   "Clause": "i",
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "3",
   "Paragraph": "B64",
   "Subparagraph": "g",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2021-en-r&anchor=para_B64_g_i&doctype=Appendix&subtype=B",
   "URIDate": "2021-03-24"
  },
  "r179": {
   "Clause": "i",
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "3",
   "Paragraph": "B64",
   "Subparagraph": "h",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2021-en-r&anchor=para_B64_h_i&doctype=Appendix&subtype=B",
   "URIDate": "2021-03-24"
  },
  "r18": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "54",
   "Subparagraph": "g",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_54_g&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r180": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "3",
   "Paragraph": "B64",
   "Subparagraph": "i",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2021-en-r&anchor=para_B64_i&doctype=Appendix&subtype=B",
   "URIDate": "2021-03-24"
  },
  "r181": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "3",
   "Paragraph": "B64",
   "Subparagraph": "m",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2021-en-r&anchor=para_B64_m&doctype=Appendix&subtype=B",
   "URIDate": "2021-03-24"
  },
  "r182": {
   "Clause": "i",
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "3",
   "Paragraph": "B64",
   "Subparagraph": "q",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2021-en-r&anchor=para_B64_q_i&doctype=Appendix&subtype=B",
   "URIDate": "2021-03-24"
  },
  "r183": {
   "Clause": "ii",
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "3",
   "Paragraph": "B64",
   "Subparagraph": "q",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2021-en-r&anchor=para_B64_q_ii&doctype=Appendix&subtype=B",
   "URIDate": "2021-03-24"
  },
  "r184": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "3",
   "Paragraph": "B64",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2021-en-r&anchor=para_B64&doctype=Appendix&subtype=B",
   "URIDate": "2021-03-24"
  },
  "r185": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "3",
   "Paragraph": "B67",
   "Subparagraph": "d",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2021-en-r&anchor=para_B67_d&doctype=Appendix&subtype=B",
   "URIDate": "2021-03-24"
  },
  "r186": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "3",
   "Paragraph": "B67",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2021-en-r&anchor=para_B67&doctype=Appendix&subtype=B",
   "URIDate": "2021-03-24"
  },
  "r187": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "3",
   "Paragraph": "IE72",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2021-en-r&anchor=para_IE72&doctype=Illustrative%20Examples",
   "URIDate": "2021-03-24"
  },
  "r188": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "3",
   "Section": "Disclosures",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2021-en-r&doctype=Standard&dita_xref=IFRS03_g59-63__IFRS03_g59-63_TI",
   "URIDate": "2021-03-24"
  },
  "r189": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "3",
   "Section": "Disclosures application of paragraphs 59 and 61",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2021-en-r&doctype=Appendix&subtype=B&dita_xref=IFRS03_gB64-B67_TI",
   "URIDate": "2021-03-24"
  },
  "r19": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "54",
   "Subparagraph": "i",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_54_i&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r190": {
   "Clause": "i",
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "5",
   "Paragraph": "33",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=5&code=ifrs-tx-2021-en-r&anchor=para_33_b_i&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r191": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "5",
   "Section": "Presentation and disclosure",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=5&code=ifrs-tx-2021-en-r&doctype=Standard&dita_xref=IFRS05_g30-42_TI",
   "URIDate": "2021-03-24"
  },
  "r192": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "21C",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_21C&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r193": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "23B",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_23B_a&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r194": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "25",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_25&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r195": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "33",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_33&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r196": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "34",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_34&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r197": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "35H",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_35H&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r198": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "35I",
   "Subparagraph": "c",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_35I_c&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r199": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "35I",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_35I&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r2": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "103",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_103&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r20": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "54",
   "Subparagraph": "j",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_54_j&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r200": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "35K",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_35K&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r201": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "35M",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_35M&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r202": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "35N",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_35N&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r203": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "36",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_36&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r204": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "42E",
   "Subparagraph": "e",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_42E_e&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r205": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "7",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_7&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r206": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "B11",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_B11&doctype=Appendix&subtype=B",
   "URIDate": "2021-03-24"
  },
  "r207": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "B35",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_B35&doctype=Appendix&subtype=B",
   "URIDate": "2021-03-24"
  },
  "r208": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "B8",
   "Subparagraph": "c",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_B8_c&doctype=Appendix&subtype=B",
   "URIDate": "2021-03-24"
  },
  "r209": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "IG20B",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_IG20B&doctype=Implementation%20Guidance",
   "URIDate": "2021-03-24"
  },
  "r21": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "54",
   "Subparagraph": "k",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_54_k&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r210": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "IG31A",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_IG31A&doctype=Implementation%20Guidance",
   "URIDate": "2021-03-24"
  },
  "r211": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "7",
   "Section": "Defined terms",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&doctype=Appendix&subtype=A&dita_xref=IFRS07_APPA_TI",
   "URIDate": "2021-03-24"
  },
  "r212": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "7",
   "Section": "Scope",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&doctype=Standard&dita_xref=IFRS07_g3-5A_TI",
   "URIDate": "2021-03-24"
  },
  "r213": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "8",
   "Paragraph": "23",
   "Subparagraph": "e",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2021-en-r&anchor=para_23_e&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r214": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "8",
   "Paragraph": "23",
   "Subparagraph": "h",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2021-en-r&anchor=para_23_h&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r215": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "8",
   "Paragraph": "23",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2021-en-r&anchor=para_23&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r216": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "8",
   "Paragraph": "28",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2021-en-r&anchor=para_28_b&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r217": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "8",
   "Paragraph": "28",
   "Subparagraph": "c",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2021-en-r&anchor=para_28_c&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r218": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "8",
   "Paragraph": "28",
   "Subparagraph": "d",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2021-en-r&anchor=para_28_d&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r219": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "8",
   "Paragraph": "28",
   "Subparagraph": "e",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2021-en-r&anchor=para_28_e&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r22": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "54",
   "Subparagraph": "m",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_54_m&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r220": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "8",
   "Paragraph": "32",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2021-en-r&anchor=para_32&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r221": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "8",
   "Paragraph": "33",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2021-en-r&anchor=para_33&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r222": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "8",
   "Paragraph": "34",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2021-en-r&anchor=para_34&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r223": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Note": "Effective 2023-01-01",
   "Number": "17",
   "Paragraph": "109",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2021-en-r&anchor=para_109&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r224": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Note": "Effective 2023-01-01",
   "Number": "17",
   "Paragraph": "109A",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2021-en-r&anchor=para_109A&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r225": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Note": "Effective 2023-01-01",
   "Number": "17",
   "Paragraph": "113",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2021-en-r&anchor=para_113_b&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r226": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Note": "Effective 2023-01-01",
   "Number": "17",
   "Paragraph": "120",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2021-en-r&anchor=para_120&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r227": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Note": "Effective 2023-01-01",
   "Number": "17",
   "Paragraph": "124",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2021-en-r&anchor=para_124&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r228": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Note": "Effective 2023-01-01",
   "Number": "17",
   "Paragraph": "125",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2021-en-r&anchor=para_125&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r229": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Note": "Effective 2023-01-01",
   "Number": "17",
   "Paragraph": "127",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2021-en-r&anchor=para_127&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r23": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "54",
   "Subparagraph": "n",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_54_n&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r230": {
   "Clause": "ii",
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Note": "Effective 2023-01-01",
   "Number": "17",
   "Paragraph": "128",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2021-en-r&anchor=para_128_a_ii&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r231": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Note": "Effective 2023-01-01",
   "Number": "17",
   "Paragraph": "128",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2021-en-r&anchor=para_128_a&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r232": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Note": "Effective 2023-01-01",
   "Number": "17",
   "Paragraph": "132",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2021-en-r&anchor=para_132_b&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r233": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Note": "Effective 2023-01-01",
   "Number": "17",
   "Paragraph": "96",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2021-en-r&anchor=para_96_a&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r234": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Note": "Effective 2023-01-01",
   "Number": "17",
   "Paragraph": "96",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2021-en-r&anchor=para_96_b&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r235": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Note": "Effective on first application of IFRS 9",
   "Number": "4",
   "Paragraph": "39L",
   "Subparagraph": "e",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=4&code=ifrs-tx-2021-en-b&anchor=para_39L_e&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r236": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Note": "Expiry date 2023-01-01",
   "Number": "7",
   "Paragraph": "37",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2017-en-b&anchor=para_37_b&doctype=Standard&book=b",
   "URIDate": "2021-03-24"
  },
  "r237": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Note": "Expiry date 2023-01-01",
   "Number": "7",
   "Paragraph": "IG29",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2017-en-b&anchor=para_IG29&doctype=Implementation%20Guidance&book=b",
   "URIDate": "2021-03-24"
  },
  "r238": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12"
  },
  "r239": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r24": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "55",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_55&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r240": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r241": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r242": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310"
  },
  "r243": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f"
  },
  "r244": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f"
  },
  "r245": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r246": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r247": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r248": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2"
  },
  "r25": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "61",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_61_a&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r26": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "61",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_61&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r27": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "66",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_66&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r28": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "68",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_68&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r29": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "69",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_69&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r3": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "104",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_104&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r30": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "7",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_7&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r31": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "78",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_78_b&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r32": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "78",
   "Subparagraph": "e",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_78_e&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r33": {
   "Clause": "i",
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "79",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_79_a_i&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r34": {
   "Clause": "iii",
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "79",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_79_a_iii&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r35": {
   "Clause": "iv",
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "79",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_79_a_iv&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r36": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "79",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_79_a&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r37": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "79",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_79&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r38": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "81A",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_81A_a&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r39": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "81A",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_81A_b&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r4": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "106",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_106_a&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r40": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "81A",
   "Subparagraph": "c",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_81A_c&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r41": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "82",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_82_b&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r42": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "82",
   "Subparagraph": "d",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_82_d&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r43": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "85",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_85&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r44": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "91",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_91_a&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r45": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "98",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_98_a&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r46": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "99",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_99&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r47": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "IG6",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_IG6&doctype=Implementation%20Guidance",
   "URIDate": "2021-03-24"
  },
  "r48": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "10",
   "Paragraph": "21",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=10&code=ifrs-tx-2021-en-r&anchor=para_21&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r49": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "10",
   "Paragraph": "22",
   "Subparagraph": "f",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=10&code=ifrs-tx-2021-en-r&anchor=para_22_f&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r5": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "106",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_106_b&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r50": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "10",
   "Section": "Disclosure",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=10&code=ifrs-tx-2021-en-r&doctype=Standard&dita_xref=IAS10_g17-22_TI",
   "URIDate": "2021-03-24"
  },
  "r51": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "12",
   "Paragraph": "79",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=12&code=ifrs-tx-2021-en-r&anchor=para_79&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r52": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "12",
   "Paragraph": "80",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=12&code=ifrs-tx-2021-en-r&anchor=para_80_a&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r53": {
   "Clause": "i",
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "12",
   "Paragraph": "81",
   "Subparagraph": "c",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=12&code=ifrs-tx-2021-en-r&anchor=para_81_c_i&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r54": {
   "Clause": "ii",
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "12",
   "Paragraph": "81",
   "Subparagraph": "c",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=12&code=ifrs-tx-2021-en-r&anchor=para_81_c_ii&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r55": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "12",
   "Paragraph": "81",
   "Subparagraph": "e",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=12&code=ifrs-tx-2021-en-r&anchor=para_81_e&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r56": {
   "Clause": "i",
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "12",
   "Paragraph": "81",
   "Subparagraph": "g",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=12&code=ifrs-tx-2021-en-r&anchor=para_81_g_i&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r57": {
   "Clause": "ii",
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "12",
   "Paragraph": "81",
   "Subparagraph": "g",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=12&code=ifrs-tx-2021-en-r&anchor=para_81_g_ii&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r58": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "12",
   "Section": "Disclosure",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=12&code=ifrs-tx-2021-en-r&doctype=Standard&dita_xref=IAS12_g79-88_TI",
   "URIDate": "2021-03-24"
  },
  "r59": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "16",
   "Paragraph": "37",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=16&code=ifrs-tx-2021-en-r&anchor=para_37&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r6": {
   "Clause": "i",
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "106",
   "Subparagraph": "d",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_106_d_i&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r60": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "16",
   "Paragraph": "73",
   "Subparagraph": "d",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=16&code=ifrs-tx-2021-en-r&anchor=para_73_d&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r61": {
   "Clause": "i",
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "16",
   "Paragraph": "73",
   "Subparagraph": "e",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=16&code=ifrs-tx-2021-en-r&anchor=para_73_e_i&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r62": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "16",
   "Paragraph": "73",
   "Subparagraph": "e",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=16&code=ifrs-tx-2021-en-r&anchor=para_73_e&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r63": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "16",
   "Paragraph": "73",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=16&code=ifrs-tx-2021-en-r&anchor=para_73&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r64": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "19",
   "Paragraph": "138",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=19&code=ifrs-tx-2021-en-r&anchor=para_138_a&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r65": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "19",
   "Paragraph": "147",
   "Subparagraph": "c",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=19&code=ifrs-tx-2021-en-r&anchor=para_147_c&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r66": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "2",
   "Paragraph": "36",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=2&code=ifrs-tx-2021-en-r&anchor=para_36_b&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r67": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "2",
   "Paragraph": "36",
   "Subparagraph": "e",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=2&code=ifrs-tx-2021-en-r&anchor=para_36_e&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r68": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "2",
   "Section": "Disclosure",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=2&code=ifrs-tx-2021-en-r&doctype=Standard&dita_xref=IAS02_g36-39__IAS02_g36-39_TI",
   "URIDate": "2021-03-24"
  },
  "r69": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "20",
   "Paragraph": "28",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=20&code=ifrs-tx-2021-en-r&anchor=para_28&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r7": {
   "Clause": "ii",
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "106",
   "Subparagraph": "d",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_106_d_ii&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r70": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "20",
   "Paragraph": "39",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=20&code=ifrs-tx-2021-en-r&anchor=para_39_b&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r71": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "21",
   "Paragraph": "52",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=21&code=ifrs-tx-2021-en-r&anchor=para_52_b&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r72": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "24",
   "Paragraph": "19",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=24&code=ifrs-tx-2021-en-r&anchor=para_19&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r73": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "24",
   "Paragraph": "21",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=24&code=ifrs-tx-2021-en-r&anchor=para_21_a&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r74": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "24",
   "Paragraph": "21",
   "Subparagraph": "e",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=24&code=ifrs-tx-2021-en-r&anchor=para_21_e&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r75": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "24",
   "Paragraph": "21",
   "Subparagraph": "i",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=24&code=ifrs-tx-2021-en-r&anchor=para_21_i&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r76": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "24",
   "Section": "Disclosures",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=24&code=ifrs-tx-2021-en-r&doctype=Standard&dita_xref=IAS24_g13-24_TI",
   "URIDate": "2021-03-24"
  },
  "r77": {
   "Clause": "viii",
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "26",
   "Paragraph": "35",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=26&code=ifrs-tx-2021-en-r&anchor=para_35_b_viii&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r78": {
   "Clause": "iii",
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "27",
   "Paragraph": "16",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=27&code=ifrs-tx-2021-en-r&anchor=para_16_b_iii&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r79": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "27",
   "Paragraph": "16",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=27&code=ifrs-tx-2021-en-r&anchor=para_16_b&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r8": {
   "Clause": "iii",
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "106",
   "Subparagraph": "d",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_106_d_iii&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r80": {
   "Clause": "iii",
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "27",
   "Paragraph": "17",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=27&code=ifrs-tx-2021-en-r&anchor=para_17_b_iii&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r81": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "27",
   "Paragraph": "17",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=27&code=ifrs-tx-2021-en-r&anchor=para_17_b&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r82": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "32",
   "Paragraph": "34",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=32&code=ifrs-tx-2021-en-r&anchor=para_34&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r83": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "32",
   "Paragraph": "IE33",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=32&code=ifrs-tx-2021-en-r&anchor=para_IE33&doctype=Illustrative%20Examples",
   "URIDate": "2021-03-24"
  },
  "r84": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "33",
   "Paragraph": "66",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=33&code=ifrs-tx-2021-en-r&anchor=para_66&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r85": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "33",
   "Paragraph": "67",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=33&code=ifrs-tx-2021-en-r&anchor=para_67&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r86": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "33",
   "Paragraph": "70",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=33&code=ifrs-tx-2021-en-r&anchor=para_70_b&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r87": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "36",
   "Paragraph": "127",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=36&code=ifrs-tx-2021-en-r&anchor=para_127&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r88": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "38",
   "Paragraph": "118",
   "Subparagraph": "c",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=38&code=ifrs-tx-2021-en-r&anchor=para_118_c&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r89": {
   "Clause": "i",
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "38",
   "Paragraph": "118",
   "Subparagraph": "e",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=38&code=ifrs-tx-2021-en-r&anchor=para_118_e_i&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r9": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "106",
   "Subparagraph": "d",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_106_d&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r90": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "38",
   "Paragraph": "118",
   "Subparagraph": "e",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=38&code=ifrs-tx-2021-en-r&anchor=para_118_e&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r91": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "38",
   "Paragraph": "118",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=38&code=ifrs-tx-2021-en-r&anchor=para_118&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r92": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "38",
   "Paragraph": "126",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=38&code=ifrs-tx-2021-en-r&anchor=para_126&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r93": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "40",
   "Paragraph": "79",
   "Subparagraph": "c",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=40&code=ifrs-tx-2021-en-r&anchor=para_79_c&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r94": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "41",
   "Paragraph": "54",
   "Subparagraph": "f",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=41&code=ifrs-tx-2021-en-r&anchor=para_54_f&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r95": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "10",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_10&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r96": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "14",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_14&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r97": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "16",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_16_a&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r98": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "17",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_17_a&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r99": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "17",
   "Subparagraph": "c",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_17_c&doctype=Standard",
   "URIDate": "2021-03-24"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>78
<FILENAME>0001410578-22-003483-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001410578-22-003483-xbrl.zip
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M""0S.VV.J(X"&8HH#?<S^?6.!&1.:\R(WGCJ!6PX\)+Y W;J&Z<?VWQ,IP#
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M4O"*WWI5%T6/[DVC-Z_?NZ__J;T9N0^A8%_UN%/>='U96<FYE?/%MVRQ-WV
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M //K5U+LQ$Y\D6PG2,Z\=(=$DL_YSJ=C78Z./OWT,@V<.:0,$?SY8/"N?^!
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M?.P"\-.BLV\7H-(GO@E2]Q- H7Q!WX%7*>.7EYG@?&VJ*+3X-IJB)\Q'$"[
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MY66'3L_;4,MVGB(Y,NO7KKZAT*.[M8>XCON2@D,N%UVP7@++.M^G88S#U_.
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MN=C(4?OWTU0G,D?CO_U_4$L#!!0    ( ,&+<55+4JCA#9P  (_D"0 5
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MN&+J/F(O/#S$_MNC3;9C;(X^1NH5+<="=5O4/M\@<E??SLGJ= B7]T*QRS"
MY:[E6B^TU4V)C<W1>V^]HD>;_Y5M47MO@\C=3ZRD9 %_T\4?A'--I7,#]AXU
M0N^S54I5;=W- %TK!>VY58=T7EE\BJ8ID:YLB]XO:U2L>15I!EY:)V_G_:;9
M/";4X*R&QNB]M4[)NN>%9N"OM0)W'O/G\R9/@\<:&J/WV#HEZU[IF8''U@K<
M_;KAC!ZV:=P-,31'[[7UBM8_=3,#SVT0^7?[.(P>7,2T\ILZ!W#%UVL6,>$1
M\3)XBF@0^W)1L'F;KR6=&7A\)].<;!2V(8(\1KKITF^K<?5&DIPTSKS%?%[G
M3H#*K?C.O.AFUQ=]M+0P@>TYK:PCZJAH(_]0Y[5$2T8XL)JLW-/T9N@"":L7
MNCH78?WC'W_ZTQ]E4,,G?_W,DKLP/H[9HZ^0AF25 A!QQ<\G#B@O%%F1^!DE
MHM<8N?_48<N(/(X/#J->Y"(^BV/"ONWA=+#>E(0+JCPXB+Q/GL/R>*P_@1?-
M]BR2<L9GHM?*/WC0#+8Q5Z75<_/+9\.4.ZT"):>V$W0($!H74)RKX%>H@*$P
M38M'&.?\\F*[YQ9G^<8B@F<%QQKD)U"5O(,(_M[AX%XAOVFP-S=%&G@V"F;)
M@*$=]N2@2>P^R0+=A0>57I:\KY!K"Y4.?@(Y@#K/!%-3NI()0J$D&GN!O.!,
M_RL1J:KXGS ^<NI:8J\\V9+P-1!1">P%(1[!/A-=R?M]L?YNY.QB*..7Z!)=
M#N?=757HNP$[TR7-85U,U248!>;D:OF%8.O=TS<(J&N5\PIU_!^NV)I%$?.>
MH.!0E05:]<8,ANW-D.&C?5?LD-E!D\XKWAF"2J;G\*D'):WDO%W/N\@[#IQA
M25RR5H6OAHET(Y2-:!0DIJB?=4UKCYB\"YCTFVH#(#CVDYZ],Z;'QZV0XF*#
M6A6'?-(FJ.=AU9+V.MB3'XN<KN"@>[7D2Y!"LQBB,#VZE(=?GH2*3"5.T(7B
MT>V%IVT4'C;;RS 0YHSE]07U=\*??0%><1+)P=&\ ].'(OX0[VNN^FLPUN1P
M0T=OK7H4_I0<R3M/\_Y>3/4D=UB6UNSE?D<N@)@S9!*<#0E0^S#F<!GYJ7EI
M:#H3ZO/"V7+\L;'\4 !:,;M !FBIQ5(+:LN)3&L9R$3IN9"3/166"(R_11^*
MZ &MM[G*@-:9'&I ZZ]5UVA,.<MYS1&@01%G 69QQ6RHN/0U#*3]I.P6L V<
MQJH'LRG-5YP&$IF#E:$,%W@98/_Z&XM6/!9YZW)?CU4M"*"'IK;&L$JM3GJC
M!I[62O1:0H@)5_<O1)PPS4)NQDLF4^V2C6:#ZQ.5.VUUFQ:069+X^DC/R=K0
MXI5&7JP6^RH7DUIT1AK7W8R0KQ[;]D2_>-Q:$3<[<&IYHIPF4,F.Q%(D#_;%
M5C3>CKP'-IY!<DYDJ1?4B61&-#>BV)$SHCA.L6P\A352]SBO<H]99$BEJS)6
ML[H.A) B:W_C6&5.1BISS*":E1EB"2I)[UXI,!Y^EM8[RQK.3@]L+]384I5O
MK<+=+IW+S@-Q%BOQ>\%Z'JS%/1Z>8^YQ&M7L9K4E,U>T:3",%=88:,P1:9I4
M&0)G:,Y3CNT95Z0H,Y2-TMO9F:WDN;"+0\P#.+9^&>Z>>4 [S_2&PYS/![CR
MI3/ >'E(XH0&<%3>:-FZ'NB1I%'=,F@8FZ/&AV:I.Q_,EY2S+#XF84Y\F(TL
M%O'0NPX:UGV'T_B"^G+;G2;R[@@+/%@@U^HCVY J7N42L^L;/WR-6SW,4-$)
M?43;*&V^N'C< W5<6PD^S@,,@CV1_'%%0&:6&^$E7X02M\%2W0,+-@LHSRT?
M56F,B=9DT$=)-\,<U^%I0P-U)'54I7MV*,)E#?Q47OCN$,M%T._36XIP@3%C
M2[Y2S7BR2\$CVV=9805<P++P_G:($XE_-V'TP"#HN,_NHW#-Y9W'1DQI0P$]
MG+0V1QE)K+NC!I'V6G0^FY]S(DE(HI05V4M>Z:VDZ7$#@4G %.29K<-(/LL-
M7\()LE4&P9B!Y88',-MHN%=<WV=FX%&I<AU<E#K,"""JY7;A_\+7R5I1'^2>
M<9L36$/J?%.K(\(XOH1C^.U,E7:99Q27%+8(8ME^?C%<%MMU",O+&SA&<*?Z
MIN&K+]!ACM\KMA<9!4_?%EOLPBCAL?RGOEQG:4 K0C.+=7OCU"% ,Y49X4(+
M95RAA5=@*0L8T )34XQ-@R(C6.?JV!I\MZ<\2L\<B7G2GD7)VQG9"P:); '[
MDWMU^@C>\..;;7(>KL\/,2,TCMDI!&,"J(^4!S"?6@97/-Z',?7C>ZWC/6@H
MS'R=ZF?Y*[4D.3/0ZF*P.OAJ0V]&0-9)+5>0MA',T[4,$<9>*L%9??QBF>R,
M:CM@5#02H-R:?V/>#, +9&<QF*M@J^7ZLXAJ]4CE0JI@:79[:C.#K)9FJD,K
M2U(S JJV&KG"*%_R)>\ J\HP!1$8A,&YYF^(PVDRL+&L-6=4NLTR1M#B@<'U
M9S#2\>>K<!-PN26FEK67TKI]LZ_AN,\,]0;^&>I0<B#6,T+5H2W@"H4+LSNY
MW_,NTJ+*"H#E+[^7FT-*7KAXI/?,-):/FEMVA6^L/TO.'[;96AFRQ_W&G&LL
M3!! Q<8P>A.*W4<L+4IU9-@V_9#B96O5LPN--IVPWV5LI4-_=XY5)5'-1GKR
M/F<T[JW%W[_J]?<41]:_E?J8\M>3^A:V$^C*CDA1L+WR=0G?::\9Y6HUPKM*
MLRJNZ@Z# %8%]097OZ;:I\/TI:R&F(+#84MU0@).6SXP'RX0+=<B;7OA<<7-
MXNY4D 9U3[-DB4Y[$MC3GAX:N<* (%2U&M)ZU_( <Z08ZZTUS;KN:.+Q*3R;
M<] C5X>8V-:")Q%,U=4*74<=^!+-& I)Y*S'WO.8RD*?84'5ROM</C21OH/U
M2QC]*GQ27^XT'/&V[((9>RT5SA^@J&^/'55MQ>_NM/+-T$!=BZ8OE ON_MCO
M20VMY67^CIOF0-);T%\7TQQ$'T7O5-FT_K)^SP[SU/"X+.(M//KI,3&'EN_W
M/+ 5XR_@HK93QE8$D2*?.V/5'W.SI3:CJ6<'I=P=>SLM4PJO[ #_PCL^42X"
MCB7\$4V657)]7VFD@FFDP>#)1 #&&6S1GAHQ70_D/:"K3&/V:%5ADG8 52 P
M:TRJTF-@&.(Y2ZRPX](J1J3)%M#GA282BEL=/FNB,7LTJ3!).S0I$)@UFE3I
M,3":J%0&TSFR8<UBA),Z0_0Y2""T/*X3!D<GV)YR3]],2!.T2E3H3@4I+O0T
M2W[DH#4)[&M&/33JC!+%-TU/*O#)DTR2>_8H^IFZ!R2YDY4O_N!K+L]>J@@:
M>0%J I,!R[P&W[NKHK4T8Z(Y2UNIYXL7 R"LY9+Z!#8RHNRQ.Q6FT\ZA5\YW
M]XFL+_,Q?&%1 -'W,:)BG+G,/'<15U2=J3)C/W*8P=B!H3)4[D$+.SR[4*U/
M]7N]1Y5O;6XR(<A&2B&C*>8[[M.(/(?>^!N<4]HHY:V,DW,GBCVY+(U6>3VH
MA;$>U @["7@,IEWHV+/HA@4KSJI\:^QC.I,;3'))7Z%0:YS,>\]\OI$O,*FS
M"? AYB6)TU2@M$I\3]_:[-+84T,Z CHR4^V=#SM2,UJZ:*N1LSL9U9.4XYV9
MO>:/8T%C+&,5IB+O<TO5F.=,_]OG])G[JBYD:;>F\,5@AQ-/K2.M<JGN#*IZ
M+ISZJ;7N<I&:CP_UHHT4KP8QH>%X8W?"V'-YYWH.C' J4--KO^M4HD)0%X.X
MXI#DZ1E).8] ?#H2R8\"9R:SU9YL7>,VT.LZ6AR2R4,6V9K/G1D^1YA9H+&F
M<5PR.77/86>\O3WU'.L3_=:V8%=%1Z3#37OEZ[?NCGO-*.FM$=[=)EW^PB^V
M^EK.E3<N$GNE=XYQ08 ZBOX$@MU3[K5;1^Y!!CT\=#/,R?M9+6B@AHZ.JO1X
M/PNN+JB'P6&'Y>QX<\ZB_/W0NU%XK(,-4P0<LSAYT"N*W4&E+9T9H$HGTQS#
M2BLBR'&EFRZ]GNP1_++E[O&!I<W]W<G-@Q-9^J4J;6C,!E%Z)"G6!&:!).,,
MP#I,,*0F3S8O>TYD&USP8?=$D]&*UMW1@T8[0W1YT@PU5+14H?-MSU9/F VS
M+A(FU*_'AI&,\;E4RJ"=*="A!EP(B?L_D%A/9HXH8F&81C2IH3$W5+%1Q3VZ
M\)0K^@<2A[3/;845< '+O3#RENKJ']7E)HO)6H6QC+9V0AH] +DS8!F4^M-%
M#50.U>L:G*D(C0^-'$^NJK!MXLG5G,R)%0#%I%%H#J=.U8V-_KC7GN*,X*ZC
MN4PHUY+<3,"MJU8N@I!GO/4]H%GA&"K+884L=:XH##8B]=VY0JU.1&<$7-V-
M9L*N]A1G E\]%',1A_H4IN!_#@(@@3%;!)O0>+%ZP"4[T8H0Q.QFXCTG\G,
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MS^Q5?F,L\&K;&3/FM39"J9RK54_LN-=>$:=% 6E"1$R1'8U^98EZ73&6*8^
M!4_*(K_?2X$FJ-8ZCFF $Y&LB.)%%#.BN!')C@A^ZNOI"K..8XXR!M+D7+C
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MXHA08"JFT9HK+-L*MN@&^7$L-".8N: QCW4Q,56^O+ O_9@]!M]ZXM"%[*P
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MBQ<6T0T3*52TXC&3ET)2V^FDKNWAF?X\9H6#CDQ:\]A4/P:SP417>KI!1GU
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MOZDMYA!I4C$+%U-#[*'3*+?C,!+\B&0H;Y]JEB-'U6 Z9\HAJU)P'X7>897
M6_+IFVBUFQSF]DACU5K5DRL=58U1+QXWR=SCNH:D*^,R>[D.X_9'A04:]D#J
M>LS1H^MV0XS-Y^;5CC#9X-?N]T@>6,S$#[M-Y5?%')CW"T^VM_L[\5$0U^R<
MM.N.U&N[&B)+HUKTQ9Y9=5'%<;(5:1%ROU]I(<BKD$*$!+F])[X29>0D;$SS
M/+2Q@T-(N!7XIO'''/A5C3"'MU&I+(A/6F /5;/ 73UN$25\!9?:(GG'-9'U
M O:2A7"ZYS<2T.00L3,BQ!!MQ/_MZ&HK/'+TUZ?=ZZZI.8RC3]QG<1(&[ '*
M%1T,^5Y#4\PQU:!@%EF&=MCCJTELQ\/>+F4G!D#%;^28&DK?3R>*#9"_BA3\
M2E#WPSW\IK4SK#;],(=?&]5/4M6Z3M@#LY4.0R6G,#'S<NY9DC910CJH+1Z:
ME)ZT(L2=H5JI W*8P]^!H7I4A[A#4M1T@ H1IZIUCYL]X 64*H!*I[_G:A#N
MC-:O(@3(0:0@4[]]-[;=/K=R*(>(O? \^8(>]0LC4);TW=,WR?"!K1A_.:E^
MVHT"9ESN9HX,BMMUQXZ^';7IGK0Q0G=P^TN^^Y@Q+R4M^41KK_C#R\&2_\@H
M.[)Q<G:DP(_DT[.4(TE93H"@T]FDUD5<XB6L7=4H=QNL_(/'O-M #!U)1%?)
M':?/W)>/6)C6PGK0PXRE+DQ56N#M2@P[SCK1S0WJUD,MUY) '<65EH7XN3#C
M+R-/9K;;FX?'>B0FJ0#B#Y**0.X&ME8]0$]JLBNGOC7M@9 '80)6>Z"IV (I
M2M>H4S[@D7V-^D#'J92=I_Y ">5!)"E9T]FCHT;S\+[:$T;%%OA]T-G*K236
MNS;;,)YX$29)N%NNI9 -#EG=%KU?UJAX]##W:4/47EHG;_>-PH#O3NO"#9O4
M3*)2GTMM\:\_!MY'%M3<:SMI@C1.ZA3*;[>5O\<^$S.)Z_J.V^-?B. #=]W&
MONCF6,&")BZ+%NR>US55"HK?8@Z.4S7R.@395]A#HD)2UY4&/EW<C%Q8P)U.
M5<+WNO4,13-OF,<BZL/X$R?1VW)][1U6\A=:!%ZZGU]W-;H]$<QQU-DHA4O6
M+2E@C\KN"CF_K@V"$"T)246!M<1,&'GR)!5G])O=8QNJM45<7H\]1.&>T>!+
M *IY+W &^%[8<BLD6VPB)K>/:V[,MNJ.&3(Z&"*_5VO?%SM,=%'%P7D9.,1@
M?ECE^@M9W"_&OH [HB64@@.$]66XV_$X%AHTQW!%VSD$K$G%D^@\;CB74#3*
M[?K6N^9'<H83A9QSC2M4<QAL7_;"+8/D^+3",E)_F5XPL^N&.01;*)Y%HT4?
M[('91H7.)U6R#?:#XI8=3<F.+Q%Y/CWE"/>UU%' *:I5C&$2S>/TW!)91B3G
M,\$F^9C:PSS@]+R2P2F& [G6QY9:]I\1[+4[EM2F\\R <-C#(#6(J)^RUM#7
M>#!D6FP<UDHG((GP3-$D!BGA9IS[SLQ.$:DKE4];FOQ":RSW=D%]F+ ND@NV
MX0%,I)?K>Q;Q\/A$OFO:2(%[$!,>'3GI3QCU&0"7^G5?,I(R"+BG"7FE#>'[
M1IZ5*$2T?DZ%@>%B+\69ZN@!)DN*9#'<!/SO<'%(1$HVN!KPLO<32FL:/TMY
MXBB14/B>^4D,_SI7J/?A_$_J&27QT5^SFU./*Q90H7C%"<JZ=DC1J%$U0!9C
M(X0HT2QK5S]-B9&OBSZ'*[OZG^;^)8CW;,77G'E7X8[RXW2XJ2UF/VQ2,?-%
M4T.L_M@H;W^?5 21';1LGI$WM47JKE8JEI,R?+/J^B1KB"G0I<6TQHEJ+RQZ
M#IN2GZDT['F%3V1IX8YE8]Q=J$\#G.8CEEV0QE@;A4MW[6K:8U_'LA6_\]6O
MPL[V\QOQ-6V8LZB-;V"=W]:?H+C:H-H+^D0QR&LWD)1%C[RN?;16YF[6G68:
ML:?9G%V/&4>MHSSO;C:!ZDCAIE#MD>[6!.ME&"?+]2/UZRJXF1IB#TJC<J5
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MCFV217(N?OESP^VC'#)=WJ?;;"*VH0G[&(5Q?!^%*\:\^(&M&'^!=^)O!$R
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M^A+J*<I9:E5R.-+RM 1&Y%W2!;K:AWB+GDY9&..,NI7;T,>I:X"9P70U0SF
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M% @AN)+G$7.^"F<9%L#<I<DQ2:G*F^WF):9'@>%Q'1.#$K]N'9=E 3OM.H$
M>$B9:HPZEHSM#1I$)BNA'@41C%BY/,$*A04O6AFR+*7I"C2L68-662= 62J_
MQ]%9D-MQ!2\*CEMB 7K?,\-D7M$*\=?X&4?)D<+;8Z+HFYB@#!Y:C)FO451,
MERQH,#*GG7JXB[-EI;>#BC$M]XOC;*X-XIB*9N!M8^&P/LG)ENT.IV$2D)WB
M(TX/8>QQN"YC7E,.\T;2 XHVQDPU>+@_AACTL),1W92]'T:?E?9G_%@((J]X
MB5NPGN"(O)S]D!SE/T/*#;!BM[Y< 6[(PK+4GH]U>Y92 ,H>L&*TPC+'RC+R
M2*L-K/DQ^ZJ\JGF#VT/X8SLN$(7;E1^"VWJOA>)JAQ+*%9#*@T?I[N^64"9[
M*/:,0$!VC\AC"-DL(5,+2,% 3\/6Z8')BA.BK.!@H6$3-(;%_,"V"I[#+$E?
M)\):H]L"0:U-\2%(D_LL%-!:5="',Z\@NV P,VJ9'B@3?( !F=F!(0\'DP4_
MV8"[\\)@E3^$NYC@I.1RCHSAZ5&"#'5ZYJGJBRJ1@0Z(FEJI%ULH\\V.A#?=
MN&2<^_EN.8Q[CB!MUS-U8ZYB2;DK3/50F4I*5>M$5Q=XZM900V,*UG','3']
MWF/O:_^2)$$V^=1E @&@0*UNC,:Y[<C>H(]*)BNA'+D4C.@$V5%6$+,]K)F#
MU?P4R:\F'30I%D@<R2D.V>B>0.>U@OJEPS6N&W0':Z(6!APJNMA),6&RV0#E
M0MDRB&0"P@>8>^3 "&0<&(2T-8%G<5^2OSZYJ9Z(?-RGR6FW%\?:](7MAZHJ
M;"9.L]L,8X@N9#@T:;H2+$T0A0ZE1G74O\Y;/(U:O^LM3G)#6DN9>!&6P16$
MB=8W]P_BNO=FB[@<2!($%9(@(0JBLB!9&'JG@8OC )U!6+%SH!E&\:LDSNES
MX"<OVCQ%X:YW^G4UAHZWO4K60+2UY1*0L5]P(V>S@CY*2@87]%@C.K%9_73*
M:0H,BL)#2#VM/+E 41+OWE-W% 7X*;] OG<,Z2XKPH2\1(?L/),CIE<<":&6
M/QZ+36#]5YJMEA#(3>F%+W$EP 'DSF-[AJ,2:531=@2*\^AYU3JR-*Y8=*#=
M3>H=6-77@^?C$UFBO2B[_/#\877(B.J!=_B*Z5B*:.&\[F*+2E0@XZ.Z64K@
MG$X".J)J:&3H.GX8;Q/"G4T%@HRY%[)0=IX@)AMJ"(<N/WS[<(%*^2Z0)*%E
M2'1@O.DVF<4DSSA]2GI %)!E)*9]9G%[-'*/GW%\PIOMRO_[*4QQ]]VUMI9
M47>$>O53C;-FH(\ONJ551T9&D:74%#111A]0Y?^9A0PD X>7RV;3.>-^=TA\
M:^91%]4-XBR)PH#%,XE&IPC:B6::;,/\-LFR$3.WHS'XR=NGY-EMTK.6H*=P
MK\ :MT0)4?0N(F1_ #R79U&>DEOD5"Z1[2HY/(4Q#EIC]V/:@Y_0 ZIVK,GU
MQJ"G]9#,!M9GOZ!<5(^@N:ZA^+6XO>.+--@</>%=&(L,'7ZGQ?D*OB#;P%GD
M1X)#;Q?P^#"L</>ROR"4&"&V,1=@L7 QHY&8J_#VX&)5N7?4V[GQPO2;%U'$
M97E7],I0&&!>Y% <KJ5G]=I-T ,/-)JFJJ.0(C'0$*6KD\9)1468)U%QRA?R
M[N4]E0EMB5#HF4KE"J-<6:G(HQ0G=O.5?^Z)MKJW0N=8@07+MZ'W%$8A??1C
M75Q0ZS1E>UOP<-JC8ATJ6QJ"AL$^>96]CXIF>6/1%8#-H=]7G$N)LO0]FKV7
M[OAKTVW'T";SP"^+!ZLE2"KNQE1EZ47>$8$BFE1Q[;UF DG:'Z\Q013H%#9K
MM.HA9%V*T ^OS2FHG[R6<_HH( Q00E9L]+(/_3T+?CXG$5$$O32?C6 > PI9
MP+20B)4Z"7"CK(ZX",?40OPQAE-,.C#RY?OPTI[)]IO-SK^$D !)(ERT&>Y"
M2MDL1$%4%E0)X^(9:.<&[#-5<WS[G:::>=50-=T;P'XE>'\+"&[DSA"'6B^7
M4!G7ZY=FB([[/$%/%)*S$\'BQ4&L/10%"I%SH*!!B!,(+LKZK^/?Z7 \WZ"O
ML\?D$M-KY6V64",#&0 U#%/BH0(-Z/"HHY*^2RMN"--KE15LYBSJY=>B/F%6
M "<K2  *-AV:D#B8Y?L=ZQ@QOH@N1CQP6 ^<K=E5H$O,BE\X0-=%#C6C[]#%
M]$X&$:*F;=,L_3$*%2*085G9*-)#=1,I0(=D=84,SA*Z'VN9&_W 2_S;E$A0
M5-')]\09ICY.=GKZ*_9SD:CE^?L0/_.*1#1PB+?L;+9\*B]#[_S2!'7^V0_6
M'\VS_2TJCG7XEH,*)>8[#2@XM8W?:AMY!,\20;@)TRR_$X]?]!Y[W6%B;3+-
M=ZTA!55"D+%<RSC5#2@5*M Q74\IC7KJ!2DZ,[94!B0]+],&\-+I*BPOVXT%
M&5=4L&7QW!;'^E'.7JB8.X!DET8:/[ N:%95AY'L8#._BZUIP9+(&\'DNE%4
M\)A3>$-8W%!(_^K__QL,-F2YZ?B[:KWK#@M[C1IG"NX:+P0@G/UUG.4IFW;9
M)A5/P65K=LA!?B#_TA?/5UG=(LE-DAYP*A=]Z0L<F60"&;-G,^I9(-L8!^B8
M/Y_".D>&<;EK#2NY4))*)X;%.2']K1".'C$V+_BQG(ZSTT91JY??O$MKZXJ7
M-7$BH42(EKQ(DB@>1=^;A+#TP/N 53A&D@EM4E1*A;A8[+=",+(^9<W5*T%<
MNEK5+H?Q>3@F9KS8A=8X*$>O5,>K&K.\-$/68T"-1:Y(<IYUC9N!!^0E;BZ3
MEBN<:0;0%[C9]%6=NTR@?RQM(Y8VH)_N[2QL0 U<K6/%3#"]G,UWU84_S%W:
ML*SNT"SS-JX'T(5J@KKURR^=S4%?@1F66G6X?VY!;X'<KB[$S*>M@<EMQ BC
MKO19,(.WVZ5X1U?R1II-7%C(5CBJB?23]T M!(!"E[HQQH6(FKVA>\=JROPC
MM.,^M&/\XPR&;5J<6VC!&.-&*0K+:UZM[BF-WI99WWOE9DPGR. [6NE:R?3>
M'M!!=KP"ZD5OZ!4;ZE/00G>[J/"B^"\5XF9>A!F<9GGB_RWC*>,)_=.678"4
M$LFA8.#\MJ,<4,?E&Z>7;N97_2I*LOEOW"B%%VZ2]+JZ.-]:%-[\D>A(II#A
MU9K1S1R9CN$('=[M&>"M^-WLHKU4%J.H4MI6&H.UI7]/I+=]RD?/R]=6%^*T
M@Q@-ILYGB;!(DK;C&9'%'=A:^09#![@VI@R0@V#5E=X"3\@+O2V3&SDX?@O+
MO#7]W\#!\EM>X!<R#M[P\KZ0+W!VTK6P1?TA3\._\4@#L=KG[V&6BX(?ET3-
MH+C'V/:%QG>%O,1.-$"Y4H[L!WW!FZJ&<HR=\2G*!+&UIV#%I\][VBH0UU>;
M]=K$S_SUR-$7LBVO&99-R</!%, %*Q[B>\^8B5O2#I ;Y)""E4%TY65[Z49,
M9X+">3N@4#JH6CU'J-$(=&90EZS*\7A"K^^L44^E/W.58I9S$O2GOYC6[*X+
MIHE7[U.M:1R$_1^Z\7CVHC9?QE8*U"R?591?,%DWIRXG0=0'G.<1<P0WVV_$
M&\;!Y\,Q2EXQWAP[ REJ9("BC:YAJNHYTVE =^AT5-*_X>LWP*U[0U_N=;)2
M/!%^>&9"(EQ(B1(NINWB-PX,R4!$8LK<.WJP4[%FUX#)+UP )"1 A0@N*N&X
M,%1M?1')#&ST31Y7!L%Z%00LQ.9%_1[>8&/(P#NH9 FOG2VA@^BPX#JGM-6+
M+A=MH=D+EM%32G".J6<A)BA1T_G,5E%&38QT@'A6]&2?O?:=YZ_&6)7%::OA
MT K^BH0@ YR6<88J,_93@0Z,>DJ9J>2E5S3F35=FG/D[7'569Y2^4'N9&C@5
M&NW9R.^T4?LHME=M]TLYIB<8KK7S G&\VPACJ^I6/1>*USV*Z%?1E0"3YYH7
MP"HC<Q>0RC5T89WNV+-D-\I627T5.SC .J\I_%93U(:;L[3VWXY)O*J\A\V6
MU28K[=!F0],,(./P+,943$T?H X=S^=1]JVDG)^.="MP[LKSNI,E4(")E\#Z
MFHHIXU0L),E%"?#:C*5HX+/#+9GV+%FL:\"R^/7)]\GPW)XB,EYIZ+K($B.[
MAAB_H" ][9!W/$:A7YRGA(3?SN :*&^4ZE5AJCFHL/*9(0MYO3-HN'*5,T 3
M^MIF4D48D::1ZY'E50>8G<ERT:B<)5D8YN("S()G^3:U,0IYB9F4Y*VPUABF
M#WG1F<.4:M>"%KX,S:+K&[CNL[3-%<#O^#:V5@ -NZR-E>;>] &3B1G,&5T\
MYP!YY9O'G*;BBPWRT%>_F;1]ZQ'&C.D-<!4$]CT-QABY:$L.,LYDW/;%4%KU
MCFE"VM"C,^SOO3C,#G2X[D\'SV@RK-(N><3B9H@NY"7-I.GT0H@+6[Z,Z@@[
MB-A<<I8019S1TI/#B #6#V@V' XDVE]%]':;(Y83TPP@KRNS&--0E'!A*\T\
MRK[A."'8+1+$+_E&-D@036M]>S1C&8GV1,Q[8K<=D1L'*_&F!9_BUV2&-SZ3
M-C&@RYT9(S6J5BA0@EW:0D<ATSF]*"W9TD5%O)(C+4[N'HH!9:@+Z0(I+#R:
M%@_KM/9D,N Q2,TP=?291@,T[BBJHA\7G> =NP,;R]9967RAJ@-'OWC?P\/I
MP-]AZ8 'E?Y <4'9%$/WTUH[0]](*^FB.M@+JO)S*=5>@&^*L^[+:5!VK%9-
MUGT=31BS>#]I/2=R*MU(<V60QIB"Y:3]CL/=/B<N*UF,O!V^(;XDVQBO\B_8
MRTXIVWQ3!W:3[W$JGD@LEZ)?4H\L1=TE"XV1!PK><QFR[NR9H0W:"32LHNIL
M%F(@C\LA;:YH@/10R2**\U!QJAAIY5#NN$2N"AH"L2>O_2 9L0@>WS_\QBTT
M0R(=/2[S]SB[25):;HR <\U[+E1;QV<U:%?5;?.^_ Y#]($BVFRF/$NA,T$<
MNCL[BZYFTN?R0B1VR//,A6KNB@L0XZYN6VENJ4"#HU0V$):M$MF$.*Q68R%0
M\_RFD(G\UE:C&TF".<QB@V37GM%*%I+.M=:M9RT%@%,<T?K+5TF64WNR? [/
MK\>,'_#1(SL''+W>$!R6.F^VJRS#>;:* _)_3H<C__$V])["B+0@>YE8O!EY
M56U".ST#]W(!7?D@F:AE$^!8*-"[!RBV48ZZ5B*\+Q1 /M6 UZ^M=)"/Q;)2
M"T0'<.V C)Z7,4U8E76OU(7^(:JTH0M[6P3+717ZI7])2<KB"\KI,L77>1?&
M?G0*L%2F.$I>,OX9DR.+(-&W?@B99R;K#^[.'][0!\GX%S&9U)XFST0_>ENL
MW&&WIG:VMP.Z$ ZJ5B61MS2"OB7KE5F_YOVQ(B_%/6RG8\^AHT044:KH6UO.
M@8U$Z;FUT\NHZ,"*4M2V0J,#Q>$G](6,*5--4.+,V([0L6>R'OIXU(B]]E\_
ML0Q3ULQ1P55'06+')>2=C@N3[T>&Q LL7G=C3[[=XR.Q%F9'I!]_:E-]N MD
M1!NI</5.9'][Z/@U5GS-X9D*JFSWE'&F//Y<//"72GS1QY_^V?;CCC/;H:#/
MP\/%VX[W#95=O.5H2>V^+VT+K3Y-1ZM/BT:K3Q/1ZM.RT>J3*[3Z! NM#-AA
M$*T^P4,K@VKW?6F3V;)1DG6JP[S&WA#4M.Z044S!$%6J[/B^T-%-116C2.=S
M ;K'?]Y(_K&=%VO10 6O;@CD>TZG83,7]A@]-F"=W7\E$'0B&^XXYX<6:G<H
MIU(!"KJ:9FG<6YI" O29LYHFRIDP2?R^8"=.=MW<D&03M__(T+5E8&')74I/
M=//7.Z)?OHH#FFM[I"N[&J@HDP./+GJ&JL.,&BW0>*.IDL:Y&&-[@8Z4,<LG
MP8*U*PP:SG^':"V#F\%[FMV_V?Z6X>D.BA(!H.BA;HQR2SBI-_1-H9HR.@GE
MGM@:-H"@F?-4UA-*J8COD^W[4X;+)#6:$23RS %<J;1K1L:-'DP2?H@S1!5'
M\@O]F\0475L'5E=6J8\36([=(_;W<1(ENU=V)V)-IF6\"Y\B!4@V1A0H3)LU
M6MW5TZ$(VN$SHI@RM)?,BQL_8<G>\?YSV/=S:KCUF9W>5?*<Y?$ZKABF'^.:
M1 (\.DTW2*,FV-L(;2FHH1PH7DA,RYE)8"&&E*BVXO4_ V(,'#[3RA;-Y^,G
M= ./#.,4KZ-!?Q_0"#!2=*U\S#(IM:@D&]#9+UBX\AUF5OPQ]0+,HD*\<$2/
MQHY= R_;K^* _D-#9^1;T6-?11]!B19X2- P4<-KF$X(-'CHZ*.\:-);='1>
ML>MTN&(+=YOBSDP";U_"?%\\@O:4A4'HI:_]=Q.+%]*@W$T$-= ,1O=9,H9B
M8']"7Z (JV2",IP_MB/T2/YD/:P&\7GZ#M#HO3W3,2NXC=AW;5U=6 +BCK5*
M1I&NFNOF<TT@!11D31BH*[-K+!W03JR&.B8RF>0B'6"#8G!L9+*,8*44)BP5
M44.3%%#4,&&@J@Z@&AWHCINN6E;]N%B>3E3<&O! <^Q<F;;BBQAC)'$&F:GA
MRE"WS2%D$I=Q?HWY-?A'[[L6+*M2 HW*6N:I0%F)#'A,UM/**B0'A:"(;']J
M:!QC5KBA]G>@.W!']B9LD>"+"&/X..W&3M==0^Q=]QB#F;JBO:>?3@?H(J!M
MFM9,EH4L */26:Q-KZLE[>$!&,?D)7E#.W=%.D"Q0=LTU?WY-[AAU]+)JFNX
MG)VZ$YM>+6J/[L1$1C;H,UZIH.E1JSA@C]+<>:\L,4KQ(H4**:#X;<) C4L3
MD^F ]O TU#&5R7<LN,+--W)@I)7OTR4N0X*=05>/J:&W#=2A Q0JM$U3NGHJ
M1*"[>EHZ677U.*A =O&<V)(Q1:6C!]S%<VBB><_(=?#VC6"L,JZ^%2R%C9\\
M01$R?MK;\[E'R=XD17L#J3DF8&U^UP&MC;<-O?*FLKB!)%EHQ4=QIY,_D0A0
MA-4S2GVK.X4"Z$VNDB+*U]@E9N4IL[@W\JX%5PU? YGR9IA5P] SYE7='JZ.
M;JSK[?7K[18^]9.#=&F!!U/-!"$M0J"A%502!M@ (B@K>6G(*@S3!XR\[VR9
MRO'AF*3T$F,0;DDW3*8$,!]/,J%.U97)9)8$3<K55Z;16 H@V;B^==V24[@$
M&')E&P$^!R^,Q?.[#* 2&E+P4@)!VR1]\=( &/[\%I\R#N!$4O:X^^_[T-]_
M39I&K6S:^1W4:(%'(@T3U>%(@1!H3-+11W7R<9[EW,+\0>P7RA?%24N>J@1;
MKO#)A9T>EP ^OR1)\!)&D9K/,[8W>("99(8ZI(SJ"AI$IFF@.AT$%]M.3#UJ
M]3@<PK%CCKL41^$AC.G62'"$!0VTJLH-K3/S&RO8N7G*B6=%/*RK),Z)23?;
M!U&AANS]-BD[XQ2OQ>/L*B+8'VY#:KVU*%&S*BO4=%I_;J[@H<B*V<^+7<W&
M$C3TV=%<JZX1+_7$7*XP1HF0D#X8345D[QM*0J(R4>6IE/,"^:6D%'/;2D8Y
MN^L ^@NL)Q;>,IC/L28FL@G!UI@"16"[1B]33V;G"#UGQ9X!M))==KN4>9 R
M#,P.RA_0'_=T@_IO2#8 ^N. #T\X_<M?[&;'P/]2ZYO[!\16328C?;PC0.L8
ME6*B0DZ:9E,SZ29%/$FO$A95TM+$G%)>M)IIT1RY4UG*M["P=,ZW^9'31&_(
M+BWV0_(UJK.N3G]F1$>@"^!TY>N[B*%>H#<"HX4WDP*\%2RZ4M_^X\=*SEOR
M_\B/XJ>"Y'_^'U!+ P04    " #!BW%5OF/WZ>!?   X_08 %0   &-V86,M
M,C R,C Y,S!?<')E+GAM;.V];7/C.+(N^'TC]C]H>S_LG(BM+K_4FR?.W!NR
M;-?H'KND:[NZ[MTO';0(29BB2#5(V>7Y]0N I$1*  B0@ B"CIZ8JK*!)#+S
M00)()#+_\[__6@6#9X!B&(7_^.WT]Y/?!B"<13X,%__X;1._\^(9A+_]]__V
M?_X?__E_O7OWOR[O;P=^--NL0)@,9@AX"? '+S!9#AZC]=H+!W< (1@$@TL$
M_048#$Y/?L=$?S\?O'N7T;CT8MPG"@>4V-GOI]O?C#)Z4?CWP>GI^]//[\].
MSLXPB;^???G[R>E@>K=M>H='.(<2;0,8_OP[^;\G_-D!9C:,__XKAO_X;9DD
MZ[^_?__R\O+[R_GO$5I@ B>G[__7W>W#; E6WCL8QHD7SL!O ]S^[S']X6TT
M\Q(JJ4+W7T\HR F<O]]^B]N"_.M=WNP=^=&[T[-WYZ>__XK]W[(ADE]+?"1O
M3GX+!>T+O*3M#^AG,CB]N+AX3W_[&Y;>8/"?* K /9@/Z,_^GKRNP3]^B^%J
M'1!:]&=+!.;_^&WV[,W>$16<7)R?$$[^[ZL,)OF?P]"_#A.8O([#>8165(Z_
M#0C][_?CTEAF&P0PN=]GT>H]^?U[.5*4-2FAO6_*VT."@4I&,@X3@.!J%(4^
M"#&N\5_B*( ^P?&V43R93]8 T6'&>.R39 G0*%JM$5CB7O 9C/&46X';*(XE
M)6)R #;+\0:&&,?0"Z91#!40I.-#-LMEM/3"!8C'X</2PTJ- A^;].N_-GB.
MF)*0\)-6R\J+ES=!]&)LKA4^<$0Y7,%X%D0Q'OTH0NL(SW90P])6$&F%'[QC
M@%BL4P36'JK'#8M$*[Q\BQ(0/T9%Z&Q-S0Y#ROS)DFV%YW$<;_!L\=8P\0*\
M_-R#&*!GH,XEGU K?%'#1[>S4^^UGMY8)%KAY0;^ OXPCD$-)DI]6QE]^O%_
M@L"_B="#1[HJ\L"@T,Y<"9\Q"B($ZTR/8M]61D_M*_2O?ZW) KG=:J;"'6T0
MPN-39DN.:$NS)K.QZ6#PT+8_N87>$PSPUK&&(F7)ML+S(_)\D"L!6RWO*:C!
M(H=**QS1,331UR&!5OBXC;Q0??!9KY:L'3EV/GJ_:MBZ;<]61EY0_NZL. [C
M!%$/!9FS]S#^>>>%WH)NOI0YK/&%5B1Q[:$0AHMX"A#=S2@S>DB@%3[N04"V
MS5,/):^[GZK/)RZ==O:H<!'".9QY88)-;AA[L]P)=/U<;\=:2; =/C=/,?AK
M@T=0EZ\# I:<=:?X0#>KLRJ)2%E\]GVLMZ%0(V[5.;@FQU7D+#D3U^2.3\A*
M.UJ72TFRUO@1KT#BP4"=42$MBZW1/<!ZV( ;%!&_;X*P@G[ 9#G:Q G>?Z*X
MKCPT?]UB"3YL5BL/O4[FW]=SA)G(IS.U6'2KE'&)N9U%>#K\&_AFI=IH1!9+
M.H=(X20Z# )R90W\Q^@>K#Q(-MIXGTVG8#@#DZ< +M)K0;,BUS,TJV4?)Y,Y
M<1P:E^3AARR6RP,(,+T%GEJX9X+@TX:H-/?E&9[G<M^V6'ID2^>AV9*P@$U2
M$*W)CX\C/<EO6RR]KR $B&Z-A_X*VQ>, 6Q0GL%QY"?]=8LE2!V;6>A(N$A]
M;F:E)ORBQ9+ZBG?O24PV9U^C9X!"&J:T "$Y;F,(/, 5##QT&?G0..[JC,2J
M\_ $#_L9@A?\HVP2D0T"^EE;</4_9)5<QJLUWD+AQ9\<C1_6>!NE6R""+UCB
M36AJNR4HVL7I[@AR$Z$IBA;(6VEG7O@12^2AC^EV.2M$2XS#Q L7\"G(P@_J
MLBA#LFU>,:KPJIZ\3@,O#>#]:P/ICE(#T]6T[8A*J<LJGU#;,2JU%R &"6LC
M5NHRJ43;XOB5^C-4B;H]T2QU&183LR*VI2YK7#KM1;K49:7<N=VXE_KV<Y]
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ML!U$=[.P;X4K? $AT\$6P\(?ZR-Q'W!M3$6_\A3$$_#DK!US(Z^\LEVIPY_
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M!D:*DC5FICD@^.:FOB0ZOZ\YS)\TC0(XDPVTP) ].9-)_C7X6TZWS?COEO.
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MUK131<UWT@]M*W*>JUIGJ)L6?=]$: 70#?)60&*MYK=V7=^*G.?ZUEG;RY;
MHWMR7RA\_[IM80TJCG=!*BN%;I67IKQ4/54M-K)0\V)]<#4H,\W;<W _8"%2
M;#[,0$@.C)SX!6:[$D_G)'/CQ[:5=(SX!7E9"!*ZM!&_D(_W>QBOP0S.(?"Y
MD0K<MM8H74T5>RI4XL[ZS+5W7K(A<!*NJL5&UBBQC86U4A""^PT+U]9M[23_
M$:[ I1?Z50LMMX>%L*A4%DO#:@Q:/[V_1<DM9@8]+KUP$H+_#3SVF5JB1UD
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M;,C/Y/Y"+5/CE\-,C84/#)+"%VBU3T"_X4K.QLM-C*$68_RLGK+UC9>F49W
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MJD%,R'7$Z!-*CB9+G.'UXF.V=2;8JY!LYYZB1E(0.5(Z[.\^.")^7V-=8@6
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M:L;\VS-T]J/K3Z<V@*.9;O>\L9HDXJ81:NL9NATXT[NF-9.$T\_0"T<CWTM
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MT+ZE?ZL,75VUV*VY9;>,FR9?E=WW,^_W_O-]"L;L=NJ__?]02P,$%     @
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M]QI(8FY5%33@0*RFE1J88V.:<I .ZD/\TTW-=+>'9=YKZH[G R,H[=8<N^\
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M#%N!?R_'3H'X%UB]:O8(7I_-*_I2C_K="(>6":3S 3O.3 MBO&D9PV)1 NS
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M(5BUB4?=2K8R1W\0!(W?_Q]02P,$%     @ P8MQ5:TEY$*=%@$ 33@+ !@
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MBTO5%75VHSI/VK1L635%>QLU<1K F );Z ![,!1;6YH'O+7KTGJ[1M38-T)
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MI;&$KU0L.^/.0<8,S%7&"+XY=S(@$!7Y-_M\UX "CATGP..<S\G"Z(D:JD,
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M)1L*.!D).(V])N#?PEM_.",3D3!C@^ -Z]-58T^8AY9ZY0FB3"(EY+9]^!O
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MVJ5@;=GUMIMH $<&6Z<T25P4ACS$[^KR#)KP%<\/XV,/32/7]]$?V,<\ E]
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MS9-8'=[!^9HRK!4;;8[V/N,.1!@W_Q3B5B*$^YIS0+1P=(>.=S*L3LCQ$C(
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ML=B;6FI5\Y=4."4D-B<6W8U[TKA/\%!MU=((DP+PN"-@0JQ33EG4A3E4@'C
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M-WH=C^1!:\=BK$"]L0U](QIZZC!(JDC?("#R00VK#GM">PY$FU^M&:>[6L.
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M=!X#8#G:6*N*N)SHA9)4EC9CULC-<0"%MC'3-)O(<I=JVLT>;V?^[4F0E^_
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M@P1_PV*3M.=)WT6EA%W@O=TNU/>P@]\'XQ]K]$Y%.V<I.=.&S''QKWSDPUU
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M#+RW#7P;#&QV:E//^\,)7ZX8F_9P4IUTZ1S" +J0EZ RW%>[DE?XF35+$#,
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MP>5XX?Z.V@H94"*JK>H^T#?1]OK1U3DQ/4=M$T41*K"11$:G/YH% ;BW)">
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MET+//%L1*.W*VV'/74.I6P9Y&PAN<XJ>>;8B.B\-ZFO54/5T!M1],IUGE50
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MO66"V?EJX[;GOV7A4[T^E1[I#9GT^[2OBK.U8";5#U8/LT[;[$P,5N33]4I
M,ZR[HU(JJDD)[7":2F1^V0_]2T=MGYG!&P/MC2S\SXI_?2C05F-_8X'^U!8D
MMI*<U6;L1D155W&)U%0JD;FX77Z6'_8W+L'U[X>W8#T9^)*2']=09:Z-.YC@
MAAU1+3E<V1Y5)8\Z,."6A"<%Z%"!EF-;+U2A/6IH?-)$AI!4!X!]%X-CE^#G
M]<HB4.;?9WFXG7V9^)RE]%$;11F<^*Z]?<N8PU\*MCF#"U*09%=7#?B1Y1XN
M4=?,[:PI9?BV7F[2@KF;;F1IDOM(2+4DQQ'-38XJ<3SOZ<EB8[A>@$X0S+I_
M_,N2"3K#G>%))_X\8PCUXR,X\M/@_LTX$F0;BV62FL^$T%@$]((:6'[AXSG2
MFAD^-Q4HAP]W5IC/62RS4E6<)L)=XLA?IVUT_M3^0GV24 /L$('NV,3(W1,
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M4I12&9"6:47D4A(GLED9B#.2@Y.4%9+,,@HUX^3'SUZG0ETDB[4Y.5J'2G/
M>J:>42]Q(#E4%[.<GU=TOP5?X5#=<;::NT37<J,V#L:;38U,!B.FV<\NP&@;
M7*)K;<SGH,&MC\GVK.=ZK2([,CKJ1;HF6T%/ 'R.#!=IMK:8#9MVX2)=RVDK
M-2XW&4, HX:;,3<SJYNY2%>OJ@?K=J\="GV&F_"Y=,O,=[IG=(4CG:#0S58E
M;2V8XVY@5X74DBOEQ/3YR"$CYWHUL6*1;5_+TL6TXA9)5+ORG*N./%@+Q<&
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MTUAI"JJ!?6X8I/LN/<0&=)#=$!09:&!AND88O&?FP<$O)8%X"69/@-YU4$
M=.'*4R4-WNL02\MQ5!"?^#]XR$.(GJI/052_M+!^E(&TH-MA<&8"EW6N I]=
M=C?06SPCR\G*;0'L?1Q[A,[Q19>ZX$()07?YPP>FX:!#A3XE^*_B84<24 +H
M<O!HOE=XK<8 ETY6F69SF>SG%#Z?'>VFTJ#0LY=LE,:@?!>?_)W&./ VB!0#
MS@XS=HBO@U#5F>W)7''1(%N+^B)3KQ<UNO[>(T1AJQJ>@5ZJ;^7D /<Z>E2
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M<>LJ.618^U'?2+ET'=GS3 36S,&>W\>:OJW_X%NG=Z Y<'EA"4>.^&?@#N!
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MFRKNB(+G N=;%S9P!>#OMT2RUU.B43%#KMBQ<#;8VR<%;HX UQ+J_X#7MI;
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MGWDC!OF/T@F?9'WAQ*BN#-L:)%>>HGD3\/U\K="96;F%UVF-N58V.U+JE>'
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MKCE@#@*AM3@I*U!YBC32W5F\/)?+C]OW:B$@/D <EA98,SKFJ:"4)"!-I)!
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MK!ZYZH'(/_?V*!H'G@$$T<%+!'98,#6\4>CA4QD=/EX0S0OLQJ<L #HHP*-
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MS. =\+D7>'M@Q4TB6#A$BL75)U"5A!4]U+C0BB!L*M?U@3\Q1@^X%E>+ /5
M3"U=%VR'\!S?;#GR\6-LBO[T<A).L.'8!*<MVV@"<Y0CJ(C)47J9R.>YU6A?
MK"Z7&5/D;L(19!Z(8($P_8J'>%_ QWN@7US9^3M"L$(@9A*>&P6AU!Q/P/C:
M_T=]G@9__5=A>T0B<;KJ'EZU^A^<8S&%8\D#+^[$*8!U:; L"PI/$ PW'P8/
M\"X$FN)/0C^,1C?1G'<TBP'-%7]2K^7[GU!=^+GO;W6,GM#<3^N_[N7?$ERB
MPZM7VBE_$'Q16)92',.OM%J2KBC-9JO'N,\-@G]O_KK2+'YD:CL>%1_9_&0]
M9A6NUK%YOD3'&QS3RR?5*IJZGHF1-!E+)<_QO:)SI%]/MC?GI;^.;#VEMMT;
M93))KGHI<IHB.PNJ/(-D2\72)!U+)\XK2Q&^!X0)!SRF8SLI(+P-"8OJ46&\
MB66#$YO7Y:\*4&7(*'OE[P33YL;Y<GXRY&@AS1KC(<5DK<]F8/I-^Y"#1 G4
M7AW0)K!HYX<NX4WIM-Q"G.>HA4;KE77''IJ9M-'YZS_R@3G/$B*Z?1>]WLRY
MWT*O^;1"QY5T<DNVLI5I3V#R\Q8$J:,?(K)T3\]2>BI$'?<-#ZQ=]FN6K"7&
MJD?-D$ !"_8NT,H;A$]_*)<^97H4+^Z0(QG40<$31Q#"3U7=@[_J=Y]#W](O
M:(=?@(OD<Y,+PDM8>(RE*^+[=TG8A?S+2[;3W8#7&\Z(=O$T[C:$ X[R?H<[
MOM(J>]0C5YJN<CN.9$9B?'/>"!I]W;<V@I(?\973#X1/"C3_#'J* 9&^M!/T
MXZ]>4&47/(\H6\OEM3CWQ_7XM:"^(PRS8S$B_,:QX_08J NGJKQ6315]1>14
M"PYF)>9@H? A)4,L$_^/8"S_)?+6 U$K$;_\Z__&Z@TAEL!4)]18\*[#(!@<
M.\>(F2T@2-I7NEZP/&M"C^4TWY]V.$T=U]CI.&TE]_KF1?-%9<.5<>"O4/8#
M\-@,X>F?"-_)495/($@$/T&RGKN5KJB*CUIM4D]WR_4=J4S8ESRW9V  _.K$
MH]#WCQ-ZFB@H:"FHRZ#K5]Y'VD%G4"P+G):FM'PI9=12Z^2&!R3YS]V<(P#X
MULY% SH@00^C4_P]\4?=R1AX#8(.@^@)UOA'3&-BO1D<D0*_!7Q4CM?[1.CH
M#W%(#!7=H*&'_D&EY$\S1'--03AWRG\H2PO9"X_SL>P0'X92LL^CVK,0:1,(
M4%G6US*<B :%"2PS[DN4K^6I;*#EG2A&C1T1P]]RJ/J>X""#K0<)>33C%V^2
M'V;1Y-).ZTPQMR;S-IEK;%-..]7IO#VX>#*Q,6!*'%JTCF%J)&-.4HZ13Q7C
M:RW>E:9RN[XT)@.8BB/)9XIGP_KA4_<8SO !^^9[<FC$XV%RW>^3][X7#=/;
M_A;G$FYY6342 KESQ]6NQ%&DV[^V+7Z;%QX5/;8AC2 E(_>7DP;)LKDQ1B3-
MC,;SP4@?2YT.RG5%[.[1?;WWK=_[UI_O6W_1>?TF3^JSW4+6="U@ 7/ HY>N
MQ2VDPE,=L0WW&V=UU(Q[',428%8%F5BVA _%@.&$9]0.T>O64>H13EQ[>/(Y
M'!L'O KK:/1#OQ&X!D +ATD4(]KS C;W^5P+?NO_-'!"H#3@9D7H*ZE!KU'X
M]L"E"<URRUG /D.?I2B+M@>#^F.5\*'I&2[A.$($G1+[4_# IR;8#B1O#O:.
M0'0FR5.$"]Y)^$\38"<><"7@<#>_XR'PJ&P_G@FP^SS14)T@Z1! ?TPM\!'X
MZ1#:!_QU_XSJ.R<X4&\T3X<][]FZ;Y\*\RRU'!C;%3<L%( 66#0LNOC.)I(\
M/"83+6Q/V8 Q&P&QVYC6D>>!YH[OVCDF8?/#6<$L9JEUO0PKN:A(!R3@8CPH
M2%=4'0L%8A /AD4BD#,?DR68W!<I-(#7$(L Z8$IGU,&75BH B6*24^0YN%K
MP)SK&2<'"A6Z,H<#DD$L^!5 7L!GE@4\JK4O+K:%1O*%'U4(?.S00W*R/E,]
M@^BQ#T09GF;*DN="&!OX&HIG8EX#?CL^R#R1=51-H;H^KP>1A2,'DUV=8Y,A
MBBP .P/Z'C-6?K;J:R'Q7UW0^$ZVAZ?G?=754;\,.N$";'.\ V\0X@+_AI*:
MRU'-<=GEF8;++>?%+=W@WRDGOB X?2L<5<(!X/X.1(K(KK18Y'7'+?.]S$@H
MYJEAHE%@X?BRYR87!ZBD/A+"U$](AECD?X(]/PS9Q//K_V<*:Y8.E>3P%MBK
M<CH4!,TT#?.;7]>#>1_P18B)C\8!G1!^GUF-\A&H#_@(.;D-G&,@?\3)Y NB
M]\ ^7+H6$#L))SW_1UGNRD O<JAZ"V>%H,UZ:36QPS@W!#J(,@0@",!%8! K
M:Q?2H^ "OP;PR11S^9!$1Y?!9FNHO9],_O+\D@Z<;(^J#L,("!*<0@K5/+SU
M4)@(9$J"*78)1KGP:#KFV^588,A]706/%O $4* :90&8:V#+82$?>/,'HATZ
M,T>NBVP;!WB%PU)1C2)< BXJ0?8!+.HY2N+CB# ]<+VDKJYQU=WS^P,!3E )
M(A U=89N/:C<T%Z(@AO@0 1DAC$<;"./^6DA*CA=H.$LE9?!S8[X92U@=7P^
MH@+,E2/-5=MSB"E@6D"18;F%OSELA:S '!*JRH&-7>!E@?['IA"QAZW)KL\$
MN!7G!48]=+;[%9K'I<-GG;$B&CX(MD.8H^U PV_#C&P">^&J^%=Q[QVL7T)[
M,\45OL)2A3,,01 (1^T%A$%N)1K=C2;=J7!F,M2ROKG!;^!W\^$JH\##: AX
M0CR"W0%JUA^P@+MU4*KWZ*.\O#945/E=IC<5,KTI/R'R5M.;DY= +$19/Y&*
MWH/@F]5693O/)S:<Q!F+.9O**^.$OCJM0TR]K=T#C8%&YK4!/$00F<+ZW-TS
MZ=MH4(_M++=E*M[F43.DIIAE!N/Q5.C\]5\BEHUR1\\F)0JZ+0M3S/DS$TU/
M5L, 3;%0X^<1)RGVI)[VT/K\0.0$&UQ;E<'5/1?H1"[[[W(NFR:XQ_)LR";0
MC#MP$JF(C*^!GA!#QP#AH>LFGMSM__E*QED"R9@TG9)(CQ.[1TU(<JIDS->6
M /-8;QRE^8+/A18)U]AS9;PZGT>VXSY#I^U1@\R7G3:33SF:OCLYR$Z^%?W%
MA[YJ*2T0Z]K.7%T&G>X5\U#=>."-.!UBCAIG[.)CP3')H9IDEYZPK75T%O40
M,.<'VO\;[N@SMN%HW&"=LNMO#^H<"J75G[D91[S/,L;QV0Z<A#50D=T\XQ[,
M']?%!_Z[]MP3)FBS$[->?IQ:6FW9J<7)B9#6>Q=C@D5JUV^R T;G\@L[5QB[
MC4V;A.'J0P0,S?MX(/*,Y9FG'%.U=ZQ()0=C7MEQ@"40?7"\2%2S25O?%WKI
M0IPT$GU+*1NF5T]USH_IHZ_[TF/ZWP4P'RIQS<"RFF,[D!NRAMA9@K.&OQ\Q
M[;/7&; !$>(#M+Z294U1M(ME+_$O 235D E6 A*(\S77DOP-%?PJ"JZ*(JH>
ML-R47S3T"Z\A\R_D?J0L!/>@^_^.G5;E"A+J!ILB'S2H857\U4.]8@B2[,&3
M.MTA<N".&,$:#M"(4\&(@;5"N$H@1<!@''XV\M[#[S\\\VS%DCP'SP3#D*''
MYC$,3 ET,W K79@ !G+K0K4.?'A!U(.P18540QP<9)8#'Q["7*$F  <% GY1
ML03'^=G$3#9A1SSD E@?">ZQ_/2V#&(YR>_B@N5@X$I4S@(3<SOHF&W@3&OP
MW[6 JI^#_ =PO!QXUHZ<//]7_!C(.70('Y5\N+T)^_=/'#<<$N&0$H6=1Z;$
M*1J4Y43]:H?N-$T&P:PN'T=9HD2B[&\V"+SBKA4'_R%$3\55(:)N21J^]NP5
M1=L24!&("4_ 9CM()>CH[RY9BWTV]2>2KXZT^7(8IV?SD5'6Y^C;H/=^\MJY
MA_7#0<Y"4N8[/FQ[.V_MS(9!RNWU(CY=%+E1O?.!619=J. ]&6(\(1:1(T^-
MUWW>SLWCMJ#UYAH7'Z[ZS7HR>EX%@I4U/1^<5< EEQ=."U]@&]X8J ('5%%=
M6$<;L1/A:#2_6$E,LU;N\+W9P%[J^_A^FV91P?'S&)-1/9PXWW#0$/]_>U?:
MFSC6I;^/-/\!]>C55$F0-F:O'K5DP"PA83=+OEC&-F ,-GC!F%\_=_$&. FI
M0$)2EKJK*HEC[G+NN6=]'A=\ C,W0K7@]%S$@/%KKE">1 'Z$"@?;AEXDZ-P
MPX\@]$: 90HU=_*D1?-_=5=4G+ 8C/PI6%WCT M&8M/=*MXYMQ6Q2QW)TKFR
MA$<I"CCN$2I1]*!$CVN325_>C!H/>C8UH.BB]=>_J;N0>A!7HN; N((AA6"!
M-MQ;A#CK<'_^\ "LO  '0I9VJK2<8AY@?JCXXOZ)TFB"B"-\?LN=D[B(!^]+
MA*D!!=.-N*)F(9_WAA/@38(O090;#+E!X3EP1 OEWI!\(0('/-@CT;VE&Z\>
MOI1>9- SR7IMRC/ 8OC@WYN*&,N[Q]%# ST& C775TU:9]G\U4_6@&NT"I+&
M9&BS)I24T4BPFY+UCI,5< K@6GJ43ZUI'RYB*;B&+DF4%J@ #1X[@=/[@EP2
MT[+T5"D\-%N[L9B&QXY\X=S%81'" MF$:@Q8EQ 5X4#6H3J'U9R.!@7O2#A?
MBJOU4K5%T>N6<%,9SFT3PSC$5PXGW]3FORU&% #]KROHN@S?V#XSSG:G(JT2
M7&N:82SAJ?D 6X*2=YD7KFCW'D9*S0/!!]MQ@%?L%S(<I0LXP7$<_!0NYR8A
M?! R_X"CKY!<@$\!VA;"3T&,!!?ST[M_7;*Q0*?C<7^GIVP\ "KT7,#Q@Y_O
M-TP>/N;D_"0P;RBT.NH><(53D("GB^R2P^%[PT1E/4ZNQ?'N@,I#HS^X=,X4
MXS+;-MGQ$]]II>3&;O:TJVZK@^GRN2)13XZ!K? 1,IVL]KG5;#KH,BW+2HWJ
MVW6CG?K="F%W= &EAB)!RLPO(W5KAR%5$_A!F;/UDM<I%>HIB-76<K*?=E=,
MHZDD'LOM1G+/ 4\A!(0P8>"W@GO)CFW5);C,_?Y:MUL8WVRXZ@3=7"GWY@K
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M>U3$\/T4!KK\D=2_WPU8=7BU+MU7--ED.Z*1VXDRGT0TJ_#R_]IW_QGU"U'
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MB$VF.K!N(J0>A=$OX!@%LHB!]\-*EBF0%G?5W*\3\%K]A=.CX/@(KV8FG<U
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M%H* ](0:()#EW?+MM^?LV;.[<Y^Y_SSESN_<F=_,W$OY3<$!''K:NMH %34
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M-B:QFT\(X.<^P\R\X@H+EXG_0ONOR/[O@$7\?R'[#V#_$Q<68*6A.G]Y-)P
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M@XM/<H;VQH[[=Z]_S73<[1K6K8;#W"UA7R=1TT-M[X_\9(,2>WY$H\CQNA2
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M;[T^^I2ZE<PDB'1V1.X)MQ*8A!/3O<$KF^[+;9=T.5O>,20E=\J H(_A$Q3
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M'[C/2(,^MY7"IHK:)S183E$:PBX-?K9/RVK"'2.W+#Z;!F@LO8\]5*!:36?
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M' ^N+\#>>)"9O@3)DM6?Y?"VA&^6^WVQX^RX=+N#FD\89=NL7+H=20$8-S7
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MG3_\-ED2.\*EDLC</V9T!Z+UGY(Z%67JOP!02P,$%     @ P8MQ561_F*S
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MIK,@^1^?OX%_<Y5%D_]Y2E?GT=\*'@W;HX^7BI8Y2N/P::&^%IT@CLZ3)V-
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M0,7><Q7 D]"S^!8])0"!4\I\]"45#W/:%DD*!B(<"AJRP7_1<<)H:(.+_0%
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MSV;9^-JC(]E/U:Q?]?9/V"J).6R1IMX$L[(;-Q_V*RI4)CK)Y335SC^7FDT
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MDO$(B-Y#:@F(-9(IUD-C';1^J'=$^:Z?WGP\\MM^'NJ?A[[TK0/S(]6-HN@
M*5L.>8CWFB[^^/I5YS4M" 76(]]I4Q3(:FU1K.XSBX??%? B=-UN!;"8K(P*
MP=V"NZ)I=)3:4=V!*=>\E!+BR'/SE[R*FROEU.<!7V>PG(P]TN$X:D0_\L/@
M'L%$8SEEXJ&)%[/Y%$XC5#*^P&UN ,\+N?JF<J:,XT8.R:,U>@">>8C_E17(
M=G@;Z .)$ ]'9<$"@#M"%4BTB'/F,GX$J(?<$QM91Q' =3DK1AK,EK.S3NP4
M>JQ0!RGS4 I4@G.=YL[EM:-*6!%!W/D VKTC8-D(XB>1\,REW_!E2JJB7,">
MC8J-A%V?T-*3@$QN-I+8QIJ<'XR# Q@& %VPG17V%!D.>OVGXQ* I9!1PI>@
M1Y/_"5A"&H7C18[<>AQDP/#HA_R_98!Y]EQ>:GX@BO^B#;$5%^$@(*Z!5.,O
M1!R_O3L[/74A$.4>=P43+->:_L'0[,GW]O9,'@@S&H;Z.)UBMPN2ZP?Z"O<,
MY((51_$!<!_[,F.0PLF:MM4,NLQ5>]?G8FH7TTH^BHDG D*^.'O[7G)\3NAD
MN5C?S)%8OA62UN:5:#0)#(SEKGN$6ST/90YACHL  1L='!"6"\?C5%IKI]['
M%Z>OSSYY_6Z_/HWC$GL;VJ=AOG,6*6G?0)5'MF1Y0KTF;+\O$P@D,-?-^^;!
M^+1%NCA3DXQ:EBX,7IJ]5]=PTXU-L9'Q#?>UL4*26O. GFE!P%SQ+!U'G)>:
M>:_)TN5D;#9TT2N0F6$C9Z\_G2*_$4^P9+/K!C*8OH]H*YU'=0R%+LC1OG#S
MXT2QJ=><D_I/I=1V6 [[S5)J2%*)0LHS<N Y:F8CC,30+!MW^ALTV;O;;T,,
M :+;B%UST4R'J5M?V5 R6<PX&AD%/0!<J#:BOUZXO/GR'+WW&.]A'P%)'.Q5
MF:,51:(4XP,745@&3N=CVW>#N(KVW(-*$,5.I+8F=JETL^-$TJUL7P-,S["P
MT(D>YY5.0=/%'/$FCT3#BE,>1/)754=!5P^[4SJS-.1R.P1':H6A*W5)G)LN
MAPQTM^HFECY#U(Z)5>FB",9?#"Y0-:3=8A*V[FUC%E:S?H=(RN:P$?G,<>J>
M;5)?3>_FGOL@Z&<5SR4;H$X7JFHO#Q+Y<$R!=]CKN=:QZ&%B:;N"JNHLLDXL
M[LK-E9^UJC63$QHE&*8%0.[W6OQ9$KSK]RR"7R&I]YJ77DMD?ZL#/^H.#]9E
MQU[?U&W>$B>NM( Q&HEU^5%MD\$F0A^M78@S?L^$6MPG&-2I].PP<)]*SV7W
M4 J90+FN/NL#9OS,[>!@H9Q?!F:2._N2;CO]].:DLU_1OE[KE 7SV#8E84)-
MM\K&0A_VCWY^=&/MX*.-><WGBE)8PS(S07ITY::DG] @+7,()M9"&^0ZK7<X
MV^$O*?%P.L%09+H&<Y=2=$).FR)X<$.8;HP\7EQ'51"VIUUWPM0J)A7/63#(
M8,#M.A6MC>0;RSBTLD;;X,Y"].E4-?]Z\C_+,9*YKL@EFS O1YRWA<V0]4D:
M/R1EID>%8"R5&)*@OD+,^TZV(34E[- 2*F(8WKZOR6#H/:P B[&&VXD"ALE5
M?;B,T 1T[#;2>L0;1_UG'E 38E)?T!)"";%!9'I)-2HL)76R!7IB:\T)J-*Q
M*'0(R^V_1?V]%'58PCI#N$0W7X.??NMS3X*-Z_7>P(F/VU /\K$YE]>R[!"9
MPA[=BGSQ:SYI3'2C4+#U=[:H#P@N4?,JPJK6M8#*Z(E/(\H*1C:S"N6AER;F
M8!T_J!!1TZR&,U3XX1)2H[25IJLIKW71"NHM^0C=]4HML9\2[K-CGM=*;A+-
M*#21=/J6SYB&$4H/=VY]-OF9T0N(\*>]5$C<\=EI8#T?_K_6O?O)9!-1)@<W
M]3+"2YJA&W^6N-XQQJ>,#SPT;9HXX"FD3$ER?#UVB'559_*8Q=]:@[Z2R#\%
M[!3%H$DA!2822FAK^2-Q;FP*00HH.H?CQ5I=;J.D&F5O#1=(/H^;9*([R1K-
MRPS2*I/HOZ5DA.C>\%(06C0[(8R9B-WF 5'>\OA*]WGV6-@6$?,HAAWG3W9Q
MW W$<=D?Q.O\SX/> Z)?>:_YG&-_//FL3X1W1KD;\UP]T7\\O85XL#X<YQL$
M.Q$B+K<3!PO0!)Y,HJ\J?.KLD!>EV^ 7&?POU N6RX8RG[T(W1__T:(O5$:E
M_#+6FG@%K/?IY30J5 =AIYXDZ27(H:?.(@3&LEBL1*DNJ?I[<X;Z+8Q,D?GK
M+2/9'_SZ.: 1O9K5N^V>-:O@7HC$*1RV9@9*(,N0_HT8W@PLM\=R#;#/S?P!
MW/AC/*W'=+P[I+PC2#FX:TCY#./\'3910)6,YHKR&!N"R V[VS;X)BP(VD<8
M.=HVJXK__E?_:.\I]V"2D2#BN4"912H%N0[X3=I"VB'Q'4?BO;N&Q+IK'Y<I
MH#W*F(<Z%=KLMA6D9JJ1*&!FMH!N]HW=XK"T!XREB]7\6A,&A]\KI=*-'KO+
M4;JBO!CL0<V73IZ4MDW4&,LP3%8NH]P9]EAKTUX94T$5V)QLVV'E5(_?FBW>
MO7@O19"F9M[V@PS&W)A'8/N.*KJQUD<>\S+#HGXQ<#_9+D*F^-$;;K0,_U-U
M/EO%4*Z @.$7S2JSODV6@^&GW'-86A;D938)I'<P,\TEMD,"F!NS^N N 7U]
M[*GG4P# 8<__EN;+%(SCB@981DKV+I9Q2"3(73/5" 24#Z%'G/BR "KZ46X/
M??I;%TFRQH+E/.0N&*?9/)76\ICH!8OYP@9N,4U#3:S6U#$)'X9FI6%=))WW
M[0 &MI)<1Y S2<-ME6F6:?+WJ;DV3>,!$SU4TKI9UYJ2"\D,>VMT;MQ<[]PV
M8EI*.SXUQ6+7BT92'A[#(\UTLKB@0BX=&E,SX1P?X>($A>'R*3G(>10G6;Z)
M2@V I<3=EH:(\"=T(.*PXPO@Y*)<W#=3:N%(#OPBRE7EM=Q5(.:" D"&6<25
M?,YK)S+2;KE6(YDTV)$N6\%N*%>*$\*#\KSDT"Q\--,:#>=B<%&)0FU*NZX1
M-O.86UP8;AX<NXK=T8)FYT+ <'2*,KLKH$Z$UCK.4&WS*SG3SU.=FPEXCNXC
MKFETO!0!#[2-=3MY:DW('FK.HHV^@*28IFG()&YR-J7 V^F!7G5L\ *,ZX]H
MCGJ5MT?[^>X-5H_)?O)%@LR.LI\JVL0J0B,H,N^M>Z:=9%EG-"GUVC-)E6[I
MT,J\W)3'.ZW <=-?NR[2.:9 Z4'V]-WL,F.$FHRR6F:@T/UHT23NRBCG%KF5
M3B8=^+J33U7<Z@$S.>%F%>03B^)4<LDE(4-G4/#23,&4S0\BQDWSG@,>>U/<
M_N1 %[$&_>[A5=D!,J"*^BT8UR+.#>=P!>R.&I&C=SP5W_"(N_-G 94[?Y*,
MBP\999S\DI?5C=#2CKH'+>H_:/XXO+!_M/_TE\=PWZ]^ PV#DOHF4 I B#7Q
MJC(CC7*F970I@??5VP^=\PQ;05=[^(JJEP6LFPMI\.EJXI)>I70RP@"6"G :
M0T5/E;LG,<@+:N-9FPG._I34RX%OR2A57:IH!G>QM+3"@^YI#J'G1J\F=8BX
MH1Z[35H YJU+.BYI&9A_W.%Q\/\MD58*"H,7W"U3 &M!!I;BG -RMWFH]2QA
MFBCK3I.MD 1N76OO(IR-&LFT:$[&YL22YGB><O6];;!=ZRG,1?+IB(:O1S14
M&WE+%9MD^L.F\G7>MW=3>9:J*2X/ VSPWWBJ0(F7\4&*!XK3C#6=WH8U$311
MA,YZT.OOUPI^@W/ QIDT*7_VNK]WV!_N'WL/Y[:CU^GG8WCY(\F!E0<2_:LQ
MBAHK7!M=\_I'NG<<WANK<PSJF0(_Z\$QIL?2\M[E*L0DTQUGJ1N& XQZDC&&
ME(@46'''@2>"6Y3I\N[L],VISTV#B5/HYEM96L"!\^Q!DZ)GM26M)$D7"%OB
M6IA1(HYJY0H=2<7!"CR<LB))3X_K'=!P)[0X6^EM3RJ0P@:;=Z CHRB[B18D
MG8Z5:]K:DA(A="Z(A<7=ZTM%#Z_-P$0?<<TY;'P;QD*B_7=2%JF8@?+FW0>A
M9P>,&TR'J\_MC43SMT'M:F 9-7^9<.6Q5V(2@=[+'73H'/]7XO5PZ+\I0#TS
ME-IMI\CD\$&W5&;CJ/X\K!(RF&ZL063.);5<%M67$M;Q1>,%X!I-S\;,'TI+
M]O8Y!U22V%^:CZ3<HK:&)0B&2Y(,^J(6^FZS22Q#&(%>E\],LK2%D#3%HSI[
M!+P.:CNM[DV*BJX*YFXS;F(023G37!_7>J(3[G5HVYT8A&T]4/[1A;IH3LMU
M1<57YPG-$R'T!MV,RI]X.U'R5XFSI$F"</EVO>W+DK$#'U\\>_WQTV^=CS*N
M589]<3C$3MV$\_FH=%SW0IEN];3"YPH=55KA?!6@-4-/$4;BH U>_B()TS&P
M>_F&N<5OZ/?"K>BA8V=C,'QBW_[P4#I_ LM^7>AVY>YXR,;8ANIH/>))3H]L
M::->4V6X,#J48]#)$>;$FEA-1ER495/\]/V*U_^T8^M8A:.Z(D;A6HGRDI,'
M "-FY]Z+A?+,\>N9$]\KV;[NTJXZ_LE7N^9,\$TH,Z;;CC<XU&Y7[:TX><4U
M<$1^E)U-]9^(:-A&1MR9^NIGJE"PQW,<5P;X=1G$!4TN.WGE5R\\>Z&G#.9E
M=A%1XR;4C"1'F=Q$SA+PNZO?X?'$8,[ -$^\Y3S&W=3W>Y9L<3O'[L29H@+,
MH'$ES@1".%Q!8[^#['Y)LAO0E#5RP$XLB_UHYS6]GVLO^H:<P]@K-L9)D[8"
M?H:M/AV1+1H(M@34NT#>[$R=2LTN=._")[>XG1N>PG%W[X#V: 0$"WRK[;_X
M.B>+<G,%TEJ$HQ>"8PA<R3@'6"KJ:)VE(TS-K^=^V)0VS'(4_['V!%VH-A>%
M[HI3.+TG1;>L'NRDI%FTDOGGO(!3U6G=VM\F3@X3'JU?3BG.S;48HZ2^+_(_
M\D*YP8RM=*)BA9PFP%YB^R4:!_,E22_!VI,@FS*;-,,L7:AJ.&% 0X\9J384
MH#A5RWII0$BFN&C7$@9W?]'[A-\!?-@AC90^#**DV <!#1=JM4F*-XV!X<:M
M8U2:=9$-)2%JCVY4-?EFG.:8 R8$TE!4OSBW31N!:5._"1Y#@9TNR>,@'D%%
M;W"G'W*=$0)&YC,E3O<)NK@)"-W/%<T=.=MFDP;?^JC)PUVSZS;5[ V'>^@)
M3LV=H0G.J =[=#"8#^M2P KL#<WTT 9QS"$11,=XB@Z&9"[O<>EBG.;B^*[/
M)]=S>JLN!^Y8HO5E9-7"@]L?KX2UF36*:NPP^')$@5I=CJ5QT-R)$X:9$S#V
MYFR"NMW,)!3(*>)NH5J;,[\5H7 ^K]+CA6W0@S+.P2(F,M!DN[HWU#I#S2Z=
M [P:= 3EJNFJOHZ5TD-%@>B >=(1V>GPRQZ;F^>ZTR1Q*!,^2NKF>(P"\#5Z
MHW$93IU9:SB"/<I=..LA3NSG8*QH>EJ=R5M.WVL1XFQF\ZWC]#PQ,6+=LEVO
MW88?:=)- J@Y*L4%SRX'7:4B=PADN-T"WVN9M[7^X+5T=PWCR,%!XU3L^+N:
M8;+,>6KZ)BZ)+>D0Z=*!=&N.F.N:V=S!RN:)OO6G, -2DU(*\4@)0 \[2JD.
M)N1CN'R.342DFYD^ZK9!U=9[)]X;N/S-NP^YKSM&LH<!QUKH_(<+I3'EZMT7
M)LC62G5.8H6=WMG>\X(:O]H4(3,IPPY.=J.0RQL9.MV(N/A\Z81?[J?X'<;\
M6D1N2@##3L@\85*A9C(KH-H6HGU6<NO<2V5;."*VTP,5SC;#2!D&6QOH;F6-
M:1;HC%DC/PO[GIE:5[&QFF!!*JX)0':$"B;P\S M INL2'<8'+O$0Z71\?J>
M1A(2-^$)5JOEFH@%!YB!'!%Z/Z\!4F<6WW7D:8XU,])<$ONN&%Y#\BV@(0D*
MLSQD[&#A-N6T'::)'2H:7SN)L)P$IZVCIDIY'X[J1ZBBCX<>K<?5YAKG5BW<
MBAWT.LL;6T],N^36 @-.5T=5@8K\_)7/70^LB)S"^Y=>[)PY0I4Z5[8=-3ZK
ME;E9<O(]W<])7[P"=58\A]H"P<[G99931M.E;NA,QK!!C!;NM*EL,%%DK?*"
M^G]I6GA<?51VGJX>/<E5DYBN06VS3(43)BN0A$NQ=8].*:/1!#-=O8R&58%S
M  #')0A..4=903'[. VPAQIP_D2/)#E'ZTI*_'#<K-:7=8<WW8.0&A@L9B;!
MQ-$4+E;L$VNMH[$>^^?43DE":ZTIS*7R)( >F-0X1(<QR4"CCU#0Y^3#B=.I
M_,4I\QTSO=35R'5S#8V>CCJL7[):'5ZJ!=/Z77V3]L ZIV[C\FV43:T\2H*#
M'B^O ^+\;H#1;5+&/_4=D;,#, 3_/34(E&:YY,%X)]:#@]!2V3BB? FZXX/8
M.W:&^)UP-0F^(!%0LH>-M[38Q1Q#S+4F'(B^-6X#QC)WED;9FDEKL+O-'*=.
M>33"J0W%:A6<U8E(9P7S>,9C5I*Y__\L^,L,>-U4I+ON<K4%7I6,O58/'C;-
M3"EQXD)FENL$U]#D+DFQ<5[/PUQ#R1$F0ZK=(E)QZ!QCJ_'^#E@-O":&2SA)
M%_7[@M0CX."4S<-S7I8Z /AE*TX:1WZA'AY-1&;K[\EC0X)!A;[Q_5'(F=L[
M)$IWAP1;$==2S2<*> [Q'/$SHU1WEA7DS$C.T6,6N>VK&&NH@QX8IYE#2/RT
M196<:+%6R]85#5BF/9/,:N$6)GV\"B0!#=.?F&(1.TGF!9'3:.$TN"/'CFYN
MFF+6CHZKT;"O#M(+7K\@3WZBQYDY)(OI*-@8SJ0/Q=+NG6G')&5HLY !LL'<
M6UXPM\JH--F0H7:5Q IQ=1OQ>R7\*^JB9GO+.-RXPON#YC/JAZE]UH2O.K5S
MKO&KZ3"O]5NG[N" Z.%"CD$Y4TY,7M%WC>G;_"5Q[Y">Z?C:*[6"9OZ(F=/7
M0OM5ES]=C@]VG+"X_4+IGE3F"%CU<%V9H%0F8L?KSG3\%DHKJJV/=*2KNW.U
MC4O7(HV]+HYFMI9_TNB&;TW'V\N@FJ3)7@JY"+_8Q9?O;7QY15-VGN7)B&%R
MKJD&)B+>+]8))T:S)E6?J>.[[4CGTR";@>%5DMZ-2<?<&RXG9J4HP$5%+-2$
MG'R*F&1'O 4U]BD8BT)6CG;?Q0G>W&6&"01QDNN  %O+W :5\8=+*AA!"N86
M6-Q7Q\S)J1*1.*@=-\H([+"$.K#0Z"OT&)[@\MF'S?X<F6KF]'.'8\7LT0*[
M*N6<!Z[-E-2,".:54:^ER/5Y(IRR@N=^\1MY[C-?4^V*8P:J:O6:@T2509G5
MP9[2Q,,\AC._(@81YFKI%F(DE%2'<T_99R4>!O+_*O)(32-1,=QE6:'2YE"5
M""C*TKK)9@4\:3<5!'".!_>K;4)JF:1('V_T 63GK^/CHDD;3H"C"@2G&R7+
M:IHQEDOUF.B6-(7==KZQ6E?HG!$IB((SP=(=:>W,E!28-Y(FKO)Q%HU4IKT*
MNLU=ZF%69="$K730Q5D"SMA(=] QOLW60(@HMT/>JBJ6=V+ZE54-\*+EY);O
MLF**BSPUA7V.DP%]-NWM<*K%-Z$:1[KG#-48N+FQ9C2?S/(T::?:"6I[%!4I
MC3\XIQ14T=O)#5\=9F7 U<B_=4HU" M0N(\QVFG>59 VJ.23$T=Q]$:2^G4]
M@7UB2RL79$0,];R"LZW23U,C(21LPK:./ZYONA*3=5R@S8>C3EJ)5IJT9,W3
ML&,;3V4(;=25G-8MRI,@@T6:KO<;X/,%)N>WN,[76R-IP=55-F(&9G1$M!ZT
M'"4;N0J6)\9D8=FH.B@=N7&ZNRNG6).[@FI\8X1M<_5X'VGP:V,H)]:[QTH:
M<8D0S?OTDH23VT&U"0S!(2L^N,P+39=*E+/IA)Q&\]P=;-X2Y/0U@]?\#5MV
M4;C6M%PS[D#KSB1'-@UM2UDQL T.36@5R"'(3"23SP>OJ)K7CDRL!6UU:-8G
M4++HY5&$[/34]1K+'\QB$;0S.!W0P&$_9O"VO%,4DGJL78-7X*CYU4O@RA>!
M[WU$MCZ>Q@#19U'**I-W]H*)_!W0/1894UYK,,/I&V1N<;&SS2VB>I]S5@",
M)[6ZA405EVGVI9+\8)BI0 B9O-Z-:1VZ@A-)*)@2>:[#RT%+9,[E>*L%MTYA
M1[I'RY]@2E"*5:8<E^U=<]6>NMD .1XH\Z(W7#MF*9;!=2)^R0_:7V]_WYRC
MMCVOD@@$)Y^8?"3#QM2L$C&D3CN^Y/2)6Z"45E"(@60JNV#2@@Y'PI-7=4D7
M.J[Y;A%IVM>W(LNGPF2<),.VS5)$#7/XG!W(Y<L#+/DZ83]06U*/36YVA$JM
MHP&NSG^A?J8.*Y3:0P%!:\:)R8V1#%A@4AV@6QQJY$:A=!4CC6VVU5U2^ZA_
MQ8DO,5;5T/R&A3R_\B -Y3R(VZ)=5\:WNMZK*X)J6*=:BZG1B1D(80H@QXSG
MV@T*FZ>&M1GK^U3JHY63$%-0L(3*=+6< 8NJ.6O<Y[,N!Y8PK%*?>,@EI:SY
M.L6'C@=WPY'5):*[1G.X?X-5-;Y;(<4Z[=0K.B5]IM>2''7=@&0S[$=7O3C5
MJ&U"E9H]-)XO.M*X$CALC52N%:"L^=ZJ4<K3[QJ4=-4Y"ME@6R>4NVW37"OM
M?-R^&':,N)/OV\0.9*89H3F2#97YZ_P,GJ=F(W9N(CA5H;-#&L@I3B-V@=@F
M(28POP8N;HB,3D688.DC'H/-)I D&,?A6V'$K9OP75<".?"74D0E,D_9P.4,
M$QW^-AK]-U5VVB BG=XJ!0SO26A8344J-K&+R,9JR=X&>EBSVXRZEJFY>A</
MT<DYZ#W]^.]@-G_ZGC[UGSYR=N>]^VRNHB_T-56KQ229L@''==8:410W/I:%
M?.=>6ZA\@'DJD5\P),Y3#&3SYFBU)E4?VP:,(NHAHTM"40KZII^ V!<S?%Y"
MDU"R1 <UJZV8JBG_K;V1ZGLWH>1*^T8P!<<X0LZ,'JRWP__#"&8Y1)<+6OLH
MK ?+,.V0$N<N4\J@FG&!;A#;2*@&=J6:=57W #,!BA0C9ZP<*RQ.DM:R=<^#
MR#3G2:PR!QI9AP;TNHU8I?N7(OP M-P[W'_:WQOZ/;!0;8\?=/7&T7EDJJ8Y
MYLW&K+[KJ'M@C%H75^MJ7%,_I$OD,7NUQSC!SN:-&^-KK^+@:WHV PK_'8--
M&VL\\+]E;*-\;8I4U:XD0#<L2L>M85A0IB8LP\6/39FOZ/1P/$>MO(OCP>:=
M@-@FGYWK[0DI_!5452G,,3UVI'X<*2=3H@Y)5QMI!5'IR^.,]+6M05KFBIO1
MF>P7;FZ3VP7,>%(8I_90.PIRG5*"OZOIF=)D]\M&.'9 #Z(<<OM==Q<-O;?1
MT&L0+2(7,>@RKW!G86DN&QY8)R&YZDTQ'PDUN(&>47/0C0/L%ES0' 4]\:S&
MW_?L<^W@E<#X0AP+Q')<&L5@_ 0Y#DL&NXX"/KJMCC@Z6KBT'B6]7(:,5'&)
M3@Q9X6!H5F@%S'Y%+JR6*+[9ZZ#E27LU0=6RWS;1=-1K>9;KRKU*7/F212--
M=9UR/E>4M[':2Y,OQN43Z'08QR5E=[$OAO-K0V-ONSJ(A"<FE!='$WD:$R!T
M8$_;(?IMY8IE(6Q\.$!T@6!%K?J*.\]U7]&IK(R=Y37LI>ANDJ,.5TJ2LZ!?
ML_Q#/$24,P,\/BM1?6S!LJK#'%^J>TT2 V&LHQQN"QK9[SH;C2;BR#9IX,:3
M13)"(J'\('<7(R147M"LY(C5K>]=*"QP0-!*;D5$RD&6+H*8D^H8S=$'94+1
M>J1A)X0'2*^A.9RMXDDEI%=0*@^0;-[X.<6&=.+=\_6<>SISV>48@)#..)0N
M3C;TZ=T425@H&QIFN$E=!Q<UM211P7K1LM 9'.DHQE 9^11688)Q8:]F9YJ-
M]4B/)AX3S4:@+CD.7R?%2W+"1C0'6 :VD2,4VW+:>=[& ;L.<1)*9(J@52&!
MAK+%A& 3]%92 CQ-.@+YWDF)83DV5,X JG]SFUAR7,!=)O?'LBH3R..N4/".
M7)F<9F&!B.F<"^%&_:RO@]OQ5[1<+3W*7!>8V:S:D:I*3>T\D?Q9PG=FJ4QH
M]#=C]S0B-V8#P37QN(C>Q4B,T8;)P8@ZHX99JU[HUL-EJH'Y-.JX%>$QQ94J
M3K A*"(3CT7B\;558POK#84]N*5W;->.P:AVTSDM-IBU$-'5:[Q-@-EH'HR]
MFLO!/7^!(5_$&ZN7KTB"-D6]:2A1G]DK2G)7&$BML?5;LY <2%/UV-+T%L?:
MP56E0/;DCW#R1M!UB]/#K'=1MSN'IP ]DZ+"H2"RL#!)Z0)P7%CM+,56'?S1
M]-6U56GM%6FK4T@'Y#O_1-R@I5(-&;F*"$E'* F$DK' & 1+F? M8I/ICKD4
M!,(P!@Z@Q(6-TA29J=&&2*/E5 H'.)%./S_G=A4Z*4<Z3GCZ7;@I[@8G/3.X
M\>*G=DQ8:42V\(96^W S'*9>LEG%=<,P;ID1M;SAGK,DJ]^W<@JMK:YG&AX9
M Z8)T9:JZH#R]]>MJF[1V+!YQ%ST-.=]G!)E7H'"$!XS04^OS23EY$8*]6*?
MPK8R;CEVCM^9YJ,?],D_I!0E&;6 10=1\L@7-87?1XL@*]8MAR':1MU/ZYUD
MZ%S0;&%CAY'YTHIR>.M_2\S+11NFD.:J9-P$6#I<#8IQ&D^>QJ%)R>2Z%6+]
M>GXN=DV.D*.%:J55O*Z:7HXZJ(2WJ^BS*&S_U55<*/.H!>K7T-Q7HK9)UURA
MA+90.W4Z)?72UPIG7<]DI\B$$TK$\B0I1&_A/(E_A'>:ISB $"5)HYS2YD"K
MJFFT26SGW7X2;:HDI5K"XUK7!'#ANOJTQ!8FMULH<ST7N$IFP6ACGN_G0"FN
MN.L?W]#[O4JGHRU6+B5-C;]VE+5*+S,V :F/K0U?UQ*"';>U>*H7#F*RB6-Z
M0X 8XU?ZU>8F;J=FF\!D9G# *_2CG8B/LP-CH+EW!2WWM,:P>+:%]A\1-Y..
M339DF2X)63H*5;/<S"T9D@[<CG=2@-^V9+]"C;;'#Z:#8KJ.K05/J3=0[ C"
MEGBH6P;IZJM >%'LUGS0N!WO];OG7;VZ>CWGR 0;(SUB?>T4-<<N<\N\'*;;
MQ%*;<T&N GU)8-Q[>@65[KW5[3MH[/@4>>9K#66YYF N[JIF;ICC%#4^#!;?
M^/1Z(ST;<O4K=D]KI*A>G6>GU_,$V<8YRDJ_7WVA/2B3$])^:AJSM0;H_=2W
MKF6C#*(KGRW"$!';>)K,E=*6PFGP%R4U6Z)7153 3O%_U2(+/_6<6&P]GF 4
MITJ;(7($-WW0&NY<'.$@6KD4C6F7/QTX$$AK+8ULK:HU>M?A;-RQI3+ :#D)
M&E!AI8CK76V)Q3#B_;17B0B(>]ZH*  [S(R;Z.?J'W)=;8[J\WHT9'/9EM"G
MQG:#7)RRCDU32,6HR"_^;46V0Z+'T;=7^J[OA*[&?'X:'%3B7#_M[UTGT/.3
M&X&A^_N#:\9W?NH?U!XQN$94A[VY@64R+6$>DZ=2HX=F2Y9E%@&I\Q6_/&7W
M+O7"URP(<F>=8_T#=O=W54T3 7$48YPM#\_JZ-6"VB%-U]<V"BR"2P<<LE:T
M_"GT@*/E2D#3'=W@$%)A:96#1KQ2;J&PRRZ^?F_CZ\LM 2.K3':3*S6%1 UG
MJBMA5.*OR9APTJTDJ'7M>O/N0T61ML%2N$ 0C=2/7'+U]'276\%U,GA=/9;5
M&KWXNINNMMA2AMC4I$5#*W*"1D'B1):Y94TTESS$M137-#$S:ZP=M+XJJ?T[
MRKA^2'WBUR7\E-S,$6%O[C)7 $8#D0602:YU88,QCG_MI[V*',!6EPDW:Q!8
MH.9#&IHQRAJ@=_5-RKV&Y]:\L[IQI"UF-;TD?NHO$WYHK-0#B8'3X!=+K\UC
M1%AKC<V4U%D-RF]H)FGFLFC44ZA)G.&I&)*L.:0VYGTXR= H*#=4[(29=V"9
M.#E=_6&;^^%YC4[JN<,K? ]Z@PWO@_ZA5MF0(QODXFW.Z81'F6<@-V@?.&47
M(&S+=2J8)H U$XW8!%&!>4-0,U&0EJIJG2' P+0FLIE)+M97/7H4G3=\2-JF
MNOR4ZFV%SS2!IJ>!5A(E]QR!8)5X0UKV,6[* ?L*3+"^):=@202%(LM\2.9A
M+S^]("V<)FJUJ<T-ZV(NA>!6BZN"N&4]NC&U]%P2&$6P_(MTS+7Z$T&Z6A'7
M]4PD;K>LYY5Q O;:C ^Y%B]2N!:QS\8BM<.#].Q&L41;4L#- >*;S@Y?"PES
MTLPBZ1=*-G/EL&J.WUGPQ9YTG6.:JIU,=P2BZ K74O=[/S=<P2WZN<Y5,'@J
MAN?AM>RFXVL:2<.U+:*U#Y^<&(X"AFP?C*:?#AR_@\O'-(GB114B;4^<6H("
M#O&YB3]^0YH:O&RGF[K@1^QE]#=IRVR@F <2SY14+HV%1LZ20R=9K!:X+C@V
M)WS')5RT.=E;R>; @98WE[Q.7+Y-"/-&FS*8OU]'!,L35DA@"E/>0 #7Y1=Q
M!'E=D"34782QT77=L>^0!GLZZ*?=O3_UN_LU2<PWR_B%X&LT*V=.V-/4VV#9
M85%-2FM C\FB(FGEDEL3M*Z I0>M)UZ#5C]=-=SZTP&G\R&8!E6W9"/]M:JU
MB'2MNM_7%Z\-/E.7MJVQ6L?2HC.N[J7O[*7'?VMOXI)]N$>42CTGI^H8D6^T
M0HV%5?^MHQXN:6MG$EI$ #<QB!-+JF4OJ_*0Z^KC>(KY ;"RZN+K><#(A['4
MQ*8NR@7&1]>"0>;I6JDUQB0CH8N =3CM?1,XU8.D#*MEZW<PYJ?!@<E=K>;.
M<>U*];L]ZP)U>RJ(#QL%WT(5YEC"*W2Y)5*[_52OH9&AKW1U7O.2I(N*]5+S
M7?>[_:KG^/AZONMNU>'PT]%U/=<K'W"=:@0W_4H?2N0F[\(15TE"Y[DXE>%R
MY.:H*9A'\<HU-4)[YQ(6VDJ5G.B'+B!E:T"K7-$XJ<=Q2OJCZT1:<W$5HOUI
MKUL[K*J0;8O[T \K-=]AURKQ%6W7$93MRBYJ&*.@H"92UU=^-Y05]]+P#3EI
MT85JN+!"IW!0IY;/VXHHM9Q>_;A6'QZOR9&R-#^C,EX&9Y9S#X-U7#I:%VRT
M]+E2G[N*Z_2[U[/]&FRCWQU>C_,X:UG]J-6QL])*@J7@(>@8!EQ3<5MTFP.C
MVO2M9D-65\7S3>.)^&@YR2:H-YBL:P6KE^EQKL?2:%1;1Z^L)?1NM8(K)=:R
M]+&&S^!Z%CF&5+7TOZ)RVS%QVC*%FV3'81%,3T^]C\$(]?:/)Y\[KQI+< V1
M*Y?QD <WO?9E@M/KUX2+^L/KEGL>_;.UXQ5.WOA99>C56=67\%V!BE>\3B9Q
MJ9*_ V^J9L'Y>5S"K_#>A[^=//*D58)OA1%J:,;]T.[BW\5-[V/<]%I>G=./
MK\\^?,02!EUMOSD/3[51U*#7/UK'R;.DLT'+QEA(^Z[[9[2HFE9U9W*E 3*W
M6J@+^+87754-),WU.>F&6["<!OEQ8\J;$UG&W'H/RZ^ERL>\S,T*O&(M3D%Q
MVY65 N/+-(O#2PQ?..IV*;&9:":MZ&G5M05?(\E1DO6X2XQW$5WPC(J.WJ<,
MT:N5@>KLTPTU?&J!W+(BCJN[KU@?P)I5IC_UKY<HM;=W7>.R>L<5UJ134(:5
M!VLH+M2N$56V-D"*BKU:KY%4)?[4&2U,QA)C&N;(+_!K^9,3F5K=939%H3V?
MJ:J[M;(4I&3R-+B"7 (49C:7:41'Q4EBI?U5)N.*JX^S\@S.E^N1=2T;HNU:
MFVV(E&;J,9RX_YKO:H>!=9-H_96RT\@'@]4HERII+:E-)\;EIO4/9TG<FK$E
MK:Z(9M)7ESM=F3N(?AR'AOLP6S^MI\ AWY],HCB2L&K+SJZ?R*%[350MLPJ!
MV=',%VDTMO?TG'LT&Y5Z95B"[B+'S]".;K]"_RUI(NMR(KPV22V%^];*J.>'
M;#X-Y%FJIECX!<?\&OX;@SHYVUQ8JCP']#<JRWYK7\L71JRNW9FI;9/>J]GH
M-^IQV?;K"B>$<WDE& :+'"U<M:#UK58I.(_3$3!+XB!-M]3RI#!JQX"IZ>)Y
M"N)*?R>WF-E[]MKK[QWVA_O'WD,:S($#&DX_'P/%/:K/#M;E+P4<=:+JL3(G
M+VI57:63N>U(,QL<<G#>N:N:YU)UI.N"S6O8LKJ%PA7<ILYHCJ[!-%S/XK((
M.@F3ZM0/OQTIC$C#)J=C1XTCB2H9D+HMZ1I(2,XW?0/>/U)C=+29Z5[-5K)H
M'W#7]#^H+,&Y681#^RM-46*EE:B5$"RD8?VM&\<NS-3T'>U@%O:^A0;Y,EOO
M:[2ER1'3TLD$Z"O*I549BG!4SF#]5]&!XW/B\>.UM/+619"H#G*LM1(]A2L"
MFF/LJ">R;4'+H.+"(A+S%4^K3]@#%*;@3UC-7%'?;BXP:+$C$$MBC&:6[)6#
M6T#43+%3$0"_=>4R@2OGOM=N:FMEB(!;.Y1F[>QH%631WYOJ[@R4 DKJA-8P
MV[)VVY#,5$RW[H6:09CQ8SP[B50:6P!BVJ/71\8;5S3U$NBDDPZLH8.-?M^\
M^R#5A4[.P0:E-+ EIE/J4NF]!9LF"0/O%95LO43_$:UP8Y+;=($U8INF!00X
MW 6%AF"[&6:P[H:6E19:3S,U/ >A=1%E)75/=SP24=,/@HX'6^+VTZ#J:C<9
MA==..FY_D-NPO&)C5,K)^@?^]8 BKL:62C6T@O<K7=;T-&%-!&$=E"CV:P6$
ME<;27"@K7HG(5&O"RKB\/.[D8ZS*'[]Z^\&=.P*<@^8EM@[4PRTWW5&O6"4Z
M85V:6I$7+-)K"MVUH+6TAXP;*RK<E$,>3Y6[X+O>^7!=Z]*A0LZ!2=/T=1_=
MFCV!@5B'H=:S>NH5G5@@(/VTX;C0C,\E_1.E1YJK\+JKXK8M'$EUZD7YT;I"
M$H<7CDG;U"X'_%U<#N1,X"*I*.%U9&[MA]SLJ"-F7-=()0H[9FS(A=7F:SWT
MVX+'5)5R-8:OX)Z6;_6ZQVWLYAOQUWDT3K-$L]@;<,=>-=+?Y([5-\A^JRQS
MB4>[ BEL(^W8#E(X1U%'!WA]!W@2<#WXQM L$P!$EL.:(A-9XH*D61!CSR@[
MDD=B532#M^L]6^54;Q-NR,XMNK0NIO9*ZJVD)Q48-[Z3RM2SLNTFY3AU: ^Z
M ^NG=7?K-W&#CJZ.#9O2PDY3')RIS_G%/.*)<A]H_)L*:2+$ZP2;>Y'X^&X%
M\FWRM;69QR0#1,+I4^XPL6;FQ>J4WM,7'UXW\GGIAZO!0_X6?$!E;I;60#YD
M:,M@E(;2B_04\5;[AII3@#)O3,PQMJ307=OJGI2*)3-A'XE3#6 ]%2VYG^WO
M-XYTLOR(0>W"O/<VS+M<O+<)\2H%M*=/$941]&P@;T6OD,![ Z8KL&04@%86
M!-Y"T<SG"3I*#,.F[#@<=</I'Y6;F@7Q-28@]#_^@F&#JY;&,HJS0/JV:1Q/
MHZW,NUZ_66&BFQ76 >E,WHF(I949!I%8L' 'M48ZA\F53<Y3B7*2VNE6"2&O
M4+.YJ44>*=.\+VSV]MCK\KIL+SBG$8YN4+'?JB_P:"Y6>TE^H561N &AZH:;
MWLZ?^@?=6LAP>>:^,\CQAK&5P5&W?QL[V9A(_J3R./!.9(#3!AT@#>VTU<"M
MDU:[;*FE6-;W2 X,=K0565!3I). .^SQ3:^R= I[32IW+XULU%^T.O6B<;4E
M&&Y M;P!JY&R?+,*:RWX9;0-!:=IWI::!O'$Y'@V$OZ:2Z% @\FIUZ-R0H63
MM:6Q9?,FBO$1?1]47"@_'5ZCETF+,M%,-W:46V>0G949UTNH;NQ$=]9O&P+0
M7YI?[RX-^]AB=WM'C#6K^TPQ'J603J@$3P[.^/ M9B['KB7%>QN/C2X?$6I$
MWTL2?:]:1-]G$7VG6O1M;$+7-68&GGPX<4>A^>1&XFP!ID&=&.^R&HQZO*4W
M>&<%6<3BHC%#!?](',:S]B#!QC,'3ELB,_07KS2E2&G5T<23>IO/TFY-ISV'
M?K<M$[="N3^L#1MN=A+F:8IKATGW+8/I>F?H+FM</ VTKD+QF3R-5;Q8(R?,
M"5EJY:"U5!]8;4($5R:@3.%C9ICB8V#:6% TJ8\^QBYY011+NC]ZM'C^H&;[
M,L$86]53(>2*B\R [C!UVW!X+_Y8.M$>*P#-VVG+N)OZ,&BI*I9-5=$ \(R&
MA7-DMDQB-. O;5G.BU-O5A;<!]CT6@[HGDR*<EYO8%PE/UI^7F-VY5A/1'!Q
MU;1!#;@@S GX@HX.0AKXES0T2Q.J]R2$(<RH(,PR?#&I5*1]?S77T=MEE!\]
M1T;Y>3/@%+EN4UXK897HH_:5DK!8XF$%2IYS)V&WH;:!QON*NC]L2P> $U8%
M'K%TT11VA),AQU^2]#)6X;F>MY>6!=I$Q&6X\(;<W8C"HZ445^NEV82<C 8O
MIJHM$*]YC7F3Z7"&HEB*8FW#XVH/)@3"QI1DCO^*]9;[M@/BBU/3<!!AIO+"
M[A!TW"2?2$DI#D:O9&(\)DLEXL(T,.I <<!=DVJ"I&/PHL'/Y,"DBP0QV<!P
M/Q?L4GY725_,IT0:@A=FS9C@Q;_4V1TF*/C7V0*%!*F)E.V>T>A>57F6WP8(
M-N3&H)BSHXLH,LB5#-KVG<;+4GXNB/+B%&UTFB>C(6;M$O5U#GB=X_Q&BL4D
M-!7)#F';2$L%H#5V$.%:7J*K$QT7&>BDE!D%$-J8"F:S@(;+AZ2>43_L%F53
M3SX]^W!BYY[B+6-B+Z2 Z58L>5ZJ4+.FO C8GJ=6V_E2N'C/NI^[8*ZELV@<
MQ>P4.9GAL(<PF'%L^AVE@F+7<,0CQ+0+%)V(:8C41&9Q!"BD, DH&%'HUWOX
M2U2!=N4P'_PZ I, LX:]"Y4D:5KDL/,Y" )DGF *?\'.PT#\\RSX I;;7U^F
M*@I_>1S]^@@I[3R02>2P5Y/U8\V-.+@TU%Q9_"0=EY+V(9IGB(GRN'<IS*O.
M4"V<MLLT4K9,HO^6K"407$,O4:D9'1N,LQ0G0^MVU3*6U"L6<U6I+SA#-DZ\
M!FM7*<0.[\FJ@22CEV*,1N?8[=OPB:G!Y0VU69Q+,LW!1A]GT4B9B0!"[H%#
M1]2W0E)HT%]FU,V\@*V=$X-"'2:,<G*_+VAX'IU]I*J0P[O,T%G@2+.(G/PN
MY+1-Q84;##6GGI 3N24M/0YE%&V\\"I#MN,(466:IL21! [X)FPAC]U430I<
M]0W\^CE _]N;G/3-)3OT1VD<KBKOC;#)"*KU[^=*S^Q^?X&Y\.IR\XL\[NX=
MR)AJ(.%R0S;N)RZ1]T6?II7D[*8@JLHIZ6!B50 .WI"[V)!$&YF8EG]4/B%V
M%@]4TT2Z=$BOKE?P-7MFY9W5,2K(A\6ZV?9+1B<!S]!CT9F;Y:ZS*3-MW&(]
M^XPY 8^8AU=IRW-B,$G'44PGB[P<Y:C!4 8=/N1<.&NNH>E14@P^G2QUMQ<8
MV@ $R10VLZAR%JV,4AX6['I/[SLH0Y(4>#PI,X706:%9>"YCE&R"X@D7+7]4
MJ K= 3(U%'"*S27198>X\MU"O_JMC*&"[;DH@A&[ 8!QY&@H2;=^WVG:7TUJ
MMLU;%P[ZVD%6W!+3%LI>9J@Q)AW,NS7IMM4R)J=/$J4'$Y^693#%8.0IL@Y8
M,"I!Q=6=PT]-2A'M3Y AMZE&%0J%M8:Q<G/0;','V3.-TE%%IV2G- [Y03TE
M +4IXU56\Z8D)UX_CU3I/*^"I9B"O5D!S"X2O(61X'E%9[8%=#;.V!Q<&C$C
M7L;:"0?)2M4A&>-;QWX_=@24%FI=[TPI[3WYZ(H>MY+WA0S&U)Z5D:(0<II5
MTQI$Q45AD6BVK\TG)A<7IX%..W%0)K8U[UW0D@S[/0..HYTRS]VYEQH8FU%-
MW&55QG&:X:6650OWKK)L<YT,CF8.B/R.)S*$\F='^WG,#6P7R0=F?&BM2%J[
MJ\C<I7.\$JDW<XX?EZEY!L+Z]"JBM^;&U!*EHC2ZJ1<DJ5KS,(Q8<B6/(YT<
M&PQ,')"AU6Y^CEBKM[K@8"V-^'K[H5,-Q$H.-T[)\M8" ;WL$@1*;G&3%KT,
M]\ >IY(.D\;+O@OV8=85E\+-,K;)*(IM?^VV=R*JYIJZ3N#;,] Z4,LU)JY)
M&2"!A.DE=8Z,;QSF$22555=:X,LSR/_+LXA!!SHW97]^1=^I%&CGZ:2XU /2
MEN0).*%FH]+AF$@VTF]V>/9)2!E8+LSEL$ONIP"QLQ#Z/ ZR+*(.9(76VYTH
MP+A1MFGM,2L;G[*'TQWR3)S/3IUR/-M76F%.Z-_.3:HMQ)E\6'?W E'S,%3=
M,[LE:D/SS6FL<YOP-*AEE58VWV2#8FU==4H"32Y2,XR%AH6T"&BV[H#G2IV>
MR;4U7..<G%7,]\0E3)X2"L',*&_3]G*6A'O@5_!6SM/ ^XQ?F2 ;+[@W7*Y3
M_R46XAIRXXK5PG<O^&I2@*@LS3%$H^1*T"R#S&;$Q9_F7-<XTR!W#I)+;7GC
M#BVNGC%KAP>[PD1/=JT(E4)"!:;T#<N( 'O+^KBT\TP:\$JJG X[Z#D\19!_
MX;9KW%3%:I.V?I.*(D<+(C908,,TR^U*V=7FJ033>'4:B%U\5(@Q)DZO2@\(
M)\P>&GE'  T%B(RM3+(XP1YE'$5-7<@['(26U1R[W!RFW/6>E848N?3Z57-C
MZZ'ZU7-CB2=)94Z,=R' K\8?0V6FSI%WS4Y1H0M^'J(:J@HR5);ZF<+%7/C[
MGEP[7!]$K+:AJE1>+U!W8.BTU5T#DAP"D6/"6-SJU^G= F Y8*5=>SI-CI2A
M !@+^J;#7,\VHF1%G90SA\=B4KI)-T"6-XE0PA9>HM"V1[7:K1GE*+F<"CVZ
MD8.Z:N&Y73G:>?S&UH/2SK*UP-#UJ/'CUP!ITU_YW/7 R@V5*3MOZ<6U4#*.
M4??L"><ZHV%Y]J_#J+0J?)U)Y]+E?<')B(H&SN.\<EU5;="@I93Q+MDXG"[&
MVOY). ..AQ/E22YOULIQ%Q94%V80A4\JYK@+L8EOI.YK=,I5$M&Y)\&YDS9=
M79ZYU_5NXIQA1968*%!:')JDBOOLC18O8:+'\QE98[V'Z$4W.C4O?#+!?@V&
M*F\;R=8+$GVDF8*T/ALEND/X?DJ:9)1;_>)=I./A;^%)T]Q[0=5&[>FN?<UP
MKG778&.:'ZNPA/JXZDF*%1R(4FBBEV;B+5=.Z)"'">1*>Q%SHJF-^TE8ITQT
M^(3*I:(9W<Q&Q-4!%1U93@PP9PQ,M?((<%6F>3G=GR)#IMAQD?I6O5=QKJ@/
M"6L>42ZQ&DH^ (&,OH8/DCWP&K,5,MP7_#+C-QYV?M^0TOX>8 OK!:..-%!]
M!O\88))AI-6+B%@G2ZT+)2H>O8G3/8V=Q7U),'V('[T J>Q)(]Y4XFI\_M*S
M9!=VN+=AA^M$NRL\I:"\L+R<H=/Q;U21R+'A<(%V7O(/L?H)X1HAF:Q \(S/
MBSPK\UP]T7^X^SV$;0@V(8#),Y14D0BS6JLX1-]43IAQR#U?_,8YK@<>R*KS
M!$Z4$JW@K I##_+^/D'TER+4WV,[(J3^#MWZA)%<'GITV.WO_^S&7^7U$HMU
MD<AY/CIE)W!:3Z91".=K/G<NLV#^A G@$L!V)6(*Q=&+]:7!" ZZ+%1EW]\H
M%M;K]@X,%OZ"UU9SN^@^^/$BRB/._]);?O KAJ)Z>T]_>8R7_MI@5(^+<(U3
MF(+0Z^3S8*R>)"E"3W8]Z.[W=^=R]\[EN'NP.Y<[>"X[>KF;YP+TLCN6;W8L
MCXL,-8!;D_8; \*PS3NP+E2^*>.XUR !516V#.KBWH.;@J??W=_[IO 9:E.!
M%\2*[6J C2KO=.'#PX.T8\5S?2J_/!XYP-E1SMVGG!:;<7T\8".O>NBW21%B
M%8J$Z<^_>F2>>MK7<'\HIFD7[TCE!R25YG\;Q/-/3*;MH1=T&MT2:'YTO-@R
MM!BT,LZ:@=-;HN]7I-.!D4ZU7=]-COR/T.QAE#!>%=.TS+&@D3^F$_Y7E5F:
M^_(W=\R::V%%,5G^,PR*X-$/1)??3K6Y/S3WT,0-']V&SF(C2D_^-1XK-9EL
M5HU9J;6YA7!.(25&,S XG:DIYI]>X-P_')3C/7R3YODC[SF0R9-;)9.[!C57
M^?LNVITH.#\Z&';8X*@U6P*%.Z=I7+E5MVK[CBL!5^Y%"_I;XE#?>BN.8*?@
MM;NWO94HZ2X<<_YIZ0]^]0[[_M'AP3VRP[_KD=['$STX\(_V^K?$9^X8EZT4
MKF^K0+UEGK2!W:U"ZM62<QE2/^P?#OW^T=&C+5>F;I=Y;<G1]_;\X^-!\^CO
MG^IT96'W3@+?+:7JIBCK#_9:$'9WIG= J[KQD0X'![?%@^Z8U+FRSGLG;G\@
M56LPW/>/!L.=JO7CJ5I[^_[QWOXV:%IK%"7NY/)6Z%K#GG\TO'W#<%L.]5Z>
MZ='0[_6/MU3;>L\%^QQ0I)GC&#W<B=G[J&+=T.E^Z!_M'^[TJ_NK7]WLW/<.
M_./>;;GF[Q(+VZE46Z52[>VUR-[=B=Y??6K8VU9E:F4&UWO#H.(TS[<Z)>L&
MV8RWK(9M,,_X!F2S'%Y+B6B_!VK;P>!V,V!_9#SZ,=&H/SCRC_>/;B6==I.H
MPD-&U&V;K]NB)]S+;+"A/QP,=YK?7=3\;G:@_9Y_V#_>3M5/,Z!=D/+'4MW6
M3!KR>_V6>/T.-;98&UO/N>'WVO(([Y\"ME)7QU(DW<R8-32O"+[>E^*]NV6G
MW#DGWHV,5[ ZR*VWPX#[IOK=DMG9\_=[!]M8Q?G:\#?=(-I[*$KAHYWDWRF%
M;@[G?G^G$VZQ3GA#*_FPM^WZX#M5W'X0Y,[N=J<!MFF Q_[1L+?3 ']D#7"P
MOY4:X.HH<*$'D]F.'6P2/T:.N-6M.K8[^ZZQ7<_;->7X/DK@MAS[?5+S#OD5
M4>45]+>>L .V<*%F.4]&D\&,>3G*U7]+E10Q#F(?QT&>1Y.()W+AL*.(9NBQ
M<AAMAVJP18'<.\3CMN5$M^= MT)YT_.=>%SB>.$%X5]E7M#@J9U\W@J];#WW
MW.'ME\QO\;%ORZGO'6Y%P>E*$_136M"T/M<$W7GC_@G#N\,^Z%OSU@WW;SG9
M^(?!D!\ 0=";=]BK!_2W0B%<*Y"!':IE7OK#49!'8VFJA(.'ZKV*MTN)V-5Z
M?'OJ&G0'_1T2[0H]_@D.];JDV3;8\V.:??JK3!F[_4FPU:.OZ^'\BP$[3NI=
MT^/PK<:"U^!.0VMIFFVUU?!W'YDK+_<N@]P#<("=\O3@H'ODP8MC[-GG#L/U
MVN?@>GJLN.]E"I CA]=2_S\O5.-,!3E-<I:''W9[^MD^>F3[O9]Q\'TZ,Q?T
MN\.;O+W?]7#\KWDE;FB>13.>*AUF8(TDWFA!CRM4-HL2ZG2OQZX_2]4T@U7#
M U_#?^.IHN'A9BPPCNS&M_@>D,)XZL7L6@[0V9R>)Y%^ENRBW[/[7&<7U5G"
M75C#VE#7@X=A:?H !\X!XJ_R_?YQ]] "'PX*IVD#7.(%#BF'+RPJR*[^AC<"
M.U.\?II8#!R- 1*<9TH&IU]&Q=1[=?:[3UL%JIO2];"H'GYM+S4CTO';T_>?
M7S_W3O1OMSG:_%KTI_OMGIE^N]^="BLM?UU:[/?VKX=(UR/&_>Z@0HU[PQHU
M]@^']I+;(\>@X*Z@-!\;R AVG9L2%QQZ?_KVO0=0O8C&\/GA),IQ[#Q->:=9
MV_BT*4@GG!<_ Z&$P[R!MG.0<]$$Q+;3U<\L.E=%IYSC[@-Z?***RS3[\LCW
MY@'(^B"&AZ63"5R&CPJ0XGGMH7>9H?2#'^EA67#IS0(<+Q_$N;"#2P4J^CQ+
MQV4FX^D!0\H)K*Q$KH(_A>68!]GG*H[Q7Z(,H =^ NKXH%+ _T#S)SYDIMW#
MM2/EE;B2L%3,=@"P.'L>Z5:>C0<TCX,DP?<Y4]"1WV5!DD^PF<4$R1[@"H]R
M;AL' $.0C' N AQ9WD. <ZCR,1P6W!$Q4T*I.>@]Y8P#6WW.":KT8_\I;)(?
M/5*PCD==[T]E>0H^J$)TP%GR IE.',A^X32\C_\.9O.GSSL&#RC@=TEPOHA"
MY<(0KT\E!<)E4GBTB<KR[FXH>U/%W$W-W0V9WIW+;BC[73^7';W<S7/9#67_
MEL=R#Z.#[4#8XGFYNZ'LWWLHNQ[Q*=,Z<3P[_\4SVOGOW:#V>TE-=WJ:Z?9,
M&-X-:M^1RFY0^VY0^P;P8LO0XH<=U+[CR/=+>;D_5/4P2K2*GY9YD(2BTJ<3
M_E>569K?^[:2._+8D<?-R*-,@C*,FME_6Y$3^4%E>9HD*M[6A+1=14Q;DN^^
M/SS>#;W] :MB^L=^[^AP&PICWNI\D/L@BW_HRN(U,7///]Z__<ZJVW*H]_),
M]X?^<5OUY5:H3I^F4192NM/"),[M1.F/I$7M]?RCXUTSZ!]0C1KL^[V]WG:H
M41$F5U+'>TSKC#'_=B=]MT*EVO,'@]T$VZW2J/K^_M&VSEP[F:6PY+\IC=SW
M0JRE&$=2^8(UN,HI_-E68?O]>S!MDT8V !.RI>O'#D5VBIM@R+%_=+ 54SJH
M%F@K9/JF6-X]Q-Z!OW>X72-T-\3,[N'9'PZ'6ZKW7=WB:M<Q8]=V90UX+;>:
M#H=^_Z@^&W6'1[>K#FX_&O7V_./C>O.T>]U\Q:V!FIH\2GNX6*>=9D_T$8YC
M%62((-.GU1\D\Q+?C$7R'9V)^;2ZM#V[#R[1/N@.AUH<2XUVY:LBG?--\^!<
M=;A6+9@4*GL2Q)?!(A>4' Z[@WV3ZLK?]9Y6J]>PDMPI4JM4BO,[J[7B\MT5
M-7$.1.HO:+MS \TVSE0<4S^*)/2>1SFW@4"GR@MWP.EW;\#A+BMTEV7:2%"'
M!]T58TF+&F9L:W1XX:8M]$A]'O'"*Y/Q-$C.54A--(.,6R%<^^']7;.#%JZ^
MJT;=%6_OSF77[."NG\N.7N[FN>R:'7S+8[E_+N\?KX1CU^Q@U^S@'J+.':6F
M.UT0M3U5NKMF!SM2V34[V#4[V !>;!E:[)H=[#CRO5!>[@]5[9H=[,AC1Q[+
MR>/>-SNHQ,2.NH-:4++#7^U:(NR*^6J)P?M[VYXXOBOD:ZVG.;PW^>#_G+>Y
M)3925&.K;.Z#G-]5_5V=*+QKHK!5B=][]SGO^Y^SK-LM=-EBD;PUJMA@L/4U
M?#M5K(7/#>Y-0X5_SM6^<\W+#U.8\"/,<._[@[W=!/=[&"'Z7N@Q'!QL4XW*
M1@8$YRK(<$8D%DVH"Q6G<YJFNMF:B<JR0F=9/,W1+9C8V^\>?[,IIH/]8UN/
M06-,A_4QIH/A_LUF&E]OC*DS?Q1^C5,  <W;7 ZEKO=RG=FFM!<:8EH$&<W-
M3,O,^S#%)0T>[WDX"Q19CU=@$TK:X.GGY#3]W/5.<KS\N1KSOF2&L7(G_ 8\
M43/7L,%AFIF:!1&-$FW,YL1U\--K[X7=/.=QIWC)),KRH@)C6 >?*;R>L$/#
M+5.).D^+"-Y MZJO45[PNY,B"W!N:EZ.ISP %'>NX.<9K:>^3GU2(<%[EN)8
M5ASO.H[F 8XJAD?3-F@J*@UP!<#'$4TX#A) G@BPG6;!FG<0#''0<U[&A<R+
M!KASK4[N7V=!/MQ;YDWXG\,M]I!Q$'.6 U0MCN\=.B5',K+:'!HL$$0#.LUP
MX;X7ZD.( %F!RM.P^<9$%?)6/'#9##Y9[T1/>]5'4!F:;5X-@'%@0SO D:Q%
M\ 57@.G.!)YQ.IM%!8*G,6IV5ZS4(MRW-YO\CF7U_[C5%G?L('[<<J0[=A [
MBK@C!_'#%AQ]FW.XF[Z[=7:]Q8E2=1]$(V/HVT)E&W*JKO)9O11C%XN'/*X;
M\NYAR="./.XQ>=SA//BKR*?B$=J1S)TGF6$=!,OK/.Y_A.>?(O?]+?;YY@=[
MW\]U5ZWS S/!:\%@IS.WU>5XIB2'G.+WL!#GQ\7\+="8[S)Q_'!5.4^_Q7R_
MS:;)74D7/^RTA[4S! _\X?%65.G<1;38-"!NC!6#8_^P?VLY\G>0$]Y^0>+F
M5*(?8[[#^KA[X ]Z]WFBP^:XU;TXWGU_;W!KTY;OA][V?4H,-UK/L=/<KDL(
M>W[OH+\-FMOFD> >X\#P\-Y,GK^)FA9@*F1./&^BX&V49GL>Y:#?>X$7J_,@
M]@AZ.SF_=7J<OW?4,N=\=[S;H<;Y!WL_F!:WO</M=\K;]:V80[\_W+(Y]SOU
M34K,]G3=X?H8,1CZ!X.#[=7DW@81EK4$R5B1-A=C-=%.JF^=TG9\^R;I]A_N
M_3C;HV&+5W6;%;8M:I-SMS2T.]PO8&UJZ/M'@Y8N=SLDV?[)I]=Q8;3U7=H:
MI6YK.^ZTYE=]]SRSC6=FKT,(-^BF,ACN _,<WM=V.W<&.;81-_;V_>.]_>_5
M:N<?R[[OWJX&^[A,TCA.+ZDY!O6:R-0D5MA>!)M4K.[40HTR5  _2_>5>9:>
M9\$LO]D$X#Z]!1/UG^P:8#2);'NKF^_VE,L?M_K_;I_+C]L>XVZ?RXY>[N:Y
M_+#-,W;3>J\#A&VOA-H02+:A#&HWK7='3=6MW1@W=M-Z=]-Z=Z1R1Z:RWNV.
M';MIO9O"BRU#BUW_CQU'OA?*R_VAJMVTWAUY[,AC.7G<^[X@J[;^NUIX'W3$
M[^'IYV&_-_"]T\]' _YW@.,0,*3'DQ$>;4=>TQ7L8;NK%>X6&';8L-&BA6\"
MA?ND'1S2*YCQW0>IOIO->V62Y8'?;^L'L3O3S9<6W'A:J3\XNL\3>E?S'E2V
MME64[H;OMJ'SWNVW(]KB<]^68^\/6^I#[I^R=*;&*5B$KU2B,NY =)I>1"&:
MCXZYV#OH]6_/7-P65+ZO&M7AP>WWA-R6,[V71]H?^KW#6V-'=T;X:)4*G54[
MT?HCJ53[>_Z@OQ6-:W]8M6KO1D>_M^<?#H?W6J_B5U!UN;=T*K9VT^_D[U;H
M5'U_OW?[Y>+;<J;W\DB/_*/]EFXG]UREXE?\@4.XTS'- J?"P8>W:-W=L;U^
M>P7K#I?IWE@!._9[Q[V=_K6]72YNBAG[/7]O_]8Z!6TT(KJM[2UN)SOHGB8O
MWP#O?[P>%QO&D!\ 0=9M=.$49-Y\0UU[NAJD] U\U)6CW?ZQFK74A%8+/:>9
MEZ3Y- AA.456J@>8(YAF_WD@Y_+ PS?^YT'_@4<W_N?!X*#;^]FD#UH1V*$;
MG^CSK'YRREF;*RK2^9->]Q!6RT@"V),H%R%,GP=L"_%  Y+;4O M_WD *QVK
M.!;<,9_QH/1GO>25'2S^&:E5#H._H=TA N)R.W&P2,OBR23ZJD+W*&3G@GY5
MJ?J/UE6C52(#6-)R:J5^)542)%NAR@)J-.HJ$O]HN?P1'P2KRF9!7$GOE:]:
MS!EOGD4 <'@G?$[R*"^P(0K_%.1YBK,UX-K+J)AZ<STKR%-?YRK)5>Y[\[4;
MT_M>L&IZA^_-VCJC.J\:PXD$-,HQRL).I7VTN8INU!?.9,J;^;5K=+$&CW&X
MBX-_V&_FJ2&<[][CYD_>V+B /0?%ZJXV!@*741S3619141:*>MG,X#R]O!SE
M19 4"!&$GNY\8^X$D$W*HLP4GG24AO1-C(/FZ?CQ04%X8<X'[@L 8^ LX4'X
MH[L<VU4G+&']8[@A"N$\\ QJ->C3[&JF"+B0H;R<MO-'/"9<J&;BO1I;V7/X
M"K7(.>@.AUJ-D!XYE:_P\/=8IIZK#O<*"": 3D^"^#)8Y$+SPV%WL&]D-'_7
M>_J@ADY?.P[#JG3JX7=6>_7(=U?T)' @4G]!VYW?'76?EPI9 >)  "9>C"%S
MX"-@Z@$/(,2BKDEPB6"-9%K3':?O/[]^WND?>Q=P+^*?01]O!#PA]!#GX+I)
ME.5%Y]P&Y&<?WYUXB$4CD(2^=ZG@1>,RR^"6JPF':"P'9A]-@/$G!;!$]16L
M4^SZA&^; E-+,Y0)P)K@?AHEN^RQN64ZW@D<+RX/6._"IT>]'Q>I*8LE0"1I
M0:^E;0!4D)Y>E%DZ5P'F&<QF4>Z2&A)DF 67L!:A-&"Z)9QWFBV\8 YD=P$_
MP1^Q?B:VM1(0PYK+&$\C2N36<0J[+N3Y.>PB"UPF#S(/=C@-+A0REB*+1B7>
M+N<+(,X4'8O<(>#Q/;A,[H63"%/<I&%H*";&='>-Z72]UXEW F(IMN"AHZ2"
M!EHUW!QXI'X Y8DX.<^4HO,D7O7J['?3R*O&E@)OE*5!V$0RZ0!61;%HAK"$
MSSEE?RQ%MJX4#8"4@VTFG?%4S1!5 (EF:0A'"X_ &WS8QC@-J6?9%-^I)B4=
M++!FS#/^&ZZ;E'$,_"$YAXWD\^@++:U0D3G]LY./9QUX66?@7419"9 F\0M"
M'E% Q#5<_N;=!_@MRNDF(A8 ^AQ1-BF(-? #X8)EP.AZ?_*C\ E+(89XML M
M(<2N !0?Y=>"NZGA#84:3Q/@ZN<+;P[+QVV WIJGB"/+P,@"+BNQV1MB _:!
MLP<>%$$GS&!_ %:%'>$<RAFIW!%'L#_EH"1Q"Y<'6.Y W)21/B\!HZ_89I-U
M 6(_*U$+RA$">&"(I(2W]%3UWY+V"49%IAJ(:YO6X5UT$EJXYLQ3B,_!E41\
MJUA3355 HD2JCA)FV9J</3EU?AZL.BH\V(DWR=(9,N\>7HS$V?U&#0!;#'$2
M,"1Y'OQZBNHJB%TFI:#PU]2/K,++1ZJYK6TF^$4M3#M ;N=WETVF_N V;2;'
MEGG0\%]LW*#Z][^.#X^.G]XQH^H]X%V95/G3%9I+DWM8_JC3"<_!A@%>I9G]
M0,MA8-<CA7@Z3CN"X=I" ][0]=XGWELB >E-.?"9X22@6(^1UTRQ*:48 ('W
M88K$WO?&H$"3<E.0S<3Z HLT>G8 -Y7A@F^J,6.S26:ES-"8H(C#+GDYB1[]
M?OO:^N/_$2PQ']/'2T_*\S)'[L% 66$+[JA]1^VKJ3U-QJ*PL)A 1.,24D.B
M(HY!S( <M506INC3R $R@*I(PTVJFY!2M)@K,C#8VUN4LS1#CPP1!XCL*>#Z
M?$%2#IX_3F>C*&'D9V(%>=[Y\)S;TH(%T;#5]7J8IE'] (.A#,1?D <358"M
M4J1HN'']&]O\$]2+QL0%>,L>&$V!=]CKP6D='#X]YQW"FN:P'#*$:$$?0''$
M_KQ9,"8;90:R-X%C\;"8KM]_RAK?&OO+*QOL].FO$?"+E>Z=NTS2M^KSW%'T
MS2BZ9M+86O"5!,T6:D-V$AHWI182-U+3'7%$.M")"CC4\2IMFZL>8B+(DW &
MVP7SBVW(%Z)9;Z8/N+NPH+HP:^<HL*B T>P=[C\]&G9['JPJUDZ1:_?Z!J0P
M5C2R\ #L##&9@"O*:P;=H7X+:!^9M_>SSY:3_#[LV0MNV'*\ZWTB(U'>?1FX
MMDU0L)N&^!ZP]UCE>9OG/"=7<$269SJ9Y*KP1@MC Y*C;J7;7CSUYW("Q+B1
MB":*_%7PM7Y1=]<8O1FCW=[.M:V,?-?9^8<_B!^W]?D=.X@=1=R1@_AAFYM_
MFW.XZ^F5RW>]Q4W9OBL,MJ%;VU6)AEO<H/R'))!A P2[%N0W(HS[WG-\A_UK
M8O^/VU7\*OC<WS;BFS_Y^W[PNT;A.S9Z1Y2(.TPHV]C[>X?Q.XQ?@?'WOIWW
M#<:R?] %*]M1EOUTRWL@U3G8\I+!GM_;ME:2MWRX]_9L!T?^\=&M=1.Y@TSI
M;6N9&^5WWP>)^\UYTKU 4K_?N\^MMF^=V=R'0]OW#_O[][A-T0UXS2=,^/&J
M"3\[<;E5NM!@Z!\>[W2AK=2%^L?^85NSO*W1A=ZLDSBXDZ_W1"LZ]/>.6P3L
MCWIJ]^/0COQ!_^#'THI.5B4T[R3H5JE'!_[!40MZ[\[V_FM'Q_[^_JW9<W>0
M35%?[)T8O2?*#[HM=\K//5-^COW^X7V>KW8#KO*=>[EN6E)^]WZN]ZJU\6H
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M8DS$K)M;"<9RKA2.[8E=RWISD_T3^@URUR3-F:P4\;#V(1&:QRXC"TZ*4KJ
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MNG$R1*8Z!Z!$A^K'6NUM??YS'3PJ$6_R[__LI]$<_KG-)^-__1]02P,$%
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MR-K48Z=JCI@U.ECZ97L'B8))WV*"DU1NH!7TT8%56>ZWA1Q\N4 Y?;TG@KY
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MK$ ;#2NL55.>BLJZ_%736,.0F@W$[$G87F)V,':FJY%163)3=B; KKLS;:Y
MEK>3*H-7X#)%#>+9XPS!W?9?Q_;?,@WJCI@ML(&5W^ - 8<SSD0G1WO#H]XE
MCASV-F3]]S[W(@5:'Y5C*N0X8 ,NMJ'5U8,IZV/VD[T5'\C;+%5]]B@&T,G3
M#B"IAQ!H;G@:%[GFN%(QP9^]]2&7U&BD/E0<E6#7B-X6G6IF8K<%IO!-77%0
MDV+!(=894K@-)/VEU0";(W78$N:JL:\;+.?>O5.-N&$[J.B"S5/P;V1(HW2F
MX-WO/OWE7BS53-9Q\[I,F+KYG21'X#+=[\71\$M#ZFI9^I0T0.TQDKE>)G]*
MH_M<X+)RW9]V%@;1[W34=:V,P(I9'?AOK&0_.;/$/_UF8ZJT,H8[[$5]P!!)
M6"X'W^L%I4\<OC#(%+"(+:1BT(@'+K2"O4;>AW+K/>\;7 G!B-"H^-33P750
MP%Z#!&Z&0W9D0[&( ?G8I>G3U<TE"GZ3[@Q<U*BR[@"SL0,:[KT[]T+:;:SI
MK%O=X2C86E'A7"L='A?,A58G%T\H/ME/'/!DN?DV<Q3$^IF"6.N N,^W0&(5
M:</*<$(-%U]S$KPKG,>K&AW,>-S5?O)3S*I6#\!HHZ(#Y4)&TG"O5#H'LX</
MN=CJ.3SQDWOBG7^B+A+A&C>:ZX-K,O5@[S@8*$>'PR/LU>K29XTB@9<RH[K
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MR;T@HG2TEZGE;BVY*QE$UR/A33PK7RL+S-9%.J;"8Q3N,**#*ZI8<)Y;^P;
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M U!+ 0(4 Q0    ( ,&+<56V%;]<V"   "IV 0 1              "  0
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M+3(P,C(P.3,P7W!R92YX;6Q02P$"% ,4    " #!BW%5VT.W_=LK   QPP$
M%               @ &W>0$ 8W9A8RTR,#(R,#DS,'@V:RYH=&U02P$"% ,4
M    " #!BW%5K27D0IT6 0!-. L &               @ '$I0$ 8W9A8RTR
M,#(R,#DS,'AE>#DY9#$N:'1M4$L! A0#%     @ P8MQ51#;6F0X)0  628
M !L              ( !E[P" &-V86,M,C R,C Y,S!X97@Y.60Q,# Q+FIP
M9U!+ 0(4 Q0    ( ,&+<55D?YBLP'X  ,.W P 8              "  0CB
M @!C=F%C+3(P,C(P.3,P>&5X.3ED,BYH=&U02P$"% ,4    " #!BW%5U(R)
M6K0=  !4H@  &               @ '^8 , 8W9A8RTR,#(R,#DS,'AE>#DY
<9#,N:'1M4$L%!@     *  H J (  .A^ P    $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
